PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, HC; Appeddu, PA; Isoda, H; Guan, JL				Chen, HC; Appeddu, PA; Isoda, H; Guan, JL			Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTORS; SRC SH2 DOMAIN; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; CELL-ADHESION; RAS PATHWAY; P85 SUBUNIT; ASSOCIATION; PP125(FAK)	We have shown previously that cell adhesion or platelet-derived growth factor (PDGF) promotes the in vivo association of focal adhesion kinase (FAK) with phosphatidylinositol (PI) 3-kinase. In vitro experiments indicated that this interaction was mediated by the p85 subunit of PI 3-kinase and dependent on the tyrosine phosphorylation of FAK. Here we report data suggesting that the major autophosphorylation site of FAK (Tyr-397) is the binding site for the SH2 domains of p85 in vitro and is also required for the association of FAK with PI 3-kinase in vivo. We also show that Tyr-397 is responsible for the increased FAK:PI 3-kinase association upon PDGF stimulation, implying that no additional site of FAK was involved in its binding to PI 3-kinase after PDGF stimulation, Finally, me present evidence that the interaction of PI 3-kinase with Tyr-397 of FAK stimulates its activity, Together, these results suggest that FAK activation and autophosphorylation at Tyr-397 may lead to its association with PI 3-kinase through the SH2 domains of p85, which can subsequently activate PI 3-kinase during cell adhesion.	CORNELL UNIV, COLL VET MED, DEPT PATHOL, CANC BIOL LABS, ITHACA, NY 14853 USA	Cornell University				Isoda, Hiroko/0000-0002-1399-9541	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050, R01GM052890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52890, GM48050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Cary LA, 1996, J CELL SCI, V109, P1787; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FURUTA Y, 1995, ONCOGENE, V11, P1989; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ILLC D, 1995, NATURE, V377, P539; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOKER A, 1994, J BIOL CHEM, V269, P32358; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	52	445	454	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26329	26334		10.1074/jbc.271.42.26329	http://dx.doi.org/10.1074/jbc.271.42.26329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824286	hybrid			2022-12-25	WOS:A1996VN18000092
J	Sasahara, Y; Kobayashi, T; Onodera, H; Onoda, M; Ohnishi, M; Kato, S; Kusuda, K; Shima, H; Nagao, M; Abe, H; Yanagawa, Y; Hiraga, A; Tamura, S				Sasahara, Y; Kobayashi, T; Onodera, H; Onoda, M; Ohnishi, M; Kato, S; Kusuda, K; Shima, H; Nagao, M; Abe, H; Yanagawa, Y; Hiraga, A; Tamura, S			Okadaic acid suppresses neural differentiation-dependent expression of the neurofilament-L gene in P19 embryonal carcinoma cells by post-transcriptional modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; MESSENGER-RNA; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; CATALYTIC SUBUNIT; CYCLOSPORINE-A; RAT-LIVER; CALCINEURIN; GROWTH; DEPHOSPHORYLATION	Mouse P19 embryonal carcinoma cells in aggregation culture in the presence of 10(-6) M retinoic acid followed by monolayer culture differentiate into nerve and glial cells, In this study, we demonstrated that the neurofilament-L (NF-L) mRNA and protein levels of these cells were enhanced in accordance with their retinoic acid-induced neural differentiation. Okadaic acid (OA) treat ment of the cells markedly suppressed this differentiation-dependent NF-L gene expression increase and neurite outgrowth of the cells, Similar results were obtained when tautomycin was used instead of OA, suggesting that inhibition of protein phosphatase(s) is involved in the suppression of neural differentiation. OA treatment did not affect the NF-L gene transcription level, determined by the nuclear run-on transcription assay, but it did reduce the stability of both the 3.5- and 2.3-kilobase NF-L mRNAs, The expression and activity levels of protein phosphatase 2A (PP2A) and 2B (PP2B) but not protein phosphatase 1 (PP1) in P19 cells increased in accordance with the enhanced NF-L gene expression, The presence of OA in the culture medium during the course of the neural differentiation caused a reduced PP2A activity but not PP1 and PP2B activities of the cell extracts, On the other hand, both PP1 and PP2B activities but not PP2A activity of cell extracts were suppressed by the addition of cyclosporin A or FK506 in the culture medium, However, both cyclosporin A and FK506 treatments affected neither NF-L gene expression nor neurite outgrowth. These results demonstrate that the OA treatment inhibits the differentiation-dependent increase in NF-L gene expression by destabilizing its mRNAs and suggest that PP2A plays key roles in the differentiation-dependent enhanced expression of the NF-L gene and is the point of the action of OA.	TOHOKU UNIV, INST DEV AGING & CANC, DEPT BIOCHEM, AOBA KU, SENDAI, MIYAGI 980, JAPAN; TOHOKU UNIV, INST DEV AGING & CANC, DEPT PEDIAT ONCOL, AOBA KU, SENDAI, MIYAGI 980, JAPAN; NATL CANC CTR, RES INST, DIV CARCINOGENESIS, TOKYO 104, JAPAN; TOKAI UNIV, SCH MED, DEPT MORPHOL, DIV HUMAN STRUCT & FUNCT, ISEHARA, KANAGAWA 25911, JAPAN	Tohoku University; Tohoku University; National Cancer Center - Japan; Tokai University			Kato, Shunsuke/F-7607-2014					BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; BALLOU LM, 1986, ENZYMES, V17, P311; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DELFRANCO AF, 1993, BIOCHIM BIOPHYS ACTA, V1171, P323; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014-5793(91)80745-O; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKENAKA K, 1990, J BIOL CHEM, V265, P19782; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KATO S, 1995, ARCH BIOCHEM BIOPHYS, V318, P387, DOI 10.1006/abbi.1995.1244; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1989, J BIOL CHEM, V264, P12800; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEDCALF RL, 1992, J BIOL CHEM, V267, P12220; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; PSHENICHKIN SP, 1995, J BIOL CHEM, V270, P5994, DOI 10.1074/jbc.270.11.5994; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SACHER MG, 1994, J BIOL CHEM, V269, P18480; SACHER MG, 1992, BIOCHEM BIOPH RES CO, V186, P524, DOI 10.1016/S0006-291X(05)80839-3; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWARTZ ML, 1995, J BIOL CHEM, V270, P26364, DOI 10.1074/jbc.270.44.26364; SHIMA H, 1994, P NATL ACAD SCI USA, V91, P9267, DOI 10.1073/pnas.91.20.9267; STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAMURA S, 1978, BIOCHIM BIOPHYS ACTA, V524, P349, DOI 10.1016/0005-2744(78)90171-7; TERASAWA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P342, DOI 10.1006/abbi.1993.1598	49	21	21	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25950	25957		10.1074/jbc.271.42.25950	http://dx.doi.org/10.1074/jbc.271.42.25950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824230	hybrid			2022-12-25	WOS:A1996VN18000036
J	Steinert, PM; Kim, SY; Chung, SI; Marekov, LN				Steinert, PM; Kim, SY; Chung, SI; Marekov, LN			The transglutaminase 1 enzyme is variably acylated by myristate and palmitate during differentiation in epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE LAMELLAR ICHTHYOSIS; CORNIFIED CELL-ENVELOPE; CROSS-LINKING ENZYMES; MEMBRANE ANCHORAGE; ALPHA-SUBUNIT; PROTEIN; EXPRESSION; PALMITOYLATION; SUBSTRATE; BINDING	The transglutaminase 1 (TGase 1) enzyme is involved in the formation of a cornified cell envelope in terminally differentiating epidermal keratinocytes. The enzyme is present in proliferating cells but is more abundantly expressed in differentiating cells and exists in several intact or proteolytically processed cytosolic or membrane-anchored forms, We show here that the equilibrium partitioning of TGase 1 between the cytosol and membranes is controlled by variable modification by myristate and palmitate, During synthesis, it is constitutively N-myristoylated. Later, it is modified by an average of two S-myristoyl adducts in proliferating cells or one S-palmitoyl adduct in differentiating cells. The three myristoyl adducts of the former provide more robust anchorage to membranes than the one myristoyl and one palmitoyl adduct of the latter, The half-lives of the S-myristoyl and especially the S-palmitoyl adducts are less than that of the TGase 1 protein, suggesting a mechanism for cycling off membranes. In in vitro overlay assays, the S-acylated 10-kDa anchorage fragment facilitates binding of TGase 1 forms, supporting a mechanism of cycling back onto membranes in vivo. We conclude that differential acylation increases the repertoire of functional TGase 1 forms, depending on the differentiation state of epidermal keratinocytes.	PACIFIC RES & DEV CORP,KIHEUNG EUP 449900,SOUTH KOREA; GREEN CROSS CO,KYOUNGGI DO 449900,SOUTH KOREA	Green Cross Corporation	Steinert, PM (corresponding author), NIAMSD,SKIN BIOL LAB,NIH,BLDG 6,ROOM 425,BETHESDA,MD 20892, USA.							AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DUVIC M, 1994, J INVEST DERMATOL, V102, P462, DOI 10.1111/1523-1747.ep12373021; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; MERDES A, 1991, J CELL BIOL, V115, P397, DOI 10.1083/jcb.115.2.397; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PARMENTIER L, 1995, HUM MOL GENET, V4, P1391, DOI 10.1093/hmg/4.8.1391; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RISINGER MA, 1992, J BIOL CHEM, V267, P5680; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1146; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SCHMIDT R, 1988, J INVEST DERMATOL, V90, P475, DOI 10.1111/1523-1747.ep12460936; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHROEDER WT, 1992, J INVEST DERMATOL, V99, P27; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; STEINERT PM, 1995, CELL DEATH DIFFER, V2, P31; STOFFEL W, 1962, ANGEW CHEM INT EDIT, V74, P905, DOI 10.1002/ange.19620742218; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TRAUPE H, 1989, ICHTHYOSES, P111	40	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26242	26250		10.1074/jbc.271.42.26242	http://dx.doi.org/10.1074/jbc.271.42.26242			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824274				2022-12-25	WOS:A1996VN18000080
J	Chen, QP; Bates, SR; Fisher, AB				Chen, QP; Bates, SR; Fisher, AB			Secretagogues increase the expression of surfactant protein A receptors on lung type II cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; PHORBOL ESTER; HIGH-AFFINITY; BINDING; PHOSPHATIDYLCHOLINE; SECRETION; INTERNALIZATION; PNEUMOCYTES	Since secretagogues have been shown to increase the internalization of surfactant phospholipid and protein by lung cells, we postulated that their action occurred through a mechanism involving increased surfactant protein A (SP-A) receptor density, Therefore, we evaluated the influence of secretagogues on the binding of iodinated SP-A to alveolar type II cells, Type II cells were isolated from rat lung and maintained in primary culture for 18 h on Transwell membranes. Upon exposure to 8-bromo-cyclic AMP (cAMP, 0.1 mM), phorbol 12-myristate 13-acetate (PMA, 10 nM), terbutaline (0.1 mM), or ATP (1 mM), the binding of SP-A increased 1.5-2-fold. This stimulation was cell substrate-dependent since type II cells plated on plastic dishes did not show this effect, A time course of the stimulation of SP-A binding due to secretagogues showed that both cAMP and PMA increased SP A binding by a-fold after 20 min, With cAMP, binding remained elevated for 2 h, while binding in the presence of PMA had returned to control values, The effects of submaximal concentrations of cAMP and PMA on binding were additive, Inhibition of cellular protein synthesis with cycloheximide did not alter the increase of SP-A binding stimulated by the secretagogues, Type II cells pretreated with PMA responded to subsequent treatment with cAMP by increasing SP-A binding, while these cells were refractory to subsequent treatment with PMA, Both constitutive and regulated binding of SP-A to type II cells were sensitive to trypsin, The binding of SP-A to type TI cells showed saturation at a concentration of 1 mu g/ml SP-A under control and secretagogue-stimulated conditions, with both total and calcium-dependent binding showing a a-fold increase upon secretagogue exposure, The data are consistent with the hypothesis that secretagogues stimulate surfactant uptake, at least in part, through recruitment of SP-A receptors to the type II cell surface, resulting in an increase in the number of SP-A binding sites.	UNIV PENN,SCH MED,INST ENVIRONM MED,PHILADELPHIA,PA 19104	University of Pennsylvania					NHLBI NIH HHS [HL-19737] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bates SR, 1996, AM J PHYSIOL-LUNG C, V271, pL258, DOI 10.1152/ajplung.1996.271.2.L258; BATES SR, 1994, AM J PHYSIOL-LUNG C, V267, pL753, DOI 10.1152/ajplung.1994.267.6.L753; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDER A, 1995, AM J PHYSIOL-LUNG C, V268, pL108, DOI 10.1152/ajplung.1995.268.1.L108; CHINOY MR, 1993, AM J PHYSIOL, V264, pL300, DOI 10.1152/ajplung.1993.264.3.L300; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DUBROVIN LC, 1992, AM J PHYSIOL, V263, pL42, DOI 10.1152/ajplung.1992.263.1.L42; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; FALLON RJ, 1986, J BIOL CHEM, V261, P5081; FISHER AB, 1985, J APPL PHYSIOL, V59, P743, DOI 10.1152/jappl.1985.59.3.743; FISHER AB, 1991, AM J PHYSIOL, V260, pL226, DOI 10.1152/ajplung.1991.260.4.L226; FISHER AB, 1989, AM J PHYSIOL, V257, pL284; GRIESE M, 1993, BIOCHIM BIOPHYS ACTA, V1167, P85, DOI 10.1016/0005-2760(93)90221-T; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HU KQ, 1990, J BIOL CHEM, V265, P13864; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSE L, 1992, MOL CELL BIOCHEM, V115, P203, DOI 10.1007/BF00230332; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; PETTENAZZO A, 1988, J APPL PHYSIOL, V64, P120, DOI 10.1152/jappl.1988.64.1.120; PHILLIPS MA, 1983, J BIOL CHEM, V258, P2875; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; STEVENS PA, 1995, BIOCHEM J, V308, P77, DOI 10.1042/bj3080077; Strayer DS, 1996, EXP CELL RES, V226, P90, DOI 10.1006/excr.1996.0206; STRAYER DS, 1993, J BIOL CHEM, V268, P18679; SUWABE A, 1991, AM J RESP CELL MOL, V4, P264, DOI 10.1165/ajrcmb/4.3.264; TSUZUKI A, 1993, AM J PHYSIOL, V265, pL193, DOI 10.1152/ajplung.1993.265.2.L193; VATICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; ZACHARIAS U, 1995, EXP CELL RES, V216, P371, DOI 10.1006/excr.1995.1047	34	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25277	25283		10.1074/jbc.271.41.25277	http://dx.doi.org/10.1074/jbc.271.41.25277			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810290	hybrid			2022-12-25	WOS:A1996VL69300034
J	Pearman, AT; Chou, WY; Bergman, KD; Pulumati, MR; Partridge, NC				Pearman, AT; Chou, WY; Bergman, KD; Pulumati, MR; Partridge, NC			Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; TRANSGENIC MICE; 5'-FLANKING REGION; EXPRESSION; TRANSCRIPTION; COLLAGENASE; SEQUENCE; GENE; AMP; IDENTIFICATION	Many parathyroid hormone (PTH)-mediated events in osteoblasts are thought to require immediate early gene expression, PTH induces the immediate early gene, c-fos, in this cell type through a cAMP-dependent pathway, The present work investigated the nuclear mechanisms involved in PTH regulation of c-fos in the osteoblastic cell line, UMR 106-01. By transiently transfecting c-fos promoter 5' deletion constructs into UMR cells, we demonstrated that PTH induction of the c-fos promoter requires the major cAMP response element (CRE). Point mutations created in the major CRE within the largest construct inhibited both PTH-stimulated and basal expression, This element, therefore, performs concerted basal and PTH-responsive cis-acting functions, Gel retardation and Western blotting techniques revealed that CRE-binding protein (CREB) constitutively binds the major CRE but becomes phosphorylated at its cAMP-dependent protein kinase consensus recognition site following PTH treatment, CREB was functionally implicated in c-fos regulation by coexpressing a dominant CREB repressor, KCREB (killer CREB), with the c-fos promoter constructs. KCREB suppressed both basal and PTH-mediated c-fos induction. We conclude that PTH activates c-fos in osteoblasts through cAMP-dependent protein kinase-phosphorylated CREB interaction with the major CRE in the promoter region of the c-fos gene.	ST LOUIS UNIV,SCH MED,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63104	Saint Louis University				Partridge, Nicola/0000-0002-5406-4814	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109, R56DK047420, R01DK047420] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39743] Funding Source: Medline; NIDDK NIH HHS [DK48109, DK47420] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; GACK S, 1994, J BIOL CHEM, V269, P10363; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; OMURA TH, 1994, J BIOL CHEM, V269, P24994; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANG WW, 1994, GENE, V143, P261, DOI 10.1016/0378-1119(94)90107-4; WU JX, 1990, ONCOGENE, V59, P89; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	33	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25715	25721		10.1074/jbc.271.41.25715	http://dx.doi.org/10.1074/jbc.271.41.25715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810350	hybrid			2022-12-25	WOS:A1996VL69300094
J	Rajamohan, F; Hussain, SRA; Cotrill, JA; Gould, F; Dean, DH				Rajamohan, F; Hussain, SRA; Cotrill, JA; Gould, F; Dean, DH			Mutations at domain II, loop 3, of Bacillus thuringiensis CryIAa and CryIAb delta-endotoxins suggest loop 3 is involved in initial binding to lepidopteran midguts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; BUTTERFLY PIERIS-BRASSICAE; IRREVERSIBLE BINDING; CRYSTAL-STRUCTURE; BOMBYX-MORI; SPECIFICITY; RESISTANCE; TOXINS; TOXICITY; INHIBITION	Alanine substitutions of loop 3 residues, (438)SGF-SNS443, Of CryIAb toxin were constructed to study the functional role of these residues in receptor binding and toxicity to Manduca sexta and Heliothis virescens. Experiments with trypsin and insect gut juice enzyme digestions of mutant toxins showed that these mutations did not produce any gross structural changes to the toxin molecule. Bioassay data showed that mutant G439A (alanine substitution of residue Gly(439)) and F440A significantly reduced toxicity toward M. sexta and H. virescens. In contrast, mutants S438A, S441A, N442A, and S443A were similar or only marginally less toxic (2-3 times) to the insects compared to the wild-type toxin. Binding studies with brush border membrane vesicles prepared from M. sexta and H. virescens midgut membranes revealed that the loss of toxicity of mutants G439A and F440A was attributable to substantially reduced initial binding. Consistent with the initial binding, mutants G349A and F440A showed 3.5 times less binding to M. sexta and H. virescens brush border membrane vesicles, although the off-rate of bound toxins was not affected. The role of hydrophobic residue, Phe(440), is distinctly different from our previous observation that alanine substitution of Phe(371) at loop 2 of CryIAb did not affect initial binding but reduced irreversible association of the toxin to the receptor or membrane toward M. sexta (Rajamohan, F., Alcantara, E., Lee, M. K., Chen, X. J., and Dean, D. H. (1995) J. Bacteriol. 177, 2276-2282). Likewise, deletion of relatively hydrophobic CryIAa loop 3 residues, (440)AAGA(443) (D3a), resulted in reduced toxicity to Bombyx mori (>62 times less) and M. sexta (28 times less). The loss of toxicity was correlated with reduced initial binding to midgut vesicles prepared from these insects. However, alanine substitution of residues (437)LSQ(439) (A3a), contiguous to loop 3, altered neither toxicity nor receptor binding toward B. mori or M. sexta. These results suggest that the loop 3 residues of CryIAb and CryIAa toxins establish hydrophobic interactions with the receptor molecule, and mutations at these hydrophobic residues affect initial binding.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,MOL CELLULAR & DEV BIOL PROGRAM,COLUMBUS,OH 43210; N CAROLINA STATE UNIV,DEPT ENTOMOL,RALEIGH,NC 27695	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of North Carolina; North Carolina State University					PHS HHS [R01 29092] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOSCH D, 1994, BIO-TECHNOL, V12, P915, DOI 10.1038/nbt0994-915; CHEN XJ, 1993, P NATL ACAD SCI USA, V90, P9041, DOI 10.1073/pnas.90.19.9041; CHEN XJ, 1995, J BIOL CHEM, V270, P6412, DOI 10.1074/jbc.270.11.6412; FEITELSON JS, 1992, BIO-TECHNOL, V10, P271, DOI 10.1038/nbt0392-271; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; GE AZ, 1989, P NATL ACAD SCI USA, V86, P17954; GOULD F, 1995, J ECON ENTOMOL, V88, P1545, DOI 10.1093/jee/88.6.1545; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; HARVEY WR, 1990, METHOD ENZYMOL, V192, P599; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KWAK IS, 1995, MEM I OSWALDO CRUZ, V90, P75, DOI 10.1590/S0074-02761995000100017; Lee MK, 1996, BIOCHEM BIOPH RES CO, V220, P575, DOI 10.1006/bbrc.1996.0445; LEE MK, 1995, BIOCHEM BIOPH RES CO, V216, P306, DOI 10.1006/bbrc.1995.2625; LEE MK, 1992, J BIOL CHEM, V267, P3115; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LIANG YZ, 1995, J BIOL CHEM, V270, P24719, DOI 10.1074/jbc.270.42.24719; LU H, 1994, J BACTERIOL, V176, P5554, DOI 10.1128/JB.176.17.5554-5559.1994; MASSON L, 1994, MOL MICROBIOL, V14, P851, DOI 10.1111/j.1365-2958.1994.tb01321.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIMOTO T, 1994, FEBS LETT, V348, P249, DOI 10.1016/0014-5793(94)00604-0; Rajamohan F, 1996, J BIOL CHEM, V271, P2390, DOI 10.1074/jbc.271.5.2390; RAJAMOHAN F, 1995, J BACTERIOL, V177, P2276, DOI 10.1128/jb.177.9.2276-2282.1995; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Raymond M., 1985, Cahiers O.R.S.T.O.M., Serie Entomologie Medicale et Parasitologie, V23, P117; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEPF HE, 1990, J BIOL CHEM, V265, P20923; SCHWARTZ JL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P250, DOI 10.1016/0005-2736(91)90237-3; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WOLFERSBERGER MG, 1989, ARCH INSECT BIOCHEM, V12, P267, DOI 10.1002/arch.940120406; WU D, 1992, J BIOL CHEM, V267, P2311; Wu SJ, 1996, J MOL BIOL, V255, P628, DOI 10.1006/jmbi.1996.0052; Yamamoto T., 1993, ADV ENG PESTICIDES, P3	36	63	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25220	25226		10.1074/jbc.271.41.25220	http://dx.doi.org/10.1074/jbc.271.41.25220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810282	hybrid			2022-12-25	WOS:A1996VL69300026
J	Shtrom, SS; Hall, ZW				Shtrom, SS; Hall, ZW			Formation of a ligand-binding site for the acetylcholine receptor in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE ISOMERASE; TRANSFECTED COS CELLS; ENDOPLASMIC-RETICULUM; ALPHA-SUBUNIT; DELTA-SUBUNIT; LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; TORPEDO-CALIFORNICA; MOLECULAR CHAPERONE; SECRETORY PROTEINS	Investigation of the mechanisms by which the subunits of ligand-gated ion channels fold and associate to form oligomers has been hampered by the lack of an in vitro system in which these reactions occur. We have established conditions in a rabbit reticulocyte translation system supplemented with canine pancreatic microsomes under which the alpha and delta subunits of the nicotinic acetylcholine receptor (AChR) fold and assemble to form a heterodimer with a cholinergic binding site comparable with that found in the intact AChR. Folding of the alpha subunit was followed by its ability to bind alpha-bungarotoxin. Folding efficiency was highly sensitive to changes in the redox potential of the translation medium and was favored by an oxidizing environment. Acquisition of the toxin binding conformation required N-Linked core glycosylation but not oligosaccharide trimming, suggesting that oligosaccharide-dependent interaction of chaperones with the alpha subunit is not essential for correct subunit folding. The conformationally mature alpha subunit specifically associated with the delta subunit but not the beta subunit to form a heterodimer with a high affinity ligand-binding site. These data demonstrate, for the first time, correct folding and assembly of the AChR subunits in an in vitro system.	NIMH, CELL BIOL LAB, SECT SYNAPT MECH, BETHESDA, MD 20892 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of California System; University of California San Francisco								ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; BIJLMAKERS MJJE, 1994, EMBO J, V13, P2699, DOI 10.1002/j.1460-2075.1994.tb06560.x; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CHAVEZ R, 1992, THESIS U CALIFORNIA; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; KADERBHAI MA, 1985, EUR J BIOCHEM, V153, P167, DOI 10.1111/j.1432-1033.1985.tb09283.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MERLIE JP, 1981, J BIOL CHEM, V256, P3605; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OLSON EN, 1984, J BIOL CHEM, V259, P5364; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2633, DOI 10.1021/bi00357a052; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; SEBBANE R, 1983, J BIOL CHEM, V258, P3294; SINE SM, 1991, J BIOL CHEM, V266, P19369; SMITH MM, 1986, J BIOL CHEM, V261, P4825; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539	63	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25506	25514		10.1074/jbc.271.41.25506	http://dx.doi.org/10.1074/jbc.271.41.25506			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810322	hybrid			2022-12-25	WOS:A1996VL69300066
J	Wang, BL; Mysliwiec, T; Feller, SM; Knudsen, B; Hanafusa, H; Kruh, GD				Wang, BL; Mysliwiec, T; Feller, SM; Knudsen, B; Hanafusa, H; Kruh, GD			Proline-rich sequences mediate the interaction of the Arg protein tyrosine kinase with Crk	ONCOGENE			English	Article						Abl; myristoylation	SRC HOMOLOGY-3 DOMAIN; C-ABL; SH3 DOMAIN; CELL-CYCLE; BINDING; PHOSPHORYLATION; IDENTIFICATION; PRODUCT; GENE; LEUKEMIA	Arg is a ubiquitously expressed member of the Abelson family of nonreceptor protein-tyrosine kinases, Defining the Arg sequences that mediate its interaction with other proteins is essential to elucidating its role in cellular signaling, In this report we demonstrate that Arg associates with c-Crk, an adaptor protein composed of an SH2 domain and two SH3 domains, and examine the molecular mechanism of the interaction, In vitro experiments revealed that three proline-rich sequences with distinct specificities for SH3 domains are located in the Arg C-terminal domain, just C-terminal to the kinase domain, and that two of these sequences bind to the Crk N-terminal SH3 domain, These two sequences conform to the PsLPxK/R motif that has been observed in other proteins that bind the Crk N-terminal SH3 domain, The interaction of Arg with c-Crk in living cells was confirmed by the detection of coimmunoprecipitation in coinfected Sf9 cells, In addition, increased phosphorylation of c-Crk was observed in cotransfected COS cells, indicating that Crk is an Arg substrate, The site of c-Crk phosphorylation by Arg was identified as tyrosine 221, a residue whose modification has been shown to result in an intramolecular SH2 interaction and a folded conformation, These experiments extend the known Arg protein interacting motifs to include SH3 binding sites and suggest that Arg may function as an effector as well as a regulator of Crk activity.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; BAVARIAN JULIUS MAXIMILIANS UNIV, INST RADIOBIOL & CELL BIOL, WURZBURG, GERMANY; ROCKEFELLER UNIV, MOL ONCOL LAB, NEW YORK, NY 10021 USA	Fox Chase Cancer Center; University of Pennsylvania; University of Wurzburg; Rockefeller University					NCI NIH HHS [CA44356, CA60453-03S1, CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA060453, R01CA057273, R55CA057273, R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAEMMLI UK, 1968, MOL GEN GENET, V101, P333, DOI 10.1007/BF00436231; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORRIS JF, 1991, ONCOGENE, V6, P2339; Mysliwiec T, 1996, ONCOGENE, V12, P631; NICHOLS GL, 1994, BLOOD, V84, P2912; OGAWA S, 1994, ONCOGENE, V9, P1669; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PEREGO R, 1991, ONCOGENE, V6, P1899; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG B, IN PRESS ONCOGENE; Wang BL, 1996, ONCOGENE, V12, P1921; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	44	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1379	1385						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875975				2022-12-25	WOS:A1996VL38400002
J	Chiang, SY; Welch, JJ; Rauscher, FJ; Beerman, TA				Chiang, SY; Welch, JJ; Rauscher, FJ; Beerman, TA			Effect of DNA-binding drugs on early growth response factor-1 and TATA box-binding protein complex formation with the herpes simplex virus latency promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLURAMYCIN ANTITUMOR ANTIBIOTICS; MINOR-GROOVE; TRANSCRIPTION INITIATION; SEQUENCE SELECTIVITY; CHROMOMYCIN; DISTAMYCIN; MITHRAMYCIN; NOGALAMYCIN; SPECIFICITY; ACTIVATION	Adjacent binding sites for early growth response factor-1 (EGR1) and TATA box-binding protein (TBP) were identified on the herpes simplex virus latency promoter in previous work. The binding of EGR1 to the GC-rich region prevented TBP binding to the AT-rich region. With the simultaneous addition of both EGR1 and TBP, the intercalator nogalamycin prevented EGR1 complex formation, resulting in a dose-dependent increase of the TBP DNA complex. The minor groove binder chromomycin A(3) inhibited EGR1 complex formation but resulted in a smaller increase of the TBP complex. In contrast, an alkylating intercalator hedamycin strongly inhibited binding of both proteins. The ability of these GC-binding drugs to prevent EGR1 DNA complex formation was in the following order: hedamycin > nogalamycin > chro momycin A(3), and the specificity was nogalamycin > chromomycin A(3) > hedamycin, With transcription factor IIA (TFIIA) in the assay, TBP was able to bind the promoter whereas formation of the EGR1 DNA complex was reduced. An AT minor groove-binding drug, distamycin A(3) disrupted the TBP TFIIA DNA complex and restored the EGR1 DNA complex. We conclude that the binding motif and sequence preference of DNA-interactive drugs are manifested in their ability to inhibit the transcription factor-DNA complexes.	ROSWELL PK CANC INST,DEPT EXPT THERAPEUT,BUFFALO,NY 14263; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Roswell Park Cancer Institute; The Wistar Institute					NATIONAL CANCER INSTITUTE [P30CA010815, P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049210] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056, CA10815] Funding Source: Medline; NIDDK NIH HHS [DK49210] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEERMAN TA, 1991, DNA TOPOISOMERASES C, P172; BENNETT GN, 1982, NUCLEIC ACIDS RES, V10, P4581, DOI 10.1093/nar/10.15.4581; BROGGINI M, 1989, NUCLEIC ACIDS RES, V17, P1051, DOI 10.1093/nar/17.3.1051; BRUZIK JP, 1987, BIOCHEMISTRY-US, V26, P950, DOI 10.1021/bi00377a040; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; FOX KR, 1985, NUCLEIC ACIDS RES, V13, P8695, DOI 10.1093/nar/13.24.8695; GAO XL, 1990, BIOCHEMISTRY-US, V29, P10940, DOI 10.1021/bi00501a012; GAO XL, 1989, BIOCHEMISTRY-US, V28, P751, DOI 10.1021/bi00428a051; HANSEN M, 1995, J AM CHEM SOC, V117, P2421, DOI 10.1021/ja00114a006; JERNIGAN HM, 1978, BIOCHEMISTRY-US, V17, P4232, DOI 10.1021/bi00613a019; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIU CD, 1994, BIOCHEMISTRY-US, V33, P1419, DOI 10.1021/bi00172a019; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MCHUGH MM, 1989, BIOCHEM PHARMACOL, V38, P2323, DOI 10.1016/0006-2952(89)90472-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MORTENSEN UH, 1990, NUCLEIC ACIDS RES, V18, P1983, DOI 10.1093/nar/18.8.1983; PORTUGAL J, 1987, EUR J BIOCHEM, V167, P281, DOI 10.1111/j.1432-1033.1987.tb13334.x; PRAKASH AS, 1995, CHEM-BIOL INTERACT, V95, P17, DOI 10.1016/0009-2797(94)03341-2; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; SEARLE MS, 1988, BIOCHEMISTRY-US, V27, P4340, DOI 10.1021/bi00412a022; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STORL K, 1993, FEBS LETT, V317, P157, DOI 10.1016/0014-5793(93)81513-Y; STRANEY DC, 1987, BIOCHEMISTRY-US, V26, P1987, DOI 10.1021/bi00381a031; SUN DY, 1993, BIOCHEMISTRY-US, V32, P8068, DOI 10.1021/bi00083a003; SUN DY, 1995, CHEM BIOL, V2, P457, DOI 10.1016/1074-5521(95)90263-5; SYNDER R C, 1991, Biochemistry, V30, P4290; VANDYKE MW, 1983, BIOCHEMISTRY-US, V22, P2373, DOI 10.1021/bi00279a011; WARING MJ, 1981, ANNU REV BIOCHEM, V50, P159, DOI 10.1146/annurev.bi.50.070181.001111; WELCH JJ, 1994, J BIOL CHEM, V269, P31051; WICKMAN G, 1995, FEBS LETT, V360, P231, DOI 10.1016/0014-5793(95)00110-U; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225; WOYNAROWAKI JM, 1988, MOL PHARMACOL, V35, P177	36	32	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23999	24004		10.1074/jbc.271.39.23999	http://dx.doi.org/10.1074/jbc.271.39.23999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798634	hybrid			2022-12-25	WOS:A1996VJ44200063
J	McLure, KG; Lee, PWK				McLure, KG; Lee, PWK			A PAb240(+) conformation of wild type p53 binds DNA	ONCOGENE			English	Article						p53 conformation; DNA binding; PAb 240; dominant negative	2 CELLULAR PROTEINS; MUTANT P53; OLIGOMERIZATION DOMAIN; COMPLEXES; SITE; MODULATION; MUTATIONS	It is generally accepted that wild type (growth suppressing) p53 is capable of binding to a consensus DNA sequence and is in a conformation recognizable by antibody PAb246 (for murine p53), but not by antibody PAb240. Conversely, mutant forms of p53 incapable of DNA binding often assume conformations that display the PAb240, but not the PAb246 epitope, Exposure of these tao epitopes on p53 is therefore believed to be mutually exclusive, We show that mild type p53 translated in vitro in rabbit reticulocyte lysate (RRL) has a PAb240 epitope that is not always cryptic, even on p53 that is bound sequence-specifically to DNA (presumably as a tetramer), All of the DNA-bound, PAb240(+) p53 concurrently displays the PAb246 epitope, and both epitopes can be occupied by antibody while p53 is bound to DNA, This novel 'dual positive' conformation also exists in the absence of DNA and suggests that p53 is not necessarily inactive when the PAb240 epitope is displayed, When the C-terminal 58 amino acids of p53 containing the dimer/tetramerization domains are replaced with a heterologous dimerization domain, the resultant dimeric p53 manifests only the PAb246(+)/PAb240(-) conformation while bound to DNA, Thus, the C-terminal 58 amino acids of p53 are required for the PAb246(+)/PAb240(+) phenotype, possibly due to tetramerization, This novel (dual positive' p53 conformation exists in an excess of wild type p53 that has the PAb246(-)/PAb240(+) 'mutant' conformation, suggesting that the 'mutant' conformation is not dominant negative in and of itself.	UNIV CALGARY,HLTH SCI CTR,CANC BIOL RES GRP,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,HLTH SCI CTR,DEPT MICROBIOL & INFECT DIS,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba								CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHODOSH LA, 1991, CURRENT PROTOCOLS MO; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P553; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FREIDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1994, ONCOGENE, V9, P299; HAINAUT P, 1992, EMBO J, V11, P3515; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	32	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1297	1303						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808704				2022-12-25	WOS:A1996VJ20200021
J	SanchezPrieto, R; Quintanilla, M; Cano, A; Lleonart, M; Martin, P; Anaya, A; Cajal, SR				SanchezPrieto, R; Quintanilla, M; Cano, A; Lleonart, M; Martin, P; Anaya, A; Cajal, SR			Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene	ONCOGENE			English	Article						carcinoma cell lines; adenovirus E1a; drug resistance; apoptosis; p53	P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; IONIZING-RADIATION; P53-INDEPENDENT MECHANISMS; CLINICAL IMPLICATIONS; DIFFERENT ONCOGENES; INDUCE APOPTOSIS; CANCER-THERAPY; PROTEIN	Squamous cell carcinomas can show different oncogenic alterations, histological patterns, and an unpredictable clinical behavior, We previously reported that the adenovirus E1a gene may induce sensitivity to DNA-damaging agents in mouse keratinocytes. In order to study whether E1a expression could be used as a therapeutic agent in different malignant cell lines carrying mutations on the p53 gene and other oncogenic alterations, we transfected and infected several murine and human carcinoma cell lines (HaCa4; MSC11A5; HeLa) with vectors containing the 13S or 12S E1a region, We evaluated the sensitivity to cisplatin (CDDP), doxorubicin (DOX) and gamma irradiation (RX) by the crystal violet method, The induction of apoptosis was assessed by flow cytometry and presence of DNA ladders in agarose gels, The expression of E1a and the tumor suppressor p53 protein was analysed by Western blotting, The carcinoma cell lines expressing E1a were about four- to ten-fold more sensitive to CDDP and RX, respectively, than the control cells, Moreover, the reduction in cell viability and cell growth after exposure to CDDP or RX was very significant in the carcinoma cells expressing E1a, With these results, we conclude that expression of E1a may confer great sensitivity to DNA-damaging agents on squamous cell carcinoma cells independently of the p53 protein status and other oncogenic alterations.	CLIN PUERTA HIERRO,DEPT PATOL,E-28035 MADRID,SPAIN; CSIC,INST INVEST BIOMED,MADRID,SPAIN	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Espinosas, Maribel/H-8083-2012; Sanchez-Prieto, Ricardo/B-6877-2008; Prieto, Ricardo/AAZ-7221-2021; Quintanilla, Miguel/K-9293-2017; Sanchez-Prieto, Ricardo/AAY-4271-2021; LLeonart, Matilde E./Q-2662-2019; Ramon y Cajal, Santiago/H-4955-2016	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; LLeonart, Matilde E./0000-0002-6196-7405; Ramon y Cajal, Santiago/0000-0002-3867-1390				AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BARBEAU D, 1994, ONCOGENE, V9, P359; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BURNS PA, 1991, ONCOGENE, V6, P2363; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARUSO M, 1993, ONCOGENE, V8, P267; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1990, ONCOGENE, V5, P75; FRITSCHE M, 1993, ONCOGENE, V8, P307; FURIHATA M, 1995, INT J ONCOL, V6, P1209; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HAVRE PA, 1995, CANCER RES, V55, P4420; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HUNTER T, 1994, CELL, V79, P547; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARCHETTI E, 1994, INT J ONCOL, V5, P611; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P1295; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAULES RS, 1995, CANCER RES, V55, P1763; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAMON, 1995, HISTOL HISTOPATHOL, V10, P811; RAMON, 1991, AM J PATHOL, V138, P349; RAMON, 1994, AM J PATHOL, V145, P846; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SANCHEZPRIETO R, 1995, ONCOL REP, V2, P457; SANCHEZPRIETO R, 1995, INT J CANCER, V60, P235; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TATSUKA M, 1989, MUTAT RES, V214, P321; TEODORO JG, 1995, ONCOGENE, V11, P467; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE P, 1989, CELL, V45, P67; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG YJ, 1995, ONCOGENE, V10, P1947	68	90	95	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1083	1092						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806698				2022-12-25	WOS:A1996VG76600022
J	Clotet, J; Posas, F; deNadal, E; Arino, J				Clotet, J; Posas, F; deNadal, E; Arino, J			The NH2-terminal extension of protein phosphatase PPZ1 has an essential functional role	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; SALT TOLERANCE; GENE; MYRISTOYLATION; CALCINEURIN; EXPRESSION; ISOFORMS; SUBUNIT; CELLS	Deletion of the yeast Ser/Thr protein phosphatase PPZ1 results in increased tolerance to sodium and Lithium. PPZ1 is also important for cell integrity, as ppz1 Delta cells undergo lysis under caffeine stress and PPZ1 over-expression overrides the lytic defect of mutants in the protein kinase C/mitogen-activated protein (MAP) kinase pathway. The PPZ1 protein can be dissected in two halves. The COOH-terminal half is related to type 1 phosphatases, whereas the NH2-terminal half is unrelated to phosphatases and contains a consensus site for N-myristoylation. Several mutated versions of PPZ1 have been constructed and tested for complementation of ppz1 Delta mutants. me show that PPZ1 can be myristoylated in vivo and that change of Gly-2 to Ala results in lack of myristoylation and loss of complementation of salt tolerance, Removal of the entire NH2-terminal half results in complete loss of function, although it does not abolish the phosphatase activity of the protein expressed in Escherichia coli. The deletion of a large region of the NH2-terminal half (residues 17-193) does not affect the ability to complement the salt tolerance phenotype but abolish complementation of caffeine sensitivity, whereas the opposite behavior is observed upon removal of residues from 241 to 318. Mutation of Arg-451 to Leu results in both complete loss of function and of phosphatase activity. These results indicates that the NH2-terminal half of the protein contains structural determinants that are specific for certain functions and that the phosphatase activity is required but not sufficient for full PPZ1 function.	UNIV AUTONOMA BARCELONA,FAC VET,DEPT BIOQUIM & BIOL MOL,BELLATERRA 08193,BARCELONA,SPAIN	Autonomous University of Barcelona			Arino, Joaquin/D-3756-2011; de Nadal, Eulàlia/J-8178-2014; Posas, Francesc/K-1364-2013	Arino, Joaquin/0000-0002-6774-2987; de Nadal, Eulàlia/0000-0003-0039-5607; Posas, Francesc/0000-0002-4164-7076; Arino Carmona, Joaquin/0000-0002-0390-4270				BLACK S, 1995, YEAST, V11, P747, DOI 10.1002/yea.320110806; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; CANNON JF, 1995, ADV PROTEIN PHOSPHAT, V9, P211; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1993, ADV PROTEIN PHOSPHAT, V7, P429; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HUGHES V, 1993, EUR J BIOCHEM, V216, P269, DOI 10.1111/j.1432-1033.1993.tb18142.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENNY TF, 1995, PROTEINS, V21, P1, DOI 10.1002/prot.340210102; JOHNSON DR, 1994, P NATL ACAD SCI USA, V91, P10158, DOI 10.1073/pnas.91.21.10158; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LIU HP, 1992, GENETICS, V132, P665; LOHR D, 1988, YEAST PRACTICAL APPR, P125; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; POSAS F, 1993, FEBS LETT, V318, P282, DOI 10.1016/0014-5793(93)80529-4; POSAS F, 1995, FEBS LETT, V368, P39, DOI 10.1016/0014-5793(95)00593-X; POSAS F, 1992, J BIOL CHEM, V267, P11734; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	39	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26349	26355		10.1074/jbc.271.42.26349	http://dx.doi.org/10.1074/jbc.271.42.26349			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824289	hybrid			2022-12-25	WOS:A1996VN18000095
J	Heiska, L; Kantor, C; Parr, T; Critchley, DR; Vilja, P; Gahmberg, CG; Carpen, O				Heiska, L; Kantor, C; Parr, T; Critchley, DR; Vilja, P; Gahmberg, CG; Carpen, O			Binding of the cytoplasmic domain of intercellular adhesion molecule-2 (ICAM-2) to alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; CYTOSKELETAL PROTEINS; MEMBRANE INTERACTIONS; LFA-1; VINCULIN; CELL; EXPRESSION; CLONING; LIGAND; GLYCOPROTEIN	Intercellular adhesion molecule-2 (ICAM-2) functions as a ligand for lymphocyte function-associated antigen-1 (LFA-1) and is involved in leukocyte adhesion, We studied intracellular associations of ICAM-2 using a peptide encompassing the cytoplasmic amino acids 231-254 as an affinity matrix, Among the proteins from placental lysates that bound to the peptide was alpha-actinin as demonstrated by immunoblotting. Purified, I-125-labeled alpha-actinin also bound to the peptide. Confocal microscopic analysis of Eahy926 cells demonstrated a colocalization of ICAM-2 and alpha-actinin. Of overlapping octapeptides covering the entire ICAM-2 cytoplasmic amino acids, ICAM-2(241-248) bound alpha-actinin most avidly and effectively competed with the longer cytoplasmic peptide for binding. The site of interaction in alpha-actinin was studied using bacterially expressed alpha-actinin fusion proteins, Several constructs covering nonoverlapping regions of alpha-actinin bound to the ICAM-2 cytoplasmic peptide suggesting that multiple regions in alpha-actinin can mediate the interaction, These results, together with previously demonstrated interactions between alpha-actinin and the adhesion proteins ICARS-1, L-selectin, beta(1)- and beta(2)-integrins emphasize the role of alpha-actinin as a linker between cell surface adhesion molecules and the actin containing cytoskeleton.	UNIV HELSINKI,DEPT BIOSCI,DIV BIOCHEM,FIN-00014 HELSINKI,FINLAND; UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV TAMPERE,SCH MED,FIN-33101 TAMPERE,FINLAND	University of Helsinki; University of Leicester; Tampere University	Heiska, L (corresponding author), UNIV HELSINKI,DEPT PATHOL,DIV BIOCHEM,HAARTMANINK 3,POB 21,FIN-00014 HELSINKI,FINLAND.		Gahmberg, Carl/AAE-1876-2019	Gahmberg, Carl/0000-0001-9892-9296				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAILLY P, 1994, P NATL ACAD SCI USA, V91, P5306, DOI 10.1073/pnas.91.12.5306; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CARPEN O, 1991, J CELL BIOL, V115, P861, DOI 10.1083/jcb.115.3.861; CARPEN O, 1983, J IMMUNOL, V131, P2695; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Gilmore A. P., 1994, Molecular Biology of the Cell, V5, p45A; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GILMORE AP, 1994, EUR J BIOCHEM, V225, P235, DOI 10.1111/j.1432-1033.1994.00235.x; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; NORTAMO P, 1991, J IMMUNOL, V146, P2530; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; RENKONEN R, 1992, AM J PATHOL, V140, P763; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; YOSHIHARA Y, 1994, NEURON, V12, P541, DOI 10.1016/0896-6273(94)90211-9	38	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26214	26219		10.1074/jbc.271.42.26214	http://dx.doi.org/10.1074/jbc.271.42.26214			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824270	hybrid			2022-12-25	WOS:A1996VN18000076
J	Kan, M; Wang, F; Kan, M; To, B; Gabriel, JL; McKeehan, WL				Kan, M; Wang, F; Kan, M; To, B; Gabriel, JL; McKeehan, WL			Divalent cations and heparin/heparan sulfate cooperate to control assembly and activity of the fibroblast growth factor receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; CELL-ADHESION; LIGAND-BINDING; ACTIVATION; AFFINITY; KINASE; FGF; IDENTIFICATION; MECHANISM; PROTECTS	Polypeptides of the fibroblast growth factor (FGF) family are ubiquitous bioregulators within tissues whose activity is controlled by heparan sulfates within the pericellular matrix. FGF and the ectodomain of their transmembrane tyrosine kinase receptors (FGFR) exhibit heparin-binding domains that when juxtaposed in a FGF . FGFR complex can accommodate a single, potentially bivalent, decameric polysaccharide chain in a ternary complex. Here we show that the interaction of heparin with FGF ligands is not affected by divalent cations. In contrast, the high affinity interaction (apparent K-d = 10 nM) Of heparin with FGFR requires Ca2+ or Mg2+ at physiological concentrations. Divalent cations maintain FGFR in a heparan sulfate-dependent state in respect to FGF binding and an FGF- and heparan sulfate-dependent state in respect to autophosphorylation. A model is proposed where divalent cations and heparan sulfate cooperate to maintain FGFR in a conformation that restricts trans-phosphorylation between intracellular kinase domains. The restriction is overcome by FGF or constitutively as a common consequence of diverse mutations in FGFR associated with skeletal and craniofacial abnormalities.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, CTR CANC BIOL & NUTR, HOUSTON, TX 77030 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Texas A&M University System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK47039, DK35310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICKMAN YG, 1995, J BIOL CHEM, V270, P24941, DOI 10.1074/jbc.270.42.24941; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HOU JZ, 1992, J BIOL CHEM, V267, P17804; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LUO Y, 1996, IN PRESS J BIOL CHEM, V271; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Matsuzaki K, 1996, IN VITRO CELL DEV-AN, V32, P345, DOI 10.1007/BF02722961; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Patstone G, 1996, J BIOL CHEM, V271, P3343; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Wang F., 1995, Molecular Biology of the Cell, V6, p123A; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; XU JM, 1992, J BIOL CHEM, V267, P17792; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	43	89	97	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26143	26148		10.1074/jbc.271.42.26143	http://dx.doi.org/10.1074/jbc.271.42.26143			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824259	hybrid			2022-12-25	WOS:A1996VN18000065
J	Krishna, MC; Russo, A; Mitchell, JB; Goldstein, S; Dafni, H; Samuni, A				Krishna, MC; Russo, A; Mitchell, JB; Goldstein, S; Dafni, H; Samuni, A			Do nitroxide antioxidants act as scavengers of O-2(.-) or as SOD mimics?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE ACTIVITY; HYDROGEN-PEROXIDE; CYTOCHROME-C; PHARMACOKINETIC PROPERTIES; POLYETHYLENE-GLYCOL; OXIDATIVE DAMAGE; ANION; DESFERRIOXAMINE; CARDIOMYOCYTES; COMPLEXES	Stable nitroxide radicals were reported to act as SOD mimics and catalyze the dismutation of O-2-radical-anion through two different catalytic pathways including reducive and oxidative reaction mechanisms (Samuni, A., Krishna, C. M., Riesz, P., Finkelstein, E, & Russo, A. (1988) J. Biol Chem. 263, 17921-17924). Recent studies directly monitoring O-2-radical-anion and employing kinetics analysis did not reveal SOD activity of nitroxides (Weiss, R. H., Flickinger, A. G., Rivers, W. J., Hardy, M. M., Aston, K. W., Ryan, U. S. & Riley, D. P. (1993) J. Biol. Chen. 268, 23049-23054). Such discrepancy may result in cases where distinction of stoichiometric scavengers from catalytic detoxifiers of O-2-radical-anion is not readily feasible. Nitroxides are effective antioxidants that protect against oxidative injury in various pathological processes. The distinction of their SOD mimic activity from O-2-radical-anion scavenging was established by examining the validity of direct and indirect methods employed to assay SOD-like catalytic activity. Kinetics analysis along with direct EPR monitoring were used to study the mechanism underlying nitroxide reactions with O-2-radical-anion. The nitroxide EPR signal decayed in the presence of NADH but otherwise did not decrease with time, thus substantiating its catalytic role in O-2-radical-anion dismutation. The catalytic rate constants for O-2-radical-anion dismutation, determined for the nitroxides tested, were found to increase with [H+], indicating that (OOH)-O-. rather than O-2-radical-anion is oxidizing the nitroxide. The results demonstrate the limitations associated with direct kinetics analysis in evaluating SOD mimic activity, underscoring the need for independent assays for valid discrimination of SOD mimics from stoichiometric scavengers of O-2-radical-anion.	HEBREW UNIV JERUSALEM, DEPT MOL BIOL, IL-91120 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, DEPT PHYS CHEM, IL-91120 JERUSALEM, ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem			Dafni, Hagit/I-1873-2019					BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BEYER WF, 1989, ARCH BIOCHEM BIOPHYS, V271, P149, DOI 10.1016/0003-9861(89)90265-8; BOCCU E, 1982, PHARMACOL RES COMMUN, V14, P113, DOI 10.1016/S0031-6989(82)80092-1; BRAWN K, 1980, ACTA PHYSIOL SCAND, P9; BRIGELIUS R, 1975, H-S Z PHYSIOL CHEM, V356, P739, DOI 10.1515/bchm2.1975.356.s1.739; BUTLER J, 1975, BIOCHIM BIOPHYS ACTA, V408, P215, DOI 10.1016/0005-2728(75)90124-3; BUTLER J, 1982, J BIOL CHEM, V257, P747; Czapski G, 1988, Free Radic Res Commun, V4, P231, DOI 10.3109/10715768809055147; DARR D, 1987, ARCH BIOCHEM BIOPHYS, V258, P351, DOI 10.1016/0003-9861(87)90354-7; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GOLDFRIED MR, 1991, J PSYCHOTHERAPY INTE, V1, P5; GOLDSTEIN S, 1988, FREE RADICAL BIO MED, V4, P295, DOI 10.1016/0891-5849(88)90050-0; GOLDSTEIN S, 1986, Journal of Free Radicals in Biology and Medicine, V2, P3, DOI 10.1016/0748-5514(86)90117-0; HAHN SM, 1991, ARCH BIOCHEM BIOPHYS, V288, P215, DOI 10.1016/0003-9861(91)90186-M; HUBER KR, 1987, BIOCHIM BIOPHYS ACTA, V915, P267, DOI 10.1016/0167-4838(87)90309-8; KOPPENOL WH, 1986, ARCH BIOCHEM BIOPHYS, V251, P594, DOI 10.1016/0003-9861(86)90368-1; KORCHERGINSKI N, 1995, NITROXIDE SPIN LABEL, P27; KRISHNA MC, 1994, METHOD ENZYMOL, V234, P580; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; Krishna MC, 1996, J BIOL CHEM, V271, P26018, DOI 10.1074/jbc.271.42.26018; LENGFELDER E, 1978, H-S Z PHYSIOL CHEM, V359, P751; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MIURA Y, 1993, ARCH BIOCHEM BIOPHYS, V300, P148, DOI 10.1006/abbi.1993.1021; MOHSEN M, 1995, MOL CELL BIOCHEM, V145, P103, DOI 10.1007/BF00935482; NAGANO T, 1989, J BIOL CHEM, V264, P9243; RABINOWITCH HD, 1989, FREE RADICAL BIO MED, V6, P45, DOI 10.1016/0891-5849(89)90158-5; RACHMILEWITZ D, 1994, GUT, V35, P1181, DOI 10.1136/gut.35.9.1181; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; ROBERTSON P, 1980, ARCH BIOCHEM BIOPHYS, V203, P830, DOI 10.1016/0003-9861(80)90246-5; SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; SAMUNI A, 1990, ADV EXP MED BIOL, V264, P85; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; TURRENS JF, 1988, FEBS LETT, V227, P43, DOI 10.1016/0014-5793(88)81410-8; VERONESE FM, 1983, J PHARM PHARMACOL, V35, P757, DOI 10.1111/j.2042-7158.1983.tb02888.x; WEISS RH, 1993, J BIOL CHEM, V268, P23049; WESER U, 1980, BIOCHIM BIOPHYS ACTA, V631, P232, DOI 10.1016/0304-4165(80)90298-6	41	328	344	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26026	26031		10.1074/jbc.271.42.26026	http://dx.doi.org/10.1074/jbc.271.42.26026			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824242				2022-12-25	WOS:A1996VN18000048
J	Himanen, JP; Mirza, UA; Chait, BT; Bookchin, RM; Manning, JM				Himanen, JP; Mirza, UA; Chait, BT; Bookchin, RM; Manning, JM			A recombinant sickle hemoglobin triple mutant with independent inhibitory effects on polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; YEAST; SITE; CYANATE; LYSINE	As part of a comprehensive effort to map the most important regions of sickle hemoglobin that are involved in polymerization, we have determined whether two sites previously shown to be involved, Leu-88(beta) and Lys-95(beta), had additive effects when substituted. The former site is part of the hydrophobic pocket that binds Val-6(beta), the natural mutation of HbS, and the latter site is a prominent part of the hemoglobin exterior. A sickle hemoglobin triple mutant with three amino acid substitutions on the beta-chain, E6V/L88A/K95I, has been expressed in yeast and characterized extensively. Its oxygen binding curve, cooperativity, response to allosteric effecters, and the alkaline Bohr effect showed that it was completely functional. The polymer solubility of the deoxy triple mutant, measured by a new micromethod requiring reduced amounts of hemoglobin, was identical to that of the E6V(beta)/K95I(beta) mutant, i.e. when the K95I(beta) substitution was present on the same tetramer together with the naturally occurring E6V(beta) substitution, the L88A(beta) replacement had no additive effect on polymer inhibition. The results suggest that Lys-95(beta) on the surface of the tetramer and its complementary binding region on the adjoining tetramer are potential targets for the design of an effective antisickling agent.	NORTHEASTERN UNIV, DEPT BIOL, BOSTON, MA 02115 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	Northeastern University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018819, R01HL028018, R37HL018819] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28018, HL-18819] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1545; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BOOKCHIN RM, 1994, BLOOD, V86, pA473; BOOKCHIN RM, 1974, CLIN RES, V22, pA384; CERAMI A, 1971, P NATL ACAD SCI USA, V68, P1180, DOI 10.1073/pnas.68.6.1180; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; DELLANO JJM, 1994, PROTEIN SCI, V3, P1206, DOI 10.1002/pro.5560030806; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P133; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; Eaton William A., 1994, P53; EDELSTEIN SJ, 1979, J MOL BIOL, V134, P851, DOI 10.1016/0022-2836(79)90491-1; FORSEN S, 1995, TRENDS BIOCHEM SCI, V20, P495, DOI 10.1016/S0968-0004(00)89115-X; HERNAN RA, 1995, J BIOL CHEM, V270, P26257, DOI 10.1074/jbc.270.44.26257; HIMANEN JP, 1995, J BIOL CHEM, V270, P13885, DOI 10.1074/jbc.270.23.13885; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Liao D, 1996, BIOPHYS J, V70, P2442, DOI 10.1016/S0006-3495(96)79815-6; Manning J M, 1981, Methods Enzymol, V76, P159; MANNING JM, 1991, ADV ENZYMOL RAMB, V64, P55; Manning LR, 1996, PROTEIN SCI, V5, P775; Nagel R. L., 1978, BIOCH CLIN ASPECTS H, P195; NAGEL RL, 1974, SICKLE CELL ANEMIA O, P51; NJIKAM N, 1973, J BIOL CHEM, V248, P8052; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; ROSS PD, 1978, BIOCH CLIN ASPECTS H, P629; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; YANASE H, 1994, PROTEIN SCI, V3, P1213, DOI 10.1002/pro.5560030807	34	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25152	25156		10.1074/jbc.271.41.25152	http://dx.doi.org/10.1074/jbc.271.41.25152			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810271	hybrid, Green Submitted			2022-12-25	WOS:A1996VL69300015
J	Ohnishi, H; Kubota, R; Ohtake, A; Sato, K; Sano, SI				Ohnishi, H; Kubota, R; Ohtake, A; Sato, K; Sano, SI			Activation of protein-tyrosine phosphatase SH-PTP2 by a tyrosine-based activation motif of a novel brain molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; CELL ANTIGEN RECEPTOR; SH2 DOMAINS; SIGNAL TRANSDUCTION; SEQUENCE SIMILARITY; CONTAINING PEPTIDES; SYP PHOSPHATASE; KINASE; INSULIN	BIT (a brain Immunoglobulin-like molecule with tyrosine-based activation motifs) is a brain-specific membrane protein which has two cytoplasmic TAMs (tyrosine-based activation motifs). Using the Far Western blotting technique, we detected association of a 70-kDa protein with the tyrosine-phosphorylated TAMs of BIT. A mouse brain cDNA library in lambda gt11 was screened for this association, and two positive clones encoding tyrosine phosphatase SH-PTP2 were isolated. SH-PTP2 has two SH2 domains and is believed to function as a positive mediator in receptor tyrosine kinase signaling. SH-PTP2 and BIT were coimmunoprecipitated from phosphorylated rat brain lysate, and BIT was a major tyrosine-phosphorylated protein associated with SH-PTP2 in this lysate. This interaction was also observed in Jurkat T cells transfected with BIT cDNA depending on tyrosine phosphorylation of BIT. Bisphosphotyrosyl peptides corresponding to BIT-TAMs stimulated SH-PTP2 activity 33-35-fold in vitro, indicating that two SH2 domains of SH-PTP2 simultaneously interact with two phosphotyrosines of BIT-TAM. Our findings suggest that the tyrosine phosphorylation of BIT results in stimulation of the signal transduction pathway promoted by SH-PTP2 and that BIT is probably a major receptor molecule in the brain located just upstream of SH-PTP2.	MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN									ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CELENZA JL, 1991, METHOD ENZYMOL, V200, P423; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PENG ZY, 1995, ONCOGENE, V11, P1955; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANO S, 1989, J BIOCHEM-TOKYO, V105, P457, DOI 10.1093/oxfordjournals.jbchem.a122686; SANO S, 1990, J NEUROCHEM, V55, P1252, DOI 10.1111/j.1471-4159.1990.tb03132.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V211, P950, DOI 10.1006/bbrc.1995.1904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YAGI T, 1994, DEV GROWTH DIFFER, V36, P543; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	46	88	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25569	25574		10.1074/jbc.271.41.25569	http://dx.doi.org/10.1074/jbc.271.41.25569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810330	hybrid			2022-12-25	WOS:A1996VL69300074
J	Minnick, DT; Astatke, M; Joyce, CM; Kunkel, TA				Minnick, DT; Astatke, M; Joyce, CM; Kunkel, TA			A thumb subdomain mutant of the large fragment of Escherichia coli DNA polymerase I with reduced DNA binding affinity, processivity, and frameshift fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE; KLENOW FRAGMENT; TEMPLATE-PRIMER; BETA; MISALIGNMENT; MECHANISM; IDENTIFICATION; TERMINATION; REPLICATION	In Klenow fragment DNA polymerase, a flexible 50-amino acid subdomain at the tip of the thumb which includes two alpha helices has been suggested to interact with the duplex template-primer (Beese, L.S., Derbyshire, V. and Steitz, T.A. (1993) Science 260, 352-355). The present study investigates the properties of Klenow polymerase containing a 24-amino acid deletion (residues 590-613) that removes a portion of the tip of the thumb. The mutant polymerase has relatively normal dNTP binding and catalytic rate. However, its DNA binding affinity is reduced by more than 100-fold relative to the intact polymerase and its ability to conduct processive synthesis is also reduced, Although the mutant polymerase has relatively normal base substitution fidelity, it has strongly reduced frameshift fidelity, being especially error-prone for single nucleotide addition errors in homopolymeric runs. The addition error rateincreases as the length of the reiterated sequence increases, indicative of errors initiated by template-primer strand slippage. These observations suggest a role for the tip of the thumb of Klenow polymerase in determining DNA binding, processivity and frameshift fidelity, perhaps by tracking the minor groove of the duplex DNA. The results are discussed in light of remarkably similar observations with T7 DNA polymerase in the presence or absence of thioredoxin, an accessory subunit that affects these same properties.	NIEHS,MOL GENET LAB,NIH,RES TRIANGLE PK,NC 27709; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Yale University			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; ASTATKE M, 1995, J BIOL CHEM, V269, P28091; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEBENEK K, 1989, J BIOL CHEM, V264, P16498; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P813; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ECKERT KA, 1993, J BIOL CHEM, V268, P13462; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P8759, DOI 10.1021/bi00100a007; HIMAWAN JS, 1992, P NATL ACAD SCI USA, V89, P9774, DOI 10.1073/pnas.89.20.9774; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; JOYCE CM, 1995, P NATL ACAD SCI USA, V262, P3; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SOUSA R, 1994, NATURE, V264, P593; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014	45	71	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24954	24961		10.1074/jbc.271.40.24954	http://dx.doi.org/10.1074/jbc.271.40.24954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798775	hybrid			2022-12-25	WOS:A1996VM67400098
J	Yamazaki, H; Bujo, H; Kusunoki, J; Seimiya, K; Kanaki, T; Morisaki, N; Schneider, WJ; Saito, Y				Yamazaki, H; Bujo, H; Kusunoki, J; Seimiya, K; Kanaki, T; Morisaki, N; Schneider, WJ; Saito, Y			Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; CHICKEN OOCYTE RECEPTOR; EPIDERMAL GROWTH-FACTOR; AMINO-ACID SEQUENCE; LDL-RECEPTOR; CELL-ADHESION; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEIN; INTERNALIZATION SIGNAL; APOLIPOPROTEIN-E	Normal cell development depends to a large part on multifunctional proteins that have evolved by recombination of proven modular elements. We now have discovered and characterized in rabbit such a multi-domain protein, and classify it as novel member of the low density lipoprotein (LDL) receptor gene family. The extracellular portion of the similar to-250-kDa membrane protein, termed LR11, contains a cluster of 11 LDL receptor ligand binding repeats, a group of 5 LDL receptor ''YWTD'' repeats, a large hexarepeat domain of structural elements found in neural cell adhesion molecules, and a domain with similarity to a yeast receptor for vacuolar protein sorting, VPS10. The cytoplasmic domain exhibits features typical of endocytosis-competent coated-pit receptors. The mosaic, and presumably multifunctional, receptor is expressed abundantly in brain, in particular the hippocampus, dentate gyrus, and cerebral cortex, and is present at significant levels in liver, adrenal glands, and testis. Western blotting of tissues and ligand blotting of LR11-transfected cells demonstrated that the novel protein binds apolipoprotein E-containing lipoproteins. In contrast to the LDL receptor, hepatic expression of LR11 is unaffected by hyperlipidemia. The identification of this highly conserved and superbly complex protein offers the opportunity to gain new insights into the emergence of multifunctional mosaic proteins akin to the ever expanding LDL receptor gene family.	KOWA CO LTD,KOWA RES INST,HIGASHIMURAYAMA,TOKYO 189,JAPAN; UNIV VIENNA,A-1030 VIENNA,AUSTRIA; BIOCTR,DEPT MOL GENET,A-1030 VIENNA,AUSTRIA	Kowa Company, Ltd.; University of Vienna	Yamazaki, H (corresponding author), CHIBA UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,1-8-1 INOHANA,CHIBA 260,JAPAN.							BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUJO H, 1995, P NATL ACAD SCI USA, V92, P9905, DOI 10.1073/pnas.92.21.9905; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; Goridis C, 1992, Semin Cell Biol, V3, P189; HAEFLIGER JA, 1987, BIOCHEMISTRY-US, V26, P3551, DOI 10.1021/bi00386a045; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; HUETTINGER M, 1984, P NATL ACAD SCI-BIOL, V81, P7599, DOI 10.1073/pnas.81.23.7599; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEG PA, 1989, NUCLEIC ACIDS RES, V17, P10321, DOI 10.1093/nar/17.24.10321; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PITAS RE, 1987, J BIOL CHEM, V262, P14352; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; Sambrook J., 2002, MOL CLONING LAB MANU; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; SPEELMAN BA, 1995, J BIOL CHEM, V270, P1583, DOI 10.1074/jbc.270.4.1583; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WESSEL GM, 1995, DEV BIOL, V167, P388, DOI 10.1006/dbio.1995.1033; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572	75	177	186	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24761	24768		10.1074/jbc.271.40.24761	http://dx.doi.org/10.1074/jbc.271.40.24761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798746	hybrid			2022-12-25	WOS:A1996VM67400068
J	Knippschild, U; Milne, D; Campbell, L; Meek, D				Knippschild, U; Milne, D; Campbell, L; Meek, D			p53 N-terminus-targeted protein kinase activity is stimulated in response to wild type p53 and DNA damage	ONCOGENE			English	Article						p53; DNA damage; protein kinase	TEMPERATURE-SENSITIVE MUTANT; GENE AMPLIFICATION; SARCOMA-CELLS; MOUSE P53; 3T3 CELLS; PHOSPHORYLATION; ANTIGEN; RADIATION; METH; UV	The p53 tumour suppressor protein plays a central role in the cellular defence against agents which cause genetic damage, The activity of p53 is regulated at different levels and is subject to multi-site phosphorylation by a variety of different protein kinases. In this paper me have characterised p53 N-terminus-targeted protein kinase (p53NK) activities, present in a range of cell lines, following fractionation of cellular lysates by ion exchange chromatography on HiTrap Q and Mono Q resins, Three peaks of p53NK activity were observed following fractionation of HeLa cell lysates; these activities were each able to catalyse phosphorylation of up to three residues (serines 4, 6 and 9 in murine p53) within the N-terminus of the p53 protein, Similarly, multiple p53NK activities were detected in the MethAp53(ts) cell line (which expresses the valine 135 temperature-sensitive p53 protein), Strikingly, when these cells were shifted from 38 degrees C (the non-permissive temperature) to 28 degrees C, at which the p53 adopts a mild type conformation, a fivefold stimulation of kinase activity was detected, Moreover, when the DNA damage-inducing drugs etoposide or camptothecin were added to the cells, a further stimulation of kinase activity was observed following growth at 28 degrees C, but not 38 degrees C, These data are consistent with a regulatory model in which p53 is sensitive to stress or DNA damage through phosphorylation at its N-terminus.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND	University of Dundee								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELIYAHU D, 1988, ONCOGENE, V3, P313; GANNON JV, 1991, NATURE, V349, P802; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OTTO A, 1993, ONCOGENE, V8, P2591; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SOUSSI T, 1990, ONCOGENE, V5, P945; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	35	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1387	1393						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875976				2022-12-25	WOS:A1996VL38400003
J	Yenush, L; Makati, KJ; SmithHall, J; Ishibashi, O; Myers, MG; White, MF				Yenush, L; Makati, KJ; SmithHall, J; Ishibashi, O; Myers, MG; White, MF			The pleckstrin homology domain is the principle link between insulin receptor and IRS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; NPEY MOTIF; SUBSTRATE-1; BINDING; SHC; PROTEINS; PATHWAYS	Interaction domains located in the NH2 terminus of IRS-1 mediate its recognition by the insulin receptor. Alignment of IRS-1 and IRS-S reveals two homology regions: the IH1(PH) contains a pleckstrin homology (PH) domain, and the IH2(PTB) contains a phosphotyrosine binding (PTB) domain. A third region in IRS-1 called SAIN was proposed to contain another functional PTB domain. Peptide competition experiments demonstrated that the IH2(PTB) in IRS-2, like the corresponding domain in IRS-1, binds directly to peptides containing NPXY motifs. In contrast, these peptides do not bind to IH1(PH) or the SAIN regions. In 32D cells the IH1(PH) was essential for insulin-stimulated tyrosine phosphorylation of IRS-1 and insulin-stimulated phosphatidylinositol 3-kinase activity and p70(s6k) phosphorylation. In contrast, the IH2(PTB) and the SAIN regions were not required for these insulin actions; however, the IH2(PTB) improved the coupling between IRS-1 and the insulin receptor. Overexpression of the insulin receptor in 32D(IR) cells increased IRS-1 tyrosine phosphorylation and mediated insulin-stimulated DNA synthesis. The sensitivity of these responses was partially reduced by deletion of either the IH1(PH) or the IH2(PTB) and significantly reduced when both regions were deleted together. Thus, the PH and PTB domains equally couple IRS-1 to high levels of insulin receptor normally expressed in most cells, whereas at low levels of insulin receptors the PTB domain is inefficient and the PH domain is essential for a productive interaction.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Yenush, Lynne/J-8815-2014	Yenush, Lynne/0000-0001-8589-7002	NIDDK NIH HHS [DK43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRISCOE J, 1994, CURR BIOL, V4, P1033, DOI 10.1016/S0960-9822(00)00236-0; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FEENER EP, 1993, J BIOL CHEM, V268, P11256; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; WANG LM, 1995, BLOOD, V86, P4218, DOI 10.1182/blood.V86.11.4218.bloodjournal86114218; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yenush L, 1996, MOL CELL BIOL, V16, P2509; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	41	136	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24300	24306		10.1074/jbc.271.39.24300	http://dx.doi.org/10.1074/jbc.271.39.24300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798677	hybrid			2022-12-25	WOS:A1996VJ44200106
J	Maier, JAM; Mariotti, M; Comoglio, PM; Soria, MR				Maier, JAM; Mariotti, M; Comoglio, PM; Soria, MR			Interleukin 1 induces an autocrine loop hepatocyte growth factor c-Met in murine Kaposi-like spindle cells	ONCOGENE			English	Article						hepatocyte growth factor; c-Met; autocrine loop; interleukin-1 alpha; Kaposi's sarcoma	FACTOR-SCATTER-FACTOR; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; TAT TRANSGENIC MICE; FACTOR-RECEPTOR; MESSENGER-RNA; FACTOR GENE; HUMAN KERATINOCYTES; EXPRESSION; PROTOONCOGENE	Several cytokines, growth factors and the HIV transactivator Tat were shown to be involved in the pathogenesis of Kaposi's sarcoma, BKV/tat transgenic mice develop Kaposi's sarcoma-like lesions, and spindle-shaped cells (TTB) have been derived from these lesions, Here we show that TTB cells co-express hepatocyte growth factor (HGF) and its receptor, the product of the oncogene c-Met. An autocrine loop HGF/Met sustains spindle cell proliferation in vitro; indeed, an antisense oligomer targeted against HGF markedly inhibited cell growth, Moreover, HGF and Met are overexpressed after exposing TTB cells to the proinflammatory cytokine interleukin 1 (IL-1), We argue that upon exposure to IL-1, an HGF/Met autocrine loop is induced which could explain the appearance of multiple foci of uncontrolled growth, In addition, due to its angiogenic activity, HGF may also sustain the neovascularization typical of Kaposi's sarcoma lesions.	SAN RAFFAELE SCI INST,DEPT BIOL & TECHNOL RES,DIBIT,I-20132 MILAN,ITALY; UNIV TURIN,SCH MED,DEPT BIOMED SCI & TECHNOL,I-10126 TURIN,ITALY	University of Turin	Maier, JAM (corresponding author), UNIV MILAN,HSR,DEPT BIOMED SCI & TECHNOL,MILAN,ITALY.		Maier, Jeanette AM/H-4820-2012	Maier, Jeanette AM/0000-0002-6326-9221; Comoglio, Paolo/0000-0002-7056-5328				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARBANTIBRODANO G, 1994, ANTIBIOT CHEMOTHER, V46, P88; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Comoglio P M, 1993, EXS, V65, P131; CORALLINI A, 1993, CANCER RES, V53, P5569; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ELLER MS, 1995, J CELL SCI, V108, P2741; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FALKENBURG JHF, 1990, J IMMUNOL, V144, P4657; FRIESEL R, 1987, J CELL BIOL, V104, P689, DOI 10.1083/jcb.104.3.689; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LIU YH, 1993, BIOCHIM BIOPHYS ACTA, V1216, P299, DOI 10.1016/0167-4781(93)90159-B; LIU YH, 1994, J BIOL CHEM, V269, P4152; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAIDU YM, 1994, P NATL ACAD SCI USA, V91, P5281, DOI 10.1073/pnas.91.12.5281; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; POLVERINI PJ, 1995, ADV CANCER RES, V66, P235, DOI 10.1016/S0065-230X(08)60256-0; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Sambrook J., 2002, MOL CLONING LAB MANU; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAMURA M, 1993, J BIOL CHEM, V268, P8140; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	56	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1009	1015						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806690				2022-12-25	WOS:A1996VG76600014
J	Kage, R; Leeman, SE; Krause, JE; Costello, CE; Boyd, ND				Kage, R; Leeman, SE; Krause, JE; Costello, CE; Boyd, ND			Identification of methionine as the site of covalent attachment of a p-benzoyl-phenylalanine-containing analogue of substance P on the substance P (NK-1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; FUNCTIONAL CDNA; BINDING DOMAINS; CELLS; LOCALIZATION	Previously we have been able to restrict the site of covalent attachment of a photolabile and radiolabeled derivative of substance P (SP), p-benzoylphenylalanine(8)-SP (Bpa(8).SP), to residues 178-183 located on the second extracellular loop (E2) of the SP (NK-1) receptor (Boyd, N. D., Rage, R., Dumas, J. J., Krause, J. E., and Leeman, S. E. (1996) Proc, Natl, Acad, Sci, U. S. A. 93, 433-437), To ascertain the specific amino acid in this sequence that serves as the site of covalent attachment for I-125-Bolton-Hunter reagent (EH)-Bpa(8)-SP, we have employed here a novel solid-phase approach to cyanogen bromide cleavage of the photolabeled receptor followed by mass spectrometric analysis of a purified labeled fragment. SP receptors on transfected Chinese hamster ovary cells were photolabeled with isotopically diluted I-125-BH-Bpa(8)-SP. A membrane preparation of the photolabeled receptors was adsorbed onto C-18-derivatized silica gel and cleaved with cyanogen bromide, A single radiolabeled fragment containing 63% of the photoincorporated radioactivity was generated and purified by high performance liquid chromatography. Mass spectrometric analysis identified a single molecular ion with a molecular mass of 1751.4 +/- 2, establishing that upon irradiation the bound photoligand forms a covalent link with the methyl group of a methionine residue at the peptide binding site, In view of our previous findings, this methionine is Met-181 on the primary sequence of the SP receptor.	WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA; BOSTON UNIV, SCH MED, DEPT BIOPHYS, BOSTON, MA 02118 USA	Washington University (WUSTL); Boston University	Kage, R (corresponding author), BOSTON UNIV, SCH MED, DEPT PHARMACOL & EXPT THERAPEUT, BOSTON, MA 02118 USA.			Leeman, Susan/0000-0002-0951-5364; Costello, Catherine/0000-0003-1594-5122	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031346] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00317] Funding Source: Medline; NINDS NIH HHS [NS31346] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; FONG TM, 1992, J BIOL CHEM, V267, P25664; GERARD NP, 1991, BIOCHEMISTRY-US, V30, P10640, DOI 10.1021/bi00108a006; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KAGE R, 1995, J NEUROCHEM, V64, P316; KEUTMANN HT, 1993, ENDOCRINOLOGY, V132, P1305, DOI 10.1210/en.132.3.1305; Krause J.E., 1994, TACHYKININ RECEPTORS; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; MAHMOOD R, 1989, BIOCHEMISTRY-US, V28, P3989, DOI 10.1021/bi00435a054; MILLER WT, 1991, METHOD ENZYMOL, V200, P500; ONEIL KT, 1989, PROTEINS, V6, P284, DOI 10.1002/prot.340060311; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; TAKEDA Y, 1992, J NEUROCHEM, V59, P740, DOI 10.1111/j.1471-4159.1992.tb09430.x; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	20	76	76	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25797	25800		10.1074/jbc.271.42.25797	http://dx.doi.org/10.1074/jbc.271.42.25797			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824208	hybrid			2022-12-25	WOS:A1996VN18000014
J	Sakaki, T; Kominami, S; Hayashi, K; AkiyoshiShibata, M; Yabusaki, Y				Sakaki, T; Kominami, S; Hayashi, K; AkiyoshiShibata, M; Yabusaki, Y			Molecular engineering study on electron transfer from NADPH-P450 reductase to rat mitochondrial P450c27 in yeast microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NADPH-CYTOCHROME-P450 REDUCTASE; FUSED ENZYME; ESCHERICHIA-COLI; CYTOCHROME; EXPRESSION; GENE; MONOOXYGENASE; STEROIDOGENESIS; FLAVOPROTEINS	We have reported the localization on yeast microsomes for a modified P450c27 (mic-P450c27) that contains the microsomal targeting signal of bovine P450c17 in front of the mature form of rat mitochondrial P450c27 (Sakaki, T., Akiyoshi-Shibata, M., Yabusaki, Y., and Ohkawa, H. (1992) J. Biol. Chem. 267, 16497-16502). In this study, we found that mic-P450c27 could be reduced by NADPH in the yeast microsomes without supplement of its physiological redox partners, adrenodoxin and NADPH-adrenodoxin reductase. In order to elucidate the direct electron transfer from NADPH-P450 reductase to mic-P450c27, we carried out simultaneous expression of mic-P450c27 and yeast P450 reductase. The reduction rate of mic-P450c27 was increased by overproduction of yeast P450 reductase, roughly in proportion to the reductase content in the microsomes. In addition, we constructed a fused enzyme between mic-P450c27 and yeast P450 reductase. The reduction rate of heme iron in the fused enzyme was too rapid to be measured. These recombinant yeast microsomes showed a notable 27-hydroxylation activity toward 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol in the absence of adrenodoxin and adrenodoxin reductase. Finally, we purified mic-P450c27 from the recombinant yeast microsomes and reconstituted the hydroxylation system in liposomal membranes using the purified mic-P450c27 and yeast NADPH-P450 reductase. Mic-P450c27 was reduced by NADPH and showed its monooxygenase activity on the reconstituted system. Therefore, yeast NADPH-P450 reductase alone was found to transfer two electrons from NADPH to mic-P450c27. These results clearly show that mic-P450c27 not only localizes on the microsomes but also functions as a microsomal cytochrome P450 that accepts electrons from NADPH-P450 reductase.	SUMITOMO CHEM CO LTD,BIOTECHNOL LAB,TAKARAZUKA,HYOGO 665,JAPAN; HIROSHIMA UNIV,FAC INTEGRATED ARTS & SCI,HIGASHIHIROSHIMA,HIROSHIMA 724,JAPAN	Sumitomo Chem Co Ltd; Hiroshima University								AOYAMA Y, 1978, ARCH BIOCHEM BIOPHYS, V185, P362, DOI 10.1016/0003-9861(78)90178-9; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BERNHARDT R, 1992, BIOCHEM BIOPH RES CO, V187, P310, DOI 10.1016/S0006-291X(05)81494-9; BLACK SM, 1994, P NATL ACAD SCI USA, V91, P7247, DOI 10.1073/pnas.91.15.7247; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; Dong MS, 1996, ARCH BIOCHEM BIOPHYS, V327, P11, DOI 10.1006/abbi.1996.0086; FULCO AJ, 1987, LIFE SCI, V40, P1769, DOI 10.1016/0024-3205(87)90087-7; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; KOMINAMI S, 1989, BIOCHIM BIOPHYS ACTA, V985, P293, DOI 10.1016/0005-2736(89)90415-X; KOMINAMI S, 1992, J STEROID BIOCHEM, V42, P57, DOI 10.1016/0960-0760(92)90011-7; LAMBETH JD, 1983, J BIOL CHEM, V258, P5596; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; MURAKAMI H, 1990, J BIOCHEM, V108, P859, DOI 10.1093/oxfordjournals.jbchem.a123293; MURAKAMI H, 1987, DNA CELL BIOL, V5, P1; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OKUDA K, 1988, J BIOL CHEM, V263, P18138; OMURA T, 1964, J BIOL CHEM, V239, P2370; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SAKAKI T, 1990, DNA CELL BIOL, V9, P603, DOI 10.1089/dna.1990.9.603; SAKAKI T, 1992, J BIOL CHEM, V267, P16497; SAKAKI T, 1987, DNA-J MOLEC CELL BIO, V6, P31, DOI 10.1089/dna.1987.6.31; SAKAKI T, 1994, BIOCHEMISTRY-US, V33, P4933, DOI 10.1021/bi00182a023; SHIBATA M, 1990, DNA CELL BIOL, V9, P27, DOI 10.1089/dna.1990.9.27; YABUSAKI Y, 1988, J BIOCHEM-TOKYO, V103, P1004, DOI 10.1093/oxfordjournals.jbchem.a122370; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020	32	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26209	26213		10.1074/jbc.271.42.26209	http://dx.doi.org/10.1074/jbc.271.42.26209			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824269	hybrid			2022-12-25	WOS:A1996VN18000075
J	Teramoto, H; Crespo, P; Coso, OA; Igishi, T; Xu, NZ; Gutkind, JS				Teramoto, H; Crespo, P; Coso, OA; Igishi, T; Xu, NZ; Gutkind, JS			The small GTP-binding protein Rho activates c-Jun N-terminal kinases stress-activated protein kinases in human kidney 293T cells - Evidence for a Pak-independent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; MAP KINASE; SACCHAROMYCES-CEREVISIAE; GTPASES; RAS; HOMOLOG; CDC42; RAC1	Work from a number of laboratories has established a role for certain small GTP-binding proteins in controlling the enzymatic activity of a family of serine-threonine kinases known as mitogen-activated protein kinases (MAPKs). MAPKs have been classified into three subfamilies: extracellular signal-regulated kinases (ERKs), also known as MAPKs; c-Jun N-terminal kinases (JNKs); and p38 kinase. Whereas Ras controls the activation of MAPKs, we and others have recently observed that in certain cells, the small GTP-binding proteins Rad and Cdc42 but not Rho regulate the activity of JNKs. Furthermore, because Rad and Cdc42 but not Rho bind and activate a kinase known as Pak1, it has been suggested that Pak1 is the most upstream component of the pathway linking these GTPases to JNK. However, in both yeast and mammalian cells, Rho1p, a Rho homologue, and RhoA, respectively, directly interact with a number of proteins, including kinases related to protein kinase C. In addition, in yeast, Rho1p controls the activity of a MAPK cascade involved in bud formation. Considering this diversity of target molecules for small GTP-binding proteins, their likely tissue specific distribution, and the potential role for Rho in signaling to a kinase cascade, we decided to extend our initial analysis, exploring the ability of Ras and Rho-related GTP-binding proteins to activate MAPK or JNK in a variety of cell lines. We found that in the human kidney epithelial cell line, 293T, Cdc42 and all Rho proteins, RhoA, RhoB, and RhoC, but not Rac or Ras can induce activation of JNK. Furthermore, we provide evidence that signaling from Rho proteins to JNK in 293T cells does not involve Pak1. Taken together these findings demonstrate that Rho signals to JNK in a cell type-specific manner and suggest the existence of a novel, Pak1-independent signaling route communicating the Rho family of small GTP-binding proteins to the JNK pathway.	NIDR,MOL SIGNALING UNIT,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	28	164	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25731	25734		10.1074/jbc.271.42.25731	http://dx.doi.org/10.1074/jbc.271.42.25731			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824197	hybrid			2022-12-25	WOS:A1996VN18000003
J	Brosh, RM; Matson, SW				Brosh, RM; Matson, SW			A partially functional DNA helicase II mutant defective in forming stable binary complexes with ATP and DNA - A role for helicase motif III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; INDUCED CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI REP; SINGLE-STRANDED-DNA; UVRD GENE-PRODUCT; MISMATCH CORRECTION; PROTEIN ABOLISHES; BINDING MOTIF; POLYMERASE-I; RNA HELICASE	To address the functional significance of motif III in Escherichia coli DNA helicase II, the conserved aspartic acid at position 248 was changed to asparagine. UvrDD248N failed to form stable binary complexes with either DNA or ATP. However, UvrDD248N was capable of forming an active ternary complex when both ATP and single-stranded DNA were present. The DNA-stimulated ATPase activity of UvrDD248N was reduced relative to that of wild-type UvrD with no significant change in the apparent K-m for ATP. The mutant protein also demonstrated a reduced DNA unwinding activity. The requirement for high concentrations of UvrDD248N to achieve unwinding of long duplex substrates Likely reflects the reduced stability of various binary and ternary complexes that must exist in the catalytic cycle of a helicase. The data suggest that motif m may act as an interface between the ATP binding and DNA binding domains of a helicase. The uvrDD248N allele was also characterized in genetic assays. The D248N protein complemented the UV-sensitive phenotype of a uvrD deletion strain to levels nearly equivalent to wild-type helicase II. In contrast, the mutant protein only partially complemented the mutator phenotype. A correlation between the level of genetic complementation and the helicase activity of UvrDD248N is discussed.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GEN & MOL BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33476] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1977, EUR J BIOCHEM, V79, P39, DOI 10.1111/j.1432-1033.1977.tb11781.x; ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CHAO KL, 1990, J BIOL CHEM, V265, P1067; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GRILLEY M, 1990, MUTAT RES, V236, P253, DOI 10.1016/0921-8777(90)90009-T; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; JINDAL HK, 1994, J BIOL CHEM, V269, P3283; KUHN B, 1979, J BIOL CHEM, V254, P1343; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Miller J. H., 1972, EXPT MOL GENETICS, P431; MODRICH P, 1989, J BIOL CHEM, V264, P6597; ORREN DK, 1992, J BIOL CHEM, V267, P780; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PLUMPTON M, 1994, EMBO J, V13, P879, DOI 10.1002/j.1460-2075.1994.tb06331.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; RICHET E, 1976, J BIOL CHEM, V251, P808; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P4128, DOI 10.1021/bi00066a039; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SHARPLES GJ, 1994, NUCLEIC ACIDS RES, V22, P308, DOI 10.1093/nar/22.3.308; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASHBURN BK, 1993, J BACTERIOL, V175, P341, DOI 10.1128/JB.175.2.341-350.1993; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WESSEL R, 1990, EUR J BIOCHEM, V192, P695, DOI 10.1111/j.1432-1033.1990.tb19278.x; WONG I, 1993, J BIOL CHEM, V268, P20386; WOOD ER, 1989, J BIOL CHEM, V264, P8297; YONG YQ, 1995, J BIOL CHEM, V270, P24509, DOI 10.1074/jbc.270.41.24509; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992; ZOLLER MJ, 1991, RECOMBINANT DNA METH, P537	58	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25360	25368		10.1074/jbc.271.41.25360	http://dx.doi.org/10.1074/jbc.271.41.25360			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810301	hybrid			2022-12-25	WOS:A1996VL69300045
J	Faull, RJ; Wang, JA; Leavesley, DI; Puzon, W; Russ, GR; Vestweber, D; Takada, Y				Faull, RJ; Wang, JA; Leavesley, DI; Puzon, W; Russ, GR; Vestweber, D; Takada, Y			A novel activating anti-beta 1 integrin monoclonal antibody binds to the cysteine-rich repeats in the beta 1 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; STIMULATED HUMAN-PLATELETS; LIGAND-BINDING; CELL-ADHESION; T-CELLS; GLANZMANN THROMBASTHENIA; FIBRONECTIN RECEPTOR; ELECTRON-MICROSCOPY; AFFINITY MODULATION; FIBRINOGEN BINDING	The functional status of an integrin depends on the conformation of its extracellular domain, which is controlled by the cell expressing that receptor. The transmission of regulatory signals from within the cell is considered to be via propagated conformational changes from the receptor's cytoplasmic tails to the extracellular ligand binding ''pocket.'' The end result is increased accessibility of the ligand binding pocket in the high affinity (''active'') form of integrins. We report a novel monoclonal antibody (QE.2E5) that binds within the cysteine-rich repeats in the integrin beta 1 chain and induces high affinity binding of fibronectin to the integrin alpha 5 beta 1. The QE.2E5 epitope is located approximately 200 residues both from the predicted binding site for fibronectin and from the epitopes recognized by other activating anti-beta 1 monoclonal antibodies. It is also expressed on beta 1 integrins from a number of nonhuman species, Although they have the same functional effects, the binding of QE.2E5 and another activating antibody (8A2) to the receptor have contrasting effects on the expression of an activation-dependent epitope in the beta 1 chain. We propose that the cysteine-rich repeats contain a regulatory region that is distinct from those previously described in the integrin beta 1 chain.	ST GEORGE HOSP, DEPT RENAL MED, KOGARAH, NSW 2217, AUSTRALIA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; QUEEN ELIZABETH HOSP, RENAL UNIT, WOODVILLE, SA 5011, AUSTRALIA; ZENTRUM MOL BIOL ENTZUNDUNG TECHNOL HOF, INST CELL BIOL, D-48149 MUNSTER, GERMANY	St George Hospital; Scripps Research Institute	Faull, RJ (corresponding author), ROYAL ADELAIDE HOSP, RENAL UNIT, N TERRACE, ADELAIDE, SA 5000, AUSTRALIA.		Leavesley, David/C-9532-2009	Leavesley, David/0000-0002-1033-5459; Vestweber, Dietmar/0000-0002-3517-732X; takada, yoshikazu/0000-0001-5481-9589				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BECKER GJ, 1981, PATHOLOGY, V13, P669, DOI 10.3109/00313028109086640; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23328; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN AB, 1977, BIOCHIM BIOPHYS ACTA, V493, P310, DOI 10.1016/0005-2795(77)90187-8; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1993, J BIOL CHEM, V268, P23087; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAM SCT, 1987, J BIOL CHEM, V262, P947; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TICCHIONI M, 1993, J IMMUNOL, V151, P119; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WEISELJW, 1992, J BIOL CHEM, V2657, P16637	58	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25099	25106		10.1074/jbc.271.41.25099	http://dx.doi.org/10.1074/jbc.271.41.25099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810264	hybrid			2022-12-25	WOS:A1996VL69300008
J	Hering, S; Aczel, S; Grabner, M; Doring, F; Berjukow, S; Mitterdorfer, J; Sinnegger, MJ; Striessnig, J; Degtiar, VE; Wang, ZY; Glossmann, H				Hering, S; Aczel, S; Grabner, M; Doring, F; Berjukow, S; Mitterdorfer, J; Sinnegger, MJ; Striessnig, J; Degtiar, VE; Wang, ZY; Glossmann, H			Transfer of high sensitivity for benzothiazepines from L-type to class A (BI) calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; LOCAL-ANESTHETICS; SKELETAL-MUSCLE; CA2+ CHANNELS; BLOCK; INACTIVATION; DILTIAZEM; VERAPAMIL; NEURONS	To investigate the molecular basis of the calcium channel block by diltiazem, we transferred amino acids of the highly sensitive and stereoselective L-type (alpha(1S) or alpha(1C)) to a weakly sensitive, nonstereoselective class A (alpha(1A)) calcium channel. Transfer of three amino acids of transmembrane segment IVSG of L-type alpha into the alpha(1A) subunit (I1804Y, S1808A, and M1811I) was sufficient to support a use-dependent block by diltiazem and by the phenylalkylamine (-) gallopamil after expression in Xenopus oocytes, An additional mutation F1805M increased the sensitivity for (-)-gallopamil but not for diltiazem, Our data suggest that the receptor domains for diltiazem and gallopamil have common but not identical molecular determinants in transmembrane segment IVS6. These mutations also identified single amino acid residues in segment IVS6 that are important for class A channel inactivation.			Hering, S (corresponding author), UNIV INNSBRUCK, INST BIOCHEM PHARMAKOL, PETER MAYR STR 1, A-6020 INNSBRUCK, AUSTRIA.		Tuluc, Petronel/C-2527-2011; Glossmann, Hartmut/AAL-9790-2020; Striessnig, Joerg/S-9334-2017	Striessnig, Joerg/0000-0002-9406-7120; Brauns, Martina/0000-0002-0547-2731; glossmann, hartmut h./0000-0002-7392-3266; Doring, Frank/0000-0003-1017-1498				BEZPROZVANNY L, 1995, MOL PHARMACOL, V48, P540; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISHIBASHI H, 1995, BRAIN RES, V695, P88, DOI 10.1016/0006-8993(95)00815-8; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; QU YS, 1995, P NATL ACAD SCI USA, V92, P11839, DOI 10.1073/pnas.92.25.11839; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; STARMER CF, 1985, MOL PHARMACOL, V28, P348; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	28	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24471	24475		10.1074/jbc.271.40.24471	http://dx.doi.org/10.1074/jbc.271.40.24471			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798706	hybrid			2022-12-25	WOS:A1996VM67400028
J	Seoane, J; GomezFoix, AM; ODoherty, RM; GomezAra, C; Newgard, CB; Guinovart, JJ				Seoane, J; GomezFoix, AM; ODoherty, RM; GomezAra, C; Newgard, CB; Guinovart, JJ			Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTES; PHOSPHORYLASE; LIVER; TRANSLOCATION; INACTIVATION; INSULIN; BINDING; GLUCOSE-6-PHOSPHATE; PREREQUISITE; QUANTITIES	In a previous study (O'Doherty, R. Ri., Lehman, D. L., Seoane, J., Gomez-Foix, A. M., Guinovart, J. J., and New-gard, C.B. (1996) J. Biol. Chem. 271, 20524-20530), we demonstrated that adenovirus-mediated overexpression of glucokinase but not hexokinase I has a potent enhancing effect on glycogen synthesis in primary hepatocytes. In an effort to understand the underlying mechanism of this differential effect of the two hexokinase isoforms, we have investigated changes in key intracellular metabolites and the activation state of glycogen synthase in cells treated with recombinant adenoviruses expressing the liver isoform of glucokinase (AdCMV-GKL) or hexokinase I (AdCMV-HKI). Glucose 6-phosphate (Glu-6-P) levels are elevated from approximately 1.5 nmol/mg protein Do 8-10 nmol/mg protein in both AdCMV-GKL- and AdCMV-HKI-treated hepatocytes as glucose is raised from 1 to 5 mM, levels four times higher than those in untreated cells. In AdCMV-GKL-treated cells, Glu-6-P continues to accumulate at glucose levels greater than 5 mM, reaching a maximum of 120 nmol/mg protein in cells incubated at 25 mM glucose, a value 10 and 50 times greater than the maximal levels achieved in AdCMV-HKI-treated and untreated cells, respectively. In parallel with the changes observed in Glu-6-P levels, increases in UDP-Glc in AdCMV-HKI- and AdCMV-GKL-treated cells were most pronounced at low (1-5 mM) and high (25 mM) glucose levels, respectively. Despite the significant increases in Glu-6-P and UDP-Glc achieved in AdCMV-HKI-treated cells, only AdCMV-GKL-treated cells exhibited increases in glycogen synthase activity ratio and translocation of the enzyme from a soluble to a particulate form relative to untreated control cells. We conclude that Glu-6-P produced by overexpressed glucokinase is glycogenic because it effectively promotes activation of glycogen synthase. Glu-6-P produced by overexpressed hexokinase, in contrast, appears to be unable to exert the same regulatory effects, probably due to the different subcellular distribution of the two glucose-phosphorylating enzymes.	UNIV BARCELONA, FAC QUIM, DEPT BIOQUIM & BIOL MOL, E-08028 BARCELONA, SPAIN; UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974	PHS HHS [1P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; AGIUS L, 1994, BIOCHEM J, V298, P237, DOI 10.1042/bj2980237; AGIUS L, 1994, BIOCHEM J, V303, P841, DOI 10.1042/bj3030841; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAHILL GF, 1958, J BIOL CHEM, V230, P125; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CIUDAD CJ, 1988, ARCH BIOCHEM BIOPHYS, V264, P30, DOI 10.1016/0003-9861(88)90566-8; CIUDAD CJ, 1979, FEBS LETT, V99, P321, DOI 10.1016/0014-5793(79)80982-5; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; KEPPLER D, 1974, METHOD ENZYMAT AN, V3, P524; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; MASSILLON D, 1995, J BIOL CHEM, V270, P19351, DOI 10.1074/jbc.270.33.19351; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Roach P. J., 1986, ENZYMES, VXVII, P499; STALMANS W, 1974, EUR J BIOCHEM, V41, P127, DOI 10.1111/j.1432-1033.1974.tb03252.x; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VANDEWERVE G, 1984, AM J PHYSIOL, V247, pE271, DOI 10.1152/ajpendo.1984.247.2.E271; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1244, P203; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WILSON JE, 1984, REGULATION CARBOHYDR, P45	30	97	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23756	23760		10.1074/jbc.271.39.23756	http://dx.doi.org/10.1074/jbc.271.39.23756			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798601	hybrid			2022-12-25	WOS:A1996VJ44200030
J	Valente, P; Melchiori, A; Paggi, MG; Masiello, L; Ribatti, D; Santi, L; Takahashi, R; Albini, A; Noonan, DM				Valente, P; Melchiori, A; Paggi, MG; Masiello, L; Ribatti, D; Santi, L; Takahashi, R; Albini, A; Noonan, DM			RB1 oncosuppressor gene over-expression inhibits tumor progression and induces melanogenesis in metastatic melanoma cells	ONCOGENE			English	Article						retinoblastoma; melanoma; melanin; tumor progression; invasion	RETINOBLASTOMA SUSCEPTIBILITY GENE; CARCINOMA-CELLS; CYCLE ARREST; PRODUCT; DIFFERENTIATION; PROTEIN; GROWTH; INDUCTION; ANTIGEN; TRANSFORMATION	The retinoblastoma gene (RB1) is frequently deleted or mutated in many tumor types and in all cases of retinoblastoma. Apart from its role in regulation of the cell cycle, the RB1 gene product (p110(RB1)) appears to be involved in control of differentiation, Malignant metastatic cells show many properties of poorly differentiated cells, and are highly invasive in vitro and in vivo. We have transfected the human RB1 cDNA in an expression vector under the control of the beta-actin promoter into B16F10 murine melanoma cells. These cells highly overexpress RB1 mRNA and the p110(RB1) product, show reduced growth rate and increased melanogenesis in vitro. Vector control transfectants showed no alteration of invasiveness. The p110(RB1) over-expressing cells also had a reduced capacity to migrate and invade through an artificial basement membrane, key characteristics of metastatic cells. When injected into nude mice, the p110(RB1) over-expressing cells showed reduced tumor growth and reduced metastatic potential, The few metastasis observed were predominantly melanotic. These data indicate that RB1 gene expression is involved in melanoma cell differentiation and plays a role in downregulation of migration, invasion and metastatic potential of these cells.	IST NAZL RIC CANC, DEPT EXPT ONCOL, I-16132 GENOA, ITALY; IST REGINA ELENA STUDIO & CURA TUMORI, ROME, ITALY; UNIV BARI, IST ANAT UMANA NORMALE & ISTOL EMBRIOL, BARI, ITALY; KYOTO UNIV, KYOTO, JAPAN	University of Genoa; IRCCS AOU San Martino IST; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro; Kyoto University			Noonan, Douglas M/A-8620-2010; Paggi, Marco G./K-3494-2018	Noonan, Douglas M/0000-0001-8058-0719; Albini, Adriana/0000-0002-9624-5103				ALBINI A, 1989, CLIN EXP METASTAS, V7, P437, DOI 10.1007/BF01753664; ALBINI A, 1987, CANCER RES, V47, P3239; ALLAVENA G, 1988, CANCER METASTASIS, P215; BENNETT DC, 1986, CANCER RES, V46, P3239; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Elias H, 1983, GUIDE PRACTICAL STER, P25; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FUNG YKT, 1993, ONCOGENE, V8, P2659; FURUKAWA Y, 1991, ONCOGENE, V6, P1343; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HANSEN M, 1989, CC MOL BIOL, P125; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1995, ONCOGENE, V11, P1179; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARPEH MS, 1995, BRIT J CANCER, V72, P986, DOI 10.1038/bjc.1995.447; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KREIDER JW, 1975, JNCI-J NATL CANCER I, V55, P641, DOI 10.1093/jnci/55.3.641; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Li J., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P78; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MANIATIS T, 1989, MOL CLONING LAB MANU, P133; MARTELLI F, 1994, ONCOGENE, V9, P3579; MENSING H, 1984, INT J CANCER, V33, P43, DOI 10.1002/ijc.2910330109; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUFSON RA, 1979, CANCER RES, V39, P3915; MUNCASTER MM, 1992, CANCER RES, V52, P654; NEVINS JR, 1992, SCIENCE, V258, P424; PAGGI MG, 1994, CANCER RES, V54, P1098; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUPINO R, 1992, MELANOMA RES, V2, P377, DOI 10.1097/00008390-199212000-00012; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; VARLEY JM, 1989, ONCOGENE, V4, P735; WEINBERG RA, 1992, CANCER SURV, V12, P43; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITTAKER JR, 1963, DEV BIOL, V8, P99, DOI 10.1016/0012-1606(63)90028-9; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAVUZER U, 1995, ONCOGENE, V10, P123	63	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1169	1178						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808691				2022-12-25	WOS:A1996VJ20200008
J	Bennett, JD; Farlie, PG; Watson, RJ				Bennett, JD; Farlie, PG; Watson, RJ			E2F binding is required but not sufficient for repression of B-myb transcription in quiescent fibroblasts	ONCOGENE			English	Article						B-myb; E2F; cell cycle; transcription repression; p107; p130	CELL-CYCLE PROGRESSION; RETINOBLASTOMA PROTEIN; GROWTH-REGULATION; S-PHASE; IN-VIVO; E2F-CYCLIN-A COMPLEX; FAMILY PROTEINS; GENE PROMOTER; EXPRESSION; ASSOCIATION	We have previously shown in mouse NIH3T3 fibroblasts that transcription of the B-myb gene, which encodes a transcription factor required for S phase entry, is repressed through a promoter E2F site in G(0)/early G(1). Transcription repression at this stage of the cell cycle was correlated with binding of a specific p107/E2F complex to this site, We report here, however, that transfection of cells with the known components of this complex, p107, E2F-4 and DP-1, did not repress the B-myb promoter in cycling NIH3T3 cells, although p107 inhibited transcription transactivation by E2F-4/DP-1. To establish definitively the contribution of E2F to repression, the effects of further mutations within and surrounding the E2F site were examined, It was evident that E2F binding and repression were closely correlated, lending greater weight to the contention that E2F itself is implicated in this activity, These studies also identified a closely linked site, designated the downstream repression site (DRS), which was not required for E2F binding or transactivation but which was necessary for repression, These findings indicated that E2F-dependent repression and activation are independently regulated phenomena and suggest that repression involves additional interactions determined by the promoter context.	LUDWIG INST CANC RES,IMPERIAL COLL,SCH MED ST MARYS,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1994, J BIOL CHEM, V269, P1306; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAGMEIER C, 1993, NUCLEIC ACIDS ERS, V21, P4998; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PORCU P, 1994, ONCOGENE, V9, P2125; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOLF DA, 1995, ONCOGENE, V10, P2067; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	52	51	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1073	1082						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806697				2022-12-25	WOS:A1996VG76600021
J	Akbarali, Y; Oettgen, P; Boltax, J; Libermann, TA				Akbarali, Y; Oettgen, P; Boltax, J; Libermann, TA			ELF-1 interacts with and transactivates the IgH enhancer pi site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN GENE-EXPRESSION; PROTEIN-BINDING-SITES; PU.1 REGULATES EXPRESSION; TRANSCRIPTION FACTOR PU.1; ETS-RELATED PROTEIN; RESTRICTED EXPRESSION; NUCLEAR FACTOR; RECEPTOR-BETA; DNA-BINDING; 3' ENHANCER	We previously identified a B-cell-specific regulatory element in the immunoglobulin heavy chain (IgH) enhancer, pi, with striking similarity to binding sites for ets-related transcription factors. Whereas the ability of ets-related factors to bind to and transactivate the pi site has been substantiated, the identification of the particular member of the ets family responsible for B-cell-specific regulation of the pi site has remained controversial. We have used antibodies specific for individual members of the ets family to evaluate which ets-related factor in B-cell nuclear extracts interacts with the IgH pi site. We present strong evidence that ELF-1 is highly expressed in B-cells and is one of two major factors specifically interacting with the murine IgH enhancer pi site in B-cell nuclear extracts. Binding of ELF-1 correlates with activity of the pi site, since mutations abolishing function of pi also inhibit binding of ELF-1. Furthermore, we demonstrate that ELF-1 can transactivate the IgH enhancer in HeLa cells, suggesting a role for ELF-1 in B-cell-specific IgH gene expression.	BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Oettgen, Peter/AAF-5026-2021; Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179	NIAID NIH HHS [AI/CA33211-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033211] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HROMAS R, 1993, BLOOD, V82, P2998; JABRANEFERRAT N, 1994, MOL CELL BIOL, V14, P7314, DOI 10.1128/MCB.14.11.7314; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEUNG S, 1993, ONCOGENE, V8, P989; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; LIBERMANN TA, 1990, MOL ASPECTS CELL REG, V6, P399; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MOREAU GF, 1994, BIOCHIM BIOPHYS ACTA, V1198, P149; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WOTTON D, 1993, LEUKEMIA BALTIMORE, pS55; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452	52	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26007	26012		10.1074/jbc.271.42.26007	http://dx.doi.org/10.1074/jbc.271.42.26007			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824239				2022-12-25	WOS:A1996VN18000045
J	Elgersma, Y; Vos, A; vandenBerg, M; vanRoermund, CWT; vanderSluijs, P; Distel, B; Tabak, HF				Elgersma, Y; Vos, A; vandenBerg, M; vanRoermund, CWT; vanderSluijs, P; Distel, B; Tabak, HF			Analysis of the carboxyl-terminal peroxisomal targeting signal 1 in a homologous context in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE SELECTION PROCEDURE; FIREFLY LUCIFERASE; TRYPANOSOMA-BRUCEI; PROTEIN IMPORT; 3-KETOACYL-COA THIOLASE; MALATE-DEHYDROGENASE; ASSEMBLY MUTANTS; SINGLE-GENE; IN-VIVO; YEAST	Most peroxisomal matrix proteins contain a carboxyl-terminal tripeptide that directs them to peroxisomes. Within limits, these amino acids may be varied, without loss of function, The specificity of this peroxisomal targeting signal (PTS1) is remarkable considering its small size and its relaxed consensus sequence. Moreover, several peroxisomal proteins have a PTS1-like signal that does not fit the reported consensus sequence. Because many of these PTS1 variants seem to be functional in a species-dependent or protein context-dependent manner, me investigated the PTS1 requirements in a homologous context, using Saccharomyces cerevisiae and endogenous peroxisomal malate dehydrogenase (MDH3). Peroxisomal import of the MDH3-PTS1 variants was tested qualitatively by the ability to complement the Delta mdh3 mutant and quantitatively by subcellular fractionation. We observed efficient import of MDH3 into peroxisomes with a large variety of PTS1 tripeptides. Many of these variants do not fit the observed PTS1 requirements for heterologously expressed proteins, which suggests that additional domains in the protein may be of decisive importance whether or not a certain PTS1 variant is recognized by the components of the peroxisomal import machinery. Because we show that dimerization of MDH3 precedes import into the organelle, these domains are most likely conformational domains.	UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PEDIAT,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN BIOCHEM,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV UTRECHT,SCH MED,DEPT CELL BIOL,NL-3584 CX UTRECHT,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University			Elgersma, Ype/F-5164-2013	Elgersma, Ype/0000-0002-3758-1297				BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; DISTEL B, 1992, NEW BIOL, V4, P157; DISTEL B, 1996, IN PRESS J CELL BIOL; ELERSMA Y, 1996, IN PRESS J CELL BIOL; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; ELGERSMA Y, 1993, GENETICS, V135, P731; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HANSEN H, 1992, MOL GEN GENET, V235, P269, DOI 10.1007/BF00279370; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; LUMB MJ, 1994, EUR J BIOCHEM, V221, P53, DOI 10.1111/j.1432-1033.1994.tb18714.x; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCALISTERHENN L, 1995, J BIOL CHEM, V270, P21220, DOI 10.1074/jbc.270.36.21220; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; ODA T, 1990, J BIOL CHEM, V265, P7513; OSINGA KA, 1985, EMBO J, V4, P3811, DOI 10.1002/j.1460-2075.1985.tb04152.x; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; QUAN F, 1986, NUCLEIC ACIDS RES, V14, P5321, DOI 10.1093/nar/14.13.5321; ROGGENKAMP R, 1992, CELL BIOCHEM FUNCT, V10, P193, DOI 10.1002/cbf.290100309; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; SOMMER JM, 1994, FEBS LETT, V350, P125, DOI 10.1016/0014-5793(94)00747-0; STEFFAN JS, 1992, J BIOL CHEM, V267, P24708; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS B, 1989, THESIS U AMSTERDAM N; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; Tabak HF, 1995, COLD SPRING HARB SYM, V60, P649, DOI 10.1101/SQB.1995.060.01.069; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VANDERLEIJ I, 1993, J CELL BIOL, V90, P11782; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; vanRoermund CWT, 1995, BBA-GEN SUBJECTS, V1245, P348, DOI 10.1016/0304-4165(95)00099-2; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65	43	135	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26375	26382		10.1074/jbc.271.42.26375	http://dx.doi.org/10.1074/jbc.271.42.26375			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824293	hybrid			2022-12-25	WOS:A1996VN18000099
J	Hiasa, H; Yousef, DO; Marians, KJ				Hiasa, H; Yousef, DO; Marians, KJ			DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; IN-VITRO; GYRASE; IV; ACID; PURIFICATION; INHIBITORS; MECHANISM; BINDING; POISONS	The formation of a topoisomerase-quinolone-DNA ternary complex leads to cell death, We show here that an active strand breakage and reunion activity is required for formation of a norfloxacin-topoisomerase IV-DNA ternary complex that can arrest the progression of replication forks in vitro, Mutant topoisomerases containing either an active site mutation, a quinolone resistance-conferring mutation, or both, could all bind DNA as well as the wild type, but unlike the wild-type, could not halt replication fork progression, The collision between the replication fork and the frozen topoisomerase converted the cleavable complex to a nonreversible form but did not generate a double-stranded break. Thus, the cytotoxicity of this class of topoisomerase inhibitors likely results from a two-step process: (i) conversion of the frozen topoisomerase-quinolone-DNA ternary complex to an unreversible form; and (ii) generation of a double-strand break by subsequent denaturation of the topoisomerase, perhaps by an aborted repair attempt.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,PROGRAM BIOCHEM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,PROGRAM STRUCT BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University					NIGMS NIH HHS [GM34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Champoux JJ, 1980, MECH STUDIES DNA REP, P809; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P16371; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; HOLM C, 1989, CANCER RES, V49, P6365; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P8571; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MADDEN KR, 1995, EMBO J, V14, P5399, DOI 10.1002/j.1460-2075.1995.tb00224.x; MORTON RM, 1989, GENE, V77, P61; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; PENG H, 1993, J BIOL CHEM, V268, P24481; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TSAO YP, 1993, CANCER RES, V53, P5908; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	27	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26424	26429		10.1074/jbc.271.42.26424	http://dx.doi.org/10.1074/jbc.271.42.26424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824300	hybrid			2022-12-25	WOS:A1996VN18000106
J	Li, FZ; Baykal, D; Horaist, C; Yan, CN; Carr, BN; Rao, GN; Runge, MS				Li, FZ; Baykal, D; Horaist, C; Yan, CN; Carr, BN; Rao, GN; Runge, MS			Cloning and identification thrombin receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; PROTEINASE-ACTIVATED RECEPTOR-2; RNA-POLYMERASE-II; MOLECULAR-CLONING; CORONARY-ARTERIES; FUNCTIONAL EXPRESSION; GROWTH-FACTOR; TRANSCRIPTION; ANGIOPLASTY	Thrombin, via activation of vascular endothelial and smooth muscle cell thrombin receptors, modulates vascular wall healing. To understand the mechanisms that regulate human thrombin receptor (HTR) expression, we cloned and characterized the HTR gene. The HTR gene consists of Exon I, which contains the 5'-regulatory region and 85 nucleotides of coding sequence; a similar to 15-kb intron; and Exon II, which contains the remainder of the coding sequence and the entire 3'-untranslated region, Multiple transcription initiation sites were identified by S1 mapping and ribonuclease protection assay. DNA sequence analysis indicated the presence of two SP-1-AP-2 consensus binding sequences, near or within the transcription initiation sites, and consensus binding sequences for numerous regulatory proteins that potentially modulate HTR expression. Functional analysis of the HTR promoter was performed by transfecting human microvascular endothelial cells with HTR promoter region-luciferase constructs. The highest level of expression was obtained with a 0.7-kb promoter sequence and was progressively less with fragments of 0.54, 1.16, 1.6, and similar to 3.2 kb. The data presented in this report provide a foundation for further characterization of the HTR gene and the mechanisms that regulate its expression within the blood vessel wall.	UNIV TEXAS,MED BRANCH,DIV CARDIOL,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,SEALY CTR MOL CARDIOL,GALVESTON,TX 77555; EMORY UNIV,SCH MED,DIV CARDIOL,ATLANTA,GA 30326; UNIV TEXAS,MED BRANCH,SEALY CTR MOL CARDIOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Emory University; University of Texas System; University of Texas Medical Branch Galveston					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048667] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48667] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA SK, 1994, J BIOL CHEM, V269, P26381; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAHOU WF, 1993, BLOOD, V82, P1532, DOI 10.1182/blood.V82.5.1532.bloodjournal8251532; CHAIKOF EL, 1995, J BIOL CHEM, V270, P7431, DOI 10.1074/jbc.270.13.7431; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHOW CW, 1995, NUCLEIC ACIDS RES, V23, P3132, DOI 10.1093/nar/23.16.3132; COLOTTA F, 1994, AM J PATHOL, V144, P975; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; FERGUSON J, 1978, J MOL BIOL, V123, P417, DOI 10.1016/0022-2836(78)90088-8; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GRANDALIANO G, 1994, J EXP MED, V179, P1737, DOI 10.1084/jem.179.5.1737; IP JH, 1991, J AM COLL CARDIOL, V17, pB77; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; LAPETINA EG, 1981, J BIOL CHEM, V256, P5037; MARI B, 1994, J BIOL CHEM, V269, P8517; MARMUR JD, 1994, J AM COLL CARDIOL, V24, P1484, DOI 10.1016/0735-1097(94)90144-9; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OZAKI H, 1992, CIRC RES, V71, P1285; PALLANSCH L, 1990, ANAL BIOCHEM, V185, P57, DOI 10.1016/0003-2697(90)90254-7; PANACCIO M, 1993, BIOTECHNIQUES, V14, P238; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; RASSMUSSEN UB, 1991, FEBS LETT, V288, P123; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; SHAMMAS NW, 1994, THROMB HAEMOSTASIS, V72, P672; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SOIFER SJ, 1994, AM J PATHOL, V144, P60; TESFAMARIAM B, 1993, AM J PHYSIOL, V265, pH1744, DOI 10.1152/ajpheart.1993.265.5.H1744; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WILCOX JN, 1994, CIRC RES, V75, P1029, DOI 10.1161/01.RES.75.6.1029; YAO SK, 1992, CIRCULATION, V86, P1993, DOI 10.1161/01.CIR.86.6.1993; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	48	39	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26320	26328		10.1074/jbc.271.42.26320	http://dx.doi.org/10.1074/jbc.271.42.26320			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824285	hybrid			2022-12-25	WOS:A1996VN18000091
J	Abrams, CS; Zhang, J; Downes, CP; Tang, XW; Zhao, W; Rittenhouse, SE				Abrams, CS; Zhang, J; Downes, CP; Tang, XW; Zhao, W; Rittenhouse, SE			Phosphopleckstrin inhibits G beta gamma-activable platelet phosphatidylinositol-4,5-bisphosphate 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ADRENERGIC-RECEPTOR KINASE; PHOSPHOINOSITIDE-3 KINASE; THROMBIN; 4,5-BISPHOSPHATE; ACTIVATION; BINDING; RHO; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; PHOSPHORYLATION	Pleckstrin, the prototypic protein containing two copies of the pleckstrin homology domain, is a prominent substrate of protein kinase C in platelets and neutrophils. Both cell types have p85 subunit-containing phosphoinositide 3-kinase (p85/PI3K) and non-p85-containing PI3K (PI3K gamma) that is activated by beta gamma subunits of heterotrimeric GTP-binding proteins. We have shown that a PI3K product, phosphatidylinositol (PI) 3,4,5-trisphosphate, promotes pleckstrin phosphorylation in platelets. Since pleckstrin homology domains are thought to interact with G beta gamma heterodimers and/or PI(4,5)P-2, we have examined the effects of recombinant pleckstrins on platelet PI3K gamma and p85/PI3K activities. Depending upon its phosphorylation/charged state, pleckstrin inhibits PI3K gamma, but not p85/PI3K. Pleckstrin-mediated inhibition of PI3K gamma is overcome by excess G beta gamma and is restricted to PI(4,5)P-2 as substrate, i.e. pleckstrin does not inhibit phosphorylation of PI(4)P or PI. Consistent with this, activation of protein kinase C by exposure of platelets to beta-phorbol diester (to increase endogenous pleckstrin phosphorylation) prior to platelet lysis causes inhibition of G beta gamma-stimulatable PI3K activity only with respect to PI(4,5)P-2 substrate. This phosphopleckstrin-mediated inhibition is overcome by increasing concentrations of G beta gamma. We propose that phosphorylation of pleckstrin may constitute an important inhibitory mechanism for PI3K gamma-mediated cell signaling.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC INST,DEPT MOL PHARMACOL & BIOCHEM,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	Jefferson University; Jefferson University; University of Pennsylvania; University of Dundee				tang, xiuwen/0000-0002-6601-1234	NHLBI NIH HHS [R29 HL53545, HL 38622] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622, R29HL053545] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1995, J BIOL CHEM, V270, P23317, DOI 10.1074/jbc.270.40.23317; ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RITTENHOUSE SE, 1995, METHOD ENZYMOL, V256, P241; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	24	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25192	25197		10.1074/jbc.271.41.25192	http://dx.doi.org/10.1074/jbc.271.41.25192			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810277	hybrid			2022-12-25	WOS:A1996VL69300021
J	Acharya, S; Karnik, SS				Acharya, S; Karnik, SS			Modulation of GDP release from transducin by the conserved Glu(134)-Arg(135) sequence in rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; CARBOXYLIC-ACID GROUP; BOVINE RHODOPSIN; ACTIVATION; MUTATIONS; BINDING; INTERACT; CASCADE	A superfamily of seven-transmembrane helix receptors catalyzes GDP release from heterotrimeric guanine nucleotide-binding proteins (G proteins) to initiate the intracellular signaling cascade, The photoreceptor rhodopsin is a prototypical member of the superfamily that activates the retinal G protein transducin (G(t)), The cytoplasmic domain of rhodopsin binds and activates G(t), but residues that stimulate GDP release from G(t) have not been identified until now, We show here that the abnormal signal transduction phenotypes of several different mutations affecting the highly conserved Glu(134)-Arg(135) charge pair result from alteration of the GDP release step in the G(t) activation cascade, We propose that Glu(134) and Arg(135) constitute the site that directly provides the signal from rhodopsin to activate GDP release from G(t), Because the Glu/Asp-Arg sequence occurs at a topologically identical location in most of the seven-transmembrane helix receptors, we propose that these residues constitute a switch for signal transfer.	CLEVELAND CLIN FDN,RES INST,DEPT MOL CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NEI NIH HHS [P30 EY025585] Funding Source: Medline; NHLBI NIH HHS [R01 HL057470] Funding Source: Medline; PHS HHS [9704] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNIS S, 1994, J BIOL CHEM, V269, P23879; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLMAN AG, 1984, CELL, V36, P577; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MIN KC, 1993, J BIOL CHEM, V268, P9400; MORTON RA, 1955, BIOCHEM J, V59, P128, DOI 10.1042/bj0590128; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUNG CH, 1993, J BIOL CHEM, V268, P26645; WANG CD, 1991, MOL PHARMACOL, V40, P168; WEISS ER, 1987, J BIOL CHEM, V262, P4319; ZHU SZ, 1994, MOL PHARMACOL, V45, P517	30	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25406	25411		10.1074/jbc.271.41.25406	http://dx.doi.org/10.1074/jbc.271.41.25406			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810308	hybrid			2022-12-25	WOS:A1996VL69300052
J	Akasawa, A; Hsieh, LS; Martin, BM; Liu, T; Lin, Y				Akasawa, A; Hsieh, LS; Martin, BM; Liu, T; Lin, Y			A novel acidic allergen, Hev b 5, in latex - Purification, cloning and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTACT URTICARIA; CROSS-REACTIVITY; GLOVES; RUBBER; BRASILIENSIS; PROTEINS	Latex allergy is recognized as a serious health problem among health care workers and children with spina bifida, A number of IgE-reactive proteins have been identified in natural and processed latex products. One of the most acidic proteins in the cytoplasm of lacticifer cells of rubber trees (Hevea brasiliensis) is demonstrated to be a potent allergen in eliciting allergic reactions in humans, This protein, with pI = 3.5, has a molecular mass of 16 kDa with a blocked N terminus and an unusual amino acid composition, This acidic protein was found in extracts prepared from latex gloves, which were shown to be allergenic, The purified protein elicits histamine release from human basophils passively sensitized with serum from latex-allergic individuals in a dose dependent manner. From a latex cDNA library, the cDNA coding for this protein was isolated and sequenced. The deduced amino acid sequence shows a high degree of homology to another acidic protein identified in kiwifruit (Actinidia deliciosa var. deliciosa). The sequence homology (47% sequence identity) between these two acidic proteins suggests a molecular explanation for the high frequency of fruit hypersensitivity in latex-allergic patients.	US FDA,DIV ALLERGEN PROD & PARASITOL,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20852; NIMH,CLIN NEUROSCI BRANCH,UNIT MOL STRUCT,BETHESDA,MD 20892	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Moussa, Luciana/M-2257-2013					AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; Akasawa A, 1996, J ALLERGY CLIN IMMUN, V97, P1116, DOI 10.1016/S0091-6749(96)70266-X; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BLANCO C, 1994, ANN ALLERGY, V73, P309; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; FORTESDIAS CL, 1994, J BIOL CHEM, V269, P15646; HARMANN CP, 1994, ALLERGY PROC, V15, P17; JONES WB, 1994, PHYSICA D, V73, P227, DOI 10.1016/0167-2789(94)90159-7; KURUP VP, 1994, ALLERGY PROC, V15, P211, DOI 10.2500/108854194778702711; LEDGER SE, 1994, PLANT MOL BIOL, V25, P877, DOI 10.1007/BF00028882; LIU TY, 1989, ANAL BIOCHEM, V182, P383, DOI 10.1016/0003-2697(89)90612-X; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MOLALES C, 1989, CLIN EXP ALLERGY, V19, P425; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V90, P279, DOI 10.1016/S0091-6749(05)80003-X; SLATER JE, 1990, ANN ALLERGY, V65, P411; SPACKMAN DH, 1967, METHOD ENZYMOL, V11, P3; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TOMAZIC VJ, 1995, J ALLERGY CLIN IMMUN, V96, P635, DOI 10.1016/S0091-6749(95)70262-8; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x	23	81	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25389	25393		10.1074/jbc.271.41.25389	http://dx.doi.org/10.1074/jbc.271.41.25389			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810305	hybrid			2022-12-25	WOS:A1996VL69300049
J	Apasov, SG; Smith, PT; Jelonek, MT; Margulies, DH; Sitkovsky, MV				Apasov, SG; Smith, PT; Jelonek, MT; Margulies, DH; Sitkovsky, MV			Phosphorylation of extracellular domains of T-lymphocyte surface proteins - Constitutive serine and threonine phosphorylation of the T cell antigen receptor ectodomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; CRYSTAL-STRUCTURE; ATP; DEPHOSPHORYLATION; CYTOTOXICITY; SPECIFICITY; ACTIVATION; RESIDUES; SUBUNIT; LYSIS	The extracellular accumulation of ATP after activation of T-lymphocytes, as well as the presence of ectoprotein kinases in these cells, led us to propose that T cell surface receptors could be regulated through the reversible phosphorylation of their extracellular domains (ectodomains). Here, in a model system, we used T cell transfectants which express T cell antigen receptor chains lacking intracellular and transmembrane protein domains and P-32(i) metabolic labeling of cells to definitively demonstrate phosphorylation of ectodomains of T cell surface proteins, We show that alpha beta TCR ectodomains were phosphorylated intracellularly and constitutively on serine and threonine residues and were then expressed on the T cell surface in phosphorylated form, TCR ectodomains also could be phosphorylated at the cell surface when extracellular [gamma-P-32]ATP or [gamma-P-32]GTP were used as phosphate donors with the same cells, Consensus phosphorylation sites for serine and threonine protein kinases were found to be strongly evolutionary conserved in both a and beta TCR chains constant regions, These results are consistent with the hypothesis, where T cell surface proteins which are phosphorylated intracellularly on their ectodomains, could subsequently be expressed at the cell surface and then be reversibly modified by ectoprotein phosphatase(s) and by ectokinase(s), Such modifications may change T cells cognate interactions by, e.g. affecting TCR-multimolecular complex formation and antigen binding affinity. It is suggested that alpha beta TCR ectodomain phosphorylation could serve as a potential mechanism for regulation of alpha beta TCR-mediated T-lymphocytes response.	NIAID,IMMUNOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Margulies, David/0000-0001-8530-7375				APASOV S, 1993, P NATL ACAD SCI USA, V90, P2837, DOI 10.1073/pnas.90.7.2837; APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/j.1600-065X.1995.tb00680.x; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Ehrlich YH, 1996, SCIENCE, V271, P278, DOI 10.1126/science.271.5247.278; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8257; HARINDRANATH N, 1989, IMMUNOGENETICS, V30, P465, DOI 10.1007/BF02421179; Hedrick Stephen M., 1993, P383; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KREBS EG, 1993, BIOSCIENCE REP, V113, P127; KUHLER DW, 1982, J BIOL CHEM, V257, P322; LAUTENBERG D, 1995, J EXP MED, V183, P249; MARCHE PN, 1986, P NATL ACAD SCI USA, V83, P2190, DOI 10.1073/pnas.83.7.2190; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; NAIK UP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256, DOI 10.1016/0167-4889(91)90165-T; PLOEGH H, 1993, NATURE, V364, P16, DOI 10.1038/364016d0; REDEGELD F, 1991, J IMMUNOL, V147, P3638; SAKIHAMA T, 1995, IMMUNOL TODAY, V16, P581, DOI 10.1016/0167-5699(95)80081-6; SAMELSON LE, 1985, P NATL ACAD SCI USA, V82, P1969, DOI 10.1073/pnas.82.7.1969; SAMELSON LE, 1991, CURRENT PROTOCOLS IM, V2; SIEGEL JN, 1992, CURRENT PROTOCOLS IM, V3; SKUBITZ KM, 1994, J IMMUNOL, V152, P5902; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; Weiss Arthur, 1993, P467; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67	31	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25677	25683		10.1074/jbc.271.41.25677	http://dx.doi.org/10.1074/jbc.271.41.25677			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810345	hybrid			2022-12-25	WOS:A1996VL69300089
J	Mahe, Y; Lemoine, Y; Kuchler, K				Mahe, Y; Lemoine, Y; Kuchler, K			The ATP binding cassette transporters Pdr5 and Snq5 of Saccharomyces cerevisiae can mediate transport of steroids in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; PLASMA-MEMBRANE; GENE-PRODUCT; DRUG-RESISTANCE; MDR-GENE; ENCODES; PHOSPHATIDYLCHOLINE; TRANSCRIPTION; DEXAMETHASONE	Multiple or pleiotropic drug resistance in the yeast Saccharomyces cerevisiae can arise from overexpression of the Pdr5 and Snq2 ATP binding cassette multidrug transporters. Expression of Pdr5 and Snq2 is regulated by the two transcription factors Pdr1 and Pdr3, as multidrug-resistant pdr1 and pdr3 gain-of-function mutants overexpress both drug efflux pumps. One such pdr1 mutant allele was previously cloned in a genetic screen by its ability to suppress the squelching toxicity mediated by an estradiol-inducible chimeric VP16-human estrogen receptor (VEO) expressed in yeast (Gilbert, D. M., Heery, D. M., Lesson, R., Chambon, P., and Lemoine, Y. (1993) Mol. Cell. Biol. 13, 462-472). In this study, we demonstrate that relief of estradiol toxicity in yeast cells expressing VEO requires functional PDR5 and SNQ2 genes, since a Delta pdr5 Delta snq2 double deletion leads to an increased estradiol toxicity. Furthermore, using URA3 as an estradiol-inducible reporter gene, we show that Pdr5 and Snq2, when overexpressed from high-copy plasmids, can reduce the intracellular concentration of estradiol. In contrast, a Delta pdr5 Delta snq2 double deletion mutant accumulates almost 30-fold more intracellular estradiol than the isogenic wild type, Indirect immunofluorescence showed that a pdr1-3 mutant massively overexpresses Pdr5 at the plasma membrane, suggesting that estradiol efflux from the cells occurs across the plasma membrane. Our data demonstrate that Pdr5 and Snq2 can transport steroid substrates in vivo and suggest that steroids and/or related membrane lipids could represent physiological substrates for certain yeast ABC transporters, which are otherwise involved in the development of pleiotropic drug resistance.	UNIV VIENNA, BIOCTR, DEPT MOL GENET, A-1030 VIENNA, AUSTRIA; UNIV STRASBOURG 1, ECOLE SUPER BIOTECHNOL STRASBOURG, F-67400 STRASBOURG, FRANCE	University of Vienna; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			kuchler, karl/AAL-6937-2020	kuchler, karl/0000-0003-2719-5955				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BORST P, 1993, PHARMACOL THERAPEUT, V60, P289, DOI 10.1016/0163-7258(93)90011-2; BOURGEOIS S, 1993, MOL ENDOCRINOL, V7, P840, DOI 10.1210/me.7.7.840; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; EGNER R, 1995, MOL CELL BIOL, V15, P5879; EGNER R, 1995, MEM PROT TR, V2, P57; GILBERT DM, 1993, MOL CELL BIOL, V13, P462, DOI 10.1128/MCB.13.1.462; GROSS SR, 1970, J CELL BIOL, V44, P103, DOI 10.1083/jcb.44.1.103; HAASE E, 1992, CURR GENET, V21, P319, DOI 10.1007/BF00351689; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; KANE SE, 1996, ADV DRUG RES, V2, P181; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUCHLER K, 1992, COLD SPRING HARB SYM, V57, P579, DOI 10.1101/SQB.1992.057.01.064; LEPPERT G, 1990, GENETICS, V125, P13; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SATHE GM, 1991, NUCLEIC ACIDS RES, V19, P4775, DOI 10.1093/nar/19.17.4775; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SIKORSKI RS, 1989, GENETICS, V122, P19; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA K, 1992, J BIOL CHEM, V267, P24248; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; VIEIRA A, 1994, CELL BIOL LAB HDB, V2, P314; WOLF DC, 1992, INT J CANCER, V52, P141, DOI 10.1002/ijc.2910520125; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	46	126	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25167	25172		10.1074/jbc.271.41.25167	http://dx.doi.org/10.1074/jbc.271.41.25167			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810273	hybrid			2022-12-25	WOS:A1996VL69300017
J	Watabe, Y; Kuramochi, H; Furuya, Y; Inagaki, N; Seino, S; Kimura, S; Shimazaki, J				Watabe, Y; Kuramochi, H; Furuya, Y; Inagaki, N; Seino, S; Kimura, S; Shimazaki, J			Identification of histone H2A.X as a growth factor secreted by an androgen-independent subline of mouse mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIONOGI CARCINOMA; BREAST-CANCER; PROTEIN; TUMOR; GENE; DNA; TESTOSTERONE; LOCALIZATION; PROGRESSION; EXPRESSION	Shionogi carcinoma 115 (SC 115) cells and Chiba subline 2 (CS 2) cells are clones of an androgen-responsive mouse tumor cell line and its autonomous subline, respectively, We have shown previously that CS 2 cells produce a heparin-binding growth factor that stimulates the growth of SC 115 cells as well as the growth of themselves. In this study, a growth factor was purified from serum-free conditioned media of CS 2 cells cultured without testosterone. A heparin-binding fr action showed growth- promoting activity on SC 115 cells and BALB/3T3 cells. The amino acid sequence analysis revealed that the components were identical to histones H2A.1 and H2A.X. Since histone H2A purified from bovine thymus had almost no growth-promoting activity on SC115 cells, histone H2A.X was assumed to be a growth factor. cDNA of histone H2A.X was cloned from a library of CS 2 cells, and its sequence was confirmed. The expressed product of histone H2A.X cDNA in Escherichia coli showed remarkable stimulatory effects on growth of SC 115 cells cultured in the absence of testesterone, These results indicate that histone H2A.X is secreted from CS 2 cells cultured without testosterone and plays a role as a growth factor.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DEPT UROL,CHUO KU,CHIBA 260,JAPAN; CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOL MED,CHUO KU,CHIBA 260,JAPAN; CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV CARDIOVASC BIOL,CHUO KU,CHIBA 260,JAPAN	Chiba University; Chiba University; Chiba University				Kimura, Sadao/0000-0001-6768-7474; Inagaki, Nobuya/0000-0001-8261-2593				ATEN RF, 1989, J BIOL CHEM, V264, P11065; BONNER WM, 1993, MOL CELL BIOL, V13, P984, DOI 10.1128/MCB.13.2.984; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOE J, 1982, P NATL ACAD SCI-BIOL, V79, P1484, DOI 10.1073/pnas.79.5.1484; DICKSON RB, 1986, ENDOCRINOLOGY, V118, P138, DOI 10.1210/endo-118-1-138; DICKSON RB, 1990, J STEROID BIOCHEM, V37, P305, DOI 10.1016/0960-0760(90)90479-5; FURUYA Y, 1990, CANCER RES, V50, P4979; FUSE H, 1983, ENDOCRINOL JAPON, V30, P189; GRUBER A, 1990, GENE, V95, P303, DOI 10.1016/0378-1119(90)90377-4; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; ICHIKAWA T, 1989, CANCER RES, V49, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; MAY GS, 1987, GENE, V58, P59, DOI 10.1016/0378-1119(87)90029-1; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MINESITA T, 1965, CANCER RES, V25, P1168; NAGATA T, 1991, NUCLEIC ACIDS RES, V19, P2441, DOI 10.1093/nar/19.9.2441; NAKAMURA H, 1994, J BIOL CHEM, V269, P25143; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; REICHHART R, 1985, P NATL ACAD SCI USA, V82, P4871, DOI 10.1073/pnas.82.15.4871; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO N, 1993, JPN J CANCER RES, V84, P1300, DOI 10.1111/j.1349-7006.1993.tb02838.x; SONODA H, 1992, BIOCHEM BIOPH RES CO, V185, P103, DOI 10.1016/S0006-291X(05)80961-1; SUZUKI N, 1983, ENDOCRINOL JAPON, V30, P657; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WEISBROD S, 1982, NATURE, V297, P289, DOI 10.1038/297289a0; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WEST MHP, 1983, COMP BIOCHEM PHYS B, V76, P455, DOI 10.1016/0305-0491(83)90275-4; YE RD, 1988, J BIOL CHEM, V263, P4869; ZAMA S, 1987, ENDOCRINOL JAPON, V34, P279; ZUCK B, 1992, J STEROID BIOCHEM, V41, P659, DOI 10.1016/0960-0760(92)90400-D	33	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25126	25130		10.1074/jbc.271.41.25126	http://dx.doi.org/10.1074/jbc.271.41.25126			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810267	hybrid			2022-12-25	WOS:A1996VL69300011
J	Bonnet, H; Filhol, O; Truchet, I; Brethenou, P; Cochet, C; Amalric, F; Bouche, G				Bonnet, H; Filhol, O; Truchet, I; Brethenou, P; Cochet, C; Amalric, F; Bouche, G			Fibroblast growth factor-2 binds to the regulatory beta subunit of CK2 and directly stimulates CK2 activity toward nucleolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; PROTEIN-KINASE; CELL-CYCLE; MITOGENIC ACTIVITY; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; CATALYTIC ACTIVITY; ENDOTHELIAL-CELLS; MOLECULAR-COMPLEX; PHOSPHORYLATION	The presence of fibroblast growth factor-2 (FGF-2) in the nucleus has now been reported both in vitro and in vivo, but its nuclear functions are unknown. Here, we show that FGF-2 added to nuclear extract binds to protein kinase CK2 and nucleolin, a CK2 natural substrate. Added to baculovirus-infected cell extracts overexpressing CK2 or its isolated subunits, FGF-2 binds to the enzyme through its regulatory beta subunit. Using purified proteins, FGF-2 is shown to directly interact with CK2 and to stimulate CK2 activity toward nucleolin. Furthermore, a mitogenic-deficient FGF-2 mutant protein has an impaired ability to interact with CK2 and to stimulate CK2 activity using nucleolin as substrate. We propose that in growing cells, one function of nuclear FGF-2 is to modulate CK2 activity through binding to its regulatory beta subunit.	CNRS, LAB BIOL MOL EUCARYOTE, F-31062 TOULOUSE, FRANCE; CEA, BIOCHIM REGULAT CELLULAIRES ENDOCRINES, INSERM, U244, F-38054 GRENOBLE 9, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)			Filhol-Cochet, Odile/I-3962-2016	Filhol, Odile/0000-0003-1964-7958; Cochet, Claude/0000-0002-1772-4270				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BALDIN V, 1990, THESIS U P SABATIER; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURWEN SJ, 1987, TRENDS BIOCHEM SCI, V12, P159, DOI 10.1016/0968-0004(87)90074-0; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; COCHET C, 1983, J BIOL CHEM, V258, P1403; DARBON JM, 1986, J BIOL CHEM, V261, P8002; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; GABRIEL B, 1992, THESIS U P SABATIER; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OLSON MOJ, 1990, EUKARYOTIC NUCLEUS M, V2, P520; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; SACKS DB, 1992, ARCH BIOCHEM BIOPHYS, V299, P275, DOI 10.1016/0003-9861(92)90275-2; SONG JW, 1994, MECH DEVELOP, V48, P141, DOI 10.1016/0925-4773(94)90055-8; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; VALERO E, 1995, J BIOL CHEM, V270, P8345, DOI 10.1074/jbc.270.14.8345; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6	49	122	124	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24781	24787		10.1074/jbc.271.40.24781	http://dx.doi.org/10.1074/jbc.271.40.24781			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798749	hybrid			2022-12-25	WOS:A1996VM67400071
J	Borset, M; Lien, E; Espevik, T; Helseth, E; Waage, A; Sundan, A				Borset, M; Lien, E; Espevik, T; Helseth, E; Waage, A; Sundan, A			Concomitant expression of hepatocyte growth factor scatter factor and the receptor c-MET in human myeloma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SEQUENCE-ANALYSIS; MULTIPLE-MYELOMA; CARCINOMA-CELLS; SERINE-PROTEASE; PROTOONCOGENE; TUMORIGENICITY; ACTIVATION; BLOOD; BETA	Myeloma cell line supernatants were screened for their ability to inhibit the activity of transforming growth factor-beta (TGF beta) in the mink lung cell (Mv-1-Lu) bioassay. Supernatant from the human myeloma cell line JJN-3 contained potent TGF beta antagonistic activity. This activity was isolated and found to be associated with a 72-78-kDa glycoprotein. Specific polyclonal and monoclonal antibodies were generated toward the 72-78-kDa protein, and these antibodies precipitated the TGF beta inhibitory activity from JJN-3 supernatant. Upon amino acid sequencing the protein appeared to be identical to hepatocyte growth factor (HGF), and some of the generated antibodies directly blocked the action of recombinant HGF in various assays. By HGF-specific polymerase chain reaction we demonstrated that HGF mRNA was expressed in five out of five tested myeloma cell lines. The level of HGF protein in supernatants showed great variation from >500 ng/ml in JJN-3 supernatant to a few ng/ml in the supernatants from other myeloma cell lines. The same five cell lines were also screened for expression the HGF receptor c-MET. Four of them expressed the receptor as shown by reverse transcriptase-polymerase chain reaction and Western blot. The receptor was shown to be constitutively phosphorylated in the human myeloma cell line JJN-3. This receptor could be dephosphorylated by anti-HGF antibodies, indicating the existence of an autocrine HGF loop in this cell line. We propose that HGF/c-MET may play a role in multiple myeloma.			Borset, M (corresponding author), NORWEGIAN UNIV TECHNOL & SCI,INST CANC RES & MOL BIOL,MED TEKN SENTER,N-7005 TRONDHEIM,NORWAY.		Waage, Anders/D-7705-2013; Helseth, Eirik/AAH-2466-2020; Borset, Magne/AAY-1713-2021	Borset, Magne/0000-0001-5179-2835				BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909; BATAILLE R, 1990, CANCER-AM CANCER SOC, V66, P167, DOI 10.1002/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO;2-9; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Borset M, 1996, J IMMUNOL METHODS, V189, P59, DOI 10.1016/0022-1759(95)00228-6; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CLARK MR, 1981, METHOD ENZYMOL, V73, P12; Comoglio P M, 1993, EXS, V65, P131; EBERT M, 1994, CANCER RES, V54, P5775; ESHHAR Z, 1986, HYBRIDOMA TECHNOLOGY, P1; ESPEVIK T, 1990, CELL IMMUNOL, V126, P47, DOI 10.1016/0008-8749(90)90299-7; FERRACINI R, 1995, ONCOGENE, V10, P739; FULLER K, 1995, BIOCHEM BIOPH RES CO, V212, P334, DOI 10.1006/bbrc.1995.1974; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HOFMANN R, 1992, BIOCHIM BIOPHYS ACTA, V1120, P343, DOI 10.1016/0167-4838(92)90258-F; HOWE PH, 1993, J BIOL CHEM, V268, P21448; JACKSON N, 1989, CLIN EXP IMMUNOL, V75, P93; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; MIZUNO K, 1994, BIOCHEM BIOPH RES CO, V198, P1161, DOI 10.1006/bbrc.1994.1164; MOORE GE, 1968, NEW YORK STATE J MED, V68, P2054; MUNDY GR, 1990, ANN NY ACAD SCI, V593, P91, DOI 10.1111/j.1749-6632.1990.tb16102.x; NAKAMURA S, 1994, BRIT J HAEMATOL, V87, P640, DOI 10.1111/j.1365-2141.1994.tb08330.x; NAKAMURA S, 1994, CYTOKINE, V6, P285, DOI 10.1016/1043-4666(94)90025-6; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1995, J CELL PHYSIOL, V164, P197, DOI 10.1002/jcp.1041640124; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Taipale J, 1996, J BIOL CHEM, V271, P4342; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TSARFATY L, 1994, SCIENCE, V263, P98; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	48	119	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24655	24661		10.1074/jbc.271.40.24655	http://dx.doi.org/10.1074/jbc.271.40.24655			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798732	hybrid			2022-12-25	WOS:A1996VM67400054
J	Krell, T; Horsburgh, MJ; Cooper, A; Kelly, SM; Coggins, JR				Krell, T; Horsburgh, MJ; Cooper, A; Kelly, SM; Coggins, JR			Localization of the active site of type II dehydroquinases - Identification of a common arginine-containing motif in the two classes of dehydroquinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; ASPERGILLUS-NIDULANS; ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; CATABOLIC 3-DEHYDROQUINASE; SUBSTRATE-BINDING; QUTE GENE; PURIFICATION; RESIDUE; CRYSTALLIZATION	A novel method based on electrospray mass spectrometry (Krell, T., Pitt, A. R., and Coggins, J. R. (1995) FEES Lett, 360, 93-96) has been used to localize active site residues in the type I and type II dehydroquinases. Both enzymes have essential hyper-reactive arginine residues, and the type II enzymes have an essential tyrosine residue. The essential hyper-reactive Arg-23 of the Streptomyces coelicolor type II enzyme has been replaced by lysine, glutamine, and alanine residues. The mutant enzymes were purified and shown by CD spectroscopy to be structurally similar to the wild-type enzyme, All three mutant enzymes were much less active, for example the k(cat) of the R23A mutant was 30,000-fold reduced. The mutants all had reduced K-m values, indicating stronger substrate binding, which was confirmed by isothermal titration calorimetry experiments, A role for Arg-23 in the stabilization of a carbanion intermediate is proposed, Comparison of the amino acid sequence around the hyper-reactive arginine residues of the two classes of enzymes indicates that there is a conserved structural motif that might reflect a common substrate binding fold at the active center of these two classes of enzyme.	UNIV GLASGOW, DIV BIOCHEM & MOL BIOL, INST BIOMED & LIFE SCI, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV GLASGOW, DEPT CHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV STIRLING, DEPT BIOL & MOL SCI, STIRLING FK9 4LA, SCOTLAND	University of Glasgow; University of Glasgow; University of Stirling			Horsburgh, Malcolm J/H-9657-2013; Kelly, Sharon/K-4611-2013; Krell, Tino/G-7296-2015; Cooper, Alan/F-7813-2011	Krell, Tino/0000-0002-9040-3166; Cooper, Alan/0000-0001-6709-7343; Kelly, Sharon/0000-0002-3516-1387				BERI RK, 1990, BIOCHEM J, V265, P337, DOI 10.1042/bj2650337; BOYS CWG, 1992, J MOL BIOL, V227, P352, DOI 10.1016/0022-2836(92)90704-N; CHAUDHURI S, 1991, BIOCHEM J, V275, P1; CHAUDHURI S, 1986, BIOCHEM J, V239, P699, DOI 10.1042/bj2390699; Cooper A, 1994, Methods Mol Biol, V22, P137; DASILVA AJF, 1986, BIOCHEM J, V240, P481, DOI 10.1042/bj2400481; DEKA RK, 1994, FEBS LETT, V349, P397, DOI 10.1016/0014-5793(94)00710-1; DEKA RK, 1992, J BIOL CHEM, V267, P22237; DUNCAN K, 1986, BIOCHEM J, V238, P475, DOI 10.1042/bj2380475; EUVERINK GJW, 1992, J GEN MICROBIOL, V138, P2449, DOI 10.1099/00221287-138-11-2449; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; GARBE T, 1991, MOL GEN GENET, V228, P385, DOI 10.1007/BF00260631; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; GILL CS, 1989, ANAL BIOCHEM, V64, P2090; GOURLEY DG, 1994, J MOL BIOL, V241, P488, DOI 10.1006/jmbi.1994.1524; HARRIS J, 1993, J CHEM SOC CHEM COMM, P1080, DOI 10.1039/c39930001080; Haslam E., 1974, SHIKIMATE PATHWAY; HAWKINS AR, 1982, BIOCHEM GENET, V20, P271, DOI 10.1007/BF00484424; HAWKINS AR, 1987, CURR GENET, V11, P491, DOI 10.1007/BF00384611; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10935; KLEANTHOUS C, 1992, BIOCHEM J, V282, P687, DOI 10.1042/bj2820687; KRELL T, 1995, FEBS LETT, V360, P93, DOI 10.1016/0014-5793(95)00083-L; LEECH AP, 1995, J BIOL CHEM, V270, P25827, DOI 10.1074/jbc.270.43.25827; PAGE MI, 1987, ENZYME MECH, P140; PATTHY L, 1980, EUR J BIOCHEM, V105, P387, DOI 10.1111/j.1432-1033.1980.tb04512.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; RUTTER WJ, 1964, FED PROC, V23, P1248; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHNEIER A, 1991, J AM CHEM SOC, V113, P9416, DOI 10.1021/ja00024a085; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAGUCHI H, 1994, J BIOCHEM-TOKYO, V115, P930, DOI 10.1093/oxfordjournals.jbchem.a124441; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; WHITE PJ, 1990, BIOCHEM J, V265, P735, DOI 10.1042/bj2650735; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	37	53	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24492	24497		10.1074/jbc.271.40.24492	http://dx.doi.org/10.1074/jbc.271.40.24492			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798709	hybrid			2022-12-25	WOS:A1996VM67400031
J	LeeFruman, KK; Collins, TL; Burakoff, SJ				LeeFruman, KK; Collins, TL; Burakoff, SJ			Role of the Lck Src homology 2 and 3 domains in protein tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; CROSS-LINKING; KINASE P56LCK; LYMPHOCYTES-T; ZETA-CHAIN; CD4 RECEPTOR; SH3 DOMAINS; ACTIVATION	Many protein tyrosine phosphorylation events that occur as a result of T cell receptor (TCR) stimulation are enhanced when CD4 is co-cross-linked with the TCR, and this increased phosphorylation is thought to be a mechanism by which T cell functions are augmented by CD4. Such enhanced tyrosine phosphorylation was originally attributed to the kinase activity of the CD4-associated tyrosine kinase Lck. However, it has been shown that CD4-associated Lck lacking the catalytic domain can enhance T cell functions, suggesting that the noncatalytic domains of Lck are also important in CD4 signaling. Using T cells expressing various CD4-Lck chimeric molecules, we assessed the role of different Lck domains in early T cell signaling, Following TCR-CD4 co-cross-linking, cells expressing a CD4-Lck full-length chimera showed enhanced tyrosine phosphorylation of many cellular proteins in a CD4-dependent manner. Surprisingly, cells expressing a CD4 Lck chimera lacking the catalytic domain (termed CD4-N32) also showed enhanced phosphorylation. This enhancement of phosphorylation required both the Src homology 2 (SH2) and SH3 domains of Lck, Lck has been postulated to dimerize through the SH2 and SH3 domains. In this way CD4-N32 may interact with endogenous Lck, and although it lacks intrinsic kinase activity, it may be capable of enhancing phosphorylation through the associated full-length Lck. Consistent with this model, when CD4-Lck chimeric molecules were expressed in J.CaM1.6 cells lacking endogenous Lck, CD4-N32 failed to enhance tyrosine phosphorylation. Moreover, a Lck SH2 and SH3 domain fragment expressed as a glutathione S-transferase fusion protein associated with Lck when incubated with activated Jurkat T cell lysates, suggesting that the SH2 and SH3 domains of Lck can associate with endogenous full-length Lck upon activation, Thus, our data suggest that dimerization is an important mechanism of Lck function in T cell activation.	HARVARD UNIV,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02215; HARVARD UNIV,DIV MED SCI,COMM IMMUNOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02215	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard University; Harvard Medical School					NIAID NIH HHS [AI17258] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1993, P NATL ACAD SCI USA, V90, P10285, DOI 10.1073/pnas.90.21.10285; ANDERSON P, 1987, J IMMUNOL, V139, P678; BUDAY L, 1994, J BIOL CHEM, V269, P9019; COLLINS TL, 1992, J IMMUNOL, V148, P2159; COLLINS TL, 1993, P NATL ACAD SCI USA, V90, P11885, DOI 10.1073/pnas.90.24.11885; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EICHMANN K, 1987, EUR J IMMUNOL, V17, P643, DOI 10.1002/eji.1830170510; EMMRICH F, 1987, EUR J IMMUNOL, V17, P529, DOI 10.1002/eji.1830170415; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OWENS T, 1987, P NATL ACAD SCI USA, V84, P9209, DOI 10.1073/pnas.84.24.9209; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1994, J IMMUNOL METHODS, V170, P261, DOI 10.1016/0022-1759(94)90401-4; VEILLETTE A, 1990, EUR J IMMUNOL, V20, P1397, DOI 10.1002/eji.1830200628; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WALKER C, 1987, EUR J IMMUNOL, V17, P873, DOI 10.1002/eji.1830170622; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1988, J IMMUNOL, V141, P3532; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	57	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25003	25010		10.1074/jbc.271.40.25003	http://dx.doi.org/10.1074/jbc.271.40.25003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798782	hybrid			2022-12-25	WOS:A1996VM67400105
J	Savenkova, MI; Newmyer, SL; deMontellano, PRO				Savenkova, MI; Newmyer, SL; deMontellano, PRO			Rescue of His-42->Ala horseradish peroxidase by a Phe-41->His mutation - Engineering of a surrogate catalytic histidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HEME-LINKED IONIZATION; CRYSTAL-STRUCTURE; PROSTHETIC HEME; HYDROGEN-PEROXIDE; COMPOUND-I; RESOLUTION; TRYPTOPHAN-51; SULFOXIDATION; REACTIVITY	Formation of the ferryl (Fe-IV=O) porphyrin radical cation known as Compound I in the reaction of horseradish peroxidase (HRP) with H2O2 is catalyzed by His-42, a residue that facilitates the binding of H2O2 to the iron and subsequent rupture of the dioxygen bond, An H42A mutation was shown earlier to decrease the rate of Compound I formation by a factor of similar to 10(6) and of guaiacol oxidation by a factor of similar to 10(4), In contrast, an F41A mutation has little effect on peroxidative catalysis (Newmyer, S. L., and Ortiz de Montellano, P. R. (1995) J. Biol. Chem. 270, 19430-19438). We report here construction, expression, and characterization of the F41H/H42A double mutant. The pH profile for guaiacol oxidation by this double mutant has a broad maximum at similar to pH 6.3. Addition of H2O2 produces a Compound I species (lambda(max) = 406 nm) that is reduced by 1 eq of K4Fe(CN)(6) to the ferric state (lambda(max) = 407 nm) without the detectable formation of Compound II. A fraction of the heme chromophore is lost in the process, The rate of Compound I formation for the F41H/H42A double mutant is 3.0 x 10(4) M(-1) s(-1). This is to be compared with 0.9 x 10(7) M(-1) s(-1) for wild-type HRP and 19 M(-1) s(-1) for the H42A mutant, The k(cat) values for guaiacol oxidation by wild-type, H42A, and F41H/H42A HRP are 300, 0.015, and 1.8 s(-1). The corresponding k(cat) values for ABTS oxidation are 4900, 0.41, and 100 s(-1), respectively. These results show that a histidine at position 41 substitutes, albeit imperfectly, for His-42 in peroxidative turnover of the enzyme, The F41H/H42A double mutant has peroxidative properties intermediate between those of the native enzyme and the H42A mutant. The F41H/H42A double mutant, however, is a considerably better thioanisole sulfoxidation and styrene epoxidation catalyst than native or H42A HRP, The surrogate catalytic residue introduced by the F41H mutation thus partially compensates for the H42A substitution used to increase access to the ferryl oxygen.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Savenkova, Marina/AAN-9927-2021	Newmyer, Sherri/0000-0003-1039-5416	NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1987, J BIOL CHEM, V262, P1542; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1995, BIOCHEM SOC T, V23, P223, DOI 10.1042/bst0230223; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; Gilfoyle DJ, 1996, EUR J BIOCHEM, V236, P714, DOI 10.1111/j.1432-1033.1996.00714.x; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; MILLER VP, 1992, J BIOL CHEM, V267, P8936; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; OZAKI S, 1995, J AM CHEM SOC, V117, P7056, DOI 10.1021/ja00132a003; OZAKI SI, 1994, J AM CHEM SOC, V116, P4487, DOI 10.1021/ja00089a052; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RODRIGUEZLOPEZ JN, 1996, IN PRESS J BIOINORG; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]	29	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24598	24603		10.1074/jbc.271.40.24598	http://dx.doi.org/10.1074/jbc.271.40.24598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798724	hybrid			2022-12-25	WOS:A1996VM67400046
J	Chen, J; Willingham, T; Shuford, M; Bruce, D; Rushing, E; Smith, Y; Nisen, PD				Chen, J; Willingham, T; Shuford, M; Bruce, D; Rushing, E; Smith, Y; Nisen, PD			Effects of ectopic overexpression of p21WAF1/CIP1 on aneuploidy and the malignant phenotype of human brain tumor cells	ONCOGENE			English	Article						cyclin-dependent kinase inhibitors; cell cycle; tumor suppressors; adenovirus; gene therapy	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; WILD-TYPE P53; CANCER-CELLS; PROSTATE-CANCER; DNA-REPLICATION; IN-VIVO; P21; INHIBITOR; GENE	p21(WAF1/CIP1) is downstream effector of the p53 tumor suppressor gene and a universal cyclin-dependent kinase (CDK) inhibitor. To determine the ability of p21(WAF1/CIP1) to function as a tumor suppressor, we constructed a replication-defective adenovirus vector containing p21(WAF1/CIP1) (Adp21(WAF1/CIP1)) to effect ectopic overexpression in a p53-defective human astrocytoma cell line, U-373MG. We observed a marked decrease in CDC2 and CDK2 kinase activity associated with a corresponding decrease in the amount of CDC2 but not CDK2 protein; a decreased growth potential of Adp21(WAF1/CIP1)-infected cells demonstrated by diminished [H-3]thymidine incorporation, increased cell doubling time and G(1)-arrested cell cycle; an association between Adp21(WAF1/CIP1)-infected cells and inhibition of aneuploid cell accumulation; and an alteration of the malignant phenotype of cells was evidenced by the loss of anchorage-independent growth in soft agar and the failure to induce tumorigenesis in both peripheral and intracerebral xenograft models, including the prevention of tumor formation AdP21(WAF1/CIP1) infection 2 days post tumor cell implantation. AdP21(WAF1/CIP1). AdP21(WAF1/CIP1) appears to be a strong candidate for gene therapy studies based on these studies indicating that Adp21(WAF1/CIP1) inhibits proliferation, tumorigenicity and aneuploidy in human brain tumor cells.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [P20CA060173] Funding Source: NIH RePORTER; NCI NIH HHS [CA60173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREW ME, 1981, J IMMUNOL, V127, P1201; CARDER P, 1993, ONCOGENE, V8, P1397; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN YQ, 1995, CANCER RES, V55, P4536; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; GAO X, 1995, ONCOGENE, V11, P1395; GOMEZFOIX A, 1992, J BIOL CHEM, V267, P25169; GRAHAM FL, 1991, METHODS MOL BIOL GEN, V1, P109; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LIU TJ, 1994, CANCER RES, V54, P3662; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; RUSSELL SJ, 1995, CANCER, V75, P1339, DOI 10.1002/1097-0142(19950315)75:6<1339::AID-CNCR2820750616>3.0.CO;2-F; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAM SW, 1994, CANCER RES, V54, P5816; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	43	68	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1395	1403						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875977				2022-12-25	WOS:A1996VL38400004
J	Pandita, TK; Hall, EJ; Hei, TK; Piatyszek, MA; Wright, WE; Piao, CQ; Pandita, RK; Willey, JC; Geard, CR; Kastan, MB; Shay, JW				Pandita, TK; Hall, EJ; Hei, TK; Piatyszek, MA; Wright, WE; Piao, CQ; Pandita, RK; Willey, JC; Geard, CR; Kastan, MB; Shay, JW			Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny	ONCOGENE			English	Article							ATAXIA-TELANGIECTASIA GENE; HUMAN COLORECTAL-CARCINOMA; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; CYTOGENETIC ANALYSIS; CELLULAR-RESPONSE; P53; RADIATION; PROTEIN; HYBRIDIZATION	Chromosome end-to-end associations seen at metaphase involve telomeres and are commonly observed in cells derived from individuals with ataxia telangiectasia and most types of human tumors, The associations may arise because of short telomeres and/or alterations of chromatin structure, There is a growing consensus that telomere length is stabilized by the activity of telomerase in immortal cells; however, it is not clear why some immortal cells display chromosome end-to-end associations. In the present study we evaluated chromosome end-to-end associations, telomere length and telomerase activity with the tumorigenic status of human bronchial epithelial cells immortalized with human papillomavirus. Oncogenic transformation was initiated using radon simulated alpha-particles and cells evaluated as primary, secondary and metastatic transformants, The fewest chromosome end associations and lowest telomerase activity were observed in the parental immortalized cells, However, increased levels of telomerase activity were detected in alpha-particle survivors while robust telomerase activity was seen in the tumorigenic cell lines, The tumorigenic cells that mere telomerase positive and had the highest frequency of cells with chromosome end-to-end associations mere also metastatic, No correlation was found between telomere length and the different stages of carcinogenicity.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL GENET, BRONX, NY 10461 USA; MED COLL OHIO, TOLEDO, OH 43699 USA; JOHNS HOPKINS MED SCH, DEPT PEDIAT ONCOL, BALTIMORE, MD 21287 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; Johns Hopkins Medicine	Pandita, TK (corresponding author), COLUMBIA UNIV, CTR RADIOL RES, NEW YORK, NY 10032 USA.		Shay, Jerry W/F-7878-2011; Pandita, Tej K/AAM-9188-2020; Piatyszek, Mieczyslaw A./F-9365-2015	Piatyszek, Mieczyslaw A./0000-0003-0502-3239	NATIONAL CANCER INSTITUTE [P01CA012536, P01CA049062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NCI NIH HHS [CA12536, CA49062] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRUZZO MA, 1991, CYTOGENET CELL GENET, V56, P149, DOI 10.1159/000133072; AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; AGGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BENN PA, 1976, AM J HUM GENET, V28, P465; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEWALD GW, 1987, MAYO CLIN PROC, V62, P558, DOI 10.1016/S0025-6196(12)62293-9; DUTRILLAUX B, 1978, CYTOGENET CELL GENET, V20, P70, DOI 10.1159/000130841; FANG G, 1995, TELOMERES, P69; FITZGERALD PH, 1984, HUM GENET, V67, P385, DOI 10.1007/BF00291396; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GRIEDER CW, 1985, CELL, V43, P405; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HEI TK, 1994, CARCINOGENESIS, V15, P431, DOI 10.1093/carcin/15.3.431; HITTELMAN WN, 1988, CANCER GENET CYTOGEN, V30, P301, DOI 10.1016/0165-4608(88)90199-9; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOVACS G, 1987, CANCER GENET CYTOGEN, V28, P363, DOI 10.1016/0165-4608(87)90225-1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS1511; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANDAHL N, 1985, HUM GENET, V71, P321, DOI 10.1007/BF00388457; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; McClintock B, 1941, GENETICS, V26, P234; MEHLA C, 1994, CANCER RES, V554, P236; MOORHEAD PS, 1963, J CELL COMPAR PHYSL, V62, P57, DOI 10.1002/jcp.1030620109; MORGAN R, 1986, HUM GENET, V73, P260, DOI 10.1007/BF00401240; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Muller H., 1938, COLLECT NET, V13, P182; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; *NAT COUNC RAD PRO, 1984, 78 NCRP; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; PANDITA TK, 1983, HUM GENET, V63, P189, DOI 10.1007/BF00291543; PATHAK S, 1988, CYTOGENET CELL GENET, V47, P227, DOI 10.1159/000132555; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRICE C M, 1992, Current Opinion in Cell Biology, V4, P379, DOI 10.1016/0955-0674(92)90002-T; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SALTMAN D, 1989, CYTOGENET CELL GENET, V50, P230, DOI 10.1159/000132766; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCOTT D, 1982, INT J RADIAT BIOL, V42, P679, DOI 10.1080/09553008214551661; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YERGANIAN G., 1962, CYTOGENETICS [BASEL], V1, P314, DOI 10.1159/000129742; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	62	57	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1423	1430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875980				2022-12-25	WOS:A1996VL38400007
J	Bolhuis, H; vanVeen, HW; Brands, JR; Putman, M; Poolman, B; Driessen, AJM; Konings, WN				Bolhuis, H; vanVeen, HW; Brands, JR; Putman, M; Poolman, B; Driessen, AJM; Konings, WN			Energetics and mechanism of drug transport mediated by the lactococcal multidrug transporter LmrP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; P-GLYCOPROTEIN; LACTIC STREPTOCOCCI; RESISTANCE PROTEIN; ACTIVE EFFLUX; GENE; SYSTEMS; CELLS; TETRACYCLINE	The gene encoding the secondary multidrug transporter LmrP of Lactococcus lactis was heterologously expressed in Escherichia coli. The energetics and mechanism of drug extrusion mediated by LmrP were studied in membrane vesicles of E. coli, LmrP-mediated extrusion of tetraphenyl phosphonium (TPP+) from right-side-out membrane vesicles and uptake of the fluorescent membrane probe 1-[4-(trimethylamino)phenyl]-6-phenylhexa-1,3,5-triene (TMA-DPH) into inside-out membrane vesicles are driven by the membrane potential (Delta psi) and the transmembrane proton gradient (Delta pH), pointing to an electrogenic drug/proton antiport mechanism, Ethidium bromide, a substrate for LmrP, inhibited the LmrP-mediated TPP+ extrusion from right-side-out membrane vesicles, showing that LmrP is capable of transporting structurally unrelated drugs. Kinetic analysis of LmrP-mediated TMA-DPH transport revealed a direct relation between the transport rate and the amount of TMA-DPH associated with the cytoplasmic leaflet of the lipid bilayer. This observation indicates that drugs are extruded from the inner leaflet of the cytoplasmic membrane into the external medium. This is the first report that shows that drug extrusion by a secondary multidrug resistance (MDR) transporter occurs by a ''hydrophobic vacuum cleaner'' mechanism in a similar way as was proposed for the primary lactococcal MDR transporter, LmrA.	UNIV GRONINGEN, DEPT MICROBIOL, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, NL-9751 NN HAREN, NETHERLANDS	University of Groningen			Driessen, Arnold J.M./D-1876-2012; van Veen, Hendrik W./A-4162-2008; Bolhuis, Henk/H-8535-2014; Bolhuis, Henk/A-4308-2008; Bolhuis, Henk/M-6677-2019; Bolhuis, Henk/S-2986-2019; Konings, Wilhelmus N./C-7063-2013	van Veen, Hendrik W./0000-0002-9658-8077; Bolhuis, Henk/0000-0002-4772-1898; Bolhuis, Henk/0000-0002-4772-1898; Driessen, Arnold J.M./0000-0001-9258-9104				AHMED M, 1993, J BIOL CHEM, V268, P11086; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BIELICKI JK, 1991, BIOCHIM BIOPHYS ACTA, V1085, P7, DOI 10.1016/0005-2760(91)90225-7; BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092; BOLHUIS H, 1996, IN PRESS EMBO J; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; GASSON MJ, 1983, J BACTERIOL, V154, P1; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Kaback H R, 1974, Methods Enzymol, V31, P698; KOK J, 1984, APPL ENVIRON MICROB, V48, P726, DOI 10.1128/AEM.48.4.726-731.1984; KUHRY JG, 1985, BIOCHIM BIOPHYS ACTA, V845, P60, DOI 10.1016/0167-4889(85)90055-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MOLENAAR D, 1992, J BACTERIOL, V174, P3118, DOI 10.1128/jb.174.10.3118-3124.1992; MULDER HS, 1993, EUR J BIOCHEM, V218, P871, DOI 10.1111/j.1432-1033.1993.tb18443.x; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHINBO T, 1978, ARCH BIOCHEM BIOPHYS, V187, P414, DOI 10.1016/0003-9861(78)90052-8; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STEIN WD, 1994, MOL PHARMACOL, V45, P763; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; VANVEEN HW, 1986, HDB BIOL PHYSICS, V2; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	47	97	99	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24123	24128		10.1074/jbc.271.39.24123	http://dx.doi.org/10.1074/jbc.271.39.24123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798651	Green Published, hybrid			2022-12-25	WOS:A1996VJ44200080
J	Ward, NE; Gravitt, KR; OBrian, CA				Ward, NE; Gravitt, KR; OBrian, CA			Covalent modification of protein kinase C isozymes by the inactivating peptide substrate analog N-biotinyl-Arg-Arg-Arg-Cys-Leu-Arg-Arg-Leu - Evidence that the biotinylated peptide is an active-site affinity label	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; RAT FIBROBLASTS; GROWTH-CONTROL; BINDING-SITE; S-THIOLATION; EXPRESSION; INHIBITION; EPSILON; DOMAIN; OVEREXPRESSION	We recently reported that the peptide substrate analog Arg-Lys-Arg-Cys-Leu-Arg-Arg-Leu (RKRCLRRL) irreversibly inactivates the protein kinase C (PKC) isozymes alpha, beta, and gamma in a dithiothreitol-sensitive manner by an active site-directed mechanism. We hypothesized that the inactivation mechanism entailed covalent complex formation between the PKC isozyme and the inactivator peptide. In this report, N-biotinylated analogs of RKRCLRRL that inactivate Ca2+-dependent PKC activity were designed and tested for their ability to covalently label PKC isozymes. A purified PKC isozyme mixture (alpha, beta, gamma, epsilon, zeta) was incubated with the N-biotinylated peptides and then subjected to denaturing gel electrophoresis, transferred to nitrocellulose, and probed for avidin-reactive species. The Ca2+-dependent PKC subfamily members PKC-alpha, -beta, and -gamma comigrated at 82 kDa and were distinguished by isozyme-specific immunoprecipitation. N-Biotinyl-RRRCLRRL covalently labeled all of the isozymes examined. When the isozymes were denatured prior to incubation with the N-biotinylated peptides, no labeling was observed, Inactivation of the Ca2+-dependent PKC subfamily by the N-biotinylated peptides was associated with covalent labeling of the 82-kDa PKC subspecies. The concentration dependence curves observed with N-biotinyl-RRRCLRRL were similar for inactivation and covalent labeling. The rank order of potency of three N-biotinylated peptides was the same for the inactivation and covalent labeling. Both the inactivation and covalent labeling were dithiothreitol-sensitive, and they were each subject to protection by MgATP and a peptide substrate analog. The covalent label was mapped to the catalytic domain of PKC by limited proteolysis of the modified enzyme. These results provide evidence that the N-biotinylated inactivator peptides are active-site affinity labels of PKC. The inactivator peptides most likely function by S-thiolating the active site Cys residue conserved in PKC. This is the first report to demonstrate covalent labeling of PKC by a peptide substrate analog.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CELL BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			reddy, indra p/C-5363-2011		NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BOTTEGA R, 1992, BIOCHEMISTRY-US, V31, P9025, DOI 10.1021/bi00152a045; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CACACE AM, 1993, ONCOGENE, V8, P2095; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; GESCHER A, 1992, BRIT J CANCER, V66, P10, DOI 10.1038/bjc.1992.209; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V47, P425, DOI 10.1016/0006-2952(94)90037-X; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; Gupta KP, 1996, J BIOL CHEM, V271, P2102, DOI 10.1074/jbc.271.4.2102; HAGIWARA M, 1990, CANCER RES, V50, P5515; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRAUSS RS, 1989, ONCOGENE, V4, P991; KUO JF, 1994, PROTEIN KINASE; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1990, BIOCHEMISTRY-US, V29, P4278, DOI 10.1021/bi00470a003; OBRIAN CA, 1989, MOL PHARMACOL, V36, P355; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SALERNO A, 1993, J BIOL CHEM, V268, P13043; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; WARD NE, 1995, J BIOL CHEM, V270, P8056, DOI 10.1074/jbc.270.14.8056; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; WILCHEK M, 1990, METHOD ENZYMOL, V184, P14; WU JC, 1989, J BIOL CHEM, V264, P7989; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	39	12	12	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24193	24200		10.1074/jbc.271.39.24193	http://dx.doi.org/10.1074/jbc.271.39.24193			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798661				2022-12-25	WOS:A1996VJ44200090
J	Wood, WM; Dowding, JM; Bright, TM; McDermott, MT; Haugen, BR; Gordon, DF; Ridgway, EC				Wood, WM; Dowding, JM; Bright, TM; McDermott, MT; Haugen, BR; Gordon, DF; Ridgway, EC			Thyroid hormone receptor beta 2 promoter activity in pituitary cells is regulated by Pit-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PIT-1; RAT PROLACTIN PROMOTER; ALPHA-SUBUNIT GENE; GROWTH-HORMONE; EXPRESSION; THYROTROPES; PROTEIN; IDENTIFICATION; BINDING; DOMAIN	There are three known thyroid hormone receptor (TR) isoforms that arise from two distinct alpha and beta gene loci. TR alpha 1 and TR beta 1 mRNAs are found in many tissues, whereas mRNA for the N-terminal TR beta 2 variant derived from the beta locus is readily detectable only in the pituitary gland and derived cell sources such as GH3 somatotropes and TtT-97 thyrotropes. We previously isolated the genomic region governing expression of the TR beta 2 isoform in thyrotropes and showed that transcription arose from multiple origins within a 400-base pair (bp) region. We now report that the region extending 500 bp upstream of the putative AUG codon (A is +1) contains six areas of interaction with the pituitary-specific transcription factor Pit-1. In addition there are separate areas that bind other factors present in thyrotrope cells. Promoter deletions revealed that removal of regions containing the Pit-1 sites at -456 to -432, -149 to -127, and -124 to -102 progressively decreased TR beta 2 promoter activity in thyrotropes. A more proximal foot printed area from -65 to -19, which accounted for the remaining promoter activity, contained sites that interacted with recombinant Pit-1; however, extracts of TtT-97 thyrotropes, which express Pit-1, footprinted this proximal region with a pattern of protection that differed from that produced by Pit-1. A comparative deletional analysis demonstrated that a shorter region extending only 204 bp from the AUG was sufficient to support TR beta 2 promoter activity in GH3 somatotropes. The more proximal Pit-1 sites, including the area from -53 to -19, whose pattern differed from Pit-1 in thyrotrope extracts, showed protection patterns with GH3 extracts that were indistinguishable from recombinant Pit-1. Site-directed mutagenesis that abrogated binding of both recombinant Pit-1 and Pit-1-containing nuclear extracts revealed that the two Pit-1 sites between -149 and -102 were important for TR beta 2 promoter activity with the more proximal being most critical. Finally, we showed that TR beta 2 promoter activity in alpha-TSH cells, which do not transcribe the endogenous TR beta 2 locus or produce Pit-1 protein, could be reconstituted to a level approaching that seen in expressing TtT-97 thyrotropes by cotransfecting a Pit-1 expression vector. Activation by Pit-1 was dependent on the same Pit-1 sites shown to be important for basal TR beta 2 promoter activity in thyrotropes as constructs lacking them by deletion or mutation were not stimulated by Pit-1.			Wood, WM (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MED ENDOCRINOL B151,DIV ENDOCRINOL,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL CANCER INSTITUTE [R01CA047411] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47411] Funding Source: Medline; NIDDK NIH HHS [DK-36842] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERBLOM IE, 1990, MOL ENDOCRINOL, V4, P589, DOI 10.1210/mend-4-4-589; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; AYLWIN SJB, 1995, J MOL ENDOCRINOL, V15, P221, DOI 10.1677/jme.0.0150221; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHILDS GV, 1991, ENDOCRINOLOGY, V129, P2767, DOI 10.1210/endo-129-5-2767; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; EISHOLTZ HP, 1991, GENE DEV, V4, P43; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORDON DF, 1993, MOL CELL ENDOCRINOL, V96, P75, DOI 10.1016/0303-7207(93)90097-4; HAUGEN BR, 1994, MOL ENDOCRINOL, V8, P1574, DOI 10.1210/me.8.11.1574; Haugen BR, 1996, J BIOL CHEM, V271, P385, DOI 10.1074/jbc.271.1.385; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN SC, 1994, DEVELOPMENT, V120, P515; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OCRAN KW, 1990, MOL ENDOCRINOL, V4, P766, DOI 10.1210/mend-4-5-766; RAJNARAYAN S, 1995, MOL ENDOCRINOL, V9, P502, DOI 10.1210/me.9.4.502; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SARAPURA VD, 1992, THYROID, V2, P31, DOI 10.1089/thy.1992.2.31; SCHWARTZ HL, 1994, J BIOL CHEM, V269, P24777; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SMITH KP, 1995, J BIOL CHEM, V270, P4484, DOI 10.1074/jbc.270.9.4484; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; SUN JD, 1993, J BIOL CHEM, V268, P1505; SUZUKI S, 1995, MOL ENDOCRINOL, V9, P1288, DOI 10.1210/me.9.10.1288; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WOOD WM, 1994, MOL ENDOCRINOL, V8, P1605, DOI 10.1210/me.8.12.1605; WOOD WM, 1991, MOL ENDOCRINOL, V5, P1049, DOI 10.1210/mend-5-8-1049; WOOD WM, 1990, MOL ENDOCRINOL, V4, P1897, DOI 10.1210/mend-4-12-1897; WOOD WM, 1989, J BIOL CHEM, V264, P14840; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	51	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24213	24220		10.1074/jbc.271.39.24213	http://dx.doi.org/10.1074/jbc.271.39.24213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798664				2022-12-25	WOS:A1996VJ44200093
J	Chen, AP; Beno, DWA; Davis, BH				Chen, AP; Beno, DWA; Davis, BH			Suppression of stellate cell type I collagen gene expression involves AP-2 transmodulation of nuclear factor-1-dependent gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(I) PROMOTER; TRANSGENIC MICE	The regulation of collagen gene expression was studied in culture-activated rat hepatic stellate cells, the fibrogenic effector cell involved in hepatic fibrogenesis, Treatment of cells with a 5-lipoxygenase-specific inhibitor caused a reduction in alpha I(I) collagen mRNA transcript abundance, which suggested that leukotriene production was involved in maintaining the activated cell's high level of collagen mRNA production. The underlying mechanism involved a decrease in collagen gene transcription, Suppression of gene transcription was localized to an nuclear factor-1 (NF-1) binding domain in the proximal promoter and an AP-2 binding domain adjacent to it, Gel retardation assays demonstrated that an increase in AP-2 binding adjacent to the NF-1 site was likely to be the transmodulator responsible for the suppression of the NF-1-dependent gene expression. The data suggest that post translational alterations in AP-2 activity are responsible for this unappreciated mechanism of regulating the collagen gene.	UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,CHICAGO,IL 60637	University of Chicago					NIDDK NIH HHS [DK 02022, DK 40223, DK 42086] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040223, P30DK042086, K08DK002022] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENO DWA, 1995, AM J PHYSIOL-CELL PH, V268, pC604, DOI 10.1152/ajpcell.1995.268.3.C604; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; Davis BH, 1996, J BIOL CHEM, V271, P11039, DOI 10.1074/jbc.271.19.11039; DAVIS BH, 1990, J CLIN INVEST, V86, P2062, DOI 10.1172/JCI114943; DUFAU ML, 1995, J STEROID BIOCHEM, V53, P283, DOI 10.1016/0960-0760(95)00115-G; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUGLUM K, 1995, J CLIN INVEST, V96, P2269, DOI 10.1172/JCI118282; LASKIN DL, 1990, SEMIN LIVER DIS, V10, P293, DOI 10.1055/s-2008-1040485; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066	15	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25994	25998		10.1074/jbc.271.42.25994	http://dx.doi.org/10.1074/jbc.271.42.25994			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824237	hybrid			2022-12-25	WOS:A1996VN18000043
J	Gonzalez, CI; Martin, CE				Gonzalez, CI; Martin, CE			Fatty acid-responsive control of mRNA stability - Unsaturated fatty acid-induced degradation of the Saccharomyces OLE1 transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; 5'->3' EXORIBONUCLEASE; YEAST-CELLS; CEREVISIAE; GENE; DESATURASE; TURNOVER; STABILIZATION; MECHANISM; PROTEIN	The Saccharomyces cerevisiae OLE1 gene encodes the Delta-9 fatty acid desaturase, a highly regulated integral membrane enzyme involved in the formation of unsaturated fatty acids from saturated acyl-coenzyme A precursors, The mRNA levels of the OLE1 gene are regulated by at least two independent control systems that respond to nutrient fatty acids, One involves the unsaturated fatty acid repression of OLE1 transcription; the second, described in this report, involves unsaturated fatty acid-responsive changes in the half-life of the OLE1 mRNA. Measurements of OLE1 mRNA half-life indicate that it is a moderately stable species (t(1/2) = 10 +/- 1.5 min) in cells grown in medium without exogenous fatty acids, Its half-life is drastically reduced (t(1/2) < 2.5 min), in a time-dependent manner, following the addition of unsaturated fatty acids to the growth medium, Saturated fatty acids that have previously been shown to increase activation of OLE1 transcription do not regulate its mRNA stability. Inhibition of translation, by the addition of cycloheximide, slows the nucleolytic degradation of the OLE1 mRNA and blocks the unsaturated fatty acid-triggered reduction in its half-life. This suggests an intimate link between the two processes of mRNA decay and protein synthesis, A chimeric mRNA, produced by replacing the upstream activation and fatty acid-regulated regions of the OLE1 promoter with the GAL1 promoter sequences is destabilized by exogenous unsaturated fatty acids. A similar chimera under GAL1 control that replaces the OLE1 mRNA 5'-untranslated region with GAL1 sequences is not regulated by unsaturated fatty acids, These results suggest that the 5'-untranslated region of the OLE1 mRNA contains sequence elements required for fatty acid-triggered destabilization. Disruption of the XRN1 gene, which encodes a 5' --> 3'-exoribonuclease, results in an approximate g-fold increase in OLE1 mRNA half-life in the absence of fatty acids, Its half-life is reduced when those cells are exposed to unsaturated fatty acids, indicating that the 5'-exoribonuclease encoded by the XRN1 gene is required for the rapid degradation of the OLE1 transcript but is not required for fatty acid-induced destabilization.	BUR BIOL RES,NELSON LABS,PISCATAWAY,NJ 08855						NIGMS NIH HHS [GM45768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BLOOMFIELD DK, 1960, J BIOL CHEM, V235, P337; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; CEREGHINO GP, 1995, MOL BIOL CELL, V6, P1125, DOI 10.1091/mbc.6.9.1125; Choi JY, 1996, J BIOL CHEM, V271, P3581; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON RM, 1993, OVEREXPRESSION OLE 1; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LOMBARDO A, 1992, MOL CELL BIOL, V12, P2941, DOI 10.1128/MCB.12.7.2941; Maniatis T, 1989, DECONTAMINATION DILU; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PARKER R, 1991, METHODS ENZYMOLOGY M, P415; PELTZ SW, 1992, MOL CELL BIOL, V12, P5778, DOI 10.1128/MCB.12.12.5778; PELTZ SW, 1993, CONTROL MRNA STABILI, P291; PIERRAT B, 1993, GENE, V131, P43, DOI 10.1016/0378-1119(93)90667-R; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WYNE KL, 1989, J BIOL CHEM, V264, P16530	31	77	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25801	25809		10.1074/jbc.271.42.25801	http://dx.doi.org/10.1074/jbc.271.42.25801			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824209	hybrid			2022-12-25	WOS:A1996VN18000015
J	Hoang, B; Moos, M; Vukicevic, S; Luyten, FP				Hoang, B; Moos, M; Vukicevic, S; Luyten, FP			Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; POLARITY GENE; EXPRESSION; OSTEOGENIN; CLEAVAGE; SITES	Articular cartilage extracts were prepared to characterize protein fractions with in vivo chondrogenic activity (Chang, S., Hoang, B., Thomas, J. T., Vukicevic, S., Luyten, F. P., Ryba, N. J. P., Kozak, C. A., Reddi, A. H., and Woos, M. (1994) J. Biol. Chem. 269, 28227-28234). Trypsin digestion of highly purified chondrogenic protein fractions allowed the identification of several unique peptides by amino acid sequencing. We discovered a novel cDNA encoding a deduced 36-kDa protein by using degenerate oligonucleotide primers derived from a 30-residue peptide in reverse transcription polymerase chain reactions. Its N-terminal domain showed similar to 50%, amino acid identity to the corresponding region of the Drosophila gene frizzled, which has been implicated in the specification of hair polarity during development. Hydropathy and structural analyses of the open reading frame revealed the presence of a signal peptide and a hydrophobic domain followed by multiple potential serine/threonine phosphorylation sites and a serine-rich C terminus. Cell fractionation studies of primary bovine articular chondrocytes and transfected COS cells suggested that the protein is membrane-associated. In situ hybridization and immunostaining of human embryonic sections demonstrated predominant expression surrounding the chondrifying bone primordia and subsequently in the chondrocytes of the epiphyses in a graded distribution that decreased toward the primary ossification center. Transcripts were present in the craniofacial structures but not in the vertebral bodies. Because it is expressed primarily in the cartilaginous cores of developing long bones during embryonic and fetal development (6-13 weeks) and is homologous to the polarity-determining gene frizzled, we believe that this gene, which we named frzb, is involved in morphogenesis of the mammalian skeleton.	NIDR,BONE RES BRANCH,NIH,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DEV BIOL LAB,BETHESDA,MD 20892; MED SCH ZAGREB,DEPT ANAT,ZAGREB 41000,CROATIA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); US Food & Drug Administration (FDA); University of Zagreb			Moos, Malcolm C/F-3673-2011; Vukicevic, Slobodan/AEG-2646-2022; Luyten, Frank/GPS-7793-2022	Moos, Malcolm C/0000-0002-9575-9938; Vukicevic, Slobodan/0000-0003-4076-0285; 				ADLER PN, 1990, GENETICS, V126, P401; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CARLSON BM, 1994, HUMAN EMBRYOLOGY DEV, P182; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHANG SC, 1994, J BIOL CHEM, V269, P28227; EPIFANO O, 1995, DEVELOPMENT, V121, P1947; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUYTEN FP, 1988, ARCH BIOCHEM BIOPHYS, V267, P416, DOI 10.1016/0003-9861(88)90047-1; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; MOOS M, 1988, J BIOL CHEM, V263, P6005; NARDI JB, 1976, J EMBRYOL EXP MORPH, V36, P489; PELTON RW, 1989, DEVELOPMENT, V106, P759; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUKICEVIC S, 1994, J HISTOCHEM CYTOCHEM, V42, P869, DOI 10.1177/42.7.8014470; Wang YS, 1996, J BIOL CHEM, V271, P4468; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060; ZHENG L, 1995, DEVELOPMENT, V121, P3045	29	207	246	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26131	26137		10.1074/jbc.271.42.26131	http://dx.doi.org/10.1074/jbc.271.42.26131			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824257				2022-12-25	WOS:A1996VN18000063
J	Maurer, F; Medcalf, RL				Maurer, F; Medcalf, RL			Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events - Identification of a functional nonameric AU-rich motif in the 3'-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; FACTOR-ALPHA; SEQUENCE; CELLS; ELEMENTS; EXPRESSION; FIBROBLASTS; STABILITY; POLY(A)	Plasminogen activator inhibitor type 2 (PAI-2) mRNA and antigen levels are synergistically induced in HT-1080 fibrosarcoma cells when treated with a combination of tumor necrosis factor (TNF) and phorbol 12-myristate 13-acetate (PMA). Here we demonstrate that this effect is not fully reflected at the level of gene transcription, suggesting a contribution of post transcriptional events in this induction. Insertion of the 8'-untranslated region (3'-UTR) of PAI-2 mRNA into the 3'-UTR of a rabbit beta-globin reporter gene reduces beta-globin-PAI-2 chimeric mRNA expression in stably transfected cells. The region within the PAI-2 3'-UTR responsible for this effect is located within the 368-nucieotide sequence preceding the poly(A) tail, a segment that includes a nonameric UUAUUUAUU motif. Mutagenesis of this element abolishes the PAI-2 3'-UTR destabilizing effect, revealing a functional role for this motif. TNF and PMA co-treatment of transfected cells increases beta-globin-PAI-2 chimeric mRNA expression 3-4-fold, indicating that the inherently unstable 3'-UTR of PAI-2 mRNA can become stabilized in response to TNF and PMA. Our results indicate that induction of PAI-2 gene expression by TNF and PMA involves both direct transcription as well as mRNA stabilization, the latter involving an AU-rich nonameric motif in the 3'-UTR.	MONASH UNIV,DEPT MED,BOX HILL HOSP,BOX HILL,VIC 3128,AUSTRALIA	Box Hill Hospital; Monash University			Medcalf, Robert L/E-9632-2011					BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P172; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSIN E, 1991, NUCLEIC ACIDS RES, V19, P3881, DOI 10.1093/nar/19.14.3881; Dear AE, 1995, FIBRINOLYSIS, V9, P321, DOI 10.1016/S0268-9499(95)80079-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; FISHER R, 1985, J BIOL CHEM, V260, P1223; GAN HX, 1995, J IMMUNOL, V155, P1304; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MEDCALF RL, 1992, J BIOL CHEM, V267, P12220; MEDCALF RL, 1988, J EXP MED, V168, P751, DOI 10.1084/jem.168.2.751; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; Mikus P, 1996, J BIOL CHEM, V271, P10048, DOI 10.1074/jbc.271.17.10048; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PYTEL BA, 1990, J CELL PHYSIOL, V144, P416, DOI 10.1002/jcp.1041440308; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; WEBB AC, 1987, J EXP MED, V166, P77, DOI 10.1084/jem.166.1.77; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	37	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26074	26080		10.1074/jbc.271.42.26074	http://dx.doi.org/10.1074/jbc.271.42.26074			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824249	hybrid			2022-12-25	WOS:A1996VN18000055
J	Soejima, A; Inoue, K; Takai, D; Kaneko, M; Ishihara, H; Oka, Y; Hayashi, J				Soejima, A; Inoue, K; Takai, D; Kaneko, M; Ishihara, H; Oka, Y; Hayashi, J			Mitochondrial DNA is required for regulation of glucose-stimulated insulin secretion in a mouse pancreatic beta cell line, MIN6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROKE-LIKE EPISODES; TRANSFER RNA(LEU(UUR)) GENE; TRANSFER RNALEU(UUR) GENE; DIABETES-MELLITUS; PROTEIN-SYNTHESIS; LACTIC-ACIDOSIS; POINT MUTATION; MYOPATHY; DELETION; MELAS	To determine whether mtDNA and mitochondrial respiratory function in pancreatic beta cells are necessary for the phenotypic expression of glucose-stimulated in sulin secretion, we used a cultured mouse pancreatic beta cell line, MIN6, and two derivative lines, mtDNA knockout MIN6 (rho(0) MIN6) and mtDNA repopulated cybrid MIN6. The MIN6 cells retain the property of glucose-stimulated insulin secretion, but their mtDNA knockout induced the loss of mitochondrial transcription, translation, and respiration activity, without inhibition of transcription of the insulin gene or loss of succinate dehydrogenase activity, indicating that the observed mitochondrial dysfunction in rho(0) MIN6 cells was not due to a cytotoxic side effect derived from the mtDNA knockout. Moreover, the mtDNA depletion also inhibited both the glucose-stimulated increase in the intracellular free Ca2+ content and the elevation of insulin secretion. The possibility of the involvement of nuclear genome encoded factors in this process was excluded by the observation that the missing sensitivity to extracellular glucose stimulation in rho(0) MIN6 cells was restored reversibly by repopulation with foreign mtDNA and isolating cybrid MIN6 clones. Therefore, these findings provide unambiguous evidence for the involvement of the mitochondrial dysfunction induced by mtDNA impairment in developing pathogeneses of some forms of diabetes mellitus.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN; NATL CANC CTR,RES INST,DIV BIOPHYS,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	University of Tsukuba; National Cancer Center - Japan; University of Tokyo; Yamaguchi University								ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619; ERIZIRIK DL, 1991, BIOCHEM PHARMACOL, V42, P2275; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HANNA MG, 1995, AM J HUM GENET, V56, P1026; HAO HL, 1995, AM J HUM GENET, V56, P1017; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1982, SOMAT CELL GENET, V8, P67, DOI 10.1007/BF01538651; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HAYASHI JI, 1984, CANCER RES, V44, P3957; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; Kaneko M, 1996, FREE RADICAL RES, V24, P299, DOI 10.3109/10715769609088027; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; LUDER A, 1994, J INHERIT METAB DIS, V17, P298, DOI 10.1007/BF00711812; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MIYABAYASHI S, 1991, J INHERIT METAB DIS, V14, P805, DOI 10.1007/BF01799954; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913; MORAES CT, 1991, AM J HUM GENET, V48, P492; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; OKA Y, 1993, LANCET, V342, P527, DOI 10.1016/0140-6736(93)91649-7; ORAHILLY SP, 1986, LANCET, V2, P360; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267; ROTIG A, 1992, AM J HUM GENET, V50, P364; SERRADAS P, 1995, ENDOCRINOLOGY, V136, P5623, DOI 10.1210/en.136.12.5623; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; SUZUKI S, 1994, DIABETES CARE, V17, P1428, DOI 10.2337/diacare.17.12.1428; TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; YADA T, 1993, ENDOCRINOLOGY, V133, P1685, DOI 10.1210/en.133.4.1685	48	128	130	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26194	26199		10.1074/jbc.271.42.26194	http://dx.doi.org/10.1074/jbc.271.42.26194			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824267	hybrid			2022-12-25	WOS:A1996VN18000073
J	Torpey, J; deMontellano, PRO				Torpey, J; deMontellano, PRO			Oxidation of the meso-methylmesoheme regioisomers by heme oxygenase - Electronic control of the reaction regiospecificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN-IX-ALPHA; CARBON-MONOXIDE; PORPHYRINS; MESSENGER; CLEAVAGE	The oxidation of heme by heme oxygenase (HO-1) results in highly regiospecific extrusion of the alpha-meso-carbon as CO and the formation of biliverdin IX alpha. The first step in the accepted mechanism for this process is alpha-meso-hydroxylation of the heme. To define further the reaction mechanism, the oxidations of the four isomers of meso-methylmesoheme by human truncated HO-1 supported by NADPH-cytochrome P450 reductase, H2O2, or ascorbate have been examined. Surprisingly, the results establish that (a) HO-1 can oxidize an alpha-meso-methyl-substituted heme to biliverdin IX alpha without proceeding via the alpha-meso-hydroxy intermediate; (b) the normal HO-1 alpha-regiospecificity is inverted in favor of the substituted gamma-position by introduction of a gamma-meso methyl group; and (c) the beta- and delta-meso-methylmesohemes are oxidized less regiospecifically to mixtures of methyl-substituted and -unsubstituted mesobiliverdins. The results indicate that electronic rather than steric effects primarily control the regiospecificity of heme cleavage by HO-1.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK030297] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01614] Funding Source: Medline; NIDDK NIH HHS [5 P30 DK26743, DK30297] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONNETT R, 1987, J CHEM SOC PERK T 1, P1063, DOI 10.1039/p19870001063; BONNETT R, 1973, J CHEM SOC PERK T 1, P881, DOI 10.1039/p19730000881; BROWN SB, 1981, NATURE, V289, P93, DOI 10.1038/289093a0; FURHOP HH, 1975, PORPHYRINS METALLOPO, P836; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; JACKSON AH, 1968, J CHEM SOC C, P302, DOI 10.1039/j39680000302; LAGARIAS JC, 1982, BIOCHIM BIOPHYS ACTA, V717, P12, DOI 10.1016/0304-4165(82)90373-7; Lemberg R, 1941, BIOCHEM J, V35, P363, DOI 10.1042/bj0350363; LEMBERG R, 1949, HEMATIN COMPOUNDS BI, P453; Lin Q., 1992, INORG CHEM, V31, P4216; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1992, HEME OXYGENASE CLIN, P109; MAINES MD, 1992, HEME OXYGENASE CLIN, P203; MARKS GS, 1994, CELL MOL BIOL, V40, P863; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; MEDFORTH CJ, 1992, J AM CHEM SOC, V114, P9859, DOI 10.1021/ja00051a019; MORELL DB, 1961, BIOCHEM J, V78, P793, DOI 10.1042/bj0780793; MORISHIMA I, 1986, J AM CHEM SOC, V108, P3858, DOI 10.1021/ja00273a067; SAITO S, 1982, P NATL ACAD SCI-BIOL, V79, P1393, DOI 10.1073/pnas.79.5.1393; SAITO S, 1986, J CHEM SOC PERK T 1, P1, DOI 10.1039/p19860000001; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; Schmid R., 1979, PORPHYRINS, V6, P258; SENGE MO, 1995, J CHEM SOC CHEM COMM, P733, DOI 10.1039/c39950000733; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAN HM, 1994, J AM CHEM SOC, V116, P5784, DOI 10.1021/ja00092a032; TENHUNEN R, 1972, BIOCHEMISTRY-US, V11, P1716, DOI 10.1021/bi00759a029; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TORPEY JW, 1995, J ORG CHEM, V60, P2195, DOI 10.1021/jo00112a045; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659	38	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26067	26073		10.1074/jbc.271.42.26067	http://dx.doi.org/10.1074/jbc.271.42.26067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824248	hybrid			2022-12-25	WOS:A1996VN18000054
J	Bunnell, SC; Henry, PA; Kolluri, R; Kirchhausen, T; Rickles, RJ; Berg, LJ				Bunnell, SC; Henry, PA; Kolluri, R; Kirchhausen, T; Rickles, RJ; Berg, LJ			Identification of Itk/Tsk Src homology 3 domain ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; WISKOTT-ALDRICH SYNDROME; CELL ANTIGEN RECEPTOR; C-CBL PROTOONCOGENE; SH3 DOMAINS; T-CELLS; PROTEIN PRODUCT; K-PROTEIN; B-CELLS	The tyrosine kinase Itk/Tsk is a T cell specific analog of Btk, the tyrosine kinase defective in the human immunodeficiency X-Linked agammaglobulinemia and in xid mice. T lymphocytes from Itk-deficient mice are refractory to mitogenic stimuli delivered through the T cell receptor (TCR). To gain insights into the biochemical role of Itk, the binding properties of the Itk SH3 domain were examined. An optimal Itk SH3 binding motif was derived by screening biased phage display libraries; peptides based on this motif bound with high affinity and selectivity to the Itk SH3 domain. Initial studies with T cell lysates indicated that the Itk SH3 domain bound Cbl, Fyn, and other tyrosine phosphoproteins from TCR-stimulated jurkat cells. Under conditions of increased detergent stringency Sam 68, Wiskott-Aldrich Syndrome protein, and hnRNP-K, but not Cbl and Fyn, were bound to the Itk SH3 domain. By examining the ability of different SH3 domains to interact with deletion variants of Sam 68 and WASP, we demonstrated that the Itk-SH3 domain and the SH3 domains of Src family kinases bind to overlapping but distinct sets of proline-rich regions in Sam 68 and WASP.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Takeda Pharmaceutical Company Ltd; Takeda Oncology; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)				Bunnell, Stephen/0000-0001-6887-0828	NIAID NIH HHS [AI37584] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037584] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Gibson S, 1996, J IMMUNOL, V156, P2716; GIBSON S, 1993, BLOOD, V82, P1561; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HOBERT O, 1994, J BIOL CHEM, V269, P20225; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; LIM H, 1994, PROTEIN SCI, V3735, P2233; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; MACHIDE M, 1995, ONCOGENE, V11, P619; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PARSEY MV, 1993, J IMMUNOL, V151, P1881; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Ribon V, 1996, MOL CELL BIOL, V16, P45; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIMON HU, 1992, J CLIN INVEST, V90, P1396, DOI 10.1172/JCI116006; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WEISS A, 1984, J IMMUNOL, V133, P123; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WIJFFELS GL, 1992, EXP PARASITOL, V74, P87, DOI 10.1016/0014-4894(92)90142-W; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	77	148	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25646	25656		10.1074/jbc.271.41.25646	http://dx.doi.org/10.1074/jbc.271.41.25646			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810341	hybrid			2022-12-25	WOS:A1996VL69300085
J	Griac, P; Swede, MJ; Henry, SA				Griac, P; Swede, MJ; Henry, SA			The role of phosphatidylcholine biosynthesis in the regulation of the INO1 gene of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-PATHWAY REGULATION; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID BIOSYNTHESIS; INOSITOL SYNTHESIS; CHOLINE KINASE; MUTANTS; METHYLATION; EXPRESSION; DEFICIENT; GROWTH	In yeast, as in other eukaryotes, phosphatidylcholine (PC) can be synthesized via methylation of phosphatidylethanolamine or from free choline via the CDP-choline pathway, In yeast, PC biosynthesis is required for the repression of the phospholipid biosynthetic genes, including the INO1 gene, in response to inositol. In this study, we analyzed the effect of mutations in genes encoding enzymes involved in PC biosynthesis on the transcriptional regulation of phospholipid biosynthetic genes. We report that repression of INO1 transcription in response to inositol is clearly dependent on ongoing PC biosynthesis, but it is independent of the route of synthesis. Our results also suggest that intermediates in the phosphatidylethanolamine methylation and CDP-choline pathways are not responsible for generating the regulatory signal that results in repression of INO1 and other coregulated genes of phospholipid biosynthesis. Furthermore, repression of INO1 is not tightly correlated to the proportion of PC in the total cellular phospholipids, Rather, we report that when the rate of synthesis of PC becomes growth limiting, the addition of inositol fails to repress the phospholipid biosynthetic genes, but when the rate of PC synthesis is sufficient to sustain normal growth, the addition of inositol to the growth medium has the effect of repressing INO1 and other phospholipid biosynthetic genes.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University			Swede, Marci/AAD-3921-2021; , Peter/ABA-9227-2020; Henry, Susan/K-5464-2014	Swede, Marci/0000-0002-3003-4258; , Peter/0000-0003-3538-0405; 	NIGMS NIH HHS [GM-19629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM019629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BJORNSTAD P, 1966, J LIPID RES, V7, P38; BREMER J, 1960, BIOCHIM BIOPHYS ACTA, V37, P173, DOI 10.1016/0006-3002(60)90104-9; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1983, J BACTERIOL, V153, P791, DOI 10.1128/JB.153.2.791-799.1983; GRIAC P, 1996, NATO ASI SER, P339; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HUDAK KA, 1994, GENETICS, V136, P475; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; LAMPING E, 1995, GENETICS, V137, P55; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; LI ZY, 1993, MOL GEN GENET, V241, P680, DOI 10.1007/BF00279911; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1978, METHODS YEAST GENETI; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; SUMMERS E, 1989, THESIS A EINSTEIN CO; SUMMERS EF, 1988, GENETICS, V120, P909; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1	30	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25692	25698		10.1074/jbc.271.41.25692	http://dx.doi.org/10.1074/jbc.271.41.25692			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810347	hybrid			2022-12-25	WOS:A1996VL69300091
J	Levy, AP; Levy, NS; Goldberg, MA				Levy, AP; Levy, NS; Goldberg, MA			Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel Lindau protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; AU-RICH ELEMENTS; UNTRANSLATED REGIONS; STABILITY; SEQUENCE; CELLS; AUUUA; GENE; STABILIZATION; VEGF	Hypoxia induces an increase in the stability of the mRNA encoding vascular endothelial growth factor (VEGF). We have previously demonstrated that a 500-base region of the 3'-untranslated region of VEGF mRNA that is critical for stabilization of VEGF mRNA in an in vitro degradation assay forms a RNA-protein complex in a hypoxia-inducible fashion. We report here the identification of three adenylate-uridylate-rich RNA elements within this region that form an identical or closely related hypoxia-inducible RNA-protein complex. This complex is constitutively elevated in a tumor cell line lacking the wild type von Hippel-Lindau tumor suppressor gene and in which VEGF mRNA is constitutively stabilized, Furthermore, the glucose transporter-1 mRNA, which is also stabilized by hypoxia, forms a hypoxia-inducible RNA-protein complex with similar sequence and protein binding characteristics to that described for VEGF mRNA. Finally, RNA affinity purification and UV cross linking were used to identify three proteins of 32, 28, and 17 kDa that are derived from this hypoxia-inducible RNA-protein complex.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BOSTON UNIV,SCH MED,EVANS DEPT MED,WHITAKER CARDIOVASC INST,BOSTON,MA 02118	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003405, F32HL008838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045098] Funding Source: NIH RePORTER; NHLBI NIH HHS [1K08HL03405-01, 1F32HL08838-02] Funding Source: Medline; NIDDK NIH HHS [DK45098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MYER VE, 1995, RNA, V1, P171; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P5007, DOI 10.1093/nar/13.14.5007; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Sharma H S, 1992, EXS, V61, P255; SHARMA HS, 1992, J CARDIOVASC PHARM, V20, pS23, DOI 10.1097/00005344-199206201-00006; SHARMA HS, 1992, J MOL CELL CARDIOL, V24, pS10, DOI 10.1016/0022-2828(92)91543-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SKOOG DA, 1988, ANAL CHEM, P74; STEIN I, 1995, MOL CELL BIOL, V15, P5363; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WANG XM, 1995, MOL CELL BIOL, V15, P1769; White FC, 1995, GROWTH FACTORS, V12, P289, DOI 10.3109/08977199509028967; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	42	189	196	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25492	25497		10.1074/jbc.271.41.25492	http://dx.doi.org/10.1074/jbc.271.41.25492			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810320	hybrid			2022-12-25	WOS:A1996VL69300064
J	Matsuoka, Y; Hughes, CA; Bennett, V				Matsuoka, Y; Hughes, CA; Bennett, V			Adducin regulation - Definition of the calmodulin-binding domain and sites of phosphorylation by protein kinase A and C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-ADDUCIN; ERYTHROCYTE-MEMBRANE; BETA-ADDUCIN; SUBSTRATE-SPECIFICITY; PLASMA-MEMBRANE; BASIC RESIDUES; IDENTIFICATION; FAMILY; MARCKS; PURIFICATION	Adducin promotes association of spectrin with actin and caps the fast growing end of actin filaments. Adducin contains N-terminal core, neck, and C-terminal tail domains, is a substrate for protein kinases A (PKA) and C (PKC), and binds to Ca2+/calmodulin. Ser-726 and Ser-713 in the C-terminal MARCKS-related domains of alpha- and beta-adducin, respectively, were identified as the major phosphorylation sites common for PKA and PKC, PKA, in addition, phosphorylated alpha-adducin at Ser-408, -436, and -481 in the neck domain, Phosphorylation by PKA,but not PKC, reduced the affinity of adducin for spectrin-F-actin complexes as well as the activity of adducin in promoting binding of spectrin to F-actin. The myristoylated alanine-rich protein kinase C substrate-related domain of beta-adducin was identified as the dominant Ca2+-dependent calmodulin-binding site. Calmodulin-binding was inhibited by phosphorylation of beta-adducin and of a MARCKS-related domain peptide by PRA and PRC. Calmodulin in turn inhibited the rate, but not the extent, of phosphorylation of beta-adducin, but not alpha-adducin, by PKA and that of each subunit by PKC. These findings suggest a complex reciprocal relationship between regulation of adducin function by calmodulin binding and phosphorylation by PKA and PKC.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Duke University	Matsuoka, Y (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; Beavo J A, 1974, Methods Enzymol, V38, P299; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLUMENTHAL DK, 1978, J BIOL CHEM, V253, P334; BYLUND DB, 1975, J BIOL CHEM, V250, P6355; DERICK LH, 1992, EUR J CELL BIOL, V57, P317; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; KUSUBATA M, 1993, BIOCHEM BIOPH RES CO, V190, P927, DOI 10.1006/bbrc.1993.1138; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; LIN BY, 1995, GENOMICS, V25, P93, DOI 10.1016/0888-7543(95)80113-Z; LING E, 1986, J BIOL CHEM, V261, P13875; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MIYAZAKI M, 1994, BIOCHEM BIOPH RES CO, V205, P460, DOI 10.1006/bbrc.1994.2688; NEHLS V, 1991, BLOOD, V78, P1692; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; PALFREY HC, 1985, J BIOL CHEM, V260, P6021; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; Schengrund CL, 1996, J NEUROCHEM, V66, P2556; SEIDEL B, 1995, BRAIN RES, V700, P13, DOI 10.1016/0006-8993(95)00962-P; SINARD JH, 1995, MOL BIOL CELL, V6, P1562; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STULL JT, 1993, MOL CELL BIOCHEM, V128, P229, DOI 10.1007/BF01076774; TRIPODI G, 1991, BIOCHEM BIOPH RES CO, V177, P939, DOI 10.1016/0006-291X(91)90629-L; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WOODGETT JR, 1994, PROTEIN KINASES, P30	51	142	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25157	25166		10.1074/jbc.271.41.25157	http://dx.doi.org/10.1074/jbc.271.41.25157			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810272	hybrid			2022-12-25	WOS:A1996VL69300016
J	Raveh, T; Hovanessian, AG; Meurs, EF; Sonenberg, N; Kimchi, A				Raveh, T; Hovanessian, AG; Meurs, EF; Sonenberg, N; Kimchi, A			Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; NF-KAPPA-B; MONOCLONAL-ANTIBODIES; GENE-TRANSFER; HELA-CELLS; P68 KINASE; BINDING; PKR; EXPRESSION; ACTIVATION	The antiproliferative functions of interferons result from specific effects that these cytokines exert on several cell cycle-controlling genes. The possible coupling between the interferon-responsive genes that are directly transactivated by the interferon signaling and the genes that constitute the basic machinery of the cell cycle is not clear yet, We report in this work that interferon-induced double-stranded RNA-activated kinase (PKR) is one of the specific mediators of the antiproliferative effects of the cytokine. Transfections of M1 myeloid leukemia cells with two catalytically inactive mutant forms of PKR abrogated the ability of interferon to suppress c-Myc without interfering with the pRB/cyclin D responses. As a consequence, these genetically manipulated cells displayed a small but significant reduction in their growth sensitivity to interferons, a phenotype that characterizes a single pathway disruption. Transfection of the parental M1 cells with the functional wildtype human PKR restricted their proliferation in the absence of interferons. This PKR-mediated growth inhibition could be efficiently rescued by the ectopic expression of deregulated c-myc. Taken together these results prove the existence of direct or indirect links between PKR and c-Myc suppression, thereby placing this gene along one of the complementary growth suppressive pathways that are triggered by interferons.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL; INST PASTEUR,CNRS,UA 1157,UNIT VIROL CELLULAR IMMUNOL,F-75015 PARIS,FRANCE; MCGILL UNIV,CTR CANC,FAC MED,MONTREAL,PQ H3G 1Y6,CANADA	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; McGill University								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; DEBENEDETTI A, 1984, NATURE, V311, P79, DOI 10.1038/311079a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; ICHIKAWA Y, 1969, CELL PHYSL, V74, P233; KADEREIT S, 1994, J INTERFERON RES, V14, P251, DOI 10.1089/jir.1994.14.251; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KLEIN E, 1968, CANCER RES, V28, P1300; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEURS EF, 1992, J VIROL, V66, P5804; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; RICE AP, 1989, J BIOL CHEM, V264, P20632; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823	41	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25479	25484		10.1074/jbc.271.41.25479	http://dx.doi.org/10.1074/jbc.271.41.25479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810318	hybrid			2022-12-25	WOS:A1996VL69300062
J	Wang, GF; Tamas, MJ; Hall, MJ; PascualAhuir, A; Perlin, DS				Wang, GF; Tamas, MJ; Hall, MJ; PascualAhuir, A; Perlin, DS			Probing conserved regions of the cytoplasmic LOOP1 segment linking transmembrane segments 2 and 3 of the Saccharomyces cerevisiae plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT PMA1 MUTANTS; SARCOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; SCHIZOSACCHAROMYCES-POMBE; YEAST; SITES; MUTATIONS; CA-2+-ATPASE	Genetic probing was used to examine conserved amino acid clusters in the first cytoplasmic loop domain (LOOP1) linking transmembrane segments 2 and 3 of the plasma membrane H+-ATPase from Saccharomyces cerevisiae. Deletion of the LOOP1 region in PMA1 resulted in a defective enzyme. Scanning alanine mutagenesis of conserved residues produced lethal cell phenotypes in 14 of 26 amino acids, suggesting major enzyme defects. Most viable mutants showed growth characteristics that were comparable to wild type. Two mutations, I183A and D185A, produced reduced growth rates, hygromycin B resistance, and low pH sensitivity, which are phenotypes associated with defects in the H+-ATPase. However, both mutant enzymes displayed near-normal kinetics for ATP hydrolysis in vitro. Localized random mutagenesis was also performed at sites Glu(195), Val(196) and Ile(210), which all showed lethal phenotypes upon conversion to alanine. Amino acids with polar side groups could substitute for Glu(195), while Val(196) could not tolerate polar side group moieties, Nine mutations at Ile(210) proved lethal, including K, R, E, P, H, N, V, G, and A, while functional enzyme was obtained with S, C, M, and L. Normal rates and extents of pH gradient formation were observed for all mutant enzymes, except I183A and D185A. Detailed analysis of the I183A enzyme indicated that it hydrolyzed ATP like wild type, but it appeared to inefficiently couple ATP hydrolysis to proton transport. In total, these results affirm that conserved amino acids in LOOP1 are important to H+-ATPase function, and purturbations in this region can alter the efficiency of energy coupling.	PUBL HLTH RES INST,NEW YORK,NY 10016				Perlin, David S/K-4013-2015; Pascual-ahuir, Amparo/K-1338-2014; Tamas, Markus J/E-8183-2010	Tamas, Markus J/0000-0002-0762-7848; PASCUAL-AHUIR, AMPARO/0000-0001-6173-1526	NIGMS NIH HHS [GM 38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BANDELL M, 1995, BIOCHIM BIOPHYS ACTA, V1280, P81; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GHISLAIN M, 1992, EUR J BIOCHEM, V209, P275, DOI 10.1111/j.1432-1033.1992.tb17286.x; GOFFEAU A, 1990, J BIOL CHEM, V265, P15508; HARRIS S, 1993, GENETICS, V135, P55; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; NA SQ, 1993, J BIOL CHEM, V268, P11792; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PERLIN DS, 1984, J BIOL CHEM, V259, P7884; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; POTENZA M, 1992, YEAST, V8, P549, DOI 10.1002/yea.320080706; RAO R, 1992, BIOPHYS J, V62, P228, DOI 10.1016/S0006-3495(92)81808-8; RESTALL CJ, 1989, BIOCHEM SOC T, V17, P509, DOI 10.1042/bst0170509; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; SCOTT TL, 1982, J MEMBRANE BIOL, V64, P137, DOI 10.1007/BF01870879; SERRANO R, 1989, BIOCHEM SOC T, V17, P973, DOI 10.1042/bst0170973; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SETOYOUNG D, 1994, J BIOL CHEM, V269, P23988; SetoYoung D, 1996, J BIOL CHEM, V271, P581, DOI 10.1074/jbc.271.1.581; SETOYOUNG D, 1991, J BIOL CHEM, V266, P1383; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TOROK K, 1988, EUR J BIOCHEM, V173, P361, DOI 10.1111/j.1432-1033.1988.tb14006.x; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	44	27	27	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25438	25445		10.1074/jbc.271.41.25438	http://dx.doi.org/10.1074/jbc.271.41.25438			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810313	hybrid			2022-12-25	WOS:A1996VL69300057
J	Elliott, S; Lorenzini, T; Yanagihara, D; Chang, D; Elliott, G				Elliott, S; Lorenzini, T; Yanagihara, D; Chang, D; Elliott, G			Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID PROGENITOR CELLS; HUMAN GROWTH-HORMONE; TYROSINE PHOSPHORYLATION; ERYTHROLEUKEMIA-CELLS; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CLONING; SUPERFAMILY; EXPRESSION; COMPLEX	Oligomerization of cytokine receptors including the erythropoietin (EPO) receptor has been advanced as a model for activation. If homodimerization of the EPO receptor activates it, then bivalent antibodies raised to the extracellular domain of the EPO receptor should also homodimerize and activate. Mouse monoclonal antibodies (IgG) raised to the soluble, extracellular domain of the human EPO receptor (EPOR) were found that would stimulate thymidine uptake of an human EPO-dependent cell line, UT-7/EPO. Dose response curves showed bell shapes where activity was low at low and high concentrations. Monovalent (Fab) fragments bound to the receptor but did not stimulate thymidine uptake, which indicates that two antibody binding sites are required for activation. The anti-EPOR antibodies stimulated the formation of burst forming unit erythroid colonies from human CD34(+) cells purified from peripheral blood. This indicates that homodimerization of the EPO receptor by anti-EPOR antibodies is sufficient for both proliferation and differentiation of erythroid progenitor cells and that the constraints on dimerization necessary for activation are rather loose.			Elliott, S (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.							BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROUDY VC, 1988, P NATL ACAD SCI USA, V85, P6513, DOI 10.1073/pnas.85.17.6513; CAMPBELL AM, 1984, LAB TECHNIQUES BIOCH, V13, P160; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAMEN JE, 1993, BLOOD, V81, P3204; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONG YJ, 1993, EXP HEMATOL, V21, P483; Elliott S, 1996, BLOOD, V87, P2714, DOI 10.1182/blood.V87.7.2714.bloodjournal8772714; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; IHLE JN, 1981, J IMMUNOL, V126, P2184; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JONES SS, 1990, BLOOD, V76, P31; KLINGMUELLER U, 1995, CELL, V80, P7629; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOMATSU N, 1993, BLOOD, V82, P456; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; PONTING ILO, 1994, EXP HEMATOL, V22, P496; SAWYER ST, 1989, J BIOL CHEM, V264, P13343; SAWYER ST, 1987, P NATL ACAD SCI USA, V84, P3690, DOI 10.1073/pnas.84.11.3690; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; SPIVAK JL, 1991, BLOOD, V77, P1228; TORTI M, 1992, J BIOL CHEM, V267, P8293; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WINKELMANN JC, 1990, BLOOD, V76, P24; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	46	64	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24691	24697		10.1074/jbc.271.40.24691	http://dx.doi.org/10.1074/jbc.271.40.24691			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798737	hybrid			2022-12-25	WOS:A1996VM67400059
J	Fan, G; Merritt, SE; Kortenjann, M; Shaw, PE; Holzman, LB				Fan, G; Merritt, SE; Kortenjann, M; Shaw, PE; Holzman, LB			Dual leucine zipper-bearing kinase (DLK) activates p46(SAPK) and p38(mapk) but not ERK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; C-FOS EXPRESSION; PROTEIN-KINASE; MAMMALIAN-CELLS; V-RAF; IDENTIFICATION; ELK-1; CDC42; JNK; PHOSPHORYLATION	Because the catalytic domain of dual leucine zipper-bearing kinase (DLK) bears sequence similarity to members of the mitogen-activated protein (MAP) kinase kinase kinase subfamily, this protein kinase was investigated for its ability to activate MAP kinase pathways. When transiently transfected and overexpressed in either COS 7 cells or NIH3T3 cells, wild type DLK potently activated p46(SAPK) (SAPK/JNK) but had no detectable effect in activating p42/44(MAPK). DLK also activated p38(mapk) when overexpressed in NIH3T3 cells. A catalytically inactive point mutant of DLK had no effect in these experiments. Consistent with its specificity in activating SAPK, DLK activated Elk-1 but not Sapla-mediated transcription. In NIH3T3 cells, activation of SAPK by v-Src was markedly attenuated by coexpression of K185A, a catalytically inactive mutant of DLK, suggesting that this mutant could function in a dominant negative fashion in a pathway that leads from v-Src to SAPKs. In a series of co-transfection experiments, activation of p46(SAPK) by DLK was not inhibited by dominant negative mutants of Rad and Cdc42Hs, PAK65-R, or PAK65-A, but was attenuated by MEKK1(K432M). DLK(K185A) did not inhibit the ability of constitutively active MEKK1 to activate SAPK. Moreover, K185A significantly inhibited the activation of SAPK by constitutively active V-12 Rad and V-12 Cdc42Hs. These results suggest that DLK lies distal to Rac1 and/or Cdc42Hs but proximal to MEKK1 in a pathway leading from v-Src to SAPKs activation.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109; DEPT VET AFFAIRS,ANN ARBOR,MI 48105; MAX PLANCK INST IMMUNBIOL,SPEMANN LABS,D-79108 FREIBURG,GERMANY	University of Michigan System; University of Michigan; Max Planck Society				Holzman, Lawrence/0000-0002-8961-234X; SHAW, Peter/0000-0002-2598-4283				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gille H, 1996, MOL CELL BIOL, V16, P1094; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Kamano H, 1995, ONCOGENE, V11, P2575; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; STRAHL T, 1996, IN PRESS P NATL ACAD; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	52	116	131	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24788	24793		10.1074/jbc.271.40.24788	http://dx.doi.org/10.1074/jbc.271.40.24788			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798750	hybrid			2022-12-25	WOS:A1996VM67400072
J	Kwiatkowski, AV; Shapleigh, JP				Kwiatkowski, AV; Shapleigh, JP			Requirement of nitric oxide for induction of genes whose products are involved in nitric oxide metabolism in Rhodobacter sphaeroides 2.4.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-STUTZERI; CONTINUOUS CULTURE; FNR FAMILY; DENITRIFICATION; ACTIVATION; REDUCTION; ENZYMES; PROTEIN; CELLS; EXPRESSION	During denitrification, freely diffusible nitric oxide (NO) is generated for use as a terminal electron acceptor. NO is produced by nitrite reductase (Nir) and reduced to nitrous oxide by nitric oxide reductase (Nor). Using Nir and Nor-deficient mutants of Rhodobacter sphaeroides 2.4.3, we have shown that the endogenous production of NO or the addition of exogenous NO induces transcription of certain genes encoding Nir and Nor. A Nor-deficient strain was found to be capable of expressing wild type levels of nirK-lacZ and norB-lacZ fusions in medium unamended with nitrogen oxides, When this experiment is performed in the presence of hemoglobin, fusion expression is eliminated. NO and the NO generator, sodium nitroprusside, can induce expression of both fusions in a strain lacking Nir and the consequent ability to produce NO. Sodium nitroprusside cannot induce expression of nirK-lacZ in a strain lacking the transcriptional activator NnrR (nitrite and nitric oxide reductase regulator). Addition of the cyclic nucleotides cAMP and 8-bromoguanosine-cGMP does not result in expression of either fusion. These results demonstrate that denitrifying bacteria produce NO as a signal molecule to activate expression of the genes encoding proteins required for NO metabolism.	CORNELL UNIV,DEPT MICROBIOL,ITHACA,NY 14853	Cornell University								ARAI H, 1995, FEBS LETT, V371, P73, DOI 10.1016/0014-5793(95)00885-D; BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; COYNE MS, 1990, FEMS MICROBIOL ECOL, V73, P263, DOI 10.1016/0378-1097(90)90738-C; DIODATI JG, 1993, J CARDIOVASC PHARM, V22, P287, DOI 10.1097/00005344-199308000-00018; FERGUSON SJ, 1994, ANTON LEEUW INT J G, V66, P89, DOI 10.1007/BF00871634; GARBERS DL, 1992, CELL, V74, P1; GORETSKI J, 1988, J BIOL CHEM, V263, P2316; GORETSKI J, 1990, J BIOL CHEM, V265, P11535; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HOCHSTEIN LI, 1988, ANNU REV MICROBIOL, V42, P231, DOI 10.1146/annurev.mi.42.100188.001311; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; JAFFREY SR, 1994, P NATL ACAD SCI USA, V91, P12994, DOI 10.1073/pnas.91.26.12994; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KOIKE I, 1975, J GEN MICROBIOL, V88, P11, DOI 10.1099/00221287-88-1-11; KOKOTEK W, 1989, GENE, V84, P467, DOI 10.1016/0378-1119(89)90522-2; KORNER H, 1989, APPL ENVIRON MICROB, V55, P1670; LAZZAZERA BA, 1996, J BIOL CHEM, V271, P2762; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LEUKING DR, 1978, J BIOL CHEM, V253, P451; Maniatis T., 1982, MOL CLONING; MARAGOS CM, 1993, CANCER RES, V53, P564; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MICHALSKI WP, 1988, FEMS MICROBIOL LETT, V52, P239; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1995, CURR OPIN IMMUNOL, V3, P65; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PARIENTE F, 1996, IN PRESS ANAL CHEM; PAYNE WJ, 1981, DENITRIFICATION, P79; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; SPIRO S, 1994, ANTON LEEUW INT J G, V66, P23, DOI 10.1007/BF00871630; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STEWART V, 1994, ANTON LEEUW INT J G, V66, P37, DOI 10.1007/BF00871631; Tosques IE, 1996, J BACTERIOL, V178, P4958, DOI 10.1128/jb.178.16.4958-4964.1996; VANSPANNING RJM, 1995, FEBS LETT, V360, P151, DOI 10.1016/0014-5793(95)00091-M; YAU KW, 1994, P NATL ACAD SCI USA, V91, P1267; YE RW, 1992, J BACTERIOL, V174, P2560, DOI 10.1128/jb.174.8.2560-2564.1992; ZUMFT WG, 1993, ARCH MICROBIOL, V160, P253, DOI 10.1007/BF00292074; ZUMFT WG, 1994, EUR J BIOCHEM, V219, P481, DOI 10.1111/j.1432-1033.1994.tb19962.x	44	71	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24382	24388		10.1074/jbc.271.40.24382	http://dx.doi.org/10.1074/jbc.271.40.24382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798693	hybrid			2022-12-25	WOS:A1996VM67400015
J	Ornatsky, OI; McDermott, JC				Ornatsky, OI; McDermott, JC			MEF2 protein expression, DNA binding specificity and complex composition, and transcriptional activity in muscle and non-muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; C-JUN PROMOTER; SKELETAL-MUSCLE; REGULATORY ELEMENTS; POSITIVE AUTOREGULATION; MYOGENIC LINEAGE; SERUM INDUCTION; MRF4 PROMOTER; TATA ELEMENT; MINOR GROOVE	Tissue-specific gene expression can be mediated by complex transcriptional regulatory mechanisms. Based on the dichotomy of the ubiquitous distribution of the myocyte enhancer factor 2 (MEF2) gene mRNAs compared to their cell type-restricted activity, we investigated the basis for their tissue specificity. Electrophoretic mobility shift assays using the muscle creatine kinase MEF2 DNA binding site as a probe showed that HeLa, Schneider, L6E9 muscle, and C2C12 muscle cells have a functional MEF2 binding activity that is indistinguishable based on competition analysis. Interestingly, chloramphenicol acetyltransferase reporter assays showed MEF2 site-dependent trans-activation in myogenic C2C12 cells but no trans-activation by the endogenous MEF2 proteins in HeLa cells. By immunofluorescence, we detected abundant nuclear localized MEF2A and MEF2D protein expression in HeLa cells and C2C12 muscle cells. Using immuno-gel shift analysis and also co-immunoprecipitation studies, we show that the predominant MEF2 DNA binding complex bound to MEF2 sites from either the muscle creatine kinase or c-jun regulatory regions in C2C12 muscle cells is comprised of a MEF2A homodimer, whereas in HeLa cells, it is a MEF2A:MEF2D heterodimer. Thus, the presence of MEF2 DNA binding complexes is not necessarily coupled with trans-activation of target genes. The ability of the MEF2 proteins to activate transcription in vivo correlates with the specific dimer composition of the DNA binding complex and the cellular context.	YORK UNIV,FAC PURE & APPL SCI,DEPT KINESIOL,TORONTO,ON M3J 1P3,CANADA; YORK UNIV,FAC PURE & APPL SCI,DEPT BIOL,TORONTO,ON M3J 1P3,CANADA	York University - Canada; York University - Canada								ANDRES V, 1995, J BIOL CHEM, V270, P23246, DOI 10.1074/jbc.270.40.23246; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DECHESNE CA, 1994, MOL CELL BIOL, V14, P5474, DOI 10.1128/MCB.14.8.5474; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Fickett JW, 1996, MOL CELL BIOL, V16, P437; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HIDAKA K, 1993, MOL CELL BIOL, V13, P6469, DOI 10.1128/MCB.13.10.6469; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LIU ML, 1994, J BIOL CHEM, V269, P28514; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; MORISAKI T, 1993, MOL CELL BIOL, V13, P5854, DOI 10.1128/MCB.13.9.5854; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; Muscat George E. O., 1992, Gene Expression, V2, P111; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NAKATSUJI Y, 1992, MOL CELL BIOL, V12, P4384, DOI 10.1128/MCB.12.10.4384; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; WANG GS, 1994, J BIOL CHEM, V269, P30595; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	50	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24927	24933		10.1074/jbc.271.40.24927	http://dx.doi.org/10.1074/jbc.271.40.24927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798771	hybrid			2022-12-25	WOS:A1996VM67400094
J	Ramjaun, AR; McPherson, PS				Ramjaun, AR; McPherson, PS			Tissue-specific alternative splicing generates two synaptojanin isoforms with differential membrane binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; NERVE-TERMINALS; SH3 DOMAINS; DYNAMIN; PROTEIN; FORMS; DROSOPHILA; ENDOCYTOSIS; MOLECULES; VESICLES	Synaptojanin is an Src homology 3 domain-binding inositol 5-phosphatase that is thought to function in synaptic vesicle endocytosis. It is encoded by a cDNA with two open reading frames separated by an in-frame stop codon. The first open reading frame encodes a 145-kDa form of the protein, whereas a 170-kDa isoform appears to be composed of both open reading frames and contains additional Src homology 3 domain-binding consensus sequences. Here, we demonstrate that the two synaptojanin isoforms are generated by the alternative use of an exon containing the stop codon. Whereas the 145-kDa isoform is highly enriched in adult brain, the 170-kDa isoform is excluded from this tissue and has a widespread distribution in non-neuronal cells. Unlike the 145-kDa isoform, which can be removed from membranes by a low salt wash, the 170-kDa isoform remains membrane-associated, even in the presence of 1 M salt. Further, the 170-kDa form, but not the 145-kDa form, can be isolated from membranes as part of a large molecular weight complex. These properties may allow the 170-kDa isoform of synaptojanin to play a unique and perhaps more general role in endocytosis as compared with the 145-kDa isoform.	MCGILL UNIV,MONTREAL NEUROL INST,CBET GRP,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	McGill University								ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bauerfeind R, 1995, COLD SPRING HARB SYM, V60, P397; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HINSHAW JE, 1995, NATURE, V374, P1905; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MCPHERSON PS, 1996, NATURE, V379, P535; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MORRIS SA, 1995, CURR BIOL, V5, P1; MOUNT SM, 1996, NATURE, V271, P1690; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	41	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24856	24861		10.1074/jbc.271.40.24856	http://dx.doi.org/10.1074/jbc.271.40.24856			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798761	hybrid			2022-12-25	WOS:A1996VM67400083
J	Reddy, SG; McIlheran, SM; Cochran, BJ; Worth, LL; Bishop, LA; Brown, PJ; Knutson, VP; Haddox, MK				Reddy, SG; McIlheran, SM; Cochran, BJ; Worth, LL; Bishop, LA; Brown, PJ; Knutson, VP; Haddox, MK			Multisite phosphorylation of ornithine decarboxylase in transformed macrophages results in increased intracellular enzyme stability and catalytic efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; MULTIPLE IONIC FORMS; AMINO-ACID SEQUENCE; MOUSE KIDNEY; CELL-LINE; POLYAMINE METABOLISM; NUCLEOTIDE-SEQUENCE; ACTIVE-SITE; RAT-HEART; ANTIZYME	Ornithine decarboxylase (ODC) is the initial inducible enzyme in the polyamine biosynthetic pathway, In the transformed macrophage-derived RAW264 cell line, ODC was overproduced and existed in both unphosphorylated and phosphorylated forms, To date, the only protein kinase known to phosphorylate mammalian ODC is casein kinase II (CKII), ODC was phosphorylated in vitro by CKII and subjected to exhaustive sequential proteolysis with trypsin and V8 protease. Two-dimensional peptide mapping showed only a single phosphopeptide; two dimensional phosphoamino acid analysis of the phosphopeptide revealed only P-32-labeled serine. ODC was metabolically radiolabeled with P-32(i) in RAW264 cells and also subjected to proteolysis, two-dimensional peptide mapping, and phosphoamino acid analysis. Two phosphopeptides were generated from the metabolically radiolabeled ODC, including one that migrated similarly to the peptide phosphorylated by CKII in vitro, Each of the in situ radiolabeled ODC peptides contained both P-32-labeled serine and threonine residues. Thus, in RAW264 cells, ODC is phosphorylated on at least one serine residue in addition to that phospho rylated by CKII and on at least two threonine residues. Phosphorylated ODC had an increased stability to intracellular proteolysis compared with unphosphorylated ODC, their half-lives being 49.2 +/- 3.78 and 23.9 +/- 2.6 min (p = 0.001), respectively. The phosphorylated and unphosphorylated forms of ODC were independently purified to homogeneity. Kinetic analysis revealed that the catalytic efficiency of the phosphorylated form of ODC was 50% greater than that of the unphosphorylated form; the unphosphorylated ODC had a V-max of 20.54 +/- 1.65 mu mol/min/mg, whereas the phosphorylated form had a V-max of 30.61 +/- 2.6 mu mol/min/mg (p = 0.005). Phosphorylation of ODC by CKII has no effect on enzyme activity. Taken together, these findings demonstrate that regulation of ODC activity is governed by as yet unidentified protein kinases.	UNIV TEXAS, SCH MED, DEPT PHARMACOL, HOUSTON, TX 77225 USA	University of Texas System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044331] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44331] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERCOVICH Z, 1993, EUR J BIOCHEM, V213, P205, DOI 10.1111/j.1432-1033.1993.tb17749.x; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; COLEMAN CS, 1994, J BIOL CHEM, V269, P3155; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FLAMIGNI F, 1984, BIOCHIM BIOPHYS ACTA, V802, P245, DOI 10.1016/0304-4165(84)90168-5; FLAMIGNI F, 1990, BIOCHIM BIOPHYS ACTA, V1052, P345, DOI 10.1016/0167-4889(90)90232-3; GREENFIELD ARL, 1986, CELL TISSUE RES, V243, P33; HADDOX MK, 1981, BIOCHEMISTRY-US, V20, P6721, DOI 10.1021/bi00526a030; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KAMEJI T, 1993, BIOCHEM J, V289, P581, DOI 10.1042/bj2890581; KAMEJI T, 1982, BIOCHIM BIOPHYS ACTA, V705, P405, DOI 10.1016/0167-4838(82)90263-1; KANAMOTO R, 1993, J BIOL CHEM, V268, P9393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAITINEN SI, 1985, BIOCHEM INT, V10, P559; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LUO R, 1960, ONCOGENE, V5, P921; MADHUBALA R, 1988, BIOCHEM J, V254, P45, DOI 10.1042/bj2540045; MEGGIO F, 1987, BIOCHIM BIOPHYS ACTA, V929, P114, DOI 10.1016/0167-4889(87)90246-1; MEGGIO F, 1984, BIOCHEM BIOPH RES CO, V122, P997, DOI 10.1016/0006-291X(84)91190-2; MITCHELL JLA, 1991, ARCH BIOCHEM BIOPHYS, V290, P143, DOI 10.1016/0003-9861(91)90600-N; MITCHELL JLA, 1982, BIOCHEM BIOPH RES CO, V105, P1189, DOI 10.1016/0006-291X(82)91095-6; MITCHELL JLA, 1988, ARCH BIOCHEM BIOPHYS, V260, P585, DOI 10.1016/0003-9861(88)90485-7; MITCHELL JLA, 1985, BIOCHIM BIOPHYS ACTA, V840, P309, DOI 10.1016/0304-4165(85)90210-7; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1989, EUR J BIOCHEM, V180, P181, DOI 10.1111/j.1432-1033.1989.tb14630.x; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OBRIEN TG, 1986, P NATL ACAD SCI USA, V83, P9448, DOI 10.1073/pnas.83.24.9448; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PENG T, 1988, BIOCHEM BIOPH RES CO, V153, P135, DOI 10.1016/S0006-291X(88)81199-9; PEREIRA MA, 1983, BIOCHEM PHARMACOL, V32, P2511, DOI 10.1016/0006-2952(83)90011-4; PERSSON L, 1984, BIOCHEMISTRY-US, V23, P3777, DOI 10.1021/bi00311a033; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REDDY SG, 1994, ANAL BIOCHEM, V218, P149, DOI 10.1006/abio.1994.1154; REICH DJ, 1985, J CELL BIOL, V101, pA935; RICHARDS JF, 1981, BIOCHEM BIOPH RES CO, V99, P1461, DOI 10.1016/0006-291X(81)90783-X; RICHARDS JF, 1993, ARCH BIOCHEM BIOPHYS, V300, P80, DOI 10.1006/abbi.1993.1012; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V197, P419, DOI 10.1111/j.1432-1033.1991.tb15927.x; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; SEELY JE, 1983, METHOD ENZYMOL, V94, P158; SUMIYOSHI H, 1991, CANCER RES, V51, P2069; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAFFET SM, 1985, J CELL PHYSIOL, V122, P215, DOI 10.1002/jcp.1041220209; TIPNIS UR, 1990, CELL MOL BIOL, V36, P275; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; TSIRKA S, 1992, J BIOL CHEM, V267, P23057; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P124; VANKRANEN HJ, 1987, GENE, V60, P145, DOI 10.1016/0378-1119(87)90222-8; WORTH LL, 1994, CANCER RES, V54, P3967; WORTH LL, 1989, J CELL BIOL, V107, pA855; ZANDOMENI R, 1988, FEBS LETT, V235, P247, DOI 10.1016/0014-5793(88)81272-9	58	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24945	24953		10.1074/jbc.271.40.24945	http://dx.doi.org/10.1074/jbc.271.40.24945			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798774	hybrid			2022-12-25	WOS:A1996VM67400097
J	Sonveaux, N; Shapiro, AB; Goormaghtigh, E; Ling, V; Ruysschaert, JM				Sonveaux, N; Shapiro, AB; Goormaghtigh, E; Ling, V; Ruysschaert, JM			Secondary and tertiary structure changes of reconstituted P-glycoprotein - A Fourier transform attenuated total reflection infrared spectroscopy analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG-RESISTANCE GENE; MEMBRANE H+-ATPASE; PLASMA-MEMBRANE; CONFORMATIONAL-CHANGES; CYSTIC-FIBROSIS; DRUG TRANSPORT; CELLS; EXPRESSION; HOMOLOGY	The structure of purified P-glycoprotein functionally reconstituted into liposomes was investigated by attenuated total reflection Fourier transform infrared spectroscopy. A quantitative evaluation of the secondary structure and a kinetic of H-2/H exchange of the P-glycoprotein were performed both in the presence and in the absence of MgATP, MgATP-verapamil, and MgADP. This approach was previously shown to be a useful tool to detect tertiary structure changes resulting from the interaction between a protein and its specific ligands, as established for the Neurospora crassa H+-ATPase. H-2/H exchange measurements provided evidence that a large fraction of the P-glycoprotein is poorly accessible to the aqueous medium. Addition of MgATP induced an increased accessibility to the solvent of a population of amino acids, while addition of MgATP-verapamil resulted in a subtraction of a part of the protein from access to the aqueous solvent. No significant changes were observed upon addition of MgADP or verapamil alone. The secondary structure of P-glycoprotein was not affected by addition of ligands. The variations observed in the H-2/H exchange rate when P-glycoprotein interacted with the above ligands therefore represented tertiary structure changes. Fluorescence quenching experiments confirmed that MgATP-induced changes are to be found in the tertiary structure of the enzyme.	BRITISH COLUMBIA CANC RES CTR,VANCOUVER,BC V5Z 1L3,CANADA	British Columbia Cancer Agency	Sonveaux, N (corresponding author), FREE UNIV BRUSSELS,CHIM PHYS MACROMOL INTERFACES LAB,CP 206-2,BD TRIOMPHE,B-1050 BRUSSELS,BELGIUM.			Goormaghtigh, Erik/0000-0002-2071-2262				ADDISON R, 1982, J BIOL CHEM, V257, P421; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHIN KV, 1993, ADV CANCER RES, V60, P157; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DEJONGH HHJ, 1995, BIOCHEMISTRY-US, V34, P172, DOI 10.1021/bi00001a021; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1994, SPECTROCHIM ACTA A, V50, P2137; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V195, P421; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; Harrick N.J., 1967, INTERNAL REFLECTION; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SONVEAUX N, 1994, J BIOL CHEM, V269, P25637; TSURUO T, 1982, CANCER RES, V42, P4730; TSURUO T, 1981, CANCER RES, V41, P1967; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; VIGNERON L, 1995, J BIOL CHEM, V270, P17685, DOI 10.1074/jbc.270.30.17685; YUSA K, 1989, CANCER RES, V49, P5002; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	43	102	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24617	24624		10.1074/jbc.271.40.24617	http://dx.doi.org/10.1074/jbc.271.40.24617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798727	hybrid			2022-12-25	WOS:A1996VM67400049
J	Tamami, M; Lindholm, PF; Brady, JN				Tamami, M; Lindholm, PF; Brady, JN			The retinoblastoma gene product (Rb) induces binding of a conformationally inactive nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIB; SUSCEPTIBILITY GENE; FACTOR E2F; LARGE-T; PROTEIN; ACTIVATION; TRANSACTIVATION; PHOSPHORYLATION; DOMAIN; P50	Nuclear factor-kappa B (NF-KB) regulates expression of several viral and cellular genes including the human immunodeficiency virus long terminal repeat, major histocompatibility complex class I, and interleukin 2R alpha cytokine genes. Here we report that the retinoblastoma gene product (Rb) stimulates binding of the NF-kappa B p50 homodimer. The addition of Rb protein to an in vitro gel shift binding assay stimulated p50 binding greater than 10-fold. Interestingly, by analyzing NF-kappa B-dependent transcription activity in vitro, we demonstrate that Rb suppresses transcriptional activity of p50. Chymotrypsin analysis suggests that Rb induces a conformational change in the NF-kappa B-DNA complex, resulting in binding of a transcriptionally inactive complex, Finally, we demonstrate by coimmunoprecipitation analysis that the Rb-p50 complex is present in Jurkat cell extracts. Our results suggest that Rb may play an important role in regulation of NF-kappa B transcriptional activity.	NCI,MOL VIROL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Bohan Cindy A., 1992, Gene Expression, V2, P391; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	39	17	17	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24551	24556		10.1074/jbc.271.40.24551	http://dx.doi.org/10.1074/jbc.271.40.24551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798717	hybrid			2022-12-25	WOS:A1996VM67400039
J	Zhu, SH; Sobolev, AY; Wek, RC				Zhu, SH; Sobolev, AY; Wek, RC			Histidyl-tRNA synthetase-related sequences in GCN2 protein kinase regulate in vitro phosphorylation of eIF-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL CONTROL; MALIGNANT TRANSFORMATION; EIF-2-ALPHA KINASE; INITIATION; YEAST; GENE; ACTIVATION; PURIFICATION	In yeast, starvation for amino acids stimulates GCN2 phosphorylation of the cu subunit of eukaryotic initiation factor-2 (eIF-2). Phosphorylation of eIF-2 alpha induces the translational expression of GCN4, a transcriptional activator of the general amino acid control pathway. It has been proposed that GCN2 sequences containing homology to histidyl-tRNA synthetases (HisRS) bind uncharged tRNA that accumulate during amino acid limitation and stimulate the activity of GCN2 kinase. In this report we address whether the HisRS-related sequences are required for GCN2 phosphorylation of eIF-2 alpha in an in vitro assay. To measure the activity of GCN2 kinase in cellular extracts, we expressed and purified a truncated form of yeast eIF-2 alpha. Phosphorylation of the recombinant eIF-2 alpha substrate was dependent on both GCN2 kinase activity and the eIF-2 alpha phosphorylation site, serine 51. Mutations in the HisRS-related domain of GCN2, which have been shown to block phosphorylation of eIF-2 alpha in vivo and the subsequent stimulation of the general control pathway, also greatly reduced eIF-2 alpha phosphorylation in the in. vitro assay. These results indicate that the HisRS-related sequences are required for activation of GCN2 kinase function.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049164, R01GM049164] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49164] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BOSTEIN D, 1979, GENE, V8, P17; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; ICELY PL, 1991, J BIOL CHEM, V266, P16073; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KAISER C, 1994, METHODS YEAST GENETI, P208; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PROUD CG, 1995, BRENDS BIOCH SCI, V20, P217; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	31	91	94	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24989	24994		10.1074/jbc.271.40.24989	http://dx.doi.org/10.1074/jbc.271.40.24989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798780	hybrid			2022-12-25	WOS:A1996VM67400103
J	Feo, S; DiLiegro, C; Mangano, R; Read, M; Fried, M				Feo, S; DiLiegro, C; Mangano, R; Read, M; Fried, M			The amplicons in HL60 cells contain novel cellular sequences linked to MYC locus DNA	ONCOGENE			English	Article						HL60 amplified DNA; c-myc; chromosome band 8q24; homogenous staining regions; double minutes; FISH	HL-60 LEUKEMIA-CELLS; ONCOGENE C-MYC; GENE AMPLIFICATION; CHROMOSOMAL LOCATION; HUMAN NEUROBLASTOMA; BURKITT-LYMPHOMA; TUMOR-CELLS; CARCINOMA; TRANSLOCATION; EXPRESSION	We have previously determined that the amplified DNA present in the HL60 promyelocytic leukaemia cell line contained 70 kb of continuous DNA sequences around the c-myc gene, In the work presented here we have further defined the HL60 amplicon and find it to be of the order of 160 kb and to contain a large region of DNA from chromosome 8q24 that is located at Least 260 kb telomeric to the c-myc gene, joined to the 70 kb of DNA from the c-myc gene region, The novel chromosome 8 DNA coamplified sequences are not lost during multiple passage of HL60 cells since the composition of the chimeric amplicon is the same in both early passage HL60 cells containing only double minutes (DMs) and late passage isolates containing homogeneous staining regions (HSRs) at different chromosomal locations, This shows that the HL60 HSRs found in late passage cells are not generated anew but are directly derived from the precursor DMs. The HL60 cells contain tao copies of chromosome 8, each with different polymorphic markers, Both these chromosome 8 homologues retain a c-myc gene as sell as the region containing the coamplified DNA sequences indicating that the HL60 amplicons were not generated by simple DNA deletion, The constraint to maintain the novel DNA sequences coamplified with c-myc gene DNA suggests that these sequences may play some role in maintaining the growth potential and/or differentiation capacity of the HL60 cells.	IMPERIAL CANC RES FUND,EUKARYOT GENE ORG & EXPRESS LAB,LONDON WC2A 3PX,ENGLAND; DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-90128 PALERMO,ITALY; CNR,IST BIOL SVILUPPO,I-90123 PALERMO,ITALY	Cancer Research UK; Consiglio Nazionale delle Ricerche (CNR)			Feo, Salvatore/C-1333-2012	Feo, Salvatore/0000-0003-3877-2906; Di Liegro, Carlo Maria/0000-0001-7362-7814				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BAR AI, 1992, GENE CHROMOSOME CANC, V4, P314; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BRENNAN J, 1986, NUCLEIC ACIDS RES, V14, P9224, DOI 10.1093/nar/14.22.9224; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CORVI R, 1995, ONCOGENE, V10, P1081; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; DONTI E, 1991, CANCER GENET CYTOGEN, V56, P57, DOI 10.1016/0165-4608(91)90362-X; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FEO S, 1990, NUCLEIC ACIDS RES, V18, P4949, DOI 10.1093/nar/18.16.4949; FEO S, 1994, ONCOGENE, V9, P955; FEO S, 1986, P NATL ACAD SCI USA, V83, P706, DOI 10.1073/pnas.83.3.706; FRANCIS F, 1994, GENET ANAL-BIOMOL E, V11, P148, DOI 10.1016/1050-3862(94)90035-3; FUKUMOTO M, 1993, SOMAT CELL MOLEC GEN, V19, P21, DOI 10.1007/BF01233951; GALLAGHER R, 1979, BLOOD, V54, P713; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; GRAHAM SV, 1985, LEUKEMIA RES, V9, P239, DOI 10.1016/0145-2126(85)90086-4; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HEARD E, 1991, P NATL ACAD SCI USA, V88, P8242, DOI 10.1073/pnas.88.18.8242; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LEHRACH H., 1990, GENOME ANAL, P39; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; POLYMEROPOULOS MH, 1992, HUM MOL GENET, V1, P65, DOI 10.1093/hmg/1.1.65; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; TYLERSMITH C, 1981, J MOL BIOL, V153, P237, DOI 10.1016/0022-2836(81)90276-X; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VONHOFF DD, 1990, J CLIN INVEST, V85, P1887, DOI 10.1172/JCI114650; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P220; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	39	8	8	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1521	1529						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875990				2022-12-25	WOS:A1996VL38400017
J	Chen, G; Branton, PE; Yang, E; Korsmeyer, SJ; Shore, GC				Chen, G; Branton, PE; Yang, E; Korsmeyer, SJ; Shore, GC			Adenovirus E1B 19-kDa death suppressor protein interacts with Bax but not with Bad	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-2 HOMOLOG BAK; INDUCE APOPTOSIS; MEMBRANE; DOMAIN; P53; INHIBITION; CYTOLYSIS; DNA	Adenovirus E1B 19-kDa protein (19K) is a member of the Bcl-2 family of suppressors of apoptosis. The suppressors function through heterodimerization with the death promoters, Bax and related proteins, thus establishing a set point within the cell that determines whether or not apoptosis is executed in response to a death signal. Sequence similarities between 19K and Bcl-2 are largely restricted to short Bcl-2 homology (BH) domains that mediate interaction with Bax. The BH1 sequence in 19K is degenerate but nevertheless contains a conserved glycine residue found in all family members that when mutated to alanine in Bcl-2 results in loss of Bcl-2 function and ability to dimerize with Bax (Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. (1994) Nature 369, 321-323). Here, we show that the analogous mutation in BH1 of 19K also abrogates the anti-apoptotic properties of 19K and its ability to interact with Bax, thus establishing the critical importance of this residue within BH1 and the likely similarity of Bcl-2 and 19K function. In distinct contrast to Bcl-2, however, 19K interaction was not detected with Bad, a Bcl-2/Bcl-X(L) dimerizing protein that can potentially regulate a Bax-Bcl-2/Bcl-X(L) survival set point and reinstate susceptibility to a death signal. Furthermore, the anti-apoptotic function of 19K was not overcome by enforced expression of Bad in transfected cells. This feature of 19K may provide adenovirus with a selective advantage in evading premature induction of apoptosis by the host cell.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	McGill University; McGill University; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)								BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boulakia CA, 1996, ONCOGENE, V12, P529; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GINGERAS TR, 1982, J BIOL CHEM, V257, P13475; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Subramanian T, 1995, ONCOGENE, V11, P2403; TEODORO JG, 1995, ONCOGENE, V11, P467; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1	39	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24221	24225		10.1074/jbc.271.39.24221	http://dx.doi.org/10.1074/jbc.271.39.24221			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798665	hybrid			2022-12-25	WOS:A1996VJ44200094
J	Couture, C; Deckert, M; Williams, S; Russo, FO; Altman, A; Mustelin, T				Couture, C; Deckert, M; Williams, S; Russo, FO; Altman, A; Mustelin, T			Identification of the site in the Syk protein tyrosine kinase that binds the SH2 domain of Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ANTIGEN RECEPTOR; JURKAT T-CELLS; NATURAL-KILLER-CELLS; FC-EPSILON-RI; ZAP-70 KINASE; ZETA-CHAIN; PHOSPHORYLATION; ACTIVATION; P72(SYK); STIMULATION	The Syk protein tyrosine kinase (PTK) is expressed in many hematopoietic cells and is involved in signaling from various receptors for antigen and Fc portions of IgG and IgE. Upon cross-linking of these receptors, Syk is rapidly phosphorylated on tyrosine residues and enzymatically activated. We and others have found that the Lck kinase, a member of the Src family of PTKs, binds through its Src homology (SH) 2 domain to tyrosine phosphorylated Syk and to the related Zap kinase. Here we report that this interaction is direct and identify the two tandem tyrosines at the autophosphorylation site of Syk, Tyr(518), and Tyr(519), as the binding site for the SH2 domain of Lck. Mutation of either or both tyrosines to phenylalanines abrogated binding, while mutation of a second repetition of the motif at Tyr(539) and Tyr(540), or of the three tyrosines in the C terminus of Syk, did not. The SH2 domain of Lck bound the autophosphorylation site only when both Tyr(518) and Tyr(519) were phosphorylated. In intact cells the binding of the SH2 domain of Lck correlated with the ability of Syk to induce tyrosine phosphorylation of cellular proteins.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, SAN DIEGO, CA 92121 USA	La Jolla Institute for Immunology			Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019	Deckert, Marcel/0000-0003-2094-559X; Mustelin, Tomas/0000-0001-5912-8840	NCI NIH HHS [CA35299] Funding Source: Medline; NIAID NIH HHS [AI35603] Funding Source: Medline; NIGMS NIH HHS [GM48960] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; ASAHI M, 1993, J BIOL CHEM, V268, P23334; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DARBY C, 1994, J IMMUNOL, V152, P5429; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HARPER JW, 1993, CELL, V75, P805; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Law CL, 1996, MOL CELL BIOL, V16, P1305; LUO K, 1990, ONCOGENE, V5, P921; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1995, EUR J IMMUNOL, V25, P942, DOI 10.1002/eji.1830250413; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; OETKEN C, 1994, ONCOGENE, V9, P1625; OETKEN C, 1994, MOL IMMUNOL, V31, P1295, DOI 10.1016/0161-5890(94)90047-7; PINCUS SH, 1989, J IMMUNOL, V142, P3070; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; STAHLS A, 1994, EUR J IMMUNOL, V24, P2491, DOI 10.1002/eji.1830241035; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; VIVIER E, 1993, EUR J IMMUNOL, V23, P1872, DOI 10.1002/eji.1830230821; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WATTS JD, 1994, J BIOL CHEM, V269, P29520; YAMADA T, 1991, BIOCHEM BIOPH RES CO, V180, P1325, DOI 10.1016/S0006-291X(05)81340-3; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	51	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24294	24299		10.1074/jbc.271.39.24294	http://dx.doi.org/10.1074/jbc.271.39.24294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798676	hybrid			2022-12-25	WOS:A1996VJ44200105
J	Marchand, P; Volkmann, M; Bond, JS				Marchand, P; Volkmann, M; Bond, JS			Cysteine mutations in the MAM domain result in monomeric meprin and alter stability and activity of the proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; ALPHA-SUBUNIT; BETA-SUBUNIT; MEMBRANE; PURIFICATION; ENZYME; METALLOENDOPEPTIDASES; ENDOPEPTIDASE-2; EXPRESSION; HYDROLYSIS	Meprins are oligomeric, glycosylated cell surface or secreted metalloendopeptidases that are composed of multidomain disulfide-linked subunits. To investigate whether subunit oligomerization is critical for intracellular transport or for the enzymatic and/or physical properties of the proteinase, specific cysteine residues were mutated, and the mutants were expressed in 293 cells. Mutation of mouse meprin alpha Cys-320 to Ala in the MAM domain (an extracellular domain found in meprin, (A) under bar-5 protein, and receptor protein-tyrosine phosphatase <(mu)under bar>) resulted in expression of a monomeric form of meprin, as determined by SDS-polyacrylamide gel electrophoresis and nondenaturing gel electrophoresis. The monomeric subunits were considerably more vulnerable to proteolytic degradation and heat inactivation in vitro compared with the oligomeric form of the enzyme. Proteolytic activity of the monomeric meprin using a bradykinin analog or aminobenzoyl-Ala-Ala Phe-p-nitroanilide as substrate was similar to that of disulfide-linked oligomeric meprin; however, activity against azocasein was markedly decreased. Mutation of another cysteine residue in the MAM domain (C289A), predicted to be involved in intrasubunit disulfide bridging, resulted in disulfide-linked oligomers and monomers. These results indicated that this mutant was capable of forming intersubunit disulfide bonds but less efficiently than wild-type meprin subunits. Mutant C289A also retained activity toward peptides but not the protein substrate and was more vulnerable to proteolytic degradation and heat inactivation compared with the wild-type enzyme. Both Cys mutants were expressed and secreted into the medium at levels comparable with the wild type and had slightly altered glycosylation. This work indicates that 1) Cys-320 of mouse meprin alpha is most likely responsible for the covalent interactions of the subunits; 2) covalent dimerization of subunits is not essential for efficient biosynthesis, trafficking, or posttranslational processing of the secreted protease; and 3) mutations in the MAM domain affect noncovalent interactions of the subunits and the stability and activity of the protease domain, indicating that domain-domain interactions are critical for structure and function of the enzyme.	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,COLL MED,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R01DK019691, R37DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BONIFACINO JS, 1991, CIRR BIOL, V113, P997; CHOUDRY Y, 1991, BIOCHEM J, V280, P57, DOI 10.1042/bj2800057; COTTON RGH, 1978, EUR J BIOCHEM, V83, P319, DOI 10.1111/j.1432-1033.1978.tb12097.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DERYNCK R, 1987, ONCOGENES GENE GROWT, P136; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FOWLER SD, 1995, FEBS LETT, V366, P72, DOI 10.1016/0014-5793(95)00501-Y; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; JIANG W, 1996, ZINC METALLOPROTEASE, P23; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KAUSHAL GP, 1994, J CELL BIOL, V126, P1319, DOI 10.1083/jcb.126.5.1319; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; STEPHENSON SL, 1988, BIOCHEM J, V255, P45, DOI 10.1042/bj2550045; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; YAMAGUCHI T, 1991, EUR J BIOCHEM, V200, P563, DOI 10.1111/j.1432-1033.1991.tb16219.x; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	32	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24236	24241		10.1074/jbc.271.39.24236	http://dx.doi.org/10.1074/jbc.271.39.24236			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798668	hybrid			2022-12-25	WOS:A1996VJ44200097
J	Muckel, E; Soll, J				Muckel, E; Soll, J			A protein import receptor of chloroplasts is inserted into the outer envelope membrane by a novel pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; TRANSLOCATION; MACHINERY; ATP; TOPOGENESIS; TRANSPORT; COMPONENT; APPARATUS; BINDING	The outer envelope protein OEP86 functions as a receptor for precursor proteins in the chloroplastic import machinery, In contrast to most other organellar outer membrane proteins it is synthesized as a precursor polypeptide (preOEP86) in the cytosol and is posttranslationally targeted to the organelles. PreOEP86 is targeted to and productively inserted into the chloroplastic outer envelope mediated by a bipartite signal consisting of the presequence and the COOH terminus of the precursor protein. The cleavable presequence alone does not seem to contain sufficient information to target preOEP86 without the COOH terminus or a hybrid protein consisting of the presequence of preOEP86 and the mature form of the small subunit of ribulose bisphosphate carboxylase to intact chloroplasts. The presequence seems to be required to maintain pre OEP86 in an integration competent state, whereas interaction of preOEP86 with chloroplasts is accomplished by a short sequence of amino acids in the COOH-terminal portion of the mature protein. The COOH-terminal portion of preOEP86 contains enough information to also direct mature OEP86 into the outer envelope membrane of pea chloroplasts. However, mature OEP86 enters the productive folding pathway much less efficiently than preOEP86. The COOH terminus of preOEP86 not only serves as a membrane anchor but seems to be required for a productive translocation through an interaction with other outer envelope proteins. Although the binding was ATP-dependent, productive folding was not, PreOEP86 seems to follow a unique road into the chloroplastic outer envelope.	CHRISTIAN ALBRECHTS UNIV KIEL, INST BOT, D-24118 KIEL, GERMANY	University of Kiel								ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LUBBEN TH, 1986, P NATL ACAD SCI USA, V83, P5502, DOI 10.1073/pnas.83.15.5502; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SOLL J, 1995, BOT ACTA, V108, P277, DOI 10.1111/j.1438-8677.1995.tb00495.x; SOLL J, 1992, MEMBRANE BIOGENESIS, P299; THEG SM, 1989, J BIOL CHEM, V264, P6730; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1992, PLANTA, V187, P89, DOI 10.1007/BF00201628; Waegemann K, 1996, J BIOL CHEM, V271, P6545, DOI 10.1074/jbc.271.11.6545; Waegemann K, 1995, METHOD CELL BIOL, V50, P255, DOI 10.1016/S0091-679X(08)61035-3; WAEGEMANN K, 1993, NATO ASI SERIES H, V74, P101; WIRTZ W, 1980, PLANT PHYSIOL, V66, P187, DOI 10.1104/pp.66.1.187; WU CB, 1994, J BIOL CHEM, V269, P32264	29	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23846	23852		10.1074/jbc.271.39.23846	http://dx.doi.org/10.1074/jbc.271.39.23846			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798615	hybrid			2022-12-25	WOS:A1996VJ44200044
J	Stevens, BR; Kakuda, DK; Yu, K; Waters, M; Vo, CB; Raizada, MK				Stevens, BR; Kakuda, DK; Yu, K; Waters, M; Vo, CB; Raizada, MK			Induced nitric oxide synthesis is dependent on induced alternatively spliced CAT-2 encoding L-arginine transport in brain astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; GLIAL-CELLS; MOLECULAR-CLONING; RAT-BRAIN; SYNTHASE; EXPRESSION; MACROPHAGES; INHIBITORS; CYTOKINES; CULTURES	The inducible isoform II of nitric-oxide synthase (iNOS) was recently cloned from brain and identified in astroglial cells. Induced nitric oxide biosynthesis occurs in brain cells only if extracellular cerebrospinal fluid contains L-arginine. This study demonstrates for the first time that induced iNOS activity is strictly dependent on concomitant induction of an alternatively spliced transcript of the cat-2 gene encoding high affinity L-arginine transporter System y(+) in cultured rat astrocytes, Inhibition profiles of radiolabeled L-arginine and L-leucine uptake identified the dominance of Na+-independent transport System y(+) serving cationic amino acids, with insignificant activities of Systems y(+)L, b(o,+), or B-o,B-+. A reverse transcription-polymerase chain reaction/sequencing/cloning strategy was used to identify a single 123-base nucleotide sequence coding the high affinity domain of alternatively spliced CAT-2 (not CAT-2a) in astrocytes activated by lipopolysaccharide/interferon-gamma. Using this sequence as a cDNA probe, it was determined that CAT-2 mRNA, iNOS mRNA, and System y(+) activity were concomitantly and strongly induced in astrocytes. Constitutive CAT-1 mRNA was weakly present in neurons and astrocytes, was not inducible in either cell type, and contributed <3% to total System y(+) activity. Although astroglial iNOS K-m similar to 10 mu M L-arginine for intracellular substrate, hyperbolic kinetics of inducible iNOS activity measured as a function of extracellular L-arginine concentration gave K-m similar to 50 mu M L-arginine with intact cells. The same K-m similar to 50 mu M was obtained for induced membrane transport System y(+) activity, iNOS activity was reduced to zero in the absence of extracellular L-arginine uptake via System y(+). These findings expand the current understanding of NO biosynthesis modulation and implicate a coordinated regulation of intracellular iNOS enzyme activity with membrane L-arginine transport in brain.	UNIV CALIF SAN DIEGO,DEPT MED,CANC CTR CANC GENET PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego	Stevens, BR (corresponding author), UNIV FLORIDA,COLL MED,DEPT PHYSIOL,GAINESVILLE,FL 32610, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030464] Funding Source: NIH RePORTER; NCI NIH HHS [CA09290] Funding Source: Medline; NIAID NIH HHS [R01-AI30464] Funding Source: Medline; NIGMS NIH HHS [GM07752] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANSO E, 1991, NEUROCHEM RES, V16, P787; BAYDOUN AR, 1994, BIOCHEM BIOPH RES CO, V200, P726, DOI 10.1006/bbrc.1994.1511; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; Buniatian HC, 1971, HDB NEUROCHEMISTRY A, P235; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; DING AH, 1988, J IMMUNOL, V141, P2407; FEINSTEIN DL, 1994, ANN NY ACAD SCI, V738, P325; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; FREDRICK M, 1992, SHORT PROTOCOLS MOL; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Kakuda DK, 1993, TRANSGENE, V1, P91; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACLEOD C, 1994, J EXP BIOL, V19, P109; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; PAN M, 1995, AM J PHYSIOL, V268, pG669; PARK SK, 1994, NEUROPHARMACOLOGY, V33, P1419, DOI 10.1016/0028-3908(94)90044-2; RAIZADA MK, 1987, P NATL ACAD SCI USA, V84, P4655, DOI 10.1073/pnas.84.13.4655; RAO RL, 1995, NEUROCHEMISTRY, V65, P677; REIZER J, 1993, PROTEIN SCI, V2, P20, DOI 10.1002/pro.5560020103; SCHMIDLIN A, 1994, GLIA, V11, P262, DOI 10.1002/glia.440110307; SCHMIDLIN A, 1995, NEUROCHEMISTRY, V65, P590; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1993, NEUROCHEMISTRY, V59, P897; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; TRAVIS J, 1994, SCIENCE, V266, P970, DOI 10.1126/science.7973679; VANWINKLE LJ, 1995, BBA-BIOMEMBRANES, V1233, P213, DOI 10.1016/0005-2736(94)00303-7; WOOD JH, 1982, HDB NEUROCHEMISTRY, V1, P415	33	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24017	24022		10.1074/jbc.271.39.24017	http://dx.doi.org/10.1074/jbc.271.39.24017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798637	hybrid			2022-12-25	WOS:A1996VJ44200066
J	Beamish, H; Williams, R; Chen, P; Khanna, KK; Hobson, K; Watters, D; Shiloh, Y; Lavin, M				Beamish, H; Williams, R; Chen, P; Khanna, KK; Hobson, K; Watters, D; Shiloh, Y; Lavin, M			Rapamycin resistance in ataxia-telangiectasia	ONCOGENE			English	Article						ataxia-telangiectasia; rapamycin; Wortmannin; cyclin kinase; cell cycle	CYCLE CHECKPOINT PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; PROTEIN-KINASE; IMMUNOSUPPRESSANT RAPAMYCIN; INDUCED INHIBITION; MAMMALIAN PROTEIN; SERINE RESIDUE; LYMPHOMA-CELLS; S6 KINASE	The gene mutated in the human genetic disorder ataxia-telangiectasia (A-T) has been described recently (Savitsky et al., 1995a) and the complete coding sequence of this gene, ATM, has been reported (Savitsky et al., 1995b). The derived amino acid sequence demonstrates significant homologies to several proteins containing a phosphatidylinositol 3-kinase (PI3-kinase) domain, including the yeast TOR proteins and the human protein FRAP. Since the TOR and FRAP proteins are targets for the immunosuppressive drug rapamycin, we have investigated the effects of this compound on A-T cells. We report here that 3 A-T cell lines are more resistant than control cells to rapamycin's growth inhibiting effects but were more sensitive to the PI3-kinase inhibitor wortmannin. As expected rapamycin (1 nM) inhibited the rate of exit of control cells from G(1) phase but failed to perturb the progression of A-T cells. This difference in cell cycle progress after rapamycin treatment is reflected in ribosomal S6 protein kinase (p70(S6K)) by both a downward mobility shift on SDS-PAGE and inhibition of activity. Furthermore, the G, phase cyclin-dependent kinase, cyclin E-cdk2, was rapidly inhibited in control cells post-treatment, whereas in A-T cells it took considerably longer to observe inhibition. There was no evidence that a GST-FKBP12 fusion protein specifically precipitated the ATM protein in the presence of rapamycin in either cell type. These results demonstrate that the ATM protein is not a direct target for rapamycin but its functional loss renders cells more resistant to this compound.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,BANCROFT CTR,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT SURG,HERSTON,QLD,AUSTRALIA; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Tel Aviv University; Sackler Faculty of Medicine			Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010	Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825; Khanna, Kum Kum/0000-0001-8650-5381				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BIEVER BE, 1990, SCIENCE, V250, P556; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P411; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FAN SJ, 1994, CANCER RES, V54, P5824; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRAUMENI JF, 1967, JNCI-J NATL CANCER I, V38, P593; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GOTTOFF SP, 1967, AM J DIS CHILD, V114, P617; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HECHT F, 1990, CANC GENET CYTOGENET, V46, P11; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LANGE E, 1995, AM J HUM GENET, V57, P112; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PARK BD, 1994, CANCER RES, V54, P896; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; SHILOH Y, 1995, IN PRESS EUR J HUM G; STAN R, 1994, J BIOL CHEM, V269, P32027; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; VI M, 1995, TRENDS BIOCHEM SCI, V20, P303; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	59	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					963	970						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806686				2022-12-25	WOS:A1996VG76600010
J	LazarovSpiegler, O; Solomon, AS; ZeevBrann, AB; Hirschberg, DL; Lavie, V; Schwartz, M				LazarovSpiegler, O; Solomon, AS; ZeevBrann, AB; Hirschberg, DL; Lavie, V; Schwartz, M			Transplantation of activated macrophages overcomes central nervous system regrowth failure	FASEB JOURNAL			English	Article						CNS; immunosuppression; inflammation; regeneration	RETINAL GANGLION-CELLS; AXONAL REGENERATION; NEURITE GROWTH; SPINAL-CORD; ADULT-RATS; INJURY; OLIGODENDROCYTES; DEGENERATION; MICROGLIA; TRANSGLUTAMINASE	Macrophages have long been known to play a key role in the healing processes of tissues that regenerate after injury; however, the nature of their involvement in healing of the injured central nervous system (CNS) is still a subject of controversy, Here we show that the absence of regrowth in transected rat optic nerve (which, like all other CNS nerves in mammals, cannot regenerate after injury) can be overcome by local transplantation of macrophages preincubated ex vivo with segments of a nerve (e.g., sciatic nerve) that can regenerate after injury, The observed effect of the transplanted macrophages was found to be an outcome of their stimulated activity, as indicated by phagocytosis, Thus, macrophage phagocytic activity was stimulated by their preincubation with sciatic nerve segments but inhibited by their preincubation with optic nerve segments. We conclude that the inability of nerves of the mammalian CNS to regenerate is related to the failure of their macrophages recruited after injury to acquire growth-supportive activity. We attribute this failure to the presence of a CNS resident macrophage inhibitory activity, which may be the biochemical basis underlying the immune privilege of the CNS, The transplantation of suitably activated macrophages into injured nerves may overcome multiple malfunctioning aspects of the CNS response to trauma, and thus may be developed into a novel, practical, and multipotent therapy for CNS injuries.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL; TEL AVIV UNIV, SACKLER SCH MED, SHEBA MED CTR, GOLDSCHLEGER EYE RES INST, TEL HASHOMER, ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine			Solomon, Arieh/AAF-4361-2021; Lazarov, Orly/F-9406-2015	Lazarov, Orly/0000-0002-5887-948X				ANDREESEN R, 1983, J IMMUNOL METHODS, V56, P295, DOI 10.1016/S0022-1759(83)80019-2; [Anonymous], 1959, DEGENERATION REGENER; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; CADELLI DS, 1992, EXP NEUROL, V115, P189, DOI 10.1016/0014-4886(92)90246-M; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; COLOTTA F, 1984, J IMMUNOL, V132, P936; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FABERELMAN A, 1995, J NEUROCHEM, V65, P1524; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; HAREL A, 1989, J NEUROCHEM, V52, P1218, DOI 10.1111/j.1471-4159.1989.tb01869.x; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; HIRSCHBERG DL, 1995, J NEUROIMMUNOL, V61, P89, DOI 10.1016/0165-5728(95)00087-I; LAVIE V, 1992, BRAIN RES, V575, P1, DOI 10.1016/0006-8993(92)90415-6; LOTAN M, 1994, EXP NEUROL, V126, P284, DOI 10.1006/exnr.1994.1066; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MERRILL JE, 1995, FASEB J, V9, P611, DOI 10.1096/fasebj.9.8.7768352; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWARTZ M, 1989, FASEB J, V3, P2371, DOI 10.1096/fasebj.3.12.2676680; SMITH GM, 1987, ANN NY ACAD SCI, V495, P185, DOI 10.1111/j.1749-6632.1987.tb23675.x; STOLL G, 1986, NEUROSCI LETT, V72, P233, DOI 10.1016/0304-3940(86)90519-7; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x; THANOS S, 1993, J NEUROSCI, V13, P455; THOMAS WE, 1992, BRAIN RES REV, V17, P61; VANFURTH R, 1985, COMP IMMUNOL MICROB, V8, P205, DOI 10.1016/0147-9571(85)90045-1; VIDALSANZ M, 1988, EXP NEUROL, V102, P92, DOI 10.1016/0014-4886(88)90081-7; VILLEGASPEREZ MP, 1988, J NEUROSCI, V8, P265	38	214	228	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1996	10	11					1296	1302		10.1096/fasebj.10.11.8836043	http://dx.doi.org/10.1096/fasebj.10.11.8836043			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836043				2022-12-25	WOS:A1996VJ71700009
J	Boisset, N; Taveau, JC; Pochon, F; Lamy, J				Boisset, N; Taveau, JC; Pochon, F; Lamy, J			Similar architectures of native and transformed human alpha(2)-macroglobulin suggest the transformation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-MACROGLOBULIN; 3-DIMENSIONAL RECONSTRUCTION; ELECTRON-MICROSCOPY; CRYOELECTRON MICROSCOPY; MONOMALEIMIDO NANOGOLD; CONFORMATIONAL-CHANGES; SINGLE PARTICLES; HUMAN-PLASMA; TILT SERIES; METHYLAMINE	The refined three-dimensional structure of native human alpha(2)-macroglobulin (alpha(2)M) has been determined by cryoelectron microscopy and three-dimensional reconstruction, New features corresponding to ''sigmoid arches,'' ''basal bodies,'' and ''apical connections'' were observed in the molecule, Since similar elements are found in the architecture of transformed alpha(2)M, the 2 volumes were aligned in three dimensions. In their common orientations, they show many similarities except near the openings of the central chamber, In the native conformation, these apertures are fully opened, allowing the proteases to access the central chamber of the molecule, while in the transformed structure, they are partially closed. These structures suggest that alpha(2)M conformational change involves a strong lateral compression and a vertical stretching of the native particle seen in its four-petaled flower view to produce the H view of the transformed form. A model of structural transformation, in which all the parts of the alpha(2)M molecule seem involved in the entrapment of the proteinases is proposed.	UNIV TOURS,GRP ANAL STRUCT ANTIGEN,F-37032 TOURS,FRANCE; CNRS,EP JO117,F-37032 TOURS,FRANCE; UNIV PARIS 11,INST CURIE BIOL,INSERM,U350,F-91405 ORSAY,FRANCE	Universite de Tours; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay								ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ANDERSEN GR, 1995, J BIOL CHEM, V270, P25133, DOI 10.1074/jbc.270.42.25133; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1982, BIOCHEM J, V207, P347; BOISSET N, 1992, J STRUCT BIOL, V109, P39, DOI 10.1016/1047-8477(92)90065-I; BOISSET N, 1993, J MOL BIOL, V232, P522, DOI 10.1006/jmbi.1993.1408; BOISSET N, 1989, J BIOL CHEM, V264, P12046; BOISSET N, 1994, ANN NY ACAD SCI, V737, P229, DOI 10.1111/j.1749-6632.1994.tb44315.x; BRETAUDIERE JP, 1988, P NATL ACAD SCI USA, V85, P1437, DOI 10.1073/pnas.85.5.1437; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; FELDMAN SR, 1985, P NATL ACAD SCI USA, V82, P5700, DOI 10.1073/pnas.82.17.5700; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P2905, DOI 10.1021/bi00408a036; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1988, J BIOL CHEM, V263, P10903; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; HARAUZ G, 1986, OPTIK, V73, P146; HERTZ J, 1988, EMBO J, V7, P4119; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IKAI A, 1983, J BIOCHEM, V93, P121, DOI 10.1093/oxfordjournals.jbchem.a134145; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; LARQUET E, 1994, J STRUCT BIOL, V113, P87, DOI 10.1006/jsbi.1994.1034; MARSHALL LB, 1992, J BIOL CHEM, V267, P6347; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; SCHRAMM HJ, 1982, H-S Z PHYSIOL CHEM, V363, P803, DOI 10.1515/bchm2.1982.363.2.803; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STOOPS JK, 1994, ANN NY ACAD SCI, V737, P212, DOI 10.1111/j.1749-6632.1994.tb44314.x; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; STOOPS JK, 1989, BIOCHEM BIOPH RES CO, V161, P216, DOI 10.1016/0006-291X(89)91583-0; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAPONBRETAUDIERE J, 1985, EMBO J, V4, P85, DOI 10.1002/j.1460-2075.1985.tb02321.x; Taveau JC, 1996, J STRUCT BIOL, V116, P223, DOI 10.1006/jsbi.1996.0034; VANLEUVEN F, 1986, J BIOL CHEM, V261, P6933; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6; ZHAO BL, 1988, BIOCHEMISTRY-US, V27, P5304, DOI 10.1021/bi00414a053	41	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25762	25769		10.1074/jbc.271.42.25762	http://dx.doi.org/10.1074/jbc.271.42.25762			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824204	hybrid			2022-12-25	WOS:A1996VN18000010
J	Sartipy, P; Johansen, B; Camejo, G; Rosengren, B; Bondjers, G; HurtCamejo, E				Sartipy, P; Johansen, B; Camejo, G; Rosengren, B; Bondjers, G; HurtCamejo, E			Binding of human phospholipase A(2) type II to proteoglycans - Differential effect of glycosaminoglycans on enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; ARTERIAL PROTEOGLYCANS; PANCREATIC PHOSPHOLIPASE-A2; ENDOTHELIAL-CELLS; HUMAN MACROPHAGES; CULTURED HUMAN; SERUM-ALBUMIN; FATTY-ACIDS; HUMAN AORTA	Phospholipase A(2) acting on low density lipoproteins in the extracellular arterial intima may form proinflammatory lipid mediators. Human nonpancreatic secretory phospholipase A(2) has three regions that may associate with sulfated glycosaminoglycans. The apoB-100 molecule in low density lipoproteins also has glycosaminoglycan binding regions that could mediate its retention in the arterial intima. Here we report that human nonpancreatic phospholipase A(2) isolated from a transfected cell line binds to glycosaminoglycans secreted by cultured human arterial smooth muscle cells. A gel mobility shift assay showed that the affinity of phospholipase A(2) for glycosaminoglycans from a heparan sulfate/chondroitin sulfate proteoglycan was higher than for chondroitin sulfate glycosaminoglycans from a larger versican-like proteoglycan. Affinity chromatography confirmed these results. All glycosaminoglycans tested, at concentrations up to 100 mu M, increased the activity of phospholipase A(2) toward phosphatidylcholine liposomes. Above this concentration, heparan sulfate and heparin inhibited the enzyme. Heparin and chondroitin 6-sulfate increased phospholipase A(2) activity on ion, density lipoproteins up to 4-fold at 100 mu M, whereas heparan sulfate had no effect. The results indicate that human nonpancreatic secretory phospholipase A(2) interacts with proteoglycans via their glycosaminoglycan moiety and that the enzyme activity may be modulated by the association of the enzyme and its substrate to the sulfated polysaccharides.	NORWEGIAN UNIV SCI & TECHNOL,DEPT BOT,UNIGEN CTR MOL BIOL,N-7035 TRONDHEIM,NORWAY; ASTRA HASSLE AB,DEPT BIOCHEM,PRECLIN RES LABS,S-43183 MOLNDAL,SWEDEN	Norwegian University of Science & Technology (NTNU)	Sartipy, P (corresponding author), GOTHENBURG UNIV,SAHLGRENS UNIV HOSP,WALLENBERG LAB CARDIOVASC RES,DEPT HEART & LUNG DIS,S-41345 GOTHENBURG,SWEDEN.							AMRI EZ, 1994, J LIPID RES, V35, P930; ANDERSEN S, 1994, PROSTAG LEUKOTR ESS, V51, P19, DOI 10.1016/0952-3278(94)90173-2; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BROWN SD, 1993, BIOCHIM BIOPHYS ACTA, V1168, P13, DOI 10.1016/0005-2760(93)90260-G; BYRNE CD, 1992, BIOCHEM J, V288, P101, DOI 10.1042/bj2880101; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CAMEJO G, 1985, BIOMED BIOCHIM ACTA, V44, P389; CAMEJO G, 1983, ATHEROSCLEROSIS, V49, P241, DOI 10.1016/0021-9150(83)90136-3; CAMEJO G, 1989, ATHEROSCLEROSIS, V79, P121, DOI 10.1016/0021-9150(89)90116-0; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CARDOSO LEM, 1994, ARTERIOSCLER THROMB, V14, P115, DOI 10.1161/01.ATV.14.1.115; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; EPPS DE, 1995, ANAL BIOCHEM, V227, P342, DOI 10.1006/abio.1995.1290; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FAGER G, 1989, IN VITRO CELL DEV B, V25, P511; FAGER G, 1995, J CELL PHYSIOL, V163, P380, DOI 10.1002/jcp.1041630218; FENSKE DB, 1990, CHEM PHYS LIPIDS, V54, P9, DOI 10.1016/0009-3084(90)90054-U; GOLDBERG RL, 1990, CONNECT TISSUE RES, V24, P265, DOI 10.3109/03008209009152154; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; HURTCAMEJO E, 1996, IN PRESS ARTERIOSCLE; HURTCAMEJO E, 1995, ARTERIOSCLER THROMB, V15, P1456; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHANSEN B, 1992, BIOCHEM BIOPH RES CO, V187, P544, DOI 10.1016/S0006-291X(05)81528-1; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; MARCUS AJ, 1993, J LIPID RES, V34, P2017; MORISAKI N, 1994, BIOCHEM J, V303, P247, DOI 10.1042/bj3030247; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SMITH EB, 1972, LANCET, V1, P463; SMITH EB, 1980, ATHEROSCLEROSIS, V37, P579, DOI 10.1016/0021-9150(80)90065-9; Spector A., 1986, BIOCH BIOL PLASMA LI, P247; SRINIVASAN SR, 1993, BIOCHIM BIOPHYS ACTA, V1168, P158, DOI 10.1016/0005-2760(93)90120-X; TAILLEUX A, 1993, J LIPID RES, V34, P719; VANDENBERG JJM, 1993, BIOCHEMISTRY-US, V32, P4962, DOI 10.1021/bi00069a035; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WIGHT TN, 1995, CURR OPIN LIPIDOL, V6, P326, DOI 10.1097/00041433-199510000-00013; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551	50	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26307	26314		10.1074/jbc.271.42.26307	http://dx.doi.org/10.1074/jbc.271.42.26307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824283	hybrid			2022-12-25	WOS:A1996VN18000089
J	Schreyer, SA; Peschon, JJ; LeBoeuf, RC				Schreyer, SA; Peschon, JJ; LeBoeuf, RC			Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; LIPOPROTEIN-LIPASE; TNF-ALPHA; MONOCYTE-MACROPHAGES; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; APOLIPOPROTEIN-E; ENDOTOXIC-SHOCK; GENETIC-CONTROL; INBRED MICE	TNF-alpha (TNF) is produced primarily from macrophages and promotes numerous inflammatory reactions associated with atherosclerosis including the induction of vascular adhesion molecules and the recruitment and proliferation of monocyte/macrophages. There are two receptors known to elicit TNF responses, termed p55 and p75. Since p55 is thought to play the primary role in inflammatory processes, we postulated that the absence of p55 in mice would protect against atherosclerosis. In contrast, C57BL/6 mice lacking p55 had aortic sinus lesion sizes 2.3 fold larger than C57BL/6 wild type mice when fed an atherogenic diet (37,123 +/- 3485 mu m(2) versus 16, 688 +/- 2887 mu m(2), respectively, p < 0.0004). Plasma lipid levels were not different between strains. A 3-fold increase in the uptake and degradation of acetylated low density lipoprotein for p55-null as compared with wild type mice was demonstrated in cultured peritoneal macrophages. Immunohistochemical staining for scavenger receptor protein in the aortic sinus was more intense in lesions from the p55 null mice as compared with wild type controls. Our results support the concept that increased scavenger receptor activity contributes to excessive fatty streak formation. We conclude that TNF p55 receptors protect against atherosclerotic lesion development in the mouse.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL50367, HL07247] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007247, R01HL050367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHT H, 1995, J INFLAMM, V45, P64; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; BONET B, 1995, ATHEROSCLEROSIS, V112, P125, DOI 10.1016/0021-9150(94)05404-7; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; COTRAN RS, 1990, J AM SOC NEPHROL, V1, P225; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; ETTINGER WH, 1994, ARTERIOSCLER THROMB, V14, P8, DOI 10.1161/01.ATV.14.1.8; FEINGOLD KR, 1989, ENDOCRINOLOGY, V124, P2336, DOI 10.1210/endo-124-5-2336; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; HUGHES DA, 1994, IMMUNOL LETT, V43, P7, DOI 10.1016/0165-2478(94)00143-X; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KIRK EA, 1995, J LIPID RES, V36, P1522; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; LEBOEUF RC, 1994, J LIPID RES, V35, P121; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MACKAY F, 1994, J IMMUNOL, V153, P5274; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARUCHA PT, 1991, J IMMUNOL, V147, P2603; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MEHRABIAN M, 1991, ARTERIOSCLER THROMB, V11, P947, DOI 10.1161/01.ATV.11.4.947; OBRIEN KD, 1994, AM J PATHOL, V144, P538; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POBER JS, 1991, LAB INVEST, V64, P301; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUTLEDGE JC, 1994, J LIPID RES, V35, P1152; SHIBANO T, 1993, AM J PHYSIOL, V264, pH403, DOI 10.1152/ajpheart.1993.264.2.H403; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STOLPEN AH, 1986, AM J PATHOL, V123, P16; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TIPPING PG, 1993, AM J PATHOL, V142, P1721; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	43	148	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26174	26178		10.1074/jbc.271.42.26174	http://dx.doi.org/10.1074/jbc.271.42.26174			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824264	hybrid			2022-12-25	WOS:A1996VN18000070
J	Romoser, V; Ball, R; Smrcka, AV				Romoser, V; Ball, R; Smrcka, AV			Phospholipase C beta 2 association with phospholipid interfaces assessed by fluorescence resonance energy transfer - G protein beta gamma subunit-mediated translocation is not required for enzyme activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ALPHA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; KINASE PATHWAY; GROWTH-FACTOR; HIGH-AFFINITY; BOVINE BRAIN; RECEPTOR; CELLS; STIMULATION	Phospholipase C beta 2 (PLC beta 2) is activated by G protein beta gamma subunits and calcium. The enzyme is soluble and its substrate, phosphatidylinositol 4,5-bisphosphate (PIP2), is present in phospholipid membranes. A potential mechanism for regulation of this enzyme is through influencing the equilibrium association of the enzyme with membrane surfaces. In this paper we describe a fluorescence resonance energy transfer (FRET) method for measuring the association of PLC beta 2 with phospholipid bilayers. The method allows equilibrium measurements to be made under a variety of conditions, including those that support enzymatic activity and ability to be regulated by G proteins. Using this method it was found that PLC beta 2 bound to vesicles containing anionic lipids and demonstrated a selective and unique interaction with PIP2 containing vesicles. The FRET data were corroborated with a centrifugation based method for estimating the affinity of PLC beta 2 for vesicles. Apparently different modes of association of PLC beta 2 with vesicles of different composition can be distinguished based on alterations in resonance energy transfer efficiency. Association of PLC beta 2 with PLP(2) vesicles requires an intact lipid bilayer, is blocked by neomycin, and is not affected by D-myo-inositol 1,4,5-trisphosphate (D-IP3). G protein beta gamma subunits do not alter the affinity of PLC beta 2 for lipid bilayers and at the PIP2 concentrations used to measure beta gamma-dependent stimulation of PLC activity, the majority of the PLC beta 2 is already associated with the vesicle surface. Furthermore, under conditions where beta gamma subunits strongly activate PLC activity, the extent of association with vesicles is unaffected by beta gamma subunits or calcium. These results indicate that activation of PLC beta 2 by G protein py subunits or Ca2+ in vitro does not involve translocation to the vesicle surface.	UNIV ROCHESTER,SCH MED & DENT,DEPT PHARMACOL,ROCHESTER,NY 14642; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75231	University of Rochester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAGA K, 1992, J BIOL CHEM, V267, P2222; HEITHIER H, 1992, EUR J BIOCHEM, V204, P1169, DOI 10.1111/j.1432-1033.1992.tb16744.x; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KWON G, 1993, BIOCHEMISTRY-US, V32, P2401, DOI 10.1021/bi00060a035; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHACHT J, 1978, J LIPID RES, V19, P1063; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; VAZIRI C, 1992, J BIOL CHEM, V267, P22973; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	35	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25071	25078		10.1074/jbc.271.41.25071	http://dx.doi.org/10.1074/jbc.271.41.25071			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810260	hybrid			2022-12-25	WOS:A1996VL69300004
J	Salgia, R; Pisick, E; Sattler, M; Li, JAL; Uemura, N; Wong, WK; Burky, SA; Hirai, H; Chen, LP; Griffin, JD				Salgia, R; Pisick, E; Sattler, M; Li, JAL; Uemura, N; Wong, WK; Burky, SA; Hirai, H; Chen, LP; Griffin, JD			p130(CAS) forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACTIN-BINDING DOMAINS; TYROSINE PHOSPHORYLATION; V-CRK; SH3 DOMAINS; MOLECULAR-CLONING; C-ABL; ADHESION; KINASE; IDENTIFICATION	The Philadelphia chromosome (Ph) translocation generates a chimeric tyrosine kinase oncogene, BCR/ABL, which causes chronic myelogenous leukemia (CML) and a type of acute lymphoblastic leukemia (ALL). In primary samples from virtually all patients with CML or Ph(+)ALL, the CRKL adapter protein is tyrosine phosphorylated and physically associated with p210(BCR/ABL). CRKL has one SH2 domain and two SH3 domains and is structurally related to c-CRK-II (CRK) and the v-Crk oncoprotein. We have previously shown that CRKL, but not the related adapter protein c-CRK, is tyrosine phosphorylated in cell lines transformed by BCR/ABL, and that CRKL binds to BCR/ABL through the CRKL-SH3 domains. Furthermore, the CRKL-SH2 domain has been shown to bind one or more cellular proteins, one of which is p120(CBL). Here we demonstrate that another cellular protein linked to BCR/ABL through the CRKL-SH2 domain is p130(CAS). p130(CAS) was found to be tyrosine phosphorylated and associated with CRKL in BCR/ABL expressing cell lines and in samples obtained from CML and ALL patients, but not in samples from controls. In both normal and BCR/ABL transformed cells, p130(CAS) was detected in focal adhesion-like structures, as was BCR/ABL. In normal cells, the focal adhesion proteins tensin, p125(FAK), and paxillin constitutively associated with p130(CAS). However, in BCR/ABL transformed cells, the interaction between p130(CAS) and tensin was disrupted, while the associations between p130(CAS), p125(FAK) and paxillin were unaffected. These results suggest that the BCR/ABL oncogene could alter the function of p130(CAS) in at least three ways: tyrosine phosphorylation, inducing constitutive binding of CRKL to a domain in p130(CAS) containing Tyr-X-X-Pro moths (substrate domain), and disrupting the normal interaction of p130(CAS) with the focal adhesion protein tensin. These alterations in the structure of signaling proteins in focal adhesion Like structures could contribute to the known adhesion abnormalities in CML cells.	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CELLULAR & MOL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV TOKYO, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Tokyo			Li, Jian-Liang/AAE-9315-2019	Li, Jian-Liang/0000-0002-6487-081X	NATIONAL CANCER INSTITUTE [K08CA060821, R37CA036167, R01CA036167] Funding Source: NIH RePORTER; NCI NIH HHS [CA36167, CA60821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1995, ONCOGENE, V10, P1465; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Law SF, 1996, MOL CELL BIOL, V16, P3327; LO SH, 1994, J BIOL CHEM, V269, P22310; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NICHOLS GL, 1994, BLOOD, V84, P2912; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1996, ONCOGENE, V12, P839; SATTLER M, 1995, EXP HEMATOL, V23, P1040; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259	45	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25198	25203		10.1074/jbc.271.41.25198	http://dx.doi.org/10.1074/jbc.271.41.25198			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810278	hybrid			2022-12-25	WOS:A1996VL69300022
J	Yang, MZ; Hayashi, K; Hayashi, M; Fujii, JT; Kurkinen, M				Yang, MZ; Hayashi, K; Hayashi, M; Fujii, JT; Kurkinen, M			Cloning and developmental expression of a membrane-type matrix metalloproteinase from chicken	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STROMELYSIN GENE; IN-SITU HYBRIDIZATION; IV COLLAGENASE; MOLECULAR-CLONING; EXTRACELLULAR-MATRIX; TRANSMEMBRANE DOMAIN; TISSUE INHIBITORS; BREAST CARCINOMAS; CYSTEINE SWITCH; MESSENGER-RNAS	We have cloned a novel matrix metalloproteinase (MMP) from cultured chicken embryo fibroblasts. The cDNA-derived protein sequence contains 608 amino acids including a C-terminal hydrophobic transmembrane domain of 24 amino acids and a cytoplasmic domain of 20 amino acids. This chicken MMP is 72% similar to a recently described membrane-type MMP (MT-MMP) from human placenta (Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994) Nature 370, 61-65). Accordingly, we name this novel MMP chicken MT-MMP. As shown by Northern blotting, two MT-MMP mRNAs of 6 and 10 kilobases are constitutively expressed but only modestly regulated by growth factors and cytokines in cultured chicken embryo fibroblasts. Both mRNAs are abundant in the head and body of 8- and 9-day-old chicken embryos. As shown by in situ mRNA hybridization, MT-MMP is expressed in embryonic neural tube, spinal ganglia, and respiratory epithelium, as web as in developing cartilage and muscle. Using reverse transcription-polymerase chain reaction, we have found MT-MMP mRNA in a-day-old chicken embryos and extraembryonic membranes. In addition, a strong correlation was observed between the mRNA expression of MT-MMP and 72-kDa type IV collagenase. Collectively, the early MT-MMP mRNA expression and its co-localization in several tissues with 72-kDa type IV collagenase mRNA suggest that the MT-MMP plays an important role in early development.	WAYNE STATE UNIV, SCH MED, CTR MOL MED & GENET, DETROIT, MI 48202 USA; WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48202 USA; WAYNE STATE UNIV, SCH MED, DEPT ANAT & CELL BIOL, DETROIT, MI 48202 USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PATHOL, PISCATAWAY, NJ 08854 USA	Wayne State University; Wayne State University; Wayne State University; Rutgers State University New Brunswick; Rutgers State University Medical Center					NICHD NIH HHS [HD 24442] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024442] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; APTE AN, 1993, BIOTECHNIQUES, V15, P890; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; IYAMA K, 1994, HISTOCHEM J, V26, P844, DOI 10.1007/BF00162929; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KNAUPER V, 1993, BIOCHEM J, V295, P581; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LOAKES D, 1995, NUCLEIC ACIDS RES, V23, P2361, DOI 10.1093/nar/23.13.2361; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NEWMAN KM, 1994, J VASC SURG, V20, P814, DOI 10.1016/S0741-5214(94)70169-5; NICHOLS R, 1994, NATURE, V369, P492, DOI 10.1038/369492a0; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Puente XS, 1996, CANCER RES, V56, P944; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; REPONEN P, 1992, J BIOL CHEM, V267, P7856; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERB Z, 1994, TXB RHEUMATOLOGY, P248; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLY JP, 1995, CANCER RES, V55, P1401; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANG MZ, 1994, EUR J BIOCHEM, V222, P651, DOI 10.1111/j.1432-1033.1994.tb18909.x	57	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25548	25554		10.1074/jbc.271.41.25548	http://dx.doi.org/10.1074/jbc.271.41.25548			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810327	hybrid			2022-12-25	WOS:A1996VL69300071
J	Fan, CY; Pan, J; Chu, RY; Lee, D; Kluckman, KD; Usuda, N; Singh, I; Yeldandi, AV; Rao, MS; Maeda, N; Reddy, JK				Fan, CY; Pan, J; Chu, RY; Lee, D; Kluckman, KD; Usuda, N; Singh, I; Yeldandi, AV; Rao, MS; Maeda, N; Reddy, JK			Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; ACID OMEGA-HYDROXYLASE; COA OXIDASE; ZELLWEGER SYNDROME; LIPID-METABOLISM; MEMBRANE-PROTEIN; CLOFIBRIC ACID; RENAL SYNDROME; RAT-LIVER; ADRENOLEUKODYSTROPHY	Peroxisomal genetic disorders, such as Zellweger syndrome, are characterized by defects in one or more enzymes involved in the peroxisomal beta-oxidation of very long chain fatty acids and are associated with defective peroxisomal biogenesis. The biologic role of peroxisomal beta-oxidation system, which consists of three enzymes: fatty acyl-CoA oxidase (ACOX), enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), and thiolase, has been examined in mice by disrupting ACOX gene, which encodes the first and rate-limiting enzyme of this system, Homozygous (ACOX -/-) mice lacked the expression of ACOX protein and accumulate very long chain fatty acids in blood. However, these homozygous mice are viable, but growth-retarded and infertile. During the first 3-4 months of age, the livers of ACOX -/- mice reveal severe microvesicular fatty metamorphosis of hepatocytes. In such steatotic cells, peroxisome assembly is markedly defective; as a result, they contain few or no peroxisomes. Few hepatocytes in 1-3-month-old ACOX -/- mice contain numerous peroxisomes, and these peroxisome-rich hepatocytes show no fatty change. At this stage, the basal mRNA levels of HD, thiolase, and other peroxisome proliferator-induced target genes were elevated in ACOX -/- mouse liver, but these mice, when treated with a peroxisome proliferator, showed no increases in the number of hepatic peroxisomes and in the mRNAs levels of these target genes. Between 4 and 5 months of age, severe steatosis resulted in scattered cell death, steatohepatitis, formation of lipogranulomas, and focal hepatocellular regeneration. In 6-7-month-old animals, the newly emerging hepatocytes, which progressively replaced steatotic cells, revealed spontaneous peroxisome proliferation. These livers showed marked increases in the mRNA levels of the remaining two genes of the beta-oxidation system, suggesting that ACOX gene disruption leads to increased endogenous ligand-mediated transcription levels. These observations demonstrate links among peroxisomal beta-oxidation, development of severe microvesicular fatty liver, peroxisome assembly, cell death, and cell proliferation in liver.	NORTHWESTERN UNIV,DEPT PATHOL,CHICAGO,IL 60611; UNIV N CAROLINA,DEPT PATHOL,SCH MED,CHAPEL HILL,NC 27599; MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29464	Northwestern University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Medical University of South Carolina					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042630, R37HL042630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42630] Funding Source: Medline; NIGMS NIH HHS [R37 GM23750] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN T, 1991, J HEPATOL, V12, P224, DOI 10.1016/0168-8278(91)90942-5; AOYAMA T, 1990, J LIPID RES, V31, P1477; ASHBY J, 1994, HUM EXP TOXICOL, V13, pS1, DOI 10.1177/096032719401300201; AUBOURG P, 1994, CURR OPIN GENET DEV, V4, P407, DOI 10.1016/0959-437X(94)90029-9; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; CHU RY, 1995, J BIOL CHEM, V270, P29636; CHU RY, 1995, J BIOL CHEM, V270, P4908, DOI 10.1074/jbc.270.9.4908; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; Dianzani M.U., 1991, HEPATOTOXICOLOGY, P327; ESPEEL M, 1995, HEPATOLOGY, V22, P497, DOI 10.1016/0270-9139(95)90571-5; FEIL R, 1991, AM J HUM GENET, V49, P1361; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FOURNIER B, 1994, J CLIN INVEST, V94, P526, DOI 10.1172/JCI117365; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HO JK, 1995, J CLIN INVEST, V96, P1455, DOI 10.1172/JCI118182; HUANG Q, 1995, INT J ONCOL, V6, P307; IMAOKA S, 1993, DNA CELL BIOL, V12, P893, DOI 10.1089/dna.1993.12.893; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lazarow P B, 1981, Methods Enzymol, V72, P315; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOODY DE, 1992, DRUG METAB DISPOS, V20, P779; MOSER AE, 1984, NEW ENGL J MED, V310, P1141, DOI 10.1056/NEJM198405033101802; MOSER HW, 1995, METABOLIC BASIS INHE, P2025; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEMALI MR, 1989, TOXICOL APPL PHARM, V97, P72, DOI 10.1016/0041-008X(89)90056-2; NOVIKOFF AB, 1969, J HISTOCHEM CYTOCHEM, V17, P675, DOI 10.1177/17.10.675; OSUMI T, 1987, J BIOL CHEM, V262, P8138; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; POWERS JM, 1974, AM J PATHOL, V76, P481; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; REDDY JK, 1985, HDB CARCINOGEN TESTI, P482; REDDY JK, 1992, MECHANISM CARCINOGEN, P225; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SUZUKI Y, 1994, AM J HUM GENET, V54, P36; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/hep.1840220616; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; USUDA N, 1988, LAB INVEST, V58, P100; Usuda N, 1996, J HISTOCHEM CYTOCHEM, V44, P13, DOI 10.1177/44.1.8543776; VARANASI U, 1994, P NATL ACAD SCI USA, V91, P3107, DOI 10.1073/pnas.91.8.3107; WANDERS RJA, 1995, J NEUROPATH EXP NEUR, V54, P726, DOI 10.1097/00005072-199509000-00016; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	63	210	220	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24698	24710		10.1074/jbc.271.40.24698	http://dx.doi.org/10.1074/jbc.271.40.24698			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798738	hybrid			2022-12-25	WOS:A1996VM67400060
J	Nichols, AF; Ong, P; Linn, S				Nichols, AF; Ong, P; Linn, S			Mutations specific to the xeroderma pigmentosum group E Ddb(-) phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; DAMAGE RECOGNITION PROTEIN; COMPLEMENTATION GROUP-E; HELA-CELLS RESISTANT; CIS-DIAMMINEDICHLOROPLATINUM(II); RNA	The activity of a damage-specific DNA-binding protein (DDB) is absent from a subset, Ddb(-), of cell strains from patients with xeroderma pigmentosum group E (XP-E). DDB is a heterodimer of 127-kDa and 48-kDa subunits. We have now identified single-base mutations in the gene of the 48-kDa subunit in cells from the three known Ddb(-) individuals, but not in XP-E strains that have the activity. An A --> G transition causes a K244E change in XP82TO and a G --> A transition causes an R273H change in XP2RO and XP3RO. No mutations were found in the cDNA of the 127-kDa subunit. Overexpression of p48 in insect cells greatly increases DDB activity in the cells, especially if p127 is jointly overexpressed. These results demonstrate that p48 is required for DNA binding activity, but at the same time necessitate further definition of the genetic basis of XP group E.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								BIRNBOIM HC, 1988, NUCLEIC ACIDS RES, V16, P1487, DOI 10.1093/nar/16.4.1487; CHAO CCK, 1991, CANCER RES, V51, P601; CHAO CCK, 1991, BIOCHEM J, V277, P875, DOI 10.1042/bj2770875; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; de Weerd-Kastelein E A, 1974, Mutat Res, V22, P87, DOI 10.1016/0165-1218(74)90056-1; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; Hwang BJ, 1996, MUTAT RES-DNA REPAIR, V362, P105, DOI 10.1016/0921-8777(95)00040-2; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KONDO S, 1989, PHOTODERMATOLOGY, V6, P89; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Sambrook J., 2002, MOL CLONING LAB MANU; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; VAISMAN A, 1995, BIOCHEMISTRY-US, V34, P105, DOI 10.1021/bi00001a013; Vaisman A, 1996, ONCOL RES, V8, P7	25	130	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24317	24320		10.1074/jbc.271.40.24317	http://dx.doi.org/10.1074/jbc.271.40.24317			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798680	hybrid			2022-12-25	WOS:A1996VM67400002
J	Wang, P; Raynoschek, C; Svensson, K; Ljunggren, HG				Wang, P; Raynoschek, C; Svensson, K; Ljunggren, HG			Binding of H-2K(b)-specific peptides to TAP and major histocompatibility complex class I in microsomes from wild-type, TAP1, and beta(2)-microglobulin mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; BETA-2-MICROGLOBULIN TRANSLATED INVITRO; HEAVY-CHAINS; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; INTACT-CELLS; T-CELLS; MOLECULES; TRANSPORTERS; TRANSLOCATION	Major histocompatibility complex (MHC) class I molecules are trimolecular complexes consisting of a heavy chain (HC), beta(2)-microglobulin (beta 2m), and a short peptide. Assembly of MHC class I molecules is thought to take place early during biosynthesis. Deficiency in either beta 2m or the transporter associated with antigen processing (TAP) results in accumulation of class I molecules in the endoplasmic reticulum (ER). In this study, we have assessed peptide binding to TAP and MHC class I in purified microsomes derived from wild-type, TAP1(-/-), beta 2m(-/-), and TAP1/beta 2m(-/-) mice using a cross-linkable H-2K(b)-binding peptide. This enabled us to study the influence of an intact TAP complex and beta 2m on peptide binding to MHC class I and to analyze the stepwise interaction of peptide with TAP and MHC class I molecules. Peptide bound both immature and mature (terminally glycosylated) class I molecules in intact as well as permeabilized microsomes from wild-type mice. Efficient peptide binding to immature class I molecules was also detected in permeabilized microsomes from TAP1(-/-) mice. In contrast, no peptide binding to beta 2m-free HC was detected in permeabilized microsomes from beta 2m(-/-) and TAP1/beta 2m(-/-) mice. However, the addition of exogenous beta 2m allowed peptide binding to class I in permeabilized beta 2m(-/-) and TAP1/beta 2m(-/-) microsomes. These results demonstrate that a preformed class I HC .beta 2m heterodimer is necessary for efficient peptide binding under physiological conditions. The observed peptide binding to class I in permeabilized TAP1(-/-) microsomes further suggests that TAP1 is not required for peptide binding to class I in the ER. Finally, kinetic studies allowed the demonstration of a stepwise binding of peptide to TAP, subsequent translocation across the ER membrane, a step that required ATP hydrolysis, and binding of peptide to preformed class I HC .beta 2m heterodimers.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet	Wang, P (corresponding author), LUDWIG INST CANC RES,STOCKHOLM BRANCH,BOX 240,S-10401 STOCKHOLM,SWEDEN.							ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BIJLMAKERS MJ, 1993, CURR OPIN IMMUNOL, V5, P21, DOI 10.1016/0952-7915(93)90076-5; BIJLMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305, DOI 10.1002/eji.1830230618; BIX M, 1992, J EXP MED, V176, P829, DOI 10.1084/jem.176.3.829; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; DAY PM, 1995, IMMUNITY, V2, P137, DOI 10.1016/S1074-7613(95)80014-X; ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; GLAS R, 1992, P NATL ACAD SCI USA, V89, P11381, DOI 10.1073/pnas.89.23.11381; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; KALTOFT MB, 1992, HYBRIDOMA, V11, P507, DOI 10.1089/hyb.1992.11.507; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOPPELMAN B, 1992, P NATL ACAD SCI USA, V89, P3908, DOI 10.1073/pnas.89.9.3908; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LEVY F, 1991, J CELL BIOL, V115, P959, DOI 10.1083/jcb.115.4.959; LJUNGGREN HG, 1995, INT IMMUNOL, V7, P975, DOI 10.1093/intimm/7.6.975; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MACHOLD RP, 1995, J EXP MED, V181, P1111, DOI 10.1084/jem.181.3.1111; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; Momburg F, 1996, J IMMUNOL, V156, P1756; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; NEEFJES JJ, 1993, J EXP MED, V178, P1971, DOI 10.1084/jem.178.6.1971; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SUCH WK, 1994, SCIENCE, V264, P1322; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	46	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24830	24835		10.1074/jbc.271.40.24830	http://dx.doi.org/10.1074/jbc.271.40.24830			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798757	hybrid			2022-12-25	WOS:A1996VM67400079
J	Colandene, JD; Garrett, RH				Colandene, JD; Garrett, RH			Functional dissection and site-directed mutagenesis of the structural gene for NAD(P)H-nitrite reductase in Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH NITRITE REDUCTASE; ESCHERICHIA-COLI; NITRATE ASSIMILATION; SULFITE REDUCTASE; NUCLEOTIDE-SEQUENCE; REGIONS	Neurospora crassa NAD(P)H-nitrite reductase, coded by the nit-6 gene, is a soluble, alpha(2)-type modimeric protein composed of 127-kDa polypeptide subunits. This multicenter oxidation-reduction enzyme utilizes either NADH or NADPH as electron donor and possesses as prosthetic groups two iron-sulfur (Fe4S4) clusters, two siroheme groups, and two FAD molecules. The native activity of the enzyme is the NAD(P)H-dependent reduction of nitrite to ammonia. In addition, N. crassa nitrite reductase displays several partial activities in vitro, including a siroheme-independent NAD(P)H-cytochrome c reductase activity and an FAD-independent dithionite-nitrite reductase activity. These partial activities are presumed to be manifestations of discrete functional domains within the protein. A full-length nit-6 cDNA was constructed and used in developing an expression system within E. coli capable of yielding high levels of NADPH-nitrite reductase activity. Maximal expression was obtained in nirB(-) E. coli cells grown anaerobically at 22 +/- 1 degrees C, in conjunction with co-expression of a plasmid-borne cysG gene (encoding the rate-limiting enzyme in siroheme synthesis) and cotransformation with plasmid pGroESL (encoding bacterial chaperonins GroES and GroEL). Dissection of gene segments encoding putative functional domains within the nit-6 gene was performed. Expression of a partial cDNA construct encoding the FAD-/NAD-binding domain yielded extracts with NADPH-cytochrome c reductase activity but no NADPH-nitrite reductase activity or dithionite-nitrite reductase activity. Expression of a cDNA construct encoding the (Fe4S4)-siroheme-binding domain resulted in extracts possessing dithionite-nitrite reductase activity but no NADPH-nitrite reductase or NADPH-cytochrome c reductase activity. Analysis of site-directed mutations altering amino acid residues Cys-331 within the FAD-/NAD-binding domain and Ser-755 within the (Fe4S4)-siroheme-binding domain of the nitrite reductase demonstrated that these residues were not essential for native or partial enzyme activity. Cys-757 within the (Fe4S4)-siroheme-binding domain was essential for native enzyme activity.	UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22903	University of Virginia								BACK E, 1988, MOL GEN GENET, V212, P20, DOI 10.1007/BF00322440; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; CRAWFORD NM, 1990, PLANT CELL, V2, P829; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DUNNCOLEMAN NS, 1984, INT REV CYTOL, V92, P1; EXLEY GE, 1993, J BACTERIOL, V175, P2379, DOI 10.1128/JB.175.8.2379-2392.1993; FRIEMANN A, 1992, MOL GEN GENET, V231, P411, DOI 10.1007/BF00292710; Garrett R H, 1978, Adv Microb Physiol, V18, P1; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HURLBURT BK, 1988, MOL GEN GENET, V211, P35, DOI 10.1007/BF00338390; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; Kinghorn J. R., 1989, Molecular and genetic aspects of nitrate assimilation., P385; LAFFERTY MA, 1974, J BIOL CHEM, V249, P7555; LAHNERS K, 1988, PLANT PHYSIOL, V88, P741, DOI 10.1104/pp.88.3.741; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15726; PEAKMAN T, 1990, EUR J BIOCHEM, V191, P315, DOI 10.1111/j.1432-1033.1990.tb19125.x; PRODOUZ KN, 1981, J BIOL CHEM, V256, P9711; Sambrook J., 2002, MOL CLONING LAB MANU; Siegal L. M., 1989, Molecular and genetic aspects of nitrate assimilation., P263; VEGA JM, 1976, ARCH MICROBIOL, V109, P237, DOI 10.1007/BF00446634; VEGA JM, 1975, P 6 C SPAN SOC BIOCH, P108; WU JY, 1991, J BACTERIOL, V173, P325, DOI 10.1128/jb.173.1.325-333.1991	25	6	6	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24096	24104		10.1074/jbc.271.39.24096	http://dx.doi.org/10.1074/jbc.271.39.24096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798648	hybrid			2022-12-25	WOS:A1996VJ44200077
J	Fischer, BE; Schlokat, U; Mitterer, A; SavidisDacho, H; Grillberger, L; Reiter, M; Mundt, W; Dorner, F; Eibl, J				Fischer, BE; Schlokat, U; Mitterer, A; SavidisDacho, H; Grillberger, L; Reiter, M; Mundt, W; Dorner, F; Eibl, J			Rational design, recombinant preparation, and in vitro and in vivo characterization of human prothrombin-derived hirudin antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THROMBIN; IDENTIFICATION; ANTICOAGULANT; COAGULATION; EXPRESSION; COMPLEX	A mutant derivative of human prothrombin in which active site aspartate at position 419 is replaced by an asparagine (D419N-prothrombin) has been designed, expressed in recombinant Chinese hamster ovary cells, and purified to homogeneity, D419N-prothrombin was converted to the related molecules D419N-meizothrombin and D419N-thrombin by limited proteolysis by Echis carinatus and Oxyuranus scutellatus venom protease, respectively, and affinity-purified using an immobilized modified C-terminal hirudin-derived peptide, Neither D419N-thrombin nor D419N-meizothrombin exhibited thrombin activity, Titration resulted in no detection of the active site, but binding to the most specific thrombin inhibitor, hirudin, was conserved in both proteins, In vitro examinations showed that D419N-thrombin and D419N-meizothrombin bind to immobilized hirudin, neutralize hirudin in human blood plasma as well as in the purified system, and reactivate the thrombin-hirudin complex, Animal model studies confirmed that D419N-thrombin and D419N-meizothrombin act as hirudin antagonist in blood circulation without detectable effects on the coagulation system, Thus, both D419N-thrombin and D419N-meizothrombin combine for the first time hirudin-neutralizing properties with the advantages of recombinant production of human coagulation factors.			Fischer, BE (corresponding author), IMMUNO AG, BIOMED RES CTR, UFERSTR 15, A-2304 ORTH DANAU, AUSTRIA.							BECKER RC, 1994, THROMB THROMBOLYSIS, V1, P7; BICHLER J, 1991, ANN HEMATOL, V63, P67, DOI 10.1007/BF01707275; DOYLE MF, 1993, METHOD ENZYMOL, V222, P299; FALKNER FG, 1992, THROMB HAEMOSTASIS, V68, P119; FAREED J, 1991, SEMIN THROMB HEMOST, V17, P137, DOI 10.1055/s-2007-1002602; FISCHER B, 1994, FEBS LETT, V351, P345, DOI 10.1016/0014-5793(94)00861-2; FISCHER B, 1995, J BIOTECHNOL, V38, P129, DOI 10.1016/0168-1656(94)00124-U; Fischer BE, 1996, THROMB RES, V81, P157, DOI 10.1016/0049-3848(95)00224-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; JOHNSON PH, 1994, ANNU REV MED, V45, P165, DOI 10.1146/annurev.med.45.1.165; KAISER B, 1991, SEMIN THROMB HEMOST, V17, P130, DOI 10.1055/s-2007-1002601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOVITS J, 1994, CIRCULATION, V90, P1522, DOI 10.1161/01.CIR.90.3.1522; LUNDBLAD RL, 1977, CHEM BIOL HEPARIN; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2356; MARAGANORE JM, 1993, ADV EXP MED BIOL, V340, P227; MARKWARDT F, 1991, HAEMOSTASIS, V21, P11; MARKWARDT F, 1991, THROMB HAEMOSTASIS, V66, P141; MARKWARDT F, 1958, H-S Z PHYSIOL CHEM, V312, P85, DOI 10.1515/bchm2.1958.312.1.85; MARKWARDT F, 1994, THROMB RES, V74, P1, DOI 10.1016/0049-3848(94)90032-9; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216	26	2	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23737	23742		10.1074/jbc.271.39.23737	http://dx.doi.org/10.1074/jbc.271.39.23737			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798598	hybrid			2022-12-25	WOS:A1996VJ44200027
J	Green, SA; Spasoff, AP; Coleman, RA; Johnson, M; Liggett, SB				Green, SA; Spasoff, AP; Coleman, RA; Johnson, M; Liggett, SB			Sustained activation of a G protein-coupled receptor via ''anchored'' agonist binding - Molecular localization of the salmeterol exosite within the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; ADRENOCEPTOR AGONISTS; MODEL; ACID; CDNA	An inherent therapeutic limitation of many G protein-coupled receptor agonists is a short duration of action due to rapid dissociation from receptors. Salmeterol is a modified beta-adrenergic receptor (beta AR) agonist that has a long duration of action at the beta(2)AR (but not the beta(1)AR) both in vitro and in vivo and that is persistent despite extensive washout of the agonist. It has been proposed that salmeterol binds not only to the active site of the beta(2)AR (localized to receptor transmembrane spanning domains (TMDs) 3 and 5) but also to another site (termed the ''exosite'') that anchors it to the receptor and provides for repetitive active-site binding events. To identify the location of this exosite, we used site-directed mutagenesis to replace beta(2)AR amino acids 149-173 (within TMD4) with beta(1)AR sequence. The resulting constructs were then expressed in COS-7 cells for radioligand binding studies. Using this approach, when this domain was replaced with the analogous beta(1)AR sequence, the ability of salmeterol to persist at the receptor under washout conditions was reduced by 67%. The results from more selective mutants (S-(149-166), S-(164-173), and S-(149-158)) indicated that a limited 10-amino acid region (beta(2)AR residues 149-158), localized at the interface of the cytoplasm and the transmembrane domain, contains a critical determinant for exosite binding. Whereas CHW cells stably expressing wild-type beta(2)AR displayed persistent salmeterol-promoted cAMP accumulation despite agonist washout, substitution of beta(2)AR residues 149-158 with beta(1)AR sequence resulted in a 56% attenuation of salmeterol-promoted cAMP accumulation under identical washout conditions. A reverse chimera was also studied, which consisted of a substitution of beta(2)AR residues 152-156 into the beta(1)AR. This substitution was found to confer exosite binding to the beta(1)AR. None of these mutations decreased the affinity of salmeterol for the receptor at the active site as assessed in competition binding studies. Anchored binding to this motif thus represents a novel mechanism by which agonists like salmeterol can repetitively activate receptors. Conceivably, with other G protein-coupled receptors that have similar motifs, anchored ligands can be designed to provide for long durations of action by this mechanism.	UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & MOL GENET,CINCINNATI,OH 45267; GLAXO WELLCOME LTD,UXBRIDGE UB11 1BT,MIDDX,ENGLAND	University of Cincinnati; GlaxoSmithKline	Green, SA (corresponding author), UNIV CINCINNATI,COLL MED,DEPT PULM MED,231 BETHESDA AVE,BOX 670564,CINCINNATI,OH 45267, USA.		liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL03346, HL45967] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045967, K08HL003346, R37HL045967, R56HL045967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GP, 1994, EUR RESPIR J, V7, P569, DOI 10.1183/09031936.94.07030569; BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clark RB, 1996, MOL PHARMACOL, V49, P182; CRONET P, 1993, PROTEIN ENG, V6, P59, DOI 10.1093/protein/6.1.59; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1992, MOL PHARMACOL, V41, P889; JACK D, 1991, BRIT J CLIN PHARMACO, V31, P501, DOI 10.1111/j.1365-2125.1991.tb05571.x; JOHNSON M, 1995, MED RES REV, V15, P225, DOI 10.1002/med.2610150303; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lewell X Q, 1992, Drug Des Discov, V9, P29; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; NIALS AT, 1993, BRIT J PHARMACOL, V108, P507, DOI 10.1111/j.1476-5381.1993.tb12833.x; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; RHODES DG, 1992, MOL PHARMACOL, V42, P596; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	27	127	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24029	24035		10.1074/jbc.271.39.24029	http://dx.doi.org/10.1074/jbc.271.39.24029			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798639	hybrid			2022-12-25	WOS:A1996VJ44200068
J	Bagarozzi, DA; Pike, R; Potempa, J; Travis, J				Bagarozzi, DA; Pike, R; Potempa, J; Travis, J			Purification and characterization of a novel endopeptidase in ragweed (Ambrosia artemisiifolia) pollen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL PEPTIDE; NEUROGENIC INFLAMMATION; SEQUENCE; NEUROPEPTIDES; ASTHMA; VIP; DEGRADATION; REACTIVITY; ALLERGENS; RESPONSES	Ragweed (Ambrosia artemisiifolia), the major cause of late summer hay fever (allergic rhinitis) in the United States and Canada, is clinically the most important source of the seasonal aeroallergens. A novel endopeptidase was extracted from the pollen of this plant and purified by a series of column chromatographic steps. It has a molecular mass of 82 kDa according to gel filtration and SDS-polyacrylamide gel electrophoresis and a pH optimum near 9.0, and its activity is unaffected by chelating or reducing agents. A 17-amino acid aminoterminal sequence of this protein showed no similarity with any other proteases. The enzyme was inhibited by diisopropyl fluorophosphate, a general serine class inhibitor, and more specifically N-p-tosyl-L-phenylalanine chloromethyl ketone, a chymotrypsin-like proteinase inhibitor. Various synthetic substrates were efficiently cleaved with a strong preference for Phe in the P-1 and P-3 position and Pro in the P-2 position. This specificity was confirmed through inhibition studies with both peptidyl chloromethyl ketone and organophosphate inhibitors. In addition to synthetic substrates, the neuropeptides, vasoactive intestinal peptide and substance P, which are required for normalized lung functions, were also rapidly hydrolyzed. Activity toward protein substrates was not detected with the exception of the inactivation of alpha-1-proteinase inhibitor, which occurred through cleavage within the reactive site loop. These results indicate that the purified enzyme is a novel endopeptidase, which may be involved in both the degradation of neuropeptides and the inactivation of protective proteinase inhibitors during pollen-initiated allergic reactions.	UNIV GEORGIA,DEPT BIOCHEM & MOL BIOL,ATHENS,GA 30605; UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND; JAGIELLONIAN UNIV,INST MOL BIOL,PL-31120 KRAKOW,POLAND	University System of Georgia; University of Georgia; University of Cambridge; Jagiellonian University				Pike, Robert/0000-0002-2083-0269				BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1984, AM REV RESPIR DIS, V130, P162; BARNES PJ, 1991, INT ARCH ALLER A IMM, V94, P303, DOI 10.1159/000235392; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTRAND C, 1993, J IMMUNOL, V150, P1479; BLANCHARD GC, 1976, ANN ALLERGY, V36, P410; BODANSZKY M, 1973, P NATL ACAD SCI USA, V70, P382, DOI 10.1073/pnas.70.2.382; BOOMSMA JD, 1992, CHEST, V101, P5389; BOUSQUET J, 1978, REV FR ALLERGOL, V18, P131, DOI 10.1016/S0335-7457(78)80014-8; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P76, DOI 10.1016/S0091-6749(05)80043-0; BUNNETT NW, 1987, AM REV RESPIR DIS, V136, P527; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; GASHI AA, 1986, AM J PHYSIOL, V251, pC223, DOI 10.1152/ajpcell.1986.251.2.C223; GOYAL RK, 1980, NATURE, V288, P378, DOI 10.1038/288378a0; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KNOX RB, 1973, J CELL SCI, V12, P421; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLY CM, 1994, J CLIN INVEST, V93, P2667, DOI 10.1172/JCI117280; LUNDBERG JM, 1984, PEPTIDES, V5, P593, DOI 10.1016/0196-9781(84)90090-1; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; MATHESON N, 1995, AM J RESP CELL MOL, V12, P441, DOI 10.1165/ajrcmb.12.4.7695924; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCORMICK S, 1991, TRENDS GENET, V7, P298, DOI 10.1016/0168-9525(91)90312-E; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MIDDLETON E, 1993, ALLERGY PRINCIPLES P, V1, P650; MIDDLETON EF, 1993, ALLERGY PRINCIPLES P, V2, P1173; NADEL JA, 1991, AM REV RESPIR DIS, V143, P533; PATON JB, 1919, P SOC EXP BIOL MED, V17, P60; RICHARDSON J, 1976, J APPL PHYSIOL, V41, P764, DOI 10.1152/jappl.1976.41.5.764; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROGERS BL, 1993, GENE, V133, P219, DOI 10.1016/0378-1119(93)90641-F; ROGERS BL, 1991, J IMMUNOL, V147, P2547; SAID SI, 1984, PEPTIDES, V5, P143, DOI 10.1016/0196-9781(84)90197-9; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRAVIS J, 1989, LUNG CELL BIOL, P1227; WANNER A, 1985, J ALLERGY CLIN IMMUN, V76, P177, DOI 10.1016/0091-6749(85)90698-0; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997; WODEHOUSE RP, 1971, HAYFEVER PLANTS, P116	42	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26227	26232		10.1074/jbc.271.42.26227	http://dx.doi.org/10.1074/jbc.271.42.26227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824272	hybrid			2022-12-25	WOS:A1996VN18000078
J	Bokoch, GM; Wang, Y; Bohl, BP; Sells, MA; Quilliam, LA; Knaus, UG				Bokoch, GM; Wang, Y; Bohl, BP; Sells, MA; Quilliam, LA; Knaus, UG			Interaction of the Nck adapter protein with p21-activated kinase (PAK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SH3 DOMAINS; PHOSPHORYLATION; RECEPTORS; ACTIVATION; CDC42; SITE	The p21-activated kinases (PAKs) link G protein-coupled receptors and growth factor receptors (S. Dharmawardhane, R. H. Daniels, and G. M. Bokoch, submitted for publication) to activation of MAP kinase cascades and to cytoskeletal reorganization (M. A. Sells, U. G. Knaus, D. Ambrose, S. Bagrodia, G. M. Bokoch, and J. Chernoff, submitted for publication), The proteins that interact with PAK to mediate its cellular effects and to couple it to upstream receptors are unknown, We describe here a specific interaction of the Nck adapter molecule with PAK1 both in vitro and in vivo. PAK1 and Nck associate in COS-7 and Swiss 3T3 cells constitutively, but this interaction is strengthened upon platelet-derived growth factor receptor stimulation. We show that Nck binds to PAK1 through its second Src homology 3 (SH3) domain, while PAK1 interacts with Nck via the first proline-rich SH3 binding motif at its amino terminus. The interaction of active PAK1 with Nck leads to the phosphorylation of Nck at multiple sites, Association of Nck with PAK1 may serve to link this important regulatory kinase to cell activation by growth factor receptors.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; INDIANA UNIV, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Scripps Research Institute; Fox Chase Cancer Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Bokoch, GM (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.		Quilliam, Lawrence/Q-4987-2019; Quilliam, Lawrence/B-6447-2015		NATIONAL CANCER INSTITUTE [R29CA063139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NCI NIH HHS [CA63139] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; YU H, 1996, CELL, V76, P933; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	24	265	269	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25746	25749		10.1074/jbc.271.42.25746	http://dx.doi.org/10.1074/jbc.271.42.25746			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824201	hybrid			2022-12-25	WOS:A1996VN18000007
J	Cherradi, N; Rossier, MF; Vallotton, MB; Capponi, AM				Cherradi, N; Rossier, MF; Vallotton, MB; Capponi, AM			Calcium stimulates intramitochondrial cholesterol transfer in bovine adrenal glomerulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; MITOCHONDRIAL CONTACT SITES; ATRIAL-NATRIURETIC-PEPTIDE; ACUTE REGULATORY PROTEIN; LEYDIG TUMOR-CELLS; ANGIOTENSIN-II; ALDOSTERONE PRODUCTION; ADRENOCORTICAL MITOCHONDRIA; STEROIDOGENESIS; POTASSIUM	In adrenal glomerulosa cells, angiotensin II (Ang II) stimulates aldosterone synthesis through rises of cytosolic calcium ([Ca2+](c)). The rate-limiting step in this process is the transfer of cholesterol to the inner mitochondrial membrane, where it is converted to pregnenolone by the P450 side chain cleavage enzyme. The aim of the present study was to examine the effect of changes in [Ca2+](c) and of Ang II on intramitochondrial cholesterol distribution, Freshly prepared bovine zona glomerulosa cells were submitted to a cytosolic Ca2+ clamp (600 nM) or stimulated with Ang II (10 nm). Mitochondria were isolated and subfractionated into outer membranes (OM), inner membranes (IM), and contact sites (CS), Cholesterol content was determined by the cholesterol oxidase assay, Stimulation of intact cells with Ca2+ led to a marked decrease in cholesterol content of OM (to 54 +/- 24% of controls, n = 5) and to a concomitant increase of cholesterol in CS and IM (to 145 +/- 14%, n = 5), When glomerulosa cells mere exposed to Ang II, a marked increase of cholesterol in CS occurred (to 172 +/- 16% of controls, n = 5), No significant changes were detected in OM cholesterol, suggesting a stimulation of cholesterol supply to the mitochondria in response to Ang II, Cycloheximide specifically and significantly reduced Ca2+-activated cholesterol transfer to CS and IM. In conclusion, our data indicate that one of the main functions of the Ca2+ messenger is to increase cholesterol supply to the P450 side chain cleavage enzyme by enhancing endogenous intermembrane cholesterol transfer to a mitochondrial site containing the enzymes responsible for the initial steps of the steroidogenic cascade.	FAC MED,DEPT MED,DIV ENDOCRINOL & DIABETOL,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva			Cherradi, Nadia/K-9695-2016; Rossier, Michel/AAW-2895-2021	Cherradi, Nadia/0000-0002-4292-774X; 				ADAMS V, 1989, BIOCHIM BIOPHYS ACTA, V981, P213, DOI 10.1016/0005-2736(89)90031-X; AMBROZ C, 1992, ENDOCRINOLOGY, V131, P408, DOI 10.1210/en.131.1.408; APPELMANS F, 1955, BIOCHEM J, V59, P438, DOI 10.1042/bj0590438; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BAKKER A, 1994, BBA-MOL CELL RES, V1224, P583, DOI 10.1016/0167-4889(94)90297-6; BAKKER A, 1993, EUR J MORPHOL, V31, P46; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; BARRETT PQ, 1991, AM J PHYSIOL, V261, pF706, DOI 10.1152/ajprenal.1991.261.4.F706; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAPPONI AM, 1984, J BIOL CHEM, V259, P8863; CAPPONI AM, 1988, J BIOL CHEM, V263, P16113; CHENG B, 1983, LIPIDS, V18, P577, DOI 10.1007/BF02534665; CHENG B, 1985, MOL CELL ENDOCRINOL, V40, P233, DOI 10.1016/0303-7207(85)90179-0; CHERRADI N, 1994, ENDOCRINOLOGY, V134, P1358, DOI 10.1210/en.134.3.1358; Clark BJ, 1995, MOL CELL ENDOCRINOL, V115, P215, DOI 10.1016/0303-7207(95)03683-0; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; ELLIOTT ME, 1984, BIOCHEM PHARMACOL, V33, P1519, DOI 10.1016/0006-2952(84)90422-2; ELLIOTT ME, 1993, ENDOCRINOLOGY, V133, P1669, DOI 10.1210/en.133.4.1669; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FAKUNDING JL, 1979, ENDOCRINOLOGY, V105, P327, DOI 10.1210/endo-105-2-327; GAMBLE W, 1978, J LIPID RES, V19, P1068; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; KOWLURU R, 1995, MOL CELL ENDOCRINOL, V107, P181, DOI 10.1016/0303-7207(94)03441-U; LAMBETH JD, 1981, J BIOL CHEM, V256, P4757; LANG U, 1987, J BIOL CHEM, V262, P8047; Muller J., 1988, REGULATION ALDOSTERO; OTSUKA S, 1964, BIOCHEM PHARMACOL, V13, P995, DOI 10.1016/0006-2952(64)90096-6; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; PRIVALLE CT, 1987, MOL CELL ENDOCRINOL, V53, P87, DOI 10.1016/0303-7207(87)90195-X; PYTHON CP, 1995, BIOCHEM J, V305, P569, DOI 10.1042/bj3050569; PYTHON CP, 1993, ENDOCRINOLOGY, V132, P1489, DOI 10.1210/en.132.4.1489; QUINN SJ, 1988, AM J PHYSIOL, V255, pE488, DOI 10.1152/ajpendo.1988.255.4.E488; ROSSIER MF, 1987, J BIOL CHEM, V262, P4053; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SPAT A, 1989, J ENDOCRINOL, V122, P361, DOI 10.1677/joe.0.1220361; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; STEVENS VL, 1992, ENDOCRINOLOGY, V130, P1557, DOI 10.1210/en.130.3.1557; STOCCO DM, 1992, J STEROID BIOCHEM, V43, P319, DOI 10.1016/0960-0760(92)90167-H	40	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25971	25975		10.1074/jbc.271.42.25971	http://dx.doi.org/10.1074/jbc.271.42.25971			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824233	hybrid			2022-12-25	WOS:A1996VN18000039
J	Davies, SR; Cole, AA; Schmid, TM				Davies, SR; Cole, AA; Schmid, TM			Doxycycline inhibits type X collagen synthesis in avian hypertrophic chondrocyte cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHMID METAPHYSEAL CHONDRODYSPLASIA; MOLECULAR WEIGHT COLLAGEN; CARTILAGE COLLAGEN; GROWTH PLATE; TETRACYCLINES; LOCALIZATION; MUTATION; CHAIN; OSTEOARTHRITIS; PROTEOGLYCAN	Doxycycline, a member of the tetracycline family, has been shown to reduce a type X collagen epitope as detected by immunohistochemistry with a monoclonal antibody in an avian explant culture system (1). It was also shown to decrease collagenase and gelatinase activities and thus matrix degradation, This study investigates the effect of doxycycline on type X collagen synthesis in monolayer cultures of hypertrophic chondrocytes. Protein synthesis was evaluated by radioisotopic labeling during doxycycline, tetracycline, or minocycline treatment, Radiolabeled proteins were analyzed by gel electrophoresis, and total collagen was quantitated by hydroxyproline analysis, Additionally, the synthesis of type X collagen was measured by immunoprecipitation, Doxycycline was found to inhibit type X production more effectively than either of the other tetracyclines at comparable dose levels, Furthermore, type X collagen was inhibited more than other collagens, non-collagenous proteins and proteoglycans, with maximal inhibition at 80 mu g/ml and an IC50 of 7 mu g/ml. This inhibition by doxycycline was specific for type X collagen at 10 mu g/ml, and the pattern was distinct from cycloheximide, a recognized inhibitor of protein translation, This suppression of type X collagen could not be overcome by excess extracellular calcium, conditions that have been demonstrated to induce synthesis of this protein (2).	RUSH PRESBYTERIAN ST LUKES MED CTR, RUSH MED COLL, DEPT BIOCHEM, CHICAGO, IL 60612 USA	Rush University				Davies, Sherri/0000-0002-7141-8354	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039239] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39239] Funding Source: Medline; NICHD NIH HHS [HD23681] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERT A, 1956, NATURE, V177, P433, DOI 10.1038/177433a0; BAX CMR, 1993, BIOSCIENCE REP, V13, P169, DOI 10.1007/BF01149961; Blackwood R. K., 1985, TETRACYCLINES, P59; BLAIR HC, 1989, CONNECT TISSUE RES, V23, P65, DOI 10.3109/03008208909103904; BONEN DK, 1991, J CELL BIOL, V115, P1171, DOI 10.1083/jcb.115.4.1171; CASWELL AH, 1971, BIOCHEM BIOPH RES CO, V43, P625, DOI 10.1016/0006-291X(71)90660-7; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; CHOPRA I, 1985, TETRACYCLINES, P317; CLARK CC, 1994, J ORTHOPAED RES, V12, P601, DOI 10.1002/jor.1100120502; COLE AA, 1994, ARTHRITIS RHEUM, V37, P1727, DOI 10.1002/art.1780371204; COLE AA, 1993, DEV BIOL, V159, P528, DOI 10.1006/dbio.1993.1261; DEAN DD, 1989, MATRIX, V9, P366, DOI 10.1016/S0934-8832(89)80041-1; DEAN DD, 1985, J CLIN INVEST, V76, P716, DOI 10.1172/JCI112026; FRANKLIN T. J., 1966, SYMP SOC GEN MICROBIOL, V16, P192; GABLER WL, 1991, J PERIODONTAL RES, V26, P52, DOI 10.1111/j.1600-0765.1991.tb01626.x; GIBSON GJ, 1986, COLLAGEN REL RES, V6, P163; Golub L M, 1992, Curr Opin Dent, V2, P80; GOLUB LM, 1983, J PERIODONTAL RES, V18, P516, DOI 10.1111/j.1600-0765.1983.tb00388.x; GOLUB LM, 1991, CRIT REV ORAL BIOL M, V2, P297, DOI 10.1177/10454411910020030201; GREENWALD RA, 1992, J RHEUMATOL, V19, P927; GREENWALD RA, 1987, J RHEUMATOL, V14, P28; GUERIN C, 1992, BIOCHEM BIOPH RES CO, V188, P740, DOI 10.1016/0006-291X(92)91118-A; GULBIS J, 1975, J AM CHEM SOC, V97, P21; IGARASHI K, 1970, EUR J BIOCHEM, V14, P41, DOI 10.1111/j.1432-1033.1970.tb00258.x; INGMAN T, 1993, J PERIODONTOL, V64, P82, DOI 10.1902/jop.1993.64.2.82; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; JOHNSON R H, 1964, J Oral Ther Pharmacol, V1, P190; KANEKO H, 1990, ANAT REC, V227, P427, DOI 10.1002/ar.1092270406; KIMURA JH, 1980, J BIOL CHEM, V255, P7134; KIRSCH T, 1991, FEBS LETT, V294, P149, DOI 10.1016/0014-5793(91)81363-D; LACHMAN RS, 1988, PEDIATR RADIOL, V18, P93, DOI 10.1007/BF02387549; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUDA K, 1994, ANAL BIOCHEM, V217, P167, DOI 10.1006/abio.1994.1105; MOLLENHAUER J, 1994, ORTHOP RES SOC T, V19, P363; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SASAKI T, 1991, ANAT REC, V231, P25, DOI 10.1002/ar.1092310105; Schach Von Wittenau M., 1971, CHEMOTHERAPY, V16, P217, DOI [10.1159/000220730, DOI 10.1159/000220730]; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; SCHMID TM, 1982, J BIOL CHEM, V257, P2451; SCHMID TM, 1982, J BIOL CHEM, V257, P2444; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; SCHMID TM, 1987, STRUCTURE FUNCTION C, P223; SOLURSH M, 1986, DEV BIOL, V117, P90, DOI 10.1016/0012-1606(86)90351-9; UITTO VJ, 1994, ANN NY ACAD SCI, V732, P140, DOI 10.1111/j.1749-6632.1994.tb24731.x; VALCAVI U, 1981, NEW TRENDS ANTIBIOTI, P3; VONDERMARK K, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P221; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WALKER GD, 1995, J ORTHOPAED RES, V13, P4, DOI 10.1002/jor.1100130104; WALLIS GA, 1994, AM J HUM GENET, V54, P169; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; WILLIAMS DN, 1986, ANTIMICROBIAL AGENTS, P188; WILLIAMSON DE, 1975, J AM CHEM SOC, V97, P2397, DOI 10.1021/ja00842a015; YU LP, 1992, ARTHRITIS RHEUM, V35, P1150, DOI 10.1002/art.1780351007; ZAIDI M, 1983, BIOSCIENCE REP, V13, P175	54	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25966	25970		10.1074/jbc.271.42.25966	http://dx.doi.org/10.1074/jbc.271.42.25966			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824232	hybrid			2022-12-25	WOS:A1996VN18000038
J	Gu, YQ; Chao, WS; Walling, LL				Gu, YQ; Chao, WS; Walling, LL			Localization and post-translational processing of the wound-induced leucine aminopeptidase proteins of tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYCOPERSICON-ESCULENTUM TOMATO; GEL-ELECTROPHORESIS; THYLAKOID MEMBRANE; SEQUENCE-ANALYSIS; EXPRESSION; GENES; PURIFICATION; INHIBITOR; ENZYME; POLYPEPTIDE	Leucine aminopeptidase (LAP) is induced by Rounding and bacterial pathogen infection in tomato. DNA blot analysis of XbaI-digested lambda Lap genomic clones demonstrated that LapA1 and LapA2 cDNAs were encoded by two different LapA genes in the tomato genome. The coding and untranslated regions of LapA1 and LapA2 mRNAs shared more than 93% identity, The deduced amino acid sequences of LapA cDNA clones and in vitro translation of LapA1 mRNA indicated that LAP-A was synthesized as a 60-kDa precursor protein. The processing of a 60-kDa preLAP-A into the mature 55-kDa LAP-A was demonstrated in vivo by expression of the full length LapA1 cDNA in insect cells. Sequencing of a single LAP-A form isolated from a two-dimensional poly acrylamide gel indicated that LAP-A proteins had two different N termini that were separated by two residues. The LAP-A presequence had features similar to chloroplast transit peptides. Comparison of LAP-A levels in chloroplast and total protein extracts from methyl jasmonate-treated leaves indicated that a small proportion of the LAP-A proteins was detected in the plastids. Inspection of the LAP-A presequence indicated the presence of a dibasic protease (Kex2/furin) processing site motif 6-8 residues upstream from the LAP-A N termini. Its potential role in LAP-A precursor biogenesis is discussed.	UNIV CALIF RIVERSIDE,DEPT BOT & PLANT SCI,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,GRAD GENET GRP,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside								BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BARTLING D, 1992, EUR J BIOCHEM, V205, P425, DOI 10.1111/j.1432-1033.1992.tb16796.x; BARTLING D, 1994, PLANT SCI, V9, P199; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHAO WS, 1995, PLANT PHYSIOL, V107, P253, DOI 10.1104/pp.107.1.253; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CREISSEN G, 1995, PLANT J, V8, P167, DOI 10.1046/j.1365-313X.1995.08020167.x; CUYPERS HT, 1982, J BIOL CHEM, V257, P7077; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLIE DR, 1993, ANNU REV PLANT PHYS, V44, P77, DOI 10.1146/annurev.pp.44.060193.000453; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Gu YQ, 1996, PLANT PHYSIOL, V110, P1257, DOI 10.1104/pp.110.4.1257; GU YQ, 1994, THESIS U CALIFORNIA; HANSON H, 1976, METHODS ENZYMOLOGY B, V45, P504; HARRIS CA, 1992, J BIOL CHEM, V267, P6865; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERBERS K, 1994, PLANTA, V194, P230, DOI 10.1007/BF01101682; HILDMANN T, 1992, PLANT CELL, V4, P1157, DOI 10.1105/tpc.4.9.1157; HURKMAN WJ, 1986, PLANT PHYSIOL, V81, P802, DOI 10.1104/pp.81.3.802; KANNO T, 1984, AM J CLIN PATHOL, V82, P700, DOI 10.1093/ajcp/82.6.700; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KESSLER SW, 1975, J IMMUNOL, V115, P1617; Linderstrom-Lang K, 1929, H-S Z PHYSIOL CHEM, V182, P151; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; MCDONALD JK, 1986, MAMMALIAN PROTEASESE, V2; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MIKKONEN A, 1992, PHYSIOL PLANTARUM, V84, P393, DOI 10.1111/j.1399-3054.1992.tb04681.x; Mikola L, 1986, PLANT PROTEOLYTIC EN, V1, P97; MILLIGAN SB, 1995, PLANT MOL BIOL, V28, P691, DOI 10.1007/BF00021194; Mireau H, 1996, PLANT CELL, V8, P1027, DOI 10.1105/tpc.8.6.1027; PAUTOT V, 1993, P NATL ACAD SCI USA, V90, P9906, DOI 10.1073/pnas.90.21.9906; PAUTOT V, 1991, MOL PLANT MICROBE IN, V4, P284, DOI 10.1094/MPMI-4-284; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PICHERSKY E, 1987, PLANT MOL BIOL, V9, P205, DOI 10.1007/BF00166457; RENDUELES PS, 1988, FEMS MICROBIOL LETT, V54, P17; SANDERINK GJ, 1988, J CLIN CHEM CLIN BIO, V26, P795; SCHALLER A, 1995, PLANT CELL, V7, P1893, DOI 10.1105/tpc.7.11.1893; SCHALLER A, 1994, P NATL ACAD SCI USA, V91, P11802, DOI 10.1073/pnas.91.25.11802; SMITH EL, 1980, ENZYMES, V4, P37; SOPANEN T, 1975, PLANT PHYSIOL, V55, P809, DOI 10.1104/pp.55.5.809; SUGITA M, 1987, MOL GEN GENET, V209, P247, DOI 10.1007/BF00329650; SUMMERS MD, 1985, TEX AGR EXP STN B, V1555; TAYLOR A, 1982, CURR EYE RES, V2, P47, DOI 10.3109/02713688208998379; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V205, P168; Walling L. L., 1996, AMINOPEPTIDASES, P173; WALLING LL, 1988, NUCLEIC ACIDS RES, V16, P10477, DOI 10.1093/nar/16.22.10477; WALLNER BP, 1993, BIOCHEMISTRY-US, V32, P9296, DOI 10.1021/bi00087a006; WANG CS, 1992, PLANT PHYSIOL, V99, P822, DOI 10.1104/pp.99.3.822; WANG JL, 1996, IN PRESS PLANTA; Wendel J. F., 1989, Isozymes in plant biology., P5; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	54	39	41	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25880	25887		10.1074/jbc.271.42.25880	http://dx.doi.org/10.1074/jbc.271.42.25880			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824220	hybrid			2022-12-25	WOS:A1996VN18000026
J	Gulbins, E; Coggeshall, KM; Brenner, B; Schlottmann, K; Linderkamp, O; Lang, F				Gulbins, E; Coggeshall, KM; Brenner, B; Schlottmann, K; Linderkamp, O; Lang, F			Fas-induced apoptosis is mediated by activation of a Ras and Rac protein-regulated signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GTP-BINDING PROTEINS; GROWTH-FACTOR DEPRIVATION; LYMPHOPROLIFERATIVE SYNDROME; ACIDIC SPHINGOMYELINASE; RECEPTOR SUPERFAMILY; TRANSCRIPTION FACTOR; SURFACE ANTIGEN; T-LYMPHOCYTES; C-MYC	Fas induces apoptosis in lymphocytes via a poorly defined intracellular signaling mechanism. We and others have previously demonstrated the involvement and significance of a signaling cascade from the Fas receptor via sphingomyelinases and ceramide to Ras in apoptosis (Gulbins, E., Bissonette, R., Mahboubi, A., Nishioka, W., Brunner, T., Baier G., Baier-Bitterlich, G., Byrd, C., Lang, F., Kolesnick, R., Altman, A., and Green, D. (1995) Immunity 2, 341; Cifone, M. G., DeMaria, R., Roncali, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A., and Testi, R. (1994) J. Exp. Med. 180, 1547-1552; Gill, B. M., Nishikata, H., Chan, G., Delovitch, T. L., and Ochi, A. (1994) Immunol. Rev. 142, 113-126). Here, we demonstrate an activation of the small G-proteins Rac 1 and Rac 2 after Fas receptor triggering. Expression of a transdominant inhibitory Ras mutant (N17Ras) prevents Rac 1 and Rac 2 stimulation, suggesting a signaling cascade from the Fas receptor via Ras to Rac 1 and Rac 2. Genetic and pharmacological inhibition of Ras or Rac 1 and Rac 2 stimulation blocks Fas-induced apoptosis, pointing to an important function of a Ras and Rac protein-regulated signaling pathway in Fas-mediated programmed cell death.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210; UNIV HEIDELBERG,DEPT PEDIAT,D-69120 HEIDELBERG,GERMANY	University System of Ohio; Ohio State University; Ruprecht Karls University Heidelberg	Gulbins, E (corresponding author), UNIV TUBINGEN,DEPT PHYSIOL,GEMLINSTR 5,D-72076 TUBINGEN,GERMANY.		Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342	NATIONAL CANCER INSTITUTE [R01CA064268, R29CA064268] Funding Source: NIH RePORTER; NCI NIH HHS [CA64268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; BERGLUND DL, 1991, CYTOMETRY, V12, P64, DOI 10.1002/cyto.990120109; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GILL BM, 1994, IMMUNOL REV, V142, P113, DOI 10.1111/j.1600-065X.1994.tb00885.x; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OEHM A, 1992, J BIOL CHEM, V267, P10709; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STEVENSON MA, 1994, CANCER RES, V54, P12; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WU JG, 1994, P NATL ACAD SCI USA, V91, P2344, DOI 10.1073/pnas.91.6.2344; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	57	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26389	26394		10.1074/jbc.271.42.26389	http://dx.doi.org/10.1074/jbc.271.42.26389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824295	hybrid			2022-12-25	WOS:A1996VN18000101
J	Lassota, P; Singh, G; Kramer, R				Lassota, P; Singh, G; Kramer, R			Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INTERACTION DOMAINS; MEDIATED DNA CLEAVAGE; BIS(2,6-DIOXOPIPERAZINE) DERIVATIVES; ANTICANCER DRUGS; POTENT INHIBITOR; ENZYME; APOPTOSIS; ETOPOSIDE; AGENTS; INDUCTION	Topoisomerase II is an essential enzyme for proliferation of eukaryotic cells, It is also a target for many antineoplastic drugs that promote stabilization of covalent complexes between topoisomerase II and DNA. Topoisomerase II and protein kinases both catalyze the transfer of phosphoester bonds from nucleotides to proteins. This similarity suggests that inhibitors may affect both classes of enzymes. In the present study, we have examined the mechanism of topoisomerase II inhibition by three different classes of protein kinase inhibitors, We report that staurosporine inhibited the catalytic activity of topoisomerase II by blocking the transfer of phosphodiester bonds from DNA to the active tyrosine site, a mechanism of inhibition not previously reported for this enzyme. In contrast, other kinase inhibitors, such as methyl 2,5-dihydroxycinnamate, most likely inactivated topoisomerase II by alkylation of essential amino acids, whereas the mechanism of inhibition of bis-indolylmaleimide possibly involved a direct interaction with DNA.			Lassota, P (corresponding author), WYETH AYERST RES, DIV ONCOL IMMUNOL CLIN RES, BLDG 200, RM 4618, 401 N MIDDLETOWN RD, PEARL RIVER, NY 10965 USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSEN AH, 1994, ADV PHARM A, V29, P89; BENCHOKROUN Y, 1995, BIOCHEM PHARMACOL, V49, P305, DOI 10.1016/0006-2952(94)00465-X; BORITZKI TJ, 1988, BIOCHEM PHARMACOL, V37, P4063, DOI 10.1016/0006-2952(88)90096-2; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DRAKE FH, 1989, CANCER RES, V49, P2578; Drolet M, 1994, Adv Pharmacol, V29A, P135; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; ISHIDA R, 1991, CANCER RES, V51, P4909; JENSEN PB, 1990, CANCER RES, V50, P3311; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KUPCHAN SM, 1970, SCIENCE, V168, P376, DOI 10.1126/science.168.3929.376; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; MARKOVITS J, 1989, CANCER RES, V49, P5111; MARKOVITS J, 1994, BIOCHEM PHARMACOL, V48, P549, DOI 10.1016/0006-2952(94)90285-2; Nitiss J L, 1994, Adv Pharmacol, V29A, P103; OHNO R, 1993, CANCER, V71, P2217, DOI 10.1002/1097-0142(19930401)71:7<2217::AID-CNCR2820710709>3.0.CO;2-8; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAHAI BM, 1986, ANAL BIOCHEM, V156, P364, DOI 10.1016/0003-2697(86)90267-8; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANABE K, 1991, CANCER RES, V51, P4903; UMEZAWA K, 1991, METHOD ENZYMOL, V201, P379; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WARD NE, 1992, MOL PHARMACOL, V41, P387	37	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26418	26423		10.1074/jbc.271.42.26418	http://dx.doi.org/10.1074/jbc.271.42.26418			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824299	hybrid			2022-12-25	WOS:A1996VN18000105
J	Mizushima, T; Sasaki, S; Ohishi, H; Kobayashi, M; Katayama, T; Miki, T; Maeda, M; Sekimizu, K				Mizushima, T; Sasaki, S; Ohishi, H; Kobayashi, M; Katayama, T; Miki, T; Maeda, M; Sekimizu, K			Molecular design of inhibitors of in vitro oriC DNA replication based on the potential to block the ATP binding of DnaA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; INITIATION PROTEIN; ORIGIN	DnaA protein, the initiation factor for chromosomal DNA replication in Escherichia coli, is activated by binding to ATP. We earlier reported that 3-acetoxy-2,2'-bi-1H-indol inhibited the ATP binding to DnaA protein (Sasaki, S., Mizushima, T., Hashimoto, T., Maeda, M., and Sekimizu, K. (1994) Bioorg. Med. Chem. Lett. 4, 1771-1774), In the present study, derivatives of 3-acetoxy-2,2'-bi-1H-indol with different lengths of aliphatic chains at the 3-O position were synthesized, and their potential to inhibit the ATP binding to DnaA protein was examined. Elongation of the aliphatic chain resulted in inhibition of the ATP binding to DnaA protein at lower concentrations. Among the derivatives, 3-[N-(11-carboxyundecyl)] carbamoylmethoxy-2,2'-bi-1H-indol (structure 7 (3-CUCM-BI)) exhibited the most potent inhibition with an IC50 value of 7 mu M. The mode of the inhibition was competitive. We further demonstrated that structure 7 (3-CUCM-BI) inhibited DNA replication of the oriC plasmid in a system reconstituted from purified proteins. This inhibition was specific for the initiation of DNA replication rather than for the elongation. The inhibition was overcome by preincubation of DnaA protein with ATP. Furthermore, structure 7 (3-CUCM-BI) showed little inhibition on DNA synthesis in the ABC primosome system. We propose that structure 7 (3-CUCM-BI) functions in the in vitro oriC DNA replication by inhibiting the ATP binding to DnaA protein.	KYUSHU UNIV, FAC PHARMACEUT SCI, HIGASHI KU, FUKUOKA 81282, JAPAN	Kyushu University				Katayama, Tsutomu/0000-0001-9994-1684				CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; Katayama T, 1995, MOL MICROBIOL, V18, P813, DOI 10.1111/j.1365-2958.1995.18050813.x; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Kornberg A., 1992, DNA REPLICATION; MASAI H, 1990, J BIOL CHEM, V265, P15134; MIKI T, 1978, P NATL ACAD SCI USA, V75, P5099, DOI 10.1073/pnas.75.10.5099; Mizushima T, 1996, J BIOL CHEM, V271, P3633; SASAKI S, 1994, BIOORG MED CHEM LETT, V4, P1771, DOI 10.1016/S0960-894X(00)80378-9; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; TRINKS U, 1994, J MED CHEM, V37, P1015, DOI 10.1021/jm00033a019; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	17	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25178	25183		10.1074/jbc.271.41.25178	http://dx.doi.org/10.1074/jbc.271.41.25178			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810275	hybrid			2022-12-25	WOS:A1996VL69300019
J	Arzumanov, AA; Semizarov, DG; Victorova, LS; Dyatkina, NB; Krayevsky, AA				Arzumanov, AA; Semizarov, DG; Victorova, LS; Dyatkina, NB; Krayevsky, AA			gamma-phosphate-substituted 2'-deoxynucleoside 5'-triphosphates as substrates for DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOSIDE 5'-TRIPHOSPHATES; ANALOGS; TRIPHOSPHATE; ALPHA; ROUTE; ACID	Several 2'-deoxythymidine 5'-triphosphate and 3'-azido-2',3'-dideoxythymidine 5'-triphosphate analogs containing a hydrophobic phosphonate group instead of the gamma-phosphate were synthesized and evaluated as substrates for human immunodeficiency virus (HIV) and avian myeloblastosis virus reverse transcriptases, human placental DNA polymerases alpha and beta, and calf thymus terminal deoxynucleotidyl transferase. They were efficiently incorporated into the DNA chain by the retroviral enzymes but were not utilized by the mammalian ones. Also, some gamma-ester and gamma-amide derivatives of dTTP and 3'-azido-2',3'-dideoxythymidine 5'-triphosphate (AZTTP) were synthesized and studied. They proved to be substrates for both the retroviral and mammalian enzymes under study. The K-m values for incorporation of the dTTP derivatives into the DNA chain were close to those for dTTP and AZTTP. The K-m for the AZTTP derivatives were one order of magnitude greater than those for dTTP and AZTTP. The results obtained indicate that HIV and avian myeloblastosis virus reverse transcriptases have no sterical obstacles for binding the triphosphate fragment bearing a bulky substituent at the gamma-position. Modification of the gamma-phosphate in AZTTP increased the selectivity of HIV reverse transcriptase inhibition versus DNA polymerase alpha. gamma-Methylphosphonate and gamma-phenylphosphonate were dephosphorylated in human serum much less rapidly than AZTTP. Besides, they were shown to be markedly more hydrophobic than AZTTP. Thus, replacement of the gamma-phosphate in AZTTP with gamma-phosphonate markedly alters its substrate properties toward some cellular DNA polymerases and blood dephosphorylating enzymes but does not change its substrate activity with respect to HIV reverse transcriptase.	RUSSIAN ACAD SCI,INST MOL BIOL,MOSCOW 117984,RUSSIA	Russian Academy of Sciences								ARMSTRONG VW, 1976, EUR J BIOCHEM, V70, P33, DOI 10.1111/j.1432-1033.1976.tb10952.x; ARZUMANOV AA, 1994, NUCLEOS NUCLEOT, V13, P1031, DOI 10.1080/15257779408011876; ATRAZHEV AM, 1987, BIOORG KHIM+, V13, P1045; BABKINA GT, 1975, BIOORG KHIM+, V1, P611; BUNEVA NV, 1983, DOKL AKAD NAUK SSSR, V268, P243; BUNEVA NV, 1980, MOL BIOL RUSSIAN, V14, P1080; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CHAMBERS RD, 1990, J CHEM SOC CHEM COMM, P1053, DOI 10.1039/c39900001053; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DORONIN SV, 1987, FEBS LETT, V216, P221, DOI 10.1016/0014-5793(87)80693-2; DYATKINA N, 1995, NUCLEOS NUCLEOT, V14, P91, DOI 10.1080/15257779508014655; EGLUND PT, 1969, J BIOL CHEM, V244, P3038; FERRIN LJ, 1986, BIOCHEMISTRY-US, V25, P5131, DOI 10.1021/bi00366a023; KILESSO TY, 1990, BIOORG KHIM, V16, P530; KNORRE DG, 1988, BIOCHIMIE, V70, P655, DOI 10.1016/0300-9084(88)90250-7; Kolocheva T. I., 1993, Molekulyarnaya Biologiya (Moscow), V27, P1368; KRAEV A S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1164; KRAUT J, 1961, ACTA CRYSTALLOGR, V14, P1146, DOI 10.1107/S0365110X61003363; LUDWIG J, 1981, ACTA BIOCHIM BIOPHYS, V16, P131; Mozzherin D. Yu., 1992, Molekulyarnaya Biologiya (Moscow), V26, P999; OKAYA Y, 1966, ACTA CRYSTALLOGR, V20, P7122; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PERRIER WG, 1962, ACTA CRYSTALLOGR, V15, P616; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; ROSOVSKAYA TA, 1993, MOL BIOL RUSSIAN, V27, P1051; ROSOVSKAYA TA, 1992, MOL BIOL RUSSIAN, V27, P618; Sambrook J., 2002, MOL CLONING LAB MANU; SEMIZAROV DG, 1993, FEBS LETT, V327, P45, DOI 10.1016/0014-5793(93)81036-Y; SLOAN DL, 1975, J BIOL CHEM, V250, P8913; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; VICTOROVA LS, 1992, NUCLEIC ACIDS RES, V20, P783, DOI 10.1093/nar/20.4.783	32	44	59	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24389	24394		10.1074/jbc.271.40.24389	http://dx.doi.org/10.1074/jbc.271.40.24389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798694	hybrid			2022-12-25	WOS:A1996VM67400016
J	Geck, RK; Larimer, FW; Hartman, FC				Geck, RK; Larimer, FW; Hartman, FC			Identification of residues of spinach thioredoxin f that influence interactions with target enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 1,6-BISPHOSPHATASE; MALATE-DEHYDROGENASE; REDUCTIVE ACTIVATION; C-4 PHOTOSYNTHESIS; CRYSTAL-STRUCTURE; PURIFICATION; RESOLUTION; MECHANISM	The necessity for two types of thioredoxins (Trx f and m) within chloroplasts of higher plants that mediate the same redox chemistry with various target enzymes is not well understood. To approach this complex issue, we have applied site-directed mutagenesis to the identification of residues of Trx f that affect its binding to and selectivity for target enzymes. Based upon amino acid sequence alignments and the three-dimensional structure of Escherichia coli thioredoxin, putative key residues of Trx f were replaced with residues found at corresponding positions of Trx m to generate the mutants K58E, Q75D, N74D, and deletion mutants Delta Asn-74 and Delta Asn-77. Kinetics of activation of oxidized recombinant sorghum leaf NADP-dependent malate dehydrogenase and oxidized spinach chloroplastic fructose-1,6-bisphosphatase by wild-type Trx f, wild-type Trx m, and Trx f mutants were compared. All of the mutants are less efficient than wild-type Trx f in the activation of fructose-1,6-bisphosphatase and are altered in both S-0.5 and V-max. In contrast to literature reports, the activation of NADP-dependent malate dehydrogenase does not display rate saturation kinetics with respect to the concentration of Trx f, thereby signifying very weak interactions between the two proteins. The mutants of Trx f likewise interact only weakly with NADP-dependent malate dehydrogenase, but the apparent second-order rate constants for activation are increased compared to that with wild-type Trx f. Thus, Lys-58, Asn-74, Gln-75, and Asn-77 of Trx f contribute to its interaction with target enzymes and influence target protein selectivity.	OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831; OAK RIDGE NATL LAB,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville								AGUILAR F, 1992, PLANT MOL BIOL, V20, P301, DOI 10.1007/BF00014497; BRANDES HK, 1993, J BIOL CHEM, V268, P18411; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; Buchanan Bob B., 1992, P171; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; CRAWFORD NA, 1986, ARCH BIOCHEM BIOPHYS, V244, P1, DOI 10.1016/0003-9861(86)90088-3; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GLEASON FK, 1992, J BACTERIOL, V174, P2592, DOI 10.1128/jb.174.8.2592-2598.1992; HABERLEIN I, 1995, BBA-PROTEIN STRUCT M, V1253, P169, DOI 10.1016/0167-4838(95)00153-1; HODGES M, 1994, PLANT MOL BIOL, V26, P225, DOI 10.1007/BF00039534; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Holmgren A., 1986, THIOREDOXIN GLUTARED; JACQUOT JP, 1993, FEBS LETT, V96, P243; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARCUS F, 1987, BIOCHEMISTRY-US, V26, P7029, DOI 10.1021/bi00396a026; NISHIZAWA AN, 1981, J BIOL CHEM, V256, P6119; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; SAARINEN M, 1995, STRUCTURE, V3, P1097, DOI 10.1016/S0969-2126(01)00245-3; SALAMON Z, 1995, BBA-BIOENERGETICS, V1230, P114, DOI 10.1016/0005-2728(95)00042-H; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIBE R, 1986, BIOCHIM BIOPHYS ACTA, V870, P191, DOI 10.1016/0167-4838(86)90221-9; SCHEIBE R, 1981, BIOCHIM BIOPHYS ACTA, V636, P58, DOI 10.1016/0005-2728(81)90075-X; SCHURMANN P, 1981, EUR J BIOCHEM, V116, P37, DOI 10.1111/j.1432-1033.1981.tb05297.x; TSUGITA A, 1983, BIOCHEM BIOPH RES CO, V115, P1, DOI 10.1016/0006-291X(83)90960-9; WEDEL N, 1992, PLANT MOL BIOL, V18, P527, DOI 10.1007/BF00040668; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; XIA TH, 1992, PROTEIN SCI, V1, P310; ZIMMERMANN G, 1976, EUR J BIOCHEM, V70, P361, DOI 10.1111/j.1432-1033.1976.tb11025.x	36	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24736	24740		10.1074/jbc.271.40.24736	http://dx.doi.org/10.1074/jbc.271.40.24736			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798742	hybrid			2022-12-25	WOS:A1996VM67400064
J	OHandley, SF; Frick, DN; Bullions, LC; Mildvan, AS; Bessman, MJ				OHandley, SF; Frick, DN; Bullions, LC; Mildvan, AS; Bessman, MJ			Escherichia coli orf17 codes for a nucleoside triphosphate pyrophosphohydrolase member of the MutT family of proteins - Cloning, purification, and characterization of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE; CATALYTIC DOMAIN; STREPTOCOCCUS-PNEUMONIAE; RUVC GENE; SEQUENCE; EXCHANGE; K-12; PYROPHOSPHATASE; IDENTIFICATION; SUBSTRATE	The product of the Escherichia coli orf17 gene is a novel nucleoside triphosphate pyrophosphohydrolase with a preference for dATP over the other canonical (deoxy)nucleoside triphosphates, and it catalyzes the hydrolysis of dATP through a nucleophilic attack at the beta-phosphorus to produce dAMP and inorganic pyrophosphate. It has a pH optimum between 8.5 and 9.0, a divalent metal ion requirement with optimal activity at 5 mm Mg2+, a K-m of 0.8 mm and a k(cat) of 5.2 s(-1) at 37 degrees C for dATP. dAMP is a weak competitive inhibitor with a K-i of approximately 4 mw, while PPi is a much stronger inhibitor with an apparent K-i of approximately 20 mu M. The enzyme contains the highly conserved signature sequence GXVEX(2)ETX(6)REVXEEX(2)I designating the MutT family of proteins. However, unlike the other nucleoside triphosphate pyrophosphohydrolases with this conserved sequence, the Orf17 protein does not complement the mutT(-) mutator phenotype, and thus must serve a different biological role in the cell.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				O'Handley, Suzanne/0000-0001-8373-0065; Frick, David/0000-0002-2434-7223	NIDDK NIH HHS [DK-28616] Funding Source: Medline; NIGMS NIH HHS [GM-18649] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028616, R37DK028616] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; ABEYGUNAWARDANA C, 1993, BIOCHEMISTRY-US, V32, P13071, DOI 10.1021/bi00211a017; AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AMES BN, 1960, J BIOL CHEM, V235, P769; AOYAMA K, 1994, MOL BIOL EVOL, V11, P829; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; Cleland W W, 1979, Methods Enzymol, V63, P103; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; DESIRAJU V, 1991, THESIS U MARYLAND BA; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRICK DN, 1994, J BIOL CHEM, V269, P1794; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; FRICK DN, 1995, THESIS J HOPKINS U B, P49; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; JOSSE J, 1966, J BIOL CHEM, V241, P1948; JOSSE J, 1966, J BIOL CHEM, V241, P1938; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; KUHKO E, 1986, EUR J BIOCHEM, V127, P347; KUKKOKALSKE E, 1989, J BACTERIOL, V171, P4498, DOI 10.1128/JB.171.8.4498-4500.1989; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWE G, 1978, J CHEM SOC CHEM COMM, P783, DOI 10.1039/c39780000783; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAY U, 1979, MOL GEN GENET, V171, P215, DOI 10.1007/BF00270007; REYNOLDS MA, 1983, J AM CHEM SOC, V105, P6663, DOI 10.1021/ja00360a020; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; WALSH C, 1979, ENZYMATIC REACTION M, P259; WEBER DJ, 1992, J BIOL CHEM, V267, P16939	38	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24649	24654		10.1074/jbc.271.40.24649	http://dx.doi.org/10.1074/jbc.271.40.24649			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798731	hybrid			2022-12-25	WOS:A1996VM67400053
J	Roy, S; Sun, A; Redman, C				Roy, S; Sun, A; Redman, C			In vitro assembly of the component chains of fibrinogen requires endoplasmic reticulum factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN FIBRINOGEN; PROTEIN DISULFIDE-ISOMERASE; SECRETORY PROTEINS; ALPHA-SUBUNIT; BETA-SUBUNIT; CALNEXIN; ASSOCIATION; MOLECULES; BONDS; BIOSYNTHESIS	Human fibrinogen (340 kDa) is a dimer, with each identical half-molecule composed of three different polypeptides (A alpha, 66 kDa; B beta, 55 kDa; and gamma, 48 kDa). To understand the mechanisms of chain assembly, a coupled in vitro transcription translation system capable of assembling fibrinogen chains was developed, Fibrinogen chain assembly was assayed in an expression system coupled to rabbit reticulocyte lysate in the presence or absence of dog pancreas microsomal membranes, Fibrinogen chain assembly required microsomal membranes and oxidized glutathione. Co-expression of two of the chains, B beta and gamma or A alpha and gamma, yielded free chains and two-chain complexes, Unlike combinations of A alpha with gamma and B beta with gamma, co expression of A alpha and B beta did not form a single two-chain complex but produced a mixture of two-chain complexes. Co-expression of all three chains yielded free chains, two-chain complexes, and higher molecular weight complexes that corresponded to a half-molecule and to fully formed fibrinogen. Upon treatment of this mixture with thrombin and factor XIIIa, a gamma .gamma dimer, similar to that obtained from crosslinked human fibrin, was produced, indicating that properly folded fibrinogen was formed in vitro. Molecular chaperones may participate in fibrinogen assembly, since antibodies to resident proteins of the endoplasmic reticulum (BiP, Hsp90, protein disulfide isomerase, and calnexin) co-precipitated the chaperones together with nascent fibrinogen chains and complexes.			Roy, S (corresponding author), NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,310 E 67 ST,NEW YORK,NY 10021, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BILJMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305; BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; CARRENO BM, 1995, J IMMUNOL, V154, P5173; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; FU YP, 1994, P NATL ACAD SCI USA, V91, P2625, DOI 10.1073/pnas.91.7.2625; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HANTGAN RR, 1994, HEMOSTASIS THROMBOSI, P277; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN A, 1964, ARK KEMI, V22, P355; Herbert Daniel N., 1995, Cell, V81, P425; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IWANAGA S, 1967, BIOCHIM BIOPHYS ACTA, V147, P606, DOI 10.1016/0005-2795(67)90025-6; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KIM P, 1995, J CELL BIOL, V12, P29; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; LOO TW, 1994, J BIOL CHEM, V269, P28683; MOSESSON M W, 1992, Seminars in Hematology, V29, P177; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROY S, 1992, J BIOL CHEM, V267, P23151; ROY SN, 1995, J BIOL CHEM, V270, P23761, DOI 10.1074/jbc.270.40.23761; ROY SN, 1991, J BIOL CHEM, V266, P4758; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, P665; ZHANG JZ, 1994, J BIOL CHEM, V269, P652; Zhang JZ, 1996, J BIOL CHEM, V271, P12674, DOI 10.1074/jbc.271.21.12674	47	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24544	24550		10.1074/jbc.271.40.24544	http://dx.doi.org/10.1074/jbc.271.40.24544			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798716	hybrid			2022-12-25	WOS:A1996VM67400038
J	Wang, ZY; Qiu, QQ; Seufert, W; Taguchi, T; Testa, JR; Whitmore, A; Callen, DF; Welsh, D; Shenk, T; Deuel, TF				Wang, ZY; Qiu, QQ; Seufert, W; Taguchi, T; Testa, JR; Whitmore, A; Callen, DF; Welsh, D; Shenk, T; Deuel, TF			Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; TUMOR SUPPRESSOR GENE; WILMS-TUMOR; PROTEASOME PATHWAY; PROMOTER ACTIVITY; WT1; PRODUCT; PROTEIN; TRANSCRIPTION; DEGRADATION	We report a novel human gene whose product specifically associates with the negative regulatory domain of the Wilms' tumor gene product (WT1) in a yeast two-hybrid screen and with WT1 in immunoprecipitation and glutathione S-transferase (GST) capture assays. The gene encodes a 17-kDa protein that has 56% amino acid sequence identity with yeast ubiquitin-conjugating enzyme (yUBC) 9, a protein required for cell cycle progression in yeast, and significant identity with other subfamilies of ubiquitin-conjugating enzymes. The human gene fully complements yeast that have a temperature-sensitive yUBC9 gene mutation to fully restore normal growth, indicating that we have cloned a functionally conserved human (h) homolog of yUBC9. Transcripts of hUBC9 of 4.4 kilobases (kb), 2.8 kb, and 1.3 kb were found in all human tissues tested. A single copy of the hUBC9 gene was found and localized to human chromosome 16p13.3. We conclude that hUBC9 retains striking structural and functional conservation with yUBC9 and suggest a possible link of the ubiquitin/proteosome proteolytic pathway and the WT1 transcriptional repressor system.	BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08560; UNIV MUNICH,INST GENET & MIKROBIOL,D-80638 MUNICH,GERMANY; FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111; WOMENS & CHILDRENS HOSP,DEPT CYTOGENET & MOL GENET,ADELAIDE,SA 5006,AUSTRALIA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Princeton University; University of Munich; Fox Chase Cancer Center; Womens & Childrens Hospital Australia			Callen, David F/G-1975-2012; Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064; Callen, David/0000-0002-6189-9991				CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CALLEN DF, 1995, GENOMICS, V29, P503, DOI 10.1006/geno.1995.9005; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; Maniatis T., 1982, MOL CLONING; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	28	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24811	24816		10.1074/jbc.271.40.24811	http://dx.doi.org/10.1074/jbc.271.40.24811			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798754	hybrid			2022-12-25	WOS:A1996VM67400076
J	Weaver, AM; McCabe, M; Kim, I; Allietta, MM; Gonias, SL				Weaver, AM; McCabe, M; Kim, I; Allietta, MM; Gonias, SL			Epidermal growth factor and platelet-derived growth factor-BB induce a stable increase in the activity of low density lipoprotein receptor-related protein in vascular smooth muscle cells by altering receptor distribution and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; TRANSFERRIN RECEPTORS; ALPHA(2)-MACROGLOBULIN RECEPTOR; ACTIVATED ALPHA-2-MACROGLOBULIN; PLASMINOGEN-ACTIVATOR; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; RAT ADIPOCYTES; BINDING DOMAIN; RATE-CONSTANT	Low density lipoprotein receptor-related protein (LRP) is a multifunctional receptor, expressed by vascular smooth muscle cells (VSMCs) in normal arteries and in atherosclerotic lesions. In this investigation, we demonstrate a novel mechanism for the regulation of LRP activity in cultured rat aortic VSMCs. Cells that were treated with platelet-derived growth factor-BB (PDGF-BB) or epidermal growth factor (EGF) for 24 h bound increased amounts of the LRP ligand, activated alpha(2)-macroglobulin (alpha(2)M), at 4 degrees C. The B-max for activated alpha(2)M was increased from 56 +/- 5 to 178 +/- 24 and 143 +/- 11 fmol/mg cell protein by PDGF-BB and EGF, respectively, while the K-D was unchanged. Northern and Western blot analyses demonstrated that neither PDGF-BB nor EGF increase LRP mRNA or protein levels. Instead, LRP was redistributed to the cell surface and remained localized primarily in coated pits, as determined by surface protein biotinylation, affinity labeling, and immunoelectron microscopy studies. The increase in cell-surface LRP was partially explained by a 50% decrease in receptor endocytosis rate; however, at 37 degrees C, PDGF-BB- and EGF-treated VSMCs still bound/internalized increased amounts of activated alpha(2)M and subsequently released increased amounts of trichloroacetic acid-soluble radioactivity. The cytokine-induced shifts in LRP subcellular distribution were stable when VSMCs were challenged with a saturating concentration of ligand and then incubated, in the absence of cytokine, for 2.5 h at 37 degrees C. Regulation of LRP distribution and activity may be an important aspect of the VSMC response to the atherogenic cytokines, PDGF-BB and EGF.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline; NIGMS NIH HHS [GM07267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAMPBELL JH, 1985, ARTERIOSCLEROSIS, V5, P318, DOI 10.1161/01.ATV.5.4.318; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DAVIS RJ, 1986, EMBO J, V5, P653, DOI 10.1002/j.1460-2075.1986.tb04263.x; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; DICKSON RB, 1981, J CELL BIOL, V89, P29, DOI 10.1083/jcb.89.1.29; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; Hussaini IM, 1996, J LEUKOCYTE BIOL, V59, P733, DOI 10.1002/jlb.59.5.733; HUSSAINI IM, 1990, J BIOL CHEM, V265, P19441; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAPLAN J, 1980, CELL, V19, P197, DOI 10.1016/0092-8674(80)90401-8; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; LUSIAK JJ, 1995, J BIOL CHEM, V270, P21919; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOSSE PRL, 1985, LAB INVEST, V53, P556; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; STOUFFER GA, 1993, J BIOL CHEM, V268, P18340; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANNER LI, 1987, J BIOL CHEM, V262, P8975; THYBERG J, 1983, DIFFERENTIATION, V25, P156; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TYCKO B, 1982, CELL, V28, P643, DOI 10.1016/0092-8674(82)90219-7; VANLEUVEN F, 1980, CELL, V20, P37, DOI 10.1016/0092-8674(80)90232-9; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; WATANABE Y, 1994, ARTERIOSCLER THROMB, V14, P1000, DOI 10.1161/01.ATV.14.6.1000; Weaver AM, 1995, J BIOL CHEM, V270, P30741, DOI 10.1074/jbc.270.51.30741; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1984, P NATL ACAD SCI-BIOL, V81, P7456, DOI 10.1073/pnas.81.23.7456	50	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24894	24900		10.1074/jbc.271.40.24894	http://dx.doi.org/10.1074/jbc.271.40.24894			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798766	hybrid			2022-12-25	WOS:A1996VM67400089
J	DSouza, SE; ByersWard, VJ; Gardiner, EE; Wang, HW; Sung, SS				DSouza, SE; ByersWard, VJ; Gardiner, EE; Wang, HW; Sung, SS			Identification of an active sequence within the first immunoglobulin domain of intercellular cell adhesion molecule-1 (ICAM-1) that interacts with fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-ENDOTHELIUM INTERACTION; GLYCOPROTEIN-IIB-IIIA; GAMMA-CHAIN; RECOGNITION SPECIFICITY; INFLAMMATORY RESPONSES; PLATELET RECEPTOR; HUMAN RHINOVIRUS; LIGAND-BINDING; PEPTIDE; MAC-1	Monocytic cells bind fibrinogen (fg) through integrin alpha(M) beta(2). fg-bound monocytic cells demonstrate an enhanced adhesion to endothelial cells, which is dependent on intercellular adhesion molecule-1 (ICAM-1). Our studies differentiate fg interactions with stimulated and resting endothelial cells, which are ICAM-1 dependent and independent, respectively. This report documents a direct interaction between fg and intact ICAM-1 and with a two-Ig domain form of ICAM-1. A small region within the first Ig domain of ICAM-1, ICAM-1-(8-21) (KVILPRGGSVLVTC), was identified to interact with fg in a specific and selective manner. ICAM-1-(8-21) bound to plasmin-derived fg fragments X, D100, and D80 but not to fragment E. Consistent with this finding, fg gamma-chain peptide, fg-gamma-117-133, blocked fg interaction with ICAM-1-(8-21). ICAM-1-(8-21) peptide and antibodies directed against ICAM-1-(8-21) also blocked the adhesion and binding of ICAM-1-bearing Raji cells with fg. ICAM-1-(8-21) and fg-gamma-117-133 are likely to be one of the contact pairs mediating fg-ICAM-1 interactions.			DSouza, SE (corresponding author), CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL, DEPT MOL CARDIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.		Gardiner, Elizabeth/P-8716-2019; Gardiner, Elizabeth/E-7774-2011	Gardiner, Elizabeth/0000-0001-9453-9688; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043721, R01HL043721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; COBB RR, 1992, BIOCHEM BIOPH RES CO, V185, P1022, DOI 10.1016/0006-291X(92)91729-A; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARVEY JS, 1977, METHODS IMMUNOL, V1, P273; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GIRANDA VL, 1990, PROTEINS, V7, P227, DOI 10.1002/prot.340070304; Hicks RCJ, 1996, NATURE, V379, P818, DOI 10.1038/379818a0; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, BLOOD, V73, P734; LANGUINO LR, 1995, P NATL ACAD SCI USA, V92, P1505, DOI 10.1073/pnas.92.5.1505; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEVESQUE JP, 1990, J BIOL CHEM, V265, P328; LEVESQUE JP, 1986, P NATL ACAD SCI USA, V83, P6494, DOI 10.1073/pnas.83.17.6494; LI R, 1993, J BIOL CHEM, V268, P17513; LI R, 1993, J BIOL CHEM, V268, P21474; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MARGUERIE GA, 1982, J BIOL CHEM, V101, P372; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; PEERSCHKE EIB, 1985, SEMIN HEMATOL, V22, P241; ROSS L, 1992, J BIOL CHEM, V267, P8537; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147; TANG LP, 1995, AM J CLIN PATHOL, V103, P466; TRANQUI L, 1989, J CELL BIOL, V108, P2519, DOI 10.1083/jcb.108.6.2519; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95	54	27	28	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24270	24277		10.1074/jbc.271.39.24270	http://dx.doi.org/10.1074/jbc.271.39.24270			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798673	hybrid			2022-12-25	WOS:A1996VJ44200102
J	Schwalbe, RA; Wang, ZG; Bianchi, L; Brown, AM				Schwalbe, RA; Wang, ZG; Bianchi, L; Brown, AM			Novel sites of N-glycosylation in ROMK1 reveal the putative pore-forming segment H5 as extracellular	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNEL; ASPARAGINE-LINKED OLIGOSACCHARIDES; POTASSIUM CHANNEL; TRANSMEMBRANE TOPOLOGY; RECEPTOR; RECTIFICATION; TERMINUS; GLYCOPROTEINS; MUTAGENESIS; EXPRESSION	Inwardly rectifying K+ channels (IRKs) maintain resting membrane potential, excitability, and K+ exchange. The proposed topological model of IRKs consists of intracellular amino and carboxyl termini and two transmembrane segments (M1 and M2) linked by a pore-forming segment (H5). Structure-function studies have identified critical pore determinants in M2 and the carboxyl terminus but not as expected by analogy with voltage-dependent K+ channels, in H5. We investigated the topology of the IRK ROMK1 by substituting novel N-glycosylation sites which act as markers for extracellular segments. N-Glycosylation, before and after an N-glycosylation inhibitor, tunicamycin, was measured directly by gel shift assays and changes in membrane currents. Tunicamycin produced gel shifts and changes in membrane currents that correlated exactly. N-Glycosylation sites substituted into the amino and carboxyl termini and the M1 segment gave results consistent with the proposed model. N-Glycosylation sites were distributed throughout H5 and its flanking regions indicating that H5 is mainly extracellular. Thus, the linker between M1 and M2 has little or no intramembranous component.	CASE WESTERN RESERVE UNIV,METROHEALTH CAMPUS,RAMMELKAMP CTR EDUC & RES,CLEVELAND,OH 44109	Case Western Reserve University; MetroHealth System			Wang, Zhiguo/GRS-4339-2022	Wang, Zhiguo/0000-0002-0811-2045				BAMBERG K, 1994, J BIOL CHEM, V269, P16909; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; PESSIA M, 1995, NEURON, V14, P1039, DOI 10.1016/0896-6273(95)90342-9; Possee RD., 1992, BACULOVIRUS EXPRESSI; SAMBROOK J, 1992, MOL CLONING LAB MANU; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TAGLIALATELA M, 1994, NEWS PHYSIOL SCI, V9, P169; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	33	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24201	24206		10.1074/jbc.271.39.24201	http://dx.doi.org/10.1074/jbc.271.39.24201			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798662	hybrid			2022-12-25	WOS:A1996VJ44200091
J	Tseng, A; Inglis, AS; Scott, KF				Tseng, A; Inglis, AS; Scott, KF			Native peptide inhibition - Specific inhibition of type II phospholipases A(2) by synthetic peptides derived from the primary sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNOVIAL-FLUID PHOSPHOLIPASE-A2; PANCREATIC PHOSPHOLIPASE-A2; CYTOSOLIC PHOSPHOLIPASE-A2; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; FUNCTIONAL ROLES; ACTIVE-SITE; N-TERMINUS; BINDING; NMR	The binding of low molecular weight type II phospholipase A(2) (EC 3.1.1.4) to membrane surfaces and hydrolysis of phospholipid are thought to involve the formation of a hydrophobic channel into which a single substrate molecule diffuses before cleavage, The floor and right side of the channel are provided by hydrophobic residues 2, 5, and 9 of an amphipathic amino-terminal helix, The channel is postulated to form via a conformational change in this helix and inward movement of a hydrophobic flap (residue 69 side chain). We show that the amino-terminal tryptic peptide of human type II phospholipase A(2) forms a noncovalent complex with the tryptic peptide from residues 70-74 of the enzyme, Further, the 70-74-peptide sequence (FLSYK) dose-dependently inhibits phospholipid hydrolysis in a mixed micelle assay. This native peptide inhibition also occurred with type II enzymes from Crotalus durissus and Crotalus atrox, which have different amino acid sequences at the amino terminus as well as different 70-74 regions of the molecules. Despite significant conservation of tertiary structure among the enzymes, inhibition by each peptide is specific to the enzyme from which the peptide sequence is derived, We propose that these native peptides inhibit enzyme activity via a sequence-specific, noncovalent interaction with the amino-terminal residues of the enzyme, thereby preventing the conformational change on binding to the micelle interface, These experiments demonstrate a new method for specific inhibition of phospholipase A(2) which, in principle, would be applicable to other biologically active polypeptides and proteins.	ST VINCENTS HOSP, UNIV NEW S WALES, DEPT MED, DARLINGHURST, NSW 2010, AUSTRALIA; ST VINCENTS HOSP, UNIV NEW S WALES, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA	St Vincents Hospital Sydney; University of New South Wales Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney				Scott, Kieran/0000-0002-6012-4107				BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; Darbre A., 1986, PRACTICAL PROTEIN CH; DEKKER N, 1991, EUR J BIOCHEM, V199, P601, DOI 10.1111/j.1432-1033.1991.tb16160.x; DIJKSTRA BW, 1984, BIOCHEMISTRY-US, V23, P2759, DOI 10.1021/bi00307a035; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DIJKSTRA BW, 1981, NATURE, V289, P604, DOI 10.1038/289604a0; DIJKSTRA BW, 1982, J MOL BIOL, V1981, P97; DIMARCO S, 1992, J BIOCHEM-TOKYO, V112, P350; DUPUREUR CM, 1992, BIOCHEMISTRY-US, V31, P6402, DOI 10.1021/bi00143a007; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; INGLIS AS, 1988, J BIOCHEM BIOPH METH, V15, P249, DOI 10.1016/0165-022X(88)90012-7; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P448, DOI 10.1016/0005-2736(86)90542-0; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; KILBY PM, 1995, BIOCHEM J, V305, P935, DOI 10.1042/bj3050935; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LIU XH, 1995, BIOCHEMISTRY-US, V34, P7322, DOI 10.1021/bi00022a005; MALIWAL BP, 1994, BIOCHEMISTRY-US, V33, P4509, DOI 10.1021/bi00181a010; MARKI F, 1993, AGENTS ACTIONS, V38, P202, DOI 10.1007/BF01976212; MARKI F, 1993, J BIOCHEM-TOKYO, V113, P734; NEVALAINEN TJ, 1993, INFLAMMATION, V17, P453, DOI 10.1007/BF00916585; ONO T, 1988, J BIOL CHEM, V263, P5732; PETERS AR, 1992, BIOCHEMISTRY-US, V31, P10024, DOI 10.1021/bi00156a023; RANDOLPH A, 1980, PHOSPHOLIPASE A2 STR; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SMITH GM, 1992, BRIT J RHEUMATOL, V31, P175; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; Tseng A, 1991, Protein Expr Purif, V2, P127, DOI 10.1016/1046-5928(91)90061-M; VANDENBERG B, 1995, NAT STRUCT BIOL, V2, P402, DOI 10.1038/nsb0595-402; Waite M, 1987, HDB LIPID RES, V5, P155; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; YANG CC, 1988, TOXICON, V26, P721, DOI 10.1016/0041-0101(88)90279-6	38	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23992	23998		10.1074/jbc.271.39.23992	http://dx.doi.org/10.1074/jbc.271.39.23992			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798633	hybrid			2022-12-25	WOS:A1996VJ44200062
J	Iida, N; Haisa, M; Igarashi, A; Pencev, D; Grotendorst, GR				Iida, N; Haisa, M; Igarashi, A; Pencev, D; Grotendorst, GR			Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides	FASEB JOURNAL			English	Article						peptide growth factor; chemokines; wound healing	PLATELET BASIC-PROTEIN; SIMIAN SARCOMA-VIRUS; SMOOTH-MUSCLE CELLS; HUMAN WOUND FLUID; CONNECTIVE-TISSUE; BETA-THROMBOGLOBULIN; STIMULATORY ACTIVITY; MITOGENIC ACTIVITY; MESSENGER-RNA; GENE	Leukocytes produce many biological mediators that orchestrate the subsequent cellular events during wound healing, We have identified a novel cytokine, leukocyte-derived growth factor (LDGF), which is mitogenic for connective tissue cells, Sequence analysis of the LDGF peptide revealed that it is a precursor of other known peptides including platelet basic protein (PBP), connective tissue activating peptide III (CTAP-III), and neutrophil activating peptide 2 (NAP-2). None of these shorter peptides are active as mitogens for fibroblasts, LDGF appears to stimulate fibroblast growth by stimulation of tyrosine kinase activity of the PDGF receptors. One of the truncated products of LDGF, NAP-S, is a potent neutrophil chemoattractant, Peptides larger than NAP-2, such as PBP and CTAP-III, are not active as neutrophil chemoattractants, Collectively, these findings demonstrate that the LDGF peptide must remain intact in order to retain its fibroblast mitogenic activity, If the LDGF peptide is processed to release the carboxyl terminal half to generate NAP-S, a peptide with proinflammatory activity is generated, These results indicate that the multiple peptides produced from the LDGF-PBP gene posses divergent biological activities that could regulate different phases of the repair process.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,MIAMI,FL 33136; UNIV S FLORIDA,DEPT BIOCHEM & MOL BIOL,COLL MED,TAMPA,FL 33612; UNIV S FLORIDA,DEPT MED,COLL MED,TAMPA,FL 33612	University of Miami; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida								ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; ANTONIADES HN, 1981, P NATL ACAD SCI-BIOL, V78, P7314, DOI 10.1073/pnas.78.12.7314; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CASTOR CW, 1983, P NATL ACAD SCI-BIOL, V80, P765, DOI 10.1073/pnas.80.3.765; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVELLI O, 1983, PEPTIDES, V4, P651, DOI 10.1016/0196-9781(83)90013-X; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLARK R. A. F., 1995, MOL CELLULAR BIOL WO; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; Cohen I. K., 1992, WOUND HEALING BIOCH; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; GROTENDORST GR, 1991, J CELL PHYSIOL, V149, P235, DOI 10.1002/jcp.1041490209; GROTENDORST GR, 1990, ADV APPL BIOTECHNOLO, V8; GROTENDORST GR, 1991, MOL CELL BIOL CYTOKI, P381; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1981, BIOCHEM J, V193, P907, DOI 10.1042/bj1930907; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; INUI H, 1993, J BIOL CHEM, V268, P17045; KARTHA S, 1988, AM J PHYSIOL, V255, pF800, DOI 10.1152/ajprenal.1988.255.4.F800; KAZLAUSKAS A, 1988, EMBO J, V7, P3727, DOI 10.1002/j.1460-2075.1988.tb03256.x; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUOKA J, 1989, P NATL ACAD SCI USA, V86, P4416, DOI 10.1073/pnas.86.12.4416; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; PAUL D, 1980, THROMB RES, V18, P883, DOI 10.1016/0049-3848(80)90210-8; PENCEV D, 1993, ONCOGENE RES, V268, P17045; PONCZ M, 1987, BLOOD, V69, P219; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SOMA Y, 1992, FASEB J, V6, P2996, DOI 10.1096/fasebj.6.11.1644262; SPORN MB, 1986, J CLIN INVEST, V78, P329, DOI 10.1172/JCI112580; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WENGER RH, 1989, BLOOD, V73, P1498; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	50	37	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1336	1345		10.1096/fasebj.10.11.8836048	http://dx.doi.org/10.1096/fasebj.10.11.8836048			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836048				2022-12-25	WOS:A1996VJ71700014
J	ZarainHerzberg, A; Rupp, H; Elimban, V; Dhalla, NS				ZarainHerzberg, A; Rupp, H; Elimban, V; Dhalla, NS			Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir	FASEB JOURNAL			English	Article						pressure-overloaded heart; cardiac mRNA signals; SR gene expression; heart hypertrophy	THYROID-HORMONE RECEPTOR; STAGE HEART-FAILURE; DIABETIC RAT-HEART; NUCLEOTIDE-SEQUENCE; CA-2+-ATPASE GENE; CA2+-ATPASE GENE; MYOSIN; MUSCLE; ACID; MYOCYTES	Pressure overload on the heart is known to produce hypertrophy of cardiomyocytes and distinct changes in protein phenotype, including reduced expression of the gene for the sarcoplasmic reticulum (SR) Ca(2+)ATPase (SERCA2). In this study we have shown that the decrease in SERCA2 gene expression (normalized by poly(A)+ mRNA or 18 S rRNA) in rats with 8 wk of aortic constriction was prevented by treatment with etomoxir, an inhibitor of carnitine palmitoyltransferase 1. The reduction in steady-state mRNA levels for SR phospholamban (PLP) and Ca2+ release channel (CRC) in the pressure-overloaded animals was also prevented without any reduction in the extent of cardiac hypertrophy by treatment with etomoxir, Although no changes in mRNA levels for GAPDH were evident in rats with pressure overload, the expression of the alpha-skeletal actin was increased; this change was prevented by etomoxir. Similar beneficial effects of etomoxir treatment were also evident when the gene expression for SR SERCA2, PLP, and CRC in the hypertrophied heart was normalized with respect to mRNA for GAPDH, These results support the view that drugs such as etomoxir may increase the abundance of, the mRNA for SR proteins in the hypertrophied heart and thus may prevent the transition of cardiac hypertrophy into heart failure.	ST BONIFACE GEN HOSP, RES CTR, DIV CARDIOVASC SCI, WINNIPEG, MB R2H 2A6, CANADA; UNIV MANITOBA, FAC MED, DEPT PHYSIOL, WINNIPEG, MB R2H 2A6, CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba			Dhalla, Naranjan/C-8279-2014	Dhalla, Naranjan/0000-0002-4894-4727				ARAI M, 1993, CIRC RES, V72, P463, DOI 10.1161/01.RES.72.2.463; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; BRILLANTES AM, 1992, CIRC RES, V71, P18, DOI 10.1161/01.RES.71.1.18; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; DHALLA N S, 1987, Canadian Journal of Cardiology, V3, P183; DOMDEY H, 1983, EUR J BIOCHEM, V131, P129, DOI 10.1111/j.1432-1033.1983.tb07239.x; GAY RG, 1988, AM J PHYSIOL, V255, pH801, DOI 10.1152/ajpheart.1988.255.4.H801; HARTONG R, 1994, J BIOL CHEM, V269, P13021; LEVITSKY D, 1991, AM J PHYSIOL, V261, P23, DOI 10.1152/ajplung.1991.261.4.L23; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MEAROW KM, 1993, MOL CELL BIOCHEM, V121, P155, DOI 10.1007/BF00925975; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; MORENHOUSE CA, 1975, STAT PRINCIPLES PROC; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; PENNOCK GD, 1993, CIRCULATION, V88, P1289, DOI 10.1161/01.CIR.88.3.1289; REINAUER H, 1990, J CLIN CHEM CLIN BIO, V28, P335; ROHRER D, 1988, J BIOL CHEM, V263, P6941; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; RUPP H, 1992, J APPL PHYSIOL, V72, P352, DOI 10.1152/jappl.1992.72.1.352; RUPP H, 1994, MOL CELL BIOCHEM, V132, P69, DOI 10.1007/BF00925676; RUPP H, 1992, FASEB J, V6, P2349, DOI 10.1096/fasebj.6.6.1531968; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SCHWARTZ K, 1992, BASIC RES CARDIOL, V87, P285; SHEN H, 1991, AM J VET RES, V52, P1527; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; Towbin H, 1992, Biotechnology, V24, P145; VETTER R, 1994, AM J PHYSIOL-HEART C, V267, pH2091, DOI 10.1152/ajpheart.1994.267.6.H2091; VETTER R, 1995, EUR HEART J, V16, P15, DOI 10.1093/eurheartj/16.suppl_C.15; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0; ZARAINHERZBERG A, 1994, BIOCHEM BIOPH RES CO, V203, P113, DOI 10.1006/bbrc.1994.2156; ZARAINHERZBERG A, 1994, J BIOL CHEM, V269, P1460	38	57	59	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1996	10	11					1303	1309		10.1096/fasebj.10.11.8836044	http://dx.doi.org/10.1096/fasebj.10.11.8836044			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836044				2022-12-25	WOS:A1996VJ71700010
J	Blancher, C; Omri, B; Bidou, L; Pessac, B; Crisanti, P				Blancher, C; Omri, B; Bidou, L; Pessac, B; Crisanti, P			Nectinepsin: A new extracellular matrix protein of the pexin family - Characterization of a novel cDNA encoding a protein with an RGD cell binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; AMINO-ACID SEQUENCE; MESSENGER-RNA; S-PROTEIN; HUMAN HEMOPEXIN; SOMATOMEDIN-B; VITRONECTIN; INTEGRINS; ADHESION; SERUM	We report the isolation and characterization of a novel cDNA from quail neuroretina encoding a putative protein named nectinepsin. The nectinepsin cDNA identifies a major 2,2-kilobase mRNA that is detected from ED 5 in neuroretina and is increasingly abundant during embryonic development. A nectinepsin mRNA is also found in quail liver, brain, and intestine and in mouse retina. The deduced nectinepsin amino acid sequence contains the RGD cell binding motif of integrin ligands. Furthermore, nectinepsin shares substantial homologies with vitronectin and structural protein similarities with most of the matricial metalloproteases. However, the presence of a specific sequence and the lack of heparin and collagen binding domains of the vitronectin indicate that nectinepsin is a new extracellular matrix protein. Furthermore, genomic Southern blot studies suggest that nectinepsin and vitronectin are encoded by different genes. Western blot analysis with an anti-human vitronectin antiserum revealed, in addition to the 65- and 70-kDa vitronectin bands, an immunoreactive protein of about 54 kDa in all tissues containing nectinepsin mRNA. It seems likely that the form of vitronectin found in chick egg yolk plasma by Nagano et al. ((1992) J. Biol. Chem. 267, 24863-24870) is the protein that corresponds to the nectinepsin cDNA. This new protein could be an important molecule involved in the early steps of the development.	UNIV PARIS 06, CNRS 9035, DEV & IMMUN SYST NERVEUX CENT, FAC MED BROUSSAIS HOTEL DIEU, F-75270 PARIS 06, FRANCE	UDICE-French Research Universities; Sorbonne Universite								ALTRUDA F, 1985, NUCLEIC ACIDS RES, V13, P3841, DOI 10.1093/nar/13.11.3841; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIDOU L, 1993, MECH DEVELOP, V43, P159, DOI 10.1016/0925-4773(93)90033-T; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; DELANNET M, 1994, DEVELOPMENT, V120, P2687; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FRYKLUND L, 1978, FEBS LETT, V87, P55, DOI 10.1016/0014-5793(78)80132-X; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEWITT AT, 1986, RETINA MODEL CELL 2, P169; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JENNE D, 1989, EUR J BIOCHEM, V185, P391, DOI 10.1111/j.1432-1033.1989.tb15127.x; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; JENNE D, 1987, BIOCHEMISTRY-US, V26, P6735, DOI 10.1021/bi00395a024; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; MANIATIS JM, 1989, BIOCHEMISTRY; Maniatis T, 1989, MOL CLONING; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; NAGANO Y, 1992, J BIOL CHEM, V267, P24863; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; PESSAC B, 1972, SCIENCE, V175, P898, DOI 10.1126/science.175.4024.898; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SATO R, 1990, J BIOL CHEM, V265, P21232; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VENSTROM KA, 1993, FASEB J, V7, P996, DOI 10.1096/fasebj.7.11.8370483; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Zheng XX, 1995, P NATL ACAD SCI USA, V92, P12426, DOI 10.1073/pnas.92.26.12426	51	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26220	26226		10.1074/jbc.271.42.26220	http://dx.doi.org/10.1074/jbc.271.42.26220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824271	hybrid			2022-12-25	WOS:A1996VN18000077
J	Finan, PM; Soames, CJ; Wilson, L; Nelson, DL; Stewart, DM; Truong, O; Hsuan, JJ; Kellie, S				Finan, PM; Soames, CJ; Wilson, L; Nelson, DL; Stewart, DM; Truong, O; Hsuan, JJ; Kellie, S			Identification of regions of the Wiskott-Aldrich syndrome protein responsible for association with selected Src homology 3 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PEPTIDES; PHAGOCYTE NADPH OXIDASE; SH3 DOMAIN; TYROSINE KINASES; CRYSTAL-STRUCTURES; FOCAL ADHESION; BINDING MOTIF; HIGH-AFFINITY; GENE; SPECIFICITY	Src homology 3 (SH3) domains have been shown to mediate selected interactions between signaling molecules and are essential for the activation of a number of receptor-driven pathways. The Wiskott-Aldrich syndrome protein was identified as a protein that associated selectively with the SH3 domains derived from c-Src, p85 alpha, phospholipase C gamma 1, and c-Fgr. Significantly reduced association was detected to the N-terminal SH3 domain and the tandem SH3 domains of p47(phox), and no binding was detected to the SH3 domain of n-Src, the C-terminal SH3 domain of p47(phox), or either of the SH3 domains of p67(phox). Three peptides corresponding to potential Wiskott-Aldrich syndrome protein SH3 domain binding moths were found to inhibit its association with c-Src, Fgr, and phospholipase C gamma 1 SH3 domains, but not the p85 alpha SH3 domain. These peptides have the sequences MRRQEPLPPPPPPSRG, TGRSGPLPPPPPGA, and KGRSGPLPPVPLGI and show homology with other SH3 domain binding motifs. It is possible that the intracellular association of Wiskott-Aldrich syndrome protein with other signaling proteins is mediated by its SH3 domain-binding regions, and this may play a role in its putative function as a regulatory molecule in immune cells.	LITTLEMORE HOSP, YAMANOUCHI RES INST, OXFORD OX4 4XN, ENGLAND; NCI, METAB BRANCH, NIH, BETHESDA, MD 20892 USA; UCL, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM & MOL BIOL, LONDON W1E 6BT, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London			Hsuan, Justin/C-8825-2009; Kellie, Stuart/A-6036-2010	Hsuan, Justin/0000-0001-6083-7564; Kellie, Stuart/0000-0002-8163-1474				Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; BLAESE RM, 1968, LANCET, V1, P1056; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER MD, 1968, AM J MED, V44, P499, DOI 10.1016/0002-9343(68)90051-X; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DERRY JMJ, 1994, CELL, V79, P923; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FINAN P, 1994, J BIOL CHEM, V269, P13752; Finan PM, 1996, FEBS LETT, V389, P141, DOI 10.1016/0014-5793(96)00552-2; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KARLSSON T, 1995, ONCOGENE, V10, P1475; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KENNEY D, 1986, BLOOD, V68, P1329; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LUI X, 1993, MOL CELL BIOL, V13, P5223; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OCHS HD, 1980, BLOOD, V55, P243; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P835; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; SIMON HU, 1992, J CLIN INVEST, V90, P1396, DOI 10.1172/JCI116006; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU QL, 1995, BLOOD, V86, P3797, DOI 10.1182/blood.V86.10.3797.bloodjournal86103797	54	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26291	26295		10.1074/jbc.271.42.26291	http://dx.doi.org/10.1074/jbc.271.42.26291			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824280	hybrid			2022-12-25	WOS:A1996VN18000086
J	Jaskiewicz, E; Zhu, GF; Bassi, R; Darling, DS; Young, WW				Jaskiewicz, E; Zhu, GF; Bassi, R; Darling, DS; Young, WW			beta 1,4-N-acetylgalactosaminyltransferase (G(M2) synthase) is released from Golgi membranes as a neuraminidase-sensitive, disulfide-bonded dimer by a cathepsin D-like protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; SUCCESSIVE COMPARTMENTS; EXPRESSION CLONING; MOLECULAR-CLONING; BREFELDIN-A; CDNA CLONE; IN-VITRO; CELLS; RAT; BETA-1,4-GALACTOSYLTRANSFERASE	Many Golgi membrane-bound glycosyltransferases are released from cells in a soluble form. To characterize this release process, we stably transfected Chinese hamster ovary cells with three myc epitope-tagged forms of cloned beta 1,4-N-acetylgalactosaminyltransferase (GalNAcT); two of these forms resided in the Golgi, while the third was retained in the ER, GalNAcT was released into the culture medium from cells transfected with the Golgi forms but not with the ER form of the enzyme. The medium from cells transfected with the Golgi forms contained disulfide-bonded dimers of GalNAcT, which carried neuraminidase sensitive, complex N-linked carbohydrate chains. This soluble species represented the major degradation product of cellular GalNAcT, which turned over with a half-time of about 1.7 h. The soluble species consisted of a mixture of truncated GalNAcT molecules, the major form of which was produced by cleavage near the boundary between the transmembrane and lumenal domains between Leu-23 and Tyr-24. This cleavage site fits the sequence pattern for sites cleaved by cathepsin D (van Noort, J.M., and van der Drift, A.C.M. (1989) J. Biol. Chem. 264, 14159-14164), These findings suggest that GalNAcT is converted from a membrane-bound to a soluble form as a result of cleavage by a cathepsin D-like protease in a compartment late in the Golgi secretory pathway.	UNIV LOUISVILLE,SCH DENT,DEPT BIOCHEM & BIOPHYS SCI,LOUISVILLE,KY 40292; UNIV LOUISVILLE,DEPT BIOCHEM,HLTH SCI CTR,LOUISVILLE,KY 40292	University of Louisville; University of Louisville			Darling, Douglas S/D-4573-2009	Darling, Douglas/0000-0002-9039-1169; BASSI, ROSARIA/0000-0001-7409-4730	NIDDK NIH HHS [DK44332] Funding Source: Medline; NIGMS NIH HHS [GM42698] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044332] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; HIDARI KIPJ, 1994, BIOCHEM J, V303, P957, DOI 10.1042/bj3030957; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Jaskiewicz E, 1996, GLYCOCONJUGATE J, V13, P213, DOI 10.1007/BF00731496; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LATALLO JFK, 1990, GENE DEV, V4, P1288; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MCCAFFREY G, 1993, COMP BIOCHEM PHYS B, V104, P91, DOI 10.1016/0305-0491(93)90342-3; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NAGATA Y, 1994, J BIOL CHEM, V269, P7045; NAGATA Y, 1992, J BIOL CHEM, V267, P29227; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; RICHARDSON K, 1995, COMP BIOCHEM PHYS B, V110, P445, DOI 10.1016/0305-0491(94)00149-O; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH PL, 1994, J BIOL CHEM, V269, P15162; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; VANNOORT JM, 1989, J BIOL CHEM, V264, P14159; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YOUNG WW, 1986, J BIOL CHEM, V261, P2279; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	52	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26395	26403		10.1074/jbc.271.42.26395	http://dx.doi.org/10.1074/jbc.271.42.26395			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824296	hybrid			2022-12-25	WOS:A1996VN18000102
J	Keller, ET; Chang, CS; Ershler, WB				Keller, ET; Chang, CS; Ershler, WB			Inhibition of NF kappa B activity through maintenance of I kappa B alpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; ANDROGEN RESPONSE ELEMENTS; RECEPTOR MESSENGER-RNA; GROWTH-FACTOR; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; C-FOS; MOLECULAR MECHANISMS; NEGATIVE REGULATION	Androgens repress expression of many genes, yet the mechanism of this activity has remained elusive. The cytokine, interleukin-6, is active in a variety of biological systems, and its expression is repressed by androgens. Accordingly we dissected the mechanism of androgen's ability to inhibit interleukin-6 expression at the molecular level. In a series of co-transfection assays, we found that 5 alpha-dihydrotestosterone, through the androgen receptor, repressed activation of the interleukin-6 promoter, in part, by inhibiting NF kappa B activity. It did not appear that 5 alpha-dihydrotestosterone inhibited NF kappa B by activating the androgen receptor to compete for the NF kappa B response element as we could not detect androgen receptor binding to the IL-6 promoter by DNase I footprinting assay. However, by electrophoretic mobility shift assay we found that 5 alpha-dihydrotestosterone repressed formation of NF kappa B . NF kappa B response element complex formation. In LNCaP prostate carcinoma cells, 5 alpha-dihydrotestosterone achieved this effect through maintenance of I kappa B alpha protein levels in the face of phorbol ester, a stimulus that results in I kappa B alpha degradation. Finally, we confirmed that I kappa B alpha inhibits NF kappa B-mediated activation of the interleukin-6 promoter. These data suggest that maintenance of I kappa B alpha levels may represent the first identified mechanism for androgen-mediated repression of a natural androgen-regulated gene.	UNIV WISCONSIN, INST AGING, DEPT MED, MADISON, WI 53706 USA; MADISON VET ADM, GRECC, MADISON, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center			Keller, Evan T/M-1446-2016	Keller, Evan T/0000-0002-7592-7535	NATIONAL INSTITUTE ON AGING [R01AG011970] Funding Source: NIH RePORTER; NIA NIH HHS [AG00451, AG11970, AG00213] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BINGAMAN EW, 1994, NEUROENDOCRINOLOGY, V59, P228, DOI 10.1159/000126663; BODINE PVN, 1995, J STEROID BIOCHEM, V52, P149, DOI 10.1016/0960-0760(94)00165-I; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; BURCIN M, 1994, SEMIN CANCER BIOL, V5, P337; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; CLAY CM, 1993, J BIOL CHEM, V268, P13556; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; DABBS JM, 1990, CHRONOBIOL INT, V7, P245, DOI 10.3109/07420529009056982; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAY ML, 1993, CANCER RES, V53, P5597; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DEVOS P, 1991, J BIOL CHEM, V266, P3439; ERIKSSON S, 1995, CALCIFIED TISSUE INT, V57, P97, DOI 10.1007/BF00298427; ERSHLER WB, 1994, DRUG AGING, V5, P358, DOI 10.2165/00002512-199405050-00005; Galien R, 1996, MOL ENDOCRINOL, V10, P713, DOI 10.1210/me.10.6.713; GUMERLOCK PH, 1992, P ANN M AM ASS CANC, V33, pA2170; GUMERLOCK PH, 1993, P ANN M AM ASS CANC, V34, pA2950; HARRIS SE, 1990, ENDOCRINOLOGY S, V126, P93; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JACKSON ME, 1991, J CELL SCI, V100, P1; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KELLER ET, 1995, J IMMUNOL, V154, P4091; Keller Evan T., 1996, Frontiers in Bioscience (online), V1, pD59; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEPPA S, 1991, CELL REGUL, V2, P1; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LINDZEY J, 1994, VITAM HORM, V49, P383; LINDZEY J, 1993, MOL ENDOCRINOL, V7, P1530, DOI 10.1210/me.7.12.1530; MANCINI MA, 1991, J HISTOCHEM CYTOCHEM, V39, P401, DOI 10.1177/39.4.1706374; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; METSIS M, 1992, GENE, V121, P247, DOI 10.1016/0378-1119(92)90128-C; MIYAMOTO S, 1995, ADV CANCER RES, V7, P2064; MIZOKAMI A, 1992, ENDOCRINOL JAPON, V39, P235; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; MORIMOTO R I, 1992, Current Opinion in Cell Biology, V4, P480, DOI 10.1016/0955-0674(92)90015-5; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; NAHOUL K, 1990, J STEROID BIOCHEM, V35, P293, DOI 10.1016/0022-4731(90)90287-3; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RENKAWITZ R, 1993, ANN NY ACAD SCI, V684, P1, DOI 10.1111/j.1749-6632.1993.tb32266.x; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SERVE H, 1991, CANCER RES, V51, P3862; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TABIBZADEH SS, 1989, J IMMUNOL, V142, P3134; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; URBAN MB, 1991, NEW BIOL, V3, P279; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEI J, 1992, LIFE SCI, V51, P1953, DOI 10.1016/0024-3205(92)90112-3; WILDING G, 1989, PROSTATE, V14, P103, DOI 10.1002/pros.2990140204; WISHART JM, 1995, CLIN ENDOCRINOL, V42, P141, DOI 10.1111/j.1365-2265.1995.tb01854.x; WOLF DA, 1992, BRIT J CANCER, V65, P376, DOI 10.1038/bjc.1992.76; WONG P, 1993, J BIOL CHEM, V268, P5021; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YEN PM, 1994, MOL ENDOCRINOL, V8, P1450, DOI 10.1210/me.8.11.1450; ZHANG J, 1996, AM GER SOC ANN M CHI, P128; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	84	147	152	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26267	26275		10.1074/jbc.271.42.26267	http://dx.doi.org/10.1074/jbc.271.42.26267			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824277	hybrid			2022-12-25	WOS:A1996VN18000083
J	Puttaraju, M; Been, MD				Puttaraju, M; Been, MD			Circular ribozymes generated in Escherichia coli using group I self-splicing permuted intron-exon sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-DELTA-VIRUS; RIBONUCLEASE-P RNA; MESSENGER-RNA; THERAPEUTIC AGENTS; CATALYTIC ACTIVITY; RIBONUCLEOPROTEIN ENZYME; HAMMERHEAD RIBOZYMES; VITRO TRANSCRIPTION; SECONDARY STRUCTURE; CELLS	A circularly permuted self-splicing group I intron from Anabaena was used to generate covalently closed circular trans-acting ribozymes in Escherichia coli. The RNA component of Bacillus subtilis RNaseP and an artificial trans-acting hepatitis delta virus ribozyme were expressed as the exon portion of the permuted intron. RNA isolated from these cells contained circular forms of the ribozymes, indicating that circles were generated from precursors expressed in these cells. Total RNA isolated from cells producing the circular RNA contained ribozyme activity. In contrast, a linear form of the delta virus ribozyme expressed as part of an unprocessed transcript yielded no detectable activity. These data extend previous in vitro and in vivo studies on splicing-mediated RNA circularization by demonstrating the intracellular production of circular ribozymes. These results have implications for the development of systems expressing therapeutic forms of small RNAs such as ribozymes and decoy-type competitors. Circular RNAs generated by splicing are devoid of flanking sequences that could potentially interfere with function. Also, because circular RNAs are not primary substrates for exonucleases, they may have increased in vivo half-lives relative to linear molecules with similar sequences.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM47233, GM40689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040689, R55GM047233, R01GM047233] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BEEN MD, 1994, TRENDS BIOCHEM SCI, V19, P251, DOI 10.1016/0968-0004(94)90151-1; BEEN MD, 1992, BIOCHEMISTRY-US, V31, P11843, DOI 10.1021/bi00162a024; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CHAN WKY, 1988, GENE, V73, P295, DOI 10.1016/0378-1119(88)90494-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DIENER TO, 1989, P NATL ACAD SCI USA, V86, P9370, DOI 10.1073/pnas.86.23.9370; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GOODCHILD J, 1992, NUCLEIC ACIDS RES, V20, P4607, DOI 10.1093/nar/20.17.4607; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HARLAND R, 1988, DEVELOPMENT, V102, P837; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1995, NUCLEIC ACIDS RES, V23, P2223, DOI 10.1093/nar/23.12.2223; HERRIN DL, 1990, J BIOL CHEM, V265, P21134; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; JARRELL KA, 1993, P NATL ACAD SCI USA, V90, P8624, DOI 10.1073/pnas.90.18.8624; KIM HG, 1995, BIOCHEMISTRY-US, V34, P8165, DOI 10.1021/bi00025a023; KOS A, 1986, NATURE, V323, P558, DOI 10.1038/323558a0; LAZINSKI DW, 1995, RNA, V1, P225; LEE SW, 1995, GENE THER, V2, P377; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MAO JR, 1995, J BIOL CHEM, V270, P19684, DOI 10.1074/jbc.270.34.19684; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PAN T, 1993, GENE, V125, P111, DOI 10.1016/0378-1119(93)90317-V; PAOLELLA G, 1992, EMBO J, V11, P1913, DOI 10.1002/j.1460-2075.1992.tb05244.x; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PRICE JV, 1987, J MOL BIOL, V196, P49, DOI 10.1016/0022-2836(87)90510-9; PUTTARAJU M, 1993, NUCLEIC ACIDS RES, V21, P4253, DOI 10.1093/nar/21.18.4253; PUTTARAJU M, 1992, NUCLEIC ACIDS RES, V20, P5357, DOI 10.1093/nar/20.20.5357; PUTTARAJU M, 1995, NUCLEIC ACIDS S SER, V33, P92; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; ROSSI JJ, 1991, PHARMACOL THERAPEUT, V50, P245, DOI 10.1016/0163-7258(91)90016-F; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SIOUD M, 1992, J MOL BIOL, V223, P831, DOI 10.1016/0022-2836(92)90244-E; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TABAK HF, 1984, CELL, V39, P623, DOI 10.1016/0092-8674(84)90469-0; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; WANG SH, 1994, NUCLEIC ACIDS RES, V22, P2326, DOI 10.1093/nar/22.12.2326; WAUGH DS, 1993, FASEB J, V7, P188, DOI 10.1096/fasebj.7.1.7678561; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; WEINTRAUB H, 1985, TRENDS GENET, V1, P22, DOI 10.1016/0168-9525(85)90010-1; ZAUG AJ, 1983, NATURE, V301, P578, DOI 10.1038/301578a0; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	59	13	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26081	26087		10.1074/jbc.271.42.26081	http://dx.doi.org/10.1074/jbc.271.42.26081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824250	hybrid			2022-12-25	WOS:A1996VN18000056
J	Warshawsky, I; Herz, J; Broze, GJ; Schwartz, AL				Warshawsky, I; Herz, J; Broze, GJ; Schwartz, AL			The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN-A; RAT HEPATOMA-CELLS; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; CELLULAR DEGRADATION; 39-KDA PROTEIN; BINDING; IDENTIFICATION; LIGANDS; COMPLEXES	Tissue factor pathway inhibitor (TFPI) is a plasma serine protease inhibitor that directly inhibits coagulation factor Xa and regulates blood coagulation via inhibition of factor VIIa-tissue factor enzymatic activity. We previously demonstrated that >90% of TFPI bound to a single population of low affinity binding sites on hepatoma cells (2 x 10(6) sites/cell, K-d = 30 nM), and, that following binding, the low density lipoprotein receptor-related protein (LRP) mediated TFPI uptake and degradation. We subsequently reported heparan sulfate proteoglycans (HSPGs) constitute a second receptor system involved in TFPI catabolism, In the present study, mouse embryonic fibroblasts heterozygous and homozygous-negative for disruption of the LRP gene were used to further examine the roles of LRP and HSPGs in TFPI endocytosis. We demonstrate that LRP is absolutely required for degrading I-125-TFPI. LRP heterozygous and homozygous-negative cells bind I-125-TFPI similarly, and the 39-kDa protein, an inhibitor of all known ligand interactions with LRP, does not alter I-125-TFPI binding to these cells, TFPI can be cross-linked to LRP on [S-35]cysteine-labeled hepatoma and LRP-heterozygous cells but not LRP-negative cells, When HSPGs are blocked with protamine, I-125-TFPI binds in a 39-kDa protein-inhibitable manner to 41,000 high affinity sites/ hepatoma cell (K-d = 2.3 nM), Blockade of HSPGs with protamine results in significantly more I-125-TFPI degradation by LRP-positive cells, TFPI can be cross-linked to LRP in the absence and presence of protamine, However, in the presence of protamine, relative to the total pool of cross-linked proteins, 5-fold more TFPI is cross-linked to LRP. Finally, we show TFPI inhibits I-125-alpha(2)-macroglobulin-methylamine binding to hepatoma cells and that carboxyl-terminal residues 115-319 of the 39-kDa protein inhibit both I-125-TFPI degradation and binding when binding conditions contain protamine, Together, our results suggest that while the majority of TFPI binds to cell surface HSPGs, LRP can function independently from HSPGs in the binding and uptake of TFPI.	WASHINGTON UNIV,SCH MED,JEWISH HOSP,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,JEWISH HOSP,DEPT MOL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,JEWISH HOSP,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,JEWISH HOSP,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034462, R01HL052040, R01HL053280] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52040, HL34462, HL53280] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREGENGAARD C, 1993, THROMB HAEMOSTASIS, V70, P454; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; DIAZCOLLIER JA, 1994, THROMB HAEMOSTASIS, V71, P339; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; HARENBERG J, 1993, THROMB HAEMOSTASIS, V70, P942; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Holtzman E, 1989, LYSOSOMES; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; JI ZS, 1993, J BIOL CHEM, V268, P10160; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	32	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25873	25879		10.1074/jbc.271.42.25873	http://dx.doi.org/10.1074/jbc.271.42.25873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824219	hybrid			2022-12-25	WOS:A1996VN18000025
J	Lenting, PJ; Christophe, OD; terMaat, H; Rees, DJG; Mertens, K				Lenting, PJ; Christophe, OD; terMaat, H; Rees, DJG; Mertens, K			Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE DOMAIN; PLASMA THROMBOPLASTIN ANTECEDENT; GAMMA-CARBOXYGLUTAMIC ACID; FACTOR-LIKE MODULES; BOVINE FACTOR-IX; FACTOR-X; CALCIUM-BINDING; CHRISTMAS FACTOR; MARFAN-SYNDROME; CA-2+ BINDING	Ca2+ binding to the first epidermal growth factor (EGF)-like domain of factor IX is known to be required for biological activity, but the mechanism by which Ca2+ contributes to factor IX function has remained unclear, We have studied recombinant factor IX mutants which lack Ca2+ binding to the first EGF-like domain, due to a replacement of Asp(64) by Glu, Lys, or Val, The purified mutants (factors IX D64E, D64K, and D64V), were compared to plasma-derived and recombinant wild-type factor IX with regard to a number of metal-ion dependent functional parameters, In the presence of Mg2+, the activated mutants were indistinguishable from normal factor IXa in hydrolyzing the synthetic substrate CH3-SO2-Leu-Gly-Arg-p-nitroanilide. Replacing Mg2+ by Ca2+ further stimulated the activity of normal factor IXa but not of mutant factor IXa, In factor Vm-independent factor X activation, factor IXa D64K and D64E displayed reduced catalytic activity compared to normal factor IXa (apparent k(cat)/K-m approximate to 1, 2, and 4 x 10(3) M(-1) s(-1), respectively), In the presence of factor VIIIa, factor X activation rates by normal and mutant factor IXa were stimulated by factor VIIIa to a different extent (approximate to 700- and 200-fold, respectively), indicating that Asp(64) replacements affect the interaction with factor VIIIa, This possibility was addressed in inhibition studies employing synthetic peptides comprising the factor IXa-binding motifs of factor VIII heavy or light chains, Whereas the heavy chain peptide (Ser(558)-Gln(565)) inhibited factor VIII-dependent factor X activation by normal and mutant factor IXa with similar efficiency, the light chain peptide (Lys(1804)-Lys(1818)) inhibited normal factor 1Xa 2-3-fold more efficiently than did mutant factor VIIIa, This indicates that the reduced response to factor VIIIa may be due to impaired binding of mutant factor IXa to the factor VIII light chain. This was further explored in direct binding studies, In the presence of Mg2+, normal and mutant factor IXa were similar in binding to the factor VIII light chain. However, in the presence of Ca2+, factor IXa mutants were less efficient than normal factor IXa, which was illustrated by a 4-5-fold lower affinity than normal factor IXa for factor VIII light chain, Collectively, our data demonstrate that a number of factor IXa functions, including enzymatic activity and assembly into the factor IXa-factor VIIIa complex, are dependent on Ca2+ binding to the first EGF-like domain of factor IX.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT PLASMA PROT TECHNOL, NL-1066 CX AMSTERDAM, NETHERLANDS; UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND	University of Oxford			Lenting, Peter/AAH-5663-2019; Lenting, Peter/F-8269-2013; Rees, Jasper/D-9672-2011; christophe, olivier/W-4268-2017	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; Rees, Jasper/0000-0003-3321-1325; christophe, olivier/0000-0002-9080-6336				AHMAD SS, 1992, J BIOL CHEM, V267, P8571; AHMAD SS, 1990, J BIOL CHEM, V265, P20907; AMPLETT GW, 1981, ARCH BIOCHEM BIOPHYS, V208, P576; ANSON DS, 1984, EMBO J, V3, P1053, DOI 10.1002/j.1460-2075.1984.tb01926.x; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1994, J BIOL CHEM, V269, P3690; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1982, J BIOL CHEM, V257, P4127; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE R, 1980, J BIOL CHEM, V255, P5336; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; HUGHES PE, 1994, PROTEIN ENG, V7, P1121, DOI 10.1093/protein/7.9.1121; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; LENTING PJ, 1995, J BIOL CHEM, V270, P14884, DOI 10.1074/jbc.270.25.14884; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LENTING PJ, 1996, J BIOL CHEM, V271, P1835; LIN SW, 1990, J BIOL CHEM, V265, P144; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; MANN KG, 1990, BLOOD, V76, P1; MERTENS K, 1982, THROMB HAEMOSTASIS, V47, P96; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; REES DJG, 1986, THESIS U OXFORD; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; SADLER JE, 1987, MOL BASIS BLOOD DISE, P575; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1991, BLOOD, V78, P1637; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VELTKAMP JJ, 1968, THROMB DIATH HAEMOST, V19, P279, DOI 10.1055/s-0038-1651206	48	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25332	25337		10.1074/jbc.271.41.25332	http://dx.doi.org/10.1074/jbc.271.41.25332			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810297	hybrid			2022-12-25	WOS:A1996VL69300041
J	MacDonald, NJ; Freije, JMP; Stracke, ML; Manrow, RE; Steeg, PS				MacDonald, NJ; Freije, JMP; Stracke, ML; Manrow, RE; Steeg, PS			Site-directed mutagenesis of nm23-H1 - Mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; X-RAY STRUCTURE; MYXOCOCCUS-XANTHUS; CRYSTAL-STRUCTURE; TUMOR-METASTASIS; HEPATOCELLULAR-CARCINOMA; PROTEIN EXPRESSION; DICTYOSTELIUM-DISCOIDEUM; DROSOPHILA DEVELOPMENT; STIMULATING PROTEIN	We report the first correlation of Nm23 sequence and its tumor metastasis-suppressive capacity using site-directed mutagenesis and an in vitro tumor cell motility assay. MDA-MB-435 human breast carcinoma cells were transfected with a control expression vector (pCMVB-amneo), the vector containing the wild type nm23-H1, or the nm23-H1 vector encoding mutations at the following amino acids: serine 44, a phosphorylation site; proline 96, the k-pn mutation in the Drosophila nm23 homolog that causes developmental defects; histidine 118, involved in Nm23's nucleoside diphosphate kinase activity; and serine 120, a site of mutation in human neuroblastomas and phosphorylation. The wild type nm23-H1 transfectants were 44-98% less motile to serum and 86-99% less motile to autotaxin than control vector transfectants. The proline 96 k-pn, serine 120 to glycine, and to a lesser extent serine 120 to alanine mutant nm23-H1-transfected cell lines exhibited motility levels at or above the control transfectants, indicating that these mutations can abrogate the motility-suppressive phenotype of nm23-H1. No effect was observed on cellular proliferation, nor were the serine 44 to alanine nm23-H1 mutant transfectants motile, demonstrating the specificity of the data. The data identify the first structural motifs of nm23-H1 that influence its metastasis suppressive effect and suggest complex biochemical associations or activities in the Nm23 suppressive pathway.	NCI,WOMENS CANC SECT,PATHOL LAB,DIV CLIN SCI,NIH,BETHESDA,MD 20892; NCI,TUMOR INVAS & METASTASIS SECT,PATHOL LAB,DIV CLIN SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Freije, José M.P./A-6535-2008	Freije, José M.P./0000-0002-4688-8266				BABA H, 1995, CANCER RES, V55, P1977; BARNES R, 1991, AM J PATHOL, V139, P245; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BERGER SL, 1993, ANAL BIOCHEM, V214, P571, DOI 10.1006/abio.1993.1540; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOIX L, 1994, GASTROENTEROLOGY, V107, P486, DOI 10.1016/0016-5085(94)90175-9; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; Boyden S, 1962, J EXP MED, V115, P435; CALIGO MA, 1992, ANTICANCER RES, V12, P969; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; CROPP CS, 1994, JNCI-J NATL CANCER I, V86, P1167, DOI 10.1093/jnci/86.15.1167; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; FLORENES VA, 1992, CANCER RES, V52, P6088; FREIJE JMP, 1996, ATTEMPTS UNDERSTAND, P215; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; GOLDEN A, 1993, NUCLEOSIDE DIPHOSPHA; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; ILIJAS M, 1994, INT J ONCOL, V5, P1455; KANTOR JD, 1993, CANCER RES, V53, P1971; KAPITANOVIC S, 1995, ANTICANCER RES, V15, P587; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KODERA Y, 1994, CANCER, V73, P259, DOI 10.1002/1097-0142(19940115)73:2<259::AID-CNCR2820730205>3.0.CO;2-V; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LAKSHMI MS, 1993, ANTICANCER RES, V13, P299; LASCU I, 1993, J BIOL CHEM, V268, P20268; LASCU I, 1992, J BIOL CHEM, V267, P12775; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LEONE A, 1993, ONCOGENE, V8, P2325; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MANDAI M, 1995, CANCER, V75, P2523, DOI 10.1002/1097-0142(19950515)75:10<2523::AID-CNCR2820751019>3.0.CO;2-L; MANDAI M, 1994, CANCER RES, V54, P1825; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; MURATA J, 1994, J BIOL CHEM, V269, P30479; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; PARHAR RS, 1995, INT J CANCER, V60, P204; PARKS RE, 1973, NUCLEOSIDE DIPHOSPHO; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; PRICE JE, 1990, CANCER RES, V50, P717; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; Scambia G, 1996, J CLIN ONCOL, V14, P334, DOI 10.1200/JCO.1996.14.2.334; SHANKAR S, 1995, J BIOL CHEM, V270, P28246; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; STRELKOV SV, 1995, J MOL BIOL, V249, P665, DOI 10.1006/jmbi.1995.0327; SU ZZ, 1993, ONCOGENE, V8, P1211; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; TROLL H, 1993, J BIOL CHEM, V268, P25469; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; XU J, 1996, IN PRESS DEV BIOL; YAMAGUCHI A, 1994, CANCER, V73, P2280, DOI 10.1002/1097-0142(19940501)73:9<2280::AID-CNCR2820730908>3.0.CO;2-3	75	115	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25107	25116		10.1074/jbc.271.41.25107	http://dx.doi.org/10.1074/jbc.271.41.25107			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810265	hybrid			2022-12-25	WOS:A1996VL69300009
J	Ritchie, ME				Ritchie, ME			Characterization of human B creatine kinase gene regulation in the heart in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C GENE; RAT-HEART; VOLUME OVERLOAD; PROMOTER REGION; MOLECULAR-BASIS; MESSENGER-RNAS; EXPRESSION; PROTEIN; ELEMENTS; MUSCLE	During cardiogenesis, genes indicative of the adult phenotype are transcriptionally activated while genes characteristic of the embryonic phenotype are down-regulated. The regulation of embryonic genes such as the brain isoform of creatine kinase (BCK) during cardiac development has not been characterized. Accordingly, the transcriptional regulation of BCK in the developing heart was determined. In vitro and in vivo promoter analyses of the human BCK gene identified an element between +25 and +57 that functioned as an enhancer. Electromobility shift assays using adult and neonatal nuclear extracts identified a specific complex binding this element, the abundance of which correlated with the developmental level of endogenous cardiac BCK expression. Mutations at +47 and +53 led to a loss of activity in transfected cells and obviated binding in electromobility shift assays. These data show that a nuclear factor in cardiocytes interacts with an enhancer element (+25 and +57), via nucleotides +47 and +53, to drive BCK expression in the heart and suggest that developmental BCK expression is via abundance of this factor. The nuclear factor has not been identified but as described previously binding sites are not present in the enhancer, it is either a known factor interacting with a new recognition site or a new factor.	UNIV CINCINNATI, COLL MED, CARDIOVASC RES CTR, CINCINNATI, OH 45267 USA; VET ADM MED CTR, DIV CARDIOL, CINCINNATI, OH 45220 USA	University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Ritchie, ME (corresponding author), UNIV CINCINNATI, COLL MED, DIV CARDIOL, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA.							ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; AUSUABEL FM, 1994, CURRENT PROTOCOLS MO; BENFIELD PA, 1988, GENE, V63, P227, DOI 10.1016/0378-1119(88)90527-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTRICK PM, 1994, J MOL CELL CARDIOL, V26, P61, DOI 10.1006/jmcc.1994.1008; BUTTRICK PM, 1993, CIRC RES, V72, P1211, DOI 10.1161/01.RES.72.6.1211; CARRIER L, 1992, CIRC RES, V70, P999, DOI 10.1161/01.RES.70.5.999; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ERLICH HA, 1993, PCR TECHNOLOGY, P171; FONTANET HL, 1991, CIRC RES, V68, P1007, DOI 10.1161/01.RES.68.4.1007; HAWKER KJ, 1993, BIOTECHNIQUES, V14, P764; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; IMAMURA T, 1994, CIRC RES, V75, P418, DOI 10.1161/01.RES.75.3.418; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LOMPRE AM, 1991, INT REV CYTOL, V124, P137; MARIMAN E, 1991, GENE, V102, P205, DOI 10.1016/0378-1119(91)90079-Q; MEHTA HB, 1988, CIRC RES, V63, P512, DOI 10.1161/01.RES.63.3.512; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; Ritchie ME, 1996, BIOCHEM BIOPH RES CO, V223, P762, DOI 10.1006/bbrc.1996.0970; RITCHIE ME, 1991, NUCLEIC ACIDS RES, V19, P6231, DOI 10.1093/nar/19.22.6231; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SCHWARTZ K, 1992, AM J PHYSIOL, V262, pR364, DOI 10.1152/ajpregu.1992.262.3.R364; TRASK RV, 1988, J BIOL CHEM, V263, P17142; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WESSELS A, 1990, ANAT RECORD, V228, P163, DOI 10.1002/ar.1092280208; WILLIAMS RE, 1994, CIRC RES, V75, P615, DOI 10.1161/01.RES.75.4.615; ZHANG JN, 1995, J BIOL CHEM, V270, P16134, DOI 10.1074/jbc.270.27.16134; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	39	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25485	25491						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810319				2022-12-25	WOS:A1996VL69300063
J	Seaman, MNJ; Sowerby, PJ; Robinson, MS				Seaman, MNJ; Sowerby, PJ; Robinson, MS			Cytosolic and membrane-associated proteins involved in the recruitment of AP-1 adaptors onto the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; FACTOR-II RECEPTOR; COATED VESICLES; PHOSPHOLIPASE-D; BINDING; CLATHRIN; ADAPTERS; COMPLEXES; SIGNALS; CELLS	The AP-1 adaptor complex is recruited from the cytosol onto the trans-Golgi network membrane, where it co-assembles with clathrin into a coat that drives vesicle budding. The GTPase ARF1 has been shown to be required for AP-1 recruitment, and here we demonstrate that we can reconstitute full GTP gamma S-dependent recruitment of adaptors onto an enriched trans-Golgi network membrane fraction by adding purified AP-1 and recombinant myristylated ARF1, indicating that these are the only soluble proteins required for binding. To identify some of the membrane proteins involved in recruitment, we have incubated permeabilized metabolically labeled cells with cytosol under conditions that promote adaptor binding, then cross-linked the samples with 3,3'-dithiobis(sulfosuccinimidylproprionate), denatured by boiling in SDS, and immunoprecipitated with antibodies against the various subunits. Under these conditions, the adaptor subunits co-precipitate not only with each other and with clathrin, but also with three novel proteins: p75, which is specifically cross-linked to gamma-adaptin; p80, which is specifically cross-linked to beta'-adaptin; and p60, which is specifically cross-linked to AP47. These proteins are all candidates for components of the adaptor docking site on the trans-Golgi network membrane.	UNIV CAMBRIDGE,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DITTIE AS, 1986, J CELL BIOL, P523; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON MS, 1986, J CELL BIOL, V102, P48, DOI 10.1083/jcb.102.1.48; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITNEY JA, 1995, CELL, V83, P703; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171	29	66	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25446	25451		10.1074/jbc.271.41.25446	http://dx.doi.org/10.1074/jbc.271.41.25446			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810314	hybrid			2022-12-25	WOS:A1996VL69300058
J	Amillet, JM; Buisson, N; LabbeBois, R				Amillet, JM; Buisson, N; LabbeBois, R			Characterization of an upstream activation sequence and two Rox1p-responsive sites controlling the induction of the yeast HEM13 gene by oxygen and heme deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; COPROPORPHYRINOGEN OXIDASE; HYPOXIC GENES; DNA-BINDING; TRANSCRIPTIONAL REGULATION; EXPRESSION; ELEMENTS; REPRESSOR; ROX1	The Saccharomyces cerevisiae HEM13 gene codes for coproporphyrinogen oxidase, an oxygen-requiring enzyme catalyzing the sixth step of heme biosynthesis, Its transcription has been shown to be induced 40-50-fold in response to oxygen or heme deficiency, in part through relief of repression exerted by Rox1p and in part by activation mediated by an upstream activation sequence (UAS), This report describes an analysis of HEM13 UAS and of the Rox1p-responsive sites by electrophoretic mobility shift assays, DNase I footprinting, and mutational mapping, HEM13 UAS is composed of two subelements: a 16-base pair sequence binding a constitutive factor acting as a transcriptional activator, and a 5'-flanking 20-base pair GC-rich region. Both subelements were required additively for transcription, but each element alone was sufficient for almost normal control by oxygen/heme deficiency, Mutations in both elements decreased the induction ratio 3-4-fold. HEM13 UAS conferred a 2-4-fold oxygen/heme control on a heterologous reporter gene, Two Rox1p-responsive sites, R1 and R3, were identified, which accounted for the 6-7-fold repression by Rox1p, A factor bound to a sequence close to site R3, This DNA-binding activity was only detected in protein extracts of aerobic heme-sufficient ROX1 TUP1 cells, suggesting a possible role in site R3 function.	UNIV PARIS 07,INST JACQUES MONOD,LAB BIOCHIM PORPHYRINES,F-75251 PARIS,FRANCE	UDICE-French Research Universities; Universite Paris Cite								AMILLET JM, 1995, CURR GENET, V28, P503, DOI 10.1007/BF00518161; ARCANGIOLI B, 1985, EMBO J, V4, P2627, DOI 10.1002/j.1460-2075.1985.tb03980.x; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DECKERT J, 1995, MOL CELL BIOL, V15, P6109; DECKERT J, 1995, GENETICS, V139, P1149; Donzeau M, 1996, MOL MICROBIOL, V20, P449, DOI 10.1111/j.1365-2958.1996.tb02631.x; FYTLOVICH S, 1993, EMBO J, V12, P1209, DOI 10.1002/j.1460-2075.1993.tb05762.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUEST JR, 1992, J GEN MICROBIOL, V138, P2253, DOI 10.1099/00221287-138-11-2253; HODGE MR, 1990, MOL CELL BIOL, V10, P5510, DOI 10.1128/MCB.10.10.5510; HODGE MR, 1989, MOL CELL BIOL, V9, P1958, DOI 10.1128/MCB.9.5.1958; IUCHI S, 1993, J BIOL CHEM, V268, P23972; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; KENG T, 1992, MOL CELL BIOL, V12, P2616, DOI 10.1128/MCB.12.6.2616; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; LAMBERT JR, 1994, P NATL ACAD SCI USA, V91, P7345, DOI 10.1073/pnas.91.15.7345; LIN ECC, 1991, ANNU REV GENET, V25, P361, DOI 10.1146/annurev.ge.25.120191.002045; LOWRY CV, 1990, MOL CELL BIOL, V10, P5921, DOI 10.1128/MCB.10.11.5921; MALININA L, 1994, J MOL BIOL, V243, P484, DOI 10.1006/jmbi.1994.1674; MEHTA KD, 1989, J BIOL CHEM, V264, P8670; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; Pinkham Jennifer L., 1994, V11, P455; Rose MD., 1990, METHODS YEAST GENETI; SABOVA L, 1993, EUR J BIOCHEM, V213, P547, DOI 10.1111/j.1432-1033.1993.tb17793.x; Sambrook J., 2002, MOL CLONING LAB MANU; Svetlov VV, 1995, YEAST, V11, P1439, DOI 10.1002/yea.320111502; TRAWICK JD, 1992, MOL CELL BIOL, V12, P2302, DOI 10.1128/MCB.12.5.2302; TURI TG, 1992, J BIOL CHEM, V267, P2046; USHINSKY SC, 1994, GENETICS, V136, P819; VERDIERE J, 1991, MOL GEN GENET, V228, P300; VINCENT O, 1995, CURR GENET, V27, P387, DOI 10.1007/BF00352109; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WRIGHT RM, 1995, BIOCHEM BIOPH RES CO, V216, P458, DOI 10.1006/bbrc.1995.2645; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZAGOREC M, 1986, J BIOL CHEM, V261, P2506; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	44	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24425	24432		10.1074/jbc.271.40.24425	http://dx.doi.org/10.1074/jbc.271.40.24425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798700	hybrid			2022-12-25	WOS:A1996VM67400022
J	Couture, C; Zhou, SY; Jascur, T; Williams, S; Tailor, P; Cantley, LC; Mustelin, T				Couture, C; Zhou, SY; Jascur, T; Williams, S; Tailor, P; Cantley, LC; Mustelin, T			Regulation of the Lck SH2 domain by tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PROTEIN-KINASE; EFFICIENT EXPRESSION; T-CELLS; P56(LCK); ACTIVATION; RECOGNITION; SPECIFICITY; STIMULATION	Src homology 2 (SH2) domains bind to phosphotyrosine (Tyr(P)) residues in specific sequence contexts in other proteins and thereby mediate tyrosine phosphorylationdependent protein-protein interactions. The SH2 domain of the Src family kinase Lck is phosphorylated at tyrosine 192 in T cells upon T cell antigen receptor triggering. We have studied the consequences of this phosphorylation on the properties of the SH2 domain and on the function of Lck in T cell activation. We report that phosphorylation at Tyr(192) reduced the capacity of the isolated SH2 domain to bind a high affinity peptide ligand and Tyr(P)-containing cellular proteins. This effect was mimicked by mutation of Tyr(192) to an acidic residue. In intact T cells, where Lck participates in T cell antigen receptor signal transduction in an SH2 domain dependent manner, phosphorylation of Tyr(192) correlated with reduced downstream signaling. Our results indicate that tyrosine phosphorylation of the SH2 domain of Lck terminates its high affinity binding to ligands, thereby negatively regulating its participation in T cell antigen receptor signaling. This represents a novel mechanism for the regulation of the function of SH2 domains.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA	La Jolla Institute for Immunology; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Mustelin, Tomas/0000-0001-5912-8840	NIAID NIH HHS [AI35603] Funding Source: Medline; NIGMS NIH HHS [GM48960] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIER G, 1994, BIOTECHNIQUES, V17, P94; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; HURLEY TR, 1989, ONCOGENE, V4, P265; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; LUO K, 1990, ONCOGENE, V5, P921; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; OETKEN C, 1992, EXP CELL RES, V202, P370, DOI 10.1016/0014-4827(92)90087-O; OETKEN C, 1994, MOL IMMUNOL, V31, P1295, DOI 10.1016/0161-5890(94)90047-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PINCUS SH, 1989, J IMMUNOL, V142, P3070; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SOULA M, 1993, J BIOL CHEM, V268, P27420; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VONBONIN A, 1994, J BIOL CHEM, V269, P33035; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATTS JD, 1993, J BIOL CHEM, V268, P23275; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WATTS JD, 1993, J IMMUNOL, V151, P6862; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	73	74	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24880	24884		10.1074/jbc.271.40.24880	http://dx.doi.org/10.1074/jbc.271.40.24880			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798764	hybrid			2022-12-25	WOS:A1996VM67400087
J	Gao, B; Esnouf, MP				Gao, B; Esnouf, MP			Elucidation of the core residues of an epitope using membrane-based combinatorial peptide libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XII; HAGEMAN-FACTOR; IDENTIFICATION; DISCOVERY; SEQUENCE; LIGANDS; GENE	Combinatorial peptide libraries have proved to be a valuable tool for the study of the interaction of a functional protein with its ligand. Here, the epitope for a monoclonal antibody 201/9, raised against beta-factor XIIa, has been identified with a two-step approach using peptide libraries attached to a polymer (polyvinylidene difluoride) membrane. First, the octapeptide libraries with two amino acids defined at position 2 and 4, represented by the formula X-O-2-X-O-4-X-X-X-X, were synthesized on a sheet of polymer membrane in which X represents a mixture of all the natural L-amino acids except cysteine, while O-2 and O-4 each represent a single amino acid, The libraries were probed with the antibody 201/9, and the bound antibody was detected with a sensitive chemiluminescent method, In the first cycle, the peptide mixtures X-Phe-X-Gln-X-X-X-X showed the strongest signal development. In the second cycle Phe and Gin were incorporated into new libraries consisting of sequences O-1-Phe-X-Gln-X-X-X-X, X-Phe-O-3-Gln-X-X-X-X, X-Phe-X-Gln-O-5-X-X-X, X-Phe-X-Gln-X-O-6-X-X, X-Phe-X-Gln-X-X-O-7-X, and X-Phe-X-Gln-X-X-X-O-8. After probing these new peptides, the residues representing the core sequence of the epitope for monoclonal antibody 201/9 were elucidated, The sequence Ser-Phe-Leu-Gln Glu-Asn, identified as the immunodominant epitope, correlates well with the sequence Ser-Phe-Leu-Gln-Glu-Ala previously identified (Gao, B., and Esnouf, M. P. (1996) J. Immunol, 157, 183-188) in a scan of overlapping peptides based on the sequence of human beta-factor XIIa.	UNIV OXFORD, RADCLIFFE INFIRM, DEPT CLIN BIOCHEM, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary; University of Oxford								COOL DE, 1987, J BIOL CHEM, V262, P13662; DEKOSTER HS, 1995, J IMMUNOL METHODS, V187, P179, DOI 10.1016/0022-1759(95)00182-A; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EICHLER J, 1994, PEPTIDE RES, V7, P300; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FUJIKAWA K, 1983, J BIOL CHEM, V258, P924; FUJIKAWA K, 1981, METHOD ENZYMOL, V80, P198; Gao B, 1996, J IMMUNOL, V157, P183; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1994, CURR BIOL, V4, P564, DOI 10.1016/S0960-9822(00)00127-5; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; PINILLA C, 1994, BIOCHEM J, V301, P847, DOI 10.1042/bj3010847; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEMBA U, 1992, BIOCHIM BIOPHYS ACTA, V1159, P113, DOI 10.1016/0167-4838(92)90014-5; SHIBUYA Y, 1994, BBA-PROTEIN STRUCT M, V1206, P63, DOI 10.1016/0167-4838(94)90073-6; WANG LF, 1995, J IMMUNOL METHODS, V178, P1, DOI 10.1016/0022-1759(94)00235-O; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	19	7	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24634	24638		10.1074/jbc.271.40.24634	http://dx.doi.org/10.1074/jbc.271.40.24634			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798729	hybrid			2022-12-25	WOS:A1996VM67400051
J	Ito, T; Tyler, JK; Bulger, M; Kobayashi, R; Kadonaga, JT				Ito, T; Tyler, JK; Bulger, M; Kobayashi, R; Kadonaga, JT			ATP-facilitated chromatin assembly with a nucleoplasmin-like protein from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; NUCLEAR-LOCALIZATION SIGNALS; HISTONE-BINDING PROTEIN; DNA-REPLICATION INVITRO; AMINO-ACID SEQUENCE; SPERM DECONDENSATION; EGG EXTRACTS; PURIFICATION; NUCLEOSOMES; CLONING	To gain a better understanding of the factors that can mediate chromatin assembly, we have purified and cloned a core histone-binding protein from Drosophila melanogaster embryos. This protein resembles Xenopus laevis nucleoplasmin, and it has therefore been termed dNLP, for Drosophila nucleoplasmin-like protein. dNLP is a nuclear protein that is present throughout development. Both purified native and recombinant dNLP bind to core histones and can function in the assembly of approximately regularly spaced nucleosomal arrays in a reaction that additionally requires DNA, purified core histones, ATP, and a partially purified fraction (containing at least one other assembly activity). We also analyzed the properties of an N-terminally truncated version of dNLP, termed dNLP-S, and found that the deletion of the N-terminal 31 residues of dNLP results in a loss of the specificity of the interaction of dNLP with core histones. We then compared the abilities of dNLP and Drosophila nucleosome assembly protein-1 (dNAP-1) to promote the decondensation of Xenopus sperm chromatin, a process that can be mediated by nucleoplasmin. We observed that dNAP-1, but not dNLP, was able to promote the decondensation of sperm chromatin. These and other data collectively suggest that dNLP may participate in parallel with other histone-binding proteins such as dNAP-1 in the assembly of chromatin.	UNIV CALIF SAN DIEGO, DEPT BIOL, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR GENET MOL, SAN DIEGO, CA 92093 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Cold Spring Harbor Laboratory				Tyler, Jessica/0000-0001-9765-1659	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046995] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46995] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Bulger M., 1994, METH MOL G, V5, P241; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; COTTEN M, 1986, BIOCHEMISTRY-US, V25, P5063, DOI 10.1021/bi00366a014; COTTEN M, 1987, EMBO J, V6, P3945, DOI 10.1002/j.1460-2075.1987.tb02736.x; CREVEL G, 1995, EMBO J, V14, P1711, DOI 10.1002/j.1460-2075.1995.tb07160.x; DILWORTH SM, 1988, BIOESSAYS, V9, P44, DOI 10.1002/bies.950090203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DREYER C, 1983, DEV BIOL, V100, P412, DOI 10.1016/0012-1606(83)90235-X; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito T, 1996, MOL CELL BIOL, V16, P3112; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KAUFMAN PD, 1994, CURR OPIN GENET DEV, V4, P229, DOI 10.1016/S0959-437X(05)80049-8; KAWASAKI K, 1994, J BIOL CHEM, V269, P10169; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; KROHNE G, 1980, EXP CELL RES, V129, P167, DOI 10.1016/0014-4827(80)90341-9; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; OHSUMI K, 1991, DEV BIOL, V148, P295, DOI 10.1016/0012-1606(91)90338-4; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; van Holde KE., 1989, SPRINGER SERIES MOL; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WEDLICH D, 1988, CELL TISSUE RES, V254, P295; Wolffe A., 1995, CHROMATIN STRUCTURE	49	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25041	25048		10.1074/jbc.271.40.25041	http://dx.doi.org/10.1074/jbc.271.40.25041			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798787	hybrid			2022-12-25	WOS:A1996VM67400110
J	Reddy, LR; Reddy, KS; Surrey, S; Adachi, K				Reddy, LR; Reddy, KS; Surrey, S; Adachi, K			Role of hydrophobic amino acids at beta 85 and beta 88 in stabilizing F helix conformation of hemoglobin S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCEPTOR POCKET; PHENYLALANINE BETA-85; VALINE BETA-6; POLYMERIZATION; YEAST	Three Hb S variants containing Glu substitutions at Phe-beta 85 and/or Leu-beta 88 were expressed in yeast in an effort to evaluate the role of hydrophobic amino acids at these sites in stabilizing F helix conformation of Hb S. Helix stability of tetrameric Hb beta F8E, beta L88E was measured by CD and compared with those of Hb S beta F85E, Hb S beta L88E, Hb A, and Hb S, The CD spectra of these Hb S variants were similar to those of Hb S and Hb A at 10 degrees C, However, changes in ellipticity at 222 nm for Hb S beta F85E in the CO form at 60 degrees C were about 15-fold greater than that of Hb S, while those for Hb S beta L88E and Hb S beta F85E, beta L88E were similar and about 30-fold greater than Hb S, Thermal stability measured by continuous scanning of spectral changes revealed the three Hb S variants were much more unstable than Hb S, and stability of Hb S beta F85E, beta L88E was similar to that of Hb S beta L88E rather than Hb S beta F85E. These results suggest that Glu insertion at both beta 85 and beta 88 makes heme insertion into the heme pocket more difficult; however, once inserted, stability of Hb S beta F85E, beta L88E is similar to Hb S beta L88E rather than Hb S beta F85E, Furthermore, these results suggest that both Phe-beta 85 and Leu-beta 88 are critical for F helix stabilization and that Glu insertion at beta 88 leads to more destabilization than insertion at beta 85.	UNIV PENN,SCH MED,CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania					NHLBI NIH HHS [HL38632] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1995, PROTEIN SCI, V4, P1272, DOI 10.1002/pro.5560040703; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; ADACHI K, 1994, J BIOL CHEM, V269, P31563; ADACHI K, 1994, J BIOL CHEM, V269, P17477; DELANO JJM, 1994, PROTEIN SCI, V3, P1206; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P125; HOFMANN OM, 1994, PROTEIN ENG, V7, P281; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; TRIFILLIS P, 1991, BLOOD, V78, P3298; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WAKS M, 1973, J BIOL CHEM, V248, P6462; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; YIP YK, 1972, J BIOL CHEM, V247, P7237	15	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24564	24568		10.1074/jbc.271.40.24564	http://dx.doi.org/10.1074/jbc.271.40.24564			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798719	hybrid			2022-12-25	WOS:A1996VM67400041
J	Strayer, DS				Strayer, DS			SV40 as an effective gene transfer vector in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOASSOCIATED VIRUS; SIMIAN VIRUS-40; DNA-REPLICATION; TUMOR-ANTIGEN; CELLS; CONSTRUCTION; INTEGRATION; EXPRESSION	SV40 was used to transduce gene expression in vitro and in vivo. Using cloned SV40 genome, we replaced large T antigen gene (Tag) with a polylinker, and inserted firefly luciferase, controlled by SV40 early promoter. Transfection into Tag-expressing cells yielded Tag-deficient virus, SVluc. SVluc was Tag-deficient and therefore replication-deficient in cells that did not supply Tag. SVluc transduced functional luciferase expression in vitro. BALB/c mice were inoculated with SVluc, and their tissues were assayed 3-21 days post-inoculation (dpi) for luciferase protein production and enzyme activity. Luciferase protein was detected by immunohistochemistry throughout the experiment, from 3 to 21 dpi. There was no inflammatory reaction against SVluc-infected cells at any time, in any tissue studied. Luciferase activity was first detected by luminometry 14 dpi, and remained level through day 21. Thus, replication-deficient recombinant SV40 can mediate gene transfer in vitro and in vivo.			Strayer, DS (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.				NATIONAL CANCER INSTITUTE [R01CA044800] Funding Source: NIH RePORTER; NCI NIH HHS [CA44800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; ANDERSON WF, 1995, J NATL CANCER I, V87, P406; ASANO M, 1985, NUCLEIC ACIDS RES, V13, P8573, DOI 10.1093/nar/13.23.8573; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CARBONE M, 1994, ONCOGENE, V9, P1781; CHIA W, 1981, P NATL ACAD SCI-BIOL, V78, P6638, DOI 10.1073/pnas.78.11.6638; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; FLOTTE TR, 1994, AM J RESP CELL MOL, V11, P517, DOI 10.1165/ajrcmb.11.5.7946381; GETHING MJ, 1981, NATURE, V293, P620, DOI 10.1038/293620a0; GIRAUD C, 1994, P NATL ACAD SCI USA, V91, P10039, DOI 10.1073/pnas.91.21.10039; GLORIOSO JC, 1994, DEV BIOL STAND, V82, P79; GOODING LR, 1977, J IMMUNOL, V118, P920; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEHN H, 1986, J GEN VIROL, V67, P1581, DOI 10.1099/0022-1317-67-8-1581; Miller AD, 1996, J VIROL, V70, P1804, DOI 10.1128/JVI.70.3.1804-1809.1996; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; MUZYCZKA N, 1994, J CLIN INVEST, V94, P1351, DOI 10.1172/JCI117468; MYERS RM, 1980, P NATL ACAD SCI-BIOL, V77, P6491, DOI 10.1073/pnas.77.11.6491; OHE Y, 1995, HUM GENE THER, V6, P325, DOI 10.1089/hum.1995.6.3-325; Purcell DFJ, 1996, J VIROL, V70, P887, DOI 10.1128/JVI.70.2.887-897.1996; ROSENBERG BH, 1981, J VIROL METHODS, V3, P167, DOI 10.1016/0166-0934(81)90051-3; ROSENFELD MA, 1993, PATHOL BIOL, V41, P677; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; Smith C, 1992, J Hematother, V1, P155, DOI 10.1089/scd.1.1992.1.155; TORNOW J, 1985, J VIROL, V53, P415, DOI 10.1128/JVI.53.2.415-424.1985; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564	30	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24741	24746						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798743				2022-12-25	WOS:A1996VM67400065
J	Lokeshwar, VB; Iida, N; Bourguignon, LYW				Lokeshwar, VB; Iida, N; Bourguignon, LYW			The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN; HOMING RECEPTOR CD44; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; CANCER-CELLS; PROTEIN; EXPRESSION; ANKYRIN; GP85; RAT	In this study we have found that endothelial cells from different origins all contain a CD44-related transmembrane glycoprotein, named GP116. Using a bovine aortic endothelial cell line and a standard pulse-chase protocol, we show that GP116 is synthesized as a 52-kDa nascent polypeptide precursor (p52) which is processed to GP116 as follows, p52 --> p63/65 --> p82 --> p100 --> GP116. GP116 contains approximate to 8 N- and approximate to 11 O-linked oligosaccharide chains (but lacks glycosaminoglycans) and interacts directly with the cytoskeletal protein, ankyrin, both in vitro (K-d approximate to 1.2 nM) and in vivo. The results of GP116 amino acid composition, reverse transcriptase polymerase chain reaction, Southern blot, Northern blot, cloning, and sequence analyses indicate that endothelial cells express this new CD44 variant that contains an exon having significant homology with human CD44 exon 14 (ex14/v10). GP116, designated as CD44 (ex14/v10), has been shown to be a major hyaluronic acid (HA) receptor (K-d approximate to 0.5-0.8 nM) responsible for cell adhesion. Most importantly, we have found that the interaction between CD44(ex14/v10) and HA or a small fragment of HA (10-15 disaccharide units) induces a mitogenic response in endothelial cells, These findings suggest that this CD44 variant plays an important role in regulating endothelial cell proliferation.	UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT R124, MIAMI, FL 33101 USA	University of Miami					NCI NIH HHS [1F32CA06047, CA 66163] Funding Source: Medline; NIGMS NIH HHS [GM 36353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BANERJEE SD, 1992, J CELL BIOL, V119, P643, DOI 10.1083/jcb.119.3.643; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BOSWORTH BT, 1991, MOL IMMUNOL, V28, P1131, DOI 10.1016/0161-5890(91)90028-I; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Bourguignon LYW, 1995, J NEURO-ONCOL, V26, P201, DOI 10.1007/BF01052623; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FOX SB, 1993, LANCET, V342, P548, DOI 10.1016/0140-6736(93)91670-H; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HULL SR, 1989, J CELL BIOCHEM, V40, P67, DOI 10.1002/jcb.240400108; HYMAN R, 1991, IMMUNOGENETICS, V33, P392, DOI 10.1007/BF00216699; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1989, J BIOL CHEM, V264, P19318; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; MORITA H, 1990, BIOCHEM J, V265, P61, DOI 10.1042/bj2650061; NUOVO GJ, 1994, BIOCHEMICA, V11, P4; OMARY MB, 1988, IMMUNOGENETICS, V27, P460, DOI 10.1007/BF00364434; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; RUDY W, 1993, CANCER RES, V53, P1262; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; UNDERHILL C, 1992, J CELL SCI, V103, P293; WELSH CF, 1995, J CELL PHYSIOL, V164, P605, DOI 10.1002/jcp.1041640319; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1989, CIBA F SYMP, V143, P187; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451	53	106	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23853	23864		10.1074/jbc.271.39.23853	http://dx.doi.org/10.1074/jbc.271.39.23853			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798616	hybrid			2022-12-25	WOS:A1996VJ44200045
J	Mamoun, CB; Beckerich, JM; Gaillardin, C				Mamoun, CB; Beckerich, JM; Gaillardin, C			The TSR1 gene of Yarrowia lipolytica is involved in the signal recognition particle-dependent translocation pathway of secretory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE EXTRACELLULAR PROTEASE; ENDOPLASMIC-RETICULUM MEMBRANE; COLI 4.5S RNA; ESCHERICHIA-COLI; SCHIZOSACCHAROMYCES-POMBE; ELONGATION ARREST; 7SL RNA; RIBONUCLEOPROTEIN; TRANSFORMATION	We have isolated suppressors (tsr1 to tsr5) of the thermosensitive growth of the scr2.II-13 mutation, which affects the stability of the signal recognition particle. The growth of these mutants is largely affected in the SCR2 context at 34 degrees C. We have studied the synthesis and secretion of an alkaline extracellular protease (AEP) in both wild-type and tsr1-1(SCR2(+)) thermosensitive mutant strains. Pulse-chase labeling and immunoprecipitation of this protein showed that the level of AEP precursors in the tsr1-1(SCR2(+)) strain is 70% less than in the wild-type strain under conditions where the global protein synthesis is practically unaffected. This defect was observed as early as 10 min after the shift to nonpermissive temperature. In neither strain was there any effect on the kinetics of secretion, and no cytoplasmic accumulation was detected, We have cloned the TSR1 gene by complementing the thermosensitive phenotype of a tsr1-1(SCR2(+)) mutant. Analysis of the TSR1 DNA sequence revealed an open reading frame of 1383 base pairs, encoding a serine-rich protein of 461 amino acids with an amino-terminal signal peptide, and a membrane-spanning domain of 20 amino acids that could act as a stop transfer signal to ensure membrane localization of Tsr1p. Two homologues of the TSR1 gene were identified in Saccharomyces cerevisiae (YHC8) and Hansenula polymorpha (YLU2). Disruption of the TSR1 gene revealed that it is an essential single-copy gene. The TSR1 gene encodes a single mRNA of 1.5 kilobase pairs. The study of the synthesis and secretion of AEP in the complemented tsr1-1(SCR2(+),TSR1(+)) strain revealed that the TSR1 gene ensures complete recovery of the synthesis defect and thus could encode an important component of the endoplasmic reticulum membrane involved in the early steps of the signal recognition particle-dependent translocation pathway.			Mamoun, CB (corresponding author), INRA PARIS GRIGNON,CTR BIOTECHNOL AGROIND,CNRS,LAB GENET MOL & CELLULAIRE,F-78850 THIVERVAL GRIGNON,FRANCE.							AGAPHONOV MO, 1994, YEAST, V10, P509, DOI 10.1002/yea.320100410; ALMASSY RJ, 1983, J MOL BIOL, V170, P497, DOI 10.1016/S0022-2836(83)80159-4; BARTH G, 1996, IN PRESS GENETICS BI; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; DAVIDOW LS, 1985, CURR GENET, V10, P39, DOI 10.1007/BF00418492; FONTECILLACAMPS JC, 1981, TRENDS BIOCHEM SCI, V6, P291, DOI 10.1016/0968-0004(81)90105-5; Gibson TJ, 1984, THESIS CAMBRIDGE U; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HE F, 1990, CURR GENET, V17, P289, DOI 10.1007/BF00314874; HE F, 1992, J BIOL CHEM, V267, P1932; HE F, 1988, CURR GENET, V16, P347; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MANIATIS T, 1982, MOL CLONING, pCH1; MATOBA S, 1988, MOL CELL BIOL, V8, P4904, DOI 10.1128/MCB.8.11.4904; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NICAUD JM, 1989, CURR GENET, V16, P253, DOI 10.1007/BF00422111; PORITZ MA, 1988, P NATL ACAD SCI USA, V85, P4315, DOI 10.1073/pnas.85.12.4315; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIBES V, 1988, EMBO J, V7, P231, DOI 10.1002/j.1460-2075.1988.tb02804.x; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848; YAVER DS, 1992, J CELL BIOL, V116, P605, DOI 10.1083/jcb.116.3.605	32	1	2	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23895	23901		10.1074/jbc.271.39.23895	http://dx.doi.org/10.1074/jbc.271.39.23895			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798620	Green Published, hybrid			2022-12-25	WOS:A1996VJ44200049
J	Rossi, F; Forne, T; Antoine, E; Tazi, J; Brunel, C; Cathala, G				Rossi, F; Forne, T; Antoine, E; Tazi, J; Brunel, C; Cathala, G			Involvement of U1 small nuclear ribonucleoproteins (snRNP) in 5' splice site-U1 snRNP interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; PREMESSENGER RNA; SR PROTEINS; 5'-SPLICE-SITE RECOGNITION; BINDING PROTEINS; U5; STEPS; U2; SPECIFICITY; ASSOCIATION	U1 small nuclear ribonucleoprotein (snRNP) is an important ribonucleoprotein involved early in the spliceosome formation to commit pre-mRNAs to the splicing pathway. We have determined the association and dissociation kinetics of the 5' splice site-U1 snRNP interaction using purified U1 snRNP and a short RNA oligonucleotide comprising the 5' splice site (5'-SS) consensus sequence of pre-mRNAs (5'-SS RNA oligo). The association is rapid, does not require ATP, and is almost irreversible. Surprisingly, oligonucleotide-directed cleavage of the U1 small nuclear RNA (snRNA) 5' end sequence with RNase H has no significant effect on the rate of association of the 5'-SS RNA oligo, but it does lead to rapid dissociation, This provides evidence that U1-specific snRNP proteins are critical for the 5' splice site recognition while base pairing ensures the stability of the interaction. The recognition of the 5' splice site by U1 snRNP does not result from the individual action of one or more proteins but rather from their organization around U1 snRNA. A consequence of this organization is that the U1-C protein makes direct contacts with the site, as it becomes cross-linked to the RNA oligo upon exposition of the reactions to shortwave UV light.	UNIV MONTPELLIER 2,INST MOL GENET,UMR CNRS 5535,F-34033 MONTPELLIER 1,FRANCE	Universite de Montpellier			Forne, Thierry/D-3718-2013	Forne, Thierry/0000-0002-9179-1551; Tazi, Jamal/0000-0002-1949-8748				BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BRINGMANN P, 1986, EMBO J, V5, P3509, DOI 10.1002/j.1460-2075.1986.tb04676.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; DAUGERON MC, 1992, NUCLEIC ACIDS RES, V20, P3625, DOI 10.1093/nar/20.14.3625; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Gunnewiek JMTK, 1995, NUCLEIC ACIDS RES, V23, P4864; HALL KB, 1992, P NATL ACAD SCI USA, V89, P10969, DOI 10.1073/pnas.89.22.10969; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KONFORTI BB, 1995, RNA, V1, P815; KONFORTI BB, 1994, GENE DEV, V8, P1962, DOI 10.1101/gad.8.16.1962; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; Moore M., 1993, RNA WORLD, P303; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; TAZI J, 1992, J BIOL CHEM, V267, P4322; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WILL CL, 1993, MOL BIOL REP, V18, P121, DOI 10.1007/BF00986766; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	40	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23985	23991		10.1074/jbc.271.39.23985	http://dx.doi.org/10.1074/jbc.271.39.23985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798632	Green Published, hybrid			2022-12-25	WOS:A1996VJ44200061
J	SunHoffman, L; Aurigemma, RE; Sun, B; Ruscetti, SK				SunHoffman, L; Aurigemma, RE; Sun, B; Ruscetti, SK			Transactivation of the GATA-1 promoter by a myb-ets-containing mouse retrovirus is mediated by CACCC elements	ONCOGENE			English	Article						ME26 virus; GATA-1 transactivation; CACCC element; Sp1	TRANSCRIPTION FACTOR GATA-1; ERYTHROPOIETIN RECEPTOR GENE; LEUKEMIA-VIRUS; FACTOR SP1; BINDING; CELLS; PROTEINS; E26	The myb-ets-containing ME26 virus causes erythroleukemia in mice by a novel mechanism involving the inappropriate activation of erythroid-specific genes in hematopoietic precursor cells, We have previously shown that the ME26 viral protein can transactivate the GATA-1 promoter in transient transactivation assays carried out in mouse fibroblasts. The mouse GATA-1 promoter, whose activity is regulated by the GATA-1 protein itself, contains a double GATA consensus sequence at its 5' end and two CACCC elements at its 3' end, both of which are crucial for promoter activity in erythroid cells, as well as a nonconsensus GATA sequence and several putative c-myb and c-ets binding sites, In order to determine which sequences in the GATA-1 promoter are crucial for activation by the ME26 viral protein, we made deletions of the promoter, cloned them into a luciferase expression vector and tested their activity in mouse fibroblasts, which do not express GATA-1, Our results indicate that sequences in the 3' end of the GATA-1 promoter, which include two CACCC elements, are essential for transactivation by ME26 virus, while other upstream sites contribute to full activation by the virus, Mutation of the CACCC sites abolishes ME26 viral transactivation. The interaction of cell extracts containing ME26 viral protein and the GATA-1 promoter fragment containing the two CACCC elements was examined by electrophoretic mobility shift analysis (EMSA) and the results showed no direct interaction between the two, However, we could detect the ubiquitous transcription factor Spl bound to this sequence, These data demonstrate that the CACCC element is necessary for GATA-1 promoter transactivation by ME26 virus and that the viral protein may indirectly transactivate the promoter by binding to Sp1.	NCI,MOL ONCOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BRADY HJM, 1989, FEBS LETT, V257, P451, DOI 10.1016/0014-5793(89)81594-7; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; FISCHER KD, 1993, J BIOL CHEM, V268, P23195; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GREGORY RC, 1996, BLOOD, V5, P1793; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Ren SC, 1996, NUCLEIC ACIDS RES, V24, P342, DOI 10.1093/nar/24.2.342; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	22	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1037	1042						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806693				2022-12-25	WOS:A1996VG76600017
J	Vairapandi, M; Duker, NJ				Vairapandi, M; Duker, NJ			Partial purification and characterization of human 5-methylcytosine-DNA glycosylase	ONCOGENE			English	Article						5-methylcytosine; DNA; demethylation; glycosylase; apyrimidinic site	TRANSIENT DNA DEMETHYLATION; DEOXYRIBONUCLEIC-ACID; APYRIMIDINIC SITES; ENZYMATIC REMOVAL; NUCLEAR EXTRACTS; MAMMALIAN-CELLS; CHICKEN EMBRYOS; EXCISION-REPAIR; METHYLATION; CYTOSINE	The molecular mechanisms by which DNA 5-methylcytosine content is modulated are incompletely understood, Reduction of DNA 5-methylcytosine content has been correlated with the transition from hyperplasia to adenoma in the genesis of human adenocarcinoma of the colon, 5-methylcytosine-DNA glycosylase removes 5-methylcytosine from DNA as a free base, but its involvement in this process is unknown, The 5-methylcytosine-DNA glycosylase activity in HeLa nuclear extracts has been partially purified, with a 460-fold enrichment, and characterized, This activity is specific for 5-methylcytosine at CpG sites in fully methylated DNA; hemimethylated DNA is not a significant substrate, DIVA containing unmethylated cytosines is not cleaved by the enzyme, There is an absolute requirement for Mg2+ ions for the activity, which is inhibited by EDTA, This 5-methylcytosine-DNA glycosylase activity could be involved in carcinogenesis, transcription, replication, differentiation and development through resultant DNA hypomethylation following enzymatic removal of 5-methylcytosine from DNA.	TEMPLE UNIV,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19122; TEMPLE UNIV,SCH MED,FES INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19122	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; CELEWICZ L, 1992, PHOTOCHEM PHOTOBIOL, V55, P823, DOI 10.1111/j.1751-1097.1992.tb08530.x; DUKER NJ, 1995, BIOCH LIF SCI ADV, V14, P1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; GENTIL A, 1992, J MOL BIOL, V227, P981, DOI 10.1016/0022-2836(92)90513-J; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JOST JP, 1994, J BIOL CHEM, V269, P10040; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; JOST JP, 1993, DNA METHYLATION MOL; KUYKENDALL JR, 1989, CANCER LETT, V47, P149, DOI 10.1016/0304-3835(89)90191-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; Mazin A. L., 1993, Molekulyarnaya Biologiya (Moscow), V27, P160; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NYCE J, 1991, SOMAT CELL MOLEC GEN, V17, P543, DOI 10.1007/BF01233619; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; STEINBERG RA, 1995, NUCLEIC ACIDS RES, V23, P1621, DOI 10.1093/nar/23.9.1621; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; VAIRAPANDI M, 1994, MUTAT RES-DNA REPAIR, V315, P85, DOI 10.1016/0921-8777(94)90009-4; VOLPE P, 1993, FEBS LETT, V329, P233, DOI 10.1016/0014-5793(93)80228-M; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WEISS RB, 1989, BIOCHEMISTRY-US, V28, P1488, DOI 10.1021/bi00430a010; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	34	13	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					933	938						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806682				2022-12-25	WOS:A1996VG76600006
J	Berard, J; Laboune, F; Mukuna, M; Masse, S; Kothary, R; Bradley, WEC				Berard, J; Laboune, F; Mukuna, M; Masse, S; Kothary, R; Bradley, WEC			Lung tumors in mice expressing an antisense RAR beta 2 transgene	FASEB JOURNAL			English	Article						retinoic acid receptor beta 2; lung tumors; tumor suppressor gene; antisense RNA; transgenic nice	RETINOIC ACID RECEPTORS; CARCINOMA CELL-LINES; RAR DOUBLE MUTANTS; EPITHELIAL-CELLS; CANCER CELLS; BETA; ABNORMALITIES; BREAST; GENES; RNA	Retinoic acid has been shown to be an anticancer agent, and a growing literature suggests that it is the nuclear retinoic acid receptor beta 2 (RAR beta 2) that is primarily responsible for mediating this effect, at least in some systems, To determine whether partial inactivation of RAR beta 2 would predispose to lung cancer in mice, we generated three transgenic lines expressing antisense sequences. When killed at 13-3/4-18 months of age, 21/36 animals had a total of 43 pulmonary tumors superficially visible upon necropsy, whereas among 23 nontransgenic mice, only 1 had a single visible lung tumor, A twofold higher incidence of lung tumors was seen in homozygous vs, hemizygous antisense mice, The endogenous RAR beta 2 message level was reduced in transgenic lung tissue and further reduced in the tumors, RAR beta 4, a truncated isoform derived from the same transcript as RAR beta 2, does not carry the sequence identified by the antisense construct and its message was not as strongly affected, Immunofluorescence studies showed that RAR beta was virtually undetectable in the tumors, but present in normal tissue, We conclude that RAR beta 2, but probably not RAR beta 4, plays an important role in suppression of murine lung tumorigenesis.	UNIV SHERBROOKE,FAC MED,DEPT PATHOL,SHERBROOKE,PQ J1H 5N4,CANADA; INST CANC MONTREAL,CTR RECH LOUIS CHARLES SIMARD,MONTREAL,PQ H2L 4M1,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL,PQ H3C 3J7,CANADA	University of Sherbrooke; Universite de Montreal; Universite de Montreal	Berard, J (corresponding author), UNIV SHERBROOKE,FAC MED,DEPT ANAT & CELLULAR BIOL,SHERBROOKE,PQ J1H 5N4,CANADA.			Kothary, Rashmi/0000-0002-9239-7310				BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; DE LUCA LM, 1991, FASEB J, V5, P2924; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; GERBERT JF, 1991, ONCOGENE, V6, P1859; GRAHAM S, 1984, JNCI-J NATL CANCER I, V73, P1423; HARRIS CC, 1973, JNCI-J NATL CANCER I, V51, P1059, DOI 10.1093/jnci/51.3.1059; Hong Waun Ki, 1994, P597; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LUO JM, 1995, MECH DEVELOP, V53, P61, DOI 10.1016/0925-4773(95)00424-6; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; NAPGAL S, 1992, P NATL ACAD SCI USA, V89, P2718; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; Roberts A, 1984, RETINOIDS; ROMAN SD, 1992, CANCER RES, V52, P2236; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; VALERA A, 1994, J BIOL CHEM, V269, P28543; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	30	102	104	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1091	1097		10.1096/fasebj.10.9.8801172	http://dx.doi.org/10.1096/fasebj.10.9.8801172			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801172				2022-12-25	WOS:A1996UY93200021
J	Chevalier, S; Ferland, G; Tuchweber, B				Chevalier, S; Ferland, G; Tuchweber, B			Lymphatic absorption of retinol in young, mature, and old rats: Influence of dietary restriction	FASEB JOURNAL			English	Article						retinoids; aging; AL rats; dietary-restricted rats	VITAMIN-A; INTESTINAL-ABSORPTION; MEMBRANE FLUIDITY; FOOD RESTRICTION; AGING RATS; LIVER; TRANSPORT; METABOLISM; STORAGE; MICE	Earlier studies have shown that hepatic vitamin A stores increase with age and that rats subjected to life-long dietary restriction (DR) have greater hepatic retinoid concentrations than ad libitum-fed rats, It was suggested that these changes may be attributed to altered intestinal absorption, and so we measured retinol absorption in 3, 12, and 22 month-old female Sprague-Dawley rats fed ad libitum (AL) or a restricted diet (40%) enriched (DR(+)) or not (DR) with vitamins and minerals, An in vivo model was used and lymph collected from the mesenteric duct while rats were infused a micellar solution containing [H-3]retinol into the proximal duodenum, Aging significantly decreased lymph flow, and at all ages DR and DR(+) rats exhibited a higher flow than age-matched AL rats, Absorption of retinol was not significantly modified by age in AL and DR(+) rats, However, in the DR group, there was a marked decrease in absorption between 3 and 12 months of age, Retinol absorption was significantly higher in 12 and 22 month-old DR(+) rats than in age-matched AL rats, a finding that may be explained by both higher lymph flow rate and higher long-term vitamin A intake per body weight, In conclusion, the increased content of vitamin A in the livers of older AL rats is not associated with changes in intestinal absorption, In DR rats, however, retinoid accumulation in the liver may be explained by increased intestinal absorption of the vitamin, though other mechanisms may be involved, A possible explanation may be a decreased output of retinol from the liver as a result of lower metabolic needs, The lower serum vitamin A concentrations observed in DR rats would tend to support this hypothesis.	UNIV MONTREAL,DEPT NUTR,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal								AHN JJ, 1995, J NUTR BIOCHEM, V6, P595, DOI 10.1016/0955-2863(95)00127-L; BLOMHOFF R, 1991, FASEB J, V5, P271, DOI 10.1096/fasebj.5.3.2001786; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOUCHARD G, 1995, GASTROENTEROLOGY, V108, pA717; BRASITUS TA, 1984, BIOCHIM BIOPHYS ACTA, V778, P341, DOI 10.1016/0005-2736(84)90378-X; BYUN DS, 1995, AGING-CLIN EXP RES, V7, P40, DOI 10.1007/BF03324291; Chevalier S., 1996, FASEB Journal, V10, pA524; CHEVALIER S, 1995, NUTR RES, V15, P859, DOI 10.1016/0271-5317(95)00051-J; DEW SE, 1994, BIOCHEMISTRY-US, V33, P12340, DOI 10.1021/bi00206a042; FERLAND G, 1992, J GERONTOL, V47, pB3, DOI 10.1093/geronj/47.1.B3; FERNANDEZ E, 1990, LIPIDS, V25, P549, DOI 10.1007/BF02537163; FLEMING BB, 1982, EXP GERONTOL, V17, P115, DOI 10.1016/0531-5565(82)90044-4; HOLLANDER D, 1980, AM J PHYSIOL, V239, pG210, DOI 10.1152/ajpgi.1980.239.3.G210; HOLLANDER D, 1990, EXP GERONTOL, V25, P61, DOI 10.1016/0531-5565(90)90010-Y; HOLLANDER D, 1986, AGE, V9, P57, DOI 10.1007/BF02432262; LAGANIERE S, 1989, MECH AGEING DEV, V48, P207, DOI 10.1016/0047-6374(89)90083-3; LEVIN G, 1992, MECH AGEING DEV, V62, P137, DOI 10.1016/0047-6374(92)90050-N; ROBERTS D, 1994, AM J PHYSIOL-GASTR L, V267, pG515, DOI 10.1152/ajpgi.1994.267.4.G515; SCARPACE PJ, 1987, J GERONTOL, V42, P442, DOI 10.1093/geronj/42.4.442; SUNDBOOM J, 1984, EXP GERONTOL, V19, P257, DOI 10.1016/0531-5565(84)90021-4; SWEDA LI, 1994, J BIOL CHEM, V269, P8712; UNDERWOOD BA, 1970, AM J CLIN NUTR, V23, P1037; WARSHAW AL, 1972, GUT, V13, P66, DOI 10.1136/gut.13.1.66; YOST RW, 1988, J BIOL CHEM, V263, P18693; YU BP, 1994, P SOC EXP BIOL MED, V205, P97, DOI 10.3181/00379727-205-43684; YU BP, 1992, MECH AGEING DEV, V65, P17, DOI 10.1016/0047-6374(92)90123-U; YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657; YU BP, 1990, REV BIOL RES AGING, V4, P349	28	24	24	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1085	1090		10.1096/fasebj.10.9.8801171	http://dx.doi.org/10.1096/fasebj.10.9.8801171			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801171				2022-12-25	WOS:A1996UY93200020
J	Burg, MA; Tillet, E; Timpl, R; Stallcup, WB				Burg, MA; Tillet, E; Timpl, R; Stallcup, WB			Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CELL-ADHESION; INTIMA COLLAGEN; HUMAN-PLACENTA; ALPHA-3 CHAIN; MESSENGER-RNA; CORE PROTEIN; HUMAN-SKIN; DECORIN; EXPRESSION	Previous studies have suggested that the NG2 proteoglycan interacts with type VI collagen. We have further characterized this interaction using a solid phase binding assay in which purified NG2 was shown to bind to pepsin-solubilized type VI collagen. In addition, NG2 bound a recombinant alpha 2 (VI) collagen chain but did not appreciably bind to the recombinant alpha 1 (VI) chain or the N-terminal domain of alpha 3 (VI) (N9-N2), Binding of NG2 to type VI collagen was shown to be concentration-dependent and saturable and to depend mainly on the NC2 core protein, since chondroitinase-treated NG2 bound the collagen as web as undigested samples. In addition, the binding studies revealed several other possible ligands for NG2, including type II collagen, type V collagen, tenascin, and laminin. Binding of the proteoglycan to these molecules was also shown to be mediated by domains contained within the NG2 core protein. The ability of NG2 to bind to these extracellular matrix molecules was compared with that of the chondroitin sulfate proteoglycan decorin, revealing an almost identical binding pattern of the two proteoglycans to the different collagen types. In addition, decorin was found to effectively inhibit the ability of NG2 to bind to collagen, thus suggesting that the two proteoglycans may bind to some of the same regions on the collagen substrates. In contrast, decorin did not bind tenascin and was ineffective in inhibiting the binding of NG2 to tenascin or laminin, indicating that NG2 may bind these two molecules using a separate domain that is distinct from its collagen binding region.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society	Burg, MA (corresponding author), BURNHAM INST, LA JOLLA CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Tillet, Emmanuelle/0000-0002-0076-8007	NINDS NIH HHS [R01 NS21990] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021990] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; DOANE KJ, 1992, EXP CELL RES, V200, P490, DOI 10.1016/0014-4827(92)90200-R; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; FLEISCHMAJER R, 1993, J HISTOCHEM CYTOCHEM, V41, P1359, DOI 10.1177/41.9.7689083; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HANEMANN CO, 1993, J HISTOCHEM CYTOCHEM, V41, P1383, DOI 10.1177/41.9.8354878; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HESSLE H, 1984, J BIOL CHEM, V259, P3955; KAMEI A, 1992, PEDIATR NEUROL, V8, P183, DOI 10.1016/0887-8994(92)90065-7; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KODA JE, 1985, J BIOL CHEM, V260, P8157; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LEVINE JM, 1987, J NEUROSCI, V7, P2721; MCDEVITT CA, 1991, FEBS LETT, V294, P167, DOI 10.1016/0014-5793(91)80660-U; MUONA P, 1993, AM J PATHOL, V142, P1586; NISHIYAMA A, 1993, MOL BIOL CELL, V4, P1097, DOI 10.1091/mbc.4.11.1097; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NISHIYAMA A, 1991, DEVELOPMENT, V111, P933; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PELTONEN J, 1990, LAB INVEST, V62, P487; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; POOLE AR, 1986, J HISTOCHEM CYTOCHEM, V34, P619, DOI 10.1177/34.5.3701029; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; RAND JH, 1991, J CLIN INVEST, V88, P253, DOI 10.1172/JCI115285; RIESSEN R, 1994, AM J PATHOL, V144, P962; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOGEL KG, 1994, EXTRACELLULAR MATRIX, P243; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	53	169	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26110	26116		10.1074/jbc.271.42.26110	http://dx.doi.org/10.1074/jbc.271.42.26110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824254	hybrid			2022-12-25	WOS:A1996VN18000060
J	delArco, PG; MartinezMartinez, S; Calvo, V; Armesilla, AL; Redondo, JM				delArco, PG; MartinezMartinez, S; Calvo, V; Armesilla, AL; Redondo, JM			JNK (c-Jun NH2-terminal kinase) is a target for antioxidants in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; SIGNAL-TRANSDUCTION PATHWAYS; SERUM RESPONSE ELEMENT; TRANSCRIPTION FACTOR; REGULATED KINASE; INTACT-CELLS; FOS; AP-1; PHOSPHORYLATION	AP-1 has been shown to behave as a redox-sensitive transcription factor that can be activated by both oxidant and antioxidant stimuli. However, the mechanisms involved in the activation of AP-1 by antioxidants are largely unknown. In this study we show that the structurally unrelated antioxidant agents pyrrolidine dithiocarbamate (PDTC), butylated hydroxyanisole, and N-acetylcysteine activated JNK (c-Jun NH2-terminal kinase) in Jurkat T cells. This activation differed substantially from that mediated by phorbol 12-myristate 13-acetate (PMA) and Ca2+ ionophore or produced by costimulation with antibodies against the T cell receptor-CD3 complex and to CD28. The activation of JNK by classical T cell stimuli was transient, whereas that mediated by PDTC and butylated hydroxyanisole (but not N-acetylcysteine) was sustained. The kinetics of JNK activation correlated with the expression of c-jun which was transient after stimulation with PMA plus ionophore and prolonged in response to PDTC, which also transiently induced c-fos. In addition, JNK activation by PMA plus ionophore was sensitive to inhibitors of signaling pathways involving Ca2+, protein kinase C, and tyrosine phosphorylation, which failed to inhibit the activation mediated by PDTC. Transfection of transdominant negative expression vectors of ras and raf, together with AP-l-dependent reporter constructs, as web as Western blot analysis using anti-ERR (extracellular signal-regulated kinase) antibodies, indicated that the Ras/Raf/ERK pathway did not appear to mediate the effect of the antioxidant. However, the combined treatment with PDTC and PMA, two agents that synergize on AP-1 activation, resulted in the persistent phosphorylation of ERR-2. In conclusion, our results identify JNK as a target of antioxidant agents which can be regulated differentially under oxidant and antioxidant conditions.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOL,HOSP PRINCESA,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,CSIC,SERV IMMUNOL,HOSP PRINCESA,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,CSIC,CTR INVEST BIOMED,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Hospital de La Princesa; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital de La Princesa; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Gomez-del Arco, Pablo/L-2728-2013; Redondo, Juan Miguel/H-6351-2015; Calvo, Victor/L-5024-2014	Gomez-del Arco, Pablo/0000-0001-6748-7157; Redondo, Juan Miguel/0000-0001-5779-9122; Calvo, Victor/0000-0002-5913-7058; Armesilla, Angel/0000-0003-3546-5580				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aragones J, 1996, J BIOL CHEM, V271, P10924, DOI 10.1074/jbc.271.18.10924; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUSCHER M, 1988, ONCOGENE, V3, P301; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LISBONA C, 1994, EUR J IMMUNOL, V24, P2746, DOI 10.1002/eji.1830241126; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNOZ E, 1992, EUR J IMMUNOL, V22, P2101, DOI 10.1002/eji.1830220821; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1995, METHOD ENZYMOL, V252, P253; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SPITS H, 1985, EUR J IMMUNOL, V15, P88, DOI 10.1002/eji.1830150117; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	49	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26335	26340						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824287				2022-12-25	WOS:A1996VN18000093
J	Dixit, RB; Chen, A; Chen, J; Sheppard, D				Dixit, RB; Chen, A; Chen, J; Sheppard, D			Identification of a sequence within the integrin beta 6 subunit cytoplasmic domain that is required to support the specific effect of alpha v beta 6 on proliferation in three-dimensional culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CELL-ADHESION; TYROSINE PHOSPHORYLATION; FIBRONECTIN; BINDING; PAXILLIN; PROTEIN; ATTACHMENT; EXPRESSION; RECEPTOR	The integrin alpha v beta 6 augments the proliferation of epithelial cells in collagen gels and in vivo. This effect depends on the presence of a unique carboxyl-terminal region of the beta 6 subunit cytoplasmic domain. In the present study, we have utilized deletional and alanine substitution mutagenesis within this region to map the amino acids responsible for alpha v beta 6-mediated proliferation in more detail, Replacement or deletion of any of 6 amino acids (glutamic acid 778, lysine 779, lysine 781, valine 782, aspartic acid 783, and leucine 784) largely abolished the proliferative effects of alpha v beta 6, but none of the mutants examined interfered with alpha v beta 6-mediated cell adhesion or with localization of alpha v beta 6 to focal adhesions, These findings suggest that residues contained within the sequence EKXKVDL are critical for the effects of alpha v beta 6 on proliferation in collagen gels and that pathways initiated by interaction with this sequence are distinct from those required for integrin-mediated cell attachment or focal adhesion formation.	UNIV CALIF SAN FRANCISCO,DEPT MED,LUNG BIOL CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053949, R01HL047412, R01HL053949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47412, HL/A 133259, HL53949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; BREUSS JM, 1995, J CELL SCI, V108, P2241; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BUSK M, 1992, J BIOL CHEM, V267, P5790; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; OTEY CA, 1993, J BIOL CHEM, V268, P21193; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SAMBROOK J, 1989, TRANSFECTION COPRECI; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WEINACKER A, 1994, J BIOL CHEM, V269, P6940	21	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25976	25980		10.1074/jbc.271.42.25976	http://dx.doi.org/10.1074/jbc.271.42.25976			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824234	hybrid			2022-12-25	WOS:A1996VN18000040
J	Engh, RA; Girod, A; Kinzel, V; Huber, R; Bossemeyer, D				Engh, RA; Girod, A; Kinzel, V; Huber, R; Bossemeyer, D			Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89 - Structural implications for selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLASE-KINASE; NUCLEOTIDE BINDING; PEPTIDE INHIBITOR; C-ALPHA; DOMAIN; EXPRESSION; APOPTOSIS; POTENT; SITE; DEPHOSPHORYLATION	The discovery of several hundred different protein kinases involved in highly diverse cellular signaling pathways is in stark contrast to the much smaller number of known modulators of cell signaling, Of these, the H series protein kinase inhibitors (1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7), N-[2-(methylamino)-ethyl]-5-isoquinolinesulfonamide (H8) N-[2-(p-Bromo-cinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89)) are frequently used to block signaling pathways in studies of cellular regulation. To elucidate inhibition mechanisms at atomic resolution and to enable structure-based drug design of potential therapeutic modulators of signaling pathways, we determined the crystal structures of corresponding complexes with the cAPK catalytic subunit. Complexes with H7 and H8 (2.2 Angstrom) and with H89 (2.3 Angstrom) define the binding mode of the isoquinoline-sulfonamide derivatives in the ATP-binding site while demonstrating effects of ligand-induced structural change. Specific interactions between the enzyme and the inhibitors include the isoquinoline ring nitrogen ligating to backbone amide of Val-123 and an inhibitor side chain amide bonding to the backbone carbonyl of Glu-170. The conservation of the ATP-binding site of protein kinases allows evaluation of factors governing general selectivity of these inhibitors among kinases. These results should assist efforts in the design of protein kinase inhibitors with specific properties.	GERMAN CANC RES CTR, DEPT PATHOCHEM 0210, D-69120 HEIDELBERG, GERMANY; MAX PLANCK INST BIOCHEM, ABT STRUKTURFORSCH 2, D-82152 MARTINSRIED, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Max Planck Society				Engh, Richard/0000-0002-6207-0560				ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; BHATNAGAR D, 1985, BIOCHEMISTRY-US, V24, P1122, DOI 10.1021/bi00326a009; BOSSEMEYER D, 1995, FEBS LETT, V369, P57, DOI 10.1016/0014-5793(95)00580-3; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DENISENKO N, 1994, J CELL SCI, V107, P969; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; ELLIOTT LH, 1990, BIOCHEM BIOPH RES CO, V171, P148, DOI 10.1016/0006-291X(90)91369-4; FELIPO V, 1994, EUR J CANCER, V30A, P525, DOI 10.1016/0959-8049(94)90431-6; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GUIZOUARN H, 1993, J BIOL CHEM, V268, P8632; HAGIWARA M, 1987, MOL PHARMACOL, V31, P523; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARTL FT, 1983, BIOCHEMISTRY-US, V22, P2347, DOI 10.1021/bi00279a007; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HONMA Y, 1991, CANCER RES, V51, P4649; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1993, CANCER LETT, V74, P37, DOI 10.1016/0304-3835(93)90041-7; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P362; KONDA Y, 1994, J BIOL CHEM, V269, P13162; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE JH, 1992, BIOCHEMISTRY-US, V31, P10616, DOI 10.1021/bi00158a026; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAY WS, 1994, J BIOL CHEM, V269, P26865; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TRAGANOS F, 1993, INT J ONCOL, V2, P47; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WIEMANN S, 1992, BIOCHIM BIOPHYS ACTA, V1171, P93, DOI 10.1016/0167-4781(92)90144-O; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	48	241	251	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26157	26164		10.1074/jbc.271.42.26157	http://dx.doi.org/10.1074/jbc.271.42.26157			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824261	hybrid			2022-12-25	WOS:A1996VN18000067
J	Hayes, JJ; Kaplan, R; Ura, K; Pruss, D; Wolffe, A				Hayes, JJ; Kaplan, R; Ura, K; Pruss, D; Wolffe, A			A putative DNA binding surface in the globular domain of a linker histone is not essential for specific binding to the nucleosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENE; COOPERATIVE BINDING; CHROMATIN; H5; TRANSCRIPTION; CORE; EXPRESSION; H1; TEMPLATES; CONTACTS	A fundamental step in the assembly of native chromatin is the specific recognition and binding of linker histones to the nucleoprotein subunit known as the nucleosome. A first step in defining this important interaction is the determination of residues within Linker histones that are important for the structure-specific recognition of the nucleosome core. By combining in vitro assays for the native binding activity of linker histones and site-directed mutagenesis, we have examined a cluster of basic residues within the globular domain of H1(0), a somatic Linker histone variant from Xenopus laevis. We show that these residues, which comprise a putative DNA binding surface within the globular domain, do not play an essential role in the structure-specific binding of a linker histone to the nucleosome.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hayes, JJ (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM52426] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; BALDWIN JP, 1992, CURRENT OPINION STRU, V2, P78; BIRKENMEIER EH, 1978, CELL, V15, P1077, DOI 10.1016/0092-8674(78)90291-X; BOULIKAS T, 1980, P NATL ACAD SCI USA, V77, P121; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BUCKLE RS, 1992, J MOL BIOL, V223, P651, DOI 10.1016/0022-2836(92)90981-O; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; CLARK DJ, 1988, THESIS CAMBRIDGE U; DRAVES PH, 1992, J MOL BIOL, V225, P1105, DOI 10.1016/0022-2836(92)90108-V; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; KHOCHBIN S, 1993, GENE, V128, P173, DOI 10.1016/0378-1119(93)90560-P; Nightingale KP, 1996, J BIOL CHEM, V271, P7090, DOI 10.1074/jbc.271.12.7090; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; RUTLEDGE RG, 1988, GENE, V70, P117, DOI 10.1016/0378-1119(88)90110-2; SHWED PS, 1992, BIOCHIM BIOPHYS ACTA, V1131, P152, DOI 10.1016/0167-4781(92)90070-G; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1986, EMBO J, V5, P3531, DOI 10.1002/j.1460-2075.1986.tb04679.x; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; URA K, 1994, J BIOL CHEM, V269, P27171; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; URA K, 1996, IN PRESS EMBO J, V15; van Holde KE., 1989, SPRINGER SERIES MOL; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WOLFFE A, 1992, CHROMATIN STRUCTURE; WOLFFE AP, 1993, METH MOL G, V2, P314	38	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25817	25822		10.1074/jbc.271.42.25817	http://dx.doi.org/10.1074/jbc.271.42.25817			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824211	hybrid			2022-12-25	WOS:A1996VN18000017
J	Isidoro, C; Maggioni, C; Demoz, M; Pizzagalli, A; Fra, AM; Sitia, R				Isidoro, C; Maggioni, C; Demoz, M; Pizzagalli, A; Fra, AM; Sitia, R			Exposed thiols confer localization in the endoplasmic reticulum by retention rather than retrieval	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; LYSOSOMAL-ENZYMES; RECOGNITION MARKER; SECRETORY PROTEIN; GOLGI-APPARATUS; QUALITY-CONTROL; CATHEPSIN-D; CELLS; PHOSPHORYLATION; GLYCOPROTEIN	The cysteine present in the Ig mu chain tailpiece (mu tp) prevents the secretion of unpolymerized IgM intermediates and causes their accumulation in the endoplasmic reticulum (ER). In principle, this can be the consequence of actual retention in this organelle or of retrieval from the Golgi. To determine which of the two mechanisms underlies the cysteine dependent ER localization, we analyze here the post-translational modifications of suitably engineered cathepsin D (CD) molecules. The glycans of this protease are phosphorylated by post-ER phosphotransferases and further modified in the trans-Golgi to generate a mannose 6-phosphate lysosome targeting signal. Only trace amounts of the mu tp-tagged CD (CDM mu tpCys) are phosphorylated, unless retention is reversed by exogenous reducing agents or the critical cysteine mutated (CDM mu tpSer). In contrast, a KDEL-tagged CD, that is retrieved from the Golgi into the ER, acquires phosphates, though mainly resistant to alkaline phosphatase. Similarly to CDM mu tpSer, the few CDM mu tpCys molecules that escape retention and acquire phosphates in the cis-Golgi are transported beyond the KDEL retrieval compartment, as indicated by their sensitivity to alkaline phosphatase. These results demonstrate that the thiol-dependent ER localization arises primarily from true retention, without recycling through the Golgi.	SAN RAFFAELE SCI INST, DIBIT, I-20132 MILAN, ITALY; UNIV TURIN, DIPARTIMENTO MED & ONCOL SPERIMENTALE, SEZ PATOL GEN, I-10125 TURIN, ITALY	University of Turin			Fra, Annamaria/I-5532-2012; Sitia, Roberto/AAB-5005-2019; Isidoro, Ciro/J-6063-2016	Fra, Annamaria/0000-0002-4327-3004; Sitia, Roberto/0000-0001-7086-4152; Isidoro, Ciro/0000-0002-5494-3034				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Cals MM, 1996, MOL IMMUNOL, V33, P15, DOI 10.1016/0161-5890(95)00132-8; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Isidoro C, 1995, INT J CANCER, V63, P866, DOI 10.1002/ijc.2910630619; ISIDORO C, 1991, EUR J CLIN CHEM CLIN, V29, P165; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; ISIDORO C, 1990, EUR J BIOCHEM, V191, P591, DOI 10.1111/j.1432-1033.1990.tb19162.x; KEREM A, 1993, J BIOL CHEM, V268, P180; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; RADONS J, 1990, BIOL CHEM H-S, V371, P567, DOI 10.1515/bchm3.1990.371.2.567; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	44	38	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26138	26142		10.1074/jbc.271.42.26138	http://dx.doi.org/10.1074/jbc.271.42.26138			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824258	hybrid			2022-12-25	WOS:A1996VN18000064
J	McIntosh, DB; Woolley, DG; Vilsen, B; Andersen, JP				McIntosh, DB; Woolley, DG; Vilsen, B; Andersen, JP			Mutagenesis of segment (487)Phe-Ser-Arg-Asp-Arg-Lys(492) of sarcoplasmic reticulum Ca2+-ATPase produces pumps defective in ATP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; ACTIVE-SITE; CATALYTIC SITE; AMINO-ACID; FUNCTIONAL CONSEQUENCES; CONFORMATIONAL CHANGE; NUCLEOTIDE-BINDING; STOPPED-FLOW; CA-ATPASE; PHOSPHOENZYME ISOMERIZATION	The lysine residue Lys(492) located in the large cytoplasmic domain of sarcoplasmic reticulum Ca2+-ATPase is implicated in nucleotide binding through affinity labeling, The contribution of segment (487)Phe-Ser Arg-Asp-Arg Lys(492) to, ATP binding and pump function has been investigated through the introduction of 11 site-directed amino acid mutations, ATP binding was measured through competitive inhibition of [gamma-P-32]2',3'-O-(2,4,6-trinitrophenyl)-8-azido-adenosine triphosphate photolabeling of Lys(492) or its substitute. Mutations F487S and positional swap F487S/S488F produced pumps that were severely defective in ATP binding (K-D > 1 mM), and mutant F487S, together with F487E, exhibited low ATPase activity and low ATP-supported calcium transport and phosphorylation and failed to show CrATP-dependent Ca2+ occlusion. Mutations F487L, R489L, and K492Y were less inhibitory to ATP binding (K-D = 8-49 mu M) and, together with K492L and R489D/D490R, produced correspondingly smaller changes in ATP-mediated activities, The ATP dependence of ATPase activity of these five mutants showed deviations from the wild type profile in the low, intermediate, and high concentration ranges, suggesting defects in ATP-dependent conformational changes, Mutations S488A and D490A had no effect on ATP binding (K-D = 0.4 mu M) or ATP-mediated activities, None of the mutations significantly affected phosphorylation from P-i or acetyl phosphate-supported Ca2+ transport. Mutations F487L and F487S, and not those at residue 492, increased the K-0.5, for Ca2+ activation of transport 2- and 8-fold, respectively, The results implicate Phe(487), Arg(489) and Lys(492) in binding ATP in both a catalytic and a regulatory mode.	UNIV AARHUS,DEPT PHYSIOL,DK-8000 AARHUS C,DENMARK	Aarhus University	McIntosh, DB (corresponding author), UNIV CAPE TOWN,SCH MED,DEPT CHEM PATHOL,ZA-7925 CAPE TOWN,SOUTH AFRICA.			Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLORE GM, 1982, EUR J BIOCHEM, V128, P113; COAN CR, 1977, J BIOL CHEM, V252, P3044; DAIHO T, 1994, J BIOL CHEM, V269, P11060; de Meis L, 1973, J Biol Chem, V248, P3691; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1967, J BIOL CHEM, V242, P4637; KAYA SJ, 1994, J BIOL CHEM, V269, P7419; KIMURA M, 1993, J CELL SCI, V104, P1129; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT EDIT, V34, P1296, DOI 10.1002/anie.199512961; KRISHNA S, 1993, J CELL BIOL, V120, P385, DOI 10.1083/jcb.120.2.385; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LEVY D, 1990, J BIOL CHEM, V265, P19524; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; ROSS DC, 1991, J BIOL CHEM, V266, P4613; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1442; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; VILSEN B, 1987, EUR J BIOCHEM, V170, P421, DOI 10.1111/j.1432-1033.1987.tb13716.x; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WANG K, 1992, J BIOL CHEM, V267, P3577; WAWRZYNOW A, 1993, BIOCHEMISTRY-US, V32, P10803, DOI 10.1021/bi00091a035; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1994, J BIOL CHEM, V269, P4129	66	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25778	25789		10.1074/jbc.271.42.25778	http://dx.doi.org/10.1074/jbc.271.42.25778			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824206	hybrid			2022-12-25	WOS:A1996VN18000012
J	Stoltz, M; Rassow, J; Buckmann, AF; Brandsch, R				Stoltz, M; Rassow, J; Buckmann, AF; Brandsch, R			Covalent attachment of FAD derivatives to a fusion protein consisting of 6-hydroxy-D-nicotine oxidase and a mitochondrial presequence - Folding, enzyme activity, and import of the modified protein into yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEMBRANE SPACE; DEHYDROGENASE; TRANSLOCATION; BINDING; MATRIX; FLAVINYLATION; MUTAGENESIS; CYTOCHROME; APOENZYME	Autoflavinylation of 6-hydroxy-D-nicotine oxidase (6-HDNO) was successfully employed to modify the protein covalently with FAD derivatives, The model compounds N-6-(2-aminoethyl)-FAD and N-6-(6-carboxyhexyl)-FAD were spontaneously bound to a fusion protein consisting of the mitochondrial targeting sequence of Neurospora crassa F-0-ATPase subunit 9 (Su9) attached to 6-HDNO. When translated in the rabbit reticulocyte lysate, Su9-6-HDNO was in the trypsin-sensitive apoenzyme form; when translated in the presence of flavins it adopted a trypsin-resistant conformation characteristic of the 6-HDNO holoenzyme. With flavin derivatives, Su9-6-HDNO exhibited approximately 50% of the 6-HDNO activity observed with FAD. The covalently modified Su9-6-HDNO was imported into Saccharomyces cerevisiae mitochondria with an efficiency equal to that of the apoenzyme, Apparently the increase in size and charge of the FAD moiety did not hamper translocation across the mitochondrial membranes. Yeast mutant ssc1-2 mitochondria deficient in mtHsp70 unfoldase activity imported the flavinylated Su9-6-HDNO protein. in mutant ssc1-3 mitochondria deficient in both mtHsp70 unfoldase and translocase activity Su9-6-HDNO was trapped as translocation intermediate; the Su9 presequence was passed to the matrix where it was proteolytically cleaved by the mitochondrial processing peptidase; (MPP); the translocation-arrested 6-HDNO moiety adopted a trypsin-sensitive conformation, Our results indicate that unfolding of the FAD-stabilized flavin-binding domain of 6-HDNO in passage through the mitochondrial general insertion pore does not require the activity of mtHsp70.	INST BIOCHEM & MOL BIOL,D-79104 FREIBURG,GERMANY; GESELL BIOTECHNOL FORSCH MBH,D-38124 BRAUNSCHWEIG,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH								BRANDSCH R, 1989, BIOCHEM J, V258, P187, DOI 10.1042/bj2580187; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BUCKMANN AF, 1993, FLAVINS FLAVOPROTEIN, P597; DAUM G, 1982, J BIOL CHEM, V257, P3028; DECKER K, 1991, BIOFACTORS, V3, P69; GAMBILL D, 1993, J CELL BIOL, V12, P3288; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KIM JH, 1994, J BACTERIOL, V176, P6349, DOI 10.1128/jb.176.20.6349-6361.1994; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; MAUCH L, 1989, FEBS LETT, V257, P86, DOI 10.1016/0014-5793(89)81792-2; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MOHLER H, 1972, EUR J BIOCHEM, V29, P152, DOI 10.1111/j.1432-1033.1972.tb01969.x; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; STOLTZ M, 1995, J BIOL CHEM, V270, P8016, DOI 10.1074/jbc.270.14.8016; VOOS, 1996, EMBO J, V15, P2668; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; ZARA V, 1992, J BIOL CHEM, V267, P12077; ZHOU BP, 1995, BIOCHEMISTRY-US, V34, P9526, DOI 10.1021/bi00029a029	23	6	6	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25208	25212		10.1074/jbc.271.41.25208	http://dx.doi.org/10.1074/jbc.271.41.25208			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810280	hybrid			2022-12-25	WOS:A1996VL69300024
J	Bradford, AP; Conrad, KE; Tran, PH; Ostrowski, MC; GutierrezHartmann, A				Bradford, AP; Conrad, KE; Tran, PH; Ostrowski, MC; GutierrezHartmann, A			GHF-1/Pit-1 functions as a cell-specific integrator of Ras signaling by targeting the ras pathway to a composite Ets-1/GHF-1 response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN PROMOTER ACTIVITY; DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; ETS DOMAIN PROTEIN; GENE-EXPRESSION; TRANSCRIPTION FACTOR; C-FOS; TRANSDUCTION PATHWAYS; ACTIVATION DOMAIN; CARCINOMA-CELLS	Activation of the rat prolactin (rPRL) promoter by Ras is a prototypical example of tissue-specific transcriptional regulation in a highly differentiated cell type. Using a series of site specific mutations and deletions of the proximal rPRL promoter we have mapped the major Ras/Raf response element (RRE) to a composite Ets-1/GHF-1 binding site located between positions -217 and -190. Mutation of either the Ets-1 or GHF-1 binding sites inhibits Ras and Raf activation of the rPRL promoter, and insertion of this RRE into the rat growth hormone promoter confers Ras responsiveness. We show that Ets-1 is expressed in GH(4) cells and, consistent with their functional synergistic interaction, both Ets-1 and GHF-1 are able to bind specifically to this bipartite RRE. We confirm that Ets-1 or a related Ets factor is the nuclear target of the Ras pathway leading to activation of the rPRL promoter and demonstrate that Elk-1 and Net do not mediate the Ras response, Thus, the pituitary-specific POU homeodomain transcription factor, GHF-1, serves as a cell-specific signal integrator by functionally interacting with an Ets-1-like factor, at uniquely juxtaposed binding sites, thereby targeting an otherwise ubiquitous Ras signaling pathway to a select subset of cell-specific GHF-1-dependent genes.	UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, PROGRAM MOL BIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, COLORADO CANC CTR, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MED, PROGRAM MOL BIOL, DENVER, CO 80262 USA; OHIO STATE UNIV, DEPT MOL GENET, COLUMBUS, OH 43210 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University System of Ohio; Ohio State University			Gutierrez-Hartmann, Arthur/F-1295-2011; Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297	NIDDK NIH HHS [DK 46868, N43-DK-2-2214] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046868, N43DK022214, R01DK046868] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERWAER M, 1993, MOL CELL ENDOCRINOL, V92, P1, DOI 10.1016/0303-7207(93)90068-U; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; ELSHOLTZ HP, 1992, SEMIN REPROD ENDOCR, V10, P183, DOI 10.1055/s-2007-1018875; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; GALANG CK, 1994, ONCOGENE, V9, P2913; GALIEN R, 1991, ONCOGENE, V6, P849; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GUTIERREZHARTMANN A, 1994, MOL ENDOCRINOL, V8, P1447, DOI 10.1210/me.8.11.1447; GUTIERREZHARTMANN A, 1987, P NATL ACAD SCI USA, V84, P5211, DOI 10.1073/pnas.84.15.5211; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JACOB KK, 1994, J BIOL CHEM, V269, P25515; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KEECH CA, 1991, MOL CELL ENDOCRINOL, V78, P55, DOI 10.1016/0303-7207(91)90185-U; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; KIM MK, 1993, J BIOL CHEM, V268, P23366; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LACAL JC, 1990, MOL CELL BIOL, V10, P2983, DOI 10.1128/MCB.10.6.2983; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; RAJNARAYAN S, 1995, MOL ENDOCRINOL, V9, P502, DOI 10.1210/me.9.4.502; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WERNERT N, 1992, AM J PATHOL, V140, P119; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; Yang BS, 1996, MOL CELL BIOL, V16, P538	72	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24639	24648		10.1074/jbc.271.40.24639	http://dx.doi.org/10.1074/jbc.271.40.24639			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798730	hybrid			2022-12-25	WOS:A1996VM67400052
J	Cui, L; Yu, WP; DeAizpurua, HJ; Schmidli, RS; Pallen, CJ				Cui, L; Yu, WP; DeAizpurua, HJ; Schmidli, RS; Pallen, CJ			Cloning and characterization of islet cell antigen-related protein-tyrosine phosphatase (PTP), a novel receptor-like PTP and autoantigen in insulin-dependent diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMIC-ACID DECARBOXYLASE; VIRULENCE DETERMINANT; TRYPTIC FRAGMENTS; ANTIBODIES; DISTINCT; EXPRESSION; IDDM; SEQUENCE; IA-2; IDENTIFICATION	Cloning of the cDNA encoding a novel human protein-tyrosine phosphatase (PTP) called islet cell antigen-related PTP (IAR) predicts a receptor-like molecule with an extracellular domain of 614 amino acids containing a hydrophobic signal peptide, one potential N-glycosylation site, and an RGDS peptide which is a possible adhesive recognition sequence. The 376-amino acid intracellular region contains a single catalytic domain. Recombinant IAR polypeptide has phosphatase activity. Northern blot analysis shows tissue-specific expression of two IAR transcripts of 5.5 and 3.7 kilobases, which are most abundant in brain and pancreas. The IAR PTP is homologous in its intracellular region to IA-2, a putative PTP that is an insulin-dependent diabetes mellitus (IDDM) autoantigen. IAR is also reactive with IDDM patient sera. IAR and IA-2 may distinguish different populations of IDDM autoantibodies since they identify overlapping but nonidentical sets of IDDM patients. Thus IAR is likely to be an islet cell antigen useful in the preclinical screening of individuals for risk of IDDM.	NATL UNIV SINGAPORE, INST MOL & CELL BIOL, CELL REGULAT LAB, SINGAPORE 117548, SINGAPORE; WALTER & ELIZA HALL INST MED RES, BURNET CLIN RES UNIT, PARKVILLE, VIC 3032, AUSTRALIA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Walter & Eliza Hall Institute				Pallen, Catherine/0000-0002-3576-5295				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BINGLEY PJ, 1994, DIABETES, V43, P1304, DOI 10.2337/diabetes.43.11.1304; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHRISTIE MR, 1993, J CLIN INVEST, V92, P240, DOI 10.1172/JCI116556; CHRISTIE MR, 1990, J EXP MED, V172, P789, DOI 10.1084/jem.172.3.789; CHRISTIE MR, 1994, DIABETES, V43, P1254, DOI 10.2337/diabetes.43.10.1254; CHRISTIE MR, 1992, DIABETES, V41, P782, DOI 10.2337/diabetes.41.7.782; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GENOVESE S, 1994, LANCET, V344, P756, DOI 10.1016/S0140-6736(94)92248-9; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAKES DJ, 1993, P NATL ACAD SCI USA, V90, P4017, DOI 10.1073/pnas.90.9.4017; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KAMBAYASHI Y, 1995, BIOCHEM J, V306, P331, DOI 10.1042/bj3060331; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LU J, 1994, BIOCHEM BIOPH RES CO, V204, P930, DOI 10.1006/bbrc.1994.2549; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; PASSINI N, 1995, P NATL ACAD SCI USA, V92, P9412, DOI 10.1073/pnas.92.20.9412; PAYTON MA, 1995, J CLIN INVEST, V96, P1506, DOI 10.1172/JCI118188; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RABIN DU, 1994, J IMMUNOL, V152, P3183; SCHMIDLI RS, 1994, J AUTOIMMUN, V7, P55, DOI 10.1006/jaut.1994.1005; Schultz Leonard D., 1993, Cell, V73, P1445; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	40	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24817	24823		10.1074/jbc.271.40.24817	http://dx.doi.org/10.1074/jbc.271.40.24817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798755	hybrid			2022-12-25	WOS:A1996VM67400077
J	Flodby, P; Barlow, C; Kylefjord, H; Ahrlund-Richter, L; Xanthopoulos, KG				Flodby, P; Barlow, C; Kylefjord, H; Ahrlund-Richter, L; Xanthopoulos, KG			Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-ALBUMIN GENE; C/EBP-ALPHA; TRANSCRIPTION FACTORS; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; HEPATOCELLULAR-CARCINOMA; LEUCINE ZIPPER; STEM-CELLS; RAT-LIVER; C-MYC	CCAAT/enhancer binding protein alpha (C/EBP alpha) is a transcription factor that has been implicated in the regulation of cell-specific gene expression mainly in hepatocytes and adipocytes but also in several other terminally differentiated cells. It has been previously demonstrated that the C/EBP alpha protein is functionally indispensable, as inactivation of the C/EBP alpha gene by homologous recombination in mice results in the death of animals homozygous for the mutation shortly after birth (Wang, N., Finegold, M. J., Bradley, A., Ou, C. N., Abdelsayed, S. V., Wilde, M. D., Taylor, L. R., Wilson, D. R., and Darlington, G. J. (1995) Science 269, 1108-1112). Here we show that C/EBP alpha-1-mice have defects in the control of hepatic growth and lung development. The liver architecture is disturbed, with acinar formation, in a pattern suggestive of either regenerating liver or pseudoglandular hepatocellular carcinoma. Pulmonary histology shows hyperproliferation of type II pneumocytes and disturbed alveolar architecture. At the molecular level, accumulation of glycogen and lipids in the liver and adipose tissues is impaired, and the mutant animals are severely hypoglycemic. Levels of c-myc and c-jun RNA are specifically induced by several fold in the livers of the C/EBP alpha -/- animals, indicating an active proliferative stage. Furthermore, immunohistologic detection with an antibody to proliferating cell nuclear antigen/cyclin shows a 5-10 times higher frequency of positively stained hepatocytes in C/EBP alpha -/- liver. These results suggest a critical role for C/EBP alpha in vivo for the acquisition of terminally differentiated functions in liver including the maintenance of physiologic energy homeostasis.	KAROLINSKA INST, NOVUM, DEPT BIOSCI, S-14157 HUDDINGE, SWEDEN; CGTB, NATL CTR HUMAN GENOME RES, NIH, BETHESDA, MD 20892 USA	Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Ahrlund-Richter, Lars/C-6226-2012					ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; ANTONSON P, 1995, EUR J BIOCHEM, V232, P397, DOI 10.1111/j.1432-1033.1995.tb20824.x; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FLODBY P, 1995, MOL CARCINOGEN, V12, P103, DOI 10.1002/mc.2940120207; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GRAYSON DR, 1988, SCIENCE, V239, P786, DOI 10.1126/science.3257586; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KUO CF, 1990, DEVELOPMENT, V109, P473; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; LI F, 1995, AM J PHYSIOL, V13, P241; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MAEDA T, 1995, J SURG ONCOL, V60, P75, DOI 10.1002/jso.2930600202; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8224; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCOTT LM, 1992, BLOOD, V80, P1725; SMITH CI, 1995, AM J PHYSIOL-LUNG C, V269, pL603, DOI 10.1152/ajplung.1995.269.5.L603; TAE HJ, 1994, J BIOL CHEM, V269, P10475; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; TONJES RR, 1992, EMBO J, V11, P127, DOI 10.1002/j.1460-2075.1992.tb05035.x; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLET V, 1995, EXP CELL RES, V216, P363, DOI 10.1006/excr.1995.1046; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XANTHOPOULOS KG, 1992, EUR J BIOCHEM, V208, P501, DOI 10.1111/j.1432-1033.1992.tb17214.x; XANTHOPOULOS KG, 1989, P NATL ACAD SCI USA, V86, P4117, DOI 10.1073/pnas.86.11.4117; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	60	250	255	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24753	24760		10.1074/jbc.271.40.24753	http://dx.doi.org/10.1074/jbc.271.40.24753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798745	hybrid			2022-12-25	WOS:A1996VM67400067
J	Mackay, F; Majeau, GR; Hochman, PS; Browning, JL				Mackay, F; Majeau, GR; Hochman, PS; Browning, JL			Lymphotoxin beta receptor triggering induces activation of the nuclear factor beta B transcription factor in some cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS; FACTOR-ALPHA; HETEROMERIC COMPLEX; ENDOTHELIAL-CELLS; MICE DEFICIENT; GROWTH-FACTORS; CROSS-LINKING; TNF RECEPTOR	NF kappa B is a pleiotropic transcription factor capable of activating the expression of a great variety of genes critical for the immunoinflammatory response. Tumor necrosis factor alpha (TNF alpha) and lymphotoxin alpha (LT alpha, originally TNF beta) are potent nuclear factor kappa B (NF kappa B) activators in various cell types. The LT alpha molecule, in addition to being secreted as a soluble trimer, can also form membrane-anchored heterotrimers with the LT beta chain, another member of the TNF family. The LT alpha 1 beta 2 heterotrimer binds a specific receptor, called the LT beta receptor (LT beta-R), which is also a member of the TNF receptor family. Here, we show that engagement of LT beta-R with a soluble form of LT alpha 1 beta 2 or with a specific anti-LT beta-R agonistic monoclonal antibody CBE11 quickly induces activation of NF kappa B in HT-29 and WiDr human adenocarcinomas. LT beta-R triggering activates NF kappa B and induces proliferation in WI-38 human lung fibroblasts. No NF kappa B activation is observed in human umbilical vein endothelial cells, correlating with the inability of LT beta-R activation to induce expression of NF kappa B-dependent cell surface adhesion molecules. Thus, like several other members of the TNF receptor family, the LT beta-R can activate NF kappa B following receptor ligation in some but not all LT beta-R-positive cells.			Mackay, F (corresponding author), BIOGEN INC,DEPT CELL BIOL,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Mackay, Fabienne/B-7440-2008	Mackay, Fabienne/0000-0002-6074-2693; Browning, Jeffrey/0000-0001-9168-5233				AGGARWAL BB, 1995, EXP CELL RES, V218, P381, DOI 10.1006/excr.1995.1169; ALDERSON MR, 1994, INT IMMUNOL, V6, P1799, DOI 10.1093/intimm/6.11.1799; ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; BANKS TA, 1995, J IMMUNOL, V155, P1685; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; Bazzoni F, 1995, J INFLAMM, V45, P221; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BISWAS P, 1995, IMMUNITY, V2, P587; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; CHATURVEDI MM, 1994, LYMPHOKINE CYTOK RES, V13, P309; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRANCIS CA, 1994, J PROD AGRIC, V7, P151, DOI 10.2134/jpa1994.0151; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HESS S, 1995, J IMMUNOL, V155, P4588; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; ISRAEL N, 1989, J IMMUNOL, V143, P3956; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEONARDO M, 1987, SCIENCE, V236, P1573; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; MICHIHIKO S, 1989, LANCET, V1, P1206; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; RENSINGEHL A, 1995, J INFLAMM, V45, P161; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIMADA Y, 1990, J CELL PHYSIOL, V142, P31, DOI 10.1002/jcp.1041420105; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TOTPAL K, 1994, J IMMUNOL, V153, P2248; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175	55	65	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24934	24938		10.1074/jbc.271.40.24934	http://dx.doi.org/10.1074/jbc.271.40.24934			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798772	hybrid			2022-12-25	WOS:A1996VM67400095
J	Ryan, SE; Demers, CN; Chew, JP; Baenziger, JE				Ryan, SE; Demers, CN; Chew, JP; Baenziger, JE			Structural effects of neutral and anionic lipids on the nicotinic acetylcholine receptor - An infrared difference spectroscopy study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; RECONSTITUTED MEMBRANES; POSTSYNAPTIC MEMBRANES; CHOLINERGIC RECEPTOR; TORPEDO-CALIFORNICA; ION-CHANNEL; CHOLESTEROL; BINDING; BACTERIORHODOPSIN; PHOSPHOLIPIDS	The effects of both neutral and anionic lipids on the structure of the nicotinic acetylcholine receptor (nAChR) have been probed using infrared difference spectroscopy, The difference between infrared spectra of the nAChR recorded using the attenuated total reflectance technique in the presence and absence of the neu rotransmitter analog, carbamylcholine, exhibits a complex pattern of positive and negative bands that provides a spectral map of the structural changes that occur in the nAChR upon ligand binding and subsequent desensitization. This spectral map is essentially identical in difference spectra recorded from native, native alkaline-extracted, and affinity purified nAChR reconstituted into either soybean asolectin or egg phosphatidylcholine membranes containing both neutral and anionic lipids, This result suggests both a similar structure of the nAChR and a similar resting to desensitized conformational change in each membrane environment. In contrast, difference spectra recorded from the nAChR reconstituted into egg phosphatidylcholine membranes lacking neutral and/or anionic lipids all exhibit an essentially identical pattern of band intensity variations, which is similar to the pattern of variations observed in difference spectra recorded in the continuous presence of the desensitizing local anesthetic, dibucaine, The difference spectra suggest that the main effect of both neutral and anionic lipids in a reconstituted egg phosphatidylcholine membrane is to help stabilize the nAChR in a resting conformation, In the absence of neutral and/or anionic lipids, the nAChR is converted into an alternate conformation that appears to be analogous to the local anesthetic-induced desensitized state, Significantly, the proportion of receptors found in the resting versus the putative desensitized state appears to be dependent upon the final lipid composition of the reconstituted membrane, A lipid-dependent modulation of the equilibrium between a channel-active resting and channel-inactive desensitized state may account for the modulations of nAChR activity that are observed in different lipid membranes.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1H 8M5,CANADA	University of Ottawa				Baenziger, John/0000-0002-2888-5328				AUGER M, 1990, J AM CHEM SOC, V112, P1373, DOI 10.1021/ja00160a013; Baenziger J. E., 1995, Biophysical Journal, V68, pA377; BAENZIGER JE, 1992, BIOPHYS J, V61, P983, DOI 10.1016/S0006-3495(92)81905-7; BAENZIGER JE, 1992, BIOPHYS J, V62, P64, DOI 10.1016/S0006-3495(92)81780-0; BAENZIGER JE, 1993, BIOCHEMISTRY-US, V32, P5448, DOI 10.1021/bi00071a022; BHUSHAN A, 1993, BIOPHYS J, V64, P716, DOI 10.1016/S0006-3495(93)81431-0; BLANCHARD SG, 1979, BIOCHEMISTRY-US, V18, P5880, DOI 10.1021/bi00593a019; BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5344, DOI 10.1021/bi00564a031; BRAIMAN MS, 1994, BIOCHEMISTRY-US, V33, P1629, DOI 10.1021/bi00173a003; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; BRASWELL LM, 1984, BRIT J PHARMACOL, V83, P305, DOI 10.1111/j.1476-5381.1984.tb10147.x; BUTLER DH, 1993, BIOCHIM BIOPHYS ACTA, V1150, P17, DOI 10.1016/0005-2736(93)90116-H; CRIADO M, 1984, J BIOL CHEM, V259, P9188; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; FERNANDEZBALLESTER G, 1994, BIOCHEMISTRY-US, V33, P4065, DOI 10.1021/bi00179a035; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; GREGORIOU VG, 1995, BIOCHEMISTRY-US, V34, P6876, DOI 10.1021/bi00020a035; HIENERWADEL R, 1995, BIOCHEMISTRY-US, V34, P2832, DOI 10.1021/bi00009a013; HORVATH LI, 1988, BIOCHEMISTRY-US, V27, P46, DOI 10.1021/bi00401a009; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KRODEL EK, 1979, MOL PHARMACOL, V15, P294; LUDLAM CFC, 1995, BIOCHEMISTRY-US, V34, P2, DOI 10.1021/bi00001a001; MARCELJA S, 1974, BIOCHIM BIOPHYS ACTA, V367, P165, DOI 10.1016/0005-2736(74)90040-6; Marsh D., 1982, LIPID PROTEIN INTERA, V2, P53; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; McNamee M., 1988, LIPID DOMAINS RELATI, P43; METHOT N, 1995, BIOCHEMISTRY-US, V34, P15142, DOI 10.1021/bi00046a021; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; MOORE MA, 1994, BBA-BIOMEMBRANES, V1190, P457, DOI 10.1016/0005-2736(94)90108-2; OCHOA ELM, 1983, BIOCHIM BIOPHYS ACTA, V727, P151, DOI 10.1016/0005-2736(83)90379-6; RAINES DE, 1993, BIOPHYS J, V64, P32; Reid SE, 1996, SPECTROCHIM ACTA A, V52, P1347, DOI 10.1016/0584-8539(96)01718-7; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; SALMON A, 1987, J AM CHEM SOC, V109, P2600, DOI 10.1021/ja00243a010; SUNSHINE C, 1992, BIOCHIM BIOPHYS ACTA, V1108, P240, DOI 10.1016/0005-2736(92)90031-G; SUNSHINE C, 1994, BBA-BIOMEMBRANES, V1191, P59, DOI 10.1016/0005-2736(94)90233-X; WEILAND G, 1977, J BIOL CHEM, V252, P7648	39	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24590	24597		10.1074/jbc.271.40.24590	http://dx.doi.org/10.1074/jbc.271.40.24590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798723	hybrid			2022-12-25	WOS:A1996VM67400045
J	Takashima, S; Klagsbrun, M				Takashima, S; Klagsbrun, M			Inhibition of endothelial cell growth by macrophage-like U-937 cell-derived oncostatin M, leukemia inhibitory factor, and transforming growth factor beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR; MOLECULAR-CLONING; SIGNAL TRANSDUCER; FORMATION INVITRO; EXPRESSION; ANGIOGENESIS; RECEPTOR; NEOVASCULARIZATION; PROLIFERATION; GP130	Conditioned media were collected from phorbol ester-treated human macrophage-like U-937 cells and analyzed for the presence of inhibitors of endothelial cell (EC) proliferation. By a combination of ion exchange and reverse-phase liquid chromatography, three inhibitors were purified to homogeneity as ascertained by microsequencing of 14-17 N-terminal amino acids. These inhibitors were identified as oncostatin M (OSM), leukemia inhibitory factor (LIF), and transforming growth factor beta 1 (TGF-beta 1). The identities of the three EC growth inhibitors were confirmed by demonstrating that recombinant human OSM, LIF, and TGF-beta 1 were inhibitory in the same concentration range. Inhibition of EC proliferation by OSM was a newly described property of this cytokine. OSM was the most potent inhibitor with a half-maximal inhibition by recombinant material of 0.15-.2 ng/ml compared with 0.6-0.9 and 0.9-1.0 ng/ml for LIF and TGF-beta 1, respectively. The three factors inhibited basal, vascular endothelial cell growth factor-stimulated, and fibroblast growth factor 2-stimulated EC proliferation. Interleukin-6 and ciliary neurotrophic factor, two cytokines related structurally to OSM and LIF, were not active as EC growth inhibitors. It was concluded that macrophage-like cells secrete a variety of potent EC growth inhibitors and that one of these, OSM, is among the most potent EC growth inhibitors yet reported.	CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NCI NIH HHS [P01 CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1986, J CELL PHYSIOL, V126, P312, DOI 10.1002/jcp.1041260223; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BESNER GE, 1991, MICROVASC RES, V42, P187, DOI 10.1016/0026-2862(91)90086-Q; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DODGE AB, 1993, J CELL BIOCHEM, V53, P21, DOI 10.1002/jcb.240530104; FERRARA N, 1992, P NATL ACAD SCI USA, V89, P698, DOI 10.1073/pnas.89.2.698; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1987, J CELL BIOL, V104, P689, DOI 10.1083/jcb.104.3.689; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; HARRIS PE, 1985, CANCER RES, V45, P9; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH AE, 1986, J LEUKOCYTE BIOL, V39, P233, DOI 10.1002/jlb.39.2.233; LAEMMLI UK, 1980, NATURE, V277, P680; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MAJEWSKI S, 1985, ARCH DERMATOL, V121, P1018, DOI 10.1001/archderm.121.8.1018; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MALIK N, 1995, MOL CELL BIOL, V15, P2349; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NGUYEN M, 1992, J BIOL CHEM, V267, P26157; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; POLVERINI PJ, 1984, LAB INVEST, V51, P635; REID IR, 1990, ENDOCRINOLOGY, V126, P1416, DOI 10.1210/endo-126-3-1416; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P997, DOI 10.1016/0006-291X(87)90350-0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; THOMA B, 1994, J BIOL CHEM, V269, P6215; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; VANOBBERGHENSCHILLING E, 1987, MOL ENDOCRINOL, V1, P693, DOI 10.1210/mend-1-10-693; YIN TG, 1994, J BIOL CHEM, V269, P3731; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	55	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24901	24906		10.1074/jbc.271.40.24901	http://dx.doi.org/10.1074/jbc.271.40.24901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798767	hybrid			2022-12-25	WOS:A1996VM67400090
J	Chang, JY; Xia, WY; Shao, RP; Hung, MC				Chang, JY; Xia, WY; Shao, RP; Hung, MC			Inhibition of intratracheal lung cancer development by systemic delivery of E1A	ONCOGENE			English	Article						EIA; HER-2/neu; gene therapy; adenoviral vector; lung cancer	GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; GENE-THERAPY; ADENOVIRUS TYPE-5; CYSTIC-FIBROSIS; OVARIAN-CANCER; SMALL-CELL; EXPRESSION; OVEREXPRESSION; METASTASIS	Amplification or overexpression of HER-2/neu in human lung cancer has been correlated with poor prognosis and chemoresistance, We have previously reported that the adenovirus type 5 early region 1A (E1A) gene product can suppress HER-2/neu-mediated transformation phenotypes through inhibition of HER-2/neu expression. To find an efficient way to treat HER-2/neu-overexpressing lung cancer with ELA, a replication-deficient adenovirus containing the E1A gene, Ad.E1A(+), was used to transduce E1A into HER-2/neu-overexpressing and low expressing human lung cancer cell lines, Tumour cell growth in vitro and colony formation in soft agarose were greatly inhibited by Ad.E1A(+) transduction in HER-2/neu-overexpressing lung cancer cell lines, In HER-2/neu low expressing cell lines, E1A could not inhibit cell growth in vitro but could reduce the colony formation ability in soft agarose, indicating different effects of E1A in these two types of cancer cells. To test the therapeutic efficacy of E1A to lung cancer by systemic delivery in vivo, tumor-bearing mice were established by intratracheal injection of lung cancer cells and treated by i.v. tail injections of Ad.E1A(+). As a result, Ad.E1A(+) suppressed HER-2/neu overexpression and inhibited intratracheal lung cancer growth. However, no significant tumor suppression effect of Ad.E1A(+) was observed in mice bearing HER-2/neu low expressing cell line when the same therapeutic procedure was followed, Thus, we conclude that systemic delivery of Ad.E1A(+) can efficiently achieve therapeutic effect in HER-2/neu-overexpressing lung cancer in vivo.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01-CA60856, R01-CA58880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880, R01CA060856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; BYRD PJ, 1988, ONCOGENE, V2, P477; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVENPORT EA, 1988, ANTICANCER RES, V8, P957; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1995, CANCER RES, V55, P5551; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Graham FL, 1991, METHOD MOL BIOL, P109; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KERN JA, 1990, CANCER RES, V50, P5284; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; Minna JD, 1989, CANCER PRINCIPLES PR, P591; PERERA FP, 1991, ORIGINS OF HUMAN CANCER, P219; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WEINBERG RA, 1989, CANCER RES, V49, P3713; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; ZHANG YJ, 1995, ONCOGENE, V10, P2263	38	26	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1405	1412						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875978				2022-12-25	WOS:A1996VL38400005
J	Coppee, F; Gerard, AC; Denef, JF; Ledent, C; Vassart, G; Dumont, JE; Parmentier, M				Coppee, F; Gerard, AC; Denef, JF; Ledent, C; Vassart, G; Dumont, JE; Parmentier, M			Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene	ONCOGENE			English	Article						thyroid cancer; metastatic tumors; hyperthyroidism; cyclic AMP cascade; E7 oncogene; transgenic model	FIBROBLAST GROWTH-FACTOR; TISSUE-SPECIFIC EXPRESSION; INVASIVE BREAST-CARCINOMA; THYROTROPIN RECEPTOR; TUMOR-GROWTH; THYROGLOBULIN GENE; CELL GROWTH; CYCLIC-AMP; ANGIOGENESIS; MUTATIONS	We report here the characterization of a transgenic mouse model (Tg-A2aR/Tg-E7) resulting from the coexpression of tao oncogenic transgenes in the thyroid, The two transgenes (Tg-A2aR and Tg-E7) were placed under control of the thyroid specific thyroglobulin gene promoter, and directed the expression of either the A2a adenosine receptor that constitutively activates the cAMP pathway, or the E7 protein of the human papillomavirus type 16, that binds and inactivates the retinoblastoma susceptibility gene product (Rbl), Transgenic mice expressing both transgenes were generated by interbreeding the Tg-A2aR and Tg-E7 transgenic lines, generated and characterized previously (Ledent et al., 1992, 1995), These mice develop a larger goiter than that of the two parental lines, and a severe hyperthyroidism comparable to that observed in the Tg-A2aR parental Line, The main feature of the Tg-A2aR/Tg-E7 mice is the rapid occurrence of malignant lesions, and the dissemination of malignant thyroid tissue through the blood stream, generating multiple differentiated and functional metastases in the lung, These metastases appeared as early as 2 months after birth and their frequency increased to 75% over 3 months, They were associated with the presence of large vascular lakes in the thyroid, Electron microscopy of the malignant cells revealed nuclear features similar to those of human thyroid papillary carcinoma, These mice, in which two oncogenes are co-expressed in the thyroid, represent the first genetic animal model developing metastatic differentiated carcinomas of the thyroid with a high frequency.	UNIV CATHOLIQUE LOUVAIN, SERV HISTOL, B-1200 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, SERV GENET MED, B-1070 BRUSSELS, BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Coppee, F (corresponding author), FREE UNIV BRUSSELS, IRIBHN, CAMPUS ERASME, 808 ROUTE LENNIK, B-1070 BRUSSELS, BELGIUM.			Parmentier, Marc/0000-0001-8081-4685				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ASANO M, 1995, CANCER RES, V55, P5296; BECHTNER G, 1993, ACTA ENDOCRINOL-COP, V129, P458, DOI 10.1530/acta.0.1290458; BERNS A, 1989, INT J CANCER, P22; BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; BOSSI P, 1995, CANCER RES, V55, P5049; BREUER M, 1991, RADIAT ENVIRON BIOPH, V30, P181, DOI 10.1007/BF01226614; CHRISTOPHE D, 1990, TRENDS ENDOCRIN MET, V1, P351, DOI 10.1016/1043-2760(90)90083-F; COLIN IM, 1995, ENDOCRINOLOGY, V136, P5283, DOI 10.1210/en.136.12.5283; DAA T, 1993, ACTA PATHOL JAPON, V43, P582; DENEF JF, 1981, ENDOCRINOLOGY, V108, P2352, DOI 10.1210/endo-108-6-2352; Dumont J E, 1971, Vitam Horm, V29, P287; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; EMOTO N, 1991, ENDOCRINOLOGY, V128, P58, DOI 10.1210/endo-128-1-58; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FEIBERG AP, 1983, ANAL BIOCHEM, V132, P6; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; GREIL W, 1989, MOL ENDOCRINOL, V3, P858, DOI 10.1210/mend-3-5-858; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GUIDI AJ, 1994, J NATL CANCER I, V86, P614, DOI 10.1093/jnci/86.8.614; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HARVEY M, 1995, CANCER RES, V55, P1146; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAENHAUT C, 1992, J BIOL CHEM, V267, P3000; NEVINS JR, 1992, SCIENCE, V258, P424; NUNEZ J, 1982, VITAM HORM, V39, P175, DOI 10.1016/S0083-6729(08)61137-1; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RANGASWAMY M, 1989, NUCL MED COMMUN, V10, P679, DOI 10.1097/00006231-198909000-00007; ROBBINS J, 1991, ANN INTERN MED, V115, P133, DOI 10.7326/0003-4819-115-2-133; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; SCHERBERG NH, 1981, ENDOCRINOLOGY, V109, P1650, DOI 10.1210/endo-109-5-1650; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUAREZ HG, 1991, ONCOGENE, V6, P677; THOMAS GA, 1989, AM J PATHOL, V134, P141; THOMAS GA, 1991, BRIT J CANCER, V63, P213, DOI 10.1038/bjc.1991.51; USUKI K, 1989, P NATL ACAD SCI USA, V86, P7427, DOI 10.1073/pnas.86.19.7427; VANHEUVERSWYN B, 1984, P NATL ACAD SCI-BIOL, V81, P5941; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WILLIAMS ED, 1992, TOXICOL LETT, V64-5, P375, DOI 10.1016/0378-4274(92)90210-B; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; WOEBER KA, 1991, MED CLIN N AM, V75, P169, DOI 10.1016/S0025-7125(16)30477-1; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	65	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1471	1482						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875985				2022-12-25	WOS:A1996VL38400012
J	Florio, SK; Prusti, RK; Beavo, JA				Florio, SK; Prusti, RK; Beavo, JA			Solubilization of membrane-bound rod phosphodiesterase by the rod phosphodiesterase recombinant delta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR CGMP PHOSPHODIESTERASE; CYCLIC-GMP PHOSPHODIESTERASE; ACID-BINDING PROTEIN; SEQUENCING PLASMID DNA; OUTER SEGMENTS; SMALL GTPASES; BETA-SUBUNIT; RETINAL RODS; CHICK RETINA; RAB GTPASES	Retinal rod and cone phosphodiesterases are oligomeric enzymes that consist of a dimeric catalytic core (alpha'(2) in cones and alpha beta in rods) with inhibitory subunits (gamma) that regulate their activity. In addition, a 17-kDa protein referred to as the delta subunit co-purifies with the rod soluble phosphodiesterase and the cone phosphodiesterase. We report here partial protein sequencing of the rod delta subunit and isolation of a cDNA clone encoding it. The predicted amino acid sequence is unrelated to any other known protein. Of eight bovine tissue mRNA preparations examined by Northern analysis, the strongest delta subunit-specific signal was present in the retina. A less intense signal was seen in the brain and adrenal mRNA. In bovine retinal sections, rod delta subunit anti peptide antibodies label rod but not cone outer segments, delta sub unit, added back to washed outer segment membranes, solubilizes a large fraction of the membrane-bound phosphodiesterase, indicating that this subunit binds to the classical membrane associated phosphodiesterase. The subunit forms a tight complex with native, but not trypsin-released phosphodiesterase, suggesting that the isoprenylated carboxyl termini of the catalytic subunits may be involved in binding of the delta subunit to the phosphodiesterase holoenzyme.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NEI NIH HHS [EY 08197] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008197] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANANT JS, 1992, J BIOL CHEM, V267, P687; ANDERSEN AS, 1992, BIOTECHNIQUES, V13, P678; ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; Ausubel F.M, 1992, CURRENT PROTOCOLS MO, V1; BEAVO JA, 1970, J BIOL CHEM, V245, P5649; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARCAMO B, 1995, J NEUROCHEM, V65, P1085; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS C, 1992, GENOMICS, V13, P698, DOI 10.1016/0888-7543(92)90144-H; DUMKE CL, 1994, J GEN PHYSIOL, V103, P1071, DOI 10.1085/jgp.103.6.1071; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GODBOUT R, 1995, EXP EYE RES, V60, P645, DOI 10.1016/S0014-4835(05)80006-5; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; Harlow E., 1988, ANTIBODIES LAB MANUA; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HURWITZ RL, 1984, J BIOL CHEM, V259, P8612; HURWITZ RL, 1985, J BIOL CHEM, V260, P568; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; KONG HM, 1993, J BIOL CHEM, V268, P1965; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; QIN N, 1992, J BIOL CHEM, V267, P8458; QIN N, 1994, J BIOL CHEM, V269, P3265; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; SELLNER P, 1994, DEV DYNAM, V200, P333, DOI 10.1002/aja.1002000408; SELLNER P, 1994, INVEST OPHTH VIS SCI, V35, P443; SHIVELY JE, 1986, METHODS PROTEIN MICR; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; SWANSON RJ, 1983, J BIOL CHEM, V258, P599; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKAI Y, 1993, CIBA F SYMP, V176, P128; TRONG HL, 1990, BIOCHEMISTRY-US, V29, P10280, DOI 10.1021/bi00496a018; UHL R, 1987, J BIOCHEM BIOPH METH, V14, P127, DOI 10.1016/0165-022X(87)90015-7; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	59	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24036	24047		10.1074/jbc.271.39.24036	http://dx.doi.org/10.1074/jbc.271.39.24036			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798640	hybrid			2022-12-25	WOS:A1996VJ44200069
J	Park, YK; Li, H; Kemper, B				Park, YK; Li, H; Kemper, B			Phenobarbital induction mediated by a distal CYP2B2 sequence in rat liver transiently transfected in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; PROTEIN-BINDING; MESSENGER-RNAS; REPORTER GENE; 2B2 GENE; DNA; CYTOCHROME-P-450; PROMOTER	The promoter activities of the genes for cytochrome P450 2B1 (CYP2B1) and cytochrome P450 2C1 (CYP2C1) have been assayed by direct injection of promoter-luciferase chimeric genes into rat liver, Activities of minimal promoters for CYP2C1 and CYP2B1 were detectable in untreated animals but were not increased by treatment of the animals with phenobarbital. After insertion to the 5' side of the minimal promoters of one to three copies of the CYP2B2 sequence from -2318 to -2155, a phenobarbital-responsive element in primary hepatocyte cultures (Trottier, E., Belzil, A., Stoltz, C., and Anderson, A. (1995) Gene (Amst.) 158, 263-268), phenobarbital treatment induced the activity of the CYP2C1 promoter by 5-15-fold and the CYP2B1 promoter by 2.5-5-fold. Mutation of a basal transcription element-like motif and a CCAAT/enhancer binding protein element in the CYP2B1 proximal promoter region reduced expression, but 3-4-fold induction by phenobarbital was retained. Mutation of the ''Barbie box,'' a putative phenobarbital-responsive element (He, J.-S., and Fulco, A. J. (1991) J. Biol. Chem. 266, 7864-7869) in the CYP2B1 proximal promoter did not reduce the relative response to phenobarbital. These results demonstrate that direct injection of DNA into rat liver may be used to assay phenobarbital responsiveness of cytochrome P450 genes. In this system, a distal CYP2B2 element mediates a response to phenobarbital, and proximal elements, including the Barbie box, are not required for the induction.	COLL MED URBANA CHAMPAIGN,DEPT MOL & INTEGRAT PHYS,URBANA,IL 61801; COLL MED URBANA CHAMPAIGN,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADESNIK M, 1981, J BIOL CHEM, V256, P340; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHEN D, 1994, DNA CELL BIOL, V13, P771, DOI 10.1089/dna.1994.13.771; FOURNIER T, 1994, J BIOL CHEM, V269, P27175; GONZALEZ FJ, 1982, J BIOL CHEM, V257, P5962; HAHN CN, 1991, J BIOL CHEM, V266, P17031; HE JS, 1991, J BIOL CHEM, V266, P7864; Hoffmann Marcel, 1992, Gene Expression, V2, P353; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; LUBET RA, 1992, BIOCHEM PHARMACOL, V43, P1067, DOI 10.1016/0006-2952(92)90614-O; Luc PV, 1996, BIOCHEM PHARMACOL, V51, P345, DOI 10.1016/0006-2952(95)02190-6; MALONE RW, 1994, J BIOL CHEM, V269, P29903; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; OMIECINSKI CJ, 1986, NUCLEIC ACIDS RES, V14, P1525, DOI 10.1093/nar/14.3.1525; Park Y, 1996, DNA CELL BIOL, V15, P693, DOI 10.1089/dna.1996.15.693; PHILLIPS IR, 1983, GENE, V24, P41; PRABHU L, 1995, P NATL ACAD SCI USA, V92, P9628, DOI 10.1073/pnas.92.21.9628; RAM N, 1995, ARCH BIOCHEM BIOPHYS, V317, P39, DOI 10.1006/abbi.1995.1133; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RAO MV, 1990, J BIOL CHEM, V265, P5617; REMMER H, 1958, NATURWISSENSCHAFTEN, V45, P189, DOI 10.1007/BF00621338; SHEPHARD EA, 1994, DNA CELL BIOL, V13, P793, DOI 10.1089/dna.1994.13.793; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; UPADHYA P, 1992, NUCLEIC ACIDS RES, V20, P557, DOI 10.1093/nar/20.3.557; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577	30	92	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23725	23728		10.1074/jbc.271.39.23725	http://dx.doi.org/10.1074/jbc.271.39.23725			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798596				2022-12-25	WOS:A1996VJ44200025
J	Schneikert, J; Peterziel, H; Defossez, PA; Klocker, H; deLaunoit, Y; Cato, ACB				Schneikert, J; Peterziel, H; Defossez, PA; Klocker, H; deLaunoit, Y; Cato, ACB			Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; COLLAGENASE GENE; MESSENGER-RNA; C-JUN; STROMELYSIN PROMOTER; HUMAN ENDOMETRIUM; AP-1 SITE	Matrix metalloproteinases belong to a family of structurally related enzymes that plays important role in tissue morphogenesis, differentiation, and wound healing. Their expression is negatively regulated by several members of the steroid hormone receptor family. This is thought to occur through interaction of the steroid receptors with the transcription factor AP-1 that is otherwise required for positive regulation. Here, we demonstrate that AP-1 is not always a target for downregulation of expression of matrix metalloproteinases by steroid receptors, Androgen receptor negatively regulates matrix metalloproteinase-1 expression not through AP-1 but through a family of Ets-related transcription factors that are also required for positive regulation. This negative regulation is specific for the androgen receptor. It does not require the DNA binding activity but needs amino terminal sequences of the receptor. These results identify a novel regulatory pathway for negative regulation utilized by a member of the steroid hormone receptor family for down-regulating the expression of matrix metalloproteinases.	FORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY; INST PASTEUR, CNRS, URA 1160, UNITE ONCOL MOL, F-59019 LILLE, FRANCE; UNIV INNSBRUCK, DEPT UROL, A-6020 INNSBRUCK, AUSTRIA	Helmholtz Association; Karlsruhe Institute of Technology; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Innsbruck			Klocker, Helmut/AAI-7130-2020; Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834; Defossez, Pierre-Antoine/0000-0002-6463-9263				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; AUER HP, 1995, THESIS U KARLSRUHE K; BEITEL LK, 1994, HUM MOL GENET, V3, P21, DOI 10.1093/hmg/3.1.21; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BRUNER KL, 1995, P NATL ACAD SCI USA, V92, P7362, DOI 10.1073/pnas.92.16.7362; CHATTERJEE B, 1987, J BIOL CHEM, V262, P822; CLAY CM, 1993, J BIOL CHEM, V268, P13556; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crepieux Pascale, 1993, Gene Expression, V3, P215; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GACK S, 1994, J BIOL CHEM, V269, P10363; GAST A, 1995, MOL CELL ENDOCRINOL, V111, P93, DOI 10.1016/0303-7207(95)03554-K; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAHN SL, 1994, ONCOGENE, V9, P2499; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KASPAR F, 1993, MOL CELL BIOL, V13, P7850, DOI 10.1128/MCB.13.12.7850; Knox JD, 1996, MOL CARCINOGEN, V15, P57; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Laget MP, 1996, ONCOGENE, V12, P1325; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; MARCELLI M, 1991, J CLIN INVEST, V87, P1123, DOI 10.1172/JCI115076; MARIOTTI A, 1981, ENDOCRINOLOGY, V109, P837, DOI 10.1210/endo-109-3-837; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCDONNELL S, 1994, BIOCHEM SOC T, V22, P58, DOI 10.1042/bst0220058; METSIS M, 1992, GENE, V121, P247, DOI 10.1016/0378-1119(92)90128-C; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MUNTZING J, 1980, Prostate, V1, P71, DOI 10.1002/pros.2990010110; NAGEL RB, 1994, J CELL BIOCHEM, V19, P232; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NEBL G, 1994, J BIOL CHEM, V269, P7371; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OIKARINEN A, 1993, J INVEST DERMATOL, V101, P205, DOI 10.1111/1523-1747.ep12363823; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; SCHNEIKERT J, 1991, THESIS L PASTEUR U S; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; STAUBER C, 1992, NEW BIOL, V4, P527; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WILSON MJ, 1991, BIOL REPROD, V44, P776, DOI 10.1095/biolreprod44.5.776; WILSON MJ, 1992, BIOL REPROD, V47, P683, DOI 10.1095/biolreprod47.5.683; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	62	136	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23907	23913		10.1074/jbc.271.39.23907	http://dx.doi.org/10.1074/jbc.271.39.23907			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798622	hybrid			2022-12-25	WOS:A1996VJ44200051
J	Hateboer, G; Hijmans, EM; Nooij, JBD; Schlenker, S; Jentsch, S; Bernards, R				Hateboer, G; Hijmans, EM; Nooij, JBD; Schlenker, S; Jentsch, S; Bernards, R			mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; E1A PROTEINS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; E1A-ASSOCIATED PROTEIN; NEGATIVE MODULATION; MOLECULAR-CLONING; TERMINAL DOMAIN; DEGRADATION	Adenovirus E1A encodes two nuclear phosphoproteins that can transform primary rodent fibroblasts in culture, Transformation by E1A is mediated at least in part through binding to several cellular proteins, including the three members of the retinoblastoma family of growth inhibitory proteins, We report here the cloning of a novel murine cDNA whose encoded protein interacts with both adenovirus type 5 and type 12 E1A proteins. The novel E1A-interacting protein shares significant sequence homology with ubiquitin-conjugating enzymes, a family of related proteins that is involved in the proteasome-mediated proteolysis of short-lived proteins. Highest homology was seen with a Saccharomyces cerevisiae protein named UBC9. importantly, the murine E1A-interacting protein complements a cell cycle defect of a S, cerevisiae mutant which harbors a temperature-sensitive mutation in UBC9, me therefore named this novel E1A-interacting protein mUBC9. We mapped the region of E1A that is required for mUBC9 binding and found that the transformation-relevant conserved region 2 of E1A is required for interaction.	NETHERLANDS CANC INST, DIV MOL CARCINOGENESIS, NL-1066 CX AMSTERDAM, NETHERLANDS; UNIV HEIDELBERG, ZENTRUM MOL BIOL, D-69120 HEIDELBERG, GERMANY	Netherlands Cancer Institute; Ruprecht Karls University Heidelberg				Bernards, Rene/0000-0001-8677-3423				ALKHODAIRY F, 1995, J CELL SCI, V108, P475; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRANTON PE, 1985, J VIROL, V56, P633, DOI 10.1128/JVI.56.2.633-638.1985; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; ISHIOKA C, 1995, ONCOGENE, V10, P841; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHENK T, 1991, ADV CANCER RES, V57, P47; SIMON R, 1990, MOL CELL BIOL, V10, P5609, DOI 10.1128/MCB.10.11.5609; SLAVICEK JM, 1988, EMBO J, V7, P3171, DOI 10.1002/j.1460-2075.1988.tb03184.x; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Watanabe TK, 1996, CYTOGENET CELL GENET, V72, P86, DOI 10.1159/000134169; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	61	66	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25906	25911		10.1074/jbc.271.42.25906	http://dx.doi.org/10.1074/jbc.271.42.25906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824223	Green Published, hybrid			2022-12-25	WOS:A1996VN18000029
J	Johansson, M; vonHeijne, G				Johansson, M; vonHeijne, G			Membrane topology of Kch, a putative K+ channel from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; PROTEIN TOPOLOGY; LEADER PEPTIDASE; FUSIONS; HYDROPHOBICITY	We have mapped the topology of the C-terminal half of the putative potassium channel protein Kch in the inner membrane of Escherichia coli using PhoA fusions. Our results are consistent with the widely assumed six-transmembrane helix model for eukaryotic voltage-gated ion channels and place both ends of the proposed channel-lining P-segment on the periplasmic side of the inner membrane. The rather hydrophobic P-segment is found to translocate only slowly across the inner membrane and seems to be near a threshold for stop-transfer function.	UNIV STOCKHOLM, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN	Stockholm University			von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				BEZANILLA F, 1994, ANNU REV BIOPH BIOM, V23, P819, DOI 10.1146/annurev.bb.23.060194.004131; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; HENN DK, 1995, P NATL ACAD SCI USA, V92, P7425, DOI 10.1073/pnas.92.16.7425; HENNESSEY ES, 1993, CURR OPIN STRUC BIOL, V3, P524, DOI 10.1016/0959-440X(93)90078-Y; HENNESSEY ES, 1993, FEBS LETT, V331, P159, DOI 10.1016/0014-5793(93)80317-N; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; LEE E, 1994, J BIOL CHEM, V269, P28822; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; MONTAL M, 1995, ANNU REV BIOPH BIOM, V24, P31, DOI 10.1146/annurev.bb.24.060195.000335; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WHITLEY P, 1994, NAT STRUCT BIOL, V1, P858, DOI 10.1038/nsb1294-858	19	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25912	25915		10.1074/jbc.271.42.25912	http://dx.doi.org/10.1074/jbc.271.42.25912			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824224	hybrid			2022-12-25	WOS:A1996VN18000030
J	Boorer, KJ; Loo, DDF; Frommer, WB; Wright, EM				Boorer, KJ; Loo, DDF; Frommer, WB; Wright, EM			Transport mechanism of the cloned potato H+/sucrose cotransporter StSUT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; BETA-VULGARIS L; NA+ GLUCOSE COTRANSPORTER; SUCROSE-H+ SYMPORTER; ELECTROGENIC PROPERTIES; ARABIDOPSIS-THALIANA; XENOPUS-OOCYTES; VOLTAGE-CLAMP; LEAF TISSUES; PHLOEM	The transport mechanism of the potato StSUT1 H+/sucrose cotransporter expressed in Xenopus oocytes was investigated using the 2-electrode voltage clamp and radiotracer flux methods. Sucrose induced inward currents through the transporter that were dependent on the extracellular sucrose and H+ concentrations and the membrane voltage. The activation of StSUT1 by H+ and sucrose displayed Michaelis-Menten-type kinetics suggestive of a 1:1 H+:sucrose stoichiometry. This was confirmed by simultaneously measuring inward currents and sucrose flux in voltage-clamped oocytes. The apparent affinities K-0.5 for H+ and sucrose were voltage-dependent, At -150 mV K-0.5(suc) was 0.5 +/- 0.07 mM at 10 mu M H-o(+) and K-0.5(H) was 0.1 +/- 0.05 mu M at 20 mM sucrose(o). StSUT1 exhibited presteady-state transient currents, which relaxed with time constants between <1 and 4 ms and fitted to the Boltzmann equation: maximum charge transfer Q(max) approximate to 1.8 nanocoulombs; apparent valence z approximate to 1; potential for 50% charge transfer V-0.5 approximate to -15 mV at 0.032 mu M H-o(+) and -45 mV at 10 mu M H-o(+). The steady state data were used to formulate a kinetic model for sucrose transport, and computer simulations were performed to obtain rate constants for the partial reaction steps. Our model is consistent with protons binding to StSUT1 before sucrose with both ligands transported simultaneously across the membrane.	UNIV TUBINGEN, INST BOT, D-72076 TUBINGEN, GERMANY	Eberhard Karls University of Tubingen	Boorer, KJ (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, 10833 LE CONTE AVE, LOS ANGELES, CA 90095 USA.		Frommer, Wolf B/K-5042-2017; Frommer, Wolf B/A-8256-2008	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115	NIDDK NIH HHS [DK 19567] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOORER KJ, 1994, J BIOL CHEM, V269, P20417; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; BUCKHOUT TJ, 1989, PLANTA, V178, P393, DOI 10.1007/BF00391867; BUCKHOUT TJ, 1994, PLANT PHYSIOL, V106, P991, DOI 10.1104/pp.106.3.991; BUSH DR, 1990, PLANT PHYSIOL, V93, P1590, DOI 10.1104/pp.93.4.1590; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; BUSH DR, 1989, PLANT PHYSIOL, V89, P1318, DOI 10.1104/pp.89.4.1318; DELROT S, 1981, PLANT PHYSIOL, V67, P560, DOI 10.1104/pp.67.3.560; DELROT S, 1981, PLANT PHYSIOL, V68, P706, DOI 10.1104/pp.68.3.706; FROMM J, 1989, PLANT PHYSIOL BIOCH, V27, P577; GAHRTZ M, 1994, PLANT J, V6, P697, DOI 10.1046/j.1365-313X.1994.6050697.x; GALLI A, 1995, J EXP BIOL, V198, P2197; GRIGNON C, 1991, ANNU REV PLANT PHYS, V42, P103, DOI 10.1146/annurev.pp.42.060191.000535; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MAYNARD JW, 1982, PLANT PHYSIOL, V70, P1436, DOI 10.1104/pp.70.5.1436; MAYNARD JW, 1982, PLANT PHYSIOL, V69, P734, DOI 10.1104/pp.69.3.734; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; RIESMEIER JW, 1994, EMBO J, V13, P1; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; RIESMEIER JW, 1993, PLANT CELL, V5, P1591, DOI 10.1105/tpc.5.11.1591; SAUER N, 1994, PLANT J, V6, P67, DOI 10.1046/j.1365-313X.1994.6010067.x; SLONE JH, 1991, PLANTA, V183, P584, DOI 10.1007/BF00194280; STADLER R, 1995, PLANT CELL, V7, P1545, DOI 10.1105/tpc.7.10.1545; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; VANBEL AJE, 1994, PLANTA, V192, P165, DOI 10.1007/BF01089031; WILLIAMS LE, 1992, PLANTA, V186, P541, DOI 10.1007/BF00198034; WILLIAMS LE, 1990, PLANTA, V182, P532, DOI 10.1007/BF02341028	30	103	110	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25139	25144		10.1074/jbc.271.41.25139	http://dx.doi.org/10.1074/jbc.271.41.25139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810269	hybrid			2022-12-25	WOS:A1996VL69300013
J	Brucker, EA; Olson, JS; Phillips, GN; Dou, Y; IkedaSaito, M				Brucker, EA; Olson, JS; Phillips, GN; Dou, Y; IkedaSaito, M			High resolution crystal structures of the deoxy, oxy, and aquomet forms of cobalt myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL HISTIDINE MUTANTS; SPERM WHALE MYOGLOBIN; REVERSIBLE OXYGENATION; HEME POCKET; HEMOGLOBINS; REFINEMENT; STEREOCHEMISTRY; PORPHYRINS; ROTATION	The structures of the deoxy, oxy, and aquomet forms of native sperm whale myoglobin reconstituted with cobalt protoporphyrin IX have been determined by x-ray crystallography, As expected, cobalt myoglobin closely resembles native iron myoglobin in overall structure, especially in their respective aquomet forms, In the cobalt oxymyoglobin structure, the N-epsilon of distal histidine 64 lies within hydrogen bonding distance to both the oxygen atom directly bonded to the cobalt and the terminal oxygen atom, in agreement with previous EPR and resonance Raman studies, The metal atom in cobaltous myoglobin does show a small 0.06-Angstrom out-of-porphyrin plane displacement when moving from the oxy to deoxy state, In the case of the native iron-containing myoglobin, the oxy to deoxy transition results in a larger 0.16-Angstrom displacement of the metal farther out of the porphyrin plane, attributed to an increase in spin from S = 0 to S = 2. The small displacement in cobalt myoglobin is due to a change in coordination geometry, not spin state (S = 1/2 for both cobalt deoxy- and oxymyoglobin). The small out of-porphyrin plane movement of cobalt which accompanies deoxygenation of myoglobin also occurs in cobalt hemoglobin and serves to explain why cooperativity, although reduced, is still preserved when iron is replaced by cobalt in human hemoglobin.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Rice University; Case Western Reserve University			Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008	Olson, John/0000-0002-0760-5403	NIAMS NIH HHS [AR40252] Funding Source: Medline; NIGMS NIH HHS [GM51588, GM35649/HL47020] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051588, R01GM035649] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANG H, 1992, J AM CHEM SOC, V114, P2843, DOI 10.1021/ja00034a014; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; CHIEN JCW, 1972, P NATL ACAD SCI USA, V60, P2783; DICKINSON LC, 1980, P NATL ACAD SCI USA, V77, P1235, DOI 10.1073/pnas.77.3.1235; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERMI G, 1982, J MOL BIOL, V155, P495, DOI 10.1016/0022-2836(82)90483-1; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; HOFFMAN BM, 1971, COLD SPRING HARB SYM, V36, P343; HOFFMAN BM, 1970, P NATL ACAD SCI USA, V67, P627; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; IKEDASAITO M, 1977, J BIOL CHEM, V252, P4882; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; IMAI K, 1977, J MOL BIOL, V109, P83, DOI 10.1016/S0022-2836(77)80047-8; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; KITAGAWA T, 1982, NATURE, V298, P869, DOI 10.1038/298869a0; LEE HC, 1994, BIOCHEMISTRY-US, V33, P7609, DOI 10.1021/bi00190a014; PADLAN EA, 1975, J BIOL CHEM, V250, P7069; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PETSKO GA, 1978, FRONTIERS BIOL ENERG, P1011; PHILLIPS GN, 1990, BIOPHYS J, V57, P381, DOI 10.1016/S0006-3495(90)82540-6; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; SCHEIDT WR, 1974, J AM CHEM SOC, V96, P90, DOI 10.1021/ja00808a014; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; YONETANI T, 1974, J BIOL CHEM, V249, P682; YONETANI T, 1974, J BIOL CHEM, V249, P2168	31	51	52	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25419	25422		10.1074/jbc.271.41.25419	http://dx.doi.org/10.1074/jbc.271.41.25419			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810310	hybrid			2022-12-25	WOS:A1996VL69300054
J	Corroyer, S; Maitre, B; Cazals, V; Clement, A				Corroyer, S; Maitre, B; Cazals, V; Clement, A			Altered regulation of G(1) cyclins in oxidant-induced growth arrest of lung alveolar epithelial cells - Accumulation of inactive cyclin E-CDK2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATION-RELATED GENES; PULMONARY OXYGEN-TOXICITY; DEPENDENT KINASE; POSTTRANSCRIPTIONAL REGULATION; FUNCTIONAL INTERACTIONS; RETINOBLASTOMA PROTEIN; DNA-DAMAGE; TGF-BETA; EXPRESSION; G1	The alveolar surface of the lung is a major target for oxidant injury, and its repair following injury is dependent on the ability of its stem cells, the type 2 cells, to initiate proliferation. From previous studies it is likely that events located before the entry into the S phase of the cell cycle and involving several components of the insulin-like growth factor system as well as of transforming growth factor-beta (TGF-beta) play a key role in growth regulation of oxidant-exposed type 2 epithelial cells. To gain further insights into these mechanisms, we explored the effects of O-2 exposure on G(1) cyclins and their cyclin-dependent kinases (CDKs). We documented an increased expression of these genes in O-2-treated type 2 cells. However, despite this induction, a dramatic decrease in cyclin E-CDK2 activity, but not in cyclin D-CDK4 activity, was found. The concomitant induction of CDK inhibitory proteins (CKIs), mainly p21(CIP1), suggests that accumulation of inactive cyclin E-CDK2 activity is due to CKI binding. We also provided evidence that the mechanisms regulating this process involved TGF-beta as anti-TGF-beta antibody treatment was able to reduce the oxidant-induced inhibition of cyclin E-CDK2 activity, Taken together, these results suggest that oxidants may block entry into S phase by acting on a subset of late G(1) events whose alterations are sufficient to impair the activation of cyclin E-CDK2 complexes.	UNIV PARIS,ST ANTOINE MED SCH,TROUSSEAU HOSP,DEPT PHYSIOL,F-75012 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite				Maitre, Bernard/0000-0002-8061-1252				ADAMSON IYR, 1974, LAB INVEST, V30, P15; AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; BRENNA P, 1983, BIOCHIM BIOPHYS ACTA, V74, pS14; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAZALS V, 1994, J BIOL CHEM, V269, P14111; CHEN X, 1985, CANCER RES, V55, P4257; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT A, 1991, EXP CELL RES, V196, P198, DOI 10.1016/0014-4827(91)90251-O; CLEMENT A, 1990, P NATL ACAD SCI USA, V87, P318, DOI 10.1073/pnas.87.1.318; CLEMENT A, 1992, J CLIN INVEST, V90, P1812, DOI 10.1172/JCI116056; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARBER JL, 1990, LAB INVEST, V62, P670; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HALLIWELL B, 1991, AM J MED S3C, V91, P14, DOI DOI 10.1016/0002-9343(91)90279-7; HARRIS JB, 1991, AM J RESP CELL MOL, V4, P115, DOI 10.1165/ajrcmb/4.2.115; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JACKSON RM, 1985, CHEST, V88, P900, DOI 10.1378/chest.88.6.900; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KAPANCI Y, 1969, LAB INVEST, V20, P101; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LI C, 1995, J BIOL CHEM, V270, P4941; LI Y, 1992, J BIOL CHEM, V267, P19097; LOYER P, 1994, J BIOL CHEM, V269, P2491; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MICHIELI P, 1994, CANCER RES, V54, P3391; MILLER BE, 1990, ENVIRON HEALTH PERSP, V85, P15, DOI 10.2307/3430661; MOUHIEDDINE OB, 1994, ENDOCRINOLOGY, V135, P83, DOI 10.1210/en.135.1.83; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THET LA, 1986, EXP LUNG RES, V11, P209, DOI 10.3109/01902148609064297; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITSCHI H, 1990, ENVIRON HEALTH PERSP, V85, P5, DOI 10.2307/3430660; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522; ZHANGW, 1995, CANCER RES, V55, P668	64	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25117	25125		10.1074/jbc.271.41.25117	http://dx.doi.org/10.1074/jbc.271.41.25117			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810266	hybrid			2022-12-25	WOS:A1996VL69300010
J	Li, JX; Liu, SS; Rosen, BP				Li, JX; Liu, SS; Rosen, BP			Interaction of ATP binding sites in the ArsA ATPase, the catalytic subunit of the Ars pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; ESCHERICHIA-COLI; H+-ATPASE; BETA-SUBUNIT; MUTAGENESIS; RESISTANCE; ARSENATE; ARSENITE; DOMAINS; SEQUENCE	The ArsA ATPase is the catalytic subunit of the Ars pump that catalyzes arsenical extrusion in Escherichia coli, thus providing resistance, The active form of ArsA is a homodimer with four nucleotide binding sites, two from each monomer, The codons for Gly-15 in the N-terminal consensus nucleotide binding sequence and Gly-334 in the C-terminal sequence were individually mutated to cysteine codons, Cells expressing an arsA(G334C) mutation retained arsenite resistance, while an arsA(G15C) mutation resulted in substantial reductions in arsenite resistance, transport, and ATPase activity. Selection for suppression of the G15C mutation that restored arsenite resistance yielded an A344V substitution, Ala-344 is located adjacent to the C-terminal nucleotide binding sequence, The second site mutation did not suppress the loss of resistance resulting from G18D, G20S, or T22I substitutions in the N-terminal nucleotide binding site, Cells expressing the G15C/A344V double mutant regained arsenite extrusion, These results suggest a spatial proximity of Gly-15 and Ala-344 and support a model for interaction of the nucleotide binding sites in ArsA.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,DETROIT,MI 48201; ACAD SINICA,INST ZOOL,STATE KEY LAB BIOMEMBRANE & MEMBRANE BIOTECHNOL,BEIJING 100080,PEOPLES R CHINA	Wayne State University; Chinese Academy of Sciences; Institute of Zoology, CAS				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; CHEN CM, 1986, J BIOL CHEM, V261, P5030; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HSU CM, 1989, J BIOL CHEM, V264, P17349; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; KAUR P, 1994, J BIOL CHEM, V269, P9698; KAUR P, 1992, J BIOL CHEM, V267, P19272; KAUR P, 1994, BIOCHEMISTRY-US, V33, P6456, DOI 10.1021/bi00187a010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEI-HSU C, 1991, Journal of Biological Chemistry, V266, P2327; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; OMOTE H, 1994, J BIOL CHEM, V269, P10265; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; ROSEN BP, 1995, J BIOENERG BIOMEMBR, V27, P85, DOI 10.1007/BF02110335; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER S, 1981, J BACTERIOL, V146, P983, DOI 10.1128/JB.146.3.983-996.1981; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; VOGEL G, 1976, BIOCHEMISTRY-US, V16, P208; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042	31	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25247	25252		10.1074/jbc.271.41.25247	http://dx.doi.org/10.1074/jbc.271.41.25247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810286	hybrid			2022-12-25	WOS:A1996VL69300030
J	Zhao, YW; Sparks, DL; Marcel, YL				Zhao, YW; Sparks, DL; Marcel, YL			Specific phospholipid association with apolipoprotein A-I stimulates cholesterol efflux from human fibroblasts - Studies with reconstituted sonicated lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELL-DERIVED CHOLESTEROL; SMOOTH-MUSCLE CELLS; ACYLTRANSFERASE ACTIVITY; DISCOIDAL LIPOPROTEINS; PLASMA-LIPOPROTEINS; GEL-ELECTROPHORESIS; ELEVATED LEVELS; PARTICLE-SIZE; LIPID EFFLUX	To understand how the lipid composition of high density lipoprotein mediates the efflux of cellular cholesterol, we have characterized the effects of variations in the lipid composition of well defined model sonicated apolipoprotein A-I (apoA-I)-containing lipoprotein (LpA-I) particle on cholesterol efflux from cultured human skin fibroblasts. LpA-I particles with varying content of phosphatidylcholine (POPC), phosphatidylinositol, sphingomyelin, cholesterol ester, and triolein were prepared by co-sonication. Association of as little as 5 mol of phosphatidylcholine with apoA-I is sufficient to transform lipid-free apoA-I into a distinct lipoprotein-like particle that is a significantly better acceptor of cellular cholesterol, Increasing the ratio of POPC/apoA-I from 5/1 to 35.5/1 in the sonicated LpA-I is associated with a significant increase in the release of cellular cholesterol, At low POPC/apoA-I ratios, native gradient gel electrophoresis of the LpA-I shows these lipoproteins to be small complexes (around 5-6 nm), with only 1 molecule of apoA-I (Lp1A-I). At a POPC/apoA-I ratio above 11/1, LpA-I form well defined complexes that contain 2 molecules of apoA-I (Lp2A-I) and range in size from 7.6 to 7.7 nm. Inclusion of sphingomyelin into an Lp1A-I further stimulates cholesterol efflux significantly. In contrast, inclusion of either sphingomyelin or phosphatidylinositol into a sonicated Lp2A-I has no effect on cholesterol efflux, Incorporation of cholesterol ester and/or triolein into an Lp2A-I particle is associated with a small reduction in cholesterol efflux to these lipoproteins. Therefore, cholesterol efflux from human fibroblasts is directly proportional to the amount and type of phospholipid in a sonicated LpA-I particle. Changes in the conformation and charge of apoA-I that result from changes in the lipid composition of a sonicated LpA-I particle appear to directly affect the ability of the lipoprotein to bind and retain cholesterol molecules. These data therefore suggest that the adsorption/desorption of cholesterol molecules to/from a sonicated LpA-I complex may be less sensitive to interfacial lipid-lipid interactions, but may depend on a conformation-dependent ability of apoA-I to bind cholesterol.	UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT PATHOL & LAB MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa								AGNANI G, 1993, BIOCHEMISTRY-US, V32, P2643, DOI 10.1021/bi00061a024; BANERJEE D, 1983, J CELL BIOL, V96, P651, DOI 10.1083/jcb.96.3.651; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BERGERON J, 1995, J BIOL CHEM, V270, P27429, DOI 10.1074/jbc.270.46.27429; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BIELICKI JK, 1991, BIOCHIM BIOPHYS ACTA, V1085, P7, DOI 10.1016/0005-2760(91)90225-7; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; CASTLE CK, 1991, J LIPID RES, V32, P439; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; COLLET X, 1991, J BIOL CHEM, V266, P9145; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; EISENBERG S, 1984, J LIPID RES, V25, P1017; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; FORTE TM, 1993, J LIPID RES, V34, P317; FRANCONE OL, 1990, EUR HEART J, V11, P218, DOI 10.1093/eurheartj/11.suppl_E.218; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FUGLER L, 1985, J BIOL CHEM, V260, P4098; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; HARA H, 1991, J BIOL CHEM, V266, P3080; HIRZ R, 1970, BIOCHIM BIOPHYS ACTA, V207, P364, DOI 10.1016/0005-2795(70)90029-2; HUSSAIN MM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P90; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1991, J LIPID RES, V32, P1993; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1994, J LIPID RES, V35, P860; KAN CC, 1991, BIOCHEMISTRY-US, V30, P7759, DOI 10.1021/bi00245a013; KUNITAKE ST, 1985, J LIPID RES, V26, P549; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; LI QQ, 1995, J BIOL CHEM, V270, P26216, DOI 10.1074/jbc.270.44.26216; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MCCALL MR, 1988, J LIPID RES, V29, P1127; MCCALL MR, 1989, J LIPID RES, V30, P1579; MIIDA T, 1992, BIOCHEMISTRY-US, V31, P11112, DOI 10.1021/bi00160a022; MIIDA T, 1990, BIOCHEMISTRY-US, V29, P10469, DOI 10.1021/bi00498a007; NEARY RH, 1987, CLIN CHEM, V33, P1163; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NUNEZ JF, 1984, J BIOL CHEM, V259, P9141; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SPARKS DL, 1995, J BIOL CHEM, V270, P26910, DOI 10.1074/jbc.270.45.26910; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1995, J BIOL CHEM, V270, P5151, DOI 10.1074/jbc.270.10.5151; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STEIN O, 1988, BIOCHIM BIOPHYS ACTA, V960, P322, DOI 10.1016/0005-2760(88)90040-9; STEIN O, 1973, BIOCHIM BIOPHYS ACTA, V326, P232, DOI 10.1016/0005-2760(73)90249-X; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; THRIFT RN, 1986, J LIPID RES, V27, P236; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175; Zhao YW, 1996, BIOCHEMISTRY-US, V35, P7174, DOI 10.1021/bi952242v	56	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25145	25151		10.1074/jbc.271.41.25145	http://dx.doi.org/10.1074/jbc.271.41.25145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810270	hybrid			2022-12-25	WOS:A1996VL69300014
J	Lee, HY; Clair, T; Mulvaney, PT; Woodhouse, EC; Aznavoorian, S; Liotta, LA; Stracke, ML				Lee, HY; Clair, T; Mulvaney, PT; Woodhouse, EC; Aznavoorian, S; Liotta, LA; Stracke, ML			Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN PC-1; FIBROBLAST GROWTH-FACTOR; HUMAN-MELANOMA CELLS; AMINO-ACID-SEQUENCE; NUCLEOTIDE PYROPHOSPHATASE; CDNA CLONING; RAT-BRAIN; MOLECULAR-CLONING; SURFACE-ANTIGENS; IV COLLAGENASE	A family of extracellular type I phosphodiesterases has recently been isolated by cDNA cloning, but a physiological function linked to the phosphodiesterase active site has remained unknown, We now present evidence that the phosphodiesterase catalytic site, (201)YMRPVYPTKTFPN(213), is essential for the motility stimulating activity of autotaxin (ATX), one member of the exophosphodiesterase family. Native ATX possesses phosphodiesterase activity at neutral and alkaline pH, binds ATP noncovalently, and undergoes threonine phosphorylation. Homogeneously purified recombinant ATX, based on the teratocarcinoma sequence, retains these same activities, A single amino acid in the phosphodiesterase catalytic site, Thr(210), is found to be necessary for motility stimulation, phosphodiesterase activity, and phosphorylation. Two mutant recombinant proteins, Ala(210)- and Asp(210)-ATX, lack motility stimulation and lack both enzymatic activities; Ser(210)-ATX possesses intermediate activities, Another mutation, with the adjacent lysine (Lys(209)) changed to Leu(209)-ATX, possesses normal motility stimulation with sustained phosphodiesterase activity but exhibits no detectable phosphorylation. This mutation eliminates the phosphorylation reaction and indicates that the dephosphorylated state is an active motility stimulating form of the ATX molecule. By demonstrating that the phosphodiesterase enzymatic site is linked to motility stimulation, these data reveal a novel role for this family of exo/ecto-enzymes and open up the possibility of extracellular enzymatic cascades as a regulatory mechanism for cellular motility.	NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BELLI SI, 1995, EUR J BIOCHEM, V228, P669, DOI 10.1111/j.1432-1033.1995.tb20308.x; BROWN PD, 1990, CANCER RES, V50, P6184; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; CHEN ZP, 1995, J NEUROENDOCRINOL, V7, P83, DOI 10.1111/j.1365-2826.1995.tb00671.x; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULP JS, 1985, J BIOL CHEM, V260, P8320; DEISSLER H, 1995, J BIOL CHEM, V270, P9849, DOI 10.1074/jbc.270.17.9849; FUNAKOSHI I, 1992, ARCH BIOCHEM BIOPHYS, V295, P180, DOI 10.1016/0003-9861(92)90504-P; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRUPE A, 1995, J CLIN INVEST, V94, P560; HALEY BE, 1974, P NATL ACAD SCI USA, V71, P3367, DOI 10.1073/pnas.71.9.3367; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KINDLERROHRBORN A, 1985, DIFFERENTIATION, V30, P53, DOI 10.1111/j.1432-0436.1985.tb00513.x; KINDLERROHRBORN A, 1994, DIFFERENTIATION, V57, P215, DOI 10.1007/s002580050057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; MARGULIES IMK, 1992, CANCER EPIDEM BIOMAR, V1, P467; MURATA J, 1994, J BIOL CHEM, V269, P30479; NARITA M, 1994, J BIOL CHEM, V269, P28235; ODA Y, 1991, J BIOL CHEM, V266, P16791; ODA Y, 1993, J BIOL CHEM, V268, P27318; RAZZELL WE, 1959, J BIOL CHEM, V234, P2105; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAKAHASHI T, 1970, J EXP MED, V131, P1325, DOI 10.1084/jem.131.6.1325; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0	33	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24408	24412		10.1074/jbc.271.40.24408	http://dx.doi.org/10.1074/jbc.271.40.24408			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798697	hybrid			2022-12-25	WOS:A1996VM67400019
J	Rahimi, N; Tremblay, E; Elliott, B				Rahimi, N; Tremblay, E; Elliott, B			Phosphatidylinositol 3-kinase activity is required for hepatocyte growth factor-induced mitogenic signals in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR-RECEPTOR; PROTEIN-KINASE-C; TYROSINE KINASE; PHOSPHOINOSITIDE 3-KINASE; HGF-RECEPTOR; ACTIVATION; MET; TRANSFORMATION; PHOSPHORYLATION; ASSOCIATION	Phosphatidylinositol (PI) 3-kinase is an important enzyme implicated in growth factor-stimulated intracellular signaling. In this study we have shown that hepatocyte growth factor (HGF) induces a rapid tyrosine phosphorylation of PI 3-kinase and association with HGF receptor/Met in Mv1Lu epithelial cells. Murine mammary carcinoma (SP1) cells, which co-express HGF and HGF receptor/Met, showed sustained phosphorylation of PI 3-kinase. Wortmannin, a potent inhibitor of PI 3-kinase, inhibited HGF-induced PI 3-kinase activity, proliferation of Mv1Lu cells, and spontaneous growth of SP1 cells in a dose-, and time-dependent manner. Transfection of a dominant negative mutant p85 (Delta p85) subunit of PI 3-kinase into SP1 cells strongly inhibited HGF-stimulated proliferation and PI 3-kinase activity. However, wortmannin did not influence HGF-induced c-Jun expression. Furthermore, HGF stimulated S6 kinase activity, but its activity was not required for HGF-induced proliferation. Overall, these results suggest that HGF-induced PI 3-kinase activity is important for the mitogenic action of HGF in epithelial cells and further demonstrate that expression of c-Jun is not influenced by inhibition of PI 3-kinase activity.	QUEENS UNIV,DEPT PATHOL,CANC RES LAB,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada				Rahimi, Nader/0000-0002-6745-1725				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CARLOW DA, 1985, J NATL CANCER I, V75, P291; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG J, 1992, CELL, V78, P35; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FIXMAN ED, 1995, ONCOGENE, V10, P237; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GANDINO L, 1990, ONCOGENE, V5, P721; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEHTOLA L, 1991, J CELL BIOCHEM, V45, P69, DOI 10.1002/jcb.240450114; LONGATI P, 1994, ONCOGENE, V9, P49; LU YL, 1995, EUR J IMMUNOL, V25, P533, DOI 10.1002/eji.1830250234; Matsumoto K, 1993, EXS, V65, P225; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NALDINI L, 1991, ONCOGENE, V6, P501; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; POWIS G, 1994, CANCER RES, V54, P2419; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SANTOS OFP, 1993, DEV BIOL, V159, P535, DOI 10.1006/dbio.1993.1262; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANG XM, 1993, DEV BIOL, V157, P308, DOI 10.1006/dbio.1993.1137; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zarnegar R, 1993, EXS, V65, P181; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHEN Z, 1994, ONCOGENE, V9, P1691	48	52	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24850	24855		10.1074/jbc.271.40.24850	http://dx.doi.org/10.1074/jbc.271.40.24850			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798760	hybrid			2022-12-25	WOS:A1996VM67400082
J	Touyz, RM; Schiffrin, EL				Touyz, RM; Schiffrin, EL			Angiotensin II and vasopressin modulate intracellular free magnesium in vascular smooth muscle cells through Na+-dependent protein kinase C pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; SALMONELLA-TYPHIMURIUM; PHOSPHOLIPASE-C; MG-2+ EFFLUX; TRANSPORT; CALCIUM; RAT; MG2+; EXCHANGE; LIVER	Vasoactive peptides mobilize cytosolic free Mg2+ in vascular smooth muscle cells, It is unknown whether angiotensin II and arginine vasopressin, potent vaso constrictor agents, influence intracellular Mg2+, The effects of angiotensin II and vasopressin on intracellular free Mg2+ concentrations ([Mg2+](i)) were therefore investigated in primary cultured unpassaged vascular smooth muscle cells (VSMC) from mesenteric arteries of Wistar Kyoto rats, and in an established cell line of rat thoracic aorta cells (A10 cells), Underlying mechanisms of agonist stimulated [Mg2+](i) changes were assessed in A10 cells by pharmacologically manipulating phospholipase C, protein kinase C, and the Na+/H+ exchanger. In addition, the dependence of [Mg2+](i) on intracellular Ca2+ was determined, [Mg2+](i) was measured in single cells by fluorescent digital imaging using mag-fura-2/AM. Basal [Mg2+](i) levels in Wistar Kyoto rat and A10 cells were 0.62 +/- 0.02 mmol/liter and 0.58 +/- 0.01 mmol/ liter, respectively, Angiotensin II and vasopressin induced a dose-dependent biphasic [Mg2+](i) response where [Mg2+](i) increased rapidly and transiently to a peak level and then declined to subbasal levels, which were sustained, Preexposure of cells to neomycin, a nonspecific phospholipase C inhibitor, U-73122, a selective phospholipase C inhibitor, calphostin C, a selective protein kinase C inhibitor, and 5-(N,N-hexamethylene)amiloride, a selective Na+/H+ exchange blocker, attenuated angiotensin II- and vasopressin-induced [Mg2+](i) responses in a concentration-dependent manner, Removal of extracellular Na+ completely inhibited agonist-elicited [Mg2+](i) transients. To determine whether intracellular free Ca2+ concentration ([Ca2+](i)) influences agonist-induced [Mg2+](i) changes, thapsigargin, a selective sarcoplasmic reticular Ca2+-ATPase inhibitor, was used to deplete intracellular Ca2+ stores, In thapsigargin-pretreated cells, angiotensin II-elicited [Ca2+](i) responses were significantly attenuated, whereas agonist-induced [Mg2+](i) responses were unchanged. These data demonstrate that in primary cultured VSMC and in an established VSMC line, angiotensin II and vasopressin modulate [Mg2+](i) through receptor-mediated pathways, which are [Ca2+](i)-independent but which involve phospholipase C, protein kinase C, and the Na+/H+ exchanger, These pathways are linked to a Na+-dependent Mg2+ transporter, which facilitates transmembrane Mg2+ transport.			Touyz, RM (corresponding author), UNIV MONTREAL,CLIN RES INST MONTREAL,MED RES COUNCIL MULTIDISCIPLINARY RES GRP HYPERTENSION,MONTREAL,PQ H2W 1R7,CANADA.		Schiffrin, Ernesto L/AAB-9061-2019; Touyz, Rhian/AAM-3564-2020	Schiffrin, Ernesto L/0000-0002-4502-2823; Touyz, Rhian/0000-0003-0670-0887				Aikawa J K, 1978, World Rev Nutr Diet, V28, P112; ALTURA BM, 1977, FED PROC, V36, P1853; ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; BAKER PF, 1972, J PHYSIOL-LONDON, V227, P855, DOI 10.1113/jphysiol.1972.sp010062; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOND M, 1987, J BIOL CHEM, V262, P15630; ELLIOTT DA, 1974, J BIOL CHEM, V249, P3985; FERAY JC, 1987, J BIOL CHEM, V262, P5763; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; GRUBBS RD, 1986, J BIOL CHEM, V261, P2550; GRUBBS RD, 1994, MOL CELL BIOCHEM, V136, P11, DOI 10.1007/BF00931599; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTHER T, 1985, BIOCHEM BIOPH RES CO, V130, P540, DOI 10.1016/0006-291X(85)90450-4; GUNTHER T, 1992, FEBS LETT, V307, P333, DOI 10.1016/0014-5793(92)80707-N; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; HATHAWAY DR, 1991, CIRCULATION, V83, P382, DOI 10.1161/01.CIR.83.2.382; HENQUIN JC, 1983, NATURE, V301, P73, DOI 10.1038/301073a0; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; HWANG DL, 1993, J CLIN ENDOCR METAB, V76, P549, DOI 10.1210/jc.76.3.549; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LI HY, 1994, BBA-MOL CELL RES, V1222, P164, DOI 10.1016/0167-4889(94)90165-1; LITOSCH I, 1991, J BIOL CHEM, V266, P4764; LOW AM, 1993, EUR J PHARMACOL, V230, P53, DOI 10.1016/0014-2999(93)90409-B; LUDI H, 1987, J PHYSIOL-LONDON, V390, P367; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MURPHY E, 1991, ANNU REV PHYSIOL, V53, P273, DOI 10.1146/annurev.physiol.53.1.273; MURPHY E, 1993, MINER ELECTROL METAB, V19, P250; NG LL, 1992, METABOLISM, V41, P772, DOI 10.1016/0026-0495(92)90319-6; OKADA K, 1992, AM J PHYSIOL, V263, pC873, DOI 10.1152/ajpcell.1992.263.4.C873; PAGE E, 1972, J PHYSIOL-LONDON, V224, P121, DOI 10.1113/jphysiol.1972.sp009884; PICADO MJ, 1994, HYPERTENSION, V23, P987, DOI 10.1161/01.HYP.23.6.987; PUSCH M, 1989, BIOPHYS J, V55, P1267, DOI 10.1016/S0006-3495(89)82922-4; QUAMME GA, 1993, AM J PHYSIOL, V265, P4281; RAJU B, 1989, LIFE SCI, V256, pC540; ROMANI A, 1993, CIRC RES, V72, P1139, DOI 10.1161/01.RES.72.6.1139; ROMANI A, 1990, FEBS LETT, V269, P37, DOI 10.1016/0014-5793(90)81113-3; SCHACHTER M, 1990, BIOCHIM BIOPHYS ACTA, V1035, P378, DOI 10.1016/0304-4165(90)90103-4; SCHIFFRIN EL, 1986, LIFE SCI, V38, P817, DOI 10.1016/0024-3205(86)90598-9; SCHWERTZ DW, 1984, J PHARMACOL EXP THER, V231, P48; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; TOUYZ RM, 1994, J HYPERTENS, V12, P663; TOUYZ RM, 1993, J HYPERTENS, V11, P551, DOI 10.1097/00004872-199305000-00011; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WALKER GM, 1986, MAGNESIUM, V531, P201; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6; ZHENG LX, 1995, ENDOCRINOLOGY, V136, P1079, DOI 10.1210/en.136.3.1079	48	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24353	24358		10.1074/jbc.271.40.24353	http://dx.doi.org/10.1074/jbc.271.40.24353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798689	hybrid			2022-12-25	WOS:A1996VM67400011
J	Zhou, MY; Wu, XJ; Ginsberg, HN				Zhou, MY; Wu, XJ; Ginsberg, HN			Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DNA-BINDING ACTIVITY; MOLECULAR CHAPERONES; MAMMALIAN-CELLS; APOLIPOPROTEIN-B; STRESS PROTEINS; CYCLIN-B; INDUCTION; DEGRADATION; EXPRESSION	Heat shock protein 72/73 (Hsp70) is a cytosolic molecular chaperone that carries out fundamental roles under both normal and stress situations, There is great interest in delineating the mechanisms whereby Hsp70 levels are regulated. We observed that N-acetyl-leucyl-leucyl-norleucinal (ALLN), a synthetic aldehydic tripeptide that inhibits proteasomes, markedly induced Hsp70 levels (up to 30-fold above base line in HepG2 cells and human endothelial cells). Induction of Hsp70 by ALLN was dose-dependent and not related to cell toxicity. ALLN selectively increased Hsp70 levels without affecting Hsp25, Hsp27, Hsp60, Hsp86, Hsp90, Hsp104, or Bip (immunoglobulin heavy chain binding protein) in HepG2 cells. ALLN induced Hsp70 not only by stabilizing the protein but also by dramatically increasing its synthesis. The modulation of Hsp70 synthesis by ALLN resulted from a rapid and marked increase in transcription of the hsp72 gene, since the induction of hsp72 mRNA was blocked in cells co-treated with actinomycin D. hsp72 mRNA levels were affected in a time-dependent manner by exposure to ALLN; significant elevations occurred within 60 min of treatment, and a decline to background levels was observed by 7 h of recovery. The ALLN-induced increase in hsp72 gene expression was associated with trimerization of the heat shock transcriptional factor (HSF1). ALLN did not affect the steady-state level of HSF1 protein. The effects of ALLN appeared to require de novo protein synthesis, since the induction of both HSF1 trimerization and hsp72 transcription was blocked by co-treatment with cycloheximide. When we tested a series of protease inhibitors, only the related aldehydic tripeptides, N-acetyl-leucyl-leucyl-methioninal and the proteasome inhibitor. Cbz-leucyl-leucyl-leucinal, induced Hsp70 levels. The specific proteasome inhibitor, lactacystin, which has a different structure, also induced Hsp70 levels. Overall, our results suggest that a rapidly turning over protein that is normally degraded by proteasomes may be involved in the regulation of Hsp70 synthesis via effects on the hsp70 transcriptional factor, HSF1.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21007, HL 36000] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CURRIE RW, 1988, CIRC RES, V63, P543, DOI 10.1161/01.RES.63.3.543; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIERKS T, 1993, PHILOS T ROY SOC B, V339, P335, DOI 10.1098/rstb.1993.0032; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FREEMAN ML, 1993, RADIAT RES, V135, P387, DOI 10.2307/3578879; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HEGDE RS, 1995, J CELL PHYSIOL, V165, P186, DOI 10.1002/jcp.1041650122; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; INOUE S, 1991, J BIOL CHEM, V266, P13311; JOHNSON AD, 1995, ARTERIOSCL THROM VAS, V15, P27, DOI 10.1161/01.ATV.15.1.27; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIU AYC, 1989, J BIOL CHEM, V264, P12037; Liu H, 1996, J BIOL CHEM, V271, P4805; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Maniatis T., 1982, MOL CLONING; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; MITANI K, 1993, BIOCHEM J, V290, P819, DOI 10.1042/bj2900819; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; OHTSUKI T, 1992, BRAIN RES, V599, P246, DOI 10.1016/0006-8993(92)90398-S; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PLUMIER JC, 1995, J CLIN INVEST, V94, P1854; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RODFORD NB, 1996, P NATL ACAD SCI USA, V93, P2339; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHISSEL SL, 1995, BIOCHEMISTRY-US, V34, P10463, DOI 10.1021/bi00033a019; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SIMON MM, 1995, J CLIN INVEST, V95, P925; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; ZAFARULLAH M, 1993, EXP CELL RES, V208, P371, DOI 10.1006/excr.1993.1258; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; [No title captured]	60	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24769	24775		10.1074/jbc.271.40.24769	http://dx.doi.org/10.1074/jbc.271.40.24769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798747	hybrid			2022-12-25	WOS:A1996VM67400069
J	Fuchs, SY; Dolan, L; Davis, RJ; Ronai, Z				Fuchs, SY; Dolan, L; Davis, RJ; Ronai, Z			Phosphorylation-dependent targeting of c-jun ubiquitination by Jun N-kinase	ONCOGENE			English	Article						c-jun; c-jun N-kinase; ubiquitination; phosphorylation	SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; DELTA-DOMAIN; PROTEASOME PATHWAY; ACTIVATION DOMAIN; HA-RAS; V-JUN; TRANSCRIPTION; CELLS; TRANSFORMATION	Ubiquitination of key cellular regulatory proteins marks them for efficient degradation via the proteasome pathway. The delta domain of c-jun is essential for its ubiquitination and also for the activating phosphorylation of neighboring serines by the stress activated jun-N-terminal kinases (JNK). Using an in vitro model system we demonstrate that JNK is among the hydrophobic binding proteins that target c-jun for efficient ubiquitination. Immunodepletion of JNK markedly inhibits c-jun ubiquitination. Conversely, c-jun ubiquitination is increased by adding purified JNK2 or extracts prepared from cells transfected with JNK2. Although c-jun ubiquitination is enhanced by JNK, the phosphorylation of c-jun on Ser(73) by JNK protects c-jun from ubiquitination and prolongs its half-life. The dual activity of JNK in targeting c-jun for ubiquitination or in protecting c-jun from entering this pathway via phosphorylation points to the role of JNK in the control of c-jun stability in cells exposed to environmental stress or inflammatory cytokines.	AMER HLTH FDN,MOL CARCINOGENESIS PROGRAM,VALHALLA,NY 10595; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,WORCESTER,MA	American Health Foundation; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester				RONAI, ZEEV/0000-0002-3859-0400; Reinhart, Lisa/0000-0001-6266-3342	NCI NIH HHS [CA59908, CA58396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908, R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FORNACE AJ, 1989, NUCLEIC ACIDS RES, V17, P1215, DOI 10.1093/nar/17.3.1215; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAMROUDKIDRON E, 1994, FEBS LETT, V337, P239, DOI 10.1016/0014-5793(94)80199-1; MORGAN IM, 1993, ONCOGENE, V8, P1135; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	29	163	167	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1531	1535						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875991				2022-12-25	WOS:A1996VL38400018
J	Gillotte, KL; Davidson, WS; LundKatz, S; Rothblat, GH; Phillips, MC				Gillotte, KL; Davidson, WS; LundKatz, S; Rothblat, GH; Phillips, MC			Apolipoprotein A-I structural modification and the functionality of reconstituted high density lipoprotein particles in cellular cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; ATHEROSCLEROSIS; TRANSPORT; ACYLTRANSFERASE; QUANTITATION; METABOLISM; MEMBRANE; EPITOPE; DISKS	The role of HDL and its major protein constituent, apolipoprotein (ape) A-I, in promoting the removal of excess cholesterol from cultured cells has been well es tablished; however, the mechanisms by which this occurs are not completely understood, To address the effects of apoA-I modification on cellular unesterified (free) cholesterol (FC) efflux, three recombinant human apoA-I deletion mutants and plasma apoA-I were combined with 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC) and FC to make reconstituted high density lipoprotein (rHDL) discoidal complexes, These particles were characterized structurally and for their efficiency as accepters of mouse L-cell fibroblast cholesterol, The deletion mutant proteins lacked NH2-terminal (apoA-I (Delta 44-126)), central (apoA-I (Delta 139-170)), or COOH-terminal (apoA-I (Delta 190-243)) domains of apoA-I, The three deletion mutants all displayed lipid-binding abilities and formed discoidal complexes that were similar in major diameter (13.2 +/- 1.5 nm) to those formed by human apoA-I when reconstituted at a 100:5:1 (POPC:FC: protein) mole ratio, Gel filtration profiles indicated unreacted protein in the preparation made with apoA-I (Delta 190-243), which is consistent with the COOH terminus portion of apoA-I being an important determinant of lipid binding, Measurements of the percent cu-helix content of the proteins, as well as the number of protein molecules per rHDL particle, gave an indication of the arrangement of the deletion mutant proteins in the discoidal complexes, The rHDL particles containing the deletion mutants had more molecules of protein present than particles containing intact apoA-I, to the extent that a similar number of helical segments was incorporated into each of the discoidal species, Comparison of the experimentally determined number of helical segments with an estimate of the available space indicated that the deletion mutant proteins are probably more loosely arranged than apoA-I around the edge of the rHDL, The abilities of the complexes to remove radiolabeled FC were compared in experiments using cultured mouse L-cell fibroblasts, All four discoidal complexes displayed similar abilities to remove FC from the plasma membrane of L-cells when compared at an acceptor concentration of 50 mu g of phospholipid/ml. Thus, none of the deletions imposed in this study notably altered the ability of the rHDL particles to participate in cellular FC efflux, These results suggest that efficient apoA-I-mediated FC efflux requires the presence of amphipathic alpha-helical segments but is not dependent on specific helical segments.	ALLEGHENY UNIV HLTH SCI,DEPT BIOCHEM,PHILADELPHIA,PA 19129; UNIV ILLINOIS,DEPT BIOCHEM,COLL MED,URBANA,IL 61801	Drexel University; University of Illinois System; University of Illinois Urbana-Champaign				Davidson, William/0000-0003-2756-2989; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANKA CL, 1994, J BIOL CHEM, V269, P10288; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; BRUCE C, 1995, CURR OPIN LIPIDOL, V6, P306, DOI 10.1097/00041433-199510000-00010; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GLOMSET JA, 1968, J LIPID RES, V9, P155; HARA H, 1991, J BIOL CHEM, V266, P3080; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1989, J BIOL CHEM, V264, P4818; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; LUCHOOMUN J, 1994, BBA-LIPID LIPID MET, V1212, P319, DOI 10.1016/0005-2760(94)90206-2; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; ROSSENEU M, 1992, HIGH DENSITY LIPOPRO, V3, P105; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; ROTHBLAT GH, 1991, CURR OPIN LIPIDOL, V2, P288; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SCHMIDT HHJ, 1995, J BIOL CHEM, V270, P5469, DOI 10.1074/jbc.270.10.5469; SEGREST JP, 1992, J LIPID RES, V33, P141; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1995, J BIOL CHEM, V270, P26910, DOI 10.1074/jbc.270.45.26910; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; VONECKARDSTEIN A, 1993, J BIOL CHEM, V268, P2616; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1	41	27	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23792	23798		10.1074/jbc.271.39.23792	http://dx.doi.org/10.1074/jbc.271.39.23792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798607	hybrid			2022-12-25	WOS:A1996VJ44200036
J	MullerSteffner, HM; Augustin, A; Schuber, F				MullerSteffner, HM; Augustin, A; Schuber, F			Mechanism of cyclization of pyridine nucleotides by bovine spleen NAD(+) glycohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; ADENINE-DINUCLEOTIDE GLYCOHYDROLASE; CALCIUM-MOBILIZING METABOLITE; NAD+-GLYCOHYDROLASE; CYCLASE ACTIVITY; HUMAN CD38; RAT-LIVER; HYDROLYSIS; ENZYME; PURIFICATION	We have shown that bovine spleen NAD(+) glycohydrolase (EC 3.2.2.5), purified to homogeneity, is a multifunctional enzyme, A time-dependent formation of cADPR from NAD(+) that did not exceed 1.5-2% of the reaction products was measurable, The cyclase activity of this enzyme was, however, best evidenced by its transformation of NGD(+) into cyclic GDP-ribose (cGDPR), The formation of the cyclic compound could be monitored spectroscopically (UV and fluorescence) and by highperformance liquid chromatography; the product ratio of cGDPR/GDP-ribose was 2:1. Bovine spleen NAD(+) glycohydrolase is also able to hydrolyze cADPR (Muller-Steffner et al. (1994) Biochem. Biophys. Res, Commun. 204, 1279-1285); the kinetic parameters (V/K-m) measured exclude, however, the possibility that cADPR is a kinetically competent reaction intermediate in the transformation of NAD(+) into ADP ribose. Experimental data indicating that NAD(+) glycohydrolase-catalyzed hydrolysis and methanolysis of NA(GD+ occurred at the expense of the formation of the cyclic compounds are in favor of a reaction mechanism involving the partitioning of a common oxocarbenium reaction intermediate between the different accepters. Thus E . A(G)DP-ribosyl oxocarbenium intermediate can react according to i) intramolecular processes with the positions N-1 of adenine and N-7 of guanine to give cA(G)DPR as reaction products, and ii) intermolecular reactions with water (formation of A(G)DP-ribose) and methanol (formation of methyl A(G)DP-ribose). We attribute the marked difference in yield of cADPR and cGDPR to the intrinsic reactivity (nucleophilicity and positioning) of the purine N-positions that are involved in the cyclization reactions within the E . A(G)DP-ribosyl oxocarbenium complexes.	UNIV STRASBOURG 1,CHIM BIOORGAN LAB,CNRS,LAB 1386,FAC PHARM,F-67400 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								AMARCOSTESEC A, 1985, J CELL BIOL, V100, P189, DOI 10.1083/jcb.100.1.189; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; BOCCHINI V, 1988, INT J DEV NEUROSCI, V6, P525, DOI 10.1016/0736-5748(88)90060-3; Brown D. M, 1974, BASIC PRINCIPLES NUC, VII, P1, DOI 10.1016/B978-0-12-701902-4.50007-1; FUNARO A, 1995, FUND CLIN IMMUNOL, V3, P101; Graeff RM, 1996, BIOCHEMISTRY-US, V35, P379, DOI 10.1021/bi952083f; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GUSE AH, 1995, J IMMUNOL, V155, P3353; HANDLON AL, 1994, J AM CHEM SOC, V116, P12087, DOI 10.1021/ja00105a073; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JONES JW, 1963, J AM CHEM SOC, V85, P193, DOI 10.1021/ja00885a019; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KIM H, 1993, BIOCHEM BIOPH RES CO, V194, P1143, DOI 10.1006/bbrc.1993.1941; KNOWLES JR, 1965, BIOCHEM J, V95, P180, DOI 10.1042/bj0950180; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1994, MOL CELL BIOCHEM, V138, P229, DOI 10.1007/BF00928466; LEE HC, 1995, BIOCHIMIE PARIS, V77, P354; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MASMOUDI A, 1987, BIOCHEMISTRY-US, V26, P1965, DOI 10.1021/bi00381a027; MULLERSTEFFNER H, 1994, BIOCHEM BIOPH RES CO, V204, P1279, DOI 10.1006/bbrc.1994.2601; MULLERSTEFFNER H, 1993, ARCH BIOCHEM BIOPHYS, V304, P154, DOI 10.1006/abbi.1993.1333; Oppenheimer N. J., 1982, PYRIDINE NUCLEOTIDE, P51, DOI DOI 10.1016/B978-0-12-244750-1.50012-9; Price S.R., 1987, PYRIDINE NUCLEOTIDE, V2B, P513; REISBIG RR, 1978, BIOCHEMISTRY-US, V17, P1974, DOI 10.1021/bi00603a028; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SCHUBER F, 1976, EUR J BIOCHEM, V69, P593, DOI 10.1111/j.1432-1033.1976.tb10945.x; SCHUBER F, 1979, BIOORG CHEM, V8, P83, DOI 10.1016/0045-2068(79)90039-7; Singer B, 1975, Prog Nucleic Acid Res Mol Biol, V15, P219, DOI 10.1016/S0079-6603(08)60121-X; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TARNUS C, 1987, BIOORG CHEM, V15, P31, DOI 10.1016/0045-2068(87)90004-6; TARNUS C, 1988, BIOORG CHEM, V16, P38, DOI 10.1016/0045-2068(88)90036-3; YOST DA, 1983, J BIOL CHEM, V258, P3075; Zhang FJ, 1995, TETRAHEDRON LETT, V36, P9289, DOI 10.1016/0040-4039(95)02004-9; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	39	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23967	23972		10.1074/jbc.271.39.23967	http://dx.doi.org/10.1074/jbc.271.39.23967			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798630	hybrid			2022-12-25	WOS:A1996VJ44200059
J	Noble, JR; Rogan, EM; Neumann, AA; Maclean, K; Bryan, TM; Reddel, RR				Noble, JR; Rogan, EM; Neumann, AA; Maclean, K; Bryan, TM; Reddel, RR			Association of extended in vitro proliferative potential with loss of p16(INK4) expression	ONCOGENE			English	Article						p16(INK4); RB; telomeres; telomerase; senescence; immortalisation	TUMOR-SUPPRESSOR GENE; FRAUMENI SYNDROME FIBROBLASTS; HUMAN PAPILLOMAVIRUS TYPE-16; KINASE-4 INHIBITOR GENE; SQUAMOUS-CELL CARCINOMA; LARGE T-ANTIGEN; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; HUMAN CANCER; FAMILIAL MELANOMA	This study addresses the question of whether loss of p16(INK4) expression contributes to the immortalization of human cells. in vitro immortalization usually proceeds through two phases. In the first phase (lifespan extension), cells continue proliferating and their telomeres continue shortening beyond the point at which normal cells become senescent. In the second phase (immortalization), the cells activate a telomere maintenance mechanism and acquire an unlimited proliferative potential. It has previously been shown that immortalized cells containing viral oncoproteins that bind and inactivate p110(RB) contain wild-type p16(INK4); we therefore examined the p16(INK4) status Of cell lines that became immortalized in vitro in the absence of these oncoproteins. Three such lines were identified: III-CF/ .2A1 and III-CF/E6A2 (both derived from Li-Fraumeni syndrome fibroblasts, probably by spontaneous immortalization) and MePV-23I (normal mesothelial cells transfected with HPV-16 E6/E7 genes that underwent deletion of these genes before immortalization). In each case p16(INK4) expression was lost at or before immortalization. Further, a cell strain was identified that had an extended but finite lifespan associated with loss of p16(INK4) (and p53) expression. Thus loss of p16(INK4) expression was associated with extended in vitro lifespan but was not sufficient for immortalization, even in the absence of wild-type p53.	CHILDRENS MED RES INST,WESTMEAD,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia			Reddel, Roger R/A-6635-2014; Bryan, Tracy M/B-8468-2014; Neumann, Axel/D-3319-2012	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; ARAP W, 1995, CANCER RES, V55, P1351; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BRENNER AJ, 1995, CANCER RES, V55, P2892; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, CANCER RES, V55, P2533; CHENG JQ, 1994, CANCER RES, V54, P5547; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1995, TELOMERES, P265; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; DREYLING MH, 1995, CANCER RES, V55, P984; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JIN XM, 1995, CANCER RES, V55, P3250; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KE Y, 1989, AM J PATHOL, V134, P979; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LAVECK MA, 1988, IN VITRO CELL DEV B, V24, P1077; LI Y, 1994, CANCER RES, V54, P6078; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; MACLEAN K, 1994, ONCOGENE, V9, P719; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUNGER K, 1989, J VIROL, V63, P4417; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; NILSSON P, 1994, ONCOGENE, V9, P3043; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; REED JA, 1995, CANCER RES, V55, P2713; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROSE BR, 1995, GYNECOL ONCOL, V56, P239, DOI 10.1006/gyno.1995.1039; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAM SW, 1994, CANCER RES, V54, P5816; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; XU L, 1994, CANCER RES, V54, P5262; YEAGER T, 1995, CANCER RES, V55, P493; ZHANG SY, 1994, CANCER RES, V54, P5050	61	54	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1259	1268						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808700				2022-12-25	WOS:A1996VJ20200017
J	Braun, JEA; Wilbanks, SM; Scheller, RH				Braun, JEA; Wilbanks, SM; Scheller, RH			The cysteine string secretory vesicle protein activates hsc70 ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; LAMBDA-DNA-REPLICATION; NUCLEOPROTEIN STRUCTURES; BACTERIOPHAGE-LAMBDA; MOLECULAR CHAPERONE; UNFOLDED PROTEINS; UNCOATING ATPASE; PEPTIDE BINDING; CLATHRIN COATS; HUMAN HOMOLOG	Cysteine string protein (CSP) is a 34 kDa secretory vesicle protein bearing a ''J-domain'' as well as a palmitoylated cysteine-rich ''string'' region used for membrane attachment. Mutation of the CSP gene causes impaired presynaptic neuromuscular transmission in Drosophila melanogaster, implicating CSP as part of the exocytotic protein machinery. The J-domain of CSP shares homology with the universally conserved DnaJ family, a group of proteins that act as co-chaperones with Hsc70 and its homologs. Hsc70 is an abundant neural protein with coupled protein binding and ATPase activities. We have investigated the CSP modulation of Hsc70 ATPase activity. Here we demonstrated that CSP enhances Hsc70 ATPase activity in a dose-dependent manner. CSP activation of Hsc70 was maximal (similar to 12 times) at 1:1 stoichiometry and above. We show that a J-domain-containing fragment (amino acids 1-82) of CSP is sufficient for the activation of Hsc70. Neither CSP nor the amino-terminal fragment stimulate the activity of the isolated Hsc70 ATPase domain (amino acids 1-386). CSP does not significantly increase the activity of N-ethylmaleimide-sensitive fusion protein, another ATPase required for transport vesicle function. Our results suggest that CSP, a DnaJ family member associated with the secretory vesicle cycle regulates Hsc70 functions. Hsc70 may function within the biochemical pathways of exo- and endocytosis to promote the formation or dissociation of multimeric complexes or to regulate conformational changes.	STANFORD UNIV,MED CTR,DEPT BIOL STRUCT,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University	Braun, JEA (corresponding author), STANFORD UNIV,MED CTR,DEPT MOL & CELLULAR PHYSIOL,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.			Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ALFANO C, 1989, J BIOL CHEM, V264, P10709; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CHELLAIAH A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P111, DOI 10.1016/0167-4781(93)90103-K; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P9798; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DODSON M, 1989, J BIOL CHEM, V264, P10719; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; Kee Y, 1996, J NEUROSCI, V16, P1975; KOHAN SA, 1995, J NEUROSCI, V15, P6230; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERSNER J, 1994, NEURON, V13, P353; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHELLER RH, 1995, NEURON, V14, P893; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; ZYLICZ M, 1988, BIOCHIM BIOPHYS ACTA, V951, P344, DOI 10.1016/0167-4781(88)90105-4; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	47	124	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25989	25993		10.1074/jbc.271.42.25989	http://dx.doi.org/10.1074/jbc.271.42.25989			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824236	hybrid			2022-12-25	WOS:A1996VN18000042
J	Artemyev, NO; Surendran, R; Lee, JC; Hamm, HE				Artemyev, NO; Surendran, R; Lee, JC; Hamm, HE			Subunit structure of rod cGMP-phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; BETA-SUBUNIT; GMP PHOSPHODIESTERASE; OUTER SEGMENTS; RETINAL DEGENERATION; PHOTORECEPTOR CELLS; BINDING DOMAIN; HIGH-AFFINITY; CDNA CLONE; RD MOUSE	The rod cGMP phosphodiesterase (PDE) is the G-protein-activated effector enzyme that regulates the level of cGMP in vertebrate photoreceptor cells. Rod cGMP PDE is generally viewed as a heterotrimeric protein composed of catalytic alpha and beta subunits (similar to 90 kDa each) and two copies of the inhibitory subunit gamma (similar to 10 kDa). However, the possibility that rod PDE could exist as distinct isoforms, such as alpha alpha gamma(2) and beta beta gamma(2) has not been ruled out. We have studied this question using cross-linking of PDE subunits with maleimidobenzoyl-N-hydroxysuccinimide ester and para-phenyldimaleimide. The cross-linking resulted in major products with molecular mass of 100 and 150 kDa, a doublet at similar to 180-190 kDa, and a doublet at similar to 210-220 kDa, Cross-linked products were analyzed using polyclonal-specific anti-PDE alpha beta, anti-PDE alpha, anti-PDE beta, or anti-PDE gamma antibodies. The anti-PDE alpha and anti-PDE alpha beta antibodies recognized all the cross-linked products, whereas anti-PDE beta and anti-PDE gamma antibodies did not interact with the 150-kDa band, indicating that the composition of this band is most likely alpha alpha. Similar analysis of cross-linked products of trypsin-treated PDE preparations revealed bands that are likely formed by PDE beta subunit. The molecular size of holo-PDE and trypsin-activated PDE were studied using analytical ultracentrifugation in order to determine if oligomerization of PDE could account for the cross-linking of identical PDE subunits. The sedimentation analysis of both holo-PDE and ta-PDE revealed homogeneous samples with molecular masses of similar to 220 and similar to 150 kDa, respectively. These results indicate that PDE is likely a mixture of the major species alpha beta gamma(2), minor species alpha alpha gamma(2), and possibly beta beta gamma(2). Our data are consistent with the detection of low PDE activity in the rd mouse, which lacks any functional PDE beta subunit.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA; UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Artemyev, NO (corresponding author), UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, 5-660 BOWEN SCI BLDG, IOWA CITY, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY006062, R01EY010843] Funding Source: NIH RePORTER; NEI NIH HHS [EY-06062, EY-10843] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANANT JS, 1992, J BIOL CHEM, V267, P687; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; FARBER DB, 1977, J NEUROCHEM, V28, P1089, DOI 10.1111/j.1471-4159.1977.tb10673.x; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEM J, 1992, P NATL ACAD SCI USA, V89, P4422, DOI 10.1073/pnas.89.10.4422; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; MURADOV KG, 1990, BIOL MEMBRANY, V7, P565; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; QIN N, 1994, J BIOL CHEM, V269, P3265; SHABB JB, 1992, J BIOL CHEM, V267, P5723; STROOP SD, 1991, J BIOL CHEM, V266, P23802; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	43	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25382	25388		10.1074/jbc.271.41.25382	http://dx.doi.org/10.1074/jbc.271.41.25382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810304	hybrid			2022-12-25	WOS:A1996VL69300048
J	Okada, S; Pessin, JE				Okada, S; Pessin, JE			Interactions between Src homology (SH) 2/SH3 adapter proteins and the guanylnucleotide exchange factor SOS are differentially regulated by insulin and epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MAP KINASE PHOSPHORYLATION; RECEPTOR TYROSINE KINASES; GTPASE-ACTIVATING PROTEIN; SIGNAL-TRANSDUCTION; PC12 CELLS; V-CRK; SOS-GRB2 COMPLEX; RAS ACTIVATION; OF-SEVENLESS	Co-immunoprecipitation of whole cell extracts demonstrated that the guanylnucleotide exchange factor SOS was associated with the small adapter proteins Grb2, CrkII, and Nck. In vitro binding indicated a similar binding affinity of SOS for all three adapter proteins but with a slightly lower K-d for GrbB (similar to 2.5-fold) compared with Nck and CrkII. Insulin stimulation resulted in co-immunoprecipitation of tyrosine-phosphorylate d IRS1 with Grb2 and to a lesser extent CrkII. Although Grb2 also associated with tyrosine-phosphorylated Shc, there was no detectable interaction of CrkII with Shc. In contrast, EGF stimulation resulted in the predominant co-immunoprecipitation of Grb2 with the EGF receptor, whereas CrkII primarily associated with an unidentified 120-130-kDa protein. Similar to the ability of insulin to induce the dissociation of the Grb2-SOS complex, there was a concomitant time-dependent dissociation of the CrkII-SOS and Nck-SOS complexes. However, EGF stimulation had no effect on the association state of the Grb2-SOS or the Nck-SOS complexes but did result in a time dependent dissociation of the CrkII from SOS. Together, these data demonstrate that different cellular pools of SOS associate with different adapter proteins forming various signaling complexes, each undergoing distinct patterns of assembly/disassembly following growth factor stimulation.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295, DK33823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1995, ONCOGENE, V10, P1465; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HU QJ, 1995, MOL CELL BIOL, V15, P1169; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KHARLUND JK, 1995, J BIOL CHEM, V270, P23421; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25533	25538		10.1074/jbc.271.41.25533	http://dx.doi.org/10.1074/jbc.271.41.25533			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810325	hybrid			2022-12-25	WOS:A1996VL69300069
J	Tinti, C; Conti, B; Cubells, JF; Kim, KS; Baker, H; Joh, TH				Tinti, C; Conti, B; Cubells, JF; Kim, KS; Baker, H; Joh, TH			Inducible cAMP early repressor can modulate tyrosine hydroxylase gene expression after stimulation of cAMP synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PHEOCHROMOCYTOMA CELL-LINE; DEPENDENT PROTEIN-KINASE; LEUCINE ZIPPER STRUCTURE; NERVE GROWTH-FACTOR; CYCLIC-AMP; TRANSCRIPTION FACTOR; TRANSGENIC MICE; MESSENGER-RNA	Members of the CREB/CREM/ATF family of transcription factors either enhance or repress transcription after binding to the cAMP response elements (CREs) of numerous genes, The rat gene for tyrosine hydroxylase (TH) bears a canonical CRE, at base pairs -38 through -45 from the transcription initiation site, that is essential for basal and cAMP-stimulated transcription (Kim, K.-S., Lee, M. K., Carroll, J., and Job, T.H. (1993) J. Biol. Chem, 268, 15689-15695; Lazaroff, M., Patankar, S., Yoon, S. O., and Chikaraishi, D. M. (1995) J. Biol. Chem. 270, 21579-21589). The current study identifies CRE-binding proteins induced in pharmacological paradigms characterized by TH activation. PC12- and rat adrenal gland-derived nuclear proteins retarded a TH-CRE oligonucleotide in gel mobility shift assays with virtually identical patterns, These differed substantially from patterns exhibited by extracts from locus ceruleus or from neuroblastoma (SK-N-BE(2)C) and locus ceruleus-derived (CATH.a) cell lines, Forskolin stimulation of PC12 cells and reserpine treatment of rats increased, in nuclear extracts derived from cells and adrenal glands, respectively, the amount of a fast moving CRE/protein complex that was supershifted by an anti-CREM antibody, Subsequent Western, Northern, and polymerase chain reaction analyses indicated that a specific member of the CREM family, the inducible cAMP early repressor (ICER), was strongly induced in both systems, Cotransfection of PC12 cells with TH2400CAT plasmid and the expression vector pCMV-ICER-Ib demonstrated that ICER efficiently represses the transcriptional activity of the TH gene promoter, In addition, PKA-stimulated transcriptional activity of the promoter was effectively suppressed by ICER. These results suggest that ICER can modulate cAMP-stimulated transcription of the TH gene and provide a model accounting for rapid reversal of increased TH transcription following elevations in cAMP.	CORNELL UNIV,COLL MED,BURKE MED RES INST,MOL NEUROBIOL LAB,WHITE PLAINS,NY 10605; UNIV BRESCIA,FAC MED & CHIRURG,I-25124 BRESCIA,ITALY	Cornell University; University of Brescia			Cubells, Joe F./V-2543-2018	Conti, Bruno/0000-0002-9185-5201	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH024285, R01MH024285] Funding Source: NIH RePORTER; NIMH NIH HHS [MH24285] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CARROLL JM, 1991, J MOL NEUROSCI, V3, P65, DOI 10.1007/BF02885527; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FAUCONBIGUET N, 1986, EMBO J, V5, P287; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUIDOTTI A, 1976, N-S ARCH PHARMACOL, V295, P135, DOI 10.1007/BF00499445; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1990, MOL ENDOCRINOL, V4, P920, DOI 10.1210/mend-4-6-920; HUANG ZM, 1991, MOL BRAIN RES, V11, P309, DOI 10.1016/0169-328X(91)90040-5; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; IUVONE PM, 1978, MOL PHARMACOL, V14, P1212; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KANEDA N, 1991, NEURON, V6, P583, DOI 10.1016/0896-6273(91)90061-4; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KIM KS, 1993, J BIOL CHEM, V268, P15689; KIM KS, 1995, GENE PROBES, V2, P151; KONRADI C, 1994, J NEUROSCI, V14, P5623; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; KONRADI C, 1995, NEUROSCIENCE, V65, P1051, DOI 10.1016/0306-4522(94)00546-H; KVETNANS.R, 1971, ENDOCRINOLOGY, V89, P46, DOI 10.1210/endo-89-1-46; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MUELLER RA, 1969, J PHARMACOL EXP THER, V169, P74; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; REIS DJ, 1974, BRAIN RES, V81, P380, DOI 10.1016/0006-8993(74)90956-1; RICHARD F, 1989, NEUROCHEM INT, V14, P199, DOI 10.1016/0197-0186(89)90122-8; ROSS RA, 1981, CELL MOL NEUROBIOL, V1, P301, DOI 10.1007/BF00710685; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; SURI C, 1993, J NEUROSCI, V13, P1280; TANK AW, 1986, MOL PHARMACOL, V30, P497; THOENEN H, 1969, J PHARMACOL EXP THER, V169, P249; THOENEN H, 1970, NATURE, V228, P861, DOI 10.1038/228861a0; THOENEN H, 1969, NATURE, V221, P1264, DOI 10.1038/2211264a0; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X; WONG SC, 1994, J NEUROCHEM, V62, P1691; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	68	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25375	25381		10.1074/jbc.271.41.25375	http://dx.doi.org/10.1074/jbc.271.41.25375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810303	hybrid			2022-12-25	WOS:A1996VL69300047
J	Brostrom, CO; Prostko, CR; Kaufmann, RJ; Brostrom, MA				Brostrom, CO; Prostko, CR; Kaufmann, RJ; Brostrom, MA			Inhibition of translational initiation by activators of the glucose-regulated stress protein and heat shock protein stress response systems - Role of the interferon-inducible double-stranded RNA-activated eukaryotic initiation factor 2 alpha kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC RETICULAR CALCIUM; NUCLEOTIDE EXCHANGE FACTOR; NF-KAPPA-B; FACTOR-II; ASIALOGLYCOPROTEIN RECEPTOR; EIF-2-ALPHA KINASE; MESSENGER-RNA; PHOSPHORYLATION; CELLS; GRP78	Depletion of endoplasmic reticulum (ER) Ca2+ perturbs protein folding and processing within the organelle while inhibiting translational initiation through activation of the double-stranded RNA-activated eukaryotic initiation factor (eIF)-2 alpha kinase (PKR) (Prostko, C. R., Dholakia, J. N., Brostrom, M. A., and Brostrom, C. O. (1995) J. Biol. Chem. 270, 6211-6215). The glucose-regulated stress protein (GRP) chaperones are subsequently induced, We now report that sodium arsenite, a prototype for stressors fostering cytoplasmic protein misfolding, also inhibits translational initiation through activation of PKR while subsequently inducing the heat shock protein (HSP) chaperones, Arsenite neither mobilized ER-associated Ca2+ nor slowed peptide chain elongation, Various HSP-inducing chemicals caused rapid phosphorylation of eIF-2 alpha. When incubated with double-stranded RNA, extracts derived from arsenite-treated cells displayed greater degrees of phosphorylation of PKR and eIF-2 alpha than did control extracts. Cells overexpressing a dominant negative PKR mutation resisted translational inhibition and eIF-2 alpha phosphorylation in response to ER or cytoplasmic stressors, Induction of either the HSP or GRP chaperones was accompanied by development of translational tolerance to either Ca2+-mobilizing agents or arsenite, Following induction of the HSPs by arsenite, cells remained susceptible to induction of the GRPs by Ca2+-mobilizing agents. Conversely, cells possessing induced GRP contents in response to Ca2+-mobilizing agents readily induced the HSPs in response to arsenite, It is concluded that the two chaperone systems function independently except for their mutual suppression of PKR.	UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Brostrom, CO (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHARMACOL, 675 HOES LANE, PISCATAWAY, NJ 08854 USA.							BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127; BROSTROM MA, 1993, NUTRITION GENE EXPRE, P117; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHIN KV, 1987, J BIOL CHEM, V262, P16509; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DUBOIS MF, 1989, J BIOL CHEM, V264, P12165; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; Gmitter D, 1996, CELL BIOL TOXICOL, V12, P101, DOI 10.1007/BF00143360; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; KUZNETSOV G, 1993, J BIOL CHEM, V268, P2001; LEDFORD BE, 1978, BIOCHIM BIOPHYS ACTA, V519, P204, DOI 10.1016/0005-2787(78)90073-4; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEVINSON W, 1980, BIOCHIM BIOPHYS ACTA, V606, P170, DOI 10.1016/0005-2787(80)90108-2; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; PORUCHYNSKY MS, 1991, J CELL BIOL, V114, P651, DOI 10.1083/jcb.114.4.651; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; TRAUGH JA, 1986, PROG NUCLEIC ACID RE, V33, P195; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071	48	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24995	25002		10.1074/jbc.271.40.24995	http://dx.doi.org/10.1074/jbc.271.40.24995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798781	hybrid			2022-12-25	WOS:A1996VM67400104
J	Davis, AJ; Butt, JT; Walker, JH; Moss, SE; Gawler, DJ				Davis, AJ; Butt, JT; Walker, JH; Moss, SE; Gawler, DJ			The Ca2+-dependent lipid binding domain of P120(GAP) mediates protein-protein interactions with Ca2+-dependent membrane-binding proteins - Evidence for a direct interaction between annexin VI and P120(GAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPID-BINDING; CARCINOMA-CELLS; RAS P21; GAP; IDENTIFICATION; HOMOLOGY; CLONING; MEMBER; FAMILY	The CaLB domain is a 43-amino acid sequence motif found in a number of functionally diverse signaling proteins including three Ras-specific GTPase activating proteins (GAPs), In the Ras GTPase activating protein, p120(GAP), this domain has the ability to confer membrane association in response to intracellular Ca2+ elevation, Here we have isolated three proteins, p55, p70, and p120, which interact with the p120(GAP) CaLB domain in vitro. We identify p70 as the Ca2+-dependent phospholipid-binding protein annexin VI, Using co-immunoprecipitation studies, we have shown that the interaction between p120(GAP) and annexin VI is also detectable in rat fibroblasts, suggesting that this interaction may have a physiological role in vivo. Thus, the CaLB domain in p120(GAP) appears to have the ability to direct specific protein-protein interactions with Ca2+-dependent membrane-associated proteins, In addition, annexin VI is known to have tumor suppressor activity, Therefore, it is possible that the interaction of annexin VI with p120(GAP) may be important in the subsequent modulation of p21(ras) activity.	UNIV LEEDS,DEPT PHARMACOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	University of Leeds; University of Leeds; University of London; University College London				Delafield-Butt, Jonathan/0000-0002-8881-8821				Barwise JL, 1996, J CELL SCI, V109, P247; BOS JL, 1989, CANCER RES, V49, P4682; BOUSTEAD CM, 1988, FEBS LETT, V233, P233, DOI 10.1016/0014-5793(88)80433-2; BOUSTEAD CM, 1991, CELLULAR CALCIUM PRA, P247; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EDWARDS HC, 1995, MOL CELL BIOCHEM, V149, P293, DOI 10.1007/BF01076591; ELLIS C, 1989, NATURE, V342, P711; GAWLER DJ, 1995, BIOCHEM J, V307, P487, DOI 10.1042/bj3070487; GAWLER DJ, 1995, ONCOGENE, V10, P817; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TAGOE CE, 1994, BBA-BIOMEMBRANES, V1192, P272, DOI 10.1016/0005-2736(94)90128-7; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	28	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24333	24336		10.1074/jbc.271.40.24333	http://dx.doi.org/10.1074/jbc.271.40.24333			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798684	hybrid			2022-12-25	WOS:A1996VM67400006
J	Goodman, TG; Bajt, ML				Goodman, TG; Bajt, ML			Identifying the putative metal ion-dependent adhesion site in the beta(2) (CD18) subunit required for alpha(L)beta(2) and alpha(M)beta(2) ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR TYPE-3; FUNCTION ASSOCIATED MOLECULE-1; INTEGRIN ALPHA-2-BETA-1 VLA-2; GLYCOPROTEIN-IIB-IIIA; AMINO-ACID SEQUENCE; I-DOMAIN; ALPHA-SUBUNIT; CELL-ADHESION; LEUKOCYTE DIFFERENTIATION; VONWILLEBRAND-FACTOR	We have previously demonstrated that Asp(134) and Ser(136) of the beta(2) subunit are essential for alpha(L) beta(2) and alpha(M) beta(2) ligand recognition. It has been proposed that these residues may be part of a metal ion-dependent adhesion site (MIDAS) within the beta subunit homologous to the alpha(M) I domain MIDAS structure (Lee, J.-0., Rieu, P., Arnaout, M. A., and Liddington, R. (1995) Cell 80, 631-638). In the present study, we evaluated the role of additional candidate metal ion-coordinating residues in the beta(2) subunit in ligand interactions. Cells bearing the recombinant alpha(L) beta(2) or alpha(M) beta(2) mutant(s) were tested for the ability to bind to immobilized ligands, Alanine substitution at Asp(232) in beta(2) produced a complete loss in the capacity of both alpha(L) beta(2) and alpha(M) beta(2) to support cell adhesion and suppressed the expression of a divalent cation-dependent conformation recognized by mAb 24. Alanine substitution at Glu(235) differentially affected receptor function dependent upon the co-transfected alpha subunit. Cells expressing alpha(L) beta(2) with a substitution at Glu(235) failed to adhere to intercellular adhesion molecule 1 (ICAM-1) but did retain the capacity to bind mAb 24. Moreover, cells expressing alpha(M) beta(2) with a substitution at Glu(235) failed to adhere to fibrinogen or ICAM-1 and did not bind mAb 24. However, these cells did retain the capacity to adhere to iC3b following antibody-induced activation, These results implicate Asp(232) and Glu(235), along with Asp(134) and Ser(136), in ligand binding function of alpha(L) beta(2) and alpha(M) beta(2).. These findings provide evidence in support of the existence of a MIDAS structure in beta(2) analogous to that seen in the alpha(M) I domain.	PHARMACIA & UPJOHN INC,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49001	Pfizer								AGRAVES WS, 1987, J CELL BIOL, V105, P1183; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1994, METABOLIC BASIS INHE; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KERN A, 1994, J BIOL CHEM, V269, P22811; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER LJ, 1986, J IMMUNOL, V137, P2891; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	53	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23729	23736		10.1074/jbc.271.39.23729	http://dx.doi.org/10.1074/jbc.271.39.23729			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798597	hybrid			2022-12-25	WOS:A1996VJ44200026
J	Latham, KE; Litvin, J; Orth, JM; Patel, B; Mettus, R; Reddy, EP				Latham, KE; Litvin, J; Orth, JM; Patel, B; Mettus, R; Reddy, EP			Temporal patterns of A-myb and B-myb gene expression during testis development	ONCOGENE			English	Article						myb; fertility; sterility; gene expression; testis development; meiosis	C-MYB; TRANSCRIPTIONAL ACTIVATOR; PROTEIN; CELLS; MOUSE; SPERMATOGENESIS; PROLIFERATION; LYMPHOCYTES; SUBUNIT; DOMAINS	We recently reported the cloning and sequencing of the mouse A-myb proto-oncogene cDNA and the abundant expression of this mRNA primarily in the testis of adult mice. The A-myb mRNA is detectable by in situ hybridization specifically in the spermatogenic cells, and is downregulated during terminal differentiation. A low level of expression is observed in a few other tissues, including ovary, spleen and brain. We have extended those studies by examining A-myb and B-myb expression during testis development in the mouse. The A-myb and B-myb genes are both expressed in a cell- and stage-specific manner during testis development. The B-myb mRNA is expressed most highly in gonocytes of the fetal testis and in spermatogonia and early spermatocytes in the adult. B-myb expression decreases at day 18 post partum, coincident with the initial appearance of Late pachytene spermatocytes. B-myb expression was also detectable in some interstitial cells of the fetal and adult testis. The A-myb mRNA was not detectable by in situ hybridization in fetal day 15.5 gonocytes but was detectable at a low abundance by RT-PCR in fetal and newborn mice. A-myb mRNA expression increased at post-natal day 10, when primary spermatocytes first appear. In the adult, the A-myb mRNA was expressed highly in a sub-population of spermatogonia and in primary spermatocytes, but was not detectable in spermatids. This expression of A-myb is consistent with the meiotic arrest that is observed in A-myb-deficient male mice. We conclude that B-myb may play a critical role in controlling the proliferation or differentiation of gonocytes and spermatogonia and possibly the somatic lineages as well, whereas A-myb is required for progression through the first meiotic prophase. These distinct roles for B-myb and A-myb during spermatogenesis may reflect distinct transactivation potentials of the two proteins. Further studies to determine the functions of A-myb and B-myb in the developing testis should improve our understanding of the molecular events associated with spermatogenesis and differentiation of the Sertoli and other somatic cell types of the testis.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Latham, KE (corresponding author), TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [P30-CA12227] Funding Source: Medline; NICHD NIH HHS [HD15563] Funding Source: Medline; NIGMS NIH HHS [GM49489] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015563] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BARLETTA C, 1991, CANCER RES, V51, P3821; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1994, ONCOGENE, V9, P2469; KLAMPNAUER KH, 1987, EMBO J, V6, P2719; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; METTUS RV, 1994, ONCOGENE, V9, P3077; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; ORTH JM, 1982, ANAT REC, V203, P485, DOI 10.1002/ar.1092030408; ORTH JM, 1996, IN PRESS MOL REPROD; RAMBHATLA L, 1995, MOL REPROD DEV, V41, P314, DOI 10.1002/mrd.1080410306; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; Sitzmann J, 1996, ONCOGENE, V12, P1889; Sitzmann J, 1995, ONCOGENE, V11, P2273; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TOSCANI A, UNPUB NATURE; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; XU LZ, 1995, MOL CELL BIOL, V15, P6572	32	42	45	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1161	1168						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808690				2022-12-25	WOS:A1996VJ20200007
J	Shibata, T; Ochiai, A; Kanai, Y; Akimoto, S; Gotoh, M; Yasui, N; Machinami, R; Hirohashi, S				Shibata, T; Ochiai, A; Kanai, Y; Akimoto, S; Gotoh, M; Yasui, N; Machinami, R; Hirohashi, S			Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells	ONCOGENE			English	Article						beta-catenin; c-erbB-2; protein-protein interaction; metastasis	EPIDERMAL GROWTH-FACTOR; ADHESION MOLECULE UVOMORULIN; HUMAN CARCINOMA-CELLS; HUMAN-BREAST-CANCER; E-CADHERIN; TYROSINE PHOSPHORYLATION; GENE-PRODUCT; EPITHELIAL-CELLS; FACTOR RECEPTOR; CYTOPLASMIC DOMAIN	tyrosine phosphorylation of beta-catenin inactivates the E-cadherin-mediated cell adhesion and invasion suppressor system in cancer cells, Elucidation of the association between beta-catenin and c-erbB-2 protein prompted us to investigate whether interference with this interaction can change the invasive phenotype, In a human gastric cancer cell line, TMK-1, N-terminally deleted beta-catenin, which binds to c-erbB-2 but not to cadherin, inhibited the association between endogenous beta-catenin and c-erbB-2 protein, and suppressed the tyrosine phosphorylation of beta-catenin. Cells expressing truncated beta-catenin exhibited markedly reduced invasiveness in vitro and peritoneal metastasis in vivo, and developed an epithelial morphology, These results suggest that tyrosine phosphorylation of beta-catenin regulated by c-erbB-2 protein may play an important role in the invasion, metastasis and morphogenesis of cancer cells and that inhibition of the aberrant tyrosine phosphorylation of beta-catenin effectively prevents invasion and metastasis of cancer cells.	NATL CANC CTR,RES INST,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,FAC MED,DEPT PATHOL,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo								ABERLE H, 1994, J CELL SCI, V107, P3655; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; BORG A, 1991, ONCOGENE, V6, P137; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; OYAMA T, 1994, CANCER RES, V54, P6268; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANIGUCHI S, 1989, CANCER RES, V49, P6738; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; YU DH, 1992, ONCOGENE, V7, P2263	43	111	111	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					883	889						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806677				2022-12-25	WOS:A1996VG76600001
J	Wang, HC; HarrisonShostak, DC; Lemasters, JJ; Herman, B				Wang, HC; HarrisonShostak, DC; Lemasters, JJ; Herman, B			Contribution of pH-dependent group II phospholipase A(2) to chemical hypoxic injury in rat hepatocytes	FASEB JOURNAL			English	Article						hypoxia; ischemia; phospholipase A(2); anti-sense; oligonucleotides; acidosis	PLASMA-MEMBRANE; ATP DEPLETION; CELL-DEATH; MYOCARDIAL-CELLS; CARDIAC MYOCYTES; ACIDOTIC PH; LIVER; ACIDOSIS; DEGRADATION; ACCUMULATION	Numerous studies have suggested that enhanced membrane phospholipid degradation contributes to hypoxic and ischemic injury, Recently, acidosis has been found to potently protect against hypoxic and ischemic injury, To investigate the interrelationships of these two events in hypoxic injury, we studied the role of a pH-dependent group II phospholipase A(2) (PLA(2), E.C. 3.1.1.4) in chemical hypoxic injury in rat hepatocytes, Northern blot analysis of RNA extracted from normoxic and hypoxic rat hepatocytes with group II rat liver PLA(2)-specific oligonucleotide cDNA probes revealed a 0.9 kb transcript whose abundance was significantly increased in rat hepatocytes within 15 min after initiation of chemical hypoxia and remained high until cells lost viability. Immunofluorescence staining of hepatocytes with polyclonal antibodies that recognize group II PLA(2) demonstrated a substantial increase in the level of PLA(2) protein in hypoxic rat hepatocytes within 30 min of initiation of hypoxic injury. Treatment of hepatocytes with group II PLA(2)-specific anti-sense DNA oligonucleotides: 1) abolished accumulation of PLA(2) protein in hypoxic rat hepatocytes as assessed by immunofluorescence staining with anti-PLA(2) antibodies; 2) decreased the enzymatic activity of PLA(2) manifested as decreased arachidonic acid release in hypoxic hepatocytes; and 3) significantly delayed cell death evoked by chemical hypoxia as indicated by a decrease in propidium iodide uptake, These findings suggest that pH-dependent group II PLA(2) plays an important role in chemical hypoxic injury of rat hepatocytes.	UNIV N CAROLINA, DEPT CELL BIOL & ANAT, SCH MED, CELL BIOL LABS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Wang, Haichao/AAU-2237-2021; Wang, Haichao/K-6310-2012	Wang, Haichao/0000-0002-0211-9000; Wang, Haichao/0000-0002-0211-9000	NIA NIH HHS [AG07218] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG007218, R01AG007218] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARMSTRONG SC, 1991, AM J PATHOL, V138, P545; BING OHL, 1973, SCIENCE, V180, P1297, DOI 10.1126/science.180.4092.1297; BOND JM, 1991, BIOCHEM BIOPH RES CO, V179, P798, DOI 10.1016/0006-291X(91)91887-I; BONVENTRE JV, 1985, AM J PHYSIOL, V249, pC149, DOI 10.1152/ajpcell.1985.249.1.C149; BUJA LM, 1985, LAB INVEST, V53, P397; CHIARIELLO M, 1987, J PHARMACOL EXP THER, V241, P560; CHIEN KR, 1978, J BIOL CHEM, V253, P4809; CHIEN KR, 1985, J CLIN INVEST, V75, P1770, DOI 10.1172/JCI111889; CHIEN KR, 1977, AM J PATHOL, V88, P539; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROWL RM, 1991, J BIOL CHEM, V266, P2647; CURRIN RT, 1991, FASEB J, V5, P207, DOI 10.1096/fasebj.5.2.2004664; FARBER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312, DOI 10.1016/0003-9861(81)90459-8; FLORINECASTEEL K, 1991, FASEB J, V5, P2078, DOI 10.1096/fasebj.5.7.2010060; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GORES GJ, 1990, HEPATOLOGY, V11, P690, DOI 10.1002/hep.1840110425; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; GUNN MD, 1985, AM J PHYSIOL, V249, P1188, DOI 10.1152/ajpheart.1985.249.6.H1188; HARRISON DC, 1991, BIOCHEM BIOPH RES CO, V174, P654, DOI 10.1016/0006-291X(91)91467-Q; HERMAN B, 1988, FASEB J, V2, P146, DOI 10.1096/fasebj.2.2.3342967; KIKUCHIYANOSHITA R, 1993, J BIOCHEM-TOKYO, V114, P33, DOI 10.1093/oxfordjournals.jbchem.a124135; LEMASTERS JJ, 1983, J CELL BIOL, V97, P778, DOI 10.1083/jcb.97.3.778; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LOFFLER BM, 1985, BIOCHIM BIOPHYS ACTA, V835, P448, DOI 10.1016/0005-2760(85)90114-6; LYONSGIORDANO B, 1989, BIOCHEM BIOPH RES CO, V164, P488, DOI 10.1016/0006-291X(89)91746-4; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; OTANI H, 1989, AM J PHYSIOL, V257, pH252, DOI 10.1152/ajpheart.1989.257.1.H252; PENTTILA A, 1974, SCIENCE, V185, P277, DOI 10.1126/science.185.4147.277; PRASAD MR, 1991, AM J PHYSIOL, V260, pH877, DOI 10.1152/ajpheart.1991.260.3.H877; SARGENT CA, 1992, J PHARMACOL EXP THER, V262, P1161; SEN A, 1988, J CLIN INVEST, V82, P1333, DOI 10.1172/JCI113735; STEENBERGEN C, 1984, J MOL CELL CARDIOL, V16, P605, DOI 10.1016/S0022-2828(84)80625-2; SUN FF, 1993, BIOCHEM PHARMACOL, V45, P1149, DOI 10.1016/0006-2952(93)90261-T; VANBILSEN M, 1990, J MOL CELL CARDIOL, V22, P155, DOI 10.1016/0022-2828(90)91112-K; VANSCHAIK RHN, 1993, BIOCHIM BIOPHYS ACTA, V1169, P1, DOI 10.1016/0005-2760(93)90075-K; Wang X. F., 1993, Bioimaging, V1, P30, DOI 10.1002/1361-6374(199303)1:1<30::AID-BIO6>3.3.CO;2-Q	37	17	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1996	10	11					1318	1325		10.1096/fasebj.10.11.8836046	http://dx.doi.org/10.1096/fasebj.10.11.8836046			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836046				2022-12-25	WOS:A1996VJ71700012
J	Cravchik, A; Sibley, DR; Gejman, PV				Cravchik, A; Sibley, DR; Gejman, PV			Functional analysis of the human D-2 dopamine receptor missense variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D2 RECEPTOR; STRUCTURAL POLYMORPHISM; MOLECULAR VARIANT; GENE; SCHIZOPHRENIA; ASSOCIATION; ALCOHOLISM; IDENTIFICATION; MUTATIONS; DISEASE	The human dopamine D-2 receptor gene (DRD2) has three poly-morphic variants that predict the amino acid substitutions Val(96) --> Ala, Pro(310) --> Ser, and Ser(311) --> Cys in the receptor protein. We have investigated the ligand binding and signal transduction properties of these human D-2 receptor variants by stably expressing them in cultured mammalian cells. The Cys(311) and Ser(310) variants of the human D-2 receptor, which involve substitutions located in the third cytoplasmic loop, were markedly less effective in inhibiting cAMP synthesis than the most prevalent form (Pro(310), Ser(311)). Despite this difference, the Cys(311) and Ser(310) variants couple to G proteins in CHO-K1 (Chinese hamster ovary) cells. The impairment of the Cys(311) and Ser(310) variants to inhibit cAMP levels thus appears to result from a reduced ability of those variant receptors to activate the appropriate G(i)-like protein. The demonstration of substantial functional differences between DRD2 gene variants found in the human population might have important pharmacological implications given the widespread use of D-2 receptor blocking drugs in the treatment of schizophrenia and other psychiatric disorders.	NIMH,UNIT MOL CLIN INVEST,CLIN NEUROGENET BRANCH,BETHESDA,MD 20892; NINCDS,MOL NEUROPHARMACOL SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)			Sibley, David/AAC-3591-2019					ARINAMI T, 1994, LANCET, V343, P703, DOI 10.1016/S0140-6736(94)91581-4; ASGHARI V, 1994, MOL PHARMACOL, V46, P364; ASGHARI V, 1995, J NEUROCHEM, V65, P1157, DOI 10.1046/j.1471-4159.1995.65031157.x; ASHERSON P, 1994, LANCET, V343, P1045; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; ERESHEFSKY L, 1993, CAN J PSYCHIAT, V38, pS80; GEJMAN PV, 1994, JAMA-J AM MED ASSOC, V271, P204, DOI 10.1001/jama.271.3.204; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HIGUCHI S, 1994, BIOCHEM BIOPH RES CO, V204, P1199, DOI 10.1006/bbrc.1994.2590; HOLDEN C, 1994, SCIENCE, V264, P1696, DOI 10.1126/science.8209249; ITOKAWA M, 1993, BIOCHEM BIOPH RES CO, V196, P1369, DOI 10.1006/bbrc.1993.2404; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; Lannfelt L., 1992, Psychiatric Genetics, V2, P249, DOI 10.1097/00041444-199210000-00003; LICHTER JB, 1993, HUM MOL GENET, V2, P767, DOI 10.1093/hmg/2.6.767; LIU Q, 1995, AM J MED GENET, V60, P165, DOI 10.1002/ajmg.1320600216; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; NANKO S, 1994, LANCET, V343, P1044, DOI 10.1016/S0140-6736(94)90167-8; NATHANS J, 1994, CELL, V78, P357, DOI 10.1016/0092-8674(94)90414-6; NAYLOR L, 1995, BIOCHEM SOC T, V23, P87, DOI 10.1042/bst0230087; NOTHEN MM, 1994, LANCET, V343, P1301, DOI 10.1016/S0140-6736(94)92194-6; RAM A, 1995, AM J MED GENET, V60, P228, DOI 10.1002/ajmg.1320600311; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; ROBINSON SW, 1994, MOL PHARMACOL, V46, P352; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; SHAIKH S, 1994, LANCET, V343, P1045; SHENKER A, 1995, BAILLIERE CLIN ENDOC, V9, P427, DOI 10.1016/S0950-351X(95)80519-2; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SMITH SS, 1992, ARCH GEN PSYCHIAT, V49, P723; SNYDER SH, 1974, SCIENCE, V184, P1243, DOI 10.1126/science.184.4143.1243; SOBELL JL, 1995, HUM MOL GENET, V4, P507, DOI 10.1093/hmg/4.4.507	36	117	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26013	26017		10.1074/jbc.271.42.26013	http://dx.doi.org/10.1074/jbc.271.42.26013			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824240	hybrid			2022-12-25	WOS:A1996VN18000046
J	Macheroux, P; Bornemann, S; Ghisla, S; Thorneley, RNF				Macheroux, P; Bornemann, S; Ghisla, S; Thorneley, RNF			Studies with flavin analogs provide evidence that a protonated reduced FMN is the substrate-induced transient intermediate in the reaction of Escherichia coli chorismate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE PROBES; MONONUCLEOTIDE; IDENTIFICATION; FLAVOPROTEINS; FLAVODOXINS; DERIVATIVES; REDUCTION; MECHANISM; KINETICS; BINDING	Chorismate synthase catalyzes the 1,4-elimination of phosphate and the C-(6-pro-R) hydrogen from 5-enolpyruvylshikimate S-phosphate (EPSP) to generate chorismate, Although this reaction does not involve an overall change in redox state, the enzyme requires reduced FMN. To investigate the role of the flavin in catalysis we have employed chemically modified flavins: 1- and 5-deaza-, 2- and 4-thio-, 6-hydroxy-, 8-nor-6-methyl-, 8-methyl-sulfonyl-, 8-chloro-, 8-fluoro-, 8-nor-methyl-, 8-S-methyl-, 8-methoxy, 8-mercapto- and 8-amino-FMN. Photoreduction of 4-thio-FMN in the presence of chorismate synthase at pH 7.5 produced a reduced flavin species with an absorbance maximum at lambda = 410 nm indicative of monoanionic, reduced 4-thio-FMN. Binding of 8-mercapto- and 6-hydroxy-FMN to chorismate synthase in the presence of EPSP or (6R)-6-fluoro-EPSP resulted in an increase of the flavin analogs' pK(a) values by 4 and 1 pH units, respectively, On the basis of these findings it is concluded that chorismate synthase preferentially binds neutral flavin species, including the protonated reduced form, rather than anionic flavin species in the presence of EPSP or the 6-fluoro-substrate analog, Further support for this conclusion was obtained using 5-deaza- and 4-thio-FMN, Addition of EPSP to enzyme bound, reduced 5-deaza-FMN produced spectral changes consistent with protonation of the flavin, Photoreduction of 4-thio-FMN in the presence of enzyme and the (6R)-6-fluoro-EPSP generated a reduced flavin species with absorbance properties of a neutral, reduced 4-thio-flavin. These results and their implications for the nature and kinetic properties of an observed flavin intermediate are discussed in the context of a possible role of reduced flavin as an electron donor to bound EPSP.	UNIV KONSTANZ,FAC BIOL,D-78434 CONSTANCE,GERMANY	University of Konstanz	Macheroux, P (corresponding author), JOHN INNES CTR PLANT SCI RES,NITROGEN FIXAT LAB,NORWICH RES PK,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Macheroux, Peter/AAB-5157-2019; Bornemann, Stephen/K-2938-2012	Macheroux, Peter/0000-0002-0242-454X; Bornemann, Stephen/0000-0001-5930-9473				ASHTON W T, 1977, Tetrahedron Letters, V30, P2551; BORNEMANN S, 1995, BIOCHEM J, V305, P707, DOI 10.1042/bj3050707; BORNEMANN S, 1995, J BIOL CHEM, V270, P22811, DOI 10.1074/jbc.270.39.22811; Bornemann S, 1996, BIOCHEMISTRY-US, V35, P9907, DOI 10.1021/bi952958q; Bornemann S, 1994, FLAVINS AND FLAVOPROTEINS 1993, P843; Bornemann S, 1995, PERSPECTIVES PROTEIN, P134; CHOONG YS, 1981, J BIOL CHEM, V256, P8671; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; DUDLEY KH, 1965, HELV CHIM ACTA, V47, P1354; ECKSTEIN JW, 1993, BIOCHEMISTRY-US, V32, P404, DOI 10.1021/bi00053a004; FRITZ BJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P113, DOI 10.1111/j.1751-1097.1987.tb08411.x; GHISLA S, 1980, BIOCHEMISTRY-US, V19, P2537, DOI 10.1021/bi00553a001; GHISLA S, 1986, BIOCHEM J, V239, P1; HALEY EE, 1954, J AM CHEM SOC, V76, P5093, DOI 10.1021/ja01649a025; KASAI S, 1983, J BIOCHEM-TOKYO, V93, P397, DOI 10.1093/oxfordjournals.jbchem.a134193; KASAI S, 1987, B CHEM SOC JPN, V60, P3041, DOI 10.1246/bcsj.60.3041; KASAI S, 1979, J NUTR SCI VITAMINOL, V25, P289; KNOWLES PF, 1970, METHOD ENZYMOL, V17, P360; KURFURST M, 1982, EUR J BIOCHEM, V123, P355, DOI 10.1111/j.1432-1033.1982.tb19775.x; LAUHON CT, 1994, BIOCHEMISTRY-US, V33, P14100, DOI 10.1021/bi00251a019; LUDWIG ML, 1990, BIOCHEMISTRY-US, V29, P10364, DOI 10.1021/bi00497a011; Macheroux P, 1996, BIOCHEMISTRY-US, V35, P1643, DOI 10.1021/bi951705u; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1984, J BIOL CHEM, V259, P9667; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Massey V., 1991, FLAVINS FLAVOPROTEIN, P581; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P289, DOI 10.1016/0005-2744(71)90207-5; MCCORMICK DB, 1964, BIOCHEM BIOPH RES CO, V14, P493, DOI 10.1016/0006-291X(64)90257-8; MCCORMICK DB, 1963, J BIOL CHEM, V238, P3095; MOORE EG, 1979, J BIOL CHEM, V254, P8173; MOORE EG, 1978, J BIOL CHEM, V253, P6413; MULLER F, 1966, HELV CHIM ACTA, V49, P2352, DOI 10.1002/hlca.660490740; MULLER F, 1969, J BIOL CHEM, V244, P4007; RAMJEE MK, 1994, ANAL BIOCHEM, V220, P137, DOI 10.1006/abio.1994.1309; RAMJEE MK, 1993, BIOORG MED CHEM LETT, V3, P1409, DOI 10.1016/S0960-894X(01)80421-2; RAMJEE MN, 1991, J AM CHEM SOC, V113, P8566, DOI 10.1021/ja00022a078; SCHOLLNHAMMER G, 1974, EUR J BIOCHEM, V44, P561, DOI 10.1111/j.1432-1033.1974.tb03514.x; SCHOPFER LM, 1981, J BIOL CHEM, V256, P7329; SPENCER R, 1977, BIOCHEMISTRY-US, V16, P3586, DOI 10.1021/bi00635a014; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; STEWART RC, 1985, J BIOL CHEM, V260, P3639; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8	44	41	43	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25850	25858		10.1074/jbc.271.42.25850	http://dx.doi.org/10.1074/jbc.271.42.25850			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824216	hybrid, Green Published, Green Submitted			2022-12-25	WOS:A1996VN18000022
J	Nakamuta, M; Chang, BHJ; Zsigmond, E; Kobayashi, K; Lei, H; Ishida, BY; Oka, K; Li, E; Chan, L				Nakamuta, M; Chang, BHJ; Zsigmond, E; Kobayashi, K; Lei, H; Ishida, BY; Oka, K; Li, E; Chan, L			Complete phenotypic characterization of apobec-1 knockout mice with a wild-type genetic background and a human apolipoprotein B transgenic: Background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of apobec-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; HUMAN ADENOVIRUS TYPE-5; MESSENGER-RNA; MOLECULAR-CLONING; PROTEIN; EXPRESSION; MOUSE; B-48; REGION; B-100	We have produced gene knockout mice by targeted disruption of the apobec-1 gene. As recently reported by Hirano et al. (Hirano, K.-I., Young, S. G., Farese, R. V., Jr., Ng, J., Sande, E., Warburton, C., Powell-Braxton, L. M., and Davidson, N. O. (1996) J. Biol. Chem. 271, 9887-9890), these animals do not edit apolipoprotein (ape) B mRNA or produce apoB-48. In this study we have performed a detailed analysis of the lipoprotein phenotypic effects of apobec-1 gene disruption that were not examined in the previous study. We first analyzed the plasma lipoproteins in knockout animals with a wild-type genetic background. Although there was no difference in plasma cholesterol between apobec-1(-/-), (+/-) (+/+) mice, there Or was a marked (176%) increase in plasma apoB-100, from 1.8 +/- 1.2 mg/dl in apobec-1(+/+) mice to 2.7 +/- 0.6 mg/dl in apobec-1(+/-) and 5.0 +/- 1.4 mg/dl in apobec-1(-/-) mice. Plasma apoE was similar in these animals. By fast protein liquid chromatography (FPLC) analysis, there was a significant decrease in plasma high density lipoprotein (HDL) cholesterol in apobec-1(-/-) mice. We further fractionated the plasma lipoproteins into d < 1.006, 1.006-1.02, 1.02-1.05, 1.05-1.08, 1.08-1.10, and 1.10-1.21 g/ml classes, and found a marked (30-40%) reduction in the cholesterol and protein content in the (d 1.08-1.10 and 1.10-1.21) HDL fractions, corroborating the FPLC data. SDS-gel analysis revealed an absence of apoB-48, an increase in apoB-100 in the very low density Lipoprotein (VLDL) and low density lipoprotein (LDL) fractions, and a small decrease in apoA-I in the HDL fractions in the apobec-1(-/-) samples. We next raised the basal plasma apoB levels in the apobec-1(-/-) animals by crossbreeding them with human apoB transgenic (TgB) mice. The plasma apoB-100 was 3-fold higher in apobec-1(-/-)/TgB(+/-) mice (26.6 +/- 18.3 mg/dl) than in apobec-1(+/+)/TgB(+/-) mice (9.8 +/- 3.9 mg/dl, p < 0.05). The apobec-1(-/-)/TgB(+/-) mice had a plasma cholesterol levels of 170 +/- 28 mg/dl and triglyceride levels of 106 +/- 31 mg/dl, which are 80% and 58% higher, respectively, than the corresponding values of 94 +/- 21 mg/dl and 67 +/- 11 mg/dl in apobec(+/+)/TgB(+/-) mice. By FPLC, the apobec-1(-/-)/TgB(+/-) animals developed markedly elevated plasma LDL cholesterol (518.5 +/- 329.5 mu g/ml) that is 373% that of apobec-1(+/+)/TgB(+/-) mice (139.0 +/- 87.0 mu g/ml) (p < 0.05). The elevated plasma triglyceride was accounted for mainly by a 97% increase in VLDL triglyceride in the apobec-1(-/-)/TgB(+/-) mice. We conclude that apobec-1(-/-) animals have a distinctive lipoprotein phenotype characterized by significant hyperapoB-100 and HDL deficiency in mice with a wild-type genetic background. Furthermore, the abolition of apoB mRNA editing elevates plasma total cholesterol and LDL cholesterol in apobec-1(-/-) animals with a TgB background. Finally, to exclude the possibility that absence of apoB mRNA editing was a secondary effect of chronic Apobec-1 deficiency, we treated apobec-1(-/-) mice with a replication-defective mouse Apobec-1 adenoviral vector and found that we could acutely restore apoB mRNA editing in the Liver. These experiments indicate that Apobec-1 is an essential component of the apoB mRNA editing machinery and absence of editing in the knockout animals is a direct consequence of the absence of functional Apobec-1.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; CHILDRENS NUTR RES CTR,USDA ARS,HOUSTON,TX 77030; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	Baylor College of Medicine; United States Department of Agriculture (USDA); Harvard University; Massachusetts General Hospital; University of California System; University of California San Francisco	Nakamuta, M (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Kobayashi, Kunihisa/V-9554-2019	Kobayashi, Kunihisa/0000-0002-7741-846X	NHLBI NIH HHS [HL56668, HL51586, HL16512] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R01HL056668, R37HL016512] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHAN L, 1993, BIOESSAYS, V15, P33, DOI 10.1002/bies.950150106; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHAN L, 1995, SCI MED, V2, P68; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chien KR, 1996, J CLIN INVEST, V97, P901, DOI 10.1172/JCI118512; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; DESILVA HV, 1994, J LIPID RES, V35, P1297; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEVE J, 1993, J LIPID RES, V34, P1367; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; Hughes SD, 1996, HUM GENE THER, V7, P39, DOI 10.1089/hum.1996.7.1-39; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; ISHIDA BY, 1992, J LIPID RES, V33, P1073; Kobayashi K, 1996, J BIOL CHEM, V271, P6852, DOI 10.1074/jbc.271.12.6852; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAKAMUTA M, 1995, 68 SCI SESS AM HEART, P54; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; Paigen Beverly, 1994, Current Opinion in Lipidology, V5, P258, DOI 10.1097/00041433-199408000-00003; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; TENG BB, 1994, J BIOL CHEM, V269, P29395; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; VANTHOOFT FM, 1982, P NATL ACAD SCI-BIOL, V79, P179; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435	34	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25981	25988		10.1074/jbc.271.42.25981	http://dx.doi.org/10.1074/jbc.271.42.25981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824235				2022-12-25	WOS:A1996VN18000041
J	Nebl, G; Meuer, SC; Samstag, Y				Nebl, G; Meuer, SC; Samstag, Y			Dephosphorylation of serine 3 regulates nuclear translocation of cofilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; PORCINE BRAIN; ACTIN-BINDING; SEQUENCE; ACTIVATION; SIGNAL; CELLS; IDENTIFICATION; TRANSPORT; YEAST	Signal transduction processes in T-cells and other cell types alter the phosphorylation state of cofilin, an actin-binding phosphoprotein. Whether reversible phosphorylation is responsible for the regulation of the functional activities of cofilin is not clear at present. Here we have identified the phosphoacceptor site of cofilin and analyzed the role of cofilin phosphorylation with respect to its subcellular localization. Site-directed mutagenesis studies show that phosphorylation occurs exclusively on Ser-3. Expression of non-phosphorylatable mutant cofilin proteins in NIH3T3 cells and determination of their subcellular localization by confocal laser scanning microscopy reveal that non phosphorylated cofilin accumulates within nuclei. This analysis shows that the subcellular localization of cofilin depends on the phosphorylation state of Ser-3.	UNIV HEIDELBERG,INST IMMUNOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; ADDISON C, 1990, ONCOGENE, V5, P423; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; IIDA K, 1993, GENE, V124, P115; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; KANAMORI T, 1995, J BIOL CHEM, V270, P8061, DOI 10.1074/jbc.270.14.8061; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; NEBL G, 1994, J BIOL CHEM, V269, P7371; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OGAWA K, 1990, NUCLEIC ACIDS RES, V18, P7169, DOI 10.1093/nar/18.23.7169; OHTA Y, 1989, J BIOL CHEM, V264, P16143; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SAMSTAG Y, 1991, J IMMUNOL, V147, P788; SAMSTAG Y, 1992, INT IMMUNOL, V4, P1255, DOI 10.1093/intimm/4.11.1255; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; Samstag Y, 1996, J IMMUNOL, V156, P4167; SUZUKI K, 1995, J BIOL CHEM, V270, P19551, DOI 10.1074/jbc.270.33.19551	25	100	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26276	26280		10.1074/jbc.271.42.26276	http://dx.doi.org/10.1074/jbc.271.42.26276			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824278				2022-12-25	WOS:A1996VN18000084
J	Thomas, CP; Doggett, NA; Fisher, R; Stokes, JB				Thomas, CP; Doggett, NA; Fisher, R; Stokes, JB			Genomic organization and the 5' flanking region of the gamma subunit of the human amiloride-sensitive epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; DNA METHYLATION; HOMOLOGOUS SUBUNITS; MEMBRANE TOPOLOGY; LIDDLES SYNDROME; EXPRESSION; CLONING; GENE; ALDOSTERONE; MUTATIONS	The amiloride sensitive epithelial sodium channel (ENaC) complex is made up of at least three different subunits alpha, beta, and gamma, which are developmentally regulated, selectively expressed, and variously up-regulated by steroid hormones. To understand mechanisms involved in regulation of the gamma subunit, we have determined the structure of the human gamma ENaC gene. By 5' rapid amplification of cDNA ends, primer extension analysis, and nuclease protection assay, we identified transcription start sites in human brain, kidney, and lung. A human genomic library was screened and overlapping cosmid clones that span similar to 50 kilobases and con tain the h gamma ENaC gene were identified. The 5'-untranslated region is 141 bases long, and the translation start codon is contained within the second exon, The human gene spans at least 35 kilobases. The 5' end of the gene including portions of 5' flanking genomic DNA and the first intron are G + C rich and contain several CPG dinucleotides, consistent with a CpG island. The 5' flanking region contains no CCAAT or TATA-like elements but does contain two GC boxes as well as several putative transcription factor binding sites including AP-2, Sp1, CRE, PEA-3, and NF-IL6. This is the first description of the structural organization and the 5' flanking region of a member of the epithelial sodium channel complex.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA USA; UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA USA; VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA; LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; United States Department of Energy (DOE); Los Alamos National Laboratory	Thomas, CP (corresponding author), UNIV IOWA HOSP & CLIN, DEPT INTERNAL MED, DIV NEPHROL, 200 HAWKINS DR, IOWA CITY, IA 52242 USA.			Fisher, Rory/0000-0003-3108-4836; Thomas, Christie/0000-0002-5989-9685	NIDDK NIH HHS [DK 25231] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025231] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHAMPIGNY G, 1994, EMBO J, V13, P2177, DOI 10.1002/j.1460-2075.1994.tb06494.x; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GARTY H, 1994, FASEB J, V8, P522, DOI 10.1096/fasebj.8.8.8181670; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; Lehman I R, 1974, Methods Enzymol, V29, P46; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; LONGMIRE JL, 1993, GENET ANAL-BIOMOL E, V10, P69, DOI 10.1016/1050-3862(93)90037-J; MASON PJ, 1993, GENE TRANSCRIPTION P, P5; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RENARD S, 1994, J BIOL CHEM, V269, P12981; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; THOMAS CP, 1995, J AM SOC NEPHROL, V6, P353; VOILLEY N, 1995, GENOMICS, V28, P560, DOI 10.1006/geno.1995.1188; Volk KA, 1995, J CLIN INVEST, V96, P2748, DOI 10.1172/JCI118344; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	39	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26062	26066		10.1074/jbc.271.42.26062	http://dx.doi.org/10.1074/jbc.271.42.26062			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824247	hybrid			2022-12-25	WOS:A1996VN18000053
J	Hembrough, TA; Li, L; Gonias, SL				Hembrough, TA; Li, L; Gonias, SL			Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; UROKINASE RECEPTOR; TUMOR INVASION; ANNEXIN-II; BINDING; EXPRESSION; CARCINOMA; METASTASIS; FIBRIN; IDENTIFICATION	Cytokeratin 8 (CK 8) has been identified on the external surfaces of viable, unpermeabilized epithelial cells (Hembrough, T. A., Vasudevan, J., Allietta, M. M., Glass, W.F., and Gonias, S. L. (1995) J. Cell Sci. 108, 1071-1082). In this study, we demonstrated that CK 8 is the major plasminogen-binding protein in plasma membrane fractions isolated from three breast cancer cell lines, BT20, MCF-7, and MDA-MB-157. To assess the function of CK 8 as a plasminogen receptor, monoclonal antibody 1E8 was raised against the carboxyl-terminal 12 amino acids of CK 8. The 1E8 epitope was present on the external surfaces of breast cancer cells, as determined by immunofluorescence microscopy. I-125-1E8 bound to MCF-7 cells; the maximum binding capacity (1.5 x 10(6) sites per cell) was comparable with that determined for plasminogen. When MCF-7 cells were incubated with Fab fragments of 1E8, specific I-125-plasminogen binding was decreased up to 82%. Specific plasminogen binding was decreased up to 67%, even when the unbound 1E8 Feb was removed by washing the cells prior to adding I-125-plasminogen. Preincubation with 1E8 Fab decreased plasminogen binding to BT20 and MDA-MB-157 cells, although to a lesser extent than with MCF-7 cells. Plasminogen activation by tissue-type plasminogen activator was greatly accelerated, due to a large decrease in K-m, when the plasminogen was bound to MCF-7 cells. Pretreatment with 1E8 Fab decreased the rate of plasminogen activation by up to 83%, implicating CK 8 in the MCF-7 cell-accelerated reaction. These studies identify cell-surface CR 8 as a major plasminogen receptor in breast cancer cells and as a required component for the rapid activation of cell-associated plasminogen by tissue-type plasminogen activator.	UNIV VIRGINIA, HLTH SCI CTR, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia								ACHTSTAETTER T, 1986, METHOD ENZYMOL, V134, P355; ALIZADEH H, 1995, CURR EYE RES, V14, P449, DOI 10.3109/02713689509003755; AZUMI N, 1987, AM J CLIN PATHOL, V88, P286, DOI 10.1093/ajcp/88.3.286; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BIANCHI E, 1994, CANCER RES, V54, P861; BURTON DR, 1987, MOL GENETICS IMMUNOG, P11; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHAN R, 1985, MONOCLONAL ANTIBODIE, P165; CHRISTENSEN U, 1985, FEBS LETT, V182, P43, DOI 10.1016/0014-5793(85)81150-9; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; CORREC P, 1990, INT J CANCER, V46, P745, DOI 10.1002/ijc.2910460432; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DUFFY MJ, 1990, CANCER RES, V50, P6827; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; EVANS DM, 1995, AM SURGEON, V61, P692; FLEISCHER S, 1986, METHOD ENZYMOL, V31, P6; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; GODFROID E, 1991, J CELL SCI, V99, P595; GONIAS SL, 1992, EXP HEMATOL, V20, P302; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HALL SW, 1990, J CELL BIOCHEM, V43, P213, DOI 10.1002/jcb.240430303; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hembrough TA, 1996, BIOCHEM J, V317, P763, DOI 10.1042/bj3170763; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KOBAYASHI H, 1994, CANCER RES, V54, P844; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1981, CANCER RES, V41, P4629; LIU JN, 1993, J BIOL CHEM, V268, P12257; MIETTINEN M, 1989, LAB INVEST, V61, P623; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; REDLITZ A, 1995, EUR J BIOCHEM, V227, P407, DOI 10.1111/j.1432-1033.1995.tb20403.x; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SCHAAFSMA HE, 1991, AM J PATHOL, V139, P1389; SCHAAFSMA HE, 1993, J PATHOL, V170, P77, DOI 10.1002/path.1711700113; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; URANO T, 1988, BIOCHEMISTRY-US, V27, P6522, DOI 10.1021/bi00417a049	47	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25684	25691		10.1074/jbc.271.41.25684	http://dx.doi.org/10.1074/jbc.271.41.25684			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810346	hybrid			2022-12-25	WOS:A1996VL69300090
J	Imamura, R; Yamanaka, K; Ogura, T; Hiraga, S; Fujita, N; Ishihama, A; Niki, H				Imamura, R; Yamanaka, K; Ogura, T; Hiraga, S; Fujita, N; Ishihama, A; Niki, H			Identification of the cpdA gene encoding cyclic 3',5'-adenosine monophosphate phosphodiesterase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE GENE; RNA-POLYMERASE; TRANSCRIPTION ACTIVATION; CELL-DIVISION; FUNCTIONAL MAP; ALPHA-SUBUNIT; PROTEIN; CHROMOSOME; DNA; EXPRESSION	We have identified a gene, cpdA, located at 66.2 min of the chromosome of Escherichia coli that encodes cyclic 3',5'-adenosine monophosphate phosphodiesterase (cAMP phosphodiesterase, EC 3.1.4.17). The expression of beta-galactosidase, which is a product of the lacZ gene, was repressed in cells that harbored multiple copies of the plasmid carrying the cpdA gene. Northern blotting showed that the transcription of the lacZ gene was inhibited in these cells. Multiple copies of the cpdA gene decreased the intracellular concentration of GAMP, which is a positive regulator for transcription of the lacZ gene, We found that the purified CpdA protein repressed in vitro transcription from the lacP1 promoter by decreasing cAMP, In addition, we showed that the CpdA protein hydrolyzed cAMP to 5'-adenosine monophosphate and that its activity was activated by iron. Our results suggested that regulation of intracellular concentration of cAMP is dependent not only on synthesis of cAMP but also on hydrolysis of cAMP by cAMP phosphodiesterase.	KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,DEPT MOL CELL BIOL,KUMAMOTO 862,JAPAN; NATL INST GENET,DEPT MOL GENET,MISHIMA,SHIZUOKA 411,JAPAN	Kumamoto University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan			IMAMURA, Ryu/D-8433-2015	Ogura, Teru/0000-0003-3784-0970; Niki, Hironori/0000-0002-5391-6595				AIBA H, 1981, J BIOL CHEM, V256, P1905; AIBA H, 1985, J BIOL CHEM, V260, P3063; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRANA H, 1965, FOLIA MICROBIOL, V11, P43; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DARI R, 1988, J BACTERIOL, V170, P65, DOI 10.1128/jb.170.1.65-70.1988; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GILBERT I, 1989, CURR MICROBIOL, V20, P83; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HUGHES P, 1988, CELL, V55, P343, DOI 10.1016/0092-8674(88)90057-8; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; IMAMURA R, 1992, RES MICROBIOL, V143, P743, DOI 10.1016/0923-2508(92)90102-T; JAFFE A, 1986, J BACTERIOL, V165, P66, DOI 10.1128/jb.165.1.66-71.1986; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P3873, DOI 10.1093/nar/11.12.3873; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOMANO T, 1991, RES MICROBIOL, V142, P269, DOI 10.1016/0923-2508(91)90040-H; Miller J.H., 1972, EXPT MOL GENETICS; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MORI K, 1985, J BIOL CHEM, V260, P4838; Nakajima E, 1991, ANAL SCI, V7, P667, DOI 10.2116/analsci.7.Supple_667; NIELSEN LD, 1973, J BACTERIOL, V116, P857, DOI 10.1128/JB.116.2.857-866.1973; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; REDDY P, 1985, P NATL ACAD SCI USA, V82, P8300, DOI 10.1073/pnas.82.24.8300; REDDY P, 1985, P NATL ACAD SCI USA, V82, P5656, DOI 10.1073/pnas.82.17.5656; REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAHL FW, 1986, GENETICS, V113, P215; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; XING XF, 1991, J BACTERIOL, V173, P4570	41	83	88	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25423	25429		10.1074/jbc.271.41.25423	http://dx.doi.org/10.1074/jbc.271.41.25423			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810311	hybrid			2022-12-25	WOS:A1996VL69300055
J	Liu, GY; Hinch, B; Beavis, AD				Liu, GY; Hinch, B; Beavis, AD			Mechanisms for the transport of alpha,omega-dicarboxylates through the mitochondrial inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN DICARBOXYLIC-ACIDS; AZELAIC ACID; RAT-LIVER; ANION CHANNEL; STAPHYLOCOCCUS-EPIDERMIDIS; PROPIONIBACTERIUM-ACNES; INTACT MITOCHONDRIA; KIDNEY MITOCHONDRIA; LIGHT-SCATTERING; BETA-OXIDATION	alpha,omega-Dicarboxylates have antibacterial properties, have been used in the treatment of hyperpigmentary disorders, are active against various melanoma cell lines, and can also undergo beta-oxidation. Little, however, is known about their transport. In this paper, we examine the mitochondrial transport of alpha,omega-dicarboxylates ranging from oxalate (DC2) to sebacate (DC10). DC2-DC10 are transported by the inner membrane anion channel (IMAC), DC6-DC10 are also transported by an electroneutral mechanism that appears to reflect transport of the acid through the lipid bilayer. At 37 degrees C and pH 7.0, DC10 is transported very rapidly at 3 mu mol/min . mg, and respiring mitochondria swell in the K+ salts of these acids. This transport mechanism is probably the major pathway by which the longer dicarboxylates enter cells, bacteria, and mitochondria, We also demonstrate that DC5-DC10 can also be transported by an electroneutral mechanism mediated by tributyltin, a potent inhibitor of IMAC, The mechanism appears to involve electroneutral exchange of a TBT-dicarboxylate-H complex for TBT-OH. Finally, we present evidence that of all the dicarboxylates tested only DC2-DC4 can be transported by the classical dicarboxylate carrier.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NHLBI NIH HHS [HL47735] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL047735] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAVIS AD, 1988, J BIOL CHEM, V263, P7574; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BERGSETH S, 1990, BIOCHIM BIOPHYS ACTA, V1042, P182, DOI 10.1016/0005-2760(90)90005-I; BOJAR RA, 1988, J APPL BACTERIOL, V64, P497, DOI 10.1111/j.1365-2672.1988.tb02441.x; BOJAR RA, 1994, J ANTIMICROB CHEMOTH, V34, P321, DOI 10.1093/jac/34.3.321; BOJAR RA, 1991, J ANTIMICROB CHEMOTH, V28, P843, DOI 10.1093/jac/28.6.843; Breathnach A S, 1989, Acta Derm Venereol Suppl (Stockh), V143, P62; BREATHNACH AC, 1989, CLIN DERMATOL, V7, P106, DOI 10.1016/0738-081X(89)90061-8; CERDAN S, 1988, J BIOL CHEM, V263, P11664; DRAYE JP, 1988, EUR J BIOCHEM, V178, P183, DOI 10.1111/j.1432-1033.1988.tb14442.x; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GREGO AV, 1995, CLIN NUTR, V14, P143, DOI 10.1016/S0261-5614(95)80011-5; HU F, 1986, BRIT J DERMATOL, V114, P17, DOI 10.1111/j.1365-2133.1986.tb02775.x; JEZEK P, 1990, J BIOL CHEM, V265, P19303; KOLVRAA S, 1986, BIOCHIM BIOPHYS ACTA, V876, P515, DOI 10.1016/0005-2760(86)90039-1; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; Liu GY, 1996, J BIOL CHEM, V271, P19717, DOI 10.1074/jbc.271.33.19717; MARTIN WH, 1984, J BIOL CHEM, V259, P2062; MORTENSEN PB, 1981, BIOCHIM BIOPHYS ACTA, V666, P394, DOI 10.1016/0005-2760(81)90298-8; MORTENSEN PB, 1981, BIOCHIM BIOPHYS ACTA, V664, P349, DOI 10.1016/0005-2760(81)90057-6; NGUYEN QH, 1995, INT J DERMATOL, V34, P75, DOI 10.1111/j.1365-4362.1995.tb03583.x; PASSI S, 1984, BIOCHEM PHARMACOL, V33, P103, DOI 10.1016/0006-2952(84)90376-9; Passi S, 1989, Acta Derm Venereol Suppl (Stockh), V143, P8; POWERS MF, 1991, J BIOL CHEM, V266, P17250; ROBINS EJ, 1985, BRIT J DERMATOL, V113, P687, DOI 10.1111/j.1365-2133.1985.tb02404.x; SELWYN MJ, 1976, ORGANOTIN COMPOUNDS, P204; SHOLTZ KF, 1993, FEBS LETT, V327, P54, DOI 10.1016/0014-5793(93)81038-2; STEIN WD, 1986, TRANSPORT DIFFUSION, P88; STRZELECKI T, 1986, J BIOL CHEM, V261, P2197; STRZELECKI T, 1989, J UROLOGY, V141, P423, DOI 10.1016/S0022-5347(17)40786-5; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; Tserng KY, 1996, METABOLISM, V45, P162, DOI 10.1016/S0026-0495(96)90047-5; TSERNG KY, 1991, J BIOL CHEM, V266, P2924; VAMECQ J, 1989, AM J PHYSIOL, V256, pG680, DOI 10.1152/ajpgi.1989.256.4.G680	38	35	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25338	25344		10.1074/jbc.271.41.25338	http://dx.doi.org/10.1074/jbc.271.41.25338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810298	hybrid			2022-12-25	WOS:A1996VL69300042
J	Pallante, KM; Niu, ZL; Zhao, YF; Cohen, AJ; Nah, HD; Adams, SL				Pallante, KM; Niu, ZL; Zhao, YF; Cohen, AJ; Nah, HD; Adams, SL			The chick alpha 2(I) collagen gene contains two functional promoters, and its expression in chondrocytes is regulated at both transcriptional and post-transcriptional levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I COLLAGEN; MESSENGER-RNAS; NUCLEAR FACTOR; DNA-SEQUENCES; BINDING-SITES; PROCOLLAGEN; ENHANCER; PRO-ALPHA-1(I); IDENTIFICATION; FIBROBLASTS	Embryonic chick cartilages contain transcripts derived from the alpha 2(I) collagen gene, although type I collagen is not normally found in these tissues; most of these RNAs are alternative transcripts initiating within intron 2, Use of the internal start site results in replacement of exons 1 and 2 with a previously undescribed exon and a change in the translational reading frame; thus, the alternative transcript cannot encode alpha 2(I) collagen. We have demonstrated that production of the alternative transcript is due to activation of an internal promoter in chondrocytes and have identified a 179-base pair domain that is required for its activity, Furthermore, we have shown that the alternative transcript resulting from activation of the internal promoter turns over relatively rapidly; thus, the steady-state level of this transcript is less than predicted based on the transcription rate, The upstream promoter is only partially repressed in chondrocytes, suggesting that the lack of authentic alpha 2(I) collagen mRNA may also be due in part to decreased mRNA stability, Thus, repression of alpha 2(I) collagen synthesis in cartilage involves both transcriptional and post-transcriptional mechanisms. In contrast, repression of alpha 1(I) collagen synthesis appears to be mediated primarily at the level of transcription.	UNIV PENN,SCH DENT MED,DEPT BIOCHEM,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007490, R01AR041042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM128840] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32 AR07490, AR41042] Funding Source: Medline; NIGMS NIH HHS [GM28840] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; ADAMS SL, 1991, EXP CELL RES, V193, P190, DOI 10.1016/0014-4827(91)90555-9; Akira S, 1995, ANN NY ACAD SCI, V762, P15; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ASKEW GR, 1991, J BIOL CHEM, V266, P16834; BAMHART KM, 1989, MOL CELL BIOL, V9, P2606; BENNETT VD, 1989, J BIOL CHEM, V264, P8402; BENNETT VD, 1987, J BIOL CHEM, V262, P14806; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BOAST S, 1990, J BIOL CHEM, V265, P13351; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; CARSWELL S, 1989, MOL CELL BIOL, V9, P4248, DOI 10.1128/MCB.9.10.4248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWET WJ, 1983, J BIOL CHEM, V258, P4385; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DOEGE KJ, 1994, J BIOL CHEM, V269, P29232; Emerson CP, 1993, CURR OPIN CELL BIOL, V5, P1057, DOI 10.1016/0955-0674(93)90092-5; ERICKSON JM, 1981, GENE, V16, P1, DOI 10.1016/0378-1119(81)90055-X; FOCHT RJ, 1984, MOL CELL BIOL, V4, P1843, DOI 10.1128/MCB.4.9.1843; GILMAN M, 1987, CURRENT PROTOCOLS MO; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMALAINEN L, 1985, J BIOL CHEM, V260, P720; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HOUGLUM K, 1994, J CLIN INVEST, V94, P808, DOI 10.1172/JCI117400; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; LEHRACH H, 1978, P NATL ACAD SCI USA, V75, P5417, DOI 10.1073/pnas.75.11.5417; LIM K, 1989, BIOTECHNIQUES, V7, P576; LYONS BL, 1984, NUCLEIC ACIDS RES, V12, P2569, DOI 10.1093/nar/12.5.2569; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Nah HD, 1996, DEV DYNAM, V206, P146, DOI 10.1002/(SICI)1097-0177(199606)206:2<146::AID-AJA4>3.0.CO;2-I; OHKUBO H, 1980, P NATL ACAD SCI-BIOL, V77, P7059, DOI 10.1073/pnas.77.12.7059; OLSEN AS, 1989, MATRIX, V9, P73, DOI 10.1016/S0934-8832(89)80024-1; PACIFICI M, 1991, EXP CELL RES, V195, P38, DOI 10.1016/0014-4827(91)90497-I; PETERKOFSKY B, 1986, J BIOL CHEM, V261, P6818; RHODES C, 1995, NUCLEIC ACIDS RES, V23, P2305, DOI 10.1093/nar/23.12.2305; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VOGELI G, 1981, P NATL ACAD SCI-BIOL, V78, P5334, DOI 10.1073/pnas.78.9.5334; VOGELI G, 1980, NUCLEIC ACIDS RES, V8, P1823, DOI 10.1093/nar/8.8.1823; Von der Mark K., 1986, RHEUMATOLOGY, V10; VONDERMARK K, 1980, CURR TOP DEV BIOL, V14, P190; VUUST J, 1985, EUR J BIOCHEM, V151, P449, DOI 10.1111/j.1432-1033.1985.tb09122.x; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WANG S, 1994, MATRIX BIOL, V14, P313, DOI 10.1016/0945-053X(94)90197-X; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WEISS MJ, 1995, EXP HEMATOL, V23, P99; YAMAMOTO T, 1980, J BIOL CHEM, V255, P2612; YOUNG MF, 1984, NUCLEIC ACIDS RES, V12, P4207, DOI 10.1093/nar/12.10.4207	54	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25233	25239		10.1074/jbc.271.41.25233	http://dx.doi.org/10.1074/jbc.271.41.25233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810284	hybrid			2022-12-25	WOS:A1996VL69300028
J	De, BP; Gupta, S; Zhao, H; Drazba, JA; Banerjee, AK				De, BP; Gupta, S; Zhao, H; Drazba, JA; Banerjee, AK			Specific interaction in vitro and in vivo of glyceraldehyde-3-phosphate dehydrogenase and LA protein with cis-acting RNAs of human parainfluenza virus type 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; LEADER RNA; MESSENGER-RNA; GENE-EXPRESSION; BINDING PROTEIN; POLIOVIRUS RNA; POLYMERASE-III; MEASLES-VIRUS; SEQUENCE; TRANSCRIPTION	Human parainfluenza virus type 3 (HPIV3) genome RNA is transcribed and replicated by the virus-encoded RNA-dependent RNA polymerase, and specific cellular proteins play a regulatory role in these processes. To search for cellular proteins potentially interacting with HPIV3 cis-acting regulatory RNAs, a gel mobility shift assay was used, Two cellular proteins specifically interacted with the viral cis-acting RNAs containing the genomic 3'-noncoding region and the plus sense leader sequence region. Surprisingly, by biochemical and immunological analyses, one of the cellular proteins was identified as the key glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The other protein was characterized as the autoantigen, LA protein. Both GAPDH and LA protein also interacted with the same cis-acting RNA sequences in vivo and were found to be associated with the HPIV3 ribonucleoprotein complex in the infected cells. By double immunofluorescent labeling, GAPDH was found to be co-localized with viral ribonucleoprotein in the perinuclear region. These observations strongly suggest that cellular GAPDH and LA Protein participate in the regulation of HPIV3 gene expression.	CLEVELAND CLIN FDN, DEPT NEUROSCI, RES INST, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation	De, BP (corresponding author), CLEVELAND CLIN FDN, DEPT MOL BIOL, RES INST, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.				NIAID NIH HHS [AI32027] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032027] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE AK, 1991, PHARMACOL THERAPEUT, V51, P47, DOI 10.1016/0163-7258(91)90041-J; BLUMBERG BM, 1991, PARAMYXOVIRUSES, P235; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; Collins P. L., 1996, FIELDS VIROLOGY, P1205; DE BP, 1993, J BIOL CHEM, V268, P5703; DE BP, 1993, VIROLOGY, V196, P344, DOI 10.1006/viro.1993.1486; DE BP, 1995, P NATL ACAD SCI USA, V92, P5204, DOI 10.1073/pnas.92.11.5204; DUGGAL R, 1994, AM SOC VIR 13 ANN M, P277; FRANCOEUR AM, 1982, P NATL ACAD SCI-BIOL, V79, P6772, DOI 10.1073/pnas.79.22.6772; Galinski M.S., 1991, PARAMYXOVIRUSES, P41; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; HABETS WJ, 1983, EMBO J, V2, P1625, DOI 10.1002/j.1460-2075.1983.tb01636.x; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HORIKAMI SM, 1991, J VIROL, V65, P5342, DOI 10.1128/JVI.65.10.5342-5347.1991; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KURILLA MG, 1982, P NATL ACAD SCI-BIOL, V79, P5240, DOI 10.1073/pnas.79.17.5240; KURILLA MG, 1984, J VIROL, V50, P773, DOI 10.1128/JVI.50.3.773-778.1984; KURILLA MG, 1983, CELL, V34, P837, DOI 10.1016/0092-8674(83)90541-X; LEOPARDI R, 1993, J VIROL, V67, P785, DOI 10.1128/JVI.67.2.785-790.1993; LERNER MR, 1981, P NATL ACAD SCI-BIOL, V78, P805, DOI 10.1073/pnas.78.2.805; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MATHEWS MB, 1984, MOL CELL BIOL, V4, P1134, DOI 10.1128/MCB.4.6.1134; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MURRAY MF, 1995, BIOCHEM BIOPH RES CO, V212, P126, DOI 10.1006/bbrc.1995.1945; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NISHIYAMA A, 1993, MOL BIOL CELL, V4, P1097, DOI 10.1091/mbc.4.11.1097; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; ROKEACH LA, 1988, P NATL ACAD SCI USA, V85, P4832, DOI 10.1073/pnas.85.13.4832; Rossmann M. G., 1975, ENZYMES, V11, P62; RYAZANOV AG, 1985, FEBS LETT, V192, P131, DOI 10.1016/0014-5793(85)80058-2; RYAZANOV AG, 1988, EUR J BIOCHEM, V171, P301, DOI 10.1111/j.1432-1033.1988.tb13790.x; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TONEGUZZO F, 1976, J VIROL, V17, P477, DOI 10.1128/JVI.17.2.477-491.1976; WILUSZ J, 1983, P NATL ACAD SCI-BIOL, V80, P5827, DOI 10.1073/pnas.80.19.5827; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0	41	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24728	24735		10.1074/jbc.271.40.24728	http://dx.doi.org/10.1074/jbc.271.40.24728			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798741	hybrid			2022-12-25	WOS:A1996VM67400063
J	Nakajima, T; Morita, K; Ohi, N; Arai, T; Nozaki, N; Kikuchi, A; Osaka, F; Yamao, F; Oda, K				Nakajima, T; Morita, K; Ohi, N; Arai, T; Nozaki, N; Kikuchi, A; Osaka, F; Yamao, F; Oda, K			Degradation of topoisomerase II alpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; CHROMATIN CONDENSATION; MITOTIC CHROMOSOMES; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; E1A PROTEINS; DNA; GENE; P53	The human epithermoid carcinoma-derived cell line MA1, established by introduction of the adenovirus E1A 12 S cDNA linked to the mouse mammary tumor virus long terminal repeat, elicits apoptosis after induction of E1A(12S) in response to dexamethasone. The level of topoisomerase II alpha begins to decrease steeply within 36 h preceding the onset of DNA fragmentation, whereas its mRNA level is unchanged (Nakajima, T., Ohi, N., Arai, T., Nozaki, N., Kikuchi, A., and Oda, K. (1995) Oncogene 10, 651-662). Topoisomerase II alpha prepared by immunoprecipitation or extraction of the nuclear matrix was degraded much more efficiently in the S10 extract prepared from MA1 cells treated with dexamethasone for 42 h (the 42-h extract) than in the extract from untreated MA1 cells (the 0-h extract) in an ATP- and ubiquitin-dependent manner. The proteolytic activity for degradation of topoisomerase II alpha was suppressed specifically by inhibitors for the proteasome and was much reduced in the 42-h extract prepared from MA1-derivative cell lines expressing E1B19k or Bcl-2. The proteolytic activity was lost after fractionation of the 42-h S10 extract into the S70 and P70 fractions by centrifugation at 70,000 x g for 6 h but partially recovered when these fractions were combined. Polyubiquitinated forms of topoisomerase II alpha could be detected by incubating it in the S70 or S100 extract, which lacks most of the proteasome activity. The ubiquitination activity in S70 prepared from the 42-h extract was 4- to 5-fold higher than that prepared from the 0-h extract. These results suggest that a component(s) in the ubiquitin proteolysis pathway, responsible for ubiquitination and degradation of topoisomerase II alpha, is activated or induced during the latent phase of E1A-induced apoptosis.	SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; KANAGAWA DENT COLL,DEPT ORAL BIOCHEM,YOKOSUKA,KANAGAWA 238,JAPAN; MITSUBISHI CHEM INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; NATL INST GENET,MISHIMA,SHIZUOKA 411,JAPAN	Tokyo University of Science; Kanagawa Dental College; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Nakajima, T (corresponding author), SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN.							ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRAHAM FL, 1984, ADENOVIRUSES, P339; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Harlow E., 1988, ANTIBODIES LAB MANUA; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HSIANG YH, 1988, CANCER RES, V48, P3230; Innis MA, 1990, PCR PROTOCOLS GUIDE; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P325, DOI 10.1016/0022-2836(82)90332-1; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MANSER T, 1984, P NATL ACAD SCI-BIOL, V81, P2470, DOI 10.1073/pnas.81.8.2470; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NAKAJIMA T, 1995, ONCOGENE, V10, P651; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TAKEMORI N, 1984, J VIROL, V52, P793, DOI 10.1128/JVI.52.3.793-805.1984; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VISNITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	72	51	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24842	24849		10.1074/jbc.271.40.24842	http://dx.doi.org/10.1074/jbc.271.40.24842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798759	hybrid			2022-12-25	WOS:A1996VM67400081
J	Wang, LP; Lim, C; Kuan, YS; Chen, CL; Chen, HF; King, K				Wang, LP; Lim, C; Kuan, YS; Chen, CL; Chen, HF; King, K			Positive charge at position 549 is essential for phosphatidylinositol 4,5-bisphosphate-hydrolyzing but not phosphatidylinositol-hydrolyzing activities of human phospholipase C delta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC-ANALYSIS; ALPHA-SUBUNITS; BETA-GAMMA; ACTIVATION; C-DELTA-1; PROTEIN; BINDING; CELLS; GQ; IDENTIFICATION	Point mutagenesis, phosphatidylinositol (PI), and phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis assays and equilibrium centrifugation PIP2 assays were used to study the functional roles of four highly conserved arginine residues in the Y region of human phospholipase C delta 1 (PLC delta 1) (Arg-527, -549, -556, -701), Most of the mutant enzymes were either partially defective or fully active in their abilities to catalyze the hydrolysis of PI or PIP2. However, upon substitution of Arg-549 by glycine or histidine, the mutant enzyme was defective in its ability to catalyze the hydrolysis of PIP2, but it is still able to hydrolyze PI. Replacing Arg-549 with lysine had little effect on the level of PI and PIP2 hydrolytic activities of the mutant enzyme, The residual PIP2 hydrolyzing activity of R549H is highly dependent on pH, R549H showed 5-10% of the PIP2-hydrolyzing activity of the native enzyme between pH 5 and 7 and nondetectable PIP2-hydrolyzing activity at pH 8. The PIP2-hydrolyzing activity of R549G was not detectable at all pH values, Kinetic analysis of PLC delta 1-catalyzed PIP2 hydrolysis revealed that the micellar dissociation constant K-s and interfacial Michaelis constant K-m were similar in the native, R549K, and R549H enzymes; but the specific activity at the saturated substrate mole fraction and infinite level of substrate (V-max) of the R549H mutant were reduced by a factor of 15, PIP2 competitively inhibits the native enzyme to hydrolyze PI at both pH 7 and 8, However, PIP2 inhibits R549H only at pH 7.0 and does not inhibit R549G at either pH. Taken together, these results suggest that positive charge at position 549 of PLC delta 1 protein is essential for the enzyme to recognize and catalyze the hydrolysis of PIP2 but not PI.	ACAD SINICA, INST BIOMED SCI, TAIPEI 11529, TAIWAN; NATL TSING HUA UNIV, DEPT CHEM, HSINCHU 30043, TAIWAN	Academia Sinica - Taiwan; National Tsing Hua University			Lim, Carmay/N-9648-2015; 鍾, 士芳/A-5645-2008; Lim, Carmay/H-5949-2011	Lim, Carmay/0000-0001-9077-7769; Lim, Carmay/0000-0001-9077-7769				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; BRUZIK KS, 1992, BIOCHEMISTRY-US, V31, P5183, DOI 10.1021/bi00137a014; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; EMILSSON A, 1984, J BIOL CHEM, V259, P3111; EMORI Y, 1989, J BIOL CHEM, V264, P21885; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; IMAI A, 1986, P NATL ACAD SCI USA, V83, P8540, DOI 10.1073/pnas.83.22.8540; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; MUELLER P, 1983, BIOPHYS J, V44, P375, DOI 10.1016/S0006-3495(83)84311-2; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RHEE SG, 1992, CELLULAR MOL MECH IN; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WILSON DB, 1985, J BIOL CHEM, V260, P1046; WILSON DB, 1984, J BIOL CHEM, V259, P1718; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179	36	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24505	24516		10.1074/jbc.271.40.24505	http://dx.doi.org/10.1074/jbc.271.40.24505			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798711	hybrid			2022-12-25	WOS:A1996VM67400033
J	Kudoh, T; Ishidate, T; Nakamura, T; Toyoshima, K; Akiyama, T				Kudoh, T; Ishidate, T; Nakamura, T; Toyoshima, K; Akiyama, T			Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apoptotic cell death in response to retinoic acid	ONCOGENE			English	Article						WT1; Wilms tumor; tumor suppressor gene; apoptosis; F9	TERATOCARCINOMA STEM-CELLS; PROMOTER ACTIVITY; BAX GENE; C-MYC; DIFFERENTIATION; P53; PRODUCT; INDUCTION; PROTEIN; LOCUS	The product of the Wilms tumor suppressor gene, WT1, is thought to be a tissue specific transcription factor regulating cell growth and differentiation. To elucidate the function of WT1 in cellular differentiation, we examined the changes in the level of WT1 expression during retinoic acid induced-differentiation of embryonal carcinoma F9 cells into parietal endoderm cells. We found that, in response to retinoic acid addition, the expression of WT1 increased significantly after 12-24 h of incubation, then decreased and finally disappeared after 4 days, by which time most of the cells had differentiated into primitive endoderm cells. To examine the significance of these changes in WT1 expression, we established cell lines constitutively expressing one of the WT1 splicing variants. These cell lines showed a phenotype very similar to parental F9 cells in the absence of retinoic acid. However, in the presence of retinoic acid, they failed to differentiate into primitive endoderm cells and underwent apoptotic death 36 h after the addition of retinoic acid. These results suggest that downregulation of WT1 expression is necessary for normal differentiation of F9 cells into parietal endoderm cells.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,OSAKA 565,JAPAN; OSAKA MED CTR CANC & CARDIOVASC DIS,OSAKA 537,JAPAN	Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases								BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KLINKEN SP, 1988, EXP CELL RES, V178, P185, DOI 10.1016/0014-4827(88)90390-4; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIWA H, 1992, LEUKEMIA, V6, P405; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORRIS JF, 1991, ONCOGENE, V6, P2339; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUCHER FJ, 1990, SCIENCE, V250, P1259; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SEKIYA M, 1994, BLOOD, V83, P1876; SELLINS KS, 1987, J IMMUNOL, V139, P3199; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	45	23	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1431	1439						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875981				2022-12-25	WOS:A1996VL38400008
J	Kelm, RJ; Sun, S; Strauch, AR; Getz, MJ				Kelm, RJ; Sun, S; Strauch, AR; Getz, MJ			Repression of transcriptional enhancer factor-1 and activator protein-1-dependent enhancer activity by vascular actin single-stranded DNA binding factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-STIMULATED FIBROBLASTS; GENE PROMOTER; CODING SEQUENCES; OSTEOCALCIN GENE; MESSENGER-RNA; GAMMA-ACTIN; C-MYC; PROTEINS; IDENTIFICATION; ELEMENT	Transcriptional repression of the murine vascular smooth muscle alpha-actin gene in fibroblasts results from the interaction of two sequence-specific single-stranded DNA binding activities (VACssBF1 and VACssBF2) with opposite strands of an essential transcriptional enhancer factor-1 (TEF-1) element (Sun, S., Stoflet, E. S., Cogan, J. G., Strauch, A. R., and Getz, M. J. (1995) Mol. Cell. Biol. 15, 2429-2436). Here, we identify a sequence element located within a protein-coding exon of the gene that bears structural similarity with the TEF-1 enhancer. This includes a 30-base pair region of purine-pyrimidine asymmetry encompassing a perfect 6-base pair GGAATG TEF-1 recognition motif. Unlike the enhancer, however, the exon sequence exhibits no TEF-1 binding activity nor does the pyrimidine-rich strand bind VACssBF1. However, VACssBF2 interacts equally well with the purine-rich strand of both the enhancer and the exon sequence. To test the ability of VACssBF2 to independently repress transcription, the exon sequence was placed upstream of a deletionally activated promoter containing an intact TEF-1 binding site. The exon sequence repressed promoter activity, whereas a mutant deficient in VACssBF2 binding did not. Moreover, VACssBF2 similarly repressed activator protein-1-dependent transcription of a heterologous tissue factor promoter. These results suggest that VACssBF2 possesses an intrinsic ability to disrupt enhancer function independently of the enhancer-binding proteins involved.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; OHIO STATE UNIV,COLL MED,BIOCHEM PROGRAM,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,COLUMBUS,OH 43210	Mayo Clinic; Ohio State University; Ohio State University					NHLBI NIH HHS [HL54281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; FOSTER JM, 1995, J BILL CHEM, V267, P11995; FRENKEL B, 1993, BIOCHEMISTRY-US, V32, P13636, DOI 10.1021/bi00212a031; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; GRAY T A, 1990, Technique (Philadelphia), V2, P147; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARNS LF, 1970, J BIOL CHEM, V270, P410; KIM E, 1989, MOL CELL BIOL, V9, P1875, DOI 10.1128/MCB.9.5.1875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MARR JH, 1990, MOL CELL BIOL, V10, P4271; MIN BH, 1988, NUCLEIC ACIDS RES, V16, P10374, DOI 10.1093/nar/16.21.10374; MIN BH, 1990, NUCLEIC ACIDS FES, V265, P1667; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MIWA T, 1991, MOL CELL BIOL, V11, P3296, DOI 10.1128/MCB.11.6.3296; PAN WT, 1990, J BIOL CHEM, V265, P7022; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; SWFEOOR EP, 1992, ONXOFWNW, V7, P841; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; TOKUNAGA K, 1988, MOL CELL BIOL, V8, P3929, DOI 10.1128/MCB.8.9.3929; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WOODRUFF KA, 1995, ONCOGENE, V10, P1335	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24278	24285		10.1074/jbc.271.39.24278	http://dx.doi.org/10.1074/jbc.271.39.24278			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798674	hybrid			2022-12-25	WOS:A1996VJ44200103
J	Li, GM; Wang, HX; Romano, LJ				Li, GM; Wang, HX; Romano, LJ			Human MutS alpha specifically binds to DNA containing aminofluorene and acetylaminofluorene adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR DEFICIENCY; NONPOLYPOSIS COLON-CANCER; HUMAN MSH2 PROTEIN; CELL-LINES; MICROSATELLITE INSTABILITY; TUMOR-CELLS; HOMOLOG; MECHANISMS; EXTRACTS; NMR	Defects in mismatch repair are associated with several types of cancer. It is also generally believed that environmental carcinogens are responsible for the initiation of cancers by the induction of mutations in critical genes. Prior genetic studies have suggested that the mismatch repair system can also recognize certain forms of DNA damage such as O-6-methylguanine and UV photoproducts, and, therefore, mismatch repair may play a role in environmental agent-induced carcinogenesis. To examine this hypothesis, hMutS alpha, a heterodimer which consists of hMSH2 and GTBP and participates in strand specific mismatch repair, was tested for its ability to recognize DNA containing a site specific C-8-guanine adduct of aminofluorene (AF) or N-acetyl-2-aminofluorene (AAF). We show here that hMutS alpha specifically binds to both AF and AAF adducts. This binding requires both hMSH2 and GTBP. Results from competition and titration experiments indicate that the binding efficiency of hMutS alpha to AF and AAF is about 60% of that to a G-T mismatch, but is at least 10-fold that to an otherwise identical homoduplex DNA without the chemical modification. The specific binding of AF and AAF adducts by hMutS alpha suggests that strand-specific mismatch repair is involved in processing DNA damage induced by environmental carcinogens.	UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,LAB MED,LEXINGTON,KY 40536; WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202	University of Kentucky; Wayne State University	Li, GM (corresponding author), UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,DEPT PATHOL,LEXINGTON,KY 40536, USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NATIONAL CANCER INSTITUTE [R01CA040605] Funding Source: NIH RePORTER; NCI NIH HHS [CA40605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BOYER JC, 1995, CANCER RES, V55, P6063; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Fazakerley GV, 1995, METHOD ENZYMOL, V261, P145; FENG WY, 1991, GENETICS, V129, P1007; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HEFLICH RH, 1994, MUTAT RES-REV GENET, V318, P73, DOI 10.1016/0165-1110(94)90025-6; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MILHE C, 1994, NUCLEIC ACIDS RES, V22, P4646, DOI 10.1093/nar/22.22.4646; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NORMAN D, 1989, BIOCHEMISTRY-US, V28, P7462, DOI 10.1021/bi00444a046; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1914; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RISINGER JI, 1995, CANCER RES, V55, P5664; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SHIBUTANI S, 1991, CARCINOGENESIS, V12, P813, DOI 10.1093/carcin/12.5.813; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; UMAR A, 1994, J BIOL CHEM, V269, P14367; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; ZHOU YZ, 1993, BIOCHEMISTRY-US, V32, P14043, DOI 10.1021/bi00213a038	41	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24084	24088		10.1074/jbc.271.39.24084	http://dx.doi.org/10.1074/jbc.271.39.24084			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798646	hybrid			2022-12-25	WOS:A1996VJ44200075
J	Simmons, WW; UngureanuLongrois, D; Smith, GK; Smith, TW; Kelly, RA				Simmons, WW; UngureanuLongrois, D; Smith, GK; Smith, TW; Kelly, RA			Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ECOTROPIC RETROVIRUS RECEPTOR; CATIONIC AMINO-ACIDS; HUMAN ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; GTP CYCLOHYDROLASE-I; GROWTH-FACTOR-BETA; CARDIAC MYOCYTES; INTERFERON-GAMMA; MESSENGER-RNA	The cytokine-inducible isoform of nitric oxide synthase (iNOS or NOS2) plays an important role in the immune response to some pathogens, Within the heart, increased activity of NOS2 in cardiac microvascular endothelial cells (CMEC) also can diminish the contractile function of adjacent cardiac myocytes, Glucocorticoids, which are known to suppress cytokine induction of NOS2 in many cell types, caused only a moderate (approximately 20%) decline in NOS2 protein content and maximal activity measured in homogenates of cytokine-treated CMEC, but almost completely inhibited synthesis of nitrogen oxides (NOx) by intact cells, To determine whether glucocorticoids were inhibiting cellular NOx production by limiting the availability of NOS co-factors or substrate, the effect of dexamethasone on tetrahydro biopterin (BH4) and L-arginine availability in cytokine-treated CMEC was examined, Dexamethasone prevented the coordinate induction of GTP cyclohydrolase I with NOS2 after exposure to interleukin-1 beta and interferon-gamma and also the increase in intracellular BH4 content in cytokine-treated CMEC. Addition of BH4 overcame dexamethasone-mediated suppression of nitrite production, Dexamethasone also prevented a cytokine-mediated increase in L-arginine uptake into CMEC by suppressing the induction of the high affinity cationic amino acid transporters CAT-1 and CAT-2B and the low affinity CAT-2A transporter, In addition, dexamethasone also inhibited cytokine induction in CMEC of argininosuccinate synthase, the rate-limiting enzyme for the de novo synthesis of arginine from citrulline, Thus, glucocorticoids regulate NOx production following cytokine exposure in cardiac microvascular endothelial cells primarily by limiting BH4 and L-arginine availability.	BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; GLAXO WELLCOME INC,RES & DEV,RES TRIANGLE PK,NC 27709	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; GlaxoSmithKline					NHLBI NIH HHS [HL36141, HL52320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141, R01HL036141, P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ALTMAN P, 1967, BLOOD OTHER BODY FLU, P75; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BALLIGAND JL, 1995, AM J PHYSIOL-HEART C, V268, pH1293, DOI 10.1152/ajpheart.1995.268.3.H1293; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BAYDOUN AR, 1993, BRIT J PHARMACOL, V110, P1401, DOI 10.1111/j.1476-5381.1993.tb13976.x; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BUNE AJ, 1995, FEBS LETT, V366, P127, DOI 10.1016/0014-5793(95)00495-U; Bune AJ, 1996, BIOCHEM BIOPH RES CO, V220, P13, DOI 10.1006/bbrc.1996.0348; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; CETKOVICCVRLJE M, 1993, ENDOCRINOLOGY, V133, P1739, DOI 10.1210/en.133.4.1739; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CITRON BA, 1990, P NATL ACAD SCI USA, V87, P6436, DOI 10.1073/pnas.87.16.6436; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; EVANS HG, 1993, CARDIOVASC RES, V27, P1486, DOI 10.1093/cvr/27.8.1486; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LC, 1982, ANAL BIOCHEM, V126, P11; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HATTORI Y, 1995, ENDOTHELIUM, V3, pS28; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Kunz D, 1996, P NATL ACAD SCI USA, V93, P255, DOI 10.1073/pnas.93.1.255; LAMBERT MA, 1986, MOL CELL BIOL, V6, P1722, DOI 10.1128/MCB.6.5.1722; Lewis NP, 1996, CIRCULATION, V93, P720, DOI 10.1161/01.CIR.93.4.720; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V273, P230, DOI 10.1016/0003-9861(89)90183-5; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Nagasaki A, 1996, J BIOL CHEM, V271, P2658, DOI 10.1074/jbc.271.5.2658; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; PINSKY DJ, 1995, J CLIN INVEST, V95, P677, DOI 10.1172/JCI117713; PLUMB JA, 1989, CANCER RES, V49, P4435; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SAKAI N, 1992, MOL PHARMACOL, V43, P6; SATO H, 1992, J LEUKOCYTE BIOL, V52, P161, DOI 10.1002/jlb.52.2.161; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; Simmons WW, 1996, J BIOL CHEM, V271, P11694, DOI 10.1074/jbc.271.20.11694; SMITH GK, 1983, ARCH BIOCHEM BIOPHYS, V227, P272, DOI 10.1016/0003-9861(83)90371-5; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P486, DOI 10.1161/01.RES.77.3.486; UNGUREANULONGROIS D, 1995, J MOL CELL CARDIOL, V27, P155, DOI 10.1016/S0022-2828(08)80015-6; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WERNER ER, 1991, BIOCHEM J, V280, P709, DOI 10.1042/bj2800709; WERNER ER, 1989, BIOCHEM J, V262, P861, DOI 10.1042/bj2620861; WERNERFELMAYER G, 1993, FEBS LETT, V322, P223, DOI 10.1016/0014-5793(93)81574-J; WERNERFELMAYER G, 1989, BIOL CHEM H-S, V370, P1063, DOI 10.1515/bchm3.1989.370.2.1063; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YANG XC, 1994, J CLIN INVEST, V94, P714, DOI 10.1172/JCI117390	86	154	156	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23928	23937		10.1074/jbc.271.39.23928	http://dx.doi.org/10.1074/jbc.271.39.23928			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798625	hybrid			2022-12-25	WOS:A1996VJ44200054
J	GonzalezAgosti, C; Xu, L; Pinney, D; Beauchamp, R; Hobbs, W; Gusella, J; Ramesh, V				GonzalezAgosti, C; Xu, L; Pinney, D; Beauchamp, R; Hobbs, W; Gusella, J; Ramesh, V			The merlin tumor suppressor localizes preferentially in membrane ruffles	ONCOGENE			English	Article						merlin; neurofibromatosis 2; meningioma; vestibular schwannoma; ERM; motility	NEUROFIBROMATOSIS TYPE-2 GENE; ERM FAMILY MEMBERS; PLASMA-MEMBRANE; NF2 GENE; SCHWANN-CELLS; MUSCLE-CELLS; EZRIN; MOESIN; ACTIN; PROTEIN	Merlin is a tumor suppressor whose inactivation underlies the familial schwannomas and meningiomas of neurofibromatosis 2 and their sporadic counterparts. It bears striking similarity to the ERM proteins, ezrin, radixin and moesin, members of the protein 4.1 superfamily that link proteins in the cytoskeleton and the plasma membrane, We have generated polyclonal and monoclonal antibodies that detect merlin as an similar to 66 kD protein in many different cell types, Using indirect immunofluorescence we have for the first time visualized endogenous merlin and localized it to the motile regions, such as leading or ruffling edges, in human fibroblast and meningioma cells. Merlin co-localizes with F-actin in these motile regions but is not associated with stress fibers. Merlin does not localize to the same structures as either ezrin or meosin in human meningioma cells, suggesting a function distinct from these ERMs. Thus, merlin is associated with motile regions of the cell and its participation in these structures may be intimately involved in control of proliferation in Schwann cells and meningeal cells.	MASSACHUSETTS GEN HOSP EAST,MOL NEUROGENET UNIT,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital					NINDS NIH HHS [NS24279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREOLI C, 1994, J CELL SCI, V107, P2509; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BIRGBAUER E, 1991, THESIS MIT; BIRGBAUER E, 1991, THESIS MIT CAMBRIDGE; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; DENBAKKER MA, 1995, ONCOGENE, V10, P757; FRANCK Z, 1993, J CELL SCI, V105, P219; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GODA S, 1991, J NEUROCHEM, V56, P1354, DOI 10.1111/j.1471-4159.1991.tb11432.x; GonzalezAgosti C, 1996, CELL MOTIL CYTOSKEL, V34, P122, DOI 10.1002/(SICI)1097-0169(1996)34:2<122::AID-CM4>3.0.CO;2-D; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; HARLOW E, 1988, ANTIBODIES; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGAN JA, 1990, CANCER GENET CYTOGEN, V45, P41, DOI 10.1016/0165-4608(90)90064-H; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; LUTCHMAN M, 1995, CANCER RES, V55, P2270; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SATO N, 1992, J CELL SCI, V103, P131; SEKIDO Y, 1995, CANCER RES, V55, P1227; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPERTINI F, 1992, J IMMUNOL, V149, P65; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; WINCKLER B, 1994, J CELL SCI, V107, P2523	45	110	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1239	1247						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808698				2022-12-25	WOS:A1996VJ20200015
J	Nakamura, T; Sanokawa, R; Sasaki, Y; Ayusawa, D; Oishi, M; Mori, N				Nakamura, T; Sanokawa, R; Sasaki, Y; Ayusawa, D; Oishi, M; Mori, N			N-Shc: A neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway	ONCOGENE			English	Article						Shc family; signal transduction; phosphotyrosine; BDNF; TrkB; EGF receptor	GUANINE-NUCLEOTIDE EXCHANGE; PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CENTRAL-NERVOUS-SYSTEM; MAP KINASE; MESSENGER-RNAS; BINDING-SITES; CONSTITUTIVE PHOSPHORYLATION; PC12 CELLS; RAS	Shc has been implicated in a variety of growth factor- and cytokine receptor-signaling through its specific binding to phosphotyrosine residues of the activated receptors. In neuronal cells, such as PC12, She has been shown to be involved in Ras-dependent MAP kinase activation following Trk receptor stimulation with NGF. While the ubiquitous role of She as an adaptor molecule in signal transduction is increasing in both neuronal and non-neuronal cells and tissues, the expression level of Shc is suprisingly low in the brain. We demonstrated here the isolation of a neural-specific member of the She family. This novel protein, named N-Shc (neuronal Shc), contains tao potential phosphotyrosine-binding domains, PTB and SH2, and is expressed exclusively in the brain; whereas Shc is present in all other non-neuronal tissues. As in Shc, N-Shc can bind activated EGF receptor, become tyrosine phosphorylated, and form a complex with Grb2 adapter protein following EGF stimulation. Furthermore, N-Shc can bind activated TrkB receptor following the stimulation with brain-derived neurotrophic factor (BDNF), which is the most abundant neurotrophin in the brain. These data suggest that N-Shc, rather than She, mediates neurotrophin and other neuronal signalings in the central nervous system.	UNIV TOKYO,INST MOL CELLULAR & BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; YOKOHAMA CITY UNIV,KIHARA INST BIOL RES,TOTSUKA KU,YOKOHAMA,KANAGAWA 244,JAPAN; RES DEV CORP JAPAN,PRESTO,INHERITANCE & VARIAT GRP,KYOTO 61902,JAPAN	University of Tokyo; Yokohama City University; Japan Science & Technology Agency (JST)	Nakamura, T (corresponding author), SUMITOMO ELECT IND,BIOMED RES & DEV DEPT,SAKAE KU,YOKOHAMA,KANAGAWA 244,JAPAN.		Sasaki, Yasnory/L-7065-2018	Sasaki, Yasnory/0000-0003-2614-7038				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BURNS LA, 1993, J BIOL CHEM, V268, P17659; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GIOGETTI S, 1994, EUR J BIOCHEM, V223, P195; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HEFTI F, 1992, NEUROTROPHIC FACTORS, P25; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HIMI T, 1994, NEUROSCIENCE, V60, P907, DOI 10.1016/0306-4522(94)90271-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sasaki Y F, 1994, DNA Res, V1, P91, DOI 10.1093/dnares/1.2.91; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WINITZ S, 1993, J BIOL CHEM, V268, P19196; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	64	109	116	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1111	1121						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808684				2022-12-25	WOS:A1996VJ20200001
J	Cook, PF; Tai, CH; Hwang, CC; Woehl, EU; Dunn, MF; Schnackerz, KD				Cook, PF; Tai, CH; Hwang, CC; Woehl, EU; Dunn, MF; Schnackerz, KD			Substitution of pyridoxal 5'-phosphate in the O-acetylserine sulfhydrylase from Salmonella typhimurium by cofactor analogs provides a test of the mechanism proposed for formation of the alpha-aminoacrylate intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE-AMINOTRANSFERASE; P-31 NMR; PHOSPHATE; SERINE; LT-2; ACID; SITE; PH	O-Acetylserine sulfhydrylase (OASS) is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that catalyzes the final step in the de novo synthesis of L-cysteine in Salmonella typhimurium. Complementary cofactor mutagenesis in which the active site PLP is substituted with cofactor analogs is used to test the mechanism proposed for the OASS, Data obtained with the pyridoxal 5'-deoxymethylenephosphonate-substituted enzyme suggest that the binding of OAS as it forms the external Schiff base is such that the acetate side chain is properly positioned for elimination (orthogonal to the developing alpha,beta-double bond) only about 1% of the time, Data support the assignment of an enzyme group with a pK of 6.7 that interacts with the acetyl side chain, maintaining it orthogonal to the developing alpha,beta-double bond, Similar studies of the 2'-methylpyridoxal 5'-phosphate-substituted enzyme suggest that, although the mechanism is identical to that catalyzed by native OASS, the reaction coordinate for alpha-proton abstraction may be decreased compared with that observed for the native enzyme.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV WURZBURG,BIOZENTRUM,THEODOR BOVERI INST BIOWISSENSCH,D-97074 WURZBURG,GERMANY	University of California System; University of California Riverside; University of Wurzburg	Cook, PF (corresponding author), UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,FT WORTH,TX 76107, USA.		Hwang, Chi-Ching/K-7933-2012	Hwang, Chi-Ching/0000-0002-8328-674X; Weber-Ban, Eilika/0000-0002-5773-9274				BECKER MA, 1969, J BIOL CHEM, V244, P2418; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1790, DOI 10.1021/bi00510a013; COOK PF, 1976, J BIOL CHEM, V251, P2023; ELLMANN GL, 1958, ARCH BIOCHEM BIOPHYS, V82, P70; Gorenstein D.G., 1984, PHOSPHORUS 31 NMR PR, P7; GROMAN E, 1972, P NATL ACAD SCI USA, V69, P3297, DOI 10.1073/pnas.69.11.3297; HARA S, 1990, Protein Expression and Purification, V1, P70, DOI 10.1016/1046-5928(90)90048-4; Hwang CC, 1996, BIOCHEMISTRY-US, V35, P6358, DOI 10.1021/bi9602472; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; KUPFER A, 1977, BIOCHEM BIOPH RES CO, V79, P1004, DOI 10.1016/0006-291X(77)91209-8; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; MERKL L, 1981, Z NATURFORSCH, V36, P778; MIURA R, 1989, ARCH BIOCHEM BIOPHYS, V270, P526, DOI 10.1016/0003-9861(89)90535-3; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; Parkin D., 1991, METHODS DETERMINATIO, P269; SCHIRCH V, 1978, BIOCHEM BIOPH RES CO, V85, P99; Schnackerz KD, 1995, ARCH BIOCHEM BIOPHYS, V324, P71, DOI 10.1006/abbi.1995.9927; SCHNACKERZ KD, 1989, EUR J BIOCHEM, V185, P525, DOI 10.1111/j.1432-1033.1989.tb15145.x; SCHNACKERZ KD, 1980, BIOCHEM BIOPH RES CO, V95, P1832, DOI 10.1016/S0006-291X(80)80112-4; SCHNACKERZ KD, 1986, VITAMIN B6 PYRIDOX A, P245; SCHNACKERZ KD, 1995, BIOCHEM BIOPH RES CO, V324, P71; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12125; SHIMOMURA S, 1978, BIOCHEMISTRY-US, V17, P5359, DOI 10.1021/bi00618a006; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Strambini GB, 1996, BIOCHEMISTRY-US, V35, P8392, DOI 10.1021/bi952919e; TAI CH, 1995, BIOCHEMISTRY-US, V34, P12311, DOI 10.1021/bi00038a027; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; Woehl EU, 1996, BIOCHEMISTRY-US, V35, P4776, DOI 10.1021/bi952938o	31	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25842	25849		10.1074/jbc.271.42.25842	http://dx.doi.org/10.1074/jbc.271.42.25842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824215				2022-12-25	WOS:A1996VN18000021
J	Wajant, H; Pfizenmaier, K				Wajant, H; Pfizenmaier, K			Identification of potential active-site residues in the hydroxynitrile Lyase from Manihot esculenta by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE CARBOXYPEPTIDASE-II; ENZYME-CATALYZED SYNTHESIS; POLYACRYLAMIDE GELS; SORGHUM-BICOLOR; PURIFICATION; PROTEINS; CLONING; (S)-CYANOHYDRINS; RESOLUTION; CASSAVA	The hydroxynitrile lyase from cassava (Manihot esculenta Crantz) (EC 4.1.2.37) catalyzes the decomposition of the achiral alpha-hydroxynitrile acetone cyanohydrin into HCN and acetone during cyanogenesis of damaged plants, This enzyme can also be used for stereoselective synthesis of a wide array of (S)-cyanohydrins by addition of HCN to aldehydes or ketones, Optically active cyanohydrins are interesting intermediates for the synthesis of alpha-hydroxy acids, alpha-hydroxy ketones, or beta-ethanolamines, all of which are important building blocks in organic synthesis, Inhibition of hydroxynitrile lyase from M. esculenta (MeHNL) by serine- and histidine-modifying reagents suggests involvement of active site seryl and histidyl residues. Furthermore, serine 80 of MeHNL is part of the active site motif Gly-X-Ser-X-Gly/Ala, often considered as the hallmark of catalytic triads having independently evolved in four groups of enzymes: the alpha/beta hydrolase fold enzymes, subtilisins, the cysteine proteases, and the eukaryotic serine proteases, By site-directed mutagenesis, three residues critical for enzyme activity have been identified: serine 80, aspartic acid 208, and histidine 236. These residues may be directly involved in MeHNL-catalyzed decomposition of cyanohydrins, providing evidence for a catalytical triad in HNLs, too. The order of the catalytic triad residues in the primary sequence of MeHNL is nucleophile-histidine-acid, suggesting that MeHNL belongs to the alpha/beta hydrolase fold group of enzymes, In contrast to all other enzymes having a catalytical triad, HNLs catalyze no net hydrolytic reactions.			Wajant, H (corresponding author), UNIV STUTTGART,INST CELL BIOL & IMMUNOL,ALLMANDRING 31,D-70569 STUTTGART,GERMANY.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				ALBRECHT J, 1993, BIOTECHNOL APPL BIOC, V17, P191; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOVE C, 1961, J BIOL CHEM, V236, P207; CHENG IP, 1993, PLANT CELL PHYSIOL, V34, P1139; EFFENBERGER F, 1987, ANGEW CHEM INT EDIT, V26, P458, DOI 10.1002/anie.198704581; EFFENBERGER F, 1990, TETRAHEDRON LETT, V31, P1249, DOI 10.1016/S0040-4039(00)88777-8; HUGHES J, 1994, ARCH BIOCHEM BIOPHYS, V311, P496, DOI 10.1006/abbi.1994.1267; KLEMPIER N, 1993, TETRAHEDRON LETT, V34, P4769, DOI 10.1016/S0040-4039(00)74084-6; KUROKI GW, 1989, P NATL ACAD SCI USA, V86, P6978, DOI 10.1073/pnas.86.18.6978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; POULTON JE, 1988, CIBA F SYMP, V140, P67; REIMMANN C, 1995, PHYSIOL MOL PLANT P, V46, P71, DOI 10.1006/pmpp.1995.1006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Seigler D. S., 1991, HERBIVORES THEIR INT, VI, P35; SELMAR D, 1987, ANAL BIOCHEM, V166, P208, DOI 10.1016/0003-2697(87)90565-3; SMITSKAMPWILMS E, 1991, RECL TRAV CHIM PAY B, V110, P209; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAJANT H, 1993, PLANT SCI, V89, P127, DOI 10.1016/0168-9452(93)90120-O; WAJANT H, 1994, PLANT MOL BIOL, V26, P735, DOI 10.1007/BF00013758; WAJANT H, 1995, PLANT SCI, V108, P1, DOI 10.1016/0168-9452(95)04118-E; WAJANT H, 1995, PLANT PHYSIOL, V109, P1231, DOI 10.1104/pp.109.4.1231	25	54	60	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25830	25834		10.1074/jbc.271.42.25830	http://dx.doi.org/10.1074/jbc.271.42.25830			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824213	hybrid			2022-12-25	WOS:A1996VN18000019
J	Cox, GW; Taylor, LS; Willis, JD; Melillo, G; White, RL; Anderson, SK; Lin, JJ				Cox, GW; Taylor, LS; Willis, JD; Melillo, G; White, RL; Anderson, SK; Lin, JJ			Molecular cloning and characterization of a novel mouse macrophage gene that encodes a nuclear protein comprising polyglutamine repeats and interspersing histidines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNAS; BULBAR MUSCULAR-ATROPHY; 3' UNTRANSLATED REGION; LARGE-T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; ANDROGEN RECEPTOR; TRIPLET REPEAT; DNA-BINDING; NEURODEGENERATIVE DISEASES	Simple tandem repeats of the trinucleotide sequence CAG encode homopolymeric stretches of glutamine. Although polyglutamine has been identified in diverse proteins, it is present predominantly in transcription factors, We observed that oncogene-immortalized mouse macrophages express several genes that contain a CAG repeat motif. Therefore, we attempted to clone a novel gene that contains a CAG repeat and is associated with cytokine activation of macrophages. Screening of a mouse macrophage cDNA library with a probe comprising 12 consecutive CAG triplets identified at least one unique clone. The cDNA encodes a protein (named GRP-1 or glutamine repeat protein-1) with 171 amino acids, a calculated molecular mass of 21.6 kDa, and a predicted pI of 10.67. Greater than two-thirds of GRP-1 are only two amino acids, namely glutamine (50%) and histidine (18%). There are four polyglutamine motifs interspersed with histidine-rich regions. There is also a putative nuclear localization signal flanked by sites for possible serine phosphorylation. GRP-1 mRNA was expressed constitutively in some macrophage cell lines and B and T cell lines. Interferon-gamma or lipopolysaccharide augmented GRP-1 mRNA expression in the mouse macrophage cell line ANA-1. Western blot analyses using an antipeptide serum revealed that GRP-1 was localized in the nucleus of ANA-1 macrophages and transfected 3T3 fibroblasts. Overexpression of GRP-1 decreased Sp1-driven chloramphenicol acetyltransferase gene expression in transient cotransfection experiments. Because polyglutamine motifs can cause protein oligomerization and can function as transcriptional activation domains, we suggest that GRP-1 may be a transcription factor associated with interferon-gamma- or lipopolysaccharide-induced activation of macrophages.	SCI APPLICAT INT CORP,EXPT IMMUNOL LAB,FREDERICK,MD; SCI APPLICAT INT CORP,BIOCHEM PHYSIOL LAB,DIV BASIC SCI,FREDERICK,MD; SCI APPLICAT INT CORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD; NCI,FREDERICK CANC RES & DEV CTR,NATL INST HLTH,FREDERICK,MD 21702	Science Applications International Corporation (SAIC); Science Applications International Corporation (SAIC); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Anderson, Stephen K/B-1727-2012	Anderson, Stephen K/0000-0002-7856-4266; White, Robert/0000-0003-2769-4340				BHAT BM, 1985, MOL CELL BIOL, V5, P3183, DOI 10.1128/MCB.5.11.3183; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BLASI E, 1987, EUR J IMMUNOL, V17, P1491, DOI 10.1002/eji.1830171016; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chomczynski P, 1993, BIOTECHNIQUES, V15, P536; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COX GW, 1992, J IMMUNOL, V149, P3290; COX GW, 1990, J IMMUNOL, V145, P1719; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; DOYLE MV, 1985, J BIOL RESP MODIF, V4, P96; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; DUBOULE D, 1987, MOL CELL BIOL, V7, P2003, DOI 10.1128/MCB.7.5.2003; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HAYNES SR, 1989, DEV BIOL, V134, P246, DOI 10.1016/0012-1606(89)90094-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KARLIN S, 1989, J MOL BIOL, V205, P165, DOI 10.1016/0022-2836(89)90373-2; KASHIMA N, 1985, NATURE, V313, P402, DOI 10.1038/313402a0; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LATCHMAN DS, 1995, EUKARYOTIC TRANSCRIP, P239; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEWFELD SJ, 1991, J MOL EVOL, V32, P415, DOI 10.1007/BF02101281; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; PERUTZ MF, 1993, CURR BIOL, V3, P249, DOI 10.1016/0960-9822(93)90174-M; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG A, 1984, SCIENCE, V224, P1431, DOI 10.1126/science.6427925; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILTROUT RH, 1990, IMMUNOPHYSIOLOGY, P365; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68; 1993, CELL, V72, P971	83	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25515	25523		10.1074/jbc.271.41.25515	http://dx.doi.org/10.1074/jbc.271.41.25515			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810323	hybrid			2022-12-25	WOS:A1996VL69300067
J	Mauviel, A; Korang, K; Santra, M; Tewari, D; Uitto, J; Iozzo, RV				Mauviel, A; Korang, K; Santra, M; Tewari, D; Uitto, J; Iozzo, RV			Identification of a bimodal regulatory element encompassing a canonical AP-1 binding site in the proximal promoter region of the human decorin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA LEVELS; GROWTH-FACTOR-BETA; HUMAN RECOMBINANT INTERLEUKIN-1-BETA; PRO-INFLAMMATORY CYTOKINES; FACTOR-ALPHA; TRANSCRIPTIONAL REGULATION; DERMAL FIBROBLASTS; C-JUN; EXPRESSION	We have previously described a tumor necrosis factor alpha (TNF-alpha) response element, located between residues -188 and -140 of the human decorin promoter, that mediates the inhibitory effect of TNF-alpha on decorin gene expression (Mauviel, A., Santra, M., Chen, Y.-Q., Uitto, J., and Iozzo, R. V. (1995) J. Biol. Chem. 270, 11692-11700). In this report, we demonstrate that interleukin 1 (IL-1), a pleiotropic cytokine that shares a wide variety of biological properties with TNF-alpha, uses the same cis element to up-regulate decorin gene expression. Specifically, IL-1 enhances the expression of the human decorin gene, and this effect is mediated by activation of the corresponding promoter, as shown in transient cell transfection experiments using decorin promoter-chloramphenicol acetyl transferase reporter gene constructs. Additional transfection experiments with various 5'-deletion promoter-chloramphenicol acetyltransferase constructs demonstrate that both the inhibitory effect of TNF-alpha and the stimulatory effect of IL-1 are mediated by a 48-base pair segment of the promoter, between residues -188 and -140. This region, which contains a canonical AP-1 binding site. TGAGTCA, allows an antagonistic effect of these two cytokines on the decorin promoter activity. When cloned upstream of the thymidine kinase promoter, this promoter fragment requires the AP-1 sequence to be responsive to IL-1. Supershift assays with various AP-1 antibodies identified c-Jun, Jun-B, and Fra-1 as components of the complex binding to the decorin promoter. Overexpression of c-jun, an oncogene encoding the c-Jun/AP-1 transcription factor, reduces the basal activity of both decorin and -188/-140 thymidine kinase promoter constructs. In contrast, blockage of c-jun expression with an antisense c-jun construct potentiates the stimulatory effect of IL-1 and reverses the response to TNF-alpha. These data indicate that the region between residues -188 and -140 of the human decorin promoter functions as a bimodal regulatory element and allows transcriptional repression by c-Jun/AP-1 complexes.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOL PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC CTR,PHILADELPHIA,PA 19107; TEMPLE UNIV,SCH DENT,DEPT ORTHODONT,PHILADELPHIA,PA 19140	Jefferson University; Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Mauviel, A (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.		Iozzo, Renato/AAS-1980-2020; MAUVIEL, Alain/F-6251-2013	Iozzo, Renato/0000-0002-5908-5112; Mauviel, Alain/0000-0002-0438-2793	NCI NIH HHS [R01-CA39481] Funding Source: Medline; NIAMS NIH HHS [T32-AR07651, R01-AR41439] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEINO J, 1988, BIOCHEM J, V252, P309, DOI 10.1042/bj2520309; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; LE JM, 1987, LAB INVEST, V56, P234; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, WOUNDS, V5, P137; MAUVIEL A, 1993, J BIOL CHEM, V268, P6520; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; PULKKINEN L, 1990, J BIOL CHEM, V265, P17780; SANTRA M, 1994, J BIOL CHEM, V269, P579; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	30	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24824	24829		10.1074/jbc.271.40.24824	http://dx.doi.org/10.1074/jbc.271.40.24824			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798756	hybrid			2022-12-25	WOS:A1996VM67400078
J	Mueller, MJ; Andberg, MB; Samuelsson, B; Haeggstrom, JZ				Mueller, MJ; Andberg, MB; Samuelsson, B; Haeggstrom, JZ			Leukotriene A(4) hydrolase, mutation of tyrosine 378 allows conversion of leukotriene A(4) into an isomer of leukotriene B-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INACTIVATION; POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-ERYTHROCYTES; EPOXIDE HYDROLASE; ARACHIDONIC-ACID; AMINOPEPTIDASE; PEPTIDASE	Leukotriene A(4) hydrolase catalyzes the final step in the biosynthesis of the proinflammatory compound leukotriene B-4, a reaction which is accompanied by suicide inactivation of the enzyme by leukotriene A(4). We have recently reported that Tyr-378 is a major structural determinant for suicide inactivation and that mutation of Tyr-378 into Phe or Gln protects leukotriene A(4) hydrolase from this catalytic restriction (Mueller, M. J., Blomster, M., Opperman, U. C. T., Jornvall, H., Samuelsson, B., and Haeggstrom, J. Z. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5931-5935), In the present study, we show that both [Y378F]- and [Y378Q]leukotriene A(4) hydrolase converts leukotriene A(4) not only into leukotriene B-4 but also into a second, previously unknown, product of the enzyme. From biophysical analyses and comparison with a synthetic standard, the structure of this product was determined to 5S,12R-dihydroxy-6,10-trans-8,14-cis-eicosatetraenoic acid, i.e. Delta(6)-trans-Delta(8)-cis-leukotriene B-4. The relative formation of Delta(6)-trans-Delta(8)-cis-leukotriene B-4 versus leukotriene B-4 by [Y378F]- and [Y378Q]leukotriene A(4) hydrolase, was 18% and 32%, respectively. For [Y378F]leukotriene A(4) hydrolase, the turnover of leukotriene A(4) into leukotriene B-4 or Delta(6)-trans-Delta(8)-cis-leukotriene B-4 was calculated to 2.5 s(-1) which is almost three times the k(cat) value of the wild type enzyme, Taken together, these findings indicate that Tyr-378 is located at the active site where it assists in the formation of the correct double-bond geometry in the product leukotriene B-4.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,DIV CHEM 2,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			mueller, martin j/C-7616-2019	Blomster Andberg, Martina/0000-0002-8021-9947				BORGEAT P, 1981, PROSTAG LEUKOTR ESS, V6, P557, DOI 10.1016/0161-4630(81)90117-8; BORGEAT P, 1988, PROSTAGLANDINS, V35, P723, DOI 10.1016/0090-6980(88)90145-1; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; COREY EJ, 1980, J AM CHEM SOC, V102, P7986, DOI 10.1021/ja00547a600; EVANS JF, 1985, J BIOL CHEM, V260, P966; FITZPATRICK FA, 1982, J BIOL CHEM, V257, P4680; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1993, J LIPID MEDIATOR, V6, P1; LINDGREN JA, 1981, FEBS LETT, V128, P329, DOI 10.1016/0014-5793(81)80110-X; MCGEE J, 1985, J BIOL CHEM, V260, P2832; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V173, P620, DOI 10.1016/S0006-291X(05)80080-4; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; Mueller MJ, 1996, P NATL ACAD SCI USA, V93, P5931, DOI 10.1073/pnas.93.12.5931; ORNING L, 1990, J BIOL CHEM, V265, P14911; ORNING L, 1992, J BIOL CHEM, V267, P22733; Stromberg F, 1996, EUR J BIOCHEM, V238, P599, DOI 10.1111/j.1432-1033.1996.0599w.x; WETTERHOLM A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P275, DOI 10.1016/0005-2760(92)90007-I; WETTERHOLM A, 1991, BIOCHIM BIOPHYS ACTA, V1080, P96, DOI 10.1016/0167-4838(91)90134-L; ZHANG YY, 1994, ANAL BIOCHEM, V220, P28, DOI 10.1006/abio.1994.1294	19	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24345	24348		10.1074/jbc.271.40.24345	http://dx.doi.org/10.1074/jbc.271.40.24345			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798687	hybrid			2022-12-25	WOS:A1996VM67400009
J	Sun, ZR; Gantt, E; Cunningham, FX				Sun, ZR; Gantt, E; Cunningham, FX			Cloning and functional analysis of the beta-carotene hydroxylase of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC-PATHWAY; GENE; CONVERSION	An Arabidopsis thaliana cDNA encoding the enzyme beta-carotene hydroxylase was identified by functional complementation in Escherichia coli. The product of this cDNA adds hydroxyl groups to both beta rings of the symmetrical beta-carotene (beta,beta-carotene) to form zeaxanthin (beta,beta-carotene-3,3'-diol) and converts the monocyclic beta-zeacarotene (7',8'-dihydro-beta,psi-carotene) to hydroxy-beta-zeacarotene (7',8'-dihydro-beta,psi-carotene-3-ol). The epsilon rings of delta-carotene (epsilon,psi-carotene) and alpha-zeacarotene (7',8'-dihydro-epsilon,psi-carotene) are poor substrates for the enzyme, The predicted amino acid sequence of the A. thaliana enzyme resembles the four known bacterial beta-carotene hydroxylase enzymes (31-37% identity) but is much longer, with an N-terminal extension of more than 130 amino acids. Truncation of the cDNA to produce a polypeptide lacking the first 69 amino acids does not impair enzyme activity in E. coli. Truncation to yield a polypeptide of a length comparable with the bacterial enzymes (lacking 129 N-terminal amino acids) resulted in the accumulation of the monohydroxy intermediate beta-cryptoxanthin (beta,beta-carotene-3-ol), predominantly, when beta-carotene was provided as the substrate. It is suggested that amino acid residues 70-129 of the A. thaliana enzyme may play a role in formation of a functional homodimer.	UNIV MARYLAND,DEPT PLANT BIOL,COLLEGE PK,MD 20742; UNIV MARYLAND,AGR EXPT STN,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park								BOUVIER F, 1994, PLANT J, V6, P45, DOI 10.1046/j.1365-313X.1994.6010045.x; Britton G, 1990, CAROTENOIDS CHEM BIO, P167; CUNNINGHAM FX, 1994, PLANT CELL, V6, P1107, DOI 10.1105/tpc.6.8.1107; CUNNINGHAM FX, 1996, IN PRESS PLANT CELL; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; Demmig-Adams B., 1993, CAROTENOIDS PHOTOSYN, P206, DOI [10.1007/978-94-011-2124-8_7, DOI 10.1007/978-94-011-2124-8_7]; GOOD TW, 1980, BIOCH CAROTENOIDS, V1; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; MISAWA N, 1995, BIOCHEM BIOPH RES CO, V209, P867, DOI 10.1006/bbrc.1995.1579; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; PERRY KL, 1986, J BACTERIOL, V168, P607, DOI 10.1128/jb.168.2.607-612.1986; POGSON B, 1996, IN PRESS PLANT CELL; Sambrook J., 2002, MOL CLONING LAB MANU; Weedon B. C. L., 1995, ISOLATION ANAL, V1A, P27	15	187	212	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24349	24352		10.1074/jbc.271.40.24349	http://dx.doi.org/10.1074/jbc.271.40.24349			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798688	hybrid			2022-12-25	WOS:A1996VM67400010
J	Pascolo, E; Toulme, JJ				Pascolo, E; Toulme, JJ			Double hairpin complexes allow accommodation of all four base pairs in triple helices containing both DNA and RNA strands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC RECOGNITION; TRYPANOSOME MESSENGER-RNAS; PARASITE LEISHMANIA-AMAZONENSIS; TETHERED OLIGONUCLEOTIDE PROBES; ANTISENSE OLIGONUCLEOTIDES; IN-VITRO; COOPERATIVE BINDING; MAJOR GROOVE; OLIGODEOXYNUCLEOTIDES; STABILITY	We investigated the binding of an antisense oligodeoxynucleotide to a stem-loop structure corresponding to the mini-exon sequence of the protozoan parasite Leishmania amazonensis. This oligomer was designed to anneal to the single-stranded region adjacent to the bottom of the hairpin and to fold back on itself, giving rise to a ''double-hairpin'' complex that involved a local triplex. This imposed the recognition, by the third strand, of a ''purine'' strand containing 6 interspersed pyrimidines out of 15 nucleic acid bases. The sequence of the complementary oligonucleotide was derived from the so-called pyrimidine motif; the third strand of the anti-mini-exon oligomer was parallel to the purine strand of the target. Electrophoretic mobility shift assays and footprinting studies demonstrated that such an antisense oligomer was able to bind to both the DNA and RNA versions of the Leishmania hairpin. These double hairpin complexes allowed the formation at pH 6.0 of a triple-stranded structure, despite the presence of 4 A:T*G and 2 G:C*T triplets out of 15.	UNIV BORDEAUX 2,INSERM,U386,IFR PATHOL INFECT,F-33076 BORDEAUX,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux				Toulme, Jean-jacques/0000-0002-8432-5034				BAUMANN U, 1988, BIOCHEM BIOPH RES CO, V157, P986, DOI 10.1016/S0006-291X(88)80971-9; BEAL PA, 1992, J AM CHEM SOC, V114, P4976, DOI 10.1021/ja00039a004; BEST GC, 1995, J AM CHEM SOC, V117, P1187, DOI 10.1021/ja00109a001; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BROSSALINA E, 1993, NUCLEIC ACIDS RES, V21, P5616, DOI 10.1093/nar/21.24.5616; BROSSALINA E, 1993, J AM CHEM SOC, V115, P796, DOI 10.1021/ja00055a065; BROSSALINA E, IN PRESS NUCLEIC ACI; CASSIDY SA, 1994, BIOCHEMISTRY-US, V33, P15338, DOI 10.1021/bi00255a015; CHOMILIER J, 1992, BIOPHYS CHEM, V45, P143, DOI 10.1016/0301-4622(92)87006-5; CLOAD ST, 1991, J AM CHEM SOC, V113, P6324, DOI 10.1021/ja00016a089; CLOAD ST, 1994, J AM CHEM SOC, V116, P437, DOI 10.1021/ja00081a002; CORNELISSEN AWCA, 1986, NUCLEIC ACIDS RES, V14, P5605, DOI 10.1093/nar/14.14.5605; CROUCH R J, 1990, New Biologist, V2, P771; DISTEFANO MD, 1991, J AM CHEM SOC, V113, P5901, DOI 10.1021/ja00015a076; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; EDER PS, 1991, J BIOL CHEM, V266, P6472; ESCUDE C, 1993, NUCLEIC ACIDS RES, V21, P5547, DOI 10.1093/nar/21.24.5547; FRANCOIS JC, 1988, NUCLEIC ACIDS RES, V16, P11431, DOI 10.1093/nar/16.24.11431; FROEHLER BC, 1992, BIOCHEMISTRY-US, V31, P1603, DOI 10.1021/bi00121a004; GIOVANNANGELI C, 1991, J AM CHEM SOC, V113, P7775, DOI 10.1021/ja00020a058; GIOVANNANGELI C, 1992, P NATL ACAD SCI USA, V89, P8631, DOI 10.1073/pnas.89.18.8631; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HAN HY, 1993, P NATL ACAD SCI USA, V90, P3806, DOI 10.1073/pnas.90.9.3806; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HUANG L, 1994, J BIOL CHEM, V269, P25922; KOH JS, 1992, J AM CHEM SOC, V114, P1470, DOI 10.1021/ja00030a050; MERGNY JL, 1992, SCIENCE, V256, P1681, DOI 10.1126/science.256.5064.1681; MERGNY JL, 1991, BIOCHEMISTRY-US, V30, P9791, DOI 10.1021/bi00104a031; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MISHRA RK, 1994, CR ACAD SCI III-VIE, V317, P977; MISHRA RK, 1995, BBA-GENE STRUCT EXPR, V1264, P229, DOI 10.1016/0167-4781(95)00145-7; MISHRA RK, 1996, IN PRESS P NTL ACAD; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; PASCOLO E, 1993, BIOCHIMIE, V75, P43, DOI 10.1016/0300-9084(93)90023-L; PASCOLO E, 1994, BBA-GENE STRUCT EXPR, V1219, P98, DOI 10.1016/0167-4781(94)90251-8; PILCH DS, 1994, P NATL ACAD SCI USA, V91, P9332, DOI 10.1073/pnas.91.20.9332; RAMAZEILLES C, 1994, P NATL ACAD SCI USA, V91, P7859, DOI 10.1073/pnas.91.17.7859; RICHARDSON PL, 1991, J AM CHEM SOC, V113, P5109, DOI 10.1021/ja00013a083; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; SEMERAD CL, 1994, NUCLEIC ACIDS RES, V22, P5321, DOI 10.1093/nar/22.24.5321; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P9357, DOI 10.1073/pnas.91.20.9357; SUN JS, 1989, P NATL ACAD SCI USA, V86, P9198, DOI 10.1073/pnas.86.23.9198; SUN JS, 1991, P NATL ACAD SCI USA, V88, P6023, DOI 10.1073/pnas.88.14.6023; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; TOULME JJ, 1996, RIBONUCLEASES; VERSPIEREN P, 1987, GENE, V61, P307, DOI 10.1016/0378-1119(87)90194-6; VERSPIEREN P, 1990, NUCLEIC ACIDS RES, V18, P4711, DOI 10.1093/nar/18.16.4711; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WANG SH, 1994, J AM CHEM SOC, V116, P8857, DOI 10.1021/ja00098a075; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625; YOON K, 1992, P NATL ACAD SCI USA, V89, P3840, DOI 10.1073/pnas.89.9.3840	53	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24187	24192		10.1074/jbc.271.39.24187	http://dx.doi.org/10.1074/jbc.271.39.24187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798660	hybrid			2022-12-25	WOS:A1996VJ44200089
J	Taylor, KB; Windsor, LJ; Caterina, NCM; Bodden, MK; Engler, JA				Taylor, KB; Windsor, LJ; Caterina, NCM; Bodden, MK; Engler, JA			The mechanism of inhibition of collagenase by TIMP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITION; C-TERMINAL DOMAIN; TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; KINETIC-ANALYSIS; FACTOR-XA; FIBROBLAST COLLAGENASE; GELATINASE-A; SLOW-BINDING; PROTEINASES	Tissue inhibitor of metalloproteinase-I (TIMP-1) is a slow, tight-binding inhibitor of fibroblast-type collagenase. Time-course data from inhibition experiments were analyzed by graphic analysis, by nonlinear regression of the analytic integrals of the rate equations and by nonlinear regression with numeric integration of the rate equations, With the same assumptions, approximations and data, all three methods of analysis produced the same model preferences and values for the kinetic parameters. The time course data for the inhibition of fibroblast-type collagenase by TIMP-1 are best described by the equations for a noncompetitive two-step mechanism, in which an inactive, rapidly formed, reversible complex slowly forms an inactive, tight complex. However, from the analysis of data from experiments at concentrations of TIMP-1 comparable to that of collagenase, it is apparent that free TIMP-1 also functions in the breakdown of the tight complex, The rapidly formed complex has a dissociation constant of 8 nM and reacts to the tight complex with a first-order rate constant of 0.003 s(-1). The back reaction of the tight complex to the rapid complex has a second-order rate constant of 5 x 10(4) M(-1) s(-1). The resulting global dissociation constant of the tight complex is 0.1 nM at 3 nM TIMP-1 and collagenase concentration. Collagenase without the carboxyl-terminal domain (mini-collagenase) is inhibited by TIMP-1 according to a mechanism, in which the rapidly formed complex has such a high dissociation constant (247 nM) that it effectively constitutes a one-step mechanism, in which TIMP-1 binds with an apparent second-order rate constant of 9.6 x 10(4) mol(-1) s(-1) and the enzyme-TIMP-1 complex dissociates with a first order rate constant of 0.00026 s(-1). The apparent global dissociation constant for the tight complex (2.7 nM) is higher than that for the fibroblast-type collagenase, Participation of TIMP-1 in the dissociation is not demonstrable, Therefore, the carboxyl-terminal domain of fibroblast type collagenase is important for the initial, rapid binding of TIMP-1 and the initial complex contributes to the overall binding.	UNIV ALABAMA,DEPT ORAL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT RESTORAT DENT,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH MED,ORAL BIOL RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,ORAL BIOL RES CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Taylor, KB (corresponding author), UNIV ALABAMA,DEPT BIOCHEM & MOL GENET,CH-19,RM 509,UNIV STN,BIRMINGHAM,AL 35294, USA.				NIDCR NIH HHS [DE08228, DE10631, DE00283] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010631, P50DE008228] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akaike H., 1976, MATH SCI, V14, P5; BAKKER AV, 1990, BIOCHEM J, V271, P559, DOI 10.1042/bj2710559; BARAGI VM, 1994, J BIOL CHEM, V269, P12692; BIGG HF, 1994, BBA-PROTEIN STRUCT M, V1208, P157, DOI 10.1016/0167-4838(94)90173-2; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; BYRNE G, 1976, UCID30132 LAWR LIV N; CHANDLER JP, 1972, COMPUT BIOMED RES, V5, P515, DOI 10.1016/0010-4809(72)90058-4; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; EMONARD H, 1990, CELL MOL BIOL, V36, P131; GUTHEIL WG, 1993, BIOCHEMISTRY-US, V32, P8723, DOI 10.1021/bi00085a001; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; JORDAN SP, 1990, BIOCHEMISTRY-US, V29, P11095, DOI 10.1021/bi00502a012; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1989, J NATL CANCER I, V81, P556, DOI 10.1093/jnci/81.8.556; MERCER E, 1985, BIOCHEM J, V231, P505, DOI 10.1042/bj2310505; *MICR SCI SOFTW, 1993, SCI HDB, P207; MORGENSTERN KA, 1994, BIOCHEMISTRY-US, V33, P3432, DOI 10.1021/bi00177a037; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MURPHY G, 1989, BIOCHEM J, V261, P1031, DOI 10.1042/bj2611031; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; WALEY SG, 1993, BIOCHEM J, V294, P195, DOI 10.1042/bj2940195; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Williams J W, 1979, Methods Enzymol, V63, P437; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201; WINDSOR LJ, 1996, IN PRESS BIOCH BIOPH; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	37	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23938	23945		10.1074/jbc.271.39.23938	http://dx.doi.org/10.1074/jbc.271.39.23938			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798626				2022-12-25	WOS:A1996VJ44200055
J	Dalley, BK; Cannon, JF				Dalley, BK; Cannon, JF			Novel, activated RAS mutations alter protein-protein interactions	ONCOGENE			English	Article						RAS; RAF; NF1; GTPase activating proteins; yeast; genetics	SITE-DIRECTED MUTAGENESIS; ADENYLATE-CYCLASE PATHWAY; SACCHAROMYCES-CEREVISIAE; GUANINE-NUCLEOTIDES; SIGNAL TRANSDUCTION; EFFECTOR RESIDUES; TERMINAL DOMAIN; GTP HYDROLYSIS; YEAST-CELLS; GENE	Random RAS2 mutants of Saccharmoyces cerevisiae were screened for activating traits, A total of 69 distinct mutations were identified, affecting 44 different amino acid residues, Many activated alleles do not bypass the requirement for the nucleotide exchange factor, CDC25, nor is the severity of RAS2 phenotypic traits strictly correlated with the capacity to bypass CDC25, In vivo interactions of mutant RAS2 proteins with RAS effecters (adenylate cyclase and RAF), CDC25 and GTPase activating proteins (IRA2 and NF1) mere assayed to assess how the various amino acid substitutions influence interactions with regulatory and target proteins of RAS, Nearly all activated RAS2 proteins mere observed to interact better with adenylate cyclase and RaF, although some distinct differences were found, Several amino acid substitutions that reduce the affinity of RAS2 for guanine nucleotides apparently elevate the fraction of nucleotide-free RAS2, which has greater CDC25 affinity. Amino acid alterations that reduce the affinity of RAS2 for GTPase activating proteins included substitutions both within the switch I/switch II domain and distinctly outside it, One mutant, RAS2-Y78F, bound a lower fraction of GTP in vivo than the wild-type protein, The Y78F substitution is localized to the switch II domain, a region of the RAS protein that undergoes guanine nucleotide-dependent conformational changes.	UNIV MISSOURI, DEPT MOL MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA	University of Missouri System; University of Missouri Columbia				Cannon, John/0000-0001-6698-176X				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barnard D, 1995, ONCOGENE, V10, P1283; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CANNON JF, 1994, GENETICS, V136, P485; CASPERSON GF, 1985, P NATL ACAD SCI USA, V82, P5060, DOI 10.1073/pnas.82.15.5060; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; DENT P, 1992, EUR J BIOCHEM, V210, P1037, DOI 10.1111/j.1432-1033.1992.tb17509.x; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eckert K A, 1991, PCR Methods Appl, V1, P17; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HU JS, 1993, BIOCHEMISTRY-US, V32, P6763, DOI 10.1021/bi00077a031; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1993, ONCOGENE, V8, P425; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PETITJEAN A, 1990, GENETICS, V124, P797; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIKORSKI RS, 1989, GENETICS, V122, P19; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILSON BA, 1993, ONCOGENE, V8, P3441; WOOD DR, 1994, J BIOL CHEM, V269, P5322; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	60	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1209	1220						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808695				2022-12-25	WOS:A1996VJ20200012
J	Pedley, J; Ablett, EM; Pettit, A; Meyer, J; Dunn, IS; Sturm, RA; Parsons, PG				Pedley, J; Ablett, EM; Pettit, A; Meyer, J; Dunn, IS; Sturm, RA; Parsons, PG			Inhibition of retinoblastoma protein translation by UVB in human melanocytic cells and reduced cell cycle arrest following repeated irradiation	ONCOGENE			English	Article						UVB; melanocytes; retinoblastoma gene product; translation; cycle arrest	GENE-PRODUCT; BILATERAL RETINOBLASTOMA; CUTANEOUS MELANOMA; PHOSPHORYLATION; DIFFERENTIATION; RADIATION; RB; EXPRESSION; IDENTIFICATION; TRANSCRIPTION	In human melanocytes and a human melanoma cell line (MM96L), the level of the retinoblastoma gene product (pRB) detected by Western blotting transiently decreased to 55% and 70% of controls respectively 9-12 h after a noncytostatic exposure (75 Jm(-2)) to UVB (280-315 mm) and to 2% and 14% 48 h after a cytostatic exposure (300 Jm(-2)). The pRB levels in fibroblasts and HeLa showed minimal loss, and under some conditions increased compared with unirradiated cells. Equitoxic doses of gamma radiation, cisplatin or the antimetabolite deoxyinosine had little effect on pRB levels. UVC (254 mn) was less inhibitory compared with equitoxic UVB. No loss of PRB mRNA was found in MM96L after UVB, nor was PRB protein stability significantly affected. Synthesis of new pRB in h MM96L 24 h after UVB was 16% of controls, suggesting that loss of pRB results from a UVB-specific inhibition of translation. Compared with HeLa cells and fibroblasts, MM96L cells exhibited reduced cycle arrest if irradiated when pRB was depleted by a previous WE exposure. These results suggest a mechanism whereby down-regulation of pRB translation by UVB may play a role in genesis of melanoma.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND LABS,HERSTON,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT PATHOL,BRISBANE,QLD 4072,AUSTRALIA; UNIV QUEENSLAND,CTR MOL & CELL BIOL,BRISBANE,QLD 4072,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland			Parsons, Peter G/H-8163-2015; Pettit, Allison/O-4462-2019; Sturm, Richard A/C-9943-2009	Parsons, Peter G/0000-0002-0473-3346; Pettit, Allison/0000-0003-4707-7892; Sturm, Richard A/0000-0003-1301-0294				ABDELMALEK Z, 1994, PIGM CELL RES, V7, P326, DOI 10.1111/j.1600-0749.1994.tb00635.x; ALBERT LS, 1990, J AM ACAD DERMATOL, V23, P1001, DOI 10.1016/0190-9622(90)70322-9; ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P251, DOI 10.1002/gcc.2870090405; AUSUBEL FM, 1989, CURRENT RPOTOCOLS MO; BARKER D, 1995, CANCER RES, V55, P4041; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COFFER PJ, 1995, ONCOGENE, V11, P561; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GALLIE BL, 1990, LAB INVEST, V62, P394; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROVITZ M, 1993, NEW STATESMAN SOC, V6, P24; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KHANNA KK, 1995, ONCOGENE, V11, P609; KLEINSZANTO AJP, 1994, CANCER RES, V54, P4569; KRANENBURG O, 1995, ONCOGENE, V10, P87; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEVY R, 1993, PRESSE MED, V22, P878; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MEDRANO EE, 1995, CANCER RES, V55, P4047; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MUNCASTER MM, 1992, CANCER RES, V52, P654; PARSONS PG, 1985, PHOTOCHEM PHOTOBIOL, V42, P287, DOI 10.1111/j.1751-1097.1985.tb08944.x; POLLOCK PM, 1995, ONCOGENE, V11, P663; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROSENSTEIN BS, 1995, PHOTOCHEM PHOTOBIOL, V61, P142, DOI 10.1111/j.1751-1097.1995.tb03952.x; SAUNDERS BM, 1989, BRIT J CANCER, V60, P358; SCHWARTZ E, 1995, J INVEST DERMATOL, V105, P65, DOI 10.1111/1523-1747.ep12312576; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; TANG A, 1989, ONCOGENE, V4, P401; YAVUZER U, 1995, ONCOGENE, V10, P123; YEN A, 1992, EUR J CELL BIOL, V57, P210; YEN A, 1992, IN VITRO CELL DEV-AN, V28A, P669; ZACHSENHAUS E, 1993, MOL CELL BIOL, V13, P4588	51	13	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1335	1342						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808708				2022-12-25	WOS:A1996VJ20200025
J	Steenbergen, RDM; Walboomers, JMM; Meijer, CJLM; vanderRaaijHelmer, EMH; Parker, JN; Chow, LT; Broker, TR; Snijders, PJF				Steenbergen, RDM; Walboomers, JMM; Meijer, CJLM; vanderRaaijHelmer, EMH; Parker, JN; Chow, LT; Broker, TR; Snijders, PJF			Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: Activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q	ONCOGENE			English	Article						human papillomavirus; keratinocytes; allelotyping; loss of heterozygosity; telomerase; immortalization	SQUAMOUS-CELL CARCINOMAS; EPITHELIAL-CELLS; CERVICAL-CARCINOMA; GENETIC-ANALYSIS; UTERINE CERVIX; CHROMOSOME 3P; CANCER; DIFFERENTIATION; SENESCENCE; HETEROZYGOSITY	This study aimed at resolving cellular genetic alterations in the process of in vitro immortalization of human keratinocytes by human papillomavirus (HPV) types 16 and 18. Four cell lines of primary human foreskin keratinocytes transfected with HPV 16 and HPV 18, respectively, were analysed during the transition from the mortal to immortal state, All cell lines showed strong telomerase activity at the immortal state, whereas no or only weak telomerase activity was detected in mortal precursor cells, This was consistent with telomere stabilization or restoration only observed in immortal cells, HPV physical state and copy number appeared constant during immortalization and HPV E6/E7 transcripts were present throughout, Immortalization was associated with clonal allele losses at 3p combined with either 11q or 18q or at 10p, dependent on the cell line, Moreover, a correlation was evident between the onset of telomerase activity and allele loss at 30 or 10p, All immortalized cells retained the capability to differentiate after growth in the presence of physiological calcium and serum, Moreover, one of the immortal cell lines displayed terminal differentiation after organotypic culturing on collagen rafts, The data suggest that (a) several pathways exist for HPV mediated immortalization that may involve genes residing at 3p, 10p, 11q and/or 18q; (b) 3p and 10p may encode genes involved in telomerase regulation; and (c) immortalization lit vitro can be correlated with a spectrum of morphological changes varying from mild to severe dysplasia.	FREE UNIV AMSTERDAM HOSP, DEPT PATHOL, UNIT MOL PATHOL, NL-1081 HV AMSTERDAM, NETHERLANDS; FREE UNIV AMSTERDAM HOSP, DEPT PATHOL, NL-1081 HV AMSTERDAM, NETHERLANDS; UNIV ALABAMA, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Alabama System; University of Alabama Birmingham				Steenbergen, Renske/0000-0002-2327-9839	NATIONAL CANCER INSTITUTE [T32CA009467, R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA36200, T32 CA09467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT JC, 1994, COLD SPRING HARB SYM, V59, P411, DOI 10.1101/SQB.1994.059.01.046; BLANTON RA, 1991, AM J PATHOL, V138, P673; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHEN TM, 1993, CANCER RES, V53, P1167; Chung GTY, 1995, ONCOGENE, V11, P2591; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1994, LANCET, V343, P955, DOI 10.1016/S0140-6736(94)90070-1; HERMSEN MAJ, 1996, IN PRESS HUMAN PATHO; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KARLSEN F, 1994, INT J CANCER, V58, P787, DOI 10.1002/ijc.2910580606; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KOHNO T, 1993, ONCOGENE, V8, P1825; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; LI SL, 1992, CARCINOGENESIS, V13, P1981, DOI 10.1093/carcin/13.11.1981; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MITRA AB, 1994, CANCER RES, V54, P4481; Muliokandov MR, 1996, CANCER RES, V56, P197; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; SASAKI M, 1994, CANCER RES, V54, P6090; SEAGON S, 1994, CANCER RES, V54, P5593; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Snijders P J, 1994, Curr Top Microbiol Immunol, V186, P177; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; STANLEY M, 1994, PAPILLOMAVIRUS REP, V5, P141; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; VANDENBRULE AJC, 1991, AM J PATHOL, V139, P1037; WALBOOMERS JMM, 1988, AM J PATHOL, V131, P587; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WILSON JL, 1992, CELL GROWTH DIFFER, V3, P471; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1990, CANCER RES, V50, P3709	49	124	126	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1249	1257						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808699				2022-12-25	WOS:A1996VJ20200016
J	Betting, J; Seufert, W				Betting, J; Seufert, W			A yeast Ubc9 mutant protein with temperature-sensitive in vivo function is subject to conditional proteolysis by a ubiquitin- and proteasome-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; CONJUGATING ENZYMES; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; 20S PROTEASOME; PEP4 GENE; S-PHASE; DEGRADATION; ENCODES	The UBC9 gene of the yeast Saccharomyces cerevisiae is essential for cell viability and encodes a soluble protein of the nucleus that is metabolically stable. Products of mutant alleles selected to confer temperature-sensitive in vivo function were found to be extremely short-lived at the restrictive but long-lived at the permissive condition. An extragenic suppressor mutation was isolated which increased thermoresistance of a ubc9-1 strain. This suppressor turned out to stabilize the mutated gene product, indicating that the physiological activity of ubc9-1 protein is primarily controlled by conditional proteolysis. The labile ubc9-1 protein appears to be a substrate for ubiquitination, and its turnover was substantially reduced by expression of a ubiquitin derivative that interferes with formation of multi-ubiquitin chains. Stabilization resulted also from competitive inhibition of Ubc4-related ubiquitin conjugating enzymes. Activity of the proteasome complex was crucial to rapid breakdown, whereas vacuolar proteases were dispensable. Thus, the heat-denatured ubc9-1 protein is targeted for proteolysis by the ubiquitin-proteasome pathway and may serve as a useful tool to further define the process by which a misfolded polypeptide is recognized.	UNIV MUNICH, INST GENET & MIKROBIOL, D-80638 MUNICH, GERMANY	University of Munich			Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064				ACHSTETTER T, 1984, J BIOL CHEM, V259, P3334; Alberts B., 1994, MOL BIOL CELL; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Ausubel FM, 1994, CURRENT PROTOCOLS MO; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CHIANG HL, 1994, NATURE, V369, P284, DOI 10.1038/369284a0; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILT W, 1993, J BIOL CHEM, V268, P3479; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEWIN B, 1994, GENES, V5; MAICAS E, 1988, MOL CELL BIOL, V8, P169, DOI 10.1128/MCB.8.1.169; MCCUSKER JH, 1991, MOL CELL BIOL, V11, P746, DOI 10.1128/MCB.11.2.746; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURRAY A, 1993, CELL CYCLE; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHORK SM, 1994, NATURE, V369, P283, DOI 10.1038/369283a0; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHARROCKS AD, 1992, NUCLEIC ACIDS RES, V20, P1147, DOI 10.1093/nar/20.5.1147; SHERMAN MY, 1992, EMBO J, V11, P71; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	65	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25790	25796		10.1074/jbc.271.42.25790	http://dx.doi.org/10.1074/jbc.271.42.25790			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824207	hybrid			2022-12-25	WOS:A1996VN18000013
J	Geider, S; Baronnet, A; Cerini, C; Nitsche, S; Astier, JP; Michel, R; Verdier, JM				Geider, S; Baronnet, A; Cerini, C; Nitsche, S; Astier, JP; Michel, R; Verdier, JM			Pancreatic lithostathine as a calcite habit modifier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STONE PROTEIN; CRYSTAL-GROWTH; CARBONATE; PHOSPHOPROTEIN; PRECIPITATION; SEQUENCE	Most biological fluids are supersaturated with calcium salts, A mechanism controlling crystal growth is therefore necessary to prevent excessive precipitation and development of a lithiasis. In pancreatic juice, calcite precipitation is prevented by lithostathine, a glycoprotein that inhibits calcite crystal growth, We describe here the interaction of lithostathine with calcite crystals, Without lithostathine, calcite crystals grew as rhombohedra showing six {10(1) over bar 4} faces. At low concentration (1 mu M), lithostathine already altered crystal growth by generating new {11(2) over bar 0} faces. At physiological concentrations (3-10 mu M), adsorption resulted in a transition from rhombohedral to sub cubic habits, Immunochemical localization demonstrated that, although all {10(1) over bar 4} faces are equivalent, lithostathine binding was restricted to the face edges distal to the c axis. Scanning electron microscopy showed that, at the site of lithostathine binding, spreading of new CaCO3 layers during crystal growth was arrested before reaching the crystal diad axis-bearing edges. The successive kinks generated during crystal growth formed the new, striated {11(2) over bar 0} faces. Similar modifications were observed with the N-terminal undecapeptide of lithostathine that bears the inhibitory activity. With 100 mu M lithostathine, {11(2) over bar 0} faces could reach the c axis outcrop of the former rhombohedron, resulting in an olive shaped crystal. Finally, the number of crystals increased and their average size decreased when lithostathine concentration increased from 0.1 to 100 mu M. Decreased Ca2+ concentration during crystal growth was delayed in the presence of lithostathine. It was concluded that lithostathine controls lithogenesis 1) by triggering germination of numerous calcite crystals and 2) by inhibiting the rate of Ca2+ ion apposition on the nuclei and therefore interfering with the apposition of new layers on calcite. Formation of smaller crystals, whose elimination is easier, is thereby favored.	INSERM,U315,UNITE RECH PHYSIOL & PATHOL DIGEST,F-13258 MARSEILLE 09,FRANCE; CNRS,CTR RECH MECANISMES CROISSANCE CRISTALLINE,MARSEILLE,FRANCE; HOP ST MARGUERITE,SERV NEPHROL & HEMODIALYSE,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille				VERDIER, Jean-Michel/0000-0002-7252-1556				ABBONA F, 1979, J CRYST GROWTH, V46, P339, DOI 10.1016/0022-0248(79)90082-4; ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; BERNARD JP, 1991, PANCREAS, V6, P162, DOI 10.1097/00006676-199103000-00006; BERNARD JP, 1992, GASTROENTEROLOGY, V103, P1277, DOI 10.1016/0016-5085(92)91516-7; Boistelle R., 1982, Interfacial Aspects of Phase Transformations. Proceedings of the NATO Advanced Study Institute, P621; BOISTELLE R, 1981, J CRYST GROWTH, V54, P275, DOI 10.1016/0022-0248(81)90472-3; DAGORN JC, 1993, PANCREAS BIOL PATHOB, P263; DECARO A, 1984, BIOCHEM J, V222, P669, DOI 10.1042/bj2220669; EDMONDSON HA, 1950, AM J PATHOL, V26, P37; GIORGI D, 1989, J CLIN INVEST, V84, P100, DOI 10.1172/JCI114128; GRUZENSKY PM, 1967, J PHYS CHEM SOLIDS S, V1, P365; HAY DI, 1973, ARCH ORAL BIOL, V18, P1531, DOI 10.1016/0003-9969(73)90128-3; HAY DI, 1979, INORG PERSPECT BIOL, V2, P271; MONTALTO G, 1986, BIOCHEM J, V238, P227, DOI 10.1042/bj2380227; MULTIGNER L, 1983, BIOCHEM BIOPH RES CO, V110, P69, DOI 10.1016/0006-291X(83)91261-5; NAKAGAWA Y, 1983, J BIOL CHEM, V258, P2594; PAQUETTE J, 1995, GEOCHIM COSMOCHIM AC, V59, P735, DOI 10.1016/0016-7037(95)00004-J; SHIMIZU S, 1989, J CLIN INVEST, V84, P1990, DOI 10.1172/JCI114389; STAUDT WJ, 1994, GEOCHIM COSMOCHIM AC, V58, P2087, DOI 10.1016/0016-7037(94)90287-9	19	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26302	26306		10.1074/jbc.271.42.26302	http://dx.doi.org/10.1074/jbc.271.42.26302			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824282	hybrid			2022-12-25	WOS:A1996VN18000088
J	Song, XL; Mott, JD; vonKampen, J; Pramanik, B; Tanaka, K; Slaughter, CA; DeMartino, GN				Song, XL; Mott, JD; vonKampen, J; Pramanik, B; Tanaka, K; Slaughter, CA; DeMartino, GN			A model for the quaternary structure of the proteasome activator PA28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT ACTIVATOR; MULTICATALYTIC PROTEINASE; 20S PROTEASOME; HOMOLOGOUS SUBUNITS; 20-S PROTEASOME; 11-S REGULATOR; PURIFICATION; COMPLEX; ACIDOPHILUM; CLONING	PA28 is a protein activator of the 20S proteasome. It has a native molecular weight of approximately 200,000 and is composed of six 28,000 dalton subunits arranged in a ring-shaped complex, Purified preparations of PA28 contain two polypeptides, alpha and beta, which are about 50% identical in primary structure. It has been unclear whether native PA28 consists of two distinct homohexameric proteins or of a single protein containing both alpha and beta subunits, To distinguish between these possibilities, we prepared antibodies that reacted specifically with either the alpha or beta subunit and used these subunit-specific antibodies in two types of experiments designed to elucidate PA28 quaternary structure. In the first experiment, the alpha and beta subunits were completely co-immunoprecipitated by each subunit-specific antibody, indicating that both subunits were part of a single protein complex, In the second experiment, PA28 was chemically cross-linked using bis(sulfosuccinimidyl)suberate. When the cross-linked products were immunoblotted after SDS-polyacrylamide gel electrophoresis, indistinguishable patterns were obtained with each subunit-specific antibody, These results confirm that the alpha and beta subunits were part of the same protein complex, The pattern of cross linked products also provided insight as to the relative abundance and arrangement of the subunits within the PA28 complex and indicated that the ring-shaped PA28 hexamer may be composed of alternating alpha and beta subunits with a stoichiometry of (alpha beta)(3). PA28 was inactivated by treatment with carboxypeptidase Y, which cleaved Tyr and Ile residues from the carboxyl terminus of the alpha subunit but had very little effect on the beta subunit, This selective and limited proteolysis prevented binding of both alpha and beta subunits to the proteasome and therefore provides additional evidence of the heterodimeric nature of PA28, These results indicate that a short carboxyl-terminal sequence of the alpha subunit is critical for binding of native PA28 to the proteasome. To learn about the relative functions of the alpha and beta subunits, PA28 alpha was expressed in Escherichia coli and purified to homogeneity. Purified PA28 alpha stimulated proteasome activity but required 5-10-fold greater concentrations than the heterodimeric PA28 to achieve a given level of activity. These results suggest that the heterodimeric structure of PA28 is required for maximal proteasome activation.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; TOKYO METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tokyo Metropolitan Institute of Medical Science					NHLBI NIH HHS [HL06296] Funding Source: Medline; NIDDK NIH HHS [DK46181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046181, R01DK046181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CHUPING M, 1993, J BIOL CHEM, V268, P22514; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MOTT JD, 1994, J BIOL CHEM, V269, P31466; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1994, J BIOL CHEM, V269, P7709; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; TANAKA K, 1992, NEW BIOL, V4, P173; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	28	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26410	26417		10.1074/jbc.271.42.26410	http://dx.doi.org/10.1074/jbc.271.42.26410			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824298	hybrid			2022-12-25	WOS:A1996VN18000104
J	Mason, MM; Grasso, JA; Gavrilova, O; Reitman, M				Mason, MM; Grasso, JA; Gavrilova, O; Reitman, M			Identification of functional elements of the chicken epsilon-globin promoter involved in stage-specific interaction with the beta/epsilon enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; HUMAN GAMMA-GLOBIN; CORRECT DEVELOPMENTAL EXPRESSION; KRUPPEL-LIKE FACTOR; BETA-GLOBIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TRANSGENIC MICE; SELECTOR ELEMENT; ERYTHROID-CELLS	Expression of the chicken globin genes is regulated in part by competition between the beta(A)-globin and epsilon-globin promoters for the enhancer found between the genes. To understand the determinants of the enhancer-promoter interaction in stage-specific regulation, the functional elements of the embryonic chicken epsilon-globin promoter were characterized. In vitro assays demonstrated that: (a) the TATA motif at -30 bound GATA-1, (b) Sp1 bound to an element centered at -54, and (c) both Sp1 and another factor, designated CACCC (which appears related to erythroid Kruppel-like factor, EKLF) bound in the -120 to -128 region. The functions of these motifs were tested using transient expression in embryonic erythroid cells, In the absence of the enhancer, promoter point mutants showed that the TATA, Sp1, and CCAAT motifs (but not the CACCC motif) contributed to promoter activity. In contrast, in the presence of the enhancer, all four motifs (including the CACCC motif) contributed to transcription. Developmental regulation of the enhancer activity was observed, with enhance ment decreasing sharply from 185-fold at 4 days (cells expressing epsilon-globin) to 16-fold at 10 days (when epsilon-globin is no longer expressed). Taken together, the data suggest that multiple transcription factors contribute to promoter-enhancer interaction and the developmental regulation of epsilon-globin expression, with EKLF-like factors having an especially important role. Regulation of stage specificity occurs at the level of enhancer/epsilon-promoter interaction, even in the absence of competition, and is not simply a property of the enhancer or promoter in isolation.	NIDDK,NIH,DIABET BRANCH,BETHESDA,MD 20892; NIDDK,NIH,MOL BIOL LAB,BETHESDA,MD 20892; UNIV CONNECTICUT,CTR HLTH,DEPT ANAT,FARMINGTON,CT 06030	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Connecticut			Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475				BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; BRUNS GAP, 1973, PHILOS T ROY SOC B, V266, P225, DOI 10.1098/rstb.1973.0050; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; CZELUSNIAK J, 1982, NATURE, V298, P297, DOI 10.1038/298297a0; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DODGSON JB, 1983, J BIOL CHEM, V258, P2685; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FENG WC, 1994, J BIOL CHEM, V269, P1493; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HESSE JE, 1986, P NATL ACAD SCI USA, V83, P4312, DOI 10.1073/pnas.83.12.4312; JACKSON PD, 1989, GENE DEV, V3, P1860, DOI 10.1101/gad.3.12a.1860; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; LIEHER MR, 1987, J CELL BIOL, V105, P1055; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MASON MM, 1995, MOL CELL BIOL, V15, P407, DOI 10.1128/MCB.15.1.407; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MINIE ME, 1992, DEVELOPMENT, V115, P1149; Moore DD, 1995, GLOB MOB SURV; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICKOL JM, 1988, P NATL ACAD SCI USA, V85, P2548, DOI 10.1073/pnas.85.8.2548; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PERKINS AC, 1995, NATURE, V375, P318; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; REITMAN M, 1993, GENOMICS, V18, P616, DOI 10.1016/S0888-7543(05)80364-7; RONINSON IB, 1982, CELL, V28, P515, DOI 10.1016/0092-8674(82)90206-9; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; YANG Z, 1995, J BIOL CHEM, V269, P10079	53	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25459	25467		10.1074/jbc.271.41.25459	http://dx.doi.org/10.1074/jbc.271.41.25459			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810316	hybrid			2022-12-25	WOS:A1996VL69300060
J	Pipe, SW; Kaufman, RJ				Pipe, SW; Kaufman, RJ			Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; COAGULATION-FACTOR-VIII; CELL ANTIGEN RECEPTOR; VONWILLEBRAND-FACTOR; ENDOPLASMIC-RETICULUM; HEMOPHILIA-A; LIGHT CHAIN; INTRACELLULAR DEGRADATION; MAMMALIAN-CELLS; PRE-GOLGI	The half-life of coagulation factor VIII (FVIII) in plasma is prolonged by noncovalent interaction with von Willebrand factor (vWF), Antibody inhibition data indicate that epitopes within the carboxyl terminus of the FVIII light chain play a role in vWF binding. Analysis of hemophilia A patient DNA samples have identified missense mutations within this carboxyl terminus of the FVIII light chain at amino acid 2307 in which arginine is replaced with either glutamine or leucine. Patients with these mutations have reduced FVIII activity proportional to reduced cross-reacting material in their plasma, It was hypothesized that the reduced levels of FVIII in plasma due to these mutations may be related to a defect in VWF binding with resultant plasma instability, Wild-type and mutant FVIII cDNA expression vectors were prepared and expressed in COS-1 monkey cells by transient DNA transfection. FVIII mutants R2307Q and R2307L were synthesized at equal rates compared to FVIII wild-type but had greater than 10-fold reduced accumulation of antigen and activity levels in the conditioned medium, An additional mutation, Y2305F, also displayed a similar defect in protein accumulation, whereas Y2332F was secreted similarly to wild-type. The specific activity of immunoaffinity purified R2307Q was mildly reduced compared to FVIII wildtype, whereas vWF binding properties were retained. Inhibition of intracellular cysteine proteases resulted in intracellular accumulation of R2307Q protein, suggesting that the mechanism leading to hemophilia A is related to a block in secretion and subsequent degradation within the secretory pathway rather than extracellular instability.	UNIV MICHIGAN,MED CTR,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Pipe, Steven W./ABC-3843-2020	Pipe, Steven W./0000-0003-2558-2089	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52173] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANTONARAKIS SE, 1995, HUM MUTAT, V5, P1, DOI 10.1002/humu.1380050102; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BACHHAWAT AK, 1991, J CELL BIOL, V115, P619, DOI 10.1083/jcb.115.3.619; BONIFACINO JS, 1994, CELLULAR PROTEOLYTIC; BRINKHOUS KM, 1985, P NATL ACAD SCI USA, V82, P8752, DOI 10.1073/pnas.82.24.8752; CASULA L, 1990, BLOOD, V75, P662; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ELIASSON E, 1992, J BIOL CHEM, V267, P15765; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; GILBERT GE, 1993, BLOOD, V82, pA59; GIRMA JP, 1987, BLOOD, V70, P605; GITSCHIER J, 1986, SCIENCE, V232, P1415, DOI 10.1126/science.3012775; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INABA H, 1989, HUM GENET, V81, P335, DOI 10.1007/BF00283686; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LE AQ, 1992, J BIOL CHEM, V267, P1072; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; OVER J, 1978, J CLIN INVEST, V62, P223, DOI 10.1172/JCI109120; PITTMAN DD, 1989, THROMB HAEMOSTASIS, V61, P161; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; RICK ME, 1990, J LAB CLIN MED, V115, P415; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; ROY S, 1992, J BIOL CHEM, V267, P23151; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SCHWAAB R, 1993, BRIT J HAEMATOL, V83, P450, DOI 10.1111/j.1365-2141.1993.tb04670.x; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TOKUNAGA F, 1995, BIOCHEMISTRY-US, V34, P1163, DOI 10.1021/bi00004a009; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TUDDENHAM EGD, 1982, BRIT J HAEMATOL, V52, P259, DOI 10.1111/j.1365-2141.1982.tb03888.x; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILEMAN T, 1990, INT IMMUNOL, V2, P743, DOI 10.1093/intimm/2.8.743; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67; WISE RJ, 1991, J BIOL CHEM, V266, P21948; ZATLOUKAL K, 1994, P NATL ACAD SCI USA, V91, P5148, DOI 10.1073/pnas.91.11.5148; ZIMMERMAN TS, 1985, CLIN HAEMATOL, V14, P343	65	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25671	25676		10.1074/jbc.271.41.25671	http://dx.doi.org/10.1074/jbc.271.41.25671			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810344	hybrid			2022-12-25	WOS:A1996VL69300088
J	VanLeeuwen, JEM; Kearse, KP				VanLeeuwen, JEM; Kearse, KP			The related molecular chaperones calnexin and calreticulin differentially associate with nascent T cell antigen receptor proteins within the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE THYMOCYTES; MONOCLONAL-ANTIBODY; INITIAL STEP; DELTA-CHAIN; GLYCOPROTEINS; RECOGNITION; EXPRESSION; MEMBRANE; ALPHA; OLIGOSACCHARIDE	Assembly of the multisubunit T cell antigen receptor (TCR) complex is an intricate process requiring coordinated regulation of at least six different gene products (alpha, beta, gamma, delta, epsilon and xi) and the ordered pairing of partner chains within the endoplasmic reticulum (ER). To date, two proteins have been implicated as functioning as molecular chaperones in the assembly of nascent TCR proteins: calnexin, a resident ER transmembrane protein, which associates with all TCR components except xi, and T cell receptor-associated protein, which selectively associates with CD3 gamma epsilon pairs, In this study, we examined the association of calreticulin, a soluble protein with significant sequence homology to calnexin, with newly synthesized TCR proteins, Analogous to calnexin, processing of glycan chains by glucosidase enzymes was required for initial association of TCR alpha and -beta proteins with calreticulin; however, several major differences were noted regarding interaction of calnexin and calreticulin chaperones with TCR proteins. First, TCR alpha and -beta proteins showed prolonged association with calnexin molecules compared with calreticulin; interaction of TCR alpha proteins with calreticulin was particularly transient, with most calreticulin-TCR alpha protein complexes dissociating within 15 min of their initial assembly, Second, we found that, unlike calnexin, which associated with clonotypic TCR alpha and -beta proteins and invariant CD3 delta and -epsilon polypeptides, calreticulin associated specifically with clonotypic TCR alpha and -beta proteins. These studies identify calreticulin as a molecular chaperone for nascent clonotypic TCR alpha and -beta proteins and demonstrate that calreticulin and calnexin differentially associate with newly synthesized TCR proteins within the ER.	NCI,EXPT IMMUNOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			van Leeuwen, Jeroen/G-3555-2010					ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BORN W, 1987, NATURE, V330, P572, DOI 10.1038/330572a0; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GRUPP SA, 1995, J EXP MED, V181, P161, DOI 10.1084/jem.181.1.161; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KEARSE KP, 1995, IMMUNITY, V2, P391; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOO TW, 1994, J BIOL CHEM, V269, P28683; MELNICK J, 1995, IMMUNOL TODAY, V16, P243, DOI 10.1016/0167-5699(95)80167-7; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; PARODI AJ, 1983, J BIOL CHEM, V258, P8260; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SCOTT JE, 1995, J IMMUNOL, V155, P143; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; WIEST DL, 1994, J EXP MED, V180, P1375, DOI 10.1084/jem.180.4.1375	35	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25345	25349		10.1074/jbc.271.41.25345	http://dx.doi.org/10.1074/jbc.271.41.25345			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810299	hybrid			2022-12-25	WOS:A1996VL69300043
J	Wilkinson, BM; Critchley, AJ; Stirling, CJ				Wilkinson, BM; Critchley, AJ; Stirling, CJ			Determination of the transmembrane topology of yeast Sec61p, an essential component of the endoplasmic reticulum translocation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN TRANSLOCATION; HUMAN P-GLYCOPROTEIN; MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; LACTOSE PERMEASE; SIGNAL SEQUENCE; SHUTTLE VECTORS; ER MEMBRANE; INSERTION	Sec61p is a highly conserved integral membrane protein that plays a role in the formation of a protein-conducting channel required for the translocation of polypeptides into, and across, the membrane of the endoplasmic reticulum. As a major step toward elucidating the structure of the endoplasmic reticulum translocation apparatus, we have determined the transmembrane topology of Sec61p using a combination of C-terminal reporter-domain fusions and the in situ digestion of specifically inserted factor Xa protease cleavage sites. Our data indicate the presence of 10 transmembrane domains, including several with surprisingly limited hydrophobicity. Furthermore, we provide evidence for complex intramolecular interactions in which these weakly hydrophobic domains require C-terminal sequences for their correct topogenesis, The incorporation of sequences with limited hydrophobicity into the bilayer may play a vital role in the formation of an aqueous membrane channel required for the translocation of hydrophilic polypeptide chains.	UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DRIESSEN AJM, 1994, J MEMBRANE BIOL, V142, P145; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN GN, 1989, J CELL SCI, P109; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HOFFMANN W, 1987, MOL GEN GENET, V210, P277, DOI 10.1007/BF00325694; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; Martoglio B, 1996, TRENDS CELL BIOL, V6, P142, DOI 10.1016/0962-8924(96)10001-5; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SAHINTOTH M, 1995, BIOCHEMISTRY-US, V34, P1107, DOI 10.1021/bi00004a001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1993, J BIOL CHEM, V268, P23552; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STIRLING CJ, 1993, NATO ASI SERIES H, V71, P293; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; ZEN KH, 1995, BIOCHEMISTRY-US, V34, P3430, DOI 10.1021/bi00010a035	60	126	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25590	25597		10.1074/jbc.271.41.25590	http://dx.doi.org/10.1074/jbc.271.41.25590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810333	hybrid			2022-12-25	WOS:A1996VL69300077
J	Arguello, JM; Peluffo, RD; Feng, JN; Lingrel, JB; Berlin, JR				Arguello, JM; Peluffo, RD; Feng, JN; Lingrel, JB; Berlin, JR			Substitution of glutamic 779 with alanine in the Na,K-ATPase alpha subunit removes voltage dependence of ion transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-KIDNEY NA+,K+-ATPASE; SODIUM-PUMP; CATION-BINDING; CHEMICAL MODIFICATION; POTASSIUM-IONS; ATP HYDROLYSIS; OUTER MEDULLA; NA+/K+ PUMP; NA,K PUMP	The effects of changing Glu-779, located in the fifth transmembrane segment of the Na,K-ATPase a subunit, on the phosphorylation characteristics and ion transport properties of the enzyme were investigated, HeLa cells were transfected with cDNA coding the E779A substitution in an ouabain-resistant sheep al subunit (RD). Steady state phosphorylation stimulated by Na+ concentrations less than 20 mM or by imidazole were similar for RD and E779A enzymes, an indication that phosphorylation and Na+ occlusion were not altered by this mutation, With E779A enzyme, higher Na+ concentrations reduced the level of phosphoenzyme and stimulated Na-ATPase activity in the absence of K+. These effects were a consequence of Na+ increasing the rate of protein dephosphorylation. In voltage-clamped HeLa cells expressing E779A enzyme, a prominent electrogenic Na+-Na+ exchange was observed in the absence of extracellular K+. Thus, increased Na-ATPase activity and Na+-dependent dephosphorylation result from Na+ acting as a K+ congener with low affinity at extracellular binding sites, These data suggest that E779A does not directly participate in ion binding but does affect the connection between extracellular ion binding and intracellular enzyme dephosphorylation, In cells expressing control RD enzyme, Na,K-pump current was dependent on membrane potential and extracellular K+ concentration. However, Na,K-pump current in cells expressing E779A enzyme was voltage independent at all extracellular K+ tested, These results indicate that Glu-779 may be part of the access channel determining the voltage dependence of ion transport by the Na,K-ATPase.	UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; GRAD HOSP PHILADELPHIA,BOCKUS RES INST,PHILADELPHIA,PA 19146	University of Cincinnati; University of Pennsylvania	Arguello, JM (corresponding author), WORCESTER POLYTECH INST,DEPT CHEM & BIOCHEM,100 INST RD,WORCESTER,MA 01609, USA.		Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NHLBI NIH HHS [HL28573, HL 03373, HL43712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028573, R01HL043712, K14HL003373, R29HL043712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arguello J. M., 1996, Biophysical Journal, V70, pA326; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; BAMBERG E, 1994, SODIUM PUMP STRUCTUR; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BLOSTEIN R, 1983, J BIOL CHEM, V258, P7948; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; GADSBY DC, 1989, J GEN PHYSIOL, V94, P511, DOI 10.1085/jgp.94.3.511; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P175, DOI 10.1113/jphysiol.1967.sp008295; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; HEYSE S, 1994, J GEN PHYSIOL, V104, P197, DOI 10.1085/jgp.104.2.197; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; KAPLAN JH, 1994, SODIUM PUMP, P321; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; LANE LK, 1973, J BIOL CHEM, V248, P7197; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LESCALEMATYS L, 1990, J BIOL CHEM, V265, P17935; LIANG SM, 1976, BIOCHIM BIOPHYS ACTA, V452, P552, DOI 10.1016/0005-2744(76)90207-2; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MALIK B, 1993, PROTEIN SCI, V2, P2103, DOI 10.1002/pro.5560021211; NAKAO M, 1986, NATURE, V323, P928; PEDEMONTE CH, 1988, J THEOR BIOL, V134, P165, DOI 10.1016/S0022-5193(88)80200-5; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Peluffo R. D., 1996, Biophysical Journal, V70, pA18; PRESSLEY TA, 1988, J MEMBRANE BIOL, V105, P187, DOI 10.1007/BF01870996; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAKOWSKI RF, 1989, J GEN PHYSIOL, V93, P903, DOI 10.1085/jgp.93.5.903; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; SAGAR A, 1994, J GEN PHYSIOL, V103, P869, DOI 10.1085/jgp.103.5.869; SCHWARZ W, 1994, SODIUM PUMP, P482; STEKHOVEN FMAHS, 1985, BIOCHIM BIOPHYS ACTA, V815, P16, DOI 10.1016/0005-2736(85)90468-7; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VASILETS LA, 1994, SODIUM PUMP, P557; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041	51	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24610	24616		10.1074/jbc.271.40.24610	http://dx.doi.org/10.1074/jbc.271.40.24610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798726	hybrid			2022-12-25	WOS:A1996VM67400048
J	Campos, SP; Wang, YP; Baumann, H				Campos, SP; Wang, YP; Baumann, H			Insulin modulates STAT3 protein activation and gene transcription in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; RAT-LIVER NUCLEI; SIGNAL TRANSDUCER; MOLECULAR-CLONING; INTERLEUKIN-6; RECEPTORS; PATHWAY; IRS-1; PHOSPHORYLATION; ASSOCIATION	Treatment of rat hepatoma cells with insulin attenuated the interleukin 6 (IL-6) stimulation of acute phase plasma protein genes, To identify the potential mechanism of this action, the influence of insulin on IL-6 signal transduction was determined, An insulin dose-dependent reduction in signal transducer and activator of transcription 3 (STAT3) gene transcription, mRNA accumulation, protein concentration, and IL-6-inducible DNA binding activity was detected, A reduction in the IL-6-activated sis-inducible element binding of STAT3 was observed within 4 h of insulin treatment, whereas a maximal 3-4-fold lower STAT protein concentration was measured after 8-24 h of insulin treatment. Insulin mediated a similar magnitude reduction in the amount of mRNA encoding the IL-6 receptor alpha subunit and IL-6 binding activity, These effects of insulin appear to contribute to the strongly suppressed transcriptional induction of the IL-6-responsive acute phase plasma protein genes.	ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,BUFFALO,NY 14263; CHILDRENS HOSP,DIV ENDOCRINOL,BUFFALO,NY 14222	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NCI NIH HHS [CA26122] Funding Source: Medline; NIDDK NIH HHS [DK33886] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN M, 1990, J BIOL CHEM, V265, P19853; CAMPOS SP, 1992, MOL CELL BIOL, V267, P19744; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; CHENG J, 1990, NUCLEIC ACIDS RES, V18, P4261, DOI 10.1093/nar/18.14.4261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMMENSCHUH S, 1994, J BIOL CHEM, V269, P12654; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEE I, 1995, AM J PHYSIOL, V266, pC319; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1994, BLOOD, V83, P3457; ORIORDAIN MG, 1995, AM J PHYSIOL-ENDOC M, V269, pE323, DOI 10.1152/ajpendo.1995.269.2.E323; REUBER MD, 1961, J NATL CANCER I, V26, P891; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; THOMPSON D, 1991, CYTOKINE, V3, P619, DOI 10.1016/1043-4666(91)90489-Z; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	30	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24418	24424		10.1074/jbc.271.40.24418	http://dx.doi.org/10.1074/jbc.271.40.24418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798699	hybrid			2022-12-25	WOS:A1996VM67400021
J	Gertler, A; Grosclaude, J; Strasburger, CJ; Nir, S; Djiane, J				Gertler, A; Grosclaude, J; Strasburger, CJ; Nir, S; Djiane, J			Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; TYROSINE KINASE JAK2; MAMMARY-GLAND; BIOLOGICAL-ACTIVITIES; ESCHERICHIA-COLI; OVINE PROLACTIN; BINDING; CELLS; SUPERFAMILY; ACTIVATION	Interactions of recombinant soluble prolactin receptors-extracellular domains (PRLR-ECDs) from rabbit, rat, and cow and human growth hormone receptor ECD with immobilized human growth hormone, several prolactins, and bovine placental lactogen were studied utilizing surface plasmon resonance. This method enables real-time kinetic measurements of the interactions and calculations of kinetic constants and of the stoichiometry of interaction, even in cases where only transient interactions occur. In contrast to gel filtration or crystallographic studies, where in most cases the interaction of PRLR-ECDs with various lactogenic hormones indicated formation of 1:1 complexes, our surface plasmon resonance experiments indicated in all cases the transient formation of a 2:1 complex. In most of the interactions the 2:1 complex was very unstable and underwent rapid dissociation to a 1:1 complex. This situation was particularly characteristic of homologous interactions involving hormone and receptor from the same species and was mainly attributed to increased dissociation constants, We suggest that as in the ease of growth hormone PRLR activation occurs via hormone-induced transient homodimerization of the receptor, lasting only a few seconds, and that this may be sufficient to initiate the biological signal. Once the signal is initiated, the receptor dimer is no longer required. Its rapid dissociation to a 1:1 complex or to its components may even be advantageous in that it permits activation of additional receptors.	HEBREW UNIV JERUSALEM,FAC AGR,DEPT SOIL SCI,IL-76100 REHOVOT,ISRAEL; UNIV MUNICH,KLINIKUM INNENSTADT,MED KLIN,D-8000 MUNICH,GERMANY; INRA,UNITE ENDOCRINOL MOL,F-78352 JOUY EN JOSAS,FRANCE	Hebrew University of Jerusalem; University of Munich; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Gertler, A (corresponding author), HEBREW UNIV JERUSALEM,FAC AGR,INST BIOCHEM FOOD SCI & NUTR,POB 12,IL-76100 REHOVOT,ISRAEL.							BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERTHON P, 1987, P SOC EXP BIOL MED, V184, P300, DOI 10.3181/00379727-184-42483; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BOULAY JL, 1993, CURR BIOL, V3, P573, DOI 10.1016/0960-9822(93)90002-6; BRAMLEY TA, 1987, J ENDOCRINOL, V113, P365, DOI 10.1677/joe.0.1130365; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUSANTERFOURT I, 1984, ENDOCRINOLOGY, V114, P1021, DOI 10.1210/endo-114-3-1021; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GERTLER A, 1984, MOL CELL ENDOCRINOL, V34, P51, DOI 10.1016/0303-7207(84)90158-8; GERTLER A, 1992, J BIOL CHEM, V267, P12655; GERTLER A, 1983, MOL CELL ENDOCRINOL, V33, P169, DOI 10.1016/0303-7207(83)90165-X; GERTLER A, 1993, FEBS LETT, V319, P277, DOI 10.1016/0014-5793(93)80562-9; GERTLER A, 1995, P 77 ANN M END SOC W; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOOPER KP, 1993, J BIOL CHEM, V268, P22347; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JERRY DJ, 1991, J ENDOCRINOL, V130, P43, DOI 10.1677/joe.0.1300043; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; NIR S, 1994, COLLOID SURFACE A, V89, P45, DOI 10.1016/0927-7757(94)02858-3; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; RUI H, 1994, J BIOL CHEM, V269, P5364; SAKAL E, 1995, P 77 ANN M END SOC W; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STATEN NR, 1993, J BIOL CHEM, V268, P18467; Strasburger CJ, 1996, J CLIN ENDOCR METAB, V81, P2613, DOI 10.1210/jc.81.7.2613; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; TCHELET A, 1995, J ENDOCRINOL, V144, P393, DOI 10.1677/joe.0.1440393; TCHELET A, 1993, PEDIAT AD E, V24, P114; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WU ZN, 1995, J BIOL CHEM, V270, P16039, DOI 10.1074/jbc.270.27.16039; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	42	98	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24482	24491		10.1074/jbc.271.40.24482	http://dx.doi.org/10.1074/jbc.271.40.24482			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798708	hybrid			2022-12-25	WOS:A1996VM67400030
J	Harley, CA; Tipper, DJ				Harley, CA; Tipper, DJ			The role of charged residues in determining transmembrane protein insertion orientation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; BETA-LACTAMASE; TOPOLOGY; RULE; KEX2; TRANSLOCATION; DOMAIN; TAILS	The first 79 residues of the yeast Ste2p G protein-coupled pheromone receptor, including the negatively charged N-terminal domain, the first transmembrane segment, and the following positively charged cytoplasmic loop, has been fused to a Kex2p-cleavable beta-lactamase reporter. Insertion orientation was determined by analysis of cell associated and secreted beta-lactamase activities and independently corroborated by analysis of membrane association and glycosylation patterns, This fusion inserts with exclusively N terminus exofacial (N-exo) topology, serving as a model type III membrane protein. Orientation is unaffected by removal of all three positively charged residues in the cytoplasmic loop or by deletion of all but 12 residues from the N-terminal domain. The residual -2 N-terminal charge apparently provides a signal sufficient to determine N-exo topology. This is entirely consistent with the statistically derived rule in which the charge difference, Delta(C-N), counted for the 15 immediately flanking residues, is the primary topology determinant, Mutations altering Delta(C-N) to zero favors N-exo insertion by 3 to 1, whereas increasingly negative values cause increasing inversion of orientation, All results are consistent with the charge difference rule and indicate that whereas positive charges promote cytoplasmic retention, negative charges promote translocation.	UNIV MASSACHUSETTS,SCH MED,DEPT MOL GENET & MICROBIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester			Harley, Carol/J-5375-2013	Harley, Carol/0000-0003-3610-0604				ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BELTZER JP, 1991, J BIOL CHEM, V266, P973; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CARTWRIGHT CP, 1991, MOL CELL BIOL, V11, P2620, DOI 10.1128/MCB.11.5.2620; CARTWRIGHT CP, 1992, YEAST, V8, P261, DOI 10.1002/yea.320080404; CARTWRIGHT CP, 1994, YEAST, V10, P497, DOI 10.1002/yea.320100409; CHAUDHURI B, 1992, FEBS LETT, V304, P41, DOI 10.1016/0014-5793(92)80585-5; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; KRISHTALIK LI, 1995, FEBS LETT, V369, P140, DOI 10.1016/0014-5793(95)00756-Y; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; NAKASHIMA H, 1992, FEBS LETT, V303, P141, DOI 10.1016/0014-5793(92)80506-C; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; von Heijne G, 1994, Subcell Biochem, V22, P1; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693	28	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24625	24633		10.1074/jbc.271.40.24625	http://dx.doi.org/10.1074/jbc.271.40.24625			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798728	hybrid			2022-12-25	WOS:A1996VM67400050
J	Inaba, T; Ishibashi, S; Harada, K; Ohsuga, JI; Ohashi, K; Yagyu, H; Yazaki, Y; Higashiyama, S; Kawata, S; Matsuzawa, Y; Yamada, N				Inaba, T; Ishibashi, S; Harada, K; Ohsuga, JI; Ohashi, K; Yagyu, H; Yazaki, Y; Higashiyama, S; Kawata, S; Matsuzawa, Y; Yamada, N			Induction of macrophage colony-stimulating factor receptor (c-fms) expression in vascular medial smooth muscle cells treated with heparin binding epidermal growth factor-like growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-DERIVED MACROPHAGES; LOW-DENSITY-LIPOPROTEIN; MESSENGER-RNA; EGF; CHOLESTEROL; PROTEIN	Vascular smooth muscle cells migrate, proliferate, and transform to foam cells during the atherosclerotic process. We have reported that smooth muscle cells derived from the intima of atherosclerotic lesions express the proto-oncogene c-fms and a scavenger receptor, which are not normally expressed in normal medial smooth muscle cells, In the present study, we demonstrated that heparin binding epidermal growth factor-like growth factor (HB-EGF) induced the expression of c-fms and the scavenger receptor in normal human medial smooth muscle cells to the level observed in the intima, The expression of c-fms was partially inhibited by a protein kinase C inhibitor, suggesting that HB-EGF induces c-fms via pathways that are both dependent on and independent of protein kinase C, By contrast, most of the scavenger receptor induction by HB-EGF was suppressed by protein kinase C inhibitors, These results indicate that two characteristic genes of monocyte-derived macrophages were induced by HB-EGF via different mechanisms. The alteration of gene expression in response to HB-EGF may play an important role in the phenotypic change of smooth muscle cells to macrophage-like foam cells during the atherosclerotic process.	UNIV TOKYO,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	University of Tokyo; Osaka University; Osaka University								ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FISCHERDZOGA K, 1973, EXP MOL PATHOL, V18, P162; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; INABA T, 1992, J BIOL CHEM, V267, P5693; INABA T, 1992, J BIOL CHEM, V267, P13107; INABA T, 1995, ARTERIOSCL THROM VAS, V15, P522, DOI 10.1161/01.ATV.15.4.522; INABA T, 1995, J CLIN INVEST, V95, P1133, DOI 10.1172/JCI117761; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; LEE LS, 1979, P NATL ACAD SCI USA, V76, P5168, DOI 10.1073/pnas.76.10.5168; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966	21	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24413	24417		10.1074/jbc.271.40.24413	http://dx.doi.org/10.1074/jbc.271.40.24413			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798698	hybrid			2022-12-25	WOS:A1996VM67400020
J	Kim, YH; Park, KH; Rho, HM				Kim, YH; Park, KH; Rho, HM			Transcriptional activation of the Cu,Zn-superoxide dismutase gene through the AP2 site by ginsenoside Rb-2 extracted from a medicinal plant, Panax ginseng	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; FACTOR AP-2; CELLS; EXPRESSION; ELEMENTS; BINDING; COPPER; STRESS; REGION; CANCER	We report here that the ginseng saponins induce the transcription of Cu,Zn-superoxide dismutase gene (SOD1), which is one of the major antioxidant enzymes, Total saponins and panaxatriol did not elevate the level of SOD1, but panaxadiol significantly increased SOD1, Among the panaxadiol fractions, ginsenoside Rb-2 was a more specific and more remarkable inducer of the SOD1 gene than ginsenoside Rb-1. Deletion analyses of the SOD1 promoter revealed that the proximal promoter is responsible for this induction, Mobility shift assays with cis-elements in the proximal promoter region showed that specific binding of the AP2 transcription factor was significantly increased by treatment with ginsenoside Rb-2. Mutations of the AP2 binding sites in the heterologous promoter and natural context systems abolished the transcriptional activation by ginsenoside Rb-2. These results suggest that the SOD1 gene was greatly activated by ginsenoside Rb-2 through transcription factor AP2 binding sites and its induction.	SEOUL NATL UNIV,DEPT BIOL MOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,RES CTR CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA; KOREA GINSENG & TOBACCO RES INST,TAEJON 305345,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BREKHMAN II, 1969, ANNU REV PHARMACOLOG, V9, P419, DOI 10.1146/annurev.pa.09.040169.002223; CARRI MT, 1991, FEBS LETT, V278, P263, DOI 10.1016/0014-5793(91)80131-L; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FRIDOVICH I, 1983, ANN REV PHARM TOXICO, V23, P238; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUBER W, 1980, CLIN RHEUM DIS, V6, P465; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KIM HT, 1994, BIOCHEM BIOPH RES CO, V201, P1526, DOI 10.1006/bbrc.1994.1877; KIM HY, 1992, BIOCHEM BIOPH RES CO, V189, P670; KIM YH, 1993, GENE, V133, P267; LALORAYA M, 1988, BIOCHEM BIOPH RES CO, V157, P146, DOI 10.1016/S0006-291X(88)80025-1; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; LEE KD, 1971, JPN J PHARMACOL, V21, P299, DOI 10.1254/jjp.21.299; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATSUDA H, 1990, PLANTA MED, V56, P19, DOI 10.1055/s-2006-960875; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NICOTERA TM, 1989, CANCER RES, V49, P5239; NISHIYAMA N, 1994, BIOL PHARM BULL, V17, P509, DOI 10.1248/bpb.17.509; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PERCIVAL SS, 1991, BIOCHEM J, V274, P153, DOI 10.1042/bj2740153; Sambrook J., 2002, MOL CLONING LAB MANU; SATO K, 1994, BIOL PHARM BULL, V17, P635; TANAKA O, 1966, CHEM PHARM BULL, V14, P1159; TODE T, 1993, J CANCER RES CLIN, V120, P24, DOI 10.1007/BF01200720; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YOKOZAWA T, 1993, PHYTOTHER RES, V7, P68, DOI 10.1002/ptr.2650070116; YOKOZAWA T, 1993, PHYTOTHER RES, V7, P240, DOI 10.1002/ptr.2650070306; YUN TK, 1990, INT J EPIDEMIOL, V19, P871, DOI 10.1093/ije/19.4.871	35	108	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24539	24543						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798715	hybrid			2022-12-25	WOS:A1996VM67400037
J	Roberts, JR; Mitchell, GA; Miziorko, HM				Roberts, JR; Mitchell, GA; Miziorko, HM			Modeling of a mutation responsible for human 3-hydroxy-3-methylglutaryl-CoA lyase deficiency implicates histidine 233 as an active site residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A LYASE; ESCHERICHIA-COLI; PSEUDOMONAS-MEVALONII; ISOCITRATE LYASE; ENZYME; MUTAGENESIS; EXPRESSION; CATALYSIS; SUBSTRATE; PROTEINS	3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase is inactivated by diethyl pyrocarbonate (DEPC); activity can be fully restored by incubation with hydroxylamine, Protection against DEPC inactivation is afforded by a substrate analogue, suggesting an active site location for a DEPC target, Included in the inherited defects that map within the HMG-CoA lyase gene is a point mutation that results in an arginine substitution for histidine 233, one of only two invariant histidines, These observations prompted a functional test of the importance of His-233. The mutant lyases H233R, H233A, and H233D were overexpressed in Escherichia coli, isolated, and kinetically characterized. In H233D, DEPC targets one less histidine than was measured using wild-type lyase, supporting the assignment of wild-type lyase His-233 as one of the DEPC targets, Substitution of His-233 results in diminution of activity by similar to 4 orders of magnitude, K-m values of the mutant lyases for both substrate HMG-CoA and activator divalent cation (Mg2+ or Mn2+) are comparable to the values measured for wild-type enzyme, indicating that these enzymes retain substantial structural integrity, This conclusion is reinforced by the observation that the affinity label, 2-butynoyl-CoA, stoichiometrically modifies the mutant lyases, indicating that they contain a full complement of active sites, In view of these data suggesting that the structures of these mutant lyases closely approximate that of the wild-type enzyme, their observed 10(4)-fold diminution in catalytic efficiency supports assignment to His-233 of a role in the chemistry of HMG-CoA cleavage.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226; HOP ST JUSTINE,MED GENET SECT,MONTREAL,PQ H3T 1C5,CANADA	Medical College of Wisconsin; Universite de Montreal					NIDDK NIH HHS [DK09018, DK21491] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009018, R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DH, 1989, J BACTERIOL, V171, P6468, DOI 10.1128/jb.171.12.6468-6472.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coon M. J., 1955, S AMINO ACID METABOL, P431; DIEHL P, 1994, J BACTERIOL, V176, P927, DOI 10.1128/jb.176.3.927-931.1994; FAULL K, 1976, NEW ENGL J MED, V294, P1013; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; GOLDFARB S, 1971, J LIPID RES, V12, P512; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HRUZ PW, 1993, BIOCHIM BIOPHYS ACTA, V1162, P149, DOI 10.1016/0167-4838(93)90141-D; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; KO YH, 1991, BIOCHEMISTRY-US, V30, P7451, DOI 10.1021/bi00244a012; KRAMER PR, 1980, J BIOL CHEM, V255, P1023; KRAMER PR, 1983, BIOCHEMISTRY-US, V22, P2353, DOI 10.1021/bi00279a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; MATHIEU M, 1994, STRUCTURE, V2, P797, DOI 10.1016/S0969-2126(94)00081-6; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MITCHELL GA, 1993, J BIOL CHEM, V268, P4376; MITCHELL LW, 1995, J BIOL CHEM, V270, P24054, DOI 10.1074/jbc.270.41.24054; MUHLRAD A., 1967, ACTA BIOCHIM BIOPHYS ACAD SCI HUNG, V2, P19; NARASIMHAN C, 1994, ARCH BIOCHEM BIOPHYS, V312, P467, DOI 10.1006/abbi.1994.1333; NARASIMHAN C, 1992, BIOCHEMISTRY-US, V31, P11224, DOI 10.1021/bi00160a037; OVADI J, 1967, ACTA BIOCHIM BIOPHYS, V2, P445; PERDIGUERO E, 1995, BIOCHEMISTRY-US, V34, P6059, DOI 10.1021/bi00018a008; Robert M.-F., 1994, American Journal of Human Genetics, V55, pA41; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; ROBERTS JR, 1995, J BIOL CHEM, V270, P17311, DOI 10.1074/jbc.270.29.17311; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEGINK LD, 1968, J BIOL CHEM, V243, P5272; WANG SP, 1993, MAMM GENOME, V4, P382, DOI 10.1007/BF00360589; Wang SP, 1996, GENOMICS, V33, P99, DOI 10.1006/geno.1996.0164; WILLIAMS SF, 1992, J BIOL CHEM, V267, P16041	34	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24604	24609		10.1074/jbc.271.40.24604	http://dx.doi.org/10.1074/jbc.271.40.24604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798725	hybrid			2022-12-25	WOS:A1996VM67400047
J	Yu, YT				Yu, YT			Distinct domains of myocyte enhancer binding factor-2A determining nuclear localization and cell type-specific transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; MUSCLE-SPECIFIC GENES; MOUSE EMBRYOGENESIS; FACTOR-II; ACTIVATION DOMAINS; MYOGENIC LINEAGE; SERUM INDUCTION; FACTOR MEF-2; EXPRESSION; PROTEINS	The myocyte enhancer binding factor 2 (MEF2) family of transcription factors plays an important role in the regulation of gene expression in multiple muscle cell types. Four mef2 genes (A, B, C, and D) have been identified in vertebrates. They share the conserved N-terminal MCM1-agamous-deficiens-serum response factor and MEF2 domains that determine DNA binding and dimerization functions. Ln this study, we have identified human IMEF2A domains that control its nuclear localization and transcriptional activation function. Studies of subcellular localization of various truncated MEF2A proteins expressed in HeLa cells demonstrated that MEF2A contains a nuclear localization signal located at its C terminus within the peptide encompassing amino acids (aa) 472-507 Examination of MEF2A mutants with sequential C-terminal deletions indicates that the region encompassing aa 321-472 is essential for transcriptional activity. Analysis of the transcriptional activity of fusion proteins consisting of different domains of MEF2A fused to the DNA binding domain of yeast transcription factor GAL4 revealed a major transcriptional activation domain located between aa 274 and 373. Further studies demonstrated that this domain contains positive and negative regulatory subdomains that cooperate with one another to regulate the transcriptional activity of MEF2A in a cell-type discriminatory manner.			Yu, YT (corresponding author), VANDERBILT UNIV,DIV CARDIOL,DEPT MED & BIOCHEM,NASHVILLE,TN 37232, USA.							Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHNSON PF, 1993, J NUTR BIOCHEM, V4, P386, DOI 10.1016/0955-2863(93)90069-9; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MEIER UT, 1992, CELL, V70, P127; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOKENTIN JD, 1995, CELL, V83, P1125; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARMACEK MS, 1991, CIRCULATION, V84, P991, DOI 10.1161/01.CIR.84.3.991; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RAWLS A, 1995, DEV BIOL, V172, P37, DOI 10.1006/dbio.1995.0004; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	65	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24675	24683						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798735				2022-12-25	WOS:A1996VM67400057
J	CherbonnelLasserre, C; Gauny, S; Kronenberg, A				CherbonnelLasserre, C; Gauny, S; Kronenberg, A			Suppression of apoptosis by Bcl-2 or Bcl-x(L) promotes susceptibility to mutagenesis	ONCOGENE			English	Article						Bcl-2; Bcl-x(L); apoptosis; mutagenesis; ionizing radiation	PROGRAMMED CELL-DEATH; DIPLOID HUMAN-LYMPHOBLASTS; DNA FRAGMENTATION; INDUCED MUTATION; HPRT LOCUS; P53 STATUS; BAX GENE; B-CELLS; IN-VIVO; PROTEIN	Bcl-2 appears to contribute to neoplasia primarily by promoting cell survival, rather than by stimulating cellular proliferation. Bcl-2, and the related protein Bcl-x(L) each suppress apoptosis induced by a wide variety of stimuli in many different cell types. Here we report that suppression of apoptosis by Bcl-2 or Bcl-x(L) markedly elevates the levels of radiation-induced mutations. This enhanced mutagenesis is the result of an increase in mutation frequency (mutations per survivor) together with a moderate increase in viability. Ectopic expression of either Bcl-2 or Bcl-x(L) enhances radiation mutagenesis in cells with wtp53. Surprisingly, we found that ectopic expression of Bcl-x(L) also promotes mutagenesis in p53(-) cells. These results support the hypothesis that apoptosis plays a crucial role in maintaining genomic integrity by selectively eliminating highly mutated cells from the population.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R01CA062364] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-62364] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDSON SA, 1992, MUTAT RES, V267, P89, DOI 10.1016/0027-5107(92)90113-G; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOLE MG, 1995, CANCER RES, V55, P2576; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FUKUNAGAJOHNSON N, 1995, CARCINOGENESIS, V16, P1761, DOI 10.1093/carcin/16.8.1761; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Gauthier ER, 1996, CANCER RES, V56, P1451; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Han ZY, 1996, CANCER RES, V56, P1621; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HAVRE PA, 1995, CANCER RES, V55, P4420; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KRONENBERG A, 1989, MUTAT RES, V211, P215, DOI 10.1016/0027-5107(89)90004-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBER HL, 1982, MUTAT RES, V94, P467, DOI 10.1016/0027-5107(82)90308-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NELSON SL, 1995, RADIAT RES, V141, P2, DOI 10.2307/3579083; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PHILLIPS EN, 1995, RADIAT RES, V143, P255, DOI 10.2307/3579211; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1994, COLD SPRING HARB SYM, V59, P403, DOI 10.1101/SQB.1994.059.01.045; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12; YANDELL DW, 1990, MUTAT RES, V229, P89, DOI 10.1016/0027-5107(90)90011-R; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZHAN QM, 1994, ONCOGENE, V9, P3743	46	85	86	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1489	1497						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875987				2022-12-25	WOS:A1996VL38400014
J	Palvimo, JJ; Reinikainen, P; Ikonen, T; Kallio, PJ; Moilanen, A; Janne, OA				Palvimo, JJ; Reinikainen, P; Ikonen, T; Kallio, PJ; Moilanen, A; Janne, OA			Mutual transcriptional interference between RelA and androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TATA-BINDING PROTEIN; GLUCOCORTICOID RECEPTORS; P65 SUBUNIT; ACTIVATION; ALPHA; TRANSACTIVATION; INTERLEUKIN-6; ASSOCIATION; GENE	Cross-modulation between androgen receptor (AR) and NF-kappa B/Rel proteins was studied using various androgen- and NF-KB-regulated reporter genes under transient transfection conditions. In COS-1 cells, elevated expression of RelA (p65) repressed AR-mediated transactivation in a dose-dependent manner, whereas NF kappa B1 (p50), another major member of the NF-kappa B family, did not influence transactivation. The repression of AR appeared to involve the N-terminal region of the protein between residue 297 and the DNA-binding domain. ReLA-mediated transrepression could not be over come by increasing the amount of AR. Transcriptional interference between RelA and AR was mutual in that cotransfected AR was able to attenuate transactivation by RelA in a dose- and steroid-dependent fashion. An excess of RelA was able to rescue the repression to some extent. Immunological analyses of RelA and AR protein levels indicated that transrepression was not due to reciprocal decrease in their amounts. Neither did AR increase the concentration of I kappa B alpha, which can sequester and inactivate RelA. Electrophoretic mobility shift assays using extracts from cotransfected cells and purified recombinant proteins showed that AR and RelA did not significantly influence each other's DNA binding activity. Nevertheless, protein-protein interaction experiments demonstrated a weak association between AR and RelA. Collectively, these data suggest that the mutual repression in intact cells is due to formation of AR-RelA complexes that are held together by another partner or to competition for a coactivator required for transcription.	UNIV HELSINKI,INST BIOMED,DEPT PHYSIOL,FIN-00014 HELSINKI,FINLAND	University of Helsinki				Palvimo, Jorma/0000-0003-2373-0578				ADEYEMO O, 1993, HUM MOL GENET, V2, P1809, DOI 10.1093/hmg/2.11.1809; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; HERRLICH P, 1994, TRENDS ENDOCRIN MET, V5, P341, DOI 10.1016/1043-2760(94)90164-3; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KALLIO PJ, 1994, J BIOL CHEM, V269, P11514; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; LIU W, 1995, MOL CELL BIOL, V15, P1005; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; NAKAJIMA Y, 1995, UROL RES, V23, P205, DOI 10.1007/BF00393299; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, BIOCHEM J, V316, P993, DOI 10.1042/bj3160993; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723	33	184	186	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24151	24156		10.1074/jbc.271.39.24151	http://dx.doi.org/10.1074/jbc.271.39.24151			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798655	hybrid			2022-12-25	WOS:A1996VJ44200084
J	Kao, CT; Lin, M; OSheaGreenfield, A; Weinstein, J; Sakamoto, KM				Kao, CT; Lin, M; OSheaGreenfield, A; Weinstein, J; Sakamoto, KM			Over-expression of p55Cdc inhibits granulocyte differentiation and accelerates apoptosis in myeloid cells	ONCOGENE			English	Article						cell division cycle; granulocyte differentiation; apoptosis; myeloid cells	COLONY-STIMULATING FACTOR; CYCLIN-DEPENDENT KINASES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; MOLECULAR CONTROLS; SUPPRESSOR GENES; WD-40 REPEAT; PROTEIN; ARREST	p55Cdc is a protein identified in cycling mammalian cells. It is highly expressed in proliferating but not in differentiated or growth-arrested cells. Structurally, p55Cdc is similar to the Cdc4 and Cdc20 proteins, which have been proposed to regulate DNA synthesis and mitosis in Saccharomyces cerevisiae. To define the role of p55Cdc during myelopoiesis, me studied the expression and regulation of this protein in response to the hematopoietic growth factors, granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte-colony stimulating factor (G-CSF). We analysed the time course of expression of p55Cdc in response to GM-CSF and G-CSF stimulation in the murine factor-dependent myeloid leukemic cell line, 32Dc13, and demonstrated differential regulation of p55Cdc in response to these two growth factors, Over-expression of p55Cdc resulted in acceleration of apoptosis in growth factor- and serum-free conditions, although no difference was observed in the rate of cell proliferation, Decreases in p55Cdc protein levels correlated with cells undergoing apoptosis, p55Cdc over-expression also inhibited granulocyte differentiation of 32Dc13 cells treated with G-CSF, Our studies suggest that p55Cdc regulation is critical for normal cell cycle control during myeloid cell proliferation and differentiation.	UNIV CALIF LOS ANGELES,SCH MED,GWYNNE HAZEN CHERRY MEM LABS,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095; AMGEN INC,THOUSAND OAKS,CA 91320	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; Amgen					NCI NIH HHS [R29 CA68221, K08 CA59463-01, 1R55 CA68221-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068221, R55CA068221, K08CA059463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ASKEW DS, 1991, ONCOGENE, V6, P1915; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOI WJ, 1994, BIOCHEM BIOPH RES CO, V172, P1324; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; EVAN G, 1995, CURR OPIN CELL BIOL, V6, P825; FEUCHTER AE, 1992, GENOMICS, V13, P1237, DOI 10.1016/0888-7543(92)90041-P; GRANA X, 1995, ONCOGENE, V11, P211; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; HALLEK M, 1994, LEUKEMIA, V8, P740; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; KREIDER BL, 1992, ONCOGENE, V7, P135; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LEE HJJ, 1995, J BIOL CHEM, V270, P15979, DOI 10.1074/jbc.270.27.15979; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SAKAMOTO KM, 1994, RECEPTOR CHANNEL, V2, P175; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TKATCH LS, 1993, LYMPHOKINE CYTOK RES, V12, P477; TOMEI LD, 1991, APOPTOSIS MOL BASIS; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wong A, 1995, J BIOL CHEM, V270, P30271, DOI 10.1074/jbc.270.51.30271; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z	48	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1221	1229						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808696				2022-12-25	WOS:A1996VJ20200013
J	Chen, P; Lee, P; Otto, L; Abrams, J				Chen, P; Lee, P; Otto, L; Abrams, J			Apoptotic activity of REAPER is distinct from signaling by the tumor necrosis factor receptor 1 death domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DROSOPHILA-MELANOGASTER; TNF RECEPTOR; FAS; PROTEIN; CYTOTOXICITY; GENE	REAPER (RPR) is a 65-amino acid protein that is critical activator of programmed cell death in Drosophila. On the basis of sequence alignment data, it was recently proposed that RPR might represent an ancestral molecule from which the death domain in a number of proteins may have evolved, We tested this idea by examining the activity of mutations in RPR that parallel inactivation mutations of the tumor necrosis factor receptor 1 death domain. The RPR mutants retained potent apoptotic function, suggesting that cell death activity mediated by RPR is distinct from signaling by the tumor necrosis factor receptor 1 death domain.			Chen, P (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.				NIA NIH HHS [AG12466] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012466] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAMS JM, 1996, APOPTOSIS NORMAL DEV, P171; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GOLSTEIN P, 1995, IMMUNOL REV, V146, P45, DOI 10.1111/j.1600-065X.1995.tb00683.x; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH N, 1993, J BIOL CHEM, V268, P10932; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; NORDSTROM W, IN PRESS DEV BIOL; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; STELLER H, 1994, PHILOS T ROY SOC B, V345, P247, DOI 10.1098/rstb.1994.0101; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	25	37	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25735	25737		10.1074/jbc.271.42.25735	http://dx.doi.org/10.1074/jbc.271.42.25735			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824198				2022-12-25	WOS:A1996VN18000004
J	Chen, YH; Tukey, RH				Chen, YH; Tukey, RH			Protein kinase C modulates regulation of the CYP1A1 gene by the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DNA-BINDING ACTIVITY; AH DIOXIN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; DEPENDENT ACTIVATION; HEPATOMA-CELLS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; EXPRESSION; RAT; REPRESSION	Transcriptional activation of the human CYP1A1 gene by halogenated and polycyclic aromatic hydrocarbons is mediated by the aryl hydrocarbon receptor (AhR) complex, a ligand-dependent transcription factor. A competent AhR comprises at least two components following nuclear translocation and DNA binding, the AhR and the AhR nuclear translocator (Arnt) protein, whose combined action on human CYP1A1 gene transcription is shown to be dependent upon functional protein kinase C (PKC). In the present study, we examined the effects of phorbol 12-myristate 13-acetate, a potent PKC activator, on the ligand-induced transcriptional activation of the CYP1A1 gene and cellular function of the AhR in human HepG2 101L cells. The 101L cells carry a stable transgene consisting of 1800 bases of 5'-flanking DNA and the promoter of the human CYP1A1 gene linked to the firefly luciferase structural gene (Postlind, H., Vu, T. P., Tukey, R. H. & Quattrochi, L. C. (1993) Toxicol. Appl. Pharmacol, 118, 255-262). Pretreatment of cells with 12-myristate 13-acetate enhanced ligand-induced CYP1A1 gene expression 2-3-fold, Inhibition of PKC activity blocked directly the transcriptional activation and the transactivation of the CYP1A1 gene, indicating a role for PKC in the AhR-mediated transcriptional activation process. However, the DNA binding activities of the in vitro activated and the induced nuclear AhR as measured by electrophoretic mobility shift analysis were not affected when CYP1A1 transcription was inhibited, indicating the actions of PKC to be a nuclear event that works in concert with or precedes AhR binding to the gene. These results illustrate that PRC is absolutely essential for the cellular and molecular events that control induction of CYP1A1 gene transcription.	UNIV CALIF SAN DIEGO, UCSD CANC CTR, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NIGMS NIH HHS [GM36590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BOISJOYEUX B, 1995, J BIOL CHEM, V270, P10204, DOI 10.1074/jbc.270.17.10204; BOMBICK DW, 1985, BIOCHEM BIOPH RES CO, V127, P296, DOI 10.1016/S0006-291X(85)80158-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CORSARO CM, 1981, SOMAT CELL GENET, V7, P603, DOI 10.1007/BF01549662; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DENISON MS, 1988, J BIOL CHEM, V263, P17221; FISHER JM, 1990, J BIOL CHEM, V265, P9676; GRADIN K, 1994, J BIOL CHEM, V269, P23800; Harlow GR, 1996, ARCH BIOCHEM BIOPHYS, V326, P85, DOI 10.1006/abbi.1996.0050; HARPER PA, 1991, ARCH BIOCHEM BIOPHYS, V290, P27, DOI 10.1016/0003-9861(91)90587-9; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Ko HSP, 1996, MOL CELL BIOL, V16, P430; LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255; MAHON MJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P166, DOI 10.1006/abbi.1995.1217; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; OKINO ST, 1992, J BIOL CHEM, V267, P6991; PASANEN M, 1988, CHEM-BIOL INTERACT, V66, P223, DOI 10.1016/0009-2797(88)90073-7; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; SAFE S, 1990, CRIT REV TOXICOL, V21, P51, DOI 10.3109/10408449009089873; SCHAFER MW, 1993, ARCH BIOCHEM BIOPHYS, V307, P267, DOI 10.1006/abbi.1993.1589; SINGH SS, 1993, ARCH BIOCHEM BIOPHYS, V305, P170, DOI 10.1006/abbi.1993.1407; STRAVITZ RT, 1995, J LIPID RES, V36, P1359; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; WEBER TJ, 1994, J BIOCHEM TOXICOL, V9, P113, DOI 10.1002/jbt.2570090302; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WU L, 1993, NUCLEIC ACIDS RES, V21, P119, DOI 10.1093/nar/21.1.119; YEN HFY, 1990, CELL, V62, P1205	44	114	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26261	26266		10.1074/jbc.271.42.26261	http://dx.doi.org/10.1074/jbc.271.42.26261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824276	hybrid			2022-12-25	WOS:A1996VN18000082
J	Griffon, N; Badens, C; LenaRusso, D; Kister, J; Bardakdjian, J; Wajcman, H; Marden, MC; Poyart, C				Griffon, N; Badens, C; LenaRusso, D; Kister, J; Bardakdjian, J; Wajcman, H; Marden, MC; Poyart, C			Hb Bruxelles, deletion of Phe(beta 42), shows a low oxygen affinity and low cooperativity of ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-HEMOGLOBIN; FUNCTIONAL-PROPERTIES; UNSTABLE HEMOGLOBIN; VARIANT; CYANOSIS; HYBRIDS; DEOXY	Functional studies of partially purified hemoglobin (Hb) Bruxelles, phe(beta 42) (CD1) --> 0 indicate a major shift in the allosteric equilibrium toward the deoxy (T state) conformation. While Hb A shows a roughly symmetrical oxygenation curve with maximum cooperativity near half-saturation, Hb Bruxelles shows mainly properties of the low affinity (T state) form, The oxygen equilibrium curves for purified (> 80%) Hb Bruxelles show little cooperativity and a P-50 (without 2,3-diphosphoglycerate) about twice that of Hb A. The low cooperativity for Hb Bruxelles is partially compensated by an increase in oxygen affinity of the deoxy conformation and a lower 2,3-diphosphoglycerate effect. The beta chains of normal Hb have consecutive phenylalanine residues at positions 41 and 42. DNA sequencing studies of Db Bruxelles showed a deletion of the codon TTT, which corresponds to residue Phe(42). The CO rebinding kinetics after flash photolysis show mainly the slow phase, characteristic of CO binding to the deoxy conformation, In phosphate buffer at pH 7, the slow phase dominates even at low photolysis levels, where the main reaction is ligand binding to the triply liganded form, This indicates a switchover point, from the deoxy to oxy conformation, occurring beyond three ligands for Hb Bruxelles, There are few natural mutants that show a change in the oxygen affinity and cooperativity as large as that observed for Hb Bruxelles.	FAC MED MARSEILLE,CTR EMSEIGNEMENT & RECH GENET,INSERM,U406,F-13385 MARSEILLE 5,FRANCE; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Griffon, N (corresponding author), HOP BICETRE,INSERM,U299,F-94275 LE KREMLIN BICETR,FRANCE.		Marden, Michael/AAA-5923-2020; Marden, Michael C/G-3139-2012; Badens, Catherine/J-8727-2016	Marden, Michael C/0000-0002-5254-6385; Badens, Catherine/0000-0001-9024-310X				ABRAHAM DJ, 1995, J MOL BIOL, V248, P845, DOI 10.1006/jmbi.1995.0265; ANDERSON L, 1975, J MOL BIOL, V94, P33, DOI 10.1016/0022-2836(75)90403-9; BAUDIN V, 1992, BIOCHIM BIOPHYS ACTA, V1159, P223, DOI 10.1016/0167-4838(92)90029-D; BLOUQUIT Y, 1989, HEMOGLOBIN, V13, P465, DOI 10.3109/03630268908998085; BOYIRI T, 1995, BIOCHEMISTRY-US, V34, P15021, DOI 10.1021/bi00046a008; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRATU V, 1971, BIOCHIM BIOPHYS ACTA, V251, P1, DOI 10.1016/0005-2795(71)90051-1; Bunn HF, 1986, HEMOGLOBIN MOL GENET; BURKERT LB, 1976, BLOOD, V48, P645; CHEN LT, 1973, BLOOD, V41, P529, DOI 10.1182/blood.V41.4.529.529; DACIE JV, 1967, NATURE, V216, P663, DOI 10.1038/216663a0; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; HONIG GR, 1989, AM J HEMATOL, V32, P36, DOI 10.1002/ajh.2830320108; HONIG GR, 1990, J BIOL CHEM, V265, P126; HONIG GR, 1988, BLOOD, V72, P63; KIGER L, 1993, BIOPHYS J, V65, P1050, DOI 10.1016/S0006-3495(93)81164-0; KISTER J, 1987, BIOPHYS J, V52, P527, DOI 10.1016/S0006-3495(87)83242-3; KISTER J, 1989, NOUV REV FR HEMATOL, V31, P54; KOHLIKUMAR M, 1995, AM J HEMATOL, V49, P43, DOI 10.1002/ajh.2830490108; KRAWCZAK M, 1991, HUM GENET, V86, P425; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LEONE L, 1985, J CHROMATOGR, V321, P407, DOI 10.1016/S0021-9673(01)90459-5; LICATA VJ, 1990, BIOCHEMISTRY-US, V29, P9771, DOI 10.1021/bi00494a003; MARDEN MC, 1987, EUR J BIOCHEM, V169, P611, DOI 10.1111/j.1432-1033.1987.tb13652.x; OGATA K, 1986, HEMOGLOBIN, V10, P469, DOI 10.3109/03630268609014132; OHBA Y, 1975, ACTA HAEMATOL JAPON, V38, P53; PRAXEDES H, 1972, P 14 INT C HEM SAO P; STABLER S, 1993, BLOOD, V82, P222; STABLER SP, 1994, MAYO CLIN PROC, V69, P237, DOI 10.1016/S0025-6196(12)61062-3; SUGAWARA Y, 1993, JPN J PHYSIOL, V43, P21, DOI 10.2170/jjphysiol.43.21; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WAJCMAN H, 1973, BIOCHIMIE, V55, P119, DOI 10.1016/S0300-9084(73)80383-9; YANASE H, 1995, PROTEIN SCI, V4, P21	33	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25916	25920		10.1074/jbc.271.42.25916	http://dx.doi.org/10.1074/jbc.271.42.25916			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824225	hybrid			2022-12-25	WOS:A1996VN18000031
J	Prigent, SA; Nagane, M; Lin, H; Huvar, I; Boss, GR; Feramisco, JR; Cavenee, WK; Huang, HJS				Prigent, SA; Nagane, M; Lin, H; Huvar, I; Boss, GR; Feramisco, JR; Cavenee, WK; Huang, HJS			Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERED AUTOPHOSPHORYLATION SITES; PROTEIN-TYROSINE KINASE; EGF-RECEPTOR; BINDING-SITES; LUNG CARCINOMAS; INTACT-CELLS; SHC PROTEINS; DOMAIN; RAS; GRB2	A mutant epidermal growth factor receptor (Delta EGFR) containing a deletion of 267 amino acids from the extracellular domain is common in human glioblastomas. We have previously shown that the mutant receptor fails to bind EGF, is constitutively phosphorylated, and confers upon U87MG glioblastoma cells expressing it (U87MG.Delta EGFR), an increased ability to form tumors in mice. Here we demonstrate that the constitutively phosphorylated Delta EGFR enhances growth of glioblastoma cells through increased activity of Ras: 1) there was an increase in the proportion of Ras present in the GTP-bound form, and 2) introduction of neutralizing anti-has 259 antibodies into U87MG and U87MG.Delta EGFR cells by microinjection inhibited DNA synthesis to the same low level in both cell populations, We also show that the truncated EGF receptor constitutively associates with the adapter proteins Shc and Grb2 which are involved in the recruitment of Ras to activated receptors, Several derivatives of Delta EGFR containing single, or multiple mutations at critical autophosphorylation sites were constructed and used to demonstrate that the major She binding site is Tyr-1148, and that Grb2 association occurs primarily through Tyr-1068, We conclude that the increased tumorigenic potential of glioblastoma cells expressing the truncated EGF receptor is due at least in part to has activation presumably involving the Shc and Grb2 adapter proteins.	UNIV CALIF SAN DIEGO, LUDWIG INST CANC RES, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR GENET MOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego				Boss, Gerry/0000-0002-9758-8714	NIGMS NIH HHS [GM49360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU T, 1994, ONCOGENE, V9, P3483; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1995, ONCOGENE, V11, P2525; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LI NX, 1994, ONCOGENE, V9, P3457; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOLER C, 1994, ONCOGENE, V9, P2207; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	145	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25639	25645		10.1074/jbc.271.41.25639	http://dx.doi.org/10.1074/jbc.271.41.25639			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810340	hybrid			2022-12-25	WOS:A1996VL69300084
J	Sun, XL; Antony, AC				Sun, XL; Antony, AC			Evidence that a specific interaction between an 18-base cis-element in the 5'-untranslated region of human folate receptor-alpha mRNA and a 46-kDa cytosolic trans-factor is critical for translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; IRON-RESPONSIVE ELEMENTS; INITIATION-FACTOR EIF-4A; AMINO-ACID SEQUENCE; HUMAN KB-CELLS; BINDING-PROTEIN; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; IN-VIVO	Folate receptors (FR) are inversely regulated by the extracellular folate concentration at the translational level in cervical carcinoma cells. Accordingly, the potential for interaction of cis-elements in FR-alpha mRNA and trans-factors in these cells was determined. Gel-shift assays identified two signals that were specifically derived from the interaction of cytosolic proteins with the 5'-untranslated region of FR-alpha mRNA. RNase T1 mapping revealed that the RNA sequences interacting with these proteins were located between nucleotides -133 to -116 (18 bases) and -158 to -116 (43-bases), upstream of the translation start site. However, selective RNase H cleavage indicated that the 18-base RNA sequence was the cis-element. The RNA-protein interaction was competed by poly(C), but not by poly(U), homopolymers. UV cross-linking and Northwestern blot analysis confirmed that the trans-factors were 46-kDa proteins. An 18-base antisense oligodeoxynucleotide complementary to the cis-element specifically quenched the RNA-protein interaction and also completely inhibited translation of FR-ru mRNA without changing its stability. Thus, the interaction of the 18-base cis-element and the 46-kDa trans-factors likely have an important role in translational regulation of FR. In addition, because the 46-kDa proteins were widely distributed in cells expressing little to no FR-alpha, these species probably have additional functions that are unrelated to translation of FR.	INDIANA UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; RICHARD L ROUDEBUSH VET AFFAIRS MED CTR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center					NATIONAL CANCER INSTITUTE [R01CA058919] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; BOTTERO F, 1993, CANCER RES, V53, P5791; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHAKRABARTI R, 1993, J BIOL CHEM, V268, P1298; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; CONEY LR, 1991, CANCER RES, V51, P6125; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DIXON KH, 1994, J BIOL CHEM, V269, P17; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENDERSON GI, 1995, J LAB CLIN MED, V126, P184; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HSUCH CT, 1994, BIOCHEM PHARMACOL, V47, P1019; HSUEH CT, 1993, BIOCHEM PHARMACOL, V45, P2537; HUANG LY, 1993, J BIOL CHEM, V268, P25769; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KLETT C, 1994, HYPERTENSION, V23, pI120, DOI 10.1161/01.HYP.23.1_Suppl.I120; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li QJ, 1996, J INVEST MED, V44, pA203; LUHRS CA, 1992, J CLIN INVEST, V90, P840, DOI 10.1172/JCI115959; MADER S, 1995, MOL CELL BIOL, V15, P4990; MASCOTTI DP, 1995, ANNU REV NUTR, V15, P239, DOI 10.1146/annurev.nu.15.070195.001323; MATSUE H, 1992, P NATL ACAD SCI USA, V89, P6006, DOI 10.1073/pnas.89.13.6006; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MCHUGH M, 1979, J BIOL CHEM, V254, P1312; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; RATNASABAPATHY R, 1990, J BIOL CHEM, V265, P14050; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; SUN XL, 1995, J CLIN INVEST, V96, P1535, DOI 10.1172/JCI118192; Sun XL, 1996, J INVEST MED, V44, pA203; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TIAN Y, 1995, RNA, V1, P317; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VERMA RS, 1992, J BIOL CHEM, V267, P4119; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	63	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25539	25547						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810326				2022-12-25	WOS:A1996VL69300070
J	McKenna, E; Smith, JS; Coll, KE; Mazack, EK; Mayer, EJ; Antanavage, J; Wiedmann, RT; Johnson, RG				McKenna, E; Smith, JS; Coll, KE; Mazack, EK; Mayer, EJ; Antanavage, J; Wiedmann, RT; Johnson, RG			Dissociation of phospholamban regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase by quercetin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-UPTAKE; ADENOSINE 5'-TRIPHOSPHATE; FUNCTIONAL ASSOCIATION; BINDING; CA2+-ATPASE; MECHANISM; CA-2+-ATPASE; STIMULATION; MODULATION; PUMP	Quercetin had a biphasic effect on Ca2+ uptake and calcium-stimulated ATP hydrolysis in isolated cardiac sarcoplasmic reticulum (SR). Stimulation of Ca(2+)ATPase was observed at low quercetin concentrations (<25 mu M) followed by inhibition at higher concentrations. The effects were dependent upon the SR protein concentration, the MgATP concentration, and intact phospholamban regulation of cardiac Ca(2+)ATPase. Only the inhibitory effects at higher quercetin concentrations were observed in skeletal muscle SR which lacks phospholamban and in cardiac SR treated to remove phospholamban regulation, Stimulation was additive with monoclonal antibody 1D11 (directed against phospholamban) at submaximal antibody concentrations; however, the maximal antibody and quercetin stimulation were identical. Quercetin increased the calcium sensitivity of the Ca(2+)ATPase like that observed with phosphorylation of phospholamban or treatment with monoclonal antibody 1D11. In addition, low concentrations of quercetin increased the steady-state formation of phosphoenzyme from ATP or P-i, but higher quercetin decreased phosphoenzyme levels. Quercetin, even under stimulatory conditions, was a competitive inhibitor of ATP, but ap pears to relieve the Ca(2+)ATPase from phospholamban inhibition, thereby, producing an activation. The subsequent inhibitory action of higher quercetin concentrations results from competition of quercetin with the nucleotide binding site of the Ca(2+)ATPase. The data suggest that quercetin interacts with the nucleotide binding site to mask phospholamban's inhibition of the SR Ca(2+)ATPase and suggests that phospholamban may interact at or near the nucleotide binding site.			McKenna, E (corresponding author), MERCK RES LABS,DEPT PHARMACOL,WP44-B124,W POINT,PA 19486, USA.							BISHOP JE, 1987, J BIOL CHEM, V262, P4658; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CHIESI M, 1994, BIOCHEM BIOPH RES CO, V202, P1668, DOI 10.1006/bbrc.1994.2126; CHIESI M, 1989, FEBS LETT, V244, P241, DOI 10.1016/0014-5793(89)81201-3; FISCHER TH, 1987, BIOCHEMISTRY-US, V26, P8024, DOI 10.1021/bi00398a070; INESI G, 1980, J BIOL CHEM, V255, P3025; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KIM HW, 1990, J BIOL CHEM, V265, P1702; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; KUPPASAMY UR, 1992, BICH PHARM, V47, P521; KUTCHAI H, 1994, BIOCHEMISTRY-US, V33, P13208, DOI 10.1021/bi00249a007; LACAPERE JJ, 1993, EUR J BIOCHEM, V211, P117, DOI 10.1111/j.1432-1033.1993.tb19877.x; LU YZ, 1994, BIOCHEMISTRY-US, V33, P5056, DOI 10.1021/bi00183a008; LU YZ, 1993, BIOCHEMISTRY-US, V32, P3105, DOI 10.1021/bi00063a023; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Mayer EJ, 1996, J BIOL CHEM, V271, P1669, DOI 10.1074/jbc.271.3.1669; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1984, BIOCHEMISTRY-US, V23, P1959, DOI 10.1021/bi00304a012; NAKAMURA J, 1995, J BIOL CHEM, V270, P17350, DOI 10.1074/jbc.270.29.17350; Racker E, 1986, Prog Clin Biol Res, V213, P257; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; Shi Yongli, 1996, Biophysical Journal, V70, pA283; SHOSHAN V, 1981, J BIOL CHEM, V256, P887; SQUIER TC, 1988, J BIOL CHEM, V263, P9162; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TADA M, 1974, J BIOL CHEM, V249, P6174; TERAO J, 1994, ARCH BIOCHEM BIOPHYS, V308, P278, DOI 10.1006/abbi.1994.1039; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VLAHOS CJ, 1993, J CELL BIOCHEM, V52, P404, DOI 10.1002/jcb.240520405; VOSS J, 1994, BIOPHYS J, V67, P190, DOI 10.1016/S0006-3495(94)80469-2; VOSS J, 1991, BIOCHEMISTRY-US, V30, P7498, DOI 10.1021/bi00244a019; XU ZC, 1989, J BIOL CHEM, V264, P16644	37	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24517	24525		10.1074/jbc.271.40.24517	http://dx.doi.org/10.1074/jbc.271.40.24517			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798712	hybrid			2022-12-25	WOS:A1996VM67400034
J	Neilson, KM; Friesel, R				Neilson, KM; Friesel, R			Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROUZON-SYNDROME; DEVELOPMENTAL EXPRESSION; SIGNAL-TRANSDUCTION; XENOPUS DEVELOPMENT; MOUSE DEVELOPMENT; TYROSINE KINASES; GENE CAUSE; FGF; MESODERM; BINDING	The fibroblast growth factor receptors (FGFRs) are a family of receptor protein tyrosine kinases that have been shown to mediate a variety of cellular processes including angiogenesis, wound healing, tumorigenesis, and embryonic development. Distinct FGFR mutations in individuals with autosomal dominant disorders of bone growth and development provide a unique opportunity to determine the function of FGFRs during embryonic development. To determine the consequences of these mutations on receptor function, we have made mutations in Xenopus FGFR1 (XFGFR1) and FGFR2 (XFGFR2) that correspond to several of the mutations identified in these dysmorphic syndromes. Analysis of mutant receptor proteins expressed in Xenopus oocytes indicates that all but one have elevated tyrosine kinase activity relative to their wild-type counterparts. Those mutations that give an unpaired cysteine residue in the extracellular domain result in intermolecular disulfide bond formation and covalent receptor dimerization. Microinjection of Xenopus embryos with RNA encoding mutant receptors with elevated tyrosine kinase activity results in ligand-independent induction of mesoderm in animal pole explants, Wild-type XFGFR1 and XFGFR2 do not induce mesoderm when injected at similar doses. Co-injection of RNA encoding a dominant negative FGF receptor, lacking the tyrosine kinase domain, together with RNA encoding various activated FGFRs inhibits mesoderm induction by a receptor activated by a transmembrane domain mutation or extracellular mutations that introduce an unpaired cysteine residue into the extracellular domain but does not inhibit mesoderm induction by receptors bearing a tyrosine kinase domain mutation. These results indicate that different point mutations may activate FGFRs by distinct mechanisms and that ligand-independent FGFR activation may be a feature in common to many skeletal disorders.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOL MOL,ROCKVILLE,MD 20855; GEORGE WASHINGTON UNIV,MED CTR,DEPT ANAT & CELL BIOL,WASHINGTON,DC 20037	American Red Cross; George Washington University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007698] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL-07698] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BROWN SAN, 1993, BIOCHEM BIOPH RES CO, V193, P1116, DOI 10.1006/bbrc.1993.1741; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL R, 1992, DEVELOPMENT, V116, P1051; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCDONALD FJ, 1994, DEV GENET, V15, P148, DOI 10.1002/dvg.1020150205; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Moon R. T., 1989, TECHNIQUE, V1, P76; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARK WJ, 1995, AM J HUM GENET, V57, P748; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PENG HB, 1991, PRACTICAL USES CELL; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WILKIE AOM, 1995, CURR BIOL, V5, P500; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	51	134	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25049	25057		10.1074/jbc.271.40.25049	http://dx.doi.org/10.1074/jbc.271.40.25049			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798788	hybrid			2022-12-25	WOS:A1996VM67400111
J	Ramsey, AJ; Hillas, PJ; Fitzpatrick, PF				Ramsey, AJ; Hillas, PJ; Fitzpatrick, PF			Characterization of the active site iron in tyrosine hydroxylase - Redox states of the iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; ESCHERICHIA-COLI; CLONED ENZYME; PURIFICATION; PHOSPHORYLATION; EXPRESSION; 3-MONOOXYGENASE; MUTAGENESIS; INHIBITORS; SERINE-40	Tyrosine hydroxylase is an iron-containing monooxygenase that uses a tetrahydropterin to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine in catecholamine biosynthesis. The role of the iron in this enzyme is not understood. Purification of recombinant rat tyrosine hydroxylase containing 0.5-0.7 iron atoms/subunit and lacking bound catecholamine has permitted studies of the redox states of the resting enzyme and the enzyme during catalysis. As isolated, the iron is in the ferric form. Dithionite or 6-methyltetrahydropterin can reduce the iron to the ferrous form. Reduction by 6-methyltetrahydropterin consumes 0.5 nmol/nmol of enzyme-bound iron, producing quinonoid 6-methyldihydropterin as the only detectable product. In the presence of oxygen, reoxidation to ferric iron occurs. During turnover the enzyme is in the ferrous form. However, a fraction is oxidized during turnover; this can be trapped by added catechol or by the dihydroxyphenylalanine formed during turnover.	TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station					NIGMS NIH HHS [R01 GM 47291, T32 GM 08523] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008523, R01GM047291] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KK, 1992, BIOCHEM J, V284, P687, DOI 10.1042/bj2840687; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; DAUBNER SC, 1993, PROTEIN SCI, V2, P1452, DOI 10.1002/pro.5560020909; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; FITZPATRICK PF, 1989, BIOCHEM BIOPH RES CO, V161, P211, DOI 10.1016/0006-291X(89)91582-9; FITZPATRICK PF, 1991, BIOCHEMISTRY-US, V30, P3658, DOI 10.1021/bi00229a010; FITZPATRICK PF, 1991, BIOCHEMISTRY-US, V30, P6386, DOI 10.1021/bi00240a006; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; FITZPATRICK PF, 1988, J BIOL CHEM, V263, P16058; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HAAVIK J, 1992, EUR J BIOCHEM, V210, P23, DOI 10.1111/j.1432-1033.1992.tb17386.x; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; HOELDTKE R, 1977, J BIOL CHEM, V252, P3160; IKEDA M, 1966, J BIOL CHEM, V241, P4452; KAUFMAN S, 1985, FOLATES PTERINS, V2, P251; MAGER HIX, 1967, RECL TRAV CHIM PAY-B, V86, P833; MARTINEZ A, 1993, BIOCHEMISTRY-US, V32, P6381, DOI 10.1021/bi00076a011; PISTORIUS EK, 1976, J BIOL CHEM, V251, P7144; RAMSEY AJ, 1995, PROTEIN SCI, V4, P2082; SHIMAN R, 1971, J BIOL CHEM, V246, P1330; SLYKHOUSE TO, 1976, J BIOL CHEM, V251, P5472; STORM CB, 1971, J ORG CHEM, V36, P3925; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	24	87	87	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24395	24400		10.1074/jbc.271.40.24395	http://dx.doi.org/10.1074/jbc.271.40.24395			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798695	hybrid			2022-12-25	WOS:A1996VM67400017
J	Wu, TL; Vasavada, RC; Yang, K; Massfelder, T; Ganz, M; Abbas, SK; Care, AD; Stewart, AF				Wu, TL; Vasavada, RC; Yang, K; Massfelder, T; Ganz, M; Abbas, SK; Care, AD; Stewart, AF			Structural and physiologic characterization of the mid-region secretory species of parathyroid hormone-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMORAL HYPERCALCEMIA; BONE-RESORPTION; PEPTIDE; CELLS; IDENTIFICATION; CALCIUM; BINDING; CANCER; PTHRP; BIOSYNTHESIS	Parathyroid hormone-related protein (PTHrP) is initially translated as a preprohormone which is posttranslationally processed to yield a family of mature secretory forms, Most attention has focused on the aminoterminal portion of the molecule which is homologous to parathyroid hormone. It is clear, however, that a midregion species of PTHrP is posttranslationally cleaved from the highly conserved mid-region of PTHrP, and that the amino terminus of this peptide is Ala(38). The purposes of the current study were three: 1) to confirm that Arg(37) immediately preceding Ala(38) serves as a posttranslational processing site in the PTHrP precursor, 2) to determine the carboxyl terminus of the mid-region secretory species of PTHrP, and 3) to synthesize this authentic mid-region secretory form of PTHrP and determine whether it is biologically active. The results indicate that: 1) Arg(37) is indeed a processing site in the PTHrP precursor; 2) three distinct mid-region PTHrP species are generated by posttranslational processing, PTHrP(38-94)amide, PTHrP(38-95), and most likely, PTHrP(38-101); and 3) synthetic mid-region PTHrP(38-94)amide is active in four different biological systems. These studies confirm the finding that PTHrP is a prohormone. More importantly, they define a novel, biologically active highly conserved mid-region secretory form of PTHrP.	VET ADM MED CTR,DIV ENDOCRINOL,W HAVEN,CT 06516; YALE UNIV,SCH MED,ENDOCRINOL SECT,NEW HAVEN,CT 06510; VET ADM MED CTR,DIV NEPHROL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; UNIV WALES,INST BIOMED SCI,ABERYSTWYTH SY23 3DD,DYFED,WALES	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Aberystwyth University			Massfelder, Thierry/I-1260-2016		NIDDK NIH HHS [DK 47168, DK 02229] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047168, K11DK002229] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBAS SK, 1989, Q J EXP PHYSIOL CMS, V74, P549, DOI 10.1113/expphysiol.1989.sp003303; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BENNET HPJ, 1993, MECH INTRACELLULAR T, P251; BOURDAIS J, 1991, J BIOL CHEM, V266, P23386; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; Broadus Arthur E., 1994, P259; BURTIS WJ, 1994, J CLIN ENDOCR METAB, V78, P317, DOI 10.1210/jc.78.2.317; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; BURTIS WJ, 1987, J BIOL CHEM, V262, P7151; CARE AD, 1990, EXP PHYSIOL, V75, P605, DOI 10.1113/expphysiol.1990.sp003437; DICKINSON CJ, 1995, J CLIN INVEST, V96, P2425; DIEFENBACHJAGGE.H, 1995, BONE, V16, pS126; EIPPER BA, 1993, ANN NY ACAD SCI, V680, P147, DOI 10.1111/j.1749-6632.1993.tb19681.x; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EverhartCaye M, 1996, J CLIN ENDOCR METAB, V81, P199, DOI 10.1210/jc.81.1.199; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P3424, DOI 10.1210/endo-129-6-3424; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; GANZ MB, 1990, AM J PHYSIOL, V259, pF269, DOI 10.1152/ajprenal.1990.259.2.F269; HATSUZAWA K, 1990, J BIOL CHEM, V265, P11075; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; LUPARELLO C, 1995, MOL CELL ENDOCRINOL, V111, P225, DOI 10.1016/0303-7207(95)03577-T; MAINS RE, 1983, TRENDS NEUROSCI, V6, P229, DOI 10.1016/0166-2236(83)90100-5; MCCAULEY LK, 1992, ENDOCRINOLOGY, V130, P300, DOI 10.1210/en.130.1.300; MERENDINO JJ, 1986, SCIENCE, V231, P388, DOI 10.1126/science.2417317; NISSENSON RA, 1992, PARATHYROID HORMONE; ORLOFF JJ, 1992, AM J PHYSIOL, V262, pE599, DOI 10.1152/ajpendo.1992.262.5.E599; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; ORLOFF JJ, 1993, J BONE MINER RES, V8, pS133; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; PLAWNER LL, 1995, J BIOL CHEM, V270, P14078, DOI 10.1074/jbc.270.23.14078; RABBANI SA, 1993, BIOCHEMISTRY-US, V32, P4931, DOI 10.1021/bi00069a030; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SOIFER NE, 1992, J BIOL CHEM, V267, P18236; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEWART AF, 1989, ENDOCRINOLOGY, V124, P642, DOI 10.1210/endo-124-2-642; STEWART AF, 1988, J CLIN INVEST, V81, P596, DOI 10.1172/JCI113358; Strewler Gordon J., 1993, P61; WEATHERLEY AJ, 1983, PLACENTA, V8, P271; WU SX, 1993, ENDOCRINOLOGY, V133, P2437, DOI 10.1210/en.133.6.2437; YANG KH, 1994, BIOCHEMISTRY-US, V33, P7460, DOI 10.1021/bi00189a054; [No title captured]	43	107	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24371	24381		10.1074/jbc.271.40.24371	http://dx.doi.org/10.1074/jbc.271.40.24371			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798692	hybrid			2022-12-25	WOS:A1996VM67400014
J	Pandey, P; Raingeaud, J; Kaneki, M; Weichselbaum, R; Davis, RJ; Kufe, D; Kharbanda, S				Pandey, P; Raingeaud, J; Kaneki, M; Weichselbaum, R; Davis, RJ; Kufe, D; Kharbanda, S			Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; DNA-DAMAGING AGENTS; MAP KINASE; IONIZING-RADIATION; JUN KINASE; CELLS; PHOSPHORYLATION; THREONINE; TYROSINE; 1-BETA-D-ARABINOFURANOSYLCYTOSINE	The p38 mitogen-activated protein (MAP) kinase defines a subgroup of the mammalian MAP kinases that are induced in response to lipopolysaccharide, hyperosmolarity, and interleukin 1. p38 MAP kinase appears to play a role in regulating inflammatory responses, including cytokine secretion and apoptosis, Here we show that diverse classes of DNA-damaging agents such as cisplatinum, 1-beta-D-arabinofuranosylcytosine, UV light, ionizing radiation, and methyl methanesulfonate activate p38 MAP kinase, We also demonstrate that cells deficient in c-Abl fail to activate p38 MAP kinase after treatment with cisplatinum and 1-beta-D-arabinofuranosylcytosine but not after exposure to UV and methyl methanesulfonate, Reconstitution of c-Abl in the Abl(-/-) cells restores that response. Similar results were obtained for induction of the Jun-NH2-kinase/stress-activated protein kinase. These findings indicate that p38 MAP and Jun-NH2-kinase/stress-activated protein kinases are differentially regulated in response to different classes of DNA-damaging agents.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOL BIOL,HOWARD HUGHES MED INST,PROGRAM MOL MED,WORCESTER,MA 01605; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Chicago					NCI NIH HHS [CA29431, CA55241, CA65861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065861, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dhar V, 1996, CELL GROWTH DIFFER, V7, P841; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHWARTZ JL, 1986, CARCINOGENESIS, V7, P159, DOI 10.1093/carcin/7.1.159; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH GJ, 1986, AM J PATHOL, V122, P488; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	42	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23775	23779		10.1074/jbc.271.39.23775	http://dx.doi.org/10.1074/jbc.271.39.23775			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798604	hybrid			2022-12-25	WOS:A1996VJ44200033
J	Tamburrini, M; DAvino, R; Fago, A; Carratore, V; Kunzmann, A; diPrisco, G				Tamburrini, M; DAvino, R; Fago, A; Carratore, V; Kunzmann, A; diPrisco, G			The unique hemoglobin system of Pleuragramma antarcticum, an Antarctic migratory teleost - Structure and function of the three components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOTOTHENIA-CORIICEPS-NEGLECTA; AMINO-ACID-SEQUENCE; FISH; BINDING; PURIFICATION; ADAPTATION	Pleuragramma antarcticum (suborder Notothenioidei, family Nototheniidae) is the most abundant fish in the antarctic shelf. This pelagic species has a circum-antarctiac distribution and is characterized by spawning migration. This species displays the highest multiplicity of major hemoglobins (three); the other notothenioids have a single one (except one species, having two) with relatively low oxygen affinity regulated by pH and organophosphates, The hemoglobins of P. antarcticum display strong Bohr and Root effects; however, they reveal important functional differences in subunit cooperativity and organophosphate regulation and, above all, in the response of oxygenation to temperature, De spite the substitution Val beta E11 --> Ile found in Hb 2, which decreases the affinity in human mutants, the hemoglobins have similar oxygen affinity, higher than that of the other notothenioids. Hb 1 has the alpha chain in common with Hb 2 and the beta in common with Hb 3. The amino acid sequence of all four chains has been established, Thus the hematological features of P. antarcticum differ remarkably from those of antarctic notothenioids, This unique and sophisticated oxygen transport system may adequately meet the requirements of the unusual mode of life of this fish.	AARHUS UNIV,DEPT ZOOPHYSIOL,INST BIOL SCI,DK-8000 AARHUS,DENMARK; INST POLAR ECOL,D-24148 KIEL,GERMANY	Aarhus University	Tamburrini, M (corresponding author), CNR,INST PROT BIOCHEM & ENZYMOL,VIA MARCONI 10,I-80125 NAPLES,ITALY.		Kunzmann, Andreas/O-5459-2019; Fago, Angela/J-5946-2013; Kunzmann, Andreas/O-1345-2013	Kunzmann, Andreas/0000-0002-9500-4332; Fago, Angela/0000-0001-7315-2628; Kunzmann, Andreas/0000-0002-9500-4332; TAMBURRINI, MAURIZIO/0000-0001-5987-0957				ANDERSEN N C, 1984, Steenstrupia, V10, P1; Andriashev A.P., 1987, P357; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BRITTAIN T, 1987, COMP BIOCHEM PHYS B, V86, P473, DOI 10.1016/0305-0491(87)90434-2; CARUSO C, 1991, BIOCHIM BIOPHYS ACTA, V1078, P273, DOI 10.1016/0167-4838(91)90569-L; COCCA E, 1995, P NATL ACAD SCI USA, V92, P1817, DOI 10.1073/pnas.92.6.1817; DAVINO R, 1989, EUR J BIOCHEM, V179, P707, DOI 10.1111/j.1432-1033.1989.tb14604.x; DAVINO R, 1994, J BIOL CHEM, V269, P9675; DAVINO R, 1989, EUR J BIOCHEM, V179, P699, DOI 10.1111/j.1432-1033.1989.tb14603.x; DAVINO R, 1988, COMP BIOCHEM PHYS B, V90, P579, DOI 10.1016/0305-0491(88)90298-2; di Prisco G., 1991, P263; DIPRISCO G, 1992, COMP BIOCHEM PHYS B, V102, P661, DOI 10.1016/0305-0491(92)90062-V; DIPRISCO G, 1988, COMP BIOCHEM PHYS B, V90, P631, DOI 10.1016/0305-0491(88)90304-5; DIPRISCO G, 1989, ANTARCT SCI, V1, P119; DIPRISCO G, 1990, POLAR BIOL, V10, P269, DOI 10.1007/BF00238425; Eastman J. T, 1993, ANTARCTIC FISH BIOL; Everson I., 1968, Bulletin British Antarctic Survey, VNo. 15, P59; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; Giardina B, 1981, Methods Enzymol, V76, P417; Hubold G., 1985, P445; HUREAU JC, 1977, ADAPTATIONS ANTARCTI, P459; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; KUNZMANN A, 1990, POLAR BIOL, V11, P9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; Mylvaganam SE, 1996, NAT STRUCT BIOL, V3, P275, DOI 10.1038/nsb0396-275; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; Root RW, 1931, BIOL BULL-US, V61, P427, DOI 10.2307/1536959; RUUD JT, 1954, NATURE, V173, P848, DOI 10.1038/173848a0; TAMBURRINI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P295, DOI 10.1016/0003-9861(92)90082-8; WELLS RMG, 1980, J FISH BIOL, V17, P517, DOI 10.1111/j.1095-8649.1980.tb02783.x	32	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23780	23785		10.1074/jbc.271.39.23780	http://dx.doi.org/10.1074/jbc.271.39.23780			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798605	hybrid			2022-12-25	WOS:A1996VJ44200034
J	Kolch, W; Philipp, A; Mischak, H; Dutil, EM; Mullen, TM; Feramisco, JR; Meinkoth, JL; Rose, DW				Kolch, W; Philipp, A; Mischak, H; Dutil, EM; Mullen, TM; Feramisco, JR; Meinkoth, JL; Rose, DW			Inhibition of Raf-1 signaling by a monoclonal antibody, which interferes with Raf-1 activation and with Mek substrate binding	ONCOGENE			English	Article						Raf-1 signaling; antibody microinjection; Mek	PROTEIN-KINASE KINASE; SERINE-THREONINE KINASE; C-FOS PROMOTER; TRANSCRIPTION FACTOR; TERNARY COMPLEX; GROWTH-FACTOR; V-RAF; TYROSINE KINASE; PLASMA-MEMBRANE; EARLY RESPONSE	Raf-1 is a serine/threonine specific kinase that integrates signaling by a large number of mitogens to elicit a transcriptional response in the nucleus, Activated Raf-1 phosphorylates and activates MAPK/ERK kinase (Mek), thus initiating the Mek-->MAP kinase cascade, which ultimately results in the phosphorylation and activation of transcription factors by MAP kinase. Here we have characterized the mechanism by which monoclonal antibody URP26K, which binds to an epitope in the Raf-1 kinase domain, inhibits intracellular signal transduction. This antibody preferentially immunoprecipitated the underphosphorylated, non-activated form of Raf-1 from quiescent cells. Baculovirus-expressed Raf-1 immunoprecipitated with URP26K was Largely refractory to. phosphorylation and activation mediated by protein kinase C (PKC)alpha or the tyrosine kinase Lck. In addition, URP26K reduced the binding of Raf-1 to its vitro, but did not disturb the Ras. Microinjection of with cells blocked DIVA synthesis initiated by serum, insulin and various purified growth factors, but it did not block DNA synthesis initiated by v-ras. Microinjected URP26K also impaired the expression of stably transfected beta-galactosidase reporter genes regulated by minimal promoter elements. These results demonstrate, (i) that the URP26K monoclonal antibody inhibits Raf-1 by preventing activating Raf-1 phosphorylation and/or association with its substrate Mek, (ii) that inhibition of Raf-1 by URP26K does not interfere with Ras-induced DNA synthesis. In contrast to dominant negative Raf-1 mutants, which also block Ras signaling by binding to the Ras effector domain, antibody mediated Raf-1 inhibition thus reveals branchpoint of mitogenic signaling at the level of Ras.	UNIV CALIF SAN DIEGO, WHITTIER DIABET PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; UNIV PENN, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; GSF MUNICH, HAEMATOLOGIKUM, INST KLIN MOL BIOL & TUMORGENET, D-81377 MUNICH, GERMANY	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Pennsylvania; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Mischak, Harald/E-8685-2011; Meinkoth, Judy L/G-2900-2010; Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Mischak, Harald/0000-0003-0323-0306; MULLEN, Tina-Marie/0000-0001-6150-8084; Kolch, Walter/0000-0001-5777-5016				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BRENNSCHEIDT U, 1994, CELL GROWTH DIFFER, V5, P367; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, ONCOGENE, V8, P361; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1991, ONCOGENE, V6, P495; RIM M, 1992, ONCOGENE, V7, P2065; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VICIANA PR, 1994, NATURE, V370, P527; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; XIAO S, 1994, J BIOL CHEM, V269, P21244	57	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1305	1314						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808705				2022-12-25	WOS:A1996VJ20200022
J	Ichimura, K; Schmidt, EE; Goike, HM; Collins, VP				Ichimura, K; Schmidt, EE; Goike, HM; Collins, VP			Human glioblastomas with no alterations of the CDKN2A (p16(INK4A), MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene	ONCOGENE			English	Article						astrocytomas; RB1; cell cycle; cyclin-dependent kinase inhibitor	DEPENDENT KINASE INHIBITORS; TUMOR-SUPPRESSOR GENE; HOMOZYGOUS DELETION; SUSCEPTIBILITY GENE; MALIGNANT GLIOMAS; HUMAN CANCER; CELL-LINES; C-MYC; AMPLIFICATION; EXPRESSION	A series of 195 human gliomas were studied as to the status of their CDKN2A, CDK4 and RB1 genes, Among 120 glioblastomas, 40% had no wild-type CDKN2A gene, 12% amplified the CDK4 gene, and 14% had no wild-type RB1 gene, With two exceptions, each tumour had only one of these abnormalities, Thus the majority of the glioblastomas (64%) had distinct genetic aberrations which would obviously disrupt the control of transition from G(1) to the S-phase of the cell cycle, A further 30% had loss of one allele of the CDKN2A and/or RB1 genes, Only seven (6%) glioblastomas had no abnormalities of these genes, Anaplastic astrocytomas showed similar changes to the glioblastomas but at lower frequencies - 34% showing no aberrations of the genes analysed, The astrocytomas showed solely loss of one allele of the RB1 gene in 28% of tumours, with retention of one wild-type copy, In the glioblastomas with no alterations of CDKN2A, CDK4 or RB1, several other genes (CCND1, CCND2, CCND3, CDK6, E2F, CDK7, MYC and MYCN) whose products take part in cell cycle regulation were examined, No abnormalities were detected, Thus some aberration of the CDKN2A, CDK4 and RB1 genes appears to be almost obligatory in glioblastomas.	KAROLINSKA HOSP,STOCKHOLM BRANCH,INST ONCOL & PATHOL,DIV TUMOR PATHOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,STOCKHOLM BRANCH,LUDWIG INST CANC RES,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research								AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAO X, 1995, ONCOGENE, V11, P1395; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRANA X, 1995, ONCOGENE, V11, P211; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HE J, 1994, CANCER RES, V54, P5804; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; HIRAMA T, 1995, BLOOD, V86, P841; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; ICHIMURA K, 1994, CANCER RES, V54, P3127; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LIU Y, 1995, HUM MOL GENET, V4, P727, DOI 10.1093/hmg/4.4.727; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLEDNAK AP, 1995, CANCER, V75, P330, DOI 10.1002/1097-0142(19950101)75:1+<330::AID-CNCR2820751315>3.0.CO;2-5; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SACHSE R, 1994, ONCOGENE, V9, P39; SAKAI T, 1991, AM J HUM GENET, V48, P880; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCRRANO M, 1993, NATURE, V366, P704; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Ueki K, 1996, CANCER RES, V56, P150; VENTER DJ, 1991, ONCOGENE, V6, P445; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	39	233	235	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1065	1072						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806696				2022-12-25	WOS:A1996VG76600020
J	Gemmill, TR; Trimble, RB				Gemmill, TR; Trimble, RB			Schizosaccharomyces pombe produces novel pyruvate-containing N-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSE; MUTANTS; YEAST	The large N-linked oligosaccharides released by endo-beta-N-acetylglucosaminidase H from Schizosaccharomyces pombe glycoproteins were analyzed for the presence of noncarbohydrate functional groups. No phosphate, sulfate, or acetate could be detected; however, approximately six molecules of pyruvic acid/molecule were found on 98% of the oligosaccharides. Pyruvate moieties were acetal (ketal)-linked to galactose residues in the R configuration to carbons 4 and 6. This is the first report of pyruvate functional groups being attached to N-linked oligosaccharides in yeast and appears only to be the second documentation of this sugar modification in eukaryotes.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23900] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ARAKI S, 1989, J BIOL CHEM, V264, P19922; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1995, P NATL ACAD SCI USA, V92, P2790, DOI 10.1073/pnas.92.7.2790; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; Downs F., 1976, METHODS CARBOHYDRATE, V7, P241; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FRIEDEMANN TE, 1957, METHOD ENZYMOL, V3, P414, DOI 10.1016/S0076-6879(57)03406-0; GORIN PA, 1961, CAN J CHEM, V39, P2274, DOI 10.1139/v61-301; GORIN PAJ, 1966, CAN J CHEM, V45, P521; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; KOBATA A, 1993, GLYCOBIOLOGY PRACTIC, P79; Manzi A, 1993, GLYCOBIOLOGY PRACTIC, P27; MASOUD H, 1994, CARBOHYD RES, V252, P223; SAHA SK, 1994, CARBOHYD RES, V254, P157; Schauer R, 1978, Methods Enzymol, V50, P374; Schauer R, 1978, Methods Enzymol, V50, P64; SILVESTRI LJ, 1982, ANAL BIOCHEM, V123, P303, DOI 10.1016/0003-2697(82)90450-X; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; ZEIGLER FD, 1994, J BIOL CHEM, V269, P12527	22	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25945	25949		10.1074/jbc.271.42.25945	http://dx.doi.org/10.1074/jbc.271.42.25945			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824229	hybrid			2022-12-25	WOS:A1996VN18000035
J	Liu, B; Maul, RS; Kaetzel, DM				Liu, B; Maul, RS; Kaetzel, DM			Repression of platelet-derived growth factor A-chain gene transcription by an upstream silencer element - Participation by sequence-specific single-stranded DNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY REGIONS; NUCLEASE-SENSITIVE REGION; PROMOTER REGION; S1 NUCLEASE; RESPONSIVE ELEMENT; VIMENTIN PROMOTER; ESTROGEN-RECEPTOR; CDNA SEQUENCE; CELL-LINES; IDENTIFICATION	Platelet-derived growth factor A-chain is a potent mitogen expressed in a restricted number of normal and transformed cells. Transient transfection and deletion analysis in BSC-1 (African green monkey, renal epithelial) cells revealed that the -1680 to -1374 region of the A-chain gene repressed homologous and heterologous promoter activities by 60-80%. An S1 nuclease-hypersensitive region (5'SHS) was identified within this region (-1418 to -1388) that exhibited transcriptional silencer activity in BSC-1 and a variety of human tumor cell lines (U87, HepG2, and HeLa). Electrophoretic mobility shift assays conducted with 5'SHS oligodeoxynucleotide probes revealed several binding protein complexes that displayed unique preferences for binding to sense, antisense, and double-stranded forms of the element. Southwestern blot analysis revealed that the antisense strand of 5'SHS binds to nuclear proteins of molecular mass 97, 87, 44, and 17 kDa, whereas the double-stranded form of 5'SHS is recognized by a 70-kDa factor. Mutations within 5'SHS element indicated the necessity of a central 5'-GGGGAGGGGG-3' motif for protein binding and silencer function, while nucleotides Banking both sides of the motif were also critical for repression, These results support a model in which silencer function of 5'SHS is mediated by antisense strand binding proteins, possibly by stabilizing single-stranded DNA conformations required for interaction with enhancer sequences in the proximal promoter region of the A-chain gene.	UNIV KENTUCKY, CHANDLER MED CTR, DEPT PHARMACOL, LEXINGTON, KY 40536 USA	University of Kentucky					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045518] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45518] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; BARTRAM CR, 1984, BLOOD, V63, P223; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; COOKE NE, 1982, NATURE, V297, P603, DOI 10.1038/297603a0; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GARZON RJ, 1994, MOL CELL BIOL, V14, P934, DOI 10.1128/MCB.14.2.934; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; HATA A, 1989, J BIOL CHEM, V264, P6404; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERMANSON M, 1992, CANCER RES, V52, P3213; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JOHNSON R, 1992, KIDNEY INT, V41, P590, DOI 10.1038/ki.1992.88; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAETZEL DM, 1993, BIOFACTORS, V4, P71; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KISS I, 1990, MOL CELL BIOL, V10, P2432, DOI 10.1128/MCB.10.5.2432; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; LIN XH, 1992, J BIOL CHEM, V267, P25614; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MIN LW, 1992, J IMMUNOL, V148, P1913; MIZUNO K, 1992, GENE, V119, P293, DOI 10.1016/0378-1119(92)90286-X; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; Potapova O, 1996, CANCER RES, V56, P280; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RYDER K, 1986, CELL, V44, P719, DOI 10.1016/0092-8674(86)90838-X; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SILVER BJ, 1992, BIOFACTORS, V3, P217; SMITH KP, 1995, J BIOL CHEM, V270, P4484, DOI 10.1074/jbc.270.9.4484; SPANA C, 1990, GENE DEV, V4, P1505, DOI 10.1101/gad.4.9.1505; STOVER DM, 1994, CANCER RES, V54, P3092; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; SWAN DC, 1982, P NATL ACAD SCI-BIOL, V79, P4691, DOI 10.1073/pnas.79.15.4691; TAKIMOTO Y, 1993, JPN J CANCER RES, V84, P1268, DOI 10.1111/j.1349-7006.1993.tb02833.x; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; VANDEKLUNDERT FAJM, 1992, GENE, V122, P337, DOI 10.1016/0378-1119(92)90223-C; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WANG ZY, 1993, J BIOL CHEM, V268, P10681; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WANG ZY, 1994, NUCLEIC ACIDS RES, V22, P457, DOI 10.1093/nar/22.3.457; WESTERMARK B, 1990, ACTA ENDOCRINOL-COP, V123, P131, DOI 10.1530/acta.0.1230131; WILKISON WO, 1990, J BIOL CHEM, V265, P477; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	68	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26281	26290		10.1074/jbc.271.42.26281	http://dx.doi.org/10.1074/jbc.271.42.26281			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824279	hybrid			2022-12-25	WOS:A1996VN18000085
J	Weiss, RH; Fretland, DJ; Baron, DA; Ryan, US; Riley, DP				Weiss, RH; Fretland, DJ; Baron, DA; Ryan, US; Riley, DP			Manganese-based superoxide dismutase mimetics inhibit neutrophil infiltration in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; FREE-RADICALS; MYELOPEROXIDASE ACTIVITY; INTESTINAL ISCHEMIA; MYOCARDIAL INJURY; REPERFUSION; MIMICS; ACTIVATION; COMPLEXES; OXIDASE	In a previous study (Hardy et al, (1994) J, Biol, Chem, 269, 18535-18540), we observed that the manganese-based superoxide dismutase mimetic Mn(II)-dichloro(1,4,7,10,13-pentaazacyclopentadecane) (MnPAM) inhibited neutrophil-mediated cell injury in vitro, We have extended these studies with the low molecular weight superoxide dismutase mimic to evaluate the role of superoxide in neutrophil-mediated tissue injury in vivo, In a dose-dependent manner, MnPAM inhibited colonic tissue injury and neutrophil accumulation into the colonic tissue induced by the intracolonic instillation of dilute aqueous acetic acid in mice, Tissue injury was assessed by visual and histological analysis, Neutrophil infiltration was determined by tissue myeloperoxidase activity and confirmed by histological analysis, Two novel Mn(II) dichloro complexes of the carbon-substituted macrocycles 2-methyl-1,4,7,10,13-pentaazacyclopentadecane (MnMAM) and 2-(2-methylpropyl)1,4,7,10,13-pentaazacyclopentadecane (MnBAM) effectively catalyzed the dismutation of superoxide with catalytic rate constants (k(cat)) of 3.31 x 10(7) M(-1) s(-1) and 1.91 x 10(7) M(-1) s(-1), respectively, as determined by stopped-flow kinetic analysis at pH 8.1 and 21 degrees C. The superoxide dismutase mimetics MnMAM and MnBAM also attenuated dilute aqueous acetic acid-induced tissue injury and neutrophil infiltration into colonic tissue; however, two Mn(II) complexes that had little or no detectable SOD activity (k(cat) less than or equal to 0.1 x 10(7) M(-1) s(-1)), specifically the Mn(II) dichloro complexes of 1,4,7,10,13-pentaazacyclohexadecane and 1,4,7,11,14-pentaazacycloheptadecane, failed to inhibit the colonic tissue injury or infiltration of neutrophils in mice treated intracolonically with dilute aqueous acetic acid, These results are consistent with a proinflammatory role for superoxide in the mediation of neutrophil infiltration in vivo.	SEARLE RES & DEV, SKOKIE, IL 60077 USA	Pfizer	Weiss, RH (corresponding author), MONSANTO CO, 800 N LINDBERGH BLVD, MAIL ZONE Q3C, ST LOUIS, MO 63167 USA.							BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BERNIER M, 1989, AM J PHYSIOL, V256, pH1344, DOI 10.1152/ajpheart.1989.256.5.H1344; BOUGHTONSMITH NK, 1988, AGENTS ACTIONS, V25, P115, DOI 10.1007/BF01969102; CHEN LY, 1995, AM HEART J, V129, P211, DOI 10.1016/0002-8703(95)90000-4; DARR D, 1987, ARCH BIOCHEM BIOPHYS, V258, P351, DOI 10.1016/0003-9861(87)90354-7; DOWLING EJ, 1993, FREE RADICAL RES COM, V18, P291, DOI 10.3109/10715769309147496; FAULKNER KM, 1994, ARCH BIOCHEM BIOPHYS, V310, P341, DOI 10.1006/abbi.1994.1176; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRETLAND DJ, 1995, INFLAMMATION, V19, P503, DOI 10.1007/BF01539131; FRETLAND DJ, 1989, AGENTS ACTIONS, V27, P395, DOI 10.1007/BF01972832; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GOLDSTEIN S, 1988, FREE RADICAL BIO MED, V4, P295, DOI 10.1016/0891-5849(88)90050-0; GOLDSTEIN S, 1991, FREE RADICAL RES COM, V12-3, P5, DOI 10.3109/10715769109145761; GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HARDY MM, 1994, J BIOL CHEM, V269, P18535; HORTON JW, 1993, J SURG RES, V55, P282, DOI 10.1006/jsre.1993.1141; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Jadot G, 1986, Free Radic Res Commun, V2, P19, DOI 10.3109/10715768609088052; KILGORE KS, 1993, CLIN BIOCHEM, V26, P359, DOI 10.1016/0009-9120(93)90112-J; KITAJIMA N, 1993, INORG CHEM, V32, P1879, DOI 10.1021/ic00062a001; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; MACPHERSON BR, 1978, DIGESTION, V17, P135, DOI 10.1159/000198104; McCord J M, 1993, New Horiz, V1, P70; MCCORD J M, 1986, Journal of Free Radicals in Biology and Medicine, V2, P307; MCCORD JM, 1979, ADV INFLAMMAT RES, V1, P273; Michelson A M, 1986, Free Radic Res Commun, V2, P43, DOI 10.3109/10715768609088054; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; NAGANO T, 1989, J BIOL CHEM, V264, P9243; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; OMAR BA, 1991, J MOL CELL CARDIOL, V23, P149, DOI 10.1016/0022-2828(91)90102-R; OOIWA H, 1991, J MOL CELL CARDIOL, V23, P119, DOI 10.1016/0022-2828(91)90099-8; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; RICHARD VJ, 1988, CIRCULATION, V78, P473, DOI 10.1161/01.CIR.78.2.473; RILEY DP, 1994, J AM CHEM SOC, V116, P387, DOI 10.1021/ja00080a051; RILEY DP, 1991, ANAL BIOCHEM, V196, P344, DOI 10.1016/0003-2697(91)90476-A; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; RYAN US, 1988, OXYGEN RADICALS BIOL, P963; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SELLKE FW, 1993, CIRCULATION, V88, P395; SORENSON JRJ, 1984, J MED CHEM, V27, P1747, DOI 10.1021/jm00378a040; TSAO PS, 1990, CIRCULATION, V82, P1402, DOI 10.1161/01.CIR.82.4.1402; WADA K, 1994, ARCH BIOCHEM BIOPHYS, V310, P1, DOI 10.1006/abbi.1994.1132; WEISS RH, 1993, J BIOL CHEM, V268, P23049; WEISS RH, 1995, OXYGEN PARADOX, P641; WERNS SW, 1988, J CARDIOVASC PHARM, V11, P36, DOI 10.1097/00005344-198801000-00006	48	40	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26149	26156		10.1074/jbc.271.42.26149	http://dx.doi.org/10.1074/jbc.271.42.26149			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824260	hybrid			2022-12-25	WOS:A1996VN18000066
J	Grotzinger, T; Jensen, K; Will, H				Grotzinger, T; Jensen, K; Will, H			The interferon (IFN)-stimulated gene Sp100 promoter contains an IFN-gamma activation site and an imperfect IFN-stimulated response element which mediate type I IFN inducibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; GUANYLATE-BINDING PROTEIN; SIGNAL TRANSDUCTION PATHWAYS; PML-RAR-ALPHA; DNA-BINDING; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; T(15-17) TRANSLOCATION; CYTOPLASMIC ACTIVATION	Expression of the nuclear domain-associated proteins Sp100, PML, and NDP52, is enhanced by interferons (IFNs) on the mRNA and protein level. Increase both of Sp100 and PML mRNA is due to enhanced transcription of the corresponding genes which occurs independently of cellular protein synthesis immediately upon IFN-beta addition, Here, we describe the molecular cloning and functional analysis of the Sp100 promoter. DNA sequence analysis revealed potential binding sites for several constitutive and IFN-inducible transcription factors. Consistent with the absence of a TATA box and an initiator element, several transcription initiation sites were found. Transient expression studies identified an imperfect IFN-stimulated response element within the first 100 nucleotides upstream of the major transcription start site. This element rendered a heterologous promoter IFN-beta-inducible and bound IFN-stimulated gene factor 2 strongly but IFN-stimulated gene factor 3 only weakly. An IFN-gamma activation site approximately 500 base pairs upstream of the IFN-stimulated response element was found to bind three IFN-alpha/beta activation factors upon IFN-beta induction and conferred both type I and type II IFN inducibility upon a heterologous promoter, These data demonstrate a novel arrangement of a nonoverlapping IFN-gamma activation site and an IFN-stimulated response element mediating type I IFN inducibility, previously not reported for other IFN-stimulable promoters.	UNIV HAMBURG,HEINRICH PETTE INST EXPT VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DECKER T, 1996, IN PRESS INTERFERON; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Grotzinger T, 1996, MOL CELL BIOL, V16, P1150; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; GUILLE MJ, 1994, EUR J BIOCHEM, V219, P547, DOI 10.1111/j.1432-1033.1994.tb19970.x; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAVAU C, 1995, ONCOGENE, V11, P871; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIN JH, 1995, J EXP MED, V181, P1965; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller M, 1994, J Viral Hepat, V1, P87, DOI 10.1111/j.1365-2893.1994.tb00109.x; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PLASS C, 1995, HEREDITAS, V122, P245, DOI 10.1111/j.1601-5223.1995.00245.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; RAZ R, 1994, J BIOL CHEM, V269, P24391; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SAMANTA H, 1986, J BIOL CHEM, V261, P1849; SAWMBROOK J, 1989, MOL CLONING LAB MANU; SEEGERT D, 1994, J BIOL CHEM, V269, P8590; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STERNSDORF T, 1995, SCAND J IMMUNOL, V42, P257, DOI 10.1111/j.1365-3083.1995.tb03652.x; SZOSTECKI C, 1992, SCAND J IMMUNOL, V36, P555, DOI 10.1111/j.1365-3083.1992.tb03224.x; SZOSTECKI C, 1987, CLIN EXP IMMUNOL, V68, P108; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TERRIS B, 1995, CANCER RES, V55, P1590; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XIE KW, 1995, P NATL ACAD SCI USA, V92, P1639, DOI 10.1073/pnas.92.5.1639; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170	70	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25253	25260		10.1074/jbc.271.41.25253	http://dx.doi.org/10.1074/jbc.271.41.25253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810287	hybrid			2022-12-25	WOS:A1996VL69300031
J	Yao, CC; Ziober, BL; Squillace, RM; Kramer, RH				Yao, CC; Ziober, BL; Squillace, RM; Kramer, RH			alpha 7 integrin mediates cell adhesion and migration on specific laminin isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAINS; ALPHA-6-BETA-1 INTEGRIN; SKELETAL-MUSCLE; RECEPTOR; EXPRESSION; VARIANTS; SUBUNIT; BINDING; PHOSPHORYLATION; ALPHA-6A-BETA-1	The laminin-binding alpha 7 beta 1 integrin receptor is expressed at high levels by skeletal and cardiac muscles and by certain melanocytic cells. We have assessed the potential role of the alpha 7A/B integrin isoforms in mediating cell adhesion and motility and determined the laminin isoform specificity of this integrin. When MCF-7 breast carcinoma cells, normally nonadherent to laminin 1, were stably transfected with cDNA for mouse alpha 7, they adhered with high efficiency and migrated on laminin 1 substrates. Function-perturbing monoclonal antibodies generated to mouse alpha 7 subunit blocked both adhesion and migration of alpha 7 transfectants on laminin 1 substrates. Additional studies with MCF-7 transfectants revealed that alpha 7 beta 1 binds well to laminin 1 and to a mixture of laminin 2 and 4 but not to laminin 5. Importantly, alpha 7 beta 1 was capable of promoting motility on both laminin 1 and laminin 2/4 substrates, However, MCF-7 cells transfected with cDNA for either alpha 7A or alpha 7B showed no significant differences in cell adhesion or motility on laminin 1 substrates. Although the role for the alternatively spliced cytoplasmic variants of alpha 7 remains unknown, the results establish that alpha 7 beta 1 mediates cell adhesive activities on a restricted number of laminin isoforms.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH DENT,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Yao, Chung-Chen/D-1470-2018	YAO, JANE CHUNG-CHEN/0000-0002-2293-7000	NATIONAL CANCER INSTITUTE [R01CA033834] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA33834] Funding Source: Medline; NIDCR NIH HHS [R01 DE10306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; COLLO G, 1993, J BIOL CHEM, V268, P19019; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; COOPMAN P, 1991, CLIN EXP METASTAS, V9, P469, DOI 10.1007/BF01785532; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DELWEL GO, 1995, ADHESION RECEPTORS T; DEWEL GO, 1994, MOL BIOL CELL, V5, P203; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; MARINKOVICH MP, 1993, LAB INVEST, V69, P295; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MUNAUT C, 1991, CELL BIOL INT REP, V15, P49; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; ROSEN EM, 1991, CANCER RES, V51, P5315; SCHWARTZ MA, 1995, ANN REV CELL DEV BIO, V11, P594; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHAW LM, 1994, MOL BIOL CELL, V5, P679, DOI 10.1091/mbc.5.6.679; SONG WK, 1993, J CELL SCI, V106, P1139; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; VANKOOYK Y, 1993, J EXP MED, V177, P185, DOI 10.1084/jem.177.1.185; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; Ziober BL, 1996, SEMIN CANCER BIOL, V7, P119, DOI 10.1006/scbi.1996.0017; ZIOBER BL, 1993, J BIOL CHEM, V268, P26733	34	99	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25598	25603		10.1074/jbc.271.41.25598	http://dx.doi.org/10.1074/jbc.271.41.25598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810334	hybrid			2022-12-25	WOS:A1996VL69300078
J	Bubulya, A; Wise, SC; Shen, XQ; Burmeister, LA; Shemshedini, L				Bubulya, A; Wise, SC; Shen, XQ; Burmeister, LA; Shemshedini, L			c-Jun can mediate androgen receptor-induced transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; RETINOIC ACID RECEPTORS; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL REGULATION; PROGESTERONE-RECEPTOR; NEGATIVE REGULATION; GENE; FOS; ACTIVATION	The proto-oncoprotein c-Jun forms as a heterodimer with c-Fos, the transcription factor AP-1. AP-1 regulates transcription through transactivation, a process requiring DNA binding. Here we report an indirect mechanism by which c-Jun can regulate transcription via the androgen receptor. In this process, c-Jun is able to support androgen receptor-mediated transactivation in the absence of an interaction with c-Fos or any apparent DNA binding. This positive effect of c-Jun was dose-dependent. Both exogenously added and endogenously induced c-Jun are able to act on the androgen receptor. Transactivation by the androgen receptor can undergo self-squelching, and this was relieved by transfected c-Jun. Using a time-course experiment, we provide evidence that the c-Jun effect is primary. c-Fos is able to block human androgen receptor activity in both the absence and presence of transfected c-Jun, Using a modified form of the yeast two-hybrid system, we show in Cos cells that c-Jun can interact with the DNA binding domain/hinge region (CD regions) of the androgen receptor, Therefore, we propose that c-Jun functions as a mediator for androgen receptor-induced transactivation.	UNIV TOLEDO,DEPT BIOL,TOLEDO,OH 43606	University System of Ohio; University of Toledo								ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DERUITER PE, 1995, MOL CELL ENDOCRINOL, V110, pR1, DOI 10.1016/0303-7207(95)03534-E; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; EVANS RM, 1988, SCIENCE, V240, P89; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HARRISON RJ, 1995, MOL ENDOCRINOL, V9, P981, DOI 10.1210/me.9.8.981; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ONATE SA, 1995, SCIENCE, V270, P1354; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; TANESE N, 1993, COLD SPRING HARB SYM, V58, P179, DOI 10.1101/SQB.1993.058.01.022; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TZUCKERMAN M, 1991, MOL ENDOCRINOL, V91, P1983; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YOUNG CYF, 1994, PROSTATE, V25, P39, DOI 10.1002/pros.2990250106; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	51	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24583	24589		10.1074/jbc.271.40.24583	http://dx.doi.org/10.1074/jbc.271.40.24583			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798722	hybrid			2022-12-25	WOS:A1996VM67400044
J	Ding, JB; Knaus, UG; Lian, JP; Bokoch, GM; Badwey, JA				Ding, JB; Knaus, UG; Lian, JP; Bokoch, GM; Badwey, JA			The renaturable 69- and 63-kDa protein kinases that undergo rapid activation in chemoattractant-stimulated guinea pig neutrophils are p21-activated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; CHEMOTACTIC FACTORS; MOLECULAR-CLONING; FAMILY MEMBERS; RAC; TRANSLOCATION; AUTOPHOSPHORYLATION; PHOSPHORYLATION; IDENTIFICATION	Neutrophils stimulated with the chemoattractant fMet-Leu-Phe (fMLP) are known to exhibit rapid activation of four protein kinases with molecular masses of similar to 69, similar to 63, similar to 49, and similar to 40-kDa. Activation of these kinases is blocked by antagonists of phosphatidylinositol 3-kinase and type 1 and/or type 2A protein phosphatases. These enzymes can be detected by their ability to undergo renaturation and catalyze the phosphorylation of a peptide substrate that corresponds to amino acid residues 297-331 of the 47-kDa subunit of the NADPH-oxidase complex fixed within a gel. In this report, we demonstrate that an antibody generated to a fusion protein containing amino acid residues 175-306 of p21-activated protein kinase 1 (Pak1) reacts with three proteins in guinea pig neutrophils with molecular masses in the 60-70-kDa range during Western blotting. This antibody immunoprecipitates both the 69- and 63-kDa renaturable kinases from lysates of stimulated cells along with a minor 60-kDa kinase. No activities were observed for any of these enzymes in immunoprecipitates from unstimulated neutrophils. However, addition of ATP and activated Rac 1 or Cdc42 to immunoprecipitates from unstimulated cells resulted in the stimulation of two renaturable kinases with molecular masses in the 69- and 63-kDa range. These immunoprecipitates also contained two novel protein kinases with masses of similar to 49 and 40 kDa that were selectively activated by Cdc42. In contrast, the 69- and 63-kDa kinases were not immunoprecipitated from lysates of stimulated neutrophils with an antibody to Pak2 or with nonimmune serum. These data indicate that the renaturable 69- and 63-kDa kinases are Paks and reveal some of the upstream events that are necessary for the rapid activation of this family of protein kinases in neutrophils.	HARVARD UNIV, SCH MED, BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02114 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Scripps Research Institute; Scripps Research Institute					NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIAMS NIH HHS [P60 AR40770] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Badwey J A, 1986, Methods Enzymol, V132, P365; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; BRUMELL JH, 1994, AM J PHYSIOL-CELL PH, V267, pC1574, DOI 10.1152/ajpcell.1994.267.6.C1574; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DING JB, 1993, BLOOD, V82, P940; DING JB, 1993, J BIOL CHEM, V268, P5234; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DING JB, 1993, J BIOL CHEM, V268, P17326; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HUANG CK, 1988, J BIOL CHEM, V263, P13144; HUANG CK, 1990, J CELL BIOCHEM, V44, P221, DOI 10.1002/jcb.240440404; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUINN MT, 1993, J BIOL CHEM, V268, P20983; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WHITE JR, 1983, J BIOL CHEM, V258, P4041; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	43	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24869	24873		10.1074/jbc.271.40.24869	http://dx.doi.org/10.1074/jbc.271.40.24869			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798763	hybrid			2022-12-25	WOS:A1996VM67400085
J	Nicoll, DA; Quednau, BD; Qui, ZY; Xia, YR; Lusis, AJ; Philipson, KD				Nicoll, DA; Quednau, BD; Qui, ZY; Xia, YR; Lusis, AJ; Philipson, KD			Cloning of a third mammalian Na+-Ca2+ exchanger, NCX3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; NA+/CA2+ EXCHANGER; CA2+-BINDING DOMAIN; MOLECULAR-CLONING; EXPRESSION; CELLS; GENE; CDNA; IDENTIFICATION; LOCALIZATION	NCX3 is the third isoform of a mammalian Na+-Ca2+ exchanger to be cloned. NCX3 was identified from rat brain cDNA by polymerase chain reaction (PCR) using degenerate primers derived from the sequences of two conserved regions of NCX1 and NCX2. The NCX3 PCR product was used to isolate two overlapping clones totalling 4.8 kilobases (kb) from a rat brain cDNA library. The overlapping clones were sequenced and joined at a unique Bsp106I restriction enzyme site to form a full-length cDNA clone. The NCX3 cDNA clone has an open reading frame of 2.8 kb encoding a protein of 927 amino acids. At the amino acid level, NCX3 shares 73% identity with NCX1 and 75% identity with NCX2 and is predicted to share the same membrane topology as NCX1 and NCX2. Following addition of a poly(A)(+) tail to the NCX3 clone, exchanger activity could be expressed in Xenopus oocytes. NCX3 was also expressed in the mammalian BHK cell line. NCX3 transcripts are 6 kb in size and are highly restricted to brain and skeletal muscle. Linkage analysis in the mouse indicated that the NCX family of genes is dispersed, since the NCX1, NCX2, and NCX3 genes mapped to mouse chromosomes 17, 7, and 12, respectively.	UNIV CALIF LOS ANGELES,DEPT PHYSIOL,SCH MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MED,SCH MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nicoll, DA (corresponding author), UNIV CALIF LOS ANGELES,CARDIOVASC RES LAB,SCH MED,3645 MRL BLDG,675 CIRCLE DR S,LOS ANGELES,CA 90095, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, R37HL048509, R01HL048509, R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568, HL49101, HL48509] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen RD, 1996, MAMM GENOME, V7, P557, DOI 10.1007/s003359900167; Condrescu M., 1996, Biophysical Journal, V70, pA206; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; DAHAN D, 1991, J BIOL CHEM, V266, P2067; DIPOLO R, 1994, AM J PHYSIOL, V266, pC1382, DOI 10.1152/ajpcell.1994.266.5.C1382; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GABELLINI N, 1995, J BIOL CHEM, V270, P6917, DOI 10.1074/jbc.270.12.6917; GILBERT JR, 1982, J MEMBRANE BIOL, V69, P77, DOI 10.1007/BF01871244; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; He Z., 1996, Biophysical Journal, V70, pA201; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; *J HOPK U, 1990, HUM GEN DAT BAS; *JACK LAB, 1995, MOUS GEN DAT BAS; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1992, J BIOL CHEM, V267, P7828; LI ZP, 1994, J BIOL CHEM, V269, P17434; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; Lytton J., 1996, Biophysical Journal, V70, pA7; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; REUTER H, 1995, NEURON, V15, P1077, DOI 10.1016/0896-6273(95)90096-9; Sambrook J., 2002, MOL CLONING LAB MANU; SHIEH BH, 1992, GENOMICS, V12, P616, DOI 10.1016/0888-7543(92)90459-6; STURZL M, 1990, ANAL BIOCHEM, V185, P164, DOI 10.1016/0003-2697(90)90274-D; VALDIVIA C, 1995, IN PRESS BIOCH BIOPH; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; Welch CL, 1996, J LIPID RES, V37, P1406	43	295	308	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24914	24921		10.1074/jbc.271.40.24914	http://dx.doi.org/10.1074/jbc.271.40.24914			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798769	hybrid			2022-12-25	WOS:A1996VM67400092
J	Oellers, N; Hafen, E				Oellers, N; Hafen, E			Biochemical characterization of rolled(Sem), an activated form of Drosophila mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; OF-FUNCTION MUTATION; ETS DOMAIN PROTEIN; MAP KINASE; MESODERM INDUCTION; REGULATED KINASE; CELLS; RAF; DIFFERENTIATION; LOCALIZATION	The rolled (rl) gene of Drosophila encodes a homologue of vertebrate mitogen-activated protein kinases. Genetic analyses have shown that the gain-of-function mutation rolled(Sevenmaker) (rl(Sem)) is sufficient to activate developmental pathways controlled by distinct receptor tyrosine kinases, such as Sevenless, Torso, and the Drosophila epidermal growth factor receptor homologue. Here we show that mutant Rl(Sem) protein, immunoprecipitated from transiently transfected COS cells, exhibits a moderate increase in kinase activity compared with wild-type Rl protein. Time course studies revealed that Rl(Sem) is more active than Rl following short term as well as prolonged treatment with epidermal growth factor. Interestingly, a more pronounced difference in kinase activity is observed when the proteins are immunoprecipitated from extracts of Drosophila rl and rl(Sem) larvae. In fact, the kinase activity of Rl(Sem) from larvae extracts is comparable to the kinase activity of larvae expressing either an activated Sevenless receptor or an activated Raf kinase. We also demonstrate that Dsor1, which has been placed upstream of rl genetically, is able to phosphorylate and activate Rl in vitro.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HAFEN E, 1993, DEVELOPMENT, P41; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KERKHOFF E, 1991, ONCOGENE, V6, P93; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; ZIPURSKY LS, 1994, ANNU REV NEUROSCI, V17, P373	32	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24939	24944		10.1074/jbc.271.40.24939	http://dx.doi.org/10.1074/jbc.271.40.24939			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798773	hybrid, Green Accepted			2022-12-25	WOS:A1996VM67400096
J	Simon, FR; Fortune, J; Alexander, A; Iwahashi, M; Dahl, R; Sutherland, E				Simon, FR; Fortune, J; Alexander, A; Iwahashi, M; Dahl, R; Sutherland, E			Increased hepatic Na,K-ATPase activity during hepatic regeneration is associated with induction of the beta(1)-subunit and expression on the bile canalicular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE PLASMA-MEMBRANES; SENSITIVE RB-86+ UPTAKE; BETA-SUBUNIT; LIVER-REGENERATION; RAT HEPATOCYTE; ALPHA-SUBUNIT; LIPID FLUIDITY; NA+/K+-ATPASE; ADENOSINE-TRIPHOSPHATASE; (NA++K+)-ATPASE ACTIVITY	Cellular and molecular mechanisms regulating the activity of the sodium pump or Na,K-ATPase during proliferation of hepatocytes following 70% liver resection have not been defined. Na,K-ATPase may be regulated by synthesis of its alpha- and beta-subunits, by sorting to either the sinusoidal or apical plasma membrane domains, or by increasing membrane lipid fluidity. This study investigated the time course of changes during hepatic regeneration for Na,K-ATPase activity, lipid composition and fluidity, and protein content of liver plasma membrane subfractions. As early as 4 h after hepatic resection, Na,K-ATPase activity was increased selectively in the bile canalicular fraction. It reached a new steady state at 12 h and remained elevated for 2 days. Although hepatic regeneration was associated with a reduced cholesterol/phospholipid molar ratio and increased fluidity, measured with two different probes, these changes in lipid metabolism were in the sinusoidal membrane domain. The Na,K-ATPase beta(1)-subunit, but not the alpha(1)-subunit, was increased selectively at the bile canalicular surface as shown by immunoblotting of liver plasma membrane subfractions and the morphological demonstration at both the light and electron microscopic levels. Furthermore, cycloheximide blocked the rise in beta(1)-subunit mRNA levels. Since the time course for beta(1)-subunit accumulation was similar to that for activation of Na,K-ATPase activity, this change implicated the beta(1)-subunit in activating sodium pump activity.	VET AFFAIRS MED CTR, DENVER, CO 80262 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Simon, FR (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT MED, HEPATOBILIARY RES CTR, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NIDDK NIH HHS [DK34914, DK15851] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015851, P30DK034914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1960, J BIOL CHEM, V235, P769; BARTLES JR, 1986, DEV BIOL, V118, P286, DOI 10.1016/0012-1606(86)90095-3; BARTLES JR, 1991, DEV BIOL, V143, P258, DOI 10.1016/0012-1606(91)90076-F; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRUSCALUPI G, 1980, BIOCHIM BIOPHYS ACTA, V597, P263, DOI 10.1016/0005-2736(80)90104-2; CAM AL, 1979, AM J PHYSIOL, V236, pE594; CHENG HC, 1993, HEPATOLOGY, V17, P280, DOI 10.1016/0270-9139(93)90089-6; CHENG S, 1979, ARCH BIOCHEM BIOPHYS, V196, P424, DOI 10.1016/0003-9861(79)90293-5; CHONG PLG, 1985, J BIOL CHEM, V260, P4484; DAVIS RA, 1978, P NATL ACAD SCI USA, V75, P4130, DOI 10.1073/pnas.75.9.4130; DELICONSTANTINOS G, 1983, BIOCHEM J, V212, P445, DOI 10.1042/bj2120445; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EMANUEL JR, 1987, P NATL ACAD SCI USA, V84, P9030, DOI 10.1073/pnas.84.24.9030; FAMBROUGH DM, 1994, CURR TOP MEMBR, V41, P45, DOI 10.1016/S0070-2161(08)60453-0; Fausto N, 1993, Prog Liver Dis, V11, P115; FAUSTO N, 1989, LAB INVEST, V60, P4; GEERING K, 1986, CURR TOP MEMBR TRANS, V27, P221; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GICK GG, 1988, J BIOL CHEM, V263, P16610; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P162; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUBERT JJ, 1986, BIOCHEMISTRY-US, V25, P4156, DOI 10.1021/bi00362a025; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KIMELBERG HK, 1975, BIOCHIM BIOPHYS ACTA, V413, P143, DOI 10.1016/0005-2736(75)90065-6; KIMELBERG HK, 1975, J BIOL CHEM, V250, P100; KIMELBERG HK, 1972, BIOCHIM BIOPHYS ACTA, V282, P277, DOI 10.1016/0005-2736(72)90334-3; KIMELBERG HK, 1976, BIOCHIM BIOPHYS ACTA, V455, P865, DOI 10.1016/0005-2736(76)90056-0; KOCH KS, 1979, CELL, V18, P153, DOI 10.1016/0092-8674(79)90364-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFFERT HL, 1985, HEPATOLOGY, V5, P501, DOI 10.1002/hep.1840050327; LEONI S, 1975, BIOCHIM BIOPHYS ACTA, V394, P317, DOI 10.1016/0005-2736(75)90268-0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XP, 1991, J BIOL CHEM, V266, P9276; MAHLER SM, 1988, INT J BIOCHEM, V20, P605, DOI 10.1016/0020-711X(88)90100-0; MARTINEZMAS JV, 1995, FEBS LETT, V362, P85, DOI 10.1016/0014-5793(95)00217-W; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MASUDA Y, 1976, BIOCHIM BIOPHYS ACTA, V426, P335, DOI 10.1016/0005-2736(76)90342-4; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mercer Robert W., 1993, V137C, P139; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; REUSS L, 1986, CURR TOP MEMBR TRANS, V27, P3; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; ROSARIO J, 1988, BIOCHEMISTRY-US, V27, P3939, DOI 10.1021/bi00411a008; SCHENK DB, 1984, J BIOL CHEM, V259, P14941; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SIMON FR, 1995, AM J PHYSIOL-CELL PH, V269, pC69, DOI 10.1152/ajpcell.1995.269.1.C69; Simon Francis R., 1993, P297; SINENSKY M, 1979, P NATL ACAD SCI USA, V76, P4893, DOI 10.1073/pnas.76.10.4893; STORCH J, 1984, BIOCHEMISTRY-US, V23, P1165, DOI 10.1021/bi00301a021; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SUTHERLAND E, 1988, P NATL ACAD SCI USA, V85, P8673, DOI 10.1073/pnas.85.22.8673; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASILETS LA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P201, DOI 10.1016/0304-4157(93)90012-D; WRIGHT GH, 1977, BIOCHIM BIOPHYS ACTA, V470, P368, DOI 10.1016/0005-2736(77)90128-6; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; ZYSSET T, 1985, HEPATOLOGY, V5, P531, DOI 10.1002/hep.1840050402	69	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24967	24975		10.1074/jbc.271.40.24967	http://dx.doi.org/10.1074/jbc.271.40.24967			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798777	hybrid			2022-12-25	WOS:A1996VM67400100
J	Cannell, EJ; Farrell, PJ; Sinclair, AJ				Cannell, EJ; Farrell, PJ; Sinclair, AJ			Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells	ONCOGENE			English	Article						Epstein-Barr virus; phosphorylation; cell cycle; immortalisation; Retinoblastoma protein	DEPENDENT KINASE INHIBITOR; SUSCEPTIBILITY GENE-PRODUCT; D-CDK COMPLEXES; RETINOBLASTOMA PROTEIN; CYCLE CONTROL; SUPPRESSOR GENES; LYMPHOCYTES-B; EXPRESSION; LINES; P16(INK4)	Infection of human primary B-lymphocytes with Epstein-Barr virus (EBV) drives quiescent cells into continual proliferation and results in the outgrowth of immortal cell lines. This requires re-programming of the mechanisms that, in the absence of appropriate antigenic stimulation, normally prevent the proliferation of B-lymphocyes. Since the Retinoblastoma protein (pRb) and its relatives, p107 and p130, play critical roles in controlling the mammalian cell division cycle, we have investigated the expression and phosphorylation status of these proteins following EBV immortalisation of primary B-lymphocytes. In this report, me show that EBV drives the hyperphosphorylation of pRb. This is achieved by a strategy involving the altered expression of several components of the signal transduction pathway that normally regulates the phosphorylation status of pRb, including the up regulation of a number of cyclins and cyclin-dependent kinases and the down regulation of a subset of cyclin-dependent kinase inhibitors. The net result is the formation of active cyclin-dependent kinase complexes that are capable of phosphorylating and inactivating pRb. The results presented here identify the activation of a normal signal transduction pathway as an important component of the strategy used by EBV to drive cell proliferation.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research				Sinclair, Alison/0000-0001-8510-8691; Farrell, Paul/0000-0002-6754-9351				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; BATES S, 1994, ONCOGENE, V9, P1633; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; DEBOER CJ, 1995, ONCOGENE, V10, P1833; FREDERSDORF S, 1996, IN PRESS AM J PATH; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GRANA X, 1995, ONCOGENE, V11, P211; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HALVEY O, 1995, SCIENCE, V267, P1018; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARA E, 1996, IN PRESS MOL CELL BI; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HOLLYOAKE M, 1995, CANCER RES, V55, P4784; JEN J, 1994, CANCER RES, V54, P6353; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KEIFF E, 1994, VIRUSES CANC, V51, P123; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; LALLE P, 1995, ONCOGENE, V10, P2447; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1994, CANCER RES, V54, P6078; Liebowitz David, 1993, P107; LUDLOW JW, 1989, CELL, V56, P67; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MAYOL X, 1995, ONCOGENE, V11, P801; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PALMERO I, 1993, ONCOGENE, V8, P1049; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PENG M, 1992, ONCOGENE, V7, P1175; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1995, ONCOGENE, V11, P635; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SINCLAIR AJ, 1995, METH MOL G, V7, P89; SZEKELY L, 1995, ONCOGENE, V10, P1869; TAM SW, 1994, CANCER RES, V54, P5816; TOYOSHIMA H, 1994, CELL, V78, P64; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU HJ, 1989, ONCOGENE, V4, P807; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	57	44	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1413	1421						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875979				2022-12-25	WOS:A1996VL38400006
J	Little, MH; Holmes, G; Pell, L; Caricasole, A; Duarte, A; Law, M; Ward, A; Wainwright, B				Little, MH; Holmes, G; Pell, L; Caricasole, A; Duarte, A; Law, M; Ward, A; Wainwright, B			A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers	ONCOGENE			English	Article						Wilms' tumour suppressor protein; Wilms' tumour; transcription factor; Zinc finger binding	DENYS-DRASH SYNDROME; FACTOR-A-CHAIN; GENE-PRODUCT; DNA-BINDING; TRANSCRIPTION FACTOR; UROGENITAL DEVELOPMENT; PROMOTER ACTIVITY; POINT MUTATIONS; SEQUENCE; KIDNEY	All isoforms of the Wilms' tumour suppressor protein, WT1, contain four consecutive zinc fingers which facilitate DNA binding. The predominant WT1 transcript contains a 9 base pair insertion resulting in an additional three amino acids, lysine-threonine-serine (KTS), between zinc fingers 3 and 4. WT1 zinc fingers 2, 3 and 4 are highly homologous to the zinc fingers of the early growth response gene, EGR1. However, only WT1-KTS is capable of binding an EGR1 consensus site. In contrast, the previously described genomic fragment, +P5 (D1S3309E), is bound by both WT1-KTS and WT1+KTS. In this study, the region within +P5 to which both WT1-KTS and WT1+KTS bind was defined as 5-GGAGAGGGAGGATC-3'. EGR1 did not bind +P5. By creating zinc finger deletions, we demonstrate that zinc finger 1, but not zinc finger 4, is critical for +P5 binding; whereas zinc finger 4, but not 1, is necessary for the binding of WT1 target sites within EGR1, PDGF A chain and IGF2 promoters. Thus, zinc finger usage can vary with target and +P5 may represent a novel type of WT1 binding site, the physiological relevance of which must be investigated.	UNIV QUEENSLAND, DEPT BIOCHEM, BRISBANE, QLD 4072, AUSTRALIA; UNIV OXFORD, DEPT ZOOL, CRC, GROWTH FACTORS UNIT, OXFORD OX1 3PS, ENGLAND	University of Queensland; University of Oxford	Little, MH (corresponding author), UNIV QUEENSLAND, CTR CELLULAR & MOL BIOL, BRISBANE, QLD 4072, AUSTRALIA.		Little, Melissa H/A-6170-2010; Duarte, Antonio/V-1178-2018	Little, Melissa H/0000-0003-0380-2263; Duarte, Antonio/0000-0002-9255-3635; Wainwright, Brandon/0000-0003-0406-2092; Ward, Andrew/0000-0001-8311-5695				BAIRD PN, 1992, ONCOGENE, V7, P2141; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BERG JM, 1993, CURR OPIN STRUC BIOL, V3, P11, DOI 10.1016/0959-440X(93)90195-Q; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARICASOLE A, 1996, IN PRESS P NATL ACAD; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; HUFF V, 1991, AM J HUM GENET, V48, P997; KENT J, 1995, ONCOGENE, V11, P1781; KONIG A, 1993, HUM MOL GENET, V2, P1967; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Negus K, 1996, CYTOGENET CELL GENET, V72, P306, DOI 10.1159/000134210; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; REDDY JC, 1996, IN PRESS BIOCH BIOPH; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; SZABO J, 1995, AM J HUM GENET, V56, P944; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Ward A, 1995, GENE, V167, P239, DOI 10.1016/0378-1119(95)00645-1; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	47	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1461	1469						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875984				2022-12-25	WOS:A1996VL38400011
J	Deloche, O; Georgopoulos, C				Deloche, O; Georgopoulos, C			Purification and biochemical properties of Saccharomyces cerevisiae's Mge1p, the mitochondrial cochaperone of Ssc1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI DNAJ; ATPASE ACTIVITY; MOLECULAR CHAPERONES; REACTION CYCLE; GRPE; HSP70; HOMOLOG; REPLICATION; IDENTIFICATION	Previous biochemical and genetic studies have demonstrated the universal conservation of the DnaK (Hsp70) chaperone machine, Its three members, DnaK, DnaJ, and GrpE, in Escherichia coli work synergistically to promote protein protection, disaggregation, and import into the various organelles, In the mitochondria of Saccharomyces cerevisiae the three corresponding members are designated as Ssc1p, Mdj1p, and Mge1p, respectively, The MGE1 gene was previously cloned by us and others, and its product has been shown to be absolutely essential for protein transport into mitochondria and hence cell viability, To better understand its biological role, we have proceeded to overexpress and purify the mature Mge1p in E. coli through the construction of the appropriate vector clone. Mge1p has been shown to functionally substitute for its E. coli GrpE counterpart in a variety of its biological functions, including suppression of the bacterial temperature-sensitive phenotype of the grpE280 nutation, formation of a stable complex with DnaK, stimulation of DnaK's ATPase activity, and the refolding of denatured luciferase by the DnaK/DnaJ chaperone proteins. Thus, the function of the GrpE homologues appears to be highly conserved across the biological kingdoms.			Deloche, O (corresponding author), CTR MED UNIV GENEVA, DEPT BIOCHIM MED, 1, RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.							ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; ANG D, 1988, THESIS U UTAH SALT L; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P129, DOI 10.1016/0968-0004(92)90319-5; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; DEMACARIO EC, 1994, J MOL BIOL, V240, P95, DOI 10.1006/jmbi.1994.1422; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HOHFELD J, 1995, CELL, V83, P589; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; JOHNSON RB, 1989, GENE, V84, P295, DOI 10.1016/0378-1119(89)90503-9; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; NAKAI M, 1994, BIOCHEM BIOPH RES CO, V200, P435, DOI 10.1006/bbrc.1994.1468; NAYLOR DJ, 1995, BBA-PROTEIN STRUCT M, V1248, P75, DOI 10.1016/0167-4838(95)00007-H; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SPENCE J, 1990, J BACTERIOL, V172, P7157, DOI 10.1128/jb.172.12.7157-7166.1990; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; VOOS W, 1994, MOL CELL BIOL, V14, P6627, DOI 10.1128/MCB.14.10.6627; WALL D, 1994, J BIOL CHEM, V269, P5446; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; WU B, 1994, J BACTERIOL, V176, P6965, DOI 10.1128/JB.176.22.6965-6973.1994; WU B, 1994, THESIS U UTAH SALT L; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	42	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23960	23966		10.1074/jbc.271.39.23960	http://dx.doi.org/10.1074/jbc.271.39.23960			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798629	hybrid			2022-12-25	WOS:A1996VJ44200058
J	Guse, AH; daSilva, CP; Weber, K; Ashamu, GA; Potter, BVL; Mayr, GW				Guse, AH; daSilva, CP; Weber, K; Ashamu, GA; Potter, BVL; Mayr, GW			Regulation of cADP-ribose-induced Ca2+ release by Mg2+ and inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; INDUCED CALCIUM-RELEASE; INOSITOL TRISPHOSPHATE; RYANODINE RECEPTOR; T-LYMPHOCYTES; IDENTIFICATION; ACCUMULATION; CELLS	cADP-ribose (cADPr) has recently been shown to release Ca2+ from an intracellular store of permeabilized T lymphocyte cell lines (Guse, A. H., da Silva, C. P., Emmrich, F., Ashamu, G. A., Potter, B. V. L., and Mayr, G. W. (1995) J. Immunol. 155, 3353-3359). Using permeabilized Jurkat and HPB.ALL T lymphocytes, the effects of varying concentrations of inorganic phosphate and Mg2+ on cADPr-induced Ca2+ release were investigated. cADPr induced Ca2+ release was dependent on the concentration of inorganic phosphate, showing very low Ca2+ release activity between 0.5 and 2 mM inorganic phosphate. At 4 to 5 mM inorganic phosphate, the cADPr-induced Ca2+ release was much more pronounced, reaching maximal values at 10 mM inorganic phosphate. The underlying mechanism for this stimulatory effect was an increased loading of the cADPr-sensitive Ca2+ store, which was demonstrated by enhanced resequestration of Ca2+ selectively into the cADPr-sensitive Ca2+ store. The free Mg2+ concentration also influenced cADPr-induced Ca2+ release in permeabilized cells: at 0 and 8.58 mM the release was nearly completely abolished, whereas at 1.06 mM maximal Ca2+ release by cADPr was observed. High performance liquid chromatographic analysis of exogenously added cADPr revealed that the catabolism of cADPr at varying Mg2+ and P-i concentrations had only minor relevance for the modulatory effects observed. To correlate the effects of inorganic phosphate and Mg2+ on cADPr-induced Ca2+ release observed in the permeabilized cell preparations, measurements of these ions in intact Jurkat T lymphocytes were carried out. Intact Jurkat T cells stimulated via the T cell receptor . CD3 complex did not respond with significant elevation of the free intracellular Mg2+ concentration. In contrast, stimulation via the T cell receptor . CD3 complex resulted in an increase in the intracellular inorganic phosphate concentration. These data indicate a role for the intracellular inorganic phosphate concentration in the regulation of cADPr-mediated Ca2+ release in T lymphocytes.	UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND	University of Bath	Guse, AH (corresponding author), UNIV HAMBURG,INST PHYSIOL CHEM,DEPT ENZYME CHEM,GRINDELALLEE 117,D-20146 HAMBURG,GERMANY.		Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012					ASHAMU GA, 1995, J CHEM SOC CHEM COMM, P1929; ASHAMU GA, 1995, J CHEM SOC CHEM COMM, P1359, DOI 10.1039/c39950001359; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; CHINI EN, 1995, AM J PHYSIOL-CELL PH, V269, pC1042, DOI 10.1152/ajpcell.1995.269.4.C1042; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; FABIATO A, 1991, CELLULAR CALCIUM PRA, P159; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GRAEFF RM, 1995, BIOCHEM BIOPH RES CO, V206, P786, DOI 10.1006/bbrc.1995.1111; GUSE AH, 1994, BIOCHEM J, V301, P83, DOI 10.1042/bj3010083; GUSE AH, 1993, J BIOL CHEM, V268, P7129; GUSE AH, 1992, BIOCHEM J, V288, P489, DOI 10.1042/bj2880489; GUSE AH, 1991, J BIOL CHEM, V266, P24498; GUSE AH, 1995, J IMMUNOL, V155, P3353; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1994, CELL SIGNAL, V6, P591, DOI 10.1016/0898-6568(94)90042-6; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S	30	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23946	23953		10.1074/jbc.271.39.23946	http://dx.doi.org/10.1074/jbc.271.39.23946			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798627				2022-12-25	WOS:A1996VJ44200056
J	Mourao, PAS; Pereira, MS; Pavao, MSG; Mulloy, B; Tollefsen, DM; Mowinckel, MC; Abildgaard, U				Mourao, PAS; Pereira, MS; Pavao, MSG; Mulloy, B; Tollefsen, DM; Mowinckel, MC; Abildgaard, U			Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm - Sulfated fucose branches on the polysaccharide account for its high anticoagulant action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; MAGNETIC-RESONANCE-SPECTRA; PLICATA CHORDATA-TUNICATA; DERMATAN SULFATE; ANTITHROMBIN-III; SEA-CUCUMBER; PENTOSAN POLYSULFATE; STYELA-PLICATA; L-GALACTANS; ASCIDIANS TUNICATES	A polysaccharide isolated from the body wall of the sea cucumber Ludwigothurea grisea has a backbone like that of mammalian chondroitin sulfate: [4-beta-D-GlcA-1-->3-beta-D-GalNAc-1](n) but substituted at the 3-position of the beta-D-glucuronic acid residues with sulfated alpha-L-fucopyranosyl branches (Vieira, R. P., Mulloy, B., and Mourao, P. A. S. (1991) J. Biol. Chem. 266, 13530-13536). Mild acid hydrolysis removes the sulfated alpha-L-fucose branches, and cleaved residues have been characterized by H-1 NMR spectroscopy; the most abundant species is fucose 4-O-monosulfate, but 2,4- and 3,4-di-O-sulfated residues are also present. Degradation of the remaining polysaccharide with chondroitin ABC lyase shows that the sulfated alpha-L-fucose residues released by mild acid hydrolysis are concentrated toward the non-reducing end of the polysaccharide chains; enzyme-resistant polysaccharide material includes the reducing terminal and carries acid resistant L-fucose substitution. The sulfated alpha-L-fucose branches confer anticoagulant activity on the polysaccharide. The specific activity of fucosylated chondroitin sulfate in the activated partial thromboplastin time assay is greater than that of a linear homopolymeric alpha-L-fucan with about the same level of sulfation; this activity is lost on defucosylation or desulfation but not on carboxyl-reduction of the polymer. Assays with purified reagents show that the fucosylated chondroitin sulfate can potentiate the thrombin inhibition activity of both antithrombin and heparin cofactor II.	NATL INST BIOL STAND & CONTROLS, POTTERS BAR EN6 3QG, HERTS, ENGLAND; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV HEMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM, DIV HEMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOL BIOPHYS, DIV HEMATOL, ST LOUIS, MO 63110 USA; AKER UNIV HOSP, DEPT MED, N-0514 OSLO, NORWAY	National Institute for Biological Standards & Control; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Oslo	Mourao, PAS (corresponding author), UNIV FED RIO DE JANEIRO, INST CIENCIAS BIOMED, DEPT BIOQUIM, CAIXA POSTAL 68041, BR-21941590 RIO DE JANEIRO, BRAZIL.		Mourao, Paulo/AAA-5386-2020; Pavao, Mauro Sergio Goncalves/B-1979-2010; Sá Pereira, Mariana/C-2211-2015; Pereira, Mariana/GSE-3546-2022	Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271; 				ABILDGAARD U, 1984, THROMB RES, V35, P257, DOI 10.1016/0049-3848(84)90357-8; ALBANO RM, 1986, J BIOL CHEM, V261, P758; ASPINALL GO, 1982, POLYSACCHARIDES, V1, P19; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CARDOSO LEM, 1994, ARTERIOSCLER THROMB, V14, P115, DOI 10.1161/01.ATV.14.1.115; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; COLLIEC S, 1991, THROMB RES, V64, P143, DOI 10.1016/0049-3848(91)90114-C; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EGGLETON CA, 1981, THROMB RES, V24, P319, DOI 10.1016/0049-3848(81)90005-0; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FISCHER AM, 1982, THROMB HAEMOSTASIS, V47, P104; HOLME KR, 1989, CARBOHYD RES, V186, P301, DOI 10.1016/0008-6215(89)84044-3; JAQUES LB, 1979, SCIENCE, V206, P528, DOI 10.1126/science.386509; KAKKAR VV, 1989, HEPARIN CHEM BIOL PR, P455; KIRCHER HW, 1960, ANAL CHEM, V32, P1103, DOI 10.1021/ac60165a016; MAGGI A, 1987, HAEMOSTASIS, V17, P329; MARCUM JA, 1987, SEMIN THROMB HEMOST, V13, P464, DOI 10.1055/s-2007-1003523; Mathews MB., 1975, CONNECT TISSUE, P93; MAURAY S, 1995, THROMB HAEMOSTASIS, V74, P1280; MCLELLAN DS, 1992, BLOOD COAGUL FIBRIN, V3, P69, DOI 10.1097/00001721-199202000-00011; MERTON RE, 1987, THROMB HAEMOSTASIS, V58, P839; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; MULLOY B, 1994, J BIOL CHEM, V269, P22113; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAGASE H, 1995, BLOOD, V85, P1527, DOI 10.1182/blood.V85.6.1527.bloodjournal8561527; NISHINO T, 1991, THROMB RES, V62, P765, DOI 10.1016/0049-3848(91)90380-F; Painter T.J., 1983, POLYSACCHARIDES, P196, DOI DOI 10.1016/B978-0-12-065602-8.50009-1; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; PAVAO MSG, 1994, BBA-GEN SUBJECTS, V1199, P229, DOI 10.1016/0304-4165(94)90001-9; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RIBEIRO AC, 1994, CARBOHYD RES, V255, P225, DOI 10.1016/S0008-6215(00)90981-9; RONDLE CJM, 1955, BIOCHEM J, V61, P586, DOI 10.1042/bj0610586; RUGGIERO J, 1994, CARBOHYD RES, V256, P275, DOI 10.1016/0008-6215(94)84213-2; SAITO H, 1968, J BIOL CHEM, V243, P1536; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SCULLY MF, 1986, THROMB RES, V41, P489, DOI 10.1016/0049-3848(86)91694-4; SCULLY MF, 1984, BIOCHEM J, V222, P571, DOI 10.1042/bj2220571; SHAKA AJ, 1983, J MAGN RESON, V53, P313, DOI 10.1016/0022-2364(83)90035-5; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUZUKI N, 1991, THROMB HAEMOSTASIS, V65, P369; Taylor R. L., 1976, METHODS CARBOHYDRATE, V7, P149; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; THOMAS DP, 1982, THROMB RES, V28, P343, DOI 10.1016/0049-3848(82)90116-5; THOMAS DP, 1989, ANN NY ACAD SCI, V556, P313; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; WELTI D, 1979, EUR J BIOCHEM, V94, P505, DOI 10.1111/j.1432-1033.1979.tb12919.x	51	264	292	1	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23973	23984		10.1074/jbc.271.39.23973	http://dx.doi.org/10.1074/jbc.271.39.23973			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798631	hybrid			2022-12-25	WOS:A1996VJ44200060
J	Kondo, S; Barna, BP; Kondo, Y; Tanaka, Y; Casey, G; Liu, JB; Morimura, T; Kaakaji, R; Peterson, JW; Werbel, B; Barnett, GH				Kondo, S; Barna, BP; Kondo, Y; Tanaka, Y; Casey, G; Liu, JB; Morimura, T; Kaakaji, R; Peterson, JW; Werbel, B; Barnett, GH			WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis	ONCOGENE			English	Article						apoptosis; cisplatin; glioma; p53/WAF1/CIP1	HUMAN GLIOBLASTOMA CELLS; WILD-TYPE P53; LEUKEMIA-CELLS; COMBINATION THERAPY; ANTICANCER AGENTS; BRAIN-TUMORS; PHASE-II; INDUCTION; GENE; EXPRESSION	Induction of apoptosis in tumor cells is an important determinant in the outcome of therapy. Molecular details of the apoptosis pathway, however, are still poorly defined. The recently discovered WAF1/CIP1 gene is a potent inhibitor of cyclin-dependent kinases and a mediator of tumor-suppressor p53-dependent apoptosis by DNA damage. In addition, WAF1/CIP1 expression is shown to be triggered through the p53-independent pathway. The relationship between WAF1/CIP1 and p53-independent apoptosis by DNA damage, however, remains unclear. In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. In contrast, the p53-independent apoptosis of GB-1 glioma cells by cisplatin did not express WAF1/CIP1. Overexpression of WAF1/CIP1 inhibited DNA synthesis in GB-1 cells, but did not induce apoptosis. Interestingly, WAF1/CIP1 increased the susceptibility of GB-1 cells to cisplatin-induced apoptosis. These results suggest that overexpression of WAF1/CIP1 may have potential for the treatment of tumors with non-functional p53.	CLEVELAND CLIN FDN,DEPT NEUROSCI,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; NATL UTANO HOSP,DEPT NEUROSURG,KYOTO 616,JAPAN	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kondo, S (corresponding author), CLEVELAND CLIN FDN,DEPT NEUROSURG S80,BRAIN TUMOR CTR CANC CTR,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Peterson, John/0000-0002-5528-8561				ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BERTOLONE SJ, 1989, J NEURO-ONCOL, V7, P5, DOI 10.1007/BF00149372; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; CASEY G, 1991, ONCOGENE, V6, P1791; CHEDID M, 1994, ONCOGENE, V9, P3021; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEAN FD, 1993, J NEUROONCOL, V16, P243; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GATELY DP, 1993, BRIT J CANCER, V67, P1171, DOI 10.1038/bjc.1993.221; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JIANG HP, 1994, ONCOGENE, V9, P3397; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAWAI K, 1990, J BIOL CHEM, V265, P13137; KELLEY SL, 1989, EUR J CANCER CLIN ON, V25, P1135, DOI 10.1016/0277-5379(89)90405-7; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KONDO S, 1995, J NEUROSURG, V82, P469, DOI 10.3171/jns.1995.82.3.0469; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1994, CANCER RES, V54, P2928; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MICHIELI P, 1994, CANCER RES, V54, P3391; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEREZ RP, 1990, PHARMACOL THERAPEUT, V48, P19, DOI 10.1016/0163-7258(90)90015-T; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SEXAUER CL, 1985, CANCER, V56, P1497, DOI 10.1002/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SOMERS KD, 1992, CANCER RES, V52, P5997; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TANAKA Y, 1995, VIRUS RES, V36, P131, DOI 10.1016/0168-1702(94)00111-O; TIMMERBOSSCHA H, 1989, J NATL CANCER I, V81, P1069, DOI 10.1093/jnci/81.14.1069; VAN MEIR EG, 1994, CANCER RES, V54, P649; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1995, CANCER RES, V55, P668	49	91	92	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1279	1285						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808702				2022-12-25	WOS:A1996VJ20200019
J	Deltour, L; Ang, HL; Duester, G				Deltour, L; Ang, HL; Duester, G			Ethanol inhibition of retinoic acid synthesis as a potential mechanism for fetal alcohol syndrome	FASEB JOURNAL			English	Article						alcohol dehydrogenase; vitamin A; embryogenesis; cranial mesenchyme; retinol	RAR DOUBLE MUTANTS; RECEPTORS RARS; DEHYDROGENASE; CYTOCHROME-P-450; OXIDATION; ABNORMALITIES; EMBRYOGENESIS; METABOLISM; EXPRESSION; INDUCTION	Retinoic acid (RA) is known to act as a signaling molecule during embryonic: development, but little is known about the regulation of RA synthesis from retinol, The rate-limiting step in RA synthesis is the oxidation of retinol, a reaction that can be catalyzed by alcohol dehydrogenase (ADH), Ethanol is also a substrate for ADH, and high levels of ethanol inhibit ADH-catalyzed retinol oxidation, This has prompted us to hypothesize that ethanol-induced defects observed in fetal alcohol syndrome involve ethanol inhibition of ADH-catalyzed RA synthesis, Here, we have examined the effect of ethanol on RA levels in cultured mouse embryos by using a bioassay, Treatment with 100 mM ethanol, but not 10 mM, led to a significant decrease in RA detection in 7.5-day-old embryos, Using whole-mount in situ hybridization, we detected mRNA for class IV ADH, but not ethanol-active cytochrome P450 2E1, in 7.5- and 8.5-day-old embryos, indicating that an ADH-linked pathway exists at these stages for metabolizing retinol and ethanol. Thus, the observed ethanol-induced reduction in RA may be caused by ethanol. inhibition of retinol oxidation catalyzed by class IV ADH, in our postulated mechanism for fetal alcohol syndrome, this enzyme may well play a crucial role.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Duester, Gregg/0000-0003-4335-3650	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007261, R01AA009731] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09731, AA07261] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Blaner William S., 1994, P229; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; Cartwright MM, 1995, ALCOHOL CLIN EXP RES, V19, P1454, DOI 10.1111/j.1530-0277.1995.tb01007.x; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; DAVIS JF, 1993, J BIOL CHEM, V268, P16584; DERSCH H, 1993, DEV BIOL, V160, P424, DOI 10.1006/dbio.1993.1318; Duester G., 1994, Vitamin A in health and disease., P343; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Hofmann Clementine, 1994, P387; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; JONES KL, 1973, LANCET, V2, P999; JONES SM, 1992, BIOCHEM PHARMACOL, V43, P1876, DOI 10.1016/0006-2952(92)90726-Y; JULIA P, 1986, EXP EYE RES, V42, P305, DOI 10.1016/0014-4835(86)90023-0; Kastner P., 1994, Vitamin A in health and disease., P189; Kaufman M.H., 1992, ATLAS MOUSE DEV; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; KIM CI, 1992, ARCH BIOCHEM BIOPHYS, V294, P388, DOI 10.1016/0003-9861(92)90700-7; LIEBER CS, 1994, J TOXICOL-CLIN TOXIC, V32, P631, DOI 10.3109/15563659409017974; LIM K, 1989, BIOTECHNIQUES, V7, P576; LOHNES D, 1994, DEVELOPMENT, V120, P2723; Maden M., 1994, Vitamin A in health and disease., P289; Mangelsdorf David J., 1994, P319; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MEZEY E, 1971, EXP MOL PATHOL, V15, P148, DOI 10.1016/0014-4800(71)90095-5; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; OHNISHI K, 1977, J BIOL CHEM, V252, P7124; OSUMIYAMASHITA N, 1994, DEV BIOL, V164, P409, DOI 10.1006/dbio.1994.1211; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SONG BJ, 1986, J BIOL CHEM, V261, P6689; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; VANTHIEL DH, 1974, SCIENCE, V186, P941, DOI 10.1126/science.186.4167.941; WAGNER M, 1992, DEVELOPMENT, V116, P55; WEBSTER WS, 1983, TERATOLOGY, V27, P231, DOI 10.1002/tera.1420270211; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309; ZAGOMBIEKNIGHT M, 1995, J BIOL CHEM, V270, P10868	47	141	143	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1050	1057		10.1096/fasebj.10.9.8801166	http://dx.doi.org/10.1096/fasebj.10.9.8801166			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801166				2022-12-25	WOS:A1996UY93200015
J	Hsu, HHT; Anderson, HC				Hsu, HHT; Anderson, HC			Evidence of the presence of a specific ATPase responsible for ATP-initiated calcification by matrix vesicles isolated from cartilage and bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; CALCIUM DEPOSITION; CA DEPOSITION; GROWTH-PLATE; IN-VITRO; INHIBITION; INVITRO; PROTEINS; MINERALIZATION; MEMBRANE	Accumulating evidence indicates that calcification by isolated mammalian matrix vesicles (MVs) can be initiated by ATP, Since ATP can be hydrolyzed by either a specific ATPase or by nonspecific alkaline phosphatase (ALP), it remains to be established whether ATPase or ALP mediates ATP-initiated Ca and P-i deposition. To support the hypothesis that specific ATPase is responsible for ATP-initiated calcification by MVs isolated from mammalian cartilage and bone, the effects of ATP analogs, ALP substrates, and specific inhibitors on ATP hydrolysis and ATP-initiated calcification were compared between intact MVs and monoclonal antibody affinity-purified MV ALP, ATP analogs such as ADP and AMP exerted marked inhibitory effects on both [gamma-P-32]ATP hydrolysis and ATP-initiated calcification by intact MVs, whereas phosphomonoesters such as beta-glycerophosphate or phosphoethanolamine had no effect, In contrast to intact MVs, purified MV ALP failed to calcify, and its [gamma-P-32]ATP hydrolytic activity was readily inhibited by phosphomonoesters. Additionally, [gamma-P-32]ATP hydrolysis by purified ALP in contrast to that by intact vesicles was completely inhibited by l-tetramisole, a specific inhibitor of ALP, suggesting a loss of specific ATPase during purification. Vanadate inhibition of ATP hydrolysis by purified ALP can be decreased by increasing ATP concentrations, On the contrary, ATP concentrations did not affect vanadate inhibition of ATP hydrolysis by intact MVs if ALP activity was blocked by l-tetramisole, These observations, therefore, suggest that: 1) a portion of [gamma-P-32]ATP hydrolysis by MVs is attributable to a specific ATPase, whereas the remaining activity is due to ALP; and 2) a specific ATPase, but not ALP, is responsible for ATP-dependent Ca- and P-i-depositing activity of MVs isolated from bone or cartilage.			Hsu, HHT (corresponding author), UNIV KANSAS,MED CTR,DEPT LAB MED & PATHOL,3901 RAINBOW BLVD,KANSAS CITY,KS 66160, USA.				NIDCR NIH HHS [DE05262] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005262] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKISAKA T, 1985, J HISTOCHEM CYTOCHEM, V33, P925, DOI 10.1177/33.9.3160764; ALI SY, 1973, BIOCHEM J, V134, P647, DOI 10.1042/bj1340647; ANDERSON HC, 1975, AM J PATHOL, V79, P237; Anderson HC, 1993, HDB EXPT PHARM, P267, DOI DOI 10.1007/978-3-642-77991-6_8; BOSKEY AL, 1994, MICROSC RES TECHNIQ, V28, P492, DOI 10.1002/jemt.1070280605; Bowness J M, 1968, Clin Orthop Relat Res, V59, P233; CARTIER P, 1955, B SOC CHIM BIOL, V37, P1159; CARTIER P, 1955, B SOC CHIM BIOL, V37, P485; CECIL RNA, 1978, METAB BONE DIS RELAT, V1, P89, DOI 10.1016/0221-8747(78)90043-7; CHAUDRY IH, 1982, YALE J BIOL MED, V55, P1; CUERVO LA, 1973, CALC TISS RES, V13, P1, DOI 10.1007/BF02015390; FALLON MD, 1980, LAB INVEST, V43, P489; FARLEY JR, 1982, MINER ELECTROL METAB, V7, P316; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; HATORI M, 1995, J CELL PHYSIOL, V165, P468, DOI 10.1002/jcp.1041650304; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HONG KC, 1978, CALC TISS RES, V25, P241, DOI 10.1007/BF02010776; HOWELL DS, 1968, J CLIN INVEST, V47, P1121, DOI 10.1172/JCI105801; HSU HHT, 1992, BIOCHIM BIOPHYS ACTA, V1116, P227, DOI 10.1016/0304-4165(92)90015-M; HSU HHT, 1994, INT J BIOCHEM, V26, P1351, DOI 10.1016/0020-711X(94)90177-5; HSU HHT, 1983, J BIOL CHEM, V258, P3463; HSU HHT, 1993, INT J BIOCHEM, V25, P1737, DOI 10.1016/0020-711X(88)90301-1; HSU HHT, 1992, BONE MINER, V17, P279, DOI 10.1016/0169-6009(92)90751-X; HSU HHT, 1978, P NATL ACAD SCI USA, V75, P3805, DOI 10.1073/pnas.75.8.3805; HSU HHT, 1977, BIOCHIM BIOPHYS ACTA, V500, P162, DOI 10.1016/0304-4165(77)90056-3; HSU HHT, 1988, INT J BIOCHEM, V20, P1285, DOI 10.1016/0020-711X(88)90233-9; KRAUSFRIEDMANN N, 1982, EUR J BIOCHEM, V129, P7, DOI 10.1111/j.1432-1033.1982.tb07014.x; KRISHNA G, 1968, J PHARMACOL EXP THER, V163, P379; LIN SH, 1985, J BIOL CHEM, V260, P7850; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBEN RA, 1976, ENDOCRINOLOGY, V99, P526, DOI 10.1210/endo-99-2-526; MARTIN JB, 1949, ANAL CHEM, V21, P965, DOI 10.1021/ac60032a024; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POLLESELLO P, 1991, BIOCHEM BIOPH RES CO, V180, P216, DOI 10.1016/S0006-291X(05)81279-3; Rapoport S, 1938, J BIOL CHEM, V126, P749; Robison R, 1923, BIOCHEM J, V17, P286, DOI 10.1042/bj0170286; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; SKILLEN AW, 1980, CALCIFIED TISSUE INT, V30, P67, DOI 10.1007/BF02408608; VANBELLE H, 1972, BIOCHIM BIOPHYS ACTA, V289, P158, DOI 10.1016/0005-2744(72)90118-0	39	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26383	26388		10.1074/jbc.271.42.26383	http://dx.doi.org/10.1074/jbc.271.42.26383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824294	hybrid			2022-12-25	WOS:A1996VN18000100
J	Hu, YH; Bloomquist, BT; Cornfield, LJ; DeCarr, LB; FloresRiveros, JR; Friedman, L; Jiang, PL; LewisHiggins, L; Sadlowski, Y; Schaefer, J; Velazquez, N; McCaleb, ML				Hu, YH; Bloomquist, BT; Cornfield, LJ; DeCarr, LB; FloresRiveros, JR; Friedman, L; Jiang, PL; LewisHiggins, L; Sadlowski, Y; Schaefer, J; Velazquez, N; McCaleb, ML			Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; CHOLECYSTOKININ RECEPTOR; PARAVENTRICULAR NUCLEUS; MOLECULAR-CLONING; FOOD-INTAKE; NPY; STIMULATION; Y1-RECEPTOR	Neuropeptide Y (NPY) plays important roles in the central control of appetite and energy balance, but the receptor subtype responsible for this function has not been cloned. Here we report the cloning by expression of a novel NPY receptor subtype from a rat hypothalamus cDNA library. The novel receptor, referred to as the NPY Y5 receptor, has a transcript of approximately 2.6 kilobases with an open reading frame of 1335 base pairs that encodes a 445-amino acid protein. The amino acid sequence deduced from the rat Y5 cDNA clone shows only 30-33% identity to other NPY receptors, including Y1, Y2, and Y4/PP1, Using the rat Y5 receptor cDNA probe, the human homologue was obtained by low stringency hybridization. The human Y5 amino acid sequence has 88% identity to the rat Y5 receptor. Importantly, pharmacological analysis shows that the rat and human Y5 receptors have high affinity for the peptides that elicit feeding (e.g, NPY, PYY, (2-36)NPY, and (LP)NPY) and low affinity for nonstimulating peptides (e.g. (13-36)NPY and rat PP), suggesting that it is the NPY feeding receptor subtype.			Hu, YH (corresponding author), BAYERS CORP,INST METAB DISORDERS,W HAVEN,CT 06516, USA.							AICHER SA, 1991, NEUROSCI LETT, V130, P32, DOI 10.1016/0304-3940(91)90220-N; BALASUBRAMANIAM A, 1994, J MED CHEM, V37, P811, DOI 10.1021/jm00032a015; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; Bockaert J, 1991, Curr Opin Neurobiol, V1, P32, DOI 10.1016/0959-4388(91)90008-U; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Gregor P, 1996, FEBS LETT, V381, P58, DOI 10.1016/0014-5793(96)00067-1; Grundemar L., 1993, BIOL NEUROPEPTIDE RE, P197, DOI [10.1007/978-1-59259-465-8_5, DOI 10.1007/978-1-59259-465-8_5]; JOLICOEUR FB, 1991, BRAIN RES BULL, V26, P309, DOI 10.1016/0361-9230(91)90243-D; KALRA SP, 1991, PHYSIOL BEHAV, V50, P5, DOI 10.1016/0031-9384(91)90490-F; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEIBOWITZ SF, 1991, PEPTIDES, V12, P1251, DOI 10.1016/0196-9781(91)90203-2; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; Lundell I, 1996, P NATL ACAD SCI USA, V93, P5111, DOI 10.1073/pnas.93.10.5111; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; MCCARTHY HD, 1991, LIFE SCI, V49, P1491, DOI 10.1016/0024-3205(91)90049-H; MCLAUGHLIN CL, 1991, PHYSIOL BEHAV, V49, P521, DOI 10.1016/0031-9384(91)90274-R; NAKAJIMA M, 1994, J PHARMACOL EXP THER, V268, P1010; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; RUDOLF K, 1994, EUR J PHARMACOL, V271, pR11, DOI 10.1016/0014-2999(94)90822-2; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1985, PEPTIDES, V6, P1205, DOI 10.1016/0196-9781(85)90452-8; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STANLEY BG, 1984, LIFE SCI, V35, P2635, DOI 10.1016/0024-3205(84)90032-8; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; Yan H, 1996, P NATL ACAD SCI USA, V93, P4661, DOI 10.1073/pnas.93.10.4661	31	211	231	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26315	26319		10.1074/jbc.271.42.26315	http://dx.doi.org/10.1074/jbc.271.42.26315			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824284	hybrid			2022-12-25	WOS:A1996VN18000090
J	Kobayashi, J; ApplebaumBowden, D; Dugi, KA; Brown, DR; Kashyap, VS; Parrott, C; Duarte, C; Maeda, N; SantamarinaFojo, S				Kobayashi, J; ApplebaumBowden, D; Dugi, KA; Brown, DR; Kashyap, VS; Parrott, C; Duarte, C; Maeda, N; SantamarinaFojo, S			Analysis of protein structure-function in vivo - Adenovirus-mediated transfer of lipase lid mutants in hepatic lipase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIPOPROTEIN-LIPASE; HIGH-DENSITY-LIPOPROTEIN; SITE-DIRECTED MUTAGENESIS; PANCREATIC LIPASE; HUMAN-PLASMA; INTERFACIAL ACTIVATION; TRIGLYCERIDE LIPASE; CATALYTIC SITE; GENE; SEQUENCE	Hepatic lipase (HL) and lipoprotein lipase (LPL) are key enzymes involved in the hydrolysis of triglycerides and phospholipids present in circulating plasma lipoproteins. Despite their similarities, the role that each of these two lipases play in the metabolism of triglyceride-rich lipoproteins and high density lipoproteins is distinct. In order to identify structural domains that may confer the different substrate specificities between HL and LPL, we have utilized a novel approach for performing structure-function analysis of a protein, in vivo, by using recombinant adenovirus vectors to express native and mutant enzymes in an animal model for a human genetic deficiency, HL-deficient mice (n = 19) characterized by increased plasma cholesterol and phospholipid concentrations were injected with adenovirus expressing luciferase (rLucif-AdV), native hepatic (rHL-AdV), and lipoprotein lipase (rLPL-AdV) or lipase mutants in which the lid covering the catalytic site of either enzyme was exchanged (rHL+LPL lid-AdV and rLPL+HL lid-AdV). Mice injected with rLucif-AdV had no changes in post-heparin HL and LPL activities (217 +/- 29 and 7 +/- 2 nmol/min/ml, respectively) as well as plasma lipids. Despite expression of similar levels of post-heparin plasma lipase activity on day 5 post-adenovirus infusion (9806 +/- 915 and 9677 +/- 2033 nmol/min/ml, respectively) mice injected with rHL-AdV or rHL+LPL lid-AdV demonstrated marked differences in the reduction of plasma phospholipids (70% and 32%, respectively, p < 0.005), Similarly, despite post-heparin plasma lipolytic activities of 4495 +/- 534 and 4844 +/- 1336 nmol/min/ml, injection of rLPL-AdV or rLPL+HL lid-AdV resulted in phospholipid reductions of 31% and 81% (p < 0.005). Exchange of the lipase lid did not significantly alter plasma triglyceride concentrations. Thus, preferential in vivo hydrolysis of phospholipids was demonstrated in animals expressing lipases containing the HL lid but not the LPL lid. These studies identify the lipase lid as a major structural motif responsible for conferring the different in vivo phospholipase activities between HL and LPL, a function which may modulate the distinct physiological roles of these two similar lipolytic enzymes in lipoprotein metabolism. The use of recombinant adenovirus to express mutant proteins in animal models for human genetic deficiencies represents a powerful, new approach for performing structure-function analysis of proteins in vivo.	NHLBI,MOL DIS BRANCH,NIH,BETHESDA,MD 20892; UNIV N CAROLINA,SCH MED,CHAPEL HILL,NC 27599	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Kashyap, Vikram/0000-0003-1780-979X				ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; BREWER HB, 1995, ENDOCRINOLOGY, P2731; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BURSTEIN M, 1970, J LIPID RES, V11, P583; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DEMANT T, 1988, J LIPID RES, V29, P1603; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DICHEK HL, 1993, J LIPID RES, V34, P1393; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; DUGI KA, 1992, J BIOL CHEM, V267, P25086; EHNHOLM C, 1975, J BIOL CHEM, V250, P6756; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; Glomset J.A., 1995, METABOLIC MOL BASES, Vseventh, P1933; GLOMSET JA, 1968, J LIPID RES, V9, P155; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HIDE WA, 1992, J LIPID RES, V33, P167; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOPFLER WP, 1994, CIRCULATION, V90, P1319, DOI 10.1161/01.CIR.90.3.1319; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; NICOLL A, 1980, EUR J CLIN INVEST, V10, P487, DOI 10.1111/j.1365-2362.1980.tb02090.x; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; Santamarina-Fojo S., 1992, CURR OPIN LIPIDOL, V3, P186; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; TALL AR, 1993, J LIPID RES, V34, P1255; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTOL A, 1980, BIOCHEM BIOPH RES CO, V94, P101, DOI 10.1016/S0006-291X(80)80193-8; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	44	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26296	26301		10.1074/jbc.271.42.26296	http://dx.doi.org/10.1074/jbc.271.42.26296			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824281				2022-12-25	WOS:A1996VN18000087
J	Offermanns, S; Hu, YH; Simon, MI				Offermanns, S; Hu, YH; Simon, MI			G alpha(12) and G alpha(13) are phosphorylated during platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HETEROTRIMERIC G-PROTEINS; SIGNAL TRANSDUCTION; ALPHA-SUBUNITS; ADENYLATE-CYCLASE; CELLS; PURIFICATION; SPECIFICITY; INHIBITION; ISOENZYMES	The ubiquitously expressed G-proteins G(12) and G(13) whose function is currently not clear have been shown to be activated in platelet membranes through receptors that stimulate platelet aggregation. We used intact human platelets to determine whether alpha subunits of both G-proteins can be phosphorylated under physiological conditions, Activation of human platelets by thrombin and the thromboxane A(2) receptor agonist U46619 lead to phosphorylation of G alpha(12) and G alpha(13). Phosphorylation occurred rapidly after addition of thrombin and was not mediated by glycoprotein IIb/IIIa (integrin alpha(IIb)beta(3)) activation, Phosphorylation of G alpha(12) and G alpha(13) could be mimicked by phorbol 12-myristate 13-acetate, and thrombin-induced phosphorylation was inhibited by the protein kinase C inhibitor calphostin C indicating an involvement of protein kinase C in G alpha(12/13) phosphorylation in duced by thrombin in human platelets, The phosphorylation of both G protein alpha subunits was reconstituted in COS-7 cells cotransfected with G alpha(12) or G alpha(12) and different protein kinase C isoforms, Among the protein knase C isoforms tested, protein kinase C beta, delta, and epsilon were most effective in promoting phosphorylation of G alpha(12) and G alpha(13) in a phorbol 12-myristate 13-acetate-dependent maimer. These data demonstrate that G alpha(12) and G alpha(13) are phosphorylated under in vivo conditions and that this phosphorylation involves protein kinase C.	CALTECH,DEPT BIOL 14775,PASADENA,CA 91125	California Institute of Technology			Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HOUSLAY MD, 1991, CELL SIGNAL, V3, P1, DOI 10.1016/0898-6568(91)90002-C; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MORII N, 1992, J BIOL CHEM, V267, P20921; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SCHUBERT R, 1990, COMPUT METH PROG BIO, V33, P93, DOI 10.1016/0169-2607(90)90065-H; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SINGER WD, 1994, J BIOL CHEM, V269, P19796; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WU DQ, 1992, J BIOL CHEM, V267, P25798	33	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26044	26048		10.1074/jbc.271.42.26044	http://dx.doi.org/10.1074/jbc.271.42.26044			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824244	hybrid			2022-12-25	WOS:A1996VN18000050
J	Kotanides, H; Reich, NC				Kotanides, H; Reich, NC			Interleukin-4-induced STAT6 recognizes and activates a target site in the promoter of the interleukin-4 receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-3 JANUS KINASE; GAMMA-CHAIN; TRANSCRIPTION FACTOR; IL-2 RECEPTOR; DNA-BINDING; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FUNCTIONAL-ANALYSIS; INTERFERON-GAMMA; CELLS	This study addresses the function of STAT6 in interleukin-4-stimulated gene expression. A specific STAT6 DNA-binding target site has been identified in the promoter of the interleukin-4 receptor gene, and STAT6 is shown to be involved in mediating activation of gene expression via this site. STAT6 can mediate transcription of a heterologous reporter gene construct containing the interleukin-4 receptor STAT6 binding site. In addition, evidence is provided that demonstrates a distinct effect of STAT6 DNA binding specificity on transcriptional regulation since transcription was not stimulated from a competent but different DNA binding site. To confirm the role of STAT6 in gene activation, STAT6 mutant proteins were generated and analyzed for their ability to function in interleukin-4-induced transcription. Although the interleukin-2 gamma chain receptor subunit has been demonstrated to be a component of the interleukin-4 receptor, it is not required for specific gene activation.	SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, GRAD PROGRAM MOL & CELLULAR BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA050773, R29CA050773] Funding Source: NIH RePORTER; NCI NIH HHS [CA50773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT B, 1994, INT IMMUNOL, V6, P1143, DOI 10.1093/intimm/6.8.1143; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; DEWIT H, 1994, BLOOD, V84, P608; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOKTER WHA, 1992, BLOOD, V80, P2721; GILMOUR KC, 1995, GENE EXPRESSION, V5, P1; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GUTCH MJ, 1993, THESIS STATE U NEW Y; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; LAI KS, 1995, J BIOL CHEM, V270, P25028, DOI 10.1074/jbc.270.42.25028; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MOND JJ, 1986, J IMMUNOL, V137, P3534; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; OHARA J, 1988, P NATL ACAD SCI USA, V85, P8221, DOI 10.1073/pnas.85.21.8221; PAUL WE, 1991, BLOOD, V77, P1859; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; PURKERSON J, 1992, FASEB J, V6, P3245, DOI 10.1096/fasebj.6.14.1385241; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SUTER U, 1989, J IMMUNOL, V143, P3087; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VELDE AAT, 1990, J IMMUNOL, V144, P3046; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	59	92	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25555	25561		10.1074/jbc.271.41.25555	http://dx.doi.org/10.1074/jbc.271.41.25555			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810328	hybrid			2022-12-25	WOS:A1996VL69300072
J	Patel, RC; Stanton, P; Sen, GC				Patel, RC; Stanton, P; Sen, GC			Specific mutations near the amino terminus of double-stranded RNA-dependent protein kinase (PKR) differentially affect its double-stranded RNA binding and dimerization properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-2; NF-KAPPA-B; INTERFERON ACTION; MESSENGER-RNAS; ALPHA-SUBUNIT; REV PROTEIN; P68 KINASE; FACTOR-II; IN-VIVO; DOMAIN	The amino-terminal region of the double-stranded (ds) RNA-dependent protein kinase, PKR, has been shown to mediate both dsRNA binding and protein dimerization, To critically examine if PKR dimerization is dependent on dsRNA binding, we generated a series of mutants that are incapable of binding dsRNA. Some, but not all, of these mutants retained the ability to dimerize, as shown by a two-hybrid transcriptional activation assay in vivo and a chemical cross-linking assay in vitro. These mutants were used further to demonstrate that the translational inhibitory activity of PKR in vivo requires dsRNA binding; PKR mutants that dimerized but did not bind dsRNA could not inhibit the translation of a transfected reporter gene.	CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68782, CA-62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BISCHOFF JR, 1985, J BIOL CHEM, V260, P8237; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHOI SY, 1992, J BIOL CHEM, V267, P286; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; JUDAWARE R, 1991, MOL CELL BIOL, V11, P3259; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SONENBERG N, 1990, New Biologist, V2, P402; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	49	78	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25657	25663		10.1074/jbc.271.41.25657	http://dx.doi.org/10.1074/jbc.271.41.25657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810342	hybrid			2022-12-25	WOS:A1996VL69300086
J	Slater, JE; Vedvick, T; ArthurSmith, A; Trybul, DE; Kekwick, RGO				Slater, JE; Vedvick, T; ArthurSmith, A; Trybul, DE; Kekwick, RGO			Identification, cloning, and sequence of a major allergen (Hev b 5) from natural rubber latex (Hevea brasiliensis)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEALTH-CARE WORKERS; ELONGATION-FACTOR; CROSS-REACTIVITY; SPINA-BIFIDA; PROTEINS; ANTIGENS; HYPERSENSITIVITY; PURIFICATION; IGE; PROPHYLAXIS	Proteins in commercial latex products, derived from the rubber tree Hevea brasiliensis, cause anaphylaxis in susceptible individuals, especially health care workers and children with spina bifida. To identify latex allergens, we utilized IgE from the serum of a latex-allergic health care worker to screen a cDNA Library from Hevea latex. The identified cDNA clone, cDNA Hev b 5, encodes an open reading frame of 163 peptide residues. Hybridization analysis of cDNA Hev b 5 with RNA extracted from Hevea tissue indicates that the full-length transcript is about 1000 bases. The nucleotide and deduced protein sequences have significant homology to sequences from kiwi and potato, which are known to cause allergic reactions in some latex-allergic patients. Fifty-six percent of spina bifida patients and 924 of health care workers with latex allergy have IgE specific to the protein encoded by cDNA Rev b 5. A monoclonal antibody raised from a mouse immunized with Hev b 5 binds to a protein in Hevea latex with an M(r) identical to that of the expressed and cleaved recombinant protein. Taken together, these results establish that the antigen Hev b 5 contains a major epitope for IgE-mediated reactions to H. brasiliensis latex products.	CORIXA CORP,SEATTLE,WA 98104; UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	Corixa; University of Birmingham	Slater, JE (corresponding author), CHILDRENS NATL MED CTR,CHILDRENS RES INST,CTR MOL MECH DIS RES,111 MICHIGAN AVE,NW,WASHINGTON,DC 20010, USA.				NIAID NIH HHS [AI 29428] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; Akasawa A, 1996, J ALLERGY CLIN IMMUN, V97, P1116, DOI 10.1016/S0091-6749(96)70266-X; ALENIUS H, 1994, J ALLERGY CLIN IMMUN, V93, P859, DOI 10.1016/0091-6749(94)90378-6; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1995, INT ARCH ALLERGY IMM, V106, P258, DOI 10.1159/000236851; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ATTANYAKA DPSTG, 1991, PLANT MOL BIOL, V16, P1079, DOI 10.1007/BF00016080; AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BEUERS U, 1990, LANCET, V335, P1095, DOI 10.1016/0140-6736(90)92664-4; BLANCO C, 1994, ANN ALLERGY, V73, P309; BONNEKOH B, 1992, JAMA-J AM MED ASSOC, V267, P2603, DOI 10.1001/jama.267.19.2603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; Dillard SF, 1992, INT LATEX C SENSITIV, P23; DOMPMARTIN A, 1994, CONTACT DERMATITIS, V30, P250, DOI 10.1111/j.1600-0536.1994.tb00662.x; GELB L, 1991, FDA MED ALERT MDA, V91, P1; HELFMAN DM, 1983, P NATL ACAD SCI-BIOL, V80, P31, DOI 10.1073/pnas.80.1.31; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; Kekwick RGO, 1989, PHYSL RUBBER TREE LA, P145; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; KWITTKEN PL, 1992, ALLERGY PROC, V13, P123, DOI 10.2500/108854192778878782; LEDGER SE, 1994, PLANT MOL BIOL, V25, P877, DOI 10.1007/BF00028882; LEE H, 1991, J BIOL CHEM, V266, P15944; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; LU LJ, 1995, ALLERGY, V50, P545, DOI 10.1111/j.1398-9995.1995.tb01197.x; MAKINENKILJUNEN S, 1992, J ALLERGY CLIN IMMUN, V90, P230, DOI 10.1016/0091-6749(92)90076-E; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; Rasmussen H B, 1993, APMIS Suppl, V39, P1; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Schultz D. J., 1994, Plant Molecular Biology Reporter, V12, P310, DOI 10.1007/BF02669273; SETLOCK MA, 1993, ANESTH ANALG, V76, P650; Shi Q., 1990, GEL ELECTROPHORESIS; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V93, P644, DOI 10.1016/S0091-6749(94)70076-1; SLATER JE, 1995, J ALLERGY CLIN IMMUN, V95, P157; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; STCYR DR, 1992, ENCY CHEM TECHNOLOGY, P468; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; YEANG HY, 1996, IN PRESS J ALLERGY C	52	101	103	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25394	25399		10.1074/jbc.271.41.25394	http://dx.doi.org/10.1074/jbc.271.41.25394			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810306	hybrid			2022-12-25	WOS:A1996VL69300050
J	Hatmi, M; Gavaret, JM; Elalamy, I; Vargaftig, BB; Jacquemin, C				Hatmi, M; Gavaret, JM; Elalamy, I; Vargaftig, BB; Jacquemin, C			Evidence for cAMP-dependent platelet ectoprotein kinase activity that phosphorylates platelet glycoprotein IV (CD36)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MYOSIN PHOSPHORYLATION; ADENYLATE-CYCLASE; INTACT PLATELETS; SURFACE; ACTIVATION; THROMBIN; DEPHOSPHORYLATION; IDENTIFICATION; THROMBOSPONDIN	The dephosphorylating enzyme alkaline phosphatase, by removing phosphate groups from the external platelet membrane proteins, modulates platelet activation (Hatmi, M., Haye, B., Gavaret, J. M., Vargaftig, B. B., and Jacquemin, C. (1991) Br. J. Pharmacol. 104, 554-558). This observation, together with findings reported by others (Ehrlich, Y. H., Davis, T. B., Beck, E., Kornecki, E., and Lenox, R. H. (1986) Nature 320, 67-70; Dusenbery, K. E., Mendiola, J. R., and Skubitz, K. M. (1988) Biochem. Biophys. Res. Commun. 153, 7-13), indicate the existence of ectoprotein kinase activity on the blood platelet surface. In this study, we demonstrate that washed human platelets phosphorylate the synthetic heptapeptide kemptide in a cAMP-dependent mode. The intensity of the phosphorylation was concentration-dependent for kemptide. In addition, incubation of platelets with [gamma-P-32]ATP resulted in a rapid incorporation of [P-32] phosphate into proteins at the outer membrane surface that was sensitive to alkaline phosphatase treatment. When cAMP was added to the medium, major phosphorylation of an 88-kDa ectoprotein occurred. Its isoelectric point determined by isoelectric focusing SDS-polyacrylamide gel electrophoresis was around pH 6.2. Phosphorylations of this 88-kDa polypeptide and of the exogenous kemptide substrate were both prevented by the specific protein kinase A inhibitor peptide. When platelets were preincubated with [P-32]inorganic phosphate to label intracellular proteins, the protein phosphorylation pattern was different from that obtained with [gamma-P-32]ATP, indicating that the latter occurred at the outer surface of the cells. Prostacyclin, which induces the increase of intracellular cAMP levels and, consequently, its liberation into the extracellular medium, increased phosphorylation of both kemptide and platelet 88-kDa polypeptide. The major protein of 88-kDa, which was phosphorylated in the presence of cAMP and external [gamma-P-32]ATP, was identified by immunoprecipitation to GPIV (CD36), one of thrombospondin and collagen binding sites on platelets. The phosphorylation of CD36 also occurred in platelet-rich plasma, suggesting a physiological role for this ectoenzyme. In the present study, we clearly demonstrate the presence of an ectoprotein kinase A activity at the surface of intact human platelets, and we revealed its principal endogenous substrate as being CD36.	HOP KREMLIN BICETRE, INSERM, U96, F-94276 LE KREMLIN BICETRE, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Hatmi, M (corresponding author), INST PASTEUR, UNITE PHARMACOL CELLULAIRE, INSERM, U285, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Vargaftig, Bernardo Boris B.B.J./C-3323-2013					ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BOOYSE FM, 1976, BIOCHIM BIOPHYS ACTA, V422, P60, DOI 10.1016/0005-2744(76)90008-5; CHENG HC, 1986, J BIOL CHEM, V261, P989; DANIEL JL, 1981, J BIOL CHEM, V256, P7510; DUSENBERY KE, 1988, BIOCHEM BIOPH RES CO, V153, P7, DOI 10.1016/S0006-291X(88)81182-3; EDELMAN P, 1986, BLOOD, V67, P56; EHRLICH YH, 1986, NATURE, V320, P67, DOI 10.1038/320067a0; FEINSTEIN MB, 1983, J BIOL CHEM, V258, P1260; FOX JEB, 1987, J BIOL CHEM, V262, P12627; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GORMAN RR, 1977, PROSTAGLANDINS, V13, P377, DOI 10.1016/0090-6980(77)90018-1; HASLAM RJ, 1979, BIOCHEM J, V178, P397, DOI 10.1042/bj1780397; HASLAM RJ, 1977, BIOCHEM BIOPH RES CO, V77, P714, DOI 10.1016/S0006-291X(77)80037-5; HATMI M, 1991, BRIT J PHARMACOL, V104, P554, DOI 10.1111/j.1476-5381.1991.tb12467.x; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; KORCGRODZICKI B, 1988, BIOCHEM BIOPH RES CO, V157, P1131; KORCGRODZICKI B, 1988, P NATL ACAD SCI USA, V85, P7541, DOI 10.1073/pnas.85.20.7541; KUBLER D, 1992, EUR J BIOCHEM, V206, P179, DOI 10.1111/j.1432-1033.1992.tb16915.x; KUBLER D, 1989, J BIOL CHEM, V264, P14549; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYONS RM, 1975, J CLIN INVEST, V56, P924, DOI 10.1172/JCI108172; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MCGREGOR JL, 1983, EUR J BIOCHEM, V131, P427, DOI 10.1111/j.1432-1033.1983.tb07281.x; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NAIK UP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256, DOI 10.1016/0167-4889(91)90165-T; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PRADELLES P, 1989, ANAL CHEM, V61, P447, DOI 10.1021/ac00180a014; SCHAFER AI, 1986, J CLIN INVEST, V78, P73, DOI 10.1172/JCI112576; SOSLAU G, 1989, BLOOD, V74, P984; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VILGRAIN I, 1991, MOL ENDOCRINOL, V5, P1003, DOI 10.1210/mend-5-7-1003	35	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24776	24780		10.1074/jbc.271.40.24776	http://dx.doi.org/10.1074/jbc.271.40.24776			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798748	hybrid			2022-12-25	WOS:A1996VM67400070
J	Kim, SO; Plow, EF; Miles, LA				Kim, SO; Plow, EF; Miles, LA			Regulation of plasminogen receptor expression on monocytoid cells by beta(1)-integrin-dependent cellular adherence to extracellular matrix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; MAMMARY EPITHELIAL-CELLS; BINDING-SITES; AFFINITY-CHROMATOGRAPHY; UROKINASE RECEPTORS; GENE-EXPRESSION; HUMAN-PLASMA; ACTIVATION; SURFACE; IDENTIFICATION	Plasminogen binding sites function to arm cell surfaces with the proteolytic activity of plasmin, critical for degradation of extracellular matrices, We have assessed the effects of adhesion of the representative monocytoid cell lines, THP-1 and U937, to purified extracellular matrix proteins on their expression of plasminogen receptors, After adhesion to immobilized fibronectin, adherent and nonadherent subpopulations of cells were separated, Plasminogen binding to the nonadherent population of cells increased 3-fold, whereas binding to the adherent population decreased by 60%. These changes were due to differences in the plasminogen binding capacities of the cells, while the affinities of the cells for plasminogen were unchanged, The up-regulation of receptor expression in the nonadherent cell population was: 1) induced rapidly and reversibly, 2) independent of new protein synthesis, 3) required an interaction between adherent and nonadherent cell populations, and 4) associated with an enhanced ability of the cells to promote plasminogen activation and to degrade fibronectin, Other immobilized adhesive proteins, laminin and vitronectin, also supported up-regulation of plasminogen receptors in the nonadherent cells, Carboxypeptidase B treatment eliminated the increment in the plasminogen binding capacity of the nonadherent cells, suggesting that the increase in binding was due to exposure of new carboxyl-terminal lysyl residues on the cell surfaces, Furthermore, both the adherence of the cells and up regulation of plasminogen binding sites was abolished by beta(1)-integrin monoclonal antibodies, These results suggest that proteins found in extracellular matrices have the capacity to modulate the expression of plasminogen binding sites, thus regulating local proteolysis and cell migration.	Scripps Res Inst, RES INST, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA; CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL, DEPT MOL CARDIOL, CLEVELAND, OH 44195 USA	Scripps Research Institute; Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045934, R29HL038272, R01HL038272, R01HL017964] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17964, HL38272, HL45934] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURGE SM, 1992, BRIT J DERMATOL, V126, P35, DOI 10.1111/j.1365-2133.1992.tb08400.x; CAMACHO M, 1989, FEBS LETT, V245, P21, DOI 10.1016/0014-5793(89)80183-8; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FELEZ J, 1993, THROMB HAEMOSTASIS, V69, P1232; FELEZ J, 1993, BLOOD, V82, P2433, DOI 10.1182/blood.V82.8.2433.bloodjournal8282433; FELEZ J, 1990, J CELL BIOL, V111, P1673, DOI 10.1083/jcb.111.4.1673; GANZ PR, 1991, BIOCHEM CELL BIOL, V69, P442, DOI 10.1139/o91-067; GONIAS SL, 1989, BLOOD, V74, P729; GONZALEZGRONOW M, 1991, ARCH BIOCHEM BIOPHYS, V286, P625, DOI 10.1016/0003-9861(91)90090-6; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HALL SW, 1991, J BIOL CHEM, V266, P12329; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; KUUSELA P, 1992, ACTA OPHTHALMOL, V70, P42; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CQ, 1995, J CELL BIOL, V129, P1115, DOI 10.1083/jcb.129.4.1115; Lottenberg Richard, 1994, Trends in Microbiology, V2, P20, DOI 10.1016/0966-842X(94)90340-9; LU H, 1989, THROMB HAEMOSTASIS, V62, P91; LU H, 1988, BIOCHEM BIOPH RES CO, V155, P418, DOI 10.1016/S0006-291X(88)81102-1; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MILES LA, 1988, BLOOD, V72, P628; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; POLLANEN J, 1989, J BIOL CHEM, V264, P5628; QUIN CQ, 1993, FASEB J, V7, P737; REINARTZ J, 1993, EXP CELL RES, V208, P197, DOI 10.1006/excr.1993.1238; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Tremble P M, 1992, Matrix Suppl, V1, P212; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; WEI Y, 1994, J BIOL CHEM, V269, P32380; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	46	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23761	23767		10.1074/jbc.271.39.23761	http://dx.doi.org/10.1074/jbc.271.39.23761			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798602	hybrid			2022-12-25	WOS:A1996VJ44200031
J	Lupher, ML; Reedquist, KA; Miyake, S; Langdon, WY; Band, H				Lupher, ML; Reedquist, KA; Miyake, S; Langdon, WY; Band, H			A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively ZAP-70 in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; C-CBL; V-CBL; ANTIGEN RECEPTORS; JURKAT CELLS; SH3 DOMAINS; PROTOONCOGENE; PRODUCT; PHOSPHORYLATION; ONCOGENE	The protooncogene product Cbl has emerged as a novel signal transduction protein downstream of a number of cell surface receptors coupled to tyrosine kinases. Recently, we and others have reported the activation-dependent association of Cbl with the Syk and ZAP-70 tyrosine kinases through presently undefined mechanisms. Potential Src homology 2 and 3 domain binding sites within the C-terminal half of Cbl mediate in vivo interactions with several signaling proteins; however, the N-terminal transforming region (Cbl-N) lacks recognizable catalytic or protein interaction motifs. Here, we show that in vitro Cbl-N (amino acids 1-357) but not Cbl-C (amino acids 358-906) binds to ZAP-70 in a T cell-activation-dependent manner. A point mutation in Cbl-N, G306E, corresponding to a loss of-function mutation in the Caenorhabditis elegans Cbl homologue, SLI-1, severely compromised Cbl-N/ZAP-70 binding. Cbl-N/ZAP-70 binding was direct and phosphotyrosine-dependent, thus identifying a phosphotyrosine-binding domain within the transforming region of Cbl. In vivo, Cbl-N expressed in T cells selectively associated with the ZAP-70/zeta complex. These results identify a novel mechanism for the direct participation of the N-terminal region of Cbl in ZAP-70 signal transduction, and suggest a biochemical mechanism for the leukemogenicity of the oncogene v-cbl through potential interaction with proliferation-related phosphotyrosyl proteins.	HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,DEPT MED,DIV RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL,BOSTON,MA 02115; UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PATHOL,NEDLANDS,WA 6009,AUSTRALIA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Western Australia					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gao QS, 1996, CANCER RES, V56, P3129; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHOU MM, 1995, NATURE, V92, P7784	36	162	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24063	24068		10.1074/jbc.271.39.24063	http://dx.doi.org/10.1074/jbc.271.39.24063			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798643				2022-12-25	WOS:A1996VJ44200072
J	Newcomb, JR; CarboyNewcomb, C; Cresswell, P				Newcomb, JR; CarboyNewcomb, C; Cresswell, P			Trimeric interactions of the invariant chain and its association with major histocompatibility complex class II alpha beta dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA-DR MOLECULES; ANTIGEN-PROCESSING MUTANT; B-LYMPHOBLASTOID CELLS; PEPTIDE BINDING; ENDOPLASMIC-RETICULUM; ENDOCYTIC COMPARTMENT; SURFACE EXPRESSION; MHC MOLECULES; IN-VIVO; DISSOCIATION	The invariant chain (I chain) associates with major histocompatibility complex class II alpha beta heterodimers upon synthesis, preventing them from binding peptides and unfolded proteins in the endoplasmic reticulum and directing class II transport to post-Golgi endosomal compartments. To assess which regions of the I chain are involved in binding class II molecules, we have studied proteolytic fragments of the I chain generated both by natural proteolytic degradation of alpha beta dimer-invariant chain complexes (alpha beta . I) within human B cells and by in vitro digestion of purified alpha beta . I complexes with proteinase K. The 18-kDa luminal I chain fragment generated by proteinase K, called K3, remains associated with alpha beta dimers and retains the complex (alpha beta . K3) in a high molecular mass nonameric configuration. The N terminus of the K3 fragment was identified as glycine 110. This indicates that the K3 fragment lies outside of the class II-associated invariant chain peptide region (amino acids 81-104) of the I chain, shown to be important for initial alpha beta . I assembly. An N-terminal 12-kDa I chain fragment called p12, generated intracellularly, was also analyzed and was found to remain associated with alpha beta dimers in a high molecular mass form analogous to the nonameric alpha beta . I complex. These results demonstrate that at least two class II contact points exist along the length of the I chain and that different regions of the I chain can stabilize the alpha beta . I nonamer. Additional evidence suggests that the O-linked glycan(s) characteristic of the I chain is added to the short C-terminal region absent from the K3 fragment.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University								AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ARUNACHALAM B, 1993, INT IMMUNOL, V6, P439; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANGIA N, 1995, INT IMMUNOL, V7, P1585, DOI 10.1093/intimm/7.10.1585; BERTOLINO P, 1995, J IMMUNOL, V154, P2620; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Busch R, 1996, EMBO J, V15, P418, DOI 10.1002/j.1460-2075.1996.tb00372.x; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P2100, DOI 10.1002/eji.1830230909; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; JASANOFF A, 1995, P NATL ACAD SCI USA, V92, P9900, DOI 10.1073/pnas.92.21.9900; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMPSON LA, 1980, J IMMUNOL, V125, P293; MACHAMER CE, 1982, J IMMUNOL, V129, P2564; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MARKS MS, 1985, J IMMUNOL, V136, P2519; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; OSULLIVAN DM, 1987, J EXP MED, V166, P444, DOI 10.1084/jem.166.2.444; PARK SJ, 1995, P NATL ACAD SCI USA, V92, P11289, DOI 10.1073/pnas.92.24.11289; PETERSON M, 1992, NATURE, V357, P596, DOI 10.1038/357596a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; PLETSCHER M, 1983, EUR J IMMUNOL, V13, P581, DOI 10.1002/eji.1830130713; PORATH J, 1973, J CHROMATOGR, V86, P53, DOI 10.1016/S0021-9673(01)81233-4; REYES VE, 1991, J IMMUNOL, V146, P3877; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SCHREIBER KL, 1994, INT IMMUNOL, V6, P101, DOI 10.1093/intimm/6.1.101; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	54	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24249	24256		10.1074/jbc.271.39.24249	http://dx.doi.org/10.1074/jbc.271.39.24249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798670	hybrid			2022-12-25	WOS:A1996VJ44200099
J	RamalhoSantos, J; deLima, MCP; Nir, S				RamalhoSantos, J; deLima, MCP; Nir, S			Partial fusion activity of influenza virus toward liposomes and erythrocyte ghosts is distinct from viral inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-ACTION ANALYSIS; SENDAI VIRUS; MEMBRANE-FUSION; PHOSPHOLIPID-VESICLES; HEMOLYTIC-ACTIVITY; HIV-1 FUSION; SIALIC-ACID; LOW PH; KINETICS; EXTENT	Final extents of fusion of influenza virus (A/PR/8/34 strain) with neutral and partially acidic liposomes were monitored with (i) a fluorescence resonance energy-transfer assay in which the liposomes were labeled and (ii) by the dequenching of octadecylrhodamine, initially incorporated in the viral membrane. The latter assay was also employed in the fusion of influenza virus and Sendai virus with erythrocyte ghosts. In all cases, a phenomenon of partial fusion activity of the virus was observed, which is distinct from low pH inactivation. The unfused influenza or Sendai virions, which were separated by sucrose gradient centrifugation from liposomes or erythrocyte ghosts exhibited again partial fusion activity toward freshly added liposomes or ghosts, respectively. The conclusion is that the fraction of initially bound and unfused virions does not consist of defective particles, but rather of particles bound to the target membranes via inactive sites on the virus (or on cellular membranes), or else, partial fusion activity is a manifestation of a certain probability of production of fusion inactive sites by irreversible association of viral glycoproteins or peptides in the target membrane.	HEBREW UNIV JERUSALEM,FAC AGR,SEAGRAM CTR SOIL & WATER SCI,IL-76100 REHOVOT,ISRAEL; UNIV COIMBRA,CTR NEUROSCI,P-3000 COIMBRA,PORTUGAL; UNIV COIMBRA,DEPT ZOOL,P-3000 COIMBRA,PORTUGAL; UNIV COIMBRA,DEPT BIOCHEM,P-3000 COIMBRA,PORTUGAL	Hebrew University of Jerusalem; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra			Ramalho-Santos, João/F-8641-2012; de Lima, Maria da Conceição Monteiro/AAS-5602-2021; Santos, João/HHZ-5595-2022	Ramalho-Santos, João/0000-0002-1172-4018; de Lima, Maria da Conceição Monteiro/0000-0003-1844-5027; 				ALFORD D, 1994, BIOCHEMISTRY-US, V33, P1977, DOI 10.1021/bi00174a002; AMSELEM S, 1986, BIOCHIM BIOPHYS ACTA, V860, P301, DOI 10.1016/0005-2736(86)90527-4; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; BENTZ J, 1992, BIOPHYS J, V63, P448, DOI 10.1016/S0006-3495(92)81622-3; CHEETHAM JJ, 1994, J BIOL CHEM, V269, P5467; DUZGUNES N, 1992, J GEN VIROL, V73, P27, DOI 10.1099/0022-1317-73-1-27; FONTEIJN TAA, 1992, BIOCHIM BIOPHYS ACTA, V1110, P185, DOI 10.1016/0005-2736(92)90357-R; HAYWOOD AM, 1982, BIOCHEMISTRY-US, V21, P6041, DOI 10.1021/bi00267a003; HOEKSTRA D, 1989, J BIOL CHEM, V264, P6786; HOEKSTRA D, 1985, BIOCHEMISTRY-US, V24, P4739, DOI 10.1021/bi00339a005; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; JUNANKAR PR, 1986, BIOCHIM BIOPHYS ACTA, V854, P198, DOI 10.1016/0005-2736(86)90111-2; LARSEN CE, 1993, BIOCHIM BIOPHYS ACTA, V1147, P223, DOI 10.1016/0005-2736(93)90007-M; LIMA M C P D, 1991, Biochimica et Biophysica Acta, V1070, P446; LIMA MCP, 1992, EUR J BIOCHEM, V205, P181; MIAO L, 1995, BIOCHEMISTRY-US, V34, P4676, DOI 10.1021/bi00014a022; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; NIR S, 1986, BIOCHEMISTRY-US, V25, P2155, DOI 10.1021/bi00356a046; NIR S, 1986, BIOCHEMISTRY-US, V25, P257, DOI 10.1021/bi00349a036; NIR S, 1983, PROG SURF SCI, V13, P1, DOI 10.1016/0079-6816(83)90010-2; NIR S, 1990, CELL BIOPHYS, V17, P181, DOI 10.1007/BF02990496; NIR S, 1986, BIOCHEMISTRY-US, V25, P8261, DOI 10.1021/bi00373a020; NIR S, 1988, MOL MECHANISMS MEMBR, P451; RAMALHOSANTOS J, 1993, BIOCHEMISTRY-US, V32, P2771, DOI 10.1021/bi00062a006; SATO SB, 1983, P NATL ACAD SCI-BIOL, V80, P3153, DOI 10.1073/pnas.80.11.3153; STAMATATOS L, 1994, J GEN VIROL, V74, P1043; Steck T L, 1974, Methods Enzymol, V31, P172; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; STEGMANN T, 1986, J BIOL CHEM, V261, P966; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0	33	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23902	23906		10.1074/jbc.271.39.23902	http://dx.doi.org/10.1074/jbc.271.39.23902			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798621	Green Published, hybrid			2022-12-25	WOS:A1996VJ44200050
J	Gunning, KB; Cohn, SL; Tomlinson, GE; Strong, LC; Huff, V				Gunning, KB; Cohn, SL; Tomlinson, GE; Strong, LC; Huff, V			Analysis of possible abnormal WT1 RNA processing in primary Wilms tumors	ONCOGENE			English	Article						WT1; RNA; editing; aberrant splicing; Wilms tumor	GENE; EXPRESSION; DELETION; MUTATIONS; CELLS	WT1 RNA processing abnormalities have been suggested to play a role in the development of Wilms tumor by reports of editing at codon 280 in the rat WT1 transcript (codon 281 in humans) and aberrant splicing of exon 2 in WT1 transcripts from Wilms tumor xenograft cell lines, Both events result in a functionally changed WT1 protein and are potential mechanisms of altering normal protein function in the absence of WT1 DNA mutations, To determine whether either of these RNA processing events occurs in primary Wilms tumors, we analysed WT1 mRNA from 15 primary tumors, There was no evidence of WT1 RNA editing at codon 281, and only one primary tumor displayed aberrant splicing of exon 2, Sequence and Southern analysis of DNA from this tumor did not reveal any alteration in or around exon 2, These results suggest that neither RNA editing at codon 281 nor abberant exon 2 splicing is a frequent mechanism of WT1 alteration during tumorigenesis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPT PEDIAT,HOUSTON,TX 77030; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611; CHILDRENS MEM HOSP,CHICAGO,IL 60614; UNIV TEXAS,SW MED SCH,DEPT PEDIAT HEMATOL ONCOL & FAMILY GENET,DALLAS,TX	University of Texas System; UTMD Anderson Cancer Center; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650	NATIONAL CANCER INSTITUTE [P01CA034936, U01CA060114] Funding Source: NIH RePORTER; NCI NIH HHS [CA34936, CA60114] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BROWN KW, 1993, GENE CHROMOSOME CANC, V8, P74, DOI 10.1002/gcc.2870080203; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1990, HUM GENET, V84, P253; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; NICHOLS KE, 1995, CANCER RES, V55, P4540; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; ZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7	17	9	10	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1179	1185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808692				2022-12-25	WOS:A1996VJ20200009
J	Beatch, M; Jesaitis, LA; Gallin, WJ; Goodenough, DA; Stevenson, BR				Beatch, M; Jesaitis, LA; Gallin, WJ; Goodenough, DA; Stevenson, BR			The tight junction protein ZO-2 contains three PDZ ((P)under-barSD-95/(d)under-bariscs-large/(Z)under-barO-1) domains and an alternatively spliced region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-CELLS; SEPTATE JUNCTIONS; GUANYLATE KINASES; MEMBRANE-PROTEIN; IDENTIFICATION; LOCALIZATION; POLYPEPTIDE; CINGULIN; OCCLUDIN	The complete cDNA sequence for canine ZO-2, a tight junction-specific protein, is presented, A single open reading frame encodes a polypeptide of 1,174 amino acids with a predicted molecular mass of 132,085 daltons, As noted previously (1), ZO-2 is a member of the membrane-associated guanylate kinase-containing (MAGUK) protein family, a family which includes an additional tight junction-associated protein, ZO-1. These proteins contain a region homologous to guanylate kinase, an SH3 domain, and variable numbers of PSD-95/discs-large/ZO-1 (PDZ) domains, shown to be involved in protein-protein interactions, ZO-2 and ZO-1 contain three PDZ domains in the N-terminal half of the molecule. Between the first and second PDZ domains, ZO-2 displays a basic region (pI = 10.27) containing 22% arginine residues. Both ZO-1 and ZO-2 have proline-rich C-terminal regions that are not homologous to other MAGUK family members. Sequence analysis of multiple ZO-2 cDNAs reveals a 36-amino acid domain in this C-terminal region present in only some of the cDNAs. Overall, ZO-2 is highly homologous to ZO-1, showing 51% amino acid identity; however, the C-terminal ends of the molecules show only 25% amino acid identity. This suggests that the C-terminal ends of ZO-1 and ZO-2 have different functions.	UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,DEPT BIOL SCI,EDMONTON,AB T6G 2H7,CANADA; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	University of Alberta; University of Alberta; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028932, R01GM018974, R37GM018974] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28932, GM18974] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDA MS, 1993, AM J PHYSIOL, V264, pC918, DOI 10.1152/ajpcell.1993.264.4.C918; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURIHARA H, 1992, P NATL ACAD SCI USA, V89, P7075, DOI 10.1073/pnas.89.15.7075; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	29	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25723	25726		10.1074/jbc.271.42.25723	http://dx.doi.org/10.1074/jbc.271.42.25723			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824195	hybrid			2022-12-25	WOS:A1996VN18000001
J	Denker, BM; Saha, C; Khawaja, S; Nigam, SK				Denker, BM; Saha, C; Khawaja, S; Nigam, SK			Involvement of a heterotrimeric G protein alpha subunit in tight junction biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; INTRACELLULAR CALCIUM; LOCALIZATION; CALMODULIN; MEMBRANE; NEPHRON; GAP-43; CELLS	The tight junction (TJ) of polarized epithelial cells is critical for maintaining an impermeant barrier and epithelial cell polarity. The signaling events important for TJ assembly require regulated calcium stores and protein kinase C (PKC), but the earliest signaling events in the cascade have not been well defined. We now show that G alpha(i2) in Madin Darby canine kidney (MDCK) cells localizes to a region overlapping with the TJ. To further analyze the localization of G alpha subunits in epithelial cells, rat G alpha(o), Q205L alpha(o) (G alpha(o) ''activated'' by point mutation) and plasmid without insert (PC) were transfected into MDCK cells and localized by immunofluorescence and confocal microscopy, Similar to endogenous G alpha(i2), G alpha(o)-MDCK cells localize G alpha(o), (84% similar to G alpha(i2)) in the subapical region overlapping with ZO-1 (zona occludens-I), a key component of the TJ, PC-MDCK cells have no detectable G alpha(o). In Ga alpha(o)-MDCK cells, a physical association of G alpha(o) with components of the TJ was detectable by immunoprecipitation of ZO-1. Immunoprecipitates of ZO-1 from G alpha(o)-MDCK cells consistently coprecipitated G alpha(o). Constitutively active Q205LG alpha(o) localized to the subapical lateral membrane similar to wild-type G alpha(o). To determine if constitutively activated G alpha subunits can affect TJ biogenesis, the formation of tight junctions in PC, G alpha(o), and Q205L alpha(o)-MDCK cells was followed by measurement of transepithelial resistance (TER) during the Ca2+ switch, a model widely used to study mechanisms of junctional assembly, Baseline and post Ca2+ switch TER values did not differ among the cell lines, However, constitutively activated Q205L alpha(o)-MDCK, cells developed TER significantly faster than PC and G alpha(o) cells in the early phase (0-4 h) (54 +/- 4 versus 23 +/- 3 (PC); 12 +/- 1 (G alpha(o)) Ohm . m(2)/h) and late phase (4-h peak) (117 +/- 10 versus 45 +/- 5 (PC); 66 +/- 7 (G alpha(o)) Ohm . cm(2)/h) after Ca2+ switch, Peak TER values were significantly higher in Q205L alpha(o)-MDCK cells (1168 +/- 107 versus 437 +/- 37 (PC); 548 +/- 54 (G alpha(o)) Ohm . cm(2)). These results indicate that G alpha(o) and Q205L alpha(o) expressed in MDCK cells are localized near the junctional complex, associate with at least one TJ protein, and that activated G alpha(o) accelerates TJ biogenesis without significantly affecting the maintenance of the TJ, Together, these results suggest an important role for heterotrimeric G proteins in TJ assembly.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	Denker, BM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002110] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02110] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BRUNSKILL N, 1991, KIDNEY INT, V40, P997, DOI 10.1038/ki.1991.307; CEREIJIDO M, 1993, J CELL SCI, P127; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; DENKER BM, 1991, FEBS LETT, V279, P98, DOI 10.1016/0014-5793(91)80260-A; DENKER BM, 1992, J BIOL CHEM, V267, P6272; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; ENDOU M, 1994, J PHARMACOL EXP THER, V269, P221; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; NEER EJ, 1992, TRENDS CARDIOVAS MED, V2, P6, DOI 10.1016/1050-1738(92)90037-S; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STOW JL, 1991, AM J PHYSIOL, V261, pF831, DOI 10.1152/ajprenal.1991.261.5.F831; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; STUART RO, 1995, SEMIN NEPHROL, V15, P315; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; VANDENBERGHE N, 1991, BIOCHEM J, V278, P565, DOI 10.1042/bj2780565; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WU K, 1992, P NATL ACAD SCI USA, V89, P8686, DOI 10.1073/pnas.89.18.8686; XIE RP, 1995, DEV BRAIN RES, V87, P77, DOI 10.1016/0165-3806(95)00061-H	30	117	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25750	25753		10.1074/jbc.271.42.25750	http://dx.doi.org/10.1074/jbc.271.42.25750			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824202	hybrid			2022-12-25	WOS:A1996VN18000008
J	Donovan, JA; Ota, Y; Langdon, WY; Samelson, LE				Donovan, JA; Ota, Y; Langdon, WY; Samelson, LE			Regulation of the association of p120(cbl) with Grb2 in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; C-CBL PROTOONCOGENE; RECEPTOR SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; SH3 DOMAIN; ZETA-CHAIN; PHOSPHORYLATED PROTEIN; HEMATOPOIETIC-CELLS; EXCHANGE PROTEIN; V-CBL	The c-cbl protooncogene product (p120(cbl)) is a known substrate of multiple tyrosine kinases. It is found in complexes with critical signal transduction molecules, including the linker protein Grb2. Here, we demonstrate using an immobilized Grb2-binding peptide that the Grb2-p120(cbl) complex dissociates in vivo following engagement of the T-cell antigen receptor in Jurkat T-cells. The early kinetics of this dissociation correlate with the known time course of tyrosine phosphorylation of p120(cbl) and other substrates. This dissociation persists In vivo even when p120(cbl) becomes dephosphorylated to basal levels. However, this decreased association is not observed in protein overlay assays on nitrocellulose membranes in which a Grb2 fusion protein is used to detect p120(cbl) from stimulated or unstimulated cells. These data suggest that the tyrosine phosphorylation of p120(cbl) does not completely account for the regulation of its association with Grb2. Additionally, we used truncation mutations of p120(cbl) to map the p120(cbl)-Grb2 interaction to amino acids 481-528 of p120(cbl); this interaction is stronger in longer constructs that include additional proline-rich motifs. The in vivo regulation of the Grb2-p120(cbl) complex further supports the idea of a significant role for p120(cbl) in receptor-mediated signaling pathways.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA; UNIV WESTERN AUSTRALIA, NEDLANDS, WA 6009, AUSTRALIA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Western Australia								ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EGERTON M, 1994, J BIOL CHEM, V269, P11435; EGERTON M, 1992, J IMMUNOL, V149, P1847; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GURUPRASAD L, 1995, J MOL BIOL, V248, P856, DOI 10.1006/jmbi.1995.0266; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; REIF K, 1994, J BIOL CHEM, V269, P14081; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Sattler M, 1996, ONCOGENE, V12, P839; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOODROW MA, 1993, J IMMUNOL, V150, P3853; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	59	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26369	26374		10.1074/jbc.271.42.26369	http://dx.doi.org/10.1074/jbc.271.42.26369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824292	hybrid			2022-12-25	WOS:A1996VN18000098
J	He, K; He, YA; Szklarz, GD; Halpert, JR; Correia, MA				He, K; He, YA; Szklarz, GD; Halpert, JR; Correia, MA			Secobarbital-mediated inactivation of cytochrome P450 2B1 and its active site mutants - Partitioning between heme and protein alkylation and epoxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE RECOGNITION SITES; DIRECTED MUTAGENESIS; AMINO-ACID; INSITU REARRANGEMENT; IRON COMPLEXES; SPECIFICITY; RAT; PURIFICATION; METABOLISM; MECHANISM	Secobarbital (SE) is a relatively selective mechanism-based inactivator of cytochrome P450 2B1, that partitions between epoxidation and heme and protein modification during its enzyme inactivation, The SB-2B1 heme adduct formed in situ in a functionally reconstituted system has been spectrally documented and structurally characterized as N-(5-(2-hydroxypropyl)-5-(1-methylbutyl)barbituric acid)protoporphyrin M. The SB-protein modification has been localized to 2B1 peptide 277-323 corresponding to the active site helix I of cytochrome P450 101., The targeting of heme and this active site peptide suggests that the 2B1 active site topology could influence the course of its inactivation, To explore this possibility, the individual SE epoxidation, heme and protein modification, and corresponding molar partition ratios of the wild type and seven structural 2B1 mutants, site-directed at specific substrate recognition sites, and known to influence 2B1 catalysis were examined after Escherichia coli expression, These studies reveal that Thr-302 is critical for SE-mediated heme N-alkylation, whereas Val-367 is a critical determinant of 2B1 protein modification, and Val-363 is important for SE epoxidation. SE docking into a refined 2B1 homology model coupled with molecular dynamics analyses provide a logical rationale for these findings.	UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOL PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOPHARMACEUT SCI & PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR LIVER, SAN FRANCISCO, CA 94143 USA; UNIV ARIZONA, DEPT PHARMACOL & TOXICOL, TUCSON, AZ 85721 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Arizona					NIDDK NIH HHS [DK26506] Funding Source: Medline; NIEHS NIH HHS [ES06694, ES03619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026506, R56DK026506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003619, P30ES006694] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BORNHEIM LM, 1986, ARCH BIOCHEM BIOPHYS, V246, P63, DOI 10.1016/0003-9861(86)90449-2; DEMONTELLANO PRO, 1983, ANNU REV PHARMACOL, V23, P481; DEXTER AF, 1995, J AM CHEM SOC, V117, P817, DOI 10.1021/ja00107a026; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GOTOH O, 1992, J BIOL CHEM, V267, P83; GRAB LA, 1988, BIOCHEMISTRY-US, V27, P4805, DOI 10.1021/bi00413a034; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HARVEY DJ, 1977, DRUG METAB DISPOS, V5, P527; He K, 1996, CHEM RES TOXICOL, V9, P614, DOI 10.1021/tx950177k; HE YA, 1992, BIOCHEMISTRY-US, V31, P9220, DOI 10.1021/bi00153a015; HE YQ, 1995, CHEM RES TOXICOL, V8, P574, DOI 10.1021/tx00046a011; HSU MH, 1993, J BIOL CHEM, V268, P6939; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; KOMIVES EA, 1987, J BIOL CHEM, V262, P9793; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LUKTON D, 1988, CHEM RES TOXICOL, V1, P208, DOI 10.1021/tx00004a004; LUNETTA JM, 1989, MOL PHARMACOL, V35, P10; Luo Zongshu, 1994, Archives of Biochemistry and Biophysics, V309, P52; NELSON DR, 1988, J BIOL CHEM, V263, P6038; PAULSEN MD, 1992, J COMPUT AID MOL DES, V6, P449, DOI 10.1007/BF00130396; PAULSEN MD, 1991, PROTEINS, V11, P184, DOI 10.1002/prot.340110304; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; SHEPHARD EA, 1983, ANAL BIOCHEM, V129, P430, DOI 10.1016/0003-2697(83)90573-0; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; SZKLARZ GD, 1994, J BIOMOL STRUCT DYN, V12, P61, DOI 10.1080/07391102.1994.10508088; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; TUCK SF, 1992, BIOCHEMISTRY-US, V31, P6911, DOI 10.1021/bi00145a007; Von Wachenfeldt Claes, 1995, P183; WALSH CT, 1984, ANNU REV BIOCHEM, V53, P493, DOI 10.1146/annurev.bi.53.070184.002425; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	32	30	30	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25864	25872		10.1074/jbc.271.42.25864	http://dx.doi.org/10.1074/jbc.271.42.25864			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824218	hybrid			2022-12-25	WOS:A1996VN18000024
J	Somasundaram, B; MahautSmith, MP; Floto, RA				Somasundaram, B; MahautSmith, MP; Floto, RA			Temperature-dependent block of capacitative Ca2+ influx in the human leukemic cell line KU-812	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; RAT MEGAKARYOCYTES; MAST-CELLS; DEPLETION; TRANSPORT; MEMBRANE; PROTEIN; STORES; CHANNELS; ENTRY	The mechanism by which depletion of intracellular Ca2+ stores activates Ca2+ influx is not understood, We recently showed that primaquine, an inhibitor of vesicular transport, blocks the activation of the calcium release-activated calcium current (I-CRAC) in rat megakaryocytes (Somasundaram, B., Norman, J. C., and Mahaut-Smith, M. P. (1995) Biochem. J, 309, 725-729), Since it is well established that vesicular transport is temperature-sensitive, we have investigated the effect of temperature on both the activation and maintenance of store-mediated Ca2+ and Mn2+ influx in the human leukemic cell line KU-812 using a combination of whole cell I-CRAC recordings and measurements of Mn2+ photoquench of fura-2, Activation of I-CRAC was temperature-sensitive, showing a nonlinear reduction when the temperature was lowered from 27 to 17 degrees C with an abrupt change at 21-22 degrees C and complete inhibition at 17 degrees C, Once activated, I-CRAC also displayed an abrupt reduction at 21-22 degrees C but was not completely blocked even when the temperature was reduced to 14 degrees C, suggesting that at least one of the temperature-sensitive components is exclusively involved in I-CRAC activation, Activation of store mediated Mn2+ influx also showed similar nonlinear temperature sensitivity and complete inhibition at 19 degrees C. However, in contrast to Io measurements, lowering the temperature following maximal activation of the influx pathway at 37 degrees C did not result in any detectable residual Mn2+ entry below 19 degrees C. We conclude that the mechanism of store-mediated Ca2+ influx involves temperature-dependent steps in both its maintenance and activation, suggesting dependence on a lipid membrane environment.			Somasundaram, B (corresponding author), UNIV CAMBRIDGE,PHYSIOL LAB,DOWNING ST,CAMBRIDGE CB2 3EG,ENGLAND.							BAMBERG E, 1974, BIOCHIM BIOPHYS ACTA, V367, P127, DOI 10.1016/0005-2736(74)90037-6; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1993, J BIOL CHEM, V268, P21486; CAVALIE A, 1985, PFLUG ARCH EUR J PHY, V405, P294, DOI 10.1007/BF00582574; CHAPMAN D, 1975, Q REV BIOPHYS, V8, P185, DOI 10.1017/S0033583500001797; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; DEAN WL, 1978, BIOCHEMISTRY-US, V17, P1683, DOI 10.1021/bi00602a016; FASALATO C, 1993, J BIOL CHEM, V268, P20737; FASALATO C, 1994, TRENDS PHARMACOL SCI, V15, P77; FISCHBACH GD, 1978, J PHYSIOL-LONDON, V280, P527, DOI 10.1113/jphysiol.1978.sp012399; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOFFMANN W, 1979, P NATL ACAD SCI USA, V76, P3860, DOI 10.1073/pnas.76.8.3860; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; LINDEN CD, 1973, P NATL ACAD SCI USA, V70, P2271, DOI 10.1073/pnas.70.8.2271; LOCKWICH TP, 1994, J MEMBRANE BIOL, V141, P289; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MARRIOTT I, 1995, AM J PHYSIOL-CELL PH, V269, pC766, DOI 10.1152/ajpcell.1995.269.3.C766; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MOREAU P, 1994, BBA-REV BIOMEMBRANES, V1197, P257; NAKAZAWA M, 1989, BLOOD, V73, P2003; NARAHASHI T, 1987, J PHYSIOL-LONDON, V383, P231; NOBILE M, 1990, PFLUG ARCH EUR J PHY, V415, P658, DOI 10.1007/BF02584002; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RAISON JK, 1972, J BIOENERGETICS, V275, P559; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; REGA AF, 1986, CA2 PLUS PUMP PLASMA, P97; ROMEY G, 1980, BIOCHIM BIOPHYS ACTA, V602, P610, DOI 10.1016/0005-2736(80)90339-9; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SARGEANT P, 1994, PHARMACOL THERAPEUT, V64, P395, DOI 10.1016/0163-7258(94)90019-1; SHUTTLEWORTH TJ, 1991, J BIOL CHEM, V266, P1410; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; SOMASUNDARAM B, 1994, J PHYSIOL-LONDON, V480, P225, DOI 10.1113/jphysiol.1994.sp020355; SONDERGAARD L, 1979, BIOCHIM BIOPHYS ACTA, V557, P208, DOI 10.1016/0005-2736(79)90103-2; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; WARREN GB, 1975, NATURE, V255, P684, DOI 10.1038/255684a0; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	45	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26096	26104		10.1074/jbc.271.42.26096	http://dx.doi.org/10.1074/jbc.271.42.26096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824252	hybrid			2022-12-25	WOS:A1996VN18000058
J	Woodcock, JM; Bagley, CJ; Zacharakis, B; Lopez, AF				Woodcock, JM; Bagley, CJ; Zacharakis, B; Lopez, AF			A single tyrosine residue in the membrane-proximal domain of the granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptor common beta-chain is necessary and sufficient for high affinity binding and signaling by all three ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; LEUKEMIA INHIBITORY FACTOR; GM-CSF RECEPTOR; GAMMA-CHAIN; ERYTHROPOIETIN RECEPTOR; PROLACTIN RECEPTOR; ALPHA-CHAIN; MOLECULAR-CLONING; FUNCTIONAL RECEPTORS; EXTRACELLULAR DOMAIN	The beta-chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and interleukin-5 (IL-5) receptors functions as a communal receptor subunit and is often referred to as beta common (beta(c)). Analogous to other shared receptor subunits including gp130 and the IL-2R gamma chain, beta(c) mediates high affinity binding and signal transduction of all of its Ligands. It is not clear, however, how these common receptor subunits can recognize several Ligands and indeed whether they exhibit a common binding pocket to accomplish this. We have performed molecular modeling of beta(c) based on the known structures of the growth hormone and prolactin receptors and targeted the putative F'-G' loop for mutagenesis. Substitution of this whole predicted loop region with alanines completely abrogated high affinity binding of GM-CSF, IL-3, and IL-5. Individual alanine substitutions across the loop revealed that a single residue, Tyr(421), is critical for high affinity binding of GM-CSF, IL-3, and IL-5, whereas alanine substitution of adjacent residues has little or no effect on high affinity binding. Significantly, reintroducing Tyr(421) into the polyalanine-substituted mutant restored high affinity ligand binding of GM-CSF, IL-3, and IL-5, indicating that within this region the tyrosine residue alone is sufficient for high affinity Ligand interaction. Functional studies measuring STAT5 activation revealed that alanine substitution of Tyr(421) severely impaired the ability of beta(c) to signal, These results show for the first time that a single residue in a shared receptor subunit acts as a binding determinant for different ligands and may have implications for other receptor systems where communal receptor subunits exhibit hydrophobic residues in their putative F'-G' loops. These results also raise the possibility that a single compound targeted to this region may simultaneously inhibit the binding and function of multiple cytokines.	INST MED & VET SCI,DIV HUMAN IMMUNOL,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia			Lopez, Angel F/E-2260-2011	Lopez, Angel F/0000-0001-7430-0135; Woodcock, Joanna/0000-0001-5127-9687				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAGLEY CJ, 1995, J LEUKOCYTE BIOL, V57, P739, DOI 10.1002/jlb.57.5.739; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1992, BLOOD, V80, P84; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOCK P, 1994, P NATL ACAD SCI USA, V91, P252, DOI 10.1073/pnas.91.1.252; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	62	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25999	26006		10.1074/jbc.271.42.25999	http://dx.doi.org/10.1074/jbc.271.42.25999			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824238	hybrid			2022-12-25	WOS:A1996VN18000044
J	Catimel, B; Ritter, G; Welt, S; Old, LJ; Cohen, L; Nerrie, MA; White, SJ; Heath, JK; Demediuk, B; Domagala, T; Lee, FT; Scott, AM; Tu, GF; Ji, H; Moritz, RL; Simpson, RJ; Burgess, AW; Nice, EC				Catimel, B; Ritter, G; Welt, S; Old, LJ; Cohen, L; Nerrie, MA; White, SJ; Heath, JK; Demediuk, B; Domagala, T; Lee, FT; Scott, AM; Tu, GF; Ji, H; Moritz, RL; Simpson, RJ; Burgess, AW; Nice, EC			Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; QUANTITATIVE-ANALYSIS; PROTEIN; CANCER; BIOSENSOR; A33	A cell surface antigen that is expressed by normal and 95% of transformed colonic epithelium and is recognized by the monoclonal antibody A33 (Welt, S., Divgi, C. R., Real F. X., Yeh, S. D., Garin-Chesa, P., Finstad, C. L., Sakamoto, J., Cohen, A., Sigurdson, E. R., Kemeny, N., Carswell, E. A., Oettgen, H. F., and Old, L. J. (1990) J. Clin. Oncol. 8, 1894-1906) has been purified to homogeneity from the human colonic carcinoma cell line LIM1215. The A33 protein was purified fi om Triton X-114 extracts of LIM1215 cells under nondenaturing conditions. These extracts were applied sequentially to Green-Sepharose HE-4BD, Mono-Q HR 10/10, Superose 12 HR 10/30, and micropreparative Brownlee Aquapore RP 300. The purification was monitored by biosensor analysis using surface plasmon resonance detection with a F(ab')(2) fragment of the humanized A33 monoclonal antibody immobilized on the sensor surface and Western blot analysis following SDS-polyacrylamide gel electrophoresis (PAGE) under nonreducing conditions using humanized A33 monoclonal antibody. The purified A33 antigen has a M(r) on SDS-PAGE of 43,000 under nonreducing conditions. By contrast, the purified protein displayed a M(r) of approximately 180,000 under native conditions on both size exclusion chromatography and native PAGE, possibly due to the formation of a homotetramer. N-terminal amino acid sequence analysis of the purified protein identified 34 amino acid residues of a unique sequence: ISVETPQDVLRASQGKSVTLPXTYHTSXXXREGLIQWD. A polyclonal antibody was raised against a synthetic peptide corresponding to residues 2-20 of this sequence. The antipeptide serum recognized the purified protein using Western blot analysis under both nonreducing (M(r) 43,000) and reducing (M(r) 49,000) conditions.	LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA; LUDWIG INST CANC RES, JOINT PROT STRUCT LAB, MELBOURNE, VIC 3050, AUSTRALIA; WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA; LUDWIG INST CANC RES, JOINT ONCOL UNIT, HEIDELBERG, VIC 3084, AUSTRALIA; AUSTIN HOSP, HEIDELBERG, VIC 3084, AUSTRALIA; MEM SLOAN KETTERING CANC CTR, LUDWIG INST CANC RES, NEW YORK, NY 10021 USA	Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center			Heath, Joan/D-3054-2012; Nice, Edouard C/B-1026-2011; Moritz, Robert L/B-9222-2011	Heath, Joan/0000-0001-6955-232X; Scott, Andrew/0000-0002-6656-295X; CATIMEL, Bruno/0000-0002-4350-6875; Simpson, Richard/0000-0002-9834-0796				BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; KING DJ, 1995, BRIT J CANCER, V72, P1364, DOI 10.1038/bjc.1995.516; LASKY M, 1978, ELECTROPHORESIS 78, P195; LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; LOW MG, 1987, BIOCHEM J, V244, P1; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MOORE AE, 1955, CANCER RES, V15, P598; MORITZ RL, 1995, TECHNIQUES PROTEIN C, V4, P331; NICE E, 1994, J CHROMATOGR A, V660, P169, DOI 10.1016/0021-9673(94)85110-7; NICE E, 1993, J CHROMATOGR, V646, P159, DOI 10.1016/S0021-9673(99)87017-4; Nice EC, 1996, MOL IMMUNOL, V33, P659, DOI 10.1016/0161-5890(96)00016-8; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PARHAM P, 1983, J IMMUNOL, V131, P2895; REID GE, 1995, ELECTROPHORESIS, V16, P1120, DOI 10.1002/elps.11501601189; SCHMOLL HJ, 1994, ANN ONCOL, V5, pS115, DOI 10.1093/annonc/5.suppl_3.S115; Shapiro H. M., 1988, PRACTICAL FLOW CYTOM; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P221, DOI 10.1016/0003-2697(89)90044-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; UBRICH N, 1995, J MOL RECOGNIT, V8, P111, DOI 10.1002/jmr.300080120; WELT S, 1990, J CLIN ONCOL, V8, P1894, DOI 10.1200/JCO.1990.8.11.1894; WELT S, 1994, J CLIN ONCOL, V12, P1561, DOI 10.1200/JCO.1994.12.8.1561; Welt S, 1996, J CLIN ONCOL, V14, P1787, DOI 10.1200/JCO.1996.14.6.1787; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759	27	50	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25664	25670		10.1074/jbc.271.41.25664	http://dx.doi.org/10.1074/jbc.271.41.25664			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810343	hybrid			2022-12-25	WOS:A1996VL69300087
J	Heymach, JV; Kruttgen, A; Suter, U; Shooter, EM				Heymach, JV; Kruttgen, A; Suter, U; Shooter, EM			The regulated secretion and vectorial targeting of neurotrophins in neuroendocrine and epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; HIPPOCAMPAL-NEURONS; PC12 CELLS; EXOGENOUS PROTEINS; MAMMALIAN-CELLS; FACTOR NGF; RAT IRIS; A-CHAIN; EXPRESSION; BDNF	The varied roles that neurotrophins play in the development and activity-dependent plasticity of the nervous system presumably require that the sites and quantity of neurotrophin release be precisely regulated, As a step toward understanding how different neurotrophins are sorted and secreted by neurons, we expressed nerve growth factor (NGF), brain-derived neurotrophic factor, and neurotrophin-3 in cell lines used as models for neuronal protein sorting. All three-neurotrophins were secreted by a regulated pathway in transfected AtT-20 and PC12 neuroendocrine cells, with a 3-6-fold increase in neurotrophin release in response to 8-bromo-cAMP or depolarization, respectively. To determine if the propeptide directs the intracellular sorting of mature NGF, we examined mutants in which regions spanning the propeptide were deleted. These mutants underwent regulated release in every case in which expression could be detected. Similarly, NGF sorting was not significantly altered by mutations which specifically abolished N-glycosylation or proteolytic processing sites within the NGF precursor. Finally, we found that all three neurotrophins were secreted 65-75% basolaterally by polarized Madin-Darby canine kidney epithelial cells, These findings suggest that the determinants of regulated neurotrophin secretion lie within the mature neurotrophin moiety and that NGF, brain-derived neurotrophic factor, and neurotrophin-3 are likely to be sorted similarly and released in a regulated manner by neurons.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Heymach, John/AAG-2361-2019; Kruttgen, Alexander P/E-9232-2010; Suter, Ueli/A-1624-2010	Heymach, John/0000-0001-9068-8942; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07249] Funding Source: Medline; NINDS NIH HHS [NS04270, NS07158] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANDERSSON M, 1994, J BIOL CHEM, V269, P926; BARTH EM, 1984, J CELL BIOL, V99, P839, DOI 10.1083/jcb.99.3.839; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRION C, 1992, J BIOL CHEM, V267, P1477; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAVEZ RA, 1994, METHOD CELL BIOL, V43, P263; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; EBENDAL T, 1989, J NEUROSCI RES, V22, P223, DOI 10.1002/jnr.490220302; EDWARDS RH, 1986, NATURE, V319, P784, DOI 10.1038/319784a0; EDWARDS RH, 1988, MOL CELL BIOL, V8, P2456, DOI 10.1128/MCB.8.6.2456; FORTENBERRY SC, 1995, J BIOL CHEM, V270, P9778, DOI 10.1074/jbc.270.17.9778; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; HOYLE GW, 1993, NEURON, V10, P1019, DOI 10.1016/0896-6273(93)90051-R; HUTTNER WB, 1995, CURR BIOL, V5, P242, DOI 10.1016/S0960-9822(95)00049-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; JONGSTRABILEN J, 1989, MOL BRAIN RES, V5, P159, DOI 10.1016/0169-328X(89)90007-7; JOURNET AM, 1993, EUR J CELL BIOL, V60, P31; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KELLY RB, 1993, ANNU REV NEUROSCI, V16, P95, DOI 10.1146/annurev.ne.16.030193.000523; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; NARHI LO, 1993, J BIOL CHEM, V268, P13309; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHWEITZER ES, 1990, J CELL SCI, V96, P375; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; SHELTON DL, 1986, J CELL BIOL, V102, P1940, DOI 10.1083/jcb.102.5.1940; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SURPRENANT A, 1982, J CELL BIOL, V95, P559, DOI 10.1083/jcb.95.2.559; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TOOZE J, 1989, EUR J CELL BIOL, V49, P259; TWISS JL, 1995, J NEUROCHEM, V64, P550; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; WETMORE C, 1994, J NEUROSCI, V14, P1688, DOI 10.1523/JNEUROSCI.14-03-01688.1994; WETMORE C, 1991, P NATL ACAD SCI USA, V88, P9843, DOI 10.1073/pnas.88.21.9843; WICK PF, 1993, J BIOL CHEM, V268, P10983	63	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25430	25437		10.1074/jbc.271.41.25430	http://dx.doi.org/10.1074/jbc.271.41.25430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810312	hybrid			2022-12-25	WOS:A1996VL69300056
J	Kim, JH; Suh, YJ; Lee, TG; Kim, Y; Bae, SS; Kim, MJ; Lambeth, JD; Suh, PG; Ryu, SH				Kim, JH; Suh, YJ; Lee, TG; Kim, Y; Bae, SS; Kim, MJ; Lambeth, JD; Suh, PG; Ryu, SH			Inhibition of phospholipase D by a protein factor from bovine brain cytosol - Partial, purification and characterization of the inhibition mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GROWTH-FACTOR; D ACTIVATION; MEMBRANE; ARF; NEUTROPHILS; RHOA; GRANULOCYTES	A specific protein inhibitor of partially purified bovine brain phospholipase D (PLD) was identified from bovine brain cytosol. The PLD inhibitor has been enriched through several chromatographic steps and characterized with respect to size and mechanism of inhibition, The inhibitor showed an apparent molecular mass of 30 kDa by Superose 12 gel exclusion chromatography and inhibited PLD activity with an IC50 of 7 nM. The inhibitor had neither proteolytic activity nor phospholipid-hydrolyzing activity. Because phosphatidylinositol 4,5-bisphosphate (PIP2), which is included in substrate vesicles, is an essential cofactor for PLD, we examined whether the inhibition might be mediated by sequestration of PIP2. PIP2 hydrolysis by phospholipase C (PLC)-beta 1 was not affected by the inhibitor and the inhibitor did not bind to substrate vesicles containing PIP2. In contrast, a PH domain derived from PLC-delta 1, which could bind to PIP2, showed a nearly identical inhibition of both PLC-beta 1 and PLD activities, Thus, the PLD inhibition by the inhibitor is due to the specific interaction with not PIP2 but PLD. The suppression of PLD activity by the inhibitor was largely eliminated by the addition of ADP-ribosylation factor (ARF) and GTP gamma S. We propose that the inhibitor plays a negative role in regulation of PLD activity by PIP2 and ARF.	POHANG UNIV SCI & TECHNOL, DEPT LIFE SCI, POHANG 790784, SOUTH KOREA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA	Pohang University of Science & Technology (POSTECH); Emory University			Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; Kim, Yong/0000-0002-1387-2962	NCI NIH HHS [CA46508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; KOBAYASHI M, 1991, METHOD ENZYMOL, V197, P575; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LEE YH, 1994, J BIOL CHEM, V269, P26842; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Takahashi K, 1996, J IMMUNOL, V156, P1229; TAKI T, 1979, J BIOL CHEM, V254, P9761; WANG P, 1991, J BIOL CHEM, V266, P14877; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	38	20	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25213	25219		10.1074/jbc.271.41.25213	http://dx.doi.org/10.1074/jbc.271.41.25213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810281	hybrid			2022-12-25	WOS:A1996VL69300025
J	Yan, C; Zhao, AZ; Bentley, JK; Beavo, JA				Yan, C; Zhao, AZ; Bentley, JK; Beavo, JA			The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; 3' UNTRANSLATED REGION; MOLECULAR-CLONING; BOVINE BRAIN; STIMULATED PHOSPHODIESTERASE; EXPRESSION; SEQUENCE; 63-KDA; 61-KDA; PURIFICATION	We report here the identification of cDNAs for three new mouse PDE1C splice variants and the characterization of their kinetics, regulation by Ca2+, sensitivities to inhibitors, and tissue/cellular expression patterns. Sequence analysis indicated that these three cDNAs (PDE1C1, PDE1C4, and PDE1C5), together with our previously reported PDE1C2 and PDE1C3, are alternative splice products of the PDE1C gene. The results from RNase protection analysis and in situ hybridization indicated that the expression of the different PDE1C splice variants is differentially regulated in a tissue/cell-specific manner. Particularly, high levels of PDE1C mRNAs were found in the olfactory epithelium, testis, and several regions of mouse brain such as cerebellar granule cells, All of these splice variants have similar kinetic properties, showing high affinities and approximately the same relative V-max values for both cAMP and cGMP. However, they responded to Ca2+ stimulation differently, In addition, they show different sensitivities to the calmodulin-dependent phosphodiesterase inhibitors, KS505a and SCH51866. Substrate competition experiments suggested the presence of only one catalytic site on these PDE1C isozymes for both cAMP and cGMP. In summary, these findings suggest that the PDE1C gene undergoes tissue-specific alternative splicing that generates structurally and functionally diverse gene products.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Bentley, John Kelley/0000-0001-8865-7979; Yan, Chen/0000-0002-1397-6358	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44948] Funding Source: Medline; NIDDK NIH HHS [DK21723] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAVO J, 1990, CYCLIC NUCLEOTIDE PH, V2, P19; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BORISY FF, 1992, J NEUROSCI, V12, P915; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; DIDIER M, 1992, MOL BRAIN RES, V12, P249, DOI 10.1016/0169-328X(92)90091-O; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HAGIWARA M, 1984, BIOCHEM PHARMACOL, V33, P453, DOI 10.1016/0006-2952(84)90240-5; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LOUGHNEY K, 1994, FASEB J, V8, P469; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MAYER B, 1992, J NEUROCHEM, V59, P2024; NAKANISHI S, 1992, J ANTIBIOT, V45, P341, DOI 10.7164/antibiotics.45.341; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; POLLI JW, 1992, P NATL ACAD SCI USA, V89, P11079, DOI 10.1073/pnas.89.22.11079; REEVES ML, 1987, BIOCHEM J, V241, P535, DOI 10.1042/bj2410535; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; ROSSI P, 1988, J BIOL CHEM, V263, P15521; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARMA RK, 1991, BIOCHEMISTRY-US, V30, P5963, DOI 10.1021/bi00238a021; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENOLIKAR S, 1985, BIOCHEMISTRY-US, V24, P672, DOI 10.1021/bi00324a020; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; VAN VBJ, 1989, J NEUROCHEM, V52, P1229; VANDERMEERS A, 1983, BIOCHEM J, V211, P341, DOI 10.1042/bj2110341; WATKINS RW, 1995, FASEB J, V9, P342; YAN C, 1994, J NEUROSCI, V14, P973; YAN C, 1995, P NATL ACAD SCI USA, V92, P9677, DOI 10.1073/pnas.92.21.9677	35	124	128	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25699	25706		10.1074/jbc.271.41.25699	http://dx.doi.org/10.1074/jbc.271.41.25699			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810348	hybrid			2022-12-25	WOS:A1996VL69300092
J	Dunsmore, SE; Rubin, JS; Kovacs, SO; Chedid, M; Parks, WC; Welgus, HG				Dunsmore, SE; Rubin, JS; Kovacs, SO; Chedid, M; Parks, WC; Welgus, HG			Mechanisms of hepatocyte growth factor stimulation of keratinocyte metalloproteinase production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; C-MET RECEPTOR; HUMAN ALVEOLAR MACROPHAGES; FACTOR SCATTER FACTOR; EPITHELIAL-CELLS; MITOGENIC ACTIVITY; TYROSINE KINASE; INTERSTITIAL COLLAGENASE; PROTOONCOGENE PRODUCT; MOLECULAR-CLONING	Matrix metalloproteinases participate in normal physiologic processes; however, their overproduction has been associated with connective tissue destruction in a variety of pathological states. Migrating basal keratinocytes transiently express collagenase-1 during normal cutaneous reepithelialization. However, the overexpression of both collagenase-1 and stromelysin-1 has been associated with the pathogenesis of chronic nonhealing ulcers, Aberrant expression of metalloproteinases in inflammation is mediated, at least in part, by soluble factors. Since hepatocyte growth factor/scatter factor (HGF/SF) has been reported to promote keratinocyte migration and proliferation, key events in wound repair, and since HGF/SF is produced by dermal fibroblasts and its c-Met receptor is expressed by basal keratinocytes in wounded skin, we have studied the effects of HGF/SF upon keratinocyte metalloproteinase expression. We have found that HGF/SF can stimulate keratinocyte collagenase-1 and stromelysin-1 production in a dose-dependent and matrix dependent manner, Expression of 92-kDa gelatinase was not affected by HGF/SF. We determined that HGF/SF regulation of collagenase-1 expression is transcriptionally mediated and requires tyrosine kinase and protein kinase C activaties. HGF/NK1, a naturally occurring, truncated form of HGF/SF, also stimulates collagenase-1 production, but much less efficiently than does the parent molecule, However, HGF/NK2, another HGF/SF splice variant, as well as heparin, potently inhibit HGF/SF-induced collagenase-1 synthesis, These results indicate that HGF/SF and its naturally occurring splice variants have diverse biological effects on keratinocytes and suggest an additional mechanism whereby HGF/SF may regulate keratinocyte function during wound repair.	WASHINGTON UNIV,SCH MED,DEPT MED DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892	Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Parks, William C./AAH-6786-2021		NIAMS NIH HHS [5T32AR07284, AR35805] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007284, R01AR035805] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARDELLI A, 1994, J BIOTECHNOL, V37, P109, DOI 10.1016/0168-1656(94)90002-7; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COOPER TW, 1983, COLLAGEN REL RES, V3, P205; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOHDA E, 1992, FEBS LETT, V301, P107, DOI 10.1016/0014-5793(92)80220-B; GOHDA E, 1994, CYTOKINE, V6, P633, DOI 10.1016/1043-4666(94)90051-5; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; MACARTNEY HW, 1983, EUR J BIOCHEM, V130, P71; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NICHOLSON R, 1989, BIOCHEMISTRY-US, V28, P5195, DOI 10.1021/bi00438a042; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; OSADA S, 1992, FEBS LETT, V297, P271, DOI 10.1016/0014-5793(92)80554-T; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V105, P190, DOI 10.1111/1523-1747.ep12317104; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SATO C, 1995, J INVEST DERMATOL, V104, P958, DOI 10.1111/1523-1747.ep12606221; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SPONSEL HT, 1994, AM J PHYSIOL, V267, pF257, DOI 10.1152/ajprenal.1994.267.2.F257; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; STRICKLIN GP, 1993, AM J PATHOL, V143, P1657; STRICKLIN GP, 1994, J INVEST DERMATOL, V103, P352, DOI 10.1111/1523-1747.ep12394926; STRICKLIN GP, 1978, BIOCHEMISTRY-US, V17, P2331, DOI 10.1021/bi00605a012; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; WATANABE S, 1994, BIOCHEM BIOPH RES CO, V199, P1453, DOI 10.1006/bbrc.1994.1394; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; ZARNEGAR R, 1990, BIOCHEM BIOPH RES CO, V173, P1179, DOI 10.1016/S0006-291X(05)80910-6; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	65	97	103	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24576	24582		10.1074/jbc.271.40.24576	http://dx.doi.org/10.1074/jbc.271.40.24576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798721	hybrid			2022-12-25	WOS:A1996VM67400043
J	Kispal, G; Steiner, H; Court, DA; Rolinski, B; Lill, R				Kispal, G; Steiner, H; Court, DA; Rolinski, B; Lill, R			Mitochondrial and cytosolic branched-chain amino acid transaminases from yeast, homologs of the myc oncogene-regulated Eca39 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INTERMEMBRANE SPACE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SHUTTLE VECTORS; IMPORT; GENE; AMINOTRANSFERASE; TRANSFORMATION; TRANSLOCATION	We have isolated a high copy suppressor of a temperature-sensitive mutation in ATM1, which codes for an ABC transporter of Saccharomyces cerevisiae mitochondria. The suppressor, termed BAT1, encodes a protein of 393 amino acid residues with an NH2-terminal extension that directs Bat1p to the mitochondrial matrix, A highly homologous protein, Bat2p, of 376 amino acid residues was found in the cytosol. Both Bat proteins show striking similarity to the mammalian protein Eca39, which is one of the few known targets of the myc oncogene, Deletion of a single BAT gene did not impair growth of yeast cells, In contrast, deletion of both genes resulted in an auxotrophy for branched chain amino acids (Ile, Leu, and Val) and in a severe growth reduction on glucose-containing media, even after supply of these amino acids, Mitochondria and cytosol isolated from bat1 and bat2 deletion mutants, respectively, contained largely reduced activities for the conversion of branched-chain 2-ketoacids to their corresponding amino acids, Thus, the Bat proteins represent the first known isoforms of yeast branched-chain amino acid transaminases. The severe growth defect of the double deletion mutant observed even in the presence of branched-chain amino acids suggests that the Bat proteins, in addition to the supply of these amino acids, perform another important function in the cell.	UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY; UNIV MUNICH, KLIN CHEM HAUNERSCHEN KINDERKLIN, D-80336 MUNICH, GERMANY	University of Munich; University of Munich				Lill, Roland/0000-0002-8345-6518; Court, Deborah A./0000-0003-1919-8339				BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; Brunner M., 1994, SIGNAL PEPTIDASES, P73; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; HAMILTON PB, 1963, ANAL CHEM, V35, P2055, DOI 10.1021/ac60206a024; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P319; HUTSON SM, 1993, J BIOL CHEM, V268, P3084; Hutson SM, 1995, J BIOL CHEM, V270, P30344, DOI 10.1074/jbc.270.51.30344; INOUE K, 1988, J BIOCHEM-TOKYO, V104, P777, DOI 10.1093/oxfordjournals.jbchem.a122549; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KURAMITSU S, 1985, J BIOCHEM-TOKYO, V97, P993, DOI 10.1093/oxfordjournals.jbchem.a135176; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; LEONGMORGENTHALER P, 1994, BIOCHIMIE, V76, P45, DOI 10.1016/0300-9084(94)90061-2; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NIWA O, 1990, NUCLEIC ACIDS RES, V18, P6709, DOI 10.1093/nar/18.22.6709; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; ROSE MD, 1993, METHODS YEAST GENETI; RYAN ED, 1973, J BACTERIOL, V116, P222, DOI 10.1128/JB.116.1.222-225.1973; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; ZELENAYATROITSKAYA O, 1995, EMBO J, V14, P3268, DOI 10.1002/j.1460-2075.1995.tb07330.x; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723	45	116	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24458	24464		10.1074/jbc.271.40.24458	http://dx.doi.org/10.1074/jbc.271.40.24458			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798704	hybrid			2022-12-25	WOS:A1996VM67400026
J	Pastor, CM; Williams, D; Yoneyama, T; Hatakeyama, K; Singleton, S; Naylor, E; Billiar, TR				Pastor, CM; Williams, D; Yoneyama, T; Hatakeyama, K; Singleton, S; Naylor, E; Billiar, TR			Competition for tetrahydrobiopterin between phenylalanine hydroxylase and nitric oxide synthase in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FORMATION; SMOOTH-MUSCLE; CELL-LINE; HEPATOCYTES; SUBSTRATE; ENZYME; ARGININE; SUBUNITS; NITRATE; FLUIDS	Tetrahydrobiopterin (BH4) is an important cofactor for two hepatic enzymes, inducible nitric oxide synthase (iNOS) and phenylalanine hydroxylase (PAH), and competition for BH4 between the two enzymes might limit hepatic iNOS or PAH activity, To test this hypothesis, we determined whether conversion of phenylalanine to tyrosine was modified by changes in NO synthase activity, and conversely whether NO synthesis was limited by the rate of phenylalanine conversion to tyrosine in rat hepatocytes and perfused livers, NO production was decreased only slightly, when flux through PAH was maximized in isolated perfused livers, and in isolated hepatocytes only when BH4 synthesis was inhibited, Increases in NO synthesis did not reduce tyrosine formation from phenylalanine. Phenylalanine markedly increased biopterin synthesis, whereas arginine had no effect, Thus, basal BH4 synthesis appears to be adequate to support iNOS activity, whereas BH4 synthesis is increased to support PAH activity.	UNIV PITTSBURGH,DEPT SURG,PRESBYTERIAN UNIV HOSP A1010,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT BIOCHEM GENET,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Yoneyama, Tohru/ABG-2670-2020	Pastor, Catherine/0000-0002-1551-3824	NIGMS NIH HHS [GM-37753, GM-44100] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037753, R01GM044100, R37GM044100, R29GM044100] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GELLER DA, 1994, ARCH SURG-CHICAGO, V129, P165; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KAUFMAN S, 1959, J BIOL CHEM, V234, P2683; KLATT P, 1994, J BIOL CHEM, V269, P13861; MELLOUK S, 1994, INFECT IMMUN, V62, P4043, DOI 10.1128/IAI.62.9.4043-4046.1994; MITNAUL LJ, 1995, P NATL ACAD SCI USA, V92, P885, DOI 10.1073/pnas.92.3.885; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NAKAYAMA DK, 1994, AM J PHYSIOL, V266, pL455, DOI 10.1152/ajplung.1994.266.4.L455; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Pastor CM, 1995, AM J PHYSIOL-GASTR L, V269, pG861, DOI 10.1152/ajpgi.1995.269.6.G861; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; XIA T, 1994, J BIOL CHEM, V269, P24657	29	32	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24534	24538		10.1074/jbc.271.40.24534	http://dx.doi.org/10.1074/jbc.271.40.24534			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798714	hybrid, Green Published			2022-12-25	WOS:A1996VM67400036
J	Pitcher, JA; Fredericks, ZL; Stone, WC; Premont, RT; Stoffel, RH; Koch, WJ; Lefkowitz, RJ				Pitcher, JA; Fredericks, ZL; Stone, WC; Premont, RT; Stoffel, RH; Koch, WJ; Lefkowitz, RJ			Phosphatidylinositol 4,5-bisphosphate (PIP2)-enhanced G protein-coupled receptor kinase (GRK) activity - Location, structure, and regulation of the PIP2 binding site distinguishes the GRK subfamilies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PLECKSTRIN-HOMOLOGY DOMAIN; CRYSTAL-STRUCTURE; RHODOPSIN KINASE; EXPRESSION; MEMBRANES; FAMILY; ISOPRENYLATION; IDENTIFICATION; PURIFICATION	The G protein-coupled receptor kinases (GRKs) phosphorylate agonist occupied G protein-coupled receptors and play an important role in mediating receptor desensitization. The localization of these enzymes to their membrane incorporated substrates is required for their efficient function and appears to be a highly regulated process. In this study we demonstrate that phosphatidylinositol 4,5-bisphosphate (PIP2) enhances GRK5-mediated beta-adrenergic receptor (beta AR) phosphorylation by directly interacting with this enzyme and facilitating its membrane association. GRK5-mediated phosphorylation of a soluble peptide substrate is unaffected by PIP2, suggesting that the PIP2-enhanced receptor kinase activity arises as a consequence of this membrane localization. The lipid binding site of GRK5 exhibits a high degree of specificity and appears to reside in the amino terminus of this enzyme. Mutation of six basic residues at positions 22, 23, 24, 26, 28, and 29 of GRK5 ablates the ability of this kinase to bind PIP2. This region of the GRK5, which has a similar distribution of basic amino acids to the PIP2 binding site of gelsolin, is highly conserved between members of the GRK4 subfamily (GRK4, GRK5, and GRK6). Indeed, all the members of the GRK4 subfamily exhibit PIP2-dependent receptor kinase activity. We have shown previously that the membrane association of beta ARK (beta-adrenergic receptor kinase) (GRK2) is mediated, in vitro, by the simultaneous binding of PIP2 and the beta gamma subunits of heterotrimeric G proteins to the carboxyl-terminal pleckstrin homology domain of this enzyme (Pitcher, J. A., Touhara, K., Payne, E. S., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 11707-11710). Thus, five members of the GRK family bind PIP2, beta ARK (GRK2), beta ARK2 (GRK3), GRK4, GRK5, and GRK6. However, the structure, location, and regulation of the PIP2 binding site distinguishes the beta ARK (GRK2 and GRK3) and GRK4 (GRK4, GRK5, and GRK6) subfamilies.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CULLEN B, 1987, METHOD ENZYMOL, V152, P687; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FREEDMAN NJ, 1996, 1995 REC PROG HORM R, V51, P319; GARCIAHIGUERA I, 1994, J BIOL CHEM, V269, P1348; HASLAM RJ, 1993, NATURE, V363, P310; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JANMEY PA, 1995, CHEM BIOL, V2, P61, DOI 10.1016/1074-5521(95)90276-7; KIM CM, 1993, RECEPTOR, V3, P39; KUHN H, 1978, BIOCHEMISTRY-US, V21, P4389; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU FX, 1992, J BIOL CHEM, V267, P14616	35	146	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24907	24913		10.1074/jbc.271.40.24907	http://dx.doi.org/10.1074/jbc.271.40.24907			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798768	hybrid			2022-12-25	WOS:A1996VM67400091
J	Xu, X; Zeng, WH; Diaz, J; Muallem, S				Xu, X; Zeng, WH; Diaz, J; Muallem, S			Spacial compartmentalization of Ca2+ signaling complexes in pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; SENSITIVE CALCIUM POOL; BETA-GAMMA-SUBUNITS; G-PROTEINS; INOSITOL TRISPHOSPHATE; INTRACELLULAR STORES; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; CELLS; RELEASE	Imaging [Ca2+](i) at high temporal resolution and measuring the properties of Ca2+ signaling in streptolysin O (SLO)-permeabilized cells were used to study the spacial organization of signaling complexes. Sequential stimulation of single cells within pancreatic acini with several Ca2+-mobilizing agonists revealed an agonist-specific pattern and propagation rate of Ca2+ waves in the same cells, with CCK8 stimulating the fastest and bombesin the slowest waves. More importantly, each agonist initiated the wave in a different region of the same cell. On the other hand, repetitive stimulation with the same agonist induced Ca2+ waves of the same pattern that were initiated from the same region of the cell. The agonist-specific Ca2+ signaling does not appear to be the result of coupling to different G proteins as infusion of an anti-G alpha q antibody into the cells through a patch pipette equally inhibited Ca2+ signaling by all agonists. Further evidence for compartmentalization of signaling complexes was developed in permeabilized cells. The time-dependent loss of Ca2+ signaling due to SLO permeabiliation occurred in an agonist specific manner in the sequence cabachol > bombesin > cholecystokinin. Signaling by all agonists could be completely restored with as low as 2 mu M guanosine 5'-3-O-(thio)triphosphate (GTP gamma S). At this low concentration GTP gamma S recoupled inositol 1,4,5-trisphosphate production and Ca2+ release, rather than enhancing phospholipase C activity. Priming of Ca2+ signaling by GTP gamma S was agonist-specific. Guanosine 5'-O-(thio)diphosphate (GDP beta S) uncoupled the ability of signaling complexes to release Ca2+ much better than stimulating inositol 1,4,5-trisphosphate production. The uncoupling of Ca2+ signaling by GDP beta S was also agonist specific. The combined findings of agonist-specific initiation sites of the Ca2+ wave and differential access of guanine nucleotides to signaling complexes suggest spacial compartmentalization of Ca2+ signaling complexes. Each complex must include a receptor, G protein, and phospholipase C that are coupled to a specific portion of the Ca2+ pool.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046591, R01DK038938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46591, DK38938] Funding Source: Medline; NIGMS NIH HHS [GM31954] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harden T. Kendall, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P11; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KLUESS C, 1992, NATURE, V358, P424; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1989, J BIOL CHEM, V264, P205; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NEER EJ, 1995, CELL, V80, P246; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Williams John A., 1993, P167; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; XU X, 1994, J BIOL CHEM, V269, P12645; XU X, 1996, J BIOL CHEM, V271, P18520; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; ZHANG BX, 1994, J BIOL CHEM, V269, P17132	43	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24684	24690		10.1074/jbc.271.40.24684	http://dx.doi.org/10.1074/jbc.271.40.24684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798736	hybrid			2022-12-25	WOS:A1996VM67400058
J	Stoppler, H; Koval, D; Schlegel, R				Stoppler, H; Koval, D; Schlegel, R			The serine protease inhibitors TLCK and TPCK inhibit the in vitro immortalization of primary human keratinocytes by HPV-18 DNA	ONCOGENE			English	Article						HPV-immortalization; E7-Rb binding; serine protease inhibitors (TLCK/TPCK)	HUMAN PAPILLOMAVIRUS TYPE-16; LYSINE CHLOROMETHYL KETONE; RAT EMBRYO FIBROBLASTS; CATALYTIC SUBUNIT; TRANSFORMING GENE; E6 ONCOPROTEIN; KINASE-C; E7 GENE; HA-RAS; CELLS	The human papillomaviruses (HPV) which are commonly found in anogenital malignancies express viral E7 oncoprotein which possesses both immortalizing and transforming activities. The E7 protein forms a complex with the cellular tumor suppressor protein Rb and alters its interaction with transcription factor E2F, presumably interfering with cell cycle control and contributing to cellular transformation/immortalization. We demonstrated earlier that the serine protease inhibitors tosyl-L-phenylalanine chloromethyl ketone (TPCK) and tosyl-L-lysine chloromethyl ketone (TLCK) modified the HPV type 18 E7 protein in cell extracts as well as in Living cells and abrogated its ability to form a complex with Rb. In the present study we evaluated the effect of TLCK or TPCK treatment on the immortalization of primary keratinocytes by transfected HPV-18 DNA. Supplementing the medium of primary foreskin keratinocytes with TLCK or TPCK during their immortalization with HPV 18 DNA demonstrated that either TLCK (5-10 mu M) or TPCK (0.25 mu M) could inhibit cellular immortalization by 50-100% without altering keratinocyte proliferation, suggesting that the topical application of these reagents in ripe could significantly interfere with HPV-mediated cellular transformation.	GEORGETOWN UNIV, MED CTR, DEPT PATHOL, MOL PATHOBIOL PROGRAM, WASHINGTON, DC 20007 USA	Georgetown University								BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KINZEL V, 1980, BIOCHEM BIOPH RES CO, V93, P349, DOI 10.1016/0006-291X(80)91083-9; KUPFER A, 1979, P NATL ACAD SCI USA, V76, P3073, DOI 10.1073/pnas.76.7.3073; LALOU CI, 1993, BIOCHIMIE, V75, P443, DOI 10.1016/0300-9084(93)90109-6; LIU ZJ, 1994, VIROLOGY, V201, P388, DOI 10.1006/viro.1994.1306; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MUNGER K, 1989, J VIROL, V63, P4417; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHNEBLI HP, 1972, P NATL ACAD SCI USA, V69, P3825, DOI 10.1073/pnas.69.12.3825; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHAW E, 1970, PHYSIOL REV, V50, P244, DOI 10.1152/physrev.1970.50.2.244; SOLOMON DH, 1985, FEBS LETT, V190, P342, DOI 10.1016/0014-5793(85)81315-6; Stoppler H, 1996, VIROLOGY, V217, P542, DOI 10.1006/viro.1996.0149; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; TROLL W, 1970, SCIENCE, V169, P1211, DOI 10.1126/science.169.3951.1211; VILLA LL, 1991, VIROLOGY, V181, P374; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167	36	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1545	1548						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875993				2022-12-25	WOS:A1996VL38400020
J	Feller, G; leBussy, O; Houssier, C; Gerday, C				Feller, G; leBussy, O; Houssier, C; Gerday, C			Structural and functional aspects of chloride binding to Alteromonas haloplanctis alpha-amylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MODEL REFINEMENT; ANGSTROM RESOLUTION; CATALYTIC MECHANISM; SUBSTRATE; ASPERGILLUS; STABILITY; ENZYMES; SITE; SEQUENCE; CRYSTAL	Chloride is the allosteric effector of vertebrate pancreatic and salivary alpha-amylases and of the bacterial alpha-amylase from Alteromonas haloplanctis, Activation experiments of A. haloplanctis alpha-amylase by several monovalent anions show that a negative charge, not restricted to that of Cl-, is essential for the amylolytic reaction, Engineering of the chloride binding site reveals that a basic residue is an essential component of the site, The mutation K337R alters the Cl--binding properties, whereas the mutation K337Q produces an active, chloride-independent enzyme. Comparison of the K-d values for Cl- in three homologous alpha-amylases also indicates that the binding affinity is dependent on the chloride coordination mode by this basic residue. Analysis of substrate and chloride binding according to the allosteric kinetic model shows that the chloride effector is not involved in substrate binding, By contrast, the pH dependence of activity and experiments of chemical modifications and Ca2+ inhibition show that the chloride ion is responsible for the pK(alpha) shift of catalytic groups and interacts with active site carboxyl groups.			Feller, G (corresponding author), UNIV LIEGE,BIOCHEM LAB,INST CHEM B6,B-4000 LIEGE,BELGIUM.							BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BRADY RL, 1991, ACTA CRYSTALLOGR B, V47, P527, DOI 10.1107/S0108768191001908; BRAKE AJ, 1974, J BIOL CHEM, V249, P5452; BRAYER GD, 1995, PROTEIN SCI, V4, P1730, DOI 10.1002/pro.5560040908; BUSH DS, 1989, J BIOL CHEM, V264, P19392; CEASE KB, 1994, PCR METH APPL, V3, P298; FELLER G, 1994, EUR J BIOCHEM, V222, P441, DOI 10.1111/j.1432-1033.1994.tb18883.x; FELLER G, 1992, J BIOL CHEM, V267, P5217; HENSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545; ISHIKAWA K, 1990, BIOCHEMISTRY-US, V29, P7119, DOI 10.1021/bi00482a025; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P6259, DOI 10.1021/bi00075a020; JANECEK S, 1994, EUR J BIOCHEM, V224, P519, DOI 10.1111/j.1432-1033.1994.00519.x; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; LEVITZKI A, 1974, EUR J BIOCHEM, V41, P171, DOI 10.1111/j.1432-1033.1974.tb03257.x; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIFSHITZ R, 1976, BIOCHEMISTRY-US, V15, P1987, DOI 10.1021/bi00654a028; MACHIUS M, 1995, J MOL BIOL, V246, P545, DOI 10.1006/jmbi.1994.0106; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McCarter JD, 1996, J BIOL CHEM, V271, P6889, DOI 10.1074/jbc.271.12.6889; Mooser G., 1992, ENZYMES, P187; PETRA PH, 1971, BIOCHEMISTRY-US, V10, P3163, DOI 10.1021/bi00793a001; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; Ramasubbu N, 1996, ACTA CRYSTALLOGR D, V52, P435, DOI 10.1107/S0907444995014119; RAUSCHER E, 1985, CLIN CHEM, V31, P14; ROBERTSON SP, 1982, J BIOL CHEM, V257, P1743; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; SWIFT HJ, 1991, ACTA CRYSTALLOGR B, V47, P535, DOI 10.1107/S0108768191001970; TAO BY, 1989, BIOCHIM BIOPHYS ACTA, V995, P214, DOI 10.1016/0167-4838(89)90038-1; THOMA JA, 1971, ENZYMES, V5, P115; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; VIOLET M, 1989, BIOCHEM J, V263, P665, DOI 10.1042/bj2630665	37	81	82	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23836	23841		10.1074/jbc.271.39.23836	http://dx.doi.org/10.1074/jbc.271.39.23836			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798613	hybrid			2022-12-25	WOS:A1996VJ44200042
J	Boddy, MN; Howe, K; Etkin, LD; Solomon, E; Freemont, PS				Boddy, MN; Howe, K; Etkin, LD; Solomon, E; Freemont, PS			PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia	ONCOGENE			English	Article						APL; PML; interacting clone; ubiquitin-like	ZINC-FINGER; RAR-ALPHA; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; RING FINGER; GROWTH-SUPPRESSOR; FUSION PROTEINS; NUCLEAR MATRIX; SEQUENCE MOTIF; MESSENGER-RNAS	Acute promyelocytic leukaemia (APL) arises following a reciprocal translocation t(15;17) that fuses PML with retinoic acid receptor alpha (PAPA), The PML-RARA fusion protein targets and disrupts nuclear multiprotein complexes called PODs, ND10 or NBs, a process which is associated with a block in myeloid differentiation leading to APL, A human B-cell cDNA library was screened for PML-interacting clones and :I single positive clone (PIC1) was isolated, The sequence of PIC1 shows 52% identity to a S. cerevisiae ubiquitin-like protein that was cloned as a suppressor of mutations in MIF2, a protein required for mitotic spindle integrity during anaphase, Transient transfection of NIH3T3 cells with PIC1 results in a nuclear staining pattern coincident with that of endogenous mouse PML, Further, cotransfection of PIC1 with human PML produces a completely overlapping staining pattern between the two proteins, An antibody raised against PIC1 detects a punctate staining pattern in HeLa cells that is coincident with endogenous human PML. There is no significant colocalisation observed between the staining of PML/PML-RARA and PIC1 in an APL-derived cell line NB4, as compared to cells expressing only wild type PML. However, following all trans retinoic acid treatment of NB4 cells a significant relocalisation of PIC1 and PML is observed, PIC1 is the first identified NB-associated protein that interacts with PML, the function of which may lead to a fuller understanding of the molecular events leading to APL.	IMPERIAL CANC RES FUND, PROT STRUCT LAB, LONDON WC2A 3PX, ENGLAND; IMPERIAL CANC RES FUND, SOMAT CELL GENET LAB, LONDON WC2A 3PX, ENGLAND; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOL GENET, HOUSTON, TX 77030 USA	Cancer Research UK; Cancer Research UK; University of Texas System; UTMD Anderson Cancer Center			Boddy, Michael/A-7214-2009					ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1992, BRIT J HAEMATOL, V82, P529, DOI 10.1111/j.1365-2141.1992.tb06463.x; BROCARD MP, 1994, EUR J BIOCHEM, V221, P421, DOI 10.1111/j.1432-1033.1994.tb18754.x; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; JOHNS MB, 1989, ANAL BIOCHEM, V180, P276, DOI 10.1016/0003-2697(89)90430-2; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LINNEN JM, 1993, GENE, V128, P181, DOI 10.1016/0378-1119(93)90561-G; MEEKSWAGNER D, 1986, CELL, V44, P53, DOI 10.1016/0092-8674(86)90484-8; MELUH PB, 1995, MOL BIOL CELL, V6, P2095; MEREDITH M, 1995, VIROLOGY, V209, P174, DOI 10.1006/viro.1995.1241; MICHIELS L, 1993, ONCOGENE, V8, P2537; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MOSCOW JA, 1994, GENE, V144, P229, DOI 10.1016/0378-1119(94)90382-4; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; RANGANATHAN G, 1995, J BIOL CHEM, V270, P7149, DOI 10.1074/jbc.270.13.7149; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; STUURMAN N, 1992, J CELL SCI, V101, P773; SUDO K, 1994, GENOMICS, V24, P276, DOI 10.1006/geno.1994.1616; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TONIOLO D, 1988, P NATL ACAD SCI USA, V85, P851, DOI 10.1073/pnas.85.3.851; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	57	320	328	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					971	982						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806687				2022-12-25	WOS:A1996VG76600011
J	Knecht, H; McQuain, C; Martin, J; Rothenberger, S; Drexler, HG; Berger, C; Bachmann, E; Kittler, ELW; Odermatt, BF; Quesenberry, PJ				Knecht, H; McQuain, C; Martin, J; Rothenberger, S; Drexler, HG; Berger, C; Bachmann, E; Kittler, ELW; Odermatt, BF; Quesenberry, PJ			Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology	ONCOGENE			English	Article						LMP1; oncoprotein; Reed-Sternberg cells; giant cells; NF-kappa B; L-428 cell line; 293 cells	EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; ONCOGENE; GENE; ACTIVATION; DOMAIN; DNA; MEMBRANE-PROTEIN-1	The latent membrane protein 1 (LMP1) oncogene is one of the major proteins synthesized by the Epstein-Barr virus (EBV) and is expressed in Reed-Sternberg (RS) cells of EBV-associated Hodgkin's disease (HD), We have studied the effect of this oncoprotein on the formation of RS cells in the EBV-negative HD cell lines L-428 and KM-H2 as well as on the formation of multinucleated cells in the mononuclear human embryonic kidney cell line 293. LMP1 prototype (B95-8) and its naturally occurring carboxy terminal 30 base pair deletion variant LMP1-del were transfected into the cell lines and cytocentrifuge preparations were analysed after 24, 48, 72, 144, 216, and 240 h. While no oncoprotein expression was seen in the KM-H2 cell lines, expression of LMP1 and LMP1-del was observed in the L-428 and 293 cell lines, In the HD cell line L-428 oncoprotein expression was infrequent but when observed was very strong and preferentially associated with multinucleated RS cell morphology (71% of LMP1 positive cells), This is in contrast with the untransfected or transfected but not expressing cells where intermediate mononuclear elements predominated over multinucleated RS cells (< 3%), Frequent oncoprotein expression was observed in the 293 cells and again was associated with multinuclearity, These LMP1 expressing 293 giant cells showed strong expression of ICAM-1 (CD54), not detectable in the untransfected cells, In the LMP1-del transfectants giant cells with more than four nuclei were frequently observed, However, giant cells were much less frequent in 293 cells transfected with the amino terminal deletion variant of LMP1 or the lytic form of LMP1, known to induce low NF-kappa B activation compared to the LMP1 prototype, Therefore, LMP1 mediated NF-kappa B activation appears to be involved in polycaria formation, The strong association of LMP1 expression with multinuclearity in a genetically unstable condition - the L-428 and 293 cells show multiple chromosomal abnormalities - suggests that this oncoprotein including its naturally occurring carboxy terminal deletion variant promote the formation of multinuclear cells, in particular of RS cells in EBV-associated HD.	PURDUE UNIV,DEPT PHARMACOL,W LAFAYETTE,IN 47907; UNIV LAUSANNE,INST PHARMACOL,LAUSANNE,SWITZERLAND; GERMAN COLLECT MICROORGANISMS & CELL CULTURES,BRAUNSCHWEIG,GERMANY; INST PATHOL,LAB IMMUNOHISTOCHEM,ZURICH,SWITZERLAND	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Lausanne; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ)	Knecht, H (corresponding author), UNIV MASSACHUSETTS,MED CTR,CTR CANC,LINK LABS,DIV HEMATOL ONCOL,55 LAKE AVE N,WORCESTER,MA 01655, USA.			Rothenberger, Sylvia/0000-0001-8633-2994	NATIONAL CANCER INSTITUTE [R29CA064610] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bankier A T, 1983, Mol Biol Med, V1, P425; BROUSSET P, 1992, LAB INVEST, V67, P457; CHEN ML, 1992, ONCOGENE, V7, P2131; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DIEHL V, 1995, NEW ENGL J MED, V332, P461, DOI 10.1056/NEJM199502163320709; DREXLER HG, 1994, LEUKEMIA LYMPHOMA, V3, P201; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALUSKA FG, 1994, BLOOD, V84, P1005, DOI 10.1182/blood.V84.4.1005.bloodjournal8441005; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; HUEN DS, 1995, ONCOGENE, V10, P549; JOSKE D, 1993, BLOOD REV, V7, P215, DOI 10.1016/0268-960X(93)90008-R; KAMESAKI H, 1986, BLOOD, V68, P285; KAZAZI F, 1994, J GEN VIROL, V75, P2795, DOI 10.1099/0022-1317-75-10-2795; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1993, ACTA HAEMATOL-BASEL, V90, P167; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENG M, 1992, ONCOGENE, V7, P1775; PENGPILON M, 1995, J GEN VIROL, V76, P767, DOI 10.1099/0022-1317-76-4-767; Rothenberger S., 1995, Blood, V86, p741A; SCHAADT M, 1979, BLUT, V38, P185, DOI 10.1007/BF01007965; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WEBERMATTHIESEN K, 1995, BLOOD, V86, P1464, DOI 10.1182/blood.V86.4.1464.bloodjournal8641464; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	38	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					947	953						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806684				2022-12-25	WOS:A1996VG76600008
J	Bouzat, C; Barrantes, FJ				Bouzat, C; Barrantes, FJ			Modulation of muscle nicotinic acetylcholine receptors by the glucocorticoid hydrocortisone - Possible allosteric mechanism of channel blockade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-SUBUNIT; STEROIDS; PROTEIN; IDENTIFICATION; KINETICS; MODIFY; FETAL	Mechanisms of ion channel blockade by noncompetitive inhibitors of the nicotinic acetylcholine receptor (AChR) have been particularly difficult to elucidate, We have combined here transient expression of embryonic, adult, and a mutated adult muscle AChR associated with a slow channel syndrome (Ohno, K., Hutchinson, D. O. Milone, M., Brengman, J. M., Bouzat, C., Sine, S., and Engel, A. (1995) Proc. Natl. Acad, Sci, U. S. A, 92, 758-762) with single channel recordings to determine subunit specificity and mechanisms of action of the prototype glucocorticoid hydrocortisone (HC), HC affected in a similar manner the gating kinetics of all types of muscle AChR, producing briefer openings with normal amplitudes, We postulate that this steroid acts as a noncompetitive inhibitor of the AChR and that its mechanism of action can be interpreted in terms of blocking models, The forward rate constant for the blocking process was also similar for all channel types, indicating that the structural differences between them are not responsible for the effect, The reduction in the channel open time was not dependent on agonist concentration; it was slightly voltage dependent, suggesting that HC binds to a site located inside the membrane that senses the electric field, Recordings at high acetylcholine concentration in the presence of HC showed a reduced number of openings per activation period and the long closed times typically observed in the desensitization phenomenon, In competition studies with the classical open channel blocker QX-222, HC induced an early termination of the burst, suggesting that the two act at different sites, Taken together the results support the existence of specific sites sensed by the membrane field, different from those of open channel blockers and probably located at the lipid-protein interface, From this site(s), glucocorticoids and other hydrophobic noncompetitive inhibitors could allosterically mediate channel blockade.	INST INVEST BIOQUIM,RA-8000 BAHIA BLANCA,ARGENTINA				Barrantes, Francisco J./HCH-0258-2022	Barrantes, Francisco J./0000-0002-4745-681X				ADAMS PR, 1977, J PHYSIOL-LONDON, V268, P291, DOI 10.1113/jphysiol.1977.sp011858; AMADOR M, 1991, SYNAPSE, V7, P207, DOI 10.1002/syn.890070305; Barann M., 1996, Biophysical Journal, V70, pA76; BARRANTES FJ, 1989, CRIT REV BIOCHEM MOL, V24, P457; BARRY MA, 1993, MICROSC RES TECHNIQ, V26, P231, DOI 10.1002/jemt.1070260306; BENOIT P, 1993, NEUROSCI LETT, V160, P81, DOI 10.1016/0304-3940(93)90918-B; BERTRAND D, 1991, NEUROREPORT, V2, P277, DOI 10.1097/00001756-199105000-00016; BERTRAND D, 1995, NEUROSCIENCES, V7, P75; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BOUZAT C, 1994, NEURON, V13, P1395, DOI 10.1016/0896-6273(94)90424-3; BOUZAT C, 1993, NEUROREPORT, V4, P143, DOI 10.1097/00001756-199302000-00007; Bouzat Cecilia B., 1993, Molecular Neuropharmacology, V3, P109; CHARNET P, 1990, NEURON, V2, P87; DILGER JP, 1992, MOL PHARMACOL, V41, P127; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; Engel A., 1994, MYOLOGY; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1984, IONIC CHANNELS EXCIT; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MIDDLEMAS DS, 1987, BIOCHEMISTRY-US, V26, P1219, DOI 10.1021/bi00379a003; MILLER KW, 1991, ANN NY ACAD SCI, V625, P600, DOI 10.1111/j.1749-6632.1991.tb33895.x; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MURRAY N, 1995, NEURON, V14, P865, DOI 10.1016/0896-6273(95)90230-9; MURRELL RD, 1991, J PHYSIOL-LONDON, V437, P431, DOI 10.1113/jphysiol.1991.sp018604; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; PAPKE RL, 1993, PROG NEUROBIOL, V41, P509, DOI 10.1016/0301-0082(93)90028-Q; RAINES DE, 1995, ANESTHESIOLOGY, V82, P276, DOI 10.1097/00000542-199501000-00033; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; UEDA I, 1994, ANESTH ANALG, V78, P718; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; VALERA S, 1992, P NATL ACAD SCI USA, V89, P9949, DOI 10.1073/pnas.89.20.9949	34	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25835	25841		10.1074/jbc.271.42.25835	http://dx.doi.org/10.1074/jbc.271.42.25835			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824214	hybrid			2022-12-25	WOS:A1996VN18000020
J	Dotson, SB; Smith, CE; Ling, CS; Barry, GF; Kishore, GM				Dotson, SB; Smith, CE; Ling, CS; Barry, GF; Kishore, GM			Identification, characterization, and cloning of a phosphonate monoester hydrolase from Burkholderia caryophilli PG2982	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PSEUDOMONAS SP; DNA FRAGMENTS; ENZYME; GLYPHOSATE; EXPRESSION; SEQUENCES; SITE	The glyphosate degrading bacterium, Burkholderia caryophilli PG2982, was observed to utilize glyceryl glyphosate as a sole phosphorus source. The hydrolysis of glyceryl glyphosate to glyphosate by a phosphonate ester hydrolase (PEH) was identified as the first metabolic step in the mineralization pathway, This observation provides the first biological role for a phosphonate ester hydrolase activity, Purified PEH enzyme hydrolyzed several phosphonate esters including p-nitrophenyl phenylphosphonate, beta-naphthyl phenylphosphonate, and 5-bromo-4-chloro-3-indolyl phenylphosphonate, The purified PEH also hydrolyzed some phosphodiesters including p-nitrophenyl 5'-thymidine monophosphate and p-nitrophenyl phosphorylcholine. The most catalytically efficient substrate identified was bis-(p-nitrophenyl) phosphate with a K-m of 0.9 mM and a k(cat) of 6.2 x 10(2) min(-1), suggesting that the enzyme may also function in vice as a phosphodiesterase. The native enzyme was a homotetramer of 58-kDa subunits and exhibited a pi of 4.2. The enzyme activity had a pH activity optimum of 9.0 and was stimulated 14-fold by Mn2+ ions, but a metal cofactor was not essential for activity, N-terminal and tryptic fragment amino acid sequences were obtained from the purified PEH protein and used to clone the B. caryophilli PG2982 gene, designated pehA. The unique substrate specificity of the enzyme and potential use as a novel conditional lethal gene in plants are discussed.	GD SEARLE & CO,PROT BIOCHEM GRP,CHESTERFIELD,MO 63198; MONSANTO CORP RES,ANALYT SCI CTR,ST LOUIS,MO 63167; CEREGEN,CHESTERFIELD,MO 63198	Monsanto	Dotson, SB (corresponding author), MONSANTO CO,GD SEARLE & CO,GLYCOBIOL GRP,MAIL ZONE T3M,800 N LINDBERGH BLVD,ST LOUIS,MO 63167, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dhingra OP, 1988, United States Patent, Patent No. [4,735,649, 4735649]; Dotson SB, 1996, PLANT J, V10, P383, DOI 10.1046/j.1365-313X.1996.10020383.x; DWORKIN M, 1958, J BACTERIOL, V75, P592, DOI 10.1128/JB.75.5.592-603.1958; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FITZGIBBON J, 1988, APPL ENVIRON MICROB, V54, P1886, DOI 10.1128/AEM.54.7.1886-1888.1988; HAMES BD, 1985, GEL ELECTROPHORESIS, P1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; HYNIE I, 1970, CAN J BIOCHEM CELL B, V48, P1141, DOI 10.1139/o70-178; KELLY SJ, 1975, BIOCHEM BIOPH RES CO, V66, P316, DOI 10.1016/S0006-291X(75)80330-5; KELLY SJ, 1975, BIOCHEMISTRY-US, V14, P4983, DOI 10.1021/bi00693a030; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; KUNITZ M, 1950, J GEN PHYSIOL, V33, P349, DOI 10.1085/jgp.33.4.349; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEATHERBARROW RJ, 1992, ENZFITTER; LIAO TH, 1988, BIOCHEM J, V255, P781, DOI 10.1042/bj2550781; LITALIEN JJ, 1986, METHODS PROTEIN MICR, P279; MOORE JK, 1983, APPL ENVIRON MICROB, V46, P316, DOI 10.1128/AEM.46.2.316-320.1983; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILLING RJ, 1994, ANAL BIOCHEM, V216, P154, DOI 10.1006/abio.1994.1019; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WILLADSEN P, 1989, BIOCHEM J, V258, P79, DOI 10.1042/bj2580079; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZANKOWALCZEWSKA M, 1987, BIOCHEMISTRY-US, V26, P1194, DOI 10.1021/bi00378a030	30	32	37	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25754	25761		10.1074/jbc.271.42.25754	http://dx.doi.org/10.1074/jbc.271.42.25754			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824203	hybrid			2022-12-25	WOS:A1996VN18000009
J	Herbert, JM; Clowes, M; Lea, HJ; Pascal, M; Clowes, AW				Herbert, JM; Clowes, M; Lea, HJ; Pascal, M; Clowes, AW			Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC MESSENGER-RNA; PHORBOL ESTERS; DNA-SYNTHESIS; 3T3 CELLS; FOS; TRANSCRIPTION; MECHANISM; GROWTH; FIBROBLASTS; PROGRESSION	Heparin is a complex glycosaminoglycan that inhibits vascular smooth muscle cell (SMC) growth in vitro and in vivo. To define the mechanism by which heparin exerts its antiproliferative effects, we asked whether heparin interferes with the activity of intracellular protein kinase C (PKC). The membrane-associated intracellular PKC activity increased following stimulation of cultured rat SMCs with fetal calf serum and was suppressed by heparin in a time- and dose-dependent manner, Heparin acted through a selective inhibition of the PKC-alpha since preincubation of the cells with a 20-mer phosphorothioate PKC-alpha antisense oligodeoxynucleotide (ODN) eliminated the heparin effect. In vivo, following balloon injury of the rat carotid artery, particulate fraction PKC content increased with a time course and to an extent comparable with the observed changes in vitro. Heparin, administered at the time of injury or shortly thereafter, inhibited the activity of the particulate PKC and suppressed the in situ phosphorylation of an 80-kDa myristoylated alanine-rich protein kinase C substrate (MARCKS), a substrate of PKC, The topical application of the phosphorothioate antisense ODN selectively suppressed the expression of the PKC-alpha isoenzyme in vivo but did not affect injury-induced myointimal proliferation. Topical application of the ODN also eliminated the antiproliferative activity of heparin. These results therefore suggest that heparin might block SMC proliferation by interfering with the PKC pathway through a selective direct inhibition of the PKC-alpha isoenzyme.	UNIV WASHINGTON,DEPT SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Herbert, JM (corresponding author), SANOFI RECH,HEMOBIOL RES DEPT,195 ROUTE DESPAGNE,F-31036 TOULOUSE,FRANCE.							ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; AU YPT, 1992, J BIOL CHEM, V267, P3438; AU YPT, 1992, CIRC RES, V70, P1062, DOI 10.1161/01.RES.70.5.1062; AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P365; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CAMPISI J, 1982, EXP CELL RES, V140, P389, DOI 10.1016/0014-4827(82)90128-8; CASTELLOT JJ, 1987, SEMIN THROMB HEMOST, V13, P489, DOI 10.1055/s-2007-1003525; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DAMON DH, 1992, EXP CELL RES, V201, P154, DOI 10.1016/0014-4827(92)90359-G; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; GOUELI SA, 1991, FEBS LETT, V282, P445, DOI 10.1016/0014-5793(91)80533-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HERBERT JM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P432; HERBERT JM, 1990, BIOCHEM PHARMACOL, V9, P201; KARIYA K, 1987, EXP CELL RES, V173, P504, DOI 10.1016/0014-4827(87)90290-4; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; REILLY CF, 1989, J BIOL CHEM, V264, P6990; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; ROSS R, 1986, NEW ENGL J MED, V314, P448; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SKOGLUND G, 1985, EUR J BIOCHEM, V148, P407, DOI 10.1111/j.1432-1033.1985.tb08854.x; SMITH CD, 1992, BIOCHEM J, V281, P803, DOI 10.1042/bj2810803; STAUBLE B, 1993, BIOCHEM MOL BIOL INT, V29, P203; URATSUJI Y, 1988, J CELL PHYSIOL, V136, P431, DOI 10.1002/jcp.1041360306; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199; WRIGHT TN, 1989, AM REV RESPIR DIS, V140, P1132	41	196	207	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25928	25935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824227				2022-12-25	WOS:A1996VN18000033
J	Hoffmann, KF; Strand, M				Hoffmann, KF; Strand, M			Molecular identification of a Schistosoma mansoni tegumental protein with similarity to cytoplasmic dynein light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-ARM DYNEIN; SURFACE-ANTIGEN; MICE; PHOSPHORYLATION; GLYCOPROTEINS; FLAGELLA; CALNEXIN; CLONING; SMIRV1; SERA	The tegument of Schistosoma mansoni contains a number of proteins that presumably function in its maintenance and/or repair against damage incurred from host-mediated humoral immune responses. Here, we show that the schistosome antigen identified by monoclonal antibody 709A2/2 is a cytoplasmic dynein light chain, Dynein light chains are components of dynein, an enzyme complex involved in various aspects of microtubule-based motility. Monoclonal antibody 709A2/2 recognizes two polypeptides, one of 8.9 kDa and a second of 7.6 kDa, as determined by SDS-polyacrylamide gel electrophoresis. me find that expression of S. mansoni dynein light chain is developmentally regulated and localized to the tegument in the schistosomula, lung stage worms, and adult worms, but is not present in the cercariae or ciliated miracidia. By Northern blot analysis of adult worm RNA, S. mansoni dynein light chain is encoded by a single message of similar to 600 base pairs. A cDNA encoding this polypeptide contains an open reading frame of 89 amino acids with a deduced molecular mass of 10.4 kDa. Coprecipitation of an apparent 18.4-kDa antigen with S. mansoni dynein light chain by monoclonal antibody 709A2/2 illustrates that this molecule has an affinity for other proteins. Such interactions may play a role in S. mansoni dynein Light chain participation in organelle trafficking in S. mansoni.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOL SCI, CTR MONOCLONAL STUDIES, BALTIMORE, MD 21205 USA	Johns Hopkins University				Hoffmann, Karl/0000-0002-3932-5502	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI019217, R37AI019217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007626] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19217, AI-55270] Funding Source: Medline; NIGMS NIH HHS [5732 GM07626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; BERGQUIST NR, 1995, PARASITOL TODAY, V11, P191, DOI 10.1016/0169-4758(95)80157-X; BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUTTERWORTH AE, 1987, PARASITOL TODAY, V3, P11, DOI 10.1016/0169-4758(87)90091-3; CIANFRIGLIA M, 1983, HYBRIDOMA, V2, P451, DOI 10.1089/hyb.1983.2.451; DALTON JP, 1986, J IMMUNOL, V136, P4689; DALTON JP, 1987, P NATL ACAD SCI USA, V84, P4268, DOI 10.1073/pnas.84.12.4268; Dick T, 1996, MOL GEN GENET, V251, P38; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harlow E., 1989, ANTIBODIES LAB MANUA; HAWN TR, 1993, J BIOL CHEM, V268, P7692; HAWN TR, 1994, J BIOL CHEM, V269, P20083; Hockley D.J., 1973, Advances Parasit, V11, P233, DOI 10.1016/S0065-308X(08)60188-8; HOCKLEY D J, 1973, International Journal for Parasitology, V3, P13, DOI 10.1016/0020-7519(73)90004-0; Holzbaur Erika L. F., 1994, V13, P251; KING SM, 1990, CELL MOTIL CYTOSKEL, V16, P266, DOI 10.1002/cm.970160406; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KOSTER B, 1994, PARASITOLOGY, V108, P433, DOI 10.1017/S0031182000075995; KOSTER B, 1994, ARCH BIOCHEM BIOPHYS, V310, P108, DOI 10.1006/abbi.1994.1146; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; LEWIS SA, 1988, THESIS J HOPKINS U; MONELL CR, 1992, THESIS J HOPKINS U; NORDEN AP, 1985, AM J TROP MED HYG, V34, P495, DOI 10.4269/ajtmh.1985.34.495; OAKS JA, 1981, J PARASITOL, V67, P761, DOI 10.2307/3280697; REYNOLDS SR, 1994, J IMMUNOL, V152, P193; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATIR P, 1995, BIOPHYS J, V68, pS222; SOISSON LMA, 1992, J IMMUNOL, V149, P3612; STEPHENS RE, 1992, J CELL SCI, V103, P999; Stirewalt M.A., 1974, Advances Parasit, V12, P115, DOI 10.1016/S0065-308X(08)60388-7; STRAND M, 1982, EXP PARASITOL, V54, P145, DOI 10.1016/0014-4894(82)90121-7; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; VALLEE R, 1993, P NATL ACAD SCI USA, V90, P8769, DOI 10.1073/pnas.90.19.8769; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WITMAN G B, 1992, Current Opinion in Cell Biology, V4, P74; Witman George B., 1994, V13, P229	40	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26117	26123		10.1074/jbc.271.42.26117	http://dx.doi.org/10.1074/jbc.271.42.26117			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824255	hybrid			2022-12-25	WOS:A1996VN18000061
J	Ricketts, WA; Rose, DW; Shoelson, S; Olefsky, JM				Ricketts, WA; Rose, DW; Shoelson, S; Olefsky, JM			Functional roles of the Shc phosphotyrosine binding and Src homology 2 domains in insulin and epidermal growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; PROTEIN SHC; PTB DOMAIN; NPXY MOTIF; ASSOCIATION; ACTIVATION; PATHWAY; SITES; RAS	Shc is involved in the activation of Ras in response to many growth factors. Shc contains two phosphotyrosine binding domains, an Src homology 2 (SH2) domain in the carboxyl terminus of the protein and a phosphotyrosine binding (PTB) domain in the amino terminus. Since functional roles for these two domains have not been established, we microinjected glutathione S-transferase fusion proteins of either the Shc PTB or SH2 domains into fibroblasts expressing insulin and epidermal growth factor receptors and measured their effects on DNA synthesis. We found that the Shc PTB was necessary for insulin-induced mitogenic signaling, whereas the SH2 domain was not. In contrast, for epidermal growth factor signaling, the Shc SH2 was functionally more important. These differential modes of signal transduction may be an important factor in determining the specificity of the response of a cell to external stimuli.	UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM RES SERV,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,BIOMED SCI GRAD PROGRAM,SAN DIEGO,CA 92103; WHITTIER DIABET PROGRAM,LA JOLLA,CA 92093; JOSLIN DIABET CTR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KABURAGI Y, 1995, ENDOCRINOLOGY, V136, P3437, DOI 10.1210/en.136.8.3437; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SOLER C, 1994, ONCOGENE, V9, P2207; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; THIES RA, 1990, J BIOL CHEM, V265, P1032; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085	28	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26165	26169		10.1074/jbc.271.42.26165	http://dx.doi.org/10.1074/jbc.271.42.26165			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824262	hybrid			2022-12-25	WOS:A1996VN18000068
J	Scholl, D; Nixon, BT				Scholl, D; Nixon, BT			Cooperative binding of DctD to the dctA upstream activation sequence of Rhizobium meliloti is enhanced in a constitutively active truncated mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA INTERACTIONS; SIGMA(54)-DEPENDENT TRANSCRIPTIONAL ACTIVATOR; C-4-DICARBOXYLATE TRANSPORT GENES; DICARBOXYLIC-ACID TRANSPORT; NITROGEN REGULATOR-I; CI-REPRESSOR; ENVIRONMENTAL STIMULI; BACTERIOPHAGE-LAMBDA; PARAMETER-ESTIMATION; SIGNAL-TRANSDUCTION	DctD, a sigma(54)-dependent, two-component regulator, binds to promoter distal (A) and promoter proximal (B) sites in an activation sequence located upstream of the dctA promoter. We report gel filtration and quantitative DNase I footprint experiments supporting a model in which DctD(2) binds to these sites cooperatively, The global analysis of upstream activation sequences containing sites A and B, A and B one-half helical turn out of phase, and only B yielded values for the intrinsic and cooperative binding free energies of Delta G(A)(0) = -9.5 +/- 0.3, Delta G(B)(0) = -11.2 +/- 0.2, and Delta G(AB)(0) = -2.5 +/- 0.5. A separate analysis of data from upstream activation sequences containing site A and a point mutant of site B, and site A and mutant site B one-half helical turn out of phase confirmed the estimate of cooperativity, yielding free energy values of Delta G(A)(0) = -9.4 +/- 0.2, Delta G(B(G-->C))(0) = -10.0 +/- 0.2, and Delta G(AB(G-->C))(0) = -2.2 +/- 0.4. We previously showed that removing the two-component receiver domain from DctD, making DctD(Delta(1-142)), yields a constitutively active truncated protein. Global analysis of binding data for DctD(Delta(1-142)) showed that this constitutively active mutant has intrinsic binding energies equal to that of the inactive DctD protein, but that it displays significantly higher cooperativity (Delta G(A)(0) = -9.4 +/- 0.6, Delta G(B)(0) = -11.1 +/- 0.3, and Delta G(AB)(0) = -3.8 +/- 0.6.).	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM40404] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040404, R55GM040404] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; ARWAS R, 1985, J GEN MICROBIOL, V131, P2059; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BOLTON E, 1986, ARCH MICROBIOL, V144, P142, DOI 10.1007/BF00414724; BRENOWITZ M, 1989, NUCLEIC ACIDS RES, V17, P3747, DOI 10.1093/nar/17.10.3747; CHEN P, 1995, J BACTERIOL, V177, P2490, DOI 10.1128/jb.177.9.2490-2496.1995; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; ENGELKE T, 1987, J GEN MICROBIOL, V133, P3019; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; FINAN TM, 1988, J BACTERIOL, V170, P3396, DOI 10.1128/jb.170.8.3396-3403.1988; GIBLIN L, 1995, FEMS MICROBIOL LETT, V126, P25, DOI 10.1016/0378-1097(94)00520-2; GU BH, 1994, MOL MICROBIOL, V13, P51, DOI 10.1111/j.1365-2958.1994.tb00401.x; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; JIANG J, 1989, J BACTERIOL, V171, P5244, DOI 10.1128/jb.171.10.5244-5253.1989; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KOBLAN KS, 1992, METHOD ENZYMOL, V210, P405; LABES M, 1993, J BACTERIOL, V175, P2674, DOI 10.1128/JB.175.9.2674-2681.1993; LEDEBUR H, 1990, J BACTERIOL, V172, P3888, DOI 10.1128/jb.172.7.3888-3897.1990; LEDEBUR H, 1992, MOL MICROBIOL, V6, P3479, DOI 10.1111/j.1365-2958.1992.tb01783.x; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; LEE JH, 1994, J BIOL CHEM, V269, P20401; Maniatis T., 1982, MOL CLONING LABORATO, P86; MERABET E, 1995, BIOCHEMISTRY-US, V34, P8554, DOI 10.1021/bi00027a005; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Ronson C. W., 1985, Nitrogen fixation research progress. Proceedings of the 6th International Symposium on Nitrogen Fixation, Corvallis, OR, USA, August 4-10. 1985., P201; RONSON CW, 1987, J BACTERIOL, V169, P2424, DOI 10.1128/jb.169.6.2424-2431.1987; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; RONSON CW, 1981, P NATL ACAD SCI-BIOL, V78, P4284, DOI 10.1073/pnas.78.7.4284; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; SAROFF HA, 1993, BIOPOLYMERS, V33, P1327, DOI 10.1002/bip.360330903; SENEAR DF, 1993, ELECTROPHORESIS, V14, P704, DOI 10.1002/elps.11501401112; SENEAR DF, 1992, METHOD ENZYMOL, V210, P463; SENEAR DF, 1986, BIOCHEMISTRY-US, V25, P7344, DOI 10.1021/bi00371a016; SENEAR DF, 1993, BIOCHEMISTRY-US, V32, P6179, DOI 10.1021/bi00075a010; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; STRAHS D, 1994, J MOL BIOL, V244, P494, DOI 10.1006/jmbi.1994.1748; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WANG YP, 1989, GENE, V85, P135, DOI 10.1016/0378-1119(89)90473-3; WATSON RJ, 1990, MOL PLANT MICROBE IN, V3, P174, DOI 10.1094/MPMI-3-174; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; YAROSH OK, 1989, MOL MICROBIOL, V3, P813, DOI 10.1111/j.1365-2958.1989.tb00230.x	46	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26435	26442		10.1074/jbc.271.42.26435	http://dx.doi.org/10.1074/jbc.271.42.26435			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824302	hybrid			2022-12-25	WOS:A1996VN18000108
J	Wimalasena, K; Dharmasena, S; Wimalasena, DS; HughbanksWheaton, DK				Wimalasena, K; Dharmasena, S; Wimalasena, DS; HughbanksWheaton, DK			Reduction of dopamine beta-monooxygenase - A unified model for apparent negative cooperativity and fumarate activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN-GRANULE GHOSTS; REDUCING EQUIVALENTS; ADRENAL-MEDULLA; ASCORBATE; MEMBRANE; MECHANISM; HYDROXYLASE; COPPER; ACID	The interactions of reductants with dopamine beta-monooxygenase (D beta M) were examined using two novel classes of reductants. The steady-state kinetics of the previously characterized D beta M reductant, N,N-dimethyl-1,4-p-phenylenediamine (DMPD), were parallel to the ascorbic acid-supported reaction with respect to pH dependence and fumarate activation, DMPD also displayed pH and fumarate-dependent apparent negative cooperativity demonstrating that the previously reported cooperative behavior of D beta M toward the reductant is not unique to ascorbic acid, The 6-OH phenyl and alkylphenyl-substituted ascorbic acid derivatives were more efficient reductants for the enzyme than ascorbic acid. Kinetic studies suggested that these derivatives behave as pseudo bisubstrates with respect to ascorbic acid and the amine substrate, The lack of apparent cooperative behavior with these derivatives suggests that this behavior of D beta M is not common for all the reductants, Based on these findings and additional kinetic evidence, the proposal that the apparent negative cooperativity in the interaction of ascorbic acid with D beta M was due to the presence of a distinct allosteric regulatory site has been ruled out, In contrast to previous models, where fumarate was proposed to interact with a distinct anion binding site, the effect of fumarate on the steady state kinetics of these novel reductants suggests that fumarate and the reductant may interact with the same site of the enzyme, In accordance with these observations and mathematical analysis of the experimental data, a unified model for the apparent negative cooperativity and fumarate activation of D beta M in which both fumarate and the reductant interact with the same site of all forms of the enzyme with varying affinities under steady state turnover conditions has been proposed.			Wimalasena, K (corresponding author), WICHITA STATE UNIV,DEPT CHEM,WICHITA,KS 67260, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045026, R01GM045026] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45026] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN N, 1983, BIOCHEMISTRY-US, V22, P3096, DOI 10.1021/bi00282a012; ALBERTY RA, 1954, J AM CHEM SOC, V76, P2485, DOI 10.1021/ja01638a053; BEERS MF, 1986, J BIOL CHEM, V261, P2529; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; Cleland W W, 1979, Methods Enzymol, V63, P103; CRAINE JE, 1973, J BIOL CHEM, V248, P7838; FERSHT A, 1984, ENZYME STRUCTURE MEC, P263; GOLDSTEIN M, 1968, BIOCHEMISTRY-US, V7, P2724, DOI 10.1021/bi00848a005; HUYGHE BG, 1991, J BIOL CHEM, V266, P11544; INGEBRETSEN OC, 1980, BIOCHIM BIOPHYS ACTA, V628, P182, DOI 10.1016/0304-4165(80)90365-7; KELLEY DM, 1986, J BIOL CHEM, V261, P6429; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; LEVIN EY, 1960, J BIOL CHEM, V235, P2080; LJONES T, 1976, EUR J BIOCHEM, V6, P525; LJONES T, 1984, COPPER PROTEINS COPP, V2, P131; Michaelis L., 1939, J AM CHEM SOC, V61, P1981; NJUS D, 1983, J BIOL CHEM, V258, P27; NJUS D, 1979, BIOCHEM J, V180, P579, DOI 10.1042/bj1800579; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; RAO PS, 1975, J PHYS CHEM-US, V79, P1063, DOI 10.1021/j100578a005; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SKOTLAND T, 1979, INORG PERSPECT BIOL, V2, P151; SLATER EP, 1981, ARCH BIOCHEM BIOPHYS, V211, P288, DOI 10.1016/0003-9861(81)90456-2; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STEWART LC, 1991, J BIOL CHEM, V266, P11537; VILLAFRANCA JJ, 1981, METAL IONS BIOL, V3, P263; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WIMALASENA K, 1994, BIOCHEM BIOPH RES CO, V200, P113, DOI 10.1006/bbrc.1994.1422; WIMALASENA K, 1991, BIOCHEM BIOPH RES CO, V175, P920, DOI 10.1016/0006-291X(91)91653-T; WIMALASENA K, 1991, ANAL BIOCHEM, V197, P353, DOI 10.1016/0003-2697(91)90404-H; WIMALASENA K, 1995, J BIOL CHEM, V270, P27516, DOI 10.1074/jbc.270.46.27516; WINKLER H, 1970, BIOCHEM J, V118, P303, DOI 10.1042/bj1180303	32	10	10	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26032	26043		10.1074/jbc.271.42.26032	http://dx.doi.org/10.1074/jbc.271.42.26032			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824243	Green Submitted, hybrid			2022-12-25	WOS:A1996VN18000049
J	Dahl, SW; Rasmussen, SK; Hejgaard, J				Dahl, SW; Rasmussen, SK; Hejgaard, J			Heterologous expression of three plant serpins with distinct inhibitory specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; AMINO-ACID; CONFORMATIONAL CHANGE; BARLEY ENDOSPERM; STRUCTURAL BASIS; PROTEIN-Z; CHYMOTRYPSIN; GENE; ALPHA-2-ANTIPLASMIN; ANTITHROMBIN	For the first time, inhibitory plant serpins, including WSZ1 from wheat, BSZ4, and the previously unknown protein BSZx from barley, have been expressed in Escherichia coli, and a procedure for fast purification of native plant serpins has been developed, BSZx, BSZ4, and WSZ1 were assayed for inhibitory activity against trypsin, chymotrypsin, and cathepsin G, and cleavage sites in the reactive center loop were identified by sequencing. BSZx proved to be a potent inhibitor with specific, overlapping reactive centers either at P-1 Arg for trypsin or at P-2 Leu for chymotrypsin, At 22 degrees C, the apparent rate constant for chymotrypsin inhibition at P-2 (k(a) = 9.4 x 10(5) M(-1) s(-1)) was only four times lower than for trypsin at P-1 (k(a) = 3.9 X 10(6) M(-1) s(-1)), and the apparent inhibition stoichiometries were close to 1. Furthermore, our data suggest that cathepsin G was inhibited by BSZx (k(a) = 3.9 x 10(6) M(-1) s(-1)) at both the P-1 Arg and P-2 Leu. These results indicate a unique adaptability of the reactive center loop of BSZx. WSZ1 inhibited chymotrypsin (k(a) = 1.1 x 10(5) M(-1) s(-1)) and cathepsin G (k(a) = 7.6 x 10(3) M(-1) s(-1)) at P-2 Gln and not, as for BSZx, at the more favorable P-2 Leu. BSZ4 inhibited cathepsin G (k(a) = 2.7 x 10(4) M(-1) s(-1)) at P-1 Met but was hydrolyzed by trypsin and chymotrypsin. The three plant serpins formed stable SDS-resistant complexes with the proteinases in accordance with the kinetic data.	TECH UNIV DENMARK,DEPT BIOCHEM & NUTR,DK-2800 LYNGBY,DENMARK; RISO NATL LAB,DEPT ENVIRONM SCI & TECHNOL,DK-4000 ROSKILDE,DENMARK	Technical University of Denmark; Technical University of Denmark			Rasmussen, Soren K./F-6728-2014	Rasmussen, Soren K./0000-0001-6169-2504				AULAK KS, 1993, PROTEIN SCI, V2, P727, DOI 10.1002/pro.5560020504; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BRANDT A, 1990, EUR J BIOCHEM, V194, P499, DOI 10.1111/j.1432-1033.1990.tb15644.x; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; DRAG B, 1994, FIBRINOLYSIS, V8, P192, DOI 10.1016/S0268-9499(05)80019-0; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; FERSHT A, 1977, ENZYME STRUCTURE MEC, P256; GETTINS P, 1989, J BIOL CHEM, V264, P3781; HEJGAARD J, 1985, FEBS LETT, V180, P89, DOI 10.1016/0014-5793(85)80238-6; HEJGAARD J, 1994, BBA-PROTEIN STRUCT M, V1204, P68, DOI 10.1016/0167-4838(94)90034-5; HEJGAARD J, 1982, PHYSIOL PLANTARUM, V54, P174, DOI 10.1111/j.1399-3054.1982.tb06322.x; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHANSSON A, 1992, PLANT MOL BIOL, V18, P1151, DOI 10.1007/BF00047718; LENNICK M, 1986, BIOCHEMISTRY-US, V25, P3890, DOI 10.1021/bi00361a023; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LUNDGARD R, 1989, CARLSBERG RES COMMUN, V54, P173, DOI 10.1007/BF02904471; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; PATSTON PA, 1995, THROMB HAEMOSTASIS, V20, P410; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RASMUSSEN SK, 1993, BIOCHIM BIOPHYS ACTA, V1172, P151, DOI 10.1016/0167-4781(93)90282-I; Rasmussen SK, 1996, PLANT MOL BIOL, V30, P673, DOI 10.1007/BF00049343; ROSENKRANDS I, 1994, FEBS LETT, V343, P75, DOI 10.1016/0014-5793(94)80610-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; WRIGHT HT, 1993, J MOL EVOL, V36, P136, DOI 10.1007/BF00166249	38	62	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25083	25088		10.1074/jbc.271.41.25083	http://dx.doi.org/10.1074/jbc.271.41.25083			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810262	hybrid			2022-12-25	WOS:A1996VL69300006
J	Kondejewski, LH; Farmer, SW; Wishart, DS; Kay, CM; Hancock, REW; Hodges, RS				Kondejewski, LH; Farmer, SW; Wishart, DS; Kay, CM; Hancock, REW; Hodges, RS			Modulation of structure and antibacterial and hemolytic activity by ring size in cyclic gramicidin S analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; OUTER-MEMBRANE; ANTIMICROBIAL ACTIVITY; SECONDARY STRUCTURE; MODEL PEPTIDES; ANTIBIOTICS; POLYMYXIN; HYDROPHOBICITY	We have evaluated the effect of ring size of gramicidin S analogs on secondary structure, lipid binding, lipid disruption, antibacterial and hemolytic activity, Cyclic analogs with ring sizes ranging from 4 to 14 residues were designed to maintain the amphipathic character as found in gramicidin S and synthesized by solid phase peptide synthesis. The secondary structure of these peptides showed a definite periodicity in beta-sheet content, with rings containing 6, 10, and 14 residues exhibiting beta-sheet structure, and rings containing 8 or 12 residues being largely disordered, Peptides containing 4 or 6 residues did not bind lipopolysaccharide, whereas longer peptides showed a trend of increasing binding affinity for Lipopolysaccharide with increasing length, Destabilization of Escherichia coli outer membranes was only observed in peptides containing 10 or more residues, Peptides containing fewer than 10 residues were completely inactive and exhibited no hemolytic activity, The 10-residue peptide showed an activity profile similar to that of gramicidin S itself, with activity against Gram-positive and Gram negative microorganisms as well as yeast, but also showed high hemolytic activity, Differential activities were obtained by increasing the size of the ring to either 12 or 14 residues, The 14-residue peptide showed no antibiotic activity but exhibited increased hemolytic activity, The 12-residue peptide lost activity against Gram-positive bacteria, retained activity against Gram-negative microorganisms and yeast, but displayed decreased hemolytic activity, Biological activities in the 12-residue peptide were optimized by a series of substitutions in residues comprising both hydrophobic and basic sites resulting in a peptide that exhibited activities comparable with gramicidin S against Gram-negative microorganisms and yeast but with substantially lower hemolytic activity, Compared with gramicidin S, the best analog showed a 10-fold improvement in antibiotic specificity for Gram-negative microorganisms and a 7-fold improvement in specificity for yeast over human erythrocytes as determined by a therapeutic index. These results indicate that it is possible to modulate structure and activities of cyclic gramicidin S analogs by varying ring sizes and further show the potential for developing clinically useful antibiotics based on gramicidin S.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON,AB T6G 2S2,CANADA; UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,CANADIAN BACTERIAL DIS NETWORK,VANCOUVER,BC V6T 1Z3,CANADA; UNIV ALBERTA,FAC PHARM,EDMONTON,AB T6G 2N8,CANADA	University of Alberta; University of Alberta; University of British Columbia; University of British Columbia; University of Alberta			Wishart, David Scott/ABI-3181-2020; Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503; Wishart, David S/0000-0002-3207-2434; Farmer, Susan/0000-0002-6712-7810				ALTMANN KH, 1990, INT J BIOCHEM, V22, P947, DOI 10.1016/0020-711X(90)90200-M; ANDO S, 1993, BIOCHIM BIOPHYS ACTA, V1147, P42, DOI 10.1016/0005-2736(93)90314-P; ANDO S, 1995, INT J PEPT PROT RES, V46, P97; ANGUS BL, 1987, J GEN MICROBIOL, V133, P2905; AOYAGI H, 1988, TETRAHEDRON, V44, P877, DOI 10.1016/S0040-4020(01)86123-8; BOMAN HG, 1989, FEBS LETT, V259, P103, DOI 10.1016/0014-5793(89)81505-4; CLARK D, 1984, FEMS MICROBIOL LETT, V21, P189; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P171; Erickson B. W., 1976, PROTEINS, VII, P255; Gause GF, 1944, NATURE, V154, P703, DOI 10.1038/154703a0; HANCOCK REW, 1984, ANTIMICROB AGENTS CH, V26, P48, DOI 10.1128/AAC.26.1.48; HANCOCK REW, 1981, J ANTIMICROB CHEMOTH, V8, P429, DOI 10.1093/jac/8.6.429; HANCOCK REW, 1993, ANTIMICROB AGENTS CH, V37, P453, DOI 10.1128/AAC.37.3.453; HODGKIN DC, 1957, BIOCHEM J, V65, P752, DOI 10.1042/bj0650752; HULL SE, 1978, NATURE, V275, P206, DOI 10.1038/275206a0; IZUMIYA N, 1979, SYNTHETIC ASPECTS BI, P49; KATAYAMA T, 1994, J PHARM SCI, V83, P1357, DOI 10.1002/jps.2600830930; KATSU T, 1993, BIOL PHARM BULL, V16, P178; KITAGAWA T, 1994, CHEM PHARM BULL, V42, P1655; Kondejewski LH, 1996, INT J PEPT PROT RES, V47, P460; KREISWIRTH BN, 1983, NATURE, V305, P704; LAMBERT HP, 1992, ANTIBIOT CHEMOTHER, P232; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; MAEDA T, 1993, J FERMENT BIOENG, V75, P173, DOI 10.1016/0922-338X(93)90110-T; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OVCHINNIKOV YA, 1975, TETRAHEDRON, V31, P2177, DOI 10.1016/0040-4020(75)80216-X; OVCHINNIKOV YA, 1982, PROTEINS, V5, P391; PATHAK N, 1995, PROTEINS, V22, P182, DOI 10.1002/prot.340220210; PETERSON AA, 1987, ANTIMICROB AGENTS CH, V31, P230, DOI 10.1128/AAC.31.2.230; PORTLOCK SH, 1990, BIOCHIM BIOPHYS ACTA, V1030, P1, DOI 10.1016/0005-2736(90)90231-C; RACKOVSKY S, 1980, P NATL ACAD SCI USA, V77, P6965, DOI 10.1073/pnas.77.12.6965; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; SCHWYZER R, 1964, HELV CHIM ACTA, V47, P441, DOI 10.1002/hlca.19640470213; SCHWYZER R, 1969, HELV CHIM ACTA, V52, P2033, DOI 10.1002/hlca.19690520726; Schwyzer R., 1958, CHIMIA, V12, P53; SCHWYZER R, 1958, CHIMIA, V12, P90; TAMAKI M, 1987, J CHROMATOGR-BIOMED, V413, P287, DOI 10.1016/0378-4347(87)80241-4; TAMAKI M, 1991, B CHEM SOC JPN, V64, P2569, DOI 10.1246/bcsj.64.2569; TAMAKI M, 1988, B CHEM SOC JPN, V61, P3925, DOI 10.1246/bcsj.61.3925; TAMAKI M, 1995, INT J PEPT PROT RES, V45, P299; THENNARASU S, 1995, INT J PEPT PROT RES, V46, P480; TYTLER EM, 1995, BIOCHEMISTRY-US, V34, P4393, DOI 10.1021/bi00013a031; Wishart DS, 1996, LETT PEPT SCI, V3, P53, DOI 10.1007/BF00131086; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WISHART DS, 1995, TECHNIQUES PROTEIN C, V4, P451; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; YUKIOKA M, 1966, J BIOCHEM, V60, P295, DOI 10.1093/oxfordjournals.jbchem.a128436; ZIDOVETZKI R, 1988, BIOCHEMISTRY-US, V27, P5686, DOI 10.1021/bi00415a044	50	163	165	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25261	25268		10.1074/jbc.271.41.25261	http://dx.doi.org/10.1074/jbc.271.41.25261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810288	hybrid			2022-12-25	WOS:A1996VL69300032
J	vanGeest, M; Lolkema, JS				vanGeest, M; Lolkema, JS			Membrane topology of the sodium ion-dependent citrate carrier of Klebsiella pneumoniae - Evidence for a new structural class of secondary transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOSE PERMEASE; GENE FUSIONS; PROTEIN; SEQUENCE; EXPRESSION; PHOA; INSERTION; BACTERIA	The predicted secondary structure model of the sodium ion-dependent citrate carrier of Klebsiella pneumoniae (CitS) presents the la-transmembrane helix motif observed for many secondary transporters, Biochemical evidence presented in this paper is not consistent with this model. N-terminal and C-terminal fusions of CitS with the biotin acceptor domain of the oxaloacetate decarboxylase of K. pneumoniae catalyze citrate transport, showing the correct folding of the CitS part of the fusion proteins in the membrane. Proteolysis experiments with these fusion proteins revealed that the N terminus of CitS is located in the cytoplasm, while the C terminus faces the periplasm, The membrane topology was studied further by constructing a set of 20 different fusions of N-terminal fragments of the citrate transporter with the reporter enzyme alkaline phosphatase (CitS-PhoA fusions), Most fusion points were selected in hydrophilic areas flanking the putative transmembrane-spanning domains in CitS that are predicted from the hydropathy profile of the primary sequence, The alkaline phosphatase activities of cells expressing the CitS-PhoA fusions suggest that the polypeptide traverses the membrane nine times and that the C-terminal half of the protein is characterized by two large hydrophobic periplasmic loops and two large hydrophilic cytoplasmic loops. CitS belongs to the family of the 2-hydroxycarboxylate transporters in which also the citrate carriers, CitPs, of lactic acid bacteria and the malate transporter, MleP, of Lactococcus lactis are found. Since the hydrophobicity profile of CitS is very similar to the hydrophobicity profiles of CitP and MleP, it is most likely that the new structural motif of nine transmembrane segments is shared within this new transporter family.	UNIV GRONINGEN,DEPT MICROBIOL,GRONINGEN BIOTECHNOL & BIOMOL SCI INST,NL-9751 NN HAREN,NETHERLANDS	University of Groningen								CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; DAVID S, 1990, J BACTERIOL, V172, P5789, DOI 10.1128/jb.172.10.5789-5794.1990; DIMROTH P, 1986, BIOL CHEM H-S, V367, P813, DOI 10.1515/bchm3.1986.367.2.813; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GUTIERREZ C, 1989, NUCLEIC ACIDS RES, V17, P3999, DOI 10.1093/nar/17.10.3999; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; Jander G, 1996, J BACTERIOL, V178, P3049, DOI 10.1128/jb.178.11.3049-3058.1996; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1993, J BIOENERG BIOMEMBR, V25, P625; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; LOLKEMA JS, 1994, BBA-BIOENERGETICS, V1187, P211, DOI 10.1016/0005-2728(94)90113-9; LOLKEMA JS, 1994, EUR J BIOCHEM, V220, P469, DOI 10.1111/j.1432-1033.1994.tb18645.x; LOLKEMA JS, 1996, HDB BIOL PHYS, V2, P229; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MartyTeysset C, 1996, J BACTERIOL, V178, P2178, DOI 10.1128/jb.178.8.2178-2185.1996; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; PONGS O, 1993, J MEMBRANE BIOL, V136, P1; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POOMAN B, 1992, J BACTERIOL, V173, P6030; POS MK, 1996, BIOCHEMISTRY-US, V35, P1018; POS MK, 1995, FEBS LETT, V374, P37; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; REED KE, 1991, J BIOL CHEM, V266, P11425; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ E, 1985, EMBO J, V4, P1599, DOI 10.1002/j.1460-2075.1985.tb03823.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; UJWAL ML, 1995, BIOCHEMISTRY-US, V34, P14909, DOI 10.1021/bi00045a036; VANDERREST ME, 1992, J BIOL CHEM, V267, P8791; VANDERREST ME, 1992, J BACTERIOL, V174, P4892; VAUGHAN EE, 1995, APPL ENVIRON MICROB, V61, P3172, DOI 10.1128/AEM.61.8.3172-3176.1995; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YUN CH, 1991, J BIOL CHEM, V266, P10967; ZEN KH, 1995, BIOCHEMISTRY-US, V34, P3430, DOI 10.1021/bi00010a035	38	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25582	25589		10.1074/jbc.271.41.25582	http://dx.doi.org/10.1074/jbc.271.41.25582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810332	hybrid, Green Published			2022-12-25	WOS:A1996VL69300076
J	Ansai, T; Dupuy, LC; Barik, S				Ansai, T; Dupuy, LC; Barik, S			Interactions between a minimal protein serine/threonine phosphatase and its phosphopeptide substrate sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; MOLECULAR-CLONING; ACID-PHOSPHATASE; CALCINEURIN; EXPRESSION; PHOSPHORYLATION; IDENTIFICATION	The protein phosphatase encoded by coliphage lambda (PP lambda) was found to be the equivalent of the minimal catalytic core of serine/threonine protein phosphatases (PP) by biochemical and mutational criteria. Bacterially expressed truncated versions of PP1 and PP5 phosphatases, representing the catalytic cores homologous to PP lambda, exhibited potent phosphatase activity. Unlike full-length PP1, but like PP lambda, the recombinant cores could use casein, p-nitrophenyl phosphate, and a wide variety of peptides as substrates and were resistant to okadaic acid, microcystin-LR, and trypsin. Mutations of His(173), Asp(208), or Arg(221) had little effect on the activity of the PP1 core protein, indicating its closer identity with PP lambda than with full-length PP1. Terminal deletions of a few amino acids of the cores destroyed their activity, supporting their minimal nature, Analysis of PP lambda mutants suggested an influence of the substrate on metal ion binding. The minimal length of a phosphopeptide substrate of PP lambda appeared to be a phosphorylated serine/threonine flanked by 1 or 2 amino acid residues on either side, the N-terminal ones being more effective.	UNIV S ALABAMA, DEPT BIOCHEM & MOL BIOL, COLL MED, MOBILE, AL 36688 USA	University of South Alabama			Ansai, Toshihiro/AAM-2203-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037938] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37938] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barik S, 1996, Subcell Biochem, V26, P115; BARIK S, 1993, P NATL ACAD SCI USA, V90, P10633, DOI 10.1073/pnas.90.22.10633; BARIK S, 1995, VIROLOGY, V213, P405, DOI 10.1006/viro.1995.0013; BARIK S, 1995, METH NEUROSCI, V26, P309; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BECKER W, 1994, J BIOL CHEM, V269, P22586; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Eadie GS, 1942, J BIOL CHEM, V146, P85; FISCHER EH, 1989, BIOCHIM BIOPHYS ACTA, V1000, P297, DOI 10.1016/S0006-3002(89)80024-1; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUGHES V, 1993, EUR J BIOCHEM, V216, P269, DOI 10.1111/j.1432-1033.1993.tb18142.x; JENNY TF, 1995, PROTEINS, V21, P1, DOI 10.1002/prot.340210102; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; MAZUMDER B, 1994, VIROLOGY, V205, P93, DOI 10.1006/viro.1994.1623; MURAMATSU T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P117, DOI 10.1016/0167-4889(93)90117-8; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; SCHLENDER KK, 1989, BIOCHEM BIOPH RES CO, V159, P72, DOI 10.1016/0006-291X(89)92406-6; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; VINCENT JB, 1991, J BIOL CHEM, V266, P17737; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; ZHANG ZJ, 1994, J BIOL CHEM, V269, P16997; ZHANG ZJ, 1994, J BIOL CHEM, V269, P13766; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZHANG ZJ, 1993, MOL CELL BIOCHEM, V128, P113, DOI 10.1007/BF01076762; ZHANG ZY, 1992, BIOCHEMISTRY-US, V31, P1701, DOI 10.1021/bi00121a018; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	41	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24401	24407		10.1074/jbc.271.40.24401	http://dx.doi.org/10.1074/jbc.271.40.24401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798696	hybrid			2022-12-25	WOS:A1996VM67400018
J	English, JD; Sweatt, JD				English, JD; Sweatt, JD			Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC TRANSMISSION; MAP KINASE; RECEPTOR ACTIVATION; PHOSPHORYLATION; STIMULATION; MAINTENANCE; INDUCTION; CELLS; CA1; LTP	Although classically studied as regulators of cell proliferation and differentiation, mitogen-activated protein kinases (MAPKs) are highly expressed in post-mitotic neurons of the adult nervous system. We have begun investigating the potential role of MAPKs in the regulation of synaptic plasticity in mature neurons. In particular, we have studied the regulation of two MAPK isoforms, p44 and p42 MAPK, in hippocampal long term potentiation (LTP), a system widely studied as a model for the cellular basis of learning and memory. We have found that p42 MAPK, but not p44 MAPK, is activated in area CA1 following direct stimulation of two required components of the LTP induction cascades: protein kinase C and the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. Furthermore, we have demonstrated that p42 MAPK, but not p44 MAPK, is activated in area CA1 in response to LTP-inducing high frequency stimulation and that this activation requires NMDA receptor stimulation. These data demonstrate that p42 MAPK can be regulated in an activity-dependent manner in the hippocampus and identify it as a potential component of the LTP induction cascades in area CA1. Such observations suggest that p42 MAPK might be an important regulator of synaptic plasticity in post-mitotic neurons.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine				Sweatt, J. David/0000-0003-3567-485X	NIMH NIH HHS [MH48186] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048186] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Huang Y Y, 1994, Learn Mem, V1, P74; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1991, J BIOL CHEM, V266, P24253; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2489	29	498	505	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24329	24332		10.1074/jbc.271.40.24329	http://dx.doi.org/10.1074/jbc.271.40.24329			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798683	hybrid			2022-12-25	WOS:A1996VM67400005
J	Godde, JS; Kass, SU; Hirst, MC; Wolffe, AP				Godde, JS; Kass, SU; Hirst, MC; Wolffe, AP			Nucleosome assembly on methylated CGG triplet repeats in the Fragile X Mental Retardation gene 1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; CPG SEQUENCES; DNA; TRANSCRIPTION; CHROMATIN; FMR-1; INSTABILITY; TEMPLATES; INVITRO; REGION	Expansion and methylation of CGG repeat sequences is associated with Fragile X syndrome in humans. We have examined the consequences of CGG repeat expansion and methylation for nucleosome assembly and positioning on the Fragile X Mental Retardation gene 1 (FMR1) gene. Short unmethylated CGG repeats are not particularly favored in terms of affinity for the histone octamer or for positioning of the reconstituted nucleosome. However, upon methylation their affinity for the histone octamer increases and a highly positioned nucleosome assembles with the repeat sequences found adjacent to the nucleosomal dyad. Expansion of these CGG repeats abolishes the preferential nucleosome assembly due to methylation. Thus, the expansion and methylation of these triplet repeats can alter the functional organization of chromatin, which may contribute to alterations in the expression of the FMR1 gene and the disease phenotype.	NICHHD,LAB MOL EMBRYOL,NIH,BETHESDA,MD 20892; JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9D4,ENGLAND	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Hirst, Mark/0000-0003-3851-9740				BALL DJ, 1983, P NATL ACAD SCI-BIOL, V80, P5490, DOI 10.1073/pnas.80.18.5490; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CAMPOY FJ, 1995, J BIOL CHEM, V270, P26473, DOI 10.1074/jbc.270.44.26473; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; Felsenfeld G, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 2, P577; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HIRST M, 1995, AM J HUM GENET, V56, P67; HIRST MC, 1991, NUCLEIC ACIDS RES, V19, P3283, DOI 10.1093/nar/19.12.3283; HIRST MC, 1991, J MED GENET, V28, P824, DOI 10.1136/jmg.28.12.824; HWU WL, 1993, BIOCHEM BIOPH RES CO, V193, P324, DOI 10.1006/bbrc.1993.1627; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LUBS HA, 1969, AM J HUM GENET, V21, P231; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; OOSTRA BA, 1995, BIOESSAYS, V17, P941, DOI 10.1002/bies.950171107; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1977, SCIENCE, V197, P256; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1995, AM SCI MED, V2, P68; WOLFFE AP, 1993, METH MOL G, V2, P314; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	50	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24325	24328		10.1074/jbc.271.40.24325	http://dx.doi.org/10.1074/jbc.271.40.24325			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology	VM674	8798682	hybrid			2022-12-25	WOS:A1996VM67400004
J	Temsamani, J; Pederson, T				Temsamani, J; Pederson, T			The C-group heterogeneous nuclear ribonucleoprotein proteins bind to the 5' stem-loop of the U2 small nuclear ribonucleoprotein particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP CORE PROTEINS; HELA-CELLS; 3' END; U1 RNA; TRANSCRIPTION; COMPLEXES; OLIGODEOXYNUCLEOTIDES; IDENTIFICATION; RECONSTITUTION	The C group heterogeneous nuclear ribonucleoprotein (hnRNP) proteins bind to nascent pre-messenger RNA. In vitro studies have indicated that the C hnRNP proteins bind particularly strongly to the intron polypyrimidine tract of pre-mRNA and may be important for pre-mRNA splicing. In addition, there is evidence that the interaction of the C hnRNP proteins with pre-mRNA is facilitated by the U1 and U2 small nuclear RNPs (snRNPs). In the present study, we have uncovered another feature of the C hnRNP proteins that may provide a unifying framework for these previous observations; the C hnRNP proteins bind to the 5' stem-loop of the U2 snRNP. This was detected by incubating human P-32-labeled U2 snRNP in micrococcal nuclease-treated HeLa nuclear extracts, followed by UV-mediated protein-RNA cross-linking, which revealed that C hnRNP proteins were cross-linked to P-32-nucleotides in the U2 snRNP. In similar experiments, no cross-linking of C hnRNP proteins to P-32-labeled U1 or U4 snRNPs was observed. The observed cross-linking of C hnRNP proteins to U2 snRNP was efficiently competed by excess U2 RNA and by poly(U) but not by poly(A). No competition was observed with an RNA molecule comprising U2 nucleotides 105-189, indicating that the C hnRNP protein interactive regions of U2 RNA reside solely in the 5' half of the molecule. Oligodeoxynucleotide-mediated RNase H cleavage experiments revealed that a 5' region of U2 RNA including nucleotides 15-28 is essential for the observed C hnRNP protein cross-linking. C hnRNP protein cross-linking to U2 snRNP was efficiently competed by a mini-RNA corresponding to the first 29 nucleotides of U2 RNA, whereas no competition was observed with a variant of this mini-RNA in which the UUUU loop of stem-loop I was mutationally configured into a single-stranded RNA by replacing the stem with non-pairing nucleotides. Competition experiments with another mutant mini-U2 RNA in which the UUUU loop was replaced by AAAA indicated that both the UUUU loop and the stem are important for C hnRNP protein cross-linking, a finding consistent with other recent data on the RNA sequence specificity of C hnRNP protein binding.	WORCESTER FDN BIOMED RES, CELL BIOL GRP, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021595] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21595-21] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; AMERO SA, 1992, P NATL ACAD SCI USA, V89, P8409, DOI 10.1073/pnas.89.18.8409; AMRUTE SB, 1994, BIOCHEMISTRY-US, V33, P8282, DOI 10.1021/bi00193a015; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BHORJEE JS, 1972, P NATL ACAD SCI USA, V69, P3345, DOI 10.1073/pnas.69.11.3345; BLACK AC, 1995, J VIROL, V69, P6852, DOI 10.1128/JVI.69.11.6852-6858.1995; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DAVIES DR, 1968, STRUCTURAL CHEM MOL, P422; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; ECONOMIDIS IV, 1983, P NATL ACAD SCI-BIOL, V80, P1599, DOI 10.1073/pnas.80.6.1599; ECONOMIDIS IV, 1982, P NATL ACAD SCI-BIOL, V79, P1469, DOI 10.1073/pnas.79.5.1469; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; FIRTEL RA, 1975, P NATL ACAD SCI USA, V72, P301, DOI 10.1073/pnas.72.1.301; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMMARSTROM K, 1982, EMBO J, V1, P737, DOI 10.1002/j.1460-2075.1982.tb01239.x; JACOBSON MR, 1993, MOL CELL BIOL, V13, P1119, DOI 10.1128/MCB.13.2.1119; KARN J, 1977, J BIOL CHEM, V252, P7307; KISH VM, 1975, J MOL BIOL, V95, P227, DOI 10.1016/0022-2836(75)90392-7; KLEINSCHMIDT AM, 1989, NUCLEIC ACIDS RES, V17, P4817, DOI 10.1093/nar/17.12.4817; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; LESER GP, 1984, J BIOL CHEM, V259, P1827; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MADORE SJ, 1984, J CELL BIOL, V99, P1140, DOI 10.1083/jcb.99.3.1140; MAYRAND S, 1981, J CELL BIOL, V90, P380, DOI 10.1083/jcb.90.2.380; MAYRAND S, 1981, P NATL ACAD SCI-BIOL, V78, P2208, DOI 10.1073/pnas.78.4.2208; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; Mayrand SH, 1996, MOL CELL BIOL, V16, P1241; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P1212, DOI 10.1021/bi951974k; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MIMORI T, 1984, J BIOL CHEM, V259, P560; Moore M., 1993, RNA WORLD, P303; PATTON JR, 1987, MOL CELL BIOL, V7, P4030, DOI 10.1128/MCB.7.11.4030; PATTON JR, 1988, P NATL ACAD SCI USA, V85, P747, DOI 10.1073/pnas.85.3.747; PATTON JR, 1994, P NATL ACAD SCI USA, V91, P3324, DOI 10.1073/pnas.91.8.3324; PATTON JR, 1989, MOL CELL BIOL, V9, P3360, DOI 10.1128/MCB.9.8.3360; PEDERSON T, 1974, P NATL ACAD SCI USA, V71, P617, DOI 10.1073/pnas.71.3.617; PEDERSON T, 1974, J MOL BIOL, V83, P163, DOI 10.1016/0022-2836(74)90386-6; PEDERSON T, 1983, J CELL BIOL, V97, P1321, DOI 10.1083/jcb.97.5.1321; PULLMAN JM, 1983, J CELL BIOL, V97, P99, DOI 10.1083/jcb.97.1.99; QUINLAN TJ, 1974, P NATL ACAD SCI USA, V71, P2632, DOI 10.1073/pnas.71.7.2632; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SAMARINA OP, 1968, J MOL BIOL, V33, P251, DOI 10.1016/0022-2836(68)90292-1; SAMARINA OP, 1965, DOKL AKAD NAUK SSSR+, V163, P1510; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TEMSAMANI J, 1991, J BIOL CHEM, V266, P468; TEMSAMANI J, 1991, J BIOL CHEM, V266, P20356; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WU JA, 1992, MOL CELL BIOL, V12, P5464, DOI 10.1128/MCB.12.12.5464	56	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24922	24926		10.1074/jbc.271.40.24922	http://dx.doi.org/10.1074/jbc.271.40.24922			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798770	hybrid			2022-12-25	WOS:A1996VM67400093
J	Vairo, G; Innes, KM; Adams, JM				Vairo, G; Innes, KM; Adams, JM			Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival	ONCOGENE			English	Article						bcl-2; differentiation; cell cycle; G(0); haemopoiesis; apoptosis	C-MYC; GROWTH-FACTORS; PROTOONCOGENE EXPRESSION; LEUKEMIA-CELLS; HL-60 CELLS; DIFFERENTIATION; APOPTOSIS; PROTEIN; DEATH; INDUCTION	Myeloid maturation appears to require exit from the cell cycle and leads to activation of apoptosis in the differentiated cells. The level of Bcl-2, which is known to promote cell survival, is shown here to influence both these critical steps. Bcl-2 function during myelomonocytic differentiation was investigated by introducing a deregulated bcl-2 gene into HL60 promyelocytic luekaemia cells, which can be induced to exit the cell cycle and differentiate into granulocytes or monocytes. Deregulated Bcl-2 expression did not itself promote differentiation but extended the lifespan of mature cells elicited by granulocytic or monocytic inducers. Unexpectedly, in response to induction, Bcl-2 overexpression markedly potentiated and hastened cell cycle withdrawal into G(0). Enhanced survival cannot account for the elevated numbers of G(0) cells, because they arose under induction conditions that did not kill control cells. Since the cell cycle status and growth of uninduced cells was not affected by Bcl-2-overexpression, its cell cycle inhibitory activity must require an induction signal. While cell cycle withdrawal may be necessary for maturation, it was not sufficient, implicating a requirement for specific differentiative signals. These results identify, for the first time, a function for the bcl-2 proto-oncogene that is separable from its enhancement of cell survival.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA12421] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; BENITO A, 1995, AM J PATHOL, V146, P481; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BREITMAN TR, 1990, METHOD ENZYMOL, V190, P118; Cochrane C. G., 1968, Advances in Immunology, V9, P97, DOI 10.1016/S0065-2776(08)60442-3; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COLLINS MKL, 1994, BIOESSAYS, V16, P133, DOI 10.1002/bies.950160210; COLLINS SJ, 1987, BLOOD, V70, P1233; CORY S, 1994, COLD SPRING HARB SYM, V59, P365, DOI 10.1101/SQB.1994.059.01.041; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Crissman H A, 1990, Methods Cell Biol, V33, P305; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DARZYNKIEWICZ Z, 1990, FLOW CYTOMETRY SORTI, P469; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DURO D, 1995, ONCOGENE, V11, P21; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Guy CT, 1996, MOL CELL BIOL, V16, P685; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LONDON L, 1987, J EXP MED, V166, P1419, DOI 10.1084/jem.166.5.1419; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MARVEL J, 1994, ONCOGENE, V9, P1117; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARK JR, 1994, BLOOD, V84, P440; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PIETENPOL JA, 1994, CANCER RES, V54, P3714; PILZ RB, 1987, J CLIN INVEST, V79, P1006, DOI 10.1172/JCI112867; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSER A, 1996, IN PRESS EMBO J; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZUCKER RM, 1983, CYTOMETRY, V3, P414, DOI 10.1002/cyto.990030605	60	161	171	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1511	1519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875989				2022-12-25	WOS:A1996VL38400016
J	Agarwala, KL; Kawabata, SI; Miura, Y; Kuroki, Y; Iwanaga, S				Agarwala, KL; Kawabata, SI; Miura, Y; Kuroki, Y; Iwanaga, S			Limulus intracellular coagulation inhibitor type 3 - Purification, characterization, cDNA cloning, and tissue localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYPLEUS-TRIDENTATUS HEMOCYTES; SERINE-PROTEASE ZYMOGEN; AMINO-ACID-SEQUENCE; PLASMINOGEN-ACTIVATOR INHIBITOR; SERPIN SUPERFAMILY; FACTOR-C; ANTIBACTERIAL ACTIVITY; BINDING-SITE; PROTEINS; DEGRADATION	We reported that limulus intracellular coagulation inhibitor type-1 (LICI-1) (Miura, Y., Kawabata, S., and Iwanaga, S. (1994) J. Biol. Chem. 269, 542-547) and LICI type-a (LICI-2) (Miura, Y., Kawabata, S., Wakamiya, Y., Nakamura, T., and Iwanaga, S. (1995) J. Biol. Chem. 270, 558-565) found in the hemocyte lysate belong to the serpin family. The LICI-1 specifically inhibits limulus lipopolysaccharide-sensitive serine protease, factor C (k(1) = 2.5 x 10(6) M(-1) S-1), whereas LICI-2 inhibits preferentially limulus clotting enzyme (k(1) = 4.3 x 10(5) M(-1) S-1). In our ongoing studies on limulus serpin, we found another inhibitor, named LICI type-3 (LICI-3), which strongly inhibits (1,3)-beta-D-glucan-sensitive serine protease, factor G (k(1) = 3.9 x 10(5) M(-1) S-1). Thus, the limulus hemolymph coagulation cascade is effectively regulated by at least the three endogenous serpins. LICI-3, newly identified in hemocytes, is a single chain glycoprotein with an apparent M(r) = 53,000, the largest one among known limulus serpins. A cDNA sequence for LICI-3 coded a mature protein of 392 amino acids, of which 68 residues were confirmed by peptide sequencing. LICI-3 showed significant sequence similarity to LICI-1 (45.8% identity) and LICI-2 (33.7% identity). LICI-3 contained a putative reactive site, -Arg-Ser-, distinct from that of LICI-2 (Lys-Ser-) but the same as that of LICI-1. Expression of LICI-3 mRNA was detected only in hemocytes, and not in heart, brain, stomach, intestine, coral gland, and skeletal muscle. Immunoblotting of the hemocyte-derived large and small granules with antiserum against LICI-3 suggested that it is stored specifically in large granules, as in the case of LICI-1 and LICI-2, and is released in response to external stimuli.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOL BIOL,FUKUOKA 81281,JAPAN	Kyushu University; Kyushu University			Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ARMSTRONG PB, 1990, BIOL BULL, V178, P137, DOI 10.2307/1541972; BJORK I, 1986, PROTEINASE INHIBITOR, P489; CHASE T, 1970, METHOD ENZYMOL, V19, P20; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; KANOST MR, 1989, J BIOL CHEM, V264, P965; KATO H, 1987, J BIOCHEM, V102, P1389, DOI 10.1093/oxfordjournals.jbchem.a122185; KATO H, 1980, J BIOCHEM-TOKYO, V88, P183; KAWABATA S, 1985, J BIOCHEM, V97, P1073, DOI 10.1093/oxfordjournals.jbchem.a135150; Kawabata Shun-ichiro, 1996, P255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; MEGA T, 1980, J BIOL CHEM, V255, P4057; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; MIURA Y, 1992, J BIOCHEM-TOKYO, V112, P476, DOI 10.1093/oxfordjournals.jbchem.a123924; MIURA Y, 1994, J BIOL CHEM, V269, P542; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; NARUMI H, 1993, EUR J BIOCHEM, V214, P181, DOI 10.1111/j.1432-1033.1993.tb17911.x; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; PANYUTICH AV, 1995, AM J RESP CELL MOL, V12, P351, DOI 10.1165/ajrcmb.12.3.7873202; PATTERSON SD, 1990, BIOCHEM INT, V20, P429; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sambrook J., 2002, MOL CLONING LAB MANU; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; TAKAGI H, 1990, J BIOCHEM, V108, P372, DOI 10.1093/oxfordjournals.jbchem.a123208; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TRAVIS J, 1990, BIOL CHEM H-S, V371, P3; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; YE RD, 1987, J BIOL CHEM, V262, P3718	48	34	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23768	23774		10.1074/jbc.271.39.23768	http://dx.doi.org/10.1074/jbc.271.39.23768			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798603				2022-12-25	WOS:A1996VJ44200032
J	Cohen-Armon, M; Hammel, I; Anis, Y; Homburg, S; Dekel, N				Cohen-Armon, M; Hammel, I; Anis, Y; Homburg, S; Dekel, N			Evidence for endogenous ADP-ribosylation of GTP-binding proteins in neuronal cell nucleus - Possible induction by membrane depolarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE SODIUM-CHANNELS; RAT-BRAIN; MUSCARINIC RECEPTORS; ADENYLATE-CYCLASE; CYSTEINE; RIBOSE; ALPHA	GTP-binding protein(s) recognized by antibodies against the alpha-subunits of G(i)- and G(o)-proteins were detected in crude nuclei isolated from rat brain stem and cortex. Immunohistochemical staining indicated that in the cortex these proteins are perinuclear, or are embedded in the nuclear membrane. Evidence is presented for an endogenous ADP-ribosylation of these proteins, which competes with their PTX-catalyzed ADP-ribosylation. The endogenous reaction has the characteristics of nonenzymatic ADP-ribosylation of cysteine residues, known to involve NAD-glycohydrolase activity. In vitro experiments showed that the alpha-subunit of G(o)-proteins in the cell membrane also acts as a substrate of this endogenous ADP-ribosylation. The in situ effect of membrane depolarization on the nuclear GTP-binding proteins may be attributable to their depolarization-induced endogenous ADP-ribosylation, suggesting a novel signaling mechanism in neuronal cells in the central nervous system.	TEL AVIV UNIV, SACKLER SCH MED, DEPT PATHOL, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	Cohen-Armon, M (corresponding author), TEL AVIV UNIV, NEUFELD CARDIAC RES INST, DEPT PHYSIOL & PHARMACOL, IL-69978 TEL AVIV, ISRAEL.							ALTHAUS FR, 1987, MOL BIOL BIOCH BIOPH, V37, P140; Ausubel FM., 2006, ENZYMATIC MANIPULATI; COHEN-ARMON M, 1986, J BIOL CHEM, V261, P2498; COHEN-ARMON M, 1991, NEUROSCI LETT, V126, P87, DOI 10.1016/0304-3940(91)90378-7; COHEN-ARMON M, 1993, J BIOL CHEM, V268, P9824; COHEN-ARMON M, 1988, BIOCHEMISTRY-US, V27, P368, DOI 10.1021/bi00401a055; COHEN-ARMON M, 1991, J BIOL CHEM, V266, P2595; CREVELING CR, 1983, MOL PHARMACOL, V23, P350; DALY JW, 1982, J TOXICOL-TOXIN REV, V1, P33, DOI 10.3109/15569548209016467; FERROLUZZI AG, 1976, BIOCHEMISTRY-US, V15, P617; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GUIDA L, 1992, BIOCHEM BIOPH RES CO, V188, P402, DOI 10.1016/0006-291X(92)92399-I; HOLLINGSWORTH EB, 1985, J NEUROSCI, V5, P2240; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; JACOBSON MK, 1990, J BIOL CHEM, V265, P10825; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONALD LJ, 1994, MOL CELL BIOCHEM, V138, P221, DOI 10.1007/BF00928465; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MCDONALD LJ, 1992, BIOCHEMISTRY-US, V31, P11881, DOI 10.1021/bi00162a029; MCNEAL ET, 1985, J MED CHEM, V28, P381, DOI 10.1021/jm00381a019; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OFFERMANS S, 1990, FEBS LETT, V260, P14, DOI 10.1016/0014-5793(90)80054-M; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; POLAK MJ, 1984, INTRO IMMUNOCYTOCHEM; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; SNELTER CH, 1979, METHOD BIOCHEM ANAL, V24, P129; SPIEGEL AM, 1990, ADP RIBOSYLATION TOX, P207; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; TANUMA S, 1988, J BIOL CHEM, V263, P5485; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDEA K, 1990, ADP RIBOSYLATING TOX, P525; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; Williamson KC, 1990, ADP RIBOSYLATING TOX, P493; ZANGERLE L, 1992, J NEUROCHEM, V59, P181, DOI 10.1111/j.1471-4159.1992.tb08889.x; ZUBIAUR M, 1993, J NEUROSCI RES, V35, P207, DOI 10.1002/jnr.490350212	41	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26200	26208		10.1074/jbc.271.42.26200	http://dx.doi.org/10.1074/jbc.271.42.26200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824268	hybrid			2022-12-25	WOS:A1996VN18000074
J	Hatch, GM; McClarty, G				Hatch, GM; McClarty, G			Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 5'-triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; CYCLOPENTENYL CYTOSINE; ESCHERICHIA-COLI; HELA-CELLS; CTP; SYNTHASE; HEART	The regulation of cardiolipin biosynthesis by CTP in H9c2 cardiac myoblasts was investigated. H9c2 cells were incubated in the presence of cyclopentenylcytosine which is converted to cyclopentenylcytosine triphosphate, a potent and specific inhibitor of CTP synthetase. Incubation of cells for 12 h with cyclopentenylcytosine reduced the cellular pool size of CTP to less than 10% of control cells but did not influence the pool size of other nucleotides. The de novo biosynthesis of phosphatidylcholine from [methyl-H-3]choline, phosphatidylethanolamine from [1-H-3]ethanolamine, and biosynthesis of all glycerol containing phospholipids from [U-C-14]glycerol or [1,3-H-3]glycerol were reduced approximately 50% after preincubation of the cells with cyclopentenylcytosine. In contrast, radioactive glycerol accumulated in phosphatidic acid, diacylglycerol, and triacylglycerol in cyclopentenylcytosine-treated cells compared with controls suggesting a re-routing of phospholipid biosynthesis away from CTP utilizing reactions toward neutral lipid synthesis. The de novo biosynthesis of all phospholipids was restored to control levels by addition of cytidine to the medium which elevated CTP levels. Cyclopentenylcytosine did not affect the in vitro enzyme activities involved in cardiolipin biosynthesis in these cells. In addition, the resynthesis of cardiolipin and most phospholipids from [1-C-14]linoleic acid was not affected by cyclopentenylcytosine. Our findings indicate that the cellular CTP level may regulate cardiolipin biosynthesis in H9c2 cardiac myoblasts and sup port the notion that the cellular CTP level may be a universal signal/switch for all phospholipid biosynthesis in eukaryotic cells.	UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,DEPT INTERNAL MED,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG,MB R3E 0W3,CANADA	University of Manitoba; University of Manitoba; University of Manitoba	Hatch, GM (corresponding author), UNIV MANITOBA,FAC MED,DEPT PHARMACOL & THERAPEUT,RM 307,CHOWN BLDG,770 BANNATYNE AVE,WINNIPEG,MB R3E 0W3,CANADA.							Arita M., 1983, NUCLEIS ACID RES S S, V12, P25; ARVIDSON GA, 1968, EUR J BIOCHEM, V4, P478, DOI 10.1111/j.1432-1033.1968.tb00237.x; BLANEY SM, 1993, BIOCHEM PHARMACOL, V45, P1493, DOI 10.1016/0006-2952(93)90050-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley D. N., 1992, BIOCH LIPIDS LIPOPRO, P171; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARTER JR, 1966, J LIPID RES, V7, P678; CHENG P, 1995, LIPIDS, V30, P513, DOI 10.1007/BF02537025; CHOY PC, 1980, J BIOL CHEM, V255, P1070; GLAZER RI, 1985, BIOCHEM PHARMACOL, V24, P2535; GROENER JEM, 1977, BIOCHIM BIOPHYS ACTA, V487, P105, DOI 10.1016/0005-2760(77)90047-9; HATCH GM, 1994, BIOCHEM J, V297, P201, DOI 10.1042/bj2970201; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P380, DOI 10.1016/0005-2760(72)90052-5; HOSTETLER KY, 1971, BIOCHIM BIOPHYS ACTA, V239, P113, DOI 10.1016/0005-2760(71)90201-3; KANG GJ, 1989, J BIOL CHEM, V264, P713; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KHYM JX, 1978, J BIOL CHEM, V253, P8741; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KIYASU JY, 1963, J BIOL CHEM, V238, P2293; LEELAVATHI DE, 1977, ANAL BIOCHEM, V83, P258, DOI 10.1016/0003-2697(77)90534-6; LIM MI, 1984, J MED CHEM, V27, P1536, DOI 10.1021/jm00378a002; LOPEZ G, 1992, J NEUROCHEM, V59, P338; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD PM, 1980, BIOCHIM BIOPHYS ACTA, V260, P80; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCMURRAY WC, 1978, CAN J BIOCHEM CELL B, V56, P414, DOI 10.1139/o78-065; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; NISHIJIMA S, 1988, J BACTERIOL, V170, P775, DOI 10.1128/jb.170.2.775-780.1988; OHNO M, 1985, NUCLEOS NUCLEOT NUCL, V4, P21, DOI 10.1080/07328318508077828; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; POLITI PM, 1995, CANCER CHEMOTH PHARM, V36, P513, DOI 10.1007/BF00685802; POORTHUIS BJHM, 1976, J LIPID RES, V17, P433; RIJCKEN WRP, 1993, BIOCHEM J, V293, P207, DOI 10.1042/bj2930207; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; SCHLAME M, 1991, J BIOL CHEM, V266, P22398; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1017, DOI 10.1515/bchm2.1968.349.2.1017; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; Vance D. E., 1996, BIOCH LIPIDS LIPOPRO; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANCE DE, 1979, TRENDS BIOCHEM SCI, V4, P145, DOI 10.1016/0968-0004(79)90001-X; VANDENBOSCH H, 1972, PHYSIOL REV, V66, P14; VANWIJK GMT, 1991, BIOCHIM BIOPHYS ACTA, V1086, P99, DOI 10.1016/0005-2760(91)90160-J; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; WHITEHEAD FW, 1981, CAN J BIOCHEM CELL B, V59, P38, DOI 10.1139/o81-006; WU WI, 1994, J BIOL CHEM, V269, P29495; ZHANG H, 1993, CANCER RES, V53, P5714; 1993, BIOCHEM J, V289, P727	55	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25810	25816		10.1074/jbc.271.42.25810	http://dx.doi.org/10.1074/jbc.271.42.25810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824210	hybrid			2022-12-25	WOS:A1996VN18000016
J	KowalskiChauvel, A; Pradayrol, L; Vaysse, N; Seva, C				KowalskiChauvel, A; Pradayrol, L; Vaysse, N; Seva, C			Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-EXTENDED PROGASTRIN; PDGF RECEPTOR; GROWTH-FACTOR; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; DNA-SYNTHESIS; CELL LINE; ACTIVATION; PROTEIN; BINDING	The growth-promoting effects of gastrin on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the gastrin/CCKB receptor, which belongs to the family of G protein-coupled receptors, However, the downstream signaling pathways activated by gastrin are not well characterized, In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor, The gastrin induced phosphorylation of IRS-1 was rapid and transient, occurring within 30 s of treatment and diminishing thereafter, IRS-1 binds several proteins containing Src homology 2 domains through its multiple tyrosine phosphorylation sites. Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase), Ln addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase. We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin, We report here that Grb2 also interacts with tyrosine-phosphorylated IRS-1 in response to gastrin. Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein coupled receptor and the insulin receptor.	CHU RANGUEIL,INSERM,U151,GRP RECH BIOL & PATHOL DIGEST,INST LOUIS BUGNARD,F-31054 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Kowalski-Chauvel, Aline/O-9212-2014; SEVA, Catherine/O-9166-2014	SEVA, Catherine/0000-0002-4265-7372				ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COUGHLIN SR, 1989, SCIENCE, V243, P1191; Edkins JS, 1905, P R SOC LOND B-CONTA, V76, P376, DOI 10.1098/rspb.1905.0029; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; ITO M, 1993, J BIOL CHEM, V268, P18300; JESSOP HW, 1980, IN VITRO, V16, P222; JOHNSON LR, 1977, ANNU REV PHYSIOL, V39, P135, DOI 10.1146/annurev.ph.39.030177.001031; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; SAAD MJA, 1995, BIOCHEM J, V310, P741, DOI 10.1042/bj3100741; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SETHI T, 1993, CANCER RES, V53, P5208; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; SEVA C, 1990, CANCER RES, V50, P5829; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1986, CANCER RES, V46, P1612; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TODISCO A, 1995, J BIOL CHEM, V270, P28337; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VEMURI GS, 1994, BIOCHEM BIOPH RES CO, V202, P1619, DOI 10.1006/bbrc.1994.2118; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; WATSON SA, 1989, INT J CANCER, V43, P692, DOI 10.1002/ijc.2910430425; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; ZHANG J, 1993, J BIOL CHEM, V268, P22251	44	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26356	26361		10.1074/jbc.271.42.26356	http://dx.doi.org/10.1074/jbc.271.42.26356			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824290	hybrid			2022-12-25	WOS:A1996VN18000096
J	Nelson, J; Scott, WN; Allen, WE; Wilson, DJ; Harriott, P; McFerran, NV; Walker, B				Nelson, J; Scott, WN; Allen, WE; Wilson, DJ; Harriott, P; McFerran, NV; Walker, B			Murine epidermal growth factor peptide (33-42) binds to a YIGSR-specific laminin receptor on both tumor and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; PENTAPEPTIDE; FIBRONECTIN; PROTEIN; CHAIN; ANGIOGENESIS; INHIBITION; SEQUENCE; DOMAINS; INVITRO	A laminin-antagonist peptide, comprising amino acids 33-42 of murine epidermal growth factor (mEGF-(33-42)), interacts with a breast cancer- and endothelial cell-associated receptor, which is specific for the laminin B1 chain sequence, CDPGYIGSR-NH2 (Lam.B1-(925-933)), and is immunologically similar to a previously described 67-kDa laminin receptor. In whole cell receptor assays, mEGF-(33-42), Lam.B1-(925-933), and laminin all have IC50 values for displacement of 125(I)-laminin in the range 1-5 nM. Cell attachment to solid-phase laminin is also blocked by all three ligands, but in contrast to the receptor assays, mEGF-(33-42) or Lam.B1-(925-933), while equipotent with each other, were less effective than laminin. The concentrations of the peptides required to produce half-maximal inhibition of attachment were in the range 230-390 nM, but those for laminin were 1000-fold lower, in the range 0.2-0.3 nM. Like laminin, solid-phase mEGF-(33-42) supports cell attachment, and this ability is blocked by anti-67-kDa receptor antibodies. Modeling studies suggest that both peptides present a tyrosyl and an arginyl residue on the same face of a right-handed helical fold with elliptical cross-section.	QUEENS UNIV BELFAST,SCH BIOMED SCI,DEPT ANAT,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND	Queens University Belfast	Nelson, J (corresponding author), QUEENS UNIV BELFAST,SCH BIOL & BIOCHEM,CTR PEPTIDE & PROT ENGN,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.		Walker, Brian/C-5263-2008					ALBINI A, 1986, P NATL ACAD SCI USA, V83, P8182, DOI 10.1073/pnas.83.21.8182; ALLEN WE, 1994, J ANAT, V184, P194; BAILIE JR, 1989, BIOCHEM SOC T, V17, P409, DOI 10.1042/bst0170409; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BERTHOD H, 1967, THEOR CHIM ACTA, V8, P212, DOI 10.1007/BF00527306; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P149, DOI 10.1007/BF01025085; CARPENTER G, 1992, HDB EXPT PHARM, P69; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GULLICK WJ, 1984, ANAL BIOCHEM, V141, P253, DOI 10.1016/0003-2697(84)90454-8; HEFFELFINGER SC, 1992, IN VITRO CELL DEV-AN, V28A, P136; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KANAMURUU H, 1989, UROL RES, V25, P259; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; LANDOWSKI TH, 1995, CLIN EXP METASTAS, V13, P357; LAZAR E, 1989, MOL CELL BIOL, V9, P860, DOI 10.1128/MCB.9.2.860; LEATHERBARROW RJ, 1992, GRAFIT VERSION 3; LIOTTA LA, 1984, BASEMENT MEMBRANES C, P146; MARANO RPC, 1995, EXP EYE RES, V60, P5, DOI 10.1016/S0014-4835(05)80079-X; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; MCCARTHY JB, 1985, CANCER METAST REV, V4, P125, DOI 10.1007/BF00050692; MCKELVEY DR, 1991, J PROTEIN CHEM, V10, P265, DOI 10.1007/BF01025625; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; NELSON J, 1995, CANCER RES, V55, P3772; OSTHEIMER GJ, 1992, J BIOL CHEM, V267, P25120; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; ROMANOV V, 1994, CELL ADHES COMMUN, V2, P201, DOI 10.3109/15419069409004438; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SAKAMOTO N, 1991, CANCER RES, V51, P903; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444; VUOLTEENAHO R, 1990, J BIOL CHEM, V265, P15611; WEWER UM, 1987, CANCER RES, V47, P5691; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	39	16	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26179	26186		10.1074/jbc.271.42.26179	http://dx.doi.org/10.1074/jbc.271.42.26179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824265	hybrid			2022-12-25	WOS:A1996VN18000071
J	Creemers, JWM; Usac, EF; Bright, NA; VandeLoo, JW; Jansen, E; VandeVen, WJM; Hutton, JC				Creemers, JWM; Usac, EF; Bright, NA; VandeLoo, JW; Jansen, E; VandeVen, WJM; Hutton, JC			Identification of a transferable sorting domain for the regulated pathway in the prohormone convertase PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROPROTEIN PROCESSING ENZYME; SECRETORY PROTEINS; FURIN; CELLS; PRECURSOR; CLEAVAGE; PROTEASE; LOCALIZATION; PROPEPTIDE	The mammalian subtilisin-like endoproteases furin and PC2 catalyze similar reactions but in different parts of the cell: furin in the trans-Golgi network and PC2 in dense-core granules. To map targeting domains within PC2, chimeras were constructed of the pro-, catalytic, and middle domains of furin with the carboxyl-terminal domain of PC2 (F-S-P) or of the pro- and catalytic domains of furin with the middle and carboxyl-terminal domains of PC2 (F-N-P). Their behavior in stable transfected AtT-20 cells was compared to a furin mutant truncated after the middle domain (F-S), wild-type furin, and with wild-type PC2. F-S-P, F-N-P, and F-S were catalytically active and underwent post-translational proteolysis and N-glycosylation with similar kinetics to wild-type furin. The truncated furin mutant was not stored intracellularly, whereas both chimeras, like PC2, showed inh acellular retention and regulated release. Immunofluorescence and immune-electron microscopy showed the presence of the chimeras and PC2 in dense-cored secretory granules together with proopiomelanocortin immunoreactivity. PC2 was sorted more efficiently than F-S-P, and the inclusion of the middle domain (F-N-P) further enhanced intracellular retention. It is concluded that sorting of PC2 into the regulated pathway depends on its carboxyl terminus. The middle domain may provide additional sorting determinants or a conformational framework for expression of the sorting signal.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; FLANDERS INTERUNIV INST BIOTECHNOL,B-3000 LOUVAIN,BELGIUM	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Creemers, JWM (corresponding author), CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,MOL ONCOL LAB,HERESTR 49,B-3000 LOUVAIN,BELGIUM.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILYES EM, 1995, BIOCHEM J, V309, P587, DOI 10.1042/bj3090587; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DESTROOPER B, 1995, BBA-PROTEIN STRUCT M, V1246, P185, DOI 10.1016/0167-4838(94)00194-L; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HALBAN PA, 1994, BIOCHEM J, V299, P1; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MAINS RE, 1995, MOL ENDOCRINOL, V9, P3, DOI 10.1210/me.9.1.3; MALIDE D, 1995, J HISTOCHEM CYTOCHEM, V43, P11, DOI 10.1177/43.1.7822759; MITRA A, 1994, J BIOL CHEM, V269, P19876; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MROZ EA, 1986, SCIENCE, V232, P871, DOI 10.1126/science.2422756; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; OUIMET T, 1993, FEBS LETT, V330, P343, DOI 10.1016/0014-5793(93)80901-6; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V32, P11586; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1992, J BIOL CHEM, V267, P17208; SCHAFER W, 1995, EMBO J, V14, P242; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMIT AB, 1992, FEBS LETT, V312, P213, DOI 10.1016/0014-5793(92)80938-D; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; TOOZE SA, 1994, BIOCHIMIE, V76, P271, DOI 10.1016/0300-9084(94)90157-0; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; [No title captured]	55	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25284	25291		10.1074/jbc.271.41.25284	http://dx.doi.org/10.1074/jbc.271.41.25284			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810291	hybrid			2022-12-25	WOS:A1996VL69300035
J	Fushinobu, S; Kamata, K; Iwata, S; Sakai, H; Ohta, T; Matsuzawa, H				Fushinobu, S; Kamata, K; Iwata, S; Sakai, H; Ohta, T; Matsuzawa, H			Allosteric activation of L-lactate dehydrogenase analyzed by hybrid enzymes with effector-sensitive and -insensitive subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE TRANSCARBAMOYLASE; BIFIDOBACTERIUM-LONGUM; DIFFERENT ARRANGEMENTS; CATALYTIC SUBUNITS; SITE; COMMUNICATION; BINDING; CHAINS; MUTAGENESIS; MOLECULES	Subunit-hybrid enzymes of mutant tetrameric L-lactate dehydrogenases from Bifidobacterium longum were studied in an examination of the mechanism of allosteric activation by fructose 1,6-bisphosphate. We earlier developed an in, vivo method for subunit hybridization in Escherichia coli and the hybrids formed were a mixture with different subunit compositions, The B. longum hybrids were separated by anion-exchange chromatography with a mutational tag, Hybrids formed between fructose 1,6-bisphosphate-desensitized subunits and wild-type subunits and also between fructose 1,6-bisphosphate-desensitized subunits and catalytically inactive subunits, Kinetic analyses of the hybrid enzymes showed that (i) those residues from two symmetrically related subunits that constituted the fructose 1,6-bisphosphate-binding site could bind fructose 1,6-bisphosphate and activate the enzyme only if intact, (ii) hybrids with only one functional fructose 1,6-bisphosphate-binding site were fully sensitive to fructose 1,6-bisphosphate, but the allosteric equilibrium had shifted partially, and (iii) activation by fructose 1,6-bisphosphate at the fructose 1,6-bisphosphate-binding site was transmitted to the active sites through a quaternary structural change, not through direct conformational change within a subunit, These results are evidence of the validity of the concerted allosteric model of this enzyme based on T- and R-state structures in the same crystal lattice proposed earlier.	UNIV TOKYO, DEPT BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Wood, David W/B-2992-2012; Fushinobu, Shinya/E-4987-2011	Fushinobu, Shinya/0000-0003-1346-6435				ACKERS GK, 1993, TRENDS BIOCHEM SCI, V18, P385, DOI 10.1016/0968-0004(93)90095-5; ADAMS MJ, 1973, J MOL BIOL, V76, P519, DOI 10.1016/0022-2836(73)90489-0; CALIGIURI MG, 1991, SCIENCE, V252, P1845, DOI 10.1126/science.2063197; CAMERON AD, 1994, J MOL BIOL, V238, P615, DOI 10.1006/jmbi.1994.1318; CHAN WWC, 1981, CAN J BIOCHEM CELL B, V59, P461, DOI 10.1139/o81-064; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; Dixon M., 1979, ENZYMES, P400; EISENSTEIN E, 1992, J BIOL CHEM, V267, P22148; EVENTOFF W, 1977, P NATL ACAD SCI USA, V74, P2677, DOI 10.1073/pnas.74.7.2677; GARVIE EI, 1980, MICROBIOL REV, V44, P106, DOI 10.1128/MMBR.44.1.106-139.1980; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P1324, DOI 10.1021/bi00651a024; GOLDBERG E, 1965, ARCH BIOCHEM BIOPHYS, V109, P134, DOI 10.1016/0003-9861(65)90298-5; HERMANN R, 1982, H-S Z PHYSIOL CHEM, V363, P1259, DOI 10.1515/bchm2.1982.363.2.1259; Holbrook JJ., 1975, ENZYMES, P191; IWATA S, 1989, AGR BIOL CHEM TOKYO, V53, P3365, DOI 10.1080/00021369.1989.10869841; IWATA S, 1994, NAT STRUCT BIOL, V1, P176, DOI 10.1038/nsb0394-176; IWATA S, 1993, J MOL BIOL, V230, P21, DOI 10.1006/jmbi.1993.1122; IWATA S, 1989, J BIOCHEM-TOKYO, V106, P558, DOI 10.1093/oxfordjournals.jbchem.a122894; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; MARKERT CL, 1963, SCIENCE, V140, P1329, DOI 10.1126/science.140.3573.1329; MINOWA T, 1989, GENE, V85, P161, DOI 10.1016/0378-1119(89)90476-9; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OHTA T, 1992, FARADAY DISCUSS, V93, P153, DOI 10.1039/fd9929300153; Perutz M.F., 1989, MECH COOPERATIVITY A; ROSSMANN MG, 1973, J MOL BIOL, V76, P533, DOI 10.1016/0022-2836(73)90491-9; SALTHE SN, 1965, NATURE, V207, P723, DOI 10.1038/207723a0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG CM, 1981, J BIOL CHEM, V256, P7028; YANG YR, 1980, P NATL ACAD SCI-BIOL, V77, P5187, DOI 10.1073/pnas.77.9.5187; YANG YR, 1987, ANAL BIOCHEM, V163, P188, DOI 10.1016/0003-2697(87)90111-4	33	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25611	25616		10.1074/jbc.271.41.25611	http://dx.doi.org/10.1074/jbc.271.41.25611			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810336	hybrid			2022-12-25	WOS:A1996VL69300080
J	Magyar, A; Zhang, YD; Kohn, H; Widger, WR				Magyar, A; Zhang, YD; Kohn, H; Widger, WR			The antibiotic bicyclomycin affects the secondary RNA binding site of Escherichia coli transcription termination factor Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-RHO; MUTANT-RHO; PHYSICAL-PROPERTIES; NUSG PROTEIN; SEQUENCE; HELICASE; DOMAIN; STABILIZATION; INHIBITION; ACTIVATION	The interaction of Rho and the antibiotic bicyclomycin was probed using in vitro transcription termination reactions, poly(C) binding assays, limited tryptic digestions, and the bicyclomycin inhibition kinetics of ATPase activity in the presence of poly(dC) and ribo(C)(10). The approximate I-50 value for the bicyclomycin inhibition of transcription termination at Rho-dependent sites within a modified trp operon template was 5 mu M. At antibiotic concentrations near the I-50 value, bicyclomycin inhibition of Rho-dependent transcripts was accompanied by the appearance of a new set of transcripts whose size was midway between the Rho-dependent transcripts and the readthrough transcripts, Bicyclomycin did not inhibit poly(C) binding to Rho, In the presence of poly(dC), bicyclomycin showed a reversible mixed inhibition of the ribo(C)(10)-stimulated ATPase activity, The extrapolated K-i for bicyclomycin was 2.8 mu M without ribo(C)(10) and increased to 26 mu M in the presence of ribo(C)(10). Correspondingly, the K-m(app) for ribo(C)(10) without bicyclomycin was 0.8 mu M and with bicyclomycin was 5 mu M at infinite inhibitor concentration, The data suggested that the antibiotic binds to Rho, influencing the secondary RNA binding (tracking) site on Rho and slows the tracking of Rho toward the bound RNA polymerase.	UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204; UNIV HOUSTON,DEPT CHEM,HOUSTON,TX 77204	University of Houston System; University of Houston; University of Houston System; University of Houston					NIGMS NIH HHS [GM 37934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUZAR S, 1989, J AM CHEM SOC, V111, P4895, DOI 10.1021/ja00195a049; ABUZAR S, 1990, J AM CHEM SOC, V112, P3114, DOI 10.1021/ja00164a036; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KAMIYA T, 1972, J ANTIBIOT, V25, P576, DOI 10.7164/antibiotics.25.576; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MIYAMURA S, 1972, J ANTIBIOT TOKYO, V25, P39; MIYOSHI T, 1972, J ANTIBIOT, V25, P569, DOI 10.7164/antibiotics.25.569; MODRAK D, 1994, BIOCHEMISTRY-US, V33, P8292, DOI 10.1021/bi00193a016; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEHRKE KW, 1994, J MOL BIOL, V243, P830, DOI 10.1006/jmbi.1994.1685; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; PARK HG, 1995, STUDIES MECH ACTION; PEREIRA S, 1995, J MOL BIOL, V251, P30, DOI 10.1006/jmbi.1995.0413; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5767; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; TSURUSHITA N, 1989, J MOL BIOL, V210, P23, DOI 10.1016/0022-2836(89)90288-X; WANG Y, 1993, J BIOL CHEM, V268, P13940; WILLIAMS RM, 1988, CHEM REV, V88, P511, DOI 10.1021/cr00085a004; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; YANOFSKY C, 1995, J BACTERIOL, V177, P4451, DOI 10.1128/jb.177.15.4451-4456.1995; ZHENG CH, 1994, P NATL ACAD SCI USA, V91, P7543, DOI 10.1073/pnas.91.16.7543; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	46	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25369	25374		10.1074/jbc.271.41.25369	http://dx.doi.org/10.1074/jbc.271.41.25369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810302	hybrid			2022-12-25	WOS:A1996VL69300046
J	Zeilinger, S; Mach, RL; Schindler, M; Herzog, P; Kubicek, CP				Zeilinger, S; Mach, RL; Schindler, M; Herzog, P; Kubicek, CP			Different inducibility of expression of the two xylanase genes xyn1 and xyn2 in Trichoderma reesei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; CCAAT-BINDING; TRANSFORMATION SYSTEM; D-XYLOSE; CELLULASE; PROTEIN; INDUCTION; CLONING; ADJACENT; PROMOTER	Regulation of formation of the extracellular xylanase system of Trichoderma reesei QM 9414 during growth on xylan, cellulose, and replacement onto a number of soluble inducers was investigated by Northern analysis of xyn1 and xyn2 transcripts and by the use of the Escherichia coli hph (hygromycin B-phosphotransferase-encoding) gene as a reporter. Whereas the xyn1 promoter is active in the presence of xylan and xylose, and virtually silenced in the presence of glucose, the xyn2 promoter enables basal transcription at a low level, but is enhanced in the presence of xylan and xylobiose and also of sophorose or cellobiose. The respective regulatory nucleotide regions were localized on a 221-base pair fragment and a 55-base pair fragment of the xyn1 and zyn2 5'-upstream noncoding sequences, respectively. Electrophoretic mobility shift assays, using cell-free extracts, identified induction-specific protein-DNA complexes: one complex of high mobility was observed under basal, noninduced conditions (glucose) with xyn2, which was in part replaced by a slow-migrating complex upon induction by xylan or sophorose. Both complexes bound to a CCAAT box. With xyn1, the induced complex also binds to a CCAAT box, but this binding is not observed in the presence of the carbon catabolite repressor Cre1, which binds to a nearby located consensus motif.	VIENNA TECH UNIV, INST BIOCHEM TECHNOL & MIKROBIOL, MIKROBIELLE BIOCHEM ABT, A-1060 VIENNA, AUSTRIA	Technische Universitat Wien			Zeilinger, Susanne/AAX-6578-2020; Robert, Mach/AAU-8968-2020	Zeilinger, Susanne/0000-0003-3112-0948; Mach, Robert, L./0000-0003-2375-7244				ABRAHAONETO J, 1995, BIOCHEMISTRY-US, V34, P10456, DOI 10.1021/bi00033a018; ARAMAYO R, 1993, EMBO J, V12, P2039, DOI 10.1002/j.1460-2075.1993.tb05853.x; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BIELY P, 1994, FEBS LETT, V356, P137, DOI 10.1016/0014-5793(94)01248-2; BIELY P, 1991, EUR J BIOCHEM, V200, P157, DOI 10.1111/j.1432-1033.1991.tb21062.x; Biely P, 1993, TRICHODERMA CELLULAS, P125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUBERO B, 1994, EMBO J, V13, P407, DOI 10.1002/j.1460-2075.1994.tb06275.x; DEGRAAFF L, 1993, MOL MICROBIOL, V12, P479; ELGOGARY S, 1989, P NATL ACAD SCI USA, V86, P6138, DOI 10.1073/pnas.86.16.6138; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GRUBER F, 1990, CURR GENET, V18, P447, DOI 10.1007/BF00309915; GRUBER F, 1990, CURR GENET, V18, P71, DOI 10.1007/BF00321118; HRMOVA M, 1986, ARCH MICROBIOL, V144, P307, DOI 10.1007/BF00410968; KUBICEK CP, 1988, J GEN MICROBIOL, V134, P1215; MACH RL, 1994, CURR GENET, V25, P567, DOI 10.1007/BF00351679; MACH RL, 1996, IN PRESS MOL MICROBI; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MULDER W, 1994, MOL GEN GENET, V245, P96, DOI 10.1007/BF00279755; OLESEN JT, 1991, MOL CELL BIOL, V11, P611, DOI 10.1128/MCB.11.2.611; PAPAGIANNOPOULO.P, 1995, FUNGAL GENET NEWSL S, V42, P16; ROYER JC, 1990, APPL ENVIRON MICROB, V56, P2535, DOI 10.1128/AEM.56.8.2535-2539.1990; SAARELAINEN R, 1993, MOL GEN GENET, V241, P497, DOI 10.1007/BF00279891; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR DJ, 1989, ACS SYM SER, V399, P641; STANGL H, 1993, CURR GENET, V23, P115, DOI 10.1007/BF00352009; STERNBERG D, 1979, J BACTERIOL, V139, P761, DOI 10.1128/JB.139.3.761-769.1979; STRAUSS J, 1995, FEBS LETT, V376, P103, DOI 10.1016/0014-5793(95)01255-5; TENKANEN M, 1992, ENZYME MICROB TECH, V14, P566, DOI 10.1016/0141-0229(92)90128-B; Timell T. E., 1965, ADV CARBOHYD CHEM, V20, P409, DOI DOI 10.1016/S0096-5332(08)60304-5; TORRONEN A, 1994, EMBO J, V13, P2493, DOI 10.1002/j.1460-2075.1994.tb06536.x; TORRONEN A, 1995, BIOCHEMISTRY-US, V34, P847, DOI 10.1021/bi00003a019; TORRONEN A, 1992, BIO-TECHNOL, V10, P1461, DOI 10.1038/nbt1192-1461; VANHEESWIJCK R, 1991, NUCLEIC ACIDS RES, V19, P2655, DOI 10.1093/nar/19.10.2655; VIIKARI L, 1994, FEMS MICROBIOL REV, V13, P335, DOI 10.1016/0168-6445(94)90090-6; WITTEVEEN CFB, 1989, J GEN MICROBIOL, V135, P2163; WONG KKY, 1988, MICROBIOL REV, V52, P305, DOI 10.1128/MMBR.52.3.305-317.1988	40	96	108	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25624	25629		10.1074/jbc.271.41.25624	http://dx.doi.org/10.1074/jbc.271.41.25624			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810338	hybrid			2022-12-25	WOS:A1996VL69300082
J	Puppe, W; Zimmann, P; Jung, K; Lucassen, M; Altendorf, K				Puppe, W; Zimmann, P; Jung, K; Lucassen, M; Altendorf, K			Characterization of truncated forms of the KdpD protein, the sensor kinase of the K+-translocating Kdp system of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM-TRANSPORT; SIGNAL TRANSDUCTION; CONTROL EXPRESSION; OPERON EXPRESSION; ATPASE; PHOSPHORYLATION; REGULATOR; AUTOPHOSPHORYLATION; OSMOREGULATION; IDENTIFICATION	The expression of the kdpFABC operon, coding for the K+-translocating Kdp system, is controlled by the two regulatory proteins, KdpD and KdpE, which belong to the group of sensor kinase/response regulator systems. This study describes the construction and analysis of KdpD sensor kinases, in which different deletions in the N-terminal part of the protein were introduced. Truncated KdpD proteins, in which the membrane-spanning segments were deleted, had lost their phosphorylation capacity. Truncated KdpD proteins, in which the four membrane-spanning helices were untouched, were still phosphorylated, and the phosphoryl group could be transferred to the response regulator KdpE in vitro. Furthermore, these truncated KdpD proteins cause dephosphorylation of KdpE(P), which is comparable with that of the wild-type protein. To investigate the effect of the deletions on signal transduction in vivo the corresponding kdp genes were transferred to the chromosome, Growth studies with the mutant strains are in accord with the data obtained from the in vitro studies. Furthermore, kdp expression was investigated using a KdpA-LacZ fusion. The data obtained support the notion that the extent of hdp expression is modulated by the N-terminal part of KdpD.	UNIV OSNABRUCK, FACHBEREICH BIOL CHEM, D-49069 OSNABRUCK, GERMANY	University Osnabruck			Lucassen, Magnus/ABA-8396-2021; Lucassen, Magnus/E-8433-2011	Lucassen, Magnus/0000-0003-4276-4781; Lucassen, Magnus/0000-0003-4276-4781				ALTENDORF K, 1994, RES MICROBIOL, V145, P374, DOI 10.1016/0923-2508(94)90084-1; ALTENDORF K, 1992, ANN NY ACAD SCI, V671, P228, DOI 10.1111/j.1749-6632.1992.tb43799.x; ARBER W, 1960, VIROLOGY, V11, P273, DOI 10.1016/0042-6822(60)90066-0; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BAKKER EP, 1993, ALKALI CATION TRANSP, P00205; BOSSEMEYER D, 1989, J BACTERIOL, V171, P2219, DOI 10.1128/jb.171.4.2219-2221.1989; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DOSCH DC, 1991, J BACTERIOL, V173, P687, DOI 10.1128/jb.173.2.687-696.1991; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; EPSTEIN W, 1985, CURR TOP MEMBR TRANS, V23, P153; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; GUTTERSON NI, 1983, P NATL ACAD SCI-BIOL, V80, P4894, DOI 10.1073/pnas.80.16.4894; HAARDT M, 1993, THESIS U KONSTANZ; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HENGGEARONIS R, 1993, J BACTERIOL, V175, P259, DOI 10.1128/JB.175.1.259-265.1993; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; LAIMINS LA, 1978, P NATL ACAD SCI USA, V75, P3216, DOI 10.1073/pnas.75.7.3216; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; LOIS AF, 1993, J BIOL CHEM, V268, P4370; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; Miller JH., 1972, EXPT MOL GENETICS; NAKASHIMA K, 1993, MOL MICROBIOL, V7, P109, DOI 10.1111/j.1365-2958.1993.tb01102.x; NAKASHIMA K, 1992, MOL MICROBIOL, V6, P1777, DOI 10.1111/j.1365-2958.1992.tb01350.x; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; Parkinson J.S., 1995, 2 COMPONENT SIGNAL T, P9; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POLAREK JW, 1988, METHOD ENZYMOL, V157, P655; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; PUPPE W, 1992, MOL MICROBIOL, V6, P3511, DOI 10.1111/j.1365-2958.1992.tb01786.x; RHOADS DB, 1976, J GEN PHYSIOL, V67, P325, DOI 10.1085/jgp.67.3.325; ROBERTS DL, 1994, J BIOL CHEM, V269, P8728; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; SIEBERS A, 1993, ALKALI CATION TRANSP, P225; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; STUMPE S, 1996, HDB BIOL PHYS, V2, P473; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	46	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25027	25034		10.1074/jbc.271.40.25027	http://dx.doi.org/10.1074/jbc.271.40.25027			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798785	hybrid			2022-12-25	WOS:A1996VM67400108
J	Neufer, PD; Benjamin, IJ				Neufer, PD; Benjamin, IJ			Differential expression of alpha B-crystallin and Hsp27 in skeletal muscle during continuous contractile activity - Relationship to myogenic regulatory factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STRESS PROTEINS; LENS CRYSTALLINS; MESSENGER-RNA; GENE; MOUSE; RAT; INDUCTION; CELLS; IDENTIFICATION	alpha B-crystallin (alpha BC) is a major structural protein (22 kDa) of the ocular lens as well as a bona fide heat shock protein in non-lens tissue. The alpha BC gene is abundantly expressed in tissues with high oxidative capacity, including the heart and type I skeletal muscle fibers, and is regulated by the MyoD family of basic helix-loop-helix transcription factors during myogenesis. To test the hypothesis that alpha BC expression may be directly regulated by the demand for oxidative metabolism, we examined the expression of alpha BC and the ancestral-related Hsp27 in rabbit tibialis anterior muscle subjected to continuous low frequency motor nerve stimulation (3 V, 10 Hz). alpha BC mRNA and protein increased within the 1st day of continuous contractile activity (5- and 2.5-fold, respectively) and achieved maximum levels (>20- and 4-fold, respectively) after 21 d of stimulation, Hsp27 mRNA and protein levels also increased with stimulation, but with a less specific and dramatic induction pattern. In agreement with the Northern analysis, in situ hybridization performed on cross sections from tibialis anterior muscle revealed progressively increasing alpha BC transcript signal, localized in a ringlet pattern, from 1 through 21 days of stimulation, Serial sections subjected to myosin immunohistochemistry revealed that alpha BC expression was confined to slow-twitch type I and a subpopulation of fast twitch type II fibers after 1 day but present in nearly all fibers after 21 days of stimulation. Transcript levels of all four myogenic regulatory factors (MyoD, myogenin, myf-5, and MRF4) also increased with stimulation in a pattern temporally similar with alpha BC, suggesting that expression of alpha BC in response to stimulation may, in part, be regulated through myogenic regulatory factor(s) interaction with the canonical E-box element located within the alpha BC promotor. These data demonstrate that expression of the small heat shock protein, alpha BC, is rapidly induced independent of the ancestrally related Hsp27 in a fiber type specific pattern in skeletal muscle subjected to the oxidative stress imposed by continuous contractile activity.	UNIV TEXAS,SW MED CTR,MOL CARDIOL RES LABS,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007360, P50HL055988] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07360, P50-HL55988-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNEX BH, 1991, AM J PHYSIOL, V260, pC266, DOI 10.1152/ajpcell.1991.260.2.C266; ATOMI Y, 1991, J BIOCHEM-TOKYO, V110, P812, DOI 10.1093/oxfordjournals.jbchem.a123665; ATOMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1323, DOI 10.1016/0006-291X(91)92083-V; BENJAMIN IJ, 1992, J CLIN INVEST, V89, P1685, DOI 10.1172/JCI115768; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CADEFAU JA, 1993, PFLUG ARCH EUR J PHY, V424, P529, DOI 10.1007/BF00374918; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EISENBERG BR, 1981, CELL TISSUE RES, V220, P449, DOI 10.1007/BF00216750; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GOEBEL HH, 1995, MUSCLE NERVE, V18, P1306, DOI 10.1002/mus.880181114; GOPALSRIVASTAVA R, 1993, MOL CELL BIOL, V13, P7144, DOI 10.1128/MCB.13.11.7144; HAMALAINEN N, 1993, J HISTOCHEM CYTOCHEM, V41, P733, DOI 10.1177/41.5.8468455; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1993, ACTA NEUROPATHOL, V85, P475; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KATO K, 1992, J BIOL CHEM, V267, P7718; KIM K, 1995, BIOCHEM J, V306, P353, DOI 10.1042/bj3060353; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KRAUS WE, 1989, AM J PHYSIOL, V256, pC506, DOI 10.1152/ajpcell.1989.256.3.C506; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LOCKE M, 1990, AM J PHYSIOL, V258, pC723, DOI 10.1152/ajpcell.1990.258.4.C723; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; NEUFER PD, 1996, IN PRESS AM J PHYSL; ORNATSKY OI, 1995, BIOCHEM J, V311, P119, DOI 10.1042/bj3110119; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PIATIGORSKY J, 1994, EXS, V71, P241; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WILLIAMS RS, 1993, HDB PHYSL, P1124; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	49	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24089	24095		10.1074/jbc.271.39.24089	http://dx.doi.org/10.1074/jbc.271.39.24089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798647	hybrid			2022-12-25	WOS:A1996VJ44200076
J	Rehrauer, WM; Lavery, PE; Palmer, EL; Singh, RN; Kowalczykowski, SC				Rehrauer, WM; Lavery, PE; Palmer, EL; Singh, RN; Kowalczykowski, SC			Interaction of Escherichia coli RecA protein with LexA repressor .1. LexA repressor cleavage is competitive with binding of a secondary DNA molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PHAGE-LAMBDA-REPRESSOR; HOMOLOGOUS RECOMBINATION; SOS INDUCTION; NUCLEOSIDE TRIPHOSPHATE; DEPENDENT PROTEOLYSIS; ENZYMATIC-PROPERTIES; DIRECTED CLEAVAGE; STABLE COMPLEXES; ATP HYDROLYSIS	Essential to the two distinct cellular events of genetic recombination and SOS induction in Escherichia coli, RecA protein promotes the homologous pairing and exchange of DNA strands and the proteolytic cleavage of the LexA repressor, respectively, Since both of these activities require single-stranded DNA (ssDNA) and ATP, the inter-relationship between these reactions was investigated and found to display many parallels, The extent of active complex formed between RecA protein and M13 ssDNA, as measured by both ATP hydrolysis and LexA proteolysis, is stimulated in a similar manner by either a reduction in magnesium ion concentration or the presence of single-stranded DNA binding (SSB) protein. However, unexpectedly, SSB protein inhibits both LexA proteolysis and ATP hydrolysis (in assays containing repressor) at concentrations of RecA protein that are substoichiometric to the ssDNA, arguing that LexA repressor affects the competition between RecA and SSB proteins for limited ssDNA binding sites. Additionally, attenuation of LexA repressor cleavage in the presence of double-stranded DNA or by an excess of ssDNA suggests that interaction of the RecA nucleoprotein filament with either LexA repressor or a secondary DNA molecule is mutually exclusive. The significance of these results is discussed in the context of both the regulation of inducible responses to DNA damage, and the competitive relationship between the processes of SOS induction and genetic recombination.	UNIV CALIF DAVIS,MICROBIOL SECT,DIV BIOL SCI,DAVIS,CA 95616; NORTHWESTERN UNIV,SCH MED,DEPT BIOL MOL,CHICAGO,IL 60611; UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DIV BIOL SCI,DAVIS,CA 95616	University of California System; University of California Davis; Northwestern University; University of California System; University of California Davis					NIAID NIH HHS [AI-18987] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGDASARIAN M, 1986, P NATL ACAD SCI USA, V83, P5723, DOI 10.1073/pnas.83.15.5723; BAGDASARIAN M, 1992, MOL MICROBIOL, V6, P885, DOI 10.1111/j.1365-2958.1992.tb01539.x; BAILONE A, 1988, MOL GEN GENET, V214, P389, DOI 10.1007/BF00330471; BRANDSMA JA, 1982, GENE, V18, P77, DOI 10.1016/0378-1119(82)90058-0; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CELERIER J, 1988, MECH CONSEQUENCES DN, P445; CHASE JW, 1984, J BIOL CHEM, V259, P805; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DICAPUA E, 1992, J MOL BIOL, V226, P707, DOI 10.1016/0022-2836(92)90627-V; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Harmon FG, 1996, J BIOL CHEM, V271, P23874, DOI 10.1074/jbc.271.39.23874; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; HIGASHITANI N, 1992, J BACTERIOL, V174, P1612, DOI 10.1128/jb.174.5.1612-1618.1992; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1992, J BIOL CHEM, V267, P10400; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1987, J BIOL CHEM, V262, P2085; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MEYER RR, 1982, MUTAT RES, V94, P299, DOI 10.1016/0027-5107(82)90293-7; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MOREAU PL, 1987, J MOL BIOL, V194, P621, DOI 10.1016/0022-2836(87)90239-7; MOREAU PL, 1989, J BIOL CHEM, V264, P2302; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PHIZICKY EM, 1981, CELL, V25, P259, DOI 10.1016/0092-8674(81)90251-8; PHIZICKY EM, 1980, J MOL BIOL, V139, P319, DOI 10.1016/0022-2836(80)90133-3; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RESNICK J, 1982, P NATL ACAD SCI-BIOL, V79, P2832, DOI 10.1073/pnas.79.9.2832; ROBERTS JW, 1978, P NATL ACAD SCI USA, V75, P4714, DOI 10.1073/pnas.75.10.4714; ROMAN LJ, 1986, BIOCHEMISTRY-US, V25, P7375, DOI 10.1021/bi00371a020; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SCHNARR M, 1984, FEBS LETT, V171, P207, DOI 10.1016/0014-5793(84)80489-5; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SWEASY JB, 1990, J BACTERIOL, V172, P3030, DOI 10.1128/jb.172.6.3030-3036.1990; TAKAHASHI M, 1986, FEBS LETT, V196, P215, DOI 10.1016/0014-5793(86)80249-6; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P883; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P2100, DOI 10.1073/pnas.78.4.2100; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254	72	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23865	23873		10.1074/jbc.271.39.23865	http://dx.doi.org/10.1074/jbc.271.39.23865			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798617	hybrid			2022-12-25	WOS:A1996VJ44200046
J	Rother, RP; Zhao, J; Zhou, QS; Sims, PJ				Rother, RP; Zhao, J; Zhou, QS; Sims, PJ			Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS SAIMIRI; INHIBITORY ACTIVITY; PROTEIN CD59; 2ND LIGAND; C9; C5B-8; EXPRESSION; BINDING; LYSIS; CD2	CD59 is a glycosylphosphatidylinositol-anchored membrane glycoprotein that serves as the principle cellular inhibitor of the C5b-9 membrane attack complex (MAC) of human complement, Approximately 50% of the total apparent mass of CD59 is attributable to glycosylation of a single Asn (Asn(18)), The deduced amino acid sequences of CD59 homologues identified in Old and New World primates as well as in rat reveal that the motif for N-linked glycosylation at the residue corresponding to Asn(18) of human CD59 is invariably conserved, despite considerable sequence divergence elsewhere in the protein, Such conservation suggests that the post translational modification at Asn(18) has importance for either expression or normal function of CD59 at the cell surface, In this study, we specifically examined how deletion or transposition of the site of N-linked glycosylation in the CD59 polypeptide affects its MAC inhibitory function. Our data demonstrate that the inhibitory potency of CD59 is unaffected when glycosylation is transposed from Asn(18) to another site in the polypeptide. Furthermore, we show that CD59 retains normal MAC regulatory function when mutated to eliminate all potential sites for N-linked glycosylation, These data suggest that the MAC inhibitory function of CD59 is entirely provided by residues exposed at the surface of the core polypeptide and that this core structure is not influenced by glycosylation at Asn(18).	BLOOD CTR SE WISCONSIN INC,MILWAUKEE,WI 53201; ALEXION PHARMACEUT INC,NEW HAVEN,CT 06511	Versiti Blood Center of Wisconsin					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036061] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL36061] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAMI T, 1994, TRANSPL P, V26, P1256; ALBRECHT JC, 1992, VIROLOGY, V190, P527, DOI 10.1016/0042-6822(92)91247-R; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG KH, 1985, J IMMUNOL, V135, P459; DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257; DECKERT M, 1992, EUR J IMMUNOL, V22, P2943, DOI 10.1002/eji.1830221128; FLETCHER CM, 1994, STRUCTURE, V2, P185, DOI 10.1016/S0969-2126(00)00020-4; FLETCHER CM, 1993, PROTEIN SCI, V2, P2015, DOI 10.1002/pro.5560021203; FODOR WL, 1995, IMMUNOGENETICS, V41, P51, DOI 10.1007/BF00188435; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; KIEFFER B, 1994, BIOCHEMISTRY-US, V33, P4471, DOI 10.1021/bi00181a006; MENU E, 1994, J IMMUNOL, V153, P2444; MERI S, 1990, IMMUNOLOGY, V71, P1; Nakano Yasuko, 1993, Molecular Immunology, V30, P37, DOI 10.1016/0161-5890(93)90307-W; NINOMIYA H, 1992, J BIOL CHEM, V267, P8404; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; RUSHMERE NK, 1994, BIOCHEM J, V304, P595, DOI 10.1042/bj3040595; SIMS PJ, 1984, BIOCHEMISTRY-US, V23, P3248, DOI 10.1021/bi00309a020; SUZUKI H, 1994, CLIN EXP IMMUNOL S2, V97, P46; ZHAO J, 1991, J BIOL CHEM, V266, P13418	26	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23842	23845		10.1074/jbc.271.39.23842	http://dx.doi.org/10.1074/jbc.271.39.23842			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798614	hybrid			2022-12-25	WOS:A1996VJ44200043
J	Farina, A; Gaetano, C; Crescenzi, M; Puccini, F; Manni, I; Sacchi, A; Piaggio, G				Farina, A; Gaetano, C; Crescenzi, M; Puccini, F; Manni, I; Sacchi, A; Piaggio, G			The inhibition of cyclin B1 gene transcription in quiescent NIH3T3 cells is mediated by an E-box	ONCOGENE			English	Article						Max; cyclin B1 promoter; cell cycle	DNA-BINDING; BREAST-CANCER; MESSENGER-RNA; MYC; MAX; EXPRESSION; PROTEIN; DIFFERENTIATION; AMPLIFICATION; DIMERIZATION	Cyclin B1 plays an important role in cell proliferation. Its expression is tightly regulated at the mRNA and protein levels during the cell cycle and is found to be deregulated in various malignancies. To enlighten the signalling pathways which lead to the cell cycle dependent expression of the cyclin B1 gene, we studied its transcriptional regulation in quiescent and proliferating NIH3T3 cells. We previously showed that the transcriptional activity of the cyclin B1 promoter decreases in quiescent cells. Here, we map a quiescence-responsive element of the human cyclin B1 promoter to an E-box sequence, CACGTG, which spans positions -124/-119. Nuclear proteins protect this sequence in a DNase I digestion assay and bind, in electromobility shift assays, an oligonucleotide spanning positions -133/-110. Max-specific antibodies block the DNA-binding activity of protein complexes to this probe. A mutation in the E-box core sequence abolishes the decrease in transcription that occurs during quiescence. Finally, we find that over-expression of Max protein in proliferating cells specifically inhibits cyclin B1 promoter activity through this E-box. Moreover, Max overexpression in proliferating NIH3T3 cells leads to down-regulation of the endogenous cyclin B1 protein. In conclusion, these data support a model whereby E-box-binding proteins mediate the decrease in the transcriptional activity of the cyclin B1 promoter observed in quiescent cells and suggest that Max contributes to this response.	IST REGINA ELENA,CTR RICERCA SPERIMENTALE,LAB ONCOGENESI MOL,I-00158 ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena			Crescenzi, Marco/J-3603-2018; Piaggio, Giulia/J-7214-2018; Piaggio, Giulia/AAD-7336-2022; Manni, Isabella/ABH-6460-2020; Gaetano, Carlo/P-9997-2019	Crescenzi, Marco/0000-0003-0156-1494; Piaggio, Giulia/0000-0003-2114-1892; Manni, Isabella/0000-0003-4823-0596; Gaetano, Carlo/0000-0002-5238-1832				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P3467; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GONG JP, 1994, CANCER RES, V54, P4285; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Hurlin P. J., 1994, V59, P109; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	36	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1287	1296						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808703				2022-12-25	WOS:A1996VJ20200020
J	Tantravahi, R; Dudek, H; Patel, G; Reddy, EP				Tantravahi, R; Dudek, H; Patel, G; Reddy, EP			Murine myeloid leukemic cells with disrupted myb loci show splicing anomalies that account for heterogeneous sizes in myb proteins	ONCOGENE			English	Article						ABPL tumors; Myb protein heterogeneity; RNA splicing	C-MYB; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; DNA-BINDING; V-MYB; DIFFERENTIAL EXPRESSION; STRUCTURAL ORGANIZATION; CELLULAR PROGENITOR; ONCOGENE ACTIVATION; GENE	The ABPL tumor cell lines represent a group of myeloid cell lines which contain an altered myb locus due viral insertional mutagenesis within the third exon of c-myb. Immunoprecipitation analysis of the proteins produced in three ABPL lines revealed an interesting anomaly. Despite the invariant position of the virus integration event, the three ABPL tumor cell lines me examined (ABPL-1, ABPL-2 and ABPL-4) produced three different sized proteins. In this report, we examined the molecular basis for this protein size heterogeneity. Molecular cloning and sequence analysis of the cDNAs derived from the myb transcripts show that ABPL-1 tumor produces a tripartate mRNA containing sequences derived from the viral gag and Env genes fused to the myb coding region. This results in the synthesis of a 74 kd protein. In the ABPL-2 tumor line, a gag-myb fusion protein is produced which is of 68 kd. In ABPL-4 cell line a gag-myb fusion protein is produced which contains an internal deletion of coding sequences derived from exons 13 and 14. This deletion results in the synthesis of a 59 kd protein in ABPL-4 tumor cell line,These observations were further confirmed by RNase protection assays which demonstrate the presence of aberrantly spliced mRNAs in ABPL-1 and ABPL-4 tumor cells but not in cells containing an undisrupted c-myb locus. In vitro translation and immuno-precipitation analysis of the cRNAs derived from the ABPL-1, ABPL-2 and ABPL-4 cDNAs show the synthesis of protein products that mere identical to Myb proteins produced by these tumors in vivo. These results suggest that integration of Mo-MuLV within the c-myb locus not only results in deletions of the 5' end of the transcript but splicing aberrations within the encoded mRNA, which results in the synthesis of a heterogeneous array of proteins, not seen in normal hematopoietic cells.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOL BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P01CA052009] Funding Source: NIH RePORTER; NCI NIH HHS [CA52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BADING H, 1987, ONCOGENE, V1, P395; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CASTLE S, 1985, BIOCHEM BIOPH RES CO, V132, P688, DOI 10.1016/0006-291X(85)91187-8; CRAIG RW, 1984, CANCER RES, V44, P442; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GERWITZ AM, 1989, SCIENCE, V242, P1303; GILMAN M, 1988, CURRENT PROTOCOLS MO; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LAVU S, 1984, CURR TOP MICROBIOL, V113, P37; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROVERA G, 1987, ONCOGENE, V1, P29; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; URBANEK P, 1988, NUCLEIC ACIDS RES, V16, P11521, DOI 10.1093/nar/16.24.11521; WATSON RJ, 1988, ONCOGENE, V2, P267; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	37	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1187	1196						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808693				2022-12-25	WOS:A1996VJ20200010
J	Spitkovsky, D; Aengeneyndt, F; Braspenning, J; Doeberitz, MV				Spitkovsky, D; Aengeneyndt, F; Braspenning, J; Doeberitz, MV			p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene	ONCOGENE			English	Article						p53; low risk and high risk HPV E6; p21 dexamethasone; transactivation; growth arrest	P53 PROTEIN; CELLULAR-RESPONSE; CARCINOMA CELLS; DNA DAMAGE; E7; ONCOPROTEINS; SUPPRESSION; EXPRESSION; APOPTOSIS; INDUCTION	Growth of cervical carcinoma cells depends on continuous expression of high risk type human papillomavirus oncogenes E6 and E7, E6 destabilizes p53, a tumor-suppressive transcription factor, which activates expression of the inhibitor of cell cycle progression p21 and other genes, E6-mediated p53 degradation can therefore result in cell cycle deregulation, It has, however, not yet been determined whether p53 inactivation is sufficient to provoke cell cycle progression in established cervical carcinoma cells, Moreover, it has not yet been clarified whether E6 confers additional p53-independent growth stimuli in cancer cells, To address these questions, we analysed p53 functions in SW 756 cervical cancer cells in which the expression of endogenous HPV 18 E6-E7 genes be downregulated by dexamethasone. This results significantly increased p53 levels and sequent cell cycle arrest in the G(1) phase, Surprisingly, p53 activities were suppressed rather than enhanced in these cervical cancer cells, However, if high risk papillomavirus type 16 E6 genes, including a mutant which does not degrade p53, were expressed in dexamethasone-treated SW 756 cells with suppressed endogenous HPV type 18 E6-E7 expression, the cells reentered the cell cycle even in the absence of a cooperating viral E7 gene, In contrast, the non oncogenic papillomavirus type 6 E6 gene did not release the cells from growth arrest under these conditions, These data indicate that suppression of p53 functions is not sufficient to provoke cell cycle progression in E6-E7-depleted cervical cancer cells and point to a p53-independent mitotic activity to oncogenic papillomavirus type E6 genes in cervical carcinoma cells.	UNIV HEIDELBERG, DIV MOL DIAGNOST & THERAPY, DEPT SURG, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, FSP6 ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)								BUTZ K, 1995, ONCOGENE, V10, P927; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRAKER PJ, 1995, METHOD CELL BIOL, V46, P57; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAVRE PA, 1995, CANCER RES, V55, P4420; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MULLER M, 1992, VIROLOGY, V187, P508; MUNGER K, 1992, CANCER SURV, V12, P197; SCHAUB LBO, 1995, MOL CELL BIOL, V15, P3032; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SEYLER FH, 1991, NUCLEIC ACIDS RES, V19, P5080; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; VONKNEBELDOEBERITZ M, 1994, J VIROL, V68, P2811, DOI 10.1128/JVI.68.5.2811-2821.1994; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	29	31	33	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					1027	1035						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806692				2022-12-25	WOS:A1996VG76600016
J	Wienecke, R; Maize, JC; Shoarinejad, F; Vass, WC; Reed, J; Bonifacino, JS; Resau, JH; deGunzburg, J; Yeung, RS; DeClue, JE				Wienecke, R; Maize, JC; Shoarinejad, F; Vass, WC; Reed, J; Bonifacino, JS; Resau, JH; deGunzburg, J; Yeung, RS; DeClue, JE			Co-localization of the TSC2 product tuberin with its target Rap1 in the golgi apparatus	ONCOGENE			English	Article						tuberous sclerosis; tuberin; localization Rap1; Golgi apparatus	EKER RAT MODEL; DOMINANTLY INHERITED CANCER; SCLEROSIS TSC2; CYTOPLASMIC DOMAIN; HUMAN NEUTROPHILS; PLASMA-MEMBRANE; MANNOSIDASE-II; GENE-PRODUCT; PROTEINS; COMPLEX	Tuberin is the protein product of the tuberous sclerosis-2 (TSC2) gene, which is associated with tuberous sclerosis (TSC), a human genetic syndrome characterized by the development of tumors in a variety of tissues, We have previously shown that tuberin is a widely expressed 180 kDa protein which exhibits specific GTPase activating activity in vitro towards the Ras-related Rap1 study we have used affinity-purified antibodies against tuberin to analyse its expression in human and rat tissues and to examine its subcellular localization, Tuberin expression was detected in all adult human tissues tested, with the highest levels found in brain, heart and kidney, organs that are commonly affected in TSC patients, By contrast, in adult rats the highest levels of tuberin were found in brain, liver and testis, Indirect immunofluorescence of tuberin in various cultured cell lines revealed a punctate, mostly perinuclear staining pattern, Double-indirect immunofluorescence analysis sera and anti-tuberin sera and antisera against known Golgi markers (mannosidase-II and furin) revealed that the staining of tuberin was consistent with its localization in the stacks of the Golgi apparatus, In support of this, treatment of cells with brefeldin A, a drug known to cause disassembly of the Golgi apparatus: abolished the perinuclear staining of tuberin, Moreover, conventional and confocal immunofluorescence demonstrated co-localization of tuberin with Rap1, which has previously been localized to the Golgi apparatus, The colocalization of tuberin and Rap1 in vivo strengthens the likelihood that the in vitro catalytic activity of tuberin toward Rap1 plays a physiologically relevant role in the tumor suppressor function of tuberin.	NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA; FOX CHASE CANC CTR, DIV MED SCI, PHILADELPHIA, PA 19111 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT DERMATOPATHOL, NEW YORK, NY 10021 USA; NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, ADV BIOSCI LABS, BASIS RES PROGRAM, FREDERICK, MD 21702 USA; INST CURIE, SECT RECH, F-74231 PARIS 05, FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fox Chase Cancer Center; Cornell University; NewYork-Presbyterian Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie				Bonifacino, Juan S./0000-0002-5673-6370				BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GEIST RT, 1995, CELL GROWTH DIFFER, V6, P1477; Givol I, 1995, ONCOGENE, V11, P2609; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Harlow E., 1988, ANTIBODIES LAB MANUA; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HINO O, 1995, MOL CARCINOGEN, V14, P23, DOI 10.1002/mc.2940140106; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; JIN F, 1996, IN PRESS P NATL ACAD; KAMEYAMA Y, 1994, LIFE SCI, V55, P213, DOI 10.1016/0024-3205(94)00882-5; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOBAYASHI T, 1995, NUCLEIC ACIDS RES, V23, P2608, DOI 10.1093/nar/23.14.2608; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MOLLINEDO F, 1993, FEBS LETT, V326, P209, DOI 10.1016/0014-5793(93)81792-X; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NELLIST M, 1993, CELL, V75, P1305; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVIKOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P4364, DOI 10.1073/pnas.80.14.4364; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1994, J CELL SCI, V107, P1661; QUARCK R, 1994, FEBS LETT, V342, P159, DOI 10.1016/0014-5793(94)80492-3; Tsuchiya H, 1996, CANCER RES, V56, P429; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; XIAO GH, 1995, ONCOGENE, V11, P81; XIAO GH, 1995, CELL GROWTH DIFFER, V6, P1185; XU L, 1995, GENOMICS, V27, P475, DOI 10.1006/geno.1995.1079; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1995, MOL CARCINOGEN, V14, P28, DOI 10.1002/mc.2940140107; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	96	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					913	923						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806680				2022-12-25	WOS:A1996VG76600004
J	Jing, YK; Zhang, J; Bleiweiss, IJ; Waxman, S; Zelent, A; MiraYLopez, R				Jing, YK; Zhang, J; Bleiweiss, IJ; Waxman, S; Zelent, A; MiraYLopez, R			Defective expression of cellular retinol binding protein type I and retinoic acid receptors alpha 2, beta 2, and gamma 2 in human breast cancer cells	FASEB JOURNAL			English	Article						RXR; breast cancer	MAMMARY EPITHELIAL-CELLS; HUMAN LUNG-CANCER; RESPONSE ELEMENT; GROWTH-INHIBITION; LINES; GENE; ABNORMALITIES; SENSITIVITY; METABOLISM; ISOFORMS	Because the retinoic acid (RA) signaling pathway regulates cell proliferation and differentiation, inactivation of genes integral to the pathway represents a potential mechanism of carcinogenesis. We have studied in human breast cancer cells (T47D, MCF-7, ZR75-1, MDA-MB-231, and BT20) the expression of a subset of retinoid signaling genes that are themselves transcriptionally up-regulated by RA, the cellular retinol binding protein type I (CRBPI) and the RA receptors (RARs) alpha 2, beta 2, and gamma 2. We find that constitutive expression of these genes is low or undetectable, and that expression levels are seldom responsive to 24 h treatment with 1 mu M all-trans or 9-cis RA (Northern blot analysis). This is in contrast to breast fibroblasts, which show RA-dependent expression of all four genes under the same conditions. Moreover, normal human breast epithelial cells express CRBPI and RAR beta 2 at the mRNA level, suggesting that loss of expression of these genes is tied to malignant transformation. RAR beta 2, but not CRBPI, was also expressed in RA-treated MTSV1-7 cells, an immortalized but nontumorigenic luminal epithelial cell Line. Lack of CRBPI and RAR beta 2 expression in cancer cells was not due to general impairment of RA signaling, as shown by RA activation of a RARE(3)-tk-CAT reporter in a subclone of MDA-MB-231 cells that did not express either CRBPI or RAR beta 2. These results suggest that at least two independent defects in the expression of proteins that function in retinoid signaling may be involved in breast carcinogenesis.	MT SINAI MED CTR,DEPT MED,NEW YORK,NY 10029; MT SINAI MED CTR,DEPT PATHOL,NEW YORK,NY 10029; INST CANC RES,CHESTER BEATTY LABS,LEUKAEMIA RES FUND CTR,LONDON SW3 6JB,ENGLAND	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Zelent, Arthur/B-3532-2009	Zelent, Arthur/0000-0002-7968-9888	NCI NIH HHS [R29 CA54273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; ESKILD W, 1991, BIOL REPROD, V44, P55; GEBERT JF, 1991, ONCOGENE, V6, P1859; Gudas Lorraine J., 1994, P443; HU L, 1991, CANCER RES, V51, P3972; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN MS, 1993, J BIOL CHEM, V268, P8267; LISSOOS TW, 1995, AM J PHYSIOL-GASTR L, V268, pG224, DOI 10.1152/ajpgi.1995.268.2.G224; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MADER S, 1993, J BIOL CHEM, V268, P591; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MOGHAL N, 1995, MOL CELL BIOL, V17, P3945; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NILSSON MHL, 1988, EUR J BIOCHEM, V173, P35, DOI 10.1111/j.1432-1033.1988.tb13963.x; Ong David E., 1994, P283; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; ROMAN SD, 1992, CANCER RES, V52, P2236; Sambrook J., 2002, MOL CLONING LAB MANU; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; VANDERLEEDE BJM, 1995, INT J ONCOL, V6, P391; WAN YJY, 1995, EXP CELL RES, V219, P392, DOI 10.1006/excr.1995.1244; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; XU XC, 1994, CANCER RES, V54, P3580; ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZHANG XK, 1994, CANCER RES, V54, P5663	46	33	34	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1064	1070		10.1096/fasebj.10.9.8801168	http://dx.doi.org/10.1096/fasebj.10.9.8801168			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801168				2022-12-25	WOS:A1996UY93200017
J	Li, N; Jiang, XN; Cai, GP; Yang, SF				Li, N; Jiang, XN; Cai, GP; Yang, SF			A novel bifunctional fusion enzyme catalyzing ethylene synthesis via 1-aminocyclopropane 1-carboxylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCURONIDASE; ESCHERICHIA-COLI; KEY ENZYME; HORMONE ETHYLENE; FORMING ENZYME; HIGHER-PLANTS; GENE FUSION; SYNTHASE; BIOSYNTHESIS; EXPRESSION	A C terminus truncated soybean 1-aminocyclopropane-1-carboxylic acid (ACC) synthase (466 aa) was fused to an N terminus truncated tomato ACC oxidase (312 aa) to create a 778-amino acid fusion polypeptide, This ACC synthase-ACC oxidase fusion enzyme (ACSO) was expressed in a heterologous prokaryotic Escherichia coli system, which is capable of converting endogenous S-adenosyl-L-methionine (AdoMet) to ethylene, The molecular weight of the fusion enzyme, ACSO, as determined by sodium dodecyl sulfate-polyacryl amide gel electrophoresis, was 90 +/- 3 kDa. Gel filtration analysis indicates that the native ACSO is oligomeric and is capable of converting exogenously supplied AdoMet to ethylene, The ethylene production rate of ACSO fusion enzyme was determined to be 6.0 nmol h(-1) mg(-1) under our assaying conditions using the partially purified enzyme extract, In the enzyme reaction mixture, an increase in ethylene production catalyzed by the bifunctional ACSO was accompanied by a decrease in ACC accumulation. Similarly, in E. coli cells, the level of ACC, produced as an intermediate during the sequential reactions from AdoMet to ethylene, was also found to arise earlier than that of ethylene, Because ACSO could produce ethylene from the ubiquitous AdoMet in living cell and the method commonly used to measure gaseous ethylene is simple, fast, and sensitive, we anticipate this bifunctional fusion enzyme to be useful as a reporter and for research in molecular biology, developmental biology, fermentation, and genetic engineering.			Li, N (corresponding author), HONG KONG UNIV SCI & TECHNOL, DEPT BIOL, CLEAR WATER BAY, HONG KONG, HONG KONG.							Abeles F, 1992, ETHYLENE PLANT BIOL; ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; BOLLER T, 1979, PLANTA, V145, P293, DOI 10.1007/BF00454455; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULOW L, 1991, TRENDS BIOTECHNOL, V9, P226, DOI 10.1016/0167-7799(91)90075-S; CHAMPE SP, 1962, J MOL BIOL, V4, P288, DOI 10.1016/S0022-2836(62)80006-0; DATLA RSS, 1991, GENE, V101, P239, DOI 10.1016/0378-1119(91)90417-A; DONG JG, 1992, P NATL ACAD SCI USA, V89, P9789, DOI 10.1073/pnas.89.20.9789; ELMAYAN T, 1994, PLANT J, V6, P433, DOI 10.1046/j.1365-313X.1994.06030433.x; HAMILTON AJ, 1991, P NATL ACAD SCI USA, V88, P7434, DOI 10.1073/pnas.88.16.7434; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HOHENESTER E, 1994, J MOL BIOL, V243, P947, DOI 10.1006/jmbi.1994.1695; JEFFERSON RA, 1987, EMBO J, V6, P3901; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li N, 1996, FEBS LETT, V378, P286, DOI 10.1016/0014-5793(95)01464-0; LI N, 1992, FEBS LETT, V306, P103, DOI 10.1016/0014-5793(92)80978-P; LI N, 1994, J BIOL CHEM, V269, P6908; LIEBERMAN M, 1979, ANNU REV PLANT PHYS, V30, P533, DOI 10.1146/annurev.pp.30.060179.002533; LIU DR, 1993, PLANT CELL PHYSIOL, V34, P1151; LIZADA MCC, 1979, ANAL BIOCHEM, V100, P140, DOI 10.1016/0003-2697(79)90123-4; MAYNARD JA, 1963, AUST J CHEM, V16, P596, DOI 10.1071/CH9630596; NAKAJIMA N, 1990, PLANT CELL PHYSIOL, V31, P1021; OWENS LD, 1971, PLANT PHYSIOL, V48, P1, DOI 10.1104/pp.48.1.1; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SATO T, 1989, P NATL ACAD SCI USA, V86, P6621, DOI 10.1073/pnas.86.17.6621; SATOH S, 1993, PLANT CELL PHYSIOL, V34, P753, DOI 10.1093/oxfordjournals.pcp.a078479; SILHAVY TJ, 1985, MICROBIOL REV, V49, P398, DOI 10.1128/MMBR.49.4.398-418.1985; SMITH MC, 1988, J BIOL CHEM, V263, P7211; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAN DER STRAETEN D, 1990, P NATL ACAD SCI USA, V87, P4859, DOI 10.1073/pnas.87.12.4859; VERVERIDIS P, 1991, PHYTOCHEMISTRY, V30, P725, DOI 10.1016/0031-9422(91)85241-Q; WHITE MF, 1994, P NATL ACAD SCI USA, V91, P12428, DOI 10.1073/pnas.91.26.12428; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1991, PLANT PHYSIOL, V95, P251, DOI 10.1104/pp.95.1.251; YU YB, 1979, ARCH BIOCHEM BIOPHYS, V198, P280, DOI 10.1016/0003-9861(79)90420-X; ZHANG ZH, 1995, BIOCHEM J, V307, P77, DOI 10.1042/bj3070077	38	18	19	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25738	25741		10.1074/jbc.271.42.25738	http://dx.doi.org/10.1074/jbc.271.42.25738			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824199	hybrid			2022-12-25	WOS:A1996VN18000005
J	Schultz, TF; Spiker, S; Quatrano, RS				Schultz, TF; Spiker, S; Quatrano, RS			Histone H1 enhances the DNA binding activity of the transcription factor EmBP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; RESPONSE ELEMENTS; RECEPTOR-BINDING; PROTEIN; WHEAT; GENE; IDENTIFICATION; RECOGNIZES; SEQUENCES; PROMOTER	Previous work indicated that nuclear extracts isolated from embryogenic rice suspension cells treated with the phytohormone abscisic acid (ABA) have enhanced binding activity to an ABA response element (Emla) in the promoter of the Em gene from wheat, We identified an activity in wheat and maize nuclear extracts that enhances binding of the recombinant transcription factor EmBP-1 to Emla by 80-fold. Fractionation of nuclear extracts led us to identify histone H1 and HMGb (but not HMGc or -d) as two factors that can enhance the ability of EmBP-1 to bind to Emla and account for at least a part of this activity of nuclear extracts. Our results, which indicate for the first time that histone ill possesses this type of activity, lend further support to the model that positively charged proteins can drastically affect the DNA binding activity of specific transcription factors. Furthermore, our study points to these chromosomal proteins as potential targets of an ABA-mediated modification (e.g. acetylation) that could affect the regulation of Em gene expression.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; N CAROLINA STATE UNIV,DEPT GENET,RALEIGH,NC 27695	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; North Carolina State University				Schultz, Thomas/0000-0001-9694-9920	NIGMS NIH HHS [GM44288] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P989, DOI 10.1021/bi00456a022; CROTHERS DM, 1994, SCIENCE, V266, P1819, DOI 10.1126/science.7997876; FINKELSTEIN RR, 1993, MOL GEN GENET, V238, P401, DOI 10.1007/BF00291999; GRANELLIPIPERNO A, 1991, P NATL ACAD SCI USA, V88, P11431, DOI 10.1073/pnas.88.24.11431; GRASSER KD, 1994, PLANT J, V6, P351, DOI 10.1046/j.1365-313X.1994.06030351.x; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; Hill A, 1996, J BIOL CHEM, V271, P3366, DOI 10.1074/jbc.271.7.3366; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; SPIKER S, 1982, J BIOL CHEM, V257, P4250; SPIKER S, 1984, J BIOL CHEM, V259, P2007; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; VASIL V, 1995, PLANT CELL, V7, P1511, DOI 10.1105/tpc.7.9.1511; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZLATANOVA J, 1991, DNA CELL BIOL, V10, P239, DOI 10.1089/dna.1991.10.239	24	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25742	25745		10.1074/jbc.271.42.25742	http://dx.doi.org/10.1074/jbc.271.42.25742			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824200	hybrid, Green Published			2022-12-25	WOS:A1996VN18000006
J	AratoOshima, T; Matsui, H; Wakizaka, A; Homareda, H				AratoOshima, T; Matsui, H; Wakizaka, A; Homareda, H			Mechanism responsible for oligomycin-induced occlusion of Na+ within Na/K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NA,K-ATPASE ALPHA-SUBUNIT; POTASSIUM-IONS; ADENOSINE-TRIPHOSPHATASE; SODIUM-PUMP; BETA-SUBUNIT; BOUND FORMS; NA+,K+-ATPASE; K+; TRANSPORT	The mechanism whereby oligomycin occludes Na+ within Na/K-ATPase was investigated to study Na+ and K+ transport mechanisms. Oligomycin stimulated Na+ binding to Na/K-ATPase but inhibited Na-H and Na-Na exchange. The oligomycin concentration required to stimulate Na+ binding to half-maximal was 4.5 mu M, which was close to the concentration that reduced Na-Na and Na-K exchange and ATPase activity to half-maximal, suggesting that Na/K-ATPase possesses an oligomycin binding site responsible for stimulating Na+ binding and reducing ion exchange and ATPase activity. In contrast, neither K+ binding nor K+ transport was affected by oligomycin. Limited tryptic digestion of Na/K-ATPase showed that, unlike Na+, K+, and ouabain, oligomycin treatment did not result in a specific digestion pattern. Oligomycin appeared to inhibit ouabain binding in a noncompetitive manner, whereas it did not affect ATP binding. Na/K-ATPase isoforms with low and high sensitivities to ouabain were equally sensitive to oligomycin. These results suggest that the oligomycin binding site is located on the extracellular side of Na/K-ATPase, at a different position from the ouabain binding site, and this antibiotic did not induce a conformational change of Na/K-ATPase. We propose that oligomycin interacts with the Na+ occlusion site from the extracellular side of Na/K-ATPase, which delays Na+ release to the extracellular side without inducing a conformational change, suggesting that the pathways responsible for Na+ and K+ transport differ.	KYORIN UNIV, SCH MED, DEPT BIOCHEM 2, MITAKA, TOKYO 181, JAPAN; KYORIN UNIV, SCH MED, DEPT BIOCHEM 1, MITAKA, TOKYO 181, JAPAN	Kyorin University; Kyorin University								ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ASKARI A, 1968, BIOCHEM BIOPH RES CO, V32, P227, DOI 10.1016/0006-291X(68)90373-2; BLOSTEIN R, 1970, J BIOL CHEM, V245, P270; CHANDLER HD, 1978, BIOCHEM J, V169, P559, DOI 10.1042/bj1690559; CORNELIUS F, 1985, BIOCHIM BIOPHYS ACTA, V818, P211, DOI 10.1016/0005-2736(85)90572-3; ESMANN M, 1991, BIOCHIM BIOPHYS ACTA, V1064, P31, DOI 10.1016/0005-2736(91)90408-Z; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FAHN S, 1966, J BIOL CHEM, V241, P1882; FAHN S, 1968, J BIOL CHEM, V243, P1993; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORTES PAG, 1984, J BIOL CHEM, V259, P1176; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P217, DOI 10.1113/jphysiol.1967.sp008297; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; HALPERIN JA, 1991, BIOCHIM BIOPHYS ACTA, V1070, P497, DOI 10.1016/0005-2736(91)90092-M; HAYASHI Y, 1977, BIOCHIM BIOPHYS ACTA, V482, P185, DOI 10.1016/0005-2744(77)90365-5; HEGYVARY C, 1976, BIOCHIM BIOPHYS ACTA, V422, P365, DOI 10.1016/0005-2744(76)90148-0; HOMAREDA H, 1982, J BIOCHEM, V92, P219, DOI 10.1093/oxfordjournals.jbchem.a133917; HOMAREDA H, 1991, J BIOCHEM-TOKYO, V109, P70; INTURRISI CE, 1968, MOL PHARMACOL, V4, P591; ISHII T, 1994, P NATL ACAD SCI USA, V91, P6103, DOI 10.1073/pnas.91.13.6103; ISHII T, 1995, SEIKAGAKU, V67, P816; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V139, P450; KAPLAN JH, 1991, SOC GEN PHY, V46, P117; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V525, P252, DOI 10.1016/0005-2744(78)90219-X; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN WH, 1994, P NATL ACAD SCI USA, V91, P9881, DOI 10.1073/pnas.91.21.9881; MATSUI H, 1982, J BIOCHEM-TOKYO, V92, P193, DOI 10.1093/oxfordjournals.jbchem.a133916; MATSUI H, 1988, METHOD ENZYMOL, V156, P29; NAGAMATSU S, 1986, ACTA ENDOCRINOL-COP, V111, P69, DOI 10.1530/acta.0.1110069; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; POST RL, 1979, CATION FLUX BIOMEMBR, P3; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; ROBINSON JD, 1979, BIOCHIM BIOPHYS ACTA, V549, P145, DOI 10.1016/0304-4173(79)90013-2; ROBINSON JD, 1971, MOL PHARMACOL, V7, P238; SACHS JR, 1980, J PHYSIOL-LONDON, V302, P219; SCHWARTZ A, 1975, PHARMACOL REV, V27, P3; SIMONS TJB, 1974, J PHYSIOL-LONDON, V237, P123, DOI 10.1113/jphysiol.1974.sp010474; SKOU JC, 1980, BIOCHIM BIOPHYS ACTA, V601, P386, DOI 10.1016/0005-2736(80)90543-X; TANIGUCHI K, 1975, J BIOL CHEM, V250, P3010; TANIGUCHI K, 1991, J BIOCHEM-TOKYO, V109, P299; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; von Glehn M, 1972, FEBS Lett, V20, P267, DOI 10.1016/0014-5793(72)80083-8; WHITTAM R, 1964, NATURE, V203, P720, DOI 10.1038/203720a0; YODA A, 1982, MOL PHARMACOL, V22, P693	52	25	25	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25604	25610						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810335				2022-12-25	WOS:A1996VL69300079
J	Gunz, D; Hess, MT; Naegeli, H				Gunz, D; Hess, MT; Naegeli, H			Recognition of DNA adducts by human nucleotide excision repair - Evidence for a thermodynamic probing mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; HUMAN CELL-EXTRACTS; XERODERMA-PIGMENTOSUM; DEOXYRIBONUCLEIC-ACID; MOLECULAR-DYNAMICS; 6-4 PHOTOPRODUCTS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; UVRABC NUCLEASE; ABASIC SITES	The mechanism by which mammalian nucleotide excision repair (NER) detects a wide range of base lesions is poorly understood, Here, we tested the ability of human NER to recognize bulky modifications that either destabilize the DNA double helix (acetylaminofluorene (AAF) and benzo[a]pyrene diol-epoxide (BPDE) adducts, UV radiation products) or induce opposite effects by stabilizing the double helix (8-methoxypsoralen (8-MOP), anthramycin, and CC-1065 adducts). We constructed plasmid DNA carrying a defined number of each of these adducts and determined their potential to sequester NER factors contained in a human cell-free extract. For that purpose, we measured the capacity of damaged plasmids to compete with excision repair of a site-directed NER substrate. This novel approach showed differences of more than 3 orders of magnitude in the efficiency by which helix-destabilizing and helix-stabilizing adducts sequester NER factors. For example, AAF modifications were able to compete with the NER substrate similar to 1740 times more effectively than 8-MOP adducts, The sequestration potency decreased with the following order of adducts, AAF > UV greater than or equal to BPDE > 8-MOP > anthramycin, CC-1065. A strong preference for helix-destabilizing lesions was confirmed by monitoring the formation of NER patches at site specific adducts with either AAF or CC-1065. This comparison based on factor sequestration and repair synthesis indicates that human NER is primarily targeted to sites at which the secondary structure of DNA is destabilized. Thus, an early step of DNA damage recognition involves thermodynamic probing of the duplex.	UNIV ZURICH,TIERSPITAL,INST PHARMACOL & TOXICOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich								ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BOLES TC, 1984, P NATL ACAD SCI-BIOL, V81, P5623, DOI 10.1073/pnas.81.18.5623; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P4145, DOI 10.1021/bi00067a001; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HEARST JE, 1984, Q REV BIOPHYS, V17, P1, DOI 10.1017/S0033583500005242; Hess MT, 1996, NUCLEIC ACIDS RES, V24, P824, DOI 10.1093/nar/24.5.824; Hess MT, 1996, CHEM BIOL, V3, P121, DOI 10.1016/S1074-5521(96)90288-4; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; HURLEY LH, 1984, PHARMACEUT RES, V1, P53; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P3373, DOI 10.1021/bi00434a037; KIM JK, 1995, EUR J BIOCHEM, V228, P849, DOI 10.1111/j.1432-1033.1995.0849m.x; KOHN KW, 1970, J MOL BIOL, V51, P551, DOI 10.1016/0022-2836(70)90008-2; KRUGH TR, 1989, BIOCHEMISTRY-US, V28, P9988, DOI 10.1021/bi00452a017; LEE CS, 1991, CHEM RES TOXICOL, V4, P203, DOI 10.1021/tx00020a013; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P5396; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAZIMIEC M, 1992, J BIOL CHEM, V267, P24716; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; PIERCE JR, 1989, BIOCHEMISTRY-US, V28, P5821, DOI 10.1021/bi00440a018; Rahn R.O., 1976, PHOTOCHEM PHOTOBIOL, V2, P97; REYNOLDS VL, 1986, J ANTIBIOT, V39, P319, DOI 10.7164/antibiotics.39.319; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SCHWARTZ A, 1989, J MOL BIOL, V207, P445, DOI 10.1016/0022-2836(89)90266-0; SHI YB, 1988, NUCLEIC ACIDS RES, V16, P8945, DOI 10.1093/nar/16.18.8945; SHI YB, 1986, BIOCHEMISTRY-US, V25, P5895, DOI 10.1021/bi00368a009; SPIELMANN HP, 1995, BIOCHEMISTRY-US, V34, P12937, DOI 10.1021/bi00040a004; SUH M, 1995, CARCINOGENESIS, V16, P2561, DOI 10.1093/carcin/16.10.2561; SUN DY, 1992, J MED CHEM, V35, P1773, DOI 10.1021/jm00088a012; SUQUET C, 1995, J BIOL CHEM, V270, P16507, DOI 10.1074/jbc.270.28.16507; SWENSON DH, 1982, CANCER RES, V42, P2821; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOOD RD, 1991, BIOESSAYS, V13, P447, DOI 10.1002/bies.950130904; XU R, 1992, NUCLEIC ACIDS RES, V20, P6167, DOI 10.1093/nar/20.23.6167; ZOU Y, 1995, BIOCHEMISTRY-US, V34, P13582, DOI 10.1021/bi00041a038	56	167	169	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25089	25098		10.1074/jbc.271.41.25089	http://dx.doi.org/10.1074/jbc.271.41.25089			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810263	hybrid			2022-12-25	WOS:A1996VL69300007
J	Panariello, L; Quadro, L; Trematerra, S; Colantuoni, V				Panariello, L; Quadro, L; Trematerra, S; Colantuoni, V			Identification of a novel retinoic acid response element in the promoter region of the retinol-binding protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; TRANSCRIPTIONAL REGULATION; VITAMIN-A; SIGNALING PATHWAYS; LIGAND SENSITIVITY; NUCLEAR RECEPTOR; DIRECT REPEATS; CELL LINES; RXR-BETA; EXPRESSION	We have previously demonstrated that the retinol-binding protein (REP) gene is induced by retinoids in hepatoma cells. In this report, we define in greater detail the region that mediates the retinoic acid response of the gene. It consists of two degenerate retinoic acid response elements, separated by 30 nucleotides that encompass a GC-rich Sp1 consensus-like sequence. We demonstrate that the entire region, as well as each element taken singly, can bind the retinoic acid receptors as homo- and heterodimers with low affinity. However, only the entire region is able to confer retinoic acid inducibility to a heterologous promoter. We also show that the correct phasing of the DNA segment is necessary to achieve full responsiveness. Site-directed mutants in each element retained partial induction after transfection, while the double mutant was no longer responsive, suggesting that the two elements act synergistically. Mutational analysis of the Spl binding site and cotransfection experiments revealed that Spl or a related protein plays an important role in the transcription of the gene. Thus, the retinoic acid induction of the REP gene is mediated by a novel and complex responsive unit formed by two distinct elements located in a specific sequence context and the interplay of the retinoid receptors with Spl is required for induction.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC FARM,I-88100 CATANZARO,ITALY	University of Naples Federico II; Universita Mediterranea di Reggio Calabria								ADAN RAH, 1993, MOL ENDOCRINOL, V7, P47, DOI 10.1210/me.7.1.47; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BLOMHOFF R, 1992, ANNU REV NUTR, V12, P37, DOI 10.1146/annurev.nu.12.070192.000345; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIXON JL, 1987, J CELL PHYSIOL, V130, P14, DOI 10.1002/jcp.1041300104; DONOFRIO C, 1985, EMBO J, V4, P1981, DOI 10.1002/j.1460-2075.1985.tb03881.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYAN WS, 1983, CELL, V35, P79; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MAJELLO B, 1995, ONCOGENE, V10, P1841; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARINARI L, 1987, J LIPID RES, V28, P941; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MOUREY MS, 1994, J CELL PHYSIOL, V160, P596, DOI 10.1002/jcp.1041600323; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SMITH JE, 1978, CELL, V15, P865, DOI 10.1016/0092-8674(78)90271-4; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; Soprano Dianne Robert, 1994, P257; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	56	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25524	25532		10.1074/jbc.271.41.25524	http://dx.doi.org/10.1074/jbc.271.41.25524			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810324	hybrid			2022-12-25	WOS:A1996VL69300068
J	Colwill, K; Feng, LL; Yeakley, JM; Gish, GD; Caceres, JF; Pawson, T; Fu, XD				Colwill, K; Feng, LL; Yeakley, JM; Gish, GD; Caceres, JF; Pawson, T; Fu, XD			SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; SR PROTEINS; SERINE-RICH; CONSERVED FAMILY; SITE SELECTION; CELL-CYCLE; SPLICEOSOME; IDENTIFICATION; REGULATORS; DOMAINS	Serine/arginine-rich (SR) proteins are essential for pre-mRNA splicing, and modify the choice of splice site during alternative splicing in a process apparently regulated by protein phosphorylation, Two protein kinases have been cloned that can phosphorylate SR proteins in vitro: SRPK1 and Clk/Sty. Here, we show that these two kinases phosphorylate the same SR proteins in. vitro, but that SRPK1 has the higher specific activity toward ASF/SF2. SRPK1, like Clk/Sty, phosphorylates ASF/SF2 in vitro on sites that are also phosphorylated in vivo. Tryptic peptide mapping of ASF/SF2 revealed that three of the phosphopeptides from full-length ASF/SF2 phosphorylated in vitro contain consecutive phosphoserine-arginine residues or phosphoserine-proline residues. In vitro, the Clk/Sty kinase phosphorylated Ser-Arg, Ser-Lys, or Ser-Pro sites, whereas SRPK1 had a strong preference for Ser-Arg sites. These results suggest that SRPK1 and Clk/Sty may play different roles in regulating SR splicing factors, and suggest that Clk/Sty has a broader substrate specificity than SRPK1.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOL MED, SAN DIEGO, CA 92093 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of California System; University of California San Diego; Cold Spring Harbor Laboratory			Caceres, Javier F/D-5260-2013; Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013; Colwill, Karen/K-5101-2012	Caceres, Javier F/0000-0001-8025-6169; Colwill, Karen/0000-0002-8979-1659				AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; ROSCIGNO RF, 1995, RNA, V1, P692; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; TAZI J, 1992, J BIOL CHEM, V267, P4322; VANDERGEER P, 1993, CELL BIOL LAB HDB, P422; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	41	161	165	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24569	24575		10.1074/jbc.271.40.24569	http://dx.doi.org/10.1074/jbc.271.40.24569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798720	hybrid			2022-12-25	WOS:A1996VM67400042
J	Craig, AWB; Cosentino, GP; Donze, O; Sonenberg, N				Craig, AWB; Cosentino, GP; Donze, O; Sonenberg, N			The kinase insert domain of interferon-induced protein kinase PKR is required for activity but not for interaction with the pseudosubstrate K3L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; FACTOR-2-ALPHA EIF-2-ALPHA KINASE; TRANSLATIONAL CONTROL MECHANISM; INITIATION FACTOR-2-ALPHA; MALIGNANT TRANSFORMATION; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; YEAST; CLONING	Interferon-induced protein kinase (PKR) is a member of a family of kinases that regulate translation initiation through phosphorylation of eukaryotic initiation factor 2 alpha. In addition to the conserved catalytic subdomains that are present in all serine/threonine kinases, the eukaryotic initiation factor 2 alpha kinases possess an insert region between catalytic subdomains IV and V that has been termed the kinase insert domain. To investigate the importance of the kinase insert domain of PKR, several deletions and point mutations were introduced within this domain and analyzed for kinase activity both in vitro and in vivo, Here we show that deletion of the kinase insert sequence or mutation of serine 355, which lies within this region, abrogates kinase activity. In addition, the kinase insert domain of PKR and adjacent amino acids (LFIQME) in catalytic subdomain V are not required for binding of the pseudosubstrate inhibitor K3L from vaccinia virus. A portion of the catalytic domain of PKR between amino acids 366 and 415 confers K3L binding in vivo, suggesting a possible role for this region of PKR in substrate interaction.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, CTR CANC, MONTREAL, PQ H3G 1Y6, CANADA; BIOMEGA BOEHRINGER INGELHEIM RES INC, LAVAL, PQ H7S 2G5, CANADA	McGill University; McGill University; Boehringer Ingelheim			Craig, Andrew/G-2312-2017; Craig, Andrew/AAC-6923-2019	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393				BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHEN JJ, 1994, BIOCHIMIE, V76, P761, DOI 10.1016/0300-9084(94)90080-9; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P945; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONZE O, 1995, NUCLEIC ACIDS RES, V23, P861, DOI 10.1093/nar/23.5.861; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale M, 1996, MOL CELL BIOL, V16, P4172; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; ICELY PL, 1991, J BIOL CHEM, V266, P16073; JAGUS R, 1994, BIOCHIMIE, V76, P779, DOI 10.1016/0300-9084(94)90082-5; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOROMILAS AE, 1955, J BIOL CHEM, V270, P25426; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; MELLOR H, 1994, J BIOL CHEM, V269, P10201; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, J SAMBROOK MOL CLONI; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	50	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24526	24533		10.1074/jbc.271.40.24526	http://dx.doi.org/10.1074/jbc.271.40.24526			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798713	hybrid			2022-12-25	WOS:A1996VM67400035
J	Han, ZY; Malik, N; Carter, T; Reeves, WH; Wyche, JH; Hendrickson, EA				Han, ZY; Malik, N; Carter, T; Reeves, WH; Wyche, JH; Hendrickson, EA			DNA-dependent protein kinase is a target for a CPP32-like apoptotic protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; KU P70/P80 AUTOANTIGEN; STRAND BREAK REPAIR; BCL-2 HOMOLOG BAK; POLY(ADP-RIBOSE) POLYMERASE; HL-60 CELLS; ANTIGENIC DETERMINANTS; V(D)J RECOMBINATION; SCID MUTATION; INHIBITION	We demonstrate that the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs) is specifically, proteolytically cleaved in HL-60 cells treated with staurosporine (STS), a potent inducer of apoptosis. The proteolysis of DNA-PKcs correlated with or preceded apoptotic chromosomal DNA degradation. Cell free extracts prepared from STS-treated HL-60 cells recapitulated the proteolysis of DNA-PKcs in an in vitro assay using purified DNA-PK as the substrate. Western blot analyses of the apoptotic cell extract showed that the 32-kDa precursor of CPP32 is expressed in HL-60 cells and processed following STS treatment. In addition, whereas the DNA-PKcs protease activity was not inhibitable by many conventional protease inhibitors, it was inhibitable by a highly selective peptide-derived inhibitor of CPP32. These data strongly suggest that CPP32, or a CPP32-like protease, is responsible for DNA-PKcs proteolysis. Finally, our results demonstrated that the cleavage of DNA-PKcs in vitro proceeded in the presence of Bcl-2, indicating that the function provided by Bcl-2 lies upstream the proteolysis of DNA-PKcs.	BROWN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, PROVIDENCE, RI 02912 USA; ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT IMMUNOL & MED MICROBIOL, THURSTON ARTHRIT RES CTR, CHAPEL HILL, NC 27599 USA	Brown University; Saint John's University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040391] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35763] Funding Source: Medline; NIAMS NIH HHS [AR40391] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; ANDERSON CW, 1996, IN PRESS CURRENT TOP; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GONG JP, 1993, J CELL PHYSIOL, V157, P263; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HAN ZY, 1994, AM J PATHOL, V145, P423; Han ZY, 1996, CANCER RES, V56, P1621; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POLTORATSKY VP, 1995, J IMMUNOL, V155, P4529; PORGES AJ, 1990, J IMMUNOL, V145, P4222; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WANG JS, 1994, J CELL SCI, V107, P3223; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; WYLLIE AH, 1987, INT REV CYTOL, P755; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	51	123	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25035	25040		10.1074/jbc.271.40.25035	http://dx.doi.org/10.1074/jbc.271.40.25035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798786	hybrid			2022-12-25	WOS:A1996VM67400109
J	Cassard, S; Choquet, D; Fridman, WH; Bonnerot, C				Cassard, S; Choquet, D; Fridman, WH; Bonnerot, C			Regulation of ITAM signaling by specific sequences in Ig-beta B cell antigen receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; SURFACE-IMMUNOGLOBULIN; CYTOPLASMIC DOMAIN; LYMPHOCYTES-B; FC-RECEPTORS; SRC FAMILY; ALPHA; ASSOCIATION	B cell antigen receptors (BCR) are composed of an antigen binding subunit, the membrane Ig, and Ig-alpha/Ig-beta heterodimers, that contain a transducing motif named ITAM for ''immuno-receptor tyrosine-based activation motif.'' Ig-alpha and Ig-beta ITAMs only differ by four amino acids located before the second conserved tyrosine (DCSM in Ig-alpha and QTAT in Ig-beta), which determine the in vitro association of Ig-alpha with the src kinase fyn. We have previously shown that Ig-alpha and Ig-beta BCR subunits activate different signaling pathways by expressing, in B cells, Fc gamma RII chimeras containing the cytoplasmic tails of Ig-alpha or Ig-beta. We report here that the signaling capacity of Ig-beta ITAM is regulated by peptide sequences located inside (QTAT region) or outside the ITAM (flanking sequences), Furthermore, when isolated, Ig-alpha and Ig-beta ITAM have similar abilities as the entire Ig-alpha tail and the whole BCR in triggering tyrosine kinase activation, an increase of intracellular calcium concentration as well as late events of cell activation as assessed by cytokine secretion, These data show that alterations that modify the ability of Ig-alpha and Ig-beta to interact in vitro with the src kinase fyn (switch between QTAT and DCSM) also determine signal transduction capabilities of these molecules expressed in B cells.	INST CURIE,INSERM,U255,F-75231 PARIS 05,FRANCE; INST PASTEUR,INSERM,U261,F-75724 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cassard, S (corresponding author), INST CURIE,CJF 9501,INSERM,12 RUE LHOMOND,F-75231 PARIS 05,FRANCE.		Choquet, Daniel/K-7893-2018; Choquet, Daniel/E-4203-2013; Choquet, Daniel/GOJ-8825-2022	Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763; fridman, wolf herman/0000-0002-1332-0973				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BAIXERAS E, 1993, IMMUNOL REV, V132, P5, DOI 10.1111/j.1600-065X.1993.tb00836.x; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DENNIS GJ, 1987, J IMMUNOL, V138, P4307; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FRIEDRICH RJ, 1993, J IMMUNOL, V150, P2814; GELFAND EW, 1988, EUR J IMMUNOL, V18, P917, DOI 10.1002/eji.1830180613; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LIN JJ, 1992, J IMMUNOL, V149, P1548; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; TADDIE JA, 1994, J BIOL CHEM, V269, P13529; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474; WILSON HA, 1987, J EXP MED, V166, P601, DOI 10.1084/jem.166.2.601; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	31	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23786	23791		10.1074/jbc.271.39.23786	http://dx.doi.org/10.1074/jbc.271.39.23786			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798606	hybrid			2022-12-25	WOS:A1996VJ44200035
J	Robins, P; Lindahl, T				Robins, P; Lindahl, T			DNA ligase IV from HeLa cell nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MAMMALIAN-CELLS; REPAIR; RECOMBINATION; LOCALIZATION; REPLICATION; EXPRESSION; ENZYME; PURIFICATION; DOMAIN	A human cDNA encoding a previously unrecognized DNA ligase IV has been identified (Wei, Y.-F., Robins, P., Carter, K., Caldecott, K., Pappin, D. J. C., Yu, G.-L., Wang, R.-P., Shell, B. K., Nash, R. A., Schar, P., Barnes, D. E., Haseltine, W. A., and Lindahl, T. (1995) Mol. Cell. Biol. 15, 3206-3216). Antibodies have been raised against predicted peptide sequences of DNA ligase IV and used to identify the enzyme during purification from HeLa cell nuclei. The 96-kDa DNA ligase IV and the 103-kDa DNA ligase III co-migrate during SDS-polyacrylamide gel electrophoresis and have similar column fractionation properties, which complicates the distinction between the two enzymes, but they have been separated by Mono S liquid chromatography. During initial size fractionation by gel chromatography in 1 M NaCl, DNA ligase IV elutes in the same position as the DNA ligase III-XRCC1 protein complex, indicating that DNA ligase IV is also bound to another protein or occurs as a dimer. DNA ligase IV has been purified free from other DNA ligases, and its enzymatic properties have been examined. The purified protein effectively joins single-strand breaks in a double-stranded polydeoxynucleotide in an ATP-dependent reaction. The substrate specificity of DNA ligase IV differs from those of the other two cloned human DNA ligases, I and III, with regard to their ability to join the hybrid substrates oligo(dT). poly(rA) and oligo(rA). poly(dT). DNA ligase IV occurs in part as an enzyme-adenylate complex in HeLa cell nuclear extracts.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND									ARRAND JE, 1986, J BIOL CHEM, V261, P9079; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; Bentley DJ, 1996, NAT GENET, V13, P489, DOI 10.1038/ng0896-489; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CHEN JW, 1995, MOL CELL BIOL, V15, P5412; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; HARLOW E, 1988, ANTIBODIES; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; ROBERTS E, 1994, J BIOL CHEM, V269, P3789; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEI YF, 1995, MOL CELL BIOL, V15, P3206	23	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24257	24261		10.1074/jbc.271.39.24257	http://dx.doi.org/10.1074/jbc.271.39.24257			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798671	hybrid			2022-12-25	WOS:A1996VJ44200100
J	Patel, G; Tantravahi, R; Oh, IH; Reddy, EP				Patel, G; Tantravahi, R; Oh, IH; Reddy, EP			Transcriptional activation potential of normal and tumor-associated myb isoforms does not correlate with their ability to block GCSF-induced terminal differentiation of murine myeloid precursor cells	ONCOGENE			English	Article						c-myb; ABPL tumor myb; transactivation; myeloid cell differentiation	COLONY-STIMULATING FACTOR; C-MYB; V-MYB; GRANULOCYTIC DIFFERENTIATION; HEMATOPOIETIC-CELLS; FUNCTIONAL DOMAINS; VIRAL INTEGRATION; GENE-EXPRESSION; LEUKEMIA-VIRUS; MIM-1 GENE	The myb gene has been shown to be an important regulator of hematopoietic cell proliferation, differentiation and apoptosis, Activation of the myb gene into an oncogenic form has involved structural alterations to the coding sequences, Thus, the v-myb gene encoded by the Avian Myeloblastosis Virus, is truncated at both the 5' and 3' ends, Additionally, tumor cells containing rearrangements in the myb locus, such as the ABPL tumors or NFS60 tumor cell line have recently been shown to display a heterogeneity of structure, In this study, we examined the growth and differentiation properties of clonal cell lines derived from 32Dcl3 which harbor myb transgenes derived from v-myb, and the ABPL-1, ABPL-2, ABPL-4 and NFS-60 cell Lines, Retroviral vectors containing the appropriate myb cDNAs were produced, transfected into packaging cell lines, and the viruses were used to generate the 32D derivative cell clones, Abrogation of IL-3 dependence was never observed in any cell line, Expression of c-my6, ABPL1-myb and ABPL-2-myb isoforms in 32D cells resulted in a block to their ability to terminally differentiate into granulocytes at the pro-myelocytic stage, However, expression of ABPL-4-myb or NFS60-myb in these cells failed:to result in a similar effect, These cells differentiated into granulocytes in the presence of G-CSF, albeit more slowly than control 32Dcl3 cells, We also examined the ability of various Myb-isoforms to transactivate transcription of reporter genes containing Myb-binding elements in their promoter/enhancer sequences, to determine whether the phenotypic effects produced by these various isoforms correlate with their ability to transactivate transcription, Our results show that while v-myb and c-myb transactivated transcription equally well, the MFS60-myb exhibited the highest levels of transcriptional transactivation. The ABPL-1, ABPL-2 and ABPL-4-myb isoforms showed very low levels of transcriptional transactivation potential with the same reporter genes. These results suggest that the ability of various Myb-isoforms to transactivate transcription does not by itself correlate with their ability to induce a block to G-CSF-induced terminal differentiation of myeloid precursor cells.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALUDA MA, 1994, ONCOGENE, V9, P2761; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GERWITZ AM, 1988, SCIENCE, V242, P1303; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Harlow E., 1988, ANTIBODIES LAB MANUA; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; MAGLI MC, 1987, P NATL ACAD SCI USA, V84, P789, DOI 10.1073/pnas.84.3.789; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1995, ONCOGENE, V11, P525; ROVERA G, 1987, ONCOGENE, V1, P29; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V84, P3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TANTRAVAHI R, 1996, IN PRESS ONCOGENE; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	51	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1197	1208						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808694				2022-12-25	WOS:A1996VJ20200011
J	Yu, DH; Liu, BL; Tan, M; Li, JZ; Wang, SS; Hung, MC				Yu, DH; Liu, BL; Tan, M; Li, JZ; Wang, SS; Hung, MC			Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms	ONCOGENE			English	Article						c-erbB-2/HER-2; oncogene; breast cancer; drug resistance; Taxol	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; PHASE-II TRIAL; NEU ONCOGENE; PROTO-ONCOGENE; MULTIDRUG RESISTANCE; MEDICAL PROGRESS; P-GLYCOPROTEIN; OVARIAN-CANCER; DNA-REPAIR	It has been reported that breast tumors that overexpress c-erbB-2/neu are less responsive to certain adjuvant chemotherapy regimens than those that express a normal amount of the gene product, To investigate whether overexpression of the c-erbB-2/neu-encoded p185 can indeed lead to increased chemoresistance in breast cancers, we introduced the human c-erbB-2/neu gene into the very low p185-expressing MDA-MB-435 human breast cancer cells and examined Taxol sensitivities among the parental MDA-MB-435 cells and stable transfectants which express increased levels of p185. The p185-overexpressing MDA-MB-435 transfectants were more resistant to Taxol than the parental cells. The increased Taxol resistance was not accompanied by changes in doubling time and S-phase fraction. The increased Taxol resistance was independent from oncogenic transformation since it was observed only in c-erbB-2/neu-transformed cells and not ras-transformed cells when oncogene-transformed NIH3T3 cells were examined. To study whether p185 induced Taxol resistance through the mdr-1 pathway, we examined the mdr-1-encoded p170 levels in these transfectants. The MDA-MB-435 cells expressed very low levels of p170 and there was no increase of p170 expression in the p185-overexpressing MDA-MB-435 transfectants. Furthermore, these transfectants were not sensitized to Taxol treatment by mdr-1 blocker thioradazine. These data demonstrated that overexpression of c-erbB-2/neu can lead to intrinsic Taxol resistance independent from mdr-1 mechanisms.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BREAST CANC BAS RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, DH (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,BOX 107,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Tan, Ming/ABD-5847-2021; Hung, Mien-Chie/ABD-5911-2021	Tan, Ming/0000-0003-2007-9898; Hung, Mien-Chie/0000-0003-4317-4740; Liu, Bolin/0000-0003-0150-8650; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R01CA060856, R01CA060488, R29CA060488, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA60488, CA60856, CA58880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CHEVALLIER B, 1995, J CLIN ONCOL, V13, P314, DOI 10.1200/JCO.1995.13.2.314; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CREE IA, 1995, ANTI-CANCER DRUG, V6, P398, DOI 10.1097/00001813-199506000-00006; EFFERTH T, 1993, CANCER LETT, V70, P197, DOI 10.1016/0304-3835(93)90231-W; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG M-C, 1988, Cancer Bulletin (Houston), V40, P300; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; LACROIX H, 1989, ONCOGENE, V4, P145; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; NOOTER K, 1991, BRIT J CANCER, V63, P663, DOI 10.1038/bjc.1991.152; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; *PROM, 1991, TECHN B PROM CORP, V169; SCHNEIDER J, 1994, J NATL CANCER I, V86, P850, DOI 10.1093/jnci/86.11.850; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; Tsai CM, 1996, CANCER RES, V56, P206; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; TSAI CM, 1995, J NATL CANCER I, V87, P685; WALL ME, 1995, CANCER RES, V55, P753; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	37	212	223	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1359	1365						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808711				2022-12-25	WOS:A1996VJ20200028
J	Bates, S; Rowan, S; Vousden, KH				Bates, S; Rowan, S; Vousden, KH			Characterisation of human cyclin G(1) and G(2): DNA damage inducible genes	ONCOGENE			English	Article						cyclins; p53; DNA damage	PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; GROWTH ARREST; G1 ARREST; BAX GENE; APOPTOSIS	Several genes have been identified as targets for transcriptional activation by the p53 tumour suppressor protein. Rodent cyclin G was previously identified as a p53 responsive gene and in order to assess the role played by cyclin G as a mediator of p53 function in humans cells we have isolated full length human cyclin G(1) and identified a related gene designated cyclin G(2). Both human G-cyclins are induced by the DNA damaging agent actinomycin-D and although the induction of cyclin G(1) is clearly p53 dependent, activation of cyclin G(2) expression was observed in the absence of p53. Based on sequence similarity, the G-cyclins and the recently identified cyclin I form a distinct sub-group within the larger cyclin family, possibly reflecting some degree of functional similarity.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Rowan, Sheldon/AAA-3271-2019	Rowan, Sheldon/0000-0002-1123-6743				ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANA X, 1995, ONCOGENE, V11, P211; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; KATO J, 1993, GENE DEV, V7, P331; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1995, ONCOGENE, V11, P2311; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LEW DJ, 1991, CELL, V66, P1191; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAKAMURA T, 1995, EXP CELL RES, V21, P534; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POON RYC, 1994, J CELL SCI, V107, P2789; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; TAMURA K, 1993, ONCOGENE, V8, P2113; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WALDMAN T, 1995, CANCER RES, V55, P5187; WU LT, 1994, ONCOL REP, V1, P705; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHAN QM, 1994, ONCOGENE, V9, P3743	52	130	139	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1103	1109						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806701				2022-12-25	WOS:A1996VG76600025
J	Bingham, CO; Murakami, M; Fujishima, H; Hunt, JE; Austen, KF; Arm, JP				Bingham, CO; Murakami, M; Fujishima, H; Hunt, JE; Austen, KF; Arm, JP			A heparin-sensitive phospholipase A(2) and prostaglandin endoperoxide synthase-2 are functionally linked in the delayed phase of prostaglandin D-2 generation in mouse bone marrow-derived mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ARACHIDONIC-ACID; II PHOSPHOLIPASE-A(2); CYTOPLASMIC PHOSPHOLIPASE-A(2); SULFATE PROTEOGLYCAN; HUMAN NEUTROPHILS; EXPRESSION; CLONING; CYCLOOXYGENASE; TRANSLOCATION	BALB/cJ mouse bone marrow-derived mast cells (BMMC) developed with interleukin (IL)-3 can be stimulated by c-kit ligand (KL) in the presence of IL-10 and IL-1 beta for sequential immediate and delayed generation of prostaglandin (PG) D-2 through utilization of constitutive prostaglandin endoperoxide synthase (PGHS) -1 and induced PGHS-2, respectively (Murakami, M., Matsumoto, R., Austen, K, F., and Arm, J. P. (1994) J. Biol, Chem, 269, 22269-22275), We now report that BALB/cJ BMMC stimulated with KL + IL-10 + IL-1 beta also exhibit the biphasic release of [H-3]arachidonic acid with an immediate phase over the first 10 min followed by a delayed phase from 2 to 7 h, The delayed phase of arachidonic acid release and of PGD(2) generation was inhibited by heparin, which concomitantly released a phospholipase (PL) A(2) from the cells into the supernatant. Both dexamethasone and a type II PLA(2) inhibitor, 12-epi-scalaradial, suppressed delayed-phase PGD(2) generation at concentrations that did not affect immediate eicosanoid generation, Transcripts for type IIA PLA(2), as assessed by reverse transcription-polymerase chain reaction, were progressively induced in BALB/cJ BMMC treated for 2 to 7 h with KL + IL-10 + IL-1 beta; the induction of these transcripts was down-regulated by 10(-6) M dexa methasone. The expression of steady-state transcripts and protein for cytosolic PLA(2) (cPLA(2)) did not change, PGHS-2-dependent delayed-phase PGD(2) generation elicited by IgE-dependent activation of BALB/cJ BMMC primed with KL + IL-10 was also accompanied by the induction of type IIA PLA(2) transcripts and was suppressed by heparin, with concomitant release of PLA(2) into the supernatant, However, both the direct, cytokine stimulated and the cytokine primed, IgE-dependent, delayed phase PGD(2) generation occurred in BMMC from C57BL/6J mice, which have a natural disruption of the type IIA PLA(2) gene. Thus, kinetic, pharmacologic, and genetic analyses suggest that an inducible, heparin-sensitive PLA(2), rather than cPLA(2), provides arachidonic acid to concomitantly induced PGHS-2 for delayed phase PGD(2) biosynthesis in activated BMMC, Further more, this heparin-sensitive PLA(2) likely represents a novel PLA(2) or a new function for a known low molecular weight PLA(2).	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Bingham, CO (corresponding author), BRIGHAM & WOMENS HOSP,DIV RHEUMATOL & IMMUNOL,DEPT MED,SEELEY G MUDD BLDG,RM 628,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI22531, AI07306, AI31599] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022531, R37AI022531, T32AI007306, U01AI031599, U19AI031599] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; DOLE VP, 1960, J BIOL CHEM, V235, P2595; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FONTEH AN, 1995, J CLIN INVEST, V96, P1432, DOI 10.1172/JCI118179; FONTEH AN, 1994, J IMMUNOL, V152, P5438; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HARA T, 1995, BLOOD, V85, P2332; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MCNISH RW, 1993, BIOCHEM BIOPH RES CO, V196, P147; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1995, P NATL ACAD SCI USA, V92, P6107, DOI 10.1073/pnas.92.13.6107; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKATANI Y, 1994, J IMMUNOL, V153, P796; OTTO JC, 1994, J BIOL CHEM, V269, P19868; RAZIN E, 1982, J BIOL CHEM, V257, P7229; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; XU XX, 1994, J BIOL CHEM, V269, P31693; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	53	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25936	25944		10.1074/jbc.271.42.25936	http://dx.doi.org/10.1074/jbc.271.42.25936			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824228	hybrid			2022-12-25	WOS:A1996VN18000034
J	Hawes, JW; Jaskiewicz, J; Shimomura, Y; Huang, BL; Bunting, J; Harper, ET; Harris, RA				Hawes, JW; Jaskiewicz, J; Shimomura, Y; Huang, BL; Bunting, J; Harper, ET; Harris, RA			Primary structure and tissue-specific expression of human beta-hydroxyisobutyryl-coenzyme A hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCES; FORM	beta-Hydroxyisobutyryl-CoA (HIBYL-CoA) hydrolase is responsible for the specific hydrolysis of HIBYL-CoA, a saline catabolite, as well as the hydrolysis of beta-hydroxypropionyl-CoA, an intermediate in a minor path way of propionate metabolism, We have obtained the amino acid sequences of several tryptic peptides derived from purified rat liver HIBYL-CoA hydrolase, and the NH2-terminal peptize sequence was matched to the translated sequence of a human expressed sequence tag present in the data base of the IMAGE Consortium (Lawrence Livermore National Laboratory, Livermore, CA), The complete nucleotide sequence and the deduced amino acid sequence showed no similarity to the sequences of well known thioesterases but showed significant homology to the enoyl-CoA hydratase/isomerase enzyme family, The cDNA fragment corresponding to the mature (processed) protein was expressed in Escherichia coli, The purified recombinant enzyme displayed substrate specificity very similar to that of the rat enzyme and was specifically bound by polyclonal antibodies raised against purified rat liver HIBYL-CoA hydrolase, Northern and Western blot analyses with various human tissues indicated predominant expression in liver, heart, and kidney, with discrepancies occurring in the amounts of HIBYL-CoA hydrolase mRNA compared to stably expressed protein in several tissues.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040441] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; DRISCOLL JR, 1992, J BACTERIOL, V174, P5063, DOI 10.1128/JB.174.15.5063-5071.1992; Hawes JW, 1995, J BIOL CHEM, V270, P31071, DOI 10.1074/jbc.270.52.31071; LETTO J, 1986, BIOCHEM J, V240, P909, DOI 10.1042/bj2400909; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; RENDINA G, 1957, J BIOL CHEM, V225, P523; SHIMOMURA Y, 1994, J BIOL CHEM, V269, P14248; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; VIJAYAKUMAR EKS, 1984, BIOPOLYMERS, V23, P877, DOI 10.1002/bip.360230505; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	11	38	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26430	26434		10.1074/jbc.271.42.26430	http://dx.doi.org/10.1074/jbc.271.42.26430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824301				2022-12-25	WOS:A1996VN18000107
J	Shida, T; Iwasaki, H; Saito, A; Kyogoku, Y; Shinagawa, H				Shida, T; Iwasaki, H; Saito, A; Kyogoku, Y; Shinagawa, H			Analysis of substrate specificity of the RuvC Holliday junction resolvase with synthetic Holliday junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY DNA JUNCTION; ESCHERICHIA-COLI; RESOLUTION; RECOMBINATION; CLEAVAGE; PROTEIN; ENDONUCLEASE; GEOMETRY	The Escherichia coli RuvC protein endonucleolytically resolves Holliday junctions, which are formed as intermediates during genetic recombination and recombination repair. Previous studies using model Holliday junctions suggested that a certain size of central core of homology and a specific sequence in the junction were required for efficient cleavage by RuvC, although not for binding. To determine the minimum length of sequence homology required for RuvC cleavage, we made a series of synthetic Holliday junctions with various lengths of homologous sequence in the core region. It was demonstrated that a monomobile junction possessing only 2 base pairs of the homology core was efficiently cleaved by RuvC. To study the sequence specificity for cleavage, we made 16 bimobile junctions, which differed only in the homologous core sequence. Among them, 6 junctions were efficiently cleaved. Cleavage occurred by introduction of nicks symmetrically at the 3'-side of thymine in all cases. However, the nucleotide bases at the 3'-side of the thymines were not always identical between the two strands nicked. These results suggest that RuvC recognizes mainly topological symmetry of the Holliday junction but not the sequence symmetry per se, that the thymine residue at the cleavage site plays an important role for RuvC-mediated resolution, and that a long homologous core sequence is not essential for cleavage.	OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; SHINSHU UNIV,FAC TEXT SCI & TECHNOL,DEPT APPL BIOL,UEDA,NAGANO 386,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Osaka University; Shinshu University; Osaka University			Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENNETT RJ, 1995, P NATL ACAD SCI USA, V92, P5635, DOI 10.1073/pnas.92.12.5635; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; CHURCHILL MEA, 1988, P NATL ACAD SCI USA, V85, P4653, DOI 10.1073/pnas.85.13.4653; COOPER JP, 1987, J MOL BIOL, V198, P711, DOI 10.1016/0022-2836(87)90212-9; COOPER JP, 1989, P NATL ACAD SCI USA, V86, P7336, DOI 10.1073/pnas.86.19.7336; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; Shida T, 1996, J BIOCHEM-TOKYO, V119, P653; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; TAKAHAGI M, 1994, J BIOL CHEM, V269, P15132; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671	18	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26105	26109		10.1074/jbc.271.42.26105	http://dx.doi.org/10.1074/jbc.271.42.26105			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824253	hybrid			2022-12-25	WOS:A1996VN18000059
J	Feliciello, A; Giuliano, P; Porcellini, A; Garbi, C; Obici, S; Mele, E; Angotti, E; Grieco, D; Amabile, G; Cassano, S; Li, Y; Musti, AM; Rubin, CS; Gottesman, ME; Avvedimento, EV				Feliciello, A; Giuliano, P; Porcellini, A; Garbi, C; Obici, S; Mele, E; Angotti, E; Grieco, D; Amabile, G; Cassano, S; Li, Y; Musti, AM; Rubin, CS; Gottesman, ME; Avvedimento, EV			The v-Ki-Ras oncogene alters cAMP nuclear signaling by regulating the location and the expression of cAMP-dependent protein kinase II beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; MESSENGER RIBONUCLEIC-ACID; THYROID EPITHELIAL-CELLS; CATALYTIC SUBUNIT; MOLECULAR-CLONING; GENE-EXPRESSION; INTRACELLULAR-LOCALIZATION; HORMONAL-REGULATION; SKELETAL-MUSCLE; CDNA STRUCTURE	The v-Ki-Ras oncoprotein dedifferentiates thyroid cells and inhibits nuclear accumulation of the catalytic subunit of cAMP-dependent protein kinase, After activation of v-Ras or protein kinase C, the regulatory subunit of type II protein kinase A, RII beta, translocates from the membranes to the cytosol. RII beta mRNA and protein were eventually depleted. These effects were mimicked by expressing AKAP45, a truncated version of the RII anchor protein, AKAP75. Because AKAP45 lacks membrane targeting domains, it induces the translocation of PKAII to the cytoplasm. Expression of AKAP45 markedly decreased thyroglobulin mRNA levels and inhibited accumulation of C-PKA in the nucleus. Our results suggest that: 1) The localization of PKAII influences cAMP signaling to the nucleus; 2) Ras alters the localization and the expression of PKAII; 3) Translocation of PKAII to the cytoplasm reduces nuclear C-PKA accumulation, resulting in decreased expression of cAMP-dependent genes, including RII beta, TSH receptor, and thyroglobulin. The loss of RII beta permanently down-regulates thyroid-specific gene expression.	UNIV NAPLES FEDERICO II,FAC MED,CONSIGLIO NAZL RIC,DIPARTIMENTO BIOL & PATOL MOL & CELLULARE,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,FAC MED CATANZARO,I-88100 CATANZARO,ITALY; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Columbia University; Yeshiva University; Albert Einstein College of Medicine			Porcellini, Antonio/E-1900-2011; Musti, Anna Maria/M-2520-2019; Porcellini, Antonio/AAC-6097-2019	Porcellini, Antonio/0000-0001-6882-9518; CASSANO, SILVANA/0000-0001-9868-7936; MUSTI, Anna Maria/0000-0003-1443-2739; GRIECO, Domenico/0000-0002-7131-5742; Feliciello, Antonio/0000-0002-7932-2170	NCI NIH HHS [2 PO1 CA23767] Funding Source: Medline; NIDDK NIH HHS [DK41146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK041146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BACHSKAI BJ, 1993, SCIENCE, V260, P222; BEEBE SJ, 1986, ENZYMES, V17, P43; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COLLETTA G, 1988, FEBS LETT, V228, P37, DOI 10.1016/0014-5793(88)80579-9; CONRAD KE, 1992, ONCOGENE, V7, P1279; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GALLO A, 1995, CELL GROWTH DIFFER, V6, P91; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; KUNO T, 1987, BIOCHEM BIOPH RES CO, V146, P878, DOI 10.1016/0006-291X(87)90612-7; LANDMARK BF, 1991, ENDOCRINOLOGY, V129, P2345, DOI 10.1210/endo-129-5-2345; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OLSON EN, 1993, MOL ENDOCRINOL, V7, P1369, DOI 10.1210/me.7.11.1369; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OYEN O, 1988, MOL ENDOCRINOL, V2, P1070, DOI 10.1210/mend-2-11-1070; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SPINA A, 1988, BIOCHEM BIOPH RES CO, V157, P1093, DOI 10.1016/S0006-291X(88)80986-0; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WEBER W, 1986, BIOCHEMISTRY-US, V25, P5661, DOI 10.1021/bi00367a047; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	59	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25350	25359		10.1074/jbc.271.41.25350	http://dx.doi.org/10.1074/jbc.271.41.25350			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810300	hybrid			2022-12-25	WOS:A1996VL69300044
J	Fischer, R; Wei, Y; Anagli, J; Berchtold, MW				Fischer, R; Wei, Y; Anagli, J; Berchtold, MW			Calmodulin binds to and inhibits GTP binding of the Ras-like GTPase Kir/Gem	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; TRANSCRIPTION; RECOGNITION; ACTIVATION; PROTEINS; KINASES; FAMILY; MUSCLE	Recently, a new subfamily of Ras-related GTP-binding proteins consisting of Rad (Ras associated with diabetes), Gem (immediate early gene expressed in mitogen-stimulated T-cells), and Kir (tyrosine kinase-inducible Ras-like) was discovered. The C terminus of these proteins contains an extension of approximately 30 amino acids not present in other members of the Ras family and which exhibits all the hallmarks typical for calmodulin (CaM)-binding domains. A peptide corresponding to the putative CaM-binding domain of the Kir/Gem protein was synthesized, and its affinity for CaM was determined by fluorescence spectrometry, Titration of dansyl-CaM with the Kir/Gem peptide gave an affinity constant of 1 nM. Furthermore, a single point mutation of the peptide, W269G, abolished this high affinity interaction. Gel-shift analysis showed that the complex formation between CaM and the Kir/Gem peptide is strictly calcium-dependent. We also demonstrate with a newly developed [P-32]CaM overlay technique that full-length Kir/Gem and Rad proteins bind CaM in a Ca2+-dependent fashion. The binding of CaM to glutathione S-transferase-Kir and GST-Gem inhibited the binding of GTP to Kir/Gem significantly. These results suggest the existence of a direct link between Ca2+/CaM and growth factor signal transduction pathways at the level of small Ras-like GTPases.	UNIV ZURICH IRCHEL,DEPT VET BIOCHEM,CH-8057 ZURICH,SWITZERLAND; ETH ZURICH,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich			Berchtold, Martin/L-1695-2014	Berchtold, Martin/0000-0001-8995-9047				ANAGLI J, 1995, EUR J BIOCHEM, V233, P701, DOI 10.1111/j.1432-1033.1995.701_3.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Dorin D, 1995, ONCOGENE, V11, P2267; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fischer R, 1996, BIOTECHNIQUES, V21, P292; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Sambrook J., 2002, MOL CLONING LAB MANU; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Zhu JH, 1996, J BIOL CHEM, V271, P768, DOI 10.1074/jbc.271.2.768; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	22	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25067	25070		10.1074/jbc.271.41.25067	http://dx.doi.org/10.1074/jbc.271.41.25067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810259	hybrid			2022-12-25	WOS:A1996VL69300003
J	Friedlander, P; Legros, Y; Soussi, T; Prives, C				Friedlander, P; Legros, Y; Soussi, T; Prives, C			Regulation of mutant p53 temperature-sensitive DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; MONOCLONAL-ANTIBODY; CELL-LINES; TRANSCRIPTIONAL ACTIVATION; PROTEINS BIND; HOT-SPOT; MUTATIONS; SEQUENCE; GENE	We have examined in detail the DNA binding properties of several immunopurified tumor-derived mutant p53 proteins (Val-143 --> Ala, Arg-175 --> His, Arg-248 --> Trp, Arg-249 --> Ser, and Arg-273 --> His). While all mutants were defective for binding to DNA at 37 degrees C, each bound specifically to several cognate p53 binding sites at sub-physiological temperatures (25-33 degrees C), and several mutants activated transcription from a p53-responsive promoter at 26 degrees C in transfected H1299 cells. Heating mutant p53 proteins at 37 degrees C irreversibly destroyed their ability to subsequently bind at 25 degrees C. However, several different monoclonal antibodies that each share the ability to recognize an epitope encompassing amino acids 46-55 markedly stabilized binding by mutant p53 proteins at 37 degrees C. Both intact antibody and FAb fragments allowed mutant p53 to bind to DNA. By contrast, antibodies that recognize epitopes located elsewhere within p53 stabilized mutant p53 binding significantly less effectively. Our data show that the major hot-spot p53 mutants have the intrinsic ability to bind to DNA and that a unique region within the N terminus of p53 may be critical for rescuing them from loss of binding at physiological temperatures. This suggests the possibility of developing small molecules that can stabilize mutant p53 proteins under physiological conditions.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; INST GENET MOL,INSERM,U301,F-75010 PARIS,FRANCE	Columbia University; Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293				ABARZUA P, 1995, CANCER RES, V55, P3490; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1993, ONCOGENE, V8, P1815; MIYASHITA T, 1995, CELL, V80, P293; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PETERSON MG, 1990, SCIENCE, V248, P1626; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROTH RA, 1983, J BIOL CHEM, V258, P2094; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SCHLICHTHOLZ B, 1994, BRIT J CANCER, V69, P809, DOI 10.1038/bjc.1994.159; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1993, ONCOGENE, V8, P2555; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124	64	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25468	25478		10.1074/jbc.271.41.25468	http://dx.doi.org/10.1074/jbc.271.41.25468			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810317	hybrid			2022-12-25	WOS:A1996VL69300061
J	Xu, LZ; Sanchez, R; Sali, A; Heintz, N				Xu, LZ; Sanchez, R; Sali, A; Heintz, N			Ligand specificity of brain lipid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; RETINOIC ACID; RAT-LIVER; GENE; EXPRESSION; PROGRAM; TRANSCRIPTION; RESOLUTION; SEQUENCE; ELEMENT	Brain lipid-binding protein (BLBP) is a member of the fatty acid-binding protein (FABP) family, Although BLBP expression in the developing central nervous system is complex, a close correlation between its expression and radial glial differentiation has been observed. Furthermore, antibodies to BLBP can block glial cell differentiation in mixed primary cell cultures. Here we describe the ligand binding properties of BLBP, The binding affinities of BLBP for oleic acid (K-d similar to 0.44 mu M) and arachidonic acid (K-d similar to 0.25 mu M) are similar to those reported for other FABPs, but BLBP does not bind to palmitic acid or arachidinic acid. These and other experiments establish that BLBP has a strong preference for binding long chain polyunsaturated fatty acids. A probable in vivo ligand for BLBP is docosahexaenoic acid (DHA), since its binding affinity (K-d similar to 10 nM) is the highest yet reported for an FABP/ligand interaction, exceeding even the affinity of retinoic acid for its binding proteins. Furthermore, the requirement of DHA for nervous system development and the coincident expression of BLBP during these developmental stages suggest that the physiologic role of BLBP may involve DHA utilization. Finally, we present a structural model of BLBP/DHA interaction that provides insight into both the structural characteristics important for ligand binding and the effects of specific mutations upon BLBP/ligand interactions.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL BIOPHYS LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030532] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30532] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; ASTROM A, 1994, J BIOL CHEM, V269, P22334; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CANNON JR, 1991, BIOCHEM J, V280, P387, DOI 10.1042/bj2800387; CHEN LX, 1995, J BIOL CHEM, V270, P4518, DOI 10.1074/jbc.270.9.4518; CHENG L, 1991, J BIOL CHEM, V266, P24404; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FENG L, 1995, DEVELOPMENT, V121, P1719; GLATZ JFC, 1984, J BIOL CHEM, V259, P4295; INNIS SM, 1994, CAN J PHYSIOL PHARM, V72, P1483, DOI 10.1139/y94-214; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHAR SG, 1993, DEVELOPMENT, V117, P97; KURTZ A, 1994, DEVELOPMENT, V120, P2637; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE J, 1995, INVEST OPHTH VIS SCI, V36, P2032; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PAULUSSEN RJA, 1988, ARCH BIOCHEM BIOPHYS, V264, P533, DOI 10.1016/0003-9861(88)90319-0; Rich MR, 1996, BIOCHEMISTRY-US, V35, P1506, DOI 10.1021/bi951574x; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SAKI RK, 1988, SCIENCE, V239, P487; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SCHOENTGEN F, 1990, MOL CELL BIOCHEM, V98, P35; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; SHA RS, 1993, J BIOL CHEM, V268, P7885; SIMOPOULOS AP, 1989, J NUTR, V119, P521, DOI 10.1093/jn/119.4.521; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WAINWRIGHT PE, 1989, LIPIDS, V24, P989, DOI 10.1007/BF02544067; WANG N, 1992, EXP EYE RES, V54, P933, DOI 10.1016/0014-4835(92)90157-N; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6	36	137	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24711	24719						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798739				2022-12-25	WOS:A1996VM67400061
J	Bertoldi, M; Moore, PS; Maras, B; Dominici, P; Voltattorni, CB				Bertoldi, M; Moore, PS; Maras, B; Dominici, P; Voltattorni, CB			Mechanism-based inactivation of dopa decarboxylase by serotonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSAMINASE; PIG-KIDNEY; ASSAY; COFACTOR	Pig kidney dopa decarboxylase (DDC) expressed in Escherichia coli is a homodimeric enzyme containing one catalytically active pyridoxal 5'-phosphate active site per subunit. In addition to catalyzing the decarboxylation of L-aromatic amino acids, DDC also reacts with 5-hydroxytryptamine (5-HT), converting it to 5-hydroxyindolacetaldehyde and ammonia. These products have been identified by means of the enzymes alcohol dehydrogenase and glutamate dehydrogenase, together with high performance liquid chromatographic and mass spectroscopic analysis. The K-cat and K-m values of this reaction were determined to be 0.48 min(-1) and 0.47 mM, respectively. The NaBH4-reduced enzyme does not catalyze this reaction. Concurrent with this reaction, 5-HT inactivates DDC in both a time- and concentration-dependent manner and exhibits saturation of the rate of inactivation at high concentrations, with K-i and K-inact values of 0.40 mM and 0.023 min(-1), respectively. Protection from inactivation by 5-HT was observed in the presence of the active site-directed inhibitor 3,4-dihydroxy-D-phenylalanine. inactivation with [2-C-14]5-HT results in the incorporation of 1 mol of label/enzyme subunit. Taken together, these findings indicate that 5-HT is both a substrate and a mechanism-based inactivator with a partition ratio for product formation versus inactivation of 21. The absorbance, CD, and fluorometric features of 5-HT-inactivated DDC have also been characterized. A speculative mechanism for the reaction and inactivation consistent with the experimental findings is presented.	UNIV VERONA,FAC MED & CHIRURG,IST CHIM BIOL,I-37134 VERONA,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM,I-00100 ROME,ITALY; UNIV VERONA,FAC SCI MATEMAT FIS & NAT,I-37134 VERONA,ITALY; UNIV ROMA LA SAPIENZA,CNR,CTR MOL BIOL,I-00100 ROME,ITALY	University of Verona; Sapienza University Rome; University of Verona; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Moore, Patrick/GVR-8294-2022; Bertoldi, Mariarita/F-1154-2010; Maras, Bruno/A-2020-2010	Bertoldi, Mariarita/0000-0002-2337-9928; 				AKHTAR M, 1990, BIOCHEMISTRY-US, V29, P7648, DOI 10.1021/bi00485a014; BAILEY GB, 1967, BIOCHEMISTRY-US, V6, P1526, DOI 10.1021/bi00857a039; BARBONI E, 1981, BIOCHEM BIOPH RES CO, V99, P576, DOI 10.1016/0006-291X(81)91784-8; BHATIA MB, 1993, J BIOL CHEM, V268, P17687; BOSSA F, 1968, ITAL J BIOCHEM, V17, P285; CHARTERIS A, 1975, ANAL BIOCHEM, V66, P365, DOI 10.1016/0003-2697(75)90604-1; DELPOZO AM, 1992, BIOCHEMISTRY-US, V31, P6018, DOI 10.1021/bi00141a009; DOMINICI P, 1993, BIOCHEM J, V295, P493, DOI 10.1042/bj2950493; DUINE JA, 1991, EUR J BIOCHEM, V200, P271, DOI 10.1111/j.1432-1033.1991.tb16183.x; GROEN BW, 1988, FEBS LETT, V237, P98, DOI 10.1016/0014-5793(88)80179-0; HUNTLEY TE, 1968, S PYRIDOXAL ENZYMES, P81; LIKOS JJ, 1982, BIOCHEMISTRY-US, V21, P4377, DOI 10.1021/bi00261a029; MARAS B, 1991, EUR J BIOCHEM, V201, P385, DOI 10.1111/j.1432-1033.1991.tb16295.x; Moore PS, 1996, BIOCHEM J, V315, P249, DOI 10.1042/bj3150249; OLEARY MH, 1978, BIOCHEMISTRY-US, V17, P1010, DOI 10.1021/bi00599a011; OLEARY MH, 1977, J BIOL CHEM, V252, P7168; OLEARY MH, 1975, NATURE, V253, P52, DOI 10.1038/253052a0; SHERALD AF, 1973, ANAL BIOCHEM, V56, P300, DOI 10.1016/0003-2697(73)90194-2; SZUTOWICZ A, 1984, ANAL BIOCHEM, V138, P86, DOI 10.1016/0003-2697(84)90773-5; VOLTATTO.CB, 1971, FEBS LETT, V17, P231, DOI 10.1016/0014-5793(71)80153-9; Voltattorni C B, 1979, Eur J Biochem, V93, P181; VOLTATTORNI CB, 1983, BIOCHEMISTRY-US, V22, P2249, DOI 10.1021/bi00278a030; VOLTATTORNI CB, 1980, B MOL BIOL MED, V5, P52	23	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23954	23959		10.1074/jbc.271.39.23954	http://dx.doi.org/10.1074/jbc.271.39.23954			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798628	hybrid			2022-12-25	WOS:A1996VJ44200057
J	Shainoff, JR; Smejkal, GB; DiBello, PM; Mitkevich, OV; Levy, PJ; Dempfle, CE; Lill, H				Shainoff, JR; Smejkal, GB; DiBello, PM; Mitkevich, OV; Levy, PJ; Dempfle, CE; Lill, H			Isolation and characterization of the fibrin intermediate arising from cleavage of one fibrinopeptide A from fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-XIIIA; ALPHA-CHAIN; POLYMERIZATION SITES; ELECTRON-MICROSCOPY; PLASMIC DEGRADATION; CROSS-LINKING; AMINO-ACIDS; THROMBIN; DERIVATIVES; RELEASE	The thrombin-catalyzed cleavage of N-terminal fibrinopeptide A (FPA) from the two A alpha-chains of fibrinogen exposes aggregation sites with the critical sequence GPR located just behind FPA. It is well known that exposure of both GPR sites transforms fibrinogen into self-aggregating, fully coagulable alpha-fibrin monomers, but the fibrin precursor with one site exposed and one FPA intact has eluded description. The formation of this ''alpha-profibrin'' in the course of thrombin reactions and its distribution among both the aggregating and non-aggregating components of the reactions are characterized here by immunoprobing electrophoretic and gel chromatographic separations using monoclonal antibodies specific for FPA and for exposed GPR sites. These analyses show alpha-profibrin to be a non-aggregating derivative indistinguishable from fibrinogen in solutions that are rich in fibrinogen relative to dissolved fibrin. But alpha-profibrin forms soluble complexes with alpha-fibrin monomer under conditions in which it and fibrin predominate over fibrinogen. It was isolated as a complex with fibrin by gel chromatography of cryoprecipitates and then separated from the fibrin either by electrophoretic gel shifts induced with a peptide analog of the GPR aggregation site or by chromatographic gel shifts induced with monoclonal anti-FPA antibody. The weak aggregation of alpha-profibrin with itself and with fibrinogen conforms with prior indications that coupled interactions through the paired GPR sites on fibrin monomers are pivotal to their aggregation. It is suggested that alpha-profibrin may be a hypercoagulable fibrin precursor because it is converted to alpha-fibrin monomer faster than fibrinogen converts to monomer.	CARDIOL RES CTR,INST EXPT CARDIOL,MOSCOW 121552,RUSSIA; KLINIKUM STADT MANNHEIM,D-8167 MANNHEIM,GERMANY; BOEHRINGER MANNHEIM GMBH,NEW DIAGNOST DIV,D-8132 TUTZING,GERMANY	National Medical Research Center of Cardiology; Ruprecht Karls University Heidelberg	Shainoff, JR (corresponding author), CLEVELAND CLIN FDN,RES INST FF40,DEPT CELL BIOL,CLEVELAND,OH 44195, USA.				NHLBI NIH HHS [HL-16361] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016361] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABILDGAARD U, 1964, SCAND J CLIN LAB INV, V16, P531, DOI 10.3109/00365516409060551; BAILEY K, 1951, NATURE, V167, P233, DOI 10.1038/167233a0; BALE MD, 1982, BIOPOLYMERS, V21, P2265, DOI 10.1002/bip.360211113; BANG NU, 1974, SEM THROMB HEMOSTASI, V1, P91; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1972, J BIOL CHEM, V247, P1496; BLOMBACK B, 1958, ACTA PHYSIOL SCAND, V43, P1; BLOMBACK B, 1958, ARK KEMI, V12, P299; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; DARDIK BN, 1979, THROMB HAEMOSTASIS, V42, P864; DARDIK BN, 1985, BLOOD, V65, P680; DEMPFLE CE, 1993, BLOOD COAGUL FIBRIN, V4, P79, DOI 10.1097/00001721-199304010-00013; DONNELLY JW, 1955, ARCH BIOCHEM BIOPHYS, V56, P369; EBERT RF, 1985, ANAL BIOCHEM, V148, P70, DOI 10.1016/0003-2697(85)90629-3; FERRY JD, 1954, PHYSIOL REV, V34, P753, DOI 10.1152/physrev.1954.34.4.753; FRANCIS CW, 1982, SEMIN THROMB HEMOST, V8, P25, DOI 10.1055/s-2007-1005040; GLADNER JA, 1959, J BIOL CHEM, V234, P62; HENSCHEN A, 1990, ADV EXP MED BIOL, V281, P49; HUNZIKER EB, 1990, J BIOL CHEM, V265, P7455; HURLETJENSEN A, 1982, THROMB RES, V27, P419, DOI 10.1016/0049-3848(82)90059-7; IKEGAKI N, 1989, J IMMUNOL METHODS, V124, P205, DOI 10.1016/0022-1759(89)90354-2; JANMEY PA, 1983, BIOCHEMISTRY-US, V22, P4336, DOI 10.1021/bi00287a026; JANMEY PA, 1983, BIOPOLYMERS, V22, P2017, DOI 10.1002/bip.360220902; JANMEY PA, 1982, BIOPOLYMERS, V21, P2253, DOI 10.1002/bip.360211112; KANAIDE H, 1975, J LAB CLIN MED, V85, P574; KAWASAKI K, 1992, CHEM PHARM BULL, V40, P3253, DOI 10.1248/cpb.40.3253; KAWASAKI K, 1993, CHEM PHARM BULL, V41, P975; KUDRYK BJ, 1974, J BIOL CHEM, V249, P3322; LANDIS WJ, 1975, ARCH BIOCHEM BIOPHYS, V168, P498, DOI 10.1016/0003-9861(75)90280-5; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1983, ANN NY ACAD SCI, V408, P315, DOI 10.1111/j.1749-6632.1983.tb23254.x; LORAND L, 1951, NATURE, V167, P992, DOI 10.1038/167992a0; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; MARSHALL AG, 1978, BIOPHYSICAL CHEM PRI; MCFARLANE AS, 1963, J CLIN INVEST, V42, P346, DOI 10.1172/JCI104721; MEH DA, 1995, J LAB CLIN MED, V125, P384; MEH DA, 1993, BLOOD COAGUL FIBRIN, V4, P107; NASKI MC, 1991, J BIOL CHEM, V266, P13003; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; PAPP AC, 1989, THROMB HAEMOSTASIS, V61, P15; PATESTOS NP, 1988, ELECTROPHORESIS, V9, P488, DOI 10.1002/elps.1150090908; PRENTICE CRM, 1970, BRIT J HAEMATOL, V13, P898; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SELMAYR E, 1988, BIOPOLYMERS, V27, P1733, DOI 10.1002/bip.360271104; SHAINOFF J R, 1986, Biotechniques, V4, P120; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SHAINOFF JR, 1983, ANN NY ACAD SCI, V408, P254, DOI 10.1111/j.1749-6632.1983.tb23249.x; SHAINOFF JR, 1962, J EXP MED, V116, P687, DOI 10.1084/jem.116.5.687; SHAINOFF JR, 1979, SCIENCE, V204, P200, DOI 10.1126/science.155308; SHAINOFF JR, 1960, CIRC RES, V8, P1013, DOI 10.1161/01.RES.8.5.1013; SHAINOFF JR, 1993, BLOOD COAGUL FIBRIN, V4, P87, DOI 10.1097/00001721-199304010-00014; SHAINOFF JR, 1994, J THORAC CARDIOV SUR, V108, P437, DOI 10.1016/S0022-5223(94)70253-5; SHAINOFF JR, 1985, FIBRINOGEN STRUCTURA, P91; SHAINOFF JR, 1993, AD ELECTROP, V6, P61; SHAINOFF JR, 1970, THROMB DIATH HAEMO, V39, P203; SHULMAN S, 1951, J PHYS COLLOID CHEM, V55, P135, DOI 10.1021/j150484a015; SIEBENLIST KR, 1990, J BIOL CHEM, V265, P18650; SMITH GF, 1980, BIOCHEM J, V185, P1; STURTEVANT JM, 1955, J AM CHEM SOC, V77, P6168, DOI 10.1021/ja01628a021; VALENZUELA R, 1992, AM J PATHOL, V141, P861; WEISEL JW, 1993, J BIOL CHEM, V268, P26618; WEISEL JW, 1986, BIOPHYS J, V50, P1079, DOI 10.1016/S0006-3495(86)83552-4; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WILF J, 1986, BIOCHEMISTRY-US, V25, P3124, DOI 10.1021/bi00359a009	66	25	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24129	24137		10.1074/jbc.271.39.24129	http://dx.doi.org/10.1074/jbc.271.39.24129			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798652	hybrid			2022-12-25	WOS:A1996VJ44200081
J	Jongmans, W; Artuso, M; Vuillaume, M; Bresil, H; Jackson, SP; Hall, J				Jongmans, W; Artuso, M; Vuillaume, M; Bresil, H; Jackson, SP; Hall, J			The role of Ataxia telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionising radiation	ONCOGENE			English	Article						DNA-PK; ataxia-telangiectasia; DNA-repair; cell cycle; WAF1/CIP1 (p21); Ku	IONIZING-RADIATION; V(D)J RECOMBINATION; BINDING FUNCTION; TERMINAL DOMAIN; SINGLE STRANDS; P53 PROTEIN; GENE; PHOSPHORYLATION; CELLS; INDUCTION	The DNA-dependent protein kinase (DNA-PK), whose catalytic subunit shows structural similarities to the Ataxia telangiectasia (AT) gene product (ATM), has also been implicated in the p53-mediated signal transduction pathway that activates the cellular response to DNA damage produced by ionizing radiation, DNA-PK activity however was not found to be related to the transcriptional induction of WAF1/CIP1(21) in AT lymphoblastoid cell lines, following treatment with ionizing radiation, Normal protein and transcription levels of Ku70 and Ku80, as sell as DNA-PK activity, mere found-in sis different AT cell lines, 1-4 h following exposure to ionizing radiation, timepoints where reduced and delayed transcriptional induction of WAF1/CIP1 (p21) was observed, WAF1/CIP1 (p21) was found to be transcriptionally induced by p53 in normal cell lines over this same time period following exposure to ionizing radiation, These results suggest that despite the findings that in vitro DNA-PK may phosphorylate p53, in vivo it mould not appear to play a central role in the activation of p53 as a transcription factor nor can it substitute for the ATM gene product in the cellular response following exposure to ionizing radiation.	INT AGCY RES CANC,UNIT MECH CARCINOGENESIS,F-69372 LYON 08,FRANCE; UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND	World Health Organization; International Agency for Research on Cancer (IARC); University of Cambridge			Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014; hall, janet/G-1372-2013	Jackson, Stephen Philip/0000-0001-9317-7937; hall, janet/0000-0002-4397-6295	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTUSO M, 1995, ONCOGENE, V11, P1427; BALKALKIN G, 1994, P NATL ACAD SCI USA, V94, P413; BLUNT T, 1995, CELL, V80, P1; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	29	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1133	1138						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808686				2022-12-25	WOS:A1996VJ20200003
J	Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM				Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM			A new form of RET rearrangement in thyroid carcinomas of children after the Chernobyl reactor accident	ONCOGENE			English	Article						RET oncogene; RT-PCR; 5'RACE; RET/PTC3; RET/Delta PTC3; papillary thyroid carcinoma	MOLECULAR CHARACTERIZATION; PROTOONCOGENE; ACTIVATION; ONCOGENE; RET/PTC3; D10S170; FUSION; CANCER; GENE; PTC	Intrachromosomal rearrangements involving the RET and the adjacent H4 or ELE1 gene are very frequent events in thyroid cancer of children from Belarus after the Chernobyl reactor accident (Klugbauer et al., 1995), The fusion product between ELE1 and RET (RET/PTC3) seems to be the prevailing type of rearrangement as shown in a recently published study using a novel RT multiplex PCR approach in combination with the identification of the rearrangement type by RT-PCR and direct sequencing. Now we found a new type of RET rearrangement: By the 5'RACE method we demonstrated in cDNA the fusion of the tyrosine kinase domain of RET with a truncated ELE1 gene shorter than the ELE1 in RET/PTC3, Sequencing of genomic DNA revealed a rearrangement breakpoint at position 41 of a new ELE1 intron (522 bp in length), The new oncogene RET/Delta PTC3 is shortened by one ELE1 exon of 144 bp in length, Structural considerations of the ele1 amino terminal of RET/Delta PTC3 suggest that the transforming activity of the fusion protein is apparently not affected by this truncation, The exon lacking in RET/Delta PTC3 was found to code in the reciprocal transcript RET/Delta ELE1 and increased its size by 144 bp, Obviously the new and possibly additional ELE/RET fusion molecules might even increase the high prevalence of ELE1/RET rearrangements in thyroid carcinomas of children after the Chernobyl reactor accident.	UNIV MUNICH, INST PATHOL, D-80337 MUNICH, GERMANY; UNIV MUNICH, INST RADIAT BIOL, MUNICH, GERMANY; MED HIGH SCH MINSK, CHAIR ONCOL, MINSK, BELARUS	University of Munich; University of Munich								BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; ITO T, 1993, CANCER RES, V53, P2940; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; SANTORO M, 1994, ONCOGENE, V9, P509; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; TONG Q, 1995, ONCOGENE, V10, P1781; TSUZUKI T, 1995, ONCOGENE, V10, P191	17	56	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					1099	1102						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806700				2022-12-25	WOS:A1996VG76600024
J	Dalton, TP; Lio, QW; Bittel, D; Liang, LC; Andrews, GK				Dalton, TP; Lio, QW; Bittel, D; Liang, LC; Andrews, GK			Oxidative stress activates metal-responsive transcription factor-1 binding activity - Occupancy in vivo of metal response elements in the metallothionein-I gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; LIGATION-MEDIATED PCR; YA-SUBUNIT GENE; NF-KAPPA-B; FACTOR MTF-1; PHENOLIC ANTIOXIDANTS; INDUCIBLE EXPRESSION; HYDROXYL RADICALS; DNA INTERACTIONS; GROWTH-FACTOR	Oxidative stress (tert-butylhydroquinone) rapidly induced metallothionein-I gene expression in mouse Hepa cells, and this effect was mediated predominantly through metal response promoter elements in transient transfection assays. In vivo genomic footprinting of the mouse metallothionein-I promoter after treatment of Hepa cells with hydrogen peroxide, tert-butylhydroquinone, or zinc suggested a rapid increase in occupancy of the metal response elements. More subtle changes also occurred in the constitutive genomic footprint at the composite major late transcription factor/antioxidant response element. This element may, in part, mediate induction by hydrogen peroxide, Electrophoretic mobility shift assays demonstrated a rapid (30 min) increase in the DNA binding activity of metal-responsive transcription factor-1 in Hepa cells treated with any of these inducers, In control cells, upstream stimulatory factor binding with the major late transcription factor site, and a nuclear protein complex distinct from AP-I, but specific for the antioxidant response element, were detected, The amounts of these complexes were not altered after these treatments, These studies indicate that metal-responsive transcription factor-1 plays a role in activating mouse metallothionein-I gene transcription in response to reactive oxygen species.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOL BIOL, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center					NATIONAL CANCER INSTITUTE [R01CA061262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005704] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61262] Funding Source: Medline; NIEHS NIH HHS [ES-05704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDREWS GK, 1990, PROG FOOD NUTR SCI, V14, P193; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAUMAN JW, 1991, TOXICOL APPL PHARM, V110, P347, DOI 10.1016/S0041-008X(05)80017-1; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; BERGELSON S, 1994, ONCOGENE, V9, P565; BERGMANN B, 1992, TOXICOLOGY, V74, P127, DOI 10.1016/0300-483X(92)90133-Y; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; DALTON T, 1994, BIOL REPROD, V51, P597, DOI 10.1095/biolreprod51.4.597; DE SK, 1990, J BIOL CHEM, V265, P15267; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KNIGHT JA, 1995, ANN CLIN LAB SCI, V25, P111; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee DK, 1996, MOL REPROD DEV, V43, P158, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;158::AID-MRD4&gt;3.0.CO;2-Q; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARET W, 1995, NEUROCHEM INT, V27, P111, DOI 10.1016/0197-0186(94)00173-R; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; Palmiter R D, 1987, Experientia Suppl, V52, P63; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHILDERMAN PAEL, 1993, CARCINOGENESIS, V14, P347, DOI 10.1093/carcin/14.3.347; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YIANGOU M, 1991, BIOCHEMISTRY-US, V30, P3798; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	60	205	213	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26233	26241		10.1074/jbc.271.42.26233	http://dx.doi.org/10.1074/jbc.271.42.26233			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824273	hybrid			2022-12-25	WOS:A1996VN18000079
J	FranchiGazzola, R; Visigalli, R; Bussolati, O; Gazzola, GC				FranchiGazzola, R; Visigalli, R; Bussolati, O; Gazzola, GC			Involvement of protein kinase C epsilon in the stimulation of anionic amino acid transport in cultured human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-DEPENDENT TRANSPORT; HUMAN SKIN FIBROBLASTS; HIGH-AFFINITY UPTAKE; RAT-BRAIN; DIFFERENTIAL REGULATION; GLUTAMATE TRANSPORTERS; PHORBOL ESTERS; EXPRESSION; CELLS; PHOSPHORYLATION	Protein kinase C (PKC) activation stimulates transport system X(AG)(-) for anionic amino acids in cultured human fibroblasts (Franchi-Gazzola, R., Visigalli, R., Bussolati, O., and Gazzola, G. C. (1994) FEBS Lett. 352, 109-112), To identify which PKC isoform is responsible for this effect, aspartate transport through system X(AG)(-), PKC activity, and the subcellular distribution of PKC isoforms have been studied before and after treatment with phorbol 12,13-dibutyrate (PDBu) in fibroblasts maintained at low serum for 1 (control cells) or 7 days (quiescent cells), In control cells aspartate transport and PKC activity in the particulate fraction were stimulated by short term PDBu treatment; both stimulatory effects were down-regulated by a prolonged exposure to the phorbol. In contrast, in quiescent cells aspartate transport and particulate PKC activity were higher than control under basal conditions, unaffected by a short term PDBu treatment, and lowered by a prolonged incubation with the phorbol, In both control and quiescent cells a short term PDBu treatment modified PKC alpha distribution, increasing its membrane associated fraction. PKC delta was mostly in the soluble fraction and scarcely sensitive to PDBu. A brief exposure to PDBu increased membrane-associated PKC epsilon in control but not in quiescent cells, In these cells epsilon isoform was found exclusively in the particulate fraction even in PDBu-untreated cells. A prolonged PDBu treatment caused a partial down-regulation of membrane-associated PKC epsilon in control cells and its marked decrease in quiescent cells, It is concluded that PKC-dependent changes in system Ii,, activity parallel the behavior of PKC epsilon, thus suggesting a specific role for this isoform in system X(AG)(-) regulation.	UNIV PARMA,IST PATOL GEN,I-43100 PARMA,ITALY	University of Parma			Bussolati, Ovidio/B-7589-2013	Bussolati, Ovidio/0000-0002-4301-2939				ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BALCAR VJ, 1992, FEBS LETT, V300, P203, DOI 10.1016/0014-5793(92)80846-9; BUSSOLATI O, 1993, BIOCHIM BIOPHYS ACTA, V1151, P153, DOI 10.1016/0005-2736(93)90099-L; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHEN CC, 1995, NEUROCHEM INT, V26, P455, DOI 10.1016/0197-0186(94)00157-P; DALLASTA V, 1983, J BIOL CHEM, V258, P6371; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FRANCHIGAZZOLA R, 1990, BIOCHEM BIOPH RES CO, V173, P1304, DOI 10.1016/S0006-291X(05)80929-5; FRANCHIGAZZOLA R, 1994, FEBS LETT, V352, P109, DOI 10.1016/0014-5793(94)00929-5; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6054; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GONZALEZ A, 1993, ANAL BIOCHEM, V215, P184, DOI 10.1006/abio.1993.1574; GOODE N, 1992, J BIOL CHEM, V267, P16878; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANAI Y, 1994, FASEB J, V8, P1450; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KARIM Z, 1995, AM J PHYSIOL-CELL PH, V269, pC134, DOI 10.1152/ajpcell.1995.269.1.C134; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEHEL C, 1994, J BIOL CHEM, V269, P4761; MCDERMOTT RH, 1993, J CELL SCI, V104, P51; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PONZONI M, 1993, FEBS LETT, V322, P120, DOI 10.1016/0014-5793(93)81550-J; RACCHI M, 1994, ARCH BIOCHEM BIOPHYS, V314, P107, DOI 10.1006/abbi.1994.1417; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; XIAO HG, 1994, J NEUROSURG, V81, P734, DOI 10.3171/jns.1994.81.5.0734; ZHANG QY, 1992, J IMMUNOL, V149, P1402	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26124	26130		10.1074/jbc.271.42.26124	http://dx.doi.org/10.1074/jbc.271.42.26124			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824256	hybrid			2022-12-25	WOS:A1996VN18000062
J	Lee, HS; Aumais, J; White, JH				Lee, HS; Aumais, J; White, JH			Hormone-dependent transactivation by estrogen receptor chimeras that do not interact with hsp90 - Evidence for transcriptional repressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-90; NUCLEAR RECEPTORS; STEROID-RECEPTORS; THYROID-HORMONE; BINDING-PROPERTIES; RETINOIC ACID; CO-REPRESSOR; IN-VIVO; ACTIVATION; SUPERFAMILY	The ligand-free estrogen receptor (ER), like other steroid receptors, interacts with the 90-kDa heat shock protein hsp90 in vitro. Analysis of the effect of potential ER-hsp90 interactions in vivo on receptor function is complicated by the fact that hsp90 binds to ER domains required for hormone binding and stable DNA binding, ER chimeras were therefore created by replacing the ER DNA binding domain with that of GAL4. In addition, the N-terminal-AF-1 domain of the ER was replaced with the strong constitutive activation domain of VP16 to create VP16-GAL-ERs. These chimeras bind DNA in a ligand-independent manner, but, importantly, are ligand-dependent transactivators, unlike VP16-GAL, which displays strong constitutive activity under the same conditions. Hormone induces transactivation by VP16-GAL-ERs to levels similar to the constitutive activity of VP16-GAL. Glycerol gradient and coimmunoprecipitation experiments showed that, unlike the wild-type ER, VP1G-GAL-ER chimeras do not interact with hsp90. Deletion analyses indicate that a region of the ER, primarily between amino acids 370 and 470, is responsible for repressed transcription. Our results suggest that interaction with hsp90 is not necessary for controlling dependent transcription by the ER and provide evidence for repressor factors that interact with the N-terminal portion of the receptor's ligand binding domain in the absence of hormone.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University			white, john h/N-9782-2013	white, john h/0000-0002-4785-2687				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERRARA J, 1994, J BIOL CHEM, V269, P2971; FUXE K, 1987, J STEROID BIOCHEM, V27, P159, DOI 10.1016/0022-4731(87)90306-2; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P389; GREENE GL, 1986, J STEROID BIOCHEM, V26, P1; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ISHIBASHI T, 1989, BIOL REPROD, V40, P1275; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; LANDEL CC, 1994, MOL ENDOCRINOL, V8, P1407, DOI 10.1210/me.8.10.1407; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MCDONNELL DP, 1992, P NATL ACAD SCI USA, V89, P10563, DOI 10.1073/pnas.89.22.10563; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; ONATE SA, 1995, SCIENCE, V270, P1354; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRESS MF, 1985, J HISTOCHEM CYTOCHEM, V33, P915, DOI 10.1177/33.9.4020102; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TZUKERMAN M, 1990, New Biologist, V2, P613; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHUANG Y, 1995, MOL ENDOCRINOL, V9, P457, DOI 10.1210/me.9.4.457	37	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25727	25730		10.1074/jbc.271.42.25727	http://dx.doi.org/10.1074/jbc.271.42.25727			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824196	hybrid			2022-12-25	WOS:A1996VN18000002
J	Cairns, W; Smith, CAD; McLaren, AW; Wolf, CR				Cairns, W; Smith, CAD; McLaren, AW; Wolf, CR			Characterization of the human cytochrome P4502D6 promoter - A potential role for antagonistic interactions between members of the nuclear receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; DNA-BINDING; SUPERFAMILY; HNF-4; EXPRESSION; LIVER; ORPHAN; RAT	The functional mapping of the human cytochrome P4502D6 (CYP2D6) promoter in HepG2 cells revealed the presence of both positive and negative regulatory elements. One of these regulatory elements overlapped a sequence that is highly conserved in most members of the CYP2 family, This element, which consists of a degenerate AGGTCA direct repeat spaced by 1 base pair (DR1) and is known to be a target for members of the steroid receptor superfamily, was found to bind in vitro translated hepatocyte nuclear factor 4 (HNF4) in gel retardation analysis. Using HepG2 nuclear extracts, three protein-DNA complexes were formed on the DR1 element, one of which was confirmed to be dependent on the binding of HNF4. The other DR1 complexes were shown to be due to the interaction of the orphan receptor chicken ovalbumin upstream promoter transcription factor I (COUP-TFI). Experiments in COS-7 cells showed that HNF4 could activate the CYP2D6 promoter 30-fold. Surprisingly, mutation of the DR1 element produced a relatively minor 23% decrease in activity in HepG2 cells. Additionally, COUP-TFI was shown to inhibit HNF4 stimulation of the CYP2D6 promoter in COS-7 cells, suggesting that COUP-TFI could attenuate the effect of HNF4 in HepG2 cells, However, when HNF4 levels were increased in HepG2 cells by co-transfection, it resulted in the enhancement of CYP2D6 promoter activity, indicating that HNF4 could overcome the repressive effect of COUP-TFI. Therefore, the contribution of the DR1 element in controlling the transcription of the CYP2D6 gene depends on the balance between positively and negatively acting transcription factors.	NINEWELLS HOSP, MOL PHARMACOL UNIT, IMPERIAL CANC RES FUND, CTR BIOMED RES, DUNDEE DD1 9SY, SCOTLAND	University of Dundee								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CB, 1994, MOL CELL BIOL, V14, P5175, DOI 10.1128/MCB.14.8.5175; CHEN D, 1994, J BIOL CHEM, V269, P5420; DALY AK, 1991, PHARMACOGENETICS, V1, P33, DOI 10.1097/00008571-199110000-00006; DALY AK, 1993, PHARMACOL THERAPEUT, V57, P129, DOI 10.1016/0163-7258(93)90053-G; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; GORMAN C, 1986, DNA CLONING, V3, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; HAHN CN, 1991, J BIOL CHEM, V266, P17031; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HENDERSON CJ, 1992, PROGR DRUG METABOLIS, V13, P73; IBEANU GC, 1995, BIOCHEMISTRY-US, V34, P8028, DOI 10.1021/bi00025a008; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOOP DR, 1990, BIOESSAYS, V12, P429, DOI 10.1002/bies.950120906; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Leng X, 1996, MOL CELL BIOL, V16, P2332; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MODE A, 1993, J REPROD FERTIL, P77; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; STROM A, 1995, J BIOL CHEM, V270, P11276, DOI 10.1074/jbc.270.19.11276; STUMPF H, 1995, CARCINOGENESIS, V16, P143, DOI 10.1093/carcin/16.1.143; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TRAUTWEIN C, 1995, J HEPATOL, V22, P50, DOI 10.1016/0168-8278(95)80259-2; TRELUYER JM, 1991, EUR J BIOCHEM, V202, P583, DOI 10.1111/j.1432-1033.1991.tb16411.x; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355; YOSHIOKA H, 1990, J BIOL CHEM, V265, P14612	50	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25269	25276		10.1074/jbc.271.41.25269	http://dx.doi.org/10.1074/jbc.271.41.25269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810289	hybrid			2022-12-25	WOS:A1996VL69300033
J	Selzer, J; Hofmann, F; Rex, G; Wilm, M; Mann, M; Just, I; Aktories, K				Selzer, J; Hofmann, F; Rex, G; Wilm, M; Mann, M; Just, I; Aktories, K			Clostridium novyi alpha-toxin-catalyzed incorporation of GlcNAc into Rho subfamily proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; ACTIN STRESS FIBERS; MASS-SPECTROMETRY; CDC42 GTPASES; GENE-PRODUCT; DIFFICILE; RAC; PURIFICATION; ELECTROSPRAY; SORDELLII	The lethal and edema-inducing alpha-toxin from Clostridium novyi causes rounding up of cultured cell lines by redistribution of the actin cytoskeleton. alpha-Toxin belongs to the family of large clostridial cytotoxins that encompasses Clostridium difficile toxin A and B and the lethal toxin from Clostridium sordellii. Toxin A and toxin B have been recently identified as monoglucosyltransferases to modify the low molecular mass GTPases of the Rho subfamily (Just, I., Selzer, J., Wilm, M., Von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500-503 and Just, I., Wilm, M., Selzer, J., Rex, G., Von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) J. Biol. Chem. 270, 13932-13936). We report here the identification of the alpha-toxin-catalyzed modification of Rho. Using electrospray mass spectrometry, the mass of the modification was determined as 203 Da, consistent with a N-acetyl-hexosamine moiety. UDP-N-acetyl-glucosamine selectively served as cosubstrate for alpha-toxin-catalyzed modification into the Rho subfamily proteins Rho, Rac, Cdc42, and RhoG. The acceptor amino acid of N-acetyl-glucosaminylation was identified by mutagenesis as Thr-37 in Rho (equivalent to Thr-35 in Rac/Cdc42), which is located in the effector domain of the GTPases. C. novyi alpha-toxin seems to mediate its cytotoxic effects on cells by mimicking endogenous post-translational modification of cellular proteins.	UNIV FREIBURG, INST PHARMAKOL & TOXIKOL, D-79104 FREIBURG, GERMANY; EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY	University of Freiburg; European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013; Aktories, Klaus/CAJ-5682-2022	Mann, Matthias/0000-0003-1292-4799; Aktories, Klaus/0000-0002-5397-0436; Wilm, Matthias/0000-0002-5461-6834				AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BAIROCH A, 1988, NATURE, V331, P22, DOI 10.1038/331022a0; BETTE P, 1989, INFECT IMMUN, V57, P2507, DOI 10.1128/IAI.57.8.2507-2513.1989; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Eichel-Streiber C. von, 1990, Gene, V96, P107, DOI 10.1016/0378-1119(90)90348-U; EICHELSTREIBER C, 1993, GENETICS MOL BIOL AN, P264; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GREEN GA, 1995, GENE, V161, P57, DOI 10.1016/0378-1119(95)00263-6; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOFMANN F, 1995, MOL GEN GENET, V247, P670, DOI 10.1007/BF00290398; IGLEWSKI WJ, 1990, ADP RIBOSYLATING TOX, P511; JACQUEMIN C, 1986, NATURE, V323, P182, DOI 10.1038/323182a0; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MCGREGOR JA, 1989, AM J OBSTET GYNECOL, V161, P987, DOI 10.1016/0002-9378(89)90768-0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MULLER H, 1992, INFECT IMMUN, V60, P3007; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKSCHE A, 1992, INFECT IMMUN, V60, P3002, DOI 10.1128/IAI.60.7.3002-3006.1992; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	44	116	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25173	25177		10.1074/jbc.271.41.25173	http://dx.doi.org/10.1074/jbc.271.41.25173			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810274	hybrid			2022-12-25	WOS:A1996VL69300018
J	Wang, Z; Chacko, S				Wang, Z; Chacko, S			Mutagenesis analysis of functionally important domains within the C-terminal end of smooth muscle caldesmon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING-SITES; ATPASE ACTIVITY; CALMODULIN-BINDING; HEAVY-MEROMYOSIN; MYOSIN SUBFRAGMENTS; F-ACTIN; TROPOMYOSIN; ACTOMYOSIN; PHOSPHORYLATION; EXPRESSION	The ability of chicken gizzard smooth muscle caldesmon (CaD) to inhibit actomyosin ATPase activity is due mainly to an inhibitory domain that resides within the C-terminal 67 amino acid residues of the CaD molecule. In the present study, a series of C-terminal truncation and internal deletion mutants of chicken gizzard smooth muscle CaD were systematically designed using a site-directed mutagenesis approach, and these mutant proteins were overexpressed in a baculovirus expression system. Analysis of actin binding and inhibition of actomyosin ATPase activity using these mutants identified a strong actin-binding motif of 6 amino acid residues (from Lys(718) to Glu(723)), which also form the core sequence for CaD-induced inhibition of actomyosin ATPase, However, maximal inhibition by CaD requires the presence of residues 728-731, which are not associated with actin binding, Our data provide direct evidence for the requirement of actin binding to a specific region in CaD for CaD-induced inhibition of actin activation of smooth muscle myosin ATPase. Furthermore, our findings also show that the region between residues 690 and 717 is responsible for the weak inhibition of actomyosin ATPase and reveal that the inhibitory determinants located in the regions between residues 690 and 717 and residues 718 and 756 can function independently.	UNIV PENN,SCH VET MED,DEPT PATHOBIOL,PHILADELPHIA,PA 19104; UNIV PENN,DIV UROL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039740, R01DK047514] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39740, DK 47514] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BARTEGI A, 1990, J BIOL CHEM, V265, P1521; CHACKO S, 1981, BIOCHEMISTRY-US, V20, P702, DOI 10.1021/bi00507a005; CHACKO S, 1990, J BIOL CHEM, V265, P2105; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DOBROWOLSKI Z, 1988, BIOCHIM BIOPHYS ACTA, V956, P140, DOI 10.1016/0167-4838(88)90260-9; HEASLIP RJ, 1985, BIOCHEMISTRY-US, V24, P2731, DOI 10.1021/bi00332a020; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HORIUCHI KY, 1995, J MUSCLE RES CELL M, V16, P11, DOI 10.1007/BF00125306; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; IKEBE M, 1988, J BIOL CHEM, V263, P3055; ISHIKAWA R, 1992, CELL MOTIL CYTOSKEL, V23, P244, DOI 10.1002/cm.970230404; LASH JA, 1986, J BIOL CHEM, V261, P6155; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1985, ADV PROTEIN PHOSPHAT, V2, P171; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NGAI PK, 1984, J BIOL CHEM, V259, P3656; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; Wang Z, 1996, J BIOL CHEM, V271, P2234, DOI 10.1074/jbc.271.4.2234; WANG Z, 1994, J MUSCLE RES CELL M, V15, P646, DOI 10.1007/BF00121072; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	41	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25707	25714		10.1074/jbc.271.41.25707	http://dx.doi.org/10.1074/jbc.271.41.25707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810349	hybrid			2022-12-25	WOS:A1996VL69300093
J	Bohme, B; Vandenbos, T; Cerretti, DP; Park, LS; Holtrich, U; RubsamenWaigmann, H; Strebhardt, K				Bohme, B; Vandenbos, T; Cerretti, DP; Park, LS; Holtrich, U; RubsamenWaigmann, H; Strebhardt, K			Cell-cell adhesion mediated by binding of membrane-anchored ligand LERK-2 to the EPH-related receptor human embryonal kinase 2 promotes tyrosine kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; MOLECULAR CHARACTERIZATION; CDNA CLONING; FAMILY; GENE; IDENTIFICATION; ECK; ELK; HEK; HTK	Human embryonal kinase 2 (HEK2) is a protein-tyrosine kinase that is a member of the EPH family of receptors. Transcripts for HEK2 have a wide tissue distribution. Recently, a still growing family of ligands, which we have named LERKs, for ligands of the ephrelated kinases, has been isolated. In order to analyze functional effects between the LERKs and the HEK2 receptor, we expressed HEK2 cDNA in an interleukin-3-dependent progenitor cell line 32D that grows as single cells in culture. Within the group of LERKs, LERK-2 and -5 were shown to bind to HEK2. Membrane-bound and soluble forms of LERK-2 were demonstrated to signal through HEK2 as judged by receptor phosphorylation. Coincubation of HEK2 and LERK-2 expressing cells induced cell-cell adhesion and formation of cell aggregates. This interaction could be inhibited by preincubation of HEK2 expressing cells with soluble LERK-2. Coexpression of HEK2 and LERK-2 in 32D cells showed reduced kinase activity and autophosphorylation of HEK2 compared with the juxtacrine stimulation, which seems to be due to a reduced sensitivity of the receptor.	GEORG SPEYER HAUS,CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; BAYER AG,INST VIROL,D-42096 WUPPERTAL,GERMANY	Octapharma; Bayer AG			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BOHME B, 1993, ONCOGENE, V8, P2857; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FOX GM, 1995, ONCOGENE, V10, P897; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; IWASE T, 1993, BIOCHEM BIOPH RES CO, V194, P698, DOI 10.1006/bbrc.1993.1878; KATO H, 1993, J BIOL CHEM, V268, P2655; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24747	24752		10.1074/jbc.271.40.24747	http://dx.doi.org/10.1074/jbc.271.40.24747			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798744	hybrid			2022-12-25	WOS:A1996VM67400066
J	Johnson, JA; Gray, MO; Chen, CH; MochlyRosen, D				Johnson, JA; Gray, MO; Chen, CH; MochlyRosen, D			A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; SUBCELLULAR-LOCALIZATION; INTRACELLULAR RECEPTORS; RAT-HEART; ACTIVATION; MYOCYTES; CELLS; EPSILON; DOMAIN; PHOSPHORYLATION	Protein kinase C (PKC) isozymes translocate to unique subcellular sites following activation. We previously suggested that translocation of activated isozymes is required for their function and that in addition to binding to lipids, translocation involves binding of the activated isozymes to specific anchoring proteins (receptors for activated protein kinase C. Using cultured cardiomyocytes we identified inhibitors, the V1 fragment of epsilon PKC (epsilon V1), and an 8-amino acid peptide derived from it that selectively inhibited the translocation of epsilon PKC. Inhibition of epsilon PKC translocation but not inhibition of delta or beta PKC translocation specifically blocked phorbol ester- or norepinephrine-mediated regulation of contraction. These isozyme-selective translocation inhibitors provide novel tools to determine the function of individual PKC isozymes in intact cells.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University				Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1995, J MOL CELL CARDIOL, V27, P2473, DOI 10.1006/jmcc.1995.0235; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; JOHNSON JA, 1995, CIRC RES, V76, P654, DOI 10.1161/01.RES.76.4.654; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LIU JD, 1989, BIOCHEM BIOPH RES CO, V162, P1105, DOI 10.1016/0006-291X(89)90787-0; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; TREJO J, 1991, J BIOL CHEM, V266, P7876; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4; WOLF M, 1986, J BIOL CHEM, V261, P3327; ZHANG Z, 1996, BIOPHYS J, V70, P391	34	338	363	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24962	24966		10.1074/jbc.271.40.24962	http://dx.doi.org/10.1074/jbc.271.40.24962			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798776	hybrid			2022-12-25	WOS:A1996VM67400099
J	Joos, H; Trouliaris, S; Helftenbein, G; Niemann, H; Tamura, T				Joos, H; Trouliaris, S; Helftenbein, G; Niemann, H; Tamura, T			Tyrosine phosphorylation of the juxtamembrane domain of the v-Fms oncogene product is required for its association with a 55-kDa protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; STIMULATING FACTOR-I; FELINE SARCOMA-VIRUS; FACTOR BETA-RECEPTOR; CSF-1 RECEPTOR; KINASE-ACTIVITY; BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS	Tyrosine autophosphorylation of the v-Fms oncogene product results in the formation of high affinity binding sites for cellular proteins with Src homology 2 (SH2) domains that are involved in various signal cascades, Tryptic digestion of the autophosphorylated v-Fms and of its cellular counterpart, the feline c-Fms polypeptide, gave rise to at least six common major phosphopeptides, four of which have been characterized previously. Employing site-directed mutagenesis and phosphopeptide mapping of in vitro phosphorylated glutathione S-transferase v-Fms fusion proteins as well as full-length v-Fms molecules expressed in various cells, we show here that Tyr(543) Of the juxtamembrane domain and Tyr(696) of the kinase insert domain constitute major autophosphorylation sites. Recombinant fusion proteins containing the tyrosine-phosphorylated kinase insert domain bind the growth factor receptor bound protein 2 and the p85 and p110 subunits of phosphatidylinositol 3'-kinase. In contrast, fusion proteins containing the juxtamembrane domain phosphorylated on Tyr(543) fail to bind any of the known SH2 domain-containing cellular proteins but associate specifically with an as yet undefined 55-kDa cellular protein that by itself is phosphorylated on tyrosine.	UNIV GIESSEN,INST VIROL,D-35392 GIESSEN,GERMANY; HANNOVER MED SCH,INST BIOCHEM,D-30625 HANNOVER,GERMANY	Justus Liebig University Giessen; Hannover Medical School								ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PLUTZKY L, 1992, P NATL ACAD SCI USA, V89, P11239; PONS S, 1995, MOL CELL BIOL, V15, P4453; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMOLA U, 1991, J VIROL, V65, P6181, DOI 10.1128/JVI.65.11.6181-6187.1991; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; TAMURA T, 1990, ONCOGENE, V5, P1259; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TROULIARIS S, 1995, ARCH VIROL, V140, P179, DOI 10.1007/BF01309733; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; TWAMLEY GM, 1993, ADV SEC MESS PHOSPH, V28, P187; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	43	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24476	24481		10.1074/jbc.271.40.24476	http://dx.doi.org/10.1074/jbc.271.40.24476			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798707	hybrid			2022-12-25	WOS:A1996VM67400029
J	Marcheselli, VL; Bazan, NG				Marcheselli, VL; Bazan, NG			Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus - Inhibition by a platelet-activating factor antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; INDUCIBLE CYCLOOXYGENASE; ELECTROCONVULSIVE SHOCK; CEREBRAL-CORTEX; GENE DISRUPTION; C-FOS; EXPRESSION; INFLAMMATION; MESSENGER; AVOIDANCE	Prostaglandin G/H synthase-2 and zif-268 mRNA expression is transiently induced in rat brain by kainic acid (KA)-induced seizures and by a single electroconvulsive shock. Induction of both genes by KA shows neuroanatomical specificity in the order hippocampus > cerebral cortex > striatum > brain stem > cerebellum. Nuclear run-on and Western blotting shows that both genes are transcriptionally activated, and that kainic acid up-regulation of prostaglandin G/H synthase-2 mRNA expression in hippocampus matches increased protein levels. Whereas the magnitude of hippocampal zif-268 mRNA induction is similar in both seizure models, peak induction of prostaglandin G/H synthase-2 mRNA is 7-fold greater in the kainic acid model than in the electroconvulsive shock model and is much more prolonged. Pretreatment of animals by intracerebroventricular injection with the intracellular platelet-activating factor receptor antagonist BN 50730 strongly attenuates kainic acid and electroconvulsive shock induction of prostaglandin G/H synthase-2 expression. The drug partially inhibits electroconvulsive shock induction of zif-268, but is relatively ineffective against kainic acid-induced zif-268 expression. Seizure-induced expression of both genes involves platelet-activating factor, but the mechanisms of induction must be otherwise distinct. The selectively elevated induction of hippocampal prostaglandin G/H synthase-2 by kainic acid correlates with a neuroanatomical region in which the agonist induces neuronal damage.	LOUISIANA STATE UNIV, CTR MED, CTR NEUROSCI, SCH MED, NEW ORLEANS, LA 70112 USA	Louisiana State University System			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023002] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23002] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams J, 1996, J NEUROCHEM, V66, P6; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; CHEN J, 1995, NEUROREPORT, V6, P245; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; HATTORI M, 1993, J BIOL CHEM, V268, P18748; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERTTING G, 1989, ANN NY ACAD SCI, V559, P84; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; IZQUIERDO I, 1995, P NATL ACAD SCI USA, V92, P5047, DOI 10.1073/pnas.92.11.5047; JERUSALINSKY D, 1994, BEHAV NEURAL BIOL, V62, P1, DOI 10.1016/S0163-1047(05)80052-4; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Marcheselli V. L., 1994, Society for Neuroscience Abstracts, V20, P1053; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; MARCHESELLI VL, 1994, J NEUROSCI RES, V37, P54, DOI 10.1002/jnr.490370108; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Mori M, 1996, J NEUROSCI, V16, P3590; NAFFAHMAZZACORATTI MG, 1995, NEUROCHEM INT, V27, P461, DOI 10.1016/0197-0186(95)00053-B; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SQUINTO SP, 1989, J NEUROSCI RES, V24, P558, DOI 10.1002/jnr.490240414; STEPHENSON DT, 1994, BRAIN RES, V637, P97, DOI 10.1016/0006-8993(94)91221-1; Sun GY, 1995, PROG BRAIN RES, V105, P231; Takechi H, 1996, J BIOL CHEM, V271, P5901, DOI 10.1074/jbc.271.10.5901; THOMPSON RJ, 1973, J NEUROCHEM, V21, P19, DOI 10.1111/j.1471-4159.1973.tb04222.x; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	40	146	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24794	24799		10.1074/jbc.271.40.24794	http://dx.doi.org/10.1074/jbc.271.40.24794			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798751	hybrid			2022-12-25	WOS:A1996VM67400073
J	Umbach, AL; Siedow, JN				Umbach, AL; Siedow, JN			The reaction of the soybean cotyledon mitochondrial cyanide-resistant oxidase with sulfhydryl reagents suggests that alpha-keto acid activation involves the formation of a thiohemiacetal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANT MITOCHONDRIA; ALTERNATIVE OXIDASE; ACTIVE-SITE; SUCCINATE-DEHYDROGENASE; MOLECULAR-BIOLOGY; CYTOCHROME; PYRUVATE; RESPIRATION; PROTEIN; TOBACCO	The cyanide-resistant alternative oxidase of plant mitochondria is known to be activated by alpha-keto acids, such as pyruvate, and by the reduction of a disulfide bond that bridges the two subunits of the enzyme homodimer. When the regulatory cysteines are oxidized, the inactivated enzyme is much less responsive to pyruvate than when these groups are reduced. When soybean cotyledon mitochondria were isolated in the presence of iodoacetate or N-ethylmaleimide, the intermolecular disulfide bond did not form and the alternative oxidase was present only as a noncovalently associated dimer. N-Ethylmaleimide inhibited alternative oxidase activity, but iodoacetate was found to stimulate activity much like pyruvate, including enhancing the enzyme's apparent affinity for reduced ubiquinone. The presence of pyruvate or iodoacetate blocked inhibition of the enzyme by N-ethylmaleimide, indicating that all three compounds acted at the same sulfhydryl group on the alternative oxidase protein, The site of pyruvate and iodoacetate action was shown to be a different sulfhydryl than that involved in the redox-active regulatory disulfide bond, because iodoacetate bound to the alternative oxidase at the activating site even when the redox-active regulatory sulfhydryls were oxidized. Given the nature of the covalent adduct formed by the reaction of iodoacetate with sulfhydryls, the activation of the alternative oxidase by alpha-keto acids appears to involve the formation of a thiohemiacetal.	DUKE UNIV,DEPT BOT,DEV CELL & MOL BIOL GRP,DURHAM,NC 27708	Duke University								ADAMS MJ, 1987, ENZYME MECHANISMS, P477; CRUZHERNANDEZ A, 1995, PLANTA, V197, P569, DOI 10.1007/BF00191562; DAY DA, 1994, PLANT PHYSIOL, V106, P1421, DOI 10.1104/pp.106.4.1421; DAY DA, 1995, AUST J PLANT PHYSIOL, V22, P497, DOI 10.1071/PP9950497; DRY IB, 1989, ARCH BIOCHEM BIOPHYS, V273, P148, DOI 10.1016/0003-9861(89)90173-2; ELTHON TE, 1986, PLANT PHYSIOL, V82, P1, DOI 10.1104/pp.82.1.1; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; ELTHON TE, 1987, P NATL ACAD SCI USA, V84, P8399, DOI 10.1073/pnas.84.23.8399; FINK AL, 1987, ENZYME MECHANISMS, P159; FRIDOVICH I, 1962, J AM CHEM SOC, V84, P3208, DOI 10.1021/ja00875a050; GRAZI E, 1973, BIOCHEMISTRY-US, V12, P2583, DOI 10.1021/bi00738a006; Hiser C, 1996, PLANT PHYSIOL, V110, P277, DOI 10.1104/pp.110.1.277; Hoefnagel MHN, 1996, PLANT PHYSIOL, V110, P1329, DOI 10.1104/pp.110.4.1329; HOEFNAGEL MHN, 1995, ARCH BIOCHEM BIOPHYS, V318, P394, DOI 10.1006/abbi.1995.1245; HOEFNAGELMHN, 1995, EUR J BIOCHEM, V233, P531; KANCHUGER MS, 1979, J AM CHEM SOC, V101, P3005, DOI 10.1021/ja00505a030; KENNEY WC, 1976, J BIOL CHEM, V251, P2369; KENNEY WC, 1975, J BIOL CHEM, V250, P3089; KYTE J, 1995, STRUCTURE PROTEIN CH, P357; LEACH GR, 1994, BIOCHEM SOC T, V22, pS406, DOI 10.1042/bst022406s; LI D, 1994, BIOPHYS J, V67, P29, DOI 10.1016/S0006-3495(94)80484-9; Li QH, 1996, GENETICS, V142, P129; LIENHARD GE, 1966, J AM CHEM SOC, V88, P3982, DOI 10.1021/ja00969a017; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCINTOSH L, 1994, PLANT PHYSIOL, V105, P781, DOI 10.1104/pp.105.3.781; Means GE, 1971, CHEM MODIFICATION PR, P105; Millar AH, 1996, PLANT PHYSIOL, V111, P613, DOI 10.1104/pp.111.2.613; MILLAR AH, 1993, FEBS LETT, V329, P259, DOI 10.1016/0014-5793(93)80233-K; MOORE AL, 1988, FEBS LETT, V235, P76, DOI 10.1016/0014-5793(88)81237-7; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; RHOADS DM, 1991, P NATL ACAD SCI USA, V88, P2122, DOI 10.1073/pnas.88.6.2122; RHOADS DM, 1993, PLANT PHYSIOL, V103, P877, DOI 10.1104/pp.103.3.877; RIBAS-CARBO M, 1995, PLANT PHYSIOL, V109, P829, DOI 10.1104/pp.109.3.829; RIBAS-CARBO M, 1995, ARCH BIOCHEM BIOPHYS, V317, P156, DOI 10.1006/abbi.1995.1148; RICH PR, 1980, BIOCHIM BIOPHYS ACTA, V592, P506, DOI 10.1016/0005-2728(80)90095-X; ROBINSON SA, 1995, AUST J PLANT PHYSIOL, V22, P487, DOI 10.1071/PP9950487; SAKAJO S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P102; SCHNACKERZ KD, 1970, J BIOL CHEM, V245, P6417; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; SIEDOW JN, 1995, PLANT CELL, V7, P821, DOI 10.1105/tpc.7.7.821; UMBACH AL, 1993, PLANT PHYSIOL, V103, P845, DOI 10.1104/pp.103.3.845; UMBACH AL, 1994, FEBS LETT, V348, P181, DOI 10.1016/0014-5793(94)00600-8; VANLERBERGHE GC, 1992, PLANT PHYSIOL, V100, P115, DOI 10.1104/pp.100.1.115; VANLERBERGHE GC, 1995, PLANT PHYSIOL, V109, P353, DOI 10.1104/pp.109.2.353; VINOGRAD.AD, 1972, BIOCHEM BIOPH RES CO, V49, P441, DOI 10.1016/0006-291X(72)90430-5; Whelan J, 1996, PLANTA, V198, P197, DOI 10.1007/BF00206244; Zhang QS, 1996, PHYSIOL PLANTARUM, V96, P551, DOI 10.1111/j.1399-3054.1996.tb00226.x	47	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25019	25026		10.1074/jbc.271.40.25019	http://dx.doi.org/10.1074/jbc.271.40.25019			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798784	hybrid			2022-12-25	WOS:A1996VM67400107
J	Harmon, FG; Rehrauer, WM; Kowalczykowski, SC				Harmon, FG; Rehrauer, WM; Kowalczykowski, SC			Interaction of Escherichia coli RecA protein with LexA repressor .2. Inhibition of DNA strand exchange by the uncleavable LexA S119A repressor argues that recombination and SOS induction are competitive processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-LAMBDA-REPRESSOR; BINDING-PROTEIN; HOMOLOGOUS RECOMBINATION; SSB PROTEIN; GENETIC-RECOMBINATION; PARTIAL SUPPRESSOR; DIRECTED CLEAVAGE; BIOCHEMICAL BASIS; ACTIVATED RECA; POLYNUCLEOTIDE	The Escherichia coli RecA protein is involved in SOS induction, DNA repair, and homologous recombination. In vitro, RecA protein serves as a co-protease to cleave LexA repressor, the repressor of the SOS regulon; in addition, RecA protein promotes homologous pairing and DNA strand exchange, steps important to homologous recombination and DNA repair. To determine if these two functions of RecA protein are competing or parallel, the effect of uncleavable LexA S119A repressor on RecA protein-dependent activities was examined, LexA S119A repressor inhibits both the single-stranded DNA (ssDNA)-dependent ATP hydrolysis and DNA strand exchange activities of RecA protein, As for wildtype LexA repressor (Rehrauer, W. M., Lavery, P. E., Palmer, E. L., Singh, R. N., and Kowalczykowski, S. C. (1996) J. Biol. Chem. 271, 23865-23873), inhibition of ATP hydrolysis is dependent upon the presence of E. coli single-stranded DNA binding (SSB) protein, arguing that LexA repressor affects the competition between RecA protein and SSB protein for ssDNA binding sites. In contrast, inhibition of DNA strand exchange activity is SSB protein-independent, suggesting that LexA S119A repressor blocks a site required for DNA strand exchange. These results imply that there is a common site on the RecA protein filament for secondary DNA and LexA repressor binding and raise the possibility that the recombination and co-protease activities of the RecA protein filament are competitive.	UNIV CALIF DAVIS,MICROBIOL SECT,DIV BIOL SCI,DAVIS,CA 95616; UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DIV BIOL SCI,DAVIS,CA 95616; UNIV CALIF DAVIS,GRAD GRP MICROBIOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; CHOW SA, 1988, J BIOL CHEM, V263, P200; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DICAPUA E, 1992, J MOL BIOL, V226, P707, DOI 10.1016/0022-2836(92)90627-V; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; KIM B, 1993, CELL, V73, P1165, DOI 10.1016/0092-8674(93)90645-7; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LAVERY PE, 1990, J BIOL CHEM, V265, P4004; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MADIRAJU MVVS, 1990, MOL GEN GENET, V224, P129, DOI 10.1007/BF00259459; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MAGEE TR, 1990, J BACTERIOL, V172, P1834, DOI 10.1128/jb.172.4.1834-1839.1990; MCENTEE K, 1977, J BACTERIOL, V132, P904, DOI 10.1128/JB.132.3.904-911.1977; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PUGH BF, 1988, J BIOL CHEM, V263, P76; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Rehrauer WM, 1996, J BIOL CHEM, V271, P23865, DOI 10.1074/jbc.271.39.23865; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5057, DOI 10.1021/bi00668a017; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SCHNARR M, 1984, FEBS LETT, V171, P207, DOI 10.1016/0014-5793(84)80489-5; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; SLILATY SN, 1986, BIOCHEMISTRY-US, V25, P6866, DOI 10.1021/bi00370a020; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P883; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254	53	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23874	23883		10.1074/jbc.271.39.23874	http://dx.doi.org/10.1074/jbc.271.39.23874			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798618	Green Submitted			2022-12-25	WOS:A1996VJ44200047
J	Wei, J; Wayman, G; Storm, DR				Wei, J; Wayman, G; Storm, DR			Phosphorylation and inhibition of type III adenylyl cyclase by calmodulin-dependent protein kinase II in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; CALCIUM; CELLS; CA2+; STIMULATION; EXPRESSION; ACCUMULATION; MOBILIZATION; NUCLEOTIDE; MECHANISM	Inhibition of type III adenylyl cyclase (III-AC) by intracellular Ca2+ in vivo provides a mechanism for attenuation of hormone-stimulated cAMP signals in olfactory epithelium, heart, and other tissues (Wayman, G. A., Impey, S., and Storm, D. R. (1995) J. Biol. Chem. 270, 21480-21486). Although the mechanism for Ca2+ inhibition of III-AC in vivo has not been defined, inhibition is not mediated by G(i), cAMP-dependent protein kinase, or protein kinase C. However, Ca2+-inhibition of III-AC is antagonized by KN-62, a CaM-dependent kinase inhibitor. In addition, constitutively activated CaM kinase II inhibits the enzyme. These data suggest that CaM kinase II regulates the activity of III-AC by direct phosphorylation or by an indirect mechanism involving phosphorylation of a protein that inhibits III-AC. Here we report that III-AC is phosphorylated in vivo when intracellular Ca2+ is increased and that phosphorylation is prevented by CaM-dependent kinase inhibitors. Site-directed mutagenesis of a CaM kinase II consensus site (Ser-1076 to Ala-1076) in III-AC greatly reduced Ca2+-stimulated phosphorylation and inhibition of III-AC in vivo. These data support the hypothesis that Ca2+ inhibition of III-AC is due to direct phosphorylation of the enzyme by CaM kinase II in vivo.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 44948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BIRNBAUMER L, 1973, BIOCHIM BIOPHYS ACTA, V300, P129, DOI 10.1016/0304-4157(73)90002-6; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BOYAJIAN CL, 1990, CELL CALCIUM, V11, P299, DOI 10.1016/0143-4160(90)90007-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; COLVIN RA, 1991, CELL CALCIUM, V12, P19, DOI 10.1016/0143-4160(91)90081-O; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GIANNATTASIO G, 1987, ENDOCRINOLOGY, V120, P2611, DOI 10.1210/endo-120-6-2611; HIRONO J, 1992, J NEUROSCI METH, V42, P185, DOI 10.1016/0165-0270(92)90098-X; JAWORSKY DE, 1995, J NEUROSCI, V15, P310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; NARAYANAN N, 1989, ENDOCRINOLOGY, V124, P484, DOI 10.1210/endo-124-1-484; Potter J D, 1980, Ann N Y Acad Sci, V356, P220, DOI 10.1111/j.1749-6632.1980.tb29613.x; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SAKAGAMI H, 1993, MOL BRAIN RES, V20, P51, DOI 10.1016/0169-328X(93)90109-3; SUGIMOTO M, 1989, ANAL BIOCHEM, V179, P309, DOI 10.1016/0003-2697(89)90134-6; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; Xia Z., 1996, REGULATORY PROPERTIE; YU HJ, 1993, MOL PHARMACOL, V44, P689	31	130	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24231	24235		10.1074/jbc.271.39.24231	http://dx.doi.org/10.1074/jbc.271.39.24231			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798667	hybrid			2022-12-25	WOS:A1996VJ44200096
J	Dorfman, K; Carrasco, D; Gruda, M; Ryan, C; Lira, SA; Bravo, R				Dorfman, K; Carrasco, D; Gruda, M; Ryan, C; Lira, SA; Bravo, R			Disruption of the erp/mkp-1 gene does not affect mouse development: Normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts	ONCOGENE			English	Article						erp; mkp-1 knockout; development; Erk1, Erk2 MAP kinases	PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; EMBRYONIC STEM-CELLS; HEAT-SHOCK; IN-VIVO; MESODERM INDUCTION; GROWTH-FACTORS; EXPRESSION; ACTIVATION	Externally regulated phosphatase (ERP or MKP-1) is a dual specificity phosphatase that has been implicated in the dephosphorylation of mitogen activated protein kinases (MAP kinases), MAP kinase is activated in response to external signals and in turn phosphorylates proteins essential to the regulation of cell growth, To study the role of ERP/MKP-1 protein in mammalian development and its function in signal transduction we have generated mice, embryonic stem (ES), cells and mouse embryo fibroblasts (MEFs) that are deficient in the ERP/MKP-1 protein, ERP/MKP-1-deficient mice are born at normal frequency, are fertile and present no phenotypic or histologic abnormalities, MAP kinase activity and the induction of c-fos mRNA is unaltered in MEFs lacking the ERP/MKP-1 protein, indicating no alteration of the MAP kinase pathway, In addition, ERP/MKP-1 deficient MEFs grow and enter DNA synthesis at the same rate as control cells, Our results demonstrate that the activity of ERP/MKP-1 is not essential for embryo development and indicate that the lack of ERP/MKP-1 activity can be compensated by other phosphatases in vivo.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BURKERT U, 1991, NEW BIOL, V3, P698; CARRASCO D, 1993, CELL GROWTH DIFFER, V4, P849; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DUFF JL, 1993, J BIOL CHEM, V268, P26037; EMSLIE EA, 1994, HUM GENET, V93, P513; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WILES MV, 1991, DEVELOPMENT, V111, P259; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; Wurst W., 1993, Gene targeting: a practical approach., P33; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	49	179	182	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					925	931						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806681				2022-12-25	WOS:A1996VG76600005
J	Fugazzola, L; Pierotti, MA; Vigano, E; Pacini, F; Vorontsova, TV; Bongarzone, I				Fugazzola, L; Pierotti, MA; Vigano, E; Pacini, F; Vorontsova, TV; Bongarzone, I			Molecular and biochemical analysis of RET/PTC4 a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer	ONCOGENE			English	Article						Chernobyl tumors; papillary thyroid carcinoma; RET arrangements; RET/PTC4	TRANSFORMING SEQUENCE; DNA REARRANGEMENT; ACTIVATION; PROTOONCOGENE; CARCINOMAS; CHILDREN; ACCIDENT; FUSION	A post-Chernobyl papillary thyroid cancer, displaying a novel ELE1/RET oncogenic rearrangement with an anomalous fusion transcript, was molecularly characterized, In spite of the presence of a normal breakpoint in exon 5 of the activating ELE1 gene, the sequence of the rearranged genomic DNA showed a previously unreported intra-exonic breakpoint in the RET proto-oncogene, As a consequence, a cDNA sequence 93 nucleotides larger than the regular one, and with the exon 5 of ELE1 joined to exon 11 instead of exon 12 of RET, is formed, To characterize the product of this new oncogenic ELE1/RET rearrangement, here designated as RET/PTC4, we performed an immunoprecipitation and Western blot analysis on cell extracts from NIH3T3 transfectants, The results showed the presence of two isoforms of the chimeric protein, displaying a constitutive tyrosine phosphorylation, As expected, the molecular weight of this protein was higher than that of RET/PTC3 protein (p80 and p85, instead of p76 and p81), Previous reports, from our and other laboratories, showed that post-Chernobyl papillary thyroid carcinomas are characterized by a high frequency (about 60%) of RET oncogenic rearrangements (Fugazzola et al., 1995; Klugbauer et al., 1995; Ito et al,, 1994), These events predominantly involve ELE1 activating sequence, thus producing RET/PTC3 oncogene (Fugazzola et al,, 1995; Klugbauer ef al., 1995), Hence, this elevated frequency of RET rearrangements could increase the probability of selecting unusual events as that here described, Alternatively, targeted radiation effects could be responsible for the atypical RET rearrangement producing RET/PTC4 oncogene.	IST NAZL TUMORI, DIV EXPT ONCOL A, I-20133 MILAN, ITALY; UNIV PISA, INST ENDOCRINOL, I-56018 PISA, ITALY; INST RADIAT MED, MINSK, BELARUS	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa			Fugazzola, Laura/F-2846-2011; Bongarzone, Italia/B-9544-2017	Bongarzone, Italia/0000-0003-2530-9170; Pierotti, Marco Alessandro/0000-0002-7431-8332				Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ITO T, 1994, LANCET, V344, P259; Klugbauer S, 1995, ONCOGENE, V11, P2459; KUNIEDA T, 1991, GENE, V107, P323, DOI 10.1016/0378-1119(91)90334-8; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOZZI G, 1994, GENE CHROMOSOME CANC, V9, P244, DOI 10.1002/gcc.2870090404; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1	15	98	120	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					1093	1097						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806699				2022-12-25	WOS:A1996VG76600023
J	Karlsson, T; Welsh, M				Karlsson, T; Welsh, M			Apoptosis of NIH3T3 cells overexpressing the Src homology 2 domain protein Shb	ONCOGENE			English	Article						Shb; Src homology 2 domain; Src homology 3 domain; NIH3T3 fibroblasts; apoptosis	DNA FRAGMENTATION; TYROSINE KINASE; NUCLEAR-DNA; FIBROBLASTS; ACTIVATION; RECEPTOR; DEATH	To understand the role of the Src homology 2 (SH2) domain protein Shb in the signal transduction of tyrosine kinase receptors, NIH3T3 cells were transfected with a DNA construct expressing the Shb cDNA (NIHSHB cells), The NIHSHB cells expressed elevated levels of proteins with the estimated molecular weights of 77, 66 and 55 kDa as determined by immunoblotting, In contrast to the control cells, the NIHSHB cells failed to increase in cell number in the presence of 1% serum, This effect was largely due to apoptosis, since staining of pyknotic nuclei was observed using the terminal transferase labeling method, The NIHSHB cells displayed similar levels of c-myc mRNA and decreased contents of the p53 protein after culture in 1% serum compared with control cells, The addition of platelet-derived growth factor (PDGF-BB) restored the growth of the NIHSHB cells, whereas insulin-like growth factor-1 (IGF-1) failed to affect the proliferation of Shb overexpressing cells in 1% serum, We conclude that Shb overexpression is associated with cell degeneration under certain conditions, and that Shb could transduce apoptotic signals from tyrosine kinase receptors.	UNIV UPPSALA,BIOMEDICUM,DEPT MED CELL BIOL,S-75123 UPPSALA,SWEDEN	Uppsala University			Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755				BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; KARLSSON T, 1995, ONCOGENE, V10, P1475; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; Maniatis T, 1982, MOL CLONING LABORATO; OBERHAMMER F, 1993, J CELL SCI, V104, P317; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; WELSH M, 1994, ONCOGENE, V9, P19; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128	23	30	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					955	961						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806685				2022-12-25	WOS:A1996VG76600009
J	Bollag, W				Bollag, W			The retinoid revolution	FASEB JOURNAL			English	Editorial Material											Bollag, W (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,CH-4070 BASEL,SWITZERLAND.								0	14	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					938	939		10.1096/fasebj.10.9.8801175	http://dx.doi.org/10.1096/fasebj.10.9.8801175			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801175				2022-12-25	WOS:A1996UY93200002
J	Murray, M; Butler, AM; Agus, C				Murray, M; Butler, AM; Agus, C			Restoration of cytochrome P450 2C11 in vitamin A-deficient rat liver by exogenous androgen	FASEB JOURNAL			English	Article						vitamin A deficiency; androgen; CYP2C11 regulation; steroid hydroxylation	HORMONAL-REGULATION; MESSENGER-RNA; RETINOIC ACID; HEPATIC CYTOCHROME-P-450; EXPRESSION; DRUG; ISOZYMES; ENZYMES; TESTOSTERONE; SUPPRESSION	Down-regulation of microsomal androgen-dependent CYP2C11 is produced in male rat liver by dietary vitamin A deficiency, Decreased circulating androgen concentrations also occur in vitamin A-deficient male rats, Both effects are prevented by addition of all-trans-retinoic acid to the diet, The present study evaluated directly whether androgen deficiency may be responsible for the down-regulation of 2C11 in vitamin A-deficient male rats, The major finding was that subcutaneous administration of the androgen methyltrienolone (MT) during the final week of the study restored CYP2C11 protein and its associated steroid 16 alpha-hydroxylation activities to control levels; CYP2C11 mRNA was also restored, Despite the efficient restoration of CYP2C11 at a pretranslational level, no alteration in vitamin A status was apparent and animals remained vitamin A deficient after MT treatment, The possibility was assessed that vitamin A can maintain the microsomal content of CYP2C11 in normal Liver, However, in contrast to MT, administration of ATRA to gonadectomized male rats did not restore 2C11 in liver, These findings establish that the major effect of vitamin A deficiency on CYP2C11 in male rat liver is mediated indirectly by androgen deficiency.			Murray, M (corresponding author), UNIV SYDNEY,DEPT MED,WESTMEAD HOSP,STORR LIVER UNIT,WESTMEAD,NSW 2145,AUSTRALIA.							AZAIS V, 1987, TOXICOLOGY, V44, P341, DOI 10.1016/0300-483X(87)90035-7; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BLOMHOFF R, 1992, ANNU REV NUTR, V12, P37, DOI 10.1146/annurev.nu.12.070192.000345; BREEN JJ, 1995, ENDOCRINOLOGY, V136, P543, DOI 10.1210/en.136.2.543; BUTLER AM, 1993, MOL PHARMACOL, V43, P902; CAMPBELL TC, 1974, PHARMACOL REV, V26, P171; CHAUDHARY LR, 1989, BIOCHEM BIOPH RES CO, V158, P400, DOI 10.1016/S0006-291X(89)80061-0; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EINARSSON K, 1973, J BIOL CHEM, V248, P4987; GUSTAFSSON JA, 1983, ANNU REV PHYSIOL, V45, P51, DOI 10.1146/annurev.ph.45.030183.000411; JANECZKO R, 1990, MOL ENDOCRINOL, V4, P295, DOI 10.1210/mend-4-2-295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC GA, 1988, J BIOL CHEM, V263, P15732; LEGRAVEREND C, 1992, FASEB J, V6, P711, DOI 10.1096/fasebj.6.2.1537461; LEMOINE A, 1988, EUR J BIOCHEM, V177, P597, DOI 10.1111/j.1432-1033.1988.tb14412.x; LIDDLE C, 1992, ARCH BIOCHEM BIOPHYS, V298, P159, DOI 10.1016/0003-9861(92)90107-8; LOWRY OH, 1951, J BIOL CHEM, V193, P3179; MALLO F, 1992, NEUROENDOCRINOLOGY, V55, P642, DOI 10.1159/000126183; MARTINI R, 1995, J PHARMACOL EXP THER, V273, P427; MARTINI R, 1994, BIOCHEM PHARMACOL, V48, P1305, DOI 10.1016/0006-2952(94)90170-8; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; MURRAY M, 1986, BIOCHEM PHARMACOL, V35, P1817, DOI 10.1016/0006-2952(86)90298-4; MURRAY M, 1983, TOXICOL APPL PHARM, V68, P66, DOI 10.1016/0041-008X(83)90355-1; MURRAY M, 1992, CHEM RES TOXICOL, V5, P60, DOI 10.1021/tx00025a010; NADIN L, 1995, GASTROENTEROLOGY, V109, P198, DOI 10.1016/0016-5085(95)90285-6; OMURA T, 1964, J BIOL CHEM, V239, P2370; RAM PA, 1991, MOL ENDOCRINOL, V5, P13, DOI 10.1210/mend-5-1-13; RENTON KW, 1976, BIOCHEM BIOPH RES CO, V73, P343, DOI 10.1016/0006-291X(76)90713-0; RICH KA, 1979, MOL CELL ENDOCRINOL, V13, P123, DOI 10.1016/0303-7207(79)90013-3; Sambrook J., 2002, MOL CLONING LAB MANU; SKETT P, 1982, BIOCHEM PHARMACOL, V32, P3115; SPORN MB, 1977, NUTR REV, V35, P65, DOI 10.1111/j.1753-4887.1977.tb06541.x; THUMMEL KE, 1990, MOL PHARMACOL, V37, P119; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAXMAN DJ, 1983, J BIOL CHEM, V258, P1937; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; YEOWELL HN, 1987, MOL PHARMACOL, V32, P340; YOSHIOKA H, 1987, J BIOL CHEM, V262, P1706	40	10	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1058	1063		10.1096/fasebj.10.9.8801167	http://dx.doi.org/10.1096/fasebj.10.9.8801167			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801167				2022-12-25	WOS:A1996UY93200016
J	Li, WQ; Li, W; Chen, XH; Kelley, CA; Alimandi, M; Zhang, JC; Chen, Q; Bottaro, DP; Pierce, JH				Li, WQ; Li, W; Chen, XH; Kelley, CA; Alimandi, M; Zhang, JC; Chen, Q; Bottaro, DP; Pierce, JH			Identification of tyrosine 187 as a protein kinase C-delta phosphorylation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATION; ACTIVATION; PKC	Protein kinase C-delta (PKC-delta) has been demonstrated to be phosphorylated on tyrosine residue(s) in many different biological systems (Li, W., Yu, J.-C., Michieli, P., Beeler, J. F., Ellmore, N., Heidaran, M. A., and Pierce, J. H. (1994) Mol. Cell. Biol. 14, 6727-6735; Li, W., Mischak, H., Yu, J.-C., Wang, L.-M., Mushinski, J. F., Heidaran, M. A., and Pierce, J. H. (1994) J. Biol. Chem. 269, 2349-2352; Denning, M. F., Dlugosz, A. A., Howett, M. A., and Yuspa, S. H. (1993) J. Biol. Chem. 268, 26079-26081). Tyrosine phosphorylation of PKC-delta has also been shown to occur in vitro when purified PKC-delta is coincubated with different tyrosine kinase sources. However, the tyrosine phosphorylation site(s) is currently unknown and the exact effect of this phosphorylation on its serine/threonine kinase activity and biological functions is still controversial. To directly investigate the potential role of PKC-delta tyrosine phosphorylation, tyrosine 187 was converted to phenylalanine (PKC-delta Y187F) by site-directed mutagenesis, and expression vectors containing PKC-delta Y187F cDNAs were transfected into both 32D myeloid progenitor cells and NIH 3T3 fibroblasts. The results showed that tyrosine 187 of PKC-delta became phosphorylated in vivo in response to 12-O-tetradecanoylphorbol-13-acetate stimulation or platelet-derived growth factor receptor activation. In vivo labeling and subsequent two-dimensional phosphopeptide analysis demonstrated that one phosphopeptide was absent in PKC-delta Y187F when compared to wild type PKC-delta, further substantiating that tyrosine 187 of PKC-delta is phosphorylated in vivo. Although the phosphotyrosine content of PKC-delta Y187F was reduced compared with PKC-delta WT, the kinase activity of PKC-delta Y187F toward a PKC-delta substrate was not altered. Moreover, 12-O-tetradecanoylphorbol-13-acetate-mediated monocytic differentiation of 32D cells was not affected by expression of the PKC-delta Y187F mutant. Taken together, these results suggest that tyrosine phosphorylation of PKC-delta on 187 may not influence PKC-delta activation and known functions.	UNIV CHICAGO, BEN MAY INST CANC RES, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; NHLBI, NATL INST HLTH, BETHESDA, MD 20892 USA	University of Chicago; University of Chicago; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Li, WQ (corresponding author), NCI, CELLULAR & MOL BIOL LAB, BLDG 37, RM 1E24, BETHESDA, MD 20892 USA.		Bottaro, Donald P/AAF-3853-2020; Alimandi, Maurizio/AAG-9246-2019; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Alimandi, Maurizio/0000-0002-1409-6803; Bottaro, Donald P/0000-0002-5057-5334				DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Li W, 1996, CURR TOP MICROBIOL, V211, P55; Li WQ, 1996, ONCOGENE, V13, P731; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMITH H, 1995, P NATL ACAD SCI USA, V92, P9112; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490	15	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26404	26409		10.1074/jbc.271.42.26404	http://dx.doi.org/10.1074/jbc.271.42.26404			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824297	hybrid			2022-12-25	WOS:A1996VN18000103
J	Taupiac, MP; Alami, M; Beaumelle, B				Taupiac, MP; Alami, M; Beaumelle, B			Translocation of full-length Pseudomonas exotoxin from endosomes is driven by ATP hydrolysis but requires prior exposure to acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A CHAIN; PURIFIED ENDOSOMES; ENDOCYTIC PATHWAY; DIPHTHERIA-TOXIN; GOLGI-APPARATUS; MEMBRANE; PROTEIN; RECEPTOR; CELL; CYTOTOXICITY	We attached human transferrin to Pseudomonas exotoxin A (PE) to specifically localize this toxin to the endosomal compartment and study its translocation from purified endosomes using a cell-free assay, Transferrin was linked to PE via a disulfide bond, Chemical derivatization inactivated the PE cell-binding domain, and transferrin-PE was found to be endocytosed via the transferrin receptor only, Transferrin was also conjugated to a truncated PE with no receptor-binding domain (PE46). After labeling mouse lymphocytes with radiolabeled transferrin-PE or transferrin-PE46 and endosome isolation, selective translocation of the full-sized toxin portion of the conjugate was observed in a cell-free system, This translocation was strictly dependent upon ATP hydrolysis and was not affected when the acidity of the endosome lumen was neutralized using weak bases, protonophores, or bafilomycin A(1), Nevertheless, when present during cell labeling, inhibitors of endosome acidification prevented PE from acquiring translocation competence, Similar inhibition was observed when endocytosis was performed in the presence of brefeldin A, a drug known to interfere with the delivery of endocytic tracers to acidic endosomes, Our data indicate that full-length PE can be transferred to the cytosol directly from endosomes during intoxication by PE conjugates and that, although exposure to acidic pH is a prerequisite for translocation, ATP hydrolysis directly provides the energy required for PE translocation.	UNIV MONTPELLIER 2,CNRS,UMR 5539,DEPT BIOL SANTE,F-34095 MONTPELLIER 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier				Beaumelle, Bruno/0000-0002-4912-9134				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; BEAUMELLE B, 1993, J BIOL CHEM, V268, P23661; BEAUMELLE BD, 1989, BIOCHEM J, V264, P137, DOI 10.1042/bj2640137; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; DOMINGO DL, 1985, METHOD ENZYMOL, V112, P238; DOUGLAS CM, 1987, J BACTERIOL, V169, P4962, DOI 10.1128/jb.169.11.4962-4966.1987; FISHMAN A, 1994, BIOCHEMISTRY-US, V33, P6235, DOI 10.1021/bi00186a025; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; JIANG JX, 1990, J BIOL CHEM, V265, P8636; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KONDO T, 1988, J BIOL CHEM, V263, P9470; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KREITMAN RJ, 1995, BIOCHEM J, V307, P29, DOI 10.1042/bj3070029; MARSH JW, 1988, J BIOL CHEM, V263, P15993; MELLBY EL, 1991, J CELL BIOCHEM, V47, P251; MORRIS RE, 1986, INFECT IMMUN, V52, P445, DOI 10.1128/IAI.52.2.445-453.1986; Olsnes S., 1988, IMMUNOTOXINS, P39; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; RASO V, 1984, J BIOL CHEM, V259, P1143; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIMMONS BM, 1986, J BIOL CHEM, V261, P7912; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; WHITNEY JA, 1995, CELL, V83, P703; WU YN, 1994, J CELL BIOL, V125, P743, DOI 10.1083/jcb.125.4.743; YAZDI PT, 1994, CANCER RES, V54, P6387; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	32	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26170	26173		10.1074/jbc.271.42.26170	http://dx.doi.org/10.1074/jbc.271.42.26170			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824263	hybrid, Green Published			2022-12-25	WOS:A1996VN18000069
J	Vaziri, C; Schneider, A; Sherr, DH; Faller, DV				Vaziri, C; Schneider, A; Sherr, DH; Faller, DV			Expression of the aryl hydrocarbon receptor is regulated by serum and mitogenic growth factors in murine 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; GENE-EXPRESSION; C-MYC; CELLS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; TRANSCRIPTION; INHIBITION; MECHANISM; TCDD	The aryl-hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates biological responses to planar aromatic hydrocarbons such as benzo[a]pyrene. However, no endogenous physiological ligand for the AhR has been identified, Since the AhR regulates bioactivity to common environmental pollutants, and since it is predicted to play an important physiological function, we have investigated the expression of the AhR during the cell cycle of murine 3T3 fibroblasts. We show here that stimulation of growth-arrested 3T3 cells with serum results in increased expression of AhR protein, Serum-induced expression of AhR in synchronized, serum-stimulated cells occurs at the onset of DNA synthesis (S phase) and is maximal at time points corresponding to late S phase. Transient transfections with an AhR-promoter-luciferase construct demonstrate that reporter gene transcription from the AhR promoter is regulated in a serum-dependent manner. Serum-dependent induction of AhR expression is prevented by an inhibitor of tyrosine kinase activity, Ligand-activated growth factor receptors (platelet-derived growth factor receptor basic fibroblast growth factor receptor) as well as an ectopically expressed tyrosine kinase (the v-Src oncoprotein) induce AhR expression in the absence of serum, Therefore, tyrosine kinase signaling is both necessary and sufficient for induction of AhR expression. Studies with the G(1) blocker sodium butyrate show that the signal transduction pathways mediating serum-stimulated progression through the cell cycle are distinct from those that induce AhR expression. These data suggest that transcriptional regulation of the AhR is important in determining cellular sensitivity to the actions of AhR Ligand(s) and that the AhR may play a role during the cellular proliferative response.	BOSTON UNIV,SCH MED,SCH PUBL HLTH,BOSTON,MA 02118	Boston University	Vaziri, C (corresponding author), BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118, USA.			Sherr, David/0000-0003-3353-0553	NCI NIH HHS [CA 50459] Funding Source: Medline; NIEHS NIH HHS [1P42ES 07381, R01-ES06086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006086, P42ES007381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; DEAN M, 1986, J BIOL CHEM, V261, P9161; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; McDonnell WM, 1996, SCIENCE, V271, P223; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS JM, 1995, TOXICOL APPL PHARM, V134, P214, DOI 10.1006/taap.1995.1186; PHILLIPS M, 1995, J CELL SCI, V108, P395; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROLLINS BJ, 1987, SCIENCE, V238, P1269, DOI 10.1126/science.3685976; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SALGUERO PF, 1995, SCIENCE, V268, P722; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; SWANSON HI, 1993, ARCH BIOCHEM BIOPHYS, V302, P167, DOI 10.1006/abbi.1993.1195; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	24	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25921	25927		10.1074/jbc.271.42.25921	http://dx.doi.org/10.1074/jbc.271.42.25921			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824226				2022-12-25	WOS:A1996VN18000032
J	Ptasznik, A; Prossnitz, ER; Yoshikawa, D; Smrcka, A; TraynorKaplan, AE; Bokoch, GM				Ptasznik, A; Prossnitz, ER; Yoshikawa, D; Smrcka, A; TraynorKaplan, AE; Bokoch, GM			A tyrosine kinase signaling pathway accounts for the majority of phosphatidylinositol 3,4,5-trisphosphate formation in chemoattractant-stimulated human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOINOSITIDE 3-KINASE ACTIVITY; MYELOID-DERIVED CELLS; PHOSPHOLIPASE-C; SH2 DOMAINS; ACTIVATED NEUTROPHILS; PROTEIN-KINASES; BINDING; TRANSDUCTION; INHIBITOR	The signaling pathway leading from G protein-coupled chemoattractant receptors to the generation of oxidants by NADPH oxidase in human neutrophils requires the formation of the lipid mediator phosphatidylinositol 3,4,5-trisphosphate (PIP3). Two mechanisms through which PIP3 can be generated have been described in human leukocytes. One pathway involves the coupling of the src-related tyrosine kinase Lyn to the ''classical'' p85/p110 form of phosphatidylinositol 3-kinase. The second paradigm utilizes a novel form of phosphatidylinositol 3-kinase whose activity is directly regulated by G protein beta gamma subunits. In this paper, we show that formation of PIP3 in chemoattractant-stimulated neutrophils is substantially attenuated by inhibitors that specifically block tyrosine kinase activity. These data suggest that the Lyn activation pathway plays a major role in the formation of this important lipid messenger during chemoattractant stimulation of human neutrophils.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV ROCHESTER, MED CTR, DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of Rochester; University of California System; University of California San Diego	Ptasznik, A (corresponding author), Scripps Res Inst, DEPT IMMUNOL IMM14, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302	NIDDK NIH HHS [DK47240] Funding Source: Medline; NIGMS NIH HHS [GM39434, GM44428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428, R01GM039434] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOKOCH GM, 1991, CURRENT TOPICS MEMBR, P65; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LEW DP, 1993, CURRENT OPINION HEMA, P106; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1994, CURR OPIN IMMUNOL, V6, P106, DOI 10.1016/0952-7915(94)90041-8; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	45	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25204	25207		10.1074/jbc.271.41.25204	http://dx.doi.org/10.1074/jbc.271.41.25204			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810279	hybrid			2022-12-25	WOS:A1996VL69300023
J	Kataoka, K; Mizushima, T; Ogata, Y; Miki, T; Sekimizu, K				Kataoka, K; Mizushima, T; Ogata, Y; Miki, T; Sekimizu, K			Heat shock-induced DNA relaxation in vitro by DNA gyrase of Escherichia coli in the presence of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICKING-CLOSING ENZYME; TOPOISOMERASE-IV; NALIDIXIC-ACID; NALA-GENE; PURIFICATION; PROTEINS; MUTATIONS; INDUCTION; MUTANTS; INVITRO	Genetic studies revealed that DNA gyrase seems to catalyze immediate and transient DNA relaxation after Escherichia coli cells are exposed to heat shock (Ogata, Y., Mizushima, T., Kataoka, K., Miki, T., and Sekimizu, K. (1994) Mol. Gen. Genet. 244, 451-455). We have now obtained biochemical evidence to support this hypothesis. DNA gyrase catalyzed an increase in the linking number of DNA and relaxation of negatively supercoiled DNA, under physiological concentrations of ATP. Analyses by gel filtration chromatography of each subunit revealed that DNA relaxation activity co-migrated with each subunit. The linking number of DNA increased as the temperature increased. Further, the reaction was inhibited by nalidixic acid or by oxolinic acid. Based on these results, we propose that DNA gyrase participates in a concerted reaction with DNA topoisomerases in the immediate relaxation of DNA in cells exposed to heat shock.	KYUSHU UNIV, FAC PHARMACEUT SCI, DEPT MICROBIOL, FUKUOKA 81282, JAPAN; TOKAI UNIV, INST MED SCI, DEPT PARASITOL, TOKYO 108, JAPAN	Kyushu University; Tokai University				Ogata, Yasuyuki/0000-0003-0316-0109				BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; COZZARELLI NR, 1980, SCIENCE, V207, P953, DOI 10.1126/science.6243420; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; ESPOSITO F, 1987, NUCLEIC ACIDS RES, V15, P5105, DOI 10.1093/nar/15.13.5105; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1980, COLD SPRING HARB SYM, V45, P391; GELLERT M, 1981, ENZYMES, V14, P345; HAQ S, 1993, J BIOCHEM, V113, P620, DOI 10.1093/oxfordjournals.jbchem.a124092; Kaneko T, 1996, MOL GEN GENET, V250, P593; KATO J, 1992, J BIOL CHEM, V267, P25676; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; KREUZER KN, 1978, MOL GEN GENET, V167, P129, DOI 10.1007/BF00266906; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; MAKI S, 1992, J BIOL CHEM, V267, P12244; MIZUSHIMA T, 1993, MOL GEN GENET, V238, P1; MIZUSHIMA T, 1994, FEMS MICROBIOL LETT, V121, P333, DOI 10.1016/0378-1097(94)90313-1; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; OGATA Y, 1994, MOL GEN GENET, V244, P451, DOI 10.1007/BF00583895; PENG H, 1993, J BIOL CHEM, V268, P24481; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1969, J MOL BIOL, V43, P25, DOI 10.1016/0022-2836(69)90076-X; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JY, 1992, MOL MICROBIOL, V6, P1861, DOI 10.1111/j.1365-2958.1992.tb01358.x	32	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24806	24810		10.1074/jbc.271.40.24806	http://dx.doi.org/10.1074/jbc.271.40.24806			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798753	hybrid			2022-12-25	WOS:A1996VM67400075
J	Krohn, M; Wagner, R				Krohn, M; Wagner, R			Transcriptional pausing of RNA polymerase in the presence of guanosine tetraphosphate depends on the promoter and gene sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL STRINGENT CONTROL; STARVED ESCHERICHIA-COLI; AMINO-ACID STARVATION; GROWTH-RATE CONTROL; RIBOSOMAL-RNA; PLASMID PBR322; INVITRO TRANSCRIPTION; TERNARY COMPLEXES; HISTIDINE OPERON; CHAIN ELONGATION	We have studied the response of the effector molecule guanosine 3',5'-bisdiphosphate (ppGpp) on RNA polymerase pausing during in vitro transcription elongation. Pausing was followed during single round extension of stalled ternary complexes excluding possible ppGpp effects on initiation. The ppGpp dependences of early pausing sites within different transcription systems controlled by promoters with known response to enhanced ppGpp levels in vivo were quantitatively characterized. Transcription of stable RNAs and mRNA genes were analyzed. In addition, the in vitro pausing behavior of two promoter variants directing the same sequence but differing in their in vivo ppGpp sensitivity were compared. In the presence of ppGpp we noted a slight general enhancement of specific pauses in all transcription systems. However, genes known to be un der stringent or growth rate control in vivo revealed a notably stronger pausing enhancement. The sites of pausing are not changed by the presence of ppGpp but appear to be sequence-specific. The effect of ppGpp on the extent of pausing depends on the particular promoter and closely adjacent sequences that the RNA polymerase has passed during initiation. Pausing enhancement requires the presence of ppGpp during elongation but not during initiation. The results underline the importance of pausing for transcription regulation and offer a plausible explanation for inhibition of stable RNA expression under conditions of elevated concentrations of ppGpp.	UNIV DUSSELDORF,INST PHYS BIOL,D-40225 DUSSELDORF,GERMANY	Heinrich Heine University Dusseldorf								ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; AXELROD VD, 1978, NUCLEIC ACIDS RES, V5, P3549, DOI 10.1093/nar/5.10.3549; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BREMER H, 1995, BBA-GENE STRUCT EXPR, V1262, P15, DOI 10.1016/0167-4781(95)00042-F; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4636; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; GAFNY R, 1994, J MOL BIOL, V243, P152, DOI 10.1006/jmbi.1994.1641; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GAUSING K, 1977, J MOL BIOL, V115, P335, DOI 10.1016/0022-2836(77)90158-9; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; GLASS RE, 1986, MOL GEN GENET, V203, P265, DOI 10.1007/BF00333964; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HECKER M, 1983, MOL GEN GENET, V190, P355, DOI 10.1007/BF00330665; HERMAN A, 1994, MOL GEN GENET, V243, P374, DOI 10.1007/BF00280467; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1983, BIOCHEMISTRY-US, V22, P5249, DOI 10.1021/bi00292a002; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; KLOTSKY RA, 1987, GENE, V55, P141, DOI 10.1016/0378-1119(87)90257-5; KROHN M, 1992, MOL MICROBIOL, V6, P581, DOI 10.1111/j.1365-2958.1992.tb01504.x; KROHN M, 1995, ANAL BIOCHEM, V225, P188, DOI 10.1006/abio.1995.1138; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LIEBIG B, 1995, MOL GEN GENET, V249, P328, DOI 10.1007/BF00290534; LINCHAO S, 1986, MOL GEN GENET, V203, P150, DOI 10.1007/BF00330396; LINCHAO S, 1986, MOL GEN GENET, V203, P143, DOI 10.1007/BF00330395; LITTLE R, 1983, J BACTERIOL, V154, P787, DOI 10.1128/JB.154.2.787-792.1983; MIZUSHIMASUGANO J, 1985, EMBO J, V4, P1053, DOI 10.1002/j.1460-2075.1985.tb03738.x; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OHLSEN KL, 1992, J BACTERIOL, V174, P6071, DOI 10.1128/JB.174.19.6071-6075.1992; OWENS JR, 1987, BIOCHEM BIOPH RES CO, V142, P964, DOI 10.1016/0006-291X(87)91508-7; PARDON B, 1994, BIOL CHEM H-S, V375, P11, DOI 10.1515/bchm3.1994.375.1.11; PARDON B, 1995, NUCLEIC ACIDS RES, V23, P932, DOI 10.1093/nar/23.6.932; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHETTERS H, 1972, BIOCHIM BIOPHYS ACTA, V272, P549, DOI 10.1016/0005-2787(72)90510-2; SCHROETER A, 1988, J BASIC MICROB, V28, P553, DOI 10.1002/jobm.3620280818; SORENSEN MA, 1994, J MOL BIOL, V236, P441, DOI 10.1006/jmbi.1994.1156; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; TEDIN K, 1992, J BIOL CHEM, V267, P2337; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; THEISSEN G, 1990, ANAL BIOCHEM, V189, P254, DOI 10.1016/0003-2697(90)90117-R; TIPPNER D, 1994, MOL MICROBIOL, V11, P589, DOI 10.1111/j.1365-2958.1994.tb00339.x; TOMIZAWA J, 1981, P NATL ACAD SCI-BIOL, V78, P1421, DOI 10.1073/pnas.78.3.1421; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; TRAVERS AA, 1986, J MOL BIOL, V189, P251, DOI 10.1016/0022-2836(86)90397-9; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VINCENTE M, 1991, MOL MICROBIOL, V5, P2085; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; VOGEL U, 1994, J BIOL CHEM, V269, P16236; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x; WOODY AYM, 1987, BIOCHIM BIOPHYS ACTA, V909, P115, DOI 10.1016/0167-4781(87)90033-9; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; ZACHARIAS M, 1990, NUCLEIC ACIDS RES, V18, P6271, DOI 10.1093/nar/18.21.6271; ZACHARIAS M, 1989, EMBO J, V8, P3357, DOI 10.1002/j.1460-2075.1989.tb08498.x	71	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23884	23894		10.1074/jbc.271.39.23884	http://dx.doi.org/10.1074/jbc.271.39.23884			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798619	hybrid			2022-12-25	WOS:A1996VJ44200048
J	Aronica, MG; Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L				Aronica, MG; Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L			p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells	ONCOGENE			English	Article						leukemia; growth factors; signaling; STATs	COLONY-STIMULATING FACTOR; ACUTE MYELOBLASTIC-LEUKEMIA; JAK2 TYROSINE KINASE; COMMON BETA-SUBUNIT; GM-CSF RECEPTOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; BLAST CELLS; PROLIFERATIVE RESPONSE; TRANSCRIPTION FACTOR	Interleukin-3 (IL-3) stimulates in vitro blast cell proliferation in a consistent proportion of acute myeloid leukemia (AML) cases, however the degree of response varies from case to case and it is not related to the FAB subtype or to other clinical parameters, IL-3-induced proliferation of myeloid cells is mediated by the interaction with an heterodimeric receptor (IL-3R) comprised of a ligand binding subunit denoted alpha and a common transducing subunit designated as beta (beta(c)). Ligand binding to the receptor activates a number of signaling molecules including proteins of the STATs (signal transducing and activators of transcription) family, To elucidate the mechanisms responsible for the abnormal proliferative response of AML cells to IL-3, we evaluated, both in the IL-3-dependent M-07e cell line and in 20 AML cases, the activation of STAT1 p91 and its association with the beta(c) subunit, On the basis of the in vitro proliferation assay, 11 out of 20 cases were found to be responsive to IL-3 and eight out of 16 to GM-CSF, Our results demonstrated that in M-07e cells and in six AML cases (five IL-3 responsive and one unresponsive) p91 tyrosine phosphorylation was ligand dependent, Ligand independent p91 tyrosine phosphorylation was detected in 10 AML cases (five responsive and five unresponsive), p91 association with the beta(c) subunit was consistent with its ligand dependent activation and with the ability to form a DNA-binding complex containing p91, In the remaining four cases (three unresponsive and one responsive) no p91 tyrosine phosphorylation and/or association were detected, These findings, together with the observation that in five IL-3 responsive cases p91 was constitutively phosphorylated, suggest that IL-3-mediated AML proliferation is only partially sustained by p91 activation and that other post-receptor molecules are required to achieve maximal proliferative response, Moreover structural abnormalities of the receptor or of post-receptor signaling proteins may account for the constitutive p91 phosphorylation and growth factor independent proliferation observed in the unresponsive AML cases.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,TURIN,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; Weizmann Institute of Science			Brizzi, Maria Felice/J-7882-2016; YARDEN, YOSEF/K-1467-2012					AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; AVANZI GC, 1991, CANCER RES, V51, P1741; BASHEY A, 1992, BLOOD, V79, P981; BEGLEY CG, 1987, LEUKEMIA, V1, P1; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; BRIZZI MF, 1995, BRIT J HAEMATOL, V90, P258, DOI 10.1111/j.1365-2141.1995.tb05145.x; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; BUDEL LM, 1990, BLOOD, V75, P1439; BUDEL LM, 1989, BLOOD, V74, P565; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DELWEL R, 1988, BLOOD, V72, P1944; DELWEL R, 1987, BLOOD, V70, P333; GAVOSTO F, 1964, NATURE, V203, P92, DOI 10.1038/203092a0; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRIFFIN JD, 1986, BLOOD, V67, P1448; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOANG T, 1986, BLOOD, V68, P313; HORIE M, 1993, J BIOL CHEM, V268, P968; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IKEDA H, 1991, BLOOD, V78, P2962; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; JUBINSKY PT, 1994, BLOOD, V84, P4174, DOI 10.1182/blood.V84.12.4174.bloodjournal84124174; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEARY AG, 1987, BLOOD, V70, P1343; MCCOLL SR, 1991, BLOOD, V78, P1842; MIYAUCHI J, 1987, BLOOD, V70, P657; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OKUDA K, 1992, BLOOD, V79, P2880; PAZDRAK K, 1995, J IMMUNOL, V155, P397; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RADICH JP, 1990, BLOOD, V76, P801; REILLY IAG, 1989, BRIT J HAEMATOL, V72, P363, DOI 10.1111/j.1365-2141.1989.tb07717.x; REILLY IAG, 1989, LEUKEMIA, V3, P145; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SADOWSKI HB, 1993, NATURE, V366, P580; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOKSOZ D, 1987, ONCOGENE, V1, P409; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VELLENGA E, 1987, LEUKEMIA, V1, P584; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YOUNG DC, 1986, BLOOD, V68, P1178; ZHONG Z, 1994, SCIENCE, V265, P1701; [No title captured]	62	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1017	1026						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806691				2022-12-25	WOS:A1996VG76600015
J	Chik, CL; Li, B; Ogiwara, T; Ho, AK; Karpinski, E				Chik, CL; Li, B; Ogiwara, T; Ho, AK; Karpinski, E			PACAP modulates L-type Ca2+ channel currents in vascular smooth muscle cells: Involvement of PKC and PKA	FASEB JOURNAL			English	Article						cAMP; L-type Ca2+ current; protein kinase C	CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN-KINASE-C; SENSITIVE CALCIUM-CHANNEL; ADENYLATE-CYCLASE; CYCLIC-AMP; K+ CHANNEL; SIGNAL-TRANSDUCTION; PARATHYROID-HORMONE; RECEPTOR-BINDING; BLOOD-FLOW	he effect of pituitary adenylate cyclase activating polypeptide (PACAP) on the L-type Ca2+ channel current (L-channel current) was studied in smooth muscle cells prepared from the rat tail artery, PACAP caused an increase in the amplitude of the L-channel current, The maximal increase (56%) occurred at a PACAP concentration of 1 x 10(-8) M; higher concentrations resulted in a smaller increase, Investigation into the intracellular mechanisms of PACAP action revealed that the increase in L-channel currents was blocked by calphostin C and bisindolylmaleimide IV [protein kinase C (PKC) inhibitors] and mimicked by 4 beta-phorbol 12-myristate 13-acetate (PMA), an activator of PKC, PACAP was also found to cause translocation of PKC, suggesting that the increase in the current by PACAP was due to PKC. In contrast, activation of cAMP-dependent protein kinase (PKA) by 8-bromo-cAMP caused an inhibition of the L-channel current. A high concentration of PACAP (1x10(-6) M) had no effect on the L-channel current, The null effect of PACAP on the L-channel current could be converted to an increase by Rp-cAMPs, a cAMP antagonist, and a decrease by calphostin C. PACAP also increased cAMP accumu lation. These observations indicate the effect of PACAP on the L-channel current represents the integration of two signaling mechanisms that involve the activation of PKA and PKC.	UNIV ALBERTA,DEPT PHYSIOL,EDMONTON,AB T6G 2H7,CANADA	University of Alberta	Chik, CL (corresponding author), UNIV ALBERTA,DEPT MED,ROOM 733,MED SCI BLDG,EDMONTON,AB T6G 2H7,CANADA.							ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BRAHA O, 1993, J NEUROSCI, V13, P1839; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHIK CL, 1995, J NEUROCHEM, V64, P2111; CHRISTOPHE J, 1993, BIOCHIM BIOPHYS ACTA, V1154, P183, DOI 10.1016/0304-4157(93)90011-C; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DAVIS PD, 1992, J MED CHEM, V35, P177, DOI 10.1021/jm00079a024; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; GALLIZI JP, 1987, J BIOL CHEM, V262, P6947; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HO AK, 1994, BIOCHEM BIOPH RES CO, V200, P569, DOI 10.1006/bbrc.1994.1486; HO AK, 1988, J BIOL CHEM, V263, P9292; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HUANG M, 1993, PEPTIDES, V14, P755, DOI 10.1016/0196-9781(93)90109-T; MINKES RK, 1992, J APPL PHYSIOL, V72, P212; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; NANDHA KA, 1991, J ENDOCRINOL, V129, P69, DOI 10.1677/joe.0.1290069; NARUSE S, 1993, PEPTIDES, V14, P505, DOI 10.1016/0196-9781(93)90139-8; NOWYCKY MC, 1985, P NATL ACAD SCI USA, V82, P2178, DOI 10.1073/pnas.82.7.2178; PAYET MD, 1992, J BIOL CHEM, V267, P18270; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; ROSSASCUITTO NT, 1993, PEDIATR RES, V34, P323, DOI 10.1203/00006450-199309000-00017; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; UDDMAN R, 1993, J CEREBR BLOOD F MET, V13, P291, DOI 10.1038/jcbfm.1993.36; WANG R, 1991, J PHYSIOL-LONDON, V441, P325, DOI 10.1113/jphysiol.1991.sp018754; WANG R, 1991, FEBS LETT, V282, P331, DOI 10.1016/0014-5793(91)80507-Y; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WARREN JB, 1991, EUR J PHARMACOL, V197, P131, DOI 10.1016/0014-2999(91)90511-N; XIONG ZL, 1994, J VASC RES, V31, P271, DOI 10.1159/000159053	38	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1310	1317		10.1096/fasebj.10.11.8836045	http://dx.doi.org/10.1096/fasebj.10.11.8836045			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836045				2022-12-25	WOS:A1996VJ71700011
J	Chen, WN; Chen, S; Yap, SF; Lim, L				Chen, WN; Chen, S; Yap, SF; Lim, L			The Caenorhabditis elegans p21-activated kinase (CePAK) colocalizes with CeRac1 and CDC42Ce at hypodermal cell boundaries during embryo elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; PROTEIN-KINASE; MOLECULAR-CLONING; RAC1; RAS; AUTOPHOSPHORYLATION; IDENTIFICATION; DROSOPHILA; EXPRESSION; FILOPODIA	The p21-activated kinase (PAK) is a downstream target of Rac and CDC42, members of the Ras-related Rho subfamily, that mediates signaling pathway leading to cytoskeletal reorganization. To investigate its function in Caenorhabditis elegans development, we have isolated the cDNA coding for the p21-activated kinase homologue (CePAK) from a C. elegarts embryonic cDNA library, This 2.35-kilobase pair cDNA encodes a polypeptide of 572 amino acid residues, with the highly conserved N-terminal p21-binding and the C-terminal kinase domains, Similar to its mammalian and Drosophila counterparts, the CePAK protein expressed in E. coli exhibits binding activity toward GTP-bound CeRac1 and CDC42Ce. Polyclonal antibodies raised against the recombinant CePAK recognize a specific 70-kDa protein from embryonic extracts that displays CeRac1/CDC42Ce-binding and kinase activities, Immunofluorescence analysis indicates that CePAK is specifically expressed at the hypodermal cell boundaries during embryonic body elongation, which involves dramatic cytoskeletal reorganization. Interestingly, CeRac1 and CDC42Ce are found at the same location, which might point to their common involvement in hypodermal cell fusion, a crucial morphogenetic event for nematode development.	INST NEUROL, LONDON WC1N 1PJ, ENGLAND; NATL UNIV SINGAPORE, INST MOL & CELL BIOL, GLAXO IMCB GRP, SINGAPORE 119260, SINGAPORE	University of London; University College London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; National University of Singapore				, Yang/0000-0002-6620-8897				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHEN WI, 1993, J BIOL CHEM, V268, P320; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CHEN WN, 1994, J BIOL CHEM, V269, P32394; CHEN WN, 1994, J BIOL CHEM, V269, P820; COUSUHRESKO M, 1994, J CELL BIOL, V124, P491; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Harden N, 1996, MOL CELL BIOL, V16, P1896; HARDEN N, 1995, DEVELOPMENT, V121, P903; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lloyd CW, 1989, CURR OPIN CELL BIOL, V1, P30, DOI 10.1016/S0955-0674(89)80033-X; LU XY, 1990, J BIOL CHEM, V265, P3293; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Miller DM, 1995, METHOD CELL BIOL, V48, P365; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sardet Christian, 1994, Trends in Cell Biology, V4, P166, DOI 10.1016/0962-8924(94)90201-1; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TUCKER JB, 1976, J CELL BIOL, V71, P207, DOI 10.1083/jcb.71.1.207; Wood WB, 1988, NEMATODE CAENORHABDI, P587	34	44	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26362	26368		10.1074/jbc.271.42.26362	http://dx.doi.org/10.1074/jbc.271.42.26362			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824291	hybrid			2022-12-25	WOS:A1996VN18000097
J	Crute, BE; Lewis, AF; Wu, ZN; Bushweller, JH; Speck, NA				Crute, BE; Lewis, AF; Wu, ZN; Bushweller, JH; Speck, NA			Biochemical and biophysical properties of the core-binding factor alpha 2 (AML1) DNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTEIN SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; RUNT DOMAIN; P-LOOP; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; GENE RUNT; EXPRESSION	The Runt domain is the DNA-binding domain defining a small family of transcription factors that are involved in important developmental processes. Developmental pathways controlled by Runt domain proteins include sex determination, neurogenesis, segmentation, and eye development in Drosophila and hematopoiesis in mammals. In addition to binding DNA, the Runt domain also mediates heterodimerization with another subunit called the core-binding factor beta (CBF beta) subunit. In this study we overexpress the Runt domain from the mouse CBF alpha 2 (AML1) protein in Escherichia coli, and purify it from the insoluble fraction. We determine the equilibrium constants for Runt domain binding to two different DNA sequences by surface plasmon resonance technology. Circular dichroism spectroscopy demonstrates that the Runt domain is a folded beta-domain with essentially no alpha-helical content. The single tryptophan residue in the CBF alpha 2 Runt domain at amino acid 79 is shown by tryptophan fluorescence spectroscopy to reside in a polar environment. Finally, we demonstrate that ATP can be UV cross-linked to the Runt domain and that ATP binding is sensitive to an amino acid substitution in the putative Kinase-1a motif (P-loop).	DARTMOUTH COLL,SCH MED,DEPT CHEM,HANOVER,NH 03755; DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; DARTMOUTH COLL,SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755	Dartmouth College; Dartmouth College; Dartmouth College				Bushweller, John/0000-0002-5386-1758	NCI NIH HHS [CA09658, CA58343] Funding Source: Medline; NIAID NIH HHS [AI07363] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058343, T32CA009658] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; ETFINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hall DR, 1996, ANAL BIOCHEM, V235, P175, DOI 10.1006/abio.1996.0109; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INGHAM P, 1988, DEVELOPMENT, V104, P51; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCABIVIK S, 1994, INT J BIOCHEM, V26, P61, DOI 10.1016/0020-711X(94)90196-1; Lakowicz JR, 1983, PRINCIPLES FLUORESCE, P187, DOI 10.1007/978-1-4615-7658-7_7; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pace C N, 1986, Methods Enzymol, V131, P266; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; YANKIE L, 1995, BIOCHEMISTRY-US, V34, P2188, DOI 10.1021/bi00007a012	57	52	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26251	26260		10.1074/jbc.271.42.26251	http://dx.doi.org/10.1074/jbc.271.42.26251			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824275	hybrid			2022-12-25	WOS:A1996VN18000081
J	Takagi, Y; Conaway, RC; Conaway, JW				Takagi, Y; Conaway, RC; Conaway, JW			Characterization of Elongin C functional domains required for interaction with Elongin B and activation of Elongin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR-SIII; TUMOR-SUPPRESSOR PROTEIN; MYELOID-LEUKEMIA; LEUCINE ZIPPER; FACTOR-EPSILON; ELONGATION; CLONING; BINDING; T(11-19)(Q23-P13.1)	The Elongin (SIII) complex stimulates the rate of elongation by RNA polymerase II by suppressing transient pausing by polymerase at many sites along DNA templates. The Elongin (SIII) complex is composed of a transcriptionally active A subunit, a chaperone-like B subunit, which promotes assembly and enhances stability of the Elongin (SIII) complex, and a regulatory C subunit, which (i) functions as a potent activator of Elongin A transcriptional activity, (ii) interacts specifically with Elongin B to form an isolable Elongin BC complex, and (iii) is bound and negatively regulated in vitro by the product of the von Hippel-Lindau tumor suppressor gene. As part of our effort to understand how Elongin C regulates the activity of the Elongin (SIII) complex, we are characterizing Elongin C functional domains. In this report, we identify Elongin C mutants that fall into multiple functional classes based on their abilities to bind Elongin B and to bind and activate Elongin A under our assay conditions. Characterization of these mutants suggests that Elongin C is composed of multiple overlapping regions that mediate functional interactions with Elongin A and B.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1994, TRANSCRIPTION MECHAN, P263; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; TAN SY, 1994, BIOTECHNIQUES, V16, P824; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250	34	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25562	25568		10.1074/jbc.271.41.25562	http://dx.doi.org/10.1074/jbc.271.41.25562			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810329	hybrid			2022-12-25	WOS:A1996VL69300073
J	Isomoto, S; Kondo, C; Yamada, M; Matsumoto, S; Higashiguchi, O; Horio, Y; Matsuzawa, Y; Kurachi, Y				Isomoto, S; Kondo, C; Yamada, M; Matsumoto, S; Higashiguchi, O; Horio, Y; Matsuzawa, Y; Kurachi, Y			A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INWARD RECTIFIER; CARDIAC-MUSCLE; GLIBENCLAMIDE; CELLS; INHIBITION	We have isolated a cDNA encoding a novel isoform of the sulfonylurea receptor from a mouse heart cDNA library. Coexpression of this isoform and BIR (Kir6.2) in a mammalian cell line elicited ATP-sensitive K+ (K-ATP) channel currents. The channel was effectively activated by both diazoxide and pinacidil, which is the feature of smooth muscle K-ATP channels. Sequence analysis indicated that this clone is a variant of cardiac type sulfonylurea receptor (SUR2), The 42 amino acid residues located in the carboxyl-terminal end of this novel sulfonylurea receptor is, however, divergent from that of SURE but highly homologous to that of the pancreatic one (SUR1). Therefore, this short part of the carboxyl terminus may be important for diazoxide activation of K-ATP channels, The reverse transcription-polymerase chain reaction analysis showed that mRNA of this clone was ubiquitously expressed in diverse tissues, including brain, heart, liver, urinary bladder, and skeletal muscle. These results suggest that this novel isoform of sulfonylurea receptor is a subunit reconstituting the smooth muscle K-ATP channel.	OSAKA UNIV,FAC MED,DEPT PHARMACOL 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC MED,DEPT OBSTET & GYNECOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University				Horio, Yoshiyuki/0000-0002-5021-5929				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ammala C, 1996, NATURE, V379, P545, DOI 10.1038/379545a0; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BEECH DJ, 1993, BRIT J PHARMACOL, V110, P573, DOI 10.1111/j.1476-5381.1993.tb13849.x; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; FAIVRE JF, 1989, BIOCHIM BIOPHYS ACTA, V984, P1, DOI 10.1016/0005-2736(89)90334-9; FINDLAY I, 1992, J PHARMACOL EXP THER, V261, P540; FINDLAY I, 1985, J MEMBRANE BIOL, V88, P165, DOI 10.1007/BF01868430; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, BIOCHEM BIOPH RES CO, V218, P286, DOI 10.1006/bbrc.1996.0050; KAJIOKA S, 1991, J PHYSIOL-LONDON, V444, P397, DOI 10.1113/jphysiol.1991.sp018885; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SPRUCE AE, 1987, J PHYSIOL-LONDON, V382, P213, DOI 10.1113/jphysiol.1987.sp016364; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525	18	470	491	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24321	24324		10.1074/jbc.271.40.24321	http://dx.doi.org/10.1074/jbc.271.40.24321			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798681	hybrid			2022-12-25	WOS:A1996VM67400003
J	Lee, JW; Romeo, A; Kosman, DJ				Lee, JW; Romeo, A; Kosman, DJ			Transcriptional remodeling and G(1) arrest in dioxygen stress in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; CELL-CYCLE BLOCKAGE; OXIDATIVE STRESS; POLYUBIQUITIN GENE; SIGNALING PATHWAY; HYDROGEN-PEROXIDE; MESSENGER-RNAS; YEAST; EXPRESSION; PROTEIN	Saccharomyces cerevisiae, which lack a functional SOD1 gene, encoding the cytosolic Cu,Zn-superoxide dismutase (SOD1), exhibit a variety of metabolic defects in aerobic but not in anaerobic growth. We test here the hypothesis that some of these defects may be due to specific transcriptional changes programmed for cell survival under dioxygen stress. Analysis of the budding pattern and generation time showed that the slower proliferation of an sod1 Delta mutant strain under air was due to an increase from 42 to 89 min spent in the G(1) phase of the cell cycle. This delay in G(1) was not due to an overall decline in biosynthetic activity since total protein and mRNA synthesis was not reduced even under 100% O-2. However, rRNA synthesis was strongly decreased, e.g. by 80% in the mutant under 100% O-2 (in comparison to N-2). Under these conditions, the mutant permanently arrested in G(1); this arrest was due to an inhibition of the Start function that prepares yeast for S phase. This Start arrest was due to an inhibition of transcription of the autoregulated G(1) cyclins, CLN1 and CLN2; the transcription of the constitutive G(1) cyclin, CLN3, was unaffected by the stress. Expression of a hyperstable Cln3 prevented the G(1) arrest, indicating that it was due solely to the inhibition of cell cycle-dependent cyclin expression. This remodeling of transcription in oxidative stress was seen also in the inhibition of glucose derepression of SUC2 expression. In contrast, the signaling and activation of mating pheromone (FUS1) and copper-responsive (CUP1) promoter activity were not affected by dioxygen stress, while genes encoding other anti-oxidant enzymes (SOD2, CTT1 and CTA1) were strongly induced. The UBI loci, encoding ubiquitin, were particularly good examples of this pattern of negative and positive transcriptional response to the stress. UBI1-UBI3 expression was repressed in the mutant under 100% O-2, while expression of UBI4 was strongly induced. The data demonstrate that extensive remodeling of transcription occurs in yeast under a strong dioxygen stress. This remodeling results in a pattern of expression of gene products needed for defense and repair, and suppression of activities associated with normal proliferative growth.	SUNY BUFFALO,DEPT BIOCHEM,SCH MED & BIOMED SCI,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46787] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS BJ, 1993, SCIENCE, V261, P1543, DOI 10.1126/science.8372349; BARNES CA, 1990, J BACTERIOL, V172, P4352, DOI 10.1128/jb.172.8.4352-4358.1990; BELAZZI T, 1991, EMBO J, V10, P585, DOI 10.1002/j.1460-2075.1991.tb07985.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DAVIES JMS, 1995, ARCH BIOCHEM BIOPHYS, V317, P1, DOI 10.1006/abbi.1995.1128; ENRIGHT HU, 1992, NUCLEIC ACIDS RES, V20, P3341, DOI 10.1093/nar/20.13.3341; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FLATTERYOBRIEN J, 1993, J GEN MICROBIOL, V139, P501, DOI 10.1099/00221287-139-3-501; GALIAZZO F, 1993, FEBS LETT, V315, P197, DOI 10.1016/0014-5793(93)81162-S; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRECO MA, 1990, J BACTERIOL, V172, P317, DOI 10.1128/JB.172.1.317-325.1990; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KRAAKMAN LS, 1993, MOL GEN GENET, V239, P196, DOI 10.1007/BF00281618; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MAGER WH, 1993, BIOCHEM J, V290, P1; Maniatis T., 1982, MOL CLONING; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MILLER J H, 1972, P466; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; ROSE MD, 1990, METHODS YEAST GENETI, P179; ROWLEY A, 1993, MOL CELL BIOL, V13, P1034, DOI 10.1128/MCB.13.2.1034; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; TIPPER DJ, 1973, J BACTERIOL, V116, P245, DOI 10.1128/JB.116.1.245-256.1973; TREGER JM, 1988, MOL CELL BIOL, V8, P1132, DOI 10.1128/MCB.8.3.1132; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VEINOTDREBOT LM, 1989, J BIOL CHEM, V264, P19528; VEINOTDREBOT LM, 1989, J BIOL CHEM, V264, P19473; WERNER D, 1984, ANAL BIOCHEM, V141, P329, DOI 10.1016/0003-2697(84)90050-2; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	53	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24885	24893		10.1074/jbc.271.40.24885	http://dx.doi.org/10.1074/jbc.271.40.24885			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798765	hybrid			2022-12-25	WOS:A1996VM67400088
J	Teusink, B; Larsson, C; Diderich, J; Richard, P; vanDam, K; Gustafsson, L; Westerhoff, HV				Teusink, B; Larsson, C; Diderich, J; Richard, P; vanDam, K; Gustafsson, L; Westerhoff, HV			Synchronized heat flux oscillations in yeast cell populations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLYTIC OSCILLATIONS; SACCHAROMYCES-CEREVISIAE; SUGAR PHOSPHATES; ENERGY BALANCES; MAKE-UP; THERMODYNAMICS; GROWTH; METABOLITES; CALORIMETRY; PATHWAY	Microcalorimetry was adapted to the study of glycolytic oscillations in suspensions of intact yeast cells. A correction procedure was developed for the distortion of the amplitude and phase of the heat signal, caused by the slow response of the calorimeter. This made it possible to observe oscillations in the heat production rate with a period of less than 1 min, and a relative amplitude of 5-10%. By simultaneously measuring the heat flux and concentrations of glycolytic metabolites, and by comparing acetaldehyde-induced phase shifts of the heat flux oscillations with those of NADH oscillations, the heat flux was found to be 100 degrees out of phase with glucose 6-phosphate, 80 degrees out of phase with fructose 1,6-bisphosphate, and in phase with NADH. The flux measurement made possible by microcalorimetry allowed the recognition of (i) changes in metabolic capacity that may affect glycolytic dynamics, (ii) implications of glucose carrier kinetics for glycolytic dynamics and (iii) the continued requirement for an acetaldehyde trapping agent for the oscillations.	UNIV AMSTERDAM,EC SLATER INST BIOCHEM RES,BIOCENTRUM,NL-1018 TV AMSTERDAM,NETHERLANDS; UNIV GOTHENBURG,DEPT GEN & MARINE MICROBIOL,S-41319 GOTHENBURG,SWEDEN; FREE UNIV AMSTERDAM,FAC BIOL,DEPT MICROBIAL PHYSIOL,NL-1081 HV AMSTERDAM,NETHERLANDS	University of Amsterdam; University of Gothenburg; Vrije Universiteit Amsterdam			Diderich, Jasper/AAH-3373-2019; Westerhoff, Hans V/I-5762-2012; Richard, Peter/A-4229-2009	Westerhoff, Hans V/0000-0002-0443-6114; Richard, Peter/0000-0003-0922-6092; Teusink, Bas/0000-0003-3929-0423; Diderich, Jasper/0000-0003-2675-9712; Larsson, Christer/0000-0002-0721-5405				ALBERTY RA, 1994, BBA-PROTEIN STRUCT M, V1207, P1, DOI 10.1016/0167-4838(94)90045-0; ALBERTY RA, 1992, BIOCHEMISTRY-US, V31, P10610, DOI 10.1021/bi00158a025; AON MA, 1991, J CELL SCI, V99, P325; AON MA, 1992, J GEN MICROBIOL, V138, P2219, DOI 10.1099/00221287-138-10-2219; BETZ A, 1978, CHRONOBIOLOGIA, V5, P45; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P585, DOI 10.1016/0003-9861(65)90404-2; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P579, DOI 10.1016/0003-9861(65)90403-0; BETZ A, 1975, J INTERDISCIPL CYCLE, V6, P167, DOI 10.1080/09291017509359480; BETZ A, 1966, PHYSIOL PLANTARUM, V19, P1049, DOI 10.1111/j.1399-3054.1966.tb07095.x; BURTON K, 1974, BIOCHEM J, V143, P365, DOI 10.1042/bj1430365; CHEN AT, 1982, J BIOCHEM BIOPH METH, V6, P297, DOI 10.1016/0165-022X(82)90011-2; COLLATZ KG, 1990, COMP BIOCHEM PHYS B, V96, P771, DOI 10.1016/0305-0491(90)90229-M; DEKONING W, 1992, ANAL BIOCHEM, V204, P118, DOI 10.1016/0003-2697(92)90149-2; DORAN PM, 1987, BIOTECHNOL BIOENG, V29, P892, DOI 10.1002/bit.260290711; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GHOSH AK, 1971, ARCH BIOCHEM BIOPHYS, V145, P319, DOI 10.1016/0003-9861(71)90042-7; GIERSCH C, 1975, BIOSYSTEMS, V7, P147, DOI 10.1016/0303-2647(75)90052-0; GNAIGER E, 1994, MOD TR BIOTHERMOKIN, V3, P207; GROSPIETSCH T, 1995, EXPERIENTIA, V51, P117, DOI 10.1007/BF01929352; GUSTAFSSON L, 1991, THERMOCHIM ACTA, V193, P145, DOI 10.1016/0040-6031(91)80181-H; HESS B, 1979, J EXP BIOL, V81, P7; HESS B, 1968, H-S Z PHYSIOL CHEM, V349, P1567, DOI 10.1515/bchm2.1968.349.2.1567; HESS B, 1973, BIOL BIOCH OSCILLATO, P229; LAMPRECHT I, 1992, INDIAN J TECHNOL, V30, P578; LARSSON C, 1991, BIOTECHNOL BIOENG, V38, P447, DOI 10.1002/bit.260380503; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULLER KH, 1987, THERMOCHIM ACTA, V119, P189, DOI 10.1016/0040-6031(87)88020-6; PLESSER T, 1985, FEBS LETT, V189, P42, DOI 10.1016/0014-5793(85)80838-3; PYE EK, 1969, CAN J BOTANY, V47, P271, DOI 10.1139/b69-040; RANDZIO SL, 1980, BIOL MICROCALORIMETR, P311; Richard P, 1996, YEAST, V12, P731; Richard P, 1996, EUR J BIOCHEM, V235, P238, DOI 10.1111/j.1432-1033.1996.00238.x; RICHARD P, 1994, FEBS LETT, V341, P223, DOI 10.1016/0014-5793(94)80461-3; RICHARD P, 1993, FEBS LETT, V318, P80, DOI 10.1016/0014-5793(93)81332-T; RICHTER PH, 1981, SCIENCE, V211, P715, DOI 10.1126/science.6450447; Spink C, 1976, Methods Biochem Anal, V23, P1, DOI 10.1002/9780470110430.ch1; SUURKUUSK J, 1982, CHEM SCRIPTA, V20, P155; TEWARI YB, 1988, J BIOL CHEM, V263, P3670; TEWARI YB, 1988, J BIOL CHEM, V263, P3664; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; VONSTOCKAR U, 1993, BIOCHIM BIOPHYS ACTA, V1183, P221, DOI 10.1016/0005-2728(93)90225-5; WALSH MC, 1994, J BACTERIOL, V176, P953, DOI 10.1128/JB.176.4.953-958.1994; WESTERHOFF HV, 1995, TRENDS BIOTECHNOL, V13, P242, DOI 10.1016/S0167-7799(00)88955-6; YATES WF, 1952, J AM CHEM SOC, V74, P4153, DOI 10.1021/ja01136a058; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	49	21	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24442	24448		10.1074/jbc.271.40.24442	http://dx.doi.org/10.1074/jbc.271.40.24442			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798702	Green Published, hybrid			2022-12-25	WOS:A1996VM67400024
J	Larsson, G; Nyman, PO; Kvassman, JO				Larsson, G; Nyman, PO; Kvassman, JO			Kinetic characterization of dUTPase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYURIDINE TRIPHOSPHATASE; URACIL INCORPORATION; PURIFICATION; PYROPHOSPHATASE; PROTEIN; ENZYME; VIRUS; DNA	The enzyme dUTPase catalyzes the hydrolysis of dUTP to dUMP and pyrophosphate, thereby preventing a deleterious incorporation of uracil into DNA. The best known dUTPase is that from Escherichia coli, which, like the human enzyme, consists of three identical subunits. In the present work, the catalytic properties of the E. coli dUTPase were investigated in the pH range 5-11. The enzyme was found to be highly specific for dUTP and discriminated both base and sugar as well as the phosphate moiety (bound dUDP was not hydrolyzed). The second best substrate among the nucleotides serving as building blocks for DNA was dCTP, which was hydrolyzed an astonishing 10(5) times less efficiently than dUTP, a decline largely accounted for by a higher K-m for dCTP. With dUTP Mg as substrate, k(cat) was found to vary little with pH and to range from 6 to 9 s(-1). K-m passed through a broad minimum in the neutral pH range with values approaching 10(-7) M. It increased with deprotonation of the uracil moiety of dUTP and showed dependence on two ionizations in the enzyme, exhibiting pK(a) values of 5.8 and 10.3. When excess dUTPase was reacted with dUTP Mg at pH 8, the two protons transferred to the reaction medium were released in a concerted mode after the rate-limiting step, The Mg2+ ion enhances binding to dUTPase of dUTP by a factor of 100 and dUDP by a factor of 10. Only one enantiomer of the substrate analog 2'-deoxyuridine-5'-(alpha-thio)-triphosphate was hydrolyzed by the enzyme. These results are interpreted to favor a catalytic mechanism involving magnesium binding to the cy-phosphate, rate-limiting hydrolysis by a shielded and activated water molecule and a fast ordered desorption of the products. The results are discussed with reference to recent data on the structure of the E. coli dUTPase dUDP complex.	LUND UNIV,CTR CHEM & CHEM ENGN,DEPT BIOCHEM,LUND,SWEDEN; HENRY FORD HLTH SCI CTR,DIV BIOCHEM RES,HENRY FORD HLTH SYST,DETROIT,MI 48202	Lund University; Henry Ford Health System; Henry Ford Hospital								ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; BERGMAN AC, 1994, VIROLOGY, V204, P420, DOI 10.1006/viro.1994.1547; BERTANI LE, 1961, J BIOL CHEM, V236, P67; BJORNBERG O, 1993, PROTEIN EXPRES PURIF, V4, P149, DOI 10.1006/prep.1993.1021; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; CEDERGRENZEPPEZAUER ES, 1988, PROTEINS, V4, P71, DOI 10.1002/prot.340040110; CLARK AM, 1951, BIOCHEM J, V48, P495, DOI 10.1042/bj0480495; CLIMIE S, 1994, PROTEIN EXPRES PURIF, V5, P252, DOI 10.1006/prep.1994.1038; COHN M, 1990, ANN NY ACAD SCI, V103, P151; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; FERSHT A, 1984, ENZYME STRUCTURE MEC, P152; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; HOFFMANN I, 1987, EUR J BIOCHEM, V164, P45, DOI 10.1111/j.1432-1033.1987.tb10990.x; HOFFMANN I, 1987, THESIS U SAARBRUCKEN; HUANG SL, 1982, BIOCHEMISTRY-US, V21, P951, DOI 10.1021/bi00534a021; KAHN MM, 1966, J AM CHEM SOC, V88, P668; Kornberg A., 1991, DNA REPLICATION; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; Lohmann K, 1932, BIOCHEM Z, V254, P381; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1994, CURR GENET, V26, P415, DOI 10.1007/BF00309928; Mildvan A.S., 1970, ENZYMES, P445; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; VILLAFRANCA JJ, 1980, ANNU REV BIOPHYS BIO, V9, P363, DOI 10.1146/annurev.bb.09.060180.002051; Walker A. C, 1944, ARCH BIOCHEM, V5, P445; ZALUD P, 1995, PURINE PYRIMIDINE ME, V8, P135	28	84	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24010	24016		10.1074/jbc.271.39.24010	http://dx.doi.org/10.1074/jbc.271.39.24010			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798636	hybrid			2022-12-25	WOS:A1996VJ44200065
J	Latimer, MT; Painter, MH; Ferry, JG				Latimer, MT; Painter, MH; Ferry, JG			Characterization of an iron-sulfur flavoprotein from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOBACTERIUM-THERMOAUTOTROPHICUM; TRANSCRIPTIONAL REGULATION; ELECTRON-TRANSPORT; ACETATE KINASE; RNA-POLYMERASE; GENES; PURIFICATION; PROTEINS; PHOSPHOTRANSACETYLASE; METHANOGENESIS	A gene (isf) encoding an iron sulfur flavoprotein (Isf) from Methanosarcina thermophila was cloned and sequenced. The gene was located directly upstream of the genes (pta and ach) encoding phosphotransacetylase and acetate kinase and is transcribed in the opposite direction. The amino acid sequence deduced from isf contained a cluster of cysteine residues reminiscent of proteins that accommodate either a [4Fe-4S] or [3Fe-4S] center. The protein was heterologously produced in Escherichia coli and purified to apparent homogeneity. The 29-kDa subunit molecular mass of heterologously produced Isf (determined by SDS-polyacrylamide gel electrophoresis) corresponded to the molecular mass of 30,451 Da calculated from the amino acid composition deduced from isf. Gel filtration estimated a molecular mass of 65 kDa for the native Isf-indicating an alpha(2) homodimer. The UV-visible absorption spectrum was characteristic of iron-sulfur flavoproteins with maxima at 484, 452, 430, 378, and 280 nm. Analyses identified 2 FMN, 7-8 non-heme iron atoms, and 6-7 acid-labile sulfur atoms per alpha(2) homodimer. Comparisons of the deduced Isf sequence with sequences in available protein data bases suggested Isf is a novel iron-sulfur flavoprotein. Western blot analysis indicated the presence of Isf in extracts of acetate-grown M. thermophila. Ferredoxin stimulated the GO-dependant reduction of Isf by the CO dehydrogenase-acetyl-CoA synthase complex that suggested ferredoxin is a physiological electron donor to Isf.	PENN STATE UNIV, DEPT BIOCHEM & MOL BIOL, UNIVERSITY PK, PA 16802 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Virginia Polytechnic Institute & State University								ALBER BE, 1994, P NATL ACAD SCI USA, V91, P6909, DOI 10.1073/pnas.91.15.6909; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARON SF, 1989, J BACTERIOL, V171, P3846, DOI 10.1128/jb.171.7.3846-3853.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMMACK R, 1983, CHEM SCRIPTA, V21, P87; CLEMENTS AP, 1992, J BACTERIOL, V174, P5244, DOI 10.1128/JB.174.16.5244-5250.1992; DAWSON RMC, 1989, DATA BIOCH RES, P126; Ferry James G., 1993, P304; FERRY JG, 1992, CRIT REV BIOCHEM MOL, V27, P473, DOI 10.3109/10409239209082570; FERRY JG, 1995, ANNU REV MICROBIOL, V49, P305, DOI 10.1146/annurev.mi.49.100195.001513; Ferry JG, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P64; Fortune WB, 1938, IND ENG CHEM, V10, P0060, DOI 10.1021/ac50118a004; GORNALL AG, 1949, J BIOL CHEM, V177, P751; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATIMER MT, 1993, J BACTERIOL, V175, P6822, DOI 10.1128/jb.175.21.6822-6829.1993; LIGHT DR, 1980, ANAL BIOCHEM, V109, P87, DOI 10.1016/0003-2697(80)90014-7; MaupinFurlow J, 1996, J BACTERIOL, V178, P340, DOI 10.1128/jb.178.2.340-346.1996; MAUPINFURLOW JA, 1995, J BIOL CHEM, V270, P28617, DOI 10.1074/jbc.270.48.28617; NOLLING J, 1995, EUR J BIOCHEM, V231, P628, DOI 10.1111/j.1432-1033.1995.0628d.x; PEER CW, 1994, J BACTERIOL, V176, P6974, DOI 10.1128/JB.176.22.6974-6979.1994; Reeve John N., 1993, P493; SANTANGELO JD, 1991, J BACTERIOL, V173, P1088, DOI 10.1128/jb.173.3.1088-1095.1991; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; SINGHWISSMANN K, 1995, J BACTERIOL, V177, P1699, DOI 10.1128/jb.177.7.1699-1702.1995; SOWERS KR, 1984, CURR MICROBIOL, V11, P227, DOI 10.1007/BF01567165; SOWERS KR, 1993, J BIOL CHEM, V268, P23172; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TERLESKY KC, 1988, J BIOL CHEM, V263, P4080; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; WASSERFALLEN A, 1995, J BACTERIOL, V177, P2436, DOI 10.1128/jb.177.9.2436-2441.1995; ZINDER SH, 1985, INT J SYST BACTERIOL, V35, P522, DOI 10.1099/00207713-35-4-522	32	24	25	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24023	24028		10.1074/jbc.271.39.24023	http://dx.doi.org/10.1074/jbc.271.39.24023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798638	hybrid			2022-12-25	WOS:A1996VJ44200067
J	Lukowski, S; Lecomte, MC; Mira, JP; Marin, P; Gautero, H; RussoMarie, F; Geny, B				Lukowski, S; Lecomte, MC; Mira, JP; Marin, P; Gautero, H; RussoMarie, F; Geny, B			Inhibition of phospholipase D activity by fodrin - An active role for the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; PERMEABILIZED CHROMAFFIN CELLS; PHOSPHATIDIC-ACID; STREPTOLYSIN-O; BRAIN SPECTRIN; HL-60 CELLS; PARTIAL-PURIFICATION; ADENYLATE-CYCLASE; D ACTIVATION	Phospholipase D (PLD) is a major enzyme implicated in important cellular processes such as secretion and proliferation. The knowledge of its regulation is essential to understand the control of these phenomena. Several proteins activating PLD have been described in the last years. In this report, we chromatographed bovine brain cytosolic proteins to identify fodrin, the nonerythroid spectrin, as the first described inhibitor of PLD. A cytosolic fraction with an inhibitory effect on PLD activity loses its capacity after immunoprecipitation of fodrin. Moreover, at 1 nM, purified fodrin blocks fully and quickly PLD activity, whatever the stimuli used. In contrast, fodrin has no effect on adenylate cyclase activity. Fodrin-analogous proteins like dimeric or tetrameric erythroid spectrin have the same inhibitory effect on PLD, at higher concentrations. Other cytoskeletal proteins, actin and vimentin, are inefficient on PLD inhibition. The mechanisms implicated in PLD modulation such as post-translational modifications of fodrin and the role of small G-proteins on the cytoskeleton regulation are discussed. In conclusion, this study reveals that fodrin is involved in the control of PLD activity, suggesting that the cytoskeleton could have an active role in control of secretion and proliferation.	INST COCHIN GENET MOL,INSERM,U332,F-75014 PARIS,FRANCE; FAC MED BICHAT,INSERM,U409,F-75018 PARIS,FRANCE; COLL FRANCE,INSERM,U114,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France								BENDER JL, 1983, J BIOL CHEM, V258, P2432; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CHNEIWEISS H, 1988, J NEUROSCI, V8, P3376; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAWSON RMC, 1967, BIOCHEM J, V102, P76, DOI 10.1042/bj1020076; GALLIARD T, 1965, BIOCHIM BIOPHYS ACTA, V106, P551, DOI 10.1016/0005-2760(65)90071-8; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GENY B, 1989, CELL SIGNAL, V1, P165, DOI 10.1016/0898-6568(89)90006-5; GLENNEY JR, 1982, CELL, V28, P843, DOI 10.1016/0092-8674(82)90063-0; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HASHIZUME T, 1994, BBA-MOL CELL RES, V1221, P179, DOI 10.1016/0167-4889(94)90011-6; HU RJ, 1991, J BIOL CHEM, V266, P18200; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; KANAHO Y, 1991, J IMMUNOL, V146, P3536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MESKINI N, 1995, EUR J BIOCHEM, V233, P907, DOI 10.1111/j.1432-1033.1995.907_3.x; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SIMMONDS AC, 1985, BIOCHIM BIOPHYS ACTA, V813, P331, DOI 10.1016/0005-2736(85)90249-4; Singer WD, 1996, J BIOL CHEM, V271, P4504; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Thompson N T, 1993, Adv Pharmacol, V24, P199, DOI 10.1016/S1054-3589(08)60938-2; XING MZ, 1992, J BIOL CHEM, V267, P6602; Yamamoto H, 1995, PROSTAGLANDINS, V50, P201, DOI 10.1016/0090-6980(95)00121-2; ZHANG H, 1990, J BIOL CHEM, V265, P21309	55	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24164	24171		10.1074/jbc.271.39.24164	http://dx.doi.org/10.1074/jbc.271.39.24164			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798657	hybrid			2022-12-25	WOS:A1996VJ44200086
J	Wang, XK; Yue, TL; Ohlstein, EH; Sung, CP; Feuerstein, GZ				Wang, XK; Yue, TL; Ohlstein, EH; Sung, CP; Feuerstein, GZ			Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNA; RAT ISCHEMIC CORTEX; ADHESION MOLECULE-1; EARLY GENE; EXPRESSION; ATHEROSCLEROSIS; CHEMOATTRACTANT; CYTOKINES; IP-10; INTERLEUKIN-8	Interferon-inducible protein-10 (IP-10) is a member of the C-X-C chemokine family. Using mRNA differential display, we isolated a rat homologue to murine and human IP-10 from lipopolysaccharide-stimulated carotid arteries. Our studies demonstrated that IP-10 is a potent mitogenic and chemotactic factor for vascular smooth muscle cells, the critical features of smooth muscle cells for their contribution to the pathogenesis of atherosclerosis and restenosis. IP-10 induced a concentration-dependent stimulation of DNA synthesis, cell proliferation, and cell migration of rat aortic smooth muscle cells. A concentration- and time-dependent IP-10 mRNA induction was observed in lipopolysaccharide- or interferon-gamma-stimulated, but not interleukin-1 beta- or tumor necrosis factor-alpha-stimulated smooth muscle cells. A marked synergistic effect on IP-10 mRNA expression was observed when smooth muscle cells were challenged with interferon-gamma together with interleukin-1 beta or tumor necrosis factor-alpha. Furthermore, IP-10 mRNA expression was induced in the rat carotid artery after balloon angioplasty. The mitogenic and chemotactic features of IP-10 for smooth muscle cells, along with its discrete induction in cultured vascular smooth muscle cells and in carotid arteries after balloon angioplasty (neointima formation) suggest that IP-10 may play an active and distinct role in vascular remodeling processes.			Wang, XK (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT CARDIOVASC PHARMACOL,709 SWEDELAND RD,POB 1539,UW 2511,KING OF PRUSSIA,PA 19406, USA.							BEDARD PA, 1993, J CELL PHYSIOL, V154, P433, DOI 10.1002/jcp.1041540227; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLINTON SK, 1992, ARCH PATHOL LAB MED, V116, P1292; DAVIES MJ, 1993, J PATHOL, V171, P223, DOI 10.1002/path.1711710311; DEWALD B, 1992, IMMUNOL LETT, V32, P81, DOI 10.1016/0165-2478(92)90203-Z; GomezChiarri M, 1996, AM J PATHOL, V148, P301; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HIDAKA Y, 1992, ATHEROSCLEROSIS, V95, P87, DOI 10.1016/0021-9150(92)90179-K; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; MARMUR JD, 1992, CIRCULATION, V86, P53; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MUKAIDA N, 1992, MICROBIOL IMMUNOL, V36, P773, DOI 10.1111/j.1348-0421.1992.tb02080.x; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; OHLSTEIN EH, 1993, DRUG DEVELOP RES, V29, P108, DOI 10.1002/ddr.430290207; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; OHMORI Y, 1994, BIOCHEM BIOPH RES CO, V198, P590, DOI 10.1006/bbrc.1994.1086; POSTON RN, 1992, AM J PATHOL, V140, P665; PRINTSEVA OY, 1992, AM J PATHOL, V140, P889; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAJCHEL A, 1988, NUCLEIC ACIDS RES, V16, P2347, DOI 10.1093/nar/16.5.2347; ROSS R, 1993, AM J PATHOL, V143, P987; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SUNG CP, 1993, J CARDIOVASC PHARM, V21, P221, DOI 10.1097/00005344-199302000-00006; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VANGURI P, 1994, J IMMUNOL, V152, P1411; VANGURI P, 1990, J BIOL CHEM, V265, P15049; WANG XK, 1995, STROKE, V26, P1665, DOI 10.1161/01.STR.26.9.1665; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; Wang XK, 1996, CIRC RES, V78, P322, DOI 10.1161/01.RES.78.2.322; WANG XK, 1992, J BIOL CHEM, V267, P9176; WANG XK, 1996, IN PRESS ATERIOSCLER; WANG XK, 1995, BIOTECHNIQUES, V18, P192; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; YUE TL, 1994, CIRC RES, V75, P1, DOI 10.1161/01.RES.75.1.1; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282	40	129	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24286	24293		10.1074/jbc.271.39.24286	http://dx.doi.org/10.1074/jbc.271.39.24286			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798675				2022-12-25	WOS:A1996VJ44200104
J	Zahedi, R; Aulak, KS; Eldering, E; Davis, AE				Zahedi, R; Aulak, KS; Eldering, E; Davis, AE			Characterization of C1 inhibitor-Ta - A dysfunctional C1INH with deletion of lysine 251	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA KALLIKREIN; REACTIVE CENTER; C1-INHIBITOR; MUTATION; REGION; QUANTIFICATION; COMPLEXES; CONTAINS; SERPINS; DISEASE	Dysfunctional C1 inhibitor (C1INH)-Ta is a naturally occurring mutant from a patient with type II hereditary angioedema. This mutant has a deletion of the codon for Lys-251, which is located in the connecting strand between helix F and strand 3A, overlying beta sheet A. Deletion of this Lys modifies the amino acid sequence at this position from Asn-Lys-Ile-Ser to Asn-Ile-Ser and creates a new glycosylation site. To further characterize the mechanism of dysfunction, we have analyzed the recombinant normal and Ta proteins expressed by COS cells in addition to the proteins in serum and isolated from serum. Recombinant C1INH-Ta revealed an intermediate thermal stability in comparison with the intact and reactive center cleaved normal proteins. Analysis of the reactivity of this recombinant protein with target proteases demonstrated no complex formation with C1s, C1r, or kallikrein. Inefficient complex formation was, however, clearly detectable with beta-factor XIIa. Each protease produced partial cleavage of the recombinant mutant inhibitor. Recombinant C1INH-Ta, on 7.5% SDS-polyacrylamide gel electrophoresis and by size fractionation on Superose 12, showed a higher molecular weight fraction that was compatible in size with dimer formation. However, no multimerization of C1INH-Ta isolated from serum or of C1INH-Ta in serum, was observed. The C1INH-Ta dimer expressed the epitopes that normally are expressed only on the protease complexed or the cleaved inhibitor. These epitopes were not expressed on the monomeric inhibitor. The data suggest that the mutation in C1INH-Ta results in a folding abnormality that behaves as if it consists of two populations of molecules, one of which is susceptible to multimerization and one of which is converted to a substrate, but which retains residual inhibitory activity.	CHILDRENS HOSP RES FDN,DIV NEPHROL,CINCINNATI,OH 45229; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT AUTOIMMUNE DIS,NL-1006 AD AMSTERDAM,NETHERLANDS	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation					NICHD NIH HHS [HD22082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022082, R37HD022082] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AULAK K S, 1989, Complement and Inflammation, V6, P310; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; AULAK KS, 1993, J BIOL CHEM, V268, P18088; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; DEAGOSTINI A, 1988, J CLIN INVEST, V82, P700, DOI 10.1172/JCI113650; DESMET BJGL, 1993, BLOOD, V81, P56, DOI 10.1182/blood.V81.1.56.bloodjournal81156; DEVRAJKIZUK R, 1988, BLOOD, V72, P1518; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; ELDERING E, 1992, J BIOL CHEM, V267, P7013; LEWIN MF, 1983, J BIOL CHEM, V258, P6415; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; Malek R, 1996, CLIN EXP IMMUNOL, V105, P191, DOI 10.1046/j.1365-2249.1996.d01-714.x; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; NUIJENS JH, 1988, BLOOD, V72, P1841; PARAD RB, 1990, P NATL ACAD SCI USA, V88, P6786; PEMBERTON PA, 1989, BIOCHEM J, V58, P193; PERRY DJ, 1989, FEBS LETT, V254, P174, DOI 10.1016/0014-5793(89)81033-6; SCHAPIRA M, 1985, Complement, V2, P111; SCHAPIRA M, 1985, J CLIN INVEST, V76, P635; SIDDIQUE ZM, 1992, HUM HERED, V2, P231; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; YORK JD, 1991, J BIOL CHEM, V266, P8495; ZAHEDI R, 1985, J CLIN INVEST, V95, P1299	29	18	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24307	24312		10.1074/jbc.271.39.24307	http://dx.doi.org/10.1074/jbc.271.39.24307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798678	hybrid			2022-12-25	WOS:A1996VJ44200107
J	Zheng, Y; Glaven, JA; Wu, WJ; Cerione, RA				Zheng, Y; Glaven, JA; Wu, WJ; Cerione, RA			Phosphatidylinositol 4,5-bisphosphate provides an alternative to guanine nucleotide exchange factors by stimulating the dissociation of GDP from Cdc42Hs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; PHOSPHOINOSITIDE 3-KINASE; MOLECULAR-CLONING; PHOSPHOLIPASE-D; RHO; RAC; ACTIVATION; GTPASES	Members of the Rho subfamily of Ras-related GTP-binding proteins play important roles in the organization of the actin cytoskeleton and in the regulation of cell growth. We have shown previously that the dbl oncogene product, which represents a prototype for a family of growth regulatory proteins, activates Rho subfamily GTP-binding proteins by catalyzing the dissociation of GDP from their nucleotide binding site. In the present study, we demonstrate that the acidic phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2), provides an alternative mechanism for the activation of Cdc42Hs. Among a variety of lipids tested, only PIP2 was able to stimulate GDP release from Cdc42Hs in a dose dependent manner, with a half-maximum effect at similar to 50 mu M. Unlike the Dbl oncoprotein, which requires the presence of (free) guanine nucleotide in the medium to replace the GDP bound to Cdc42Hs, PIP2 stimulates GDP release from Cdc42Hs in the absence of free guanine nucleotide. PIP2, when incorporated into phosphatidylcholine carrier vesicles, binds tightly to the guanine nucleotide-depleted form of Cdc42Hs and weakly to the GDP-bound form of the GTP-binding protein but does not bind to GTP-bound Cdc42Hs, similar to what was observed for the Dbl oncoprotein. However, mutational analysis of Cdc42Hs indicates that the site that Is essential for the functional interaction between PIP2 and Cdc42Hs is distinct from the Dbl binding site and is located at the positively charged carboxyl-terminal end of the GTP-binding protein. The GDP-releasing activity of PIP2 is highly effective toward Cdc42Hs and Rho (and is similar to the reported effects of PIP2 on Arf (Terui, T., Kahn, R. A., and Randazzo, P. A., (1994) J. Biol. Chem. 269, 28130-28135)), is less effective with Rac, and is not observed with Ras, Rap1a, or Ran. The ability of PIP2 to activate Cdc42Hs (or Rho) and Arf provides a possible point of convergence for the biological pathways regulated by these different GTP-binding proteins and may be related to the synergism observed between Arf and Rho-subtype proteins in the stimulation of phospholipase D activity (Singer, W. D., Brown, H. A., Bokoch, G. M., and Sternweis, P. C. (1995) J. Biol. Chem. 270, 14944-14950).	CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University			Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM47458, GM40654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHOU MM, 1996, CELL, V85, P575; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TERUI T, 1994, J BIOL CHEM, V269, P28130; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	47	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23815	23819		10.1074/jbc.271.39.23815	http://dx.doi.org/10.1074/jbc.271.39.23815			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798610	hybrid			2022-12-25	WOS:A1996VJ44200039
J	DeBenedetti, VMG; Radice, P; Mondini, P; Spatti, G; Conti, A; Illeni, MT; Caligo, MA; Cipollini, G; Bevilaqua, G; Pilotti, S; Pierotti, MA				DeBenedetti, VMG; Radice, P; Mondini, P; Spatti, G; Conti, A; Illeni, MT; Caligo, MA; Cipollini, G; Bevilaqua, G; Pilotti, S; Pierotti, MA			Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test	ONCOGENE			English	Article						breast cancer; ovarian cancer; hereditary tumours; BRCA1; PTT	SUSCEPTIBILITY GENE; FAMILIAL BREAST; HISTOPROGNOSTIC GRADE; TUMORS; LINKAGE	The most common mutations in the familial breast and ovarian cancer susceptibility gene BRCA1 are frameshift and nonsense mutations, which lead to the synthesis of truncated proteins. On this ground, we have analysed BRCA1 exon 11, which includes about 61% of coding region, in germline DNA from 70 Italian breast and/or ovarian cancer patients, using the protein truncation test (PTT). BRCA1 mutations were identified in nine of 29 (similar to 31%) patients with a family history of cancer and in three of 41 (similar to 7%) women with early-onset breast carcinomas, and were subsequently characterized by sequence analysis. In addition, BRCA1 mutations were also detected in six affected relatives of two positive index cases, The observed frequencies of mutations were not significantly different from those expected on the basis of the phenotypic characteristics of patients and their families, indicating that PTT is a rapid and sensitive method that can be used for a first BRCA1 mutational screening, The histological findings in BRCA1 mutated cases showed that eight of nine (similar to 89%) breast carcinomas were of grade III and nine of 9 (100%) ovarian carcinomas were of the endometrioid type (eight of grade III and one of grade II). This suggests that specific histological characteristics may represent additional criteria for selection of cases eligible to BRCA1 mutational analysis.	IST NAZL TUMORI, DIV EXPT ONCOL A, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV SURG GYNECOL ONCOL, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV SURG ONCOL C, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV IMMUNOHEMATOL, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV ANAT PATHOL & CITOL, I-20133 MILAN, ITALY; UNIV PISA, INST PATHOL ANAT, I-56126 PISA, ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Pisa			Radice, Paolo/O-3119-2013; Pierotti, Marco Alessandro/AAC-4728-2022; Caligo, Adelaide Maria/K-4289-2018	Radice, Paolo/0000-0001-6298-4111; Pierotti, Marco Alessandro/0000-0002-7431-8332; Caligo, Adelaide Maria/0000-0003-0589-1829				BIGNON YJ, 1995, LANCET, V346, P258, DOI 10.1016/S0140-6736(95)91310-6; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1457; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HOULSTON RS, 1991, ANN HUM GENET, V55, P291, DOI 10.1111/j.1469-1809.1991.tb00856.x; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; LINDBLOM A, 1995, BREAST CANCER RES TR, V34, P171, DOI 10.1007/BF00665789; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD S, 1994, LANCET, V343, P236, DOI 10.1016/S0140-6736(94)91021-9; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; Scully R. E, 1979, TUMORS OVARY MALDEVE; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TORNOS C, 1995, AM J SURG PATHOL, V19, P1343, DOI 10.1097/00000478-199512000-00001; VANRENSBURG EJ, 1995, J CLIN PATHOL, V48, P789, DOI 10.1136/jcp.48.9.789; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	32	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1353	1357						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808710				2022-12-25	WOS:A1996VJ20200027
J	Okuda, K; Golub, TR; Gilliland, DG; Griffin, JD				Okuda, K; Golub, TR; Gilliland, DG; Griffin, JD			p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell Lines	ONCOGENE			English	Article						leukemia; signal transduction; BCR/ABL	BCR-ABL ONCOGENE; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TYROSINE KINASE; ADAPTER PROTEIN; TEL GENE; C-ABL; FUSION; PHOSPHORYLATION; TRANSFORMATION	The Philadelphia chromosome translocation generates a chimeric oncogene, BCR/ABL which causes chronic myelogenous leukemia, Two different fusion proteins can be produced, p190BCR/ABL and p210BCR/ABL, depending on the location of the breakpoint in BCR, Although the ABL tyrosine kinase activity of the resulting oncoprotein is essential for transformation, the exact functional contribution of BCR to transformation is unclear, A novel oncogene containing ABL is formed by the (9;12) translocation which fuses part of the ets-family member TEL to c-ABL in patients with acute leukemia, In an effort to compare the biological effects of various ABL oncogenes, rye transformed two different factor-dependent murine hematopoietic cell Lines with cDNA's encoding p210 BCR/ABL, p190 BCR/ABL, or TEL/ABL, Transfection of each of the three activated ABL oncogenes resulted in rapid emergence of growth factor-independence, and 2-4 sublines from each cell line with each oncogene were further studied, Each oncogene induced an increase in the tyrosine phosphorylation of cellular proteins and autophosphorylation of the oncoprotein itself, Overall, the pattern of increased tyrosine phosphorylation was similar in the cell lines, suggesting that many of the major substrates were identical, We specifically examined a series of proteins known to be p210 BCR/ABL substrates, including rasGAP, Shc, SH-PTP2, SH-PTP1, CRK-L, CBL, paxillin, and STATs, and found that each were also tyrosine phosphorylated in response to p190 BCR/ABL and TEL/ABL. These results suggest that the function of BCR can be largely replaced by the unrelated protein TEL with regards to transformation of murine hematopoietic cell lines to factor-independence, and support the hypothesis that a major contribution of both fusion partners is to activate the ABL tyrosine kinase.	DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BUIJS A, 1995, ONCOGENE, V10, P1511; CAMPBELL ML, 1990, ONCOGENE, V5, P773; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUKER B, 1992, BLOOD, V79, P2215; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOLUB TR, 1996, IN PRESS MOL CELL BI; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JANSSEN JWG, 1995, BRIT J HAEMATOL, V90, P222, DOI 10.1111/j.1365-2141.1995.tb03407.x; LANEUVILLE P, 1992, BLOOD, V80, P1788; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ODA T, 1994, J BIOL CHEM, V269, P22925; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RON D, 1991, NEW BIOL, V3, P372; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SETH A, 1990, ONCOGENE, V5, P1761; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	44	95	101	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1147	1152						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808688				2022-12-25	WOS:A1996VJ20200005
J	Yuan, ZM; Huang, YY; Kraeft, SK; Chen, LB; Kharbanda, S; Kufe, D				Yuan, ZM; Huang, YY; Kraeft, SK; Chen, LB; Kharbanda, S; Kufe, D			Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylctosine	ONCOGENE			English	Article						cyclin dependent kinase; protein tyrosine kinase; 1-beta-D-arabinofuranosylcytosine; DNA damage; cell cycle arrest	MYELOID-LEUKEMIA CELLS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; ACTIVATING KINASE; HUMAN FIBROBLASTS; EPITHELIAL-CELLS; ANTIGEN RECEPTOR; MAMMALIAN-CELLS; SERINE KINASE	The cyclin dependent kinase 2 (Cdk2) is required for initiation and progression of DNA replication, Activation of Cdk2 involves binding to cyclin E or cyclin A and dephosphorylation of Tyr15, The present studies demonstrate that treatment of U-937 cells with 1-beta-D-arabinofuranosylcytosine (ara-C) is associated with tyrosine phosphorylation of Cdk2 and inhibition of Cdk2 activity, The results also demonstrate that Cdk2 directly associates with the Src-like tyrosine kinase Lyn as a consequence of ara-C-treatment, Confocal microscopy studies show that Lyn is detectable in the nucleus and that it colocalises with Cdk2, Subcellular fractionation and coimmunoprecipitation studies further demonstrate nuclear binding of Lyn and Cdk2, We also show that Lyn phosphorylates Tyr15 of Cdk2 and that incubation of Lyn with Cdk2 results in inhibition of Cdk2 activity, These findings suggest that the association of Lyn and Cdk2 in ara-C-treated cells may contribute to regulation of Cdk2-dependent cell cycle checkpoints.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOL BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NCI NIH HHS [CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FRAM RJ, 1982, CANCER RES, V42, P4050; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUNJI H, 1991, CANCER RES, V51, P741; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; OHNO Y, 1988, CANCER RES, V48, P1494; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	54	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					939	946						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806683				2022-12-25	WOS:A1996VG76600007
J	Bartsevich, VV; Pakrasi, HB				Bartsevich, VV; Pakrasi, HB			Manganese transport in the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CADMIUM; MAGNESIUM; SYSTEMS; MUTANT	We have inactivated the genes encoding components of MntABC, an ABC (ATP binding cassette) transporter system for manganese in the cyanobacterium Synechocystis sp, PCC 6803. The growth rates of these mutant strains were significantly lower in a manganese-deficient medium and were restored to near normal levels upon addition of micromolar concentrations of Mn2+, indicating the presence of a second transport system for manganese in this organism, Mn-54(2+) uptake experiments indicated that the MntABC transporter was induced under manganese starvation conditions, whereas the second transporter system was induced in the presence of micromolar levels of manganese, Both of these systems were nonfunctional at low temperatures and could transport trace levels of Mn-54(2+), reflecting high affinity active transport, The initial rates of Mn2+ uptake for cells grown with or without manganese exhibited biphasic saturation kinetics, suggesting that Mn2+ can also be accumulated by a low affinity system in these bacteria. The kinetic parameters for the MntABC transporter system are K-m = 1-3 mu M and V-max = 3-8 pmol/min . 10(8) cells, Accumulation of manganese by this system was competitively inhibited by Cd2+ (K-i = 4-8 mu M), Co2+ and Zn2+ (K-i = 8-15 mu M). In contrast, the second high affinity system was highly specific for manganese and was not inhibited by any tested metal ion. We have also demonstrated that in this organism, photosynthetic electron transport is necessary for optimal rates of manganese uptake.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	Washington University (WUSTL)								ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; ARCHIBALD FS, 1984, J BACTERIOL, V158, P1; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; CHENIAE GM, 1969, PLANT PHYSIOL, V44, P351, DOI 10.1104/pp.44.3.351; DIXON M, 1964, ENZYMES, P327; EISENSTADT E, 1973, J BACTERIOL, V113, P1363, DOI 10.1128/JB.113.3.1363-1372.1973; JASPER P, 1978, J BACTERIOL, V133, P1323, DOI 10.1128/JB.133.3.1323-1328.1978; LADDAGA RA, 1985, J BACTERIOL, V162, P1100, DOI 10.1128/JB.162.3.1100-1105.1985; LADDAGA RA, 1985, J BACTERIOL, V162, P1106, DOI 10.1128/JB.162.3.1106-1110.1985; PARK MH, 1976, J BACTERIOL, V126, P1096, DOI 10.1128/JB.126.3.1096-1103.1976; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SILVER S, 1970, J BACTERIOL, V104, P1299, DOI 10.1128/JB.104.3.1299-1306.1970; SILVER S, 1977, MICROORGANISMS MINER, P105; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; WEISS AA, 1978, ANTIMICROB AGENTS CH, V14, P856, DOI 10.1128/AAC.14.6.856; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	16	84	88	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26057	26061		10.1074/jbc.271.42.26057	http://dx.doi.org/10.1074/jbc.271.42.26057			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824246	hybrid			2022-12-25	WOS:A1996VN18000052
J	Fink, M; Duprat, F; Lesage, F; Heurteaux, C; Romey, G; Barhanin, J; Lazdunski, M				Fink, M; Duprat, F; Lesage, F; Heurteaux, C; Romey, G; Barhanin, J; Lazdunski, M			A new K+ channel beta subunit to specifically enhance Kv2.2 (CDRK) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; RAT-BRAIN; MOLECULAR-CLONING; DENDROTOXIN-I; MAMMALIAN BRAIN; XENOPUS-OOCYTES; INACTIVATION; LOCALIZATIONS	Cloned K+ channel beta subunits are hydrophilic proteins which associate to pore-forming alpha subunits of the Shaker subfamily. The resulting alpha beta heteromultimers K+ channels have inactivation kinetics significantly more rapid than those of the corresponding alpha homomultimers. This paper reports the cloning and the brain localization of mKv beta(4) (m for mouse), a new beta subunit. This new beta subunit is highly expressed in the nervous system but is also present in other tissues such as kidney. In contrast with other beta subunits, coexpression of the mKv beta(4) subunit with alpha subunits of Shaker-type K+ channel does not modify the kinetic properties or voltage-dependence of these channels in Xenopus oocytes. Instead, mKv beta(4) associates to Kv2.2 (CDRK), a Shab K+ channel, to specifically enhance (a factor of up to 6) its expression level without changing its elementary conductance or kinetics. It is without effect on another closely related Shab K+ channel Kv2.1 (DRK1). Chimeras between Kv2.1 and Kv2.2 indicate that the COOH-terminal end of the Kv2.2 protein is essential for its mKv beta(4) sensitivity. The functional results associated with the observation of the co-localization of mKv beta(4) and Kv2.2 transcripts in most brain areas strongly suggest that both subunits interact in vivo to form a slowly-inactivating K+ channel. A chaperone-like effect of mKv beta(4) seems to permit the integration of a larger number of Kv2.2 channels at the plasma membrane.	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Lesage, Florian/D-5097-2011; HEURTEAUX, Catherine/M-4947-2016; Duprat, Fabrice/D-1221-2013; Lesage, Florian/P-9780-2019	Lesage, Florian/0000-0002-4406-7106; HEURTEAUX, Catherine/0000-0002-9741-9777; Duprat, Fabrice/0000-0001-8774-1220; Lesage, Florian/0000-0002-4406-7106				ADELMAN JP, 1995, CURR OPIN NEUROBIOL, V5, P286, DOI 10.1016/0959-4388(95)80040-9; ALDRICH RW, 1994, CURR BIOL, V4, P839, DOI 10.1016/S0960-9822(00)00187-1; ATTALI B, 1992, J BIOL CHEM, V267, P8650; ATTALI B, 1993, J BIOL CHEM, V268, P24283; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BIDARD JN, 1987, BIOCHEM BIOPH RES CO, V143, P383, DOI 10.1016/0006-291X(87)90677-2; CATTERALL WA, 1992, PHYSIOL REV, V72, pS2; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; HWANG PM, 1993, J NEUROSCI, V13, P1569; HWANG PM, 1993, NEUROSCIENCE, V55, P613, DOI 10.1016/0306-4522(93)90427-H; HWANG PM, 1992, NEURON, V8, P473, DOI 10.1016/0896-6273(92)90275-I; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; REHM H, 1988, BIOCHEMISTRY-US, V27, P1827, DOI 10.1021/bi00406a005; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	45	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26341	26348		10.1074/jbc.271.42.26341	http://dx.doi.org/10.1074/jbc.271.42.26341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824288	hybrid			2022-12-25	WOS:A1996VN18000094
J	Inoue, Y; Kimura, A				Inoue, Y; Kimura, A			Identification of the structural gene for glyoxalase I from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA; HANSENULA-MRAKII; METHYLGLYOXAL REDUCTASE; ESCHERICHIA-COLI; YEAST GLYOXALASE; PURIFICATION; METABOLISM; CLONING; GLUTATHIONE; CATABOLISM	The structural gene for glyoxalase I (GLO1) of Saccharomyces cerevisiae was identified, The GLO1 gene contained an open reading frame with 326 amino acids, and the molecular weight of the gene product (Glo1p) deduced from the DNA sequence was calculated to be 37,207.06. Glyoxalase I activity increased approximately 95-fold when the GLO1 gene was introduced into the yeast cell with a multicopy plasmid, and the resultant transformant showed the increased resistance against methylglyoxal, Since the knockout mutant of the GLO1 gene of haploid strain of S. cerevisiae was still viable, the GLO1 gene was thought to be unnecessary for growth of the yeast, The GLO1 gene was overexpressed in two kinds of glutathione-deficient mutants, gamma-glutamylcysteine synthetase-deficient (gsh1(-)) and glutathione synthetase-deficient (gsh2(-)), respectively, and the sensitivites to methylglyoxal mere compared, The gsh1-deficient mutant, which could not produce glutathione at all, was hypersensitive to methylglyoxal, and overproduction of the Glo1p did not restore the growth arrest caused by exogenously added methylglyoxal. The gsh2-deficient mutant, which accumulates gamma-glutamylcysteine (an intermediate of glutathione biosynthesis), was also sensitive to methylglyoxal compared with the isogenic wild type strain, although the growth arrest caused by methylglyoxal was partially restored by overexpression of the GLO1 gene. Purified glyoxalase I from yeast could use gamma-glutamylcysteine as a substrate (k(cat)/K-m = 1.89 x 10(7) m(-1)s(-1), glutathione; 3.47 x 10(4) M(-1) s(-1), gamma-glutamylcysteine).			Inoue, Y (corresponding author), KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN.		kimura, akira/D-1215-2010					BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; COOPER RA, 1974, EUR J BIOCHEM, V44, P81, DOI 10.1111/j.1432-1033.1974.tb03459.x; COOPER RA, 1984, ANNU REV MICROBIOL, V38, P49, DOI 10.1146/annurev.mi.38.100184.000405; COOPER RA, 1970, FEBS LETT, V11, P273, DOI 10.1016/0014-5793(70)80546-4; Cryer D R, 1975, Methods Cell Biol, V12, P39; Dakin HD, 1913, J BIOL CHEM, V14, P155; DOUGLAS KT, 1986, INT J BIOCHEM, V18, P549, DOI 10.1016/0020-711X(86)90167-9; EGYUD LG, 1966, P NATL ACAD SCI USA, V56, P203, DOI 10.1073/pnas.56.1.203; FODOR G, 1967, P NATL ACAD SCI USA, V57, P1644, DOI 10.1073/pnas.57.6.1644; HIGGINS IJ, 1969, BIOCHIM BIOPHYS ACTA, V184, P464, DOI 10.1016/0304-4165(69)90052-X; HOPPER DJ, 1971, FEBS LETT, V13, P213, DOI 10.1016/0014-5793(71)80538-0; HOPPER DJ, 1972, BIOCHEM J, V128, P321, DOI 10.1042/bj1280321; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; INOUE Y, 1987, J BIOCHEM-TOKYO, V102, P583, DOI 10.1093/oxfordjournals.jbchem.a122091; INOUE Y, 1985, EUR J BIOCHEM, V153, P243, DOI 10.1111/j.1432-1033.1985.tb09293.x; INOUE Y, 1991, J FERMENT BIOENG, V71, P131, DOI 10.1016/0922-338X(91)90239-D; INOUE Y, 1994, J FERMENT BIOENG, V77, P557, DOI 10.1016/0922-338X(94)90129-5; INOUE Y, 1990, J BIOCHEM-TOKYO, V108, P4, DOI 10.1093/oxfordjournals.jbchem.a123159; INOUE Y, 1992, J FERMENT BIOENG, V74, P46, DOI 10.1016/0922-338X(92)90266-W; INOUE Y, 1991, BIOTECHNOL APPL BIOC, V14, P391; INOUE Y, 1991, J FERMENT BIOENG, V71, P134, DOI 10.1016/0922-338X(91)90240-H; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; KIM NS, 1993, J BIOL CHEM, V268, P11217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU TF, 1994, GENE, V150, P93, DOI 10.1016/0378-1119(94)90864-8; MARMSTAL E, 1979, BIOCHEM J, V183, P23, DOI 10.1042/bj1830023; MURATA K, 1986, J FERMENT BIOENG, V64, P1, DOI 10.1016/0385-6380(86)90049-X; MURATA K, 1985, EUR J BIOCHEM, V151, P631, DOI 10.1111/j.1432-1033.1985.tb09151.x; MURATA K, 1985, BIOCHEM BIOPH RES CO, V131, P190, DOI 10.1016/0006-291X(85)91788-7; Neuberg C, 1913, BIOCHEM Z, V49, P502; OHTAKE Y, 1990, AGR BIOL CHEM TOKYO, V54, P3145, DOI 10.1080/00021369.1990.10870487; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; RHEE H, 1986, BIOCHEM BIOPH RES CO, V141, P993, DOI 10.1016/S0006-291X(86)80142-5; RHEE H, 1987, AGR BIOL CHEM TOKYO, V51, P1059, DOI 10.1080/00021369.1987.10868174; RHEE HI, 1988, AGR BIOL CHEM TOKYO, V52, P2243; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; SZENTGYO.A, 1967, SCIENCE, V155, P539, DOI 10.1126/science.155.3762.539; TAYLOR DG, 1980, J GEN MICROBIOL, V118, P159; TSAI PK, 1976, J BIOL CHEM, V251, P364; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; WILLETTS AJ, 1970, BIOCHIM BIOPHYS ACTA, V222, P668, DOI 10.1016/0304-4165(70)90195-9; Woodward GE, 1942, J BIOL CHEM, V145, P471; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	48	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25958	25965		10.1074/jbc.271.42.25958	http://dx.doi.org/10.1074/jbc.271.42.25958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824231	hybrid			2022-12-25	WOS:A1996VN18000037
J	Chen, T; Repetto, B; Chizzonite, R; Pullar, C; Burghardt, C; Dharm, E; Zhao, AC; Carroll, R; Nunes, P; Basu, M; Danho, W; Visnick, M; Kochan, J; Waugh, D; Gilfillan, AM				Chen, T; Repetto, B; Chizzonite, R; Pullar, C; Burghardt, C; Dharm, E; Zhao, AC; Carroll, R; Nunes, P; Basu, M; Danho, W; Visnick, M; Kochan, J; Waugh, D; Gilfillan, AM			Interaction of phosphorylated Fc epsilon RI gamma immunoglobulin receptor tyrosine activation motif-based peptides with dual and single SH2 domains of p72(syk) - Assessment of binding parameters and real, time binding kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; AFFINITY PHOSPHOTYROSYL PEPTIDE; SRC HOMOLOGY-2 DOMAIN; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN; KINASES; ZAP-70; SYK	To examine the characteristics of the interaction of the Fc epsilon RI gamma ITAM with the SH2 domains of p72(syk), the binding of an I-125-labeled dual phosphorylated Fc epsilon RI gamma ITEM-based peptide to the p72(syk) SH2 domains was monitored utilizing a novel scintillation proximity based assay. The K-d for this interaction, determined from the saturation binding isotherm, was 1.4 nM. This high affinity binding was reflected in the rapid rate of association for the peptide binding to the SH2 domains. Competition studies utilizing a soluble C-terminal SH2 domain knockout and N-terminal SH2 domain knockouts revealed that both domains contribute cooperatively to the high affinity binding. I-125-labeled dual phosphorylated peptide competed with the I-125-labeled peptide for binding to the dual p72(syk) SH2 domains with an IC50 value of 4.8 nM. Monophosphorylated 24-mer Fc epsilon RI gamma ITAM peptides, and phosphotyrosine also competed for binding, but with substantially higher IC50 values. This, and other data discussed, suggest that high affinity binding requires both tyrosine residues to be phosphorylated and that the preferred binding orientation of the ITAM is such that the N-terminal phosphotyrosine occupies the C-terminal SH2 domain and the C-terminal phosphotyrosine occupies the N-terminal SH2 domain.	HOFFMANN LA ROCHE INC, DEPT INFLAMMAT & AUTOIMMUNE DIS, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT ANTISENSE RES, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT CHEM PHYS, NUTLEY, NJ 07110 USA	Roche Holding; Roche Holding; Roche Holding; Roche Holding								BANNWARTH W, 1992, HELV CHIM ACTA, V75, P707, DOI 10.1002/hlca.19920750305; BERNATOWICZ MS, 1989, TETRAHEDRON LETT, V30, P4645, DOI 10.1016/S0040-4039(01)80764-4; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EISEMAN E, 1992, NATURE, V355, P78; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GILMER T, 1994, J BIOL CHEM, V269, P31711; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW CL, 1994, J BIOL CHEM, V269, P12310; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NAKAMURA K, 1994, BBA-MOL CELL RES, V1224, P495, DOI 10.1016/0167-4889(94)90287-9; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PULLAR CE, 1996, FASEB J, V10, pA1215; REPH M, 1989, NATURE, V338, P383; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SIERKE SL, 1993, BIOCHEMISTRY-US, V32, P10102, DOI 10.1021/bi00089a028; SWIETER M, 1995, J IMMUNOL, V155, P5330; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TSAO KL, 1996, GENE AMST, V149, P59; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WILCHEK M, 1990, METHOD ENZYMOL, V184, P123; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	58	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25308	25315		10.1074/jbc.271.41.25308	http://dx.doi.org/10.1074/jbc.271.41.25308			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810294	hybrid			2022-12-25	WOS:A1996VL69300038
J	Chambers, RS; Kane, CM				Chambers, RS; Kane, CM			Purification and characterization of an RNA polymerase II phosphatase from yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TATA-BINDING PROTEIN; MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; POLYACRYLAMIDE GELS; SUBUNIT-IIA; PHOSPHORYLATION; CTD; INITIATION; CELLS	RNA polymerase (RNAP) II is subject to extensive phosphorylation on the heptapeptide repeats of the C-terminal domain (CTD) of the largest subunit, An activity that is required for the dephosphorylation of yeast RNAP II in vitro has been purified from a yeast whole cell extract by >30,000-fold, The yeast CTD phosphatase activity copurified with two bands with apparent molecular masses of 100 and 103 kDa, The properties of the yeast CTD phosphatase are similar to those of a previously characterized CTD phosphatase from HeLa cells, These properties include stimulation by the general transcription factor IIF (TFIIF), competitive inhibition by RNAP II, magnesium dependence, and resistance to okadaic acid. Both the HeLa and yeast CTD phosphatases are highly specific for their cognate polymerases. Neither phosphatase functions upon the polymerase molecule from the other species, even though the heptapeptide repeats of the CTDs in yeast RNAP II and mammalian RNAP II are essentially identical. The activity of the highly purified CTD phosphatase is stimulated >300-fold by a partially purified fraction of TFIIF. Recombinant TFIIF did not substitute for the TFIIF fraction, indicating that an additional factor present in the TFIIF fraction is required for CTD phosphatase activity, These results show that yeast contains a CTD phosphatase activity similar to that of mammalian cells that is likely composed of at least two components, one of which is 100 and/or 103 kDa.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIGMS NIH HHS [GM 34963] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUERMEYER AB, 1995, J BIOL CHEM, V270, P6798, DOI 10.1074/jbc.270.12.6798; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DEMORENO MR, 1985, ANAL BIOCHEM, V151, P466, DOI 10.1016/0003-2697(85)90206-4; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; KANG ME, 1993, J BIOL CHEM, V268, P25033; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; PAYNE JM, 1993, J BIOL CHEM, V268, P80; POON D, 1993, J BIOL CHEM, V268, P15325; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; SHENOLIKAR S, 1995, CURRENT PROTOCOLS MO, V3; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; WANG YX, 1995, J BIOL CHEM, V270, P25607, DOI 10.1074/jbc.270.43.25607; WEST ML, 1995, GENETICS, V140, P1223; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	38	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24498	24504		10.1074/jbc.271.40.24498	http://dx.doi.org/10.1074/jbc.271.40.24498			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798710	hybrid			2022-12-25	WOS:A1996VM67400032
J	Crabeel, M; Soetens, O; DeRijcke, M; Pratiwi, R; Pankiewicz, R				Crabeel, M; Soetens, O; DeRijcke, M; Pratiwi, R; Pankiewicz, R			The ARG11 gene of Saccharomyces cerevisiae encodes a mitochondrial integral membrane protein required for arginine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; YEAST; SEQUENCE; CARRIER; EXPRESSION; MUTATIONS; RECEPTOR; VECTORS; CLONING; PLASMID	Prototype strain MG409 (arg11-1) is a severe arginine bradytroph with greatly reduced ornithine and arginine pools, although all known enzymes required for arginine biosynthesis are functional. To identify the function required for normal arginine production impaired in MG409, we have cloned, sequenced, and performed a first molecular characterization of ARG11. We show that the ARG11 open reading frame encodes a putative 292-residue protein with a predicted molecular mass of 31.5 kDa. Sequence similarities, a tripartite organization, and six potential hydrophobic transmembrane spans suggest that Arg11p belongs to the mitochondrial integral inner membrane carrier family. We have used immune-Western blotting and hemagglutinin epitope-tagged derivatives of Arg11p, Arg8p (a mitochondrial matrix marker), and Arg3p (a cytosolic marker) to demonstrate that Arg11p is confined to the mitochondria and behaves like an integral membrane protein. A deletion created in ARG11 causes the same arginine-leaky behavior as the original arg11-1 mutation, which yields a premature stop codon at residue 266. Arg11p thus appears to fulfill a partially redundant function requiring its 27 carboxyl-terminal amino acids. As a working hypothesis, we propose that Arg11p participates in the export of matrix-made ornithine into the cytosol.	FREE UNIV BRUSSELS, DEPT GENET & MICROBIOL, B-1050 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Crabeel, M (corresponding author), COOVI, RES INST, VLAAMS INTERUNIV INST BIOTECHNOL, 1 E GRYSONLAAN, B-1070 BRUSSELS, BELGIUM.		Pratiwi, Rarastoeti/AAK-1315-2021	Pratiwi, Rarastoeti/0000-0002-8421-2056; De Rycke, Martine/0000-0001-7861-9426				BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BOONCHIRD C, 1991, EUR J BIOCHEM, V199, P325, DOI 10.1111/j.1432-1033.1991.tb16128.x; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CRABEEL M, 1981, P NATL ACAD SCI-BIOL, V78, P5026, DOI 10.1073/pnas.78.8.5026; CRABEEL M, 1983, EMBO J, V2, P205, DOI 10.1002/j.1460-2075.1983.tb01406.x; CRABEEL M, 1988, CURR GENET, V13, P113, DOI 10.1007/BF00365645; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; DEGRIJSE E, 1947, FEBS LETT, V43, P285; DELFORGE J, 1975, EUR J BIOCHEM, V57, P231, DOI 10.1111/j.1432-1033.1975.tb02295.x; EMMERMANN M, 1991, CURR GENET, V20, P405, DOI 10.1007/BF00317069; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAF R, 1993, YEAST, V9, P301, DOI 10.1002/yea.320090310; HEIMBERG H, 1990, GENE, V90, P69, DOI 10.1016/0378-1119(90)90440-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1978, J BACTERIOL, V133, P1096, DOI 10.1128/JB.133.3.1096-1107.1978; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; MESSENGUY F, 1980, EUR J BIOCHEM, V108, P439, DOI 10.1111/j.1432-1033.1980.tb04740.x; MINET M, 1971, THESIS U LIBRE BRUXE; MURAKAMI H, 1990, NATURE, V347, P488, DOI 10.1038/347488a0; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RAMOS F, 1979, EUR J BIOCHEM, V94, P409, DOI 10.1111/j.1432-1033.1979.tb12908.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WIAME JM, 1971, RECENT ADV MICROBIOL, P243; Wiemann S, 1996, YEAST, V12, P281; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; ZARA V, 1991, EUR J BIOCHEM, V198, P405, DOI 10.1111/j.1432-1033.1991.tb16029.x	32	50	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25011	25018		10.1074/jbc.271.40.25011	http://dx.doi.org/10.1074/jbc.271.40.25011			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798783	hybrid			2022-12-25	WOS:A1996VM67400106
J	Desmarais, D; Royal, A				Desmarais, D; Royal, A			The TATA motif is a target for efficient transcriptional activation and nerve growth factor induction of the peripherin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; NEGATIVE REGULATORY ELEMENT; NEURON-SPECIFIC EXPRESSION; RNA POLYMERASE-II; BINDING PROTEIN; CORE PROMOTER; CELL-LINES; PC12 CELLS; DIFFERENTIAL EXPRESSION; MESSENGER-RNAS	Three proximal elements, PERI, PER2, and PER3, have been implicated in the regulation of peripherin gene expression. PER1 contains the TATA motif and was identified as the principal mediator of neuronal specificity. Here, we demonstrate by transfection of constructs mutated in PER1 that the in vitro protein binding activity of PER1 is irrelevant to its function. However, mutations or substitutions in the TATA box decreased promoter activity by up to 80%. We have investigated this unusual preference for a particular TATA sequence in PC12 cells. In these cells, nerve growth factor induces neuronal differentiation, increasing peripherin gene expression 3-4-fold, while dexamethasone elicits chromaffin differentiation and a 3-fold decrease in peripherin mRNA. Experiments with stably transfected PC12 cells revealed that the specific TATA box of the peripherin gene was crucial for nerve growth factor response. However, it did not affect dexamethasone down-regulation. Therefore, nerve growth factor acts through an element essential for neuronal peripherin gene expression. The results predict that proteins interacting in the vicinity of the TATA box, by inference factors associated with the preinitiation complex, are important for peripherin gene regulation and provide new insights into the mechanisms underlying neuronal differentiation.	UNIV MONTREAL, DEPT PATHOL, GRP RECH ONCOGENET, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal								ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BELECKYADAMS T, 1993, J NEUROSCI, V13, P5056, DOI 10.1523/JNEUROSCI.13-12-05056.1993; BRODY BA, 1989, J NEUROSCI, V9, P2391; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIN LS, 1994, J BIOL CHEM, V269, P18507; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ESCURAT M, 1990, J NEUROSCI, V10, P764; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; FERRARI N, 1995, GENE, V159, P159, DOI 10.1016/0378-1119(95)00140-2; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; GORHAM JD, 1990, DEV BRAIN RES, V57, P235, DOI 10.1016/0165-3806(90)90049-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HUANG DH, 1988, J BIOL CHEM, V263, P12596; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MINNA J, 1972, NATURE-NEW BIOL, V235, P225, DOI 10.1038/newbio235225a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OBLINGER MM, 1989, J NEUROSCI, V9, P3766; PARYSEK LM, 1987, J NEUROSCI, V7, P781; PARYSEK LM, 1988, J NEUROSCI, V8, P555; Portier Marie-Madeleine, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1124; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SIMON MC, 1990, P NATL ACAD SCI USA, V87, P513, DOI 10.1073/pnas.87.2.513; STARR DB, 1995, J MOL BIOL, V250, P434; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THEILL LE, 1987, MOL CELL BIOL, V7, P4329, DOI 10.1128/MCB.7.12.4329; THOMPSON MA, 1992, MOL CELL BIOL, V12, P2501, DOI 10.1128/MCB.12.6.2501; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TROY CM, 1990, NEUROSCIENCE, V36, P217, DOI 10.1016/0306-4522(90)90364-A; VANDEKLUNDERT FAJM, 1993, EUR J BIOCHEM, V214, P351; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WILKINSON M, 1991, NUCLEIC ACIDS RES, V19, P679, DOI 10.1093/nar/19.3.679; WONG J, 1990, J NEUROSCI RES, V27, P332, DOI 10.1002/jnr.490270312; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	63	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24976	24981		10.1074/jbc.271.40.24976	http://dx.doi.org/10.1074/jbc.271.40.24976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798778	hybrid			2022-12-25	WOS:A1996VM67400101
J	Webb, DJ; Wen, J; Lysiak, JJ; Umans, L; VanLeuvenn, F; Gonias, SL				Webb, DJ; Wen, J; Lysiak, JJ; Umans, L; VanLeuvenn, F; Gonias, SL			Murine alpha-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-beta and as inducers of nitric oxide synthesis - A possible mechanism for the endotoxin insensitivity of the alpha(2)-macroglobulin gene knock-out mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APPARENT EQUILIBRIUM CONDITIONS; MACROPHAGE CELL-LINE; CARCINOMA FET CELLS; HUMAN ALPHA-2-MACROGLOBULIN; SEPTIC SHOCK; DIFFERENTIAL INDUCTION; INTERFERON-GAMMA; SYNTHASE; BINDING; EXPRESSION	alpha(2)-Macroglobulin null mice demonstrate increased resistance to endotoxin challenge (Umans, L., Serneels, L., Overbergh, L., Van Leuven, F., and Van den Berghe, H. (1995) J. Biol. Chem. 270, 19778-19785). We hypothesized that this phenotype might reflect the function of murine alpha(2)M (m alpha(2)M) as a neutralizer of transforming growth factor-beta (TGF-beta) and inducer of nitric oxide synthesis in vivo. When incubated with wild-type mouse plasma, TGF-beta 1 and TGF-beta 2 bound only to m alpha(2)M. Alternative TGF-beta-binding proteins were not detected in plasma from alpha(2)M(-/-) mice. Wild-type mouse plasma, but not plasma from alpha(2)M(-/-) mice, inhibited TGF-beta 1 binding to TGF-beta receptors on fibroblasts. Purified alpha(2)M bound TGF-beta 1 and TGF-beta 2 with similar affinity; the K-D values were 28 +/- 4 and 33 +/- 4 nm, respectively. Murinoglobulin, the second murine cu-macroglobulin, bound both TGF-beta isoforms with 30-fold lower affinity, M alpha(2)M counteracted the activities of TGF-beta 1 and TGF-beta 2 in an endothelial cell growth assay. M alpha(2)M also induced NO synthesis when incubated with RAW 264.7 cells, an activity which probably results from the neutralization of autocrine TGF-beta activity. Human alpha(2)M induced NO synthesis comparably to m alpha(2)M; however, MUG had no effect. These studies demonstrate that the ability to neutralize TGF-beta is a property of m alpha(2)M, which is not redundant in the murine alpha-macroglobulin family or in murine plasma, M alpha(2)M is the only murine alpha-macroglobulin that promotes NO synthesis. The absence of m alpha(2)M, in alpha(2)M(-/-) mice, may allow TGF-beta to more efficiently suppress excessive iNOS expression following endotoxin challenge.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; KATHOLIEKE UNIV LEUVEN,DEPT HUMAN GENET,EXPT GENET GRP,B-3000 LOUVAIN,BELGIUM	University of Virginia; University of Virginia; KU Leuven					NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE K, 1989, J BIOCHEM-TOKYO, V106, P564; ANONICK PK, 1989, BIOCHEM J, V264, P745, DOI 10.1042/bj2640745; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BERMUDEZ LE, 1993, J IMMUNOL, V150, P1838; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; BURRELL R, 1994, CIRC SHOCK, V43, P137; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, BIOCHEM BIOPH RES CO, V200, P1578, DOI 10.1006/bbrc.1994.1631; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; CUNHA FQ, 1994, IMMUNOLOGY, V81, P211; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DENHOLM EM, 1993, AM J PHYSIOL, V264, pL36, DOI 10.1152/ajplung.1993.264.1.L36; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; GIRI SN, 1993, THORAX, V48, P6959; GONIAS SL, 1983, BIOCHEM J, V209, P99, DOI 10.1042/bj2090099; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAAKFRENDSCHO M, 1990, CLIN EXP IMMUNOL, V82, P404; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAMARRE J, 1994, BIOCHEM J, V302, P199, DOI 10.1042/bj3020199; LAMBERT LE, 1989, CELL IMMUNOL, V120, P401, DOI 10.1016/0008-8749(89)90208-6; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OCONNORMCCURT M, 1987, J BIOL CHEM, V262, P1400; OVERBERGH L, 1994, GENOMICS, V22, P530, DOI 10.1006/geno.1994.1426; OVERBERGH L, 1991, J BIOL CHEM, V266, P16903; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; PIZZO SV, 1984, RECEPTORS, V1, P177; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SAITO A, 1985, J BIOL CHEM, V260, P775; SZABO C, 1993, BRIT J PHARMACOL, V108, P786, DOI 10.1111/j.1476-5381.1993.tb12879.x; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; VANLEUVEN F, 1992, EUR J BIOCHEM, V210, P319; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; Weaver AM, 1995, J BIOL CHEM, V270, P30741, DOI 10.1074/jbc.270.51.30741; WEBB DJ, 1995, BIOCHEM J, V312, P579, DOI 10.1042/bj3120579; WEBB DJ, 1994, J BIOL CHEM, V269, P30402; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WOLF BB, 1994, BIOCHEMISTRY-US, V33, P11270, DOI 10.1021/bi00203a024; WOLFE TA, 1995, ANN PHARMACOTHER, V29, P36, DOI 10.1177/106002809502900108; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	58	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24982	24988		10.1074/jbc.271.40.24982	http://dx.doi.org/10.1074/jbc.271.40.24982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798779	hybrid			2022-12-25	WOS:A1996VM67400102
J	Caligo, MA; Ghimenti, C; Cipollini, G; Ricci, S; Brunetti, I; Marchetti, V; Olsen, R; Neuhausen, S; ShattuckEidens, D; Conte, PF; Skolnick, MH; Bevilacqua, G				Caligo, MA; Ghimenti, C; Cipollini, G; Ricci, S; Brunetti, I; Marchetti, V; Olsen, R; Neuhausen, S; ShattuckEidens, D; Conte, PF; Skolnick, MH; Bevilacqua, G			BRCA1 germline mutational spectrum in Italian families from Tuscany: A high frequency of novel mutations	ONCOGENE			English	Article						hereditary breast ovarian cancer; BRCA1; mutation	CANCER SUSCEPTIBILITY GENE; OVARIAN-CANCER; BREAST-CANCER; LINKAGE; TUMORS; MAP	BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer, Mutational hot spots have never been detected in BRCA1 cDNA, Some mutations have been reported several times whereas some others appear to be population-related. In this study a group of 36 Italian families were analysed for BRCA1 germline mutations, All of them mere screened by allele-specific oligonucleotide hybridization (ASO) for three recurrent mutations (185delAG, 5382insC, nt332T>G), Twenty families, selected because of their high risk of carrying BRCA1 mutations, were subjected to analysis of the entire coding sequence of the gene, A total of eight mutations were found, ASO screening demonstrated only one known mutation in one patient, whereas cycle sequencing revealed five new mutations, Three of these new mutations were frameshifts: one occurred in exon 11 (1499insA), one in exon 16 (4873delCA) and one in the splice site of exon 3 (252delAAgt). Two were missense mutations (Cys64Arg; Asn158Tyr. The same frameshift mutation, 1499insA, was detected in three unrelated families, Haplotype analysis supported the hypothesis that two of these families may have had common ancestors, whereas in the third family the analysis was uninformative, BRCA1 germ line mutations mere found in one out of two families with ovarian cancer, in five out of eight families with breast-ovarian cancer, and in two out of 11 families with breast canter, All three families with 1499insA mutations included at least one case of ovarian cancer, The majority of the ovarian cancers (4/5) associated with detectable BRCA1 germline mutations were of serous histotype.	MYRIAD GENET, SALT LAKE CITY, UT USA; UNIV UTAH, DEPT MED INFORMAT, SALT LAKE CITY, UT 84112 USA; SANTA CHIARA HOSP, DEPT MED ONCOL, PISA, ITALY	Myriad Genetics, Inc; Utah System of Higher Education; University of Utah; Santa Chiara Hospital	Caligo, MA (corresponding author), UNIV PISA, INST PATHOL, PISA, ITALY.		Conte, PierFranco/F-7418-2014; Caligo, Adelaide Maria/K-4289-2018	Conte, PierFranco/0000-0002-5210-5344; Caligo, Adelaide Maria/0000-0003-0589-1829; BEVILACQUA, GENEROSO/0000-0001-8857-2609				BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; NAROD SA, 1991, LANCET, V338, P82; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAKAHASHI H, 1995, CANCER RES, V55, P2998; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	26	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1483	1488						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875986				2022-12-25	WOS:A1996VL38400013
J	Mangeney, M; Schmitt, JR; Leverrier, Y; Thomas, J; Marvel, J; Brun, G; Gillet, G				Mangeney, M; Schmitt, JR; Leverrier, Y; Thomas, J; Marvel, J; Brun, G; Gillet, G			The product of the v-src-inducible gene nr-13 is a potent anti-apoptotic factor	ONCOGENE			English	Article						v-src; apoptosis; cell transformation	QUAIL NEURORETINAL CELLS; BONE-MARROW CELLS; B-CELLS; DEATH; BCL-2; VIRUS; PROTEIN; TRANSFORMATION; INDUCTION; ONCOGENES	Tumorigenesis can be induced either by activating cell proliferation or by inhibiting metabolic pathways regulating programmed cell death (apoptosis). There is evidence suggesting that p60(v-src) and other tyrosine kinases protect cells against apoptosis. This effect could contribute to cell transformation by the Rous sarcoma virus, Mechanism of cell death inhibition by p60(v-src) remains Largely unknown, We have recently reported that in avian cells p60(v-src) activates the expression of nr-13, a bcl-2-related gene, In this paper, we demonstrate, using the bone marrow derived cell line Baf-3 as an experimental model, that the product of this avian gene (nr-13) is a potent anti-apoptotic factor, In addition, we report that, in quail neuroretinal cells, nr-13 expression is activated upon infection by the Rous sarcoma virus (RSV) but not by other oncogenic retroviruses like FSV or MH2, suggesting that nr-13 is a specific target of v-src. Activation of nr-13 expression may be a key step in cellular transformation by v-src.	ECOLE NORMALE SUPER LYON,UMR 49 CNRS,BIOL CELLULAIRE & MOL LAB,IMMUNOL CELLULAIRE GRP,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,UMR 49 CNRS,BIOL CELLULAIRE & MOL LAB,BIOL REGULAT CELLULAIRES RES GRP,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON)			marvel, jacqueline/H-8638-2014; LEVERRIER, Yann/M-3767-2014; gillet, germain/A-9095-2013	marvel, jacqueline/0000-0001-6241-459X; LEVERRIER, Yann/0000-0002-4227-5446; Mangeney, Marianne/0000-0002-9102-191X; Thomas, Joelle/0000-0002-0461-6131; GILLET, Germain/0000-0002-1514-327X				BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN J, 1994, J BIOL CHEM, V269, P7957; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; MARVEL J, 1994, ONCOGENE, V9, P1117; MICHEL D, 1989, ONCOGENE RES, V4, P127; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; VAUX D, 1992, SCIENCE, V258, P1195; WIERDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	33	25	25	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1441	1446						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875982				2022-12-25	WOS:A1996VL38400009
J	Wang, JW; Shackleford, GM				Wang, JW; Shackleford, GM			Murine Wnt10a and Wnt10b: Cloning and expression in developing limbs, face and skin of embryos and in adults	ONCOGENE			English	Article						breast neoplasms; oncogene; embryonic development; alternative splicing; limb development; Wnt	MAMMARY-TUMOR VIRUS; GENE FAMILY; TRANSGENIC MICE; CELL-LINE; INT-1 PROTOONCOGENE; PROVIRAL INSERTION; ONCOGENE INT-1; MOUSE; WNT-1; TRANSFORMATION	Wnt genes encode a family of secreted proteins having oncogenic potential and important roles in developmental processes, We report the isolation of cDNAs for a novel murine Wnt gene, Wnt10a, and for two alternatively spliced transcripts of Wnt10b, as well as analyses of the expression patterns of these genes in adult and embryonic tissues, Wnt10a and full length Wnt10b encode relatively closely related (62% identity) Wnt proteins containing the 24 cysteines characteristic of most Wnt proteins, The deduced protein encoded by the alternatively spliced Wnt10b transcript lacks a central region encompassing 25% of the full length isoform, Both Wnt genes were widely expressed in the adult, although the levels of expression varied significantly, Wnt10a RNA was most abundant in adult brain with a high concentration in the pituitary gland, and expression of Wnt10b was highest in adult lung and uterus, RNAs of both genes mere detected in thymus and spleen, tissues not previously reported as sites for Wnt gene expression, Wnt10a and Wnt10b expression broadly peaked at approximately 13.5 and 15.5 days of gestation, respectively, and Northern blot analyses of RNAs from dissected embryos revealed that expression of both genes was strongest in the face, limbs and skin and that Wnt10a was also expressed in the Liver, the major site of hematopoiesis in the embryo, These expression patterns suggest that Wnt10a and Wnt10b may function in various tissues of the adult and embryo with notable expression in tissues responsible for the formation and maturation of blood cells, in the pituitary gland (Wnt10a), and in the face, Limbs and skin of developing embryos.	CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,RES INST,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; University of Southern California					NATIONAL CANCER INSTITUTE [R01CA054436] Funding Source: NIH RePORTER; NCI NIH HHS [CA54436] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONOHOWER LA, 1995, GENE DEV, V9, P882; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; IOZZO RV, 1995, CANCER RES, V55, P3495; KELLY GM, 1993, DEV BIOL, V158, P113, DOI 10.1006/dbio.1993.1172; KOZAK M, 1983, MICROBIOL REV, V47, P1; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1992, CIBA F SYMP, V165, P199; MOON RT, 1993, DEVELOPMENT, P85; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; RUGH R, 1968, MOUSE ITS REPRODUCTI; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; SU SJ, 1995, MOL CELL BIOL, V15, P2625; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAUTZ D, 1992, IN SITU HYBRIDIZATIO, P61; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	49	79	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1537	1544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875992				2022-12-25	WOS:A1996VL38400019
J	Jang, SI; Steinert, PM; Markova, NG				Jang, SI; Steinert, PM; Markova, NG			Activator protein 1 activity is involved in the regulation of the cell type-specific expression from the proximal promoter of the human profilaggrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-18; DIFFERENTIATION-SPECIFIC EXPRESSION; KERATINOCYTE-SPECIFIC TRANSCRIPTION; EPIDERMAL DIFFERENTIATION; TRANSGENIC MICE; DNA-BINDING; HUMAN LORICRIN; RETINOIC ACID; AP-1 ELEMENT; AP1 SITES	The human profilaggrin gene is expressed in the granular layer during the late stages of terminal differentiation of the epidermis. In in vitro transcription experiments we show that the abundance of the mRNA and the specificity of the expression are regulated primarily at the level of transcription. We found that the 5'-flanking sequences control the transcription in a keratinocyte-specific mode and that as little as 116 base pairs preceding the mRNA initiation site is sufficient to restrict the transcription to epidermal cells in vitro. This specificity depends critically on the presence of an activator protein 1 (AP1) motif at position -77. Binding of c-jun/c-fos heterodimers to this sequence confers high levels of expression to the reporter constructs in cultured epidermal keratinocytes, while having little effect in HeLa cells. The transactivating properties of c-jun are essential in this process. On the other hand, junB and junD, which are involved in transactivating the transcription of earlier epidermal differentiation markers, control profilaggrin expression through a pathway which does not depend on a direct binding at the AP1 site and is not cell-type specific. These data indicate that AP1 factors are involved in a complex, multipathway regulation of the profilaggrin gene expression.	NIAMS,NATL INST HLTH,SKIN BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ANDDERSON B, 1992, SCIENCE, V260, P78; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; Bernerd Francoise, 1993, Gene Expression, V3, P187; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; Blumenberg Miroslav, 1993, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; FISCHER C, 1987, J INVEST DERMATOL, V88, P661; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HU L, 1994, J BIOL CHEM, V269, P183; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MCKINLEYGRANT L, 1990, P NATL ACAD SCI USA, V86, P4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; OSHIMA R G, 1992, Current Opinion in Cell Biology, V4, P110, DOI 10.1016/0955-0674(92)90067-M; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PARRY DAD, 1995, INTRMEDIATE FILAMENT; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; Resing K.A., 1991, PHYSL BIOCH MOL BIOL, V1, P148; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEMAT A, 1988, DIFFERENTIATION, V37, P40, DOI 10.1111/j.1432-0436.1988.tb00794.x; SNAPE AM, 1991, DEVELOPMENT, V113, P283; STEINERT PM, 1991, PHYSL BIOCH MOL BIOL, P113; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TAKAHASHI H, 1992, J INVEST DERMATOL, V100, P10; TAMAI K, 1994, J BIOL CHEM, V269, P493; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; THOREY IS, 1992, DEV DYNAM, V195, P100, DOI 10.1002/aja.1001950204; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WU RL, 1994, J BIOL CHEM, V269, P28450; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YANG-YEN H-F, 1990, New Biologist, V2, P351; YUKAWA K, 1993, GENE, V133, P163; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	71	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24105	24114		10.1074/jbc.271.39.24105	http://dx.doi.org/10.1074/jbc.271.39.24105			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798649	hybrid			2022-12-25	WOS:A1996VJ44200078
J	McInerney, EM; Katzenellenbogen, BS				McInerney, EM; Katzenellenbogen, BS			Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTORS; PROMOTER-CONTEXT; DISTINCT CLASSES; BINDING DOMAINS; HORMONE; CELLS; TRANSACTIVATION; IDENTIFICATION; LIGAND; YEAST	The human estrogen receptor (ER) is a ligand-inducible transcription factor that contains two transcriptional activation functions, one located in the NH2-terminal region of the protein (AF-1) and the second in the COOH-terminal region (AF-2). Antiestrogens, such as trans-hydroxytamoxifen (TOT), have partial agonistic activity in certain cell types, and studies have implied that this agonism is AF-1-dependent. We have made progressive NH2-terminal and other segment deletions and ligations in the A/B domain, and studied the transcriptional activity of these mutant ERs in ER-negative MDA-MB-231 human breast cancer and HEC-1 human endometrial cancer cells. Using several estrogens and several partial agonist/antagonist antiestrogens, we find that estrogens and antiestrogens require different regions of AF-1 for transcriptional activation. Deletion of the first 40 amino acids has no effect on receptor activity. Antiestrogen agonism is lost upon deletion to amino acid 87, while estrogen agonism is not lost until deletions progress to amino acid 109. Antiestrogen agonism has been further defined to require amino acids 41-64, as deletion of only these amino acids results in an ER that exhibits 100% activity with E(2), but no longer shows an agonist response to TOT. With A/B-modified receptors in which antiestrogens lose their agonistic activity, the antiestrogens then function as pure estrogen antagonists. Our studies show that in these cellular contexts, hormone-dependent transcription utilizes a range of the amino acid sequence within the A/B domain. Furthermore, the agonist/antagonist balance and activity of antiestrogens such as TOT are determined by specific sequences within the A/B domain and thus may be influenced by differences in levels of specific factors that interact with these regions of the ER.	UNIV ILLINOIS,DEPT MOL & INTEGRAT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL CANCER INSTITUTE [R37CA018119, R01CA060514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007238] Funding Source: NIH RePORTER; NCI NIH HHS [2R37CA18119, CA60514] Funding Source: Medline; NIGMS NIH HHS [T32GM07238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHEN C, 1987, MOL CELL BIOL, V8, P5323; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; KATZENELLENBOGEN BS, 1979, ENDOCRINOLOGY, V105, P33, DOI 10.1210/endo-105-1-33; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VONANGERER E, 1995, ANN NY ACAD SCI, V761, P176; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647	33	171	176	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24172	24178		10.1074/jbc.271.39.24172	http://dx.doi.org/10.1074/jbc.271.39.24172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798658	hybrid			2022-12-25	WOS:A1996VJ44200087
J	Richardson, RT; ORand, MG				Richardson, RT; ORand, MG			Site-directed mutagenesis of rabbit proacrosin - Identification of residues involved in zona pellucida binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOAR SPERM PROACROSIN; ACROSOME REACTION; GLYCOPROTEINS; PROTEINS; POLYSACCHARIDES; LOCALIZATION; ACTIVATION; POLYMERS; PORCINE; MATRIX	The mammalian acrosomal sperm protease proacrosin plays a role in fertilization by proteolysis of the oocyte's outer investments, In addition to its serine protease activity, acrosin from several species is known to have binding activity for the zona pellucida, and this action may serve to anchor sperm during zona penetration. In this study, proacrosin was purified from acid extracts of rabbit sperm and shown to bind to homologous zona pellucida using an in vitro assay. Measurement of this binding activity indicated a high affinity saturable interaction with a K-D = 1.4 x 10(-8) M. Using cDNAs obtained from previously cloned and sequenced rabbit proacrosin and a splice variant that encodes a shorter form of acrosin (Richardson, R. T., and O'Rand, M. G. (1994) Biochim. Biophys. Acta 1219, 215-218), constructs of various sizes were produced using polymerase chain reaction and expressed as recombinant proteins. In the same in vitro zona binding assay, a construct representing residues 1-279 of rabbit proacrosin was found to bind to zona with a high affinity similar to that of native proacrosin, K-D = 2.1 x 10(-8) M. By making smaller recombinant fragments and assaying them for zona binding activity, the location of the binding site was mapped to residues 47-94. Protein modeling of rabbit proacrosin using chymotrypsinogen A as a three-dimensional model indicated that an exposed loop Asp(35) to His(40) in chymotrypsinogen A is extended with an additional five amino acid residues in rabbit proacrosin from Ile(43) to His(53) containing arginine residues Arg(47), Arg(50) and Arg(51). Site-directed mutagenesis of arginine residues Arg(50) and Arg(51) to alanine produced a recombinant without significant zona binding activity. These results are consistent with the hypothesis that rabbit proacrosin contains a specific zona pellucida binding site and that the loop containing arginine residues 50 and 51 is critical for zona binding activity.			Richardson, RT (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CB 7090,CHAPEL HILL,NC 27599, USA.				NICHD NIH HHS [P30HD18968, HD 14232] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018968, R01HD014232] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BABA T, 1989, J BIOL CHEM, V264, P11920; DUNBAR BS, 1980, BIOCHEMISTRY-US, V19, P356, DOI 10.1021/bi00543a017; DUNBAR BS, 1981, BIOL REPROD, V24, P1111; EBERSPAECHER U, 1991, MOL REPROD DEV, V30, P164, DOI 10.1002/mrd.1080300214; HARDY DM, 1994, J BIOL CHEM, V269, P19000; HEDRICK JL, 1989, BIOCATALYSIS AGR BIO, P215; JANSEN S, 1993, BIOCHEM SOC T, V21, P470; JONES R, 1991, DEVELOPMENT, V111, P1155; KLEMM U, 1991, HUM GENET, V87, P635; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGGIO LL, 1994, J REPROD FERTIL, V100, P177, DOI 10.1530/jrf.0.1000177; MUKERJI SK, 1979, J BIOL CHEM, V254, P1721; ORAND MG, 1988, DEV BIOL, V129, P231, DOI 10.1016/0012-1606(88)90177-7; ORAND MG, 1986, MOL CELLULAR ASPECTS, P131; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; RICHARDSON DC, 1992, PROTEIN SCI, V1, P3; RICHARDSON RT, 1991, BIOL REPROD, V45, P20, DOI 10.1095/biolreprod45.1.20; RICHARDSON RT, 1994, BBA-GENE STRUCT EXPR, V1219, P215, DOI 10.1016/0167-4781(94)90275-5; RICHARDSON RT, 1994, DEV BIOL, V165, P688, DOI 10.1006/dbio.1994.1285; Schleuning W D, 1976, Methods Enzymol, V45, P330; TOPFERPETERSEN E, 1987, FEBS LETT, V226, P38, DOI 10.1016/0014-5793(87)80546-X; TOPFERPETERSEN E, 1990, FEBS LETT, V265, P51, DOI 10.1016/0014-5793(90)80881-I; TOPFERPETERSEN E, 1990, INT J ANDROL, V13, P190, DOI 10.1111/j.1365-2605.1990.tb00976.x; URCH UA, 1991, DEVELOPMENT, V111, P1165; WILLIAMS RM, 1993, J EXP ZOOL, V266, P65, DOI 10.1002/jez.1402660110; Zaneveld L. J. D., 1991, A comparative overview of mammalian fertilization., P63	26	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24069	24074		10.1074/jbc.271.39.24069	http://dx.doi.org/10.1074/jbc.271.39.24069			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798644				2022-12-25	WOS:A1996VJ44200073
J	Sorgenfrei, O; Duin, EC; Klein, A; Albracht, SPJ				Sorgenfrei, O; Duin, EC; Klein, A; Albracht, SPJ			Interactions of Se-77 and (CO)-C-13 with nickel in the active site of active F-420-nonreducing hydrogenase from Methanococcus voltae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-GIGAS HYDROGENASE; ELECTRON-PARAMAGNETIC-RES; IRON-SULFUR CENTERS; CHROMATIUM-VINOSUM; VULGARIS HILDENBOROUGH; METHANOBACTERIUM-THERMOAUTOTROPHICUM; REDOX PROPERTIES; EPR; ACTIVATION; IDENTIFICATION	The selenium-containing F-420-nonreducing hydrogenase from Methanococcus voltae was prepared in the Ni-a(I). CO state. The effect of illumination on this light-sensitive species was studied. EPR studies were carried out with enzyme containing natural selenium or with enzyme enriched in Se-77. Samples were prepared with either CO or (CO)-C-13. In the Ni-a(I). CO state, the nuclear spins of both Se-77 (I = 1/2) and C-13 (I = 1/2) interacted with the nickel based unpaired electron, suggesting that they are positioned on opposite sites of the nickel ion, In the light-induced signal, the interaction with (CO)-C-13 was lost. The Se-77 nuclear spin introduced an anisotropic hyperfine splitting in both the dark and light-induced EPR signals, The data on the active enzyme of M. voltae are difficult to reconcile with the crystal structure of the inactive hydrogenase of Desulfovibrio gigas (Volbeda, A., Charon, M. H., Piras, C, Hatchikian, E. C., Frey, M., and Fontecilla Camps, J. C. (1995) Nature 373, 580-587) and suggest a structural change in the active site upon activation of the enzyme.	BIOCENTRUM AMSTERDAM,EC SLATER INST,NL-1018 TV AMSTERDAM,NETHERLANDS	University of Amsterdam	Sorgenfrei, O (corresponding author), UNIV MARBURG,DEPT BIOL,KARL VON FRISCH STR,D-35032 MARBURG,GERMANY.							ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ALBRACHT SPJ, 1983, BIOCHIM BIOPHYS ACTA, V724, P309, DOI 10.1016/0005-2728(83)90089-0; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; ALBRACHT SPJ, 1982, FEBS LETT, V140, P311, DOI 10.1016/0014-5793(82)80921-6; BEINERT H, 1982, BIOCHIM BIOPHYS ACTA, V683, P245, DOI 10.1016/0304-4173(82)90003-9; CAMMACK R, 1987, BIOCHIM BIOPHYS ACTA, V912, P98, DOI 10.1016/0167-4838(87)90252-4; COREMANS JMC, 1991, THESIS U AMSTERDAM N; COREMANS JMCC, 1992, BIOCHIM BIOPHYS ACTA, V1119, P148, DOI 10.1016/0167-4838(92)90385-Q; FAN CL, 1991, J AM CHEM SOC, V113, P20, DOI 10.1021/ja00001a003; FERNANDEZ VM, 1985, BIOCHIM BIOPHYS ACTA, V832, P69, DOI 10.1016/0167-4838(85)90175-X; FERNANDEZ VM, 1986, BIOCHIM BIOPHYS ACTA, V883, P145, DOI 10.1016/0304-4165(86)90145-5; FRIEDRICH B, 1981, J BACTERIOL, V145, P1144, DOI 10.1128/JB.145.3.1144-1149.1981; GRAF EG, 1981, FEBS LETT, V136, P165, DOI 10.1016/0014-5793(81)81238-0; HAGEN WR, 1986, FEBS LETT, V201, P158, DOI 10.1016/0014-5793(86)80590-7; HAGEN WR, 1986, FEBS LETT, V203, P59, DOI 10.1016/0014-5793(86)81436-3; HALBOTH S, 1992, MOL GEN GENET, V233, P217, DOI 10.1007/BF00587582; HE SH, 1989, J BIOL CHEM, V264, P2678; KOJIMA N, 1983, P NATL ACAD SCI-BIOL, V80, P378, DOI 10.1073/pnas.80.2.378; KRASNA AI, 1954, J AM CHEM SOC, V76, P3015, DOI 10.1021/ja01640a045; MARGANIAN CA, 1995, J AM CHEM SOC, V117, P1584, DOI 10.1021/ja00110a013; MARGANIANGOLDMA.C, 1995, COMMENTS INORG CHEM, V18, P1; MEDINA M, 1994, J CHEM SOC FARADAY T, V90, P2921, DOI 10.1039/ft9949002921; MEYER J, 1991, BIOCHEMISTRY-US, V30, P9697, DOI 10.1021/bi00104a018; MOURA JJG, 1982, BIOCHEM BIOPH RES CO, V108, P1388, DOI 10.1016/S0006-291X(82)80060-0; NEESE F, 1995, 136 QCMP; PIERIK AJ, 1992, EUR J BIOCHEM, V206, P697, DOI 10.1111/j.1432-1033.1992.tb16976.x; RITTENBERG D, 1955, DISCUSS FARADAY SOC, V20, P185; SORGENFREI O, 1993, FEBS LETT, V332, P291, DOI 10.1016/0014-5793(93)80652-B; SORGENFREI O, 1993, EUR J BIOCHEM, V213, P1355, DOI 10.1111/j.1432-1033.1993.tb17888.x; SURERUS KK, 1994, BIOCHEMISTRY-US, V33, P4980, DOI 10.1021/bi00182a029; TEIXEIRA M, 1983, EUR J BIOCHEM, V130, P481, DOI 10.1111/j.1432-1033.1983.tb07175.x; TEIXEIRA M, 1985, J BIOL CHEM, V260, P8942; VANDERZWAAN JW, 1985, FEBS LETT, V179, P271, DOI 10.1016/0014-5793(85)80533-0; VANDERZWAAN JW, 1990, BIOCHIM BIOPHYS ACTA, V1041, P101, DOI 10.1016/0167-4838(90)90051-G; VANDERZWAAN JW, 1986, BIOCHIM BIOPHYS ACTA, V872, P208, DOI 10.1016/0167-4838(86)90273-6; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; VOORDOUW G, 1992, ADV INORG CHEM, V38, P397, DOI 10.1016/S0898-8838(08)60069-0; VOORDOUW G, 1985, EUR J BIOCHEM, V148, P515, DOI 10.1111/j.1432-1033.1985.tb08869.x; Wertz J. E., 1972, ELECT SPIN RESONANCE; WHITEHEAD JP, 1993, J AM CHEM SOC, V115, P5629, DOI 10.1021/ja00066a032; WHITMAN WB, 1982, J BACTERIOL, V149, P852, DOI 10.1128/JB.149.3.852-863.1982; YAMAZAKI S, 1982, J BIOL CHEM, V257, P7926	42	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23799	23806		10.1074/jbc.271.39.23799	http://dx.doi.org/10.1074/jbc.271.39.23799			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798608	Green Published, hybrid			2022-12-25	WOS:A1996VJ44200037
J	OHagan, RC; Tozer, RG; Symons, M; McCormick, F; Hassell, JA				OHagan, RC; Tozer, RG; Symons, M; McCormick, F; Hassell, JA			The activity of the ets transcription factor PEA3 is regulated by two distinct MAPK cascades	ONCOGENE			English	Article						PEA3; Ets; MAPK; Ras; transcription	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; COMPLEX FACTOR ELK-1; DNA-BINDING MOTIF; C-JUN; RAS TRANSFORMATION; MAMMALIAN-CELLS; DOMAIN PROTEIN; PHOSPHORYLATION; GENE	PEA3, a member of the Ets family of transcriptional regulatory proteins, binds to the PEA3 promoter element and stimulates transcription through this site, The activity of the PEA3 element is regulated by mitogens, activated receptor tyrosine kinases, members Ras signal However, not clear whether transcriptional regulation by these agents because a number of different Ets proteins can functionally interact with the PEA3 element. To specifically learn whether the activity of PEA3 is regulated, we investigated the ability of constitutively-activated Ras (Ha-RasV12) and signaling proteins downstream of Ras to alter PEA3-dependent reporter gene expression in COS cells, Ha-RasV12 and activated proteins in both the extra-cellular regulated kinase (ERK) and the stress-activated protein kinase (SAPK) or Jun N-terminal kinase (JNK) cascades independently stimulated PEA3-mediated gene expression. Ha-RasV12 stimulation of PEA3 activity was reduced by dominant-negative mutants in each of these protein kinase cascades, suggesting that Ras activates PEA3 through both pathways. Furthermore, the ability of unique activators of each kinase cascade to stimulate PEA3-dependent gene expression was selectively reduced by dominant-negative mutants within the homologous but not the heterologous pathway. Hence two distinct mitogen-activated protein kinase (MAPK) cascades regulate PEA3 activity, PEA3 was phosphorylated in vivo at serine residues consistent with the possibility that it may be a direct target of MAPKs.	MCMASTER UNIV, CANC RES GRP, INST MOL BIOL & BIOTECHNOL, HAMILTON, ON L8S 4K1, CANADA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	McMaster University								BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FISHER RJ, 1991, ONCOGENE, V6, P2249; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KYRIAKIS JM, 1994, PROTEIN KINASES FRON, P85; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAN MH, 1994, NATURE, V372, P798; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	57	146	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1323	1333						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808707				2022-12-25	WOS:A1996VJ20200024
J	Glaser, M; Wanaski, S; Buser, CA; Boguslavsky, V; Rashidzada, W; Morris, A; Rebecchi, M; Scarlata, SF; Runnels, LW; Prestwich, GD; Chen, J; Aderem, A; Ahn, J; McLaughlin, S				Glaser, M; Wanaski, S; Buser, CA; Boguslavsky, V; Rashidzada, W; Morris, A; Rebecchi, M; Scarlata, SF; Runnels, LW; Prestwich, GD; Chen, J; Aderem, A; Ahn, J; McLaughlin, S			Myristoylated alanine-rich C kinase substrate (MARCKS) produces reversible inhibition of phospholipase C by sequestering phosphatidylinositol 4,5-bisphosphate in lateral domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ASSOCIATION; CA2+-ACTIVATED SECRETION; MEDIATED PHAGOCYTOSIS; QUANTITATIVE-ANALYSIS; HUMAN-MONOCYTES; HIGH-AFFINITY; PROTEIN; BINDING; PHOSPHORYLATION; PEPTIDES	The myristoylated alanine-rich protein kinase C substrate (MARCKS) is a major protein kinase C (PRC) substrate in many different cell types. MARCKS is bound to the plasma membrane, and several recent studies suggest that this binding requires both hydrophobic insertion of its myristate chain into the bilayer and electrostatic interaction of its cluster of basic residues with acidic lipids. Phosphorylation of MARCKS by PKC introduces negative charges into the basic cluster, reducing its electrostatic interaction with acidic lipids and producing translocation of MARCKS from membrane to cytoplasm. The present study shows that physiological concentrations of MARCKS (<10 mu M) inhibit phospholipase C (PLC)-catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) in phospholipid vesicles. A peptide corresponding to the basic cluster, MARCKS(151-175), produces a similar inhibition, which was observed with both PLC-delta(1) and -beta(1). Direct fluorescence microscopy observations demonstrate that the MARCKS peptide forms lateral domains enriched in the acidic lipids phosphatidylserine and PIP2 but not PLC, which accounts for the observed inhibition of PIP2 hydrolysis. Phosphorylation of MARCKS(151-175) by PKC releases the inhibition and allows PLC to produce a burst of inositol 1,4,5-trisphosphate and diacylglycerol.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA; SUNY STONY BROOK, DEPT CHEM, STONY BROOK, NY 11794 USA; ROCKEFELLER UNIV, LAB SIGNAL TRANSDUCT, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Illinois System; University of Illinois Urbana-Champaign; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rockefeller University				Runnels, Loren/0000-0002-2537-7360				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; CEVC G, 1987, PHOSPHOLIPID BILAYER, P348; Chen J, 1996, J ORG CHEM, V61, P6305, DOI 10.1021/jo960895r; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DEER JLR, 1995, J BIOL CHEM, V270, P12623, DOI 10.1074/jbc.270.21.12623; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; EVANS EA, 1980, MECHANICS THERMODYNA, P85; EXTON JH, 1990, J BIOL CHEM, V265, P1; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FROMHERZ P, 1975, REV SCI INSTRUM, V46, P1380, DOI 10.1063/1.1134025; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GONI FM, 1994, BIOCHEM SOC T, V22, P839, DOI 10.1042/bst0220839; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HELM CA, 1992, BIOCHEMISTRY-US, V31, P1794, DOI 10.1021/bi00121a030; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MOSIOR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185, DOI 10.1016/0005-2736(92)90178-O; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1992, J BIOL CHEM, V267, P15263; OSTRANDER DB, 1995, J BIOL CHEM, V270, P27045, DOI 10.1074/jbc.270.45.27045; PAP EHW, 1995, BIOCHEMISTRY-US, V34, P9118, DOI 10.1021/bi00028a022; Ponting CP, 1996, PROTEIN SCI, V5, P162; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; RAND RP, 1986, ANNU REV PHYSIOL, V48, P201; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RHEE SG, 1991, METHOD ENZYMOL, V197, P502; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; RYU SH, 1990, J BIOL CHEM, V265, P17941; SANCHEZMIGALLON MP, 1994, ARCH BIOCHEM BIOPHYS, V314, P205, DOI 10.1006/abbi.1994.1431; SEELIG A, 1992, BIOCHEMISTRY-US, V31, P2897, DOI 10.1021/bi00126a008; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TAMM LK, 1991, BIOCHIM BIOPHYS ACTA, V1071, P123, DOI 10.1016/0304-4157(91)90021-N; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; Thorgeirsson TE, 1996, BIOCHEMISTRY-US, V35, P1803, DOI 10.1021/bi952300c; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WERNER MH, 1992, MOL PHARMACOL, V41, P382; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; YANG L, 1995, BIOCHEMISTRY-US, V34, P1500, DOI 10.1021/bi00005a005; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	68	203	208	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26187	26193		10.1074/jbc.271.42.26187	http://dx.doi.org/10.1074/jbc.271.42.26187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824266	hybrid			2022-12-25	WOS:A1996VN18000072
J	Hogg, PJ; Jackson, CM; Labanowski, JK; Bock, PE				Hogg, PJ; Jackson, CM; Labanowski, JK; Bock, PE			Finding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; BLOOD-COAGULATION PROTEINASES; PEPTIDE CHLOROMETHYL KETONES; ANTITHROMBIN-III; ACTIVE-SITE; QUANTITATIVE CHARACTERIZATION; FLUORESCENCE PROBES; BINDING EXOSITE; INACTIVATION; SPECIFICITY	Interaction of the blood clotting proteinase, thrombin, with fibrin monomer and heparin to form a thrombin fibrin monomer heparin ternary complex is accompanied by a change in thrombin catalytic specificity, Equilibrium binding interactions in the assembly of the ternary complex were characterized quantitatively using thrombin labeled at the active site with a fluorescent probe and related to changes in thrombin specificity toward exosite I-dependent binding of hirudin and cleavage of fibrinogen, Changes in the active site environment accompanying binding of heparin or fibrin to thrombin in binary complexes were reported by fluorescence enhancements which contributed additively to the perturbation accompanying formation of the ternary complex, Quantitative analysis of the interactions supports a preferentially ordered path of ternary complex assembly, in which initial binding of heparin to thrombin facilitates binding of fibrin monomer with an similar to 40-fold increased affinity, Binding of fibrin monomer in the ternary complex decreased the affinity of native thrombin for hirudin by > 100-fold and inhibited cleavage of fibrinogen, but this inhibition was overcome when fibrin(ogen)-fibrin interactions occurred, These results support a ternary complex model in which heparin binding through exosite II of thrombin facilitates fibrin monomer binding via exosite I, with accompanying changes in thrombin catalytic specificity resulting from perturbations in the active site and reduced accessibility of exosite I to hirudin and fibrinogen.	OHIO SUPERCOMP CTR,COLUMBUS,OH 43212; VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232; AMER RED CROSS,BLOOD SERV,SE MICHIGAN REG,DETROIT,MI 48232	Vanderbilt University; American Red Cross	Hogg, PJ (corresponding author), UNIV NEW S WALES,SCH PATHOL,CTR THROMBOSIS & VASC RES,SYDNEY,NSW 2052,AUSTRALIA.		Jackson, Craig M/AAC-6338-2020	Jackson, Craig/0000-0001-9484-4420; Hogg, Philip/0000-0001-6486-2863	NHLBI NIH HHS [HL-38779, HL-02832] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, R01HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINNIE CG, 1993, BLOOD, V81, P3186; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DECRISTOFARO R, 1991, J PROTEIN CHEM, V10, P455, DOI 10.1007/BF01025473; DUGGLEBY RG, 1977, BIOCHIM BIOPHYS ACTA, P297; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; GAN ZR, 1994, J BIOL CHEM, V269, P1301; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HOTCHKISS KA, 1994, BLOOD, V84, P498; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; KAMINSKI M, 1983, J BIOL CHEM, V258, P530; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; LIU CY, 1979, J BIOL CHEM, V254, P421; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MIHALYI E, 1988, BIOCHEMISTRY-US, V27, P976, DOI 10.1021/bi00403a021; NASKI MC, 1993, THROMB RES, V69, P453, DOI 10.1016/0049-3848(93)90234-F; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SACHE E, 1982, THROMB RES, V25, P443, DOI 10.1016/0049-3848(82)90086-X; SCULLEY MJ, 1986, BIOCHIM BIOPHYS ACTA, V874, P44, DOI 10.1016/0167-4838(86)90100-7; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; STONE SR, 1995, TRENDS CARDIOVAS MED, V5, P134, DOI 10.1016/1050-1738(95)00049-F; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; STONE SR, 1993, METHOD ENZYMOL, V223, P312; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; WEITZ J, 1993, J LAB CLIN MED, V122, P364; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WEITZ JI, 1995, AM J CARDIOL, V75, pB18, DOI 10.1016/0002-9149(95)80005-D	48	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26088	26095		10.1074/jbc.271.42.26088	http://dx.doi.org/10.1074/jbc.271.42.26088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824251	hybrid			2022-12-25	WOS:A1996VN18000057
J	Krishna, MC; Samuni, A; Taira, J; Goldstein, S; Mitchell, JB; Russo, A				Krishna, MC; Samuni, A; Taira, J; Goldstein, S; Mitchell, JB; Russo, A			Stimulation by nitroxides of catalase-like activity of hemeproteins - Kinetics and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; HYDROGEN-PEROXIDE; FREE-RADICALS; SUPEROXIDE; OXIDATION; FERRYLMYOGLOBIN; EPOXIDATION; HEMOGLOBIN; REDUCTION; STYRENE	The ability of stable nitroxide radicals to detoxify hypervalent heme proteins such as ferrylmyoglobin (MbFe(IV)) produced in the reaction of metmyoglobin (MbFe(III)) and H2O2 was evaluated by monitoring O-2 evolution, H2O2 depletion, and redox changes of the heme prosthetic group, The rate of H2O2 depletion and O-2 evolution catalyzed by MbFe(III) was enhanced by stable nitroxides such as 4-OH-2,2,6,6-tetramethyl-piperidinoxyl (TPL) in a catalytic fashion, The reduction of MbFe(IV) to MbFe(III) was the rate-limiting step, Excess TPL over MbFe(III) enhanced catalase-like activity more than 4-fold. During dismutation of H2O2, [TPL] and [MbFe(IV)] remained constant, NADH caused: (a) inhibition of H2O2 decay; (b) progressive reduction of TPL to its respective hydroxylamine TPL-H; and (c) arrest/inhibition of oxygen evolution or elicit consumption of O-2. Following depletion of NADH the evolution of O-2 resumed, and the initial concentration of TPL was re stored, Kinetic analysis showed that two distinct forms of MbFe(IV) might be involved in the process, In summary, by shuttling between two oxidation states, namely nitroxide and oxoammonium cation, stable nitroxides enhance the catalase mimic activity of MbFe(III), thus facilitating H2O2 dismutation accompanied by O-2 evolution and providing protection against hypervalent heme proteins.	HEBREW UNIV JERUSALEM,SCH MED,DEPT BIOL MOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	Krishna, MC (corresponding author), NCI,RADIAT BIOL BRANCH,NIH,BLDG 10,RM B3-B69,BETHESDA,MD 20892, USA.			Taira, Junsei/0000-0003-0431-3242				ABUGO OO, 1994, J BIOL CHEM, V269, P24845; ARDUINI A, 1990, ARCH BIOCHEM BIOPHYS, V281, P41, DOI 10.1016/0003-9861(90)90410-Z; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CHANCE M, 1986, BIOCHEMISTRY-US, V25, P1259, DOI 10.1021/bi00354a010; CHOE YS, 1994, ARCH BIOCHEM BIOPHYS, V314, P126, DOI 10.1006/abbi.1994.1420; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DEBONO D, 1994, FREE RADICAL RES, V20, P327, DOI 10.3109/10715769409145632; DEGRAFF W, 1994, BIOCHEM PHARMACOL, V48, P1427, DOI 10.1016/0006-2952(94)90567-3; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; FISH JR, 1988, J PHYS CHEM-US, V92, P3745, DOI 10.1021/j100324a012; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GELVAN D, 1991, P NATL ACAD SCI USA, V88, P4680, DOI 10.1073/pnas.88.11.4680; GIULIVI C, 1992, ARCH BIOCHEM BIOPHYS, V299, P302, DOI 10.1016/0003-9861(92)90279-6; GIULIVI C, 1994, METHOD ENZYMOL, V233, P189; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; HAHN SM, 1992, CANCER RES, V52, P1750; HOCHANADEL CJ, 1952, J PHYS CHEM-US, V56, P587, DOI 10.1021/j150497a008; KALYANARAMAN B, 1983, J BIOL CHEM, V258, P3855; KARMELI F, 1995, GUT, V37, P386, DOI 10.1136/gut.37.3.386; KEILIN D, 1950, NATURE, V166, P513, DOI 10.1038/166513a0; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; Kocherginski N., 1995, NITROXIDE SPIN LABEL; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; LARANJINHA J, 1995, FREE RADICAL BIO MED, V19, P329, DOI 10.1016/0891-5849(95)00039-Z; LIEBMANN J, 1994, LIFE SCI, V54, P503; MEHLHORN RJ, 1992, FREE RADICAL RES COM, V17, P157, DOI 10.3109/10715769209068163; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; RAO SI, 1994, J BIOL CHEM, V269, P7210; RAO SI, 1993, J BIOL CHEM, V268, P803; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; STADTMAN ER, 1990, P NATL ACAD SCI USA, V87, P384, DOI 10.1073/pnas.87.1.384; TAJIMA G, 1987, J BIOL CHEM, V262, P12603; TEW D, 1988, J BIOL CHEM, V263, P17880; TURNER JJO, 1991, BIOCHEM J, V277, P833, DOI 10.1042/bj2770833; UYEDA M, 1981, BIOCHEMISTRY-US, V20, P2028, DOI 10.1021/bi00510a045; WHITBURN KD, 1982, J BIOL CHEM, V257, P1860; YAMAGUCHI T, 1984, BIOCHEM BIOPH RES CO, V120, P534, DOI 10.1016/0006-291X(84)91287-7; YONETANI T, 1967, J BIOL CHEM, V242, P1974	42	159	164	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26018	26025		10.1074/jbc.271.42.26018	http://dx.doi.org/10.1074/jbc.271.42.26018			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824241	hybrid			2022-12-25	WOS:A1996VN18000047
J	Murante, RS; Rumbaugh, JA; Barnes, CJ; Norton, JR; Bambara, RA				Murante, RS; Rumbaugh, JA; Barnes, CJ; Norton, JR; Bambara, RA			Calf RTH-1 nuclease can remove the initiator RNAs of Okazaki fragments by endonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND DNA-REPLICATION; ESCHERICHIA-COLI; CLEAVAGE; 5'-EXONUCLEASE; 3'-EXONUCLEASE; COMPLETION; CHROMOSOME; PROTEINS; ORIGIN; GENE	In eukaryotes, the endonucleolytic activity of the calf RTH-1 class 5'- to 3'-exo/endonuclease can function without RNase H1 to remove initiator RNA from Okazaki fragments, Cleavage requires that the RNA be displaced to form an unannealed single-stranded 5'-tail or flap structure, On substrates with RNA-initiated primers, DNA oligomers that competed with the RNA for template binding simulated strand displacement syn thesis from an upstream Okazaki fragment, This allowed cutting of displaced RNA segments by RTH-1 nuclease, Requirements for the reaction also were examined on substrates in which the tail was unannealed because it was intentionally mispaired. On both types of substrate, the nuclease slides over the RNA region from the 5'-end and cleaves at the beginning of the annealed region, irrespective of whether ribo- or deoxyribonucleotides are at the cleavage site. Presence of a triphosphate or a 7-methyl 3'G5' ppp5' G cap structure at the 5'-end of the RNA does not affect cleavage, The previously reported stimulation of the nuclease by an upstream primer was not always observed, suggesting that not every site in the downstream Okazaki fragment is equally susceptible to cleavage during displacement synthesis in vice, The biological role of the endonuclease activity of RTH-1 nuclease in Okazaki fragment processing is discussed.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007102, R13GM073536, R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM073536, T32-GM07102, GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL AB, 1977, CELL, V12, P183, DOI 10.1016/0092-8674(77)90196-9; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; HUANG L, 1994, J BIOL CHEM, V269, P25922; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SAMBROOK J, 1989, MOL CLONING LAB MANU, P636; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1984, J BIOL CHEM, V259, P1854	21	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25888	25897		10.1074/jbc.271.42.25888	http://dx.doi.org/10.1074/jbc.271.42.25888			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824221	hybrid			2022-12-25	WOS:A1996VN18000027
J	Green, SP; Chuntharapai, A; Curnutte, JT				Green, SP; Chuntharapai, A; Curnutte, JT			Interleukin-8 (IL-8), melanoma growth-stimulatory activity, and neutrophil-activating peptide selectively mediate priming of the neutrophil NADPH oxidase through the type A or type B IL-8 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SUPEROXIDE ANION PRODUCTION; SIGNAL-TRANSDUCTION; RESPIRATORY BURST; FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; PHAGOCYTIC-CELLS; BINDING-PROTEINS; OXIDATIVE BURST; CHEMOKINES	The capacity of neutrophils to generate superoxide (O-2(T)) can be enhanced by prior exposure to ''priming'' agents such as interleukin-8 (IL-8), melanoma growth-stimulatory activity (MGSA), and neutrophil-activating peptide (ENA-78). The biological effects of these chemokines are mediated by at least two distinct receptors: type A (IL-8-RA) and type B (IL-8-RB). Using neutralizing monoclonal antibodies to ILS-RA and IL-8-RB, we have investigated the contribution each receptor makes to the priming response, Preincubation with IL-8, MGSA, or ENA-78 enhanced the ability of neutrophils to generate O-2(T) following stimulation with the bacterial peptide formyl-Met-Leu-Phe. The priming effect of IL-8 was eliminated by an anti-IL-8 monoclonal antibody (mAb) that is known to bind IL-8 with high affinity and prevent receptor occupancy. Incubation of neutrophils with a neutralizing mAb specific for IL-8-RA blocked IL-8-induced priming but had no effect on priming by MGSA or ENA-78. In contrast, treatment with a neutralizing mAb specific for IL-8-RB faded to inhibit the priming effect of IL-8 but blocked both MGSA and ENA-78-induced priming. These observations indicate that the priming effect of IL-8 on the neutrophil respiratory burst is predominantly mediated via IL-8-RA whereas priming by MGSA and ENA-78 is mediated by IL-8-RB.	GENENTECH INC,DEPT BIOANAL TECHNOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech	Green, SP (corresponding author), GENENTECH INC,DEPT IMMUNOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							AKIMARU K, 1992, ARCH BIOCHEM BIOPHYS, V298, P703, DOI 10.1016/0003-9861(92)90469-D; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; Baggiolini M, 1992, Cytokines, V4, P1; BAJAJ MS, 1992, INFLAMMATION, V16, P241, DOI 10.1007/BF00918813; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BROADDUS VC, 1995, CRC HDB CHEMOATTRACT; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; CHUNTHARAPAI A, 1994, J IMMUNOL, V153, P5682; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; DANIELS RH, 1994, IMMUNOLOGY, V82, P465; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; ELBIM C, 1994, INFECT IMMUN, V62, P2195, DOI 10.1128/IAI.62.6.2195-2201.1994; GUDEWICZ PW, 1994, BIOCHEM BIOPH RES CO, V205, P706, DOI 10.1006/bbrc.1994.2723; HALLETT MB, 1995, IMMUNOL TODAY, V16, P2654; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1992, CELLULAR MOL MECHANI, V4, P43; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; LEE J, 1992, J BIOL CHEM, V267, P16283; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEPIDI H, 1995, J CELL SCI, V108, P1771; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; LLOYDS D, 1995, IMMUNOLOGY, V84, P220; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; MCCOLL SR, 1989, BLOOD, V73, P588; METZNER B, 1995, J INVEST DERMATOL, V104, P789, DOI 10.1111/1523-1747.ep12606993; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARBOOSINGH JS, 1995, ARCH NEUROL-CHICAGO, V52, P1160, DOI 10.1001/archneur.1995.00540360038013; Quan JM, 1996, BIOCHEM BIOPH RES CO, V219, P405, DOI 10.1006/bbrc.1996.0246; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RICHARD S, 1994, J IMMUNOL, V152, P2479; ROBERTS PJ, 1993, BRIT J HAEMATOL, V84, P586, DOI 10.1111/j.1365-2141.1993.tb03132.x; SHAPIRA L, 1995, INFLAMMATION, V19, P289, DOI 10.1007/BF01534388; SMITH RJ, 1992, J LEUKOCYTE BIOL, V52, P17, DOI 10.1002/jlb.52.1.17; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WALZ A, 1993, ADV EXP MED BIOL, V351, P129; WOZNIAK A, 1993, IMMUNOLOGY, V79, P608; YUO A, 1991, BLOOD, V78, P2708	50	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25400	25405		10.1074/jbc.271.41.25400	http://dx.doi.org/10.1074/jbc.271.41.25400			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810307	hybrid			2022-12-25	WOS:A1996VL69300051
J	Hammani, K; Blakis, A; Morsette, D; Bowcock, AM; Schmutte, C; Henriet, P; DeClerck, YA				Hammani, K; Blakis, A; Morsette, D; Bowcock, AM; Schmutte, C; Henriet, P; DeClerck, YA			Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; TUMOR-CELL-LINES; TIMP GENE; MATRIX METALLOPROTEINASES; DNA METHYLATION; BINDING-SITES; EXPRESSION; TRANSCRIPTION; PROMOTER; COLLAGENASE	We report here the characterization of the human tissue inhibitor of metalloproteinases-2 (TIMP-2) gene. The gene is 83 kilobase pairs (kb) long with exon-intron splicing sites located in preserved positions among the three members of the TIMP family. A 2.6-kb genomic DNA fragment flanking the 5'-end of the gene contains several regulatory elements including five Sp1, two AP-2, one AP-1, and three PEA-3 binding sites, Despite the presence of a complete AP-1 consensus at position -281, the promoter did not respond to 12-O-tetradecanoylphorbol-13-acetate treatment; However, 12-O-tetradecanoylphorbol-13-acetate response was generated by insertion of a similar AP-1 consensus at position -71, indicating the importance of the positioning of this motif. The promoter contains a typical CpG island; however, methylation of this island did not seem to influence gene expression. Analysis of the 3'-end of the gene revealed that the two mRNAs for TIMP-2 (1.2 and 3.8 kb) differ by the selection of their polyadenylation signal sites, but selection of these sites does not affect RNA stability. In summary, the TIMP-2 gene has several features observed in housekeeping genes, and differs significantly from TIMP-1 and TIMP-3 genes. These differences are likely to explain the specific roles that these inhibitors play in the regulation of matrix metalloproteinases.	CHILDRENS HOSP LOS ANGELES,DEPT PEDIAT,DIV HEMATOL ONCOL,LOS ANGELES,CA 90054; UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV SO CALIF,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Southern California			Hammani, khalil/GSD-7743-2022	Bowcock, Anne/0000-0001-8691-9090; Hammani, Khalil/0000-0002-4005-4244; Henriet, Patrick/0000-0003-4602-8888; DeClerck, Yves/0000-0002-3688-0113	NATIONAL CANCER INSTITUTE [R01CA042919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043177] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 42919] Funding Source: Medline; NIAMS NIH HHS [AR 43177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHLERING TE, 1987, CANCER RES, V47, P6660; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CHANDLER LA, 1986, CANCER RES, V46, P2944; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; COUCH FJ, 1995, GENOMICS, V25, P264, DOI 10.1016/0888-7543(95)80134-8; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; D'ORAZI G, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P316; DECLERCK Y, 1992, GENOMICS, V14, P782, DOI 10.1016/S0888-7543(05)80186-7; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; DETWET JR, 1987, MOL CELL BIOL, V7, P725; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hammani K, 1996, GENE, V170, P287, DOI 10.1016/0378-1119(95)00864-0; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lim YT, 1996, J CELL PHYSIOL, V167, P333, DOI 10.1002/(SICI)1097-4652(199605)167:2<333::AID-JCP18>3.0.CO;2-8; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SHAPIRO SD, 1992, J BIOL CHEM, V267, P13890; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; TANAKA K, 1995, CANCER RES, V55, P2927; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WICK M, 1995, BIOCHEM J, V311, P549, DOI 10.1042/bj3110549; WILLIARD H F, 1989, Human Genetics, V81, P235; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	50	101	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25498	25505		10.1074/jbc.271.41.25498	http://dx.doi.org/10.1074/jbc.271.41.25498			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810321	hybrid			2022-12-25	WOS:A1996VL69300065
J	Holmes, JK; Solomon, MJ				Holmes, JK; Solomon, MJ			A predictive scale for evaluating cyclin-dependent kinase substrates - A comparison of p34(cdc2) and p33(cdk2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; PROTEIN-KINASE; CDC2 KINASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; CELL-CYCLE; MYOSIN-II; A-TYPE; PHOSPHORYLATION; P34CDC2	Protein phosphorylation by members of the Cdk (cyclin dependent kinase) family of protein kinases is necessary for progression through the cell cycle. However, the primary sequence determinants of Cdk substrate specificity have get to be examined quantitatively. We have used a panel of glutathione S-transferase peptide fusions to investigate the fine-structure specificity of p33(cdk2) and p34(cdc2). Our data indicate that the generally held consensus sequences for p34(cdc2) represent a significant oversimplification of its true specificity and that this specificity is conserved between species. p33(cdk2) and p34(cdc2) have similar but distinct substrate specificities that are affected modestly by the associated cyclin subunit, We derive specific values of phosphorylation efficiencies by these enzymes that can be used to estimate the phosphorylation potential of proposed Cdk substrates.	YALE UNIV, SCH MED, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA	Yale University					NIGMS NIH HHS [GM47830] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; HARPER JW, 1993, CELL, V75, P805; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO J, 1993, GENE DEV, V7, P331; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Nigg E A, 1991, Semin Cell Biol, V2, P261; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; THOMAS L, 1992, J BIOL CHEM, V267, P6183; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	28	129	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25240	25246		10.1074/jbc.271.41.25240	http://dx.doi.org/10.1074/jbc.271.41.25240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810285	hybrid			2022-12-25	WOS:A1996VL69300029
J	Lomasney, JW; Cheng, HF; Wang, LP; Kuan, YS; Liu, SM; Fesik, SW; King, K				Lomasney, JW; Cheng, HF; Wang, LP; Kuan, YS; Liu, SM; Fesik, SW; King, K			Phosphatidylinositol 4,5-bisphosphate binding to the pleckstrin homology domain of phospholipase C-delta 1 enhances enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; ADP-RIBOSYLATION FACTOR; PH DOMAIN; INOSITOL PHOSPHATES; HIGH-AFFINITY; SIGNALING PROTEINS; ACID PHOSPHOLIPIDS	The pleckstrin homology (PH) domain is a newly recognized protein module believed to play an important role in signal transduction. While the tertiary structures of several PH domains have been determined, some co-complexed with ligands, the function of this domain remains elusive. In this report, the PH domain located in the N terminus of human phospholipase C-delta 1 (PLC delta 1) was found to regulate enzyme activity, The hydrolysis of phosphatidylinositol (PI) was stimulated by phosphatidylinositol 4,5-bisphosphate (PIP2) in a dose dependent manner with an EC(50) = 1 mu M (0.3 mol%), up to 9-fold higher when 5 mu M (1.5 mol%) of PIP2 was incorporated into the PI/phosphatidylserine (PS)/phosphatidylcholine (PC) vesicles (30 mu M of PI with a molar ratio of PI:PS:PC = 1:5:5). Stimulation was specific for PIP2, since other anionic phospholipids including phosphatidylinositol 4-phosphate had no stimulatory effect. PIP2-mediated stimulation was, however, inhibited by inositol 1,4,5-triphosphate (IP3) in a dose-dependent manner, suggesting a modulatory role for this inositol, When a nested set of PH domain deletions up to 70 amino acids from the N terminus of PLC delta 1 were constructed, the deletion mutant enzymes all catalyzed the hydrolysis of the micelle forms of PI and PIP2 with specific activities comparable with those of the wild type enzyme. However, the stimulatory effect of PIP2 was greatly diminished when more than 20 amino acid residues were deleted from the N terminus. To identify the specific residues involved in PIP2-mediated enzyme activation, amino acids with functional side chains between residues 20 and 40 were individually changed to glycine, While all these mutations had little effect on the ability of the enzyme to catalyze the hydrolysis of PI or PIP2 micelles, the catalytic activity of mutants K24G, K30G, K32G, R38G, or W36G was markedly unresponsive to PIP2. Analysis of PIP2-stimulated PI hydrolysis by a dual substrate binding model of catalysis revealed that the micellar dissociation constant (K-s) of PLC delta 1 for the PI/PS/PC vesicles was reduced from 558 mu M to 53 mu M, and the interfacial Michaelis constant (K-m) was reduced from 0.21 to 0.06 by PIP2. The maximum rate of PI hydrolysis (V-max) was not affected by PIP2. These results demonstrate that a major function of the PH domain of PLC delta 1 is to modulate enzyme activity, Further, our results identify PIP2 as a functional ligand for a PH domain and suggest a general mechanism for the regulation of other proteins by PIP2.	ACAD SINICA,INST BIOMED SCI,TAIPEI 115,TAIWAN; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,FEINBERG CARDIOVASC RES INST,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,DEPT PHARMACOL,CHICAGO,IL 60611; ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Academia Sinica - Taiwan; Northwestern University; Northwestern University; Abbott Laboratories								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5712; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; EMORI Y, 1989, J BIOL CHEM, V264, P21885; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; OGEL ZB, 1992, PROTEIN ENG, V5, P467, DOI 10.1093/protein/5.5.467; ORR JW, 1992, J BIOL CHEM, V267, P15263; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PAWELCZYK T, 1993, BIOCHEM J, V291, P693, DOI 10.1042/bj2910693; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; TERUI T, 1994, J BIOL CHEM, V269, P28130; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TUMA PL, 1993, J BIOL CHEM, V268, P17240; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU FX, 1992, J BIOL CHEM, V267, P14616; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	60	99	100	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25316	25326		10.1074/jbc.271.41.25316	http://dx.doi.org/10.1074/jbc.271.41.25316			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810295	hybrid			2022-12-25	WOS:A1996VL69300039
J	McGee, TP; Cheng, RH; Kumagai, H; Omura, S; Simoni, RD				McGee, TP; Cheng, RH; Kumagai, H; Omura, S; Simoni, RD			Degradation of 3-hydroxy-3-methylglutaryl-CoA reductase in endoplasmic reticulum membranes is accelerated as a result of increased susceptibility to proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; UBIQUITIN-PROTEASOME PATHWAY; HMG COA REDUCTASE; REGULATED DEGRADATION; ORNITHINE DECARBOXYLASE; PROTEIN-DEGRADATION; CELLS; MEVALONATE; ENZYME; INHIBITION	The endoplasmic reticulum (ER) membrane protein 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is subject to regulated degradation when cells are presented with an excess of sterols or mevalonate, In this report, we demonstrate the degradation of HMG-CoA reductase in ER membranes prepared from cells which have been pretreated with mevalonate or sterols prior to membrane purification, Degradation of HMG-CoA reductase in membranes prepared from pretreated cells is more rapid than in membranes prepared from cells which have received no regulatory molecules, In vitro degradation is blocked by protease inhibitors previously shown to inhibit reductase degradation in vivo and is specific for intact HMG-CoA reductase, The lumenal contents of the ER membranes are dispensible for the regulated proteolysis and the proteases responsible for reductase degradation are stably associated with the ER membrane, Regulated proteolysis of HMG-CoA reductase is inhibited by lactacystin, a newly defined inhibitor of the multicatalytic protease, the proteasome, and in vitro degradation of reductase correlates with the presence of proteasome subunits in purified ER membranes, The ubiquitin system for protein degradation, which has recently been shown to be required for the degradation of several ER membrane proteins, is not required for the degradation of HMG-CoA reductase. Finally, we conclude that the regulated proteolysis of HMG-CoA reductase in response to regulatory molecules such as mevalonate or sterols is mediated by increased susceptibility of the reductase to ER proteases, rather than the induction of a new proteolytic activity.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; KITASATO INST,BIOL FUNCT RES CTR,TOKYO 108,JAPAN	Stanford University; Kitasato University			Cheng, Holland/A-8973-2008	McGee, Todd/0000-0002-3901-1001	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017363] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 F32 GM17363-01] Funding Source: Medline; OHS HRSA HHS [ST32 CA09302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BONAFACINO JS, 1994, CELLULAR PROTEOLYTIC, P137; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORRELL CC, 1994, J BIOL CHEM, V269, P633; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GIBSON DM, 1987, ENZYMES, V88, P179; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HARDEMAN EC, 1984, ARCH BIOCHEM BIOPHYS, V232, P549, DOI 10.1016/0003-9861(84)90572-1; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; INOUE S, 1991, J BIOL CHEM, V266, P13311; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LISCUM L, 1985, J BIOL CHEM, V260, P522; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; ORCI L, 1984, CELL, V36, P835, DOI 10.1016/0092-8674(84)90033-3; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PEFFLEY DM, 1992, SOMAT CELL MOLEC GEN, V18, P19, DOI 10.1007/BF01233446; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1985, J BIOL CHEM, V260, P1991; TANAKA RD, 1986, J LIPID RES, V27, P261; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; URADE R, 1993, J BIOL CHEM, V268, P22004; URBANI L, 1990, J BIOL CHEM, V265, P1919; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	43	93	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25630	25638		10.1074/jbc.271.41.25630	http://dx.doi.org/10.1074/jbc.271.41.25630			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810339	hybrid			2022-12-25	WOS:A1996VL69300083
J	Preugschat, F; Averett, DR; Clarke, BE; Porter, DJT				Preugschat, F; Averett, DR; Clarke, BE; Porter, DJT			A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP HELICASE; ADENINE-NUCLEOTIDE BINDING; DNA-INDUCED DIMERIZATION; RNA HELICASE; NUCLEIC-ACID; P80 PROTEIN; HELA-CELLS; PESTIVIRUS; MECHANISM; HYDROLYSIS	The helicase domain of hepatitis C virus NS3 (genotype 1b) was expressed in Escherichia coli and purified to homogeneity. The purified protein catalyzed the hydrolysis of nucleoside triphosphates (NTP) and the unwinding of duplex RNA in the presence of divalent metal ion. The enzyme was not selective for the NTP substrate. For example, UTP and acyclovir triphosphate were hydrolyzed efficiently by the enzyme. The rate of NTP hydrolysis was stimulated up to 27-fold by oligomeric nucleic acids (NA). Furthermore, NA bound to the enzyme with concomitant quenching of the intrinsic protein fluorescence. The dissociation constants of the enzyme for selected NA in the absence of NTP were between 10 and 35 mu M at pH 7.0 and 25 degrees C. The enzyme had maximal affinity for NA with 12 or more nucleotides. A detailed steady-state and pre-steady-state kinetic analysis of ATP hydrolysis was made with (dU)(18) as the effector. The k(cat) values for ATP hydrolysis in the presence and absence of (dU)(18) were 80 s(-1) and 2.7 s(-1), respectively. The association (dissociation) rate constants for the enzyme and (dU),, in the presence and absence of ATP were 5.7 mu M(-1) s(-1) (3.9 s(-1)) and 290 mu M(-1) s(-1) (2.27 s(-1)), respectively. The association (dissociation) rate constants for the enzyme and ATP in the presence and absence of (dU)(18) were 0.4 mu M(-1) s(-1) (<0.5 s(-1)) and 0.9 mu M(-1) s(-1) (<10(-1) s(-1)), respectively. These data were consistent with a random kinetic mechanism.	GLAXO WELLCOME INC,DIV BIOCHEM,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME INC,MED RES CTR,DIV CELLULAR SCI,STEVENAGE,HERTS,ENGLAND	GlaxoSmithKline; GlaxoSmithKline					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUKH J, 1994, P NATL ACAD SCI USA, V91, P8239, DOI 10.1073/pnas.91.17.8239; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CLARKE BE, 1990, J GEN VIROL, V71, P1109, DOI 10.1099/0022-1317-71-5-1109; CLAUDE A, 1991, J BIOL CHEM, V266, P10358; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; KANAI A, 1995, FEBS LETT, V376, P221, DOI 10.1016/0014-5793(95)01283-X; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; LAIN S, 1991, J VIROL, V65, P1, DOI 10.1016/0042-6822(91)90641-N; LEE CG, 1992, J BIOL CHEM, V267, P4398; Lohman T. M., 1995, BIOPHYS J, V68, p180S; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MAGRIN S, 1994, HEPATOLOGY, V19, P273; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PAUSE A, 1992, EMBO J, V11, P2654; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SEGAL IH, 1993, ENZYME KINETICS, P54; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; TAMURA JK, 1993, VIROLOGY, V193, P1, DOI 10.1006/viro.1993.1097; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WONG I, 1992, J BIOL CHEM, V267, P7596; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016	32	130	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24449	24457		10.1074/jbc.271.40.24449	http://dx.doi.org/10.1074/jbc.271.40.24449			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798703	hybrid			2022-12-25	WOS:A1996VM67400025
J	Woo, SB; Neet, KE				Woo, SB; Neet, KE			Characterization of histidine residues essential for receptor binding and activity of nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; HUMAN NEUROTROPHIC FACTOR; MOLECULAR-CLONING; FACTOR FAMILY; BIOLOGICAL-ACTIVITY; LOW-AFFINITY; SIGNAL-TRANSDUCTION; NGF RECEPTOR; PC12 CELLS; TYROSINE	The role of the four histidine residues in receptor binding and activity of mouse nerve growth factor (NGF) was investigated using both site directed mutagenesis and chemical modification with diethyl pyrocarbonate, Replacement of His-75 or His-84 with alanine resulted in decreased biological activity and decreased affinity for p140(trkA); however, with H75A only, a 5-fold increased affinity toward p75(LANR) was observed, The effect of simultaneous replacement of both His-75 and His-84 was neither additive nor synergistic. Slight perturbations in circular dichroism spectra and weakened self-association of the mutants indicated that His-75 and His-84 may be involved in stability, dimerization, and/or folding of NGF, Diethyl pyrocarbonate modification of His-4 and His-8 in the H75A/H84Q double mutant abolished neuritogenesis, binding to both receptors, and phosphorylation of p140(trkA) in PC12 cells, These chemi cal and mutational results confirm and clarify previous evidence for the involvement of His-75 and His-84 (Dunbar, J. C., Tregear, G. W., and Bradshaw, R. A. (1984) J. Protein Chem, 3, 349-356) or His-4 and His-8 (Shih, A., Laramee, G. R., Schmelzer, C. H., Burton, L. E., and Winslow, J. W. (1994) J. Biol. Chem. 269, 27679-27686) in receptor binding of NGF. At least three and possibly all four histidines, which are located in three spatially distinct regions, contribute to maintenance of functional sites that are essential for receptor binding and activity of NGF.	FINCH UNIV HLTH SCI CHICAGO MED SCH,DEPT BIOL CHEM,N CHICAGO,IL 60064	Chicago Medical School					NINDS NIH HHS [NS24380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; DRINKWATER CC, 1991, P ROY SOC B-BIOL SCI, V246, P307, DOI 10.1098/rspb.1991.0159; DUNBAR JC, 1984, J PROTEIN CHEM, V3, P349, DOI 10.1007/BF01025171; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FRAZIER WA, 1973, BIOCHEMISTRY-US, V12, P3281, DOI 10.1021/bi00741a021; GODFREY EW, 1986, J NEUROSCI, V6, P2543; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1994, J NEUROBIOL, V25, P1349, DOI 10.1002/neu.480251104; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LONGO FM, 1989, NERVE GROWTH FACTORS, P3; LUO Y, 1992, J BIOL CHEM, V267, P12275; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; NANDURI J, 1994, J NEUROSCI RES, V37, P433, DOI 10.1002/jnr.490370402; NEET KE, 1987, METHOD ENZYMOL, V147, P186; PETTMANN B, 1988, J NEUROSCI, V8, P3624; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SHIH A, 1994, J BIOL CHEM, V269, P27679; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUTER U, 1992, J NEUROSCI, V12, P306; THOENEN H, 1987, REV PHYSIOL BIOCH P, V109, P145, DOI 10.1007/BFb0031026; VALE RD, 1985, METHOD ENZYMOL, V109, P21; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026	56	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24433	24441		10.1074/jbc.271.40.24433	http://dx.doi.org/10.1074/jbc.271.40.24433			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798701	hybrid			2022-12-25	WOS:A1996VM67400023
J	DiasKadambi, BL; Combs, KA; Drum, CL; Hanck, DA; Blumenthal, KM				DiasKadambi, BL; Combs, KA; Drum, CL; Hanck, DA; Blumenthal, KM			The role of exposed tryptophan residues in the activity of the cardiotonic polypeptide anthopleurin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-AUSTRALIS HECTOR; NUCLEAR-MAGNETIC-RESONANCE; RESISTANT NA+ CHANNELS; SEA-ANEMONE TOXIN; SODIUM-CHANNEL; 3-DIMENSIONAL STRUCTURE; SCORPION NEUROTOXINS; CATIONIC RESIDUES; EXCITABLE CELLS; RECEPTOR-SITE	Scorpion and sea anemone venoms contain several polypeptides that delay inactivation of voltage-sensitive sodium channels via interaction with a common site. In this report, we target exposed hydrophobic residues at positions 33 and 45 of anthopleurin B (ApB) by polymerase chain reaction mutagenesis to ascertain their contribution to toxin activity. Nonconservative replacements are not permitted at position 33, indicating that Trp-33 may play an important structural role. Strikingly, the relatively conservative substitution of Trp-33 by phenylalanine results in major reductions in binding affinity for both the cardiac and neuronal channel isoforms as measured by ion flux, whereas substitution with tyrosine is tolerated and exhibits near wild type affinities, suggesting that either the ability to form a hydrogen bond or the amphiphilic nature of the side chain are important at this position. Electrophysiological analysis of W33F indicates that its diminished affinity is primarily due to a decreased association rate. Analysis of a panel of mutants at Trp-45 shows only modest changes in apparent binding affinity for both channel isoforms but significant effects on V-max. In neuronal channels, the maximal levels of uptake for W45A/S/F are about 50% those seen with ApB. This effect is also observed for W45A and W45S in the cardiac model, wherein W45F is normal, These results suggest that a hydrophobic contact is involved in toxin-induced stabilization of the open conformation of the cardiac sodium channel. We conclude that Trp-33 contributes significantly to apparent affinity, whereas Trp-45 does not appear to affect binding per se, Furthermore, W33F is the first ApB mutant that displays a significantly altered association rate and may prove to be a useful probe of the channel binding site.	UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	University of Cincinnati; University of Chicago; University of Chicago			Drum, Chester/A-6089-2015	Drum, Chester/0000-0001-6327-4584	NHLBI NIH HHS [HL-41543, HL-PO1-20592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041543, P01HL020592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; Cleland W W, 1979, Methods Enzymol, V63, P103; DARBON H, 1991, BIOCHEMISTRY-US, V30, P1836, DOI 10.1021/bi00221a016; DiasKadambi BL, 1996, J BIOL CHEM, V271, P9422, DOI 10.1074/jbc.271.16.9422; DOGGRELL S, 1994, CLIN EXP PHARMACOL P, V21, P833, DOI 10.1111/j.1440-1681.1994.tb02454.x; DONAHUE LM, 1991, DEV BIOL, V147, P415, DOI 10.1016/0012-1606(91)90299-I; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; ELAYEB M, 1986, EUR J BIOCHEM, V155, P289; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1981, TRENDS BIOCHEM SCI, V6, P291, DOI 10.1016/0968-0004(81)90105-5; FONTECILLACAMPS JC, 1982, TOXICON, V20, P1, DOI 10.1016/0041-0101(82)90137-4; FRELIN C, 1981, EUR J BIOCHEM, V119, P437, DOI 10.1111/j.1432-1033.1981.tb05627.x; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GOOLEY PR, 1986, J BIOL CHEM, V261, P1536; GROSS GJ, 1985, EUR J PHARMACOL, V110, P271, DOI 10.1016/0014-2999(85)90223-7; KHERA PK, 1995, BIOCHEMISTRY-US, V34, P8533, DOI 10.1021/bi00027a003; KHERA PK, 1994, J BIOL CHEM, V269, P921; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Maniatis T., 1982, MOL CLONING; MONKS SA, 1995, STRUCTURE, V3, P791, DOI 10.1016/S0969-2126(01)00214-3; NEWCOMB R, 1980, FRONTIERS PROTEIN CH, P539; NORTON RS, 1986, EUR J BIOCHEM, V157, P343, DOI 10.1111/j.1432-1033.1986.tb09674.x; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; NORTON TR, 1976, J PHARM SCI, V65, P1368, DOI 10.1002/jps.2600650927; NORTON TR, 1981, FED PROC, V40, P21; PALLAGHY PK, 1995, BIOCHEMISTRY-US, V34, P3782, DOI 10.1021/bi00011a036; RENAUD JF, 1986, EUR J PHARMACOL, V120, P161, DOI 10.1016/0014-2999(86)90536-4; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SCRIABINE A, 1979, J CARDIOVASC PHARM, V1, P571, DOI 10.1097/00005344-197909000-00009; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; TANAKA JC, 1983, J BIOL CHEM, V258, P7519; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VINCENT JP, 1980, P NATL ACAD SCI-BIOL, V77, P1646, DOI 10.1073/pnas.77.3.1646; Zeng DW, 1996, AM J PHYSIOL-CELL PH, V270, pC1522, DOI 10.1152/ajpcell.1996.270.5.C1522	43	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23828	23835		10.1074/jbc.271.39.23828	http://dx.doi.org/10.1074/jbc.271.39.23828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798612	hybrid			2022-12-25	WOS:A1996VJ44200041
J	Klickstein, LB; York, MR; deFougerolles, AR; Springer, TA				Klickstein, LB; York, MR; deFougerolles, AR; Springer, TA			Localization of the binding site on intercellular adhesion molecule-3 (ICAM-3) for lymphocyte function-associated antigen 1 (LFA-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; COUNTER-RECEPTOR; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN; CLONING; DOMAINS; PEPTIDE; LIGAND; INVOLVEMENT; ARRANGEMENT	Intercellular adhesion molecule 3 (ICAM-3; CD50) is the predominant counter receptor on resting T cells and monocytes for the leukocyte integrin, lymphocyte function associated antigen 1 (LFA-1; CD11a/CD18), and may play an important role in the initial stages of the T cell-dependent immune response, Deletion of individual immunoglobulin superfamily (IgSF) domains of ICAM-3 and ICAM-3 IgSF domain chimeras with CD21 showed there is a single LFA-1 binding site in ICAM-3 and that IgSF domain 1 is necessary and sufficient for LFA-1 binding. Epitope mapping and functional studies performed with 17 anti-ICAM-3 monoclonal antibodies demonstrated that only some monoclonal antibodies, with epitopes wholly within domain 1 of ICAM-3, were able to block binding of ICAM-3 bearing cells to purified LFA-1, in agreement with the data obtained from the domain deletion mutants and CD21 chimeras. Analysis of a panel of 45 point mutants of domain 1 of ICAM-3 identified five residues that may contact LFA-1 as part of the binding site, Asn(23), Ser(25), Glu(37), Phe(54), and Gln(75). These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn(23) and Ser(25)) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75). The residues, Asn(23) and Ser(25), comprise a consensus N-linked glycosylation site.	CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School				York, Michael/0000-0002-2507-3834	NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CORDELL JL, 1994, J CLIN PATHOL, V47, P143, DOI 10.1136/jcp.47.2.143; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; GARRETT TPJ, 1993, J MOL BIOL, V234, P763, DOI 10.1006/jmbi.1993.1625; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERNANDEZCASELLES T, 1993, EUR J IMMUNOL, V23, P2799, DOI 10.1002/eji.1830231112; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; JUAN M, 1993, EUR J IMMUNOL, V23, P1508, DOI 10.1002/eji.1830230717; Klickstein L. B., 1993, Tissue Antigens, V42, P270; KLICKSTEIN LB, 1995, LEUCOCYTE TYPING, V5, P1546; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LI R, 1993, J BIOL CHEM, V268, P17513; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; ROSS L, 1992, J BIOL CHEM, V267, P8537; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SETH R, 1991, FEBS LETT, V282, P193, DOI 10.1016/0014-5793(91)80475-I; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SLATKO B, 1991, CURRENT PROTOCOLS MO; STARLING GC, 1995, LEUKOCYTE TYPING, V5, P1578; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VILELLA R, 1990, TISSUE ANTIGENS, V36, P203, DOI 10.1111/j.1399-0039.1990.tb01830.x; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714	43	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23920	23927		10.1074/jbc.271.39.23920	http://dx.doi.org/10.1074/jbc.271.39.23920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798624	hybrid			2022-12-25	WOS:A1996VJ44200053
J	Monaghan, A; Hay, RT				Monaghan, A; Hay, RT			Pyridoxal 5'-phosphate inhibition of adenovirus DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; VIRUS REVERSE-TRANSCRIPTASE; SUBSTRATE-BINDING DOMAIN; AMINO-ACID-SEQUENCE; CRYSTAL-STRUCTURE; ACTIVE-SITE; ESCHERICHIA-COLI; FUNCTIONAL DOMAINS; PREINITIATION COMPLEX; ANGSTROM RESOLUTION	Pyridoxal phosphate modification of adenovirus DNA polymerase results in loss of DNA polymerase activity, whereas the 3' --> 5' exonuclease activity is unaffected. Inhibition by pyridoxal phosphate is time-dependent, displays saturation kinetics, and is reversible in the presence of excess primary amine unless the pyridoxal phosphate-enzyme adduct is first reduced with NaBH4. Thus, inhibition is the consequence of Schiff base formation between the aldehyde moiety of pyridoxal phosphate and primary amino groups on the enzyme. In addition to inhibiting DNA polymerase activity, pyridoxal phosphate also inhibited the ability of the enzyme to initiate viral DNA replication, by transfer of dCMP onto the preterminal protein. Neither template-primer nor dNTP protect against pyridoxal phosphate inhibition, but the combination of template-primer and complementary substrate dNTP protected both initiation and DNA polymerase activities. Thus, it is likely that both the dCMP transfer activity required for initiation and DNA polymerase activity are carried out at the same site of the enzyme.	UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND	University of St Andrews			Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024				BASU A, 1988, J BIOL CHEM, V263, P1648; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU A, 1989, J BIOL CHEM, V264, P8746; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BESSE LS, 1993, BIOCHEMISTRY-US, V32, P14095; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BLASCO MA, 1993, J BIOL CHEM, V268, P24106; BLASCO MA, 1992, CHROMOSOMA, V102, P32; BOSHER J, 1990, New Biologist, V2, P1083; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BULL P, 1975, BIOCHEM BIOPH RES CO, V64, P1152, DOI 10.1016/0006-291X(75)90814-1; CHEN M, 1990, J BIOL CHEM, V265, P18634; CHEN M, 1989, P NATL ACAD SCI USA, V86, P6116, DOI 10.1073/pnas.86.16.6116; DIFFLEY JFX, 1988, J BIOL CHEM, V263, P14669; DIFFLEY JX, 1988, J BIOL CHEM, V263, P19156; DONG Q, 1994, J BIOL CHEM, V270, P21563; FANSLER BS, 1974, METHOD ENZYMOL, V29, P52; FIELD J, 1984, J BIOL CHEM, V259, P9487; GODING CR, 1983, EMBO J, V2, P339, DOI 10.1002/j.1460-2075.1983.tb01428.x; HARZA AK, 1984, BIOCHEMISTRY-US, V23, P2073; HAY RT, 1984, J MOL BIOL, V175, P493, DOI 10.1016/0022-2836(84)90181-5; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOUNG I, 1992, J VIROL, V66, P5788, DOI 10.1128/JVI.66.10.5788-5796.1992; JUNG G, 1990, BIOCHEM BIOPH RES CO, V170, P12294; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; LICHY JH, 1982, P NATL ACAD SCI-BIOL, V79, P5225, DOI 10.1073/pnas.79.17.5225; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; MARTIAL J, 1975, BIOCHEMISTRY-US, V14, P4907, DOI 10.1021/bi00693a020; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; MONAGHAN A, 1994, NUC ACIDS RES, V5, P742; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; MUL YM, 1992, EMBO J, V11, P751, DOI 10.1002/j.1460-2075.1992.tb05108.x; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STOW ND, 1982, NUCLEIC ACIDS RES, V10, P5105, DOI 10.1093/nar/10.17.5105; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; VANDERVLIET PC, 1991, SEMINARS VIROLOGY, V2, P271; VENEGAS A, 1973, BIOCHEM BIOPH RES CO, V55, P1053, DOI 10.1016/S0006-291X(73)80001-4; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; ZIJDERVELD DC, 1993, NUCLEIC ACIDS RES, V21, P641	52	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24242	24248		10.1074/jbc.271.39.24242	http://dx.doi.org/10.1074/jbc.271.39.24242			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798669	hybrid			2022-12-25	WOS:A1996VJ44200098
J	Wu, DF; Cederbaum, AI				Wu, DF; Cederbaum, AI			Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOLIC LIVER-DISEASE; LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; CYTO-TOXICITY; MICROSOMAL OXIDATION; RADICAL GENERATION; COLORIMETRIC ASSAY; HYDROGEN-PEROXIDE; FED RATS; METABOLISM	The effect of ethanol on the viability of a HepG2 cell model which was developed to constitutively express human CYP2E1 was studied in an attempt to establish a linkage between CYP2E1, reactive oxygen intermediates, and ethanol toxicity, Assays of toxicity included leakage of lactate dehydrogenase, trypan blue uptake, morphology, and formazan production, Ethanol was toxic to HepG2 E9 cells, which express CYP2E1, but not to HepG2 MV5 cells, which do not express CYP2E1. The ethanol toxicity was dependent on the concentration of ethanol, starting with 10 mM ethanol, and on the time of incubation with ethanol, Phorbol 12-myristate 13-acetate, which increases the expression of CYP2E1 in this model, increased the toxicity by ethanol, Ethanol toxicity was prevented by 4-methylpyrazole and by diallyl sulfide, inhibitors of CYP2E1, The ethanol toxicity was also prevented by radical trapping agents such as N-acetylcysteine and N-t-butyl-alpha-phenylnitrone, antioxidative agents such as catalase, superoxide dismutase, thiourea, and uric acid, and inhibitors of lipid peroxidation, such as vitamin E phosphate, Trolox, and diphenylphenylenediamine. Besides ethanol, other substrates such as Me(2)SO, CCl4, isoniazid, and N,N-dimethylnitrosamine were cytotoxic to cells expressing CYP2E1 but not to control cells, These results indicate that ethanol was toxic to HepG2 cells which express human CYP2E1 by a pathway sensitive to inhibitors of CYP2E1 and to a variety of antioxidative agents, This model appears to be useful in efforts to establish a CYP2E1-dependent ethanol hepatotoxicity system and to evaluate the role of oxidative stress and reactive radical species in the toxicity by ethanol.	MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006610, R56AA003312, R01AA003312, R37AA006610] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-03312, AA-06610] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALBANO E, 1991, BIOCHEM PHARMACOL, V41, P1895, DOI 10.1016/0006-2952(91)90129-S; Albano E, 1987, Free Radic Res Commun, V3, P243, DOI 10.3109/10715768709069789; AOYAMA T, 1990, ENDOCRINOLOGY, V126, P3101, DOI 10.1210/endo-126-6-3101; BRADY JF, 1991, CHEM RES TOXICOL, V4, P642, DOI 10.1021/tx00024a008; CARMICHAEL J, 1987, CANCER RES, V47, P936; CARROCCIO A, 1994, BIOCHEM BIOPH RES CO, V203, P727, DOI 10.1006/bbrc.1994.2242; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4; CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P559, DOI 10.1016/0891-5849(89)90033-6; CLAY KL, 1977, TOXICOL APPL PHARM, V39, P39, DOI 10.1016/0041-008X(77)90175-2; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; Dai Y, 1995, J PHARMACOL EXP THER, V275, P1614; DAI Y, 1995, J PHARMACOL EXP THER, V273, P1497; DIANZANI MU, 1985, ALCOHOL ALCOHOLISM, V20, P161; DICKER E, 1988, FASEB J, V2, P2901, DOI 10.1096/fasebj.2.13.3169467; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; FEIERMAN DE, 1985, ALCOHOL CLIN EXP RES, V9, P421, DOI 10.1111/j.1530-0277.1985.tb05576.x; FEIERMAN DE, 1986, BIOCHEM J, V239, P671, DOI 10.1042/bj2390671; FRENCH SW, 1993, EXP MOL PATHOL, V58, P61, DOI 10.1006/exmp.1993.1006; FRENCH SW, 1992, CRIT REV CL LAB SCI, V29, P83, DOI 10.3109/10408369209114597; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KNECHT KT, 1993, ARCH BIOCHEM BIOPHYS, V303, P339, DOI 10.1006/abbi.1993.1293; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KUKIELKA E, 1994, BIOCHEM J, V302, P773, DOI 10.1042/bj3020773; KYLE ME, 1988, J BIOL CHEM, V263, P3784; KYLE ME, 1987, BIOCHEM BIOPH RES CO, V149, P889, DOI 10.1016/0006-291X(87)90491-8; MAGNUSSON G, 1972, EXPERIENTIA, V28, P1198, DOI 10.1007/BF01946169; MALORNI W, 1995, CHEM-BIOL INTERACT, V96, P113, DOI 10.1016/0009-2797(94)03576-T; MCMARTIN KE, 1980, ARCH BIOCHEM BIOPHYS, V199, P606, DOI 10.1016/0003-9861(80)90318-5; MORIMOTO M, 1993, ALCOHOL, V10, P459, DOI 10.1016/0741-8329(93)90065-V; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NANJI AA, 1993, ALCOHOL CLIN EXP RES, V17, P598, DOI 10.1111/j.1530-0277.1993.tb00806.x; NANJI AA, 1989, LIFE SCI, V44, P223, DOI 10.1016/0024-3205(89)90599-7; NEUMAN MG, 1995, GASTROENTEROLOGY, V109, P555, DOI 10.1016/0016-5085(95)90345-3; NEUMAN MG, 1993, BIOCHEM BIOPH RES CO, V197, P932, DOI 10.1006/bbrc.1993.2569; NIEMELA O, 1995, HEPATOLOGY, V22, P1208, DOI 10.1016/0270-9139(95)90630-4; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; PALAKODETY RB, 1988, J BIOL CHEM, V263, P878; PARACCHINI L, 1993, ANTICANCER RES, V13, P1607; PATTEN CJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P163, DOI 10.1016/0003-9861(92)90258-X; PUNTARULO S, 1988, ARCH BIOCHEM BIOPHYS, V266, P435, DOI 10.1016/0003-9861(88)90275-5; RASHBASTEP J, 1993, ARCH BIOCHEM BIOPHYS, V300, P401, DOI 10.1006/abbi.1993.1054; REINKE LA, 1987, P NATL ACAD SCI USA, V84, P9223, DOI 10.1073/pnas.84.24.9223; REINKE LA, 1994, FREE RADICAL RES, V21, P213, DOI 10.3109/10715769409056573; SADRZADEH SMH, 1994, J PHARMACOL EXP THER, V269, P632; SASSA S, 1987, BIOCHEM BIOPH RES CO, V143, P52, DOI 10.1016/0006-291X(87)90628-0; TAKAHASHI H, 1992, PHARMACOL TOXICOL, V70, P347, DOI 10.1111/j.1600-0773.1992.tb00485.x; TSUKAMOTO H, 1986, HEPATOLOGY, V6, P814, DOI 10.1002/hep.1840060503; TSUKAMOTO H, 1995, J CLIN INVEST, V96, P620, DOI 10.1172/JCI118077; TSUKAMOTO H, 1993, ALCOHOL, V10, P439, DOI 10.1016/0741-8329(93)90061-R; WAXMAN DJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P160, DOI 10.1016/0003-9861(91)90602-F; YANG CS, 1991, METHOD ENZYMOL, V206, P595	57	163	167	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23914	23919		10.1074/jbc.271.39.23914	http://dx.doi.org/10.1074/jbc.271.39.23914			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798623	hybrid			2022-12-25	WOS:A1996VJ44200052
J	Ribeiro, JCC; Hanley, JR; Russell, PJ				Ribeiro, JCC; Hanley, JR; Russell, PJ			Studies of X-irradiated bladder cancer cell lines showing differences in p53 status: Absence of a p53-dependent cell cycle checkpoint pathway	ONCOGENE			English	Article						p53; bladder cancer; cell lines; ionising irradiation; cell cycle; flow cytometry	WILD-TYPE P53; ATAXIA-TELANGIECTASIA CELLS; BRONCHIAL EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; KINASE INHIBITOR P21; DNA-DAMAGE; G(1) ARREST; NASOPHARYNGEAL CARCINOMA; P53-INDEPENDENT PATHWAY; IONIZING-RADIATION	Cell growth arrest is a common response to DNA damage by ionising irradiation and the p53 gene has been shown to play an important role in this mechanism, possibly in a tissue-specific manner. Mutations in the p53 gene are frequent in invasive bladder cancers, which are often treated by radiotherapy. In this paper we have investigated the growth response to X-irradiation of three bladder cancer cell lines with differing p53 status: UCRU-BL-17 overexpresses mutant p53, while UCRU-BL-13 and UCRU-BL-28 contain wt p53. We have also examined the expression of proteins reported to be part of the p53 control pathway in response to irradiation-induced DNA damage. No G1 arrest was detectable in any of the cell lines after ionising irradiation; furthermore, in a downstream event reported to be correlated with p53 function there was no increase in WAF-1 protein levels regardless of p53 status. Rather, ionising irradiation resulted in G2 arrest, but the extent of this was not related to p53 status. p16 levels were also not affected by irradiation, Our results suggest that the UCRU-BL-28 cell line may have a defect in the p53-cell control pathway upstream of p53, while UCRU-BL-13 cells may have a defect downstream between p53 and WAF-1.			Ribeiro, JCC (corresponding author), PRINCE WALES HOSP,ONCOL RES CTR,VILLA 1,HIGH ST,RANDWICK,NSW 2031,AUSTRALIA.		Russell, Pamela J/G-1685-2010; Russell, Pamela/O-8504-2019	Russell, Pamela J/0000-0002-3995-1239; 				AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bernhard E. J., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P602; CAAMANO J, 1991, AM J PATHOL, V139, P839; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EBLEN ST, 1995, CANCER RES, V55, P1994; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESRIG D, 1993, AM J PATHOL, V143, P1389; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GIRINSKY T, 1995, CANCER RES, V55, P3726; GONG JP, 1993, CANCER RES, V53, P5096; GONG JP, 1994, CANCER RES, V54, P4285; GOZY M, 1993, INT J RADIAT ONCOL, V27, P83, DOI 10.1016/0360-3016(93)90424-T; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUIS NA, 1995, AM J PATHOL, V146, P1199; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HAIN J, 1993, CANCER RES, V53, P1507; HARPER JW, 1993, CELL, V75, P805; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1993, ENVIRON HEALTH PERSP, V101, P55, DOI 10.2307/3431842; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LI CY, 1995, ONCOGENE, V11, P1885; LI Y, 1994, ONCOGENE, V9, P2261; LICHTER AS, 1995, NEW ENGL J MED, V332, P371, DOI 10.1056/NEJM199502093320607; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MOLINARI M, 1995, ONCOGENE, V10, P1849; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NASRIN N, 1994, CANCER GENET CYTOGEN, V77, P14, DOI 10.1016/0165-4608(94)90142-2; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAULES RS, 1995, CANCER RES, V55, P1763; PODUST N, 1995, CANCER RES, V34, P8869; PRICE BD, 1994, CANCER RES, V54, P896; REDDEL RR, 1988, CANCER RES, V48, P1904; RIBEIRO JC, 1994, J CELL BIOCHEM, V18, P196; RUSSELL PJ, 1988, INT J CANCER, V41, P74, DOI 10.1002/ijc.2910410115; RUSSELL PJ, 1989, INT J CANCER, V44, P276, DOI 10.1002/ijc.2910440216; RUSSELL PJ, 1993, J UROLOGY, V150, P1038, DOI 10.1016/S0022-5347(17)35682-3; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WIMMEL A, 1994, ONCOGENE, V9, P995; YASUI W, 1993, INT J CANCER, V53, P36, DOI 10.1002/ijc.2910530108; ZHAN QM, 1994, CANCER RES, V54, P2755	62	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1269	1278						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808701				2022-12-25	WOS:A1996VJ20200018
J	Baasner, S; vonMelchner, H; Klenner, T; Hilgard, P; Beckers, T				Baasner, S; vonMelchner, H; Klenner, T; Hilgard, P; Beckers, T			Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase	ONCOGENE			English	Article						HER2/c-erbB2 receptor tyrosine kinase; tetracycline regulated gene expression; conditional mutant; nude mice xenotransplants; secreted human placental alkaline phosphatase	GROWTH-FACTOR-RECEPTOR; INDUCIBLE GENE-EXPRESSION; HIGHER EUKARYOTIC CELLS; MAMMALIAN-CELLS; NEU-ONCOGENE; TRANSGENIC MICE; REGULATED EXPRESSION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; HUMAN-BREAST	In the present study we describe the reversible transformation of NIH3T3 fibroblasts by overexpression of the HER2/c-erbB2 receptor tyrosine kinase. Cell lines expressing HER2 under control of a tetracycline-responsive promoter were isolated. Induction of HER2 expression resulted in cellular transformation in vitro as depicted by growth in soft agar and focus formation in tissue culture. Subsequent treatment of these cells with the effector anhydrotetracyline switched-off HER2 expression and induced morphological and functional changes characteristic for non-transformed cells. Subcutaneous transplantation of cells in nude mice resulted in the formation of solid tumors. Interestingly tumor formation was completely suppressed by treatment of the animals with anhydrotetracyline. Our findings indicate that overexpression of HER2 induces the transformed phenotype of NIH3T3 cells and is required for tumor formation and progression in nude mice. By linking the expression of the marker gene secreted placental alkaline phosphatase to the expression of HER2, a sensitive monitoring of tumor development in nude mice was feasible.	ASTA MED AG, DEPT CANC RES, D-60314 FRANKFURT, GERMANY; UNIV FRANKFURT, SCH MED, DEPT HEMATOL, LAB MOL HEMATOL, D-60596 FRANKFURT, GERMANY	Goethe University Frankfurt								ALIMANDI M, 1995, ONCOGENE, V10, P1813; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BECKERS T, 1990, EUR J BIOCHEM, V189, P657, DOI 10.1111/j.1432-1033.1990.tb15534.x; BECKERS T, 1994, BIOTECHNIQUES, V16, P1074; BECKERS T, 1995, EUR J BIOCHEM, V231, P535, DOI 10.1111/j.1432-1033.1995.tb20729.x; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRANDTRAUF PW, 1994, CRIT REV ONCOGENESIS, V5, P313, DOI 10.1615/CritRevOncog.v5.i2-3.100; BRONSTEIN I, 1994, BIOTECHNIQUES, V17, P172; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DRUCKREY H, 1956, DRUG RES, V6, P539; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LABOW MA, 1995, METHOD ENZYMOL, V254, P375; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; LONARDO F, 1990, New Biologist, V2, P992; PESCINI R, 1994, BIOCHEM BIOPH RES CO, V202, P1664, DOI 10.1006/bbrc.1994.2125; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODER FT, 1994, MOL GEN GENET, V243, P32, DOI 10.1007/BF00283873; SCAHILL SJ, 1983, P NATL ACAD SCI-BIOL, V80, P4654, DOI 10.1073/pnas.80.15.4654; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCUDIERO DA, 1988, CANCER RES, V48, P4827; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WALKER AK, 1995, METHOD ENZYMOL, V254, P469; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; WIMMEL A, 1994, ONCOGENE, V9, P995; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yarranton Geoffrey T., 1992, Current Opinion in Biotechnology, V3, P506, DOI 10.1016/0958-1669(92)90078-W	56	35	39	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					901	911						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806679				2022-12-25	WOS:A1996VG76600003
J	Auguste, P; Robledo, O; Olivier, C; Froger, J; Praloran, V; PouplardBarthelaix, A; Gascan, H				Auguste, P; Robledo, O; Olivier, C; Froger, J; Praloran, V; PouplardBarthelaix, A; Gascan, H			Alanine substitution for Thr(268) and Asp(269) of soluble ciliary neurotrophic factor (CNTF) receptor alpha component defines a specific antagonist for the CNTF response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; IL-6 SIGNAL TRANSDUCER; HUMAN GROWTH-HORMONE; ONCOSTATIN-M; MOLECULAR-CLONING; SYMPATHETIC NEURONS; REACTIVE GLIOSIS; GP130; BINDING; EXPRESSION	Ciliary neurotrophic factor (CNTF) associates with an cu subunit (CNTFR alpha) of the receptor complex to initiate signal transduction by facilitating heterodimerization of the gp130 transducing protein and the leukemia inhibitory factor receptor (LIFR) beta. CNTFR alpha is anchored to the membrane by a glycosylphosphatidylinositol Linkage; however, a soluble form of the alpha subunit can still bind CNTF to recruit the signal transducing components of the receptor complex. In the present study me show that alanine substitution for residues Thr(268) and Asp(269) of the CNTFR alpha subunit results in a mutated receptor subunit (R3), which can bind CNTF with an affinity similar to that of the wild type CNTFR alpha but, when expressed as a soluble receptor subunit, lowers the binding of CNTF to its tripartite receptor. In addition, CNTFR3 alpha inhibits the proliferation of the TF1 hematopoietic cell line triggered by CNTF plus soluble wild type CNTFR alpha but not by IL-6 or oncostatin M. Similarly, CNTFR3 alpha specifically antagonizes the induction of gp130 and LIFR beta tyrosine phosphorylation observed in response to CNTF and wild type soluble CNTFR alpha in the HepG2 hepatoma cell line, as well as the subsequent events leading to haptoglobin synthesis. Positions 268 and 269 of CNTFR alpha appear to be critical for its interaction with gp130 and LIFR beta, whereby alanine substitution of the residues at these positions results in antagonism of the CNTF-induced response.	CHU ANGERS,BIOL CELLULAIRE LAB,F-49033 ANGERS,FRANCE; CHU LIMOGES,HEMATOL LAB,F-87025 LIMOGES,FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Limoges			OLIVIER, Christophe/L-1598-2015	Auguste, Patrick/0000-0003-1485-0295				ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CHEREL M, 1995, BLOOD, V86, P2534; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; CONOVER JC, 1993, DEVELOPMENT, V119, P559; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; EDDELSTON M, 1993, NEUROSCIENCE, V54, P15; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P465; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Robledo O, 1996, J NEUROCHEM, V66, P1391; SAGGIO I, 1995, EMBO J, V14, P3045, DOI 10.1002/j.1460-2075.1995.tb07307.x; SALVATI AL, 1995, J BIOL CHEM, V270, P12242, DOI 10.1074/jbc.270.20.12242; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; WINTER CG, 1995, P NATL ACAD SCI USA, V92, P5865, DOI 10.1073/pnas.92.13.5865; WONG VV, 1995, J BIOL CHEM, V270, P313, DOI 10.1074/jbc.270.1.313; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YIN TG, 1993, J IMMUNOL, V151, P2555	50	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26049	26056		10.1074/jbc.271.42.26049	http://dx.doi.org/10.1074/jbc.271.42.26049			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824245	hybrid			2022-12-25	WOS:A1996VN18000051
J	Prince, RJ; Sine, SM				Prince, RJ; Sine, SM			Molecular dissection of subunit interfaces in the acetylcholine receptor - Identification of residues that determine agonist selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; BINDING; MOUSE; ACTIVATION; CONTRIBUTE; KINETICS; CELLS	Agonists and antagonists select between the alpha gamma and alpha delta binding sites of the fetal muscle acetylcholine receptor owing to different contributions by the gamma and delta subunits, To identify determinants of selectivity for agonists, we constructed a panel of gamma-delta subunit chimeras, co-expressed them with the alpha subunit in 293 HEK cells, and measured carbamylcholine binding affinity of intracellular complexes, Wild-type alpha delta complexes bind carbamyl choline about 30-fold more tightly than alpha gamma complexes. This degree of selectivity is similar to that of the resting state of the receptor determined by kinetic analysis of single-channel events, We identify a primary set of determinants of selectivity, Lys(gamma 34)/Ser(delta 36) and phe(gamma 172)/Ile(delta 178), and a secondary set, Glu(gamma 57)/Asp(delta 59) and Cys(gamma 115)/Tyr(delta 117). The contributions of all four determinants are subunit-dependent and are modified by interaction with one another, Coexpression of point mutant subunits with complementary wild-type subunits to form cell surface pentamers shows that Lys(gamma 34)/Ser(delta 36) and phe(gamma 172)/Ile(delta 178) contribute in a manner consistent with affecting selectivity of the resting state of the receptor, while Glu(gamma 57) appears to contribute to the affinity of the desensitized state. The four determinants either coincide with or are close to residues known to contribute to the acetylcholine binding site. These results suggest that a minimum of four loops in the gamma and delta subunits contribute to the agonist binding site.			Prince, RJ (corresponding author), MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,RECEPTOR BIOL LAB,ROCHESTER,MN 55905, USA.							BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23028; CHIARA D C, 1992, Biophysical Journal, V61, pA106; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; FIGL A, 1992, FEBS LETT, V308, P245, DOI 10.1016/0014-5793(92)81284-S; FU DX, 1994, J BIOL CHEM, V269, P26152; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; JACKSON MB, 1989, P NATL ACAD SCI USA, V86, P2199, DOI 10.1073/pnas.86.7.2199; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1990, J GEN PHYSIOL, V96, P395, DOI 10.1085/jgp.96.2.395; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; ZHANG YN, 1995, J PHYSIOL-LONDON, V486, P189, DOI 10.1113/jphysiol.1995.sp020802	16	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25770	25777		10.1074/jbc.271.42.25770	http://dx.doi.org/10.1074/jbc.271.42.25770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824205				2022-12-25	WOS:A1996VN18000011
J	Sorensen, PG; Lutkenhaus, J; Young, K; Eveland, SS; Anderson, MS; Raetz, CRH				Sorensen, PG; Lutkenhaus, J; Young, K; Eveland, SS; Anderson, MS; Raetz, CRH			Regulation of UDP-3-0-[R-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase in Escherichia coli - The second enzymatic step of lipid a biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; SALMONELLA-TYPHIMURIUM; ENDOTOXIN BIOSYNTHESIS; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; LIPOPOLYSACCHARIDE BIOSYNTHESIS; SIGNAL-TRANSDUCTION; DEFICIENT MUTANT; 1ST STEP; PROTEIN	The first enzyme of lipid A assembly in Escherichia coli is an acyltransferase that attaches an R-3-hydroxy-myristoyl moiety to UDP-GlcNAc at the GlcNAc 3-OH. This reaction is reversible and thermodynamically unfavorable. The subsequent deacetylation of the product, UDP-3-O-[R-3-hydroxymyristoyl]-GlcNAc, is therefore the first committed step of lipid A biosynthesis. We now demonstrate that inhibition of either the acyltransferase or the deacetylase in living cells results in a 5-10-fold increase in the specific activity of the deacetylase in extracts prepared from such cells. Five other enzymes of the lipid A pathway are not affected. The elevated specific activity of deacetylase observed in extracts of lipid A-depleted cells is not accompanied by a significant change in the K-m for the substrate, but is mainly an effect on V-max. Western blots demonstrate that more deacetylase protein is indeed made. However, deacetylase messenger RNA levels are not significantly altered. Inhibition of lipid A biosynthesis must either stimulate bit the translation of available mRNA or slow the turnover of pre-existing deacetylase. In contrast, inhibition of 3-deoxy-D-manno-octulosonic acid (Kdo) biosynthesis has no effect on deacetylase specific activity. The under-acylated lipid A-like disaccharide precursors that accumulate during inhibition of Kdo formation may be sufficient to exert normal feedback control.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV KANSAS,MED CTR,DEPT MICROBIOL,KANSAS CITY,KS 66103; MERCK RES LABS,DEPT ANTIBIOT DISCOVERY & DEV,RAHWAY,NJ 07065; MERCK RES LABS,DEPT ENZYMOL,RAHWAY,NJ 07065	Duke University; University of Kansas; University of Kansas Medical Center; Merck & Company; Merck & Company					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, T32GM007754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310, 5T32GM-07754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ARMSTRONG KA, 1984, J MOL BIOL, V175, P331, DOI 10.1016/0022-2836(84)90352-8; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BEALL B, 1987, J BACTERIOL, V169, P5408, DOI 10.1128/jb.169.12.5408-5415.1987; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GOLDMAN RC, 1988, J BACTERIOL, V170, P2185, DOI 10.1128/jb.170.5.2185-2191.1988; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; HELLINGWERF KJ, 1995, FEMS MICROBIOL REV, V16, P309; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KENNEDY EP, 1987, ESCHERICHIA COLI SAL, V1, P672; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIVE L, 1974, ANN NY ACAD SCI, V235, P109, DOI 10.1111/j.1749-6632.1974.tb43261.x; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J.H., 1972, EXPT MOL GENETICS; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MUTA T, 1991, J BIOL CHEM, V266, P6554; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; NISHIJIMA M, 1981, J BACTERIOL, V145, P113, DOI 10.1128/JB.145.1.113-121.1981; NISHIJIMA M, 1981, J BIOL CHEM, V256, P690; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RADIKA K, 1988, J BIOL CHEM, V263, P14859; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAETZ CRH, 1981, J BIOL CHEM, V256, P2109; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1990, J BIOL CHEM, V265, P1285; RAY BL, 1987, J BIOL CHEM, V262, P1122; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; Russo F D, 1993, Trends Microbiol, V1, P306, DOI 10.1016/0966-842X(93)90007-E; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SHIBUYA I, 1992, PROG LIPID RES, V31, P245, DOI 10.1016/0163-7827(92)90010-G; SPARROW CP, 1983, J BIOL CHEM, V258, P9963; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; VUORIO R, 1992, ANTIMICROB AGENTS CH, V37, P354; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384	63	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25898	25905		10.1074/jbc.271.42.25898	http://dx.doi.org/10.1074/jbc.271.42.25898			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824222	hybrid			2022-12-25	WOS:A1996VN18000028
J	Tanti, JF; Gremeaux, T; Grillo, S; Calleja, V; Klippel, A; Williams, LT; VanObberghen, E; LeMarchandBrustel, Y				Tanti, JF; Gremeaux, T; Grillo, S; Calleja, V; Klippel, A; Williams, LT; VanObberghen, E; LeMarchandBrustel, Y			Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote glut 4 translocation in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; STIMULATED GLUCOSE-TRANSPORT; INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE-B; 3T3-L1 ADIPOCYTES; 1-PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GLYCOGEN-SYNTHASE; OKADAIC ACID; MAP KINASE	Insulin stimulates glucose transport in its target cells by recruiting the glucose transporter Glut 4 from an intracellular compartment to the cell surface. Previous studies have indicated that phosphatidylinositol 3-kinase (PI 3-kinase) is a necessary step in this insulin action. We have investigated whether PI 3-kinase activation is sufficient to promote Glut 4 translocation in transiently transfected adipocytes. Rat adipose cells were cotransfected with expression vectors that allowed transient expression of epitope-tagged Glut 4 and a constitutively active form of PI 3-kinase (p110*). The expression of p110* induced the appearance of epitope-tagged Glut 4 at the cell surface at a level similar to that obtained after insulin treatment, whereas a kinase-dead version of p110* had no effect. The p110* effect was observed over a wide range of the transfected cDNA. When subcellular fractionation of adipocytes was performed, p110* was found, similar to the endogenous PI 3-kinase, enriched in the low density microsomal compartment, which also contains the Glut 4 vesicles. This could suggest that a specific localization of PI 3-kinase in this compartment is required for the action on Glut 4, The observations made with PI 3-kinase are in contrast with those seen with the MAP kinase cascade. Indeed, a constitutively active form of MAP kinase kinase had no effect on Glut 4 translocation in basal conditions. At the highest degree of expression, the constitutively active form of MAP kinase kinase slightly inhibited the insulin stimulation of Glut 4 translocation. Taken together, our results indicate that Glut 4 translocation can be efficiently promoted by an active form of PI 3-kinase but not by the activation of the MAP kinase pathway.	CHIRON CORP,EMERYVILLE,CA 94143	Novartis	Tanti, JF (corresponding author), FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE,FRANCE.			Tanti, Jean-Francois/0000-0003-1782-1318				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; GOULD GW, 1994, CELL SIGNAL, V6, P313, DOI 10.1016/0898-6568(94)90036-1; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEMARCHANDBRUSTEL Y, 1990, ENDOCRINOLOGY, V127, P2687; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; Tozzo E, 1996, J BIOL CHEM, V271, P10490, DOI 10.1074/jbc.271.18.10490; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125	39	143	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25227	25232		10.1074/jbc.271.41.25227	http://dx.doi.org/10.1074/jbc.271.41.25227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810283	hybrid			2022-12-25	WOS:A1996VL69300027
J	Ybarra, J; Horowitz, PM				Ybarra, J; Horowitz, PM			Nucleotides reveal polynucleotide phosphorylase activity from conventionally purified GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNASE-E; PROTEIN; DEGRADATION; IDENTIFICATION; PURIFICATION; COMPLEX	GroEL, as conventionally purified, can be incubated with nucleotides to produce high molecular weight material with an absorption maximum at 260 nm. This material is most clearly demonstrated when samples are subjected to gel filtration under conditions where GroEL is monomeric. There is a time-dependent increase in the high molecular weight material that occurs on incubation with ADP or, more slowly, with ATP, This material is generated during incubation, and none is present in the initial samples. Experiments with nucleases, proteases, radiolabeled nucleotides, and chemical cleavage reagents demonstrate that the high molecular weight material is polyadenylic acid whose formation is inhibited by phosphate. These results are consistent with the GroEL samples containing polynucleotide phosphorylase activity. Nondenaturing gels stained with acridine orange, after incubation in ADP, reveal that the activity producing the poly(A) coelectrophoreses with authentic polynucleotide phosphorylase. Conditions that remove the tryptophan-like fluorescence from preparations of GroEL also remove the PNPase activity, Thus, this activity is not associated with GroEL itself, The results are consistent with reports that GroEL can associate with RNase E and with other studies showing that RNase E and PNPase can form complexes, Thus, the present experiments support suggestions that GroEL can participate in multiprotein complexes that are involved in mRNA processing and degradation.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DESSAUER CW, 1994, J BIOL CHEM, V269, P19766; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GEORGELLIS D, 1995, MOL MICROBIOL, V16, P1259, DOI 10.1111/j.1365-2958.1995.tb02347.x; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; NEUHOFF V, 1986, ELECTROPHORESIS, V7, P56, DOI 10.1002/elps.1150070110; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; THANG MN, 1967, BIOCHEM BIOPH RES CO, V28, P374, DOI 10.1016/0006-291X(67)90320-8; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; YBARRA J, 1995, J BIOL CHEM, V270, P22962, DOI 10.1074/jbc.270.39.22962	16	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25063	25066		10.1074/jbc.271.41.25063	http://dx.doi.org/10.1074/jbc.271.41.25063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810258	hybrid			2022-12-25	WOS:A1996VL69300002
J	Desdouits, F; Buxbaum, JD; DesdouitsMagnen, J; Nairn, AC; Greengard, P				Desdouits, F; Buxbaum, JD; DesdouitsMagnen, J; Nairn, AC; Greengard, P			Amyloid beta peptide formation in cell-free preparations - Regulation by protein kinase C, calmodulin, and calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MUTATION; SECRETION; INHIBITION; ACTIVATION; RELEASE; CALCIUM; GENE	Amyloid beta peptide (A beta) is a short peptide that is the major constituent of the amyloid plaques and cerebrovascular amyloid deposits found in Alzheimer's disease. The lack of availability of a cell-free system in which to study A beta formation has limited our understanding of the molecular mechanisms involved in its production, We report here the reconstitution of such a cell-free system. The reconstituted A beta formation was temperature-dependent and required ATP, Preincubation with purified protein kinase C (PKC) induced a pronounced inhibition of A beta formation, similar to that observed in intact cells upon stimulation of PKC. The calmodulin antagonists W-7 and trifluoperazine inhibited A beta formation and enhanced the action of PKC in both the cell-free system and intact cells. A role for the calcium/calmodulin-activated protein phosphatase calcineurin in the regulation of A beta formation was demonstrated using a specific peptide inhibitor of calcineurin in vitro as well as cyclosporin A, a cell-permeant inhibitor of calcineurin, in intact cells. Our results suggest that a single substrate might mediate opposing actions of PKC and calcineurin in the regulation of A beta formation.	ROCKEFELLER UNIV, MOL & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, ELIZABETH M FISHER CTR RES ALZHEIMER DIS, NEW YORK, NY 10021 USA	Rockefeller University; Rockefeller University			Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313; Nairn, Angus/0000-0002-7075-0195	NIA NIH HHS [AG 09464, AG 08051] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG008051, P01AG009464] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; KHACHATURIAN ZS, 1989, ANN NY ACAD SCI, V568, P1, DOI 10.1111/j.1749-6632.1989.tb12485.x; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SILVA EFDE, 1995, MOL MED, V1, P535, DOI 10.1007/BF03401590; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	30	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24670	24674		10.1074/jbc.271.40.24670	http://dx.doi.org/10.1074/jbc.271.40.24670			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798734	hybrid			2022-12-25	WOS:A1996VM67400056
J	Economides, AN; Everdeen, D; Panayotatos, N				Economides, AN; Everdeen, D; Panayotatos, N			A shared, non-canonical DNA conformation detected at DNA/protein contact sites and bent DNA in the absence of supercoiling or cognate protein binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 ENDONUCLEASE-I; HOLLIDAY JUNCTIONS; ESCHERICHIA-COLI; KINETOPLAST DNA; PROMOTER; CLEAVAGE; INVITRO; REPLICATION; SPECIFICITY; RESOLUTION	A hybrid protein (H144), consisting of Lac repressor and T7 endonuclease I, binds at the lac operator and cleaves relaxed double stranded DNA at distal but distinct sites. These sites are shown here to coincide with a bacterial promoter, a phage T7 promoter, a site for gyrase and intrinsically bent DNA. The targets do not seem to share a particular DNA sequence, and in bent DNA, cleavage occurs at the physical center rather than at the common A-tracts. These results indicate that protein contact sites and intrinsic bends assume a non-canonical conformation in the absence of supercoiling or cognate protein binding. This feature may serve as a recognition signal or facilitate protein binding to initiate transcription and recombination.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Regeneron				Economides, Aris/0000-0002-6508-8942				BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BROSIUS J, 1982, J BIOL CHEM, V257, P9205; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; CAMILLONI G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P73, DOI 10.1016/0167-4781(91)90214-7; CASERTA M, 1989, NUCLEIC ACIDS RES, V17, P8463, DOI 10.1093/nar/17.21.8463; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; DICKIE P, 1988, J MOL BIOL, V201, P19, DOI 10.1016/0022-2836(88)90435-4; DICKIE P, 1987, J BIOL CHEM, V262, P14826; ECONOMIDES AN, 1993, THESIS MICHIGAN STAT; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GRZESKOWIAK K, 1993, BIOCHEMISTRY-US, V32, P8923, DOI 10.1021/bi00085a025; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HUBNER P, 1989, J MOL BIOL, P493; JENSCH F, 1989, EMBO J, V8, P4325, DOI 10.1002/j.1460-2075.1989.tb08619.x; JEYASEELAN R, 1988, BIOCHEM BIOPH RES CO, V156, P1054, DOI 10.1016/S0006-291X(88)80951-3; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LU M, 1991, J BIOL CHEM, V266, P2531; MARINI JC, 1984, J BIOL CHEM, V259, P8974; MASHAL RD, 1995, NAT GENET, V9, P177, DOI 10.1038/ng0295-177; MULLER B, 1990, NUCLEIC ACIDS RES, V18, P5633, DOI 10.1093/nar/18.19.5633; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; PANAYOTATOS N, 1989, J BIOL CHEM, V264, P15070; PANAYOTATOS N, 1989, J BIOL CHEM, V264, P15066; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PEREZMARTIN J, 1994, J MOL BIOL, V241, P7, DOI 10.1006/jmbi.1994.1468; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; STROTHKAMP RE, 1980, BIOCHEMISTRY-US, V19, P1074, DOI 10.1021/bi00547a005; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YOUNG MA, 1995, BIOPHYS J, V68, P2454, DOI 10.1016/S0006-3495(95)80427-3; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0	43	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24836	24841		10.1074/jbc.271.40.24836	http://dx.doi.org/10.1074/jbc.271.40.24836			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798758	hybrid			2022-12-25	WOS:A1996VM67400080
J	Medina, R; Grishina, G; Meloni, EG; Muth, TR; Berlot, CH				Medina, R; Grishina, G; Meloni, EG; Muth, TR; Berlot, CH			Localization of the effector-specifying regions of G(i2 alpha) and G(q alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; RECOMBINANT-GQ-ALPHA; ADENYLYL-CYCLASE; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; GTP HYDROLYSIS; GS-ALPHA; ACTIVATION; CHIMERAS; BINDING	Heterotrimeric G proteins transmit hormonal and sensory signals received by cell surface receptors to effector proteins that regulate cellular processes. Members of the highly conserved family of cu subunits specifically modulate the activities of a diverse array of effector proteins. To investigate the determinants of alpha subunit-effector specificity, we localized the effector-specifying regions of alpha(i2), which inhibits adenylyl cyclase, and alpha(q), which stimulates phosphoinositide phospholipase C using chimeric alpha subunits. The chimeras were generated using an in vivo recombination method in Escherichia coli. The effector-specifying regions of both alpha(i2) and alpha(q) were localized within the GTPase domain. An alpha(q) alpha(i2)alpha(q) chimera containing only 78 alpha(i2) residues within the GTPase domain robustly inhibited adenylyl cyclase. This alpha(i2) segment includes regions corresponding to two of the three regions of alpha(s) that activate adenylyl cyclase, but does not include any of the alpha subunit regions that switch conformation upon binding GTP. Replacement of the alpha(q) residues that comprise the helical domain with the homologous alpha(i2) residues resulted in a chimeric alpha subunit that activated phospholipase C. Combined with previous studies of the effector-specifying residues of alpha(s) and alpha(t) our results suggest that the effector specificity of alpha subunits is generally determined by the GTPase and not the helical domain.	YALE UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, INTERDEPARTMENTAL NEUROSCI PROGRAM, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Yale University				Muth, Theodore/0000-0002-6882-1193				ANTONELLI M, 1994, FEBS LETT, V340, P249, DOI 10.1016/0014-5793(94)80148-7; ARKINSTALL S, 1995, FEBS LETT, V364, P45, DOI 10.1016/0014-5793(95)00351-9; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEBERNARDI MA, 1993, MOL PHARMACOL, V43, P451; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAY GL, 1986, J BACTERIOL, V166, P635, DOI 10.1128/jb.166.2.635-643.1986; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MOORE KR, 1994, BIOTECHNIQUES, V17, P130; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PARIS S, 1987, J BIOL CHEM, V262, P1970; QUAN F, 1991, P NATL ACAD SCI USA, V88, P1898, DOI 10.1073/pnas.88.5.1898; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	57	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24720	24727		10.1074/jbc.271.40.24720	http://dx.doi.org/10.1074/jbc.271.40.24720			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798740	hybrid			2022-12-25	WOS:A1996VM67400062
J	Venable, ME; Bielawska, A; Obeid, LM				Venable, ME; Bielawska, A; Obeid, LM			Ceramide inhibits phospholipase D in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; HUMAN-NEUTROPHILS; HL-60 CELLS; PLASMA-MEMBRANE; D ACTIVATION; GRANULOCYTES; FAMILY; ARF	Recent evidence in whole cells has implicated ceramide in the regulation of phospholipase D (PLD). In intact HL-60 cells, phorbol myristate acetate (PMA) activated PLD as measured by [H-3]palmitate-labeled phosphatidylcholine conversion to phosphatidylethanol in the presence of 2% ethanol. C-6-Ceramide completely inhibited PLD activation after 4 h of treatment and was maximally active at 10 mu m. The activity was structurally specific in that the structural analogs 4,5-dihydro-C-6-ceramide and dioctanoylglycerol were inactive. Although ceramide inhibited PMA-induced activation of PLD, it did not inhibit translocation of protein kinase C (PKC) to the membrane in response to PMA. In a cell-free system, we confirmed that PLD is activated by guanosine 5'-O-(3-thiotriphosphate (GTP gamma S); however, ceramide had no effect on this activity under a variety of conditions. Activation of PLD by GTP gamma S was synergistically enhanced by the addition of PKC activators. This upstream effect was inhibited rapidly and specifically by ceramide (30 mu m). Recombinant ARF plus PKC alpha substituted for crude cytosol in the activation of PLD, and this activity was inhibited by C-6-ceramide. Taken together, these data show that ceramide interferes with PKC-mediated activation of PLD.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,DURHAM,NC 27710	Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Venable, ME (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3345,DURHAM,NC 27710, USA.			Venable, Mark/0000-0003-1708-9163; obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE ON AGING [R29AG012467] Funding Source: NIH RePORTER; NIA NIH HHS [1R29-AG-12467] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KISS Z, 1992, BIOCHIM BIOPHYS ACTA, V1124, P300, DOI 10.1016/0005-2760(92)90143-J; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MARTINSON EA, 1994, CELL MOL BIOL, V40, P627; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; Nakamura Y, 1996, J IMMUNOL, V156, P256; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1988, J BIOL CHEM, V263, P12472; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	41	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24800	24805		10.1074/jbc.271.40.24800	http://dx.doi.org/10.1074/jbc.271.40.24800			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798752	hybrid			2022-12-25	WOS:A1996VM67400074
J	BirchenallRoberts, MC; Kim, SJ; Bertolette, DC; Turley, JM; Fu, T; Bang, OS; Kasper, JJ; Yoo, YD; Ruscetti, FW				BirchenallRoberts, MC; Kim, SJ; Bertolette, DC; Turley, JM; Fu, T; Bang, OS; Kasper, JJ; Yoo, YD; Ruscetti, FW			P120-v-Abl expression overcomes TGF-beta 1 negative regulation of c-myc transcription but not cell growth	ONCOGENE			English	Article						v-Abl; E2F-1; RB; c-myc; TGF-beta 1	RETINOBLASTOMA GENE-PRODUCT; MURINE LEUKEMIA-VIRUS; TUMOR-SUPPRESSOR PROTEIN; FACTOR-BETA; MOLECULAR-CLONING; TRANS-ACTIVATION; EPITHELIAL-CELLS; KINASE-ACTIVITY; E2F SITE; ABL	Transformation of interleukin-3 dependent (IL-3) 32D-123 myeloid cells by p120-v-Abl produced the factor-independent 32D-abl cell Line, In 32D-abl cells, myc expression was found to be significantly higher than in the parental cells and was correlated with increased E2F-1 protein expression and DNA binding ability, Surprisingly, in 32D-abl cells, TGF-beta 1, a potent G(1)/S inhibitor of 32D-123 and 32D-abl cell growth, increased E2F transactivation as shown by increased c-myc promoter-CAT and GAL4-E2F-1 activity, In addition, TGF-beta 1 was also found to increase E2F-1 protein levels but had no effect on steady-state retinoblastoma (RE) protein levels or phosphorylation state, In the absence of TGF-beta 1, transient expression of RE in v-Abl expressing cells resulted in decreased c-myc transcription, inhibition of GAL4-E2F-1 driven transactivation and inhibition of cellular proliferation, RE and v-Abl were found to physically asssociate in vivo and in vitro via v-Abl's ATP binding region, In summary, these studies established that in myeloid cells: (1) v-Abl binds RE resulting in increased E2F-1-driven c-myc transcription, and (2) an alternative pathway exists for TGF-beta 1-mediated growth inhibition of v-Abl-transformed cells, in which increased rather than decreased E2F-mediated c-myc transcription is observed.	NCI, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; NCI, DIV BASIC SCI, CHEMOPREVENT LAB, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, LAB LEUKOCYTE BIOL, DIV BASIC SCI, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	BirchenallRoberts, MC (corresponding author), SAIC FREDERICK, INTRAMURAL RES SUPPORT PROGRAM, FREDERICK, MD 21702 USA.							ABELSON HT, 1970, CANCER RES, V30, P2213; ARCINAS M, 1994, J BIOL CHEM, V269, P21919; Bang OS, 1996, J BIOL CHEM, V271, P7811, DOI 10.1074/jbc.271.13.7811; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BIRCHENALLROBERTS MC, 1991, J BIOL CHEM, V266, P9617; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FALTYNEK CR, 1988, J BIOL CHEM, V263, P7112; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GREENBERGER JS, 1984, LEUKEMIA RES, V8, P363, DOI 10.1016/0145-2126(84)90076-6; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KELLER J, 1988, BLOOD, V75, P506; KELLER JR, 1990, ONCOGENE, V5, P549; KELLER JR, 1990, TRANSFORMING GROWTH; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; LONGSTREET M, 1992, ONCOGENE, V7, P1549; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MILLER TL, 1993, MOL CELL ENDOCRINOL, V91, P83, DOI 10.1016/0303-7207(93)90258-L; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1985, CANCER CELL, V3, P65; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEVINS JR, 1992, SCIENCE, V258, P424; OSWALD F, 1994, ONCOGENE, V9, P2029; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SING GK, 1988, BLOOD, V72, P1504; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WANG JYJ, 1984, CELL, V36, P349; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG KK, 1995, MOL CELL BIOL, V15, P6535; YAN ZF, 1992, ONCOGENE, V7, P801; ZAMMANIAN M, 1992, EMBO J, V11, P2603; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	63	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1499	1509						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875988				2022-12-25	WOS:A1996VL38400015
J	DavidPfeuty, T; NouvianDooghe, Y				DavidPfeuty, T; NouvianDooghe, Y			Human cyclin B1 is targeted to the nucleus in G(1) phase prior to its accumulation in the cytoplasm	ONCOGENE			English	Article						cell-cycle regulation; cyclin B1; cyclin A; transformation	CDK-ACTIVATING KINASE; ROUS-SARCOMA VIRUS; HUMAN WEE1 KINASE; SEA-URCHIN EGGS; FISSION YEAST; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; DNA-REPLICATION; PROTEIN-KINASE; S-PHASE	The immunolocalisation patterns of cyclin B1 have been investigated in various tumour-derived and untransformed human cells, using one polyclonal (B7/B8) and tao different monoclonal anti-human cyclin B1 antibodies, GNS1 and GNS11. In actively dividing cell populations, GNS11 reveals uniquely a cytoplasmic pool of cyclin B1 that rapidly increases after the onset of S phase; yet, B7/B8 and GNS1 detect, besides this cytoplasmic cyclin B1 population, a moderate but clear nuclear concentration of the protein in cells that have not yet entered S phase. As for confluent populations of untransformed and tumour cells, they become enriched in G(1)- and G(2)-arrested cells that characteristically display a discreet nuclear or an intense cytoplasmic GNS1 immunostaining respectively. Altogether, our immunofluorescence data conjugated with the results of a detailed biochemical analysis suggest that human cyclin B1 would exist in situ as two distinguishable molecular entities differentially susceptible to in vitro degradation and exhibiting different timing, kinetics and site of accumulation during the cell cycle: one form (recognized by the polyclonal and GNS1 antibodies but apparently not by GNS11) starts to build up inside the nucleus prior to entry in S phase and the other (in which both the GNS11 and GNS1 epitopes are readily accessible) emerges and accumulates in the cytoplasm beyond the G(1)/S boundary.			DavidPfeuty, T (corresponding author), CTR UNIV ORSAY, INST CURIE, SECT RECH, BATIMENT 110, F-91405 ORSAY, FRANCE.							AFLA CE, 1990, NATURE, V347, P680; ALFA CE, 1989, J CELL SCI, P9; BAILLY E, 1992, J CELL SCI, V101, P529; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BALDIN V, 1995, J CELL SCI, V108, P2425; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; DARBON JM, 1994, ONCOGENE, V9, P3127; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GENEVIEREGARRIGUES AM, 1995, J CELL SCI, V108, P2693; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1988, CELL, V54, P739; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1995, EMBO J, V14, P2760, DOI 10.1002/j.1460-2075.1995.tb07276.x; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARIDOR G, 1993, J CELL SCI, V106, P535; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STARGER JM, 1978, J CELL BIOL, V78, P93, DOI 10.1083/jcb.78.1.93; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	56	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1447	1460						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875983				2022-12-25	WOS:A1996VL38400010
J	Lee, DY; Clayton, D				Lee, DY; Clayton, D			Properties of a primer RNA-DNA hybrid at the mouse mitochondrial DNA leading-strand origin of replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED PROTEINS; TELOMERIC DNA; SWITCH REGION; G-QUARTET; INITIATION; TRANSCRIPTION; SITE; BACTERIOPHAGE-T7; POLYMERASE; MODEL	Primers for vertebrate mitochondrial leading-strand DNA replication are products of transcription synthesized by mitochondrial RNA polymerase. The precursor primer RNA exists as a persistent RNA-DNA hybrid, known as an R-loop, formed during transcription through the replication origin (Xu, B., and Clayton, D. A. (1996) EMBO J. 15, 3135-3143). In an effort to examine the precise structure of this primer RNA intermediate, we have used two methods to reconstitute model R-loops containing the mouse mitochondrial DNA origin sequence. First, we demonstrate that bacteriophage SP6 RNA polymerase can efficiently catalyze the formation of an R-loop at the mouse mtDNA origin sequence. Second, the R-loop can be assembled by annealing presynthesized RNA and supercoiled DNA template in the presence of formamide. R-loop formation by either method is dependent on specific template sequences. The reconstituted R-loop is exceptionally stable and exhibits an unexpected structure. Structural studies indicate that the RNA strand is organized within the RNA-DNA base-paired region, suggesting that the heteroduplex interaction occurs through a specific conformation. We propose that the organized structure of the R-loop is critical for primer RNA function in vivo with important implications for the RNA processing and DNA replication machinery.	STANFORD UNIV,DEPT DEV BIOL,BECKMAN CTR MOL & GENET MED,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033088, T32GM007365, R01GM033088] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33088-25, GM07365-18] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BOGENHAGEN D, 1978, J MOL BIOL, V119, P69, DOI 10.1016/0022-2836(78)90270-X; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHEONG CJ, 1992, BIOCHEMISTRY-US, V31, P8406, DOI 10.1021/bi00151a003; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; FULLER CW, 1985, J BIOL CHEM, V260, P3185; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GILLUM AM, 1979, J MOL BIOL, V135, P353, DOI 10.1016/0022-2836(79)90441-8; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; KORNBERG A, 1992, DNA REPLICATION, P209; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; REABAN ME, 1994, J BIOL CHEM, V269, P21850; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; ROMANO LJ, 1981, P NATL ACAD SCI-BIOL, V78, P4107, DOI 10.1073/pnas.78.7.4107; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; THOMAS M, 1976, P NATL ACAD SCI USA, V73, P2294, DOI 10.1073/pnas.73.7.2294; VINOGRAD J, 1968, J MOL BIOL, V33, P173, DOI 10.1016/0022-2836(68)90287-8; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; XU BJ, 1995, MOL CELL BIOL, V15, P580, DOI 10.1128/MCB.15.1.580; Xu BJ, 1996, EMBO J, V15, P3135, DOI 10.1002/j.1460-2075.1996.tb00676.x; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	31	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24262	24269		10.1074/jbc.271.39.24262	http://dx.doi.org/10.1074/jbc.271.39.24262			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798672	hybrid			2022-12-25	WOS:A1996VJ44200101
J	Rezaie, AR				Rezaie, AR			Role of residue 99 at the S2 subsite of factor Xa and activated protein C in enzyme specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; HUMAN ALPHA-THROMBIN; COAGULATION FACTOR-V; PRO-TRP INSERTION; BLOOD-COAGULATION; ANTITHROMBIN-III; KUNITZ INHIBITORS; DOMAIN; SITE; RECONSTITUTION	It is thought that only a limited number of residues in the extended binding pocket of coagulation proteases are critical for substrate and inhibitor specificity, A candidate residue from the crystal structures of thrombin and factor Xa (FXa) that may be critical for specificity at the S2 subsite is residue 99, Residue 99 is Tyr in FXa and Thr in activated protein C (APC), To determine the role of residue 99 in S2 specificity, a Gla-domainless mutant of protein C (GDPC) was prepared in which Thr(99) was replaced with Tyr of FXa, GDPC T99Y bound Ca2+ and was activated by the thrombin-thrombomodulin complex normally, The T99Y mutant, similar to FXa, hydrolyzed the chromogenic substrates with a Gly at the P2 positions, This mutant was also inhibited by antithrombin (AT) (k(2) = 4.2 +/- 0.2 x 10(1) M(-1) s(-1)), and heparin accelerated the reaction >350-fold (k(2) = 1.5 +/- 0.1 x 10(4) M(-1) s(-1)). The T99Y mutant, however, did not activate prothrombin but inactivated factor Va approximate to 2-fold better than wild type, To try to switch the specificity of FXa, both Tyr(99) and Gln(192) of FXa were replaced with those of APC in the Gla-domainless factor X (GDFX Y99T/Q192E), This mutant was folded correctly as it bound Ca2+ with a similar affinity as GDFX and was also activated by the Russell's viper venom at similar rate, but it cleaved the chromogenic substrates with a Gly at the P2 positions poorly, The mutant, instead, cleaved the APC-specific chromogenic substrates efficiently, The Y99T/Q192E mutant became resistant to inhibition by AT in the absence of heparin but was inhibited by AT almost normally in the presence of heparin (k(2) = 3.4 +/- 0.5 x 10(5) M(-1) s(-1)). The Y99T/Q192E mutant did not inactivate factor Va, and prothrombin activation by this mutant was impaired, These results indicate that 1) residue 99 is critical for enzyme specificity at the S2 subsite, 2) a role for heparin in acceleration of FXa inhibition by AT may involve the S2-P2 modulation, and 3) the exchange of residues 99 and 192 in FXa and APC may switch the enzyme specificity with the chromogenic substrates and inhibitors but not with the natural substrates.			Rezaie, AR (corresponding author), OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NHLBI NIH HHS [P01 HL54804] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1977, CHEM BIOL THROMBIN, P403; ESMON CT, 1973, THESIS WASHINGTON U; FISHER CL, 1994, PROTEIN SCI, V3, P588; Furie B.C., 1976, Methods Enzymol, V45, P191; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GRIFFITH MJ, 1982, THROMB RES, V25, P245, DOI 10.1016/0049-3848(82)90244-4; GUINTO ER, 1994, J BIOL CHEM, V269, P18395; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; KANE WH, 1988, BLOOD, V71, P539; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; MANN KG, 1990, BLOOD, V76, P1; MESTERS RM, 1993, PROTEIN SCI, V2, P1482, DOI 10.1002/pro.5560020912; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1995, J BIOL CHEM, V270, P16176, DOI 10.1074/jbc.270.27.16176; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEEHAN JP, 1993, THROMB HAEMOSTASIS, V69, P1044; SKOGEN WF, 1983, BIOCHEM BIOPH RES CO, V111, P14, DOI 10.1016/S0006-291X(83)80110-7; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1994, J BIOL CHEM, V269, P17965	41	43	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23807	23814		10.1074/jbc.271.39.23807	http://dx.doi.org/10.1074/jbc.271.39.23807			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798609				2022-12-25	WOS:A1996VJ44200038
J	Sun, DX; Funk, CD				Sun, DX; Funk, CD			Disruption of 12/15-lipoxygenase expression in peritoneal macrophages - Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONATE 12-LIPOXYGENASE; MESSENGER-RNA; TARGETED DISRUPTION; ATHEROSCLEROTIC LESIONS; HUMAN 15-LIPOXYGENASE; PORCINE LEUKOCYTES; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; PLATELET-TYPE; LIPOXYGENASE	Previously, we isolated the murine ''leukocyte-type'' 12-lipoxygenase (L-12LO) cDNA from RNA of peritoneal-elicited cells that consisted predominantly of leukocytes (Chen, X.-S., Kurre, U., Jenkins, N. A., Copeland, N. G., and Funk, C. D. (1994) J. Biol. Chem. 269, 13979-13987). By in situ hybridization we show that the L-12LO gene is expressed abundantly in a subset of peritoneal macrophages but not in elicited leukocytes, alveolar macrophages, or bone marrow-derived macrophages. L-12LO is highly related to human and rabbit 15-lipoxygenases, enzymes that have been implicated in the maturation process of red blood cells, and the oxidative modification of low density lipoproteins that is implicated in atherogenesis. Accordingly, these enzymes have been referred to as 12/15-lipoxygenases. We have inactivated the L-12LO gene in mice using homologous recombination in embryonic stem cells. Macrophage expression of L-12LO was abolished in homozygous deficient mice as was formation of 12-hydroxyeicosatetraenoic acid (12-HETE). In zymosan-stimulated cells, there was significant diversion of metabolism to the 5-lipoxygenase products leukotriene C-4 and 5-HETE and in A23187-treated cells to 5-HETE only. The enhanced formation of 5-lipoxygenase metabolites was not due to compensatory changes of 5-lipoxygenase or 5-lipoxygenase activating protein but rather an apparent substrate diversion. L-12LO-deficient mice have no obvious abnormalities in reticulocyte or mature red blood cells, which suggest that in mice this pathway is not functionally important for erythrocytic development. Indices for oxidation of low density lipoprotein (measured as either thiobarbituric acid-reactive substances or the oxidant stress marker isoprostane 8-epi-prostaglandin F-2 alpha) were identical in incubations with unstimulated wild type and L-12LO deficient macrophages, but the zymosan-induced increase observed with wild-type macrophages was abolished in L-12LO-deficient cells, Thus, 12/15-lipoxygenase-deficient mice will be useful for the study of interaction between lipoxygenase pathways and determination of the in vivo role of 12/15-lipoxygenase-catalyzed oxidation of LDL in atherogenesis.	UNIV PENN, STELLAR CHANCE LAB, CTR EXPT THERAPEUT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Sun, Duxin/AAA-1774-2022; Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053558, R01HL046017, K04HL002710] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BOLTZNITULESCU G, 1981, CELL IMMUNOL, V59, P106, DOI 10.1016/0008-8749(81)90438-X; CARLSON RP, 1985, AGENTS ACTIONS, V17, P197, DOI 10.1007/BF01966592; CATHCART MK, 1988, IN VITRO CELL DEV B, V24, P1001; CHANG WC, 1993, J BIOL CHEM, V268, P18734; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; COWAN HB, 1992, ARCH BIOCHEM BIOPHYS, V296, P314, DOI 10.1016/0003-9861(92)90578-K; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; DING AH, 1988, J IMMUNOL, V141, P2407; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HARATS D, 1995, TRENDS CARDIOVAS MED, V5, P29, DOI 10.1016/1050-1738(94)00029-U; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HUSSAIN H, 1994, AM J PHYSIOL, V266, pC243, DOI 10.1152/ajpcell.1994.266.1.C243; JESSUP W, 1991, BIOCHEM J, V278, P163, DOI 10.1042/bj2780163; KUHN H, 1990, J BIOL CHEM, V265, P1454; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; NADEL JA, 1991, J CLIN INVEST, V87, P1139, DOI 10.1172/JCI115110; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; NISHIYAMA M, 1993, J HISTOCHEM CYTOCHEM, V41, P111, DOI 10.1177/41.1.8417106; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; SHINJO F, 1986, J BIOL CHEM, V261, P3377; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPARROW CP, 1992, P NATL ACAD SCI USA, V89, P128, DOI 10.1073/pnas.89.1.128; SPARROW CP, 1988, J LIPID RES, V29, P745; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P16443; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; WALKER WS, 1974, IMMUNOLOGY, V26, P1025; WALSTRA P, 1987, BIOCHIM BIOPHYS ACTA, V921, P312, DOI 10.1016/0005-2760(87)90032-4; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142	54	214	215	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24055	24062		10.1074/jbc.271.39.24055	http://dx.doi.org/10.1074/jbc.271.39.24055			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798642	hybrid			2022-12-25	WOS:A1996VJ44200071
J	Yokosaki, Y; Monis, H; Chen, J; Sheppard, D				Yokosaki, Y; Monis, H; Chen, J; Sheppard, D			Differential effects of the integrins alpha 9 beta 1, alpha v beta 3, and alpha v beta 6 on cell proliferative responses to tenascin - Roles of the beta subunit extracellular and cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; FIBRONECTIN; ADHESION; GROWTH; EXPRESSION; PROTEIN; MATRIX; ANGIOGENESIS; ATTACHMENT; BINDING	Members of the integrin family manifest considerable overlap in ligand specificity, and many cells have the capacity to express multiple integrin receptors for the same ligand. For example, at least 5 different integrins recognize tenascin as a ligand, and 4 of these bind to the same region of the protein, the third fibronectin type III repeat (TNfn3). We utilized colon carcinoma cells (SW480) that do not normally attach to TNfn3 to examine the possibility that ligation of different integrin receptors for this ligand would induce different effects on cell behavior and intracellular signaling. Heterologous expression of the tenascin receptors alpha v beta 3 and alpha 9 beta 1 produced comparable effects on cell adhesion and spreading on TNfn3, but alpha v beta 3-transfectants proliferated considerably better on each concentration examined, alpha v beta 6-transfectants attached (although less avidly), but completely failed to spread or proliferate. Expression of a chimeric beta subunit composed of the beta 3 extracellular domain fused to the beta 6 transmembrane and cytoplasmic domains resulted in adhesion and spreading similar to that seen with beta 3-transfectants, but considerably less proliferation. When the same cell lines were plated on fibronectin, alpha v beta 6-transfectants spread and proliferated as well as cells transfected with the chimeric beta 3/beta 6 subunit, but, again, neither cell line proliferated as well as cells expressing alpha v beta 3. Cell proliferation was always associated with spreading and with phosphorylation of the focal adhesion kinase, paxillin, and the mitogen-activated kinase, Erk2, but cell attachment in the absence of spreading or proliferation was not associated with phosphorylation of any of these proteins. These data suggest that different integrin receptors for a single ligand can produce markedly different effects on cell proliferation, and that both the extracellular and cyto plasmic domains of integrin beta subunits contribute to these differences.	UNIV CALIF SAN FRANCISCO,LUNG BIOL CTR,CTR ENVIRONM & OCCUPAT HLTH,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NHLBI NIH HHS [HL/A133259, HL53949, HL47412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047412, R01HL053949, R37HL053949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; BREUSS JM, 1995, J CELL SCI, V108, P2241; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DITTEL BN, 1993, BLOOD, V81, P2272; END P, 1992, EUR J BIOCHEM, V209, P1041, DOI 10.1111/j.1432-1033.1992.tb17380.x; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GRINNELL F, 1977, EXP CELL RES, V110, P175, DOI 10.1016/0014-4827(77)90284-1; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KANNO S, 1994, PATHOL INT, V44, P96, DOI 10.1111/j.1440-1827.1994.tb01693.x; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; NEWMAN PJ, 1985, BLOOD, V65, P227; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Rulo H. F. C., 1993, Journal of Dermatological Science, V5, P54, DOI 10.1016/0923-1811(93)90106-Y; SAMBROOK J, 1989, TRANSFECTION COPRECI; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WNG A, 1996, IN PRESS AM J RESPIR; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; YOUNG SL, 1994, DEV BIOL, V161, P615, DOI 10.1006/dbio.1994.1057; ZAGZAG D, 1995, CANCER RES, V55, P907; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	35	130	144	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24144	24150		10.1074/jbc.271.39.24144	http://dx.doi.org/10.1074/jbc.271.39.24144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798654	hybrid			2022-12-25	WOS:A1996VJ44200083
J	Das, R; Vonderhaar, BK				Das, R; Vonderhaar, BK			Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells	ONCOGENE			English	Article						prolactin; breast cancer; JAK2; SHC; STAT5	HUMAN-BREAST-CANCER; ACTIVATED PROTEIN-KINASE; GROWTH-HORMONE RECEPTOR; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LYMPHOMA-CELLS; MAP KINASE; ASSOCIATION; JAK2	The peptide hormone prolactin (Prl) regulates proliferation of normal and malignant mammary cells, In the present study me demonstrate that tate Prl responsive cell Lines, NOG-8 and T47D, activate the JAK2-SHC-MAPK pathway in a rapid and transient manner, Within 1 min of Prl treatment there was an increase in association of JAK2 with SHC, followed by rapid phosphorylation of both the 52 kDa and 46 kDa SHC proteins, Grb2 and Sos associated with the SHC proteins within 1-3 min of Prl treatment in these mammary cells, Within 5 min of hormone treatment we observe an increase in ras-GTP suggesting activation of ras, We also showed a rapid and transient tyrosine phosphorylation of STAT5 in proliferating T47D cells which reached its peak after 30 min of Prl treatment, These results indicate that Prl receptors, after binding the ligand, activate several pathways for signal transduction leading to mitogenesis.	NCI,TUMOR IMMUNOL & BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; BISWAS R, 1987, CANCER RES, V47, P3509; BONNETERRE J, 1982, EUR J CANCER CLIN ON, V18, P1157, DOI 10.1016/0277-5379(82)90097-9; BUCKLEY AR, 1994, BIOCHEM BIOPH RES CO, V204, P1158, DOI 10.1006/bbrc.1994.2584; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAS R, 1996, IN PRESS BREAST CANC; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FINIDORI J, 1995, J ENDOCRINOL, V147, P11, DOI 10.1677/joe.0.1470011; GINSBURG E, 1995, CANCER RES, V55, P2591; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LEPROVOST F, 1994, NEUROENDOCRINOLOGY, V60, P305, DOI 10.1159/000126763; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAO YP, 1995, CELL GROWTH DIFFER, V6, P1235; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUI H, 1994, J BIOL CHEM, V269, P5364; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STEINMETZ RW, 1993, J ENDOCRINOL, V136, P271, DOI 10.1677/joe.0.1360271; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XIUWEN L, 1995, P NATL ACAD SCI USA, V92, P8831; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	40	87	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1139	1145						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808687				2022-12-25	WOS:A1996VJ20200004
J	Lanoix, J; DAgati, V; Szabolcs, M; Trudel, M				Lanoix, J; DAgati, V; Szabolcs, M; Trudel, M			Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD)	ONCOGENE			English	Article						ADPKD; proliferation; apoptosis	C-MYC; TRANSGENIC MICE; PROTOONCOGENE EXPRESSION; EPITHELIAL HYPERPLASIA; B-CELLS; DEATH; BCL-2; GENE; PROTEIN; P53	The proto-oncogene c-myc has been implicated in both cellular proliferation and apoptosis, and we have shown that overexpression of c-myc can induce polycystic kidney disease in transgenic mice, To elucidate the molecular and cellular defects underlying cystogenesis, we have investigated the potential roles of cell proliferation and apoptosis as they relate to c-myc and modulators of c-myc function in human autosomal dominant polycystic kidney disease (ADPKD), Renal c-myc expression was consistently elevated, up to 15-fold, in ADPKD, High levels of c-myc expression correlated with 10- to 100-fold increased proliferation index in cystic epithelium, Interestingly, steady-state levels of bcl-2 mRNA were also increased up to 20-fold and Bcl-2 protein was markedly elevated. In contrast, the expression of bax and p53 was virtually unchanged. However, apoptosis was consistently and significantly increased in ADPKD kidneys, unchecked by high levels of Bcl-2, Together with proliferation, apoptosis may thus represent a general mechanism for cyst growth and tissue remodeling. We conclude that both epithelial cell proliferation and apoptosis required for normal kidney homeostasis are deregulated in ADPKD, regulating the renal developmental program. Furthermore, abnormal expression of proto-oncogenes regulating these processes is an important mediator of cystogenesis in human ADPKD.	UNIV MONTREAL,FAC MED,INST RECH CLIN MONTREAL,MONTREAL,PQ,CANADA; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Columbia University					NIDDK NIH HHS [DK 44864] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044864] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, CELL, V77, P881; [Anonymous], 1995, CELL, V81, P289; AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BARISONI L, 1995, AM J PATHOL, V147, P1728; BERNSTEIN J, 1987, AM J PATHOL, V129, P92; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CHEN IT, 1986, P NATL ACAD SCI USA, V83, P6907, DOI 10.1073/pnas.83.18.6907; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Daoust Martin C., 1994, Clinical and Investigative Medicine, V17, pB97; EVAN AP, 1979, KIDNEY INT, V16, P743, DOI 10.1038/ki.1979.191; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; MICHAUD J, 1994, AM J MED GENET, V51, P240, DOI 10.1002/ajmg.1320510314; MIYASHITA T, 1995, CELL, V80, P293; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NADASDY T, 1995, J AM SOC NEPHROL, V5, P1462; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Szabolcs Matthias J., 1993, Journal of the American Society of Nephrology, V4, P690; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; TRUDEL M, 1994, MAMM GENOME, V5, P149, DOI 10.1007/BF00352345; VANADELSBERG JS, 1995, NAT MED, V1, P359, DOI 10.1038/nm0495-359; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WILSON PD, 1991, KIDNEY INT, V39, P450, DOI 10.1038/ki.1991.56; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194; WOO D, 1995, NEW ENGL J MED, V333, P18, DOI 10.1056/NEJM199507063330104; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394	50	164	171	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1153	1160						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808689				2022-12-25	WOS:A1996VJ20200006
J	Cairo, G; Castrusini, E; Minotti, G; BernelliZazzera, A				Cairo, G; Castrusini, E; Minotti, G; BernelliZazzera, A			Superoxide and hydrogen peroxide-dependent inhibition of iron regulatory protein activity: A protective stratagem against oxidative injury	FASEB JOURNAL			English	Article						superoxide anion; superoxide dismutase; IRP; intra-cellular stores; iron-responsive element	ELEMENT-BINDING-PROTEIN; FE-S CLUSTER; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; LIPID-PEROXIDATION; FERRITIN SYNTHESIS; GENE-EXPRESSION; REDOX REACTIONS; STRESS; ACONITASE	Cellular iron homeostasis is regulated by the cytoplasmic iron regulatory protein (IRP), which binds to iron-responsive elements (IRE) of mRNAs, modulating iron uptake and sequestration, respectively. When iron is scarce, IRP binds to IRE and coordinately increases the synthesis of transferrin receptor and decreases that of ferritin, thus providing the cell with readily available free iron. When iron is in excess, IRP does not bind and iron sequestration prevails over iron uptake. We have found that incubation of rat liver lysates with xanthine oxidase (XO), which generates superoxide (O-2(.-)) and hydrogen peroxide (H2O2), caused a remarkable but reversible inhibition of IRP activity, as the formation of IRE-IRP decreased by 70-80% but returned to baseline values upon exposure to a reducing agent like 2-mercaptoethanol. IRP inhibition was prevented by separate or simultaneous addition of superoxide dismutase and catalase, showing that both O-2(.-). and H2O2 were involved. By contrast, iron chelators and hydroxyl radical scavengers did not impede the inhibition of IRP, suggesting that O-2(.-) and H2O2 acted independently of fi ee iron sources. Ferritin enhanced IRP inhibition, but this process involved tightly bound iron centers that shunted reducing equivalents from XO and returned them to oxygen, thus increasing the formation of O-2(.-). In agreement with the exclusive role of O-2(.-) and H2O2, XO also inhibited recombinant human IRP in the absence of iron. These results demonstrate that O2(.-). and H2O2 can directly but reversibly down-regulate the RNA-binding activity of IRP, causing transient decrease of free iron that otherwise would convert them into more potent oxidants such as hydroxyl radicals or equally aggressive iron-peroxo complexes. This establishes a novel protective stratagem against oxidative injury under pathophysiologic conditions characterized by the excessive generation of O2(.-) and H2O2.	UNIV CATTOLICA SACRO CUORE,IST FARMACOL,ROME,ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Cairo, G (corresponding author), UNIV MILAN,IST PATOL GEN,CNR,CTR STUDIO PATOL CELLULARE,VIA MANGIAGALLI 31,I-20133 MILAN,ITALY.		Cairo, Gaetano/M-5104-2016	Cairo, Gaetano/0000-0002-8147-4720; Minotti, Giorgio/0000-0002-5678-6175				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; BALLA G, 1992, J BIOL CHEM, V267, P18148; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; BIEMOND P, 1986, BIOCHEM J, V239, P169, DOI 10.1042/bj2390169; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CHU E, 1994, J BIOL CHEM, V269, P20289; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; FLECHA BG, 1991, FREE RADICAL BIO MED, V10, P93; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FLISS HF, 1991, ARCH BIOCHEM BIOPHYS, V293, P195; GORDEUK VR, 1987, ANNU REV NUTR, V7, P485, DOI 10.1146/annurev.nu.07.070187.002413; GUO B, 1994, J BIOL CHEM, V269, P24252; HENDERSON BR, 1993, J BIOL CHEM, V269, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; KADIR FHA, 1991, BIOCHEM J, V278, P817, DOI 10.1042/bj2780817; KEHRER JP, 1989, FREE RADICAL RES COM, V5, P305, DOI 10.3109/10715768909073412; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LIN JJ, 1990, ENZYME, V44, P59, DOI 10.1159/000468747; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; MINOTTI G, 1993, CHEM RES TOXICOL, V6, P134, DOI 10.1021/tx00032a001; MINOTTI G, 1987, ARCH BIOCHEM BIOPHYS, V253, P257, DOI 10.1016/0003-9861(87)90659-X; MINOTTI G, 1992, ARCH BIOCHEM BIOPHYS, V297, P189, DOI 10.1016/0003-9861(92)90661-F; MINOTTI G, 1995, J CLIN INVEST, V95, P1595, DOI 10.1172/JCI117833; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; RADY R, 1991, ARCH BIOCHEM BIOPHYS, V286, P117; ROMANIUK PJ, 1985, BIOCHEMISTRY-US, V24, P4239, DOI 10.1021/bi00336a064; RUBIN E, 1994, PATHOLOGY, P11; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; STRALIN P, 1994, BIOCHEM J, V298, P347, DOI 10.1042/bj2980347; THEIL EC, 1990, J BIOL CHEM, V265, P4771; THEIL EC, 1994, BIOCHEM J, V304, P1; THOMAS JP, 1986, BIOCHIM BIOPHYS ACTA, V884, P448, DOI 10.1016/0304-4165(86)90195-9; TORCHINSKY YM, 1981, SULFUR PROTEINS, P48; ULVIK R, 1979, BIOCHIM BIOPHYS ACTA, V588, P256, DOI 10.1016/0304-4165(79)90209-5; VILE GF, 1993, J BIOL CHEM, V268, P14678; WATT RK, 1992, BIOCHEMISTRY-US, V31, P9673, DOI 10.1021/bi00155a021; WORWOOD M, 1989, J INT MED, P381; YAMAZAKI I, 1990, J BIOL CHEM, V265, P13589; YAMAZAKI I, 1991, J AM CHEM SOC, V113, P7588, DOI 10.1021/ja00020a021	53	103	105	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1326	1335		10.1096/fasebj.10.11.8836047	http://dx.doi.org/10.1096/fasebj.10.11.8836047			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836047				2022-12-25	WOS:A1996VJ71700013
J	Caulfield, JL; Singh, SP; Wishnok, JS; Deen, WM; Tannenbaum, SR				Caulfield, JL; Singh, SP; Wishnok, JS; Deen, WM; Tannenbaum, SR			Bicarbonate inhibits N-nitrosation in oxygenated nitric oxide solutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXYNITRITE; SUPEROXIDE; KINETICS; OXIDATION; LUMINOL; DAMAGE; DNA	N-Nitrosation in oxygenated nitric oxide (NO.) solutions was previously shown to be significantly inhibited by phosphate and chloride presumably by anion scavenging of the nitrosating agent nitrous anhydride, N-2O3 (Lewis, R. S., Tannenbaum, S, R., and Deen, W. M. (1995) J. Am. Chem. Sec. 117, 3933-3939), Here, bicarbonate is shown to exhibit this same inhibitory effect, Rate constants for reaction of morpholine, phosphate, and bicarbonate with N2O3 relative to N2O3 hydrolysis at pH 8.9 were determined to be (3.7 +/- 0.2) x 10(4) M(-1), (4.0 +/- 0.9) x 10(2) M(-1), and (9.3 +/- 1.5) x 10(2) M(-1), respectively, The morpholine and phosphate rate constants at pH 8.9 are similar to those reported at pH 7.4 assuring that these results are relevant to physiological conditions, The rate constant for this previously unrecognized reaction of bicarbonate with N2O3 suggests the strong scavenging ability of bicarbonate; accordingly, bicarbonate may contribute to reducing deleterious effects of N2O3, This is biologically important due to substantial bicarbonate concentrations in vivo, approximately 30 mM. Bicarbonate was previously shown to alter peroxynitrite reactivity; however, carbon dioxide is the probable reactive species, Bicarbonate is therefore potentially important in determining the fate of two reactive species generated from nitric oxide, N2O3 and ONOO-, and may thus act as a regulator of NO.-induced toxicity.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,DIV TOXICOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Wishnok, John S./A-3173-2009		NATIONAL CANCER INSTITUTE [P01CA026731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004675] Funding Source: NIH RePORTER; NCI NIH HHS [CA26731, CA09112] Funding Source: Medline; NIEHS NIH HHS [ES04675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Carola R., 1990, HUMAN ANATOMY PHYSL; DEROJASWALKER T, 1995, CHEM RES TOXICOL, V8, P473, DOI 10.1021/tx00045a020; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KEITH WG, 1969, J CHEM SOC, pA90; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; LEWIS RS, 1995, J AM CHEM SOC, V117, P3933, DOI 10.1021/ja00119a006; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MICHELSON AM, 1983, BIOCHIMIE, V65, P95, DOI 10.1016/S0300-9084(83)80179-5; MONCADA S, 1991, PHARMACOL REV, V43, P109; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; TREININ A, 1970, J AM CHEM SOC, V92, P5821, DOI 10.1021/ja00723a001; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	18	90	92	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25859	25863		10.1074/jbc.271.42.25859	http://dx.doi.org/10.1074/jbc.271.42.25859			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824217	hybrid			2022-12-25	WOS:A1996VN18000023
J	Lee, SH; Minowa, MT; Mouradian, MM				Lee, SH; Minowa, MT; Mouradian, MM			Two distinct promoters drive transcription of the human D-1A dopamine receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MESSENGER-RNA; MOLECULAR-CLONING; GROWTH-HORMONE; ALTERNATIVE PROMOTER; MULTIPLE PROMOTERS; PREFRONTAL CORTEX; RAT-BRAIN; EXPRESSION; D1	The human D-1A dopamine receptor gene has a GC-rich, TATA-less promoter located upstream of a small, noncoding exon 1, which is separated from the coding exon 2 by a 116-base pair (bp)-long intron. Serial 3'-deletions of the 5'-noncoding region of this gene, including the intron and 5'-end of exon 2, resulted in 80 and 40% decrease in transcriptional activity of the upstream promoter in two D-1A-expressing neuroblastoma cell lines, SK-N-MC and NS20Y, respectively. To investigate the function of this region, the intron and 245 bp at the 5'-end of exon 2 were investigated, Transient expression analyses using various chloramphenicol acetyltransferase constructs showed that the transcriptional activity of the intron is higher than that of the upstream promoter by 12-fold in SK-N-MC cells and by 5.5-fold in NS20Y cells in an orientation-dependent manner, indicating that the D-1A intron is a strong promoter. Primer extension and ribonuclease protection assays revealed that transcription driven by the intron promoter is initiated at the junction of intron and exon 2 and at a cluster of nucleotides located 50 bp downstream from this junction. The same transcription start sites are utilized by the chloramphenicol acetyltransferase constructs employed in transfections as well as by the D-1A gene expressed within the human caudate. The relative abundance of D-1A transcripts originating from the upstream promoter compared with those transcribed from the intron promoter is 1.5-2.9 times in SK-N-MC cells and 2 times in the human caudate. Transcript stability studies in SK-N-MC cells revealed that longer D-1A mRNA molecules containing exon 1 are degraded 1.8 times faster than shorter transcripts lacking exon 1, Although gel mobility shift assay could not detect DNA-protein interaction at the D-1A intron, competitive co-transfection using the intron as competitor confirmed the presence of trans-acting factors at the intron, These data taken together indicate that the human D-1A gene has two functional TATA-less promoters, both in D-1A expressing cultured neuroblastoma cells and in the human striatum.	NINCDS,NIH,EXPT THERAPEUT BRANCH,GENET PHARMACOL UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Mouradian, M. Maral/0000-0002-9937-412X				ARAKI E, 1987, J BIOL CHEM, V262, P16186; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BISHOP JF, 1994, MOL BRAIN RES, V26, P225, DOI 10.1016/0169-328X(94)90094-9; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; BOYSON SJ, 1986, J NEUROSCI, V6, P3177; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHELLY J, 1990, NATURE, V344, P64, DOI 10.1038/344064a0; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093; COURTOIS SJ, 1992, J BIOL CHEM, V267, P19736; COX LA, 1995, BIOCHEM BIOPH RES CO, V212, P925, DOI 10.1006/bbrc.1995.2058; CREESE I, 1987, RECEPTOR BIOCH METHO, V8; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FOYT HL, 1991, J BIOL CHEM, V266, P7300; FOYT HL, 1992, MOL ENDOCRINOL, V6, P1881, DOI 10.1210/me.6.11.1881; GONZALEZCRESPO S, 1991, P NATL ACAD SCI USA, V88, P8749, DOI 10.1073/pnas.88.19.8749; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRENADER AC, 1995, AM J PHYSIOL-RENAL, V268, pF423, DOI 10.1152/ajprenal.1995.268.3.F423; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KIKINIS Z, 1995, NUCLEIC ACIDS RES, V23, P4190, DOI 10.1093/nar/23.20.4190; LEE T, 1978, NATURE, V273, P59, DOI 10.1038/273059a0; LI Y, 1993, J BIOL CHEM, V268, P3563; LIDOW MS, 1991, NEUROSCIENCE, V40, P657, DOI 10.1016/0306-4522(91)90003-7; LIN YH, 1995, J BIOL CHEM, V270, P26968; MINOWA MT, 1993, J BIOL CHEM, V268, P23544; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ren HZ, 1995, MOL PHARMACOL, V48, P975; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SEEMAN P, 1984, SCIENCE, V225, P728, DOI 10.1126/science.6147018; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; TAYLOR LA, 1991, LIFE SCI, V49, P1505, DOI 10.1016/0024-3205(91)90051-C; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZHOU QY, 1992, J NEUROCHEM, V59, P1875, DOI 10.1111/j.1471-4159.1992.tb11023.x; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	55	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25292	25299		10.1074/jbc.271.41.25292	http://dx.doi.org/10.1074/jbc.271.41.25292			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810292	hybrid			2022-12-25	WOS:A1996VL69300036
J	Adachi, K; Pang, JA; Reddy, LR; Bradley, LE; Chen, QK; Trifillis, P; Schwartz, E; Surrey, S				Adachi, K; Pang, JA; Reddy, LR; Bradley, LE; Chen, QK; Trifillis, P; Schwartz, E; Surrey, S			Polymerization of three hemoglobin A(2) variants containing Val(delta 6) and inhibition of hemoglobin S polymerization by hemoglobin A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL DISEASE; DELTA-GLOBIN GENE; DEOXYHEMOGLOBIN; GELATION; SEQUENCE; YEAST	To understand determinants for hemoglobin (Hb) stability and Hb A(2) inhibition of Hb S polymerization, three Val(delta 6) Hb A(2) variants (Hb A(2) delta E6V, Hb A(2) delta E6V, delta Q87T, and Hb A(2) delta E6V, delta A22E, delta Q87T) were expressed in yeast, and stability to mechanical agitation and polymerization properties were assessed. Oxy forms of Hb A(2) delta E6V and Hb A(2) delta E6V, delta Q87T were 2- and 1.6-fold, respectively, less stable than oxy-Hb S, while the stability of Hb A(2) delta E6V, delta A22E, delta Q87T was similar to that of Hb S, suggesting that Ala(delta 22) and Gln(delta 87) contribute to the surface hydrophobicity of Rb A(2). Deoxy Hb A(2) delta E6V polymerized without a delay time, like deoxy Hb F gamma EGV, while deoxy Hb A(2) delta E6V, delta Q87T and deoxy Hb A(2) delta E6V, delta A22E, delta Q87T polymerized after a delay time, like deoxy Hb S, suggesting that beta 87 Thr is required for the formation of nuclei. Deoxy Hb F gamma E6V, gamma Q87T showed no delay time and required a 3.5-fold higher concentration than deoxy Hb S for polymerization, suggesting that Thr effects on Val(delta 6) Hb A(2) and Val(gamma 6) Hb F variants are different. Mixtures of deoxy Hb S/Hb A(2) delta E6V, delta Q87T polymerized, like deoxy Hb S, while polymerization of Hb S/Hb A(2) delta E6V mixtures was inhibited, like Hb S/Hb F gamma E6V mixtures. These results suggest alpha(2) beta(S) delta(6 Val, 87 Thr) hybrids and Hb A(2) delta E6V, delta 87T participate in Hb S nucleation, while only 50% of alpha(2) beta(S) delta(6Val) hybrids and none of the Hb A(2) delta E6V participate. These findings are in contrast to those of mixtures of Hb S with Hb F gamma E6V or Hb F gamma E6V, Q87T, which both inhibit Hb S polymerization. Our results also suggest participation in nucleation of some alpha(2) beta(S) delta hybrids in A(2)S mixtures but not alpha(2) beta(S) gamma hybrids in FS mixtures.			Adachi, K (corresponding author), UNIV PENN,SCH MED,CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,ABRAMSON CTR,34TH ST & CIV CTR BLVD,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016691] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38632] Funding Source: Medline; NIDDK NIH HHS [DK16691] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI K, 1990, BLOOD, V75, P2070; ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1980, J BIOL CHEM, V255, P7595; Adachi K, 1996, BLOOD, V87, P1617, DOI 10.1182/blood.V87.4.1617.bloodjournal8741617; ADACHI K, 1978, J BIOL CHEM, V253, P382; ADACHI K, 1994, J BIOL CHEM, V269, P9562; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; ADACHI K, 1994, J BIOL CHEM, V269, P17477; ADACHI K, 1992, FEBS LETT, V315, P47; Antonini E., 1971, FRONT BIOL, V21, P19; ASAKURA T, 1974, P NATL ACAD SCI USA, V71, P1594, DOI 10.1073/pnas.71.5.1594; BENESCH RE, 1980, P NATL ACAD SCI-BIOL, V77, P5130, DOI 10.1073/pnas.77.9.5130; BOOKCHIN RM, 1975, NATURE, V256, P667, DOI 10.1038/256667a0; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P452; CHEETHAM RC, 1979, J MOL BIOL, V129, P45, DOI 10.1016/0022-2836(79)90058-5; EMBURY SH, 1994, SICKLE HEMOGLOBINS S; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; HEBBEL RP, 1991, BLOOD, V77, P214; ITANO HA, 1953, ARCH BIOCHEM BIOPHYS, V47, P148, DOI 10.1016/0003-9861(53)90444-5; KINDERLE.J, 1970, BIOCHEM J, V119, pP66; MCCUNE SL, 1994, P NATL ACAD SCI USA, V91, P9852, DOI 10.1073/pnas.91.21.9852; Nagel R. L., 1995, Blood, V86, p251A; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; Oosawa F., 1975, THERMODYNAMICS POLYM; OU CN, 1983, J CHROMATOGR, V266, P197, DOI 10.1016/S0021-9673(01)90893-3; PALDAN EA, 1985, J BIOL CHEM, V260, P8280; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; SPRITZ RA, 1980, CELL, V21, P639, DOI 10.1016/0092-8674(80)90427-4; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; TRIFILLIS P, 1991, BLOOD, V78, P3298; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; Wang Z. P., 1996, Biophysical Journal, V70, pA435; WATERMAN MR, 1979, J MOL BIOL, V128, P337; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WITKOWSKA HE, 1991, NEW ENGL J MED, V325, P1150, DOI 10.1056/NEJM199110173251607; YAMASHIRO DJ, 1994, J BIOL CHEM, V269, P23996	38	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24557	24563		10.1074/jbc.271.40.24557	http://dx.doi.org/10.1074/jbc.271.40.24557			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798718	hybrid			2022-12-25	WOS:A1996VM67400040
J	Bhattacharjee, H; Rosen, BP				Bhattacharjee, H; Rosen, BP			Spatial proximity of Cys(113), Cys(172), and Cys(422) in the metalloactivation domain of the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ATPASE; ANION PUMP	ArsA ATPase activity is allosterically activated by salts of the semimetal arsenic or antimony. Activation is associated with the presence of three cysteine residues in ArsA: Cys(113), Cys(172), and Cys(422). To determine the distance between cysteine residues, wild type ArsA and ArsA proteins with cysteine to serine substitutions were treated with the bifunctional alkylating agent dibromobimane, which reacts with thiol pairs within 3-6 Angstrom of each other to form a fluorescent adduct. ArsA proteins in which single cysteine residues were altered by site-directed mutagenesis still formed fluorescent adducts. Proteins in which two of the three cysteine residues were substituted did not form fluorescent adducts, These results demonstrate that Cys(113), Cys(172), and Cys(422) are in close proximity of each other. We propose a model in which As(III) or Sb(III) interacts with these three cysteines in a trigonal pyramidal geometry, forming a novel soft metal-thiol cage.	WAYNE STATE UNIV,DEPT BIOCHEM & MOL BIOL,SCH MED,DETROIT,MI 48201	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; HAUGLAND RP, 1994, HDB FLUORESCENT PROB, P56; HSU CM, 1989, J BIOL CHEM, V264, P17349; HSU CM, 1991, J BIOL CHEM, V266, P2327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORNET D, 1985, P NATL ACAD SCI USA, V82, P1658, DOI 10.1073/pnas.82.6.1658; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSEN BP, 1995, J BIOENERG BIOMEMBR, V27, P85, DOI 10.1007/BF02110335; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Sambrook J., 2002, MOL CLONING LAB MANU; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; SOWERBY DB, 1994, CHEM ORGANIC ARSENIC, P25; VOGEL G, 1976, BIOCHEMISTRY-US, V16, P208	17	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24465	24470		10.1074/jbc.271.40.24465	http://dx.doi.org/10.1074/jbc.271.40.24465			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798705	hybrid			2022-12-25	WOS:A1996VM67400027
J	Coqueret, O; Berube, G; Nepveu, A				Coqueret, O; Berube, G; Nepveu, A			Dna binding by cut homeodomain proteins is down-modulated by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CELL TYPE SPECIFICATION; SENSORY ORGAN IDENTITY; RAT FIBROBLASTS; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; ZETA-ISOFORM; DROSOPHILA; ISOZYMES	The Drosophila and mammalian Cut homeodomain proteins contain, in addition to the homeodomain, three other DNA binding regions called Cut repeats. Cut-related proteins thus belong to a distinct class of homeodomain proteins with multiple DNA binding domains. Using nuclear extracts from mammalian cells, Cut-specific DNA binding was increased following phosphatase treatment, suggesting that endogenous Cut proteins are phosphorylated in vivo. Sequence analysis of Cut repeats revealed the presence of sequences that match the consensus phosphorylation site for protein kinase C (PKC). Therefore, we investigated whether PKC can modulate the activity of mammalian Cut proteins. In vitro, a purified preparation of PKC efficiently phosphorylated Cut repeats, which inhibited DNA binding. In vivo, a brief treatment of cells with calphostin C, a specific inhibitor of PKC, led to an increase in Cut-specific DNA binding, whereas phorbol 12-myristate 13-acetate, a specific activator of PKC, caused a decrease in DNA binding. The PKC phosphorylation sites within the murine Cut (mCut) protein were identified by in vitro mutagenesis as residues Thr(415), Thr(804), and Ser(987) within Cut repeats 1-3, respectively. Cut homeodomain proteins were previously shown to function as transcriptional repressors. Activation of PKC by phorbol 12-myristate 13-acetate reduced transcriptional repression by mCut, whereas a mutant mCut protein containing alanine substitutions at these sites was not affected. Altogether, our results indicate that the transcriptional activity of Cut proteins is modulated by PKC.	MCGILL UNIV,MOL ONCOL GRP,DEPT MED,ROYAL VICTORIA HOSP,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,MOL ONCOL GRP,DEPT ONCOL,ROYAL VICTORIA HOSP,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,MOL ONCOL GRP,DEPT BIOCHEM,ROYAL VICTORIA HOSP,MONTREAL,PQ H3A 1A1,CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital			Coqueret, Olivier/K-9660-2015; /AAB-8315-2020	Coqueret, Olivier/0000-0002-2843-7867; 				ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CACACE AM, 1993, ONCOGENE, V8, P2095; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HA KS, 1993, J BIOL CHEM, V268, P10534; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JACK J, 1991, DEVELOPMENT, V113, P735; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU S, 1992, DEV BIOL, V150, P133, DOI 10.1016/0012-1606(92)90013-7; LIU S, 1991, GENETICS, V127, P151; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VALARCHE I, 1993, DEVELOPMENT, V119, P881; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YOON SO, 1994, J BIOL CHEM, V269, P18453	56	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24862	24868		10.1074/jbc.271.40.24862	http://dx.doi.org/10.1074/jbc.271.40.24862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798762	hybrid			2022-12-25	WOS:A1996VM67400084
J	Ericsson, J; Jackson, SM; Edwards, PA				Ericsson, J; Jackson, SM; Edwards, PA			Synergistic binding of sterol regulatory element-binding protein and NF-Y to the farnesyl diphosphate synthase promoter is critical for sterol-regulated expression of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR PROMOTER; LEUCINE ZIPPER PROTEIN; MOLECULAR-CLONING; TRANSCRIPTION; DNA; IDENTIFICATION; ACTIVATION; SREBP-1; DOMAIN; PRENYLTRANSFERASE	Sterol-regulated transcription of the farnesyl diphosphate (FPP) synthase gene is dependent on two cis elements in the proximal promoter. These elements, an inverted CCAAT box and sterol regulatory element 3 (SRE-3), bind NF-Y and sterol regulatory element-binding protein 1 (SREBP-1), respectively. We now demonstrate that the binding of recombinant SREBP-1 to its cognate site (SRE-3) within the FPP synthase promoter in vitro is enhanced by binding of NF-Y to the upstream inverted CCAAT box, Using an FPP synthase promoter fragment containing the binding sites for both NF-Y and SREBP-1 in gel mobility shift assays, we demonstrate that the addition of NF-Y increases the binding of SREBP-1 to SRE-3 over 20-fold. In contrast, NF-Y does not stimulate the binding of SREBP-1 to SRE-3 when the inverted CCAAT box is either mutated or 4 base pairs (bp) are inserted between the inverted CCAAT box and SRE-3. Promoter-reporter genes, containing either the wildtype FPP synthase promoter sequence or containing the 4-bp insertion between the inverted CCAAT box and SRE-3, were transiently transfected into cells. The activity of the wild-type promoter-reporter gene increased when the cells were either incubated in sterol-depleted medium or were co-transfected with an expression vector encoding transcriptionally active SREBP-1. This increase in activity was attenuated when the promoter contained the 4-bp insert, consistent with defective binding of SREBP to the promoter in vivo. These studies suggest that the binding of SREBP-1 to SRE-3 in the FPP synthase promoter, and subsequent stimulation of transcription, is dependent on synergistic binding and a functional interaction between SREBP-1 and NF-Y.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EDWARDS PA, 1996, BIOCH LIPIDS LIPOPRO; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRAY JC, 1987, ADV BOT RES, V14, P25; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; KIM JB, 1995, MOL CELL BIOL, V15, P2582; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; LI XY, 1992, J BIOL CHEM, V267, P8984; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SATO R, 1994, J BIOL CHEM, V269, P17267; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; SPEAR DH, 1994, J BIOL CHEM, V269, P25212; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; TJIAN R, 1995, CELL, V77, P5; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	36	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24359	24364		10.1074/jbc.271.40.24359	http://dx.doi.org/10.1074/jbc.271.40.24359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798690	hybrid			2022-12-25	WOS:A1996VM67400012
J	Frank, S; Werner, S				Frank, S; Werner, S			The human homologue of the yeast CHL1 gene is a novel keratinocyte growth factor-regulated gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME TRANSMISSION; MORPHOGENESIS; CELLS; KGF	Keratinocyte growth factor (KGF) is a potent and specific mitogen for different types of epithelial cells, including keratinocytes of the skin. To gain insight into the mechanisms of KGF action in this tissue, we attempted to identify genes that are regulated by KGF in keratinocytes. Using the differential display reverse transcription polymerase chain reaction technology, a gene was identified which was strongly induced in these cells by treatment with KGF but not with serum growth factors or pro-inflammatory cytokines. This gene seems to be part of a multigene family as assessed by Southern blot analysis. Molecular cloning and sequencing of the full-length cDNA revealed a strong homology with the yeast CHL1 gene. The latter encodes a putative helicase, which is involved in correct chromosome transmission and cell cycle progression. Furthermore, the CHL1 gene product and the protein encoded by the novel KGF-regulated gene were identical in size, indicating that we had cloned the human CHL1 homologue. This finding suggests a novel and specific role of KGF in correct chromosome segregation and/or cell cycle progression.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society								ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; Amann J, 1996, GENOMICS, V32, P260, DOI 10.1006/geno.1996.0113; BAUER D, 1994, PCR METH APPL, V4, P97; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BURATOWSKI S, 1993, SCIENCE, V260, P37, DOI 10.1126/science.8465198; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNHA GR, 1994, INT CONGR SER, V1064, P45; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Maniatis T., 1982, MOL CLONING; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; SPENCER F, 1990, GENETICS, V124, P237; WERNER S, 1989, INT J CANCER, V43, P1137, DOI 10.1002/ijc.2910430629; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639	22	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24337	24340		10.1074/jbc.271.40.24337	http://dx.doi.org/10.1074/jbc.271.40.24337			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798685	hybrid			2022-12-25	WOS:A1996VM67400007
J	Inoue, S; Kitajima, K; Inoue, Y				Inoue, S; Kitajima, K; Inoue, Y			Identification of 2-keto-3-deoxy-D-glycero-D-galactonononic acid (KDN, deaminoneuraminic acid) residues in mammalian tissues and human lung carcinoma cells - Chemical evidence of the occurrence of KDN glycoconjugates in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAMINATED NEURAMINIC ACID; PERFORMANCE LIQUID-CHROMATOGRAPHY; TROUT EGG POLYSIALOGLYCOPROTEINS; RICH GLYCOPROTEIN; 3-DEOXY-D-GLYCERO-D-GALACTO-NONULOSONIC ACID; VITELLINE ENVELOPE; JELLY COAT; CHAINS; SEQUENCES; SERA	Since the discovery of KDN glycoprotein in 1986, the occurrence of KDN (= 2-keto-3-deoxy-D-glycero-D-galactonononic acid) glycan chains has been reported for different organisms ranging from bacteria to lower vertebrates, including amphibians and fish. Recently, the presence of alpha 2-->8-linked oligo/polyKDN groups in mammalian tissues was shown by immunohistochemical and immunoblotting methods. In this communication we report the detection and quantitation of the KDN residues in glycoprotein and glycolipid fractions of rat tissues and human lung cancer cell lines by a highly sensitive fluorometric highperformance liquid chromatography (HPLC) method. We now provide unequivocal chemical proof of the occurrence of KDN in mammals by isolation of KDN from pig submaxillary gland and by structural assignment using chemical methods including fast atom bombardment-mass spectrometry, fluorescence-assisted HPLC analysis, gas-liquid chromatography, and H-1 NMR spectroscopy.	UNIV TOKYO,DEPT BIOCHEM & BIOPHYS,GRAD SCH SCI,TOKYO 113,JAPAN	University of Tokyo	Inoue, S (corresponding author), ACAD SINICA,INST BIOL CHEM,NANKANG,TAIPEI 115,TAIWAN.							AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ANGATA T, 1994, GLYCOCONJUGATE J, V11, P493, DOI 10.1007/BF00731286; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; INOUE S, 1979, CARBOHYD RES, V74, P361, DOI 10.1016/S0008-6215(00)84795-3; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KANAMORI A, 1994, HISTOCHEMISTRY, V101, P333, DOI 10.1007/BF00268994; KANAMORI A, 1989, BIOCHEM BIOPH RES CO, V164, P744, DOI 10.1016/0006-291X(89)91522-2; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KANAMORI A, 1990, THESIS U TOKYO; KIMURA M, 1994, J BIOL CHEM, V269, P32138; KITAJIMA K, 1994, J BIOL CHEM, V269, P21415; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; NADANO D, 1986, J BIOL CHEM, V261, P1550; Nishino S, 1996, J BIOL CHEM, V271, P2909, DOI 10.1074/jbc.271.6.2909; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; QU B, 1996, IN PRESS P NATL ACAD; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; SHAUER R, 1978, METHOD ENZYMOL, V50, P64; SONG Y, 1991, J BIOL CHEM, V266, P21929; STRECKER G, 1992, BIOCHEM J, V287, P905, DOI 10.1042/bj2870905; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TERADA T, 1993, J BIOL CHEM, V268, P2640; TEZUKA T, 1993, BIOCHEMISTRY-US, V33, P6495; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; YU S, 1993, BIOCHEMISTRY-US, V32, P9221; Ziak M, 1996, P NATL ACAD SCI USA, V93, P2759, DOI 10.1073/pnas.93.7.2759	30	69	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24341	24344		10.1074/jbc.271.40.24341	http://dx.doi.org/10.1074/jbc.271.40.24341			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798686	hybrid			2022-12-25	WOS:A1996VM67400008
J	Valenti, G; Frigeri, A; Ronco, PM; DEttorre, C; Svelto, M				Valenti, G; Frigeri, A; Ronco, PM; DEttorre, C; Svelto, M			Expression and functional analysis of water channels in a stably AQP2-transfected human collecting duct cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; MOLECULAR-CLONING; MEMBRANE; PERMEABILITY; PROTEIN; IMMUNOLOCALIZATION; LOCALIZATION; GLYCEROL; HOMOLOGS; NEPHRON	In this study, we describe the establishment of a stably transfected epithelial cell line with the cDNA for the rat aquaporin 2 (AQP2). To this end, we used a human cell line (HCD) derived from the cortical collecting duct and having characteristics of principal cells (Prie, D., Friedlander, G., Coureau, C., Vandewalle, A., Cassigena, R., and Ronco, P. M. (1995) Kidney Int. 47, 1310-1318). The HCD cells were first screened for the constitutive expression of AQPs. By Western blot analysis, we found a low expression of immunoreactive AQP2 and AQP4 proteins. In contrast, transfected cells (clone CD8) probed with AQP2 antiserum expressed an intense 29-kDa protein on immunoblot in addition to a broad band between 35-45 kDa corresponding to the glycosylated form of the protein, indicating that full maturity of the protein is attained in transfected cells. Immunofluorescence demonstrated that AQP2 was located in intracellular vesicles. After vasopressin stimulation, the staining redistributed from an intracellular site to the apical pole of the cells, an effect similar to that described on collecting duct principal cells in vivo (Sabolic, I., Katsura, T., Verbavatz, J. M., and Brown, D. (1995) J. Membr. Biol. 143, 165-175) and in perfused tubules (Nielsen, S., Chou, C. L., Marples, D., Christensen, E. I., Kishore, B. K., and Knepper, M. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1013-1017). The redistribution of AQP2 in CD8 cells was accompanied by an approximately B-fold increase in osmotic water permeability coefficient (P-f), which was inhibited by 0.3 mM HgCl2. These data indicate that functional vasopressin-sensitive water channels are expressed in transfected cells. The stably transfected cells represent a suitable model to unravel by direct experimental approach the intracellular signals involved in the translocation of AQP2 to the apical plasma membrane in the presence of vasopressin.	DOMPE SPA, LAQUILA, ITALY; HOP TENON, INSERM, U64, F-75970 PARIS, FRANCE	Dompe; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Valenti, G (corresponding author), UNIV BARI, IST FIS GEN, VIA AMENDOLA 165A, I-70126 BARI, ITALY.		Svelto, Maria/P-6186-2014; Ronco, Pierre/AAC-8390-2022; frigeri, Antonio/AAC-6336-2022	Svelto, Maria/0000-0002-5584-9541; Frigeri, Antonio/0000-0002-5284-2934; VALENTI, GIOVANNA/0000-0003-0233-0778				AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; BENEDETTI PA, 1995, P SOC PHOTO-OPT INS, V2412, P56, DOI 10.1117/12.205348; BENEDETTI PA, 1995, ZOOL STUD, V34, P186; CHABARDES D, 1980, J CLIN INVEST, V65, P439, DOI 10.1172/JCI109687; DILLINGHAM MA, 1985, J MEMBRANE BIOL, V88, P277, DOI 10.1007/BF01871091; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; FARINAS J, 1995, BIOPHYS J, V68, P1613, DOI 10.1016/S0006-3495(95)80335-8; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; FUSHIMI K, 1994, AM J PHYSIOL-RENAL, V267, pF573, DOI 10.1152/ajprenal.1994.267.4.F573; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SABOLIC I, 1995, J MEMBRANE BIOL, V143, P165, DOI 10.1007/BF00233445; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775, DOI 10.1152/ajprenal.1995.269.6.F775; VALENTI G, 1994, AM J PHYSIOL, V267, pC812, DOI 10.1152/ajpcell.1994.267.3.C812; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	29	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24365	24370		10.1074/jbc.271.40.24365	http://dx.doi.org/10.1074/jbc.271.40.24365			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798691	hybrid			2022-12-25	WOS:A1996VM67400013
J	Konrad, RJ; Dean, RM; Young, RA; Billings, PC; Wolf, BA				Konrad, RJ; Dean, RM; Young, RA; Billings, PC; Wolf, BA			Glucose-induced tyrosine phosphorylation of p125 in beta cells and pancreatic islets - A novel proximal signal in insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN AUTOPHOSPHORYLATION; GROWTH-FACTOR RECEPTOR; ACYL-COA ESTERS; ARACHIDONIC-ACID; PHOSPHATIDYLINOSITOL 3'-KINASE; ION CHANNELS; MALONYL-COA; PROTEIN; RELEASE; IRS-1	In this study, we demonstrate that stimulation of beta cells with carbachol and glucose causes increased tyrosine phosphorylation of a 125-kDa protein concurrently with increased insulin secretion. The effect was observed in two different insulin-secreting cell lines and in rat pancreatic islets. Tyrosine phosphorylation was largely calcium independent and occurred within 2 min after stimulation of beta cells with glucose and the muscarinic agonist carbachol. In islets, the effect of glucose was greatly diminished by the addition of mannoheptulose, a seven-carbon sugar that inhibits glucokinase, suggesting that glucose metabolism is required for tyrosine phosphorylation of the protein to occur. Neither insulin nor insulin-like growth factor I significantly increased tyrosine phosphorylation of the 125-kDa protein, suggesting that it was not an autocrine effect. Depolarization of beta cells with glyburide or 50 mM potassium dramatically increased insulin secretion but had no significant effect on tyrosine phosphorylation. Addition of phorbol ester caused a less than 2-fold increase in tyrosine phosphorylation, whereas the calcium ionophore A23187 had no effect. Among the various fuel secretagogues tested, only D-glucose stimulated tyrosine phosphorylation, both alone and in combination with carbachol. Finally, the tyrosine kinase inhibitor AG879 inhibited both tyrosine phosphorylation and insulin secretion in a dose-dependent manner. Taken together, these data demonstrate the presence of a novel signaling pathway in glucose-induced insulin secretion: tyrosine phosphorylation of beta cell p125, which is a proximal step in insulin secretion. Our current working hypothesis is that glucose stimulation of beta cell p125 tyrosine phosphorylation is an essential step for insulin secretion.	UNIV PENN,DEPT PATHOL & LAB MED,SCH MED,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043354, K04DK002217] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43354, K04 DK02217] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; COLCA JR, 1985, BIOCHEM J, V228, P529, DOI 10.1042/bj2280529; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; CORBETT JA, 1994, AM J PHYSIOL, V267, pC48, DOI 10.1152/ajpcell.1994.267.1.C48; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; EASOM RA, 1990, J BIOL CHEM, V265, P14938; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOLLY YC, 1993, BIOCHEMISTRY-US, V32, P12209, DOI 10.1021/bi00096a034; KAVANAUGH WM, 1994, BIOCHEMISTRY-US, V33, P11046, DOI 10.1021/bi00202a026; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KONRAD RJ, 1992, BIOCHEM J, V287, P283, DOI 10.1042/bj2870283; KONRAD RJ, 1994, BIOCHEMISTRY-US, V33, P13284, DOI 10.1021/bi00249a015; KONRAD RJ, 1993, MOL CELL ENDOCRINOL, V92, P135, DOI 10.1016/0303-7207(93)90084-W; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OHMICHI M, 1992, J BIOL CHEM, V267, P21601; OLSZEWSKI S, 1994, J BIOL CHEM, V269, P27987; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RADVANYI F, 1993, MOL CELL BIOL, V13, P423; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	44	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24179	24186		10.1074/jbc.271.39.24179	http://dx.doi.org/10.1074/jbc.271.39.24179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798659	hybrid			2022-12-25	WOS:A1996VJ44200088
J	Davis, P; Bazar, K; Huper, G; Lozano, G; Marks, J; Iglehart, JD				Davis, P; Bazar, K; Huper, G; Lozano, G; Marks, J; Iglehart, JD			Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells	ONCOGENE			English	Article						p53; transactivation; tumor suppressor	TUMOR-SUPPRESSOR P53; MUTANT P53; BINDING PROTEIN; CANCER CELLS; E6 PROTEINS; T-ANTIGEN; GENE; TRANSACTIVATION; MUTATIONS; TRANSFORMATION	The p53 gene is a recessive oncogene whose loss of function can result in cell transformation, Approximately 25% of human breast cancers contain missense mutations in one p53 allele, leading to inactivation of the mutated protein. In almost all of these cases, the wild-type allele is also lost, However, it remains uncertain whether mutant p53 acts in a dominant negative fashion over the wild-type protein, Two parameters of p53 function, transcriptional activation and transcriptional repression, were studied under a variety of experimental conditions within malignant and normal breast epithelial cells, Transient transfection of DNA encoding wild-type p53 was able to transactivate p53-responsive promoters, Wild-type p53 functioned equally wed in malignant cells which harbored an endogenous mutation in p53, in malignant cells containing normal p53 and in normal mammary epithelial cells, Co-transfection of cDNAs encoding mutant p53 proteins mere unable to inhibit the ability of wild-type p53 to transactivate the reporter constructs, Repression of viral promoters by normal p53 protein was not inhibited transfected mutant p53 proteins, regulated gene WBF1/CIP1/p21 was induced following gamma irradiation in normal mammary cells, containing endogenous wild-type p53 and in the same cells transfected with mutant p53 genes, From these experiments me conclude that mutant p53 proteins do not inactivate the transactivating (or repressing) function of a co-expressed normal p53 protein in these cells implying that complete loss of mild-type p53 is required to eliminate these functions in breast epithelium.	DUKE UNIV,MED CTR,SCH MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030	Duke University; Duke University; Duke University; University of Texas System; UTMD Anderson Cancer Center	Davis, P (corresponding author), DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710, USA.				NCI NIH HHS [1P50-CA68438, R01-CA56749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056749, P50CA068438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BARTEK J, 1990, ONCOGENE, V5, P893; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAN SJ, 1995, CANCER RES, V55, P1649; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORRESTER K, 1995, ONCOGENE, V10, P2103; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPER G, 1992, IN VITRO CELL DEV-AN, V28A, P730; IGLEHART JD, 1990, CANCER RES, V50, P6701; JING H, 1994, ONCOGENE, V9, P3397; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MICHIELI P, 1994, CANCER RES, V54, P3391; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OROURKE RW, 1990, ONCOGENE, V5, P1829; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PARK DJ, 1994, ONCOGENE, V9, P1899; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RON D, 1994, P NATL ACAD SCI USA, V91, P10985; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10567; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAYLORS RL, 1991, CANCER RES, V51, P4721; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; UNGER T, 1992, EMBO J, V11, P1393; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WYLLIE FS, 1996, ONCOGENE, V10, P1077; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	57	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1315	1322						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808706				2022-12-25	WOS:A1996VJ20200023
J	Kaul, SC; Mitsui, Y; Komatsu, Y; Reddel, RR; Wadhwa, R				Kaul, SC; Mitsui, Y; Komatsu, Y; Reddel, RR; Wadhwa, R			A highly expressed 81 kDa protein in immortalized mouse fibroblasts: Its proliferative function and identity with ezrin	ONCOGENE			English	Article						ezrin; mouse fibroblasts; proliferation; contact inhibition	MEMBRANE-CYTOSKELETAL LINKER; ACTIN-BASED CYTOSKELETONS; ERM FAMILY MEMBERS; CELLULAR MORTALITY; APICAL MICROVILLI; PARIETAL-CELLS; IDENTIFICATION; PHOSPHORYLATION; ASSOCIATION; CLEAVAGE	An 81 kDa protein was found to be highly expressed in spontaneously immortalized CD1-ICR mouse fibroblasts, RS-4, as compared to normal fibroblasts. RS-4 cells have a reduced serum requirement and exhibit multilayered growth in vitro but are not tumorigenic, The protein was purified from RS-4 cell extracts and used to obtain a polyclonal antibody that specifically immunoprecipitated an 81 kDa protein from cell lysates. Immunocloning of its cDNA and sequence analysis revealed its identity with ezrin, an F-actin binding protein that is a component of the cortical cytoskeleton, Microinjection of the purified IgG fraction of the anti-p81 antiserum into the cytoplasm of RS-4 cells blocked their entry into S phase suggesting that the protein has a proliferative function, Immunostaining of normal mouse tissues showed that the expression of p81/ezrin was highest in proliferating cell populations. Unlike RS-4, NIH3T3 cells exhibit contact inhibition and express levels of p81/ezrin similar to those of normal fibroblasts, When NIH3T3 cells were transfected with p81/ezrin cDNA they lost contact inhibition and thus resembled RS-4 cells, The study demonstrates a proliferative function of p81/ezrin and suggests its involvement in pathways that negatively regulate contact inhibition.	CHILDRENS MED RES INST,SYDNEY,NSW 2145,AUSTRALIA; CHUGAI RES INST MOL MED,NIIHARI,IBARAKI 30041,JAPAN	Children's Medical Research Institute - Australia; University of Sydney	Kaul, SC (corresponding author), AGCY IND SCI & TECHNOL,NATL INST BIOSCI & HUMAN TECHNOL,1-1 HIGASHI,TSUKUBA,IBARAKI 305,JAPAN.		Reddel, Roger R/A-6635-2014; Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Reddel, Roger R/0000-0002-6302-6107; Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; FAZIOLI F, 1993, ONCOGENE, V8, P1335; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HENRY M, 1995, 1995 M CYT CELL FUNC, P69; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Sambrook J., 2002, MOL CLONING LAB MANU; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; WADHWA R, 1994, CELL STRUCT FUNCT, V19, P1, DOI 10.1247/csf.19.1; WADHWA R, 1991, BIOCHEM BIOPH RES CO, V178, P269, DOI 10.1016/0006-291X(91)91809-Q; YAO XB, 1993, AM J PHYSIOL, V265, pC36, DOI 10.1152/ajpcell.1993.265.1.C36; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	29	41	45	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1231	1237						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808697				2022-12-25	WOS:A1996VJ20200014
J	Ording, E; Bergholtz, S; Brendeford, EM; Jamin, N; Gabrielsen, OS				Ording, E; Bergholtz, S; Brendeford, EM; Jamin, N; Gabrielsen, OS			Flexibility in the second half-site sequence recognised by the c-Myb R(2) domain - In vitro and in vivo analysis	ONCOGENE			English	Article						c-Myb; DNA-binding; flexibility; yeast	DNA-BINDING DOMAIN; HELIX-RELATED MOTIF; V-MYB; TRANSCRIPTIONAL ACTIVATOR; PROTOONCOGENE PRODUCT; ONCOGENE PRODUCT; SACCHAROMYCES-CEREVISIAE; ONCOPROTEIN; PROTEIN; YEAST	The oncoprotein c-Myb is a transcription factor that recognises its specific target sequences through two subdomains. The R(3)-domain binds the first half-site, YAAC, and plays a dominant role in sequence recognition, while the homologous R(2)-domain interacts with a more loosely defined sequence in the second half-site, The difficulty in precisely defining a preferred second half-site sequence might reflect the flexible nature of R(2) which only attains its fully folded structure upon binding to DNA, a process that might allow the protein to adapt to different half-site sequences, Here we report that shifting the most conserved base in the second half-site, the G6, into position 5 resulted only in a minor reduction of complex stability in vitro. From an analysis of a series of second half-site variants by EMSA and DMS-interference, we conclude that the preferred recognition sequence should be revised to read [YAACNG or YAACGN], Modeling the structure of c-Myb R(2)R(3) in complex with a GT half-site variant revealed specific interactions with G5, When second half-site variants were tested in vivo using a sensitive yeast effector-reporter system, both the TG and GT half-site variants were functional mediating c-Myb-dependent transactivation, Unexpectedly, we observed large differences between the best second half-site variants at low levels of c-Myb-effector, the GG variant being five- to fifteen-fold more active in vivo than the single-G half-sites, the GH or HG variants.	UNIV OSLO,DEPT BIOCHEM,N-0316 OSLO,NORWAY; CEA SACLAY,DIEP,F-91191 GIF SUR YVETTE,FRANCE	University of Oslo; CEA; UDICE-French Research Universities; Universite Paris Saclay			Jamin, Nadege/AAA-7067-2021					BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BONNER JJ, 1991, GENE, V104, P113, DOI 10.1016/0378-1119(91)90475-Q; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; DASGUPTA P, 1992, J VIROL, V66, P270, DOI 10.1128/JVI.66.1.270-276.1992; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; ESS KC, 1995, MOL CELL BIOL, V15, P5705; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HOVERING PI, 1994, J BIOL CHEM, V269, P17663; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KNEGTEL RMA, 1994, J MOL BIOL, V235, P318, DOI 10.1016/S0022-2836(05)80035-X; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Miller JH., 1972, EXPT MOL GENETICS; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PLAZA S, 1995, ONCOGENE, V10, P329; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; SAIKUMAR P, 1994, ONCOGENE, V9, P1279; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SOLANO R, 1995, EMBO J, V14, P1773, DOI 10.1002/j.1460-2075.1995.tb07166.x; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WILLIAMSON JR, 1990, NUCLEIC ACIDS RES, V18, P379, DOI 10.1093/nar/18.2.379	42	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1043	1051						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806694				2022-12-25	WOS:A1996VG76600018
J	White, DW; Gilmore, TD				White, DW; Gilmore, TD			Bcl-2 and CrmA have different effects on transformation, apoptosis and the stability of I kappa B-alpha in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins	ONCOGENE			English	Article						v-Rel; Bcl-2; CrmA; I kappa B-alpha; malignant transformation; apoptosis	INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; UBIQUITIN-PROTEASOME PATHWAY; IL-1-BETA-CONVERTING ENZYME; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; RECOGNITION SEQUENCE; PRECURSOR PROTEIN; MAMMALIAN HOMOLOG; C-MYC	The retroviral oncoprotein v-Rel is a member of the Rel/ NF-kappa B family of transcription factors, We have previously characterized two v-Rel mutants (v-G37E and v-R273H) that are temperature-sensitive (ts) for transformation and immortalization of chicken spleen cells in vitro. We have now constructed vectors for the co-expression of wild-type or ts mutant v-Rel proteins and the anti-apoptosis proteins Bcl-2 or CrmA. The formation of v-Rel-transformed colonies is enhanced in the presence of overexpressed Bcl-2, Moreover, coexpression of Bcl-2 suppresses apoptosis that is induced when ts v-Rel-transformed cells are shifted to the nonpermissive temperature. However, co-expression of Bcl-2 in these cells does not affect ts functions of v-Rel, such as DNA binding and stabilization of I kappa B-alpha. In contrast, coexpression of CrmA does not suppress apoptosis, but does block an amino-terminal proteolysis of I kappa B-alpha that occurs in ts v-G37E-transformed cells shifted to the nonpermissive temperature, indicating that an ICE-like protease activity is not involved in apoptosis in these cells but is involved in proteolysis of I kappa B-alpha. In addition, CrmA can block cycloheximide-induced amino-terminal processing of I kappa B-alpha in spleen cells transformed by wild-type v-Rel. In summary, these results suggest that v-Rel immortalizes chicken spleen cells through a pathway that involves the Bcl-2 family of proteins, and suggest that one pathway of proteolysis of I kappa B-alpha involves an ICE-like protease.	BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215	Boston University					NCI NIH HHS [CA 47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAZELSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GIOMORE TD, 1995, DNA PROVIRUS H TEMIN, P109; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HRDLICKOVA R, 1995, J VIROL, V69, P403; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LU D, 1991, ONCOGENE, V6, P1235; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MORRISON LE, 1991, ONCOGENE, V6, P1657; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; WHITE DW, 1995, ONCOGENE, V10, P857; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605	73	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					891	899						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806678				2022-12-25	WOS:A1996VG76600002
